
From: Cindi Callaghan <CindiCallaghan@isv-online.org>
Sent: Thursday, August 8, 2019 12:01 PM
To: Lu, Shan; Margaret Liu; Joon Haeng Rhee; dr.annie.degroot@gmail.com; Marc Girard; Dennis Klinman; Peter Nara; John Oxford; Clarisa Palatnik de Sousa; Ted Ross; John Shiver; David Weiner; Alan D. T. Barrett; Emilio A. Emini; Bruno Guy; Ken J. Ishii; Myron M. Levine; Peter Palese; Stanley A. Plotkin; Rino Rappuoli; Mark K. Slifka; Ronald Ellis; Kathrin Jansen; Paul-Henri Lambert; Connie Schmaljohn; Matthias Schnell; Frederic Tangy; Yu-Mei Wen; Denise Doolan; Linda Klavinskis; Jeffrey Ulmer; Britta Wahren; Rafi Ahmed; Albrecht, Randy; Nathalie Garçon; Adrian Hill; Paul Offit; Adolfo Garcia-Sastre; Manon Cox; marie-paule.kieny@inserm.fr; indresh.srivastava@sanofi.com
Cc: Cindi Callaghan
Subject: 2019 ISV Fellows Election on behalf of Margaret Liu
Attachments: 2019 ISV Fellows Ballot.pdf; 2019 FISV candidate Pitisuttithum.pdf; 2019 FISV candidate Williamson.pdf

Sent on behalf of Margaret Liu

Dear ISV Fellows,

Attached please find the background packages and the ballot for the ISV Fellows election. Thank you to those of you who nominated individuals. This year the committee (comprised of the officers, who are all Fellows), decided that we really needed to adhere to the previously approved criteria which include both international recognition for work in vaccinology, *and* contributions to ISV. Thus we selected only two candidates.

Please return your ballot to Cindi no later than August 21. We would also suggest that for future elections, you work with people whom you would like to nominate to help them become involved with ISV, including of course paid membership. The EB is working on ways to involve more of the fellows and members in ISV, which you will hear about soon.

Thank you.

Best regards,
Margaret

From: Cindi Callaghan <CindiCallaghan@isv-online.org>
Sent: Friday, August 23, 2019 8:00 AM
To: Adolfo Garcia-Sastre; Adrian Hill; Alan D. T. Barrett; Albrecht, Randy; 'AnnieD@epivax.com' (AnnieD@epivax.com); Britta Wahren; Bruno Guy; Clarisa Palatnik de Sousa; Connie Schmaljohn; David Weiner; Denise Doolan; Dennis Klinman; Emilio A. Emini; Frederic Tangy; indresh.srivastava@sanofi.com; Jeffrey Ulmer; John Oxford; John Shiver; Joon Haeng Rhee; Kathrin Jansen; Ken J. Ishii; Linda Klavinskis; Manon Cox; Marc Girard; Margaret Liu; marie-paule.kieny@inserm.fr; Mark K. Slifka; Matthias Schnell; Myron M. Levine; Nathalie Garçon; Paul Offit; Paul-Henri Lambert; Peter Nara; Peter Palese; Rafi Ahmed; Rino Rappuoli; Ronald Ellis; Lu, Shan; Stanley A. Plotkin; Ted Ross; Yu-Mei Wen
Cc: Punnee Pitisuttithum; Anna-Lise Williamson
Subject: 2019 ISV Fellows Election Results

Sent on behalf of Margaret Liu

Dear ISV Fellows,

Thank you to all of you who voted in the recent Fellows election. I am pleased to announce that both the nominations passed, so please welcome our new ISV Fellows:

Punnee Pitisuttithum and Anna-Lise Williamson

Congratulations to both. We look forward to your continued active efforts in ISV and your significant contributions to the field of vaccinology.

Sincerely,
The ISV Fellows Committee

From: TEMI-production@journals.tandf.co.uk
Sent: Thursday, February 20, 2020 12:14 AM
To: liu.6244@osu.edu
Cc: Lu, Shan; lishan_su@med.unc.edu
Subject: 1733440 #TrackingId:5682455

Thank you, Shan-Lu.

Regards,

Malathi

Emerging Microbes & Infections

From: liu.6244@osu.edu
Sent:
To: TEMI-production@journals.tandf.co.uk, liu.6244@osu.edu
Cc: shan.lu@umassmed.edu, lishan_su@med.unc.edu
Subject: 1733440

We are fixing it right now and will submit very shortly.

Thank you.

Shan-Lu

From: "TEMI-production@journals.tandf.co.uk" <TEMI-production@journals.tandf.co.uk>
Date: Wednesday, February 19, 2020 at 9:07 PM
To: Shan-Lu Liu <liu.6244@osu.edu>
Cc: "shan.lu@umassmed.edu" <shan.lu@umassmed.edu>, "lishan_su@med.unc.edu" <lishan_su@med.unc.edu>
Subject: Re: Re: Welcome to Taylor & Francis Production: Emerging Microbes & Infections 1733440 #TrackingId:5682455

Hi Shan,

Your copyright form was rejected as there were no article title and author names filled in the form. Please fill and resubmit the form.

Regarding publication time, normally this would publish articles in 18 days. If editor asks us to prioritise, we will do. I will discuss with editor and get back to you on this.

Regards,

Malathi

Emerging Microbes & Infections

From:liu.6244@osu.edu

Sent:

To:liu.6244@osu.edu

Cc:lishan_su@med.unc.edu,Shan.Lu@umassmed.edu

Subject:Re: Re: Welcome to Taylor & Francis Production: Emerging Microbes & Infections 1733440

I am currently out of town, but may I ask my co-corresponding author Dr, Lishan Su, who is copied, to sign on the agreement on behalf of us.

Another piece of note, because this commentary is extremely time-sensitive, is it possible to process it with an accelerated speed? Last few days, similar comments have been published by other journals.

Thank you.

Shan-Lu Liu sent from iPhone

On Feb 19, 2020, at 3:51 PM, TEMI-production@journals.tandf.co.uk <cats@taylorandfrancis.com> wrote:

Article: SARS-CoV-2: no evidence of a laboratory origin

Journal: *Emerging Microbes & Infections* TEMI

Article ID: TEMI 1733440

Dear Shan-Lu Liu,

We are delighted that you have chosen to publish your article in *Emerging Microbes & Infections*. I will be your Production Editor and will work with you to oversee the production of your article through to publication. My contact details are given at the end of this email.

- Please print and sign the attached Author Publishing Agreement. Then return the completed agreement to Taylor & Francis, by uploading to CATS (see below), or post it to the address below.

Proofs will be ready for you to check in approximately 7 working days and we would like you to return your corrections within 3 days. Please let me know if there will be any difficulty in meeting this schedule.

We will be sending proofs to you through our workflow system, CATS (Central Article Tracking System).

- You can check the status of your paper online through the CATS system at:
<https://cats.informa.com/PTS/in?ut=B2AB6692AA414D96905B59E6C51FA240>

- Your User Name is: lius876

- Your Password is: Liua4764#\$ (You will be required to change this first time you log in)

- The DOI of your paper is: 10.1080/22221751.2020.1733440. Once your article has published online, it will be available at the following permanent link: <https://doi.org/10.1080/22221751.2020.1733440>.

Yours sincerely,

Malathi Boopalan

Email: TEMI-production@journals.tandf.co.uk

<Copyright_Form.pdf>

From: Tang, Yi-Wei <yi-wei.tang@cepheid.com>
Sent: Saturday, June 6, 2020 10:15 PM
To: Lu, Shan; Yumei Wen (ymwen@shmu.edu.cn)
Subject: A thought about COVID-19 manuscripts

Teacher Wen, Shan,

By screening EMI papers, I noticed that less and less new manuscripts on COVID-19 have been submitted to EMI recently. I wonder if we can solicit a series of metanalysis and literature review articles from authoritative groups. As you know, I have been involved as a curator in ASM's COVID-19 Registry curating lots of good resources and papers: <https://asm.org/COVID/COVID-19-Research-Registry/Home>. Quickly going through the curator list, Zhengli Shi, Susan Weiss, and Linda Saif are on it. With your permission, I think I could start soliciting for (maybe participating in) a metanalysis on serology. The review paper Michael Loeffelholz and I contributed for EMI has reached over 50,000 hits and 100 citations in Google Scholar. Hopefully these authoritative metanalysis papers will reach similar influences.

Yi-Wei

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

From: KY Yuen <kyyuen@hku.hk>
Sent: Thursday, January 16, 2020 10:32 PM
To: Lu, Shan
Cc: 'Shibo Jiang'; 'wen yumei'
Subject: About the citations of my articles in EMI

Dear Editor Professor Lu,

Thanks for your kind reminder that editorial board members have the obligation to maintain the standard of the journal as reflected by the number of citations of the articles that we have contributed to EMI.

I therefore ask another colleague in my department with no authorship with me in ANY journals to find out all the citations of my 22 EMI articles as tabulated below. Excluding the article 1 that we just published at the end of last year, the citations varies from 1 to 107. The two papers with only one citation included the historical review article (No. 19) on “the father of tropical medicine Patrick Manson”. Another one (No. 3) on influenza gene mutations is the one that you mentioned. This has only 1 citation, not zero, but is BAD enough. Note that I am NOT the corresponding author, though being the last author. My colleague herself has made the decision of sending this paper to EMI.

In summary, the total citation of my EMI publications is 523 per 22 articles, ie average of almost 24 citations per article. It would be useful to me if you can compare my citations with other contributing authors so that we can have an objective self-assessment to ensure the standard of EMI being upheld.

Just want to say again that an ULTRARAPID review and publication of my recent submission on the 2010 novel coronavirus would likely improve the impact factor of EMI. As you can see that article (12) on the bioinformatics comparison of Zika virus which was immediately published on submission was later cited 107 times. Hope that we can set a record again this time.

An early happy Chinese New Year of the rat. Warmest regards.
KY

1. [SMRT sequencing revealed the diversity and characteristics of defective interfering RNAs in influenza A \(H7N9\) virus infection.](#) Lui WY, Yuen CK, Li C, Wong WM, Lui PY, Lin CH, Chan KH, Zhao H, Chen H, To KKW, Zhang AJX, **Yuen KY**, Kok KH. **Emerg Microbes Infect.** 2019;8(1):662-674. doi: 10.1080/22221751.2019.1611346. (Citation= 0)
2. [Replication of MERS and SARS coronaviruses in bat cells offers insights to their ancestral origins.](#) Lau SKP, Fan RYY, Luk HKH, Zhu L, Fung J, Li KSM, Wong EYM, Ahmed SS, Chan JFW, Kok RKH, Chan KH, Wernery U, **Yuen KY**, Woo PCY. **Emerg Microbes Infect.** 2018 Dec 10;7(1):209. doi: 10.1038/s41426-018-0208-9. (Citation=4)
3. [Large-scale sequence analysis reveals novel human-adaptive markers in PB2 segment of seasonal influenza A viruses.](#) Wen L, Chu H, Wong BH, Wang D, Li C, Zhao X, Chiu MC, Yuan S, Fan Y, Chen H, Zhou J, Yuen KY. **Emerg Microbes Infect.** 2018 Mar 29;7(1):47. doi: 10.1038/s41426-018-0050-0. (Citations=1)
4. [Low population serum microneutralization antibody titer against the predominating influenza A\(H3N2\) N121K virus during the severe influenza summer peak of Hong Kong in 2017.](#) Zhu H, Lee ACY, Li C, Mak WWN, Chen YY, Chan KH, Zhang AJX, Fung WF, Zhang RQ, Fung YF, Poon RWS, Lam JY, Tam S, Hung IFN, Chen H, **Yuen KY**, To KKW. **Emerg Microbes Infect.** 2018 Mar 6;7(1):23. doi: 10.1038/s41426-018-0041-1. (Citations=6)

5. [Rapid detection of MERS coronavirus-like viruses in bats: potential for tracking MERS coronavirus transmission and animal origin.](#) Woo PCY, Lau SKP, Chen Y, Wong EYM, Chan KH, Chen H, Zhang L, Xia N, **Yuen KY**. **Emerg Microbes Infect.** 2018 Mar 7;7(1):18. doi: 10.1038/s41426-017-0016-7. (Citations=6)
6. [Coronavirus HKU15 in respiratory tract of pigs and first discovery of coronavirus quasispecies in 5'-untranslated region.](#) Woo PC, Lau SK, Tsang CC, Lau CC, Wong PC, Chow FW, Fong JY, **Yuen KY**. **Emerg Microbes Infect.** 2017 Jun 21;6(6):e53. doi: 10.1038/emi.2017.37. (Citations=8)
7. [Additional molecular testing of saliva specimens improves the detection of respiratory viruses.](#) To KK, Lu L, Yip CC, Poon RW, Fung AM, Cheng A, Lui DH, Ho DT, Hung IF, Chan KH, **Yuen KY**. **Emerg Microbes Infect.** 2017 Jun 7;6(6):e49. doi: 10.1038/emi.2017.35. (Citations=6)
8. [Polyphyletic origin of MERS coronaviruses and isolation of a novel clade A strain from dromedary camels in the United Arab Emirates.](#) Lau SK, Wernery R, Wong EY, Joseph S, Tsang AK, Patteril NA, Elizabeth SK, Chan KH, Muhammed R, Kinne J, **Yuen KY**, Wernery U, Woo PC. **Emerg Microbes Infect.** 2016 Dec 21;5(12):e128. doi: 10.1038/emi.2016.129. (Citations=10)
9. [Differential cell line susceptibility to the emerging Zika virus: implications for disease pathogenesis, non-vector-borne human transmission and animal reservoirs.](#) Chan JF, Yip CC, Tsang JO, Tee KM, Cai JP, Chik KK, Zhu Z, Chan CC, Choi GK, Sridhar S, Zhang AJ, Lu G, Chiu K, Lo AC, Tsao SW, Kok KH, Jin DY, Chan KH, **Yuen KY**. **Emerg Microbes Infect.** 2016 Aug 24;5:e93. doi: 10.1038/emi.2016.99. (Citations=64)
10. [Middle East respiratory syndrome coronavirus M protein suppresses type I interferon expression through the inhibition of TBK1-dependent phosphorylation of IRF3.](#) Lui PY, Wong LY, Fung CL, Siu KL, Yeung ML, Yuen KS, Chan CP, Woo PC, **Yuen KY**, Jin DY. **Emerg Microbes Infect.** 2016 Apr 20;5:e39. doi: 10.1038/emi.2016.33. (Citations=26)
11. [A 10-year study reveals clinical and laboratory evidence for the 'semi-invasive' properties of chronic pulmonary aspergillosis.](#) Chan JF, Lau SK, Wong SC, To KK, So SY, Leung SS, Chan SM, Pang CM, Xiao C, Hung IF, Cheng VC, **Yuen KY**, Woo PC. **Emerg Microbes Infect.** 2016 Apr 20;5:e37. doi: 10.1038/emi.2016.31. (Citations=5)
12. [Comparative genomic analysis of pre-epidemic and epidemic Zika virus strains for virological factors potentially associated with the rapidly expanding epidemic.](#) Zhu Z, Chan JF, Tee KM, Choi GK, Lau SK, Woo PC, Tse H, **Yuen KY**. **Emerg Microbes Infect.** 2016 Mar 16;5:e22. doi: 10.1038/emi.2016.48. (Citations=107)
13. [Talaromyces \(Penicillium\) marneffeii infection in non-HIV-infected patients.](#) Chan JF, Lau SK, **Yuen KY**, Woo PC. **Emerg Microbes Infect.** 2016 Mar 9;5:e19. doi: 10.1038/emi.2016.18. Review. (Citations=43)
14. [A phylogenetically distinct Middle East respiratory syndrome coronavirus detected in a dromedary calf from a closed dairy herd in Dubai with rising seroprevalence with age.](#) Wernery U, El Rasoul IH, Wong EY, Joseph M, Chen Y, Jose S, Tsang AK, Patteril NA, Chen H, Elizabeth SK, **Yuen KY**, Joseph S, Xia N, Wernery R, Lau SK, Woo PC. **Emerg Microbes Infect.** 2015 Dec 2;4(12):e74. doi: 10.1038/emi.2015.74. (Citations=14)
15. [A sensitive and specific antigen detection assay for Middle East respiratory syndrome coronavirus.](#) Chen Y, Chan KH, Kang Y, Chen H, Luk HK, Poon RW, Chan JF, **Yuen KY**, Xia N, Lau SK, Woo PC. **Emerg Microbes Infect.** 2015 Apr;4(4):e26. doi: 10.1038/emi.2015.26. Epub 2015 Apr 22. (Citations=22)
16. [Strategic measures for the control of surging antimicrobial resistance in Hong Kong and mainland of China.](#) Cheng VC, Wong SC, Ho PL, **Yuen KY**. **Emerg Microbes Infect.** 2015 Feb;4(2):e8. doi: 10.1038/emi.2015.8. Epub 2015 Feb 11. Review. (Citations=26)
17. [Identification of specific metabolites in culture supernatant of Mycobacterium tuberculosis using metabolomics: exploration of potential biomarkers.](#) Lau SK, Lam CW, Curreem SO, Lee KC, Lau CC, Chow WN, Ngan AH, To KK, Chan JF, Hung IF, Yam WC, **Yuen KY**, Woo PC. **Emerg Microbes Infect.** 2015 Jan;4(1):e6. doi: 10.1038/emi.2015.6. Epub 2015 Jan 28. (Citations=19)

18. [Genetic relatedness of the novel human group C betacoronavirus to Tylonycteris bat coronavirus HKU4 and Pipistrellus bat coronavirus HKU5](#). Woo PC, Lau SK, Li KS, Tsang AK, **Yuen KY**. **Emerg Microbes Infect.** 2012 Nov;1(11):e35. doi: 10.1038/emi.2012.45. Epub 2012 Nov 7. (Citations=48)
19. [In memory of Patrick Manson, founding father of tropical medicine and the discovery of vector-borne infections](#). To KK, **Yuen KY**. **Emerg Microbes Infect.** 2012 Oct;1(10):e31. doi: 10.1038/emi.2012.32. Epub 2012 Oct 24. Review. (Citations=1)
20. [Avian influenza A H5N1 virus: a continuous threat to humans](#). To KK, Ng KH, Que TL, Chan JM, Tsang KY, Tsang AK, Chen H, **Yuen KY**. **Emerg Microbes Infect.** 2012 Sep;1(9):e25. doi: 10.1038/emi.2012.24. Epub 2012 Sep 19. Review. (Citations=49)
21. [A significant number of reported Absidia corymbifera \(Lichtheimia corymbifera\) infections are caused by Lichtheimia ramosa \(syn. Lichtheimia hongkongensis\): an emerging cause of mucormycosis](#). Woo PC, Leung SY, Ngan AH, Lau SK, **Yuen KY**. **Emerg Microbes Infect.** 2012 Aug;1(8):e15. doi: 10.1038/emi.2012.11. Epub 2012 Aug 22. (Citations=16)
22. [Streptococcus pyogenes and re-emergence of scarlet fever as a public health problem](#). Wong SS, **Yuen KY**. **Emerg Microbes Infect.** 2012 Jul;1(7):e2. doi: 10.1038/emi.2012.9. Epub 2012 Jul 11. Review. (Citations=42)

From: Lu, Shan [mailto:Shan.Lu@umassmed.edu]

Sent: Friday, January 17, 2020 6:26 AM

To: 'kyyuen'

Subject: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0053 has been submitted online

Dear KY,

I just noticed that one of your EMI papers published in 2017 have not had any citation (title below). Maybe you can verify if it is correct.

Shan

Large-scale sequence analysis reveals novel human-adaptive markers in PB2 segment of seasonal influenza A viruses

From: kyyuen <kyyuen@hku.hk>

Sent: Thursday, January 16, 2020 10:39 AM

To: Lu, Shan <Shan.Lu@umassmed.edu>; Shibo Jiang <shibojiang@fudan.edu.cn>; wen yumei <ymwen@shmu.edu.cn>

Subject: Fwd: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0053 has been submitted online

For your urgent and kind attention.

Ky

從我的 iPhone 傳送

以下為轉寄郵件：

寄件人: Emerging Microbes and Infections <onbehalf@manuscriptcentral.com>

日期: 2020 年 1 月 16 日 GMT+8 下午 11:31:45

收件人: kyyuen <kyyuen@hku.hk>

副本: jfwchan <jfwchan@hku.hk>, Raven Kok <khkok@hku.hk>, "zzeightzz@gmail.com" <zzeightzz@gmail.com>, hinchu <hinchu@hku.hk>, Kelvin To <kelvinto@hku.hk>, "yuanshuofeng@gmail.com" <yuanshuofeng@gmail.com>, skplau <skplau@hku.hk>, pcywoo <pcywoo@hku.hk>, kyyuen <kyyuen@hku.hk>

標題: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0053 has been submitted online

回覆給: temi-peerreview@journals.tandf.co.uk

16-Jan-2020

Dear Professor Yuen:

Your manuscript entitled "Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from patients with acute respiratory disease in Wuhan, Hubei, China" has been successfully submitted online and is presently being given full consideration for publication in Emerging Microbes & Infections.

Your manuscript ID is TEMI-2020-0053.

Please mention the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your street address or e-mail address, please log in to ScholarOne Manuscripts at <https://mc.manuscriptcentral.com/temi> and edit your user information as appropriate.

You can also view the status of your manuscript at any time by checking your Author Center after logging in to <https://mc.manuscriptcentral.com/temi>.

Thank you for submitting your manuscript to Emerging Microbes & Infections.

Sincerely,

Emerging Microbes & Infections Editorial Office

From: Liu, Shan-Lu <liu.6244@osu.edu>
Sent: Monday, October 12, 2020 9:46 PM
To: zhengzhiming4@gmail.com; tzhou@mail.nih.gov; GCheng@mednet.ucla.edu; liangy@umn.edu; rli@vcu.edu; xjmeng@vt.edu; Zhijian.Chen@UTSouthwestern.edu; mluo@gsu.edu; zhangyj@umd.edu; xzhu1@umd.edu; jqiu@kumc.edu; lijun@uic.edu; fengwei.bai@usm.edu; andyu@iupui.edu; reachxw@vt.edu; gluo@uab.edu; ldu@nybc.org; hxu@tulane.edu; liu_fy@berkeley.edu; Lu, Shan; haihu@UTMB.edu; wenzheho@temple.edu; Qfeng4@central.uh.edu; tang@bio.fsu.edu; feng.li@sdsstate.edu; ruilu@lsu.edu; sxian2@unl.edu; qiyi.tang@howard.edu; dingsw@ucr.edu; guohua@missouri.edu; bling@tulane.edu; junwang@pharmacy.arizona.edu; lifang@umn.edu; wang518@umd.edu; gaos8@upmc.edu; pewang@uchc.edu; xiangy@uthscsa.edu; fzhu@bio.fsu.edu; chen.liang@mcgill.ca; lyuan@vt.edu; fgao@duke.edu; wangjw28@163.com; xfyu1@zju.edu.cn; bzhao@partners.org; jianw@musc.edu; zyang@ksu.edu; yu.cong@nih.gov; weiming.yuan@usc.edu; Zongdi.feng@nationwidechildrens.org; juh13@psu.edu; hengx@missouri.edu; lsu@med.unc.edu; ywu8@gmu.edu; jwu@whu.edu.cn; tshuo@uic.edu; Shibojian@fudan.edu.cn; sjian@nybc.org; pinwang@usc.edu; rzhaoh@som.umaryland.edu; shuylong@mail.sysu.edu.cn; xuefeng.liu@georgetown.edu; yuxingli@som.umaryland.edu; Wang, Shixia; ye@ipbcams.ac.cn; Pinghui.feng@usc.edu; ju-tao.guo@bblumberg.org; lin.liu@okstate.edu; hua.zhu@rutgers.edu; Jinhong.chang@bblumberg.org; jianzhu1012@gmail.com; ronghai@ucr.edu; jun.zhu@nih.gov; jliu4@uams.edu; xiangpeng.kong@med.nyu.edu; haoquanwu@outlook.com; Wenjun.liu@defence.gov.au; Liang.shan@wustl.edu; hliao@duke.edu; yuan2@upenn.edu; zxing@umn.edu; hongmin.li@health.ny.gov; pzheng@ihv.umaryland.edu; yaliu@ihv.umaryland.edu; jxw103@case.edu; xiangguo.qiu@canada.ca; Feng Shao; zlshi@wh.iov.cn; klan@whu.edu.cn; zengmsh@mail.sysu.edu.cn; Nan Yan; liliwang@upenn.edu; Linheng Li; kli1@uthsc.edu; tsx@case.edu; ssun@mdanderson.org; ysang@tnstate.edu; Liu, Shan-Lu; wu@crystal.harvard.edu; Sun.Jie@mayo.edu; peijun@strubi.ox.ac.uk; jiayu@coh.org; bchen@crystal.harvard.edu; Wen, Haitao; Qu, Feng; Hezhao.Ji@umanitoba.ca; zhengyo@msu.edu; zhanglingqi@tsinghua.edu.cn; Whu@temple.edu; RSun@mednet.ucla.edu; Gao, Guangping; PZheng@ihv.umaryland.edu; GMSWANG@nus.edu.sg; peshi@UTMB.EDU; yaliu@ihv.umaryland.edu; ziyang-yan@uiowa.edu; lqiao@luc.edu; yong.xiong@yale.edu; Wang, Qihong; shuping_tong_md@brown.edu; pinghuif@usc.edu; gaof@im.ac.cn; zihai@musc.edu; zqin@uams.edu; guoh4@upmc.edu; wma@missouri.edu; Feng.Li@uky.edu; xiaow@iu.edu; sli38@tulane.edu; guodeyin@mail.sysu.edu.cn
Subject: ACVA/SCBA-Virology 2020 meeting

Dear colleagues,

As you know, our ACVA/SCAB-Virology 2020 annual meeting originally scheduled in July was cancelled due to the pandemic. Now the Advisory Board has decided to have a virtual meeting on **December 30-31, 2020**. The date is chosen to specially mark the first public revelation of COVID-19 outbreak in Wuhan, which is December 30, 2019. The current board members will serve as organizing and also scientific program committees to facilitate the process.

The meeting will be held in the morning of December 30 and 31 (9-12 pm) and in the afternoon of December 30 (1:30-4:30 pm). Six scientific sessions focusing on the molecular virology, viral pathogenesis, and viral therapeutics and vaccines, etc. will be dedicated to this day-and-half event. Three focused panel discussions will also be arranged.

We are pleased that Drs. Susan Weiss and X.J. Meng have agreed to deliver keynote address during the meeting.

Xiang-Jin (X.J.) Meng, MD, PhD

Virginia Tech

“Expanding host range and extrahepatic manifestation of hepatitis E virus infection”

Susan R. Weiss, PhD

University of Pennsylvania

“Coronaviruses: Old and New”

Please submit your abstract to Dr. Tongqing Zhou (tzhou@mail.nih.gov) by Nov 30, 2020 for full consideration of selected talks. We especially encourage young investigators to submit abstracts and participate in this meeting. As we wish to cover as many topics as possible, the talk will be limited to 12 min of presentation plus 3 min of questions.

Please let me know if you have questions or suggestions.

P.S. This meeting will be open to all SCBA members (not restricted to the Virology Division). Will update.

Thank you.

Shan-Lu Liu, MD, PhD

ACVA/SCBA-Virology President

The Ohio State University



From: Liu, Shan-Lu <liu.6244@osu.edu>
Sent: Monday, June 8, 2020 7:22 AM
To: Liu, Shan-Lu
Subject: ACVA/SCBA-Virology Division announcements
Attachments: ACVA Announcements_June 8'2020.pdf

June 8, 2020

RE: Announcements

Dear colleagues and friends:

Greetings! I hope this email finds you well at this unprecedented time - it seems that we all have been busier than ever working from home!

First, we would like to provide updates on our scientific meeting originally planned for June of this year, which has now been cancelled because of the pandemic. However, we may consider a virtual symposium sometime this year to discuss COVID-19/SARS-CoV-2 along with other selected topics. Suggestions are welcome!

Second, my two-year term as President of ACVA/SCAB-Virology Division will come to an end on December 31, 2020. I would like to use this opportunity to thank each one of you for your encouragement and support. In particular, I wanted to thank the following ACVA board members, Drs. **Genhong Cheng, Haitao Guo, Renfeng Li, Yuying Liang, Wenjun Ma, Zhi-Ming Zheng and Tongqing Zhou**, for their hard work and assistance. In addition, I wish to thank many of you for nominating me as President-elect of SCBA (2022-2023), a position that I have recently accepted – thanks again for your trust and support.

Third, according to SCBA bylaws, a new leadership team of ACVA/SCBA-Virology Division will assume responsibility on January 1, 2021. On July 15, 2018 at our first meeting at the University of Maryland at College Park, the following colleagues were elected for the 2021-2022 term, they are: President: **Dr. Haitao Guo**; Secretary: **Dr. Tongqing Zhou**; Treasurers: **Dr. Yuying Liang and Wenjun Ma**. Congratulations! Thank you for your willingness to serve!

Last but not least, according to SCBA bylaws, this year we will need to elect officers for the 2023-2024 term. For this purpose, the ACVA/SCBA-Virology board has decided to call for nominations for President-elect, Secretary-elect and Treasurer-elect. Self-nomination is encouraged and all current SCBA members are eligible to nominate and to be elected. Except for the position of President, re-election is permitted for other posts of ACVS/SCAB-Virology Division as per SCBA rules and regulations. Please submit your nominations to Dr. Tongqing Zhou email: tzhou@mail.nih.gov.

Thank you and take care!

Shan-Lu

Shan-Lu Liu, M.D., Ph.D.
President, ACVA/SCBA-Virology Division
Professor, The Ohio State University

From: Liu, Shan-Lu <liu.6244@osu.edu>
Sent: Sunday, December 29, 2019 9:56 AM
To: zhengzhiming4@gmail.com; haitguo@iupui.edu; tzhou@mail.nih.gov; GCheng@mednet.ucla.edu; liangy@umn.edu; rli@vcu.edu; wjma@ksu.edu; xjmeng@vt.edu; Zhijian.Chen@UTSouthwestern.edu; mluo@gsu.edu; zhangyj@umd.edu; xzhu1@umd.edu; jqiu@kumc.edu; lijun@uic.edu; fengwei.bai@usm.edu; andyu@iupui.edu; reachxw@vt.edu; gluo@uab.edu; ldu@nybc.org; hxu@tulane.edu; liu_fy@berkeley.edu; shitao.li@okstate.edu; Lu, Shan; haihu@UTMB.edu; wenzheho@temple.edu; Qfeng4@central.uh.edu; tang@bio.fsu.edu; feng.li@sdsstate.edu; ruilu@lsu.edu; sxiang2@unl.edu; qiyi.tang@howard.edu; dingsw@ucr.edu; guohua@missouri.edu; bling@tulane.edu; junwang@pharmacy.arizona.edu; lifang@umn.edu; wang518@umd.edu; gaos8@upmc.edu; pewang@uchc.edu; xiangy@uthscsa.edu; fzhu@bio.fsu.edu; chen.liang@mcgill.ca; lyuan@vt.edu; fgao@duke.edu; wangjw28@163.com; xfyu1@zju.edu.cn; bzhao@partners.org; jianw@musc.edu; zyang@ksu.edu; yu.cong@nih.gov; weiming.yuan@usc.edu; Zongdi.feng@nationwidechildrens.org; juh13@psu.edu; hengx@missouri.edu; lsu@med.unc.edu; ywu8@gmu.edu; jwu@whu.edu.cn; tshuo@uic.edu; Shibojian@fudan.edu.cn; sjian@nybc.org; pinwang@usc.edu; rzhao@som.umaryland.edu; shuylong@mail.sysu.edu.cn; xuefeng.liu@georgetown.edu; yuxingli@som.umaryland.edu; Wang, Shixia; yhe@ipbcams.ac.cn; Pinghui.feng@usc.edu; ju-tao.guo@bblumberg.org; lin.liu@okstate.edu; hua.zhu@rutgers.edu; Jinhong.chang@bblumberg.org; jianzhu1012@gmail.com; ronghai@ucr.edu; jun.zhu@nih.gov; jliu4@uams.edu; xiangpeng.kong@med.nyu.edu; haoquanwu@outlook.com; Wenjun.liu@defence.gov.au; Liang.shan@wustl.edu; hliao@duke.edu; yuan2@upenn.edu; zxing@umn.edu; hongmin.li@health.ny.gov; pzheng@ihv.umaryland.edu; yaliu@ihv.umaryland.edu; jxw103@case.edu; xiangguo.qiu@canada.ca; Feng Shao; zlshi@wh.iov.cn; klan@whu.edu.cn; zengmsh@mail.sysu.edu.cn; Nan Yan; Zhang, Rong; liliwang@upenn.edu; Linheng Li; kli1@uthsc.edu; tsx@case.edu; ssun@mdanderson.org; ysang@tnstate.edu; Liu, Shan-Lu; wu@crystal.harvard.edu; Sun.Jie@mayo.edu; peijun@strubi.ox.ac.uk; jiayu@coh.org; bchen@crystal.harvard.edu; Wen, Haitao; Qu, Feng; Hezhao.Ji@umanitoba.ca; Li, Zihai; zhengyo@msu.edu; zhanglinqi@tsinghua.edu.cn; wxiao@temple.edu; Whu@temple.edu; RSun@mednet.ucla.edu; Gao, Guangping; PZheng@ihv.umaryland.edu; GMSWANG@nus.edu.sg; peshi@UTMB.EDU; yaliu@ihv.umaryland.edu; ziyiing-yan@uiowa.edu; lqiao@luc.edu; yong.xiong@yale.edu; Wang, Qihong; shuping_tong_md@brown.edu; pinghuif@usc.edu; gaof@im.ac.cn; zihai@musc.edu; zqin@uams.edu; guodeyin@www.sysu.edu.cn
Subject: ACVA/SCBA-Virology Division: 2019 Year in Review
Attachments: ACVASCBA-Virology 2019 year in review.pdf

LIU.6244@OSU.EDU appears similar to someone who previously sent you email, but may not be that person. [Learn why this could be a risk](#) [Feedback](#)

Dear Colleagues and Friends:

Happy new year! I wish you all a healthy and productive 2020!

I would like to share the below summary on our major activities in 2019.

ACVA/SCBA-Virology Division: 2019 Year in Review (chronologically)

1. Continuous and focused discussion on the Science letter "Racial Profiling Harms Science" (original title "Racial Profiling Harms American Science and Innovation").

2. Seven Chinese or Chinese American scientists, including 5 members of ACVA/SCBA-Virology Division, elected to the American Academy of Microbiology (AAM) - Genhong Cheng (程根宏), Pinghui Feng (冯平辉), Guangping Gao (高光坪), Jake T Liang (連展阳), Zhengli Shi (石正丽), Yumei Wen (闻玉梅), Richard Zhao (赵玉琪) .
3. Themed discussion on the universal influenza vaccine, vectored ImmunoProphylaxis, and attenuated influenza vaccine.
4. Themed discussion of Open Access journal publishing.
5. Debate and discussion on the definition of “racial profiling”: Chinese translations, differences between “racial profiling” and “racial discrimination”, and differences in Chinese translations: “种族标签, 种族偏见, 种族歧视”.
6. Themed discussion on virus-host evolutionary arms races: HIV and others.
7. Ultimate publication of the Science letter on March 21, 2019 (online) – sagas and stories behind the scenes.
8. Responses to the Science letter and media reports – “The Scientist”, “知识分子”, and others.
9. Discussion and responses to US institution’s statements, Emory/MD Anderson faculty firing, and NIH’s foreign influences and FBI investigations.
10. Establishment of the ACVA/SCBA-Virology Division website (<https://sites.google.com/view/scba-virology/home>), as well as collection and distribution of membership list (<https://sites.google.com/view/scba-virology/members>).
11. Dr. George F. Gao elected to the US National Academy of Sciences as International Member (formerly called Foreign Associate).
12. Dr. Zongdi Feng (冯枏棣) won the 2019 ASV’s Ann Palmenberg Junior Investigator’s award.
13. ACVA/SCBA-Virology participation in the 17th SCBA International Symposium, Kunming, July 24-28, 2019, and scientific workshop and social gathering at the 2nd ACVA/SCBA-virology meeting in Kunming, July 28, 2019.
14. Response and discussion on the role of $\alpha 4\beta 7$ antibody in the control of HIV/SIV infection: 3 Science papers with all negative results - what has gone wrong and what is next?
15. Dr. Feng Shao won the 2019 Future Scientific Prize in Biological Sciences: congratulations and discussions on the scientific evaluation systems in China – ideas and solutions.
16. Three members among the 2019 Journal of Virology top 25 reviewers: Drs. Dongdi Feng (冯枏棣), Bin He (何斌), and Dong-Yan Jin (金冬雁); note that Dr. Bin He is PhD advisor of Dr. Feng, and both have been on the list multiple times, including 2018 (Drs. Ju-tao Guo and Jianming Hu were among the 2018’s JVI top 25 reviewers)
17. Response and discussion about the 2019 Lasker award for the discovery of T and B development.

18. Overwhelming responses to Dr. Xuetao Cao's publication issues raised by [Pubpeer.com](https://pubpeer.com), and heated discussion on scientific misconduct in general.
19. Heated discussion on publishing in CNS (Cell, Nature and Science), selection of conference speakers, and scientific community networking.
20. Themed discussion on self-plagiarism and direct feedback from Editor in Chiefs of Journal of Virology (Roz Sandri-Goldin), Journal of Immunology (Gene Oltz), Viruses (Eric Freed), Emerging Microbes and Infections (Shan Lu), etc.
21. Themed discussion on publications of structural biology studies in CNS - a scientific favor or true advance in biology?
22. Themed discussion on US patents and institution royalties - why are they different?
23. Themed discussion on viral entry: definition of viral receptors – requirements and pitfalls.

Shan-Lu Liu, MD, PhD
President of ACVA/SCBA-Virology
The Ohio State University

From: Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>
Sent: Sunday, February 21, 2021 7:22 AM
To: editorial@emi2012.org; Lu, Shan
Cc: Yang Min 杨旻
Subject: Application for APC waiver or discount

Dear Prof. Lu,

Because of publishing too many research articles in this budget year, I do not have enough budget left to pay for the APC for publication of our Commentary (ID TEMI-2021-0175) in EMI. Here I am applying for an APC waiver or discount. I would appreciate it very much if you could approve my application and provide me an APC waiver or discount code before submission of our revised manuscript online.

Thank you very much for your consideration,

Shibo

Shibo Jiang, M.D.

Professor and Director, Institute of Medical Microbiology Key Laboratory of Medical Molecular Virology

(MOE/NHC/CAMS) School of Basic Medical Sciences, Fudan University

131 Dong An Road, Fuxing Building, 4th Fl, Rm 413 Xuhui District, Shanghai 200032, China

Phone: +86-21-54237673

E-mail: shibojiang@fudan.edu.cn

Website:

https://nam10.safelinks.protection.outlook.com/?url=http%3A%2F%2Fmedicine.fudan.edu.cn%2Fen%2Fshow.aspx%3Finfo_lb%3D27%26flag%3D3%26info_id%3D124&data=04%7C01%7Cshan.lu%40umassmed.edu%7C7ebf278d564248ec09e608d8d663588e%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637495069491298917%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzliLCJBTiI6IjEhaWwiLCJXVCi6Mn0%3D%7C1000&sdata=V0X2V5K%2F5SFXdPMCM2Lj8y4iY5wmmRambUHRXOpXh0%3D&reserved=0

Publications:

<https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F%3Fterm%3Dshibo%2Bjiang%26sort%3Ddate%26size%3D200&data=04%7C01%7Cshan.lu%40umassmed.edu%7C7ebf278d564248ec09e608d8d663588e%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637495069491308875%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzliLCJBTiI6IjEhaWwiLCJXVCi6Mn0%3D%7C1000&sdata=0xnvE0sGbVw04Wd%2FmV37Eo5RZexsPWPGPaFkdMkvg8w%3D&reserved=0>

> -----原始邮件-----

> 发件人: "Emerging Microbes and Infections"

> <onbehalf@manuscriptcentral.com>

> 发送时间: 2021-02-19 23:02:23 (星期五)

> 收件人: 14111010010@fudan.edu.cn, yshao@bjmu.edu.cn,

> shibojiang@fudan.edu.cn

> 抄送:

> 主题: Emerging Microbes & Infections - Decision on Manuscript ID

> TEMI-2021-0175

>

> 19-Feb-2021

>

> Dear Professor Jiang:

>

> Your manuscript entitled "Human challenge trials to assess the efficacy of currently approved COVID-19 vaccines against SARS-CoV-2 variants", which you submitted to Emerging Microbes & Infections, has been reviewed. The reviewer comments are included at the bottom of this letter.

>

> The reviews are in general favourable and suggest that, subject to minor revisions, your paper could be suitable for publication. Please consider these suggestions, and I look forward to receiving your revision.

>

> When you revise your manuscript please highlight the changes you make in the manuscript by using the track changes mode in MS Word or by using bold or coloured text.

>

> In addition, please submit a clean, editable version of your revised paper. These files should be in either Word (.doc) or LaTeX format. Any figures should be saved as either .ps, .eps, .tif or .jpeg file types.

>

> To start the revision, please click on the link below:

>

> *** PLEASE NOTE: This is a two-step process. After clicking on the

> link, you will be directed to a webpage to confirm. ***

>

> https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fmc.manuscriptcentral.com%2Ftemi%3FURL_MASK%3De6f9bcea3944fca4baf20ae84873c7&data=04%7C01%7Cshan.lu%40umassmed.edu%7C7ebf278d564248ec09e608d8d663588e%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637495069491308875%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzliLCJBTil6Ikl1haWwiLCJXVCi6Mn0%3D%7C1000&sdata=LcqHwhK1nn%2Bely3o4dokQ2pqk2QHbNppscwmcigzfew%3D&reserved=0

>

> This will direct you to the first page of your revised manuscript. Please enter your responses to the comments made by the reviewer(s) in the space provided. You can use this space to document any changes you made to the original manuscript. Please be as specific as possible in your response to the reviewer(s).

>

> This link will remain active until you have submitted your revised manuscript. If you begin a revision and intend to finish it at a later time, please note that your draft will appear in the "Revised Manuscripts in Draft" queue in your Author Center.

>

> IMPORTANT: Your original files are available to you when you upload your revised manuscript. Please delete any redundant files before completing the submission.

>

> Because we are trying to facilitate timely publication of manuscripts submitted to Emerging Microbes & Infections, your revised manuscript should be uploaded by 21-Mar-2021. If it is not possible for you to submit your revision by this date, we may have to consider your paper as a new submission.

>

> Once again, thank you for submitting your manuscript to Emerging Microbes & Infections and I look forward to receiving your revision.

>

> Sincerely,

>

> Shan Lu

> Editor-in-Chief

> Emerging Microbes & Infections

>

>

> Review Editor Comments to the Author:

>

> This is an important topic and we did a fast review with input from some of the leading authorities in this area. Here is the key summary:

>

> 1. Reviewers in general agree with the authors about the need for human challenges to determine what protection is offered by current vaccines against the new strains.

> 2. However, the reviewers felt that the paper needs more discussion about how to do those studies. This paper is more like a public decision debate but not enough scientific and technical details to accomplish such challenge studies.

> 3. For example, can you extrapolate from monkey challenges to humans, as the authors suggest?

> 4. Does one need to challenge unvaccinated subjects to show infectivity? Do you then challenge current vaccinees with the same dose?

> 5. If they are resistant to the dose infectious for seronegatives, do you increase the challenge dose to determine how much current virus they can resist vs. mutant virus?

> 6. Is it necessary that the challenges be compared in people with the same titers, or can people with different titers be challenged?

> 7. Do we need to measure both IgA and IgG antibodies?

>

> The point here is that challenge studies must be done with a lot of insight so that the answers obtained are valid. By the way, people with high immunity will resist challenge with the mutants, but people with lower titers will not. So the protection is not a black and white with variants. Rather there is a quantitative range and different variants may be different, and may also depending on the individual vaccines. Therefore a small group of challenge studies may not truly reflect the population protection efficacy of a vaccine. It is the same idea that a lab based neutralizing assay can not predict the field vaccine protection. The authors need to be very careful not turning the small group challenge study into something like a lab based neutralizing assay.

From: TEMI-peerreview@journals.tandf.co.uk
Sent: Thursday, October 22, 2020 9:26 AM
To: ymwen@shmu.edu.cn; Lu, Shan
Cc: alexa.josaphouitch@taylorandfrancis.com
Subject: Article Transfer Service now live on your journal: finding the right home for all submitted works
#TrackingId:7534226

Dear Professor Wen & Professor Lu,

We're delighted to confirm that your journal is now using the Article Transfer Service. The service puts researchers first, helping authors **transfer rejected submissions to other suitable journals so they can publish important work quickly**. You, your reviewers, and Editorial Office team will continue to use your current peer review system, however there are some changes to be aware of during this transition.

Article transfers and Reject decisions

At the point you decide to reject an article from your journal, you will be given the opportunity to identify whether the manuscript may be suitable for publication elsewhere. You will therefore have two reject options:

- **Reject Unsound** – use this for unsound articles only; where the article in question should NOT be published e.g. because you have concerns over the method, research question or conclusions.
- **Reject Unsuitable** – for all articles that do not meet the editorial threshold of your journal or are out of scope, but appear to describe a valid research question, follow clear methodology and conclusions based on the results.

These options are not visible to authors; they will continue to receive a standard reject decision.

When you select the 'Reject Unsuitable' option, authors of these papers will be contacted with a selection of suitable alternative journals to consider. Articles transferred will go through peer review as normal by the journal receiving the submission via the transfer service.

For changes in full, please see our [FAQs](#).

Need further help?

There's more information on the [Article Transfer Service](#) on our Editor Resources website. For further assistance or support, don't hesitate to get in touch with us at: TEMI-peerreview@journals.tandf.co.uk

Best wishes,

Transfer Team at Taylor & Francis

From: Liu, Lin <lin.liu@okstate.edu>
Sent: Thursday, November 19, 2020 3:52 PM
To: 'Tang, Qiyi'; Liu, Shan-Lu; zhengt@exchange.nih.gov; haitguo@iupui.edu; tzhou@mail.nih.gov; GCheng@mednet.ucla.edu; liangy@umn.edu; rli@vcu.edu; wma@vet.kstate.edu; xjmeng@vt.edu; Zhijian.Chen@UTSouthwestern.edu; mluo@gsu.edu; zhangyj@umd.edu; xzhu1@umd.edu; jqu@kumc.edu; lijun@uic.edu; fengwei.bai@usm.edu; andyu@iupui.edu; reachxw@vt.edu; gluo@uab.edu; ldu@nybc.org; hxu@tulane.edu; liu_fy@berkeley.edu; shitao.li@okstate.edu; Lu, Shan; haihu@UTMB.edu; wenzheho@temple.edu; Qfeng4@central.uh.edu; tang@bio.fsu.edu; feng.li@sdsu.edu; ruilu@lsu.edu; sxian2@unl.edu; dingsw@ucr.edu; guohua@missouri.edu; bling@tulane.edu; junwang@pharmacy.arizona.edu; lifang@umn.edu; wang518@umd.edu; gaos8@upmc.edu; pewang@uchc.edu; xiangy@uthscsa.edu; fzhu@bio.fsu.edu; chen.liang@mcgill.ca; lyuan@vt.edu; fgao@duke.edu; wangjw28@163.com; xfyu1@zju.edu.cn; bzhao@partners.org; jianw@usc.edu; zyang@ksu.edu; yu.cong@nih.gov; weiming.yuan@usc.edu; Zongdi.feng@nationwidechildrens.org; juh13@psu.edu; hengx@missouri.edu; lsu@med.unc.edu; ywu8@gmu.edu; jwu@whu.edu.cn; tshuo@uic.edu; Shibojiang@fudan.edu.cn; sjiang@nybc.org; pinwang@usc.edu; rzhao@som.umaryland.edu; shuylong@mail.sysu.edu.cn; xuefeng.liu@georgetown.edu; yuxingli@som.umaryland.edu; Wang, Shixia; yhe@ipbcams.ac.cn; Pinghui.feng@usc.edu; jutao.guo@bblumberg.org; hua.zhu@rutgers.edu; Jinhong.chang@bblumberg.org; jianzhu1012@gmail.com; ronghai@ucr.edu; jun.zhu@nih.gov; jliu4@uams.edu; xiangpeng.kong@med.nyu.edu; haoquanwu@outlook.com; Wenjun.liu@defence.gov.au; Liang.shan@wustl.edu; hliao@duke.edu; Yuan, Yan; zxing@umn.edu; hongmin.li@health.ny.gov; pzheng@ihv.umaryland.edu; yaliu@ihv.umaryland.edu
Subject: Assistant Professor/Associate Professor/Professor position in Respiratory and Infectious Diseases
Attachments: Faculty Position-CVM-OCRID-2020-10.DOC

Good afternoon,

Anyone who is interested in the attached position can apply directly. We are still accepting applications. Feel free to contact me if you have any questions.

Best

Lin Liu

From: Perlman, Stanley <stanley-perlman@uiowa.edu>
Sent: Wednesday, July 15, 2020 10:28 PM
To: Lu, Shan
Subject: Automatic reply: Second ISV Virtual Congress; Presenter Acceptance

I am out of office with occasional email contact

From: wen yumei <ymwen@shmu.edu.cn>
Sent: Thursday, July 23, 2020 8:16 PM
To: Lu, Shan; 袁正宏; zhangwenhong; YiWei Tang; Winter999
Subject: Becker co-editors-in-chief
Attachments: Becker_CV 12 2019.pdf

Dear All

I think Becker is a good candidate for Co-editors-in-chief. Please respond within two days for your comment. Otherwise, Shan and I will invite him. YMWen

-----Original Messages-----

From: "Sabine Fischbach" <fischbach@staff.uni-marburg.de>
Sent Time: 2020-07-23 13:28:07 (Thursday)
To: "wen yumei" <ymwen@shmu.edu.cn>
Cc: shan.lu@umassmed.edu
Subject: CV - now attached

Dear Dr. Wen,

sorry – I forgot to send the document. Now it is attached.

Best regards
Sabine Fischbach

Von: Sabine Fischbach [mailto:fischbach@staff.uni-marburg.de]
Gesendet: Mittwoch, 22. Juli 2020 13:17
An: 'wen yumei' <ymwen@shmu.edu.cn>
Betreff: WG: co-editors in chief

Dear Dr. Wen,

Please find attached the CV of Dr. Stephan Becker.

Best regards
Sabine Fischbach

Von: Hans-Dieter Klenk [mailto:klenk@staff.uni-marburg.de]
Gesendet: Mittwoch, 22. Juli 2020 11:34
An: wen yumei <ymwen@shmu.edu.cn>
Cc: Lu_Shan <Shan.Lu@umassmed.edu>; YiWei Tang <yiweitangmd@gmail.com>; yuan zhenhong <zhyuan@shmu.edu.cn>; Winter999 <Winter999@hotmail.com>; zhangwenhong <zhangwenhong@fudan.edu.cn>; Sabine Fischbach <fischbach@staff.uni-marburg.de>
Betreff: Re: co-editors in chief

Dear Yu-mei,

The scientist I suggested as co-editor in chief is Stephan Becker who is my successor as director of the Marburg institute. He is an expert in emerging viruses and now also heavily engaged in COVID-19 research. His CV will follow.

Regards
Hans

Prof. Dr. Hans-Dieter Klenk
Institut für Virologie
Hans-Meerwein-Str. 2
35043 Marburg
Germany

Tel.: +49 6421 286 6191
Sek.: +49 6421 286 6254
Fax: +49 6421 286 8962
[E-Mail: klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)

Am 21.07.2020 um 02:45 schrieb wen yumei <ymwen@shmu.edu.cn>:

Hi, Hans.

We are still looking for an editor-in-chief for EMI from Europe. As mentined before, you suggested that one scientist from your institute might be a candidate. Due to your long term support and contriubtion to EMI, with your guidance,we would like to consider this candidate as one of the editors-in-chief. Would you please ask him, if he is willing to take this post, and send us his CV?

Thank you. Germany is great in participating combating COvVID-19. Regards,
Yu-mei

From: wen yumei <ymwen@shmu.edu.cn>
Sent: Monday, July 20, 2020 8:46 PM
To: hd.klenk; Klenk
Cc: Lu, Shan; YiWei Tang; yuan zhenhong; Winter999; zhangwenhong
Subject: co-editors in chief

Hi, Hans.

We are still looking for an editor-in-chief for EMI from Europe. As mentined before, you suggested that one scientist from your institute might be a candidate. Due to your long term support and contriubtion to EMI, with your guidance,we would like to consider this candidate as one of the editors-in-chief. Would you please ask him, if he is willing to take this post, and send us his CV?

Thank you. Germany is great in participating combating COvVID-19. Regards, Yu-mei

From: Min Yang <min.yang@emi2012.org>
Sent: Monday, May 4, 2020 10:50 AM
To: linfa.wang@duke-nus.edu.sg
Cc: TEMI-production@journals.tandf.co.uk; Lu, Shan
Subject: Copyright for your manuscript TEMI-2020-0499.R1

Dear Dr Wang,

Regarding your manuscript TEMI-2020-0499.R1, we would be appreciated if you could process and finish the copyright paperwork and the author review corrections soon as to avoid any delay in publication.

Please feel free to let me know if any questions.

Thanks and regards,

Min Yang

Emerging Microbes & Infections (EMI) Editorial Office
4F Fuxing Building
131 Dongan Road
Shanghai
China
Tel: 86-21-54237992
E-mail: min.yang@emi2012.org

From: Sabine Fischbach <fischbach@staff.uni-marburg.de>
Sent: Thursday, July 23, 2020 1:28 AM
To: 'wen yumei'
Cc: Lu, Shan
Subject: CV - now attached
Attachments: Becker_CV 12 2019.pdf

Dear Dr. Wen,

sorry – I forgot to send the document. Now it is attached.

Best regards
Sabine Fischbach

Von: Sabine Fischbach [<mailto:fischbach@staff.uni-marburg.de>]
Gesendet: Mittwoch, 22. Juli 2020 13:17
An: 'wen yumei' <ymwen@shmu.edu.cn>
Betreff: WG: co-editors in chief

Dear Dr. Wen,

Please find attached the CV of Dr. Stephan Becker.

Best regards
Sabine Fischbach

Von: Hans-Dieter Klenk [<mailto:klenk@staff.uni-marburg.de>]
Gesendet: Mittwoch, 22. Juli 2020 11:34
An: wen yumei <ymwen@shmu.edu.cn>
Cc: Lu_ Shan <Shan.Lu@umassmed.edu>; YiWei Tang <yiweitangmd@gmail.com>; yuan zhenhong <zhyuan@shmu.edu.cn>; Winter999 <Winter999@hotmail.com>; zhangwenhong <zhangwenhong@fudan.edu.cn>; Sabine Fischbach <fischbach@staff.uni-marburg.de>
Betreff: Re: co-editors in chief

Dear Yu-mei,

The scientist I suggested as co-editor in chief is Stephan Becker who is my successor as director of the Marburg institute. He is an expert in emerging viruses and now also heavily engaged in COVID-19 research. His CV will follow.

Regards
Hans

Prof. Dr. Hans-Dieter Klenk
Institut für Virologie
Hans-Meerwein-Str. 2
35043 Marburg

Germany

Tel.: +49 6421 286 6191

Sek.: +49 6421 286 6254

Fax: +49 6421 286 8962

E-Mail: klenk@staff.uni-marburg.de

Am 21.07.2020 um 02:45 schrieb wen yumei <ymwen@shmu.edu.cn>:

Hi, Hans.

We are still looking for an editor-in-chief for EMI from Europe. As mentined before, you suggested that one scientist from your institute might be a candidate. Due to your long term support and contriubtion to EMI, with your guidance,we would like to consider this candidate as one of the editors-in-chief. Would you please ask him, if he is willing to take this post, and send us his CV?

Thank you. Germany is great in participating combating COvVID-19. Regards,
Yu-mei

From: Cindi Callaghan <CindiCallaghan@isv-online.org>
Sent: Friday, February 12, 2021 10:39 AM
To: Adolfo Garcia-Sastre; Adrian Hill; Alan D. T. Barrett; Anna-Lise Williamson; Annie De Groot; Britta Wahren; Clarisa Palatnik de Sousa; Connie Schmaljohn; David Weiner; Denise Doolan; Dennis Klinman; Emilio A. Emini; Frederic Tangy; Gary Kobinger; Indresh Srivastava; Jeffrey Ulmer (ulmerjeffrey@gmail.com); John Oxford; johnwshiver@gmail.com; Joon Haeng Rhee; Kathrin Jansen; Ken J. Ishii; Lars Frelin; Lenny Moise; Linda Klavinskis; Manon Cox; Marc Girard; Margaret Liu; Marie-Paule Kieny; Mark K. Slifka; Matthias Schnell; Myron M. Levine; Nathalie Garçon; Paul Offit; Paul-Henri Lambert; Peter Nara; Peter Palese; Punnee Pitisuttithum; Rafi Ahmed; 'Randy Albrecht'; Rino Rappuoli; Ronald Ellis; Lu, Shan; Stanley A. Plotkin; Ted Ross; Xavier Saelens; Yu-Mei Wen
Cc: Cindi Callaghan
Subject: Deadline TODAY: Voting is open for 2020 ISV Papers of the Year

A reminder that the deadline to vote is TODAY! Thank you to those who have already voted.

From: Cindi Callaghan
Sent: Saturday, February 6, 2021 12:44 PM
Subject: Voting is open for 2020 ISV Papers of the Year

Dear ISV Fellows and ISV Board,

We are pleased to present the nominations for 2020 ISV Papers of the Year for your consideration. Nominations were made in two categories: COVID-19 and non-COVID-19. Thank you to those who submitted nominations.

In recognition of the vaccine community's remarkable response to COVID-19, several papers were nominated. Vote for up to 20 COVID-19 papers. In the non-COVID-19 category, vote for one paper only.

Click on the following link to vote: <https://www.surveymonkey.com/r/FXW3VWB>

The poll closes on Friday, February 12 at 11:59 PM ET.

We look forward to your participation.

Sincerely,

Ted Ross
ISV President

Lenny Moise
ISV Outreach Committee Chair



From: shibojiang@fudan.edu.cn
Sent: Thursday, January 23, 2020 4:10 AM
To: Lu, Shan
Cc: 杨旻 EMI
Subject: Dr. Zhengli Shi's accession no provided
Attachments: Jiang S_Commentary_2019-nCoV_EMI_TEMI-2020-0055_rev.pdf; Figure 1_2019-nCoV_commentary_EMI_20200118.pptx

Dear Shan,

Dr. Zhengli Shi put her accession no in the commentary so that Dr. Yongzheng Zhang cannot complain to us. Is it possible to ask the publisher to replace the original one with one before online publication.

In addition, Dr. Shi agreed to provide KY the permission if he wants.

Thanks,

Shibo

From: Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>
Sent: Saturday, January 11, 2020 11:49 PM
To: Shi Zhengli; Guo Deyin; Du Lanying_NYBC
Cc: Lu, Shan
Subject: Emerging and Re-emerging CoV-introduction-20200111
Attachments: Editorial_WARS-CoV_EMI_20200112.docx

Dear Drs. Shi, Guo and Du,

EMI has assembled a special issue entitled "Emerging and Re-emerging Coronaviruses". As the Guest Editor for this special issue, I invite you to contribute research or review articles related to the "Wuhan coronavirus" to this special issue in the future.

Now I am going to write an Editorial about "Wuhan coronavirus" (about 2500-3000 words). I invite you to write a few paragraphs related to the topic of your expertise for this Editorial (the the outline of the manuscript attached). Each of us can write 800-1000 words. I will assemble them together and finalize the manuscript.

If you agree, please write it as soon as possible. I plan to submit it before next weekend.

Thank you very much for your consideration,

Shibo

Emerging and Re-emerging Coronaviruses
Guest Editor: Shibo Jiang (Fudan University, China)

Emerging and re-emerging coronaviruses, including Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and the latest "Wuhan Coronavirus", may cause epidemics or potentially pandemics of highly pathogenic human infectious diseases, posing great threats to the global health. EMI Special Topic - Emerging and Re-emerging Coronaviruses covers research and review articles on the basic, translational and clinical studies related to these coronaviruses.

From: Emerging Microbes and Infections <onbehalf@manuscriptcentral.com>
Sent: Thursday, April 23, 2020 9:22 AM
To: ymw@shmu.edu.cn
Cc: Lu, Shan; yi-wei.tang@cepheid.com
Subject: Emerging Microbes & Infections - Invitation to Review Manuscript ID TEMI-2020-0643

23-Apr-2020

Dear Yu-Mei Wen:

The above manuscript, entitled "Dynamic surveillance of SARS-CoV-2 shedding in children with COVID-19" has been submitted to Emerging Microbes & Infections.

I would be grateful if you would kindly agree to act as a reviewer for this paper. The abstract appears at the end of this letter.

Please let me know as soon as possible if you will be able to accept my invitation to review. To do this please either click the appropriate link below to automatically register your reply with our online manuscript submission and review system, or e-mail me with your reply.

*** PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a webpage to confirm. ***

Agreed:

https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fmc.manuscriptcentral.com%2Ftemi%3FURL_MASK%3D5eda7c3dad3944d0b98ad5198c40dddc&data=02%7C01%7CShan.Lu%40umassmed.edu%7Ce7092cc888b84eea3ede08d7e789556a%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637232449356496015&sdata=uiyTq%2FjBlQ9FivUF4Q5KwDYm1%2FHVOq8ijjnWmjMC68o%3D&reserved=0

Declined:

https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fmc.manuscriptcentral.com%2Ftemi%3FURL_MASK%3Dcfe33be9175d4bfc9f35ae87dd36f3f4&data=02%7C01%7CShan.Lu%40umassmed.edu%7Ce7092cc888b84eea3ede08d7e789556a%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637232449356496015&sdata=PbEUghynOLPBju%2F5Yf4rR6nsY7wBWlXuPb%2F75d1fUsl%3D&reserved=0

Unavailable:

https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fmc.manuscriptcentral.com%2Ftemi%3FURL_MASK%3D19eca91590834ec982cf1fa57c87cfe4&data=02%7C01%7CShan.Lu%40umassmed.edu%7Ce7092cc888b84eea3ede08d7e789556a%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637232449356496015&sdata=6Y0RlGYp0SjleX0j%2BmF77xNDq92Q59%2BAd1MLFzSj84g%3D&reserved=0

Should you accept my invitation to review this manuscript, you will be sent an email with a direct link to the scoresheet, which will be made available to you. You will then have access to the manuscript and reviewer instructions in your Reviewer Center.

If you are unable to review the manuscript, click on the "decline" option to register your response. This will direct you to a screen where you will be given the opportunity to provide details of any alternative reviewers.

I realise that our expert reviewers greatly contribute to the high standards of the Journal, and I thank you for your present and/or future participation.

Sincerely,
Dr Yi-Wei Tang
Emerging Microbes & Infections

MANUSCRIPT DETAILS

TITLE: Dynamic surveillance of SARS-CoV-2 shedding in children with COVID-19

AUTHORS: Dr Pengcheng Liu

ABSTRACT: NONE as this is a letter.

From: Dr. Johannes Möst <jm@mb-lab.com>
Sent: Monday, June 15, 2020 11:57 AM
To: ymw@shmu.edu.cn; Lu, Shan
Cc: editorial@emi2012.org
Subject: Emerging Microbes & Infections, Manuscript ID TEMI-2020-0796
Attachments: TEMI-2020-0796_Proof_hi.pdf

Dear editors,

I am one of the senior authors of a manuscript (Antibody kinetics in primary- and secondary-care physicians with mild to moderate SARS-CoV-2 infection by D. Orth-Höller et al.) that was submitted almost six weeks ago for possible publication as a Letter in Emerging Microbes & Infections. One reason for submitting our work to your journal was that we expected (or at least hoped for) a rapid decision. I am aware of the actual huge workload for editors and reviewers. Nevertheless I am surprised (and to be honest, I consider it a bit unfair) that it takes that long to review a letter of just a few pages. Several articles dealing with Covid-19 and recently published in your journal were accepted within a few weeks.

May I kindly ask you to tell me whether there is something wrong with our letter? And whether it could take still much longer for a decision?

Given the enormous speed and the huge amount of submissions and publications for studies concerning SARS-CoV-2, the chances for publication in a prestigious journal like Emerging Microbes & Infections are going down with every week passing by.

Thank you for your understanding.

Best regards,

Johannes Möst, Assoc.-Prof., MD

--

Univ.-Doz. Dr. Johannes Möst

Mikrobiologisches Labor

Franz-Fischer-Straße 7b

6020 Innsbruck

Tel.: +43 (0)512-563380

FAX: +43 (0)512-563380-40

<https://nam01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.mb-lab.com%2F&data=02%7C01%7Cshan.lu%40umassmed.edu%7Cc9009f860a4a49ef10a208d81144c5ed%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C1%7C637278334530620344&sdata=X0uiuijabk9%2BTjYonjv9tK2o%2FIprEarzwUqPIFEjMyE%3D&reserved=0>

From: Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>
Sent: Saturday, January 18, 2020 3:25 AM
To: Lu, Shan
Cc: Yang Min 杨旻; min.yang@emi2012.org; Shi Zhengli; Du Lanying_NYBC
Subject: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online
Attachments: Jiang S_Commentary_2019-nCoV_EMI_TEMI-2020-0055.pdf

Dear Prof. Lu,

Per your request, I just submitted the invited Commentary to EMI online (see the attachment). During the submission, I accidentally put in the contact information of Drs. Lu Lu and Shuai Xia (my postdoc), rather than Drs. Shi and Du, into the authors' list. I thus immediately called Min about the possibility of withdrawing and resubmitting the manuscript. Min told me that I would not have to withdraw the manuscript since the authors' information in the manuscript is correct, but I would have to inform Drs. Lu and Xia that they may receive the email from EMI about this manuscript. I informed them already.

I will cite Prof. Yuen's paper once the citation information is available during the proof-reading stage.

Thank you very much for your consideration,

Shibo

-----原始邮件-----

发件人: "Emerging Microbes and Infections" <onbehalf@manuscriptcentral.com>
发送时间: 2020-01-18 15:21:06 (星期六)
收件人: shibojiang@fudan.edu.cn
抄送: shibojiang@fudan.edu.cn
主题: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

18-Jan-2020

Dear Professor Jiang:

Your manuscript entitled "An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies" has been successfully submitted online and is presently being given full consideration for publication in Emerging Microbes & Infections.

Your manuscript ID is TEMI-2020-0055.

Please mention the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your street address or e-mail address, please log in to ScholarOne Manuscripts at <https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fmc.manuscriptcentral.com%2Ftemi&data=02%7C01%7Cshan.lu%40umassmed.edu%7C5bf67dcea80543172df308d79beffa7f%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C637149327594484021&sdata=q3fFDQyJZmoHlceFvohL5YzdF2gO11sHHBts3o6gm3l%3D&r eserved=0> and edit your user information as appropriate.

You can also view the status of your manuscript at any time by checking your Author Center after logging in to <https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fmc.manuscriptcentral.com%2Ftemi&data=02%7C01%7Cshan.lu%40umassmed.edu%7C5bf67dcea80543172df308d79beffa7f%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637149327594484021&sdata=q3fFDQyJZmoHlceFvohL5YzdF2gO11sHHBts3o6gm3I%3D&r eserved=0>.

Thank you for submitting your manuscript to Emerging Microbes & Infections.

Sincerely,
Emerging Microbes & Infections Editorial Office

From: Min Yang <min.yang@emi2012.org>
Sent: Thursday, December 12, 2019 2:09 AM
To: wen yumei; Lu, Shan; yuanzhenghong; Tang, Yi-Wei; yiweitangmd@gmail.com; Martin martin; Emily
Cc: Editorial Office
Subject: EMI 12/15 Lunch Meeting

Dear All EMI Leaders, Min Yu and other EMI colleagues,

Thank you very much for attending EMI 12/15 Lunch Meeting, please check and confirm the following information.

What: EMI 12/15 Lunch Meeting

Where: Shanghai Min(上海小南国). 5F, Junyaoguoji Plaza, No.798, Zhaojiabang Rd, Xuhui District, Shanghai.

When: 12:00 noon, December 15, 2019.

Contact: Yang Min 13817220577

Should you have any questions, please feel free to let me know.

Thanks and regards,

Min Yang

Emerging Microbes & Infections (EMI) Editorial Office
4F Fuxing Building
131 Dongan Road
Shanghai
China
Tel: 86-21-54237992
E-mail: editorial@emi2012.org

From: Josaphouitch, Alexa <Alexa.Josaphouitch@taylorandfrancis.com>
Sent: Tuesday, February 11, 2020 7:02 AM
To: hexijun@caas.cn; buzhighao@caas.cn
Cc: editorial@emi2012.org; wen yumei; Lu, Shan; min.yang@emi2012.org
Subject: EMI 2019 Best Paper Award - First Place
Attachments: 2019 Best Paper_first place.pdf

Dear Dongming Zhao, Renqiang Liu, Xianfeng Zhang, Fang Li, Jingfei Wang, Jiwen Zhang, Xing Liu, Lulu Wang, Jiaoer Zhang, Xinzhou Wu, Yuntao Guan, Weiye Chen, Xijun Wang, Xijun He & Zhigao Bu,

On behalf of Editors-in-Chief, Yu-Mei Wen and Shan Lu, EMI and Taylor & Francis, we would like to congratulate you on winning first place for *Emerging Microbes & Infections* 2019 Best Papers Award for the paper entitled "Replication and virulence in pigs of the first African swine fever virus isolated in China."

EMI made this decision based on the fact that your paper is a timely report with thorough molecular virology work to isolate the pathogen which caused the outbreak of African Swine Fever Virus in China.

In addition to the attached certificate, a link on the journal's homepage will be included to [celebrate the news](#). The first-place winner also receives 1,000 USD. Please contact Alexa Josaphouitch, alexa.jo@taylorandfrancis.com, for more details about the monetary award.

Thank you and congratulations on your achievement!

Sincerely,

Alexa Josaphouitch

Portfolio Manager for Hematology and Immunology Journals

Taylor & Francis Group

530 Walnut Street, Suite 850, Philadelphia, PA 19106

Tel: (215) 606-4170

Fax: (215) 207-0050

Email: alexa.josaphouitch@taylorandfrancis.com

Web: www.tandfonline.com

(she/her/hers)

Information Classification: General

From: Josaphouitch, Alexa <Alexa.Josaphouitch@taylorandfrancis.com>
Sent: Tuesday, February 11, 2020 7:02 AM
To: e.devilliers@dkfz.de
Cc: editorial@emi2012.org; Lu, Shan; wen yumei; min.yang@emi2012.org
Subject: EMI 2019 Best Paper Award - Third Place
Attachments: 2019 Best Paper_third place_de Villiers.pdf

Dear Ethel-Michele de Villiers, Karin Gunst, Deblina Chakraborty, Claudia Ernst, Timo Bund & Harald zur Hausen,

On behalf of Editors-in-Chief, Yu-Mei Wen and Shan Lu, EMI and Taylor & Francis, we would like to congratulate you on winning third place for *Emerging Microbes & Infections* 2019 Best Papers Award for the paper entitled "A specific class of infectious agents isolated from bovine serum and dairy products and peritumoral colon cancer tissue."

EMI made this decision based on the fact that your paper is a novel report with out-of-box thinking and potential major health impact.

In addition to the attached certificate, a link on the journal's homepage will be included to [celebrate the news](#). The third-place winner also receives 250 USD. Please contact Alexa Josaphouitch, alexa.jo@taylorandfrancis.com, for more details about the monetary award.

Thank you and congratulations on your achievement!

Sincerely,

Alexa Josaphouitch

Portfolio Manager for Hematology and Immunology Journals

Taylor & Francis Group

530 Walnut Street, Suite 850, Philadelphia, PA 19106

Tel: (215) 606-4170

Fax: (215) 207-0050

Email: alexa.josaphouitch@taylorandfrancis.com

Web: www.tandfonline.com

(she/her/hers)

Information Classification: General

From: Josaphouitch, Alexa <Alexa.Josaphouitch@taylorandfrancis.com>
Sent: Tuesday, February 11, 2020 7:02 AM
To: jlr54@psu.edu
Cc: editorial@emi2012.org; wen yumei; Lu, Shan; min.yang@emi2012.org
Subject: EMI 2019 Best Paper Awards - Second Place
Attachments: 2019 Best Paper_second place.pdf

Dear Sujit Pujhari, Marco Brustolin, Vanessa M. Macias, Ruth H. Nissly, Masashi Nomura, Suresh V. Kuchipudi & Jason L. Rasgon,

On behalf of Editors-in-Chief, Yu-Mei Wen and Shan Lu, EMI and Taylor & Francis, we would like to congratulate you on winning second place for *Emerging Microbes & Infections* 2019 Best Papers Award for the paper entitled "Heat shock protein 70 (Hsp70) mediates Zika virus entry, replication, and egress from host cells."

EMI made this decision based on the fact that your paper is a key report to identify Hsp70 as a major player in Zika virus infection.

In addition to the attached certificate, a link on the journal's homepage will be included to [celebrate the news](#). The second-place winner also receives 500 USD. Please contact Alexa Josaphouitch, alexa.jo@taylorandfrancis.com, for more details about the monetary award.

Thank you and congratulations on your achievement!

Sincerely,

Alexa Josaphouitch

Portfolio Manager for Hematology and Immunology Journals

Taylor & Francis Group

530 Walnut Street, Suite 850, Philadelphia, PA 19106

Tel: (215) 606-4170

Fax: (215) 207-0050

Email: alexa.josaphouitch@taylorandfrancis.com

Web: www.tandfonline.com

(she/her/hers)

Information Classification: General

From: Josaphouitch, Alexa <Alexa.Josaphouitch@taylorandfrancis.com>
Sent: Tuesday, February 11, 2020 7:02 AM
To: wqzeng@visionmedicals.com; zhangwenhong@fudan.edu.cn
Cc: editorial@emi2012.org; wen yumei; Lu, Shan; min.yang@emi2012.org
Subject: EMI 2019 Best Paper Awards - Third Place
Attachments: 2019 Best Paper_third place_Ai.pdf

Dear Jing-Wen Ai, Xian Zhou, Teng Xu, Minling Yang, Yuanyuan Chen, Gui-Qing He, Ningp Pan, Yuwei Cai, Yongjun Li, Xiaorui Wang, Hang Su, Ting Wang, Weiqi Zeng & Wen-Hong Zhang,

On behalf of Editors-in-Chief, Yu-Mei Wen and Shan Lu, EMI and Taylor & Francis, we would like to congratulate you on winning third place for *Emerging Microbes & Infections* 2019 Best Papers Award for the paper entitled "CRISPR-based rapid and ultra-sensitive diagnostic test for Mycobacterium tuberculosis."

EMI made this decision based on the fact that your paper is a highly novel and potentially useful approach to diagnose TB infection.

In addition to the attached certificate, a link on the journal's homepage will be included to [celebrate the news](#). The third-place winner also receives 250 USD. Please contact Alexa Josaphouitch, alexa.jo@taylorandfrancis.com, for more details about the monetary award.

Thank you and congratulations on your achievement!

Sincerely,

Alexa Josaphouitch

Portfolio Manager for Hematology and Immunology Journals

Taylor & Francis Group

530 Walnut Street, Suite 850, Philadelphia, PA 19106

Tel: (215) 606-4170

Fax: (215) 207-0050

Email: alexa.josaphouitch@taylorandfrancis.com

Web: www.tandfonline.com

(she/her/hers)

Information Classification: General

From: Liu, Shan-Lu <liu.6244@osu.edu>
Sent: Wednesday, February 12, 2020 9:58 PM
To: Su, Lishan; Saif, Linda; Weiss, Susan
Cc: min.yang@emi2012.org; Lu, Shan
Subject: EMI commentary
Attachments: EMI_Commentary_submitted.pdf

Dear all,

I have just submitted a commentary to EMI. See attached the submitted version.

Thank you.

Shan-Lu



Shan-Lu Liu, M.D., Ph.D.
Professor
Co-Director, Viruses and Emerging Pathogens Program
Infectious Diseases Institute
Center for Retrovirus Research
Departments of Veterinary Biosciences, Microbial Infection and Immunity, and Microbiology
The Ohio State University
1900 Coffey Rd, Room 480 VMAB
Columbus, Ohio 43210
Phone: (614) 292-8690
Fax: (614) 292-6473
Email: liu.6244@osu.edu; shan-lu.liu@osumc.edu

From: Liu, Shan-Lu <liu.6244@osu.edu>
Sent: Wednesday, February 12, 2020 5:13 PM
To: Lu, Shan
Cc: Su, Lishan; Saif, Linda; Weiss, Susan
Subject: EMI commentary
Attachments: EMI-2019-nCoV_Commentary_Final for submission .docx

Hi Shan,

Attached please find the final version of the commentary for your consideration to be published at EMI.

Kindly advise.

Regards.

Shan-Lu

From: 102459053 <102459053@qq.com>
Sent: Saturday, July 4, 2020 3:36 AM
To: Teacher Wen; Lu, Shan; Wenhong; zhyuan
Subject: EMI financial report
Attachments: 2019 Shangyixun's annual expenses-new.xlsx; 2020 annual accounts (1).xlsx

Teacher Wen and everyone,

Attached are the financial statements of EMI2019 for the whole year and the first half of 2020. Please pass them through, and I will report to them at the meeting tomorrow.
Xiaodong

From: Min Yang <min.yang@emi2012.org>
Sent: Friday, July 3, 2020 10:02 PM
To: wen yumei; Lu, Shan; yuanzhenghong; yuan zhenghong; ZhangWenhong; Tang, Yi-Wei; Martin martin
Cc: xinyi
Subject: EMI Founders Virtual Meeting Invitation

Dear EMI Leaders,

Below please find the login details for the upcoming EMI Founders Virtual Meeting.

Time: 2020-07-5 10:00-12:00 (Beijing time)
2020-07-4 22:00-24:00 (US ET)

Zoom Meeting ID: 1774415303

Link to the meeting: <https://huawan.zoomus.cn/j/1774415303>

Please confirm the receipt and feel free to contact me if you have any questions.

Thanks and regards,

Min Yang

Emerging Microbes & Infections (EMI) Editorial Office
4F Fuxing Building
131 Dongan Road
Shanghai
China
Tel: 86-21-54237992
E-mail: min.yang@emi2012.org

From: Guanghua Huang <huanggh@fudan.edu.cn>
Sent: Wednesday, November 13, 2019 2:51 AM
To: Lu, Shan
Cc: ymwen@shmu.edu.cn
Subject: EMI presubmission enquiry
Attachments: presubmission enquiry-EMI-liang et al2019.pdf

Dear Profs. Lu and Wen,

I am writing to inquire if our manuscript (see the attached file) is fit for the scope of EMI. To our knowledge, this is the first study to uncover the genetic regulatory mechanism of mating projection development in the major human fungal pathogen *Candida albicans*. This biology process is important for sexual reproduction in *C. albicans* and is thus important for the development of antifungal resistance and the evolution of new traits.

Thank you in advance for your consideration!

Best regards,
Guanghua

Guanghua Huang, Ph.D
State Key Laboratory of Genetic Engineering
School of Life Sciences
Fudan University

From: Min Yang <min.yang@emi2012.org>
Sent: Tuesday, October 20, 2020 10:05 AM
To: wen yumei; Lu, Shan; yuan zhenghong; ZhangWenhong; Tang, Yi-Wei
Subject: EMI Q3 Most Read Paper Selection-due on 28 October 2020
Attachments: EMI 2020 Q3 Publication-20201009.xlsx

Dear All EMI Founders,

Recently, we are updating EMI's most read recent articles' list for the 3rd quarter, in that case, could you please check the attached EMI publication list for Q3 and tick the 5 articles you would like to select no later than 28 October 20, 2020?

Thank you for your time and please do not hesitate to let me know if you have any questions.

Thanks and regards,

Min Yang

Emerging Microbes & Infections (EMI) Editorial Office
4F Fuxing Building
131 Dongan Road
Shanghai
China
Tel: 86-21-54237992
E-mail: min.yang@emi2012.org

From: xinyi <1563993396@qq.com>
Sent: Tuesday, December 29, 2020 11:43 PM
To: wen yumei
Cc: zhangwenhong; Winter999; Lu, Shan; Min Yang 杨旻
Subject: EMI symposium poster
Attachments: POSTER.jpg

Importance: High

Dear Prof Wen,
The attchment is for your information.

Thanks

Best Regards,
Xinyi

----- 原始邮件 -----

发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>;
发送时间: 2020 年 12 月 28 日(星期一) 晚上 11:53
收件人: "wen yumei" <ymwen@shmu.edu.cn>; "xinyi" <1563993396@qq.com>;
抄送: "zhangwenhong" <zhangwenhong@fudan.edu.cn>; "Winter999" <Winter999@hotmail.com>;
主题: RE: 回复 : RE: EMI symposium

Yes, it was a draft and was hoping to get your formal version. Now it will be updated.

From: wen yumei <ymwen@shmu.edu.cn>
Sent: Monday, December 28, 2020 7:16 AM
To: xinyi <1563993396@qq.com>
Cc: zhangwenhong <zhangwenhong@fudan.edu.cn>; Winter999 <Winter999@hotmail.com>; Lu, Shan <Shan.Lu@umassmed.edu>
Subject: Re: 回复 : RE: EMI symposium

Please note, I am from Fudan University, Shanghai Medical College. It was not correctly stated. YM Wen

-----Original Messages-----

From: xinyi <1563993396@qq.com>
Sent Time: 2020-12-28 11:46:20 (Monday)
To: "wen yumei" <ymwen@shmu.edu.cn>
Cc: zhangwenhong <zhangwenhong@fudan.edu.cn>, Winter999 <Winter999@hotmail.com>, "Lu, Shan"

<Shan.Lu@umassmed.edu>

Subject: 回复: RE: EMI symposium

Prof. Wen,

Attachment is EMI symposium program, please review.

Thanks.

Best Regards,

Xinyi

----- 原始邮件 -----

发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>;

发送时间: 2020 年 12 月 24 日(星期四) 晚上 9:15

收件人: "wen yumei" <ymwen@shmu.edu.cn>;

抄送: "zhangwenhong" <zhangwenhong@fudan.edu.cn>; "Winter999" <Winter999@hotmail.com>; "xinyi" <1563993396@qq.com>;

主题: RE: EMI symposium

Thanks, Prof Wen.

Xinyi from Xiaodong's group will follow up with you to arrange the recording of your opening remarks (no more than 5 min). We will send you the official program soon for your ref.

Also, please let us know if you have a photo that we can use.

Best.

Shan

From: wen yumei <ymwen@shmu.edu.cn>
Sent: Thursday, December 24, 2020 1:34 AM
To: Lu, Shan <Shan.Lu@umassmed.edu>
Subject: Re: EMI symposium

Very good suggestion. I like it. YM Wen

Beisdes, please ask min Yang to send out seasons greetings to our oversea editorial board members.. Wen

-----Original Messages-----

From: "Lu, Shan" <Shan.Lu@umassmed.edu>
Sent Time: 2020-12-23 23:58:34 (Wednesday)
To: "M. Yu-Mei Wen (ymwen@shmu.edu.cn)" <ymwen@shmu.edu.cn>
Cc: zhangwenhong <zhangwenhong@fudan.edu.cn>, "袁正宏" <Zhyuan@shmu.edu.cn>, zhangwenhong <zhangwenhong@fudan.edu.cn>, "Tang, Yi-Wei" <yi-wei.tang@cepheid.com>, Winter999 <Winter999@hotmail.com>
Subject: EMI symposium

Dear Prof Wen and others,

Wenhong and Xiaodong approached me last week about their plan to organize a new year symposium by their group, and suggested to work with EMI together.

I think this is a good idea since we have been thinking organizing an EMI conference for a few years but never make it. This can be a good start with the online conference.

After further discussion with Wenhong and Xiaodong, we prepared a draft invitation to potential speakers (see attached). It is scheduled on Jan 10 to give a summary and future outlook of COVID-19.

It will be a small group of leading experts (about 6 people or so) and their talks will be pre-recorded. Then we can put them together as one full symposium. Prof Wen should give a short opening remark to start the symposium.

We are reaching out to potential speakers. Once we have the responses, a formal program can be prepared.

Please let me, Wenhong and Xiaodong know your advice and comment so we can finalize the plan.

Thanks.

Shan

From: xinyi <1563993396@qq.com>
Sent: Wednesday, December 30, 2020 10:33 PM
To: wen yumei
Cc: zhangwenhong; Winter999; Lu, Shan; Min Yang 杨旻
Subject: EMI symposium Video recording guide
Attachments: EMI Symposium 嘉宾演讲视频录制指南 2020-12-31.pdf

Dear Prof Wen,

The attachment is Video recording guide, please review it. Thanks.

And wishing you health, joy and happiness through the coming year !

Best Regards,
Xinyi

----- 原始邮件 -----

发件人: "xinyi " <1563993396@qq.com>;
发送时间: 2020 年 12 月 30 日(星期三) 中午 12:42
收件人: "wen yumei" <ymwen@shmu.edu.cn>;
抄送: "zhangwenhong" <zhangwenhong@fudan.edu.cn>; "Winter999" <Winter999@hotmail.com>; "Lu, Shan" <Shan.Lu@umassmed.edu>; "Min Yang 杨旻" <min.yang@emi2012.org>;
主题: EMI symposium poster

Dear Prof Wen,
The attchment is for your information.

Thanks

Best Regards,
Xinyi

----- 原始邮件 -----

发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>;
发送时间: 2020 年 12 月 28 日(星期一) 晚上 11:53
收件人: "wen yumei" <ymwen@shmu.edu.cn>; "xinyi " <1563993396@qq.com>;
抄送: "zhangwenhong" <zhangwenhong@fudan.edu.cn>; "Winter999" <Winter999@hotmail.com>;
主题: RE: 回复 : RE: EMI symposium

Yes, it was a draft and was hoping to get your formal version. Now it will be updated.

From: wen yumei <ymwen@shmu.edu.cn>
Sent: Monday, December 28, 2020 7:16 AM
To: xinyi <1563993396@qq.com>
Cc: zhangwenhong <zhangwenhong@fudan.edu.cn>; Winter999 <Winter999@hotmail.com>; Lu, Shan <Shan.Lu@umassmed.edu>
Subject: Re: 回复 : RE: EMI symposium

Please note, I am from Fudan University, Shanghai Medical College. It was not correctly stated. YM Wen

-----Original Messages-----

From:xinyi <1563993396@qq.com>
Sent Time:2020-12-28 11:46:20 (Monday)
To: "wen yumei" <ymwen@shmu.edu.cn>
Cc: zhangwenhong <zhangwenhong@fudan.edu.cn>, Winter999 <Winter999@hotmail.com>, "Lu, Shan" <Shan.Lu@umassmed.edu>
Subject: 回复: RE: EMI symposium

Prof. Wen,

Attachment is EMI symposium program, please review.

Thanks.

Best Regards,

Xinyi

----- 原始邮件 -----

发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>;

发送时间: 2020 年 12 月 24 日(星期四) 晚上 9:15

收件人: "wen yumei" <ymwen@shmu.edu.cn>;

抄送: "zhangwenhong" <zhangwenhong@fudan.edu.cn>; "Winter999" <Winter999@hotmail.com>; "xinyi" <1563993396@qq.com>;

主题: RE: EMI symposium

Thanks, Prof Wen.

Xinyi from Xiaodong's group will follow up with you to arrange the recording of your opening remarks (no more than 5 min). We will send you the official program soon for your ref.

Also, please let us know if you have a photo that we can use.

Best.

Shan

From: wen yumei <ymwen@shmu.edu.cn>
Sent: Thursday, December 24, 2020 1:34 AM
To: Lu, Shan <Shan.Lu@umassmed.edu>
Subject: Re: EMI symposium

Very good suggestion. I like it. YM Wen

Beisdes, please ask min Yang to send out seasons greetings to our oversea editorial board members.. Wen

-----Original Messages-----

From: "Lu, Shan" <Shan.Lu@umassmed.edu>
Sent Time: 2020-12-23 23:58:34 (Wednesday)
To: "M. Yu-Mei Wen (ymwen@shmu.edu.cn)" <ymwen@shmu.edu.cn>
Cc: zhangwenhong <zhangwenhong@fudan.edu.cn>, "袁正宏" <Zhyuan@shmu.edu.cn>, zhangwenhong <zhangwenhong@fudan.edu.cn>, "Tang, Yi-Wei" <yi-wei.tang@cepheid.com>, Winter999 <Winter999@hotmail.com>
Subject: EMI symposium

Dear Prof Wen and others,

Wenhong and Xiaodong approached me last week about their plan to organize a new year symposium by their group, and suggested to work with EMI together.

I think this is a good idea since we have been thinking organizing an EMI conference for a few years but never make it. This can be a good start with the online conference.

After further discussion with Wenhong and Xiaodong, we prepared a draft invitation to potential speakers (see attached). It is scheduled on Jan 10 to give a summary and future outlook of COVID-19.

It will be a small group of leading experts (about 6 people or so) and their talks will be pre-recorded. Then we can put them together as one full symposium. Prof Wen should give a short opening remark to start the symposium.

We are reaching out to potential speakers. Once we have the responses, a formal program can be prepared.

Please let me, Wenhong and Xiaodong know your advice and comment so we can finalize the plan.

Thanks.

Shan

From: Josaphouitch, Alexa <Alexa.Josaphouitch@taylorandfrancis.com>
Sent: Tuesday, February 23, 2021 2:31 PM
To: zlshi@wh.iov.cn; peng.zhou@wh.iov.cn
Cc: editorial@emi2012.org; Lu, Shan; M. Yu-Mei Wen (ymwen@shmu.edu.cn); 'Min Yang'
Subject: EMI's 2020 Best Paper Award - Second Place
Attachments: 2020 Best Paper_second place.pdf

Dear Wei Zhang, Rong-Hui Du, Bei Li, Xiao-Shuang Zheng, Xing-Lou Yang, Ben Hu, Yan-Yi Wang, Geng-Fu Xiao, Bing Yan, Zheng-Li Shi & Peng Zhou,

On behalf of Editors-in-Chief, Yu-Mei Wen and Shan Lu, EMI and Taylor & Francis, we would like to congratulate you on winning second place for *Emerging Microbes & Infections* 2020 Best Paper Award for the paper entitled, "Molecular and serological investigation of 2019-nCoV infected patients: Implication of multiple shedding routes."

EMI made this decision based on the fact that your paper is the first report from Wuhan to show the SARS-CoV-2 specific IgM and IgG responses in patients' sera and the detection of SARS-CoV-2 virus in GI track.

In addition to the attached certificate, a link on the journal's homepage will be included to [celebrate the news](#). The second-place winner also receives 500 USD. Please contact Alexa Josaphouitch, alexa.jo@taylorandfrancis.com, for more details about the monetary award.

Thank you and congratulations on your achievement!

Sincerely,

Alexa Josaphouitch

Portfolio Manager for Hematology and Immunology Journals

Taylor & Francis Group

530 Walnut Street, Suite 850, Philadelphia, PA 19106


Tel: (212) 600-3459

Fax: (215) 207-0050

Email: alexa.josaphouitch@taylorandfrancis.com

Web: www.tandfonline.com

(she/her/hers)



Information Classification: General

From: Josaphouitch, Alexa <Alexa.Josaphouitch@taylorandfrancis.com>
Sent: Tuesday, February 23, 2021 2:31 PM
To: khkok@hku.hk; kyyuen@hku.hk
Cc: editorial@emi2012.org; Lu, Shan; M. Yu-Mei Wen (ymwen@shmu.edu.cn); 'Min Yang'
Subject: EMI's 2020 Best Paper Award - First Place
Attachments: 2020 Best Paper_first place.pdf

Dear Jasper Fuk-Woo Chan, Kin-Hang Kok, Zheng Zhu, Hin Chu, Kelvin Kai-Wang To, Shuofeng Yuan & Kwok-Yung Yuen,

On behalf of Editors-in-Chief, Yu-Mei Wen and Shan Lu, EMI and Taylor & Francis, we would like to congratulate you on winning first place for *Emerging Microbes & Infections* 2020 Best Paper Award for the paper entitled, "Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan."

EMI made this decision based on the fact that your paper is one of the first COVID-19 reports in the world with well described SARS-CoV-2 viral gene structure.

In addition to the attached certificate, a link on the journal's homepage will be included to [celebrate the news](#). The first-place winner also receives 1,000 USD. Please contact Alexa Josaphouitch, alexa.jo@taylorandfrancis.com, for more details about the monetary award.

Thank you and congratulations on your achievement!

Sincerely,

Alexa Josaphouitch

Portfolio Manager for Hematology and Immunology Journals

Taylor & Francis Group

530 Walnut Street, Suite 850, Philadelphia, PA 19106


Tel: (212) 600-3459

Fax: (215) 207-0050

Email: alexa.josaphouitch@taylorandfrancis.com

Web: www.tandfonline.com

(she/her/hers)



Information Classification: General

From: Josaphouitch, Alexa <Alexa.Josaphouitch@taylorandfrancis.com>
Sent: Tuesday, February 23, 2021 2:31 PM
To: Liu.6244@osu.edu; lsu@med.unc.edu
Cc: editorial@emi2012.org; Lu, Shan; M. Yu-Mei Wen (ymwen@shmu.edu.cn); 'Min Yang'
Subject: EMI's 2020 Best Paper Award - Third Place
Attachments: 2020 Best Paper_third place_Liu.pdf

Dear Shan-Lu Liu, Linda J. Saif, Susan R. Weiss & Lishan Su,

On behalf of Editors-in-Chief, Yu-Mei Wen and Shan Lu, EMI and Taylor & Francis, we would like to congratulate you on winning third place for *Emerging Microbes & Infections* 2020 Best Papers Award for the paper entitled, "No credible evidence supporting claims of the laboratory engineering of SARS-CoV-2."

EMI made this decision based on the fact that your paper provided scientific analysis to reject the theory that SARS-CoV-2 is a laboratory engineered virus.

In addition to the attached certificate, a link on the journal's homepage will be included to [celebrate the news](#). The third-place winner also receives 250 USD. Please contact Alexa Josaphouitch, alexa.jo@taylorandfrancis.com, for more details about the monetary award.

Thank you and congratulations on your achievement!

Sincerely,

Alexa Josaphouitch

Portfolio Manager for Hematology and Immunology Journals

Taylor & Francis Group

530 Walnut Street, Suite 850, Philadelphia, PA 19106


Tel: (212) 600-3459

Fax: (215) 207-0050



Email: alexa.josaphouitch@taylorandfrancis.com

Web: www.tandfonline.com


(she/her/hers)



EXPLORE OUR
HEMATOLOGY
JOURNALS
CLICK HERE FOR MORE INFO



EXPLORE OUR
IMMUNOLOGY
JOURNALS
CLICK HERE FOR MORE INFO



Information Classification: General

From: Josaphouitch, Alexa <Alexa.Josaphouitch@taylorandfrancis.com>
Sent: Tuesday, February 23, 2021 2:31 PM
To: wcao_pumch@163.com; litsh@263.net
Cc: editorial@emi2012.org; Lu, Shan; M. Yu-Mei Wen (ymwen@shmu.edu.cn); 'Min Yang'
Subject: EMI's 2020 Best Paper Award - Third Place
Attachments: 2020 Best Paper_third place_Lin.pdf

Dear Ling Lin, Lianfeng Lu, Wei Cao & Taisheng Li,

On behalf of Editors-in-Chief, Yu-Mei Wen and Shan Lu, EMI and Taylor & Francis, we would like to congratulate you on winning third place for *Emerging Microbes & Infections* 2020 Best Paper Award for the paper entitled, "Hypothesis for potential pathogenesis of SARS-CoV-2 infection—a review of immune changes in patients with viral pneumonia."

EMI made this decision based on the fact that your paper is a report from frontline physicians working in Wuhan observing COVID-19 caused vasculitis and treatment with low molecular weight heparin (LVWH).

In addition to the attached certificate, a link on the journal's homepage will be included to [celebrate the news](#). The third-place winner also receives 250 USD. Please contact Alexa Josaphouitch, alexa.jo@taylorandfrancis.com, for more details about the monetary award.

Thank you and congratulations on your achievement!

Sincerely,

Alexa Josaphouitch

Portfolio Manager for Hematology and Immunology Journals

Taylor & Francis Group

530 Walnut Street, Suite 850, Philadelphia, PA 19106


Tel: (212) 600-3459

Fax: (215) 207-0050



Email: alexa.josaphouitch@taylorandfrancis.com

Web: www.tandfonline.com


(she/her/hers)



EXPLORE OUR
HEMATOLOGY
JOURNALS
CLICK HERE FOR MORE INFO



EXPLORE OUR
IMMUNOLOGY
JOURNALS
CLICK HERE FOR MORE INFO



Information Classification: General

From: "Liu, Shan-Lu" <liu.6244@osu.edu>
Date: Friday, February 21, 2020 at 7:22 PM
To: "Su, Lishan" <lishan_su@med.unc.edu>, "Saif, Linda" <saif.2@osu.edu>, Susan Weiss <weissr@pennmedicine.upenn.edu>
Subject: Fwd: Submitted Corrections for article TEMI 1733440

Shan-Lu Liu sent from iPhone

Begin forwarded message:

From: "TEMI-production@journals.tandf.co.uk" <cats@taylorandfrancis.com>
Date: February 21, 2020 at 4:04:41 PM PST
To: "TEMI-production@journals.tandf.co.uk" <TEMI-production@journals.tandf.co.uk>, "Liu, Shan-Lu" <liu.6244@osu.edu>
Subject: Submitted Corrections for article TEMI 1733440
Reply-To: TEMI-production@journals.tandf.co.uk

Article: No credible evidence supporting claims of the laboratory engineering of SARS-CoV-2

Journal: *Emerging Microbes & Infections* (TEMI)

Article ID: TEMI 1733440

Dear author,

This email confirms that you have submitted your corrections to your article proofs.

The submitted corrections have been successfully uploaded.

If you want to check your submitted corrections please log into CATS and click on the "Corrections Submitted" button.

Yours sincerely,

Malathi Boopalan

Email: TEMI-production@journals.tandf.co.uk

From: kyyuen <kyyuen@hku.hk>
Sent: Saturday, April 4, 2020 11:02 PM
To: Lu, Shan; 'wen yumei' (ymwen@shmu.edu.cn)
Subject: Fast track submission of TEMI-2020-0510 to EMI for your kind consideration
Attachments: EMI-Del-mut-Revised.pdf

Dear Professor Lu and Professor Wen,

Sorry for the typo. It should be 15-30bp. I have corrected that in the attached file. Please kindly use the attached file for your actions.

For the question: are these variants naturally occurring from infected COVID-19 patients, or generated during cell culture in your lab?

Answer: Because Del-mut variants show very stable in the passage in culture, we believe they are most likely present at low level in patients.

The information of this paper is to raise immediate attention that we should begin to screen minor population of variants amount patients, in particular among those covert cases or asymptomatic infected people. Hope we can deliver this important message to people as soon as possible.

KY

From: kyyuen <kyyuen@hku.hk>
Sent: Sunday, April 5, 2020 7:29 AM
To: Honglin Chen <hlchen@hku.hk>
Subject: FW: Fast track submission of TEMI-2020-0510 to EMI for your kind consideration

From: Lu, Shan [<mailto:Shan.Lu@umassmed.edu>]
Sent: Sunday, 5 April 2020 12:51 AM
To: kyyuen
Cc: Editorial Office; wen yumei
Subject: RE: Fast track submission of TEMI-2020-0510 to EMI for your kind consideration

Dear KY,

I was about to write to you for something else which I will still write to you in a separate email later.

Congratulations to you and your colleagues for a long list of important papers published in many leading journals.

I am very interested in this new submission and I will process it quickly. One question to this report: are these variants naturally occurring from infected COVID-19 patients, or generated during cell culture in your lab? Also, I am not sure I understand this phrase "15- 0-bp deletions" in the following sentence in Abstract: "we found a series of variants which contain 15- 0-bp deletions (Del-mut) or point mutations respectively at the S1/S2 junction.

As you may know, EMI has implemented a new system that a newly accepted paper can be published online in about 1 day after its acceptance. It will be in its original preprint format but it offers a significant benefit to authors who can see their research report available to the general scientific community quickly.

Please let your colleague formally submit this report to EMI when it is possible.

Best.

Shan

From: KY Yuen <kyyuen@hku.hk>

Sent: Saturday, April 4, 2020 6:11 AM

To: Lu, Shan <Shan.Lu@umassmed.edu>

Subject: Fast track submission of TEMI-2020-0510 to EMI for your kind consideration

Dear Editor Professor Lu,

My team has noticed an interesting phenomenon about a series of attenuated SARS-CoV-2 variants with a deletion or point mutations at the S1/S2 junction.

We believe this finding on a series of deleted mutant variant of SARS-CoV-2 (Del-mut) and point mutation mutants which have lost the polybasic cleavage site in the S1/S2 junction of the spike protein, may be essential for efficient virus replication and transmission in humans.

This finding provides information critical for understanding the properties of SARS-CoV-2 and material useful for research concerning drug screening and vaccine development.

We would be most grateful if you can expedite the review of this important work which should be highly cited.

Warmest regards.

KY

From: tangy@mskcc.org
Sent: Friday, August 30, 2019 8:21 AM
To: Lu, Shan
Cc: ymw@shmu.edu.cn
Subject: FW: FDA in Brief: FDA's 2019 Science Forum highlights latest regulatory science in emerging technologies and leading public health challenges

FYI.

From: U.S. Food and Drug Administration <fda@info.fda.gov>
Sent: Thursday, August 29, 2019 2:45 PM
To: Tang, Yi-Wei/Laboratory Medicine <tangy@mskcc.org>
Subject: [EXTERNAL] FDA in Brief: FDA's 2019 Science Forum highlights latest regulatory science in emerging technologies and leading public health challenges

If your email program has trouble displaying this email, [view it as a web page](#).



FDA in Brief: FDA's 2019 Science Forum highlights latest regulatory science in emerging technologies and leading public health challenges

The U.S. Food and Drug Administration is holding the 2019 FDA Science Forum, "Transforming Health: Innovation in FDA Science," on the agency's White Oak campus on Sept. 11, 2019, from 8:30 a.m. - 4:45 p.m. and Sept. 12, 2019, from 9 a.m. - 4 p.m. The [two-day event](#) will showcase the collaborative efforts of FDA's scientists as well as nationally renowned scientists from outside the agency.

Highlights from key topic areas include:

- **Precision Health:** Presenting a novel proposed regulatory framework for digital health, the potential for genomic biomarker use in cardiovascular disease trials, and research on sex differences during drug development.
- **Advanced Technologies:** The latest on methods, tools, materials, and products used either to make or evaluate products FDA regulates, such as genome editing or sequencing (in food safety), predictive tools for toxicity and efficacy, and modeling and simulation for medical devices.

- **Product Accessibility, Integrity, and Security:** Strategies for protecting the U.S. food system against attack; an advanced, risk-based method for screening imported food shipments for security and safety; strategies for preventing and mitigating biological product shortages.
- **Advancing Digital Health and Artificial Intelligence:** The potential impact of artificial intelligence in medical devices; using computers for modeling and simulation of phenomena relevant to the FDA's mission, e.g. analyzing large data sets; collecting and assessing real-world evidence, such as understanding and harnessing artificial intelligence and evaluating digital health devices; using large datasets for predictive modeling of polypharmacy issues.
- **Novel approaches to emerging disease threats or foodborne outbreaks:** The FDA's approach to preventing and responding to infectious disease and foodborne pathogen outbreaks, including the use of the animal rule, emergency communication devices, rapid diagnostic tests, anti-microbial resistance, and protecting people from emerging infectious disease threats.
- **Addiction:** Overview of drug abuse and addiction in the U.S.; chemical and in vivo strategies for determining potency and efficacy of novel synthetic opioids in the rat model; FDA assessment of the abuse potential of central nervous system-acting drugs; chemistry, biology, user behavior and exposure, social science and marketing, modeling, and prescribing behavior.

[Read More](#)



U.S. Food and Drug Administration
10903 New Hampshire Avenue, Silver Spring, MD 20993
1-888-INFO-FDA (1-888-463-6332)

[Privacy Policy](#) | www.fda.gov

[Manage Preferences or Unsubscribe from this List](#) | [Unsubscribe from all Email Lists](#)

From: wen yumei <ymwen@shmu.edu.cn>
Sent: Monday, March 9, 2020 11:33 PM
To: Lu, Shan; 杨旻
Subject: Fw: [SPAM] RE: Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235 #TrackingId:5820255

This author wants to withdraw thier paper. I presume they have sent it to another journal and have been accepted. We better keep this as their bad record. Wen

-----Original Messages-----

From: "Nur Khairiah Binte Mohd Ismail" <micnkmi@nus.edu.sg>
Sent Time: 2020-03-10 11:22:45 (Tuesday)
To: "ymwen@shmu.edu.cn" <ymwen@shmu.edu.cn>, "shan.lu@umassmed.edu" <shan.lu@umassmed.edu>
Cc: "Tan Yee Joo" <mictyj@nus.edu.sg>, "Zheng Zhiqiang" <miczz@nus.edu.sg>, "TEMI-peerreview@journals.tandf.co.uk" <TEMI-peerreview@journals.tandf.co.uk>, "editorial@emi2012.org" <editorial@emi2012.org>
Subject: [SPAM] RE: Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235 #TrackingId:5820255

Dear Editors-in-Chief,

I would like to withdraw my manuscript titled "Monoclonal antibodies for the S2 subunit of spike of SARS-CoV cross-react with the newly-emerged SARS-CoV-2" from further consideration by your journal. The manuscript ID is TEMI-2020-0235 and the date of submission was 02-Mar-2020. Due to fundamental errors in the way some of the figures are displayed, it is unlikely that this manuscript will receive a favourable review. Unfortunately, despite several emails to the Editorial Office, we have not been able to rectify this issue.

Please confirm that the withdrawal process is complete as we need to resubmit this ASAP.

I apologize for any inconvenience caused.

Sincerely,

Khairiah

From: TEMI-peerreview@journals.tandf.co.uk [mailto:TEMI-peerreview@journals.tandf.co.uk]
Sent: Tuesday, 10 March, 2020 9:14 AM
To: editorial@emi2012.org; Nur Khairiah Binte Mohd Ismail
Subject: Re: Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235 #TrackingId:5820255

Dear Dr. Mohd-Ismail,

Thank you for your email.

With regards to the update on your submission, I can confirm that your paper, TEMI-2020-0235 is under review and with some reviewers awaiting their approval to review.

As soon as the reviewer comments are completed and an editorial decision has been reached, the editor will correspond with you directly.

Should you require further assistance or have other queries, please do not hesitate to contact me.

Kind regards,

Jorgie Lyn Luna - Journal Editorial Office
Taylor & Francis Group
4 Park Square | Milton Park | Abingdon | Oxon | OX14 4RN UK
Web: www.tandfonline.com

Taylor & Francis is a trading name of Informa UK Limited,
registered in England under no. 1072954

Emerging Microbes & Infections

From: micnkmi@nus.edu.sg
Sent: 09-03-2020 10:42
To: editorial@emi2012.org, JorgieLyn.Luna@spi-global.com
Cc:
Subject: Re: Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235

Dear Editors,

May I get an update on the status of this case? Thank you.

Best regards,

Khairiah

From: Nur Khairiah Binte Mohd Ismail

Sent: 08 March 2020 08:51

To: Editorial Office <editorial@emi2012.org>

Subject: Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235

Dear Jorgie,

Please let us know as soon as possible if we are still able to edit the figures. I have also reached out to you previously via the submission portal with the updated figures. If it's not possible or we don't hear back from you soon, we may consider to withdraw the submission. Hope to hear from you soon.

Dear Min,

Thank you for attending to our query.

Best regards,

Khairiah

----- Original message -----

From: Editorial Office <editorial@emi2012.org>

Date: 06/03/2020 17:41 (GMT+08:00)

To: Nur Khairiah Binte Mohd Ismail <micnkmi@nus.edu.sg>

Subject: Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235

- External Email -

Dear Author,

Thank you for reaching us.

My colleague Miss Jorgie will assist you on this.

Hi Jorgie,

FYI.

Could you please help dealing with this case?

Many thanks,

Min

获取 [Outlook for iOS](#)

发件人: Nur Khairiah Binte Mohd Ismail <micnkmi@nus.edu.sg>

发送时间: Friday, March 6, 2020 4:12:35 PM

收件人: Editorial Office <editorial@emi2012.org>

主题: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235

Dear Editors-in-Chief,

Following submission of manuscript ID TEMI-2020-0235 to EMI on 2 March 2020, we found that several of the figures were not displayed properly in the PDF proof. May we replace these figures before they are sent out for review?

Thank you.

Best regards,

Khairiah

Nur Khairiah Mohd Ismail
Research Fellow | TYJ Lab | Department of Microbiology & Immunology | MD4 | Yong Loo Lin School of
Medicine | National University of Singapore | 5 Science Drive 2 | Singapore 117545 | Tel: +65 6601 3024 |

Important: This email is confidential and may be privileged. If you are not the intended recipient, please delete it and notify us immediately; you should not copy or use it for any purpose, nor disclose its contents to any other person. Thank you.

Important: This email is confidential and may be privileged. If you are not the intended recipient, please delete it and notify us immediately; you should not copy or use it for any purpose, nor disclose its contents to any other person. Thank you.

Important: This email is confidential and may be privileged. If you are not the intended recipient, please delete it and notify us immediately; you should not copy or use it for any purpose, nor disclose its contents to any other person. Thank you.

From: Liu, Shan-Lu <liu.6244@osu.edu>
Sent: Wednesday, February 19, 2020 11:53 PM
To: Su, Lishan; Lu, Shan
Subject: FW: Author Publishing Agreement Received for article TEMI 1733440

Done, thank you Lishan!

SL

From: "TEMI-production@journals.tandf.co.uk" <cats@taylorandfrancis.com>
Reply-To: "TEMI-production@journals.tandf.co.uk" <TEMI-production@journals.tandf.co.uk>
Date: Wednesday, February 19, 2020 at 8:51 PM
To: Shan-Lu Liu <liu.6244@osu.edu>
Subject: Author Publishing Agreement Received for article TEMI 1733440

Article: SARS-CoV-2: no evidence of a laboratory origin

Journal: *Emerging Microbes & Infections* (TEMI)

Article ID: TEMI 1733440

Dear Shan-Lu Liu,

Thank you for submitting your author publishing agreement for the article listed above. You will receive an email once your author publishing agreement has been accepted, or if any problems are identified.

Yours sincerely,

Malathi Boopalan

Email: TEMI-production@journals.tandf.co.uk

From: Zheng, Zhi-Ming (Thomas) (NIH/NCI) [E] <zhengt@exchange.nih.gov>
Sent: Friday, February 14, 2020 12:31 PM
To: Liu, Shan-Lu; Lu, Shan
Subject: FW: Boston case
Attachments: Opinion Disclosures Scientists Must Make of Foreign Ties The Scientist Magazine®.pdf

This is for your reference. You may upload it to our group.

Thanks,

Thomas

From: Liu, Shan-Lu <liu.6244@osu.edu>
Sent: Wednesday, March 10, 2021 10:45 AM
To: Lu, Shan
Subject: FW: Comment and request for phone call, rejection of TEMI-2021-0062.R2

See my reply below.

From: "Liu, Shan-Lu" <liu.6244@osu.edu>
Date: Wednesday, March 10, 2021 at 10:44 AM
To: "Mockenhaupt, Frank" <frank.mockenhaupt@charite.de>
Cc: "Lindner, Andreas" <andreas.lindner@charite.de>, "'editorial@emi2012.org'" <editorial@emi2012.org>
Subject: Re: Comment and request for phone call, rejection of TEMI-2021-0062.R2

Dear Prof. Mockenhaupt:

Thank you for your email. However, I am not Dr. Shan Lu and have nothing to do with your paper. You may reach out to Dr. Lu at Shan.Lu@umassmed.edu.

I understand that this is confusing but hope this email helps.

Sincerely,

Shan-Lu Liu (not Shan Lu) 😊



Shan-Lu Liu, M.D., Ph.D.
Professor
Co-Director, Viruses and Emerging Pathogens Program
Infectious Diseases Institute
Center for Retrovirus Research
Veterinary Biosciences, Microbial Infection and Immunity, and Microbiology
The Ohio State University
1900 Coffey Rd, Room 480 VMAB
Columbus, Ohio 43210
Phone: (614) 292-8690
Fax: (614) 292-6473
Email: liu.6244@osu.edu; shan-lu.liu@osumc.edu



From: "Mockenhaupt, Frank" <frank.mockenhaupt@charite.de>

Date: Wednesday, March 10, 2021 at 6:45 AM

To: "Liu, Shan-Lu" <liu.6244@osu.edu>

Cc: "Lindner, Andreas" <andreas.lindner@charite.de>, "'editorial@emi2012.org'" <editorial@emi2012.org>

Subject: Comment and request for phone call, rejection of TEMI-2021-0062.R2

Dear Prof. Shan Lu,

Please find attached a letter expressing our astonishment about the review process of our manuscript.
We would like to ask for the opportunity to discuss this issue on the phone (Skype, etc) this week.

Thank you for your attention.

Yours sincerely,

Frank Mockenhaupt

Prof. Dr. med. Frank P. Mockenhaupt
Acting Director
Institute of Tropical Medicine and International Health
Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum
Augustenburger Platz 1, 13353 Berlin, Germany
Tel.: +49 (0)30 450 565721
Fax: +49 (0)30 450 565989
frank.mockenhaupt@charite.de

From: wen yumei <ymwen@shmu.edu.cn>
Sent: Saturday, January 30, 2021 9:40 PM
To: Lu, Shan
Subject: Fw: CoVID-19 Manuscript in EMI

I was hit by a motorcycle last monday. Fortunately, there was no bone fracture, but my right eye was hurt. I can only use my eyes rarely to help the recovery. Please look after this mail. Wen

-----原始邮件-----

发件人: "Munir, Muhammad" <muhammad.munir@lancaster.ac.uk>
发送时间: 2021-01-29 07:45:43 (星期五)
收件人: "editorial@emi2012.org" <editorial@emi2012.org>, "ymwen@shmu.edu.cn" <ymwen@shmu.edu.cn>
抄送:
主题: CoVID-19 Manuscript in EMI

Dear You-Mei Wen,

I hope you are doing good.

With this email I would like to have your opinions on the suitability of the following manuscript in EMI. Can you please take a look of the Abstract and if it falls within EMI, I will proceed to submit for formal review process. Looking forward hearing from you soon and positive.

Immunogenicity and Protective Efficacy of an Intranasal Live-attenuated Vaccine Against SARS-CoV-2 in Preclinical Animal Models

Jun-Guy Park¹⁺, Fatai S. Oladunni¹⁺, Mohammed A. Rohaim^{2,3+}, Jayde Whittingham-Dowd², James Tollitt², Bakri M Assas⁴, Wafaa Alhazmi⁵, Abdullah Almilaibary⁶, Munir Iqbal⁷, Pengxiang Chang⁷, Renee Escalona¹, Vinay Shivanna¹, Jordi B. Torrelles¹, John J Worthington², Lucy H. Jackson-Jones², Luis Martinez-Sobrido¹, Muhammad Munir^{2}*

¹Texas Biomedical Research Institute, Host-Pathogen Interactions and Population Health Programs, San Antonio, TX, 78227, USA; ²Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster LA1 4YG, UK; ³Department of Virology, Faculty of Veterinary Medicine, Cairo University, Giza, 12211, Egypt; ⁴Faculty of Applied Medical Sciences, Department of Medical Laboratory Technology, Immunology Group, King Abdul Aziz University, Jeddah, Saudi Arabia; ⁵Faculty of Applied Medical Sciences, Department of Medical Laboratory Technology, Microbiology Group, King Abdul Aziz University, Jeddah, Saudi Arabia; ⁶Faculty of Medicine, Al Baha University, Al Baha, Saudi Arabia; ⁷The Pirbright Institute, United Kingdom

ABSTRACT

The global deployment of an effective and safe vaccine is currently a public health priority to curtail the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we evaluated a Newcastle disease virus (NDV)-based intranasal vectored-vaccine in mice and hamsters for its immunogenicity, safety and protective efficacy in challenge studies with SARS-CoV-2. The recombinant (r)NDV-S vaccine expressing spike (S) protein of SARS-CoV-2 administered via intranasal route in mice induced high levels of SARS-CoV-2-specific neutralizing immunoglobulin A (IgA) and IgG2a antibodies and T cell-mediated immunity. Hamsters vaccinated

with two doses of vaccine showed complete protection from clinical disease including lung infection, inflammation, and pathological lesions after SARS-CoV-2 challenge. Importantly, a single or double dose of intranasal rNDV-S vaccine completely blocked SARS-CoV-2 shedding in nasal turbinate and lungs within 4 days of vaccine administration in hamsters. Taken together, intranasal administration of rNDV-S has the potential to control infection at the site of inoculation, which should prevent both the clinical disease and transmission to halt the spread of the COVID-19 pandemic.

Kind Regards,

Muhammad MUNIR (PhD & FHEA) | Lecturer in Molecular Virology

Biomedical and Life Sciences | Lancaster University

Office: Furness, B69

Tel: +44 (0)1524 595083

Mob: +44 (0)7585184915

University Profile Page: [Click here](#)



From: wen yumei <ymwen@shmu.edu.cn >
Sent: Friday, April 10, 2020 6:56 AM
To: Lu, Shan
Subject: Fw: COVID-19 paper
Attachments: Cover_letter.doc; Manuscript-Lanjuan Li and CharlieXiang.pdf; Final accepted H7N9 Article-Engineering.pdf

Shan: This article was sent to me by Li and her associates asking for rapid publication in EMI. There were only two patients treated, without any controls. They tried to prove the application of this technology in H7N9 in the journal Engineering is worthless, as that journal is an official journal of CAE, which I regret could have published that article..

I do not think this article is appropriate for our journal. Please write a rejection letter diplomatically to me, so I can forward to them as our response. YMW

-----Original Messages-----

From: "项春生" <cxiang@zju.edu.cn >
Sent Time: 2020-04-10 12:51:24 (Friday)
To: ymw@shmu.edu.cn
Cc:
Subject: COVID-19 paper

Hello, Academician Wen! The attachment is the manuscript we are going to submit. Thank you for your review.

I also attach the work we did during H7N9 in 2013. The paper has been published in Engineering. The results of the study show that: The mortality of ARDS patients in the stem cell treatment group was significantly lower than that in the control group, which were 17.6% and 54.5%, respectively. During the treatment of No acute toxicity or other serious adverse reactions related to stem cell infusion were found. Four of the patients underwent a 5-year laboratory examination, Long-term follow-up of lung function and quality of life showed that MSC provides a safe and effective therapy for saving severe lung diseases induced by H7N9.

Thanks again!

Xiang Chun生

First Affiliated Hospital of Zhejiang University School of Medicine

From: wen yumei <ymwen@shmu.edu.cn>
Sent: Monday, June 15, 2020 5:37 PM
To: Lu, Shan
Subject: Fw: Emerging Microbes & Infections, Manuscript ID TEMI-2020-0796
Attachments: TEMI-2020-0796_Proof_hi.pdf

Please respond. Ning shoubao is not well, and will be hospitalized today. wen

-----Original Messages-----

From: "Dr. Johannes Möst" <jm@mb-lab.com> Sent Time: 2020-06-15 23:57:04 (Monday)
To: ymwen@shmu.edu.cn, shan.lu@umassmed.edu
Cc: editorial@emi2012.org
Subject: Emerging Microbes & Infections, Manuscript ID TEMI-2020-0796

Dear editors,

I am one of the senior authors of a manuscript (Antibody kinetics in primary- and secondary-care physicians with mild to moderate SARS-CoV-2 infection by D. Orth-Höller et al.) that was submitted almost six weeks ago for possible publication as a Letter in Emerging Microbes & Infections. One reason for submitting our work to your journal was that we expected (or at least hoped for) a rapid decision. I am aware of the actual huge workload for editors and reviewers. Nevertheless I am surprised (and to be honest, I consider it a bit unfair) that it takes that long to review a letter of just a few pages. Several articles dealing with Covid-19 and recently published in your journal were accepted within a few weeks.

May I kindly ask you to tell me whether there is something wrong with our letter? And whether it could take still much longer for a decision?

Given the enormous speed and the huge amount of submissions and publications for studies concerning SARS-CoV-2, the chances for publication in a prestigious journal like Emerging Microbes & Infections are going down with every week passing by.

Thank you for your understanding.

Best regards,

Johannes Möst, Assoc.-Prof., MD

--

Univ.-Doz. Dr. Johannes Möst

Mikrobiologisches Labor

Franz-Fischer-Straße 7b

6020 Innsbruck

Tel.: +43 (0)512-563380

FAX: +43 (0)512-563380-40

[https://nam01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.mb-](https://nam01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.mb-lab.com%2F&data=02%7C01%7Cshan.lu%40umassmed.edu%7Cf70993f7e36b4aed181408d81174369c%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637278538297113633&sdata=W%2F7i%2FaJbgA%2Ffg%2BG5t1L%2BD%2BcqkMXeVMrptnBzDHImeYQ%3D&reserved=0)

[lab.com%2F&data=02%7C01%7Cshan.lu%40umassmed.edu%7Cf70993f7e36b4aed181408d81174369c%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637278538297113633&sdata=W%2F7i%2FaJbgA%2Ffg%2BG5t1L%2BD%2BcqkMXeVMrptnBzDHImeYQ%3D&reserved=0](https://nam01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.mb-lab.com%2F&data=02%7C01%7Cshan.lu%40umassmed.edu%7Cf70993f7e36b4aed181408d81174369c%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637278538297113633&sdata=W%2F7i%2FaJbgA%2Ffg%2BG5t1L%2BD%2BcqkMXeVMrptnBzDHImeYQ%3D&reserved=0)

From: Wang Linfa <linfa.wang@duke-nus.edu.sg>
Sent: Monday, April 20, 2020 11:16 PM
To: Lu, Shan
Subject: FW: Emerging Microbes & Infections - Decision on Manuscript ID TEMI-2020-0499.R1

Dear Shan,

Sincere thanks for fast review on this paper and we can not claim we are the FIRST to document the lack of cross neutralization by SARS sera against SARS-CoV-2, despite previous publications indicating some level of cross neutralization using hyperimmune sera and/or pseudovirus!

Hope it will get a good citation for EMI as well.

Cheers,

LF

Linfa (Lin-Fa) WANG, PhD FTSE
Professor & Director
Programme in Emerging Infectious Disease Duke-NUS Medical School,
8 College Road, Singapore 169857
Tel: +65 6516 8397

-----Original Message-----

From: Emerging Microbes and Infections <onbehalf@manuscriptcentral.com>
Sent: Tuesday, 21 April 2020 11:04 AM
To: Danielle Anderson <danielle.anderson@duke-nus.edu.sg>; Tan Chee Wah <cheewah.tan@duke-nus.edu.sg>; Chia Wan Ni <wanni.chia@duke-nus.edu.sg>; barnaby_young@ncid.sg; Martin Linster <martin.linster@duke-nus.edu.sg>; Jenny Low Guek Hong (SHHQ - SGH) <jenny.low@singhealth.com.sg>; Tan Yee Joo <mictyj@nus.edu.sg>; Mark_Ic_Cheng@ncid.sg; Gavin James Smith <gavin.smith@duke-nus.edu.sg>; Wang Linfa <linfa.wang@duke-nus.edu.sg>; David_Lye@ncid.sg; Yee_Sin_Leo@ncid.sg
Subject: Emerging Microbes & Infections - Decision on Manuscript ID TEMI-2020-0499.R1

- External Email -

20-Apr-2020

Dear Professor Wang:

Ref: Lack of cross neutralization by SARS patient sera towards SARS-CoV-2

Our reviewers have now considered your paper and have recommended publication in Emerging Microbes & Infections. We are pleased to accept your paper in its current form which will now be forwarded to the publisher for copy editing and typesetting. The reviewer comments are included at the bottom of this letter, along with those of the editor who coordinated the review of your paper.

You will receive proofs for checking, and instructions for transfer of copyright in due course.

The publisher also requests that proofs are checked through the publisher's tracking system and returned within 48 hours of receipt.

Taylor & Francis strives to be compliant with the open access (OA) policies of the major national and international funding bodies. Information about funder compliance and OA policies can be found on our Author Services website. Details of our Green OA policy, including deposit in institutional and subject repositories, can be found on the Sharing your work (<https://nam01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fauthorservices.taylorandfrancis.com%2Fsharing-your-work%2F&data=02%7C01%7Cshan.lu%40umassmed.edu%7C0ca1e08ae18449266a5e08d7e5a25f08%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637230357876032733&sdata=libQG9AzimrwnfOvAtkRcux%2F%2BCwQliEul4UGXeIb2c%3D&reserved=0>) page. We recommend that you retain your Accepted Manuscript for this purpose.

For more information regarding the versions of your article that can be used to meet Green OA requirements, and the embargo period that applies, please see the open access journal finder (<https://nam01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fauthorservices.taylorandfrancis.com%2Fjournal-list%2F&data=02%7C01%7Cshan.lu%40umassmed.edu%7C0ca1e08ae18449266a5e08d7e5a25f08%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637230357876032733&sdata=Rhej5I6SwVoIN%2B94Hf1WLHymD%2FjeB88wOTn5svoV%2Fv4%3D&reserved=0>) page.

Thank you for your contribution to Emerging Microbes & Infections and we look forward to receiving further submissions from you.

Sincerely,

Shan Lu
Editor-in-Chief
Emerging Microbes & Infections

Important: This email is confidential and may be privileged. If you are not the intended recipient, please delete it and notify us immediately; you should not copy or use it for any purpose, nor disclose its contents to any other person. Thank you.

From: Tang, Yi-Wei <yi-wei.tang@cepheid.com>
Sent: Sunday, July 26, 2020 11:06 PM
To: Yumei Wen (ymwen@shmu.edu.cn); Lu, Shan
Cc: Min Yang (min.yang@emi2012.org)
Subject: FW: Emerging Microbes & Infections - Manuscript ID TEMI-2020-1295 has been submitted online

Teacher Wen, Shan,

This is the metanalysis manuscript that I requested/solicited several weeks ago.

Thank you for your attention.

Yi-Wei

-----Original Message-----

From: Emerging Microbes and Infections <onbehalf@manuscriptcentral.com>
Sent: Monday, July 27, 2020 10:49 AM
To: 14301050265@fudan.edu.cn
Cc: 14301050265@fudan.edu.cn; jingwenai1990@126.com; Loeffelholz, Michael J <Michael.Loeffelholz@cepheid.com>; Tang, Yi-Wei <yi-wei.tang@cepheid.com>; wenhongzhang_hs@126.com
Subject: Emerging Microbes & Infections - Manuscript ID TEMI-2020-1295 has been submitted online

26-Jul-2020

Dear Dr Wang:

Your manuscript entitled "Meta-analysis of Diagnostic Performance of Serology Tests for COVID-19: Impact of Assay Design and Post-symptom-onset Intervals" has been successfully submitted online and is presently being given full consideration for publication in Emerging Microbes & Infections.

Your manuscript ID is TEMI-2020-1295.

Please mention the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your street address or e-mail address, please log in to ScholarOne Manuscripts at https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.proofpoint.com%2Fv%2Furl%3Fu%3Dhttps-3A__mc.manuscriptcentral.com_temi%26d%3DDwICaQ%26c%3D9mghv0deYPYDGP-W745IEdQLV1kHpn4XJRvR6xMRXtA%26r%3DSOVakuu2E4HoaHBSZ5JSdOWTU0zcfLMPHqDYeFUmV3Y%26m%3DtFb4dOcr1lrGcvnx_NsfFjoLFtZOkEHNQhWvcDMY6CM%26s%3Dez3HB_MAEbfAU7ZCUkFyDW9dO55rkAf_xnSRGlk27sw%26e%3D&data=02%7C01%7CShan.Lu%40umassmed.edu%7C6cd112c13f8a4ac9591e08d831d9f8c9%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637314159543094312&sdata=Wx8U2Qqe55L5OEmFDin4I3PnFnEJVsGKnmAaOq6lLcQ%3D&reserved=0 and edit your user information as appropriate.

You can also view the status of your manuscript at any time by checking your Author Center after logging in to https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.proofpoint.com%2Fv%2Furl%3Fu%3Dhttps-3A__mc.manuscriptcentral.com_temi%26d%3DDwICaQ%26c%3D9mghv0deYPYDGP-W745IEdQLV1kHpn4XJRvR6xMRXtA%26r%3DSOVakuu2E4HoaHBSZ5JSdOWTU0zcfLMPHqDYeFUmV3Y%26m%3DtFb4dOcr1lrGcvnx_NsfFjoLFtZOkEHNQhWvcDMY6CM%26s%3Dez3HB_MAEbfAU7ZCUkFyDW9dO55rkAf_xnSRGlk27sw%26e%3D&data=02%7C01%7CShan.Lu%40umassmed.edu%7C6cd112c13f8a4ac9591e08d831d9f8c9%7Cee9155fe2da3437

8a6c44405faf57b2e%7C0%7C0%7C637314159543094312&data=Wx8U2Qqe55L5OEmFDin4I3PnFnEJVsGKnmAaOq6lLcQ%3D&reserved=0 .

Thank you for submitting your manuscript to Emerging Microbes & Infections.

Sincerely,

Emerging Microbes & Infections Editorial Office Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

From: Nur Khairiah Binte Mohd Ismail <micnkmi@nus.edu.sg>
Sent: Saturday, March 7, 2020 9:03 PM
To: ymw@shmu.edu.cn; Lu, Shan
Subject: Fw: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235

Dear Editors-in-Chief,

I have been in touch with the EMI Editorial Board regarding a request to replace some figures that are not properly displayed in the above-mentioned manuscript submission. May I kindly request for your help to expedite this matter? Thank you.

Best regards,
Khairiah

From: Nur Khairiah Binte Mohd Ismail
Sent: 08 March 2020 08:51
To: Editorial Office <editorial@emi2012.org>
Subject: Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235

Dear Jorgie,

Please let us know as soon as possible if we are still able to edit the figures. I have also reached out to you previously via the submission portal with the updated figures. If it's not possible or we don't hear back from you soon, we may consider to withdraw the submission. Hope to hear from you soon.


Dear Min,

Thank you for attending to our query.

Best regards,
Khairiah

----- Original message -----

From: Editorial Office <editorial@emi2012.org>
Date: 06/03/2020 17:41 (GMT+08:00)
To: Nur Khairiah Binte Mohd Ismail <micnkmi@nus.edu.sg>
Subject: Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235

 - External Email -

Dear Author,

Thank you for reaching us.
My colleague Miss Jorgie will assist you on this.

Hi Jorgie,

FYI.

Could you please help dealing with this case?

Many thanks,
Min

获取 [Outlook for iOS](#)

发件人: Nur Khairiah Binte Mohd Ismail <micnkmi@nus.edu.sg>
发送时间: Friday, March 6, 2020 4:12:35 PM
收件人: Editorial Office <editorial@emi2012.org>
主题: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235

Dear Editors-in-Chief,

Following submission of manuscript ID TEMI-2020-0235 to EMI on 2 March 2020, we found that several of the figures were not displayed properly in the PDF proof. May we replace these figures before they are sent out for review?

Thank you.

Best regards,
Khairiah

Nur Khairiah Mohd Ismail
Research Fellow | TYJ Lab | Department of Microbiology & Immunology | MD4 | Yong Loo Lin School of
Medicine | National University of Singapore | 5 Science Drive 2 | Singapore 117545 | Tel: +65 6601 3024 |

Important: This email is confidential and may be privileged. If you are not the intended recipient, please delete it and notify us immediately; you should not copy or use it for any purpose, nor disclose its contents to any other person. Thank you.

Important: This email is confidential and may be privileged. If you are not the intended recipient, please delete it and notify us immediately; you should not copy or use it for any purpose, nor disclose its contents to any other person. Thank you.

From: wen yumei <ymwen@shmu.edu.cn>
Sent: Friday, May 8, 2020 9:58 PM
To: Lu, Shan; YiWei Tang
Cc: Yang Min
Subject: Fw: Fw: Emerging microbes & infections
Attachments: EMI.zip

This letter was submitted on April 25th. Please check, as this is still under review.YMW

-----The original message-----

From 人 : "CHEN WEI" <cw0226@foxmail.com>

Sending time: 2020-05-09 06:50:43 (Saturday)

Recipient : "Academician Wen Mei" <ymwen@shmu.edu.cn>

CC :

Main **topic:** Fw: Microbes & Emerging infections

Hello, Mr. Wen, the attachment is the submission, thank you!

Chen Wei

---Original---

From: "Dong Yunzhu" <13811429044@163.com>

Date: Sat, May 9, 2020 06:48 AM

To: "CHEN WEI" <cw0226@foxmail.com>;

Subject: Emerging microbes & infections

Teacher Chen, the attached compressed file is the manuscript submitted to EMI.

Yunzhu

From: wen yumei <ymwen@shmu.edu.cn>
Sent: Wednesday, August 5, 2020 1:52 AM
To: Lu, Shan
Subject: Fw: RE: manuscript submission

-----Original Messages-----

From: "wen yumei" <ymwen@shmu.edu.cn>
Sent Time: 2020-08-05 13:44:49 (Wednesday)
To: "zgyi@fudan.edu.cn" <zgyi@fudan.edu.cn>
Cc: "shan.lu" <shan.lu@emi2012.org>
Subject: Fw: RE: manuscript submission

zhigang:

I have forwarded your mail to Prof Shan.Lu, and you can see his very frank and professional response.

Due to the shortage of time for me at this period, maybe I should not simply directly forward your mail to him, and write him another letter. Anyway, I think his response and statement is reasonable, and beneficial for you in the future, as a young scientist.

I suggest that you wait for the final response and comment for a few days, which I am sure will help you to improve your current manuscript.

I hope you will note that only to repeat or confirm what other paper has reported should not be taken as a credit for your paper, and should be avoided. You should concentrate on what new findings you have got to ensure it is worth publication. Hope you success. YM Wen

-----Original Messages-----

From: "Lu, Shan" <Shan.Lu@umassmed.edu>
Sent Time: 2020-08-05 09:44:57 (Wednesday)
To: "wen yumei" <ymwen@shmu.edu.cn>, "YiWei Tang" <yiweitangmd@gmail.com>
Cc:
Subject: RE: manuscript submission

Hi, Prof Wen,

I checked on the status of this paper.

It was reviewed following EMI's standard process.

1

2. Given the VIP status (Prof Yuan Zhenghong is a co-author), I took the role of Review Editor.
3. We invited 28 experts in the field, and only two finally agreed to review after a very long work to get their agreement. This is usually a bad sign for any paper if no one is willing to review indicating a low quality of the paper.
4. At this point, one review is scheduled to submit back comments on Aug 8, and the other is scheduled to submit comment by Aug 17.
5. So it is not true that "may have not been officially reviewed" Also he could contact me at any time if he works for Fudan Group. He wrote to JEO and he did not fully understand the reply when he was told that "the paper is under review".
6. I don't understand what does he mean that there are two papers showing the same data by others groups. Does it mean his own paper has no value at all since other people already published same finding? These two papers were submitted on May 4 and May 27 respectively, two full months earlier than the current paper.

I reject anyone's attempt to use you to interfere with EMI's normal operation. I don't appreciate such statement as "Our EMI may also need to consider absorbing more young scholars with deep professional knowledge to join the editorial board in order to speed up and improve the operational efficiency". In many journals, such open personal attack to Editors is the basis for rejection. I will reserve such right.

Best.

Shan

From: wen yumei <ymwen@shmu.edu.cn>
Sent: Tuesday, August 4, 2020 7:15 PM
To: Lu, Shan <Shan.Lu@umassmed.edu>; YiWei Tang <yiweitangmd@gmail.com>
Subject: Fw: manuscript submission

For your ref. Please give me your comments. Thanks. Wen

-----Original Messages-----

From: "Zhigang Yi" <zgyi@fudan.edu.cn >
Sent Time: 2020-08-04 09:31:26 (Tuesday)
To: "wen yumei" <ymwen@shmu.edu.cn >
Cc:
Subject: manuscript submission

Hello, smell teacher,

2

The email you sent me last time about Vaccine's submission to you thing. My document was posted to EMI on 7月6日 and it hasn't been returned. Yesterday I sent an e-mail inquiry and learned that it may not have been review. While we were still working on it, we

There are already two chapters for similar works (I'm attaching 面). Our findings have some points that I think are meaningful:

1. The new coronavirus has a certain dominant epitope in the human body. O
The two main advantages identified by Nature communication
The potential epitopes are highly overlapped, and we have also identified ad
(Maybe our egg core method is better than their Elisa sieve
Choose the method, and our sick people are 120 more than theirs less than 30
人)
2. Antibodies against some of these dominant epitopes lift up in neutralizing
To be useful because we can partially compete with these epitope peptides
Neutralizing activity of neutralizing antibody. All our neutralization experim
It's done by the virus. This can explain the problem very well, suggesting the
Have the potential to develop into a vaccine (the related work is the Cell rese
It is also mentioned that they may be developing the use of coupling method
Strengthen its immunogenicity).

3

 Page 4

3. We also found that the antibody response against RBD is very weak, this
Beyond our expectation. Prompt that there may be multiple spatial tables of l
Position, or whether the strong decoy antibody of RBD in the body is worth
Pay more attention.
4. We have found that many people who have recovered from the disease hav
Not strong. At a dilution of 1:200, 120 parts of recovery are clear, which can
Only 5 copies of neutralization are clear. Similar conclusion Rockefeller Kin
Qiao's original research group was published in Nature. Prompt vaccine rese
Hair may still have a long way to go.
5. Some strong dominant epitopes are actually very strong for comparison
Cross-reaction, this is unique to our research, the other research

In the end, there is no clear comparison of the non-coronary respiratory disease. Show the necessity of similar research comparisons.

So our research should have reference value in the field of vaccine research. I also want to publish it as soon as possible, and then I can do further research. Research. This work was completed by the school's new crown research team. I do it all in a very busy time, and then I'm the most. Afterwards, the data was sorted out and the script was written.

4

Page 5

The review speed and quality of a magazine often affect the views of content. Sense, our EMI may also need to consider absorbing more professional knowledge. Young scholars with deep knowledge enter the editorial board to speed up and Zhi's operational efficiency. I think if your Vaccine draft is not yet available. Find a suitable manuscript, I am willing to withdraw the manuscript from EMI Vaccine.

I am attaching my manuscript and see if you think it is appropriate.

Best Regards!

Zhigang

-----Original Messages-----

From: TEMI-peerreview@journals.tandf.co.uk

Sent Time: 2020-08-03 19:14:28 (Monday)

To: zgyi@fudan.edu.cn

Cc:

Subject: Re: No Subject #TrackingId:6958226

Hi Dr. Yi,

Thank you for your inquiry.

Checking the system from here, I can confirm that your submission is currently under review. One referee has now agreed to review your manuscript and the editor is still selecting one more reviewer to oversee your manuscript.

Rest assured that the Editor is aware of the status of your submission and is giving the proper attention it needs.

5

Page 6

Many thanks for your patience and understanding. Should you require any further assistance, please do let me know.

Kind regards,

Jorgie Lyn Luna -Journal Editorial Office
Taylor & Francis Group
4 Park Square | Milton Park | Abingdon | Oxon | OX14 4RN UK
Web: www.tandfonline.com

Taylor & Francis is a trading name of Informa UK Limited,
registered in England under no. 1072954

Image cannot be displayed. Your computer may not have enough memory to open the image, or the image may have been deleted. Restart your computer and try again.

Emerging Microbes & Infections

From: onbehalf@manuscriptcentral.com
Sent: 03-08-2020 09:09
To: JorgieLyn.Luna@spi-global.com
Cc:
Subject: Re: No Subject

To whom it may concern,

I am sorry to write this letter, but on behalf of other corresponding authors professor Hongzhou Lu and Zhenghogn Yuan, we would like to inquiry the process of our submission"TEMI-2020-1187, Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population". As this manuscript is about COVID-19, this area is highly competitive and any timely progress contributes to the combat against the diseases. As this work posted on Medrxiv, it attracted many readers. We understand that EMI is likely heavily burdened by a flood of submissions, we are still wondering if our submission could be processed in an accelerated manner.

Sincerely,

Zhigang Yi

-

Zhigang Yi, Ph.D Associate professor, Shanghai Medical College, Fudan University, Yi Xue Yuan Road 138, Shanghai, PRChina, Tel: 086-21-54237669

6

Page 7

From: wen yumei <ymwen@shmu.edu.cn>
Sent: Wednesday, August 28, 2019 10:12 PM
To: Lu, Shan
Subject: Fw: Fwd: Request for being a reviewer: Emerging Microbes and Infection
Attachments: CV- Gaurav Shrivastava 2019.pdf

for you to consider。 It seems these candidates are urgent to be a reviewer, to make their CVs more attractive. Wen

-----原始邮件-----

发件人: "Editorial Office" <editorial@emi2012.org>
发送时间: 2019-08-28 13:45:33 (星期三)
收件人: wenyumei <ymwen@shmu.edu.cn>
抄送:
主题: Fwd: Request for being a reviewer: Emerging Microbes and Infection

Dear Prof Wen,

FYI the below email.

Thanks and regards,
Min

发件人: Shrivastava, Gaurav (NIH/NIAID) [F] <gaurav.shrivastava@nih.gov>
发送时间: 星期二, 八月 27, 2019 11:14 下午
收件人: Editorial Office
主题: Request for being a reviewer: Emerging Microbes and Infection

Dr. Yu-Mei Wen
Editor in Chief
Emerging Microbes and Infection

Greeting

My name is Dr. Gaurav Shrivastava, a postdoc at NIH (National Institute of Health), USA. I have been focusing my research in the area of virology/immunology/Inflammasome biology. I would like to become a reviewer in your reputed Journal as your journal publishes a high end and great level science in the area of immunology. I would like to be a reviewer for not only helping the journal to publish a better paper, however I would like to be updated with current science that will ultimately help me developing new thinking. It will also help me in improving my own scientific writing, boosting my career, and opportunity to join the journal's community. I am attaching my CV along with this mail for your reference. I have already reviewed paper in the "Journal of general virology" and "Journal of Virology". I would like to review more frequently at this moment. Looking forward to hearing from you.

Thanks and Regards

Gaurav Shrivastava, PhD
IRTA Postdoc Research Fellow
Laboratory of Malaria and Vector Research
National Institute of Allergy and Infectious Diseases
National Institutes of Health
12735 Twinbrook Parkway TW3/2W09
Rockville 20852, Maryland
Telephone: +1-301-761-7272
Email: gaurav.shrivastava@nih.gov

From: wen yumei <ymwen@shmu.edu.cn>
Sent: Monday, June 1, 2020 5:44 PM
To: Lu, Shan
Cc: zhangwenhong
Subject: Fw: Greeting and seeking to publish a review in your Journal
Attachments: COVID19_review_1(1).docx

There are too many reviews, and I do not think a general review is worth publication. Please comment. Wen

-----Original Messages-----

From: wenhuazheng <wenhuazheng@um.edu.mo>
Sent Time: 2020-05-31 19:01:03 (Sunday)
To: "ymwen@shmu.edu.cn" <ymwen@shmu.edu.cn>
Cc:
Subject: Greeting and seeking to publish a review in your Journal

Dear Prof. Yu

In view of COVID-19 pandemic and the rapid increase of the number of publications reporting the advances and efforts that have been made to halt the virus spreading, I wish to enquire whether the manuscript entitled "Current progresses of COVID-19" is suitable for publication as a Review in your reputed journal. The article aims to provide an overview of the information currently available about the COVID-19 with special emphasis on the virus epidemiology, origin and transmission, clinical manifestations of the disease, diagnosis and therapeutics. With new evidences surfacing every day and the commitment in finding a proper treatment, I believe it is very important to provide a comprehensive review of the data gathered so far. This effort would be of great interest for those who work in the field and stand in the front lines of the fight against the virus. We are willing to make any alterations that you may suggest to improve the review content. As the information about COVID-19 is being continually updated it would be of great interest if you could expedite your decision.

Thank you very much for your consideration. I look forward for your response.

Kind regards,

Wenhua Zheng, MD, PhD

Professor,

Faculty of Health Sciences, University of Macau

From: Tang, Yi-Wei <yi-wei.tang@cepheid.com>
Sent: Saturday, May 16, 2020 1:42 AM
To: Lu, Shan; Yumei Wen (ymwen@shmu.edu.cn)
Subject: FW: Letter from the Curator-in-Chief - May 10th 2020

FYI.

From: Nguyen, Khoi Nguyen <NNguyen@asmusa.org>
Sent: Thursday, May 14, 2020 10:02 PM
To: Tang, Yi-Wei <yi-wei.tang@cepheid.com>; Lynn W. Enquist (lenquist@Princeton.EDU) <lenquist@Princeton.EDU>; Covid-19 Registry <Covid-19registry@asmusa.org>
Subject: RE: Letter from the Curator-in-Chief - May 10th 2020

Hello Yi-Wei,

Thanks for recommending these resources. Lynn has approved to post the special edition of the COVID-19 EMI journal. We will post them soon.

For CLSI guidelines, I will link to the free COVID resources that they offer.

Thanks,

Nguyen

From: Tang, Yi-Wei <yi-wei.tang@cepheid.com>
Sent: Tuesday, May 12, 2020 11:18 PM
To: Lynn W. Enquist (lenquist@Princeton.EDU) <lenquist@Princeton.EDU>; Covid-19 Registry <Covid-19registry@asmusa.org>
Subject: FW: Letter from the Curator-in-Chief - May 10th 2020

Lynn,

This is a unique one that journal EMI is doing for COVID-19 researches. Please advise if this could be a Research Resource for our Registry.

Thank you, Yi-Wei

From: Lu, Shan <Shan.Lu@umassmed.edu>
Sent: Wednesday, May 13, 2020 9:59 AM
To: Tang, Yi-Wei <yi-wei.tang@cepheid.com>
Subject: RE: Letter from the Curator-in-Chief - May 10th 2020

From: Tang, Yi-Wei <yi-wei.tang@cepheid.com>
Sent: Tuesday, May 12, 2020 9:55 PM
To: Lu, Shan <Shan.Lu@umassmed.edu>
Subject: FW: Letter from the Curator-in-Chief - May 10th 2020

Shan,

Are there any unique resources at EMI site or related places that I can recommend to ASM COVID-19 Registry?

Yi-Wei

From: Enquist, Lynn W. <lenquist@Princeton.EDU>
Sent: Tuesday, May 12, 2020 10:00 PM
To: Tang, Yi-Wei <yi-wei.tang@cepheid.com>
Cc: Covid-19 Registry <Covid-19registry@asmusa.org>; Weigang Qiu (Weigang@GENECTR.HUNTER.CUNY.EDU) <Weigang@genectr.hunter.cuny.edu>
Subject: Re: Letter from the Curator-in-Chief - May 10th 2020

Thank you. Very interesting resource indeed.

Lynn

Sent from my iPhone

On May 11, 2020, at 9:54 PM, Tang, Yi-Wei <yi-wei.tang@cepheid.com> wrote:

Lynn,

Please allow me to recommend below to our COVID-19 Registry as a **Research Resource**.

Thank you.

Yi-Wei

From: Weigang Qiu <Weigang@GENECTR.HUNTER.CUNY.EDU>
Sent: Tuesday, May 12, 2020 12:27 PM
To: Tang, Yi-Wei <yi-wei.tang@cepheid.com>
Subject: RE: Letter from the Curator-in-Chief - May 10th 2020

Title: CoV Genome Tracker

Link: <http://cov.genometracker.org/>

Reference: Akther S., E. Bezrucenkovas, B. Sulkow, C. Panlasigui, L. Li, W.Qiu & L. Di (2020). CoV Genome Tracker: tracing genomic footprints of Covid-19 pandemic. doi: <https://doi.org/10.1101/2020.04.10.036343>

A brief description:

The CoV Genome Tracker aims for real-time tracking of Covid-19 pandemic based on genome sequences and associated metadata released to the GISAID database (www.gisaid.org). It provides real-time comparative analysis of SARS-CoV-2 genomes, including viral phylogeny, geographic origins, and genome mutations. A companion web browser provides a broader evolutionary context including gene-by-gene sequence alignments, phylogenetic trees, and sequence variability at each codon positions.

The CoV Genome Tracker is similar to the CoV Genome Browser maintained by Neststrain.org (<https://nextstrain.org/ncov/global>) in data source and scope. The CoV Genome Tracker is however novel in using an interactive phylogenetic network, which is a more accurate model than phylogenetic tree for the newly evolved SARS-CoV-2 populations.

Typical usages of CoV Genome Tracker include:

- Epidemiology: One could search and browse viral information by geographic origins, isolate names, and phylogenetic positions.
 - Research: One could browse mutational changes, viral phylogeny, and codon-by-code sequence variability.
 - Education & presentation: One could use it as an interactive teaching tool (for CoV genome structure, phylogeny, and evolution), as well as a presentation tool (for a live audience or using screenshots).
-

Weigang Qiu, Ph.D. Professor
Department of Biological Sciences
Hunter College of the City University of New York
Belfer Research Building
413 East 69th Street, Room 402
New York, NY 10021
Office Tel: 1-212-896-0445
Lab Tel: 1-212-896-0446
Fax: 212-772-5227
Email: weigang@genectr.hunter.cuny.edu
Lab website: <http://diverge.hunter.cuny.edu/labwiki/>

Google

Map: <https://www.google.com/maps/place/413+E+69th+St,+New+York,+NY+10021/@40.7655886,-73.9561743,17z/data=!3m1!4b1!4m2!3m1!1s0x89c258c3d235f76f:0x4f3d0d5d8a78fe6?hl=en>

Google Scholar:

https://scholar.google.com/citations?hl=en&user=Ds6u39QAAAAJ&view_op=list_works&sortby=pubdate

NCBI Publications:

<https://www.ncbi.nlm.nih.gov/myncbi/browse/collection/42770924/?sort=date&direction=descending>

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

From: wen yumei <ymwen@shmu.edu.cn>
Sent: Wednesday, May 13, 2020 4:29 PM
To: Lu, Shan
Subject: Fw: Letter of Intent: Meta-analysis on CT features in COVID-19 Patients
Attachments: Chest Computed Tomography Findings in Hospitalized COVID-19 Patients A Systematic Review and Meta-Analysis.docx

Shan, I do not think this is appropriate for EMI. We may suggest them to submit to clinical journals. YMWen

-----Original Messages-----

From: "Syed Zaki" <syedzakimd@gmail.com>
Sent Time: 2020-05-14 00:29:20 (Thursday)
To: ymwen@shmu.edu.cn
Cc: shahzebkhan@gmail.com, shariqusman@outlook.com
Subject: Letter of Intent: Meta-analysis on CT features in COVID-19 Patients

Dear Dr. Yu-Mei Wen,

My colleagues and I have conducted a systematic review and meta-analysis of Chest Computed Tomography findings in hospitalized COVID-19 patients. Individual studies in this area have been small-sized and heterogenous, hence producing variable findings. Thus, we conducted a meta-analysis to provide holistic and generalizable results regarding CT findings in COVID-19 patients. Please find attached in this email the draft of this manuscript for your kind perusal. We are interested in submitting this article to Emerging Microbes and Infection. Given the quickly changing landscape of COVID-19, we would like to request a quick review for this manuscript.

Please kindly let us know if the editors would be interested in considering this article.

Many thanks and regards,

Syed Zaki Muhammad

From: wen yumei <ymwen@shmu.edu.cn>
Sent: Tuesday, August 4, 2020 7:15 PM
To: Lu, Shan; YiWei Tang
Subject: Fw: manuscript submission
Attachments: Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients.pdf; Mining of Epitopes on Spike Protein of SARS-CoV-2 from COVID-19 Patients.pdf; Cover letter for EMI.docx; Maintext_EMI.doc; supplementary Fig1_CPE.png; Supplementary table 1 _peptide information.xlsx; Supplementary Table 2_CPE of Neutrilizing experiment.docx

For your ref. Please give me your comments. Thanks. Wen

-----Original Messages-----

From: "Zhigang Yi" <zgyi@fudan.edu.cn>
Sent Time: 2020-08-04 09:31:26 (Tuesday)
To: "wen yumei" <ymwen@shmu.edu.cn>
Cc:
Subject: manuscript submission

Hello, Teacher Wen,

The email you sent me last time about Vaccine's appointment to you situation. My article was submitted to EMI on July 6th and there has been no I sent an email yesterday and learned that it may not have been officially reviewed. When we were still working on it, our work was similar There are already two articles out of his work (I am attaching it). I Our findings have some points that I think are meaningful:

1. The new coronavirus has a certain dominant epitope in the human body. Our The two main advantages identified by Nature communication

1

The potential epitopes are highly overlapped, and we have also identified additional

(Maybe our egg white chip method is better than their Elisa sieve Selection method, and our 120 patients are more than theirs less than 30)

2. Antibodies against some of these dominant epitopes lift up in neutralizing t To be useful because we can partially compete with these epitope peptides Neutralizing activity of neutralizing antibody. All our neutralization experime It's done by the virus. This can explain the problem very well. It suggests the Has the potential to develop into a vaccine (the related article is also a Cell re It's mentioned that they may be using coupling methods to enhance Its immunogenicity).

3. We also found that the antibody response against RBD is very weak, this Beyond our expectation. Propose the possibility of RBD multi-space table in Bit, or whether RBD has strong decoy antibodies in the body is worth Pay more attention.

4. We have found that many people who have recovered from the disease hav Not strong. 120 parts of healing serum at a dilution of 1:200 can completely

2

Only 5 serums were neutralized. Similar conclusion Rockefeller King Qiao's original research group was published in Nature. Propose vaccine rese Hair may still have a long way to go.

5. Some strong dominant epitopes are actually very strong for comparison Cross-reaction, this is unique to our research, the other research

There is no comparison with the status of non-coronary respiratory diseases. 1
The need for similar research comparisons.

So our research should have reference value in the field of vaccine research.
I also want to publish it as soon as possible, and then I can do in-depth research
. This work was jointly completed by the school's new crown research team a
, Everyone did it when they were very busy, and then I finally
The data was sorted out and articles were written.

The review speed and quality of a magazine greatly affect the contributor's
Sense, our EMI may also need to consider absorbing more professional know
Young scholars with deep knowledge enter the editorial board to speed up and
Zhi's operational efficiency. I think if you haven't found your Vaccine draft

3

Page 4

I am willing to withdraw the manuscript from EMI and submit it to Vaccine
.

I am attaching my manuscript and see if you think it is appropriate.

Best Regards!

Zhigang

-----Original Messages-----

From: TEMI-peerreview@journals.tandf.co.uk
Sent Time: 2020-08-03 19:14:28 (Monday)
To: zgyi@fudan.edu.cn
Cc:
Subject: Re: No Subject #TrackingId:6958226

Hi Dr. Yi,

Thank you for your inquiry.

Checking the system from here, I can confirm that your submission is currently under review. One referee

5/31/2021 Hello, Mr. Wen, the email you sent to me last time about Vaccine's appointment to you. My article has not been published since it was submitted to EMI... has now agreed to review your manuscript and the editor is still selecting one more reviewer to oversee your manuscript.

Rest assured that the Editor is aware of the status of your submission and is giving the proper attention it needs.

Many thanks for your patience and understanding. Should you require any further assistance, please do let me know.

Kind regards,

Jorgie Lyn Luna -Journal Editorial Office
Taylor & Francis Group
4 Park Square | Milton Park | Abingdon | Oxon | OX14 4RN UK
Web: www.tandfonline.com

Taylor & Francis is a trading name of Informa UK Limited,
registered in England under no. 1072954

4

Page 5

https://www.tandfonline.com/doi/full/10.1080/22447591.2020.1811111 by guest on 08 August 2020

Emerging Microbes & Infections

From: onbehalf@manuscriptcentral.com
Sent: 03-08-2020 09:09
To: JorgieLyn.Luna@spi-global.com
Cc:
Subject: Re: No Subject

To whom it may concern,

I am sorry to write this letter, but on behalf of other corresponding authors professor Hongzhou Lu and Zhenghogn Yuan, we would like to inquire the process of our submission "TEMI-2020-1187, Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population". As this manuscript is about COVID-19, this area is highly competitive and any timely progress contributes to the combat against the diseases. As this work posted on Medrxiv, it attracted many readers. We understand that EMI is likely heavily burdened by a flood of submissions, we are still wondering if our submission could be processed in an accelerated manner.

Sincerely,

Zhigang Yi

-

Zhigang Yi, Ph.D Associate professor, Shanghai Medical College, Fudan University, Yi Xue Yuan Road 138, Shanghai, PRChina, Tel: 086-21-54237669

From: Tang, Yi-Wei <yi-wei.tang@cepheid.com>
Sent: Sunday, March 22, 2020 7:55 AM
To: Lu, Shan; Yumei Wen (ymwen@shmu.edu.cn); ZhangWenhong; Yuan Zhenghong 袁正宏; Martin martin
Subject: FW: Pdf request

FYI. What a power of online. Our review has been read 1,945 times within two days!

<https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.tandfonline.com%2Fdoi%2Ffull%2F10.1080%2F22221751.2020.1745095&data=02%7C01%7CShan.Lu%40umassmed.edu%7C8fb7f2c88d864228dd8e08d7ce57d846%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637204749003803262&sdata=IRdwOkjNb1bO5b711DNvd8YefOjE8DincWgR12BPjU%3D&reserved=0>

Yi-Wei

-----Original Message-----

From: Tang, Yi-Wei
Sent: Sunday, March 22, 2020 7:48 PM
To: ggrassi@units.it; Loeffelholz, Michael J <Michael.Loeffelholz@cepheid.com>
Subject: RE: Pdf request

You should be able to download full article from:

<https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.tandfonline.com%2Fdoi%2Ffull%2F10.1080%2F22221751.2020.1745095&data=02%7C01%7CShan.Lu%40umassmed.edu%7C8fb7f2c88d864228dd8e08d7ce57d846%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637204749003803262&sdata=IRdwOkjNb1bO5b711DNvd8YefOjE8DincWgR12BPjU%3D&reserved=0>

Take care.

Yi-Wei Tang, MD, PhD, FAAM, FIDSA
Chief Medical Officer, China
518 North Fuquan Road, Shanghai, P. R. China

DIRECT +86 21 6015.8408

CELL +86 136.8177.1862

EMAIL yi-wei.tang@cepheid.com

<https://nam01.safelinks.protection.outlook.com/?url=WWW.CEPHEID.COM&data=02%7C01%7CShan.Lu%40umassmed.edu%7C8fb7f2c88d864228dd8e08d7ce57d846%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637204749003803262&sdata=wRT4UYI7HRF95x9KnmgoQY85x8AP1HL8mh7kwW%2BhWZo%3D&reserved=0>

-----Original Message-----

From: ggrassi@units.it <ggrassi@units.it>
Sent: Sunday, March 22, 2020 7:26 PM
To: Loeffelholz, Michael J <Michael.Loeffelholz@cepheid.com>; Tang, Yi-Wei <yi-wei.tang@cepheid.com>
Subject: Pdf request

Dear Prof Loeffelholz MJ and Tang YW

I wish to receive the pdf of your paper

Emerg Microbes Infect. 2020 Mar 20:1-26. doi:
10.1080/22221751.2020.1745095. [Epub ahead of print] Laboratory Diagnosis of Emerging Human Coronavirus
Infections - The State of the Art.

Which is not available in our library.

Regards

Prof G Grassi
University of Trieste
Italy

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

From: wen yumei <ymwen@shmu.edu.cn>
Sent: Monday, September 14, 2020 5:22 AM
To: Lu, Shan
Subject: Fw: Pre-submission inquiry_Characterization of newly SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster

Ythough there is no clinical significance,I am inclined to ask them yo submit, to promote genomic studies combined with clinical studies worldwide. . Please comment. Wen

-----Original Messages-----

From: antonin.bal@chu-lyon.fr
Sent Time: 2020-09-14 17:05:58 (Monday)
To: ymwen@shmu.edu.cn, editorial@emi2012.org
Cc: laurence.josset@chu-lyon.fr, antonin.bal@chu-lyon.fr, bruno.lina@chu-lyon.fr, gregory.queromes@univ-lyon1.fr, gregory.destras@chu-lyon.fr
Subject: Pre-submission inquiry_Characterization of newly SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster

Dear Pr. Wen,

We would like to submit a pre-submission inquiry regarding the suitability of our manuscript entitled **“Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster during routine genomic surveillance, Lyon, France”** for publication in *Emerging Microbes & Infections*, as an Original Article. (bioRxiv: <https://www.biorxiv.org/content/10.1101/2020.08.07.241653v1.full>)

Since February we have sequenced **229 SARS-CoV-2 whole genome** with a metagenomic next-generation sequencing approach as part of the routine surveillance performed at the French National Reference Center for Respiratory Viruses. We detected **two newly discovered frame-shifting deletion variants of the ORF6** (34- and 26-nucleotide deletions). **The 34-nucleotide deletion variant was found in 6 samples** (from 5 patients and **1 health-care worker**) within a cluster of COVID-19 cases from a single geriatric unit at the university hospital of Lyon. Both the presence of the 34-nucleotide deletion variant limited to a hospital unit and the clustering of the corresponding whole genome sequences by phylogeny analysis strongly **suggested a nosocomial transmission between patients**. Interestingly, **prolonged viral excretion of the 34-nucleotide deletion variant was found in a stool sample** 14 days after initial diagnosis for one patient. Furthermore, clinical data revealed **no significant difference in disease severity** between patients harboring the wild-type or the 34-nucleotide ORF6 deletion variant. The in vitro infection of the two deletion variants on primate endothelial kidney cells (BGM) and human lung adenocarcinoma cells (Calu-3) yielded **comparable replication kinetics** with the wild-type strain. In addition, **high viral loads** were found in vivo regardless of the presence or absence of the ORF6 deletion.

Overall, our study highlights **the transmission and replication capacity of two newly described deletion variants in the same ORF6 region**. Given the role of ORF6 in interferon modulation, further characterization, such as mechanistic interactions and interferon monitoring in patients should be performed. By the identification of the first nosocomial cluster harboring a large deletion newly described, **we emphasize the importance of real-time genomic surveillance for the detection of circulating variants and for the investigation of COVID-19 clusters**.

We would be very grateful if you could consider this pre-submission inquiry and look forward to hearing from you.

Yours sincerely,

Laurence Josset, PharmD PhD
Research Assistant Professor
National reference center for respiratory viruses (Pr. Bruno Lina)
University hospital of Lyon, France

From: Gibson, Edward
Sent: Friday, June 19, 2020 11:24 AM
To: 'Perlman, Stanley'
Cc: Lu, Shan
Subject: FW: Presenter Information for ISV 1st COVID-19 Virtual Congress

Hi Dr. Perlman,

Please let me know if you are having any issues joining. We are on now. Thank you.

Regards,

Ted Gibson

From: Gibson, Edward
Sent: Thursday, June 18, 2020 5:14 PM
To: 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; Lu, Shan <Shan.Lu@umassmed.edu>
Subject: RE: Presenter Information for ISV 1st COVID-19 Virtual Congress



Thanks, yes 10:15 (CDT) 11:15 (EDT) works well.

Also, please be sure to download the Teams Desktop Application [HERE](#) (if you haven't already). Please click "Download for desktop". Once the Teams application is installed on your computer please open and login with the guest sign in info below:

Login: Guest12@isvcongress.org

Password: Yag413450

Once you are signed into teams please go to the calendar located on the left side and click the meeting "Dr. PerlmanTraining." Please click the "Join" blue button to enter the meeting as a presenter. I have included some snips below. Please let me know if you have any questions prior to the training. Thanks again.



Stanley Perlman Training



Invite attendees

To invite attendees, copy the link and share it or send it in a calendar invite.

Get attendee link

Learn more

Friday, June 19, 2020
11:15 AM - 11:45 AM (30 minutes)
Microsoft Teams Meeting

Join

Chat

Cancel meeting

Live event resources

Refresh

Organizer

Edward Gibson
Producer, Organ

Event group

ISVCongress.c
Producer

Guest 12
Presenter

Close

Regards,

Ted Gibson

From: Perlman, Stanley <stanley-perlman@uiowa.edu>

Sent: Thursday, June 18, 2020 4:51 PM

To: Gibson, Edward <Edward.Gibson@umassmed.edu>

Subject: Re: Presenter Information for ISV 1st COVID-19 Virtual Congress

10:15 ok?

Stanley Perlman, MD, Ph.D.

Professor

Depts of Microbiology and Immunology, and Pediatrics

BSB 3-712

University of Iowa

Iowa City, IA 52242

319-335-8549

On Jun 18, 2020, at 3:48 PM, Gibson, Edward <Edward.Gibson@umassmed.edu> wrote:

Hi Dr. Perlman, yes and thank you. Would you be able to do 10AM CDT? Otherwise can you let me know some available times? Thanks.

Ted

From: Perlman, Stanley <stanley-perlman@uiowa.edu>
Sent: Thursday, June 18, 2020 4:43 PM
To: ISV Congress <info@isvcongress.org>
Subject: Re: Presenter Information for ISV 1st COVID-19 Virtual Congress

I just realized that I did not sign up for a practice session. Can we do this tomorrow?

Stanley

Stanley Perlman, MD, Ph.D.
Professor
Depts of Microbiology and Immunology, and Pediatrics
BSB 3-712
University of Iowa
Iowa City, IA 52242
319-335-8549

On Jun 13, 2020, at 9:55 AM, ISV Congress <info@isvcongress.org> wrote:



Dear Presenters (including Chairs),
Once again, ISV would like to thank you for accepting our invitation to update the world with the newest information of SARS-CoV-2 and the progress of COVID-19 vaccine development at the 1st ISV Virtual Congress (www.isvcongress.org), to be held on Monday, June 22, 2020. Below is the starting time depending on where you will be:

Monday, June 22, 2020

Los Angeles
0600-0900
New York 0900-1200
London 1400-1700
Paris 1500-1800
Beijing 2100-2400
Tokyo-Seoul 2200-0100
Sydney 2300-0200

The meeting will be run on the Microsoft Teams platform. If you do not already have the Teams desktop application, please download via the below link. Please be aware you **cannot** present in the live event from the web version of Teams.

<https://www.microsoft.com/en-us/microsoft-365/microsoft-teams/download-app>

We will work with each of you individually to ensure that you're comfortable with Teams. By June 15, Monday noon (EDT), please let us know two 30-minute blocks of time (from June 15

to June 17) that you're available for training, and hold these times in your calendar. Please reply to me at EdwardGibson@isvcongress.org. You can also reach me at any time with questions.

Also, if you have an assistant/PA, please provide us with their name, email address and phone for our use as a second method to reach you.

We look forward to this first virtual congress!



Ted Gibson

Congress Secretariat

ISV COVID-19 Vaccine Virtual Congress Series

EdwardGibson@isvcongress.org

+1-508-856-1179



If you no longer wish to receive email from us, please click [here](#):

From: wen yumei <ymwen@shmu.edu.cn>
Sent: Monday, March 23, 2020 8:53 PM
To: Lu, Shan
Cc: zhangwenhong
Subject: Fw: Presubmission enquiries
Attachments: Final Metronidazole-COVID-19.docx

Shan and Wenhong:

i am not a clinician, and thus hope you will decide on the quality of this paper. Wen

-----Original Messages-----

From: "Dr Fatemeh Heidary" <drfatemehheidari@yahoo.com>
Sent Time: 2020-03-24 08:23:29 (Tuesday)
To: "ymwen@shmu.edu.cn" <ymwen@shmu.edu.cn>
Cc:
Subject: Presubmission enquiries

Dear Prof Yu-Mei Wen

I am highly interested to submit the attached review article to your valuable Journal.

Prior to official submission, refer to the importance of the COVID-19 outbreak and to save the time, it would be highly appreciated if may let me know the compatibility of the attached manuscript to the scope of your Journal and the possibility of the prompt peer-review process.

In this review, we presented strong immunological evidence to introduce Metronidazole as the supplementary treatment regimen to the COVID-19.

The main contribution of our paper is a better understanding of Metronidazole as the available and cost-effective treatment against COVID-19. In vitro and in vivo studies revealed that Metronidazole decreases the following cytokines including IL8, IL6, IL1B, TNF α , IL12, and IFN γ , as well as CRP, and neutrophils count. Interestingly, those parameters are shown to be increased during COVID-19.

We have read and understood your journal's policies on copyright, ethics, etc., and believe that neither the manuscript nor the study violates any of these. Furthermore, it has been uploaded to pre-print server as below:

https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3559020

I hope our work meets your expectations. Thank you for your consideration.
And of course, our best wishes to you, your colleagues and your families in this time of crisis.

Sincerely, Heidary

Fatemeh Heidary MD, MPH, PhD, FICO, FAAO

PhD in Clinical Immunology
Fellowship in Ocular Pathology
Head of Ophthalmology Division,
Taleghani Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

From: wen yumei <ymwen@shmu.edu.cn>
Sent: Thursday, June 4, 2020 10:13 PM
To: Lu, Shan
Subject: Fw: Presubmission Inquiry letter

I do not think this is appropriate for EMI. Wen

-----Original Messages-----

From: "Nguyen Hai Nam" <nguyenhainam@kuhp.kyoto-u.ac.jp>
Sent Time: 2020-06-05 06:20:08 (Friday)
To: ymwen@shmu.edu.cn
Cc:
Subject: Presubmission Inquiry letter

Dear Dr. Yu-Mei Wen,

In response to the spread of the coronavirus disease 2019 (COVID-19), public health authorities and international organizations from countries around the world had proposed and recommended many control measures for it. However, finding the relevant strategy that can control the pandemic without causing adverse impacts on other aspects of societies is still extremely challenging. Together with the world against this pandemic, our specialized team for infectious disease research has written the report entitled "Early centralized isolation strategy for all confirmed cases of COVID-19 remains a core intervention to disrupt the pandemic spreading significantly". We are writing to inquire about the suitability of our report for the Emerging Microbes and Infections. We believe that our point of view, as well as our given information related to current situations in selected countries, would be satisfied to the readers of your leading journal, and we hope you will consider evaluating the manuscript to see if it falls within your journal's scope.

If you have any questions about the manuscript, please don't hesitate to let us know.

Thank you very much, and I look forward to your reply.

Best regards,

Nguyen Hai Nam

Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan.

Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, 70000, Vietnam.

Nguyen Tien Huy

School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki 852-8523, Japan.

Abstract

In response to the spread of the coronavirus disease 2019 (COVID-19), plenty of control measures had been proposed and recommended by public health authorities and international organizations from countries around the world. However, its controlling is still extremely challenging. In the aim of assessing the impact of current control measures on the number of new cases, 13 countries with highest confirmed cases, highest mortality rate, and having a close relationship with the outbreak's origin such as China, Hong Kong, Korea, Japan, Singapore, Taiwan, Italy, Spain, France, Germany, United Kingdom (UK), the United States of America (USA), and Canada were enrolled and analyzed. In the study, we analyzed the impact of each control measure adopted by the government of these targeted countries according to its timing to highlight and assess its significance in keeping the outbreak under control. Our analysis determined that early centralized isolation was represented as a core intervention in significantly disrupting the pandemic spreading. This strategy helped in successfully controlling the crisis in the early stage when the total number of cases under 100 without the requirement of the closure of cities and public areas that could impose such a negative impact to the society and economy. Moreover, when the number of cases increased with the apparition of new clusters, coordination between centralized isolation and social distancing would facilitate controlling the crisis efficiently.

From: wen yumei <ymwen@shmu.edu.cn>
Sent: Monday, June 1, 2020 5:50 PM
To: Lu, Shan
Subject: Fw: Presubmission Inquiry
Attachments: Final.Trim.Presubmission.docx

This is only a prediction, which needs experiments to confirm. I do not think we should consider this paper.

How is the situation in your city? Hope you are safe. Wen

-----Original Messages-----

From: "drfatemehheidari@yahoo.com" <drfatemehheidari@yahoo.com>
Sent Time: 2020-06-01 05:57:48 (Monday)
To: "ymwen@shmu.edu.cn" <ymwen@shmu.edu.cn>, "editorial@2012EMI.org" <editorial@2012EMI.org>
Cc:
Subject: Presubmission Inquiry

Dear Dr. Yu-Mei Wen
Dear Dr. Shan Lu

Editor-in-Chief

Emerging Microbes and Infections (EMI)

I wish to submit the attached manuscript for consideration in your valuable journal, titled "Systematic Review of the Antiviral Properties of TRIM56: A Potential Therapeutic Intervention for COVID-19."

Prior to official submission, it would be highly appreciated if you may kindly evaluate the compatibility of the manuscript to the scope of your valuable Journal.

We believe that our study makes a significant contribution to the literature because tripartite motif (TRIM) 56 exerts immunological and direct antiviral actions against several distinct negative-sense single-strand RNA viruses, and thus it may have effects against SARS-CoV-2, the causative agent of COVID-19.

In addition, TRIM56 is highly expressed in the lung, suggesting it may play a role in the immune defense against respiratory viruses. Our review provides evidence for the potential of a TRIM56-based strategy to treat SARS-CoV-2 and can serve as a basis for further study of its efficacy against SARS-CoV-2.

Further, we believe that this paper will be of interest to the readership of your journal because of the pandemic spread of SARS-CoV-2 infection and the morbidity and

mortality associated with COVID-19 and its threat to human health and economies worldwide. With the lack of a vaccine or effective treatment, all potential therapeutics should be explored.

Thank you for your consideration. I look forward to hearing from you.

And of course, our best wishes to you, your colleagues and your families in this time of health crisis.

Sincerely, Heidary

Fatemeh Heidary MD, MPH, PhD, FICO, FAAO
PhD in Clinical Immunology
Fellowship in Ocular Pathology

From: Zheng, Zhi-Ming (Thomas) (NIH/NCI) [E] <zhengt@exchange.nih.gov>
Sent: Friday, February 14, 2020 12:49 PM
To: Liu, Shan-Lu; Lu, Shan
Subject: FW: Professional Liability Insurance

Hi Shan-Lu and Shan,

I would encourage you all to have this professional liability insurance to protect yourselves, at the current toxic atmosphere. Here below is the link. I have been under this insurance and NIH covers half of our payment. At the end, I paid ~\$200/year.

Best,

Zhi-Ming

From: Wray, Tripp (NIH/NCI) [E] <tripp.wray@nih.gov>
Sent: Monday, December 16, 2019 3:44 PM
Subject: Professional Liability Insurance

Good afternoon,

In response to those of you interested in liability insurance, I thought it would be best to send the information to everyone in one email. The Starr Wright Insurance Agency is the group that I have seen other scientists use. It is \$400/year and the NIH will reimburse you 50%. The reimbursement process is annual and quite simple.

The product page for Starr Wright is [here](#) and the recommended amount is the Managers/Supervisors Career Protection plan. You would need to complete the purchase online and the plan is effective immediately upon them receiving the first payment whether you choose to pay it all or pay in installments.

After you have contacted Starr Wright and purchased your professional liability insurance, you would send the final receipt and certificate to your respective admin person to begin the reimbursement process. Let me know if you have any questions and I would be happy to answer them.

Thank you,

Tripp Wray

NCI/NIH

From: Gibson, Edward
Sent: Tuesday, July 21, 2020 7:37 AM
To: 'stanley-perlman@uiowa.edu'; Lu, Shan
Subject: FW: Question for animal models panel discussion

Good Morning, I received this question last night in case you want to use. Thank you.

Ted

From: jonathanmarrone@gmail.com <jonathanmarrone@gmail.com>
Sent: Monday, July 20, 2020 11:20 PM
To: EdwardGibson@isvcongress.org
Subject: Question for animal models panel discussion

Hello Edward,

I was hoping to pose a question to the panel discussion if possible. As a veterinarian and amongst peers, our biggest and most common question is whether covid-19 would be similar to feline coronavirus and feline infectious peritonitis and if so, how prevalent is it for previously studied strains of corona to mutate and cause similar disease and what is known about covid-19 in this regard. Furthermore, what is known about the potential for antibody-dependent enhancement of previous corona strains for which vaccine trials have been pursued as well as covid-19?

Thank you,
Jonathan Marrone

From: wen yumei <ymwen@shmu.edu.cn>
Sent: Saturday, October 24, 2020 9:19 PM
To: yuan zhenhong
Cc: zgyi@fudan.edu.cn; yhxie; Qiao Wang; jieliangchen; xywang; bwang3; Lu, Shan
Subject: Fw: Re: Congratulation

See the response from Charlie, I am really honored. Wen

-----Original Messages-----

From: "Charles Rice" <ricec@rockefeller.edu> Sent Time: 2020-10-25 03:45:22 (Sunday)
To: "wen yumei" <ymwen@shmu.edu.cn>
Cc:
Subject: Re: Congratulation

Thanks Yu-Mei! As one of your many admirers, your note means a great deal to me. It has been a true pleasure and honor to get to know you and your amazing group of trainees. Looking back, it has been a remarkable period for science yet there are many challenges ahead (not to mention that other persistent troublemaker, HBV!). I hope you are well and I look forward to the next time our paths cross. Warm regards, Charlie

> On Oct 5, 2020, at 8:29 AM, wen yumei <ymwen@shmu.edu.cn> wrote:

>

> Dear Charlie,

> The news of you and the other two scientists received the Nobel Prize was immediately spread in our lab, and everybody is thrilled, because of your long time collaboration with us and some of them were trained in your lab.

> Congratulation ! Your contribution in virology is worldwide recognized, and of course your outstanding contribution in HCV has saved the lives of many people.

> Thank you for helping Zhenghong and our lab in all aspects, and hope

> you all the best, and keep fit. Yu-mei

>

>

>

>

From: wen yumei <ymwen@shmu.edu.cn>
Sent: Friday, April 10, 2020 9:32 PM
To: Lu, Shan
Subject: Fw: Re: Fw: New York Magazine Query

See the forwarded letter. she does not know anything on immunity, and does not want to learn. Wen

-----Original Messages-----

From: "wen yumei" <ymwen@shmu.edu.cn>
Sent Time: 2020-04-11 09:29:36 (Saturday)
To: "Jinghe Huang" <jinghehuang@fudan.edu.cn>
Cc:
Subject: Re: Fw: New York Magazine Query

Please first draft a response, and I will give you my advise. Wen

-----Original Messages-----

From: "Jinghe Huang" <jinghehuang@fudan.edu.cn>
Sent Time: 2020-04-10 23:38:50 (Friday)
To: "闻玉梅老师" <ymwen@shmu.edu.cn>
Cc:
Subject: Fw: New York Magazine Query

Dear Wen Laoshi,

Our preprint attracted a lot of attentions by scientific community and media. 35 news stories cited and reported our results. It was also cited in the weekly report of the U.S. department of Science and Technology. A reporter of Nature News called me and talked about our manuscript. I also got an email from a reporter of *New York* magazine with the following complicated questions. Do you have any suggestion about those questions? Thank you very much.

Very best regards,
Jinghe

-----原始邮件-----

发件人: "James Walsh" <james.walsh@nymag.com>
发送时间: 2020-04-09 22:34:37 (星期四)
收件人: Jinghehuang@fudan.edu.cn
抄送:
主题: New York Magazine Query

Professor Huang,

I am a reporter for *New York* magazine and I am working on a story about COVID-19 immunity. I am wondering if you might be able to answer a few questions for me about your recent antibody research? I would appreciate any help, insight, or clarity you might be able to provide.

- Based on your research, might the low antibody count in younger people mean that younger people are more likely to be reinfected?
- If someone fought back an infection with T cells or cytokines, would they be able to fight reinfection with T Cells or cytokines?
- Do antibody levels fluctuate over time? i.e., Might someone recently recovered have high levels of antibodies than someone who recovered earlier? How might this affect immunity?
- How do you think your research correlates to [recent reports from South Korea](#) on reinfection?

Again, any help or insight you might be able to offer would go a long way! Thank you!

Sincerely,
James Walsh

--

James Walsh • Writer



Intelligencer and New York Magazine are part of **Vox Media**.

From: wen yumei <ymwen@shmu.edu.cn>
Sent: Tuesday, October 6, 2020 8:50 AM
To: Lu, Shan
Subject: Fw: Submission inquiry_Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster

For your ref. Wen

-----Original Messages-----

From: "QUEROMES GREGORY" <gregory.queromes@univ-lyon1.fr>
Sent Time: 2020-10-05 21:37:16 (Monday)
To: "ymwen@shmu.edu.cn" <ymwen@shmu.edu.cn>, "editorial@emi2012.org" <editorial@emi2012.org>
Cc: "laurence.josset@chu-lyon.fr" <laurence.josset@chu-lyon.fr>, "bruno.lina@chu-lyon.fr" <bruno.lina@chu-lyon.fr>, "gregory.destras@chu-lyon.fr" <gregory.destras@chu-lyon.fr>, "antonin.bal@chu-lyon.fr" <antonin.bal@chu-lyon.fr>, "Emilie FROBERT" <emilie.frobert@chu-lyon.fr>
Subject: Submission inquiry_Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster

Dear Pr. Wen,

Having submitted our manuscript describing a nosocomial cluster of a SARS-CoV-2 ORF6 deletion variant in France (Manuscript ID TEMI-2020-1518) to EMI September 17th, we were hoping to receive an update on your review of our manuscript.

We look forward to hearing from you and exchanging on our research.

Best regards,

Laurence Josset, PharmD PhD
Research Assistant Professor
National reference center for respiratory viruses (Pr. Bruno Lina)
University hospital of Lyon, France

Grégory Quéromès
PhD student - CIRI U1111 "Virology and Human Pathology" Team
University of Lyon - Claude Bernard Lyon 1 - France
MSc - Molecular Microbiology, Pathogenesis, and Microbial Ecology

From: antonin.bal@chu-lyon.fr <antonin.bal@chu-lyon.fr>
Sent: Thursday, September 17, 2020 06:10
To: ymwen@shmu.edu.cn; shan.lu@umassmed.edu; yiweitangmd@gmail.com
Cc: editorial@emi2012.org; laurence.josset@chu-lyon.fr; bruno.lina@chu-lyon.fr; QUEROMES GREGORY; gregory.destras@chu-lyon.fr; antonin.bal@chu-lyon.fr
Subject: RE: [SPAM] Re: Pre-submission inquiry_Characterization of newly SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster

Thank you very much for your response.
The manuscript has been submitted (Manuscript ID TEMI-2020-1518). We are looking forward to hearing from you.

Best regards,

Laurence Josset, PharmD PhD
Research Assistant Professor
National reference center for respiratory viruses (Pr. Bruno Lina)
University hospital of Lyon, France

De : wen yumei <ymwen@shmu.edu.cn>

Envoyé : mardi 15 septembre 2020 02:06:54

À : BAL, Antonin; shan.lu@umassmed.edu; YiWei Tang

Cc : editorial@emi2012.org; JOSSET, Laurence; LINA, Bruno; gregory.queromes@univ-lyon1.fr; DESTRAS, Gregory

Objet : [SPAM] Re: Pre-submission inquiry_Characterization of newly SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster

Laurence Josset, PharmD PhD

Thank you for your mail. After discussion with Prof. Shan Lu, co-editor-in-chief, we welcome you to submit your article through EMI website: www.tandfonline.com/TEM1. However, there are many submissions to EMI, your submission will be evaluated through a strict review system, and this letter does not mean acceptance. Regards, Yu-mei Wen

-----Original Messages-----

From: antonin.bal@chu-lyon.fr

Sent Time: 2020-09-14 17:05:58 (Monday)

To: ymwen@shmu.edu.cn, editorial@emi2012.org

Cc: laurence.josset@chu-lyon.fr, antonin.bal@chu-lyon.fr, bruno.lina@chu-lyon.fr, gregory.queromes@univ-lyon1.fr, gregory.destras@chu-lyon.fr

Subject: Pre-submission inquiry_Characterization of newly SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster

Dear Pr. Wen,

We would like to submit a pre-submission inquiry regarding the suitability of our manuscript entitled **“Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster during routine genomic surveillance, Lyon, France”** for publication in *Emerging Microbes & Infections*, as an Original Article. (bioRxiv: <https://www.biorxiv.org/content/10.1101/2020.08.07.241653v1.full>)

Since February we have sequenced **229 SARS-CoV-2 whole genome** with a metagenomic next-generation sequencing approach as part of the routine surveillance performed at the French National Reference Center for Respiratory Viruses. We detected **two newly discovered frame-shifting deletion variants of the ORF6** (34- and 26-nucleotide deletions). **The 34-nucleotide deletion variant was found in 6 samples** (from 5 patients and **1 health-care worker**) within a cluster of COVID-19 cases from a single geriatric unit at the university hospital of Lyon. Both the presence of the 34-nucleotide deletion variant limited to a hospital unit and the clustering of the corresponding whole genome sequences by phylogeny analysis strongly **suggested a nosocomial transmission between patients**. Interestingly, **prolonged viral excretion of the 34-nucleotide deletion variant was found in a stool sample** 14 days after initial diagnosis for one patient. Furthermore, clinical data revealed **no significant difference in disease severity** between patients harboring the wild-type or the 34-nucleotide ORF6 deletion variant. The in vitro infection of the two deletion variants on primate endothelial kidney cells (BGM) and human lung adenocarcinoma cells (Calu-3) yielded **comparable replication kinetics** with the wild-type strain. In addition, **high viral loads** were found in vivo regardless of the presence or absence of the ORF6 deletion.

Overall, our study highlights **the transmission and replication capacity of two newly described deletion variants in the same ORF6 region**. Given the role of ORF6 in interferon modulation, further characterization, such as mechanistic interactions and interferon monitoring in patients should be performed. By the identification of the first nosocomial

cluster harboring a large deletion newly described, **we emphasize the importance of real-time genomic surveillance for the detection of circulating variants and for the investigation of COVID-19 clusters.**

We would be very grateful if you could consider this pre-submission inquiry and look forward to hearing from you.

Yours sincerely,

Laurence Josset, PharmD PhD
Research Assistant Professor
National reference center for respiratory viruses (Pr. Bruno Lina)
University hospital of Lyon, France

From: Su, Lishan <lishan_su@med.unc.edu>
Sent: Thursday, October 29, 2020 10:21 AM
To: Lu, Shan
Subject: FW: SYMPOSIUM: Vaccine Development and Deployment

Fyi.

---Lishan

From: "Cameron, Craig Eugene" <craig_cameron@med.unc.edu>
Reply-To: "Cameron, Craig Eugene" <craig_cameron@med.unc.edu>
Date: Thursday, October 29, 2020 at 7:16 AM
To: Microbiology & Immunology <micro-immuno-all@listserv.unc.edu>
Subject: SYMPOSIUM: Vaccine Development and Deployment

From Celia Shau...

The Biotechnology Program is excited to invite you to join us for a symposium with 3 featured guests who will talk about the very current topic of vaccines! This event will take place on **Wednesday, November 4 from 2:00-4:00pm via zoom**. Each speaker will give a short talk, followed by a panel discussion with questions to be taken from the audience. Registered guests will receive the zoom link and further information.

For more information and to [register for this event](https://biotech.ncsu.edu/2020symposium/featured/), please visit: <https://biotech.ncsu.edu/2020symposium/featured/>

Registered guests will receive the zoom link and further information. All are welcome to participate! Please share the information with any groups who may have an interest.

NC STATE Biotechnology Program

Molecular Biotechnology Training Program
SYMPOSIUM: Vaccine Development and Deployment
November 4, 2020 2:00-4:00pm



Kizzmekia S. Corbett, PhD
NIH-NIAID-Vaccine Research Center

SARS-CoV-2 mRNA Vaccine
Design Enabled by Prototype
Pathogen Preparedness



Natalie E. Dean, PhD
University of Florida, Biostatistics

Vaccine Efficacy Trials for
Emerging Pathogens



Matthew Johnson, PhD
Duke Human Vaccine Institute

A New Paradigm for
Early Phase Vaccine Development:
GMP Development in Academia
for HIV, Influenza and SARS-CoV-2

Virtual Presentations and Panel Discussion via Zoom

Register for the link by RSVP here:
<https://biotech.ncsu.edu/2020symposium/featured/>

Questions?
Contact bit-program@ncsu.edu



**North Carolina
Biotechnology Center.**



From: Tang, Yi-Wei <yi-wei.tang@cepheid.com>
Sent: Friday, March 20, 2020 11:33 PM
To: Yumei Wen (ymwen@shmu.edu.cn); Yuan Zhenghong 袁正宏; ZhangWenhong; Lu, Shan; Martin martin
Subject: FW: Taylor & Francis author update: your accepted manuscript is now online

Teacher Wen and EMI founding members,

The lag time between accepting and publication in EMI has been solved thanks to efforts of Shan and T&F staff! By coincidence, the review I authored on lab diag of COVID-19 is online as the lucky one on the first set 😊.

Thank you, Shan, very much for making this happen in a timely manner.

Yi-Wei

From: Taylor & Francis <noreply@tandfonline.com>
Sent: Saturday, March 21, 2020 12:20 AM
To: Tang, Yi-Wei <yi-wei.tang@cepheid.com>
Subject: Taylor & Francis author update: your accepted manuscript is now online



The online platform for Taylor & Francis Group content

[Author Services](#) | [FAQ](#) | [Twitter](#) | [Facebook](#)

Dear author,

We're delighted to let you know your accepted manuscript [Laboratory Diagnosis of Emerging Human Coronavirus Infections — The State of the Art](#) is now Open Access on Taylor & Francis Online. This is the version of your manuscript which has been through peer review and been accepted by the journal editor.

After your manuscript has been typeset, you'll be able to check the proofs. We will then email you when the final version of your article (the Version of Record) is published, and when it has been assigned to an issue. But what should you do now?

Register now to access your Authored Works

Your **Authored Works** is where you can view all articles you have published with Taylor & Francis. You can check how many people have viewed your articles and how many times they have been cited, as well as access your Altmetric data enabling you to quickly assess the impact of your work.

How to register

You will need to register with the email you used whilst your manuscript was going through production. This is:

yi-wei.tang@cepheid.com

Once you've completed the quick registration you'll be sent an email asking you to confirm. Click on the verification link and you can then login (using the above email address) whenever you want to by going to [Taylor & Francis Online](#). Once you have logged in, click on "[Your Account](#)" at the top of the page to see the latest updates on your article.

Next steps

We'll be in touch to let you know when your proofs are ready, but if you have any queries in the interim don't hesitate to get in touch with your production editor.

Kind regards,

Stewart Gardiner
Global Production Director, Journals
Taylor & Francis Group

Interested in insights, tips, and updates for Taylor & Francis authors? Be part of our researcher community on:

[Twitter](#)

[Facebook](#)

[Taylor & Francis Author Services](#)



Taylor & Francis

Please do not reply to this email. To ensure that you receive your alerts and information from Taylor & Francis Online, please add "alerts@tandfonline.com" and "info@tandfonline.com" to your safe senders list.

Taylor & Francis, an Informa business.

Taylor & Francis is a trading name of Informa UK Limited, registered in England under no. 1072954. Registered office: 5 Howick Place, London, SW1P 1WG.

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

From: Liu, Shan-Lu <liu.6244@osu.edu>
Sent: Friday, April 9, 2021 10:12 AM
To: zhengzhiming4@gmail.com; tzhou@mail.nih.gov; GCheng@mednet.ucla.edu; liangy@umn.edu; rli@vcu.edu; xjmeng@vt.edu; Zhijian.Chen@UTSouthwestern.edu; mluo@gsu.edu; zhangyj@umd.edu; xzhu1@umd.edu; jqiu@kumc.edu; lijun@uic.edu; fengwei.bai@usm.edu; andyu@iupui.edu; reachxw@vt.edu; gluo@uab.edu; ldu@nybc.org; hxu@tulane.edu; liu_fy@berkeley.edu; Lu, Shan; haihu@UTMB.edu; wenzheho@temple.edu; Qfeng4@central.uh.edu; tang@bio.fsu.edu; feng.li@sdsta.edu; ruilu@lsu.edu; sxian2@unl.edu; qiyi.tang@howard.edu; dingsw@ucr.edu; guohua@missouri.edu; bling@tulane.edu; junwang@pharmacy.arizona.edu; lifang@umn.edu; wang518@umd.edu; gaos8@upmc.edu; pewang@uchc.edu; xiangy@uthscsa.edu; fzhu@bio.fsu.edu; chen.liang@mcgill.ca; lyuan@vt.edu; fgao@duke.edu; wangjw28@163.com; xfyu1@zju.edu.cn; bzhao@partners.org; jianw@muscu.edu; zyang@ksu.edu; yu.cong@nih.gov; weiming.yuan@usc.edu; Zongdi.feng@nationwidechildrens.org; juh13@psu.edu; hengx@missouri.edu; lsu@med.unc.edu; ywu8@gmu.edu; jwu@whu.edu.cn; tshuo@uic.edu; Shibojian@fudan.edu.cn; sjian@nybc.org; pinwang@usc.edu; rzhao@som.umaryland.edu; shuylong@mail.sysu.edu.cn; xuefeng.liu@georgetown.edu; yuxingli@som.umaryland.edu; Wang, Shixia; ye@ipbcams.ac.cn; Pinghui.feng@usc.edu; ju-tao.guo@bblumberg.org; lin.liu@okstate.edu; hua.zhu@rutgers.edu; Jinhong.chang@bblumberg.org; jianzhu1012@gmail.com; ronghai@ucr.edu; jliu4@uams.edu; xiangpeng.kong@med.nyu.edu; haoquanwu@outlook.com; Wenjun.liu@defence.gov.au; Liang.shan@wustl.edu; hliao@duke.edu; yuan2@upenn.edu; zxing@umn.edu; hongmin.li@health.ny.gov; pzheng@ihv.umaryland.edu; yaliu@ihv.umaryland.edu; jxw103@case.edu; Feng Shao; zlshi@wh.iov.cn; klan@whu.edu.cn; zengmsh@mail.sysu.edu.cn; Nan Yan; liliwang@upenn.edu; Linheng Li; kli1@uthsc.edu; tsx@case.edu; ssun@mdanderson.org; ysang@tstate.edu; Liu, Shan-Lu; wu@crystal.harvard.edu; Sun.Jie@mayo.edu; peijun@strubi.ox.ac.uk; jiayu@coh.org; bchen@crystal.harvard.edu; Wen, Haitao; Qu, Feng; Hezhao.Ji@umanitoba.ca; zhengyo@msu.edu; zhanglinqi@tsinghua.edu.cn; Whu@temple.edu; RSun@mednet.ucla.edu; Gao, Guangping; PZheng@ihv.umaryland.edu; GMSWANG@nus.edu.sg; peshi@UTMB.EDU; yaliu@ihv.umaryland.edu; ziyang-yan@uiowa.edu; lqiao@luc.edu; yong.xiong@yale.edu; Wang, Qihong; shuping_tong_md@brown.edu; Pinghui Feng; gaof@im.ac.cn; zihai@muscu.edu; zqin@uams.edu; guoh4@upmc.edu; wma@missouri.edu; Feng.Li@uky.edu; xiaow@iu.edu; sli38@tulane.edu; guodeyin@mail.sysu.edu.cn; hli1@pharmacy.arizona.edu; xiaow@iu.edu; ashuang@caltech.edu; jamesou@usc.edu; cwood1@unl.edu; dongfang.liu@rutgers.edu
Subject: FW: Tell the NIH to Stop the Racial Profiling of Asian Scientists and Researchers (Due Fri 4/9 at 5pm ET)

From: Chinese Biological Investigators Society <cbisociety@gmail.com>
Date: Thursday, April 8, 2021 at 9:59 AM
To: Chinese Biological Investigators Society <cbisociety@gmail.com>
Subject: Tell the NIH to Stop the Racial Profiling of Asian Scientists and Researchers (Due Fri 4/9 at 5pm ET)

Hi all,

Asian Americans Advancing Justice | AAJC is submitting a comment to the National Institutes of Health (NIH) to raise our concern on the mass racial profiling and discriminatory investigations and

prosecutions of Asian American and immigrant scientists, researchers, and scholars and NIH's role in these efforts.

Asian American communities have been grossly impacted by the profiling and unjust prosecutions for espionage of students, scientists, and researchers of Asian descent under the pretext of securing American research particularly under the Justice Department's "China Initiative." NIH intervention and investigations have led to the dismissal, resignation, and termination of Asian scientists, as well as a growing fear among Asian Americans and Asian immigrants of being targeted and scapegoated based on their race, ethnicity, and national origin.

NIH has launched an effort to end structural racism in biomedical research through its new [UNITE initiative](#). Individuals and organizations are invited to submit suggestions through its [Request for Information \(RFI\)](#) platform on ways NIH can stand against structural racism and achieve racial equity in biomedical research.

Join us by signing on to Asian Americans Advancing Justice | AAJC's comment or submitting your own comment to NIH on the harms resulting from the racial discrimination and profiling of Asian Americans and Asian immigrants in the scientific research environment. The comment also includes a set of recommendations on appropriate measures to address racial profiling and promote racial equity within the agency.

Full text of Advancing Justice | AAJC's comment is available [here](#).

You can take action now by:

- [Signing on to our comment to NIH](#) on the racial profiling and targeting of Asian American and Asian immigrant scientists, researchers, and scholars. **The deadline to sign on is April 9 at 5pm ET.**

**Please note we accept both individual and organizational signatories. We encourage impacted persons to consult with their attorneys first before signing on to the comment to reduce risk. If you are concerned about signing publicly, you may also submit comments anonymously.*

- [Submitting your own comment to NIH](#) We encourage you to add new recommendations, modify existing recommendations to align with your priorities, and include additional evidence, data and references. Comments may be submitted anonymously. **The submission deadline is April 9 at 11:59PM ET.**
 - [Letter template for individuals](#)
 - [Letter template for organizations](#)
 - Note: If you are submitting a letter using this template, please send a copy to Vivin Qiang at vqiang@advancingjustice-aajc.org. This assists our organization in further combating the racial profiling of Asian Americans and Asian immigrants.

If you have any questions, please reach out to Gisela Kusakawa at gkusakawa@advancingjustice-aajc.org.

If you believe you are being targeted by the government and you are looking for attorney referrals, please contact 202-935-6014 using the Signal app and a staff member from Advancing Justice |

AAJC will reach out to you directly (Available in English & Mandarin/普通话). Please contact Vivin Qiang to learn more.

We hope you consider signing on or submitting your own comment to NIH. Thank you for your time and consideration of this request!

If you would no longer like to receive updates and action alerts from Advancing Justice | AAJC, please contact Vivin Qiang.

Best,

Vivin

Vivin Qiang | 强雪儿 | she/hers

Program Coordinator, Anti-Racial Profiling Project

1620 L Street NW, Suite 1050 Washington, DC 20036

vqiang@advancingjustice-aajc.org

[Asian Americans Advancing Justice | AAJC](#)

[Join our email list](#)

Error! Filename not specified.

WeChat:

Error! Filename not specified.

PRIVACY AND CONFIDENTIALITY NOTICE: The information contained in this communication is confidential and may be legally privileged. It is intended solely for the use of the individual or entity to whom it is addressed and others authorized to receive it. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or taking of any action in reliance on the contents of this information is strictly prohibited. If you received this communication in error, please notify the sender immediately and delete the message. Thank you.

From: Wang Linfa <linfa.wang@duke-nus.edu.sg>
Sent: Saturday, April 25, 2020 12:08 PM
To: Lu, Shan
Subject: FW: Thank you for submitting your review of Manuscript ID TEMI-2020-0665 for Emerging Microbes & Infections

Dear Shan,

I did a "same day review" for this, as a way to thank the journal for fast review of my submission.

Cheers,

LF

Linfa (Lin-Fa) WANG, PhD FTSE
Professor & Director
Programme in Emerging Infectious Disease Duke-NUS Medical School,
8 College Road, Singapore 169857
Tel: +65 6516 8397

-----Original Message-----

From: Emerging Microbes and Infections <onbehalf@manuscriptcentral.com>
Sent: Sunday, 26 April 2020 12:06 AM
To: Wang Linfa <linfa.wang@duke-nus.edu.sg>
Subject: Thank you for submitting your review of Manuscript ID TEMI-2020-0665 for Emerging Microbes & Infections

- External Email -

25-Apr-2020

Dear Professor Lin-Fa Wang:

Thank you for reviewing the above manuscript, entitled "Identification of super-transmitters of SARS-CoV-2" for Emerging Microbes & Infections.

We greatly appreciate the voluntary contribution that each reviewer gives to the Journal. We hope that we may continue to seek your assistance with the refereeing process for Emerging Microbes & Infections, and hope also to receive your own research papers that are appropriate to our aims and scope.

Sincerely,
Professor Shan Lu
Emerging Microbes & Infections

Important: This email is confidential and may be privileged. If you are not the intended recipient, please delete it and notify us immediately; you should not copy or use it for any purpose, nor disclose its contents to any other person.
Thank you.

From: wen yumei <ymwen@shmu.edu.cn>
Sent: Saturday, August 24, 2019 10:36 PM
To: Lu, Shan; YiWei Tang; Zheng, Zhi-Ming (Thomas) (NIH/NCI) [E]
Cc: 杨旻
Subject: Fw: To Dr.Wen - Virologica Sinica, Volume 34, Issue 4

See forwrding message, which may serve as a ref for EMI.

-----原始邮件-----

发件人:Virologica-1 <virosin@wh.iov.cn>

发送时间:2019-08-24 12:08:09 (星期六)

收件人: ymwen@shmu.edu.cn

抄送:

主题: To Dr.Wen - Virologica Sinica, Volume 34, Issue 4

If you do not wish to receive this newsletter please click here [Unsubscribe](#).

The 8th Wuhan International Symposium
on Modern Virology
September 18–20 2019, Wuhan, China



Chinese Society for Microbiology
2019 Annual Meeting
October 11–15, 2019, Jinan, China

Virologica
Sinica



Serving the Society Since 1986

Dear Dr. Wen,



It is my pleasure to present you the review, research articles, letters and meeting report recently published in *Virologica Sinica*.

Your suggestions are welcome!

Zheng-Li Shi, Ph.D.
Editor-in-Chief, *Virologica Sinica*

Browse the website www.virosin.org for more information

Enjoy **rapid & free** publication in *Virologica Sinica*



Virologica Sinica is an academic journal which aims at presenting the cutting-edge basic and applied research on viruses all over the world. The journal publishes peer-reviewed original research articles and reviews, as well as commentaries and letters to the editor, to encompass the latest developments in all branches of virology, including research on animal, plant and microbe viruses. *Virologica Sinica*, the official journal of Chinese Society for Microbiology, will serve as a platform for the communication and exchange of academic information and ideas in an international context.

The journal is indexed by: Science Citation Index (SCI), JCR, PubMed/Medline, Scopus, BIOSIS, Google Scholar, and SCImago.



About the cover: Mitochondria are multifunctional eukaryotic organelles with diverse roles, including energy production and distribution, apoptosis, innate immunity, metabolic regulation, cell-cycle control and signal transduction. The interactions between viruses and the host mitochondria are crucial for virus replication and pathogenicity. Yang Yang *et al.* found that Enterovirus A71 (EV-A71) infection resulted in a perinuclear redistribution of the mitochondria, and the microtubule skeleton and the dynein motor complex were required for this redistribution. They further revealed that the interaction between EV-A71 2BC protein and mitochondrial Rho GTPase 1 played a crucial role in the regulation of mitochondrial motility, and the mitochondria redistribution was required for EV-A71 replication and proliferation. Their study reports a novel function of the EV-A71 2BC protein and provides an insight into the regulation of organelle transport in the EV-A71-infected cells. Please see page 397–411 for details.

Why *Virologica Sinica*?

- ✓ Indexed/Abstracted by SCI, PubMed/Medline, Scopus, Google Scholar
- ✓ Global visibility and increasing impact
- ✓ Publish special issues and topics
- ✓ Rapid peer review and publication
- ✓ No page/color charges, open-access options
- ✓ Free language editing

Submit now!

SCHOLARONE™
Manuscripts

2019, Vol. 34, Issue 4

Review


Specific and Selective Bacteriophages in the Fight against Multidrugresistant *Acinetobacter baumannii*

Free Full Text (HTML) **Free Full Text (PDF)**

Natalia Bagińska, Anna Pichlak, Andrzej Górski, Ewa Jończyk-Matysiak

Acinetobacter baumannii causes serious infections especially in immunocompromised and/or hospitalized patients. Several *A. baumannii* strains are multidrug resistant and infect wounds, bones, and the respiratory tract. Current studies are focused on finding new effective agents against *A. baumannii*. Phage therapy is a promising means to fight this bacterium and many studies on procuring and applying new phages against *A. baumannii* are currently being conducted. As shown in animal

models, phages against multidrug-resistant *A. baumannii* may control bacterial infections caused by this pathogen and may be a real hope to solve this dangerous health problem.




Research Article

Prevalence of HIV Indeterminate Western Blot Tests and Follow-up of HIV Antibody Sero-Conversion in Southeastern China

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

Shouli Wu, Min Gao, Jian Zheng, Pingping Yan, Wei Wang, Xiaoli Lu, Yuefeng Qiu, Yansheng Yan

HIV-indeterminate Western blotting (WB) results are typically obtained in WB confirmatory assays, and the number of indeterminate samples may increase with the detection of HIV infections, which will present considerable challenges for the management of HIV/AIDS. Nucleic acid detection has been used as a laboratory test for screening suspected or indeterminate samples. However, the effectiveness of these assays for the differential diagnosis of HIV-indeterminate WB samples remained undetermined. In this study, 210 subjects with HIV-indeterminate WB results were detected from 6360 positive HIV screening samples between 2015 and 2016 in southeastern China, in which HIV-indeterminate WB results accounted for 3.30%. The highest proportion of indeterminate results was observed in pregnant and lying-in women receiving physical examinations (16.67%), followed by that in voluntary blood donors (8.82%). The most common WB band patterns were p24, gp160 and p24, and gp160. The follow-up study revealed that the highest negative and positive conversion rates of HIV antibodies were in samples with a single p24 band (80.28%), and with gp160 and p24 bands (86.21%), respectively. Among the Env, Gag, and Pol antibodies, samples with a Gag band showed the highest negative conversion rate (81.25%), whereas the highest positive conversion rate was observed in samples with an Env band (56.76%). In addition, quantitative and qualitative HIV nucleic acid testing exhibited the highest sensitivity (96.3%) and specificity (97.85%), respectively. Our results indicate a lower proportion of HIV indeterminate WB results in southeastern China compared to previous reports, and the follow-up re-examination of patients with HIV indeterminate results should be performed. Nucleic acid testing facilitates the identification of HIV infections.




Research Article

Cross-sectional Seroprevalence and Genotype of Hepatitis E Virus in Humans and Swine in a High-density Pig-farming Area in Central China

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

Yilin Shu, Yameng Chen, Sheng Zhou, Shoude Zhang, Qin Wan, Changcai Zhu, Zhijiang Zhang, Hailong Wu, Jianbo Zhan, Ling Zhang

Hepatitis E virus (HEV) infection is a common public health problem in developing countries. However, the current prevalence of HEV and the relationship of HEV genotype between swine and human within high-density pig-farming areas in central China are still inadequately understood. Here, cross-sectional serological and genotypic surveys of HEV among the 1232 general population, 273 workers occupationally exposed to swine, and 276 pigs in a high-density pig-breeding area, were undertaken by ELISA and nested RT-PCR methods. Anti-HEV IgG was detected in 26.22% of general population and 48.35% of occupational workers. The prevalence of swine serum HEV-Ag was 6.52%. The prevalence of anti-HEV IgG was significantly higher among the workers occupationally exposed to swine than among the general population. An increased HEV seropositivity risk among the general population was associated with either being a peasant or male and was very strongly associated with the increase of age. Among the occupationally exposed group, the prevalence of anti-HEV IgG antibodies increased with age and working years. Among the 30 HEV-IgM-positive people, the infection rates of clerks in the public, peasants, pork retailers, and pig farmers were higher than those of others. A phylogenetic analysis revealed that all the isolates belonged to subgenotype 4_d, and four people and four pigs shared 97.04%–100% sequence homology. This study revealed a high HEV seroprevalence among the general population and workers occupationally exposed to swine in the Anlu City, and supports the notion that swine are a source of human HEV infection.




Research Article

Complementation of Wild-Type and Drug-Resistant Hepatitis B Virus Genomes to Maintain Viral Replication and Rescue Virion Production under Nucleos(t)ide Analogs **Free Full Text (HTML) Free Full Text (PDF)**

Chunchen Wu, Baolin Li, Xiaoyong Zhang, Kaitao Zhao, Yingshan Chen, Yifei Yuan, Yan Liu, Rongjuan Chen, Dongping Xu, Xinwen Chen, Mengji Lu

As the open reading frames of hepatitis B virus (HBV) genomes are overlapping, resistance mutations (MTs) in HBV polymerase may result in stop codon MTs in hepatitis B surface proteins, which are usually detected as a mixed population with wild-type (WT) HBV. The question was raised how the coexistence of nucleos(t)ide analogs (NAs) resistance MTs and WT sequences affects HBV replication. In the present study, HBV genomes with frequently detected reverse transcriptase (RT)/surface truncation MTs, rtA181T/sW172*, rtV191I/sW182* and rtM204I/sW196*, were phenotypically characterized alone or together with their WT counterparts in different ratios by transient transfection in the absence or presence of NAs. In the absence of NAs, RT/surface truncation MTs impaired the expression and secretion of HBV surface proteins, and had a dose-dependent negative effect on WT HBV virion secretion. However, in the presence of NAs, coexistence of MTs with WT maintained viral replication, and the presence of WT was able to rescue the production of MT HBV virions. Our findings reveal that complementation of WT and MT HBV genomes is highly effective under drug treatment.




Research Article

Effect of Loss-of-function of the Herpes Simplex Virus-1 microRNA H6-5p on Virus Replication

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

Rongquan Huang, Xusha Zhou, Shuqi Ren, Xianjie Liu, Zhiyuan Han, Grace Guoying Zhou

To date, 29 distinct microRNAs (miRNAs) have been reported to be expressed during herpes simplex virus infections. Sequence analysis of mature herpes simplex virus-1 (HSV-1) miRNAs revealed five sets of miRNAs that are complementary to each other: miR-H6-5p/H1-3p, miR-H6-3p/H1-5p, H2-5p/H14-3p, miR-H2-3p/H14-5p, and miR-H7/H27. However, the roles of individual miRNAs and consequences of this complementarity remain unclear. Here, we focus on two of these complementary miRNAs, miR-H6-5p and miR-H1-3p, using loss-of-function experiments *in vitro* and in a mouse model of infection using an miRNA sponge approach, including tandem multiplex artificial miRNA-binding sequences that do not match perfectly to the target miRNA inserted downstream of a green fluorescent protein reporter gene. Infection with recombinant virus expressing the miR-H6-5p sponge reduced viral protein levels and virus yield. Decreased accumulation of viral proteins was also observed at early stages of infection in the presence of both an miR-H6-5p inhibitor and plasmid-expressed miR-H1-3p. Moreover, establishment of latency and reactivation did not differ between the recombinant virus expressing the miR-H6-5p sponge and wild-type HSV-1. Taken together, these data suggest that miR-H6-5p has an as-yet-unidentified role in the early stages of viral infection, and its complement miR-H1-3p suppresses this role in later stages of infection. This report extends understanding of the roles of miRNAs in infection by herpes simplex viruses, supporting a model of infection in which the production of virus and its virulent effects are tightly controlled to maximize persistence in the host and population.




Research Article

Mitochondria Redistribution in Enterovirus A71 Infected Cells and Its Effect on Virus Replication

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

Yang Yang, Haolong Cong, Ning Du, Xiaodong Han, Lei Song, Wenliang Zhang, Chunrui Li, Po Tien

Enterovirus A71 (EV-A71) is one of the main causative agents of hand, foot and mouth disease (HFMD) and it also causes severe neurologic complications in infected children. The interactions between some viruses and the host mitochondria are crucial for virus replication and pathogenicity. In this study, it was observed that EV-A71 infection resulted in a perinuclear redistribution of the mitochondria. The mitochondria rearrangement was found to require the microtubule network, the dynein complex and a low cytosolic calcium concentration. Subsequently, the EV-A71 non-structural protein 2BC was identified as the viral protein capable of inducing mitochondria clustering. The protein was found localized on mitochondria and interacted with the mitochondrial Rho GTPase 1 (RHOT1) that is a key protein required for attachment between the mitochondria and the motor proteins, which are responsible for the control of mitochondria movement. Additionally, suppressing mitochondria clustering by treating cells with nocodazole, EHNA, thapsigargin or A23187 consistently inhibited EV-A71 replication, indicating that mitochondria recruitment played a crucial role in the EV-A71 life cycle. This study identified a novel function of the EV-A71 2BC protein and provided a potential model for the regulation of mitochondrial motility in EV-A71 infection.




Research Article

Trans Complementation of Replication-defective Omsk Hemorrhagic Fever Virus for Antiviral Study

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

Qiuyan Zhang, Na Li, Chenglin Deng, Zherui Zhang, Xiaodan Li, Kentaro Yoshii, Hanqing Ye, Bo Zhang

Omsk hemorrhagic fever virus (OHFV) is a tick-borne flavivirus classified as a biosafety level-4 (BSL4) pathogen. Studies of OHFV are restricted to be conducted within BSL4 laboratories. Currently, no commercial vaccines or antiviral drugs are available against OHFV infection. In this study, we recovered a replication-deficient OHFV with an NS1 deletion (OHFV-ΔNS1) and reporter virus replacing NS1 with the *Gaussia* luciferase (Gluc) (OHFV-ΔNS1-Gluc). Both the defective OHFV-ΔNS1 and OHFV-ΔNS1-Gluc virus could only replicate efficiently in the BHK21 cell line expressing NS1 (BHK21_{NS1}) but not in naïve BHK21 cells. The Gluc reporter gene of OHFV-ΔNS1-Gluc virus was maintained stably after serial passaging of BHK21_{NS1} cells and was used to surrogate the replication of OHFV. Using NITD008, OHFV-ΔNS1-Gluc virus was validated for antiviral screening, and high-throughput screening parameters were optimized in a 96-well plate format with a calculated Z' value above 0.5. The OHFV-ΔNS1-Gluc reporter virus is a powerful tool for antiviral screening as well as viral replication and pathogenesis studies in BSL2 laboratories.



Research Article


In Vitro Infectious Risk Assessment of Heliothis virescens ascovirus 3j (HvAV-3j) toward Non-target Vertebrate Cells

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

Huan Yu, Yi-Yi Ou-Yang, Ni Li, Madoka Nakai, Guo-Hua Huang

As specific pathogens of noctuid pests, including *Spodoptera exigua*, *S. litura*, *Helicoverpa armigera*, and *Mythimna separata*, ascoviruses are suitable for the development of bioinsecticides. In this study, the infectivity of *Heliothis virescens* ascovirus 3j (HvAV-3j) on insect and mammalian cells was evaluated. HvAV-3j infection induced drastic morphological changes in Sf9, HzAM1, SeFB, and HaFB cells, including swelling and detachment. Notably, the latter phenomena did not occur in HvAV-3j-inoculated mammalian cells (HEK293, 7402, HePG2, PK15, ST, and TM3). MTT assays indicated that

HvAV-3j inhibited the growth of host insect cells from the 6th hpi, but no effects were detected in the HvAV-3j-inoculated mammalian cells. Furthermore, viral DNA replication, gene transcription, and protein expression were investigated, and the results consistently suggested that HvAV-3j viruses were not able to replicate their genomic DNA, transcribe, or express their proteins in the non-target vertebrate cells. The HvAV-3j genes were only transcribed and expressed in the four insect cell lines. These results indicated that HvAV-3j was infectious to cells derived from *S. frugiperda*, *S. exigua*, *H. armigera*, and *H. zea* but not to cells derived from human, pig, and mouse, suggesting that ascoviruses are safe to nontarget vertebrate cells.




Research Article

Molecular Characterization and Expression Analysis of *ftr01*, *ftr42*, and *ftr58* in Zebrafish (*Danio rerio*)

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

Wanmeng Liu, Ming Kuang, Ze Zhang, Yuanan Lu, Xueqin Liu

Tripartite motif (TRIM) proteins were shown to play an important role in innate antiviral immunity. FinTRIM (*ftr*) is a new subset of TRIM genes that do not possess obvious orthologs in higher vertebrates. However, little is known about its function. In this study, we used bioinformatic analysis to examine the phylogenetic relationships and conserved domains of zebrafish (*Danio rerio*) *ftr01*, *ftr42*, and *ftr58*, as well as qualitative real-time PCR to examine their expression patterns in zebrafish embryonic fibroblast (ZF4) cells and zebrafish tissues. Sequence analysis showed that the three finTRIMs are highly conserved, and all contain a RING domain, B-box domain, and SPRY-PRY domain. In addition, *ftr42* and *ftr58* had one coiled-coil domain (CCD), whereas *ftr01* had two CCDs. Tissue expression analysis revealed that the mRNA level of *ftr01* was the highest in the liver, whereas those of *ftr42* and *ftr58* were the highest in the gill; the expression of these finTRIMs was clearly upregulated not in the eyes, but in the liver, spleen, kidney, gill, and brain of zebrafish following spring viremia of carp virus (SVCV) infection. Similarly, the expression of these three finTRIM genes also increased in ZF4 cells after SVCV infection. Our study revealed that *ftr01*, *ftr42*, and *ftr58* may play an important role in antiviral immune responses, and these findings validate the need for more in-depth research on the finTRIM family in the future.




Research Article

Construction of a One-Vector Multiplex CRISPR/Cas9 Editing System to Inhibit Nucleopolyhedrovirus Replication in Silkworms

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

Zhanqi Dong, Qi Qin, Zhigang Hu, Peng Chen, Liang Huang, Xinling Zhang, Ting Tian, Cheng Lu, Minhui Pan

Recently the developed single guide (sg)RNA-guided clustered regularly interspaced short palindromic repeats/associated protein 9 nuclease (CRISPR/Cas9) technology has opened a new avenue for antiviral therapy. The CRISPR/Cas9 system uniquely allows targeting of multiple genome sites simultaneously. However, there are relatively few applications of CRISPR/Cas9 multigene editing to target insect viruses. To address the need for sustained delivery of a multiplex CRISPR/Cas9-based genome-editing vehicle against insect viruses, we developed a one-vector (pSL1180-Cas9-U6-sgRNA) system that expresses multiple sgRNA and Cas9 protein to excise *Bombyx mori* nucleopolyhedrovirus (BmNPV) in insect cells. We screened the immediate-early-1 gene (*ie-1*), the major envelope glycoprotein gene (*gp64*), and the late expression factor gene (*lef-11*), and identified multiple sgRNA editing sites through flow cytometry and viral DNA replication analysis. In addition, we constructed a multiplex editing vector (PSL1180-Cas9-sgIE1-sgLEF11-sgGP64, sgMultiple) to efficiently regulate multiplex gene-editing and inhibit BmNPV replication after viral infection. This is the first report of the application of a multiplex CRISPR/Cas9 system to inhibit insect virus replication. This multiplex system can significantly enhance the potential of CRISPR/Cas9-based multiplex genome engineering in insect virus.




Research Article

Improving Baculovirus Transduction of Mammalian Cells by Incorporation of Thogotovirus Glycoproteins

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

Liangbo Hu, Yimeng Li, Fei Deng, Zhihong Hu, Hualin Wang, Manli Wang

Baculovirus can transduce a wide range of mammalian cells and is considered a promising gene therapy vector. However, the low transduction efficiency of baculovirus into many mammalian cells limits its practical application. Co-expressing heterologous viral glycoproteins (GPs), such as vesicular stomatitis virus G protein (VSV G), with baculovirus native envelope protein GP64 is one of the feasible strategies for improving virus transduction. Tick-borne thogotoviruses infect mammals and their GPs share sequence/structure homology and common evolutionary origins with baculovirus GP64. Herein, we tested whether thogotovirus GPs could facilitate the entry of the prototype baculovirus *Autographa californica* multiple multiple nucleopolyhedrovirus (AcMNPV) into mammalian cells. The *gp* genes of two thogotoviruses, Thogoto virus and Dhori virus, were inserted into the AcMNPV genome. Both GPs were properly expressed and incorporated into the envelope of the recombinant AcMNPVs. The transduction rates of recombinant AcMNPVs expressing the two thogotovirus GPs increased for approximately 4–12 fold compared to the wild type AcMNPV in six of the 12 tested mammalian cell lines. It seemed that thogotovirus GPs provide the recombinant AcMNPVs with different cell tropisms and showed better performance in several mammalian cells compared to VSV G incorporated AcMNPV. Further studies showed that the improved transduction was a result of augmented virus-endosome fusion and endosome escaping, rather than increased cell binding or internalization. We found the AcMNPV envelope protein GP64-mediated fusion was enhanced by the thogotovirus GPs at relatively higher pH conditions. Therefore, the thogotovirus GPs represent novel candidates to improve baculovirus-based gene delivery vectors.




Letter

Establishment of Novel Monoclonal Fabs Specific for Epstein-Barr Virus Encoded Latent Membrane Protein 1

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

Gaoxin Li, Ling Ding, Xiaojing Ma, Qiliang Cai, Tianlei Ying, Fang Wei

Here we isolated the Fab clones 1-A11, 6-C6, 10-B2, and 15-H10 and confirmed their recognition of LMP1 expressed on the surface of EBV⁺ B95.8 cells. Recognition of LMP1 on the cell membrane by clone 15-H10 was verified through immunofluorescent assay, while other clones failed the recognition. One of the possible reasons could be the stringent washing in this assay that ruptured the low affinity Fab-LMP1 binding. EBV infection is related with multiple diseases, and conventional approaches used in laboratory diagnostic tests for EBV infection and pathogenesis have their limitations [(generate false positive results or lack the ability to localize the expression of EBV within target cells) (Young and Rickinson 2004)]. The LMP1-specific Fab clones reported here need further evaluation in both affinity and specificity in testing EBV⁺ patient samples, and hopefully it could have potential applications in EBV diagnostics and directly targeting EBV-related tumors in adoptive T cell therapy.




Letter

Genomic Characterization of the First Parechovirus in Bats

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

Chang Zhang, Jinliang Sheng, Zihan Zhao, Chao Yan, Changchun Tu, Biao He

As important hosts for several pathogenic viruses, bats harbor viruses from almost all families of vertebrate viruses, including several genera of family *Picornaviridae*, including *Hepatovirus*, *Kobuvirus*, *Crohivirus*, and *Sapelovirus* (Drexler *et al.* 2015; Wu *et al.* 2016; Yinda *et al.* 2017). However, PeVs were not reported in bats until our recent viral metagenomic analysis of 122 adult healthy bats (*Pipistrellus pipistrellus*) obtained from two locations in Xinjiang (Xinyuan, $n = 46$; Qapqal, $n = 76$) in 2016, revealing thousands of reads related to PeV (Zhang *et al.* 2018). PCR-based screening revealed that 6.5% and 10.5% bats from Xinyuan and Qapqal, respectively, harbored this virus, and preliminary phylogenetic analysis of 396-nt-long amplicons targeting the VP1 region (GenBank accession numbers: MH921430–MH921443) revealed $> 91.5\%$ identities among each other and 63.7%–64.2% identity with their closest phylogenetic neighbor, FPeV (Smits *et al.* 2013; Zhang *et al.* 2018). This study reports the complete genomic characterization of the first bat PeV to better understand its evolutionary history.



Meeting Report

Virology at the Lorne Infection and Immunity Conference 2019

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

Sarah L. Londrigan, Gregor Ebert, Prasad N. Paradkar

The Lorne Infection and Immunity Conference is one of five scientific meetings held during each month of February at the Cumberland resort in the picturesque seaside town of Lorne, on the Great Ocean Road in Victoria (Australia). The specific aim of the meeting is to bring together basic, clinical and translational researchers—those who examine microbes and their impact on the innate or adaptive immune response, researchers who study the mechanisms that regulate immune responses, and those who apply this knowledge to preventing and treating infectious and inflammatory diseases. The average number of attendees is 220, with registrants appreciative of the welcoming and relaxed atmosphere.

Copyright © 2019. All rights reserved.

Virologica Sinica



Virologica Sinica respects your right to privacy. To see the types of information we may hold or collect about you and how we may use that information, please see our [Privacy Policy](#).

From: wen yumei <ymwen@shmu.edu.cn>
Sent: Saturday, August 24, 2019 10:33 PM
To: Lu, Shan; YiWei Tang; Zheng, Zhi-Ming (Thomas) (NIH/NCI) [E]
Cc: 杨旻
Subject: Fw: To Dr.Wen - Virologica Sinica, Volume 34, Issue 4

I am forwarding you the design of the informatioan from Birologica sinica, which may be a reference for us to improve the design for EMI.

In addition, hope Yiwei and Zhiming can help to get someone wirte good reviews for EMI.Wen

-----原始邮件-----

发件人:Virologica-1 <virosin@wh.iov.cn>

发送时间:2019-08-24 12:08:09 (星期六)

收件人: ymwen@shmu.edu.cn

抄送:

主题: To Dr.Wen - Virologica Sinica, Volume 34, Issue 4

If you do not wish to receive this newsletter please click here [Unsubscribe](#).

The 8th Wuhan International Symposium
on Mordern Virology
September 18–20 2019, Wuhan, China



Chinese Society for Microbiology
2019 Annual Meeting
October 11–15, 2019, Jinan, China

Virologica
Sinica



Serving the Society Since 1986

Dear Dr. Wen,



It is my pleasure to present you the review, research articles, letters and meeting report recently published in *Virologica Sinica*.

Your suggestions are welcome!

Zheng-Li Shi, Ph.D.
Editor-in-Chief, *Virologica Sinica*

Browse the website www.virosin.org for more information

Enjoy rapid & free publication in *Virologica Sinica*



Virologica Sinica is an academic journal which aims at presenting the cutting-edge basic and applied research on viruses all over the world. The journal publishes peer-reviewed original research articles and reviews, as well as commentaries and letters to the editor, to encompass the latest developments in all branches of virology, including research on animal, plant and microbe viruses. *Virologica Sinica*, the official journal of Chinese Society for Microbiology, will serve as a platform for the communication and exchange of academic information and ideas in an international context.

The journal is indexed by: Science Citation Index (SCI), JCR, PubMed/Medline, Scopus, BIOSIS, Google Scholar, and SCImago.



About the cover: Mitochondria are multifunctional eukaryotic organelles with diverse roles, including energy production and distribution, apoptosis, innate immunity, metabolic regulation, cell-cycle control and signal transduction. The interactions between viruses and the host mitochondria are crucial for virus replication and pathogenicity. Yang Yang *et al.* found that Enterovirus A71 (EV-A71) infection resulted in a perinuclear redistribution of the mitochondria, and the microtubule skeleton and the dynein motor complex were required for this redistribution. They further revealed that the interaction between EV-A71 2BC protein and mitochondrial Rho GTPase 1 played a crucial role in the regulation of mitochondrial motility, and the mitochondria redistribution was required for EV-A71 replication and proliferation. Their study reports a novel function of the EV-A71 2BC protein and provides an insight into the regulation of organelle transport in the EV-A71-infected cells. Please see page 397–411 for details.

Why *Virologica Sinica*?

- ✓ Indexed/Abstracted by SCI, PubMed/Medline, Scopus, Google Scholar
- ✓ Global visibility and increasing impact
- ✓ Publish special issues and topics
- ✓ Rapid peer review and publication
- ✓ No page/color charges, open-access options
- ✓ Free language editing

Submit now!

SCHOLARONE™
Manuscripts

2019, Vol. 34, Issue 4

Review


Specific and Selective Bacteriophages in the Fight against Multidrug-resistant *Acinetobacter baumannii*

Free Full Text (HTML) **Free Full Text (PDF)**

Natalia Bagińska, Anna Pichlak, Andrzej Górski, Ewa Jończyk-Matysiak

Acinetobacter baumannii causes serious infections especially in immunocompromised and/or hospitalized patients. Several *A. baumannii* strains are multidrug resistant and infect wounds, bones, and the respiratory tract. Current studies are focused on finding new effective agents against *A. baumannii*. Phage therapy is a promising means to fight this bacterium and many studies on procuring and applying new phages against *A. baumannii* are currently being conducted. As shown in animal

models, phages against multidrug-resistant *A. baumannii* may control bacterial infections caused by this pathogen and may be a real hope to solve this dangerous health problem.




Research Article

Prevalence of HIV Indeterminate Western Blot Tests and Follow-up of HIV Antibody Sero-Conversion in Southeastern China

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

Shouli Wu, Min Gao, Jian Zheng, Pingping Yan, Wei Wang, Xiaoli Lu, Yuefeng Qiu, Yansheng Yan

HIV-indeterminate Western blotting (WB) results are typically obtained in WB confirmatory assays, and the number of indeterminate samples may increase with the detection of HIV infections, which will present considerable challenges for the management of HIV/AIDS. Nucleic acid detection has been used as a laboratory test for screening suspected or indeterminate samples. However, the effectiveness of these assays for the differential diagnosis of HIV-indeterminate WB samples remained undetermined. In this study, 210 subjects with HIV-indeterminate WB results were detected from 6360 positive HIV screening samples between 2015 and 2016 in southeastern China, in which HIV-indeterminate WB results accounted for 3.30%. The highest proportion of indeterminate results was observed in pregnant and lying-in women receiving physical examinations (16.67%), followed by that in voluntary blood donors (8.82%). The most common WB band patterns were p24, gp160 and p24, and gp160. The follow-up study revealed that the highest negative and positive conversion rates of HIV antibodies were in samples with a single p24 band (80.28%), and with gp160 and p24 bands (86.21%), respectively. Among the Env, Gag, and Pol antibodies, samples with a Gag band showed the highest negative conversion rate (81.25%), whereas the highest positive conversion rate was observed in samples with an Env band (56.76%). In addition, quantitative and qualitative HIV nucleic acid testing exhibited the highest sensitivity (96.3%) and specificity (97.85%), respectively. Our results indicate a lower proportion of HIV indeterminate WB results in southeastern China compared to previous reports, and the follow-up re-examination of patients with HIV indeterminate results should be performed. Nucleic acid testing facilitates the identification of HIV infections.




Research Article

Cross-sectional Seroprevalence and Genotype of Hepatitis E Virus in Humans and Swine in a High-density Pig-farming Area in Central China

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

Yilin Shu, Yameng Chen, Sheng Zhou, Shoude Zhang, Qin Wan, Changcai Zhu, Zhijiang Zhang, Hailong Wu, Jianbo Zhan, Ling Zhang

Hepatitis E virus (HEV) infection is a common public health problem in developing countries. However, the current prevalence of HEV and the relationship of HEV genotype between swine and human within high-density pig-farming areas in central China are still inadequately understood. Here, cross-sectional serological and genotypic surveys of HEV among the 1232 general population, 273 workers occupationally exposed to swine, and 276 pigs in a high-density pig-breeding area, were undertaken by ELISA and nested RT-PCR methods. Anti-HEV IgG was detected in 26.22% of general population and 48.35% of occupational workers. The prevalence of swine serum HEV-Ag was 6.52%. The prevalence of anti-HEV IgG was significantly higher among the workers occupationally exposed to swine than among the general population. An increased HEV seropositivity risk among the general population was associated with either being a peasant or male and was very strongly associated with the increase of age. Among the occupationally exposed group, the prevalence of anti-HEV IgG antibodies increased with age and working years. Among the 30 HEV-IgM-positive people, the infection rates of clerks in the public, peasants, pork retailers, and pig farmers were higher than those of others. A phylogenetic analysis revealed that all the isolates belonged to subgenotype 4_d, and four people and four pigs shared 97.04%–100% sequence homology. This study revealed a high HEV seroprevalence among the general population and workers occupationally exposed to swine in the Anlu City, and supports the notion that swine are a source of human HEV infection.




Research Article

Complementation of Wild-Type and Drug-Resistant Hepatitis B Virus Genomes to Maintain Viral Replication and Rescue Virion Production under Nucleos(t)ide Analogs **Free Full Text (HTML) Free Full Text (PDF)**

Chunchen Wu, Baolin Li, Xiaoyong Zhang, Kaitao Zhao, Yingshan Chen, Yifei Yuan, Yan Liu, Rongjuan Chen, Dongping Xu, Xinwen Chen, Mengji Lu

As the open reading frames of hepatitis B virus (HBV) genomes are overlapping, resistance mutations (MTs) in HBV polymerase may result in stop codon MTs in hepatitis B surface proteins, which are usually detected as a mixed population with wild-type (WT) HBV. The question was raised how the coexistence of nucleos(t)ide analogs (NAs) resistance MTs and WT sequences affects HBV replication. In the present study, HBV genomes with frequently detected reverse transcriptase (RT)/surface truncation MTs, rtA181T/sW172*, rtV191I/sW182* and rtM204I/sW196*, were phenotypically characterized alone or together with their WT counterparts in different ratios by transient transfection in the absence or presence of NAs. In the absence of NAs, RT/surface truncation MTs impaired the expression and secretion of HBV surface proteins, and had a dose-dependent negative effect on WT HBV virion secretion. However, in the presence of NAs, coexistence of MTs with WT maintained viral replication, and the presence of WT was able to rescue the production of MT HBV virions. Our findings reveal that complementation of WT and MT HBV genomes is highly effective under drug treatment.




Research Article

Effect of Loss-of-function of the Herpes Simplex Virus-1 microRNA H6-5p on Virus Replication

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

Rongquan Huang, Xusha Zhou, Shuqi Ren, Xianjie Liu, Zhiyuan Han, Grace Guoying Zhou

To date, 29 distinct microRNAs (miRNAs) have been reported to be expressed during herpes simplex virus infections. Sequence analysis of mature herpes simplex virus-1 (HSV-1) miRNAs revealed five sets of miRNAs that are complementary to each other: miR-H6-5p/H1-3p, miR-H6-3p/H1-5p, H2-5p/H14-3p, miR-H2-3p/H14-5p, and miR-H7/H27. However, the roles of individual miRNAs and consequences of this complementarity remain unclear. Here, we focus on two of these complementary miRNAs, miR-H6-5p and miR-H1-3p, using loss-of-function experiments *in vitro* and in a mouse model of infection using an miRNA sponge approach, including tandem multiplex artificial miRNA-binding sequences that do not match perfectly to the target miRNA inserted downstream of a green fluorescent protein reporter gene. Infection with recombinant virus expressing the miR-H6-5p sponge reduced viral protein levels and virus yield. Decreased accumulation of viral proteins was also observed at early stages of infection in the presence of both an miR-H6-5p inhibitor and plasmid-expressed miR-H1-3p. Moreover, establishment of latency and reactivation did not differ between the recombinant virus expressing the miR-H6-5p sponge and wild-type HSV-1. Taken together, these data suggest that miR-H6-5p has an as-yet-unidentified role in the early stages of viral infection, and its complement miR-H1-3p suppresses this role in later stages of infection. This report extends understanding of the roles of miRNAs in infection by herpes simplex viruses, supporting a model of infection in which the production of virus and its virulent effects are tightly controlled to maximize persistence in the host and population.




Research Article

Mitochondria Redistribution in Enterovirus A71 Infected Cells and Its Effect on Virus Replication

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

Yang Yang, Haolong Cong, Ning Du, Xiaodong Han, Lei Song, Wenliang Zhang, Chunrui Li, Po Tien

Enterovirus A71 (EV-A71) is one of the main causative agents of hand, foot and mouth disease (HFMD) and it also causes severe neurologic complications in infected children. The interactions between some viruses and the host mitochondria are crucial for virus replication and pathogenicity. In this study, it was observed that EV-A71 infection resulted in a perinuclear redistribution of the mitochondria. The mitochondria rearrangement was found to require the microtubule network, the dynein complex and a low cytosolic calcium concentration. Subsequently, the EV-A71 non-structural protein 2BC was identified as the viral protein capable of inducing mitochondria clustering. The protein was found localized on mitochondria and interacted with the mitochondrial Rho GTPase 1 (RHOT1) that is a key protein required for attachment between the mitochondria and the motor proteins, which are responsible for the control of mitochondria movement. Additionally, suppressing mitochondria clustering by treating cells with nocodazole, EHNA, thapsigargin or A23187 consistently inhibited EV-A71 replication, indicating that mitochondria recruitment played a crucial role in the EV-A71 life cycle. This study identified a novel function of the EV-A71 2BC protein and provided a potential model for the regulation of mitochondrial motility in EV-A71 infection.




Research Article

Trans Complementation of Replication-defective Omsk Hemorrhagic Fever Virus for Antiviral Study

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

Qiuyan Zhang, Na Li, Chenglin Deng, Zherui Zhang, Xiaodan Li, Kentaro Yoshii, Hanqing Ye, Bo Zhang

Omsk hemorrhagic fever virus (OHFV) is a tick-borne flavivirus classified as a biosafety level-4 (BSL4) pathogen. Studies of OHFV are restricted to be conducted within BSL4 laboratories. Currently, no commercial vaccines or antiviral drugs are available against OHFV infection. In this study, we recovered a replication-deficient OHFV with an NS1 deletion (OHFV-ΔNS1) and reporter virus replacing NS1 with the *Gaussia* luciferase (Gluc) (OHFV-ΔNS1-Gluc). Both the defective OHFV-ΔNS1 and OHFV-ΔNS1-Gluc virus could only replicate efficiently in the BHK21 cell line expressing NS1 (BHK21_{NS1}) but not in naïve BHK21 cells. The Gluc reporter gene of OHFV-ΔNS1-Gluc virus was maintained stably after serial passaging of BHK21_{NS1} cells and was used to surrogate the replication of OHFV. Using NITD008, OHFV-ΔNS1-Gluc virus was validated for antiviral screening, and high-throughput screening parameters were optimized in a 96-well plate format with a calculated Z' value above 0.5. The OHFV-ΔNS1-Gluc reporter virus is a powerful tool for antiviral screening as well as viral replication and pathogenesis studies in BSL2 laboratories.



Research Article


In Vitro Infectious Risk Assessment of Heliothis virescens ascovirus 3j (HvAV-3j) toward Non-target Vertebrate Cells

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

Huan Yu, Yi-Yi Ou-Yang, Ni Li, Madoka Nakai, Guo-Hua Huang

As specific pathogens of noctuid pests, including *Spodoptera exigua*, *S. litura*, *Helicoverpa armigera*, and *Mythimna separata*, ascoviruses are suitable for the development of bioinsecticides. In this study, the infectivity of *Heliothis virescens* ascovirus 3j (HvAV-3j) on insect and mammalian cells was evaluated. HvAV-3j infection induced drastic morphological changes in Sf9, HzAM1, SeFB, and HaFB cells, including swelling and detachment. Notably, the latter phenomena did not occur in HvAV-3j-inoculated mammalian cells (HEK293, 7402, HePG2, PK15, ST, and TM3). MTT assays indicated that

HvAV-3j inhibited the growth of host insect cells from the 6th hpi, but no effects were detected in the HvAV-3j-inoculated mammalian cells. Furthermore, viral DNA replication, gene transcription, and protein expression were investigated, and the results consistently suggested that HvAV-3j viruses were not able to replicate their genomic DNA, transcribe, or express their proteins in the non-target vertebrate cells. The HvAV-3j genes were only transcribed and expressed in the four insect cell lines. These results indicated that HvAV-3j was infectious to cells derived from *S. frugiperda*, *S. exigua*, *H. armigera*, and *H. zea* but not to cells derived from human, pig, and mouse, suggesting that ascoviruses are safe to nontarget vertebrate cells.




Research Article

Molecular Characterization and Expression Analysis of *ftr01*, *ftr42*, and *ftr58* in Zebrafish (*Danio rerio*)

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

Wanmeng Liu, Ming Kuang, Ze Zhang, Yuanan Lu, Xueqin Liu

Tripartite motif (TRIM) proteins were shown to play an important role in innate antiviral immunity. FinTRIM (*ftr*) is a new subset of TRIM genes that do not possess obvious orthologs in higher vertebrates. However, little is known about its function. In this study, we used bioinformatic analysis to examine the phylogenetic relationships and conserved domains of zebrafish (*Danio rerio*) *ftr01*, *ftr42*, and *ftr58*, as well as qualitative real-time PCR to examine their expression patterns in zebrafish embryonic fibroblast (ZF4) cells and zebrafish tissues. Sequence analysis showed that the three finTRIMs are highly conserved, and all contain a RING domain, B-box domain, and SPRY-PRY domain. In addition, *ftr42* and *ftr58* had one coiled-coil domain (CCD), whereas *ftr01* had two CCDs. Tissue expression analysis revealed that the mRNA level of *ftr01* was the highest in the liver, whereas those of *ftr42* and *ftr58* were the highest in the gill; the expression of these finTRIMs was clearly upregulated not in the eyes, but in the liver, spleen, kidney, gill, and brain of zebrafish following spring viremia of carp virus (SVCV) infection. Similarly, the expression of these three finTRIM genes also increased in ZF4 cells after SVCV infection. Our study revealed that *ftr01*, *ftr42*, and *ftr58* may play an important role in antiviral immune responses, and these findings validate the need for more in-depth research on the finTRIM family in the future.




Research Article

Construction of a One-Vector Multiplex CRISPR/Cas9 Editing System to Inhibit Nucleopolyhedrovirus Replication in Silkworms

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

Zhanqi Dong, Qi Qin, Zhigang Hu, Peng Chen, Liang Huang, Xinling Zhang, Ting Tian, Cheng Lu, Minhui Pan

Recently the developed single guide (sg)RNA-guided clustered regularly interspaced short palindromic repeats/associated protein 9 nuclease (CRISPR/Cas9) technology has opened a new avenue for antiviral therapy. The CRISPR/Cas9 system uniquely allows targeting of multiple genome sites simultaneously. However, there are relatively few applications of CRISPR/Cas9 multigene editing to target insect viruses. To address the need for sustained delivery of a multiplex CRISPR/Cas9-based genome-editing vehicle against insect viruses, we developed a one-vector (pSL1180-Cas9-U6-sgRNA) system that expresses multiple sgRNA and Cas9 protein to excise *Bombyx mori* nucleopolyhedrovirus (BmNPV) in insect cells. We screened the immediate-early-1 gene (*ie-1*), the major envelope glycoprotein gene (*gp64*), and the late expression factor gene (*lef-11*), and identified multiple sgRNA editing sites through flow cytometry and viral DNA replication analysis. In addition, we constructed a multiplex editing vector (PSL1180-Cas9-sgIE1-sgLEF11-sgGP64, sgMultiple) to efficiently regulate multiplex gene-editing and inhibit BmNPV replication after viral infection. This is the first report of the application of a multiplex CRISPR/Cas9 system to inhibit insect virus replication. This multiplex system can significantly enhance the potential of CRISPR/Cas9-based multiplex genome engineering in insect virus.




Research Article

Improving Baculovirus Transduction of Mammalian Cells by Incorporation of Thogotovirus Glycoproteins

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

Liangbo Hu, Yimeng Li, Fei Deng, Zhihong Hu, Hualin Wang, Manli Wang

Baculovirus can transduce a wide range of mammalian cells and is considered a promising gene therapy vector. However, the low transduction efficiency of baculovirus into many mammalian cells limits its practical application. Co-expressing heterologous viral glycoproteins (GPs), such as vesicular stomatitis virus G protein (VSV G), with baculovirus native envelope protein GP64 is one of the feasible strategies for improving virus transduction. Tick-borne thogotoviruses infect mammals and their GPs share sequence/structure homology and common evolutionary origins with baculovirus GP64. Herein, we tested whether thogotovirus GPs could facilitate the entry of the prototype baculovirus *Autographa californica* multiple multiple nucleopolyhedrovirus (AcMNPV) into mammalian cells. The *gp* genes of two thogotoviruses, Thogoto virus and Dhori virus, were inserted into the AcMNPV genome. Both GPs were properly expressed and incorporated into the envelope of the recombinant AcMNPVs. The transduction rates of recombinant AcMNPVs expressing the two thogotovirus GPs increased for approximately 4–12 fold compared to the wild type AcMNPV in six of the 12 tested mammalian cell lines. It seemed that thogotovirus GPs provide the recombinant AcMNPVs with different cell tropisms and showed better performance in several mammalian cells compared to VSV G incorporated AcMNPV. Further studies showed that the improved transduction was a result of augmented virus-endosome fusion and endosome escaping, rather than increased cell binding or internalization. We found the AcMNPV envelope protein GP64-mediated fusion was enhanced by the thogotovirus GPs at relatively higher pH conditions. Therefore, the thogotovirus GPs represent novel candidates to improve baculovirus-based gene delivery vectors.




Letter

Establishment of Novel Monoclonal Fabs Specific for Epstein-Barr Virus Encoded Latent Membrane Protein 1

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

Gaoxin Li, Ling Ding, Xiaojing Ma, Qiliang Cai, Tianlei Ying, Fang Wei

Here we isolated the Fab clones 1-A11, 6-C6, 10-B2, and 15-H10 and confirmed their recognition of LMP1 expressed on the surface of EBV⁺ B95.8 cells. Recognition of LMP1 on the cell membrane by clone 15-H10 was verified through immunofluorescent assay, while other clones failed the recognition. One of the possible reasons could be the stringent washing in this assay that ruptured the low affinity Fab-LMP1 binding. EBV infection is related with multiple diseases, and conventional approaches used in laboratory diagnostic tests for EBV infection and pathogenesis have their limitations [(generate false positive results or lack the ability to localize the expression of EBV within target cells) (Young and Rickinson 2004)]. The LMP1-specific Fab clones reported here need further evaluation in both affinity and specificity in testing EBV⁺ patient samples, and hopefully it could have potential applications in EBV diagnostics and directly targeting EBV-related tumors in adoptive T cell therapy.




Letter

Genomic Characterization of the First Parechovirus in Bats

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

Chang Zhang, Jinliang Sheng, Zihan Zhao, Chao Yan, Changchun Tu, Biao He

As important hosts for several pathogenic viruses, bats harbor viruses from almost all families of vertebrate viruses, including several genera of family *Picornaviridae*, including *Hepatovirus*, *Kobuvirus*, *Crohivirus*, and *Sapelovirus* (Drexler *et al.* 2015; Wu *et al.* 2016; Yinda *et al.* 2017). However, PeVs were not reported in bats until our recent viral metagenomic analysis of 122 adult healthy bats (*Pipistrellus pipistrellus*) obtained from two locations in Xinjiang (Xinyuan, $n = 46$; Qapqal, $n = 76$) in 2016, revealing thousands of reads related to PeV (Zhang *et al.* 2018). PCR-based screening revealed that 6.5% and 10.5% bats from Xinyuan and Qapqal, respectively, harbored this virus, and preliminary phylogenetic analysis of 396-nt-long amplicons targeting the VP1 region (GenBank accession numbers: MH921430–MH921443) revealed $> 91.5\%$ identities among each other and 63.7%–64.2% identity with their closest phylogenetic neighbor, FPeV (Smits *et al.* 2013; Zhang *et al.* 2018). This study reports the complete genomic characterization of the first bat PeV to better understand its evolutionary history.



Meeting Report

Virology at the Lorne Infection and Immunity Conference 2019

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

Sarah L. Londrigan, Gregor Ebert, Prasad N. Paradkar

The Lorne Infection and Immunity Conference is one of five scientific meetings held during each month of February at the Cumberland resort in the picturesque seaside town of Lorne, on the Great Ocean Road in Victoria (Australia). The specific aim of the meeting is to bring together basic, clinical and translational researchers—those who examine microbes and their impact on the innate or adaptive immune response, researchers who study the mechanisms that regulate immune responses, and those who apply this knowledge to preventing and treating infectious and inflammatory diseases. The average number of attendees is 220, with registrants appreciative of the welcoming and relaxed atmosphere.

Copyright © 2019. All rights reserved.

Virologica Sinica



Virologica Sinica respects your right to privacy. To see the types of information we may hold or collect about you and how we may use that information, please see our [Privacy Policy](#).

From: Liu, Shan-Lu <liu.6244@osu.edu>
Sent: Sunday, December 13, 2020 11:40 AM
To: Lu, Shan
Subject: FW: Undeliverable: Re: Slides

Even with split, part 1 still cannot be sent. Did you receive part 2?

From: Microsoft Outlook
<MicrosoftExchange329e71ec88ae4615bbc36ab6ce41109e@buckeyemailosu.onmicrosoft.com>
Date: Sunday, December 13, 2020 at 11:37 AM
To: "Lu, Shan" <Shan.Lu@umassmed.edu>
Subject: Undeliverable: Re: Slides

Your message wasn't delivered to anyone because it's too large. The limit is 30 MB. Your message is 36 MB.

[Lu, Shan \(Shan.Lu@umassmed.edu\)](mailto:Shan.Lu@umassmed.edu)

Your message is larger than the size limit for messages. Please make it smaller and try sending it again.

smtp.service.osu.edu gave this error:
SMTPSEND.OverAdvertisedSize; message size exceeds fixed maximum size

Diagnostic information for administrators:

Generating server: DM6PR01MB4313.prod.exchangelabs.com

Shan.Lu@umassmed.edu

smtp.service.osu.edu

Remote Server returned '550 5.3.4 SMTPSEND.OverAdvertisedSize; message size exceeds fixed maximum size'

Original message headers:

ARC-Seal: i=1; a=rsa-sha256; s=arcselector9901; d=microsoft.com; cv=none;

b=BPae1cgKJLL3t3TyYNkSNMVjCmX4MIkRcD6+MIaO7+PkrpvxrUK+WOP+V09+0aFOuhMF2AUfpszOkCCB6V0crB
MO04aEkKWlfQYSas1HTnR5/IeuSkp6GBkbhtXgv6FGMLZa8YamlyeilDhiCR3bwf1zuONriXT6RhIsbrVQvyGhm7G
0nly1tI4pS2QQ9triyujgaAc2zqr9id7IQSdzf0IV9TU95n+4WywbYGvAxIZHh4CQWJwzT8QBuk+8KCRGwjO2IGkP
wVMrvCZGx1T3Tje2XK816XVvJJkR2fgNskgNSIJqKplWTRN90LLJvN/ND11AEtzKYOlWuEaxU9gWA==

ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=microsoft.com;
s=arcselector9901;

h=From:Date:Subject:Message-ID:Content-Type:MIME-Version:X-MS-Exchange-SenderADCheck;

bh=2So3urZrW3Gy3EtGmDUe1WP78BM5a8hE1hNfw1kAlW4=;

b=Rbtw07cXrcFt66UC/cz9vIxW37UM0dn+LRj/zPaNCKGsVwzP/R/i7sQfzOyXbHwCxGusJQ3Yn4OJhDzEBB+9m16

uFx0S4qaV+wuBUhbmICZY0jGVYAsoguKSkLznZzzD100c1oV876/9SAQoOkkN1oTqefhYtKSAmXkfm/sVnN2dMu2p
b6MiiXL3kV35QyyFOO2Bw0SKYmjNzT1XWVVHfOeU2aejyHA9db5gAsbWu/2KcmQl1KG4MCugr46MfRSAuWoLxhZMr
Wp7JjP36dweFJZv3otJQqDuyNcuZZ6NmujZ394y1Tj6RGuW1xqHmbrntIsGa09oiKqmDDlpacQZGw==
ARC-Authentication-Results: i=1; mx.microsoft.com 1; spf=pass
smtp.mailfrom=osu.edu; dmarc=pass action=none header.from=osu.edu; dkim=pass
header.d=osu.edu; arc=none
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=osu.edu; s=selector1;
h=From:Date:Subject:Message-ID:Content-Type:MIME-Version:X-MS-Exchange-SenderADCheck;
bh=2So3urZrW3Gy3EtGmDUe1WP78BM5a8hE1hNfw1kAlW4=;

b=J0zqJ/zJBdnELYO96t4JGZ73+CJycLqg6yHYfEg9qgS2EsIhk67/19eIwAwd26tM2PWZJDFfc1W6zFJLqC9ohOS
/zV8cZlqTIBwBHPD7GyCKxWZgvb2X1VIybbspW3HRSb+2vCbXJeQPX9BGgTT3XLdJCTq1Y5tXfN+w6ew6qIA=
Received: from DM6PR01MB5147.prod.exchangelabs.com (2603:10b6:5:5e::20) by
DM6PR01MB4313.prod.exchangelabs.com (2603:10b6:5:22::23) with Microsoft SMTP
Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id
15.20.3654.20; Sun, 13 Dec 2020 16:37:33 +0000
Received: from DM6PR01MB5147.prod.exchangelabs.com
([fe80::414a:60b1:1bdf:db2f]) by DM6PR01MB5147.prod.exchangelabs.com
([fe80::414a:60b1:1bdf:db2f%7]) with mapi id 15.20.3654.018; Sun, 13 Dec 2020
16:37:33 +0000
From: "Liu, Shan-Lu" <liu.6244@osu.edu>
To: "Lu, Shan" <Shan.Lu@umassmed.edu>
Subject: Re: Slides
Thread-Topic: Slides
Thread-Index: AQHW006ZMZ4zUPbkhEqt8QfUJkgIM6nz6IyAgABTH9CAAKosgA==
Date: Sun, 13 Dec 2020 16:37:31 +0000
Message-ID: <D554F48F-CD18-4B07-A3DA-D34F944525B7@osu.edu>
References: <DF14698E-2511-458E-A957-A874F569DE7C@osu.edu>
<A3F515D3-1A8D-426F-96BF-B01C56E87D0A@osu.edu>
<MN2PR10MB416041A14BFB2B7E090D3A3F96C80@MN2PR10MB4160.namprd10.prod.outlook.com>
In-Reply-To:
<MN2PR10MB416041A14BFB2B7E090D3A3F96C80@MN2PR10MB4160.namprd10.prod.outlook.com>
Accept-Language: en-US
Content-Language: en-US
X-MS-Has-Attach: yes
X-MS-TNEF-Correlator:
user-agent: Microsoft-MacOutlook/16.43.20110804
authentication-results: umassmed.edu; dkim=none (message not signed)
header.d=none;umassmed.edu; dmarc=none action=none header.from=osu.edu;
x-originating-ip: [107.11.248.9]
x-ms-publictraffictype: Email
x-ms-office365-filtering-correlation-id: b01f7d71-d80e-468d-2962-08d89f856435
x-ms-traffictypediagnostic: DM6PR01MB4313;
x-microsoft-antispam-prvs:
<DM6PR01MB4313547ABA7F1037D173AD6393C80@DM6PR01MB4313.prod.exchangelabs.com>
x-header-sapphire: true
x-ms-oob-tlc-oobclassifiers: OLM:10000;
x-ms-exchange-senderadcheck: 1
x-microsoft-antispam: BCL:0;
x-microsoft-antispam-message-info:
wfNbPRgk4YdWdlW+QCyqXc8q/7vp1sy0x89UU36C8eMfeZKh6M1VPfj1+8fmB+N9j8gN9G1WjCCJ9D0BwThmPEvpr
mtkyZFfNvP9lj4Bzk0joMcffPf/pt5XORqqOwdjSPMpt6PoEivnr/Z0GfqUhDq9x3Yt34s7sT3Gq3nZBDGQKWD1+O
xaGx1VBCaPskFODqKlSIDsQa7M84lqyGbBZr3UTs5bzhRAU+gQoRWE2nmWwPL3yVVEy8IvyuB4uPmCIP0s5qb2YZe
Be4D4t930oLvrn4Ms0HusTKGV1/oj15NO4eKdZbCy9tMOJ8yHF5d3EUVzOsLwPbm7dxX3Kz2n4e66U4I3+I9wXPYE
N5vUi3Y=
x-forefront-antispam-report:
CIP:255.255.255.255;CTRY:;LANG:en;SCL:1;SRV:;IPV:NLI;SFV:NSPM;H:DM6PR01MB5147.prod.exchan
gelabs.com;PTR:;CAT:NONE;SFS:(4636009)(366004)(346002)(136003)(376002)(66556008)(53546011
)(8936002)(91956017)(76116006)(7116003)(99936003)(6916009)(8676002)(86362001)(33656002)(2
906002)(3480700007)(4744005)(26005)(66616009)(66476007)(5660300002)(6506007)(186003)(2616
005)(786003)(64756008)(6512007)(66446008)(66946007)(6486002)(71200400001)(508600001)(3675
6003)(75432002);DIR:OUT;SFP:1102;


x-ms-exchange-antispam-messagedata: =?utf-8?B?ZXAvMFdWYWFkQTM0L3RBSEhyMmdJYk92TjVQalo3aHRHZlZnK29oWFhEdnla?=
=?utf-8?B?QUsxU2RCQ3JwUGZMZGhOaHoleFdUUUVivQVFHVWc0R3ZZd1BmanNoa091L2Y5?=
=?utf-8?B?NGNJVFRCVm54bXM0NnRGKzcwa2lCMTlUaDhEN3FyQWVMaUs5WU1md3lNd3pj?=
=?utf-8?B?bE42QXNiUnp4V1ZnZ0paQUtKVzA2UkpKb09WNn14dGpyOXNIZlcvOW1hSTJr?=
=?utf-8?B?cTVZYThwTDEvaGpvRyt5SUVQcTdzeUJ0cUlheExCUUnZYN1paeUlZd1Iycmt2?=
=?utf-8?B?OVhaejZiVDhtZl1dWk1FyTHQ4WXB3NG5ITjBPVDR4NnZICXNJRE51dnhWL2lM?=
=?utf-8?B?RGtZdW9xU3J3NHdMMkg0djEzZzNGQ3NacG16Wk5manBiVEMxbUtuNmRUQWtZ?=
=?utf-8?B?c1ZTN0M1emJYWXFlRStjOG9Vakc4dERLdnpWclNIS0owRWxmS3dkVUJUbkNw?=
=?utf-8?B?OVBUVR4SWhvRXJuQnNBbTl0L2oxK3dPU1hMdWdDcjkvL1dIV1E3Rkd5eGJm?=
=?utf-8?B?bGpxcWhUN20vb11dZFdObExpbzM4bmxxUFNRRNVVsRTFMemd1M01oN09DUjlJ?=
=?utf-8?B?dUtlbkJib0ljV1Iycno5TERXUGQ0ame4UkRmUEVIMkZ3UnA3VHJYdWhFVnZk?=
=?utf-8?B?RHpEOEcxa0EyQ2wzSDJPci9rT3YzNnUrNHhLZ05wUmY2c1FjYi8vanEwdGs2?=
=?utf-8?B?QnhFNi9ydnR3cWh5eFNJUmn0aWRjWHFPaFR2Ujh4NWI2QlZkd1V6cWE4Y3FS?=
=?utf-8?B?TlVGZ1ROL0FoL2l6cUx5bFdleTdlaU84c1hQUVVBLytsNzFUZGdTTmNoeWZH?=
=?utf-8?B?SDdXZ3FxrLpuVGNLZfK5aVh2YTNPK2FLRzN4SWtkUVZUMmwvWjg4TkF4NFhp?=
=?utf-8?B?UGJlVlRQSnZsOEJQc1NhZDBualA2OFJGUkMzeXZ5WDVQSkFPTU02RUVISGp3?=
=?utf-8?B?cGtmSTZYYkFpdXZQekQ1M3NOanVWdGRtdWxhK0ZWbi85Uk1zTDV3U2wrcy93?=
=?utf-8?B?VDJQVjdHVTgzZ3MzN2x5YWZaM2hkbFJwRVdmamw4YnYxYkMzRDBNZ3M4bENI?=
=?utf-8?B?WXpKb2c3Y3h2UmFoUGpNMUtydlVMSVArdfJsMEVSVWsvckVudFl0eXJnN3N3?=
=?utf-8?B?UVVIZjArenZ0eE9DQTDqdHhkemRvdVhHV29hajVUM2NiY0RXZzN0NFBuK3kr?=
=?utf-8?B?U1B2dkdveUxNaHNKVWVrdkoxNERreDF3TThLM21kV2tTR1E3eDBaazI4aUlj?=
=?utf-8?B?TlRMYVZGS3ZJckJ1b082bVNHNzN2NWRxeUs0T2RUUmNxSGw3Z3krSlprMG1W?=
=?utf-8?Q?w0hw1K7Zv7rMR53/W1qU3TFUwzVlPKOAMn?=
x-ms-exchange-transport-forked: True
Content-Type: multipart/mixed;
 boundary="_004_D554F48FCD184B07A3DAD34F944525B7osuedu_"
MIME-Version: 1.0
X-OriginatorOrg: osu.edu
X-MS-Exchange-CrossTenant-AuthAs: Internal
X-MS-Exchange-CrossTenant-AuthSource: DM6PR01MB5147.prod.exchangelabs.com
X-MS-Exchange-CrossTenant-Network-Message-Id: b01f7d71-d80e-468d-2962-08d89f856435
X-MS-Exchange-CrossTenant-originalarrivaltime: 13 Dec 2020 16:37:32.5401
 (UTC)
X-MS-Exchange-CrossTenant-fromentityheader: Hosted
X-MS-Exchange-CrossTenant-id: eb095636-1052-4895-952b-1ff9df1d1121
X-MS-Exchange-CrossTenant-mailboxtype: HOSTED
X-MS-Exchange-CrossTenant-userprincipalname:
Lfm6aTWuwUOmxCRCp9/B42Z2vxur7DH1sELz64Ix6AoMfDMPN7DpiT+Hty+PaL94GU3BcbkNLQRTSEabZjB2OA==
X-MS-Exchange-Transport-CrossTenantHeadersStamped: DM6PR01MB4313

From: wen yumei <ymwen@shmu.edu.cn>
Sent: Tuesday, July 14, 2020 8:25 PM
To: Lu, Shan
Subject: Fw: UPDATES: 2nd ISV COVID-19 Vaccines Virtual Congress

I would like to join this virtual congress. However, they need my membership. Can you ask someone to help? Wen

-----Original Messages-----

From: "International Society for Vaccines" <info@isv-online.org>
Sent Time: 2020-07-14 01:33:09 (Tuesday)
To: ymwen@shmu.edu.cn
Cc:
Subject: UPDATES: 2nd ISV COVID-19 Vaccines Virtual Congress



Dear Colleagues,

The International Society for Vaccines would like to thank everyone for the immediate responses we have already received for the **Second ISV COVID-19 Vaccines Virtual Congress** taking place **Tuesday, July 21st at 9:00AM (ET)**. The final program is online at <https://www.isvcongress.org/> and registration is OPEN!

The 2nd Virtual Congress will present to the global vaccine community another great speaker panel:

- The opening keynote speaker, **Dr. Larry Corey** from Fred Hutchinson Cancer Research Center, will describe the clinical study design of COVID-19 which is an unprecedented challenge in the history of vaccinology.
- The second keynote speaker, **Dr. Marion Gruber** from US FDA, will provide an overview on the regulatory review of COVID-19 vaccines.
- **Drs. Greg Glenn** (Novavax), **George Gao** (China CDC), **Hanneke Schuitemaker** (J&J/Janssen) and **Kena Swanson** (Pfizer) will present the progress of their respective COVID-19 vaccine programs.
- The final panel discussion will include world experts **Stanley Perlman** (University of Iowa; moderator), **Bart Haagmans** (Erasmus University), **Vincent Munster** (RML/NIH) and **Linda Saif** (The Ohio State University) to discuss the value of animal models for the development of COVID-19 vaccines.

Live Event Link:

Registrants only will receive the official live event link two days before the 2nd ISV Virtual Congress. Please do not forward this link to anyone as this event is for registered participants only.

Joining the Live Event:












To attend the Live event, click the link in forthcoming email referenced above and choose to join anonymously. This will direct you into the event. For best viewing experience we encourage everyone to download the free Teams Desktop Application [HERE](#) prior to the meeting.

For those in a country where there is online access restriction, you may need to use the international VPN system to have the access to ISV Virtual Congress. We will happy to assist you in testing your system before the congress.

Once again, thank you all for your participation and support.

Linda Klavinskis, PhD
Margaret Liu, MD
Shan Lu, MD, PhD
ISV COVID-19 Vaccine Virtual Congress co-Chairs

REGISTER HERE

Please email Info@ISVCongress.org with any questions.

If you no longer wish to receive email from us, please click [here](#):



From: Liu, Shan-Lu <liu.6244@osu.edu>
Sent: Friday, February 21, 2020 7:42 AM
To: Su, Lishan; Lu, Shan
Subject: FW: Your article proofs for review (ID# TEMI 1733440)

From: "TEMI-production@journals.tandf.co.uk" <cats@taylorandfrancis.com>
Reply-To: "TEMI-production@journals.tandf.co.uk" <TEMI-production@journals.tandf.co.uk>
Date: Friday, February 21, 2020 at 4:13 AM
To: Shan-Lu Liu <liu.6244@osu.edu>
Subject: Your article proofs for review (ID# TEMI 1733440)

Article: No credible evidence supporting claims of the laboratory engineering of SARS-CoV-2

Journal: *Emerging Microbes & Infections* (TEMI)

Article ID: TEMI 1733440

Dear Shan-Lu Liu,

Your article proofs are now available for review through the Central Article Tracking System (CATS) at:
<https://cats.informa.com/PTS/in?ut=B2AB6692AA414D96905B59E6C51FA240>.

PLEASE NOTE: The CATS system only supports Internet Explorer 6 (and later), or Firefox 3 (and later) browser software. Popup blockers should be disabled. If you have any difficulty using CATS, please contact me.

- Your User Name is: LIUS876
- If you do not know your password, you may reset it here: <http://cats.informa.com/PTS/forgottenPassword.do>

1. Click on 'Review Proofs'.
2. Select 'Download PDF'.
3. Follow the guidance on the proof cover sheet to return your corrections. Please limit changes to answering any author queries and to correcting errors. We would not expect to receive more than 30 corrections.

Please check your proofs thoroughly before submitting your corrections as once they have been submitted we are unable to accept further corrections. If you have any queries, please email me.

To avoid delaying publication of your article, please approve these proofs or return any corrections by 26 Feb 2020.

Reprint and issue orders may be placed by logging in to your CATS account and accessing the order form on the "Additional Actions" menu. If you have any questions on this process, please contact me or visit our author services site <https://authorservices.taylorandfrancis.com/ordering-print-copies-of-your-article/>

- The DOI of your paper is: 10.1080/22221751.2020.1733440. Once your article has published online, it will be available at the following permanent link: <https://doi.org/10.1080/22221751.2020.1733440> .

Thank you,

Malathi Boopalan

Email:TEMI-production@journals.tandf.co.uk

From: Liu, Shan-Lu <liu.6244@osu.edu>
Sent: Thursday, October 22, 2020 9:58 AM
To: Lu, Shan; Su, Lishan; Saif, Linda; Weiss, Susan
Subject: FW: Your paper features in T&F's top ten OA articles of 2020

See below. FYI.

Cheers.

Shan-Lu



Shan-Lu Liu, M.D., Ph.D.
Professor
Co-Director, Viruses and Emerging Pathogens Program
Infectious Diseases Institute
Center for Retrovirus Research
Veterinary Biosciences, Microbial Infection and Immunity, and Microbiology
The Ohio State University
1900 Coffey Rd, Room 480 VMAB
Columbus, Ohio 43210
Phone: (614) 292-8690
Fax: (614) 292-6473
Email: liu.6244@osu.edu; shan-lu.liu@osumc.edu



From: "Bergan, Rachel" <Rachel.Bergan@tandf.co.uk>
Date: Thursday, October 22, 2020 at 4:59 AM
To: "Liu, Shan-Lu" <liu.6244@osu.edu>
Subject: Your paper features in T&F's top ten OA articles of 2020

Dear Shan-Lu,

I'm very pleased to let you know that your recent article "No credible evidence supporting claims of the laboratory engineering of SARS-CoV-2" was one of the most-downloaded open access articles published by Taylor & Francis so far this year.

Many congratulations!

To mark Open Access Week, we have published [a blog post on our Author Services website](#) about the Top 10, including links to the articles, and details of each Altmetric score to reflect the discussion of your article online and in the media.

This is a great excuse to further highlight your research to your contacts and communities. We will be promoting the blog post on our social media platforms: [Twitter](#), [LinkedIn](#), and [Facebook](#). You could share our posts/tweets or write your own (please use the same hashtags).

We'll also be featuring the Top 10 in our [Insights newsletter](#), to further reach researchers and the wider academic community.

Please do not hesitate to contact me if you have any further questions or queries.

Kind Regards,
Rachel

Rachel Bergan (she/her)
Communications Coordinator
Taylor & Francis Group

Email: rachel.bergan@tandf.co.uk
Tel: +44 (0) 20 755 19259
4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN, UK



Information Classification: General

From: Tang, Yi-Wei <yi-wei.tang@cepheid.com>
Sent: Thursday, October 22, 2020 5:43 PM
To: Lu, Shan; Yumei Wen (ymwen@shmu.edu.cn)
Subject: FW: Your paper features in T&F's top ten OA articles of 2020

Among the top most-downloaded articles, majority of them are on COVID-19 and EMI cover six.

Yi-Wei

From: Bergan, Rachel <Rachel.Bergan@tandf.co.uk>
Sent: Thursday, October 22, 2020 5:10 PM
To: Tang, Yi-Wei <yi-wei.tang@cepheid.com>
Subject: Your paper features in T&F's top ten OA articles of 2020

Dear Yi-Wei,

I'm very pleased to let you know that your recent article "Laboratory diagnosis of emerging human coronavirus infections – the state of the art" was one of the most-downloaded open access articles published by Taylor & Francis so far this year.

Many congratulations!

To mark Open Access Week, we have published [a blog post on our Author Services website](#) about the Top 10, including links to the articles, and details of each Altmetric score to reflect the discussion of your article online and in the media.

This is a great excuse to further highlight your research to your contacts and communities. We will be promoting the blog post on our social media platforms: [Twitter](#), [LinkedIn](#), and [Facebook](#). You could share our posts/tweets or write your own (please use the same hashtags).

We'll also be featuring the Top 10 in our [Insights newsletter](#), to further reach researchers and the wider academic community.

Please do not hesitate to contact me if you have any further questions or queries.

Kind Regards,
Rachel

Rachel Bergan (she/her)
Communications Coordinator
Taylor & Francis Group

Email: rachel.bergan@tandf.co.uk
Tel: +44 (0) 20 755 19259
4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN, UK



Taylor & Francis Group
an **informa** business

4 skills for researchers of the future



Information Classification: General

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

From: wen yumei <ymwen@shmu.edu.cn >
Sent: Tuesday, April 21, 2020 9:22 PM
To: Lu, Shan; YiWei Tang
Subject: Fw: Children's New Crown Paper
Attachments: TEMI-2020-0643_Proof-Jin Xu.pdf

Please comment, Wen

-----Original Messages-----

From:xujin <janexu@fudan.edu.cn >
Sent Time: 2020-04-21 14:39:08 (Tuesday)
To:ymwen@shmu.edu.cn
Cc:
Subject: Children's New Crown Essay

Hello, teacher Wen!

I took the liberty to disturb you! My name is Xu Jin from the Clinical Laboratory Center of the Sub-Fudan School Affiliated to Fudan University. I am mainly engaged in clinical virology. For related research work, I asked you to write a letter of recommendation for my "New Century Excellent Talents Project" a few years ago. Do you remember me?

During the COVID-19 outbreak, for the 9 children with COVID-19 admitted to our hospital, I and the clinician began to investigate the pathogens during the whole process from admission to discharge. The study of nucleic acid monitoring. It was observed that the detection rate of the swab was 100%, the feces was 89%, the pharynx test was 33%, and the detoxification time of the nasal test (median 4 days) far more than the pharyngeal test (median 4 days), the detoxification time in the feces is quite long, and the oldest one, the child, did not turn negative until 46 days after being discharged. Physical characteristics are different from adults, which has certain significance for understanding the detoxification characteristics of children with new coronary disease and strengthening prevention. I wrote Letter and voted for EMI. I would like to ask Mr. Wen for advice to see if it is suitable for publication.

The attachment is the content of the article, please pass it.

Thank you very much for your help and support! I wish you good health!

Xu Jinshang

Clinical Laboratory Center of Pediatric Hospital Affiliated to Fudan University
399 Wanyuan Road, Shanghai

From: wen yumei <ymwen@shmu.edu.cn >
Sent: Friday, December 25, 2020 6:54 AM
To: Lu, Shan
Subject: Fw: An article by Mr. Gui Zhiliang
Attachments: 1The need of psychiatry in China. The China Critic, 1930-3-27,298.jpg; 2The need of psychiatry in China. The China Critic, 1930-3-27, 299.jpg ; 3The need of psychiatry in China. The China Critic, 1930-3-27, 300.jpg

Just to share with you. I am really impressed, as this article was in press 90 years ago. YMW

-----Original Messages-----

From: "范庭卫" <fantingwei@suda.edu.cn >
Sent Time: 2020-12-23 15:56:28 (Wednesday)
To: "wen yumei" <ymwen@shmu.edu.cn >
Cc: xiebin@smhc.org.cn
Subject: An article by Gui Zhiliang

Wenyuan, hello:

I recently read an article by Gui Zhiliang in 1930 (attachment). This is an article she published when she returned to China after studying. It can be seen that she put the development of mental illness in Learning as a self-employed business.

This year marks the 120th anniversary of Gui Zhiliang's birth. Reading the letter and archives about Gui Zhiliang, I deeply feel her sense of responsibility and responsibility for the development of psych Profession, admiration, worth learning.

It is the end of the year. Thank you Wen Yuan and Secretary Xie Bin for your care and help over the past year. I wish you a happy new year!

Sincerely, Fan Tingwei
 Suzhou University

From: wen yumei <ymwen@shmu.edu.cn >
 Delivery date: 2020-02-20 12:49:52
 Recipient: "Fan Tingwei" <fantingwei@suda.edu.cn >
 Cc: "Xie Bin" <xiebin@smhc.org.cn >
 Topic: Re: Re Research and Questions on Gui Zhiliangxian

Mr. Fan, received. Thank you. The re-production of the cover can be very interesting by the application.

My mother once told me that she chose psychiatry because she likes philosophy. Psychiatry and psychological health are sciences that are closer to philosophy in medicine.

In addition, she believes that in addition to physical health, mental and mental health are also very important. In the preface of her book published in 1942, she wrote "China's little masters are not only You must have a healthy body and a good spirit and morality."

Regarding the latter question, I don't know if Gui Yuehua is because Gui Yuehua has no experience in medicine.

-----Original Messages-----

From: "范庭卫" <fantingwei@ suda.edu.cn >
Sent Time: 2020-02-20 11:56:07 (Thursday)
To: "wen yumei" <ymwen@ shmu.edu.cn >
Cc:
Subject: Re Research and questions about Gui Zhiliangxian

Wen Yuan is good,

I recently contacted the U.S. Archives and attached a letter from Gui Zhiliang dated June 5, 1925. please check.

I would like to ask you 2 questions.

The first question is, after Gui Zhiliang graduated from Wesley, why did he study medicine and choose to study psychiatry?

My inference is that at that time, the Anglican Wuchang Tongren Hospital needed psychiatric talents to build a "psychiatric department." This is just my analysis and judgment. Gui Zhiliangyou Didn't talk specifically about her professional choice?

The second question is, was Gui Zhiliang's sister Gui Zhiliang who worked at Wuchang Tongren Hospital from 1929 to 1930? Did Guihua ever serve as Central China? School doctor?

Mishima, S. Seo of Japan mentioned in her book Gui Zhiliang, a classmate who started studying in Wesleyan in the United States, and also mentioned Gui Zhiliang from Wuchang (Tongren) Hospital. Sister, once corresponded with her. Mishima, S. Seo didn't specify which sister it was. I judged it was Gui hua.

Thank you Wen Yuan! I was on TV and saw your speech about fighting the new crown virus, especially the use of hoods. I am now, in accordance with your method, fully benefit

Use a cover. A good method that is scientific and practical.

Good luck!

Fan Tingwei
 Suzhou University

From: wen yumei <ymwen@ shmu.edu.cn >
 Delivery date: 2020-01-25 20:31:04
 Recipient: "Fan Tingwei" <fantingwei@ suda.edu.cn >
 Topic: Re: Research and Questions about Gui Zhiliangxian

见Reply·

-----Original Messages-----

From: "范庭卫" <fantingwei@ suda.edu.cn >

2

Sent Time: 2020-01-24 12:01:23 (Friday)
To: ymwen@ shmu.edu.cn
Cc:
Subject: Research and questions about Gui Zhiliangxian

Wen Yuan is good,

First of all, I wish you a happy Chinese New Year, a healthy body and a happy family!

I am a teacher of the Department of Science in Suzhou University. In 2013, I wrote the article "Gu Zhiliang—A Strong Woman in the War of Resistance Against Japan". The information at that time made improvements.

Recently, I read Gui Zhiliang's letters from 1930-1931, and I am sorting them.

There are a few questions, please worry about the hospital. 1. Gui Zhiliang's residence in Beijing, Pei Chung Pu Hutung, the Chinese name of this hutong

I don't know, I was born after·····town street-2·· (I was born after 1934-1940)

. 2. Gui Zhiliang and Wen also rumored to get married in 1930?
do not know·

3.1 How many months do you live and hear in 931? .

Wen Ping 1931·September·Born·

4. It is also rumored that Xian's English name is Robert?

may·

Judging from the letters, in 1930, Gui Zhiliang planned to go to England to study for one year. The Chinese bishop and American psychiatrist Maier both went for Gui Xian Yingxue made a recommendation. In 1932, Gui Zhiliang traveled to Britain via Shanghai, but encountered the war in Shanghai, and then moved to Hong Kong to go to Britain. 又Suddenly heard th
Due to illness, I canceled my study and work in the UK.

correct

Gui Zhiliang was dedicated to the study and research of psychiatry. Soon after he got married, he applied to study psychiatry in the UK. Soon after Wenping came out, I was going to the UK
. I really want to know how many months I got married in 1930, and I heard peace in 1931. In this way, the content of the letter is more accurate. At the same time, it can better reflect
Leaving Gui Zhiliang first led to the precious spirit of psychiatry learning.

I would take the liberty to write to you, please criticize and correct any inappropriateness.

Fan Tingwei

Department of Psychology, Suzhou Institute of Education

New Year's Eve on January 24, 2020

"

5/17/2021

Just to share with you. I am really impressed, as this article was in press 90 years ago. YMW -----Original Messages----- From:&

4

From: wen yumei <ymwen@shmu.edu.cn >
Sent: Sunday, January 5, 2020 2:47 AM
To: Lu, Shan
Cc: shibojiang
Subject: Fw: System bounce/Systems bounce
Attachments: ATT00002.bin ; Re_ Special Issue for EMI_Highly Pathogenic Emerging CoVs.eml

-----Original Messages-----

From: postmaster@shmu.edu.cn
Sent Time: 2020-01-05 15:45:33 (Sunday)
To: ymwen@shmu.edu.cn
Cc:
Subject: System bounce/Systems bounce

Sorry, your **email has been returned...**

Time/Time: 2020-01-05 15:45:17

The original e-mail message/
Original e-mail message: Subject: Re: Special Issue for EMI_Highly Pathogenic Emerging CoVs

Recipient/To: shan.lu @ emi2012.org

Recipients reject **absolutely the sender automatically receives Face mail.**

Reason for Bounce: **Mail from this address is rejected by recipient.**
Bounce reason: SMTP error, RCPT TO: 550 5.4.1 Recipient address rejected: Access denied. AS(201806281) [P
U1APC01FT022.eop-APC01.prod.protection.outlook.com]

Sorry, your email has been returned...

- Warm reminder from the postman: please contact the recipient to add you to the white list.

Suggested solution/

Please contact recipient to add your address to whitelist.

Proposed Solution:

- If you have other bounce questions, please contact the customer service center

Bounce code/

Bounce Code:

address rejected

This message is generated by Coremail.

You have received a letter from Coremail's professional mail system.

1

From: wen yumei <ymwen@shmu.edu.cn>
Sent: Wednesday, March 25, 2020 11:46 PM
To: Lu, Shan
Subject: Fw: Forward: Emerging Microbes & Infections
Attachments: TEMI-2020-0082_Proof_hi.pdf; Emerging WuHan (COVID-19) coronavirus.pdf

I presume that was what he submitted, and we did not edit his paper, or we corrected his title? YM wen e

-----Original Messages-----

From: "杨福全" <fqyang@ibp.ac.cn>
 Sent Time: 2020-03-26 11:12:41 (Thursday)
 To: ymwen@shmu.edu.cn
 Cc: Shan.Lu@umassmed.edu, who@chn.wpro.who.int
 Subject: Forward: Emerging Microbes & Infections

Wenyuan 士: Hello!

Please excuse me for taking the liberty to write to you! I am Yang Fuquan from the Institute of Physical Physics, Chinese Academy of Sciences. In February of this year, I was invited to review

A manuscript submitted for review by the editorial department of "Microbes and Infections" (Attachment). The title of the article "Emerging WuHan (2019-nCoV) Coronavirus:

Glycan shield and structure prediction of Spike glycoprotein and its interaction with Human CD26" and its text in

Coronavirus and its related proteins are prefixed with the word "Wuhan". This practice seriously violates the naming principle of WHO, and it uses the word "Wuhan" without authorization.

Eyes are discriminatory and insulting, and they have lost their scientific research spirit. I have clearly pointed out this issue in the review comments and proposed amendments.

However, what makes people angry is that the editor of "Emerging Microbes and Infections" did not adopt my revised intention and published the paper online with recent

(见Attachment). This practice is totally unacceptable to me and the Chinese people. I hope the editorial department of "Emerging Microbes and Infections" will immediately

Correct the mistake and apologize to me for writing.

good luck!

Yang Fuquan

----- Original email-----

From 人: Lu, Shan [mailto:Shan.Lu@umassmed.edu]
 Delivery time: February 17, 2020 0:01
 Recipient: Yang Fuquan
 Cc: Editorial Office
 Subject: RE: Emerging Microbes & Infections

Thanks I will ask the EMI office to send your comments to the author in a separate email.

Appreciate your great help! You take care since you are in the epicenter of this outbreak.

Shan

1

-----Original Message-----

From: Yang Fuquan<fqyang@ibp.ac.cn>

Sent: Sunday, February 16, 2020 10:58 AM
 To: Lu, Shan <Shan.Lu@umassmed.edu>
 Subject: Re: Emerging Microbes & Infections

Dear Prof. Lu,
 Thank you very much for your e-mail. That is very funny.
 My comments are as following:

1. This study is worthwhile work for the drug development.
2. This study has compared the glycosylation sites in spike glycoproteins of 2019-nCoV and SARS-CoV-1, and the interaction with human CD26, and found a number of conserved glycosylation sites in spike glycoproteins between 2019-nCoV and SARS-CoV-1, and several unique glycosylation sites 2019-nCoV. This suggests that 2019-nCoV may take a slightly different immunogenicity in host cell interactions to that of SARS, but might have the same targets and can respond to a similar therapeutic approach to SARS.
3. The novel Coronavirus found in Wuhan, in 2019 has only been named as 2019-nCoV by WHO, so the names such as Wuhan (2019-nCoV), Wuhan-Hu-Cov-1, Wuhan-Hu-1 should not be used for the novel Coronavirus and their proteins in the Title, Fig.S1, Fig.S2 and Table S1.

Best regards
 Fuquan

> -----Original Mail-----
 > From: "Emerging Microbes and Infections" <onbehalf@manuscriptcentral.com>
 > Sending time: 2020-02-16 23:27:06 (Sunday)
 > Recipient: fqyang@ibp.ac.cn
 > CC:
 > Subject: Emerging Microbes & Infections
 >
 > 16-Feb-2020
 >
 > TEMI-2020-0082-Emerging WuHan (2019-nCoV) Coronavirus: Glycan shield and structure prediction of Spike glycoprotein and its interaction with Human CD26
 >
 > Dear Professor Fuquan Yang:
 >
 > Thank you very much for sending in your decision to this paper. However, I did not see the reviewer's comments. In the comments box, I only found the following:
 >
 > "on't let your reviewing work go unnoticed! Researchers the world over use Publons to effortlessly track their valuable peer review contributions for any journal. If you opt in, your Publons profile will automatically be updated to show a verified record of this review in full compliance with the journal's review policy. If you don't have a Publons profile, you will be prompted to create a free account.Learn more about Publons "
 >
 > I wonder this may be some error. At any rate, we will send out the decision now and thank you for your quick feedback.

>
 >
 > Sincerely,
 > Professor Shan Lu
 > Emerging Microbes & Infections

From: Tang, Yi-Wei <yi-wei.tang@cepheid.com>
Sent: Wednesday, October 14, 2020 10:31 PM
To: Yumei Wen (ymwen@shmu.edu.cn); Lu, Shan
Subject: Fwd: An urgent manuscript on COVID-19 surveillance

Teacher Wen, Shan,

Please see below and give your advice. I myself would be happy to be a review editor to give it a quick process.

Thank you.

Yi-Wei

Get [Outlook for iOS](#)

From: Tang, Yi-Wei <yi-wei.tang@cepheid.com>
Sent: Thursday, October 15, 2020 10:27
To: SIU, Gilman [HTI]
Subject: Re: An urgent manuscript on COVID-19 surveillance

Gilman, thank you for sharing. I will discuss with EMI eic and get back to you soon.

Yi-Wei

Get [Outlook for iOS](#)

From: SIU, Gilman [HTI] <gilman.siu@polyu.edu.hk>
Sent: Thursday, October 15, 2020 9:18:00 AM
To: Tang, Yi-Wei <yi-wei.tang@cepheid.com>
Subject: An urgent manuscript on COVID-19 surveillance

Dear Tang,

I am writing to seek for your advices on publishing an urgent manuscript on COVID-19 surveillance. As you may know, Hong Kong experienced the largest COVID-19 outbreak during this summer. The virus swept through the city, affecting care homes for the elderly and the disabled, public hospitals, detention facilities, wet markets and a container terminal. The total number of cases has increased five-fold from just over 1,000 in early July to over 5,000 as of August 31, 2020. The outbreak has eventually died down since September and daily local cases came to zero on 25 Sept 2020.

However, since 1 October, a series of locally acquired cases (n=51) re-appeared since September 30, 2020. The Government believes that the relapse of local cases was due to untraceable infections leftover in the community from the third wave after the recent easing of restrictions. However, our team completed whole-genome sequencing this Monday (12 October) for around 10 new local cases. Surprisingly, we found that the genomes of these cases are significantly different from those found in the summer outbreak. In fact, they belong to different phylogenetic clade. We then investigated the genomes of the recent imported case (incoming travellers from other countries). Phylogenetical analysis confirmed that the new local cases are all closely related to the imported cases from India and Nepal.

Our results suggest that the new spike in local infections may be triggered by a sudden increase of imported infections in late September, instead of hidden cases in the community leftover from the previous wave. More disturbingly, some

locally acquired cases with the new viral genome did not have apparent epidemiological linkage and were geographically distant from each other (Supplementary Figure 2), indicating that the newly imported GH clade SARS-CoV-2 is disseminating in our community. This could be a warning sign that a fourth wave of COVID-19 infections is looming in Hong Kong. Something wrong is happening for our quarantine and infection control measures at the borders for incoming travellers.

I think we have an urgent message for the government that we have strengthen the testing and quarantine arrangement for the travellers. We plan to submit a manuscript as a letter to Emerging Microbes and Infections (EMI). But time required for review process is a matter in our case. I know you are an associate editor of EMI. May I seek for your advice if EMI is a good choice or you would recommend other journals?

Thank you very much for your help.

Regards
Gilman



Disclaimer:

This message (including any attachments) contains confidential information intended for a specific individual and purpose. If you are not the intended recipient, you should delete this message and notify the sender and The Hong Kong Polytechnic University (the University) immediately. Any disclosure, copying, or distribution of this message, or the taking of any action based on it, is strictly prohibited and may be unlawful.

The University specifically denies any responsibility for the accuracy or quality of information obtained through University E-mail Facilities. Any views and opinions expressed are only those of the author(s) and do not necessarily represent those of the University and the University accepts no liability whatsoever for any losses or damages incurred or caused to any party as a result of the use of such information.

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

From: Tang, Yi-Wei <yi-wei.tang@cepheid.com>
Sent: Tuesday, December 15, 2020 10:11 PM
To: Lu, Shan; ymwen@shmu.edu.cn
Subject: Fwd: An urgent manuscript on COVID-19 surveillance

A nice note from EMI authors.

Happy Holidays.

Yi-Wei

Get [Outlook for iOS](#)

From: Tang, Yi-Wei <yi-wei.tang@cepheid.com>
Sent: Wednesday, December 16, 2020 11:07:09 AM
To: SIU, Gilman [HTI] <gilman.siu@polyu.edu.hk>
Subject: Re: An urgent manuscript on COVID-19 surveillance

Congratulations, Gilman. I will share the information with EMI editors in chief.

Yi-Wei

Get [Outlook for iOS](#)

From: SIU, Gilman [HTI] <gilman.siu@polyu.edu.hk>
Sent: Wednesday, December 16, 2020 10:50:44 AM
To: Tang, Yi-Wei <yi-wei.tang@cepheid.com>
Subject: RE: An urgent manuscript on COVID-19 surveillance

Dear Prof. Tang,

Thank you for your kind arrangement on publishing our paper in EMI. For your information, our work were widely reported by different media in Hong Kong. Attached please find the media report related to our research.

Most importantly, we got an opportunity to meet the Secretary of Food and Health Bureau and we have successfully convinced the government to implement the following measures:

1. Make law to prohibit visiting to the inbound travellers who are under compulsory quarantine.
2. Establish designated quarantine hotels for all inbound travellers, in which public health officers are stationed.
3. Arrange point-to-point transport between airport and quarantine hotels, avoiding the inbound traveller to take public transport.

Although we are having the 4th wave of community outbreak with ~100 cases each day, attributed to the GH strain we reported in our paper, I hope the new measure could fill the gap to avoid further imported infection. All in all, thank you very much for catering our publication in EMI that eventually impacted the government's policy.

Regards
Gilman

From: Tang, Yi-Wei <yi-wei.tang@cepheid.com>
Sent: Sunday, 25 October 2020 10:13 AM
To: SIU, Gilman [HTI] <gilman.siu@polyu.edu.hk>
Subject: RE: An urgent manuscript on COVID-19 surveillance

I think we give the consented reviewers three weeks to review and submit their comments. The system will start reminding the reviewers after the due day. Again, I will watch for you.

Yi-Wei

From: SIU, Gilman [HTI] <gilman.siu@polyu.edu.hk>
Sent: Sunday, October 25, 2020 9:41 AM
To: Tang, Yi-Wei <yi-wei.tang@cepheid.com>
Subject: Re: An urgent manuscript on COVID-19 surveillance

Dear Prof. Tang,

Thank you very much for your information. Your help in the review process is highly appreciated. May I know how long the regular review process usually takes?

Regards
Gilman

On 25 Oct 2020, at 07:39, Tang, Yi-Wei <yi-wei.tang@cepheid.com> wrote:

Gilman,

Unfortunately, EMI has stopped expedite process for COVID-19 papers. Your paper has passed initial screening and been sent out for a full review. But this is a regular process although I will keep my eyes open on it.

Yi-Wei

From: SIU, Gilman [HTI] <gilman.siu@polyu.edu.hk>
Sent: Saturday, October 24, 2020 6:38 PM
To: Tang, Yi-Wei <yi-wei.tang@cepheid.com>
Subject: RE: An urgent manuscript on COVID-19 surveillance

Dear Prof. Tang,

Sorry to contact you that frequent. However, my collaborators and I really want to know about the status of the review process. May I know if you have any information on it? We ask because the University insists NOT to disclose any of our findings to the Department of Health and the public before the manuscript is being published. Thank you so much for your help.

Regards
Gilman

From: SIU, Gilman [HTI]
Sent: Friday, 16 October 2020 1:41 PM
To: Tang, Yi-Wei <yi-wei.tang@cepheid.com>
Subject: RE: An urgent manuscript on COVID-19 surveillance

Dear Prof Tang,

Thank you so much for your help. We have just submitted our manuscript to the journal.

Regards
Gilman

From: Tang, Yi-Wei <yi-wei.tang@cepheid.com>
Sent: Thursday, 15 October 2020 12:33 PM
To: SIU, Gilman [HTI] <gilman.siu@polyu.edu.hk>
Subject: RE: An urgent manuscript on COVID-19 surveillance

Gilman,

I have chatted with EMI eic. Yes, please submit your manuscript to EMI at your earliest convenience, we will arrange a quick process.

No worry about calling. Like Yam, Tang is fine as well 😊.

Yi-Wei

From: SIU, Gilman [HTI] <gilman.siu@polyu.edu.hk>
Sent: Thursday, October 15, 2020 10:32 AM
To: Tang, Yi-Wei <yi-wei.tang@cepheid.com>
Subject: RE: An urgent manuscript on COVID-19 surveillance

Dear Prof. Tang,

Your help is highly appreciated. And I noticed that I rudely called you "Tang" in my last email. Sorry that it is a mistake as I wrote the last email on a public transport.

Regards
Gilman

From: Tang, Yi-Wei <yi-wei.tang@cepheid.com>
Sent: Thursday, 15 October 2020 10:27 AM
To: SIU, Gilman [HTI] <gilman.siu@polyu.edu.hk>
Subject: Re: An urgent manuscript on COVID-19 surveillance

Gilman, thank you for sharing. I will discuss with EMI eic and get back to you soon.

Yi-Wei

Get [Outlook for iOS](#)

From: SIU, Gilman [HTI] <gilman.siu@polyu.edu.hk>
Sent: Thursday, October 15, 2020 9:18:00 AM
To: Tang, Yi-Wei <yi-wei.tang@cepheid.com>
Subject: An urgent manuscript on COVID-19 surveillance

Dear Tang,

I am writing to seek for your advices on publishing an urgent manuscript on COVID-19 surveillance. As you may know, Hong Kong experienced the largest COVID-19 outbreak during this summer. The virus swept through the city, affecting care homes for the elderly and the disabled, public hospitals, detention facilities, wet markets and a container terminal. The total number of cases has increased five-fold from just over 1,000 in early July to over 5,000 as of August 31, 2020. The outbreak has eventually died down since September and daily local cases came to zero on 25 Sept 2020.

However, since 1 October, a series of locally acquired cases (n=51) re-appeared since September 30, 2020. The Government believes that the relapse of local cases was due to untraceable infections leftover in the community from the third wave after the recent easing of restrictions. However, our team completed whole-genome sequencing this Monday (12 October) for around 10 new local cases. Surprisingly, we found that the genomes of these cases are significantly different from those found in the summer outbreak. In fact, they belong to different phylogenetic clade. We then investigated the genomes of the recent imported case (incoming travellers from other countries). Phylogenetical analysis confirmed that the new local cases are all closely related to the imported cases from India and Nepal.

Our results suggest that the new spike in local infections may be triggered by a sudden increase of imported infections in late September, instead of hidden cases in the community leftover from the previous wave. More disturbingly, some locally acquired cases with the new viral genome did not have apparent epidemiological linkage and were geographically distant from each other (Supplementary Figure 2), indicating that the newly imported GH clade SARS-CoV-2 is disseminating in our community. This could be a warning sign that a fourth wave of COVID-19 infections is looming in Hong Kong. Something wrong is happening for our quarantine and infection control measures at the borders for incoming travellers.

I think we have an urgent message for the government that we have strengthen the testing and quarantine arrangement for the travellers. We plan to submit a manuscript as a letter to Emerging Microbes and Infections (EMI). But time required for review process is a matter in our case. I know you are an associate editor of EMI. May I seek for your advice if EMI is a good choice or you would recommend other journals?

Thank you very much for your help.

Regards
Gilman



Disclaimer:

This message (including any attachments) contains confidential information intended for a specific individual and purpose. If you are not the intended recipient, you should delete this

message and notify the sender and The Hong Kong Polytechnic University (the University) immediately. Any disclosure, copying, or distribution of this message, or the taking of any action based on it, is strictly prohibited and may be unlawful.

The University specifically denies any responsibility for the accuracy or quality of information obtained through University E-mail Facilities. Any views and opinions expressed are only those of the author(s) and do not necessarily represent those of the University and the University accepts no liability whatsoever for any losses or damages incurred or caused to any party as a result of the use of such information.

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.




Disclaimer:

This message (including any attachments) contains confidential information intended for a specific individual and purpose. If you are not the intended recipient, you should delete this message and notify the sender and The Hong Kong Polytechnic University (the University) immediately. Any disclosure, copying, or distribution of this message, or the taking of any action based on it, is strictly prohibited and may be unlawful.

The University specifically denies any responsibility for the accuracy or quality of information obtained through University E-mail Facilities. Any views and opinions expressed are only those of the author(s) and do not necessarily represent those of the University and the University accepts no liability whatsoever for any losses or damages incurred or caused to any party as a result of the use of such information.

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.



Disclaimer:

This message (including any attachments) contains confidential information intended for a specific individual and purpose. If you are not the intended recipient, you should delete this message and notify the sender and The Hong Kong Polytechnic University (the University) immediately. Any disclosure, copying, or distribution of this message, or the taking of any action based on it, is strictly prohibited and may be unlawful.

The University specifically denies any responsibility for the accuracy or quality of information obtained through University E-mail Facilities. Any views and opinions expressed are only those of the author(s) and do not necessarily represent those of the University and the University accepts no liability whatsoever for any losses or damages incurred or caused to any party as a result of the use of such information.

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.



Disclaimer:

This message (including any attachments) contains confidential information intended for a specific individual and purpose. If you are not the intended recipient, you should delete this message and notify the sender and The Hong Kong Polytechnic University (the University) immediately. Any disclosure, copying, or distribution of this message, or the taking of any action based on it, is strictly prohibited and may be unlawful.

The University specifically denies any responsibility for the accuracy or quality of information obtained through University E-mail Facilities. Any views and opinions expressed are only those of the author(s) and do not necessarily represent those of the University and the University accepts no liability whatsoever for any losses or damages incurred or caused to any party as a result of the use of such information.

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.



Disclaimer:

This message (including any attachments) contains confidential information intended for a specific individual and purpose. If you are not the intended recipient, you should delete this message and notify the sender and The Hong Kong Polytechnic University (the University) immediately. Any disclosure, copying, or distribution of this message, or the taking of any action based on it, is strictly prohibited and may be unlawful.

The University specifically denies any responsibility for the accuracy or quality of information obtained through University E-mail Facilities. Any views and opinions expressed are only those of the author(s) and do not necessarily represent those of the University and the University accepts no liability whatsoever for any losses or damages incurred or caused to any party as a result of the use of such information.

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

From: kyyuen <kyyuen@hku.hk>
Sent: Thursday, January 16, 2020 10:39 AM
To: Lu, Shan; Shibo Jiang; wen yumei
Subject: Fwd: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0053 has been submitted online

For your urgent and kind attention.
Ky

從我的iPhone傳送

以下為轉寄郵件：

寄件人: Emerging Microbes and Infections <onbehalf@manuscriptcentral.com>
日期: 2020年1月16日 GMT+8 下午11:31:45
收件人: kyyuen <kyyuen@hku.hk>
副本: jfwchan <jfwchan@hku.hk>, Raven Kok <khkok@hku.hk>, "zzeightzz@gmail.com" <zzeightzz@gmail.com>, hinchu <hinchu@hku.hk>, Kelvin To <kelvinto@hku.hk>, "yuanshuofeng@gmail.com" <yuanshuofeng@gmail.com>, skplau <skplau@hku.hk>, pcywoo <pcywoo@hku.hk>, kyyuen <kyyuen@hku.hk>
標題: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0053 has been submitted online
回覆給: temi-peerreview@journals.tandf.co.uk

16-Jan-2020

Dear Professor Yuen:

Your manuscript entitled "Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from patients with acute respiratory disease in Wuhan, Hubei, China" has been successfully submitted online and is presently being given full consideration for publication in Emerging Microbes & Infections.

Your manuscript ID is TEMI-2020-0053.

Please mention the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your street address or e-mail address, please log in to ScholarOne Manuscripts at <https://mc.manuscriptcentral.com/temi> and edit your user information as appropriate.

You can also view the status of your manuscript at any time by checking your Author Center after logging in to <https://mc.manuscriptcentral.com/temi>.

Thank you for submitting your manuscript to Emerging Microbes & Infections.

Sincerely,
Emerging Microbes & Infections Editorial Office

From: Yaqoub Ashhab <yashhab@ppu.edu>
Sent: Monday, March 1, 2021 2:24 AM
To: Lu, Shan
Cc: ymw@shmu.edu.cn
Subject: Fwd: Emerging Microbes & Infections - TEMI-2021-0198 - changes required to your submission

Dear Prof. Shan,
I hope this email finds you well. I received this email from the editorial office requesting a valid waiver code. Could you please help.
Many thanks for your time and cooperation.
Kindest regards and stay safe
Yaqoub

----- Forwarded message -----

From: **Emerging Microbes and Infections** <onbehalf@manuscriptcentral.com>
Date: Mon, Mar 1, 2021 at 5:07 AM
Subject: Emerging Microbes & Infections - TEMI-2021-0198 - changes required to your submission
To: <yashhab@ppu.edu>

28-Feb-2021

Dear Dr. Yaqoub Ashhab,

Thank you for submitting your manuscript to Emerging Microbes & Infections.

In order for us to proceed with your submission, please could you provide a valid waiver code?

You may contact the Editorial Office if you have further questions.

Sincerely,

Emerging Microbes & Infections Editorial Office


From: Liu, Shan-Lu <liu.6244@osu.edu>
Sent: Thursday, February 27, 2020 1:43 AM
To: Lishan Su; Saif, Linda; Susan Weiss; Lu, Shan
Subject: Fwd: Taylor & Francis author update: access to your article published in an issue of Emerging Microbes & Infections

It is now online, thanks to you all.

Shan-Lu Liu sent from iPhone

Begin forwarded message:

From: Taylor & Francis <noreply@tandfonline.com>
Date: February 27, 2020 at 12:45:33 AM EST
To: "Liu, Shan-Lu" <liu.6244@osu.edu>
Subject: Taylor & Francis author update: access to your article published in an issue of Emerging Microbes & Infections
Reply-To: support@tandfonline.com



[Author Services](#) | [FAQ](#) | [Twitter](#) | [Facebook](#)

Dear author,

Your Open Access article, [No credible evidence supporting claims of the laboratory engineering of SARS-CoV-2](#), published in Emerging Microbes & Infections, [Volume 9 Issue 1](#), is now available to access via tandfonline.com.

Share your article now

You'll hopefully want to share your article with friends or colleagues (and then check its downloads, citations and Altmetric data on [Authored Works](#), our dedicated center for all Taylor & Francis published authors). Publishing Open Access means your article can be read by anyone, anywhere, and we want to work with you to ensure it reaches as wide (and as appropriate) an audience as possible.



Author feedback tells us that something as simple as posting about your article's publication on social media is a highly effective way of highlighting your research. Find out more about how you can work with us to [promote your work](#).

Not sure how to access your Authored Works?

If you haven't yet registered, you can do so using liu.6244@osu.edu (this is the email you used whilst your manuscript was going through production).

Once you've completed the quick registration you'll be sent an email asking you to confirm. Click on the verification link and you can then login (using the above email address) whenever you want to by going to [Taylor & Francis Online](#). Once you have logged in, click on "[Your Account](#)" at the top of the page to see the latest

updates on your article.

If you have any problems accessing your Taylor & Francis Online account please [contact us](#). Thank you for publishing Open Access with us.

Kind regards,

Stewart Gardiner
Global Production Director, Journals
Taylor & Francis Group

Interested in insights, tips, and updates for Taylor & Francis authors? Be part of our researcher community on:

[Twitter](#)

[Facebook](#)

[Taylor & Francis Author Services](#)



Taylor & Francis

Please do not reply to this email. To ensure that you receive your alerts and information from Taylor & Francis Online, please add "alerts@tandfonline.com" and "info@tandfonline.com" to your safe senders list.

Taylor & Francis, an Informa business.

Taylor & Francis is a trading name of Informa UK Limited, registered in England under no. 1072954. Registered office: 5 Howick Place, London, SW1P 1WG.

From: kyyuen <kyyuen@hku.hk>
Sent: Friday, January 17, 2020 7:24 AM
To: Lu, Shan; Shibo Jiang; wen yumei
Cc: pcywoo; skplau
Subject: Fwd: URGENT submission for fast track review

Dear Editor Professor Lu,

Below is the email from two of our coauthors Patrick and Susanna who are invited by another virology journal to submit a similar paper. They will now withdraw from the authorship of our paper.

We would resubmit again tonight after deleting their names. They are CC. In this email.

Apology for the inconvenience.

Ky

從我的iPhone傳送

以下為轉寄郵件：

寄件人: skplau <skplau@hku.hk>
日期: 2020年1月17日 GMT+8 上午11:56:46
收件人: kyyuen <kyyuen@hku.hk>, pcywoo <pcywoo@hku.hk>
副本: Jasper Chan <jaspchan@gmail.com>
標題: 回覆：URGENT submission for fast track review

Dear Prof Yuen and Jasper

Thanks a lot for including us in this paper. However, we have previously promised another journal to submit a paper on similar topic and will submit it soon. To avoid double publication, I think it is better for us to be skipped in your paper, either before you submit it or during revision process. Sorry for the inconvenience and thanks for your understanding.

Best regards

Susanna

From: KY Yuen <kyyuen@hku.hk>
Sent: 17 January 2020 9:12
To: pcywoo; skplau
Cc: 'Jasper Chan'
Subject: URGENT submission for fast track review

Dear Patrick and Susanna,

Attached is a quick paper on a comprehensive bioinformatics analysis of the 6 available 2019-nCoV genomes for submission to EMI

Your kind and speedy track change amendment is appreciated before evening.

Many thanks.
KY

From: Liu, Shan-Lu <liu.6244@osu.edu>
Sent: Wednesday, February 19, 2020 7:37 PM
To: Lu, Shan; Lishan Su
Subject: Fwd: Welcome to Taylor & Francis Production: Emerging Microbes & Infections 1733440
Attachments: Copyright_Form.pdf; ATT00001.htm

Shan-Lu Liu sent from iPhone

Begin forwarded message:

From: "TEMI-production@journals.tandf.co.uk" <cats@taylorandfrancis.com>
Date: February 19, 2020 at 3:51:06 PM PST
To: "Liu, Shan-Lu" <liu.6244@osu.edu>
Subject: Welcome to Taylor & Francis Production: Emerging Microbes & Infections 1733440
Reply-To: TEMI-production@journals.tandf.co.uk

Article: SARS-CoV-2: no evidence of a laboratory origin

Journal: *Emerging Microbes & Infections* TEMI

Article ID: TEMI 1733440

Dear Shan-Lu Liu,

We are delighted that you have chosen to publish your article in *Emerging Microbes & Infections*. I will be your Production Editor and will work with you to oversee the production of your article through to publication. My contact details are given at the end of this email.

- Please print and sign the attached Author Publishing Agreement. Then return the completed agreement to Taylor & Francis, by uploading to CATS (see below), or post it to the address below.

Proofs will be ready for you to check in approximately 7 working days and we would like you to return your corrections within 3 days. Please let me know if there will be any difficulty in meeting this schedule.

We will be sending proofs to you through our workflow system, CATS (Central Article Tracking System).

- You can check the status of your paper online through the CATS system at:
<https://cats.informa.com/PTS/in?ut=B2AB6692AA414D96905B59E6C51FA240>
- Your User Name is: lius876
- Your Password is: Liua4764#\$ (You will be required to change this first time you log in)

- The DOI of your paper is: 10.1080/22221751.2020.1733440. Once your article has published online, it will be available at the following permanent link: <https://doi.org/10.1080/22221751.2020.1733440> .

Yours sincerely,

Malathi Boopalan

Email:TEMI-production@journals.tandf.co.uk

From: Liu, Shan-Lu <liu.6244@osu.edu>
Sent: Wednesday, February 26, 2020 4:13 AM
To: Lu, Shan; Lishan Su
Subject: Fwd: Your Open Access article publishing charge invoice [ref:_00D0Y35lji._5002X2h5qN4:ref]
Attachments: Invoice 952282459.pdf; ATT00001.htm

Shan-Lu Liu sent from iPhone

Begin forwarded message:

From: "apc@tandf.co.uk" <apc@tandf.co.uk>
Date: February 26, 2020 at 3:54:27 AM EST
To: "Liu, Shan-Lu" <liu.6244@osu.edu>
Subject: Your Open Access article publishing charge invoice [ref:_00D0Y35lji._5002X2h5qN4:ref]



Dear Mr Shan-Lu Liu,

Ref : No credible evidence supporting claims of the laboratory engineering of SARS-CoV-2
DOI: 10.1080/22221751.2020.1733440

Congratulations on the acceptance of your paper.

Publication in the journal is subject to payment of an APC (article publishing charge). Thank you for accepting responsibility for payment of this charge when you submitted your paper. Please find attached your APC invoice. Should you have any queries about this document, please don't hesitate to contact us

To pay by credit card online please click [here](#).

Once published online your paper will be made open access in perpetuity, available to anyone, anywhere, at any time.

A number of institutions have signed up to an open access membership scheme with Taylor & Francis, to help authors cover the costs of publishing OA. See <http://www.tandfonline.com/page/openaccess/members> for a full list; if you are affiliated with one of these institutions please inform us by replying to this email.

For more information around our Open programme, please visit <http://authorservices.taylorandfrancis.com/publishing-open-access> which contains a wealth of information and resources, including information on how to promote your paper and optimise citations once it is published online.

Kind regards,
Evelyn Wong
Customer Service Executive

Taylor & Francis Customer Services
www.tandfonline.com

[Sign up to receive offers and updates about products and services from Taylor & Francis Group.](#)



ref:_00D0Y35Iji._5002X2h5qN4:ref

From: Liu, Shan-Lu <liu.6244@osu.edu >
Sent: Saturday, June 13, 2020 6:11 AM
To: Lu, Shan; Lishan Su
Subject: Fwd: Beijing News interview invitation-on whether seafood products will spread the new crown virus

Brother Lu: This compatriot is confused; or you, an expert with words, will answer together.

Shan-Lu Liu sent from iPhone

Begin forwarded message:

From: hanqinke <hanqinke92@163.com >
Date: June 13, 2020 at 2:17:36 AM EDT
To: "Liu, Shan-Lu" <liu.6244@osu.edu >
Subject: New Beijing newspaper in an interview invitation - on the sea niikappu virus will spread whether fresh products

Hello, Teacher Lu,

Excuse me, I'm Han Qinke, a reporter from the Beijing News. I have a question about the spread of the new crown virus.

Yesterday, the new crown virus was detected on the chopping board of a seafood stall in a large farmer's wholesale market in Beijing, and 6 people have a history of this market activity. Of the people were diagnosed. Another 45 market practitioners' throat swab samples were positive, and 40 environmental samples in the market were also positive.

. For details, please refer to <http://www.bjnews.com.cn/news/2020/06/13/737864.html>

The questions are as follows, if it is convenient, I hope you can help to answer them

1. Is it possible that the sandwich or other seafood is the vector of the new coronavirus? Is it possible for the virus to mutate into a virus that can be transmitted through the virus?
2. Can the new coronavirus be spread through contact or eating seafood?
3. What are the possible ways in which seafood products that are publicly sold may be infected with the new coronavirus? How long can the virus survive on seafood?
4. The epidemic in Wuhan also broke out from a seafood farmer's market, and Beijing also has a large number of cases in the seafood market this time. Does it mean that the farmer's market is the environment of the wholesale market more likely to become a hotbed of viruses?
5. How to reduce the risk of virus outbreaks in such environments as farmers' markets?

Thank you, Mr. Lu, looking forward to your reply

Han Qinke 15810824611 (same as WeChat)

From: wen yumei <ymwen@shmu.edu.cn>
Sent: Monday, December 23, 2019 6:33 AM
To: Klenk
Cc: Lu, Shan
Subject: Greetings

Dear Hans: Hope you and your family a merry christmas and happy new year.
We have not heard from Gotz, though Shan has sent letters to invite him to join EMI editorial board. Can you hlep us to contact ham? incase he missed the mails. u-meì

From: Lu, Shan
Sent: Thursday, December 31, 2020 11:34 AM
To: Editorial Office
Cc: M. Yu-Mei Wen (ymwen@shmu.edu.cn); min.yang@emi2012.org; editorial2@emi2012.org; 'jingee'
Subject: Happy New Year from EMI

Dear EMI Editorial Board Members,

On behalf of Prof Wen, Editor-in-Chief of EMI, and EMI Editorial Office, I would like to thank everyone in the big EMI family, especially review editors and editorial members for your great support in 2020 which brought unprecedented challenges to all of us. We hope you and your family have been safe and well, and wish you a Happy New Year for 2021!

EMI was launched in 2012 with the full realization that emerging infections are major threats to human society in the 21st century and our journal is strategically placed in China. EMI has stood up from the first report by Prof KY Yuan in January 2020 about the first evidence of human-to-human transmission to devote fully in the fight against COVID-19 for the whole year. EMI covered a broad range of topics from basic virology, epidemiology, diagnosis, treatment, vaccines and anti-conspiracy among others. We also covered reports from many countries including Africa.

In 2020, EMI received about 1800 total submissions and published 303 papers while we published 173 papers in 2019, a 195% increase.

The quality of EMI papers are also improving significantly: 30 papers published in 2020 had more than 10,000 download reads, the top one had more than 100,000 download reads. Six EMI papers are among the top 10 open access papers from over 2500 journals within the Taylor & Francis family. Quite a few papers received immediate citation: the top one received 674 citations and another three had over 200 citations each.

Looking forward in 2021, EMI is expecting to further improve the quality of published papers and spread the key scientific knowledge to more people such as the following:

- We hope to invite more high quality reviews by leading experts in their own fields. You are welcome to nominate and self-nominate for high quality reviews;
- EMI will launch a completely novel Virtual Journal Club (VJC) which is like a small seminar focusing on one EMI paper with the lead author presenting that paper live with global readers. More details will be shared with you in the near future.
- A completely re-designed EMI own website: www.emi2012.org which will provide more information about EMI, EMI papers and community interaction beyond the current Taylor & Francis paper website (www.tandfonline.com/TEMI).
- A more regular update and communication will be established with you so we want to have more direct involvement from you.

2022 will be the 10th Anniversary for EMI. We hope EMI will reach a new level by then. We will celebrate with you together and look for the exciting work in the next 10 years.

EMI started with a very humble background, and we remain to be optimistic and believe the mission of EMI. We hope to receive your continued support. Please let us know any feedback you may have.

Best.

Shan

Shan Lu, MD, PhD
Co-Editor-in-Chief
Emerging Microbes and Infections (EMI)
www.tandfonline.com/TEMI
editorial@2012EMI.org

From: vinu arumugham <igesynth@yahoo.com>
Sent: Tuesday, October 27, 2020 1:29 PM
Subject: How dirty vaccines turned COVID-19 into a killer; Make Famotidine/Cetirizine standard of care for COVID-19; COVID-19 vaccines are unsafe

Immunological mechanisms explaining the role of vaccines, IgE, mast cells, histamine, elevating ferritin, IL-6, D-dimer, VEGF levels in COVID-19 and dengue, potential treatments such as mast cell stabilizers, antihistamines: Predictions and confirmations

<https://doi.org/10.5281/zenodo.4100663>

"Trump had been administered a Regeneron polyclonal antibody cocktail and has been taking zinc, vitamin D, **famotidine**, melatonin and a daily aspirin."

<https://www.cnn.com/2020/10/02/politics/president-donald-trump-walter-reed-coronavirus/index.html>

Trump gets **famotidine** for COVID-19 but it is not "standard of care" (SOC) for you and me.

The IDSA is killing hundreds of thousands by **DENYING** them **famotidine**, a cheap, safe and effective over-the-counter drug for COVID-19.

Did the money from vaccine makers and remdesivir maker Gilead, sloshing around at IDSA, influence their decision?

<https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/>

"The guideline panel suggests against famotidine for the sole purpose of treating COVID-19, unless in the context of a clinical trial."

Here's what the authors collected:

KATHRYN M EDWARDS collected ~\$150k from vaccine makers.

<https://openpaymentsdata.cms.gov/physician/651167>

Lindsey Baden collected ~\$50k from Janssen Pharma (a vaccine maker).

<https://openpaymentsdata.cms.gov/physician/884460>

RAJESH TIM GANDHI collected ~\$40k from Gilead and Merck.

<https://openpaymentsdata.cms.gov/physician/1273478>

WILLIAM J MULLER collected ~\$140k from Astrazeneca, Merck and Janssen

<https://openpaymentsdata.cms.gov/physician/613576>

SHUMEL SHOHAM collected \$180k from Merck, Gilead, Emergent, Janssen

<https://openpaymentsdata.cms.gov/physician/780712>

Mechanistic evidence (prediction)

Proteins that contaminate influenza vaccines have high homology to SARS-CoV-2 proteins thus increasing risk of severe COVID-19 disease and mortality

<https://doi.org/10.5281/zenodo.3996984>

Epidemiological evidence (confirmation)

Flu shot increases risk of COVID-19 Hospitalization **240%**, ICU admission **204%**, Hospital mortality **232%**.

Safety of Influenza Vaccine during COVID-19

<https://doi.org/10.1017/cts.2020.543>

"Among individuals with a positive SARS-CoV-2 test, patients previously vaccinated for influenza in 2019 were more likely to be hospitalized. Once hospitalized, they were more likely to be admitted to the ICU and die during hospitalization."

From Table 1:

	Never Vaccinated (N=1,125)	Vaccinated in 2019 (N=309)
Hospitalization - no.(%)	192 (17.1)	127 (41.1)
ICU Admission - no.(%)	77 (6.8)	43 (13.9)
Hospital Mortality - no.(%)	32 (2.8)	20 (6.5)

My comment posted in the Annals of Internal Medicine

The iatrogenic cascade of illnesses

https://www.acpjournals.org/doi/full/10.7326/M20-2470#_comments

COVID-19 vaccines are **fundamentally flawed and unsafe**. Details below:

The CanSino Biologics vaccine:

<https://publons.com/r/9024531/>

The Oxford vaccine:

<https://publons.com/r/9015091/>

The Moderna mRNA vaccine:

<https://publons.com/r/9025990/>

The Pfizer/BioNTech vaccine:

<https://publons.com/r/9026177/>

The Novavax vaccine

<https://publons.com/review/9108287/>

Prof. Kounis' team and I, describe the common immunological mechanisms involved in cardiac injury in COVID-19, severe dengue infection and allergic reactions/anaphylaxis (Kounis syndrome). The medications for prevention/treatment include famotidine/cetirizine.

The passepartout wayfares of Covid-19, Cytokine storm and Kounis syndrome

<https://doi.org/10.5281/zenodo.3977923>

Dual-Histamine Blockade with Cetirizine - Famotidine Reduces Pulmonary Symptoms in COVID-19 Patients

<https://www.medrxiv.org/content/10.1101/2020.06.30.20137752v1>

I predicted in **JANUARY 2020** (email below) that mast cell stabilizers and antihistamines can help in COVID-19. I notified health authorities and thousands of doctors/researchers, worldwide. Hundreds of thousands of lives could have been saved.

The **key is to understand that COVID-19 severity is a result of an allergic reaction to the virus**, a "slow rolling anaphylaxis". **WE HAVE PROVEN TREATMENTS FOR ANAPHYLAXIS. NO CLINICAL TRIALS NEEDED.**

The diagnosis and management of anaphylaxis: An updated practice parameter

[https://www.jacionline.org/article/S0091-6749\(05\)00115-6/fulltext](https://www.jacionline.org/article/S0091-6749(05)00115-6/fulltext)

"These protocols have recommended the administration of **H1 and H2 antagonists, ??-agonists, antileukotrienes, and corticosteroids.**"

Cetirizine is an histamine H1 blocker or antagonist. Famotidine is an histamine H2 blocker or antagonist.

These safe, OTC drugs above can be used immediately upon COVID-19 symptoms (or even a low dose if exposure is suspected). Mast cell stabilizers, ??-agonists, antileukotrienes, and corticosteroids can be prescribed as standard of care. Hundreds of thousands of lives can be saved.

As I wrote in my comment posted in the Annals of Internal Medicine:

Please see comments section:

<https://annals.org/aim/fullarticle/2764199/use-hydroxychloroquine-chloroquine-during-covid-19-pandemic-what-every-clinician>

Understanding mechanisms is better than demanding clinical trials in the middle of a pandemic

More details:

Immunological mechanisms explaining the role of IgE, mast cells, histamine, elevating ferritin, IL-6, D-dimer, VEGF levels in COVID-19 and dengue, potential treatments such as mast cell stabilizers, antihistamines, Vitamin C, hydroxychloroquine, ivermectin and azithromycin

<https://doi.org/10.5281/zenodo.3748303>

COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms

<https://www.researchsquare.com/article/rs-30934/v2>

Repositioning Chromones for Early Anti-inflammatory Treatment of COVID-19

<https://www.frontiersin.org/articles/10.3389/fphar.2020.00854/full>

Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy??

<https://pubmed.ncbi.nlm.nih.gov/32013309/>

Thanks,
Vinu

----- Forwarded Message -----

Subject: Wuhan 2019-nCoV treatment; Vaccines induce autoimmunity: Epitope database evidence; Ebola vaccine will cause rice allergy epidemic

Date: Fri, 24 Jan 2020 17:42:02 -0800

From: vinu arumugham <igesynth@yahoo.com>

To: jay.slater@fda.hhs.gov <jay.slater@fda.hhs.gov>, jane.woo@fda.hhs.gov <jane.woo@fda.hhs.gov>, maureen.hess@fda.hhs.gov <maureen.hess@fda.hhs.gov>, Richard.Forshee@fda.hhs.gov <Richard.Forshee@fda.hhs.gov>, Mark.Walderhaug@fda.hhs.gov <Mark.Walderhaug@fda.hhs.gov>, CBER OCOD Consumer Account <cberocod@fda.hhs.gov>, Destefano, Frank (CDC/OID/NCEZID) <fxd1@cdc.gov>, isq8@cdc.gov <isq8@cdc.gov>, nar5@cdc.gov <nar5@cdc.gov>, hjn0@cdc.gov <hjn0@cdc.gov>, Secretary@HHS.gov <Secretary@HHS.gov>, CommissionerFDA@fda.hhs.gov <CommissionerFDA@fda.hhs.gov>, olx1@cdc.gov <olx1@cdc.gov>, directorsincoming@cdc.gov <directorsincoming@cdc.gov>, francis.collins@nih.gov <francis.collins@nih.gov>, mrolfes1@cdc.gov <mrolfes1@cdc.gov>, xzd2@cdc.gov <xzd2@cdc.gov>, acy9@cdc.gov <acy9@cdc.gov>, dbj0@cdc.gov <dbj0@cdc.gov>, jmk9@cdc.gov <jmk9@cdc.gov>, tft9@cdc.gov <tft9@cdc.gov>, gll9@cdc.gov <gll9@cdc.gov>, sharplessne@nih.hhs.gov <sharplessne@nih.hhs.gov>, tnc4@cdc.gov <tnc4@cdc.gov>, kok4@cdc.gov <kok4@cdc.gov>, rxl3@cdc.gov <rxl3@cdc.gov>, gbq7@cdc.gov <gbq7@cdc.gov>, fwf7@cdc.gov <fwf7@cdc.gov>, megan.mcseveney@fda.hhs.gov <megan.mcseveney@fda.hhs.gov>, afauci@niaid.nih.gov <afauci@niaid.nih.gov>, Emelia.Benjamin@bmc.org <Emelia.Benjamin@bmc.org>, mjessup@leducq.com <mjessup@leducq.com>, tavori@ohsu.edu <tavori@ohsu.edu>, jessica.lilley@vanderbilt.edu

[<jessica.lilley@vanderbilt.edu>](mailto:jessica.lilley@vanderbilt.edu), [<web@beasleyallen.com>](mailto:web@beasleyallen.com),
[<dr.flegg@bfwhospitals.nhs.uk>](mailto:dr.flegg@bfwhospitals.nhs.uk)

IgE mediated sensitization to peptides that have homology to 2019-nCoV peptides may contribute to disease severity. In that case, antihistamines and other allergy treatments such as mast cell stabilizers may help reduce infection severity.

A BLASTP analysis of 2019-nCoV proteome against common vaccine antigens was performed. Preliminary results suggest that IgE mediated sensitization to common vaccine antigens can result in cross reactive immune responses to 2019-nCoV.

Please see details of the mechanisms here:

Influenza vaccines and dengue-like disease

<https://www.bmj.com/content/360/bmj.k1378/rr-15>

<https://www.quora.com/Why-was-the-flu-so-deadly-in-outbreaks-in-the-past-And-what-made-the-flu-become-less-deadly/answers/86456279>

"Scientists" at the global vaccine safety summit spill the beans: There is no science behind vaccine safety claims, it's a fairy tale.

The party is over folks.

<https://youtu.be/s2lujhTdCLE>

ERVEBO Ebola vaccine will create a rice allergy epidemic, add to numerous autoimmune diseases, cancer and make Ebola disease even more severe. Design for safety and vaccine safety regulation remain abject failures. Incompetence or indifference?

<https://doi.org/10.5281/zenodo.3595020>

Analyzing 23000+ epitopes covering 82 autoimmune diseases in the Immune Epitope Database, 57% have only one and 78% have up to two amino acid residue differences compared to animal, fungal or plant peptides present in vaccines; an unmistakable signature of the role of vaccines in their etiologies

<https://doi.org/10.5281/zenodo.3603480>

Analyzing 23000+ epitopes covering 82 autoimmune diseases in the Immune Epitope Database, 57% have only one and 78% have up to two amino acid residue differences compared to animal, fungal

or plant peptides present in vaccines; an unmistakable signature of the role of vaccines in their etiologies

Vinu Arumugham

Jan 2020

vinucubeacc@gmail.com

Lay summary

Proteins are a chain of amino acids. Proteins can have up to several hundred amino acids. Snippets of proteins (peptides), 7-15 amino acids in length are important in immunology. There are 20 types of amino acids. Each is assigned a letter (1 letter code).

Antibodies are proteins that can bind to peptides that have a specific amino acid sequence. Such a target peptide is known as an epitope.?? When an antibody binds to a peptide (which is part of a protein, which in turn may be part of a cell surface), it can trigger an immune attack on the cell. If the cell were a bacterium, the bacterium would be killed.

Humans (like all organisms) are made of numerous proteins (self proteins). So we have self-proteins, self-peptides and self-epitopes. In a healthy person, the body will not make antibodies that bind strongly to self-peptides (self-tolerance).

DNA is a chain of base-pairs. The DNA base-pair sequence determines the amino acid sequence in the protein produced. If there is a mutation that alters a single base-pair, the resulting protein will have a single amino acid that is altered. To prevent cancer, the immune system is capable of making antibodies against such altered peptides. Such antibodies can also weakly bind (cross react) to the unaltered normal peptide thus resulting in destruction of some healthy cells.

Say a normal protein has the following peptide (10 amino acids, each represented by its 1 letter code):

ALSTLVV~~N~~KI

Say DNA in a cell mutates due to a carcinogen exposure and it alters the protein thus resulting in this peptide with a single amino acid change:

ALSTLVVSKI

When the immune system makes antibodies targeted at ALSTLVVSKI (to attack the cell with the DNA mutation), the same antibodies can weakly bind to the normal ALSTLVV~~N~~KI peptide.

ALSTLVV~~N~~KI is an epitope associated with rheumatoid arthritis (RA).

So as a result of the immune system defending against cancer, the person can develop RA.

Now consider vaccines containing animal proteins. Animal proteins are very similar to human proteins, containing only occasional amino acid differences. An animal peptide could therefore have the ALSTLVVSKI sequence. Such a vaccine

would fool the immune system into creating an anti-cancer immune response, creating antibodies targeted at ALSTLVVSKI. The result is vaccine induced RA.

Therefore one can predict that analyzing epitopes associated with autoimmune diseases, such single amino acid difference compared to animal peptides present in vaccines, would occur more frequently than can be expected merely by chance. The analysis confirms that this prediction is valid.

Abstract

The National Institute of Allergy and Infectious Diseases (NIAID) sponsors the Immune Epitope Data Base (IEDB). IEDB contains epitopes identified from the medical literature and organized by diseases and categories of diseases. All epitopes (23000+) associated with 82 autoimmune diseases in humans were analyzed.

The role of animal, plant, fungal proteins contained in vaccines in the etiology of autoimmune diseases have been described in humans and animals. BLASTP was used to analyze IEDB derived epitopes for sequence alignment to animal, plant, fungal (APF) proteins present in vaccines and biologics. Specifically, the search was performed against bovine, chicken, porcine, guinea pig, African green monkey, Chinese hamster, murine, peanut, soy, wheat, corn, sesame and *Saccharomyces cerevisiae* proteomes.

The results show that 57% of epitopes differed by exactly one amino acid residue from an APF peptide. 78% of the epitopes differed by up to two amino acid residues from an APF peptide. The rest of the epitopes were either identical or differed by more than two amino acid residues.

A majority of IEDB epitopes analyzed were 9-mer peptides. Comparing randomly selected 9-mer human peptides with APF proteomes, the probability of single amino acid residue difference (SAARD) outcomes was derived. This was used to estimate the probability that actual IEDB SAARD alignments to APF peptides were merely a chance outcome. The estimates show that the probability that the observed IEDB alignments to APF being merely a chance outcome are vanishingly small. So the results make it absolutely clear that APF proteins in vaccines cause all these autoimmune diseases.

Introduction

Vaccines contain thousands of residual animal, plant and fungal (APF) proteins from the manufacturing process (1)???. 293 chicken proteins were identified in the influenza vaccine (7)???, for example. Actin and vimentin proteins were detected in the Priorix Tetra vaccine (8)???. Immunization with homologous xenogeneic antigens resulting in autoimmune diseases has been known for at least 40 years (9)???. Vaccines that contain bovine proteins caused autoimmunity in dogs (10)???. We previously described the immunological mechanism involved in autoimmunity induction by immunization with homologous xenogeneic antigens (11)???

Cancer cells have minor differences when compared to healthy cells. Due to mutation of the DNA encoding the proteins, cancer cells can display altered proteins on their surface. Healthy cancer defense mechanisms include immune responses directed at such altered proteins. Therefore an immune response directed against cancer cells always carries a risk of cross reactive immune responses against healthy cells displaying the unaltered protein. Therefore, cancer induced autoimmune responses are a consequence of normal, healthy immune system behavior.

Animal proteins have minor differences compared to human proteins. Peptides that are identical between humans and animals are unlikely to cause any problem due to strong self tolerance. However, peptides with one amino acid residue difference produce the strongest cross reactive immune responses (11)???. They are ideally suited to induce autoimmune diseases. Injecting animal proteins results in anti-cancer immune responses because the immune system perceives animal proteins as altered human proteins. Adjuvants in the vaccine boost this anti-cancer immune response.

This artificial anti-cancer response directed at thousands of APF proteins in vaccines or biologics, therefore cross react and cause numerous autoimmune disorders.

For this reason, one can predict that single amino acid residue difference (SAARD) between autoimmune disease related epitopes in the IEDB and homologous APF peptides in vaccines, would occur at a higher probability than by mere chance. We perform a BLASTP analysis to verify.

Methods

Basic local alignment search tool for proteins (BLASTP) (12)???, Universal Protein Resource (UniProt)(13)??? and the Immune Epitope Database (IEDB) (14)??? were used for bioinformatics analysis.

Specifically, the BLASTP sequence alignment of IEDB peptides was performed against bovine, chick, porcine, guinea pig, African green monkey, Chinese hamster, murine, peanut, soy, wheat, corn, sesame and *Saccharomyces cerevisiae* proteomes. Vaccines and biologics contain residual proteins from all these organism due to media used to grow viruses or bacteria, recombinant cells/organisms used for protein expression or as excipients.

Results

57% of IEDB peptides have a SAARD and 78% have up to two amino acid differences compared to animal, fungal or plant peptides present in vaccines.

Discussion

Could this result be a chance occurrence?

A majority of IEDB epitopes analyzed were 9-mer peptides. Five thousand 9-mer peptides were chosen at random from the human proteome. BLASTP was run using these peptides to compare against each organism???'s proteome or a subset. This provides us the probability that randomly selected human peptides have an alignment providing a SAARD compared to peptides from these organisms. These are listed in table 1 under ??? Random SAARD alignment???. Given this, we can compute the probability of the actual SAARD alignment to IEDB epitopes, occurring by chance. This is listed in table 1 under ???Estimated probability of actual SAARD outcome occurring just by chance???

For a simple coin toss example, we would perform the calculation as follows:

Computing probability of say a 7 heads, 3 tails outcome of 10 trials of a fair coin:

$$\text{Probability} = (0.5^7) \times (0.5^3) \times 10! / (7! \times 3!)$$

Where:

0.5 is the probability of a head or tail outcome of a fair coin.

For an unfair coin, say probability of head outcome = 0.4 and tail outcome 0.6, we would have:

$$\text{Probability} = (0.4^7) \times (0.6^3) \times 10! / (7! \times 3!)$$

For the IEDB peptide probability analysis, the outcome is for 23192 trials (peptides).

The head outcome is the Random SAARD alignment entries in table 1. The tail outcome probability is 1-head outcome.

Sample calculation for Chinese Hamster:

$$\text{Probability} = ((889/5000)^{4574}) \times ((4111/5000)^{18618}) \times 23192! / (4574! \times 18618!)$$

$$\text{Probability} = 1.488\text{e-}15$$

Where: $889 \times 100 / 5000 = 17.8\%$ is the entry in Table 1 for Chinese Hamster. BLASTP analysis shows 889 SAARD out of 5000 peptides analyzed.

And, $4574 \times 100 / 23192 = 19.7\%$ is the IEDB entry in Table 1 for Chinese Hamster. BLASTP analysis shows 4574 SAARD out of 23192 peptides analyzed.

So the $1.488\text{e-}15$ value is the probability that we will have exactly 4574 SAARD alignments out of 23192 peptides. The probability goes down for all values > 4574 . Conservatively, applying the same probability as for 4574, to all values > 4574 , we can calculate the probability of the chance occurrence of 4574 or greater number of SAARD alignments as $1.488\text{e-}15 \times 18618 = 27\text{e-}12$, entry in table.

The Gnome calculator was used to perform these calculations and the results were verified using the Qalculate! calculator and WolframAlpha (15) since spreadsheets are unable to perform these calculations.

Table 1

Organism	Random SAARD alignment Number of Peptides(%)	Actual (IEDB) SAARD alignment Number of Peptides (%)	Estimated probability of actual SAARD outcome occurring just by chance	Remarks
African green monkey (<i>Chlorocebus aethiops</i>)	26 (0.5)	420 (1.8)	$\sim 1.7\text{e-}96$	Probability vanishingly caused these
Cow (<i>Bos taurus</i>)	936 (18.7)	4385 (18.9)	~ 1	There are two by chance. present in the that cow? used in vacuoles tissues in the proteins may explanation

Organism	Random SAARD alignment Number of Peptides(%)	Actual (IEDB) SAARD alignment Number of Peptides (%)	Estimated probability of actual SAARD outcome occurring just by chance	Remarks
Cow's Milk (<i>Bos taurus</i>)	0 (0)	12 (0.05)	0	Probability these animal
Chinese Hamster (<i>Cricetulus griseus</i>)	889 (17.8)	4574 (19.7)	~27e-12	Probability vanishingly biologics ca
Chicken (<i>Gallus gallus</i>)	536 (10.7)	3901 (16.8)	<1e-100	Probability vanishingly caused these proteins, sin manufactur
Guinea Pig (<i>Cavia porcellus</i>)	837 (16.7)	4439 (19.1)	~1e-18	Probability vanishingly caused these
Mice (<i>Mus musculus</i>)	940 (18.8)	4467 (19.3)	~1	There are tw by chance. present in b that mice m proteins and present in b present. Th
Maize (<i>Zea mays</i>)	303 (6.1)	1667 (7.2)	~5e-9	Probability vanishingly caused these
Peanut (<i>Arachis hypogaea</i>)	223 (4.5)	1697 (7.3)	~79e-81	Probability vanishingly caused these
Yeast (<i>Saccharomyces cerevisiae</i>)	64 (1.3)	828 (3.6)	<1e-100	Probability vanishingly biologics ca
Sesame (<i>Sesamum indicum</i>)	155 (3.1)	1398 (6.0)	<1e-100	Probability vanishingly caused these
Soy (<i>Glycine max</i>)	215 (4.3)	1548 (6.7)	~86e-59	Probability vanishingly caused these
Pig (<i>Sus scrofa</i>)	963 (19.3)	4407 (19.0)	~1	There are tw by chance.

Organism	Random SAARD alignment Number of Peptides(%)	Actual (IEDB) SAARD alignment Number of Peptides (%)	Estimated probability of actual SAARD outcome occurring just by chance	Remarks
				present in the that porcine proteins pre vaccines bu is the more
Wheat (<i>Triticum aestivum</i>)	138 (2.8)	977 (4.2)	~18e-33	Probability vanishingly caused these

The calculations make it clear that the findings cannot be merely a chance outcome and that immunization against animal/plant/fungal antigens in the vaccines do cause these autoimmune diseases in the IEDB.

Conclusion

Vaccines containing animal, plant or fungal proteins are extremely dangerous and cause numerous autoimmune diseases and cancer (16-19). All non-target proteins in vaccines must be immediately removed using processes such as affinity chromatography (20).

References

1. Kattan JD, Cox AL, Nowak-Wegrzyn A, Gimenez G, Bardina L, Sampson HA, et al. Allergic reactions to diphtheria, tetanus, and acellular pertussis vaccines among children with milk allergy. *J Allergy Clin Immunol*. 2011;Conference(var.pagings):AB238.
2. Arumugham V. Oxford Vaccine Group Vaccine Knowledge Project's Vaccine Ingredient and vaccine safety misinformation exposed [Internet]. 2019 [cited 2019 Dec 11]. Available from: <https://doi.org/10.5281/zenodo.3477854>
3. National Academies of Sciences and Medicine E. Finding a Path to Safety in Food Allergy: Assessment of the Global Burden, Causes, Prevention, Management, and Public Policy. Stallings VA, Oria MP, editors. Washington, DC: The National Academies Press; 2017.
4. Gardasil Package Insert [Internet]. Available from: <http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM111263.pdf>
5. ENGERIX-B HIGHLIGHTS OF PRESCRIBING INFORMATION [Internet]. Available from: <https://www.fda.gov/media/79341/download>

6. Arumugham V, Trushin M V. Role of NMDA receptor autoimmunity induced by food protein containing vaccines, in the etiology of autism, type 1 diabetes, neuropsychiatric and neurodegenerative disorders [Internet]. International Journal of Pharmaceutical Research. 2019 [cited 2019 Apr 15]. p. 428???37. Available from: <https://doi.org/10.5281/zenodo.1463600>
7. Jacob L, Leib R, Ollila HM, Bonvalet M, Adams CM, Mignot E. Comparison of Pandemrix and Arepanrix, two pH1N1 AS03-adjuvanted vaccines differentially associated with narcolepsy development. Brain Behav Immun. 2015 Jul;47:44???57.
8. Corvelva. Vaccinegate:Study on the chemical composition profile of Priorix Tetra [Internet]. 2018 [cited 2019 Aug 24]. Available from: <https://drive.google.com/file/d/1cNtdBczAX1-xowPEDep1kZOjy84IypAB/view>
9. Arumugham V. Vaccination with bovine, chick, yeast antigens synthesizes cross-reactive antibodies targeting human acetylcholine receptor and MuSK protein to cause Myasthenia Gravis: Confirmed by natural experiment (VAERS data), bioinformatics, case reports, animal experiments and titer study [Internet]. 2019 [cited 2019 Sep 16]. Available from: <https://doi.org/10.5281/zenodo.3421558>
10. Hogenesch H, Azcona-Olivera J, Scott-Moncrieff C, Snyder PW, Glickman LT. Vaccine-induced autoimmunity in the dog. Adv Vet Med. 1999;41:733???47.
11. Arumugham V, Trushin M V. Cancer immunology, bioinformatics and chemokine evidence link vaccines contaminated with animal proteins to autoimmune disease: a detailed look at Crohn???s disease and Vitiligo. J Pharm Sci Res. 2018;10(8):2106.
12. Altschul SF, Madden TL, Sch???ffer AA, Zhang J, Zhang Z, Miller W, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997;25(17):3389???402.
13. UniProt: the universal protein knowledgebase. Nucleic Acids Res. 2017 Jan 4;45(D1):D158???69.
14. Vita R, Mahajan S, Overton JA, Dhanda SK, Martini S, Cantrell JR, et al. The Immune Epitope Database (IEDB): 2018 update. Nucleic Acids Res. Oxford University Press; 2019;47(D1):D339???43.
15. Wolfram|Alpha: Computational Intelligence [Internet]. [cited 2020 Jan 8]. Available from: <https://www.wolframalpha.com/>
16. Arumugham V. Vaccines and Biologics injury table based on mechanistic evidence ??? Mar 2019 [Internet]. 2019 [cited 2019 May 16]. Available from: <https://zenodo.org/record/2582635/files/viittoc0302http.pdf?download=1>
17. Arumugham V. As predicted, animal protein containing biologics induce de novo autoimmune disorders [Internet]. 2019 [cited 2019 Dec 29]. Available from: <https://doi.org/10.5281/zenodo.3483322>

18. Arumugham V. Expanding ASIA to GAVIDOTTIR???: GAMut of Vaccine Induced Damage emphasizing Off Target Immune Responses [Internet]. 2019 [cited 2019 Oct 23]. Available from: <https://doi.org/10.5281/zenodo.3478840>
19. Arumugham V. Role of anti-carbonic anhydrase 2 antibodies induced by vaccine antigens, in the etiology of acute myeloid leukemia and other malignancies [Internet]. 2019 [cited 2019 Nov 14]. Available from: <https://doi.org/10.5281/zenodo.3534442>
20. Zhao M, Vandersluis M, Stout J, Haupts U, Sanders M, Jacquemart R. Affinity chromatography for vaccines manufacturing: Finally ready for prime time? Vaccine. Netherlands; 2018 Apr;

From: wen yumei <ymwen@shmu.edu.cn>
Sent: Wednesday, January 8, 2020 9:56 PM
To: 'dyjin'
Cc: Lu, Shan
Subject: invitation

Dongyan:

Based on your previous review published in 2016, on host innate antiviral response and emerging human coronaviruses, would you please write another reivew on the emerging of new or old human coronaviruses in association with host responses for EMI? Thank you for your consideration. YMWen

From: Manon Cox <manoncox@gmail.com>
Sent: Thursday, April 1, 2021 9:09 AM
To: rahmed@emory.edu; randy.albrecht@mssm.edu; abarrett@utmb.edu; manoncox@gmail.com; annied@epivax.com; denise.doolan@jcu.edu.au; rellis.hvi@gmail.com; emilio.emini@gatesfoundation.org; adolfo.garcia-sastre@mssm.edu; nathalie.garcon@bioaster.org; marc.girard36@wanadoo.fr; bruno.guy@sanofipasteur.com; adrian.hill@ndm.ox.ac.uk; kenishii@biken.osaka-u.ac.jp; kathrin.jansen@pfizer.com; marie-paule.kieny@inserm.fr; linda.klavinskis@kcl.ac.uk; klinmand@gmail.com; paul.lambert@unige.ch; mlevine@medicine.umaryland.edu; liu@protherimmune.com; Lu, Shan; nara@bmi-md.com; offit@email.chop.edu; j.oxford@qmul.ac.uk; immgcpa@micro.ufrj.br; peter.palese@mssm.edu; punnee.pit@mahidol.ac.th; stanley.plotkin@vaxconsult.com; rino.r.rappuoli@gsk.com; jhrhee@chonnam.ac.kr; tedross@uga.edu; connie.s.schmaljohn.civ@mail.mil; matthias.schnell@jefferson.edu; johnwshiver@gmail.com; slifkam@ohsu.edu; indresh.srivastava@sanofi.com; ftangy@pasteur.fr; jeffreylulmerllc@gmail.com; britta.wahren@ki.se; dweiner@wistar.org; ymwen@shmu.edu.cn; anna-lise.williamson@uct.ac.za
Cc: 'Klavinskis, Linda'; Lu, Shan; Gibson, Edward
Subject: ISV Congress 2021: Your input is requested

Please respond to this email no later than April 8th, 2021

Dear ISV-fellows:

As you may have expected, ISV officers decided that it would be too risky to organize this years' ISV congress as an in-person meeting given the uncertainties surrounding travel during the ongoing COVID situation.

I am honoured that I was asked to Chair the next (virtual) ISV congress scheduled for September 12 -15, 2021. Not an easy task as many of us have reached a certain Zoom fatigue and ISV has already organized multiple successful short seminars with excellent attendance.

We would like to come up with an original conference design that will attract many of our colleagues and young scientists. I am seeking **your help** in coming up with ideas and topics for this conference.

The plan is to offer some pre-recorded sessions on relevant topics such as New Vaccines on the Horizon; Regulatory Affairs; RNA vaccines – what is next? etc. and keynote lectures. These sessions can be watched by attendees at any given point in time.

We are also looking to arrange submission for presentations or posters in a somewhat different format, such as asking people who apply for a “oral presentation” to send in a 5-minute pre-recorded pitch. We can make a collage of the best presentations and/or select speakers this way.

In addition, to this we would like to offer some dynamic interaction where participants can sign up to break-out rooms to discuss topics of interest. For example, one session could be “Meet the ISV fellows”; “Meet the Key Note Speakers” or “Meet the Poster presenters”.

I would like to conclude with three specific questions:

- 1) Would you be willing to help organize?
- 2) Would you be willing to be present in a break-out room to meet w attendees?

3) Do you have ideas/suggestions for format and/or content?

Thank you in advance for your response!

Warm regards, Manon

From: Gibson, Edward
Sent: Sunday, June 21, 2020 9:39 PM
To: 'stanley-perlman@uiowa.edu'
Cc: Lu, Shan; 'cindicallaghan@isv-online.org'; 'EdwardGibson@isvcongress.org'
Subject: ISV Virtual Congress Reminder
Attachments: Panelist Instructions - Stanley Perlman.pdf

Dear Professor Perlman,

We are very excited that our virtual congress will start in 12 hrs. Here are a few key last-minute reminders to you:

- You will join the congress as a speaker so there is no link for you to connect.
- As in our training you need to join through your desktop Microsoft Teams software: Double click to bring it up >> enter the Guest ID and the password we sent you >> you are inside Teams >> looking at the left side of Teams field locate a button called "Calendar" >> click that to open calendar and find "First ISV COVID-19 Vaccine Virtual Congress" box, click that once>> on the new page, find a small box called "Join", click it once, then you should be joining the presenter's room.
- After you have joined the presenter room, you will see quite a few monitors. If the congress is live, you need to keep quiet. If you mute yourself or are placed on mute, please unmute yourself prior to your presentation.
- You need to follow the instruction of your session chair.
- When your name is mentioned by your chair, your video will have a RED outside box, that means you are live and you should start talking.
- Please see attached instructions if you need any reminders.

Please feel free to let us know if you have any questions. You can reply to Edward and Cindi (cc 'ed here).

If there is any issue requiring a phone call, here is the international free dialing number. You will need to email us to let us know a call is required.

18005018979 toll-free within US and Canada
Access Code: 8566791

Also, we will record the congress and make it available for public viewing. Please let us know if you have any concern or objection within 12 hrs after the congress. Your support is greatly appreciated.

Best.

Shan Lu
Co-Chair
ISV 1st Virtual Congress
<https://isvcongress.org/>



From: Gibson, Edward
Sent: Sunday, June 7, 2020 4:07 PM
To: stanley-perlman@uiowa.edu
Subject: ISV Virtual Congress; Presenter Acceptance

Dear Professor Perlman,

Thank you for your acceptance to participate as a presenter for the **1st ISV COVID-19 Vaccine Virtual Congress** taking place **June 22nd**. I will be your contact person regarding this very important event.

In order to highlight your participation please send me the following by **Tuesday, June 9th**:

- A Photo of Yourself
- Short 1-Paragraph Bio
- Title of Talk

The platform for the virtual Congress will be **Microsoft Teams**. Have you had any experience using Teams in the past? Do you have a Microsoft 365 account?

Please note in order to present you will need the **Microsoft Teams Desktop Application**. Please let me know in your reply email and we will work to ensure you have the correct software installed.

We will be hosting a training for presenters the week of 6/15. Details will follow in a separate email. If you have a personal assistant who would like to attend the training, please send me their contact information as well.

We understand this is short notice however the need to fully control COVID-19 is imperative and as a vaccine society we feel this must happen now. Please let me know any questions. Thank you.

Regards,

Ted Gibson

~~~~~

Ted Gibson

+1-508-856-1179

[EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org)



---

**From:** Vinu Arumugham <igesynth@outlook.com>  
**Sent:** Tuesday, March 23, 2021 11:29 PM  
**To:** francis.chan@umassmed.edu; Aroian, Raffi; jeffrey.bailey@umassmed.edu; Berg, Leslie; Wang, Shixia; Brass, Abraham; Brehm, Michael; Cavacini, Lisa; Clapham, Paul; Finberg, Robert; Fingerroth, Joyce; Flotte, Terence; Gao, Guangping; Garber, Manuel; Gazzinelli, Ricardo T; Woodland, Robert; Goguen, Jon; douglas.goglenbock@umassmed.edu; Gottlinger, Heinrich; Gravalles, Ellen M; Green, Sharone; Greiner, Dale; Grunwald, David; Harris, John; jun.huh@umassmed.edu; Huseby, Eric S; Irazoqui, Javier; Wang, Jennifer; Kang, Joonsoo; Kelliher, Michelle; Kornfeld, Hardy; Kowalik, Timothy; Kurt-Jones, Evelyn; Levitz, Stuart M; dan.libraty@umassmed.edu; Lien, Egil; vladimir.litvak@umassmed.edu; Lu, Shan; Luban, Jeremy; Luna, Elizabeth J; Mandrekar, Pranoti; McCormick, Beth; Zapp, Maria; Morrison, Trudy; Munson, Mary; Murphy, Kenan; Newburger, Peter; Pukkila-Worley, Read; Ram, Sanjay; Reboldi, Andrea; Yeneneh.Haileselassie@umassmed.edu; Bruno.Trindade@umassmed.edu; Rice, Peter; Rock, Kenneth; Rothstein, Ann; Luzuriaga, Katherine; Sasseti, Christopher; Schafer, Dorothy (Dori); Schiffer, Celia; Schmidt, Madelyn; Selin, Liisa; Socolovsky, Merav; Sontheimer, Erik; Stern, Lawrence; Swain, Susan; Szabo, Gyongyi; Szomolanyi-Tsuda, Eva; Thompson, Paul; Mondal, Santanu; Mitesh.Nagar@umassmed.edu; Padmavathy.NandhaPremnath@umassmed.edu; Venkatesh.Nemmara@umassmed.edu; Son.Nguyen@umassmed.edu; Parelkar, Sangram; Salinger, Ari; Ronak.Tilvawala@umassmed.edu; Li.Zheng@umassmed.edu; Volkert, Michael; microimm@med.unc.edu; janelle\_arthur@med.unc.edu; bourret@med.unc.edu; miriam\_braunstein@med.unc.edu; willie\_brickey@med.unc.edu; brian.patrick.conlon@gmail.com; pcotter@med.unc.edu; lcramer@med.unc.edu; damania@med.unc.edu; abelk@email.unc.edu; aravinda\_desilva@med.unc.edu; ddittmer@med.unc.edu; gina\_donato@med.unc.edu; gdotti@med.unc.edu; rjohnston@globalvaccines.org; goldman@med.unc.edu; nilu\_goonetilleke@med.unc.edu; jdjg@med.unc.edu; sbjoseph@email.unc.edu; kafri@med.unc.edu; prem@med.unc.edu; helen.lazear@med.unc.edu; gkmats@med.unc.edu; karen\_mckinnon@med.unc.edu; edmia01@gmail.com; camoody@email.unc.edu; nmoorman@email.unc.edu; jnelson@med.unc.edu; raymond\_pickles@med.unc.edu; nrt@med.unc.edu; seconlon@email.unc.edu; silversr@med.unc.edu; leormego@med.unc.edu; lishan\_su@med.unc.edu; rtamayo@med.unc.edu; shaomin\_tian@med.unc.edu; rmtisch@med.unc.edu; dgk501@med.unc.edu; walkerka@email.unc.edu; wany@email.unc.edu; cbwhiteh@med.unc.edu; matthew\_wolfgang@med.unc.edu; rbaric@email.unc.edu; bruce\_cairns@med.unc.edu; mscohen@med.unc.edu; newboldje@gmail.com; lad@email.unc.edu; garciama@email.unc.edu; celtsfan@med.unc.edu; jonathan\_hansen@med.unc.edu; heisem@med.unc.edu; mhirsch@email.unc.edu; mmhobbs@med.unc.edu; ilona\_jaspers@med.unc.edu; smlemon@med.unc.edu; zhiliu@med.unc.edu; robmaile@med.unc.edu; dmargo@med.unc.edu; markovics@neurology.unc.edu; clyde@email.unc.edu; meshnick@email.unc.edu; vlmiller@med.unc.edu; Nagaraja@email.unc.edu; robert\_nicholas@med.unc.edu; joseph\_pagano@med.unc.edu; david\_peden@med.unc.edu; redinbo@unc.edu; howard\_reisner@med.unc.edu; rbs@med.unc.edu; John.Schmitz@unchealth.unc.edu; jonathan\_serody@med.unc.edu; eshank@unc.edu; masu@email.unc.edu; risunc@med.unc.edu; jenny\_ting@med.unc.edu; jwebster@email.unc.edu; jwhitmir@email.unc.edu; steven\_bachenheimer@med.unc.edu; ken\_bott@med.unc.edu; jgc@med.unc.edu; marshall@med.unc.edu; susan\_fiscus@med.unc.edu; zman@med.unc.edu; hgooder@mindspring.com; jhandy@med.unc.edu; jcj@med.unc.edu; ronald\_falk@med.unc.edu; stephan\_moll@med.unc.edu  
**Subject:** It's a lab virus; Killer, clotting COVID-19 vaccines; CDC's "Vaccines do not cause autism" lie, taken down; Judge to FCC on radiation danger: 'I am Inclined to Rule Against You'

How the FDA squashed any discussion of safety and rushed to authorize the Pfilthy Pfizer vaccine:

## SARS-CoV-2 vaccines and clotting disorders

### IgE mediated clotting disorders

There are hundreds of [reports](#) of clotting disorders following vaccination with Pfizer/Moderna and AstraZeneca vaccines. Many countries have suspended use of AstraZeneca vaccines for this reason.

COVID-19 severity is due to IgE mediated sensitization to antigens with homology to SARS-CoV-2 proteins, which results in "slow rolling anaphylaxis" upon infection as described [here](#).

People with IgE that recognize SARS-CoV-2 spike protein due to cross-reaction will suffer "slow rolling anaphylaxis" upon infection **OR VACCINATION**. One signature of this condition is low platelet count. This is likely what is being observed following vaccination. The anaphylaxis after vaccination in these cases is delayed (not the usual <30 min. immediate reaction) because the mRNA translation to spike protein takes hours. Similarly, viral vector infection of cells using the AstraZeneca vaccine that subsequently produce spike proteins, takes hours. So again we have delayed, "slow rolling anaphylaxis". So treatment to avoid this problem with COVID-19 as well as post-vaccination may be the same - H1/H2 histamine blockers like famotidine/cetirizine.

*A case series: Association of anaphylaxis with a significant decrease in platelet levels and possible secondary risk of thrombosis*

<https://onlinelibrary.wiley.com/doi/full/10.1002/iid3.224>

*Platelet function in anaphylaxis*

[pubmed.ncbi.nlm.nih.gov/16599241/](https://pubmed.ncbi.nlm.nih.gov/16599241/)

### Autoimmunity related clotting disorders

The spike protein epitopes have homology to thrombocytopenia related epitopes. So spike proteins induced by the vaccines can cause the development autoimmunity directed at these epitopes, thus resulting in clotting disorders.

LLPDPSAPT is a thrombocytopenia associated epitope in the Immune Epitope Database (IEDB.org). Below is BLASTP comparison to spike protein (QHD43416.1)

### unnamed protein product

Sequence ID: Query\_30841Length: 9Number of Matches: 1

Range 1: 1 to 9[Graphics](#)Next MatchPrevious Match

| Score         | Expect | Method                   | Identities | Positives | Gaps    |
|---------------|--------|--------------------------|------------|-----------|---------|
| 19.6 bits(39) | 0.002  | Composition-based stats. | 6/9(67%)   | 8/9(88%)  | 0/9(0%) |

```

Query   805   ILPDPSKPS   813
          +LPDPS P+
Sbjct   1     LLPDPSAPT   9

```

Integrin beta is also listed as a thrombocytopenia target in IEDB.

Below is BLASTP comparison to spike protein (QHD43416.1)

**tr|H3BM21|H3BM21\_HUMAN Integrin beta (Fragment) OS=Homo sapiens OX=9606  
PE=3 SV=1**

**Sequence ID: Query\_59343Length: 787Number of Matches: 91**

Range 1: 360 to 382[Graphics](#)[Next Match](#)[Previous Match](#)

| Score         | Expect                     | Method                       | Identities | Positives  | Gaps      |
|---------------|----------------------------|------------------------------|------------|------------|-----------|
| 22.3 bits(46) | 0.18                       | Compositional matrix adjust. | 13/26(50%) | 16/26(61%) | 4/26(15%) |
| Query 197     | IDGYFKIYSKHTPINL-VRDLPQGFS | 221                          |            |            |           |
|               | +D Y KI SK + L VRDLP+ S    |                              |            |            |           |
| Sbjct 360     | VDAYGKIRSK---VELEVRLPEELS  | 382                          |            |            |           |

These match scores are comparable to the 19.7 BLASTP match score for the epitope shown to cause Pandemrix induced narcolepsy.

Nucleocapsid protein [Influenza A virus (A/reassortant/NYMC X-179A(California/07/2009 x NYMC X-157)(H1N1))] ADE29096.1 vs. human hypocretin receptor 2 (HCRTR2) produces a BLASTP score of 19.7

---

**"Truncated and modified mRNA species" in the Pfizer/Moderna vaccines will cause autoimmunity, allergies, asthma, etc.**

People forget the old saying **"If it sounds too good to be true, it probably is"**.

Traditional vaccines took a decade to develop and they were ineffective and unsafe in most cases. Now they want us to believe that they magically created "safe and effective" vaccines based on never-used-before mRNA technology, in just months. That's like winning the lottery. Twice. The Pharma CEOs certainly won the lottery but now Pfizer's Pfilth is being exposed.

"Cyberattackers" exposed the cover up by our corrupted regulators.

*The EMA covid-19 data leak, and what it tells us about mRNA instability*

<https://www.bmj.com/content/372/bmj.n627>

On a good day at the vaccine plant, as much as 30% of the mRNA in the vaccine can be "truncated and modified" due to instability. That means instead of producing the target spike protein, this mRNA will direct the cell to produce RANDOM proteins with RANDOM peptides that can have high homology to ANYTHING. These random proteins can have peptides that have high homology to peptides in self-proteins, food proteins, aeroallergen proteins, etc. The result is the immune system is being trained to attack self-proteins (autoimmunity), food proteins (food allergy), aeroallergen (asthma) etc. These mRNA vaccines come with a powerful lipid-in-water-emulsion adjuvant that boosts all the above diseases.

So this is an ALL-diseases-in-one, shot. Making them Pharma's most sickening vaccines yet. With **85 millions doses, the vaccines have killed AT LEAST 1500 people** by VAERS documentation alone.

We have not even started to count how many will be maimed for life. **CORRUPTED SCIENCE KILLS EFFICIENTLY.**

---

### **SARS-CoV-2 originated in a lab**

In a world of conspiring criminals, it takes "conspiracy theorists" to expose the truth ...

*A Bayesian analysis concludes beyond a reasonable doubt that SARS-CoV-2 is not a natural zoonosis but instead is laboratory derived*

<https://doi.org/10.5281/zenodo.4470232>

---

### **FDA/CDC's Bell's palsy lie exposed. What else are they lying about? Plenty.**

[www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html](http://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html)

"Cases of Bell's palsy were reported following vaccination in participants in both the Pfizer-BioNTech and Moderna COVID-19 vaccines clinical trials. However, the FDA does not consider these to be above the frequency expected in the general population and has not concluded that these cases were causally related to vaccination."

I exposed the FDA/CDC lie above back in Dec 2020 and now a team has exposed the lie again in the Lancet Infectious Disease journal.

*Bell's palsy and SARS-CoV-2 vaccines*

[www.thelancet.com/journals/laninf/article/PIIS1473-3099\(21\)00076-1/fulltext#%20](http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00076-1/fulltext#%20)

"Therefore, the observed incidence of Bell's palsy in the vaccine arms is between 3.5-times and 7-times higher than would be expected in the general population. This finding signals a potential safety phenomenon and suggests inaccurate reporting of basic epidemiological context to the public."

[www.statnews.com/2020/12/28/chance-illnesses-after-covid-19-vaccinations-could-test-public-confidence-even-if-the-problems-are-unrelated/](http://www.statnews.com/2020/12/28/chance-illnesses-after-covid-19-vaccinations-could-test-public-confidence-even-if-the-problems-are-unrelated/)

Article above says: "Eight people in the Pfizer and Moderna trials, which enrolled nearly 74,000 participants in total, were diagnosed with the condition — seven in the vaccine arms and one in the placebo arm of the Moderna trial. The jury is still out on whether Bell's palsy, which afflicts about 40,000 people a year in the U.S., is an occasional side effect of taking a Covid-19 vaccine."

So about 1 in 8250 (330,000,000/40,000) will develop Bell's palsy each year in the US. Say the trial ran for 3 months. That makes it 1 in 33,000 probability of occurrence during the trial. One case in the placebo arms consisting of 37000 people is therefore as expected.

What's the probability of 7 cases of Bell's palsy occurring merely by chance, in the vaccine arms?

$$(((32999 \div 33000)^{36993}) \times ((1 \div 33000)^7) \times (37000!)) \div (36993! \times 7!) = 0.00014$$

1 in ~7,000. Why is "the jury still out"? The vaccine caused the Bell's palsy cases.

---

VAERS shows >1000 deaths after COVID-19 vaccines. Clustering of deaths on days post-vaccination and comparing with the same data following flu vaccines, makes it clear that most of these deaths were CAUSED by the COVID-19 vaccines.

<https://childrenshealthdefense.org/defender/facebook-posts-vaers-link-covid-vaccines-injuries-death>

<https://childrenshealthdefense.org/defender/latest-data-cdc-vaers/>

---

## "Misinformation" and censorship

Facebook censors were wrong 80% of the time.

<https://businessinsider.com/facebook-supreme-court-oversight-board-overturms-4-of-5-cases-2021-1>

People don't trust BigTech, mainstream media and the government.

Fauci's no mask needed, then wear a mask, then wear TWO now, does not earn him any trust. Fauci admitted lying about vaccine-related herd immunity targets.

*Should Leaders Tell Noble Lies? - Strategic Leaders Academy*

<https://strategicleadersacademy.com/should-leaders-tell-noble-lies/>

Then Fauci admitted that injected vaccines do not offer herd Immunity at all.

"Administration of parenterally administered vaccines alone typically does not result in potent mucosal immunity that might interrupt infection or transmission"

<http://acpjournals.org/doi/10.7326/M21-0111>

The WHO flip-flopped on COVID-19 vaccine safety in pregnancy.

*Moderna's COVID-19 vaccine now recommended for pregnant women, WHO says in guidance reversal*

[www.foxnews.com/health/moderna-covid-vaccine-pregnant-women-who-guidance-reversal](http://www.foxnews.com/health/moderna-covid-vaccine-pregnant-women-who-guidance-reversal)

So the "authorities", mainstream media and BigTech are not even trying to EARN trust because they spread **"OFFICIAL" MISINFORMATION**. With censorship and fraudulent "fact-checking", they are only **REAFFIRMING** that they all have plenty to hide.

Even the Wall Street Journal and MEDPAGETODAY have become victims of the "fact-check" mafia.

<https://www.wsj.com/articles/fact-checking-facebooks-fact-checkers-11614987375>

---

### **Vaccines absolutely do cause autism**

The CDC has flip-flopped twice in ~5 months on the fraudulent claim that "Vaccines do not cause autism", on their website. It suggests that the CDC's vaccine/autism claims are based on the conjunction of Jupiter and Saturn, not science.

They were forced to take the false claim down because ICAN demonstrated there was **ZERO** science behind that claim.

*The CDC Finally Capitulated To ICAN's Legal Demands and Removed the Claim that "Vaccines Do Not Cause Autism" From Its Website!*

[https://www.icandecide.org/ican\\_press/the-cdc-finally-capitulated-to-icans-legal-demands-and-removed-the-claim-that-vaccines-do-not-cause-autism-from-its-website/](https://www.icandecide.org/ican_press/the-cdc-finally-capitulated-to-icans-legal-demands-and-removed-the-claim-that-vaccines-do-not-cause-autism-from-its-website/)

*THE CDC JUST SOLIDIFIED THAT ITS DECISIONS ARE NOT DRIVEN BY SCIENCE*

[https://www.icandecide.org/ican\\_press/the-cdc-just-solidified-that-its-decisions-are-not-driven-by-science/](https://www.icandecide.org/ican_press/the-cdc-just-solidified-that-its-decisions-are-not-driven-by-science/)

**FACT:** Milk protein contaminated vaccines (DTap/Tdap/Prevnar 13/ActHiB) cause at least 75% of autism cases.

*Autism pathogenesis: Piecing it all together, from end to beginning ...*  
<https://doi.org/10.5281/zenodo.1477515>

CDC caught lying, again about the COVID-19 vaccine this time.

*CDC Investigation*

<http://fullmeasure.news/news/cover-story/cdc-investigation>

---

**Vaccine mandates are based on a lie; Repeal all mandates immediately; Try the corrupted liars who created mandates, for CRIMES AGAINST HUMANITY**

"Administration of parenterally administered vaccines alone typically does not result in potent mucosal immunity that might interrupt infection or transmission"

*SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn*

[www.acpjournals.org/doi/10.7326/M21-0111](http://www.acpjournals.org/doi/10.7326/M21-0111)

So Fauci admits now that **ALL** injected vaccines are for individual protection only. **No herd/community immunity**. So no vaccine mandates are justifiable for **ANY** injected vaccine.

And of course this also means the vaccinated can become infected super-spreaders as occurs with the failed flu shot and failed pertussis vaccines.



Yan J, Grantham M, Pantelic J, de Mesquita PJ, Albert B, Liu F, et al. Infectious virus in exhaled breath of symptomatic seasonal influenza cases from a college community. Adamson W, Beato-Arribas B, Bischoff W, Booth W, Cauchemez S, Ehrman S, et al., editors. Proc Natl Acad Sci. National Academy of Sciences; 2018;

*The potential role of subclinical Bordetella Pertussis colonization in the etiology of multiple sclerosis*  
pubmed.ncbi.nlm.nih.gov/26724970/

This is the consequence of **insanely injecting** antigens of pathogens whose natural routes of exposure are mucosal surfaces in the nose, mouth or eyes.

---

NOTICE!

By authority of the Nuremberg Code on Medical Experimentation, I do hereby exercise my right to refuse to submit to or to administer the Covid-19 vaccine. The United States Government has prosecuted, convicted and executed Medical Doctors who have violated the Nuremberg Code on Medical Experimentation. Aiders and abettors of Nuremberg Crimes are equally guilty and have also been prosecuted, convicted, and executed.

Francis A. Boyle  
Professor of Law.

---

My comment in the Annals of Internal Medicine, against Fauci's "SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn"

<https://www.acpjournals.org/doi/10.7326/M21-0111>

Vinu Arumugham Independent 18 January 2021

**These vaccines are unsafe, unnecessary and must be immediately withdrawn**

The vaccine safety claims made by the authors are unsupported by evidence. Vaccines must be designed for safety. These vaccines were not designed at all. So they are unsafe by definition. I predicted the allergic sensitization and autoimmunity risks with these vaccines which have now been confirmed.

*The Pfizer/BioNTech vaccine is unnecessary, unsafe and should not be authorized.*

<https://www.regulations.gov/document?D=FDA-2020-N-1898-0039>

Robert F Kennedy Jr. warned the FDA months back about the risk of allergic reactions due to the use of polyethylene glycol (PEG) in the vaccines.

<https://childrenshealthdefense.org/defender/pfizer-covid-vaccine-allergic-reactions/>

The FDA/VRBPAC ignored us and authorized these horrendously dangerous vaccines.

Recently, Dr. Peter Marks of the FDA admitted that the population was sensitized by PEG-containing pharmaceutical preparations (that include other vaccines/injections).

[https://www.wsj.com/articles/scientists-eye-potential-culprit-for-covid-19-vaccine-allergic-reactions-11608901200?mod=hp\\_lead\\_pos2](https://www.wsj.com/articles/scientists-eye-potential-culprit-for-covid-19-vaccine-allergic-reactions-11608901200?mod=hp_lead_pos2)

“What we’re learning now is that those **allergic reactions could be somewhat more common** than the highly uncommon that we thought they were **because people do get exposed to polyethylene glycol in various pharmaceutical preparations,**” - Peter Marks, Director, CBER, FDA.

We of course already knew that any vaccine/injection that has enough allergen to cause a reaction, has more than enough allergen to guarantee sensitization/priming (causing the development of new allergy).

*Evidence that Food Proteins in Vaccines Cause the Development of Food Allergies and Its Implications for Vaccine Policy*

[https://papers.ssrn.com/sol3/papers.cfm?abstract\\_id=3571073](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3571073)

[www.sciencemag.org/news/2020/12/suspicious-grow-nanoparticles-pfizer-s-covid-19-vaccine-trigger-rare-allergic-reactions](http://www.sciencemag.org/news/2020/12/suspicious-grow-nanoparticles-pfizer-s-covid-19-vaccine-trigger-rare-allergic-reactions)

**"he worries anti-PEG antibodies triggered by the first shot could increase the risk of an allergic reaction to the second or to PEGylated drugs."**

- Janos Szebeni, an immunologist at Semmelweis University

So now, these vaccines have sensitized millions to PEG. The goal is to sensitize/boost PEG allergy in a 100 million more in the next 100 days.

PEG is contaminated with 1,4-dioxane, a carcinogen.

<https://www.fda.gov/cosmetics/potential-contaminants-cosmetics/14-dioxane-cosmetics-manufacturing-byproduct>

As predicted, Pfizer COVID-19 vaccine induced autoimmunity (thrombocytopenia) killed a Florida doctor. This is just the tip of the iceberg. Thousands of cases of vaccine induced autoimmune diseases may take months/years to be diagnosed and will be dismissed as unrelated to the vaccine.

<https://www.nytimes.com/2021/01/12/health/covid-vaccine-death.html>

Only a few lots were tested in the trial. No one has a clue what other lots will do. 100-fold variation of contaminants in vaccines makes trials and epidemiological studies worthless as I detailed in my comments in the Annals of Internal Medicine before. Vaccine safety remains an oxymoron.

<https://www.acpjournals.org/doi/10.7326/m18-2101>

*California calls for pause of 330,000 doses, investigation after allergic reactions to Moderna vaccine batch*

<https://www.mercurynews.com/2021/01/18/coronavirus-california-calls-for-pause-investigation-after-allergic-reactions-to-moderna-vaccine-batch/>

What's worse? Effective, life-saving, cheap, safe medicines such as famotidine/cetirizine/ivermectin are being ignored in this blind race to vaccinate at any cost.

*Immunological mechanisms explaining the role of vaccines, IgE, mast cells, histamine, elevating ferritin, IL-6, D-dimer, VEGF levels in COVID-19 and dengue, potential treatments such as mast cell stabilizers, antihistamines: Predictions and confirmations*

<https://europepmc.org/article/PPR/PPR241819>

---

Big picture of the damage vaccines do:

Vaccines and Biologics injury table based on mechanistic evidence – Feb 2020

Covering over 125 conditions [https://zenodo.org/record/3647593/files/vbitr2\\_final.pdf?download=1](https://zenodo.org/record/3647593/files/vbitr2_final.pdf?download=1)

The organized suppression of vaccine safety science:

*Retraction of scientific papers: the case of vaccine research*  
<https://www.tandfonline.com/doi/full/10.1080/09581596.2021.1878109>

---

## **The WHO's flip-flopping "science" competes with CDC's incompetence**

*WHO Recommends Against Moderna, Pfizer Vaccines for Most Pregnant Women*

<https://www.wsj.com/articles/who-recommends-against-moderna-pfizer-vaccines-for-most-pregnant-women-11611775138>

*Pregnant Women May Receive Covid Vaccines Safely, W.H.O. Says*  
<https://www.nytimes.com/2021/01/29/health/covid-vaccine-pregnancy.html>

*Moderna's COVID-19 vaccine now recommended for pregnant women, WHO says in guidance reversal*

<https://www.foxnews.com/health/moderna-covid-vaccine-pregnant-women-who-guidance-reversal>

Not to be outdone by the flip-flopping CDC, WHO did a flip-flop on COVID-19 vaccine during pregnancy.

Latest evidence that there is ZERO science behind vaccines or vaccine safety. They just pull their "science" out of a hat. Follow the money.

These flip-flopping, lying, organized criminals at the CDC/WHO, are the "reputable sources" for your "fact-checkers".

---

*Judge to FCC: 'I am Inclined to Rule Against You'*

<https://childrenshealthdefense.org/defender/judge-to-fcc-i-am-inclined-to-rule-against-you/>

The New Hampshire Commission report below has ripped FCC's 5G ( and all other cellular) RF safety claims:


*Final Report of the Commission to Study The Environmental and Health Effects of Evolving 5G Technology*

<http://www.gencourt.state.nh.us/statstudcomm/committees/1474/reports/5G%20final%20report.pdf>

"RECOMMENDATION 1- Propose a resolution of the House to the US Congress and Executive Branch to **require the Federal Communication Commission (FCC) to commission an independent review** of the current radiofrequency (RF) standards of the electromagnetic radiation in the 300MHz to 300GHz microwave spectrum as well as a health study to assess and recommend mitigation for the health risks associated with the use of cellular communications and data transmittal."

"A likely explanation as to why **regulatory agencies have opted to ignore the body of scientific evidence demonstrating the negative impact of cellphone radiation** is that **those agencies are "captured"** (see Harvard University publication entitled, "Captured Agency: How the Federal Communications Commission Is Dominated by the Industries It Presumably Regulates" linked in Appendix G). This report documents how **the leadership roles in some agencies (the FCC in particular) are filled by individuals with strong industry ties** and hence are more **focused on**

**industry interests than the health of citizens"**



## Major Litigation Updates & Recent Local Victories

*It's been a strong week for our movement!*

There are a lot of exciting things to report on this week, so let's dive right in...

---

### Lake Tahoe, CA - Landmark Federal Lawsuit Filed to Block Saturation of Lake Tahoe Region with Cell Towers



Hundreds of hazardous, unsightly wireless antennas and cell towers are quickly blanketing the Lake Tahoe, California region.

Three environmental non-profits and Monica Eisenstecken, a lifelong resident of South Lake Tahoe, have filed a potentially **precedent-setting litigation** against the Tahoe Regional Planning Agency, Verizon Wireless, the Tahoe Prosperity Center, and a local property owner...all in an effort **to protect one of the world's greatest natural treasures from a looming telecom takeover.**

[Read Today's Press Release](#)

[Visit the New Tahoe Safe Tech Website](#)

[Support the Landmark Litigation](#)

---

### D.C. Court of Appeals - Environmental Health Trust et al. v. FCC Oral Arguments, January 25th, 2021



"A federal appeals panel in Washington voiced skepticism that the Federal Communications Commission had adequately considered dangerous health effects when it established guidelines for radiation emission from cell towers and wireless devices."

- Bloomberg Law

**Congratulations** to both the Environmental Health Trust and the Children's Health Defense for their tireless efforts challenging the FCC's outdated and insufficient wireless radiation public exposure guidelines.

Following yesterday's fabulous presentation, we are hopeful the judges will rule against the FCC.

[Read the News](#)

[Listen to Recording of the Oral Arguments](#)

---

## **RECENT VICTORIES**

### **FLORIDA**

1. Palm Coast, FL defeats 150-foot cell tower to be installed in the heart of the city's oldest neighborhood.

Read the news [here](#).



2. Lakeland, FL defeats 110-foot cell tower slated to be installed mere feet from homes. This is the second cell tower in three months that has been defeated by Lakeland representatives due to resident opposition.

Read the news [here](#).




---

## NEW JERSEY

3. Lavallette, NJ Borough Council approves five "small cell" antennas with challenging conditions: certification from the U.S. Department of Defense and the Federal Aviation Administration that 5G frequencies emitted by the equipment will not interfere with critical avionics equipment. Lavallette is situated just a few miles from one of the country's most active military air bases - Joint Base McGuire-Dix-Lakehurst.

Read the news [here](#).



---

## CALIFORNIA

4. Petaluma, CA defeats Verizon application to install 16 wireless antennas at the Petaluma Creamery, just 75 feet from homes. Read the legal memorandum in opposition to Verizon's application [here](#).



---

## SOUTH CAROLINA

5. Residents in Mt. Pleasant, SC defeat a cell tower to be installed next to the Long Point playground.

Read the news [here](#).



---

As always, let's keep raking in the wins and working together to protect our communities from the telecom industry's ever-growing wireless footprint.

If you need assistance pushing back against 5G and/or other wireless infrastructure deployments in your area, please don't hesitate to reply to this email or call us at 516-883-0887.

-The 5G Crisis Team

**Contribute to 5G Crisis**

 **Share**

 **Forward**



*Copyright © Grassroots Communications Inc. All rights reserved.*

Contact us:

Email [report@5gcrisis.com](mailto:report@5gcrisis.com)

Call 516-883-0887

Want to change how you receive these emails?

You can [update your preferences](#) or [unsubscribe from this list](#).

Thanks,

Vinu



\*\*\*\*\*

**From:** xywang <xywang@shmu.edu.cn>  
**Sent:** Wednesday, November 20, 2019 1:34 AM  
**To:** 'wen yumei'; Lu, Shan; Tang Yiwei  
**Attachments:** Enterovirus infections in children with encephalitis and aseptic meningitis in Shanghai, 2016-2018 serotypes and clinical characteristics.docx

Teacher Wen, Professor Lu, Professor Tang:

The appendix is the enterovirus pathogen spectrum of our hospital infection department, which is of great reference value for the next step in the development of domestic disease vaccines. Previously, doi A credible similar report. Please review it and see if it can be published in EMI?

I wish Dongan!

Xuan Yi

Xuan-Yi Wang, MD & Ph.D.  
Professor, Key Laboratory Medical Molecular Virology, MoE/MoH, Shanghai Medical College, Fudan University  
Research Scientist, the Institutes of Biomedical Sciences, Fudan University  
Deputy Director, National Engineering Laboratory for Therapeutic Vaccines

---

**From:** xywang <xywang@shmu.edu.cn>  
**Sent:** Wednesday, November 20, 2019 1:34 AM  
**To:** 'wen yumei'; Lu, Shan; 汤一苇  
**Attachments:** Enterovirus infections in children with encephalitis and aseptic meningitis in Shanghai, 2016-2018 serotypes and clinical characteristics.docx

闻老师、卢教授、汤教授：

附件是我们儿科医院感染科的肠病毒病原谱，对于国内下一步手足口病疫苗的研发很有借鉴价值。目前，国内尚未见到可信的类似报道。请各位主编审阅，看看是否可以在 EMI 发表？

祝东安！

萱怡

---

Xuan-Yi Wang, M.D. & Ph.D.

Professor, Key Laboratory Medical Molecular Virology, MoE/MoH, Shanghai Medical College, Fudan University

Research Scientist, the Institutes of Biomedical Sciences, Fudan University

Deputy Director, National Engineering Laboratory for Therapeutic Vaccines

---

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Friday, January 31, 2020 10:44 PM  
**To:** Lu, Shan  
**Cc:** Lu Shan\_EMI  
**Subject:** Jiang\_Rename 2019-nCoV as PARS-CoV\_2020-2-1  
**Attachments:** Jiang\_Rename 2019-nCoV as PARS-CoV\_2020-2-1.docx

Dear Shan,

After extensive discussion in my group, we strongly believe that the names of "severe acute respiratory infection (SARI)", "novel coronavirus-infected pneumonia (NCIP)", "severe acute respiratory infection coronavirus (SARI-CoV)", "novel coronavirus-infected pneumonia coronavirus (NCIP-CoV) will be changed to the terms like SARS-CoV and MERS-CoV.

Therefore, we suggest to rename them as "pneumonia-associated respiratory syndrome (PARS) coronavirus (PARS-CoV), to retain equivalent terminology as SARS-CoV and MERS-CoV. We want to submit it to EMI and at the same time to bioRxiv. In this way, this manuscript may be widely cited, so that WHO may accept our suggestion eventually.

I just wonder whether you are interested or not. If not, we will submit it to another journal.

Thank you very much for your consideration,

Shibo

---

**From:** Wang Linfa <linfa.wang@duke-nus.edu.sg>  
**Sent:** Thursday, April 2, 2020 10:07 AM  
**To:** Lu, Shan  
**Subject:** Letter submitted

**Importance:** High

Dear Shan,

I have now submitted the Letter "Lack of cross neutralization by SARS patient sera towards SARS-CoV-2" to EMI. And the ID is TEMI-2020-0499. Potential reviewers for your consideration: Prof Jiang Shibo, Fudan University; Prof John Mackenzie, Curtin University ([J.Mackenzie@curtin.edu.au](mailto:J.Mackenzie@curtin.edu.au)); Jeremy Farrar, Wellcome Trust ([J.Farrar@wellcome.ac.uk](mailto:J.Farrar@wellcome.ac.uk)); S Wacharapluesadee, Thai CDC ([spwa@hotmail.com](mailto:spwa@hotmail.com)). Thanks for helping to have a rapid review.

Cheers,

LF

*Linfa (Lin-Fa) WANG, PhD FTSE*  
**Professor & Director**  
**Programme in Emerging Infectious Disease**  
**Duke-NUS Medical School,**  
**8 College Road, Singapore 169857**  
**Tel: +65 6516 8397**

---

Important: This email is confidential and may be privileged. If you are not the intended recipient, please delete it and notify us immediately; you should not copy or use it for any purpose, nor disclose its contents to any other person. Thank you.

---

**From:** Jie Fu <jfu9799@gmail.com>  
**Sent:** Saturday, January 25, 2020 3:50 PM  
**To:** Lu, Shan; liu.6244@osu.edu  
**Subject:** Letter to Wu Han

,  
Hello Dr. Lu and Dr. Liu,

I just read the letter that you and others drafted. I support this letter and hope to sign this letter as well. My name is Jie Fu and I work at NYC Public Health Laboratory, Virology Unit.

Here is my name in Chinese:

傅洁

纽约市公共卫生实验室

Thanks,  
Jie Fu, Ph.D.  
Chief, Virology Lab  
NYC PHL

---

**From:** 应天雷 <tlying@fudan.edu.cn>  
**Sent:** Friday, January 24, 2020 12:20 PM  
**To:** Lu, Shan; 闻老师  
**Subject:** Manuscript submission from Tianlei  
**Attachments:** EMI-Tianlei.pdf

Dear Prof. Lu,

We just submitted a manuscript entitled "Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody" (Manuscript ID: TEMI-2020-0062) for your consideration as a letter in EMI. Attached please find the combined file we used for submission. Would be very appreciated if you could handle the manuscript promptly. Thanks a lot!

Best wishes  
Tianlei

---

**From:** Wesson, Simon <Simon.Wesson@tandf.co.uk>  
**Sent:** Wednesday, September 16, 2020 6:39 AM  
**To:** Lu, Shan; jml8328@126.com  
**Cc:** editorial; ymwen; Josaphouitch, Alexa; zlshi; Harris, Laura; Chilton, Abbie; Bell, Jodie; 05yisan@163.com; hjzhang@wh.iov.cn; gaovet@126.com; kunhuang@webmail.hzau.edu.cn; 1941396675@qq.com; xianfenghui@163.com; 1243769394@qq.com; cfli@webmail.hzau.edu.cn; 13296622651@126.com; zya9811@163.com; pengcheng@wh.iov.cn; gaoxiaoxiao@wh.iov.cn; chenhch@mail.hzau.edu.cn; zz19841024@126.com; zlshi@wh.iov.cn; Zhang, Bessie; editorial@emi2012.org; Cho, Clara  
**Subject:** Media report: A serological survey of SARS-CoV-2 in cat in Wuhan  
**Attachments:** media report A serological survey of SARS-CoV-2 in cat in Wuhan.pdf

Good morning both

I wanted to thank you for your recent work with us in helping to promote the *Emerging Microbes & Infections* article 'A serological survey of SARS-CoV-2 in cat in Wuhan', via our recent [press campaign](#).

The campaign has successfully met our objective of reaching mainstream and trade publications internationally, with a vast amount of coverage across the world – especially from the press in the UK, India and the US.

This has helped to generate 4,388 views of the article, in addition to a current Altmetric Attention Score of 428. This places the article among the top 5 of *Emerging Microbes & Infections* publications, when looking at impact scores. This will likely increase over time too.

Attached is a report, put together by my colleague Laura, with further information about the press coverage. If you have any questions, please let me know.

Best wishes,  
Simon

**Simon Wesson** – Press & Media Relations Executive

Taylor & Francis Group

4 Park Square, Milton Park, Abingdon, OX14 4RN, UK

Tel: +44 (0) 20 701 74468  
Mob: +44 7825975874

Email: [simon.wesson@tandf.co.uk](mailto:simon.wesson@tandf.co.uk)

Journals Press & Media Team: [newsroom@taylorandfrancis.com](mailto:newsroom@taylorandfrancis.com)

Newsroom: <http://newsroom.taylorandfrancisgroup.com>

Taylor & Francis is a trading name of Informa UK Limited, registered in England under no. 107295

Information Classification: General



---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Thursday, August 22, 2019 10:34 PM  
**To:** chenxw  
**Cc:** Lu, Shan  
**Subject:** message

XW: As Wuhan has hosted a series of molecular virology meetings, can you recommend candidates from Europe who has the potential to take the post as a co-editor-in-chief? Thank you. YM Wen

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Saturday, August 31, 2019 10:01 PM  
**To:** george wang; Wang, Hua; wangmw; Wen Danyi; Yi Ning; Nan-ping Weng; antonio\_bertoletti; lowried; stephen.locarnini; ricec; rahmed  
**Cc:** Lu, Shan; shan.lu  
**Subject:** message  
**Attachments:** Senior Editor Position Opening In Shanghai.docx

Dear All:

Emerging microbes and infections ( journal, IF 6.2, 2018) is looking for a senior editor. Please distribute this information in your circle, and help to send us information for candidates. Regards. Yu-mei Wen

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Wednesday, March 18, 2020 8:56 PM  
**To:** Lu, Shan  
**Subject:** message  
**Attachments:** Neutralizing Antibodies in Patients with Severe Acute Respiratory Syndrome-Associated Coronavirus Infection(1).pdf; observation of NAB in COVID-19-wen-clear.docx; 2020.03.11.987958v1.full.pdf

Shan, while Jinghe is working on developing NTb from B cells of recovered patients, She wrote a paper while screening for high NTb patients. Attached is a draft I helped her. Also two relative papers are attached. Please comment. Wen

-----

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Saturday, September 26, 2020 3:44 PM  
**To:** Lu, Shan  
**Subject:** message

Shan, I have forwarded you a SMS, not WeChat from Department of Microbiology, Zhejiang Medical College · Yan Jie, to me, regarding an article on leptospiral which was accused as repeated use of figures in EMI. I have known this professor for many years, and he was a good scientist. He wrote to show that they designed and did all the experiments, while the student and he did not check the figures carefully.

He asked if they can write to the journal and make a revision on errors, instead of withdrawing the article.

I have written and asked you about this issue, but have not yet heard from you. Please respond. YMW



---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Saturday, October 24, 2020 9:46 PM  
**To:** Christian Brechot  
**Cc:** Lu, Shan; 袁正宏  
**Subject:** message

Dear Christian,

It was my pleasure to see you and participate at the same web meeting recently hosted by David Ho. I still remember your last visit to our lab, and informed me regarding your plan to organize a web with Bob Gallo among virological labs.

Since the retirement of Prof Hans Klenk as co-editors-in-chief from the journal Emerging Microbes and Infections (EMI), we are looking for another co-editors-in-chief to join us. In fact, co-editors-in-chief, Prof Shan Lu from UMass, has been looking after EMI, and has taken a lot of responsibility of EMI, and this journal has grown into a well recognized journal on infectious diseases. If interested, please go to our web to know more about EMI. It will be our honor to invite you to join us as a co-editors-in-chief. If interested, Shan Lu will contact you for more details.

Regards, Yu-mei

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Sunday, December 20, 2020 8:00 PM  
**To:** Lu, Shan; shan.lu; Winter999  
**Cc:** zhangwenhong; YiWei Tang; 袁正宏  
**Subject:** news  
**Attachments:** 牛杂志-rev-wen.doc

I only checked the parts on EMI. For reference. Wen

---

**From:** Manon Cox <manoncox@nextwavebio.com>  
**Sent:** Monday, July 27, 2020 8:50 AM  
**To:** stanley-perlman@uiowa.edu; vincent.munster@nih.gov; b.haagmans@erasmusmc.nl; saif.2@osu.edu  
**Cc:** Lu, Shan; Klavinskis, Linda; Gibson, Edward  
**Subject:** Panel Discussion last week

Dear Panel Members!

On behalf of ISV I would like to thank you for your contribution to the discussion on challenges for COVID-19 vaccine development and the role of animal models last week.

As you can see from the list of questions sent by Shan earlier there were many more for the panel than you were able to address during the short time available.

We are wondering whether you would be interested in writing a paper/review that includes your presentation and addresses relevant questions from the audience.

If there is sufficient interest from the speakers we could see whether we could arrange a special edition of Vaccine or publish in the Journal Shan recommended which is EMI ([www.tandfonline.com/TEMI](http://www.tandfonline.com/TEMI)) with a higher impact factor (5.7-6.2 range in the last two years) than most vaccine journals. It also published quite a few exciting COVID-19 papers, and it is open access.

We would love to hear from you!

So here is the list of questions for the panel that Shan submitted last week once again –

**Panel discussion**

**Bart Haagmans, PhD, Erasmus University; Vincent Munster, PhD, NIAID / NIH; Dr. Linda Saif, The Ohio State University**

**Title: Challenges for COVID-19 Vaccines Development: The Role of Animal Models**

- There was an outbreak of SARS-CoV2 in mink farms in the Netherlands. Will this be an interesting animal model to study SARS-CoV2?
- Guinea pig or mini-pig with metabolic syndrome might demonstrate efficacy against severe disease?
- Still don't have knowledge about if the cats can spread the virus to human??
- How does the different microbiome affect the efficacy of vaccines?
- What is the best animal model to study Covid-19?
- How about dogs as dogs are almost universally domesticated
- The chimpanzee cannot seriously be considered as a challenge model?
- Overall, there seems to be little justification for the continuing use of NHP for SARS CoV-2
- Please comment on what would you consider be best models for evaluating antivirals for treatment of disease vs prevention of infection/transmission by vaccines?
- Do you think that in veterinary medicine we must work in a vaccine for animals for covid?
- And don't forget, microbiome is not just about the gut... It can be very important with regard to mucosal immunity
- Does any model reflect the human nasal tract? Most animals forage
- Gut microbiome has to do with oral vaccines. Does it affect injected vaccines too?
- What about rabbits?



- Is it possible to infer the viral infectious dose in humans by working with animals?
- What models are best suited for assess VAERD and ADE?
- Have anyone used an animal model to test the effectiveness of wearing a mask to prevent the spread of COVID-19
- How are the Africans captured in the development and clinical trials of the COVID 19 vaccines, putting human genomics in consideration?

Sincerely!

Manon

Manon Cox  
Founder & CEO  
NextWaveBio

[manoncox@nextwavebio.com](mailto:manoncox@nextwavebio.com)

Phone: 203 249 3898

---

**From:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
**Sent:** Thursday, April 16, 2020 9:44 PM  
**To:** Emily  
**Cc:** Lu, Shan; Yumei Wen (ymwen@shmu.edu.cn)  
**Subject:** Please help

**Importance:** High

EMI editorial officers,

Can I get your help on monitoring COVID-19 papers? It will be great if you could check them daily and let the review reviewer know.

I have just checked couple myself:

1. 0537 – I emailed one of reviewers (Charles Stratton) he said he has not received invitation. Could you resend invitations to all reviewer candidates to make sure they received and responded.
2. 0325 – I noticed one declined reviewer candidates suggested couple; please go ahead to invite them.

We really need to move our process quickly; your prompt help is highly appreciated.

Yi-Wei

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

---

**From:** Liu, Shan-Lu <liu.6244@osu.edu>  
**Sent:** Tuesday, December 22, 2020 8:28 AM  
**To:** weissr@pennmedicine.upenn.edu; xjmeng@vt.edu; dyjin@hku.hk; shibojiang@fudan.edu.cn; peshi@UTMB.EDU; peijun@strubi.ox.ac.uk; GMSWANG@nus.edu.sg; lzhang2@unl.edu; pewang@uchc.edu; Liang.shan@wustl.edu; DengL@MSKCC.ORG; rli@vcu.edu; Sun.Jie@mayo.edu; jianw@musc.edu; dongfang.liu@rutgers.edu; junwang@pharmacy.arizona.edu; Zongdi.feng@nationwidechildrens.org; zyang@ksu.edu; zhengzhiming4@gmail.com; hengx@missouri.edu; wux4@ccf.org; GCheng@mednet.ucla.edu; liangy@umn.edu; wma@missouri.edu; tzhou@mail.nih.gov; guoh4@upmc.edu; Liu, Shan-Lu; Feng Gao; zlshi@wh.iov.cn; Lu, Shan; chen.liang@mcgill.ca; ufeeng.liu@georgetown.edu; xiangy@uthscsa.edu; cxiao@utep.edu; ywu8@gmu.edu; dingsw@ucr.edu; lsu@med.unc.edu; Feng.Li@uky.edu; zqin@lsuhsc.edu; Zihai.Li@osumc.edu; lijun@uic.edu; wangx472@umn.edu; wenzheho@temple.edu; gaos8@upmc.edu; lyuan@vt.edu; juh13@psu.edu; yuan2@upenn.edu; jling@txbiomed.org; reachxw@vt.edu; andyu@iupui.edu; fzhu@bio.fsu.edu; qiyi.tang@howard.edu; Wang, Qihong; gluo@uab.edu  
**Subject:** Pre-registration confirmation

Dear colleagues and friends:

Happy holidays!

I wish to thank you all for your help in planning our symposium Dec 30-31. By now, you should have received an email for confirmation of pre-registration, with a valid link. If you have not received email, please reply to this email and I will look into it. You may add the Zoom link to your calendar directly – there should be such an option in your email.

For direct login, please use the following information. You may save it somewhere just in case.



Thanks again, all the best.

Shan-Lu



Shan-Lu Liu, M.D., Ph.D.  
Professor  
Co-Director, Viruses and Emerging Pathogens Program  
Infectious Diseases Institute  
Center for Retrovirus Research  
Veterinary Biosciences, Microbial Infection and Immunity, and Microbiology  
The Ohio State University  
1900 Coffey Rd, Room 480 VMAB  
Columbus, Ohio 43210  
Phone: (614) 292-8690  
Fax: (614) 292-6473  
Email: [liu.6244@osu.edu](mailto:liu.6244@osu.edu); [shan-lu.liu@osumc.edu](mailto:shan-lu.liu@osumc.edu)



---

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Wednesday, January 22, 2020 8:22 AM  
**To:** Lu, Shan  
**Subject:** Presubmission inquiry  
**Attachments:** Xia S\_RBD & 6HB\_2019-nCoV+figures\_EMI\_20120-1-22\_Jiang.pdf

Dear Shan,

As suggested by Prof. Wen, we have completed this project and written a research paper. Please quickly check the manuscript (I am still working on it) and let me know whether you are interested in it or whether it is suitable for EMI. If yes, I will submit it to EMI immediately after I complete the revision. If not, I will submit it to another journal.

Thank you very much for your consideration,

Shibo

---

**From:** Macit İlkit <macitilkit@gmail.com>  
**Sent:** Friday, May 1, 2020 3:13 PM  
**To:** Lu, Shan; ymw@shmu.edu.cn; editorial@emi2012.org  
**Cc:** Amir Arastehfar  
**Subject:** Presubmission inquiry

Prof Shan Lu  
Prof Yu-Mei Wen  
Editors-in-Chiefs  
*Emerging Microbes and Infections.*

Dear Editors:

Currently, we have finalized a comprehensive study on emerging azole-resistant *C. parapsilosis* bloodstream infection in the fifth largest hospital in Turkey for a period of 13 years and we would like to send a presubmission inquiry and we hope that our findings will be suitable for publication in *Emerging Microbes and Infections*.

Our paper describes the emergence of clonal fluconazole-resistant *Candida parapsilosis* blood isolates harboring known accountable mutations in *ERG11* from the fifth largest hospital in Turkey, Ege University, Izmir. Fluconazole resistance (FLZR) was detected in 26.4% of the whole isolates ( $n=60/227$ ) recovered from 2007-2019 and FLZR showed an increasing trend reaching the highest peak in 2018. *ERG11*, *TAC1*, *UPC2*, and *MRR1* loci implicated in azole-resistance were sequenced for 91 isolates, including all resistant ( $n=60$ ), susceptible dose-dependent ( $n=3$ ), and susceptible ( $n=28$ ) isolates. Upon emergence in 2011, FLZR isolates carrying Y132F or Y132F+K143R in Erg11p conquered many wards in our hospital. Interestingly Y132F isolates tripled in 2015-2019 when the azole use was three times more than 2007-2014, while 1.8 times increase in the number of Y132F+K143R isolates in 2007-2014 coincided with 6-fold increase in voriconazole prophylaxis. Shockingly, Y132F isolates were significantly associated with mortality compared to Y132F+K143R isolates ( $r^2=0.44$ ,  $p < 0.004$ ), showing that Y132F isolates are implicated in both FLZR and mortality. Moreover, comparing the biofilm production revealed that Y132F isolates produced significantly less biofilm than those FLZR isolates lacking this mutation ( $r^2=0.66$ ,  $p < 0.001$ ), which may question the hypothesis that Y132F isolates have a higher propensity to stay in the hospital settings. To discover the clonality of our isolates ( $n=227$ ), they were all subjected to AFLP and microsatellite typing. AFLP indistinguishably clustered all isolates together, while the application of microsatellite typing revealed distinct clusters. Interestingly, FLZR isolates clustered in three distinct clusters containing only FLZR isolates carrying Y132F or Y132F+K143R mutations in Erg11p showing the clonal expansion of these isolates in our hospital. This study showed that future environmental screening studies are required to find the source of infection followed by the application of strict infection control strategies to control the clonal spread of *C. parapsilosis* in our hospital. Moreover, appropriate antifungal stewardship is necessary to reduce the burden of fatal FLZR isolates carrying mutations in Erg11p.

Looking forward to hearing from you.  
Sincerely,

Prof Macit Ilkit

Division of Mycology, Department of Microbiology, Faculty of Medicine, ukurova University, Adana, 01330,  
Turkey

---

**From:** Amir Arastehfar <a.arastehfar.nl@gmail.com>  
**Sent:** Wednesday, March 24, 2021 5:09 PM  
**To:** editorial@emi2012.org; Lu, Shan; ymw@shmu.edu.cn  
**Subject:** Presubmission inquiry  
**Attachments:** Table 3.docx; Table 1.docx; C. parapsilosis Turkey.docx; Table 2.docx; Figure 1.tif; Figure 2.tif; Figure 3.tif; Figure 5.tif; Figure 4.tif; Figure 6.tif; Figure 7.tif; Figure 8.tif; Figure 10.tif; Figure 9.tif

Dear Dr. Lu and Wen,

Currently, we have finalized a study addressing a question behind the deadly outbreaks caused by fluconazole-resistant *Candida parapsilosis* carrying Y132F isolates for which we would like to send a presubmission inquiry to hear your opinion and if you find it interesting for the readership of the Emerging Microbes and Infections. Attached also, please find the draft, figures, and tables.

Although neglected, deadly infections due to outbreaks caused by fluconazole-resistant *Candida parapsilosis* (FLZR-CP) carrying Y132F in the azole drug-target are increasingly identified in South-East Asian, European, Latin American, and African countries. Once established, eradication of such outbreaks is challenging and relapse of outbreaks persistently occurs despite applying disinfectants. Despite all these clinical significances, the reason behind such outbreaks remained enigmatic. Herein, for the first time, we used an extensive number of *C. parapsilosis* blood isolates ( $n=96$ ) collected during the outbreaks and subjected them to biofilm formation and host-related stresses. Our experiments indicated that Y132F isolates are not biofilm producers, but interestingly they are significantly more tolerant to low pH, oxidative stress, low sugar concentrations, high salt concentration, and high temperature. Moreover, Y132F isolates did not show any growth defect compared to fluconazole-susceptible isolates when grown in stress-free YPD broth. Our macrophage analysis revealed that the survival after phagocytosis is the same for all isolates tested but isolates carrying Y132F had significantly higher CFU counts in the supernatant, which could be an indication of being more immunoevasive or causing more damages to macrophages. Our epidemiological analysis exploring the burden of FLZR-CP in a center struggling with a persistent outbreak since 2012 onward further reinforced the significance of our study. Alarming, patients infected with FLZR-CP and Y132F isolates constituted 90% and 57% of the patients infected with *C. parapsilosis* during 2020-2021, respectively, and the latter was associated with a much more mortality rate, required treatment with multiple antifungal drugs and caused outbreaks in several wards. Collectively, our study revealed that tolerance to host-related stresses, but not biofilm formation, maybe the reason behind the the exponential expansion of Y132F *C. parapsilosis* isolates and that clonal outbreaks due to Y132F *C. parapsilosis* require



immediate attention and warrants judicious antifungal use and strict infection control to stop the surge of this deadly bug.

Kind regards

Amir Arastehfar, Postdoc Fellow Infectious Diseases, Center for Discovery and Innovation, Nutley, New Jersey, the USA

---

**From:** Matthew R MCKAY <m.mckay@ust.hk>  
**Sent:** Thursday, February 6, 2020 8:38 AM  
**To:** ymw@shmu.edu.cn; Lu, Shan  
**Cc:** Ahmed Abdul QUADEER  
**Subject:** Publication query regarding our pre-print on potential vaccine targets for 2019-nCoV (novel coronavirus)

Dear Prof. Wen and Prof. Lu,

We are writing to seek your feedback regarding a potential publication in *Emerging Microbes and Infection*.

Specifically, we have prepared a research article tentatively entitled:

**Preliminary identification of potential vaccine targets for 2019-nCoV based on SARS-CoV immunological studies**

and we would like to enquire about the interest from your journal as a possible publication venue.

Our work proposes a novel study that leverages known immunological information for SARS-CoV together with available sequence data for 2019-nCoV to identify potential targets for subunit vaccine design for 2019-nCoV. As a main discovery, we identify a set of screened B cell and T cell epitopes that are promising candidates for potentially inducing protective immune responses against 2019-nCoV. These are epitopes in the structural proteins (namely, the spike and nucleocapsid proteins) that have been reported to induce immune responses in SARS-CoV, and which we find to map identically to genetic regions of 2019-nCoV. Some of these epitopes have known functional importance, lying within the receptor binding motif. In the T-cell case, to help with potential immunogen design, we also use population-based MHC statistics to provide sets of epitopes that are estimated to cover a very large fraction of the global population, including that in China.

We believe these results are highly relevant and timely, and may be useful in guiding current experimental efforts towards developing a vaccine for 2019-nCoV.

We have uploaded a pre-print to the bioRxiv server (<https://www.biorxiv.org/content/10.1101/2020.02.03.933226v1>), and I have copied the abstract below. We have also prepared a slightly updated version, based on additional sequences available as of 6th Feb. (the current pre-print uses sequences available up to 29th Jan 2020).

Given the nature of this topic, it is of course important for us to consider avenues for possible rapid publication. Hence, we would appreciate your feedback about whether our work may be appealing for consideration for your journal, and if so, whether a suitably rapid review mechanism would be possible.

We would also be happy to provide any further information, as desired.

Sincerely,  
Matthew McKay (corresponding author, together with Dr. Ahmed Quadeer, cc'd).

-----  
Matthew R. McKay

Professor

Department of Electronic and Computer Engineering

Department of Chemical and Biological Engineering

Hong Kong University of Science and Technology

Clear Water Bay, Kowloon, Hong Kong

Web: <https://www.mckayspcb.com/>

## Abstract

The beginning of 2020 has seen the emergence of the 2019 novel coronavirus (2019-nCoV) outbreak. Since the first reported case in the Wuhan city of China, 2019-nCoV has spread to other cities in China as well as to multiple countries across four continents. There is an imminent need to better understand this novel virus and to develop ways to control its spread. In this study, we sought to gain insights for vaccine design against 2019-nCoV by considering the high genetic similarity between 2019-nCoV and the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), and leveraging existing immunological studies of SARS-CoV. By screening the experimentally-determined SARS-CoV-derived B cell and T cell epitopes in the immunogenic structural proteins of SARS-CoV, we identified a set of B cell and T cell epitopes derived from the spike (S) and nucleocapsid (N) proteins that map identically to 2019-nCoV proteins. As no mutation has been observed in these identified epitopes among the available 2019-nCoV sequences (as of 29 January 2020), immune targeting of these epitopes may potentially offer protection against 2019-nCoV. For the T cell epitopes, we performed a population coverage analysis of the associated MHC alleles and proposed a set of epitopes that is estimated to provide broad coverage globally, as well as in China. Our findings provide a screened set of epitopes that can help guide experimental efforts towards the development of vaccines against 2019-nCoV.

---

**From:** yiweitangmd@gmail.com  
**Sent:** Wednesday, November 27, 2019 7:28 PM  
**To:** Lu, Shan  
**Cc:** ZhangWenhong; Martin martin; yuan zhenghong; wen yumei  
**Subject:** Re: EMI year end gathering

Thank you, Shan, for the great and exciting summary. See you all soon.

Yi-Wei

Sent from my iPhone

On Nov 27, 2019, at 22:10, Lu, Shan <Shan.Lu@umassmed.edu> wrote:

Dear Prof Wen and others,

First, thanks to Yi-Wei and Wenhong for your feedback.

I would like to provide some further highlights about EMI so it will get some basic information to you to prepare for our meeting on 12/15, and these will be useful for those who can not attend.

- EMI has been transferred to T&F platform for close to one year, and I would say that the overall outcome is much better than my best estimate, with the following data:
  - I have not heard a single complaint from authors, EB members or reviewers about our transfer. Our strategy to establish EMI as an independent brand name has been working, not as part of Nature or T&F.
  - The overall development of EMI is accelerating (see data below)
  - The communication/support from T&F is much better than what we had with NPG in the previous years.
- Some key data related to EMI in 2019
  - EMI processed 642 papers in the first 10 months of 2019. The final acceptance rate is 143 papers (24.3%)
  - The full text downloads through standard EMI site at T&F is 203,144 for the first 10 months. This number to me is shocking! It is almost double of routine well established journals as I was told by T&F experts.
  - While 42.3% downloads are from Asia (including China), the combination of USA/Canada and Europe is 47.2% which indicates that EMI is well recognized beside just China which has been one of the key objectives from the start of EMI.
  - Among the top 10 key downloads (and also by the "10 most read" parameter), 6 papers are from 2019. This is a very good sign to point to the sustainable nature of EMI reputation and to keep the high IF in the coming years.
  - The two papers from 哈兽研 on ASFV and one paper from 文宏lab on using CRISPR to diagnose TB are among the most read papers.
  - NIH library and US CDC library are two key institutions outside China to download EMI papers indicating the global leading researchers in related areas are paying high level attention to EMI.
  - A special 10-month summary prepared by T&F is attached.

- Interaction with T&F
  - T&F is treating EMI as a special flagship journal after some initial struggling to find a good arrangement. T&F has recently reorganized their journal line-up and EMI is now part of the Medicine/Health group with its head based in New York-Philadelphia area.
  - Three levels of T&F managers (portfolio manager responsible for EMI, her director and the group director) paid a special visit to me last week and we had several hours productive discussion). The meeting minutes is attached.
  - More specific work is planned: the operation of an even more active Editorial Board, a further improved marketing program, and re-activated Special Topics program.
- EMI internal operation
  - Personnel: we are very fortunate to recruit a part time experienced staff member so we can have a better operation management rather than depending on other volunteers who have their own work.
  - Finance: EMI is anticipating a very healthy revenue in 2019 and coming years. EMI is stopping the arrangement with original donor to fund EMI employees.
  - We established a new Email system using Microsoft 365 which is more stable with much powerful functions.
  - We re-launched EMI's own web site: [www.emi2012.org](http://www.emi2012.org) which will provide a much needed extra and flexible platform to introduce EMI.
- Recruitment of more senior members
  - In 2019, we added a few leading experts in their specific fields: Friedrich Götz (bacteria), Malik Peiris (flu), Yuping Ran (fungus)
  - We are working to identify some rare areas that are missing from EMI EB, based on the papers we have received.
- Key next step work
  - Inviting leading experts for high impact reviews. I have invited several to submit and we need to invite more.
  - Promote EMI at various international conferences.
  - Election of best EMI papers in 2019
  - How to distribute financial revenue in 2020
  - A possible update on EMI cover

There are more to discuss, and please add anything you may be interested. The above will give us something to start with. Please feel free to provide your feedback before or during our meeting.

Best.

Shan

**From:** ZhangWenhong [mailto:zhangwenhong@fudan.edu.cn]

**Sent:** Tuesday, November 26, 2019 5:00 PM

**To:** Lu, Shan <Shan.Lu@umassmed.edu>

**Cc:** Martin martin <winter999@hotmail.com>; yuan zhenghong <zhyuan@shmu.edu.cn>; yiweitangmd@gmail.com; wen yumei <ymwen@shmu.edu.cn>

**Subject:** Re: EMI year end gathering

谢谢卢教授安排！我因为在北京参加中华医学会感染病学分会常委会不能参加这个有意义的聚会。但编辑部人员更新后，我们还会继续保持对编辑部工作的支持。文宏上

-----原始邮件-----

发件人:"Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

发送时间:2019-11-23 09:34:56 (星期六)

收件人: ZhangWenhong <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>, "Martin martin"

<[winter999@hotmail.com](mailto:winter999@hotmail.com)>, "yuan zhenghong" <[zhyuan@shmu.edu.cn](mailto:zhyuan@shmu.edu.cn)>, "[yiweitangmd@gmail.com](mailto:yiweitangmd@gmail.com)"

<[yiweitangmd@gmail.com](mailto:yiweitangmd@gmail.com)>, "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>

抄送:

主题: EMI year end gathering

Dear EMI colleagues,

I have discussed with Prof Wen and Xiaodong to have a gathering for us, plus EMI staff members at the noon time on Dec. 15, Sunday.

The purpose is to meet and review the work of EMI in 2019, after it has been moved to T&F.

In addition, we hired a part time new staff member, Min Yu, in addition to the original editorial staff Min Yang and Jing Wu. Three junior scientists from Hua Shan Hospital will terminate their work for EMI by the end of this year. They will also join us for lunch.

Xiaodong will send out the location and exact time later once we are close to Dec. 15.

Thanks.

Shan

--

张文宏 Wenhong Zhang, M.D. & Ph.D. Professor of Medicine Director, Division of Infectious Diseases  
Huashan Hospital, Fudan University PI, Institute of Biomedical Science, Fudan University 12 M. Wulumuqi  
Road Shanghai 200040, China Phone: (8621)52888123 Fax: (8621)52888714 Email:  
[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)

<EMI\_November Report.pdf>

<Minutes for meeting 20191120.pdf>

<Email copy to EMI founders - Nov 27 2019.pdf>

---

**From:** tangy@mskcc.org  
**Sent:** Friday, August 30, 2019 9:41 AM  
**To:** zhengzhiming4@gmail.com  
**Cc:** Lu, Shan; ymw@shmu.edu.cn; luhongzhou@fudan.edu.cn  
**Subject:** RE: Re: ...EMI update - Aug 29, 2019...

Thanks a lot, Zhi-Ming!

**From:** Zhi-Ming Zheng <zhengzhiming4@gmail.com>  
**Sent:** Friday, August 30, 2019 9:26 AM  
**To:** Tang, Yi-Wei/Laboratory Medicine <tangy@mskcc.org>  
**Cc:** Shan.Lu@umassmed.edu; ymw@shmu.edu.cn  
**Subject:** [EXTERNAL] Re: ...EMI update - Aug 29, 2019...

It has been done! Cheers for Yi-Wei!

Zhi-Ming

On Fri, Aug 30, 2019 at 7:53 AM <[tangy@mskcc.org](mailto:tangy@mskcc.org)> wrote:

Thank you, Shan. I am pleased that the HIV commentary gets some attention.

Zhi-Ming, do you mind pass this to the virology wechat group: instead of attaching the paper, please use this link:  
<https://www.tandfonline.com/doi/full/10.1080/22221751.2019.1656550>

Thank you, Yi-Wei

---

**From:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Sent:** Thursday, August 29, 2019 10:16 PM  
**To:** Zhi-Ming Zheng <[zhengzhiming4@gmail.com](mailto:zhengzhiming4@gmail.com)>; Tang, Yi-Wei/Laboratory Medicine <[tangy@mskcc.org](mailto:tangy@mskcc.org)>  
**Cc:** wen yumei <[ymw@shmu.edu.cn](mailto:ymw@shmu.edu.cn)>  
**Subject:** [EXTERNAL] ...EMI update - Aug 29, 2019...

Dear Zhi-Ming

Based on your suggestion, EMI has reversed the order of new papers published in 2019 at our website: the newest on top as you suggested.

As result, your paper on blood transmission of HPV is now among the top ones and early for people to find. It has attracted 274 reads in just one month.

Dear Yi-Wei,

Your paper co-authored with Hongzhou on HIV diagnosis is now published online. It attracted 324 reads in 3 days!

Thank you both for sending good papers to EMI.

Shan



---

**From:** tangy@mskcc.org  
**Sent:** Monday, October 21, 2019 7:58 AM  
**To:** ymw@shmu.edu.cn; Lu, Shan  
**Cc:** zhyuan@shmu.edu.cn; zhangwenhong@fudan.edu.cn; winter999@hotmail.com; minyang0216@163.com; wanglancui@fudan.edu.cn  
**Subject:** RE: Re: A new journal from your neighborhood

Thank you, Shan and Teacher Wen, for sharing us the information.

Creation of the new journal might provide another chance for daily increasing microbiome papers.

Yi-Wei

**From:** wen yumei <ymw@shmu.edu.cn>  
**Sent:** Saturday, October 19, 2019 9:49 PM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Cc:** yuan zhenghong <zhyuan@shmu.edu.cn>; ZhangWenhong <zhangwenhong@fudan.edu.cn>; Tang, Yi-Wei/Laboratory Medicine <tangy@mskcc.org>; Martin martin <winter999@hotmail.com>; 杨旻 <minyang0216@163.com>; 王兰翠 <wanglancui@fudan.edu.cn>  
**Subject:** [EXTERNAL] Re: A new journal from your neighborhood

Shan,  
I am not worried about this journal. I think Li is recognized as a hepatologist, mostly for treatment with her artificial liver. and her group is good in microbiota research. However, in the field of infectious diseases, Huashan hospital has been the number one in China for many years. You and I have far more influences in the field of microbiology and infectious diseases and vaccines than them.  
Chen Jin is good in bioinformatics. not specialist in infectious diseases like Wenhong. However, they have the government support, and huge financial support. Last week I visited their new hospital, Shulan hospital, with the names of Li and her husband. A private hospital with very good facility, and the income last year has reached 9 billion RMB. We are based on medical sciences, not politics, which is most important for a journal. for a university to launch a journal is not enough, it needs experience and reputation. We can wait and see.

Rafi was here visiting us, and I will ask him to write a review on his new discovery on a new subtype of CD8+ stem cells in persistent infections. There is a meeting on infectious diseases organized by our lab this coming week, and I will give a short introduction on EMI. The agenda for this meeting is attached, and if you think anyone is a candidate for submitting papers, I will ask Yang to contact them. YM Wen

-----原始邮件-----

发件人: "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

发送时间: 2019-10-19 09:52:15 (星期六)

收件人: "wen yumei" <[ymw@shmu.edu.cn](mailto:ymw@shmu.edu.cn)>, "yuan zhenghong" <[zhyuan@shmu.edu.cn](mailto:zhyuan@shmu.edu.cn)>, ZhangWenhong <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>, "[tangy@mskcc.org](mailto:tangy@mskcc.org)" <[tangy@mskcc.org](mailto:tangy@mskcc.org)>, "Martin martin"

<[winter999@hotmail.com](mailto:winter999@hotmail.com)>

抄送:

主题: A new journal from your neighborhood

Dear Prof Wen and other EMI colleagues,

This morning, T&F Beijing office sent me a notice about the launch of another journal *Infectious Microbes & Diseases* (IMD). <https://journals.Lww.com/imd>

*"Infectious Microbes & Diseases* (IMD) is jointly sponsored by Zhejiang University and the First Affiliated Hospital, school of Medicine, Zhejiang University and published by Wolters Kluwer and Zhejiang University Press."

Editor-in-chief is Lanjuan Li, Deputy Editor-in-Chief is Jing Cheng (biochip), and Fernando Arenzana-Seisdedos (Institute of Pasteur of Shanghai), Executive Editor is Stijn van der Veen (Assistant Dean, the School of Basic Medicine of Zhejiang University, Hangzhou, China).

IMD is the main product from Zhejiang University and Prof Li's group.

"Relying on the discipline advantages of Zhejiang University and its First Affiliated Hospital, the journal combines domestic and international experts and scholars in the field of infectious diseases and has formed a scientific and technological innovation system that is a trinity of State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, and Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases. It also makes full use of the high-level publishing ability of international publishers to publish the latest research results of basic research, clinical practice and technological progress in the field of infectious diseases in a timely and comprehensive manner."

T&F is very concerned about this competitor. I am not worried as it will be a long process for IMD to catch up. I am sure you have a much better assessment than me on this news. We can chat more when we meet next time. Only one message I suddenly realized from this news: in order to do a good international journal, it can not be just owned and based on one scientific group.

I will update you more soon on the new events at EMI, especially the hiring of YU, Min, a person with significant experience in journal publishing and good knowledge about T&F operation. She will contribute significantly to our next phase work.

Best.

Shan

\*\*\* Only open attachments or links from trusted senders. Report phishing to [infosec@mskcc.org](mailto:infosec@mskcc.org) \*\*\*

---

**From:** Zheng, Zhi-Ming (Thomas) (NIH/NCI) [E] <[zhengt@exchange.nih.gov](mailto:zhengt@exchange.nih.gov)>  
**Sent:** Wednesday, August 28, 2019 6:26 PM  
**To:** Paul Liu; [tangy@mskcc.org](mailto:tangy@mskcc.org); Lu, Shan  
**Cc:** Zheng, Hui; Liu, Shan-Lu  
**Subject:** RE: Re: C100 Co-Sponsor Confirmation & Registration Instructions for Sino-Micro

Excellent! Thanks for the notice, Paul!

Thomas

---

**From:** Paul Liu <[paul06liu@yahoo.com](mailto:paul06liu@yahoo.com)>  
**Sent:** Wednesday, August 28, 2019 4:57 PM  
**To:** [tangy@mskcc.org](mailto:tangy@mskcc.org); [Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu); Zheng, Zhi-Ming (Thomas) (NIH/NCI) [E] <[zhengt@exchange.nih.gov](mailto:zhengt@exchange.nih.gov)>  
**Cc:** Zheng, Hui <[huiz@bcm.edu](mailto:huiz@bcm.edu)>; Liu, Shan-Lu <[liu.6244@osu.edu](mailto:liu.6244@osu.edu)>  
**Subject:** Re: Re: C100 Co-Sponsor Confirmation & Registration Instructions for Sino-Micro

Thomas,

Thanks for your message. Things are under control. There are five SCBA members attending the C100 meeting (including Shan and Hui, while Shan-Lu has a schedule conflict so he cannot attend) and I will be on the conference call this Friday, representing SCBA.

Paul

On Wednesday, August 28, 2019, 04:15:46 PM EDT, Zheng, Zhi-Ming (Thomas) (NIH/NCI) [E] <[zhengt@exchange.nih.gov](mailto:zhengt@exchange.nih.gov)> wrote:

Thanks for the notice, Yi-Wei and Shan! I would strongly suggest to have Paul, Hui and Shan-Lu on the conference call as I copied to.

Best,

Thomas

---

**From:** [tangy@mskcc.org](mailto:tangy@mskcc.org) <[tangy@mskcc.org](mailto:tangy@mskcc.org)>  
**Sent:** Wednesday, August 28, 2019 9:11 AM  
**To:** [Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu); Zheng, Zhi-Ming (Thomas) (NIH/NCI) [E] <[zhengt@exchange.nih.gov](mailto:zhengt@exchange.nih.gov)>  
**Subject:** FW: Re: C100 Co-Sponsor Confirmation & Registration Instructions for Sino-Micro

FYI.

Yi-Wei

---

**From:** Tang, Yi-Wei/Laboratory Medicine  
**Sent:** Wednesday, August 28, 2019 9:01 AM  
**To:** 'Christina Lu' <[clu@committee100.org](mailto:clu@committee100.org)>; [wang.707@osu.edu](mailto:wang.707@osu.edu)  
**Cc:** Silicon Valley Conference <[svconf@committee100.org](mailto:svconf@committee100.org)>; 'Chuanwu Xi' ([cxi@umich.edu](mailto:cxi@umich.edu)) <[cxi@umich.edu](mailto:cxi@umich.edu)>; [yongqunh@med.umich.edu](mailto:yongqunh@med.umich.edu)  
**Subject:** RE: [EXTERNAL] Re: C100 Co-Sponsor Confirmation & Registration Instructions for Sino-Micro

I will be able to join the conference call. Please send me an Outlook invitation along with a call bridge/number.

Yi-Wei

**Yi-Wei Tang, MD, PhD, D(ABMM), F(AAM), FIDSA**

Chief of Clinical Microbiology Service

Center for Laboratory Medicine

Memorial Sloan Kettering Cancer Center

Professor of Pathology and Laboratory Medicine

Weill Medical College of Cornell University

327 East 64th St, Rm 521

New York, NY 10065, USA

Tel: 646-608-1380; Fax: (929) 321-7208; Email: [tangy@mskcc.org](mailto:tangy@mskcc.org)

<http://www.mskcc.org/cancer-care/doctor/yi-wei-tang>

**From:** Christina Lu <[clu@committee100.org](mailto:clu@committee100.org)>  
**Sent:** Tuesday, August 27, 2019 4:31 PM  
**To:** [wang.707@osu.edu](mailto:wang.707@osu.edu)  
**Cc:** Silicon Valley Conference <[svconf@committee100.org](mailto:svconf@committee100.org)>; Tang, Yi-Wei/Laboratory Medicine <[tangy@mskcc.org](mailto:tangy@mskcc.org)>; 'Chuanwu Xi' ([cxi@umich.edu](mailto:cxi@umich.edu)) <[cxi@umich.edu](mailto:cxi@umich.edu)>; [yongqunh@med.umich.edu](mailto:yongqunh@med.umich.edu)  
**Subject:** [EXTERNAL] Re: C100 Co-Sponsor Confirmation & Registration Instructions for Sino-Micro

Dear Dr. Wang,

I write to follow-up on the below and ask if you or a representative from Sino-Micro are planning to join the **conference call for our co-sponsors on Friday, August 30 at 2PM Pacific Time / 5pm Eastern Time?** The purpose of the call is to provide you updates on the conference agenda and answer any questions you may have about the roundtable discussion. It would be greatly appreciated if you could let me know if a representative will be joining from Sino-Micro.

Thank you.

Best regards,

Christina



National Program Director

**COMMITTEE OF 100** | *EXTRAORDINARY CHINESE AMERICANS* - Ensuring Full Inclusion in America, Advancing U.S.-China Relations

[257 Park Ave. South, 19th Floor, New York, NY 10010](#)

T: (212) 371-6565 | C: (646) 623-7904 | E: [clu@committee100.org](mailto:clu@committee100.org)

[www.committee100.org](http://www.committee100.org)

On Mon, Aug 19, 2019 at 4:25 PM Christina Lu <[clu@committee100.org](mailto:clu@committee100.org)> wrote:

Dear Dr. Wang,

Thank you for serving as a **co-sponsor** at Committee of 100's upcoming conference entitled "**Science and Technology Caught Between the United States and China: The Challenges Facing Chinese American Researchers**". This one-day, by-invitation high-level conference will take place on **September 28, 2019** at the **Four Seasons Hotel Silicon Valley in Palo Alto**. Please find attached your co-sponsor confirmation letter. Once we receive your logo, we will add it to the flier.

Please register using the below custom codes for Sino-Micro. When you enter the codes separately, you will find the price of the "General Admission Ticket" will change.

To register your 6 complimentary tickets [please click here](#) (the roundtable representative is included in the six). Please enter "**SINOMICROcomp**" in the promotional code box. Please register your 6 complimentary tickets no later than **September 8, 2019**. If there are unassigned tickets after September 8, the complimentary seats will be released back to C100 to be re-assigned.

For your other members who would like to attend, [please click here](#) and instruct them to enter "**SINOMICROdiscount**" in the promotional code box. This code also allows you and your members to purchase additional tickets at the **discount rate of \$45**. Please note that seating is limited and discounted tickets are offered exclusively for interested members of our conference partners. This rate will not be available to the public at large.

Please find attached a copy of the **conference flier** for you to share internally with your members.

I would also like to inform you that we will have a **conference call for our co-sponsors** on **Friday, August 30 at 2PM Pacific Time / 5pm Eastern Time**. The purpose of the call is to provide you updates on the conference agenda and answer any additional questions. Please confirm a representative from your organization can join the call. Call-in details will be provided upon confirmation.

We are grateful for your partnership towards the success of this conference. Please do not hesitate to reach out to me if you have any questions.

Best regards,  
Christina Lu



National Program Director

**COMMITTEE OF 100** | *EXTRAORDINARY CHINESE AMERICANS* - Ensuring Full Inclusion in America, Advancing U.S.-China Relations

[257 Park Ave. South, 19th Floor, New York, NY 10010](#)

T: (212) 371-6565 | C: (646) 623-7904 | E: [clu@committee100.org](mailto:clu@committee100.org)

[www.committee100.org](http://www.committee100.org)

----- Forwarded message -----

From: **Wang, Hua** <[wang.707@osu.edu](mailto:wang.707@osu.edu)>

Date: Mon, Aug 19, 2019 at 12:54 PM

Subject: RE: Sino-micro's position

To: Frank H. Wu <[frankhwu@committee100.org](mailto:frankhwu@committee100.org)>

Cc: [tangy@mskcc.org](mailto:tangy@mskcc.org) <[tangy@mskcc.org](mailto:tangy@mskcc.org)>, 'Chuanwu Xi' (<[cxi@umich.edu](mailto:cxi@umich.edu)> <[cxi@umich.edu](mailto:cxi@umich.edu)>, [yongqunh@med.umich.edu](mailto:yongqunh@med.umich.edu) <[yongqunh@med.umich.edu](mailto:yongqunh@med.umich.edu)>, Christina Lu <[clu@committee100.org](mailto:clu@committee100.org)>

Sure. Oliver, can you help send our "official" log to Christina? Thank you so much!!-Hua

---

**From:** Frank H. Wu [mailto:[frankhwu@committee100.org](mailto:frankhwu@committee100.org)]

**Sent:** Monday, August 19, 2019 12:53 PM

**To:** Wang, Hua <[wang.707@osu.edu](mailto:wang.707@osu.edu)>

**Cc:** [tangy@mskcc.org](mailto:tangy@mskcc.org); 'Chuanwu Xi' (<[cxi@umich.edu](mailto:cxi@umich.edu)> <[cxi@umich.edu](mailto:cxi@umich.edu)>; [yongqunh@med.umich.edu](mailto:yongqunh@med.umich.edu); Christina Lu <[clu@committee100.org](mailto:clu@committee100.org)>

**Subject:** Re: Sino-micro's position

Great! Christina Lu of the C100 office is cc'd. Would you send your logo?

Frank H. Wu

William L. Prosser Distinguished Professor, University of California Hastings College of the Law

President, Committee of 100

On Aug 19, 2019, at 09:45, Wang, Hua <[wang.707@osu.edu](mailto:wang.707@osu.edu)> wrote:



Dear Professor Wu,

Thank you very much for considering Sino-micro and informing us about the conference on “Science and Technology Caught Between the United States and China, The Challenges Facing Chinese American Researchers”, organized by Committee 100. I have consulted our past presidents and president-elect, as well as sent out a ballot on the topic to the board. Besides unanimous support from the past and current senior officers, dominant majority of the board members voted “yes” supporting Sino-Micro to be a co-sponsor of the event.

Due to academic obligations, most board members won't be able to attend the event in person. I will share with you additional information on potential participation when available.

Thank you again very much for your leadership on this topic of great important to academia and our broad society. We look forward to working with you.

Sincerely,

Hua Wang, Ph.D.

President, Sino-Micro

Professor, Food Science, Microbiology, Interdisciplinary Nutrition

The Ohio State University

2015 Fyffe Court

Columbus, OH 43210

[Wang.707@osu.edu](mailto:Wang.707@osu.edu)

---

**From:** Paul Liu <paul06liu@yahoo.com>  
**Sent:** Wednesday, August 28, 2019 4:57 PM  
**To:** tangy@mskcc.org; Lu, Shan; Zheng, Zhi-Ming (Thomas) (NIH/NCI) [E]  
**Cc:** Zheng, Hui; Liu, Shan-Lu  
**Subject:** Re: Re: C100 Co-Sponsor Confirmation & Registration Instructions for Sino-Micro

Thomas,

Thanks for your message. Things are under control. There are five SCBA members attending the C100 meeting (including Shan and Hui, while Shan-Lu has a schedule conflict so he cannot attend) and I will be on the conference call this Friday, representing SCBA.

Paul

On Wednesday, August 28, 2019, 04:15:46 PM EDT, Zheng, Zhi-Ming (Thomas) (NIH/NCI) [E] <zhengt@exchange.nih.gov> wrote:

Thanks for the notice, Yi-Wei and Shan! I would strongly suggest to have Paul, Hui and Shan-Lu on the conference call as I copied to.

Best,

Thomas

---

**From:** tangy@mskcc.org <tangy@mskcc.org>  
**Sent:** Wednesday, August 28, 2019 9:11 AM  
**To:** Shan.Lu@umassmed.edu; Zheng, Zhi-Ming (Thomas) (NIH/NCI) [E] <zhengt@exchange.nih.gov>  
**Subject:** FW: Re: C100 Co-Sponsor Confirmation & Registration Instructions for Sino-Micro

FYI.

Yi-Wei

---

**From:** Tang, Yi-Wei/Laboratory Medicine  
**Sent:** Wednesday, August 28, 2019 9:01 AM  
**To:** 'Christina Lu' <clu@committee100.org>; wang.707@osu.edu  
**Cc:** Silicon Valley Conference <svconf@committee100.org>; 'Chuanwu Xi' (cxi@umich.edu) <cxi@umich.edu>;

[yongqunh@med.umich.edu](mailto:yongqunh@med.umich.edu)

**Subject:** RE: [EXTERNAL] Re: C100 Co-Sponsor Confirmation & Registration Instructions for Sino-Micro

I will be able to join the conference call. Please send me an Outlook invitation along with a call bridge/number.

Yi-Wei

**Yi-Wei Tang, MD, PhD, D(ABMM), F(AAM), FIDSA**

Chief of Clinical Microbiology Service

Center for Laboratory Medicine

Memorial Sloan Kettering Cancer Center

Professor of Pathology and Laboratory Medicine

Weill Medical College of Cornell University

327 East 64th St, Rm 521

New York, NY 10065, USA

Tel: 646-608-1380; Fax: (929) 321-7208; Email: [tangy@mskcc.org](mailto:tangy@mskcc.org)

<http://www.mskcc.org/cancer-care/doctor/yi-wei-tang>

**From:** Christina Lu <[clu@committee100.org](mailto:clu@committee100.org)>

**Sent:** Tuesday, August 27, 2019 4:31 PM

**To:** [wang.707@osu.edu](mailto:wang.707@osu.edu)

**Cc:** Silicon Valley Conference <[svconf@committee100.org](mailto:svconf@committee100.org)>; Tang, Yi-Wei/Laboratory Medicine <[tangy@mskcc.org](mailto:tangy@mskcc.org)>; 'Chuanwu Xi' ([cxi@umich.edu](mailto:cxi@umich.edu)) <[cxi@umich.edu](mailto:cxi@umich.edu)>; [yongqunh@med.umich.edu](mailto:yongqunh@med.umich.edu)

**Subject:** [EXTERNAL] Re: C100 Co-Sponsor Confirmation & Registration Instructions for Sino-Micro

Dear Dr. Wang,


I write to follow-up on the below and ask if you or a representative from Sino-Micro are planning to join the **conference call for our co-sponsors on Friday, August 30 at 2PM Pacific Time / 5pm Eastern Time?** The purpose of the call is to

provide you updates on the conference agenda and answer any questions you may have about the roundtable discussion. It would be greatly appreciated if you could let me know if a representative will be joining from Sino-Micro.

Thank you.

Best regards,

Christina



National Program Director

**COMMITTEE OF 100** | *EXTRAORDINARY CHINESE AMERICANS* - Ensuring Full Inclusion in America, Advancing U.S.-China Relations

[257 Park Ave. South, 19th Floor, New York, NY 10010](#)

T: (212) 371-6565 | C: (646) 623-7904 | E: [clu@committee100.org](mailto:clu@committee100.org)

[www.committee100.org](http://www.committee100.org)

On Mon, Aug 19, 2019 at 4:25 PM Christina Lu <[clu@committee100.org](mailto:clu@committee100.org)> wrote:

Dear Dr. Wang,

Thank you for serving as a **co-sponsor** at Committee of 100's upcoming conference entitled "**Science and Technology Caught Between the United States and China: The Challenges Facing Chinese American Researchers**". This one-day, by-invitation high-level conference will take place on **September 28, 2019** at the **Four Seasons Hotel Silicon Valley in Palo Alto**. Please find attached your co-sponsor confirmation letter. Once we receive your logo, we will add it to the flier.

Please register using the below custom codes for Sino-Micro. When you enter the codes separately, you will find the price of the "General Admission Ticket" will change.

To register your 6 complimentary tickets [please click here](#) (the roundtable representative is included in the six). Please enter "**SINOMICROcomp**" in the promotional code box. Please register your 6 complimentary tickets no later than **September 8, 2019**. If there are unassigned tickets after September 8, the complimentary seats will be released back to C100 to be re-assigned.

For your other members who would like to attend, [please click here](#) and instruct them to enter "**SINOMICROdiscount**" in the promotional code box. This code also allows you and your members to purchase additional tickets at the **discount rate of \$45**. Please note that seating is limited and discounted tickets are offered exclusively for interested members of our conference partners. This rate will not be available to the public at large.

Please find attached a copy of the **conference flier** for you to share internally with your members.

I would also like to inform you that we will have a **conference call for our co-sponsors** on **Friday, August 30 at 2PM Pacific Time / 5pm Eastern Time**. The purpose of the call is to provide you updates on the conference agenda and answer any additional questions. Please confirm a representative from your organization can join the call. Call-in details will be provided upon confirmation.

We are grateful for your partnership towards the success of this conference. Please do not hesitate to reach out to me if you have any questions.

Best regards,  
Christina Lu



National Program Director

**COMMITTEE OF 100** | **EXTRAORDINARY CHINESE AMERICANS** - Ensuring Full Inclusion in America, Advancing U.S.-China Relations

[257 Park Ave. South, 19th Floor, New York, NY 10010](#)

T: (212) 371-6565 | C: (646) 623-7904 | E: [clu@committee100.org](mailto:clu@committee100.org)

----- Forwarded message -----

From: **Wang, Hua** <[wang.707@osu.edu](mailto:wang.707@osu.edu)>  
Date: Mon, Aug 19, 2019 at 12:54 PM  
Subject: RE: Sino-micro's position  
To: Frank H. Wu <[frankhwu@committee100.org](mailto:frankhwu@committee100.org)>  
Cc: [tangy@mskcc.org](mailto:tangy@mskcc.org) <[tangy@mskcc.org](mailto:tangy@mskcc.org)>, 'Chuanwu Xi' (<[cxi@umich.edu](mailto:cxi@umich.edu)> <[cxi@umich.edu](mailto:cxi@umich.edu)>),  
[yongqunh@med.umich.edu](mailto:yongqunh@med.umich.edu) <[yongqunh@med.umich.edu](mailto:yongqunh@med.umich.edu)>, Christina Lu <[clu@committee100.org](mailto:clu@committee100.org)>

Sure. Oliver, can you help send our “official” log to Christina? Thank you so much!!-Hua

---

**From:** Frank H. Wu [mailto:[frankhwu@committee100.org](mailto:frankhwu@committee100.org)]  
**Sent:** Monday, August 19, 2019 12:53 PM  
**To:** Wang, Hua <[wang.707@osu.edu](mailto:wang.707@osu.edu)>  
**Cc:** [tangy@mskcc.org](mailto:tangy@mskcc.org); 'Chuanwu Xi' (<[cxi@umich.edu](mailto:cxi@umich.edu)> <[cxi@umich.edu](mailto:cxi@umich.edu)>); [yongqunh@med.umich.edu](mailto:yongqunh@med.umich.edu); Christina Lu <[clu@committee100.org](mailto:clu@committee100.org)>  
**Subject:** Re: Sino-micro's position

Great! Christina Lu of the C100 office is cc'd. Would you send your logo?

Frank H. Wu

William L. Prosser Distinguished Professor, University of California Hastings College of the Law

President, Committee of 100

On Aug 19, 2019, at 09:45, Wang, Hua <[wang.707@osu.edu](mailto:wang.707@osu.edu)> wrote:

Dear Professor Wu,

Thank you very much for considering Sino-micro and informing us about the conference on “Science and Technology Caught Between the United States and China, The Challenges Facing Chinese American Researchers”, organized by Committee 100. I have consulted our past presidents and president-elect, as well as sent out a ballot on the topic to the board. Besides unanimous support from the past and current senior officers, dominant majority of the board members voted “yes” supporting Sino-Micro to be a co-sponsor of the event.

Due to academic obligations, most board members won't be able to attend the event in person. I will share with you additional information on potential participation when available.

Thank you again very much for your leadership on this topic of great important to academia and our broad society. We look forward to working with you.

Sincerely,

Hua Wang, Ph.D.

President, Sino-Micro

Professor, Food Science, Microbiology, Interdisciplinary Nutrition

The Ohio State University

2015 Fyffe Court

Columbus, OH 43210

[Wang.707@osu.edu](mailto:Wang.707@osu.edu)

---

**From:** Zhi-Ming Zheng <zhengzhiming4@gmail.com>  
**Sent:** Friday, August 30, 2019 9:26 AM  
**To:** tangy@mskcc.org  
**Cc:** Lu, Shan; ymw@shmu.edu.cn  
**Subject:** Re: ...EMI update - Aug 29, 2019...

It has been done! Cheers for Yi-Wei!

Zhi-Ming

On Fri, Aug 30, 2019 at 7:53 AM <[tangy@mskcc.org](mailto:tangy@mskcc.org)> wrote:

Thank you, Shan. I am pleased that the HIV commentary gets some attention.

Zhi-Ming, do you mind pass this to the virology wechat group: instead of attaching the paper, please use this link:  
<https://www.tandfonline.com/doi/full/10.1080/22221751.2019.1656550>

Thank you, Yi-Wei

---

**From:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Sent:** Thursday, August 29, 2019 10:16 PM  
**To:** Zhi-Ming Zheng <[zhengzhiming4@gmail.com](mailto:zhengzhiming4@gmail.com)>; Tang, Yi-Wei/Laboratory Medicine <[tangy@mskcc.org](mailto:tangy@mskcc.org)>  
**Cc:** wen yumei <[ymw@shmu.edu.cn](mailto:ymw@shmu.edu.cn)>  
**Subject:** [EXTERNAL] ...EMI update - Aug 29, 2019...

Dear Zhi-Ming

Based on your suggestion, EMI has reversed the order of new papers published in 2019 at our website: the newest on top as you suggested.

As result, your paper on blood transmission of HPV is now among the top ones and early for people to find. It has attracted 274 reads in just one month.

Dear Yi-Wei,



Your paper co-authored with Hongzhou on HIV diagnosis is now published online. It attracted 324 reads in 3 days!

Thank you both for sending good papers to EMI.

Shan

---

**From:** tangy@mskcc.org  
**Sent:** Friday, August 30, 2019 7:53 AM  
**To:** Lu, Shan; zhengzhiming4@gmail.com  
**Cc:** ymw@shmu.edu.cn  
**Subject:** RE: ...EMI update - Aug 29, 2019...

Thank you, Shan. I am pleased that the HIV commentary gets some attention.

Zhi-Ming, do you mind pass this to the virology wechat group: instead of attaching the paper, please use this link:  
<https://www.tandfonline.com/doi/full/10.1080/22221751.2019.1656550>

Thank you, Yi-Wei

---

**From:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Sent:** Thursday, August 29, 2019 10:16 PM  
**To:** Zhi-Ming Zheng <zhengzhiming4@gmail.com>; Tang, Yi-Wei/Laboratory Medicine <tangy@mskcc.org>  
**Cc:** wen yumei <ymw@shmu.edu.cn>  
**Subject:** [EXTERNAL] ...EMI update - Aug 29, 2019...

Dear Zhi-Ming

Based on your suggestion, EMI has reversed the order of new papers published in 2019 at our website: the newest on top as you suggested.

As result, your paper on blood transmission of HPV is now among the top ones and early for people to find. It has attracted 274 reads in just one month.

Dear Yi-Wei,

Your paper co-authored with Hongzhou on HIV diagnosis is now published online. It attracted 324 reads in 3 days!

Thank you both for sending good papers to EMI.

Shan

---

**From:** Wen-Zhe Ho <wenzheho@temple.edu>  
**Sent:** Thursday, November 28, 2019 2:16 PM  
**To:** Sun, Jie, Ph.D.  
**Cc:** Liu, Shan-Lu; zhengzhiming4@gmail.com; haitguo@iupui.edu; tzhou@mail.nih.gov; GCheng@mednet.ucla.edu; liangy@umn.edu; rli@vcu.edu; wjma@ksu.edu; xjmeng@vt.edu; Zhijian.Chen@UTSouthwestern.edu; mluo@gsu.edu; zhangyj@umd.edu; xzhu1@umd.edu; jqiu@kumc.edu; lijun@uic.edu; fengwei.bai@usm.edu; andyu@iupui.edu; reachxw@vt.edu; gluo@uab.edu; ldu@nybc.org; hXu@tulane.edu; liu\_fy@berkeley.edu; shitao.li@okstate.edu; Lu, Shan; haihu@UTMB.edu; Qfeng4@central.uh.edu; tang@bio.fsu.edu; feng.li@sdstate.edu; ruilu@lsu.edu; sxiang2@unl.edu; qiyi.tang@howard.edu; dingsw@ucr.edu; guohua@missouri.edu; bling@tulane.edu; junwang@pharmacy.arizona.edu; lifang@umn.edu; wang518@umd.edu; gaos8@upmc.edu; pewang@uchc.edu; xiangy@uthscsa.edu; fzhu@bio.fsu.edu; chen.liang@mcgill.ca; lyuan@vt.edu; fgao@duke.edu; wangjw28@163.com; xfyu1@zju.edu.cn; bzhao@partners.org; jianw@musc.edu; zyang@ksu.edu; yu.cong@nih.gov; weiming.yuan@usc.edu; Zongdi.feng@nationwidechildrens.org; juh13@psu.edu; hengx@missouri.edu; lsu@med.unc.edu; ywu8@gmu.edu; jwu@whu.edu.cn; tshuo@uic.edu; Shibojian@fudan.edu.cn; sjiang@nybc.org; pinwang@usc.edu; rzhao@som.umaryland.edu; shuylong@mail.sysu.edu.cn; xuefeng.liu@georgetown.edu; yuxingli@som.umaryland.edu; Wang, Shixia; yhe@ipbcams.ac.cn; Pinghui.feng@usc.edu; ju-tao.guo@bblumberg.org; lin.liu@okstate.edu; hua.zhu@rutgers.edu; Jinhong.chang@bblumberg.org; jianzhu1012@gmail.com; ronghai@ucr.edu; jun.zhu@nih.gov; jliu4@uams.edu; xiangpeng.kong@med.nyu.edu; haoquanwu@outlook.com; Wenjun.liu@defence.gov.au; Liang.shan@wustl.edu; hliao@duke.edu; yuan2@upenn.edu; zxing@umn.edu; hongmin.li@health.ny.gov; pzhang@ihv.umaryland.edu; yaliu@ihv.umaryland.edu; jxw103@case.edu; xiangguo.qiu@canada.ca; Feng Shao; zls@whu.edu.cn; klan@whu.edu.cn; zengmsh@mail.sysu.edu.cn; Nan Yan; Zhang, Rong; liliwang@upenn.edu; Linheng Li; kli1@uthsc.edu; tsx@case.edu; ssun@mdanderson.org; ysang@tstate.edu; wu@crystal.harvard.edu; peijun@strubi.ox.ac.uk; jiayu@coh.org; bchen@crystal.harvard.edu; Wen, Haitao; Qu, Feng; Hezhao.Ji@umanitoba.ca; Li, Zihai; zhengyo@msu.edu; zhanglinqi@tsinghua.edu.cn; wxiao@temple.edu; Whu@temple.edu; RSun@mednet.ucla.edu; Gao, Guangping; GMSWANG@nus.edu.sg; peshi@UTMB.EDU; ziyang-yan@uiowa.edu; lqiao@luc.edu; yong.xiong@yale.edu; Wang, Qihong; shuping\_tong\_md@brown.edu; pinghuif@usc.edu; gaof@im.ac.cn  
**Subject:** Re: [EXTERNAL] Happy Thanksgiving and meeting next year, June 12-13, 2020

Hi, Shan-Lu, Thank you for the information. I did not see the attachment

Wenzhe

On Thu, Nov 28, 2019 at 9:37 AM Sun, Jie, Ph.D. <[Sun.Jie@mayo.edu](mailto:Sun.Jie@mayo.edu)> wrote:

Thanks for sharing. Happy Thanksgiving to everyone!

Best wishes,

Jie

Jie Sun, Ph.D.

Associate Professor

Department of Medicine

Department of Immunology

Mayo Clinic

Stabile 8-26

200 1st St SW

Rochester, MN 55905

Tel: 507-284-9503

Email: [Sun.Jie@mayo.edu](mailto:Sun.Jie@mayo.edu)

<http://www.mayo.edu/research/faculty/sun-jie-ph-d/bio-20348662>

---

**From:** "Liu, Shan-Lu" <[liu.6244@osu.edu](mailto:liu.6244@osu.edu)>

**Date:** Thursday, November 28, 2019 at 10:54 AM

**To:** "[zhengzhiming4@gmail.com](mailto:zhengzhiming4@gmail.com)" <[zhengzhiming4@gmail.com](mailto:zhengzhiming4@gmail.com)>, "[haitguo@iupui.edu](mailto:haitguo@iupui.edu)" <[haitguo@iupui.edu](mailto:haitguo@iupui.edu)>, "[tzhou@mail.nih.gov](mailto:tzhou@mail.nih.gov)" <[tzhou@mail.nih.gov](mailto:tzhou@mail.nih.gov)>, "[GCheng@mednet.ucla.edu](mailto:GCheng@mednet.ucla.edu)" <[GCheng@mednet.ucla.edu](mailto:GCheng@mednet.ucla.edu)>, "[liangy@umn.edu](mailto:liangy@umn.edu)" <[liangy@umn.edu](mailto:liangy@umn.edu)>, "[rli@vcu.edu](mailto:rli@vcu.edu)" <[rli@vcu.edu](mailto:rli@vcu.edu)>, "[wjma@ksu.edu](mailto:wjma@ksu.edu)" <[wjma@ksu.edu](mailto:wjma@ksu.edu)>, "[xjmeng@vt.edu](mailto:xjmeng@vt.edu)" <[xjmeng@vt.edu](mailto:xjmeng@vt.edu)>, "Zhijian.Chen@UTSouthwestern.edu" <[Zhijian.Chen@UTSouthwestern.edu](mailto:Zhijian.Chen@UTSouthwestern.edu)>, "[mluo@gsu.edu](mailto:mluo@gsu.edu)" <[mluo@gsu.edu](mailto:mluo@gsu.edu)>, "[zhangyj@umd.edu](mailto:zhangyj@umd.edu)" <[zhangyj@umd.edu](mailto:zhangyj@umd.edu)>, "[xzhu1@umd.edu](mailto:xzhu1@umd.edu)" <[xzhu1@umd.edu](mailto:xzhu1@umd.edu)>, "[jqu@kumc.edu](mailto:jqu@kumc.edu)" <[jqu@kumc.edu](mailto:jqu@kumc.edu)>, "[lijun@uic.edu](mailto:lijun@uic.edu)" <[lijun@uic.edu](mailto:lijun@uic.edu)>, "[fengwei.bai@usm.edu](mailto:fengwei.bai@usm.edu)" <[fengwei.bai@usm.edu](mailto:fengwei.bai@usm.edu)>, "[andyu@iupui.edu](mailto:andyu@iupui.edu)" <[andyu@iupui.edu](mailto:andyu@iupui.edu)>, "[reachxw@vt.edu](mailto:reachxw@vt.edu)" <[reachxw@vt.edu](mailto:reachxw@vt.edu)>, "[gluo@uab.edu](mailto:gluo@uab.edu)" <[gluo@uab.edu](mailto:gluo@uab.edu)>, "[ldu@nybc.org](mailto:ldu@nybc.org)" <[ldu@nybc.org](mailto:ldu@nybc.org)>, "[hxu@tulane.edu](mailto:hxu@tulane.edu)" <[hxu@tulane.edu](mailto:hxu@tulane.edu)>, "[liu\\_fy@berkeley.edu](mailto:liu_fy@berkeley.edu)" <[liu\\_fy@berkeley.edu](mailto:liu_fy@berkeley.edu)>, "[shitao.li@okstate.edu](mailto:shitao.li@okstate.edu)" <[shitao.li@okstate.edu](mailto:shitao.li@okstate.edu)>, "[Shan.lu@umassmed.edu](mailto:Shan.lu@umassmed.edu)" <[Shan.lu@umassmed.edu](mailto:Shan.lu@umassmed.edu)>, "[haihu@UTMB.edu](mailto:haihu@UTMB.edu)" <[haihu@UTMB.edu](mailto:haihu@UTMB.edu)>, "[wenzheho@temple.edu](mailto:wenzheho@temple.edu)" <[wenzheho@temple.edu](mailto:wenzheho@temple.edu)>, "[Qfeng4@central.uh.edu](mailto:Qfeng4@central.uh.edu)" <[Qfeng4@central.uh.edu](mailto:Qfeng4@central.uh.edu)>, "[tang@bio.fsu.edu](mailto:tang@bio.fsu.edu)" <[tang@bio.fsu.edu](mailto:tang@bio.fsu.edu)>, "[feng.li@sdstate.edu](mailto:feng.li@sdstate.edu)" <[feng.li@sdstate.edu](mailto:feng.li@sdstate.edu)>, "[ruilu@lsu.edu](mailto:ruilu@lsu.edu)" <[ruilu@lsu.edu](mailto:ruilu@lsu.edu)>, "[sxiang2@unl.edu](mailto:sxiang2@unl.edu)" <[sxiang2@unl.edu](mailto:sxiang2@unl.edu)>, "[qiyi.tang@howard.edu](mailto:qiyi.tang@howard.edu)" <[qiyi.tang@howard.edu](mailto:qiyi.tang@howard.edu)>, "[dingsw@ucr.edu](mailto:dingsw@ucr.edu)" <[dingsw@ucr.edu](mailto:dingsw@ucr.edu)>, "[guohua@missouri.edu](mailto:guohua@missouri.edu)" <[guohua@missouri.edu](mailto:guohua@missouri.edu)>, "[bling@tulane.edu](mailto:bling@tulane.edu)" <[bling@tulane.edu](mailto:bling@tulane.edu)>, "[junwang@pharmacy.arizona.edu](mailto:junwang@pharmacy.arizona.edu)" <[junwang@pharmacy.arizona.edu](mailto:junwang@pharmacy.arizona.edu)>, "[lifang@umn.edu](mailto:lifang@umn.edu)" <[lifang@umn.edu](mailto:lifang@umn.edu)>, "[wang518@umd.edu](mailto:wang518@umd.edu)" <[wang518@umd.edu](mailto:wang518@umd.edu)>, "[gaos8@upmc.edu](mailto:gaos8@upmc.edu)" <[gaos8@upmc.edu](mailto:gaos8@upmc.edu)>, "[pewang@uchc.edu](mailto:pewang@uchc.edu)" <[pewang@uchc.edu](mailto:pewang@uchc.edu)>, "[xiangy@uthscsa.edu](mailto:xiangy@uthscsa.edu)" <[xiangy@uthscsa.edu](mailto:xiangy@uthscsa.edu)>, "[fzhu@bio.fsu.edu](mailto:fzhu@bio.fsu.edu)" <[fzhu@bio.fsu.edu](mailto:fzhu@bio.fsu.edu)>, "[chen.liang@mcgill.ca](mailto:chen.liang@mcgill.ca)" <[chen.liang@mcgill.ca](mailto:chen.liang@mcgill.ca)>, "[lyuan@vt.edu](mailto:lyuan@vt.edu)" <[lyuan@vt.edu](mailto:lyuan@vt.edu)>, "[fgao@duke.edu](mailto:fgao@duke.edu)" <[fgao@duke.edu](mailto:fgao@duke.edu)>, "[wangjw28@163.com](mailto:wangjw28@163.com)" <[wangjw28@163.com](mailto:wangjw28@163.com)>, "[xfyu1@zju.edu.cn](mailto:xfyu1@zju.edu.cn)" <[xfyu1@zju.edu.cn](mailto:xfyu1@zju.edu.cn)>, "[bzhao@partners.org](mailto:bzhao@partners.org)" <[bzhao@partners.org](mailto:bzhao@partners.org)>, "[jianw@muscu.edu](mailto:jianw@muscu.edu)" <[jianw@muscu.edu](mailto:jianw@muscu.edu)>, "[zyang@ksu.edu](mailto:zyang@ksu.edu)" <[zyang@ksu.edu](mailto:zyang@ksu.edu)>, "[yu.cong@nih.gov](mailto:yu.cong@nih.gov)" <[yu.cong@nih.gov](mailto:yu.cong@nih.gov)>, "[weiming.yuan@usc.edu](mailto:weiming.yuan@usc.edu)" <[weiming.yuan@usc.edu](mailto:weiming.yuan@usc.edu)>, "[Zongdi.feng@nationwidechildrens.org](mailto:Zongdi.feng@nationwidechildrens.org)" <[Zongdi.feng@nationwidechildrens.org](mailto:Zongdi.feng@nationwidechildrens.org)>,

[juh13@psu.edu](mailto:juh13@psu.edu) <[juh13@psu.edu](mailto:juh13@psu.edu)>, [hengx@missouri.edu](mailto:hengx@missouri.edu) <[hengx@missouri.edu](mailto:hengx@missouri.edu)>, [lsu@med.unc.edu](mailto:lsu@med.unc.edu) <[lsu@med.unc.edu](mailto:lsu@med.unc.edu)>, [ywu8@gmu.edu](mailto:ywu8@gmu.edu) <[ywu8@gmu.edu](mailto:ywu8@gmu.edu)>, [jwu@whu.edu.cn](mailto:jwu@whu.edu.cn) <[jwu@whu.edu.cn](mailto:jwu@whu.edu.cn)>, [tshuo@uic.edu](mailto:tshuo@uic.edu) <[tshuo@uic.edu](mailto:tshuo@uic.edu)>, [Shibojiang@fudan.edu.cn](mailto:Shibojiang@fudan.edu.cn) <[Shibojiang@fudan.edu.cn](mailto:Shibojiang@fudan.edu.cn)>, [sjiang@nybc.org](mailto:sjiang@nybc.org) <[sjiang@nybc.org](mailto:sjiang@nybc.org)>, [pinwang@usc.edu](mailto:pinwang@usc.edu) <[pinwang@usc.edu](mailto:pinwang@usc.edu)>, [rzhao@som.umaryland.edu](mailto:rzhao@som.umaryland.edu) <[rzhao@som.umaryland.edu](mailto:rzhao@som.umaryland.edu)>, [shuylong@mail.sysu.edu.cn](mailto:shuylong@mail.sysu.edu.cn) <[shuylong@mail.sysu.edu.cn](mailto:shuylong@mail.sysu.edu.cn)>, [xuefeng.liu@georgetown.edu](mailto:xuefeng.liu@georgetown.edu) <[xuefeng.liu@georgetown.edu](mailto:xuefeng.liu@georgetown.edu)>, [yuxingli@som.umaryland.edu](mailto:yuxingli@som.umaryland.edu) <[yuxingli@som.umaryland.edu](mailto:yuxingli@som.umaryland.edu)>, [shixia.wang@umassmed.edu](mailto:shixia.wang@umassmed.edu) <[shixia.wang@umassmed.edu](mailto:shixia.wang@umassmed.edu)>, [yhe@ipbcams.ac.cn](mailto:yhe@ipbcams.ac.cn) <[yhe@ipbcams.ac.cn](mailto:yhe@ipbcams.ac.cn)>, [Pinhui.feng@usc.edu](mailto:Pinhui.feng@usc.edu) <[Pinhui.feng@usc.edu](mailto:Pinhui.feng@usc.edu)>, [ju-tao.guo@bblumberg.org](mailto:ju-tao.guo@bblumberg.org) <[ju-tao.guo@bblumberg.org](mailto:ju-tao.guo@bblumberg.org)>, [lin.liu@okstate.edu](mailto:lin.liu@okstate.edu) <[lin.liu@okstate.edu](mailto:lin.liu@okstate.edu)>, [hua.zhu@rutgers.edu](mailto:hua.zhu@rutgers.edu) <[hua.zhu@rutgers.edu](mailto:hua.zhu@rutgers.edu)>, [Jinhong.chang@bblumberg.org](mailto:Jinhong.chang@bblumberg.org) <[Jinhong.chang@bblumberg.org](mailto:Jinhong.chang@bblumberg.org)>, [jianzhu1012@gmail.com](mailto:jianzhu1012@gmail.com) <[jianzhu1012@gmail.com](mailto:jianzhu1012@gmail.com)>, [ronghai@ucr.edu](mailto:ronghai@ucr.edu) <[ronghai@ucr.edu](mailto:ronghai@ucr.edu)>, [jun.zhu@nih.gov](mailto:jun.zhu@nih.gov) <[jun.zhu@nih.gov](mailto:jun.zhu@nih.gov)>, [jliu4@uams.edu](mailto:jliu4@uams.edu) <[jliu4@uams.edu](mailto:jliu4@uams.edu)>, [xiangpeng.kong@med.nyu.edu](mailto:xiangpeng.kong@med.nyu.edu) <[xiangpeng.kong@med.nyu.edu](mailto:xiangpeng.kong@med.nyu.edu)>, [haoquanwu@outlook.com](mailto:haoquanwu@outlook.com) <[haoquanwu@outlook.com](mailto:haoquanwu@outlook.com)>, [Wenjun.liu@defence.gov.au](mailto:Wenjun.liu@defence.gov.au) <[Wenjun.liu@defence.gov.au](mailto:Wenjun.liu@defence.gov.au)>, [Liang.shan@wustl.edu](mailto:Liang.shan@wustl.edu) <[Liang.shan@wustl.edu](mailto:Liang.shan@wustl.edu)>, [hliao@duke.edu](mailto:hliao@duke.edu) <[hliao@duke.edu](mailto:hliao@duke.edu)>, [yuan2@upenn.edu](mailto:yuan2@upenn.edu) <[yuan2@upenn.edu](mailto:yuan2@upenn.edu)>, [zxing@umn.edu](mailto:zxing@umn.edu) <[zxing@umn.edu](mailto:zxing@umn.edu)>, [hongmin.li@health.ny.gov](mailto:hongmin.li@health.ny.gov) <[hongmin.li@health.ny.gov](mailto:hongmin.li@health.ny.gov)>, [pzheng@ihv.umaryland.edu](mailto:pzheng@ihv.umaryland.edu) <[pzheng@ihv.umaryland.edu](mailto:pzheng@ihv.umaryland.edu)>, [yaliu@ihv.umaryland.edu](mailto:yaliu@ihv.umaryland.edu) <[yaliu@ihv.umaryland.edu](mailto:yaliu@ihv.umaryland.edu)>, [jxw103@case.edu](mailto:jxw103@case.edu) <[jxw103@case.edu](mailto:jxw103@case.edu)>, [xianguo.qiu@canada.ca](mailto:xianguo.qiu@canada.ca) <[xianguo.qiu@canada.ca](mailto:xianguo.qiu@canada.ca)>, Feng Shao <[shaofeng@nibs.ac.cn](mailto:shaofeng@nibs.ac.cn)>, [zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn) <[zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn)>, [klan@whu.edu.cn](mailto:klan@whu.edu.cn) <[klan@whu.edu.cn](mailto:klan@whu.edu.cn)>, [zengmsh@mail.sysu.edu.cn](mailto:zengmsh@mail.sysu.edu.cn) <[zengmsh@mail.sysu.edu.cn](mailto:zengmsh@mail.sysu.edu.cn)>, Nan Yan <[Nan.Yan@UTSouthwestern.edu](mailto:Nan.Yan@UTSouthwestern.edu)>, Zhang, Rong <[rongzhang@wustl.edu](mailto:rongzhang@wustl.edu)>, [liliwang@upenn.edu](mailto:liliwang@upenn.edu) <[liliwang@upenn.edu](mailto:liliwang@upenn.edu)>, Linheng Li <[LIL@stowers.org](mailto:LIL@stowers.org)>, [kli1@uthsc.edu](mailto:kli1@uthsc.edu) <[kli1@uthsc.edu](mailto:kli1@uthsc.edu)>, [tsx@case.edu](mailto:tsx@case.edu) <[tsx@case.edu](mailto:tsx@case.edu)>, [ssun@mdanderson.org](mailto:ssun@mdanderson.org) <[ssun@mdanderson.org](mailto:ssun@mdanderson.org)>, [ysang@tnstate.edu](mailto:ysang@tnstate.edu) <[ysang@tnstate.edu](mailto:ysang@tnstate.edu)>, "Liu, Shan-Lu" <[liu.6244@osu.edu](mailto:liu.6244@osu.edu)>, [wu@crystal.harvard.edu](mailto:wu@crystal.harvard.edu) <[wu@crystal.harvard.edu](mailto:wu@crystal.harvard.edu)>, "Sun, Jie, Ph.D." <[Sun.Jie@mayo.edu](mailto:Sun.Jie@mayo.edu)>, [peijun@strubi.ox.ac.uk](mailto:peijun@strubi.ox.ac.uk) <[peijun@strubi.ox.ac.uk](mailto:peijun@strubi.ox.ac.uk)>, [jiayu@coh.org](mailto:jiayu@coh.org) <[jiayu@coh.org](mailto:jiayu@coh.org)>, [bchen@crystal.harvard.edu](mailto:bchen@crystal.harvard.edu) <[bchen@crystal.harvard.edu](mailto:bchen@crystal.harvard.edu)>, "Wen, Haitao" <[Haitao.Wen@osumc.edu](mailto:Haitao.Wen@osumc.edu)>, "Qu, Feng" <[qu.28@osu.edu](mailto:qu.28@osu.edu)>, [Hezhao.Ji@umanitoba.ca](mailto:Hezhao.Ji@umanitoba.ca) <[Hezhao.Ji@umanitoba.ca](mailto:Hezhao.Ji@umanitoba.ca)>, "Li, Zihai" <[zihai@musc.edu](mailto:zihai@musc.edu)>, [zhengyo@msu.edu](mailto:zhengyo@msu.edu) <[zhengyo@msu.edu](mailto:zhengyo@msu.edu)>, [zhanglingqi@tsinghua.edu.cn](mailto:zhanglingqi@tsinghua.edu.cn) <[zhanglingqi@tsinghua.edu.cn](mailto:zhanglingqi@tsinghua.edu.cn)>, [wxiao@temple.edu](mailto:wxiao@temple.edu) <[wxiao@temple.edu](mailto:wxiao@temple.edu)>, [Whu@temple.edu](mailto:Whu@temple.edu) <[Whu@temple.edu](mailto:Whu@temple.edu)>, [RSun@mednet.ucla.edu](mailto:RSun@mednet.ucla.edu) <[RSun@mednet.ucla.edu](mailto:RSun@mednet.ucla.edu)>, [Guangping.Gao@umassmed.edu](mailto:Guangping.Gao@umassmed.edu) <[Guangping.Gao@umassmed.edu](mailto:Guangping.Gao@umassmed.edu)>, [PZheng@ihv.umaryland.edu](mailto:PZheng@ihv.umaryland.edu) <[PZheng@ihv.umaryland.edu](mailto:PZheng@ihv.umaryland.edu)>, [GMSWANG@nus.edu.sg](mailto:GMSWANG@nus.edu.sg) <[GMSWANG@nus.edu.sg](mailto:GMSWANG@nus.edu.sg)>, [peshi@UTMB.EDU](mailto:peshi@UTMB.EDU) <[peshi@UTMB.EDU](mailto:peshi@UTMB.EDU)>, [yaliu@ihv.umaryland.edu](mailto:yaliu@ihv.umaryland.edu) <[yaliu@ihv.umaryland.edu](mailto:yaliu@ihv.umaryland.edu)>, [ziying-yan@uiowa.edu](mailto:ziying-yan@uiowa.edu) <[ziying-yan@uiowa.edu](mailto:ziying-yan@uiowa.edu)>, [lqiao@luc.edu](mailto:lqiao@luc.edu) <[lqiao@luc.edu](mailto:lqiao@luc.edu)>, [yong.xiong@yale.edu](mailto:yong.xiong@yale.edu) <[yong.xiong@yale.edu](mailto:yong.xiong@yale.edu)>, "Wang, Qihong" <[wang.655@osu.edu](mailto:wang.655@osu.edu)>, [shuping\\_tong\\_md@brown.edu](mailto:shuping_tong_md@brown.edu) <[shuping\\_tong\\_md@brown.edu](mailto:shuping_tong_md@brown.edu)>, [pinghuif@usc.edu](mailto:pinghuif@usc.edu) <[pinghuif@usc.edu](mailto:pinghuif@usc.edu)>, [gaof@im.ac.cn](mailto:gaof@im.ac.cn) <[gaof@im.ac.cn](mailto:gaof@im.ac.cn)>

**Subject:** [EXTERNAL] Happy Thanksgiving and meeting next year, June 12-13, 2020

Dear friends and colleagues,

I wish you all a great Thanksgiving holiday!

A few updates:

1. We will have our first scientific meeting on June 12-13, 2020, right before the ASV annual meeting (June 13-17) in Fort Collins, Colorado State University. Organizing and scientific committees will be formed soon.
2. I am excited to share that Dr. Xiang-Jin (XJ) Meng of Virginia Tech, a distinguished virology and a member of the US National Academy of Science, will be the keynote speaker of this meeting. Details will follow.
3. In addition to scientific programs, we will also hold an election; a new leadership team will be elected to serve our community for the next two years.
4. Attached please find a brief report of our Kunming meeting, along with a few photos.

Please let me know if you have comments and suggestions.

All best wishes, and happy holidays!

Shan-Lu



Shan-Lu Liu, M.D., Ph.D.

Professor

Co-Director, Viruses and Emerging Pathogens Program

Infectious Diseases Institute

Center for Retrovirus Research

Departments of Veterinary Biosciences, Microbial Infection and Immunity, and Microbiology

The Ohio State University

1900 Coffey Rd, Room 480 VMAB

Columbus, Ohio 43210

Phone: (614) 292-8690

Fax: (614) 292-6473

Email: [liu.6244@osu.edu](mailto:liu.6244@osu.edu); [shan-lu.liu@osumc.edu](mailto:shan-lu.liu@osumc.edu)

--

Wenzhe Ho M.D. MPH  
Professor  
Dept. Pathology & Laboratory Medicine  
Dept. Anatomy & Cell Biology  
Temple University School of Medicine  
MERB 843  
3500 N. Broad Street  
Philadelphia, PA 19140  
Office: 215-707-8858  
Lab: 215-707-2370  
Email: [wenzheho@temple.edu](mailto:wenzheho@temple.edu)  
<https://medicine.temple.edu/wenzhe-ho>

---

**From:** Liu, Shan-Lu <liu.6244@osu.edu>  
**Sent:** Thursday, November 28, 2019 2:26 PM  
**To:** Wen-Zhe Ho; Sun, Jie, Ph.D.  
**Cc:** zhengzhiming4@gmail.com; haitguo@iupui.edu; tzhou@mail.nih.gov; GCheng@mednet.ucla.edu; liangy@umn.edu; rli@vcu.edu; wjma@ksu.edu; xjmeng@vt.edu; Zhijian.Chen@UTSouthwestern.edu; mluo@gsu.edu; zhangyj@umd.edu; xzhu1@umd.edu; jqiu@kumc.edu; lijun@uic.edu; fengwei.bai@usm.edu; andyu@iupui.edu; reachxw@vt.edu; gluo@uab.edu; ldu@nybc.org; hxu@tulane.edu; liu\_fy@berkeley.edu; shitao.li@okstate.edu; Lu, Shan; haihu@UTMB.edu; Qfeng4@central.uh.edu; tang@bio.fsu.edu; feng.li@sdstate.edu; ruilu@lsu.edu; sxiang2@unl.edu; qiyi.tang@howard.edu; dingsw@ucr.edu; guohua@missouri.edu; bling@tulane.edu; junwang@pharmacy.arizona.edu; lifang@umn.edu; wang518@umd.edu; gaos8@upmc.edu; pewang@uchc.edu; xiangy@uthscsa.edu; fzhu@bio.fsu.edu; chen.liang@mcgill.ca; lyuan@vt.edu; fgao@duke.edu; wangjw28@163.com; xfyu1@zju.edu.cn; bzhao@partners.org; jianw@muscd.edu; zyang@ksu.edu; yu.cong@nih.gov; weiming.yuan@usc.edu; Zongdi.feng@nationwidechildrens.org; juh13@psu.edu; hengx@missouri.edu; lsu@med.unc.edu; ywu8@gmu.edu; jwu@whu.edu.cn; tshuo@uic.edu; Shibojiang@fudan.edu.cn; sjiang@nybc.org; pinwang@usc.edu; rzhao@som.umaryland.edu; shuylong@mail.sysu.edu.cn; xuefeng.liu@georgetown.edu; yuxingli@som.umaryland.edu; Wang, Shixia; yhe@ipbcams.ac.cn; Pinghui.feng@usc.edu; ju-tao.guo@bblumberg.org; lin.liu@okstate.edu; hua.zhu@rutgers.edu; Jinhong.chang@bblumberg.org; jianzhu1012@gmail.com; ronghai@ucr.edu; jun.zhu@nih.gov; jliu4@uams.edu; xiangpeng.kong@med.nyu.edu; haoquanwu@outlook.com; Wenjun.liu@defence.gov.au; Liang.shan@wustl.edu; hliao@duke.edu; yuan2@upenn.edu; zxing@umn.edu; hongmin.li@health.ny.gov; pzheng@ihv.umaryland.edu; yaliu@ihv.umaryland.edu; jxw103@case.edu; xiangguo.qiu@canada.ca; Feng Shao; zlshi@wh.iov.cn; klan@whu.edu.cn; zengmsh@mail.sysu.edu.cn; Nan Yan; Zhang, Rong; liliwang@upenn.edu; Linheng Li; kli1@uthsc.edu; tsx@case.edu; ssun@mdanderson.org; ysang@tnstate.edu; wu@crystal.harvard.edu; peijun@strubi.ox.ac.uk; jiayu@coh.org; bchen@crystal.harvard.edu; Wen, Haitao; Qu, Feng; Hezhao.Ji@umanitoba.ca; Li, Zihai; zhengyo@msu.edu; zhanglinqi@tsinghua.edu.cn; wxiao@temple.edu; Whu@temple.edu; RSun@mednet.ucla.edu; Gao, Guangping; GMSWANG@nus.edu.sg; peshi@UTMB.EDU; ziyang-yan@uiowa.edu; lqiao@luc.edu; yong.xiong@yale.edu; Wang, Qihong; shuping\_tong\_md@brown.edu; pinghuif@usc.edu; gaof@im.ac.cn  
**Subject:** Re: [EXTERNAL] Happy Thanksgiving and meeting next year, June 12-13, 2020  
**Attachments:** Meeting report\_ACVA\_SCBA-virology\_Kunming.pdf; Kunming\_1.JPG; Kunming\_2.JPG

Wen-Zhe and others:

Due to the size of the attached photos, some of you may not have received them. I am now sending you individual files in two emails, and hope this time it will work.

Best.

Shan-Lu

---

**From:** Wen-Zhe Ho <wenzheho@temple.edu>  
**Date:** Thursday, November 28, 2019 at 2:16 PM  
**To:** "Sun, Jie, Ph.D." <Sun.Jie@mayo.edu>  
**Cc:** Shan-Lu Liu <liu.6244@osu.edu>, "zhengzhiming4@gmail.com" <zhengzhiming4@gmail.com>,



"haitguo@iupui.edu" <haitguo@iupui.edu>, "tzhou@mail.nih.gov" <tzhou@mail.nih.gov>,  
 "GCheng@mednet.ucla.edu" <GCheng@mednet.ucla.edu>, "liangy@umn.edu" <liangy@umn.edu>,  
 "rli@vcu.edu" <rli@vcu.edu>, "wjma@ksu.edu" <wjma@ksu.edu>, "xjmeng@vt.edu" <xjmeng@vt.edu>,  
 Zhijian Chen <Zhijian.Chen@utsouthwestern.edu>, "mluo@gsu.edu" <mluo@gsu.edu>, "zhangyj@umd.edu"  
 <zhangyj@umd.edu>, "xzhu1@umd.edu" <xzhu1@umd.edu>, Jianming Qiu <jqiu@kumc.edu>,  
 "lijun@uic.edu" <lijun@uic.edu>, "fengwei.bai@usm.edu" <fengwei.bai@usm.edu>, "andyu@iupui.edu"  
 <andyu@iupui.edu>, "reachxw@vt.edu" <reachxw@vt.edu>, "gluo@uab.edu" <gluo@uab.edu>,  
 "ldu@nybc.org" <ldu@nybc.org>, "hxu@tulane.edu" <hxu@tulane.edu>, "liu\_fy@berkeley.edu"  
 <liu\_fy@berkeley.edu>, "shitao.li@okstate.edu" <shitao.li@okstate.edu>, "Shan.lu@umassmed.edu"  
 <Shan.lu@umassmed.edu>, "haihu@UTMB.edu" <haihu@utmb.edu>, "Qfeng4@central.uh.edu"  
 <Qfeng4@central.uh.edu>, "tang@bio.fsu.edu" <tang@bio.fsu.edu>, "feng.li@sdsstate.edu"  
 <feng.li@sdsstate.edu>, "ruilu@lsu.edu" <ruilu@lsu.edu>, Shi-Hua Xiang <sxiang2@unl.edu>,  
 "qiyi.tang@howard.edu" <qiyi.tang@howard.edu>, "dingsw@ucr.edu" <dingsw@ucr.edu>,  
 "guohua@missouri.edu" <guohua@missouri.edu>, "bling@tulane.edu" <bling@tulane.edu>,  
 "junwang@pharmacy.arizona.edu" <junwang@pharmacy.arizona.edu>, "lifang@umn.edu"  
 <lifang@umn.edu>, "wang518@umd.edu" <wang518@umd.edu>, "gaos8@upmc.edu" <gaos8@upmc.edu>,  
 "pewang@uchc.edu" <pewang@uchc.edu>, "xiangy@uthscsa.edu" <xiangy@uthscsa.edu>,  
 "fzhu@bio.fsu.edu" <fzhu@bio.fsu.edu>, chen liang <chen.liang@mccgill.ca>, "lyuan@vt.edu" <lyuan@vt.edu>,  
 "fgao@duke.edu" <fgao@duke.edu>, "wangjw28@163.com" <wangjw28@163.com>, "xfyu1@zju.edu.cn"  
 <xfyu1@zju.edu.cn>, "bzhao@partners.org" <bzhao@partners.org>, "jianw@musc.edu" <jianw@musc.edu>,  
 "zyang@ksu.edu" <zyang@ksu.edu>, "yu.cong@nih.gov" <yu.cong@nih.gov>, "weiming.yuan@usc.edu"  
 <weiming.yuan@usc.edu>, "Zongdi.feng@nationwidechildrens.org" <Zongdi.feng@nationwidechildrens.org>,  
 Jianming Hu <juh13@psu.edu>, "hengx@missouri.edu" <hengx@missouri.edu>, "lsu@med.unc.edu"  
 <lsu@med.unc.edu>, "ywu8@gmu.edu" <ywu8@gmu.edu>, "jwu@whu.edu.cn" <jwu@whu.edu.cn>,  
 "tshuo@uic.edu" <tshuo@uic.edu>, Jiang Shibo <Shibojiang@fudan.edu.cn>, "sjiang@nybc.org"  
 <sjiang@nybc.org>, "pinwang@usc.edu" <pinwang@usc.edu>, "rzhao@som.umaryland.edu"  
 <rzhao@som.umaryland.edu>, "shuylong@mail.sysu.edu.cn" <shuylong@mail.sysu.edu.cn>,  
 "xuefeng.liu@georgetown.edu" <xuefeng.liu@georgetown.edu>, "yuxingli@som.umaryland.edu"  
 <yuxingli@som.umaryland.edu>, "shixia.wang@umassmed.edu" <shixia.wang@umassmed.edu>,  
 "yhe@ipbcams.ac.cn" <yhe@ipbcams.ac.cn>, "Pinghui.feng@usc.edu" <Pinghui.feng@usc.edu>, "ju-  
 tao.guo@bblumberg.org" <ju-tao.guo@bblumberg.org>, "lin.liu@okstate.edu" <lin.liu@okstate.edu>,  
 "hua.zhu@rutgers.edu" <hua.zhu@rutgers.edu>, "Jinhong.chang@bblumberg.org"  
 <Jinhong.chang@bblumberg.org>, "jianzhu1012@gmail.com" <jianzhu1012@gmail.com>, "ronghai@ucr.edu"  
 <ronghai@ucr.edu>, "jun.zhu@nih.gov" <jun.zhu@nih.gov>, "jliu4@uams.edu" <jliu4@uams.edu>,  
 "xiangpeng.kong@med.nyu.edu" <xiangpeng.kong@med.nyu.edu>, "haoquanwu@outlook.com"  
 <haoquanwu@outlook.com>, Jenna Liu <Wenjun.liu@defence.gov.au>, "Liang.shan@wustl.edu"  
 <Liang.shan@wustl.edu>, "hliao@duke.edu" <hliao@duke.edu>, "yuan2@upenn.edu" <yuan2@upenn.edu>,  
 Zheng Xing <zxing@umn.edu>, "hongmin.li@health.ny.gov" <hongmin.li@health.ny.gov>,  
 "pzheng@ihv.umaryland.edu" <pzheng@ihv.umaryland.edu>, "yaliu@ihv.umaryland.edu"  
 <yaliu@ihv.umaryland.edu>, "jxw103@case.edu" <jxw103@case.edu>, "xiangguo.qiu@canada.ca"  
 <xiangguo.qiu@canada.ca>, Feng Shao <shaofeng@nibs.ac.cn>, 石正丽 <zlshi@wh.iov.cn>,  
 "klan@whu.edu.cn" <klan@whu.edu.cn>, "zengmsh@mail.sysu.edu.cn" <zengmsh@mail.sysu.edu.cn>, Nan  
 Yan <Nan.Yan@utsouthwestern.edu>, "Zhang, Rong" <rongzhang@wustl.edu>, "liliwang@upenn.edu"  
 <liliwang@upenn.edu>, Linheng Li <LIL@stowers.org>, "kli1@uthsc.edu" <kli1@uthsc.edu>, "tsx@case.edu"  
 <tsx@case.edu>, "ssun@mdanderson.org" <ssun@mdanderson.org>, "ysang@tnstate.edu"  
 <ysang@tnstate.edu>, "wu@crystal.harvard.edu" <wu@crystal.harvard.edu>, "peijun@strubi.ox.ac.uk"  
 <peijun@strubi.ox.ac.uk>, "jiayu@coh.org" <jiayu@coh.org>, "bchen@crystal.harvard.edu"

<bchen@crystal.harvard.edu>, "Wen, Haitao" <Haitao.Wen@osumc.edu>, "Qu, Feng" <qu.28@osu.edu>, "Hezhao.Ji@umanitoba.ca" <Hezhao.Ji@umanitoba.ca>, "Li, Zihai" <zihai@musc.edu>, "zhengyo@msu.edu" <zhengyo@msu.edu>, "zhanglinqi@tsinghua.edu.cn" <zhanglinqi@tsinghua.edu.cn>, "wxiao@temple.edu" <wxiao@temple.edu>, "Whu@temple.edu" <Whu@temple.edu>, "RSun@mednet.ucla.edu" <RSun@mednet.ucla.edu>, "Guangping.Gao@umassmed.edu" <Guangping.Gao@umassmed.edu>, "GMSWANG@nus.edu.sg" <GMSWANG@nus.edu.sg>, "peshi@UTMB.EDU" <peshi@utmb.edu>, "ziying-yan@uiowa.edu" <ziying-yan@uiowa.edu>, "lqiao@luc.edu" <lqiao@luc.edu>, Yong Xiong <yong.xiong@yale.edu>, "Wang, QiuHong" <wang.655@osu.edu>, "shuping\_tong\_md@brown.edu" <shuping\_tong\_md@brown.edu>, "pinghuif@usc.edu" <pinghuif@usc.edu>, "gaof@im.ac.cn" <gaof@im.ac.cn>

**Subject:** Re: [EXTERNAL] Happy Thanksgiving and meeting next year, June 12-13, 2020

Hi, Shan-Lu, Thank you for the information. I did not see the attachment

Wenzhe

On Thu, Nov 28, 2019 at 9:37 AM Sun, Jie, Ph.D. <[Sun.Jie@mayo.edu](mailto:Sun.Jie@mayo.edu)> wrote:

Thanks for sharing. Happy Thanksgiving to everyone!

Best wishes,

Jie

Jie Sun, Ph.D.

Associate Professor

Department of Medicine

Department of Immunology

Mayo Clinic

Stabile 8-26

200 1st St SW

Rochester, MN 55905

Tel: 507-284-9503

Email: [Sun.Jie@mayo.edu](mailto:Sun.Jie@mayo.edu)

<http://www.mayo.edu/research/faculty/sun-jie-ph-d/bio-20348662>

---

**From:** "Liu, Shan-Lu" <[liu.6244@osu.edu](mailto:liu.6244@osu.edu)>

**Date:** Thursday, November 28, 2019 at 10:54 AM

**To:** "[zhengzhiming4@gmail.com](mailto:zhengzhiming4@gmail.com)" <[zhengzhiming4@gmail.com](mailto:zhengzhiming4@gmail.com)>, "[haitguo@iupui.edu](mailto:haitguo@iupui.edu)" <[haitguo@iupui.edu](mailto:haitguo@iupui.edu)>, "[tzhou@mail.nih.gov](mailto:tzhou@mail.nih.gov)" <[tzhou@mail.nih.gov](mailto:tzhou@mail.nih.gov)>, "[GCheng@mednet.ucla.edu](mailto:GCheng@mednet.ucla.edu)" <[GCheng@mednet.ucla.edu](mailto:GCheng@mednet.ucla.edu)>, "[liangy@umn.edu](mailto:liangy@umn.edu)" <[liangy@umn.edu](mailto:liangy@umn.edu)>, "[rli@vcu.edu](mailto:rli@vcu.edu)" <[rli@vcu.edu](mailto:rli@vcu.edu)>, "[wjma@ksu.edu](mailto:wjma@ksu.edu)" <[wjma@ksu.edu](mailto:wjma@ksu.edu)>, "[xjmeng@vt.edu](mailto:xjmeng@vt.edu)" <[xjmeng@vt.edu](mailto:xjmeng@vt.edu)>, "Zhijian.Chen@UTSouthwestern.edu" <[Zhijian.Chen@UTSouthwestern.edu](mailto:Zhijian.Chen@UTSouthwestern.edu)>, "[mluo@gsu.edu](mailto:mluo@gsu.edu)" <[mluo@gsu.edu](mailto:mluo@gsu.edu)>, "[zhangyj@umd.edu](mailto:zhangyj@umd.edu)" <[zhangyj@umd.edu](mailto:zhangyj@umd.edu)>, "[xzhu1@umd.edu](mailto:xzhu1@umd.edu)" <[xzhu1@umd.edu](mailto:xzhu1@umd.edu)>, "[jqu@kumc.edu](mailto:jqu@kumc.edu)" <[jqu@kumc.edu](mailto:jqu@kumc.edu)>, "[lijun@uic.edu](mailto:lijun@uic.edu)" <[lijun@uic.edu](mailto:lijun@uic.edu)>, "[fengwei.bai@usm.edu](mailto:fengwei.bai@usm.edu)" <[fengwei.bai@usm.edu](mailto:fengwei.bai@usm.edu)>, "[andyu@iupui.edu](mailto:andyu@iupui.edu)" <[andyu@iupui.edu](mailto:andyu@iupui.edu)>, "[reachxw@vt.edu](mailto:reachxw@vt.edu)" <[reachxw@vt.edu](mailto:reachxw@vt.edu)>, "[gluo@uab.edu](mailto:gluo@uab.edu)" <[gluo@uab.edu](mailto:gluo@uab.edu)>, "[ldu@nybc.org](mailto:ldu@nybc.org)" <[ldu@nybc.org](mailto:ldu@nybc.org)>, "[hxu@tulane.edu](mailto:hxu@tulane.edu)" <[hxu@tulane.edu](mailto:hxu@tulane.edu)>, "[liu\\_fy@berkeley.edu](mailto:liu_fy@berkeley.edu)" <[liu\\_fy@berkeley.edu](mailto:liu_fy@berkeley.edu)>, "[shitao.li@okstate.edu](mailto:shitao.li@okstate.edu)" <[shitao.li@okstate.edu](mailto:shitao.li@okstate.edu)>, "[Shan.lu@umassmed.edu](mailto:Shan.lu@umassmed.edu)" <[Shan.lu@umassmed.edu](mailto:Shan.lu@umassmed.edu)>, "[haihu@UTMB.edu](mailto:haihu@UTMB.edu)" <[haihu@UTMB.edu](mailto:haihu@UTMB.edu)>, "[wenzheho@temple.edu](mailto:wenzheho@temple.edu)" <[wenzheho@temple.edu](mailto:wenzheho@temple.edu)>, "[Qfeng4@central.uh.edu](mailto:Qfeng4@central.uh.edu)" <[Qfeng4@central.uh.edu](mailto:Qfeng4@central.uh.edu)>, "[tang@bio.fsu.edu](mailto:tang@bio.fsu.edu)" <[tang@bio.fsu.edu](mailto:tang@bio.fsu.edu)>, "[feng.li@sdsu.edu](mailto:feng.li@sdsu.edu)" <[feng.li@sdsu.edu](mailto:feng.li@sdsu.edu)>, "[ruilu@lsu.edu](mailto:ruilu@lsu.edu)" <[ruilu@lsu.edu](mailto:ruilu@lsu.edu)>, "[sxiang2@unl.edu](mailto:sxiang2@unl.edu)" <[sxiang2@unl.edu](mailto:sxiang2@unl.edu)>, "[qiyi.tang@howard.edu](mailto:qiyi.tang@howard.edu)" <[qiyi.tang@howard.edu](mailto:qiyi.tang@howard.edu)>, "[dingsw@ucr.edu](mailto:dingsw@ucr.edu)" <[dingsw@ucr.edu](mailto:dingsw@ucr.edu)>, "[guohua@missouri.edu](mailto:guohua@missouri.edu)" <[guohua@missouri.edu](mailto:guohua@missouri.edu)>, "[bling@tulane.edu](mailto:bling@tulane.edu)" <[bling@tulane.edu](mailto:bling@tulane.edu)>, "[junwang@pharmacy.arizona.edu](mailto:junwang@pharmacy.arizona.edu)" <[junwang@pharmacy.arizona.edu](mailto:junwang@pharmacy.arizona.edu)>, "[lifang@umn.edu](mailto:lifang@umn.edu)" <[lifang@umn.edu](mailto:lifang@umn.edu)>, "[wang518@umd.edu](mailto:wang518@umd.edu)" <[wang518@umd.edu](mailto:wang518@umd.edu)>, "[gaos8@upmc.edu](mailto:gaos8@upmc.edu)" <[gaos8@upmc.edu](mailto:gaos8@upmc.edu)>, "[pewang@uchc.edu](mailto:pewang@uchc.edu)" <[pewang@uchc.edu](mailto:pewang@uchc.edu)>, "[xiangy@uthscsa.edu](mailto:xiangy@uthscsa.edu)" <[xiangy@uthscsa.edu](mailto:xiangy@uthscsa.edu)>, "[fzhu@bio.fsu.edu](mailto:fzhu@bio.fsu.edu)" <[fzhu@bio.fsu.edu](mailto:fzhu@bio.fsu.edu)>, "[chen.liang@mcgill.ca](mailto:chen.liang@mcgill.ca)" <[chen.liang@mcgill.ca](mailto:chen.liang@mcgill.ca)>, "[lyuan@vt.edu](mailto:lyuan@vt.edu)" <[lyuan@vt.edu](mailto:lyuan@vt.edu)>, "[fgao@duke.edu](mailto:fgao@duke.edu)" <[fgao@duke.edu](mailto:fgao@duke.edu)>, "[wangjw28@163.com](mailto:wangjw28@163.com)" <[wangjw28@163.com](mailto:wangjw28@163.com)>, "[xfyu1@zju.edu.cn](mailto:xfyu1@zju.edu.cn)" <[xfyu1@zju.edu.cn](mailto:xfyu1@zju.edu.cn)>, "[bzhao@partners.org](mailto:bzhao@partners.org)" <[bzhao@partners.org](mailto:bzhao@partners.org)>, "[jianw@musc.edu](mailto:jianw@musc.edu)" <[jianw@musc.edu](mailto:jianw@musc.edu)>, "[zyang@ksu.edu](mailto:zyang@ksu.edu)" <[zyang@ksu.edu](mailto:zyang@ksu.edu)>, "[yu.cong@nih.gov](mailto:yu.cong@nih.gov)" <[yu.cong@nih.gov](mailto:yu.cong@nih.gov)>, "[weiming.yuan@usc.edu](mailto:weiming.yuan@usc.edu)" <[weiming.yuan@usc.edu](mailto:weiming.yuan@usc.edu)>, "[Zongdi.feng@nationwidechildrens.org](mailto:Zongdi.feng@nationwidechildrens.org)" <[Zongdi.feng@nationwidechildrens.org](mailto:Zongdi.feng@nationwidechildrens.org)>, "[juh13@psu.edu](mailto:juh13@psu.edu)" <[juh13@psu.edu](mailto:juh13@psu.edu)>, "[hengx@missouri.edu](mailto:hengx@missouri.edu)" <[hengx@missouri.edu](mailto:hengx@missouri.edu)>, "[lsu@med.unc.edu](mailto:lsu@med.unc.edu)" <[lsu@med.unc.edu](mailto:lsu@med.unc.edu)>, "[ywu8@gmu.edu](mailto:ywu8@gmu.edu)" <[ywu8@gmu.edu](mailto:ywu8@gmu.edu)>, "[jwu@whu.edu.cn](mailto:jwu@whu.edu.cn)" <[jwu@whu.edu.cn](mailto:jwu@whu.edu.cn)>, "[tshuo@uic.edu](mailto:tshuo@uic.edu)" <[tshuo@uic.edu](mailto:tshuo@uic.edu)>, "[Shibojiang@fudan.edu.cn](mailto:Shibojiang@fudan.edu.cn)" <[Shibojiang@fudan.edu.cn](mailto:Shibojiang@fudan.edu.cn)>, "[sjiang@nybc.org](mailto:sjiang@nybc.org)" <[sjiang@nybc.org](mailto:sjiang@nybc.org)>, "[pinwang@usc.edu](mailto:pinwang@usc.edu)" <[pinwang@usc.edu](mailto:pinwang@usc.edu)>, "[rzhao@som.umaryland.edu](mailto:rzhao@som.umaryland.edu)" <[rzhao@som.umaryland.edu](mailto:rzhao@som.umaryland.edu)>, "[shuylong@mail.sysu.edu.cn](mailto:shuylong@mail.sysu.edu.cn)" <[shuylong@mail.sysu.edu.cn](mailto:shuylong@mail.sysu.edu.cn)>, "[xuefeng.liu@georgetown.edu](mailto:xuefeng.liu@georgetown.edu)" <[xuefeng.liu@georgetown.edu](mailto:xuefeng.liu@georgetown.edu)>, "[yuxingli@som.umaryland.edu](mailto:yuxingli@som.umaryland.edu)" <[yuxingli@som.umaryland.edu](mailto:yuxingli@som.umaryland.edu)>, "[shixia.wang@umassmed.edu](mailto:shixia.wang@umassmed.edu)" <[shixia.wang@umassmed.edu](mailto:shixia.wang@umassmed.edu)>, "[yhe@ipbcams.ac.cn](mailto:yhe@ipbcams.ac.cn)" <[yhe@ipbcams.ac.cn](mailto:yhe@ipbcams.ac.cn)>, "[Pinghui.feng@usc.edu](mailto:Pinghui.feng@usc.edu)" <[Pinghui.feng@usc.edu](mailto:Pinghui.feng@usc.edu)>, "[ju-tao.guo@bblumberg.org](mailto:ju-tao.guo@bblumberg.org)" <[ju-tao.guo@bblumberg.org](mailto:ju-tao.guo@bblumberg.org)>, "[lin.liu@okstate.edu](mailto:lin.liu@okstate.edu)" <[lin.liu@okstate.edu](mailto:lin.liu@okstate.edu)>, "[hua.zhu@rutgers.edu](mailto:hua.zhu@rutgers.edu)" <[hua.zhu@rutgers.edu](mailto:hua.zhu@rutgers.edu)>, "[Jinhong.chang@bblumberg.org](mailto:Jinhong.chang@bblumberg.org)" <[Jinhong.chang@bblumberg.org](mailto:Jinhong.chang@bblumberg.org)>, "[jianzhu1012@gmail.com](mailto:jianzhu1012@gmail.com)" <[jianzhu1012@gmail.com](mailto:jianzhu1012@gmail.com)>, "[ronghai@ucr.edu](mailto:ronghai@ucr.edu)" <[ronghai@ucr.edu](mailto:ronghai@ucr.edu)>, "[jun.zhu@nih.gov](mailto:jun.zhu@nih.gov)" <[jun.zhu@nih.gov](mailto:jun.zhu@nih.gov)>, "[jliu4@uams.edu](mailto:jliu4@uams.edu)" <[jliu4@uams.edu](mailto:jliu4@uams.edu)>, "[xiangpeng.kong@med.nyu.edu](mailto:xiangpeng.kong@med.nyu.edu)" <[xiangpeng.kong@med.nyu.edu](mailto:xiangpeng.kong@med.nyu.edu)>, "[haoquanwu@outlook.com](mailto:haoquanwu@outlook.com)" <[haoquanwu@outlook.com](mailto:haoquanwu@outlook.com)>, "[Wenjun.liu@defence.gov.au](mailto:Wenjun.liu@defence.gov.au)" <[Wenjun.liu@defence.gov.au](mailto:Wenjun.liu@defence.gov.au)>, "[Liang.shan@wustl.edu](mailto:Liang.shan@wustl.edu)" <[Liang.shan@wustl.edu](mailto:Liang.shan@wustl.edu)>, "[hliao@duke.edu](mailto:hliao@duke.edu)" <[hliao@duke.edu](mailto:hliao@duke.edu)>, "[yuan2@upenn.edu](mailto:yuan2@upenn.edu)" <[yuan2@upenn.edu](mailto:yuan2@upenn.edu)>, "[zxing@umn.edu](mailto:zxing@umn.edu)" <[zxing@umn.edu](mailto:zxing@umn.edu)>, "[hongmin.li@health.ny.gov](mailto:hongmin.li@health.ny.gov)" <[hongmin.li@health.ny.gov](mailto:hongmin.li@health.ny.gov)>, "[pzheng@ihv.umaryland.edu](mailto:pzheng@ihv.umaryland.edu)" <[pzheng@ihv.umaryland.edu](mailto:pzheng@ihv.umaryland.edu)>, "[yaliu@ihv.umaryland.edu](mailto:yaliu@ihv.umaryland.edu)" <[yaliu@ihv.umaryland.edu](mailto:yaliu@ihv.umaryland.edu)>, "[jxw103@case.edu](mailto:jxw103@case.edu)" <[jxw103@case.edu](mailto:jxw103@case.edu)>, "[xianguo.qiu@canada.ca](mailto:xianguo.qiu@canada.ca)" <[xianguo.qiu@canada.ca](mailto:xianguo.qiu@canada.ca)>, Feng Shao <[shaofeng@nibs.ac.cn](mailto:shaofeng@nibs.ac.cn)>, "[zshi@wh.iov.cn](mailto:zshi@wh.iov.cn)" <[zshi@wh.iov.cn](mailto:zshi@wh.iov.cn)>, "[kian@whu.edu.cn](mailto:kian@whu.edu.cn)" <[kian@whu.edu.cn](mailto:kian@whu.edu.cn)>, "[zengmsh@mail.sysu.edu.cn](mailto:zengmsh@mail.sysu.edu.cn)" <[zengmsh@mail.sysu.edu.cn](mailto:zengmsh@mail.sysu.edu.cn)>, Nan Yan <[Nan.Yan@UTSouthwestern.edu](mailto:Nan.Yan@UTSouthwestern.edu)>, "Zhang, Rong" <[rongzhang@wustl.edu](mailto:rongzhang@wustl.edu)>, "[liliwang@upenn.edu](mailto:liliwang@upenn.edu)" <[liliwang@upenn.edu](mailto:liliwang@upenn.edu)>, Linheng Li <[LIL@stowers.org](mailto:LIL@stowers.org)>, "[kli1@uthsc.edu](mailto:kli1@uthsc.edu)" <[kli1@uthsc.edu](mailto:kli1@uthsc.edu)>, "[tsx@case.edu](mailto:tsx@case.edu)" <[tsx@case.edu](mailto:tsx@case.edu)>, "[ssun@mdanderson.org](mailto:ssun@mdanderson.org)" <[ssun@mdanderson.org](mailto:ssun@mdanderson.org)>, "[ysang@tnstate.edu](mailto:ysang@tnstate.edu)" <[ysang@tnstate.edu](mailto:ysang@tnstate.edu)>, "Liu, Shan-Lu" <[liu.6244@osu.edu](mailto:liu.6244@osu.edu)>, "[wu@crystal.harvard.edu](mailto:wu@crystal.harvard.edu)" <[wu@crystal.harvard.edu](mailto:wu@crystal.harvard.edu)>, "Sun, Jie, Ph.D." <[Sun.Jie@mayo.edu](mailto:Sun.Jie@mayo.edu)>, "[peijun@strubi.ox.ac.uk](mailto:peijun@strubi.ox.ac.uk)" <[peijun@strubi.ox.ac.uk](mailto:peijun@strubi.ox.ac.uk)>, "[jiayu@coh.org](mailto:jiayu@coh.org)"

<[jiayu@coh.org](mailto:jiayu@coh.org)>, "[bchen@crystal.harvard.edu](mailto:bchen@crystal.harvard.edu)" <[bchen@crystal.harvard.edu](mailto:bchen@crystal.harvard.edu)>, "Wen, Haitao" <[Haitao.Wen@osumc.edu](mailto:Haitao.Wen@osumc.edu)>, "Qu, Feng" <[qu.28@osu.edu](mailto:qu.28@osu.edu)>, "[Hezhao.Ji@umanitoba.ca](mailto:Hezhao.Ji@umanitoba.ca)" <[Hezhao.Ji@umanitoba.ca](mailto:Hezhao.Ji@umanitoba.ca)>, "Li, Zihai" <[zihai@muscu.edu](mailto:zihai@muscu.edu)>, "[zhengyo@msu.edu](mailto:zhengyo@msu.edu)" <[zhengyo@msu.edu](mailto:zhengyo@msu.edu)>, "[zhanglingqi@tsinghua.edu.cn](mailto:zhanglingqi@tsinghua.edu.cn)" <[zhanglingqi@tsinghua.edu.cn](mailto:zhanglingqi@tsinghua.edu.cn)>, "[wxiao@temple.edu](mailto:wxiao@temple.edu)" <[wxiao@temple.edu](mailto:wxiao@temple.edu)>, "[Whu@temple.edu](mailto:Whu@temple.edu)" <[Whu@temple.edu](mailto:Whu@temple.edu)>, "[RSun@mednet.ucla.edu](mailto:RSun@mednet.ucla.edu)" <[RSun@mednet.ucla.edu](mailto:RSun@mednet.ucla.edu)>, "[Guangping.Gao@umassmed.edu](mailto:Guangping.Gao@umassmed.edu)" <[Guangping.Gao@umassmed.edu](mailto:Guangping.Gao@umassmed.edu)>, "[PZheng@ihv.umaryland.edu](mailto:PZheng@ihv.umaryland.edu)" <[PZheng@ihv.umaryland.edu](mailto:PZheng@ihv.umaryland.edu)>, "[GMSWANG@nus.edu.sg](mailto:GMSWANG@nus.edu.sg)" <[GMSWANG@nus.edu.sg](mailto:GMSWANG@nus.edu.sg)>, "[peshi@UTMB.EDU](mailto:peshi@UTMB.EDU)" <[peshi@UTMB.EDU](mailto:peshi@UTMB.EDU)>, "[yaliu@ihv.umaryland.edu](mailto:yaliu@ihv.umaryland.edu)" <[yaliu@ihv.umaryland.edu](mailto:yaliu@ihv.umaryland.edu)>, "[ziying-yan@uiowa.edu](mailto:ziying-yan@uiowa.edu)" <[ziying-yan@uiowa.edu](mailto:ziying-yan@uiowa.edu)>, "[lqiao@luc.edu](mailto:lqiao@luc.edu)" <[lqiao@luc.edu](mailto:lqiao@luc.edu)>, "[yong.xiong@yale.edu](mailto:yong.xiong@yale.edu)" <[yong.xiong@yale.edu](mailto:yong.xiong@yale.edu)>, "Wang, QiuHong" <[wang.655@osu.edu](mailto:wang.655@osu.edu)>, "[shuping\\_tong\\_md@brown.edu](mailto:shuping_tong_md@brown.edu)" <[shuping\\_tong\\_md@brown.edu](mailto:shuping_tong_md@brown.edu)>, "[pinghuif@usc.edu](mailto:pinghuif@usc.edu)" <[pinghuif@usc.edu](mailto:pinghuif@usc.edu)>, "[gaof@im.ac.cn](mailto:gaof@im.ac.cn)" <[gaof@im.ac.cn](mailto:gaof@im.ac.cn)>

**Subject:** [EXTERNAL] Happy Thanksgiving and meeting next year, June 12-13, 2020

Dear friends and colleagues,

I wish you all a great Thanksgiving holiday!

A few updates:

1. We will have our first scientific meeting on June 12-13, 2020, right before the ASV annual meeting (June 13-17) in Fort Collins, Colorado State University. Organizing and scientific committees will be formed soon.
2. I am excited to share that Dr. Xiang-Jin (XJ) Meng of Virginia Tech, a distinguished virology and a member of the US National Academy of Science, will be the keynote speaker of this meeting. Details will follow.
3. In addition to scientific programs, we will also hold an election; a new leadership team will be elected to serve our community for the next two years.
4. Attached please find a brief report of our Kunming meeting, along with a few photos.

Please let me know if you have comments and suggestions.

All best wishes, and happy holidays!

Shan-Lu

Shan-Lu Liu, M.D., Ph.D.

Professor

Co-Director, Viruses and Emerging Pathogens Program

Infectious Diseases Institute

Center for Retrovirus Research

Departments of Veterinary Biosciences, Microbial Infection and Immunity, and Microbiology

The Ohio State University

1900 Coffey Rd, Room 480 VMAB

Columbus, Ohio 43210

Phone: (614) 292-8690

Fax: (614) 292-6473

Email: [liu.6244@osu.edu](mailto:liu.6244@osu.edu); [shan-lu.liu@osumc.edu](mailto:shan-lu.liu@osumc.edu)

--

Wenzhe Ho M.D. MPH

Professor

Dept. Pathology & Laboratory Medicine

Dept. Anatomy & Cell Biology

Temple University School of Medicine

MERB 843

3500 N. Broad Street

Philadelphia, PA 19140

Office: 215-707-8858

Lab: 215-707-2370

Email: [wenzheho@temple.edu](mailto:wenzheho@temple.edu)

<https://medicine.temple.edu/wenzhe-ho>

---

**From:** Sun, Jie, Ph.D. <Sun.Jie@mayo.edu>  
**Sent:** Thursday, November 28, 2019 12:37 PM  
**To:** Liu, Shan-Lu; zhengzhiming4@gmail.com; haitguo@iupui.edu; tzhou@mail.nih.gov; GCheng@mednet.ucla.edu; liangy@umn.edu; rli@vcu.edu; wjma@ksu.edu; xjmeng@vt.edu; Zhijian.Chen@UTSouthwestern.edu; mluo@gsu.edu; zhangyj@umd.edu; xzhu1@umd.edu; jqiu@kumc.edu; lijun@uic.edu; fengwei.bai@usm.edu; andyu@iupui.edu; reachxw@vt.edu; gluo@uab.edu; ldu@nybc.org; hxu@tulane.edu; liu\_fy@berkeley.edu; shitao.li@okstate.edu; Lu, Shan; haihu@UTMB.edu; wenzheho@temple.edu; Qfeng4@central.uh.edu; tang@bio.fsu.edu; feng.li@sdsu.edu; ruilu@lsu.edu; sxian2@unl.edu; qiyi.tang@howard.edu; dingsw@ucr.edu; guohua@missouri.edu; bling@tulane.edu; junwang@pharmacy.arizona.edu; lifang@umn.edu; wang518@umd.edu; gaos8@upmc.edu; pewang@uchc.edu; xiangy@uthscsa.edu; fzhz@bio.fsu.edu; chen.liang@mcgill.ca; lyuan@vt.edu; fgao@duke.edu; wangjw28@163.com; xfyu1@zju.edu.cn; bzhao@partners.org; jianw@muscu.edu; zyang@ksu.edu; yu.cong@nih.gov; weiming.yuan@usc.edu; Zongdi.feng@nationwidechildrens.org; juh13@psu.edu; hengx@missouri.edu; lsu@med.unc.edu; ywu8@gmu.edu; jwu@whu.edu.cn; tshuo@uic.edu; Shibojian@fudan.edu.cn; sjian@nybc.org; pinwang@usc.edu; rzhaoh@som.umaryland.edu; shuylong@mail.sysu.edu.cn; xuefeng.liu@georgetown.edu; yuxingli@som.umaryland.edu; Wang, Shixia; yhe@ipbcams.ac.cn; Pinghui.feng@usc.edu; ju-tao.guo@bblumberg.org; lin.liu@okstate.edu; hua.zhu@rutgers.edu; Jinhong.chang@bblumberg.org; jianzhu1012@gmail.com; ronghai@ucr.edu; jun.zhu@nih.gov; jliu4@uams.edu; xiangpeng.kong@med.nyu.edu; haoquanwu@outlook.com; Wenjun.liu@defence.gov.au; Liang.shan@wustl.edu; hliao@duke.edu; yuan2@upenn.edu; zxing@umn.edu; hongmin.li@health.ny.gov; pzheng@ihv.umaryland.edu; yaliu@ihv.umaryland.edu; jxw103@case.edu; xiangguo.qiu@canada.ca; Feng Shao; zlshe@wh.iov.cn; klan@whu.edu.cn; zengmsh@mail.sysu.edu.cn; Nan Yan; Zhang, Rong; liliwang@upenn.edu; Linheng Li; kli1@uthsc.edu; tsx@case.edu; ssun@mdanderson.org; ysang@tnstate.edu; wu@crystal.harvard.edu; peijun@strubi.ox.ac.uk; jiaju@coh.org; bchen@crystal.harvard.edu; Wen, Haitao; Qu, Feng; Hezhao.Ji@umanitoba.ca; Li, Zihai; zhengyo@msu.edu; zhanglinqi@tsinghua.edu.cn; wxiao@temple.edu; Whu@temple.edu; RSun@mednet.ucla.edu; Gao, Guangping; PZheng@ihv.umaryland.edu; GMSWANG@nus.edu.sg; peshi@UTMB.EDU; yaliu@ihv.umaryland.edu; ziyang-yan@uiowa.edu; lqiao@luc.edu; yong.xiong@yale.edu; Wang, Qihong; shuping\_tong\_md@brown.edu; pinghuif@usc.edu; gaof@im.ac.cn  
**Subject:** Re: [EXTERNAL] Happy Thanksgiving and meeting next year, June 12-13, 2020

Thanks for sharing. Happy Thanksgiving to everyone!

Best wishes,

Jie

Jie Sun, Ph.D.  
Associate Professor  
Department of Medicine  
Department of Immunology  
Mayo Clinic  
Stabile 8-26  
200 1st St SW  
Rochester, MN 55905  
Tel: 507-284-9503  
Email: [Sun.Jie@mayo.edu](mailto:Sun.Jie@mayo.edu)  
<http://www.mayo.edu/research/faculty/sun-jie-ph-d/bio-20348662>

---

**From:** "Liu, Shan-Lu" <liu.6244@osu.edu>

**Date:** Thursday, November 28, 2019 at 10:54 AM

**To:** "zhengzhiming4@gmail.com" <zhengzhiming4@gmail.com>, "haitguo@iupui.edu" <haitguo@iupui.edu>, "tzhou@mail.nih.gov" <tzhou@mail.nih.gov>, "GCheng@mednet.ucla.edu" <GCheng@mednet.ucla.edu>, "liangy@umn.edu" <liangy@umn.edu>, "rli@vcu.edu" <rli@vcu.edu>, "wjma@ksu.edu" <wjma@ksu.edu>, "xjmeng@vt.edu" <xjmeng@vt.edu>, "Zhijian.Chen@UTSouthwestern.edu" <Zhijian.Chen@UTSouthwestern.edu>, "mluo@gsu.edu" <mluo@gsu.edu>, "zhangyj@umd.edu" <zhangyj@umd.edu>, "xzhu1@umd.edu" <xzhu1@umd.edu>, "jqiu@kumc.edu" <jqiu@kumc.edu>, "lijun@uic.edu" <lijun@uic.edu>, "fengwei.bai@usm.edu" <fengwei.bai@usm.edu>, "andyu@iupui.edu" <andyu@iupui.edu>, "reachxw@vt.edu" <reachxw@vt.edu>, "gluo@uab.edu" <gluo@uab.edu>, "ldu@nybc.org" <ldu@nybc.org>, "hxu@tulane.edu" <hxu@tulane.edu>, "liu\_fy@berkeley.edu" <liu\_fy@berkeley.edu>, "shitao.li@okstate.edu" <shitao.li@okstate.edu>, "Shan.lu@umassmed.edu" <Shan.lu@umassmed.edu>, "haihu@UTMB.edu" <haihu@UTMB.edu>, "wenzheho@temple.edu" <wenzheho@temple.edu>, "Qfeng4@central.uh.edu" <Qfeng4@central.uh.edu>, "tang@bio.fsu.edu" <tang@bio.fsu.edu>, "feng.li@sdsu.edu" <feng.li@sdsu.edu>, "ruilu@lsu.edu" <ruilu@lsu.edu>, "sxiang2@unl.edu" <sxiang2@unl.edu>, "qiyi.tang@howard.edu" <qiyi.tang@howard.edu>, "dingsw@ucr.edu" <dingsw@ucr.edu>, "guohua@missouri.edu" <guohua@missouri.edu>, "bling@tulane.edu" <bling@tulane.edu>, "junwang@pharmacy.arizona.edu" <junwang@pharmacy.arizona.edu>, "lifang@umn.edu" <lifang@umn.edu>, "wang518@umd.edu" <wang518@umd.edu>, "gaos8@upmc.edu" <gaos8@upmc.edu>, "pewang@uchc.edu" <pewang@uchc.edu>, "xiangy@uthscsa.edu" <xiangy@uthscsa.edu>, "fzhu@bio.fsu.edu" <fzhu@bio.fsu.edu>, "chen.liang@mcgill.ca" <chen.liang@mcgill.ca>, "lyuan@vt.edu" <lyuan@vt.edu>, "fgao@duke.edu" <fgao@duke.edu>, "wangjw28@163.com" <wangjw28@163.com>, "xfyu1@zju.edu.cn" <xfyu1@zju.edu.cn>, "bzhao@partners.org" <bzhao@partners.org>, "jianw@musc.edu" <jianw@musc.edu>, "zyang@ksu.edu" <zyang@ksu.edu>, "yu.cong@nih.gov" <yu.cong@nih.gov>, "weiming.yuan@usc.edu" <weiming.yuan@usc.edu>, "Zongdi.feng@nationwidechildrens.org" <Zongdi.feng@nationwidechildrens.org>, "juh13@psu.edu" <juh13@psu.edu>, "hengx@missouri.edu" <hengx@missouri.edu>, "lsu@med.unc.edu" <lsu@med.unc.edu>, "ywu8@gmu.edu" <ywu8@gmu.edu>, "jwu@whu.edu.cn" <jwu@whu.edu.cn>, "tshuo@uic.edu" <tshuo@uic.edu>, "Shibojiang@fudan.edu.cn" <Shibojiang@fudan.edu.cn>, "sjiang@nybc.org" <sjiang@nybc.org>, "pinwang@usc.edu" <pinwang@usc.edu>, "rzhao@som.umaryland.edu" <rzhao@som.umaryland.edu>, "shuylong@mail.sysu.edu.cn" <shuylong@mail.sysu.edu.cn>, "xuefeng.liu@georgetown.edu" <xuefeng.liu@georgetown.edu>, "yuxingli@som.umaryland.edu" <yuxingli@som.umaryland.edu>, "shixia.wang@umassmed.edu" <shixia.wang@umassmed.edu>, "yhe@ipbcams.ac.cn" <yhe@ipbcams.ac.cn>, "Pinghui.feng@usc.edu" <Pinghui.feng@usc.edu>, "ju-tao.guo@bblumberg.org" <ju-tao.guo@bblumberg.org>, "lin.liu@okstate.edu" <lin.liu@okstate.edu>, "hua.zhu@rutgers.edu" <hua.zhu@rutgers.edu>, "Jinhong.chang@bblumberg.org" <Jinhong.chang@bblumberg.org>, "jianzhu1012@gmail.com" <jianzhu1012@gmail.com>, "ronghai@ucr.edu" <ronghai@ucr.edu>, "jun.zhu@nih.gov" <jun.zhu@nih.gov>, "jliu4@uams.edu" <jliu4@uams.edu>, "xiangpeng.kong@med.nyu.edu" <xiangpeng.kong@med.nyu.edu>, "haoquanwu@outlook.com" <haoquanwu@outlook.com>, "Wenjun.liu@defence.gov.au" <Wenjun.liu@defence.gov.au>, "Liang.shan@wustl.edu" <Liang.shan@wustl.edu>, "hliao@duke.edu" <hliao@duke.edu>, "yuan2@upenn.edu" <yuan2@upenn.edu>, "zxing@umn.edu" <zxing@umn.edu>, "hongmin.li@health.ny.gov" <hongmin.li@health.ny.gov>, "pzheng@ihv.umaryland.edu" <pzheng@ihv.umaryland.edu>, "yalu@ihv.umaryland.edu" <yalu@ihv.umaryland.edu>, "jxw103@case.edu" <jxw103@case.edu>, "xiangguo.qiu@canada.ca" <xiangguo.qiu@canada.ca>, Feng Shao <shaofeng@nibs.ac.cn>, "zlshi@wh.iov.cn" <zlshi@wh.iov.cn>, "klan@whu.edu.cn" <klan@whu.edu.cn>,



"zengmsh@mail.sysu.edu.cn" <zengmsh@mail.sysu.edu.cn>, Nan Yan <Nan.Yan@UTSouthwestern.edu>, "Zhang, Rong" <rongzhang@wustl.edu>, "liliwang@upenn.edu" <liliwang@upenn.edu>, Linheng Li <LIL@stowers.org>, "kli1@uthsc.edu" <kli1@uthsc.edu>, "tsx@case.edu" <tsx@case.edu>, "ssun@mdanderson.org" <ssun@mdanderson.org>, "ysang@tnstate.edu" <ysang@tnstate.edu>, "Liu, Shan-Lu" <liu.6244@osu.edu>, "wu@crystal.harvard.edu" <wu@crystal.harvard.edu>, "Sun, Jie, Ph.D." <Sun.Jie@mayo.edu>, "peijun@strubi.ox.ac.uk" <peijun@strubi.ox.ac.uk>, "jiayu@coh.org" <jiayu@coh.org>, "bchen@crystal.harvard.edu" <bchen@crystal.harvard.edu>, "Wen, Haitao" <Haitao.Wen@osumc.edu>, "Qu, Feng" <qu.28@osu.edu>, "Hezhao.Ji@umanitoba.ca" <Hezhao.Ji@umanitoba.ca>, "Li, Zihai" <zihai@muscu.edu>, "zhenggyo@msu.edu" <zhenggyo@msu.edu>, "zhanglinqi@tsinghua.edu.cn" <zhanglinqi@tsinghua.edu.cn>, "wxiao@temple.edu" <wxiao@temple.edu>, "Whu@temple.edu" <Whu@temple.edu>, "RSun@mednet.ucla.edu" <RSun@mednet.ucla.edu>, "Guangping.Gao@umassmed.edu" <Guangping.Gao@umassmed.edu>, "PZheng@ihv.umaryland.edu" <PZheng@ihv.umaryland.edu>, "GMSWANG@nus.edu.sg" <GMSWANG@nus.edu.sg>, "peshi@UTMB.EDU" <peshi@UTMB.EDU>, "yaliu@ihv.umaryland.edu" <yaliu@ihv.umaryland.edu>, "ziying-yan@uiowa.edu" <ziying-yan@uiowa.edu>, "lqiao@luc.edu" <lqiao@luc.edu>, "yong.xiong@yale.edu" <yong.xiong@yale.edu>, "Wang, Qihong" <wang.655@osu.edu>, "shuping\_tong\_md@brown.edu" <shuping\_tong\_md@brown.edu>, "pinghuif@usc.edu" <pinghuif@usc.edu>, "gaof@im.ac.cn" <gaof@im.ac.cn>

**Subject:** [EXTERNAL] Happy Thanksgiving and meeting next year, June 12-13, 2020

Dear friends and colleagues,

I wish you all a great Thanksgiving holiday!

A few updates:

1. We will have our first scientific meeting on June 12-13, 2020, right before the ASV annual meeting (June 13-17) in Fort Collins, Colorado State University. Organizing and scientific committees will be formed soon.
2. I am excited to share that Dr. Xiang-Jin (XJ) Meng of Virginia Tech, a distinguished virology and a member of the US National Academy of Science, will be the keynote speaker of this meeting. Details will follow.
3. In addition to scientific programs, we will also hold an election; a new leadership team will be elected to serve our community for the next two years.
4. Attached please find a brief report of our Kunming meeting, along with a few photos.

Please let me know if you have comments and suggestions.

All best wishes, and happy holidays!

Shan-Lu



Shan-Lu Liu, M.D., Ph.D.

Professor

Co-Director, Viruses and Emerging Pathogens Program

Infectious Diseases Institute

Center for Retrovirus Research

Departments of Veterinary Biosciences, Microbial Infection and Immunity, and Microbiology

The Ohio State University



1900 Coffey Rd, Room 480 VMAB  
Columbus, Ohio 43210  
Phone: (614) 292-8690  
Fax: (614) 292-6473  
Email: [liu.6244@osu.edu](mailto:liu.6244@osu.edu); [shan-lu.liu@osumc.edu](mailto:shan-lu.liu@osumc.edu)

---

**From:** Ahmed, Rafi <rahmed@emory.edu>  
**Sent:** Saturday, August 31, 2019 11:55 PM  
**To:** wen yumei; george wang; Wang, Hua; wangmw; Wen Danyi; Yi Ning; Nan-ping Weng; antonio\_bertoletti; lowried; stephen.locarnini; ricec  
**Cc:** Lu, Shan; shan.lu  
**Subject:** RE: [External] message

Thanks, Yu-Mei. Will do.

Hope you are doing well.

Best,

Rafi

-----Original Message-----

From: wen yumei [mailto:ymwen@shmu.edu.cn]

Sent: Saturday, August 31, 2019 10:01 PM

To: george wang <wanggeorge@yahoo.com>; Wang, Hua <wang.707@osu.edu>; wangmw <wangmw@mail.shcnc.ac.cn>; Wen Danyi <danyi.wen@lidebiotech.com>; Yi Ning <yining5@jhmi.edu>; Nan-ping Weng <wnp2060@gmail.com>; antonio\_bertoletti <antonio\_bertoletti@sics.a-star.edu.sg>; lowried <lowried@fudan.edu.cn>; stephen.locarnini <stephen.locarnini@mh.org.au>; ricec <ricec@mail.rockefeller.edu>; Ahmed, Rafi <rahmed@emory.edu>

Cc: shan.lu@umassmed.edu; [https://urldefense.proofpoint.com/v2/url?u=http-3A\\_\\_shan.lu&d=DwlGaQ&c=WJBj9sUF1mbpVIAf3biu3CPHX4MeRjY\\_w4DerPIOmhQ&r=hZDMww3K9O7rzy3q4N\\_MarCa-e8TYh2O7LAAQeN9Bdk&m=Eavlyb5VI5V5diJWrS0Rg7pR-Vfq1VGuB9p8i4r\\_GEY&s=hI5P694ah6qtXIT3MKiJsfQPfk-Qj63GYBAGCz7\\_-hs&e=<shan.lu@emi2012.org>](https://urldefense.proofpoint.com/v2/url?u=http-3A__shan.lu&d=DwlGaQ&c=WJBj9sUF1mbpVIAf3biu3CPHX4MeRjY_w4DerPIOmhQ&r=hZDMww3K9O7rzy3q4N_MarCa-e8TYh2O7LAAQeN9Bdk&m=Eavlyb5VI5V5diJWrS0Rg7pR-Vfq1VGuB9p8i4r_GEY&s=hI5P694ah6qtXIT3MKiJsfQPfk-Qj63GYBAGCz7_-hs&e=<shan.lu@emi2012.org>)

Subject: [External] message

Dear All:

Emerging microbes and infections ( journal, IF 6.2, 2018) is looking for a senior editor. Please distribute this information in your circle, and help to send us information for candidates. Regards. Yu-mei Wen

---

This e-mail message (including any attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this message (including any attachments) is strictly prohibited.

If you have received this message in error, please contact the sender by reply e-mail message and destroy all copies of the original message (including attachments).

---

**From:** Josaphouitch, Alexa <Alexa.Josaphouitch@taylorandfrancis.com>  
**Sent:** Tuesday, February 23, 2021 2:31 PM  
**To:** Liu.6244@osu.edu; lsu@med.unc.edu  
**Cc:** editorial@emi2012.org; Lu, Shan <Shan.Lu@umassmed.edu>; M. Yu-Mei Wen (ymwen@shmu.edu.cn) <ymwen@shmu.edu.cn>; 'Min Yang' <min.yang@emi2012.org>  
**Subject:** EMI's 2020 Best Paper Award - Third Place

Dear Shan-Lu Liu, Linda J. Saif, Susan R. Weiss & Lishan Su,

On behalf of Editors-in-Chief, Yu-Mei Wen and Shan Lu, EMI and Taylor & Francis, we would like to congratulate you on winning third place for *Emerging Microbes & Infections* 2020 Best Papers Award for the paper entitled, "No credible evidence supporting claims of the laboratory engineering of SARS-CoV-2."

EMI made this decision based on the fact that your paper provided scientific analysis to reject the theory that SARS-CoV-2 is a laboratory engineered virus.

In addition to the attached certificate, a link on the journal's homepage will be included to [celebrate the news](#). The third-place winner also receives 250 USD. Please contact Alexa Josaphouitch, [alexa.jo@taylorandfrancis.com](mailto:alexa.jo@taylorandfrancis.com), for more details about the monetary award.

Thank you and congratulations on your achievement!

Sincerely,

**Alexa Josaphouitch**

Portfolio Manager for Hematology and Immunology Journals

Taylor & Francis Group

530 Walnut Street, Suite 850, Philadelphia, PA 19106


Tel: (212) 600-3459

Fax: (215) 207-0050

Email: [alexa.josaphouitch@taylorandfrancis.com](mailto:alexa.josaphouitch@taylorandfrancis.com)

Web: [www.tandfonline.com](http://www.tandfonline.com)

(she/her/hers)



Information Classification: General

---

**From:** "Bergan, Rachel" <[Rachel.Bergan@tandf.co.uk](mailto:Rachel.Bergan@tandf.co.uk)>  
**Date:** Thursday, October 22, 2020 at 4:59 AM  
**To:** "Liu, Shan-Lu" <[liu.6244@osu.edu](mailto:liu.6244@osu.edu)>  
**Subject:** Your paper features in T&F's top ten OA articles of 2020

Dear Shan-Lu,

I'm very pleased to let you know that your recent article "No credible evidence supporting claims of the laboratory engineering of SARS-CoV-2" was one of the most-downloaded open access articles published by Taylor & Francis so far this year.

Many congratulations!

To mark Open Access Week, we have published [a blog post on our Author Services website](#) about the Top 10, including links to the articles, and details of each Altmetric score to reflect the discussion of your article online and in the media.

**This is a great excuse to further highlight your research to your contacts and communities.** We will be promoting the blog post on our social media platforms: [Twitter](#), [LinkedIn](#), and [Facebook](#). You could share our posts/tweets or write your own (please use the same hashtags).

We'll also be featuring the Top 10 in our [Insights newsletter](#), to further reach researchers and the wider academic community.

Please do not hesitate to contact me if you have any further questions or queries.

Kind Regards,  
Rachel

Rachel Bergan (she/her)  
Communications Coordinator  
Taylor & Francis Group

Email: [rachel.bergan@tandf.co.uk](mailto:rachel.bergan@tandf.co.uk)  
Tel: +44 (0) 20 755 19259  
4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN, UK



**4 skills for  
researchers  
of the future**



Rachel Bergan (she/her)  
Communications Coordinator  
Taylor & Francis Group

Email: [rachel.bergan@tandf.co.uk](mailto:rachel.bergan@tandf.co.uk)

Tel: +44 (0) 20 755 19259

4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN, UK



## 4 skills for researchers of the future



Information Classification: General

---

**From:** antonin.bal@chu-lyon.fr  
**Sent:** Thursday, September 17, 2020 12:10 AM  
**To:** ymw@shmu.edu.cn; Lu, Shan; yiweitangmd@gmail.com  
**Cc:** editorial@emi2012.org; laurence.josset@chu-lyon.fr; bruno.lina@chu-lyon.fr; gregory.queromes@univ-lyon1.fr; gregory.destras@chu-lyon.fr; antonin.bal@chu-lyon.fr  
**Subject:** RE: [SPAM] Re: Pre-submission inquiry\_Characterization of newly SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster

Thank you very much for your response.

The manuscript has been submitted (Manuscript ID TEMI-2020-1518). We are looking forward to hearing from you.

Best regards,

Laurence Josset, PharmD PhD  
Research Assistant Professor  
National reference center for respiratory viruses (Pr. Bruno Lina)  
University hospital of Lyon, France

---

**De :** wen yumei <ymw@shmu.edu.cn>  
**Envoyé :** mardi 15 septembre 2020 02:06:54  
**À :** BAL, Antonin; shan.lu@umassmed.edu; YiWei Tang  
**Cc :** editorial@emi2012.org; JOSSET, Laurence; LINA, Bruno; gregory.queromes@univ-lyon1.fr; DESTRAS, Gregory  
**Objet :** [SPAM] Re: Pre-submission inquiry\_Characterization of newly SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster

Laurence Josset, PharmD PhD

Thank you for your mail. After discussion with Prof. Shan Lu, co-editor-in-chief, we welcome you to submit your article through EMI website: [www.tandfonline.com/TEMI](http://www.tandfonline.com/TEMI) . However, there are many submissions to EMI, your submission will be evaluated through a strict review system, and this letter does not mean acceptance. Regards, Yu-mei Wen

-----Original Messages-----

**From:** antonin.bal@chu-lyon.fr  
**Sent Time:** 2020-09-14 17:05:58 (Monday)  
**To:** ymw@shmu.edu.cn, editorial@emi2012.org  
**Cc:** laurence.josset@chu-lyon.fr, antonin.bal@chu-lyon.fr, bruno.lina@chu-lyon.fr, gregory.queromes@univ-lyon1.fr, gregory.destras@chu-lyon.fr  
**Subject:** Pre-submission inquiry\_Characterization of newly SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster

Dear Pr. Wen,

We would like to submit a pre-submission inquiry regarding the suitability of our manuscript entitled “**Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster during routine genomic surveillance, Lyon, France**” for publication in *Emerging Microbes & Infections*, as an Original Article. (bioRxiv: <https://www.biorxiv.org/content/10.1101/2020.08.07.241653v1.full>)

Since February we have sequenced **229 SARS-CoV-2 whole genome** with a metagenomic next-generation sequencing approach as part of the routine surveillance performed at the French National Reference Center for Respiratory Viruses. We detected **two newly discovered frame-shifting deletion variants of the ORF6** (34- and 26-nucleotide deletions). **The 34-nucleotide deletion variant was found in 6 samples** (from 5 patients and **1 health-care worker**) within a cluster of COVID-19 cases from a single geriatric unit at the university hospital of Lyon. Both the presence of the 34-nucleotide deletion variant limited to a hospital unit and the clustering of the corresponding whole genome sequences by phylogeny analysis strongly **suggested a nosocomial transmission between patients**. Interestingly, **prolonged viral excretion of the 34-nucleotide deletion variant was found in a stool sample** 14 days after initial diagnosis for one patient. Furthermore, clinical data revealed **no significant difference in disease severity** between patients harboring the wild-type or the 34-nucleotide ORF6 deletion variant. The in vitro infection of the two deletion variants on primate endothelial kidney cells (BGM) and human lung adenocarcinoma cells (Calu-3) yielded **comparable replication kinetics** with the wild-type strain. In addition, **high viral loads** were found in vivo regardless of the presence or absence of the ORF6 deletion.

Overall, our study highlights **the transmission and replication capacity of two newly described deletion variants in the same ORF6 region**. Given the role of ORF6 in interferon modulation, further characterization, such as mechanistic interactions and interferon monitoring in patients should be performed. By the identification of the first nosocomial cluster harboring a large deletion newly described, **we emphasize the importance of real-time genomic surveillance for the detection of circulating variants and for the investigation of COVID-19 clusters**.

We would be very grateful if you could consider this pre-submission inquiry and look forward to hearing from you.

Yours sincerely,

Laurence Josset, PharmD PhD  
Research Assistant Professor  
National reference center for respiratory viruses (Pr. Bruno Lina)  
University hospital of Lyon, France



---

**From:** Josaphouitch, Alexa <Alexa.Josaphouitch@taylorandfrancis.com>  
**Sent:** Thursday, September 24, 2020 1:42 PM  
**To:** Lu, Shan  
**Cc:** Cochran, Sarah; Min Yang; M. Yu-Mei Wen (ymwen@shmu.edu.cn)  
**Subject:** RE: "A serological survey of SARS-CoV-2 in cat in Wuhan"

Hi Shan,

Thank you for your response below! I appreciate you taking an extra look and sharing your knowledge on this area.

Sincerely,  
Alexa

---

**Information Classification:** General

**From:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Sent:** Thursday, September 17, 2020 9:34 AM  
**To:** Josaphouitch, Alexa <Alexa.Josaphouitch@taylorandfrancis.com>  
**Cc:** Cochran, Sarah <sarah.cochran@taylorandfrancis.com>; Min Yang <min.yang@emi2012.org>; M. Yu-Mei Wen (ymwen@shmu.edu.cn) <ymwen@shmu.edu.cn>  
**Subject:** RE: "A serological survey of SARS-CoV-2 in cat in Wuhan"

Hi, Alexa,

Thanks for sharing this feedback to me. It is true that nowadays the gel image is becoming a big area of concern.

I just took a closer look at Fig. 2b and read the section and fig legend. I consider myself an expert of western as we do it daily in my own lab. Here is my comments:

1. Technically, there is nothing to talk about as these are single bands data and quality of SDS-PAGE and staining are good.
2. Since the authors are using different sera to do the western, it is not possible to have these gels in one run by Western approach. They have to be run individually with each cat, negative, positive sera etc at each run. So we can not fault them for the images not from the same run.
3. We could potentially ask the authors to show a much bigger gel with a negative control lane for each run, at the time of paper review. But the return is minimal. The authors will easily achieve that with negatives so it is not very useful.
4. The fact that the authors included three cat sera runs and three control runs showed the thoughtfulness to address the negative and positive control questions regarding to the assay quality itself.

Also see my comments to each of the two author service requirements below in red. So I do not have much concern there.

At the same time, I do not like the current common practice that a gel image is allowed to cut with only the band of interest and leaving everything vertically above or below out. This practice started about 25 years ago with the start of signal transduction research field, by leading journals and big name scientists. I was shocked at the time but it is well accepted since then. So if we can accept that, we can not demand the authors not to cut the gel to show only one band vertically.

---

**From:** B.L. Haagmans <b.haagmans@erasmusmc.nl>  
**Sent:** Friday, July 17, 2020 3:10 AM  
**To:** Lu, Shan; Saif, Linda; Perlman, Stanley; Munster, Vincent (NIH/NIAID) [E]  
**Cc:** Gibson, Edward  
**Subject:** Re: 2nd ISV Virtual Congress Discussion Panel

Dear all

I think I will be first in line so I should present a short overview off animal models available and how these reflect what we see in COVID-19 patients.

Furthermore some more focus on possibilities to measure immunogenicity/immune correlates in the preferred animal models and whether this would be sufficient for vaccine approval under the FDA animal rule.

Bart

---

**Van:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Verzonden:** Friday, July 17, 2020 2:55:59 AM  
**Aan:** Saif, Linda <saif.2@osu.edu>; Perlman, Stanley <stanley-perlman@uiowa.edu>; Munster, Vincent (NIH/NIAID) [E] <vincent.munster@nih.gov>; B.L. Haagmans <b.haagmans@erasmusmc.nl>  
**CC:** Gibson, Edward <Edward.Gibson@umassmed.edu>  
**Onderwerp:** RE: 2nd ISV Virtual Congress Discussion Panel

Dear Bart, Vincent and Linda,

Stanley is out on vacation this week. He asked me to forward some ideas about the panel discussion. Specifically, he and I talked about the following questions to be covered at this panel discussion session:

- How can animal models be used to test the vaccine immunogenicity and protection against SSARS-COV-2, if the phase 3 efficacy trial is not feasible?
- What constitutes a successful Pre-clinical study and how well does this predict efficacy in the target population?

It will be great if you can share with this group on what you plan to cover in your short presentation so each of you can focus something different.

Best.

Shan

---

**From:** Lu, Shan  
**Sent:** Wednesday, July 8, 2020 10:10 PM  
**To:** Saif, Linda <saif.2@osu.edu>; Perlman, Stanley <stanley-perlman@uiowa.edu>; Munster, Vincent (NIH/NIAID) [E] <vincent.munster@nih.gov>; B.L. Haagmans <b.haagmans@erasmusmc.nl>  
**Cc:** Gibson, Edward <Edward.Gibson@umassmed.edu>  
**Subject:** 2nd ISV Virtual Congress Discussion Panel

Dear Stanley, Linda, Vincent and Bart,

First I would like to express our sincere gratitude to your support to the 2<sup>nd</sup> ISV Virtual Congress on COVID-19 vaccines.

Enclosed is the draft program of 2<sup>nd</sup> Virtual Congress (and the copy of first Congress for your information).

Our congress so far is the only one to bring all major COVID-19 vaccine programs together so the focus is on real products candidates (at least vaccines with NHP or human data). It will be 3-congress series (June, July and Aug). For the 1<sup>st</sup> one, we had about 1600 registered attendees via live virtual event. The event was recorded and current available at YouTube for public viewing.

At the last session of each congress we will address ONE key question related to the vaccine development. For the first one, we focused on human challenge with live SARS-CoV-2 virus. The panel included three leading experts with clinical viral/vaccine development experience. It worked quite well and the audience liked it very much.

For the 2<sup>nd</sup> congress, it was felt that the animal model is very important for vaccine development. We have invited you as the panelists (Stanley will be the moderator).

Due to the limitation of virtual congress, each session has to be short. So the design of the panel discussion is: each of three panelists (3, not including moderator) will give about 5-min slides presentation, and then will have an open discussion to key questions from moderator and audience. Stanley Perlman agreed to be the moderator– he will introduce each of you, and ask questions, then at the end giving a short summary.

Some related tech issues:

- The organizer will run your slides so you don't have to worry about the desktop sharing etc. So please send the final slides set at least 24 hrs before the session.
- There will be a tech training. Ted Gibson will contact you to arrange a time of your convenience. It should be very easy.
- Ted will also for your photo and a brief bio.

Please feel free to discuss among yourself on how to organize the session. Let me know if there is anything I can assist.

Best.

Shan

\*\*\*\*\*

*Shan Lu, MD, PhD*  
*Co-Chair*  
*ISV Congress Series*  
*&*  
*Professor*  
*Department of Medicine*  
*U Mass Med School*  
*Worcester, MA01605*  
*USA*  
*Tel. 1-508-856-6791*  
*Email: [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu)*

---

**From:** Saif, Linda <saif.2@osu.edu>  
**Sent:** Sunday, July 19, 2020 9:16 PM  
**To:** B.L. Haagmans; Lu, Shan; Perlman, Stanley; Munster, Vincent (NIH/NIAID) [E]  
**Cc:** Gibson, Edward  
**Subject:** Re: 2nd ISV Virtual Congress Discussion Panel

Hi All

Since Bart will provide the specific overview, I will just review some of the general challenges for animal models in regard to authentic disease in COVID-19 patients.

Regards,

Linda

Linda J. Saif, PhD

Distinguished University Professor

Food Animal Health Research Program

OARDC/The Ohio State University

1680 Madison Ave

Wooster, Oh 44691

---

**From:** "B.L. Haagmans" <[b.haagmans@erasmusmc.nl](mailto:b.haagmans@erasmusmc.nl)>  
**Date:** Friday, July 17, 2020 3:10 AM  
**To:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>, Linda Saif <[saif.2@osu.edu](mailto:saif.2@osu.edu)>, "Stanley-Perlman@uiowa.edu" <[Stanley-Perlman@uiowa.edu](mailto:Stanley-Perlman@uiowa.edu)>, "Munster, Vincent (NIH/NIAID) [E]" <[vincent.munster@nih.gov](mailto:vincent.munster@nih.gov)>  
**Cc:** "Gibson, Edward" <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Subject:** Re: 2nd ISV Virtual Congress Discussion Panel

Dear all

I think I will be first in line so I should present a short overview off animal models available and how these reflect what we see in COVID-19 patients.

Furthermore some more focus on possibilities to measure immunogenicity/immune correlates in the preferred animal models and whether this would be sufficient for vaccine approval under the FDA animal rule.

Bart

---

**Van:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Verzonden:** Friday, July 17, 2020 2:55:59 AM  
**Aan:** Saif, Linda <[saif.2@osu.edu](mailto:saif.2@osu.edu)>; Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>; Munster, Vincent (NIH/NIAID) [E] <[vincent.munster@nih.gov](mailto:vincent.munster@nih.gov)>; B.L. Haagmans <[b.haagmans@erasmusmc.nl](mailto:b.haagmans@erasmusmc.nl)>  
**CC:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Onderwerp:** RE: 2nd ISV Virtual Congress Discussion Panel

Dear Bart, Vincent and Linda,

Stanley is out on vacation this week. He asked me to forward some ideas about the panel discussion. Specifically, he and I talked about the following questions to be covered at this panel discussion session:

- How can animal models be used to test the vaccine immunogenicity and protection against SSARS-COV-2, if the phase 3 efficacy trial is not feasible?
- What constitutes a successful Pre-clinical study and how well does this predict efficacy in the target population?

It will be great if you can share with this group on what you plan to cover in your short presentation so each of you can focus something different.

Best.

Shan

---

**From:** Lu, Shan

**Sent:** Wednesday, July 8, 2020 10:10 PM

**To:** Saif, Linda <[saif.2@osu.edu](mailto:saif.2@osu.edu)>; Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>; Munster, Vincent (NIH/NIAID) [E] <[vincent.munster@nih.gov](mailto:vincent.munster@nih.gov)>; B.L. Haagmans <[b.haagmans@erasmusmc.nl](mailto:b.haagmans@erasmusmc.nl)>

**Cc:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>

**Subject:** 2nd ISV Virtual Congress Discussion Panel

Dear Stanley, Linda, Vincent and Bart,

First I would like to express our sincere gratitude to your support to the 2<sup>nd</sup> ISV Virtual Congress on COVID-19 vaccines.

Enclosed is the draft program of 2<sup>nd</sup> Virtual Congress (and the copy of first Congress for your information).

Our congress so far is the only one to bring all major COVID-19 vaccine programs together so the focus is on real products candidates (at least vaccines with NHP or human data). It will be 3-congress series (June, July and Aug). For the 1<sup>st</sup> one, we had about 1600 registered attendees via live virtual event. The event was recorded and current available at YouTube for public viewing.

At the last session of each congress we will address ONE key question related to the vaccine development. For the first one, we focused on human challenge with live SARS-CoV-2 virus. The panel included three leading experts with clinical viral/vaccine development experience. It worked quite well and the audience liked it very much.

For the 2<sup>nd</sup> congress, it was felt that the animal model is very important for vaccine development. We have invited you as the panelists (Stanley will be the moderator).

Due to the limitation of virtual congress, each session has to be short. So the design of the panel discussion is: each of three panelists (3, not including moderator) will give about 5-min slides presentation, and then will have an open discussion to key questions from moderator and audience. Stanley Perlman agreed to be the moderator– he will introduce each of you, and ask questions, then at the end giving a short summary.

Some related tech issues:

- The organizer will run your slides so you don't have to worry about the desktop sharing etc. So please send the final slides set at least 24 hrs before the session.
- There will be a tech training. Ted Gibson will contact you to arrange a time of your convenience. It should be very easy.
- Ted will also for your photo and a brief bio.

Please feel free to discuss among yourself on how to organize the session. Let me know if there is anything I can assist.

Best.

Shan

\*\*\*\*\*

*Shan Lu, MD, PhD*  
*Co-Chair*  
*ISV Congress Series*  
*&*  
*Professor*  
*Department of Medicine*  
*U Mass Med School*  
*Worcester, MA01605*  
*USA*  
*Tel. 1-508-856-6791*  
*Email: [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu)*

---

**From:** B.L. Haagmans <b.haagmans@erasmusmc.nl>  
**Sent:** Monday, July 20, 2020 10:07 AM  
**To:** Perlman, Stanley; Saif, Linda; Lu, Shan; Munster, Vincent (NIH/NIAID) [E]  
**Cc:** Gibson, Edward  
**Subject:** RE: 2nd ISV Virtual Congress Discussion Panel  
**Attachments:** Haagmans\_ISV2020.ppt

Dear Stanley,

Taking the 5 minute timeslot into account I probably focus just on the intro of animal models available and something on the animal rule to raise the point made by you to start that discussion later on?

I don't have that much time to prepare so only made some basic slides...

Bart

---

**Van:** Perlman, Stanley <stanley-perlman@uiowa.edu>  
**Verzonden:** maandag 20 juli 2020 04:09  
**Aan:** Saif, Linda <saif.2@osu.edu>; B.L. Haagmans <b.haagmans@erasmusmc.nl>; Lu, Shan <Shan.Lu@umassmed.edu>; Munster, Vincent (NIH/NIAID) [E] <vincent.munster@nih.gov>  
**CC:** Gibson, Edward <Edward.Gibson@umassmed.edu>  
**Onderwerp:** Re: 2nd ISV Virtual Congress Discussion Panel

Linda and Bart,

I am back from my mini-vacation. For the first Virtual Congress, we each presented on a single topic; the approach that both of you describe is a little different but it sounds very good. One challenge is speaking for only 5 minutes.

See you on Tuesday.

Stanley

Stanley Perlman, M.D., Ph.D.  
Professor  
Department of Microbiology  
University of Iowa

---

**From:** Saif, Linda <saif.2@osu.edu>  
**Sent:** Sunday, July 19, 2020 8:16 PM  
**To:** B.L. Haagmans <b.haagmans@erasmusmc.nl>; Lu, Shan <Shan.Lu@umassmed.edu>; Perlman, Stanley <stanley-perlman@uiowa.edu>; Munster, Vincent (NIH/NIAID) [E] <vincent.munster@nih.gov>  
**Cc:** Gibson, Edward <Edward.Gibson@umassmed.edu>  
**Subject:** Re: 2nd ISV Virtual Congress Discussion Panel

Hi All

Since Bart will provide the specific overview, I will just review some of the general challenges for animal models in regard to authentic disease in COVID-19 patients.

Regards,

Linda

Linda J. Saif, PhD

Distinguished University Professor

Food Animal Health Research Program  
OARDC/The Ohio State University  
1680 Madison Ave  
Wooster, Oh 44691

---

**From:** "B.L. Haagmans" <[b.haagmans@erasmusmc.nl](mailto:b.haagmans@erasmusmc.nl)>  
**Date:** Friday, July 17, 2020 3:10 AM  
**To:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>, Linda Saif <[saif.2@osu.edu](mailto:saif.2@osu.edu)>, "Stanley-Perlman@uiowa.edu" <[Stanley-Perlman@uiowa.edu](mailto:Stanley-Perlman@uiowa.edu)>, "Munster, Vincent (NIH/NIAID) [E]" <[vincent.munster@nih.gov](mailto:vincent.munster@nih.gov)>  
**Cc:** "Gibson, Edward" <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Subject:** Re: 2nd ISV Virtual Congress Discussion Panel

Dear all

I think I will be first in line so I should present a short overview off animal models available and how these reflect what we see in COVID-19 patients.

Furthermore some more focus on possibilities to measure immunogenicity/immune correlates in the preferred animal models and whether this would be sufficient for vaccine approval under the FDA animal rule.

Bart

---

**Van:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Verzonden:** Friday, July 17, 2020 2:55:59 AM  
**Aan:** Saif, Linda <[saif.2@osu.edu](mailto:saif.2@osu.edu)>; Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>; Munster, Vincent (NIH/NIAID) [E] <[vincent.munster@nih.gov](mailto:vincent.munster@nih.gov)>; B.L. Haagmans <[b.haagmans@erasmusmc.nl](mailto:b.haagmans@erasmusmc.nl)>  
**CC:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Onderwerp:** RE: 2nd ISV Virtual Congress Discussion Panel

Dear Bart, Vincent and Linda,

Stanley is out on vacation this week. He asked me to forward some ideas about the panel discussion. Specifically, he and I talked about the following questions to be covered at this panel discussion session:

- How can animal models be used to test the vaccine immunogenicity and protection against SSARS-COV-2, if the phase 3 efficacy trial is not feasible?
- What constitutes a successful Pre-clinical study and how well does this predict efficacy in the target population?

It will be great if you can share with this group on what you plan to cover in your short presentation so each of you can focus something different.

Best.

Shan

---

**From:** Lu, Shan  
**Sent:** Wednesday, July 8, 2020 10:10 PM  
**To:** Saif, Linda <[saif.2@osu.edu](mailto:saif.2@osu.edu)>; Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>; Munster, Vincent (NIH/NIAID) [E] <[vincent.munster@nih.gov](mailto:vincent.munster@nih.gov)>; B.L. Haagmans <[b.haagmans@erasmusmc.nl](mailto:b.haagmans@erasmusmc.nl)>



**Cc:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>

**Subject:** 2nd ISV Virtual Congress Discussion Panel

Dear Stanley, Linda, Vincent and Bart,

First I would like to express our sincere gratitude to your support to the 2<sup>nd</sup> ISV Virtual Congress on COVID-19 vaccines.

Enclosed is the draft program of 2<sup>nd</sup> Virtual Congress (and the copy of first Congress for your information).

Our congress so far is the only one to bring all major COVID-19 vaccine programs together so the focus is on real products candidates (at least vaccines with NHP or human data). It will be 3-congress series (June, July and Aug). For the 1<sup>st</sup> one, we had about 1600 registered attendees via live virtual event. The event was recorded and current available at YouTube for public viewing.

At the last session of each congress we will address ONE key question related to the vaccine development. For the first one, we focused on human challenge with live SARS-CoV-2 virus. The panel included three leading experts with clinical viral/vaccine development experience. It worked quite well and the audience liked it very much.

For the 2<sup>nd</sup> congress, it was felt that the animal model is very important for vaccine development. We have invited you as the panelists (Stanley will be the moderator).

Due to the limitation of virtual congress, each session has to be short. So the design of the panel discussion is: each of three panelists (3, not including moderator) will give about 5-min slides presentation, and then will have an open discussion to key questions from moderator and audience. Stanley Perlman agreed to be the moderator– he will introduce each of you, and ask questions, then at the end giving a short summary.

Some related tech issues:

- The organizer will run your slides so you don't have to worry about the desktop sharing etc. So please send the final slides set at least 24 hrs before the session.
- There will be a tech training. Ted Gibson will contact you to arrange a time of your convenience. It should be very easy.
- Ted will also for your photo and a brief bio.

Please feel free to discuss among yourself on how to organize the session. Let me know if there is anything I can assist.

Best.

Shan

\*\*\*\*\*

*Shan Lu, MD, PhD*  
*Co-Chair*  
*ISV Congress Series*  
*&*  
*Professor*  
*Department of Medicine*  
*U Mass Med School*  
*Worcester, MA01605*  
*USA*  
*Tel. 1-508-856-6791*  
*Email: [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu)*

---

**From:** Gibson, Edward  
**Sent:** Monday, July 20, 2020 2:19 PM  
**To:** 'Perlman, Stanley'  
**Cc:** Lu, Shan  
**Subject:** RE: 2nd ISV Virtual Congress Discussion Panel  
**Attachments:** Moderator Instructions - Stanley Perlman.pdf

Dear Dr. Perlman,

Thanks for joining the training today. Even though we went through most of this please see your attached moderator instructions. It includes some info on the Q & A as well as contact info if you run into any issues. Please review and let me know if you have any questions.

Thank you again for your support and see you tomorrow!

Regards,

Ted Gibson

---

**From:** Gibson, Edward  
**Sent:** Monday, July 20, 2020 11:56 AM  
**To:** 'Perlman, Stanley' <stanley-perlman@uiowa.edu>  
**Subject:** RE: 2nd ISV Virtual Congress Discussion Panel

Yes I just set it up. If you can sign into teams with your guest 12 sign in you will see Stanley Perlman Training in the calendar for 12PM. Please click to join. We will be in in just a minute.

|                                   |
|-----------------------------------|
| Guest12@isvcongress.org Yag413450 |
|-----------------------------------|

Regards,

Ted

---

**From:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Sent:** Monday, July 20, 2020 11:50 AM  
**To:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Subject:** Re: 2nd ISV Virtual Congress Discussion Panel

Can we do this in the next few minutes?

Stanley Perlman, MD, Ph.D.  
Professor  
Depts of Microbiology and Immunology, and Pediatrics  
BSB 3-712  
University of Iowa  
Iowa City, IA 52242  
319-335-8549

On Jul 15, 2020, at 2:02 PM, Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)> wrote:

Hi Dr. Perlman, the more I think about I think we should set up a quick 15 minute session if you have any time in the next few days or weekend. Not so much technical training but rather to go over the moderator role as well as the Q & A function.

Please let me know if you have any time. We are very flexible and can do on short notice as well. Thanks.

Ted

---

**From:** Gibson, Edward  
**Sent:** Wednesday, July 15, 2020 12:43 PM  
**To:** 'Perlman, Stanley' <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** RE: 2nd ISV Virtual Congress Discussion Panel

Hi Dr. Perlman, of course. I will send once its created and it will also be on our website.

Ted

---

**From:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Sent:** Wednesday, July 15, 2020 12:39 PM  
**To:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** Re: 2nd ISV Virtual Congress Discussion Panel

Ted,

Could you also send me a second link so that I can be a participant before I am a moderator?

Stanley

Stanley Perlman, M.D., Ph.D.  
Professor  
Department of Microbiology  
University of Iowa

---

**From:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Sent:** Wednesday, July 15, 2020 11:36 AM  
**To:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** RE: 2nd ISV Virtual Congress Discussion Panel

Dear Dr. Perlman,

Thank you for serving as the moderator for the panel discussion at the upcoming virtual congress on July 21<sup>st</sup>. Attached is an updated program including chairs. We may have to update 1 or 2 speaker titles as we have not received them all yet. Other than that this is final.

Additionally I wanted to mention your sign in and password for Teams will be the same as the 1<sup>st</sup> Virtual Congress. It is listed again below. If you have any questions or want to set up another training please just let me know. I will be sending out formal instructions as a reminder.

Login: [Guest12@isvcongress.org](mailto:Guest12@isvcongress.org)

Password: Yag413450

Thank you again.

Regards,

Ted Gibson

---

**From:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Sent:** Wednesday, July 8, 2020 10:10 PM

**To:** Saif, Linda <[saif.2@osu.edu](mailto:saif.2@osu.edu)>; Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>; Munster, Vincent (NIH/NIAID) [E] <[vincent.munster@nih.gov](mailto:vincent.munster@nih.gov)>; B.L. Haagmans <[b.haagmans@erasmusmc.nl](mailto:b.haagmans@erasmusmc.nl)>

**Cc:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>

**Subject:** 2nd ISV Virtual Congress Discussion Panel

Dear Stanley, Linda, Vince and Bart,

First I would like to express our sincere gratitude to your support to the 2<sup>nd</sup> ISV Virtual Congress on COVID-19 vaccines.

Enclosed is the draft program of 2<sup>nd</sup> Virtual Congress (and the copy of first Congress for your information).

Our congress so far is the only one to bring all major COVID-19 vaccine programs together so the focus is on real products candidates (at least vaccines with NHP or human data). It will be 3-congress series (June, July and Aug). For the 1<sup>st</sup> one, we had about 1600 registered attendees via live virtual event. The event was recorded and current available at YouTube for public viewing.

At the last session of each congress we will address ONE key question related to the vaccine development. For the first one, we focused on human challenge with live SARS-CoV-2 virus. The panel included three leading experts with clinical viral/vaccine development experience. It worked quite well and the audience liked it very much.

For the 2<sup>nd</sup> congress, it was felt that the animal model is very important for vaccine development. We have invited you as the panelists (Stanley will be the moderator).

Due to the limitation of virtual congress, each session has to be short. So the design of the panel discussion is: each of three panelists (3, not including moderator) will give about 5-min slides presentation, and then will have an open discussion to key questions from moderator and audience. Stanley Perlman agreed to be the moderator– he will introduce each of you, and ask questions, then at the end giving a short summary.

Some related tech issues:

- The organizer will run your slides so you don't have to worry about the desktop sharing etc. So please send the final slides set at least 24 hrs before the session.
- There will be a tech training. Ted Gibson will contact you to arrange a time of your convenience. It should be very easy.

- Ted will also for your photo and a brief bio.

Please feel free to discuss among yourself on how to organize the session. Let me know if there is anything I can assist.

Best.

Shan

\*\*\*\*\*

*Shan Lu, MD, PhD*  
*Co-Chair*  
*ISV Congress Series*  
*&*  
*Professor*  
*Department of Medicine*  
*U Mass Med School*  
*Worcester, MA01605*  
*USA*  
*Tel. 1-508-856-6791*  
*Email: [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu)*

---

**From:** Perlman, Stanley <stanley-perlman@uiowa.edu>  
**Sent:** Sunday, July 19, 2020 10:25 PM  
**To:** Lu, Shan  
**Subject:** Re: 2nd ISV Virtual Congress Discussion Panel

Thanks.

Stanley Perlman, M.D., Ph.D.  
Professor  
Department of Microbiology  
University of Iowa

---

**From:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Sent:** Sunday, July 19, 2020 9:15 PM  
**To:** Perlman, Stanley <stanley-perlman@uiowa.edu>  
**Cc:** Gibson, Edward <Edward.Gibson@umassmed.edu>  
**Subject:** RE: 2nd ISV Virtual Congress Discussion Panel

Hi, Stanley,

Here is the bios for the panel for your ref.

One important thing: we have not heard from Vincent Munster in the last two weeks. He did not respond to ted's request for bio/photo (we found from web by ourselves), and he did not respond to our request for IT training. I sent him an email earlier today. Not sure if he is on vacation and may be back tomorrow. I will keep you posted.

Best.

Shan

---

**From:** Perlman, Stanley <stanley-perlman@uiowa.edu>  
**Sent:** Sunday, July 19, 2020 10:11 PM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Subject:** Re: 2nd ISV Virtual Congress Discussion Panel

Shan,

Don't forget to send me a blurb or CV for each panelist.

Stanley

Stanley Perlman, M.D., Ph.D.  
Professor  
Department of Microbiology  
University of Iowa

---

**From:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Sent:** Sunday, July 19, 2020 8:36 PM  
**To:** Saif, Linda <[saif.2@osu.edu](mailto:saif.2@osu.edu)>; B.L. Haagmans <[b.haagmans@erasmusmc.nl](mailto:b.haagmans@erasmusmc.nl)>; Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>

[perlman@uiowa.edu](mailto:perlman@uiowa.edu)>; Munster, Vincent (NIH/NIAID) [E] <[vincent.munster@nih.gov](mailto:vincent.munster@nih.gov)>

**Cc:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>

**Subject:** RE: 2nd ISV Virtual Congress Discussion Panel

Hi, Linda,

Thanks.

Shan

---

**From:** Saif, Linda <[saif.2@osu.edu](mailto:saif.2@osu.edu)>

**Sent:** Sunday, July 19, 2020 9:16 PM

**To:** B.L. Haagmans <[b.haagmans@erasmusmc.nl](mailto:b.haagmans@erasmusmc.nl)>; Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>; Munster, Vincent (NIH/NIAID) [E] <[vincent.munster@nih.gov](mailto:vincent.munster@nih.gov)>

**Cc:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>

**Subject:** Re: 2nd ISV Virtual Congress Discussion Panel

Hi All

Since Bart will provide the specific overview, I will just review some of the general challenges for animal models in regard to authentic disease in COVID-19 patients.

Regards,

Linda

Linda J. Saif, PhD

Distinguished University Professor

Food Animal Health Research Program

OARDC/The Ohio State University

1680 Madison Ave

Wooster, Oh 44691

---

**From:** "B.L. Haagmans" <[b.haagmans@erasmusmc.nl](mailto:b.haagmans@erasmusmc.nl)>

**Date:** Friday, July 17, 2020 3:10 AM

**To:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>, Linda Saif <[saif.2@osu.edu](mailto:saif.2@osu.edu)>, "Stanley-Perlman@uiowa.edu" <[Stanley-Perlman@uiowa.edu](mailto:Stanley-Perlman@uiowa.edu)>, "Munster, Vincent (NIH/NIAID) [E]" <[vincent.munster@nih.gov](mailto:vincent.munster@nih.gov)>

**Cc:** "Gibson, Edward" <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>

**Subject:** Re: 2nd ISV Virtual Congress Discussion Panel

Dear all

I think I will be first in line so I should present a short overview off animal models available and how these reflect what we see in COVID-19 patients.

Furthermore some more focus on possibilities to measure immunogenicity/immune correlates in the preferred animal models and whether this would be sufficient for vaccine approval under the FDA animal rule.

Bart

---

**Van:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Verzonden:** Friday, July 17, 2020 2:55:59 AM

**Aan:** Saif, Linda <[saif.2@osu.edu](mailto:saif.2@osu.edu)>; Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>; Munster, Vincent (NIH/NIAID) [E] <[vincent.munster@nih.gov](mailto:vincent.munster@nih.gov)>; B.L. Haagmans <[b.haagmans@erasmusmc.nl](mailto:b.haagmans@erasmusmc.nl)>

**CC:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>

**Onderwerp:** RE: 2nd ISV Virtual Congress Discussion Panel

Dear Bart, Vincent and Linda,

Stanley is out on vacation this week. He asked me to forward some ideas about the panel discussion. Specifically, he and I talked about the following questions to be covered at this panel discussion session:

- How can animal models be used to test the vaccine immunogenicity and protection against SARS-COV-2, if the phase 3 efficacy trial is not feasible?
- What constitutes a successful Pre-clinical study and how well does this predict efficacy in the target population?

It will be great if you can share with this group on what you plan to cover in your short presentation so each of you can focus something different.

Best.

Shan

---

**From:** Lu, Shan

**Sent:** Wednesday, July 8, 2020 10:10 PM

**To:** Saif, Linda <[saif.2@osu.edu](mailto:saif.2@osu.edu)>; Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>; Munster, Vincent (NIH/NIAID) [E] <[vincent.munster@nih.gov](mailto:vincent.munster@nih.gov)>; B.L. Haagmans <[b.haagmans@erasmusmc.nl](mailto:b.haagmans@erasmusmc.nl)>

**Cc:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>

**Subject:** 2nd ISV Virtual Congress Discussion Panel

Dear Stanley, Linda, Vincent and Bart,

First I would like to express our sincere gratitude to your support to the 2<sup>nd</sup> ISV Virtual Congress on COVID-19 vaccines.

Enclosed is the draft program of 2<sup>nd</sup> Virtual Congress (and the copy of first Congress for your information).

Our congress so far is the only one to bring all major COVID-19 vaccine programs together so the focus is on real products candidates (at least vaccines with NHP or human data). It will be 3-congress series (June, July and Aug). For the 1<sup>st</sup> one, we had about 1600 registered attendees via live virtual event. The event was recorded and current available at YouTube for public viewing.

At the last session of each congress we will address ONE key question related to the vaccine development. For the first one, we focused on human challenge with live SARS-CoV-2 virus. The panel included three leading experts with clinical viral/vaccine development experience. It worked quite well and the audience liked it very much.

For the 2<sup>nd</sup> congress, it was felt that the animal model is very important for vaccine development. We have invited you as the panelists (Stanley will be the moderator).

Due to the limitation of virtual congress, each session has to be short. So the design of the panel discussion is: each of three panelists (3, not including moderator) will give about 5-min slides presentation, and then will have an open discussion to key questions from moderator and audience. Stanley Perlman agreed to be the moderator– he will introduce each of you, and ask questions, then at the end giving a short summary.

Some related tech issues:



- The organizer will run your slides so you don't have to worry about the desktop sharing etc. So please send the final slides set at least 24 hrs before the session.
- There will be a tech training. Ted Gibson will contact you to arrange a time of your convenience. It should be very easy.
- Ted will also for your photo and a brief bio.

Please feel free to discuss among yourself on how to organize the session. Let me know if there is anything I can assist.

Best.

Shan

\*\*\*\*\*

*Shan Lu, MD, PhD*  
*Co-Chair*  
*ISV Congress Series*  
 &  
*Professor*  
*Department of Medicine*  
*U Mass Med School*  
*Worcester, MA01605*  
*USA*  
*Tel. 1-508-856-6791*  
*Email: [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu)*

---

**From:** Perlman, Stanley <stanley-perlman@uiowa.edu>  
**Sent:** Wednesday, July 15, 2020 12:39 PM  
**To:** Gibson, Edward  
**Cc:** Lu, Shan  
**Subject:** Re: 2nd ISV Virtual Congress Discussion Panel

Ted,

Could you also send me a second link so that I can be a participant before I am a moderator?

Stanley

Stanley Perlman, M.D., Ph.D.  
Professor  
Department of Microbiology  
University of Iowa

---

**From:** Gibson, Edward <Edward.Gibson@umassmed.edu>  
**Sent:** Wednesday, July 15, 2020 11:36 AM  
**To:** Perlman, Stanley <stanley-perlman@uiowa.edu>  
**Cc:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Subject:** RE: 2nd ISV Virtual Congress Discussion Panel

Dear Dr. Perlman,

Thank you for serving as the moderator for the panel discussion at the upcoming virtual congress on July 21<sup>st</sup>. Attached is an updated program including chairs. We may have to update 1 or 2 speaker titles as we have not received them all yet. Other than that this is final.

Additionally I wanted to mention your sign in and password for Teams will be the same as the 1<sup>st</sup> Virtual Congress. It is listed again below. If you have any questions or want to set up another training please just let me know. I will be sending out formal instructions as a reminder.

Login: [Guest12@isvcongress.org](mailto:Guest12@isvcongress.org)  
Password: Yag413450

Thank you again.

Regards,

Ted Gibson

---

**From:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Sent:** Wednesday, July 8, 2020 10:10 PM  
**To:** Saif, Linda <saif.2@osu.edu>; Perlman, Stanley <stanley-perlman@uiowa.edu>; Munster, Vincent (NIH/NIAID) [E] <vincent.munster@nih.gov>; B.L. Haagmans <b.haagmans@erasmusmc.nl>  
**Cc:** Gibson, Edward <Edward.Gibson@umassmed.edu>  
**Subject:** 2nd ISV Virtual Congress Discussion Panel

Dear Stanley, Linda, Vince and Bart,

First I would like to express our sincere gratitude to your support to the 2<sup>nd</sup> ISV Virtual Congress on COVID-19 vaccines.

Enclosed is the draft program of 2<sup>nd</sup> Virtual Congress (and the copy of first Congress for your information).

Our congress so far is the only one to bring all major COVID-19 vaccine programs together so the focus is on real products candidates (at least vaccines with NHP or human data). It will be 3-congress series (June, July and Aug). For the 1<sup>st</sup> one, we had about 1600 registered attendees via live virtual event. The event was recorded and current available at YouTube for public viewing.

At the last session of each congress we will address ONE key question related to the vaccine development. For the first one, we focused on human challenge with live SARS-CoV-2 virus. The panel included three leading experts with clinical viral/vaccine development experience. It worked quite well and the audience liked it very much.

For the 2<sup>nd</sup> congress, it was felt that the animal model is very important for vaccine development. We have invited you as the panelists (Stanley will be the moderator).

Due to the limitation of virtual congress, each session has to be short. So the design of the panel discussion is: each of three panelists (3, not including moderator) will give about 5-min slides presentation, and then will have an open discussion to key questions from moderator and audience. Stanley Perlman agreed to be the moderator— he will introduce each of you, and ask questions, then at the end giving a short summary.

Some related tech issues:

- The organizer will run your slides so you don't have to worry about the desktop sharing etc. So please send the final slides set at least 24 hrs before the session.
- There will be a tech training. Ted Gibson will contact you to arrange a time of your convenience. It should be very easy.
- Ted will also for your photo and a brief bio.

Please feel free to discuss among yourself on how to organize the session. Let me know if there is anything I can assist.

Best.

Shan

\*\*\*\*\*

*Shan Lu, MD, PhD*  
*Co-Chair*  
*ISV Congress Series*  
*&*  
*Professor*  
*Department of Medicine*  
*U Mass Med School*  
*Worcester, MA01605*  
*USA*  
*Tel. 1-508-856-6791*  
*Email: [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu)*

---

**From:** Anna-Lise Williamson <anna-lise.williamson@uct.ac.za>  
**Sent:** Friday, August 23, 2019 10:16 AM  
**To:** Punnee Pitisuttithum; Cindi Callaghan  
**Cc:** Adolfo Garcia-Sastre; Adrian Hill; Alan D. T. Barrett; Albrecht, Randy; 'AnnieD@epivax.com' (AnnieD@epivax.com); Britta Wahren; Bruno Guy; Clarisa Palatnik de Sousa; Connie Schmaljohn; David Weiner; Denise Doolan; Dennis Klinman; Emilio A. Emini; Frederic Tangy; indresh.srivastava@sanofi.com; Jeffrey Ulmer; John Oxford; John Shiver; Joon Haeng Rhee; Kathrin Jansen; Ken J. Ishii; Linda Klavinskis; Manon Cox; Marc Girard; Margaret Liu; marie-paule.kieny@inserm.fr; Mark K. Slifka; Matthias Schnell; Myron M. Levine; Nathalie Garçon; Paul Offit; Paul-Henri Lambert; Peter Nara; Peter Palese; Rafi Ahmed; Rino Rappuoli; Ronald Ellis; Lu, Shan; Stanley A. Plotkin; Ted Ross; Yu-Mei Wen  
**Subject:** RE: 2019 ISV Fellows Election Results

Thank you so much – I really appreciate the recognition!

Regards  
Anna-Lise

Professor Anna-Lise Williamson PhD,

Institute of Infectious Disease and Molecular Medicine,  
& Division of Medical Virology, Department of Pathology,  
Faculty of Health Sciences,  
University of Cape Town,  
Observatory 7925.

Email: [anna-lise.williamson@uct.ac.za](mailto:anna-lise.williamson@uct.ac.za) Tel: 021 4066124 (office) 021 5312900 (home). PA: Sue Lanfear (9am-1pm) 021 4066679 - [susan.lanfear@uct.ac.za](mailto:susan.lanfear@uct.ac.za)

---

**From:** Punnee Pitisuttithum [mailto:punnee.pit@mahidol.ac.th]  
**Sent:** 23 August 2019 04:10 PM  
**To:** Cindi Callaghan <CindiCallaghan@isv-online.org>  
**Cc:** Adolfo Garcia-Sastre <adolfo.garcia-sastre@mssm.edu>; Adrian Hill <adrian.hill@ndm.ox.ac.uk>; Alan D. T. Barrett <abarrett@utmb.edu>; Albrecht, Randy <randy.albrecht@mssm.edu>; 'AnnieD@epivax.com' (AnnieD@epivax.com) <AnnieD@epivax.com>; Britta Wahren <britta.wahren@ki.se>; Bruno Guy <bruno.guy@sanofipasteur.com>; Clarisa Palatnik de Sousa <immgcpa@micro.ufrj.br>; Connie Schmaljohn <connie.s.schmaljohn.civ@mail.mil>; David Weiner <dweiner@wistar.org>; Denise Doolan <denise.doolan@jcu.edu.au>; Dennis Klinman <klinmand@mail.nih.gov>; Emilio A. Emini <emilio.emini@gatesfoundation.org>; Frederic Tangy <ftangy@pasteur.fr>; indresh.srivastava@sanofi.com; Jeffrey Ulmer <jeffrey.b.ulmer@gsk.com>; John Oxford <j.oxford@qmul.ac.uk>; John Shiver <john.shiver@sanofipasteur.com>; Joon Haeng Rhee <jhrhee@chonnam.ac.kr>; Kathrin Jansen <kathrin.jansen@pfizer.com>; Ken J. Ishii <kenishii@biken.osaka-u.ac.jp>; Linda Klavinskis <linda.klavinskis@kcl.ac.uk>; Manon Cox <manoncox@gmail.com>; Marc Girard <marc.girard36@wanadoo.fr>; Margaret Liu <liu@protherimmune.com>; marie-paule.kieny@inserm.fr; Mark K. Slifka <slifkam@ohsu.edu>; Matthias Schnell <matthias.schnell@jefferson.edu>; Myron M. Levine <mlevine@medicine.umaryland.edu>; Nathalie Garçon <nathalie.garcon@bioaster.org>; Paul Offit <offit@email.chop.edu>; Paul-Henri Lambert <paul.lambert@unige.ch>; Peter Nara <nara@bmi-md.com>; Peter Palese <peter.palese@mssm.edu>; Rafi Ahmed <rahmed@emory.edu>; Rino Rappuoli <rino.r.rappuoli@gsk.com>; Ronald Ellis <rellis.hvi@gmail.com>; Shan Lu <shan.lu@umassmed.edu>; Stanley A. Plotkin <stanley.plotkin@vaxconsult.com>; Ted Ross <tedross@uga.edu>; Yu-Mei Wen <ymwen@shmu.edu.cn>;

Anna-Lise Williamson <anna-lise.williamson@uct.ac.za>

**Subject:** Re: 2019 ISV Fellows Election Results

Dear All,  
Thank you very very much.  
Punnee

Prof. Dr. Punnee Pitisuttithum

Head, Department of Clinical Tropical Medicine  
Faculty of Tropical Medicine , Mahidol University  
tel +6626435599, +66818294906

On 23 Aug BE 2562, at 19:00, Cindi Callaghan <[CindiCallaghan@isv-online.org](mailto:CindiCallaghan@isv-online.org)> wrote:

*Sent on behalf of Margaret Liu*

Dear ISV Fellows,

Thank you to all of you who voted in the recent Fellows election. I am pleased to announce that both the nominations passed, so please welcome our new ISV Fellows:

Punnee Pitisuttithum and Anna-Lise Williamson

Congratulations to both. We look forward to your continued active efforts in ISV and your significant contributions to the field of vaccinology.

Sincerely,  
The ISV Fellows Committee

Disclaimer - University of Cape Town This email is subject to UCT policies and email disclaimer published on our website at <http://www.uct.ac.za/main/email-disclaimer> or obtainable from +27 21 650 9111. If this email is not related to the business of UCT, it is sent by the sender in an individual capacity. Please report security incidents or abuse via <https://csirt.uct.ac.za/page/report-an-incident.php>.

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Wednesday, February 17, 2021 8:44 AM  
**To:** Lu, Shan  
**Subject:** Re: 2020 EMI Best Paper Award

Thank you all for your participation in the selection. YM Wen

-----原始邮件-----

发件人:"Lu, Shan" <Shan.Lu@umassmed.edu>

发送时间:2021-02-16 00:43:27 (星期二)

收件人: "'M. Yu-Mei Wen (ymwen@shmu.edu.cn)'" <ymwen@shmu.edu.cn>, "'Tang,&nbsp;Yi-Wei'" <yi-wei.tang@cepheid.com>, 'zhangwenhong' <zhangwenhong@fudan.edu.cn>, "'yuan zhenghong'" <zhyuan@shmu.edu.cn>

抄送: "'Martin&nbsp;martin&nbsp;老章医生'" <winter999@hotmail.com>

主题: 2020 EMI Best Paper Award

Dear Prof Wen and other colleagues,

I would like to share with you the final outcome of 2020 Best Paper Awards. It is based on everyone's vote and Prof Wen made the final decision.

#### **First Place Award**

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

**Authors:** Jasper Fuk-Woo Chan, Kin-Hang Kok, Zheng Zhu, Hin Chu, Kelvin Kai-Wang To, Shuofeng Yuan & Kwok-Yung Yuen

#### **Second Place Award**

Molecular and serological investigation of 2019-nCoV infected patients: Implication of multiple shedding routes

**Authors:** Wei Zhang, Rong-Hui Du, Bei Li, Xiao-Shuang Zheng, Xing-Lou Yang, Ben Hu, Yan-Yi Wang, Geng-Fu Xiao, Bing Yan, Zheng-Li Shi & Peng Zhou

#### **Third Place Awards (two)**

1) Hypothesis for potential pathogenesis of SARS-CoV-2 infection—a review of immune changes in patients with viral pneumonia

**Authors:** Ling Lin, Lianfeng Lu, Wei Cao & Taisheng Li

2) No credible evidence supporting claims of the laboratory engineering of SARS-CoV-2

**Authors:** Shan-Lu Liu, Linda J. Saif, Susan R. Weiss & Lishan Su

EMI comments for each selected paper can be found in attached document.

Please let me know if you have any questions.

Best.

Shan

---

**From:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
**Sent:** Saturday, May 9, 2020 11:52 PM  
**To:** Lu, Shan; wen yumei; Yuan Zhenghong 袁正宏; zhangwenhong  
**Cc:** Martin martin  
**Subject:** RE: a new idea: EMI Virtual Journal Club

Thank you, Shan. I fully support this action 😊.

Yi-Wei

---

**From:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Sent:** Saturday, May 9, 2020 11:06 AM  
**To:** wen yumei <ymwen@shmu.edu.cn>; Tang, Yi-Wei <yi-wei.tang@cepheid.com>; Yuan Zhenghong 袁正宏 <zhyuan@shmu.edu.cn>; zhangwenhong <zhangwenhong@fudan.edu.cn>  
**Cc:** Martin martin <winter999@hotmail.com>  
**Subject:** a new idea: EMI Virtual Journal Club

Dear Prof Wen and other EMI leaders,

Recently I developed an idea to develop a Virtual Journal Club to introduce key EMI papers to the global scientific community.

Journal Club is a very common format of academic study. The new development of online meeting and training provides a unique opportunity to develop an online journal club.

Please see attached ppt for the entire plan.

I have discussed this with Xiaodong who has a lot of experience in running online meetings. He likes this idea very much.

I have had some technical discussion with EMI editorial staff and Xiaodong's staff. Technically it is feasible.

Please let me know your feedback. We can try an online meeting among use first to discuss this.

Best.

Shan

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.



---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Saturday, October 19, 2019 9:49 PM  
**To:** Lu, Shan  
**Cc:** yuan zhenghong; ZhangWenhong; tangy@mskcc.org; Martin martin; 杨旻; 王兰翠  
**Subject:** Re: A new journal from your neighborhood  
**Attachments:** 第二届国际感染病科学与应用研讨会大会议程及安排.pdf

Shan,

I am not worried about this journal. I think Li is recognized as a hepatologist, mostly for treatment with her artificial liver. and her group is good in microbiota research. However, in the field of infectious diseases, Huashan Hospital has been the number one in China for many years. You and I have far more influences in the field of microbiology and infectious diseases and vaccines than them.

Chen Jin is good in bioinformatics. not specialist in infectious diseases like Wenhong. However, they have the government support, and huge financial support. Last week I visited their new hospital, Shulan Hospital, with the names of Li and her husband. A private hospital with very good facility, and the income last year has reached 9 billion RMB. We are based on medical sciences, not politics, which is most important for a journal. For a university to launch a journal is not enough, it needs experience and reputation. We can wait and see.

Rafi was here visiting us, and I will ask him to write a review on his new discovery on a new subtype of CD8<sup>+</sup> stem cells in persistent infections. There is a meeting on infectious diseases organized by our lab this coming week, and I will give a short introduction on EMI. The agenda for this meeting is attached, and if you think anyone is a candidate for submitting papers, I will ask Yang to contact them. YM Wen

-----原始邮件-----

发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>

发送时间: 2019-10-19 09:52:15 (星期六)

收件人: "wen yumei" <ymwen@shmu.edu.cn>, "yuan zhenghong" <zhyuan@shmu.edu.cn>, ZhangWenhong <zhangwenhong@fudan.edu.cn>, "tangy@mskcc.org" <tangy@mskcc.org>, "Martin martin" <winter999@hotmail.com>

抄送:

主题: A new journal from your neighborhood

Dear Prof Wen and other EMI colleagues,

This morning, T&F Beijing office sent me a notice about the launch of another journal *Infectious Microbes & Diseases* (IMD). <https://journals.lww.com/imd>

*"Infectious Microbes & Diseases (IMD) is jointly sponsored by Zhejiang University and the First Affiliated Hospital, School of Medicine, Zhejiang University and published by Wolters Kluwer and Zhejiang University Press."*

Editor-in-chief is Lanjuan Li, Deputy Editor-in-Chief is Jing Cheng (biochip), and Fernando Arenzana-Seisdedos (Institute of Pasteur of Shanghai), Executive Editor is Stijn van der Veen (Assistant Dean, the School of Basic Medicine of Zhejiang University, Hangzhou, China).

IMD is the main product from Zhejiang University and Prof Li's group.

"Relying on the discipline advantages of Zhejiang University and its First Affiliated Hospital, the journal combines domestic and international experts and scholars in the field of infectious diseases and has formed a scientific and technological innovation system that is a trinity of State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, and Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases. It also makes full use of the high-level publishing ability of international publishers to publish the latest research results of basic research, clinical practice and technological progress in the field of infectious diseases in a timely and comprehensive manner."

T&F is very concerned about this competitor. I am not worried as it will be a long process for IMD to catch up. I am sure you have a much better assessment than me on this news. We can chat more when we meet next time. Only one message I suddenly realized from this news: in order to do a good international journal, it can not be just owned and based on one scientific group.

I will update you more soon on the new events at EMI, especially the hiring of YU, Min, a person with significant experience in journal publishing and good knowledge about T&F operation. She will contribute significantly to our next phase work.

Best.

Shan

---

**From:** Liu, Shan-Lu <liu.6244@osu.edu>  
**Sent:** Tuesday, June 2, 2020 6:23 PM  
**To:** Lu, Shan  
**Subject:** Re: A potential manuscript submission to EMI

Hi Shan,

First, I have to disclose that Chen Liang is a long-time collaborator of mine back to McGill...that said, he is an outstanding scientist and the work seems very interesting and important, so definitely worth considering.

Best.

Shan-Lu

On 6/2/20, 5:49 PM, "Lu, Shan" <Shan.Lu@umassmed.edu> wrote:

Hi, Shan-Lu,

What do you think about this work since you are the expert in this area?

Thanks.

Shan

-----Original Message-----

From: Chen Liang, Dr. <chen.liang@mcgill.ca>  
Sent: Tuesday, June 2, 2020 4:05 PM  
To: Lu, Shan <Shan.Lu@umassmed.edu>  
Subject: A potential manuscript submission to EMI

Dear Shan,

This is Chen Liang, from the Lady Davis Institute, McGill University, Montreal, Canada.

I have known your outstanding work on vaccines for a long time, hope that our paths will cross at the right moment.

The reason I am writing to you is to inquire whether one of our manuscripts fits the scope of our Journal EMI. This study is about HIV and the host restriction factor MxB which we reported back to 2013 with two other labs. We recently found that, in addition to deterring the nuclear entry of HIV DNA, MxB also impairs the nuclear localization of HIV Rev protein. And we presented data showing this activity of MxB is transportin 1-dependent, and HIV-1 is able to evade by changing Rev or increasing Rev expression.

I included the abstract below for your information. I will be happy to send you the full manuscript if you need to make a decision.

Thank you, hope that our manuscript can be a good addition to your journal.

All the best,

Chen.

-----  
Chen Liang, PhD  
Professor of Medicine  
McGill University

HIV-1 resists MxB inhibition of viral Rev protein Abstract The interferon-inducible myxovirus resistance B (MxB) protein has been reported to inhibit HIV-1 and herpesviruses by blocking the nuclear import of viral DNA. Here, we report a new antiviral mechanism in which MxB restricts the nuclear import of HIV-1 regulatory protein Rev, and as a result, diminishes Rev-dependent expression of HIV-1 Gag protein. Specifically, MxB disrupts the interaction of Rev with the nuclear transport receptor, transportin 1 (TNPO1). Supporting this, the TNPO1-independent Rev variants become less restricted by MxB. In addition, HIV-1 can overcome this inhibition by MxB through increasing the expression of multiply spliced viral RNA and hence Rev protein. Therefore, MxB exerts its antiviral function through interfering the nuclear import of both viral DNA and essential viral proteins.

---

**From:** Liu, Shan-Lu <liu.6244@osu.edu>  
**Sent:** Tuesday, June 9, 2020 11:36 PM  
**To:** Lu, Shan  
**Subject:** Re: a quick consultation

Hi Shan,

I must say that the quality of these images is poor and they have been adjusted/manipulated badly in contrast and background. But I am not very certain if they have been stitched/cropped...

Maybe get additional thoughts from someone else?

Best.

Shan-Lu

---

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Date:** Tuesday, June 9, 2020 at 11:14 PM  
**To:** Shan-Lu Liu <liu.6244@osu.edu>  
**Subject:** a quick consultation

Hi, Shan-Lu,

One reviewer of an EMI paper sent back to me this PDF document pointing out :

“Unfortunately, several of the figures appear to be manipulated, stitched together and/or cropped (see highlights in attached PDF).

In case my conjectures turn out to be true and the authors cannot provide compelling explanations for the appearance of the figures, I must need to assume an act of scientific misconduct.

Therefore, I refuse to provide an in-depth review of the manuscript in its seemingly flawed form.

I would be heartbroken, if my accusations turn out to be untenable.

In this case, I would deeply regret the inconvenience I would have caused.

However, unfortunately I cannot think of another explanation for the appearance of the figures. “

I wonder with your expert’s eyes, would you agree with this reviewer?

Thanks.

Shan

---

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Wednesday, January 29, 2020 10:29 AM  
**To:** Lu, Shan  
**Subject:** Re: a quick review  
**Attachments:** Reviewer 1's Comment on TEMI-2020-0064.docx

Dear Shan,

The attached please find my comments on TEMI-2020-0064. Please let me know if you have any question with my comments.

Best,

Shibo

-----原始邮件-----

发件人:"Lu, Shan" <Shan.Lu@umassmed.edu>  
发送时间:2020-01-29 12:36:36 (星期三)  
收件人: "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>  
抄送:  
主题: a quick review

Hi, Shibo,

This is a new EMI paper from Lan Ke (Wuhan U) and his collaborators. Do you mind to do a quick review by sending me some comments by e-mail so I can incorporate into the system.

Thanks.

Shan

*Shan Lu, MD, PhD*

*Professor*

*Department of Medicine*

*U Mass Med School*

*Worcester, MA01605*

*USA*

*Tel. 1-508-856-6791*

*Email: [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu)*

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Saturday, June 6, 2020 10:54 PM  
**To:** Tang, Yi-Wei  
**Cc:** Lu, Shan; zhangwenhong; 袁正宏; Winter999  
**Subject:** Re: A thought about EMI  
**Attachments:** 2020.5.30 revision for JAMA-FW-JH final-clean.docx; 2020\_Viral and host factors related to the clinical outcome of COVID-19.pdf

I agree to start to organize and please give us the detailed plan, so all founders will know and follow the outcome.

Attached is a revised paper on antibodiesHuangJH submitted to JAMA, which is expected to be accepted .

Another paper on Nature collaborated by Fudan and Ruijin , the modified experimental virological daignostic technology was developed by Yi ZG from our lab, and I have asked him to write an article on this technology .Hope Yiwei will comment.

As we have not been able to meet and discuss important issues on EMI for qutie sometime, I suggest that we hold a tele-meeting with all founders in June. Hope all will discuss on the future of EMI, at this unstable situation. If agreed, please give me the time and dates when you will be avaiable.YM Wen

-----Original Messages-----

**From:**"Tang, Yi-Wei" <yi-wei.tang@cepheid.com>  
**Sent Time:**2020-06-07 10:14:30 (Sunday)  
**To:** "shan.lu@umassmed.edu" <shan.lu@umassmed.edu>, "Yumei Wen (ymwen@shmu.edu.cn)" <ymwen@shmu.edu.cn>  
**Cc:**  
**Subject:** A thought about COVID-19 manuscripts

Teacher Wen, Shan,

By screening EMI papers, I noticed that less and less new manuscripts on COVID-19 have been submitted to EMI recently. I wonder if we can solicit a series of metanalysis and literature review articles from authoritative groups. As you know, I have been involved as a curator in ASM's COVID-19 Registry curating lots of good resources and papers: <https://asm.org/COVID/COVID-19-Research-Registry/Home>. Quickly going through the curator list, Zhengli Shi, Susan Weiss, and Linda Saif are on it. With your permission, I think I could start soliciting for (maybe participating in) a metanalysis on serology. The review paper Michael Loeffelholz and I contributed for EMI has reached over 50,000 hits and 100 citations in Google Scholar. Hopefully these authoritative metanalysis papers will reach similar influences.

Yi-Wei



Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

---

**From:** kyyuen <kyyuen@hku.hk>  
**Sent:** Friday, January 17, 2020 9:00 AM  
**To:** Lu, Shan  
**Cc:** 'Shibo Jiang'; 'wen yumei'  
**Subject:** RE: About the citations of my articles in EMI

Dear Professor Lu,  
Many thanks for your kind words.  
I am getting old and not as versatile as when we first met many years ago. Thus I have stepped down from my headship for 7 years by now.  
I have to admit that I tend to lapse on "nonacademic issues" from time to time.  
Let me apologize again for giving you troubles.  
KY

---

**From:** Lu, Shan [mailto:Shan.Lu@umassmed.edu]  
**Sent:** Friday, 17 January 2020 9:51 PM  
**To:** kyyuen  
**Cc:** 'Shibo Jiang'; 'wen yumei'  
**Subject:** RE: About the citations of my articles in EMI

Dear Prof Yuen,

Thanks for your summary. EMI is happy to be the chosen place to publish papers from your group. It is exactly due to the high citations from your papers, I was wondering why that one in 2017 had only 0-1 citation. While I never fully believed the significance of impact factor to a journal, it is important to wonder why almost no one read a paper. By looking at your list, we can certainly learn a lot. It will help authors to select what to research, before even considering a paper.

Again, thanks to your great support in the last 8 years to EMI. Wish the new 2019-nCoV paper from your group will be another big success!

Best.

Shan

---

**From:** KY Yuen <kyyuen@hku.hk>  
**Sent:** Thursday, January 16, 2020 10:32 PM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Cc:** 'Shibo Jiang' <shibojiang@fudan.edu.cn>; 'wen yumei' <ymwen@shmu.edu.cn>  
**Subject:** About the citations of my articles in EMI

Dear Editor Professor Lu,

Thanks for your kind reminder that editorial board members have the obligation to maintain the standard of the journal as reflected by the number of citations of the articles that we have contributed to EMI.

I therefore ask another colleague in my department with no authorship with me in ANY journals to find out all the citations of my 22 EMI articles as tabulated below. Excluding the article 1 that we just published at the end

of last year, the citations varies from 1 to 107. The two papers with only one citation included the historical review article (No. 19) on “the father of tropical medicine Patrick Manson”. Another one (No. 3) on influenza gene mutations is the one that you mentioned. This has only 1 citation, not zero, but is BAD enough. Note that I am NOT the corresponding author, though being the last author. My colleague herself has made the decision of sending this paper to EMI.

In summary, the total citation of my EMI publications is 523 per 22 articles, ie average of almost 24 citations per article. It would be useful to me if you can compare my citations with other contributing authors so that we can have an objective self-assessment to ensure the standard of EMI being upheld.

Just want to say again that an ULTRARAPID review and publication of my recent submission on the 2010 novel coronavirus would likely improve the impact factor of EMI. As you can see that article (12) on the bioinformatics comparison of Zika virus which was immediately published on submission was later cited 107 times. Hope that we can set a record again this time.

An early happy Chinese New Year of the rat. Warmest regards.  
KY

1. [SMRT sequencing revealed the diversity and characteristics of defective interfering RNAs in influenza A \(H7N9\) virus infection.](#) Lui WY, Yuen CK, Li C, Wong WM, Lui PY, Lin CH, Chan KH, Zhao H, Chen H, To KKW, Zhang AJX, **Yuen KY**, Kok KH. **Emerg Microbes Infect.** 2019;8(1):662-674. doi: 10.1080/22221751.2019.1611346. (Citation= 0)
2. [Replication of MERS and SARS coronaviruses in bat cells offers insights to their ancestral origins.](#) Lau SKP, Fan RYY, Luk HKH, Zhu L, Fung J, Li KSM, Wong EYM, Ahmed SS, Chan JFW, Kok RKH, Chan KH, Wernery U, **Yuen KY**, Woo PCY. **Emerg Microbes Infect.** 2018 Dec 10;7(1):209. doi: 10.1038/s41426-018-0208-9. (Citation=4)
3. [Large-scale sequence analysis reveals novel human-adaptive markers in PB2 segment of seasonal influenza A viruses.](#) Wen L, Chu H, Wong BH, Wang D, Li C, Zhao X, Chiu MC, Yuan S, Fan Y, Chen H, Zhou J, Yuen KY. **Emerg Microbes Infect.** 2018 Mar 29;7(1):47. doi: 10.1038/s41426-018-0050-0. (Citations=1)
4. [Low population serum microneutralization antibody titer against the predominating influenza A\(H3N2\) N121K virus during the severe influenza summer peak of Hong Kong in 2017.](#) Zhu H, Lee ACY, Li C, Mak WWN, Chen YY, Chan KH, Zhang AJX, Fung WF, Zhang RQ, Fung YF, Poon RWS, Lam JY, Tam S, Hung IFN, Chen H, **Yuen KY**, To KKW. **Emerg Microbes Infect.** 2018 Mar 6;7(1):23. doi: 10.1038/s41426-018-0041-1. (Citations=6)
5. [Rapid detection of MERS coronavirus-like viruses in bats: potential for tracking MERS coronavirus transmission and animal origin.](#) Woo PCY, Lau SKP, Chen Y, Wong EYM, Chan KH, Chen H, Zhang L, Xia N, **Yuen KY**. **Emerg Microbes Infect.** 2018 Mar 7;7(1):18. doi: 10.1038/s41426-017-0016-7. (Citations=6)
6. [Coronavirus HKU15 in respiratory tract of pigs and first discovery of coronavirus quasispecies in 5'-untranslated region.](#) Woo PC, Lau SK, Tsang CC, Lau CC, Wong PC, Chow FW, Fong JY, **Yuen KY**. **Emerg Microbes Infect.** 2017 Jun 21;6(6):e53. doi: 10.1038/emi.2017.37. (Citations=8)
7. [Additional molecular testing of saliva specimens improves the detection of respiratory viruses.](#) To KK, Lu L, Yip CC, Poon RW, Fung AM, Cheng A, Lui DH, Ho DT, Hung IF, Chan KH, **Yuen KY**. **Emerg Microbes Infect.** 2017 Jun 7;6(6):e49. doi: 10.1038/emi.2017.35. (Citations=6)
8. [Polyphyletic origin of MERS coronaviruses and isolation of a novel clade A strain from dromedary camels in the United Arab Emirates.](#) Lau SK, Wernery R, Wong EY, Joseph S, Tsang AK, Patteril NA, Elizabeth SK, Chan KH, Muhammed R, Kinne J, **Yuen KY**, Wernery U, Woo PC. **Emerg Microbes Infect.** 2016 Dec 21;5(12):e128. doi: 10.1038/emi.2016.129. (Citations=10)
9. [Differential cell line susceptibility to the emerging Zika virus: implications for disease pathogenesis, non-vector-borne human transmission and animal reservoirs.](#) Chan JF, Yip CC, Tsang JO, Tee KM, Cai

- JP, Chik KK, Zhu Z, Chan CC, Choi GK, Sridhar S, Zhang AJ, Lu G, Chiu K, Lo AC, Tsao SW, Kok KH, Jin DY, Chan KH, **Yuen KY**. **Emerg Microbes Infect.** 2016 Aug 24;5:e93. doi: 10.1038/emi.2016.99. (Citations=64)
10. [Middle East respiratory syndrome coronavirus M protein suppresses type I interferon expression through the inhibition of TBK1-dependent phosphorylation of IRF3.](#) Lui PY, Wong LY, Fung CL, Siu KL, Yeung ML, Yuen KS, Chan CP, Woo PC, **Yuen KY**, Jin DY. **Emerg Microbes Infect.** 2016 Apr 20;5:e39. doi: 10.1038/emi.2016.33. (Citations=26)
  11. [A 10-year study reveals clinical and laboratory evidence for the 'semi-invasive' properties of chronic pulmonary aspergillosis.](#) Chan JF, Lau SK, Wong SC, To KK, So SY, Leung SS, Chan SM, Pang CM, Xiao C, Hung IF, Cheng VC, **Yuen KY**, Woo PC. **Emerg Microbes Infect.** 2016 Apr 20;5:e37. doi: 10.1038/emi.2016.31. (Citations=5)
  12. [Comparative genomic analysis of pre-epidemic and epidemic Zika virus strains for virological factors potentially associated with the rapidly expanding epidemic.](#) Zhu Z, Chan JF, Tee KM, Choi GK, Lau SK, Woo PC, Tse H, **Yuen KY**. **Emerg Microbes Infect.** 2016 Mar 16;5:e22. doi: 10.1038/emi.2016.48. (Citations=107)
  13. [Talaromyces \(Penicillium\) marneffeii infection in non-HIV-infected patients.](#) Chan JF, Lau SK, **Yuen KY**, Woo PC. **Emerg Microbes Infect.** 2016 Mar 9;5:e19. doi: 10.1038/emi.2016.18. Review. (Citations=43)
  14. [A phylogenetically distinct Middle East respiratory syndrome coronavirus detected in a dromedary calf from a closed dairy herd in Dubai with rising seroprevalence with age.](#) Wernery U, El Rasoul IH, Wong EY, Joseph M, Chen Y, Jose S, Tsang AK, Patteril NA, Chen H, Elizabeth SK, **Yuen KY**, Joseph S, Xia N, Wernery R, Lau SK, Woo PC. **Emerg Microbes Infect.** 2015 Dec 2;4(12):e74. doi: 10.1038/emi.2015.74. (Citations=14)
  15. [A sensitive and specific antigen detection assay for Middle East respiratory syndrome coronavirus.](#) Chen Y, Chan KH, Kang Y, Chen H, Luk HK, Poon RW, Chan JF, **Yuen KY**, Xia N, Lau SK, Woo PC. **Emerg Microbes Infect.** 2015 Apr;4(4):e26. doi: 10.1038/emi.2015.26. Epub 2015 Apr 22. (Citations=22)
  16. [Strategic measures for the control of surging antimicrobial resistance in Hong Kong and mainland of China.](#) Cheng VC, Wong SC, Ho PL, **Yuen KY**. **Emerg Microbes Infect.** 2015 Feb;4(2):e8. doi: 10.1038/emi.2015.8. Epub 2015 Feb 11. Review. (Citations=26)
  17. [Identification of specific metabolites in culture supernatant of Mycobacterium tuberculosis using metabolomics: exploration of potential biomarkers.](#) Lau SK, Lam CW, Curreem SO, Lee KC, Lau CC, Chow WN, Ngan AH, To KK, Chan JF, Hung IF, Yam WC, **Yuen KY**, Woo PC. **Emerg Microbes Infect.** 2015 Jan;4(1):e6. doi: 10.1038/emi.2015.6. Epub 2015 Jan 28. (Citations=19)
  18. [Genetic relatedness of the novel human group C betacoronavirus to Tylonycteris bat coronavirus HKU4 and Pipistrellus bat coronavirus HKU5.](#) Woo PC, Lau SK, Li KS, Tsang AK, **Yuen KY**. **Emerg Microbes Infect.** 2012 Nov;1(11):e35. doi: 10.1038/emi.2012.45. Epub 2012 Nov 7. (Citations=48)
  19. [In memory of Patrick Manson, founding father of tropical medicine and the discovery of vector-borne infections.](#) To KK, **Yuen KY**. **Emerg Microbes Infect.** 2012 Oct;1(10):e31. doi: 10.1038/emi.2012.32. Epub 2012 Oct 24. Review. (Citations=1)
  20. [Avian influenza A H5N1 virus: a continuous threat to humans.](#) To KK, Ng KH, Que TL, Chan JM, Tsang KY, Tsang AK, Chen H, **Yuen KY**. **Emerg Microbes Infect.** 2012 Sep;1(9):e25. doi: 10.1038/emi.2012.24. Epub 2012 Sep 19. Review. (Citations=49)
  21. [A significant number of reported Absidia corymbifera \(Lichtheimia corymbifera\) infections are caused by Lichtheimia ramosa \(syn. Lichtheimia hongkongensis\): an emerging cause of mucormycosis.](#) Woo PC, Leung SY, Ngan AH, Lau SK, **Yuen KY**. **Emerg Microbes Infect.** 2012 Aug;1(8):e15. doi: 10.1038/emi.2012.11. Epub 2012 Aug 22. (Citations=16)
  22. [Streptococcus pyogenes and re-emergence of scarlet fever as a public health problem.](#) Wong SS, **Yuen KY**. **Emerg Microbes Infect.** 2012 Jul;1(7):e2. doi: 10.1038/emi.2012.9. Epub 2012 Jul 11. Review. (Citations=42)

From: Lu, Shan [<mailto:Shan.Lu@umassmed.edu>]

Sent: Friday, January 17, 2020 6:26 AM

To: 'kyyuen'

Subject: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0053 has been submitted online

Dear KY,

I just noticed that one of your EMI papers published in 2017 have not had any citation (title below). Maybe you can verify if it is correct.

Shan

Large-scale sequence analysis reveals novel human-adaptive markers in PB2 segment of seasonal influenza A viruses

From: kyyuen <[kyyuen@hku.hk](mailto:kyyuen@hku.hk)>

Sent: Thursday, January 16, 2020 10:39 AM

To: Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; Shibo Jiang <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>; wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>

Subject: Fwd: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0053 has been submitted online

For your urgent and kind attention.

Ky

從我的 iPhone 傳送

以下為轉寄郵件：

寄件人: Emerging Microbes and Infections <[onbehalf@manuscriptcentral.com](mailto:onbehalf@manuscriptcentral.com)>

日期: 2020 年 1 月 16 日 GMT+8 下午 11:31:45

收件人: kyyuen <[kyyuen@hku.hk](mailto:kyyuen@hku.hk)>

副本: jfwchan <[jfwchan@hku.hk](mailto:jfwchan@hku.hk)>, Raven Kok <[khkok@hku.hk](mailto:khkok@hku.hk)>, "[zzeightzz@gmail.com](mailto:zzeightzz@gmail.com)" <[zzeightzz@gmail.com](mailto:zzeightzz@gmail.com)>, hinchu <[hinchu@hku.hk](mailto:hinchu@hku.hk)>, Kelvin To <[kelvinto@hku.hk](mailto:kelvinto@hku.hk)>, "[yuanshuofeng@gmail.com](mailto:yuanshuofeng@gmail.com)" <[yuanshuofeng@gmail.com](mailto:yuanshuofeng@gmail.com)>, skplau <[skplau@hku.hk](mailto:skplau@hku.hk)>, pcywoo <[pcywoo@hku.hk](mailto:pcywoo@hku.hk)>, kyyuen <[kyyuen@hku.hk](mailto:kyyuen@hku.hk)>

標題: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0053 has been submitted online

回覆給: [temi-peerreview@journals.tandf.co.uk](mailto:temi-peerreview@journals.tandf.co.uk)

16-Jan-2020

Dear Professor Yuen:

Your manuscript entitled "Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from patients with acute respiratory disease in Wuhan, Hubei, China" has been successfully submitted online and is presently being given full consideration for publication in Emerging Microbes & Infections.

Your manuscript ID is TEMI-2020-0053.

Please mention the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your street address or e-mail address, please log in to ScholarOne Manuscripts at <https://mc.manuscriptcentral.com/temi> and edit your user information as appropriate.

You can also view the status of your manuscript at any time by checking your Author Center after logging in to <https://mc.manuscriptcentral.com/temi>.

Thank you for submitting your manuscript to Emerging Microbes & Infections.

Sincerely,

Emerging Microbes & Infections Editorial Office

---

**From:** Tang, Qiyi <qiyi.tang@Howard.edu>  
**Sent:** Tuesday, November 17, 2020 7:58 PM  
**To:** Liu, Shan-Lu; zhengt@exchange.nih.gov; haitguo@iupui.edu; tzhou@mail.nih.gov; GCheng@mednet.ucla.edu; liangy@umn.edu; rli@vcu.edu; wma@vet.kstate.edu; xjmeng@vt.edu; Zhijian.Chen@UTSouthwestern.edu; mluo@gsu.edu; zhangyj@umd.edu; xzhu1@umd.edu; jqu@kumc.edu; lijun@uic.edu; fengwei.bai@usm.edu; andyu@iupui.edu; reachxw@vt.edu; gluo@uab.edu; ldu@nybc.org; hXu@tulane.edu; liu\_fy@berkeley.edu; shitao.li@okstate.edu; Lu, Shan; haihu@UTMB.edu; wenzheho@temple.edu; Qfeng4@central.uh.edu; tang@bio.fsu.edu; feng.li@sdsu.edu; ruilu@lsu.edu; sxian2@unl.edu; dingsw@ucr.edu; guohua@missouri.edu; bling@tulane.edu; junwang@pharmacy.arizona.edu; lifang@umn.edu; wang518@umd.edu; gaos8@upmc.edu; pewang@uchc.edu; xiangy@uthscsa.edu; fzhu@bio.fsu.edu; chen.liang@mccgill.ca; lyuan@vt.edu; fgao@duke.edu; wangjw28@163.com; xfyu1@zju.edu.cn; bzhao@partners.org; jianw@usc.edu; zyang@ksu.edu; yu.cong@nih.gov; weiming.yuan@usc.edu; Zongdi.feng@nationwidechildrens.org; juh13@psu.edu; hengx@missouri.edu; lsu@med.unc.edu; ywu8@gmu.edu; jwu@whu.edu.cn; tshuo@uic.edu; Shibojiang@fudan.edu.cn; sjiang@nybc.org; pinwang@usc.edu; rzhao@som.umaryland.edu; shuylong@mail.sysu.edu.cn; xuefeng.liu@georgetown.edu; yuxingli@som.umaryland.edu; Wang, Shixia; yhe@ipbcams.ac.cn; Pinghui.feng@usc.edu; jutao.guo@bblumberg.org; lin.liu@okstate.edu; hua.zhu@rutgers.edu; Jinhong.chang@bblumberg.org; jianzhu1012@gmail.com; ronghai@ucr.edu; jun.zhu@nih.gov; jliu4@uams.edu; xiangpeng.kong@med.nyu.edu; haoquanwu@outlook.com; Wenjun.liu@defence.gov.au; Liang.shan@wustl.edu; hliao@duke.edu; Yuan, Yan; zxing@umn.edu; hongmin.li@health.ny.gov; pzheng@ihv.umaryland.edu; yaliu@ihv.umaryland.edu  
**Subject:** Re: ACVA email list  
**Attachments:** JiaHe CV.pdf

Dear All,

Sorry for interrupting you.

One of the students, Jia He (from UMD), is looking for a post-doc position. The attached please see her CV.

Jia is a very nice person and you will be lucky to have her in your lab. Please contact her (jhe1@umd.edu) directly if you are interested in having her. Thanks a lot.

Best regards,

Qiyi  
Qiyi Tang Ph.D  
Professor  
Department of Microbiology, Adam's building room 3002  
Howard University College of Medicine  
Chairman of IBC at Howard University  
520 W Street NW  
Washington, DC 20059, USA  
tel: [202 806 3915](tel:2028063915) (office)

---

**From:** Jianming Hu <juh13@psu.edu>  
**Sent:** Sunday, December 29, 2019 10:42 AM  
**To:** Shan-Lu Liu  
**Cc:** zhengzhiming4@gmail.com; Haitao Guo; tzhou@mail.nih.gov; GCheng@mednet.ucla.edu; liangy@umn.edu; rli@vcu.edu; wjma@ksu.edu; xjmeng@vt.edu; Zhijian.Chen@UTSouthwestern.edu; mluo@gsu.edu; zhangyj@umd.edu; xzhu1@umd.edu; jqiu@kumc.edu; lijun@uic.edu; fengwei.bai@usm.edu; andyu@iupui.edu; reachxw@vt.edu; Guangxiang G Luo; ldu@nybc.org; hxu@tulane.edu; liu\_fy@berkeley.edu; shitao.li@okstate.edu; Lu, Shan; haihu@UTMB.edu; wenzheho@temple.edu; Qfeng4@central.uh.edu; tang@bio.fsu.edu; feng.li@sdstate.edu; ruilu@lsu.edu; sxian2@unl.edu; qiyi.tang@howard.edu; dingsw@ucr.edu; guohua@missouri.edu; bling@tulane.edu; junwang@pharmacy.arizona.edu; lifang@umn.edu; wang518@umd.edu; gaos8@upmc.edu; pewang@uchc.edu; xiangy@uthscsa.edu; fzhu@bio.fsu.edu; chen.liang@mcgill.ca; lyuan@vt.edu; fgao@duke.edu; wangjw28@163.com; xfyu1@zju.edu.cn; bzhao@partners.org; jianw@musc.edu; zyang@ksu.edu; yu.cong@nih.gov; weiming.yuan@usc.edu; Zongdi.feng@nationwidechildrens.org; hengx@missouri.edu; lsu@med.unc.edu; ywu8@gmu.edu; jwu@whu.edu.cn; tshuo@uic.edu; Shibojiang@fudan.edu.cn; sjiang@nybc.org; pinwang@usc.edu; rzhao@som.umaryland.edu; shuylong@mail.sysu.edu.cn; xuefeng.liu@georgetown.edu; yuxingli@som.umaryland.edu; Wang, Shixia; yhe@ipbcams.ac.cn; Pinghui.feng@usc.edu; ju-tao.guo@bblumberg.org; lin.liu@okstate.edu; hua.zhu@rutgers.edu; Jinhong.chang@bblumberg.org; jianzhu1012@gmail.com; ronghai@ucr.edu; jun.zhu@nih.gov; jliu4@uams.edu; xiangpeng.kong@med.nyu.edu; haoquanwu@outlook.com; Wenjun.liu@defence.gov.au; Liang.shan@wustl.edu; hliao@duke.edu; yuan2@upenn.edu; zxing@umn.edu; hongmin.li@health.ny.gov; pzheng@ihv.umaryland.edu; yaliu@ihv.umaryland.edu; jxw103@case.edu; xiangguo.qiu@canada.ca; Feng Shao; zlshi@wh.iov.cn; klan@whu.edu.cn; zengmsh@mail.sysu.edu.cn; Nan Yan; Zhang, Rong; liliwang@upenn.edu; Linheng Li; kli1@uthsc.edu; tsx@case.edu; ssun@mdanderson.org; ysang@tnstate.edu; wu@crystal.harvard.edu; Sun.Jie@mayo.edu; peijun@strubi.ox.ac.uk; jiayu@coh.org; bchen@crystal.harvard.edu; Wen, Haitao; Qu, Feng; Hezhao.Ji@umanitoba.ca; Li, Zihai; zhengyo@msu.edu; zhanglinqi@tsinghua.edu.cn; wxiao@temple.edu; Whu@temple.edu; RSun@mednet.ucla.edu; Gao, Guangping; GMSWANG@nus.edu.sg; peshi@UTMB.EDU; ziyang-yan@uiowa.edu; lqiao@luc.edu; yong.xiong@yale.edu; Wang, Qihong; shuping.tong\_md@brown.edu; pinghuif@usc.edu; gaof@im.ac.cn; zqin@uams.edu; guodeyin@www.sysu.edu.cn  
**Subject:** Re: ACVA/SCBA-Virology Division: 2019 Year in Review

Great summary for a great year of our Society. Kudos to the outstanding leadership of Shan-Lu and the Board.

Happy New Year to all!

Jianming

On Dec 29, 2019, at 9:56 AM, Liu, Shan-Lu <[liu.6244@osu.edu](mailto:liu.6244@osu.edu)> wrote:

**Dear Colleagues and Friends:**

Happy new year! I wish you all a healthy and productive 2020!

I would like to share the below summary on our major activities in 2019.



## **ACVA/SCBA-Virology Division: 2019 Year in Review (chronologically)**

1. Continuous and focused discussion on the Science letter “Racial Profiling Harms Science” (original title “Racial Profiling Harms American Science and Innovation”).
2. Seven Chinese or Chinese American scientists, including 5 members of ACVA/SCBA-Virology Division, elected to the American Academy of Microbiology (AAM) - Genhong Cheng (程根宏), Pinghui Feng (冯平辉), Guangping Gao (高光坪), Jake T Liang (連展阳), Zhengli Shi (石正丽), Yumei Wen (闻玉梅), Richard Zhao (赵玉琪).
3. Themed discussion on the universal influenza vaccine, vectored ImmunoProphylaxis, and attenuated influenza vaccine.
4. Themed discussion of Open Access journal publishing.
5. Debate and discussion on the definition of “racial profiling”: Chinese translations, differences between “racial profiling” and “racial discrimination”, and differences in Chinese translations: “种族标签, 种族偏见, 种族歧视”.
6. Themed discussion on virus-host evolutionary arms races: HIV and others.
7. Ultimate publication of the Science letter on March 21, 2019 (online) – sagas and stories behind the scenes.
8. Responses to the Science letter and media reports – “The Scientist”, “知识分子”, and others.
9. Discussion and responses to US institution’s statements, Emory/MD Anderson faculty firing, and NIH’s foreign influences and FBI investigations.
10. Establishment of the ACVA/SCBA-Virology Division website (<https://sites.google.com/view/scba-virology/home>), as well as collection and distribution of membership list (<https://sites.google.com/view/scba-virology/members>).
11. Dr. George F. Gao elected to the US National Academy of Sciences as International Member (formerly called Foreign Associate).
12. Dr. Zongdi Feng (冯枫棣) won the 2019 ASV’s Ann Palmenberg Junior Investigator’s award.
13. ACVA/SCBA-Virology participation in the 17<sup>th</sup> SCBA International Symposium, Kunming, July 24-28, 2019, and scientific workshop and social gathering at the 2<sup>nd</sup> ACVA/SCBA-virology meeting in Kunming, July 28, 2019.

14. Response and discussion on the role of  $\alpha 4\beta 7$  antibody in the control of HIV/SIV infection: 3 Science papers with all negative results - what has gone wrong and what is next?
15. Dr. Feng Shao won the 2019 Future Scientific Prize in Biological Sciences: congratulations and discussions on the scientific evaluation systems in China – ideas and solutions.
16. Three members among the 2019 Journal of Virology top 25 reviewers: Drs. Dongdi Feng (冯枫棣), Bin He (何斌), and Dong-Yan Jin (金冬雁); note that Dr. Bin He is PhD advisor of Dr. Feng, and both have been on the list multiple times, including 2018 (Drs. Ju-tao Guo and Jianming Hu were among the 2018's JVI top 25 reviewers)
17. Response and discussion about the 2019 Lasker award for the discovery of T and B development.
18. Overwhelming responses to Dr. Xuetao Cao's publication issues raised by [Pubpeer.com](https://pubpeer.com), and heated discussion on scientific misconduct in general.
19. Heated discussion on publishing in CNS (Cell, Nature and Science), selection of conference speakers, and scientific community networking.
20. Themed discussion on self-plagiarism and direct feedback from Editor in Chiefs of Journal of Virology (Roz Sandri-Goldin), Journal of Immunology (Gene Oltz), Viruses (Eric Freed), Emerging Microbes and Infections (Shan Lu), etc.
21. Themed discussion on publications of structural biology studies in CNS - a scientific favor or true advance in biology?
22. Themed discussion on US patents and institution royalties - why are they different?
23. Themed discussion on viral entry: definition of viral receptors – requirements and pitfalls.

Shan-Lu Liu, MD, PhD  
President of ACVA/SCBA-Virology  
The Ohio State University

<ACVASCBA-Virology 2019 year in review.pdf>

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Monday, March 8, 2021 6:55 PM  
**To:** Lu, Shan  
**Subject:** Re: adding a new EMI Editorial Board member

OK

-----原始邮件-----

发件人:"Lu, Shan" <Shan.Lu@umassmed.edu>

发送时间:2021-03-08 10:11:30 (星期一)

收件人: "M. Yu-Mei Wen (ymwen@shmu.edu.cn)" <ymwen@shmu.edu.cn>, "yuan zhenghong" <zhyuan@shmu.edu.cn>, zhangwenhong <zhangwenhong@fudan.edu.cn>, "Martin martin" <winter999@hotmail.com>, "Tang, Yi-Wei" <yi-wei.tang@cepheid.com>

抄送:

主题: adding a new EMI Editorial Board member

Dear Prof Wen and other colleagues,

Wenhong nominated a new member, Yu Hongjie from Fudan School of Public Health, to join EMI editorial board. His CV is attached. I had some interactions with him in recent EMI organized activities. He is very supportive and interested in doing more for EMI. Most importantly, his long experience working at China CDC will be very useful to us.

While there are multiple EB members from Fudan system, they have become too busy or taking too much other work. Yu's background is in emerging infection, public health and vaccines. I think it is a good idea to have some new blood and I would support the proposal to add this candidate to EMI EB.

The current EB members will have joined for 3 years by the end of this year. We can review and remove those who do not contribute much to EMI work.

Please advise if you have any comments.

Best.



---

**From:** Wang Linfa <linfa.wang@duke-nus.edu.sg>  
**Sent:** Sunday, May 17, 2020 3:02 AM  
**To:** Lu, Shan  
**Subject:** RE: advice

Dear Shan,

This is very typical “Chinese science product”: an important discovery with very poor writing and “laziness” in dig a bit deeper!

In its current form, it is NOT EMI level, my view anyway.

But I would ask them to enhance this for reconsideration by doing the following:

- 1) In vitro study to show any virologic difference: be it replication efficiency or cell tropism
- 2) Present some epi data: to me the most important finding was summarized in a poorly written sentence “It worth noting that the HE recombinant BCoV strain seems to have stronger epidemic ability”. What does this mean and where is the data?

If they can provide data for 1) and 2), I am happy to do a more detail review for you, but not the present form. Also, they need to improve the writing/English as well.

Cheers,

LF

**Linfa (Lin-Fa) WANG, PhD FTSE**  
**Professor & Director**  
**Programme in Emerging Infectious Disease**  
**Duke-NUS Medical School,**  
**8 College Road, Singapore 169857**  
**Tel: +65 6516 8397**

---

**From:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Sent:** Sunday, 17 May 2020 9:11 AM  
**To:** Wang Linfa <linfa.wang@duke-nus.edu.sg>  
**Subject:** advice

- External Email -

Hi, Linfa,

EMI received this new manuscript. I wonder if you think it is worthwhile for a formal peer-review? We intend to make an editorial rejection.

Thanks.

Shan

(keep this confidential)

\*\*\*\*\*

Shan Lu, MD, PhD

Editor-in-Chief

Emerging Microbes and Infections (EMI)

[www.tandfonline.com/TEMI](http://www.tandfonline.com/TEMI)

[editorial@2012EMI.org](mailto:editorial@2012EMI.org)

---

Important: This email is confidential and may be privileged. If you are not the intended recipient, please delete it and notify us immediately; you should not copy or use it for any purpose, nor disclose its contents to any other person. Thank you.

---

**From:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
**Sent:** Thursday, October 15, 2020 12:30 AM  
**To:** Lu, Shan; Yumei Wen (ymwen@shmu.edu.cn)  
**Subject:** RE: An urgent manuscript on COVID-19 surveillance

Thank you, Shan.

Yi-Wei

---

**From:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Sent:** Thursday, October 15, 2020 10:36 AM  
**To:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>; Yumei Wen (ymwen@shmu.edu.cn) <ymwen@shmu.edu.cn>  
**Subject:** RE: An urgent manuscript on COVID-19 surveillance

Hi, Yi-Wei,

It is not surprising that new cases in certain countries and regions are imported cases so I am not sure why this author makes his work so surprising.

At the same time, we do not have such reports documented in EMI so it is worthwhile to let this author to submit. Thanks for willing to be RE which is great. Please do include KY as a reviewer as he may or may not agree with the author.

Love to know what is Prof Wen opinion.

Best.

Shan

---

**From:** Tang, Yi-Wei <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>  
**Sent:** Wednesday, October 14, 2020 10:31 PM  
**To:** Yumei Wen ([ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)) <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>; Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** Fwd: An urgent manuscript on COVID-19 surveillance

Teacher Wen, Shan,

Please see below and give your advice. I myself would be happy to be a review editor to give it a quick process.

Thank you.

Yi-Wei

Get [Outlook for iOS](#)

---

**From:** Tang, Yi-Wei <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>  
**Sent:** Thursday, October 15, 2020 10:27  
**To:** SIU, Gilman [HTI]  
**Subject:** Re: An urgent manuscript on COVID-19 surveillance

Gilman, thank you for sharing. I will discuss with EMI eic and get back to you soon.

Yi-Wei

Get [Outlook for iOS](#)

---

**From:** SIU, Gilman [HTI] <[gilman.siu@polyu.edu.hk](mailto:gilman.siu@polyu.edu.hk)>  
**Sent:** Thursday, October 15, 2020 9:18:00 AM  
**To:** Tang, Yi-Wei <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>  
**Subject:** An urgent manuscript on COVID-19 surveillance

Dear Tang,

I am writing to seek for your advices on publishing an urgent manuscript on COVID-19 surveillance. As you may know, Hong Kong experienced the largest COVID-19 outbreak during this summer. The virus swept through the city, affecting care homes for the elderly and the disabled, public hospitals, detention facilities, wet markets and a container terminal. The total number of cases has increased five-fold from just over 1,000 in early July to over 5,000 as of August 31, 2020. The outbreak has eventually died down since September and daily local cases came to zero on 25 Sept 2020.

However, since 1 October, a series of locally acquired cases (n=51) re-appeared since September 30, 2020. The Government believes that the relapse of local cases was due to untraceable infections leftover in the community from the third wave after the recent easing of restrictions. However, our team completed whole-genome sequencing this Monday (12 October) for around 10 new local cases. Surprisingly, we found that the genomes of these cases are significantly different from those found in the summer outbreak. In fact, they belong to different phylogenetic clade. We then investigated the genomes of the recent imported case (incoming travellers from other countries). Phylogenetical analysis confirmed that the new local cases are all closely related to the imported cases from India and Nepal.

Our results suggest that the new spike in local infections may be triggered by a sudden increase of imported infections in late September, instead of hidden cases in the community leftover from the previous wave. More disturbingly, some locally acquired cases with the new viral genome did not have apparent epidemiological linkage and were geographically distant from each other (Supplementary Figure 2), indicating that the newly imported GH clade SARS-CoV-2 is disseminating in our community. This could be a warning sign that a fourth wave of COVID-19 infections is looming in Hong Kong. Something wrong is happening for our quarantine and infection control measures at the borders for incoming travellers.

I think we have an urgent message for the government that we have strengthen the testing and quarantine arrangement for the travellers. We plan to submit a manuscript as a letter to Emerging Microbes and Infections (EMI). But time required for review process is a matter in our case. I know you are an associate editor of EMI. May I seek for your advice if EMI is a good choice or you would recommend other journals?

Thank you very much for your help.

Regards  
Gilman



*Disclaimer:*



*This message (including any attachments) contains confidential information intended for a specific individual and purpose. If you are not the intended recipient, you should delete this message and notify the sender and The Hong Kong Polytechnic University (the University) immediately. Any disclosure, copying, or distribution of this message, or the taking of any action based on it, is strictly prohibited and may be unlawful.*

*The University specifically denies any responsibility for the accuracy or quality of information obtained through University E-mail Facilities. Any views and opinions expressed are only those of the author(s) and do not necessarily represent those of the University and the University accepts no liability whatsoever for any losses or damages incurred or caused to any party as a result of the use of such information.*

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

---

**From:** Martin martin <winter999@hotmail.com>  
**Sent:** Monday, August 19, 2019 10:28 PM  
**To:** Lu, Shan; wen yumei  
**Subject:** Re: Application for the Senior Editor Position of EMI

Hi, Shan,  
I am Ok with this candidate, I can join the interview when you be in Shanghai.  
xiaodong

---

**From:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Sent:** Sunday, August 18, 2019 12:20 PM  
**To:** wen yumei <ymwen@shmu.edu.cn>; Martin martin <winter999@hotmail.com>  
**Subject:** FW: Application for the Senior Editor Position of EMI

Dear Prof Wen and Xiaodong,

Here is another applicant. I have talked to her after receiving her email and resume. She seems to be a good candidate for us. Please take a look.

One issue is that she lives in Beijing and she does not plan to move at this point. Given the open access journal, I am fine with a person working from other city. We can organize some regular in person meetings in Shanghai, such as a quarterly meeting to go over things, especially when I am back.

At this stage, the key to see if you feel that she is acceptable to EMI. So far we have not had much responses beside her and the other person working with Bio-Rad whom I talked to and she does not want to apply the job after my discussion with her by phone. So this new applicant is the only candidate at this point.

I can arrange her to talk to you by phone if you like. We can also have an in-person interview when I am back in late Sept to Shanghai.

Best.

Shan

**From:** muqimeng [mailto:muqimeng@126.com]  
**Sent:** Wednesday, August 14, 2019 9:42 AM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>; min.yang@emi2012.org  
**Subject:** Application for the Senior Editor Position of EMI

Dear Professor,

I would like to apply the Senior Editor Position of EMI. The position is attractive for me, and I think I am competent for it. I have more than two years' editorial experience in peer review journal publishing and nearly three years' academic research experience.

I have attached my resume both in English and Chinese.  
Looking forward to your reply and thanks for your consideration.

Best regards  
Mu Qimeng



---

**From:** Liu, Shan-Lu <liu.6244@osu.edu>  
**Sent:** Thursday, August 1, 2019 6:17 AM  
**To:** Zhi-Ming Zheng  
**Cc:** Lu, Shan; zihai.li@osumc.edu  
**Subject:** Re: Assistance with sign-on statement about monitoring of Chinese scholars and students

Forwarded; no response from the SCBA leadership yet.

Shan-Lu Liu sent from iPhone

On Aug 1, 2019, at 10:53 AM, Zhi-Ming Zheng <[zhengzhiming4@gmail.com](mailto:zhengzhiming4@gmail.com)> wrote:

I totally agree that SCBA should sign the letter. Did you forward it to Paul Liu and Hui Zheng?

Thanks for the notice!

Zhu-Ming

On Wed, Jul 31, 2019 at 7:27 PM Liu, Shan-Lu <[liu.6244@osu.edu](mailto:liu.6244@osu.edu)> wrote:

Shared with SCBA, no sure if SCBA would be interested in signing.

Shan-Lu Liu sent from iPhone

Begin forwarded message:

**From:** "Gao, Shou-jiang" <[gaos8@upmc.edu](mailto:gaos8@upmc.edu)>  
**Date:** August 1, 2019 at 6:03:43 AM GMT+8  
**To:** "Liu, Shan-Lu" <[liu.6244@osu.edu](mailto:liu.6244@osu.edu)>  
**Subject:** **Fw: Assistance with sign-on statement about monitoring of Chinese scholars and students**

Hi Shan-Lu,

Please see the e-mail below from Committee on Human Rights at National Academies of Sciences, Engineering, and Medicine, and the attached statement. The virologists association should join in for the effort!

Thanks,

SJ

*Shou-Jiang Gao*

---

**From:** Zhang, Lin <[ZhangLx@upmc.edu](mailto:ZhangLx@upmc.edu)>  
**Sent:** Wednesday, July 31, 2019 5:49 PM  
**To:** Moore, Patrick S <[psm9@pitt.edu](mailto:psm9@pitt.edu)>; Chang, Yuan <[yc70@pitt.edu](mailto:yc70@pitt.edu)>; Gao, Shou-jiang <[gaos8@upmc.edu](mailto:gaos8@upmc.edu)>; Yu, Jian <[YuJ2@upmc.edu](mailto:YuJ2@upmc.edu)>  
**Subject:** FW: Assistance with sign-on statement about monitoring of Chinese scholars and students

Pat,

I have been busy reaching out to several organizations for this. Thanks.

Lin

---

**From:** Evers, Patty <[PEvers@nas.edu](mailto:PEvers@nas.edu)>  
**Sent:** Wednesday, July 31, 2019 11:35 AM  
**To:** Zhang, Lin <[ZhangLx@upmc.edu](mailto:ZhangLx@upmc.edu)>  
**Subject:** Assistance with sign-on statement about monitoring of Chinese scholars and students

Dear Dr. Lin Zhang,

I work with Rebecca Everly at the Committee on Human Rights of the National Academies of Sciences, Engineering, Medicine. Becca is out of the office this week, so I am writing to tell you about an initiative that PEN America and Scholars at Risk (SAR) are working on. They have prepared a statement (see attached) in response to the FBI's move to advise some U.S. universities to develop protocols for monitoring students and scholars from Chinese state-affiliated research institutions. The statement was prepared in consultation with the American Association of University Professors and the Association of American Colleges and Universities. They are now reaching out to a broad coalition of organizations (scientific, educational, freedom of expression, etc.) who may be interested in signing it. We wondered whether the Association of Chinese Americans in Cancer Research might be interested in joining this initiative. If you think they would and/or you know of any other organizations who might be interested, would you be able to help us to connect our SAR colleague with them? Unfortunately, the timing is tight - they hope to issue the statement this Friday, August 2, or Monday, August 5.

Thank you for your consideration.

Best regards,  
Patty Evers

\*\*\*\*\*

Patricia Evers  
Deputy Director  
Committee on Human Rights  
National Academies of Sciences, Engineering, and Medicine  
[500 Fifth Street, NW](#)  
[Washington, DC 20001](#)  
Tel: 202-334-2690

---

**From:** Zhi-Ming Zheng <zhengzhiming4@gmail.com>  
**Sent:** Wednesday, July 31, 2019 10:53 PM  
**To:** Liu, Shan-Lu  
**Cc:** Lu, Shan; zihai.li@osumc.edu  
**Subject:** Re: Assistance with sign-on statement about monitoring of Chinese scholars and students

I totally agree that SCBA should sign the letter. Did you forward it to Paul Liu and Hui Zheng?

Thanks for the notice!

Zhu-Ming

On Wed, Jul 31, 2019 at 7:27 PM Liu, Shan-Lu <[liu.6244@osu.edu](mailto:liu.6244@osu.edu)> wrote:

Shared with SCBA, no sure if SCBA would be interested in signing.

Shan-Lu Liu sent from iPhone

Begin forwarded message:

**From:** "Gao, Shou-jiang" <[gaos8@upmc.edu](mailto:gaos8@upmc.edu)>  
**Date:** August 1, 2019 at 6:03:43 AM GMT+8  
**To:** "Liu, Shan-Lu" <[liu.6244@osu.edu](mailto:liu.6244@osu.edu)>  
**Subject:** **Fw: Assistance with sign-on statement about monitoring of Chinese scholars and students**

Hi Shan-Lu,

Please see the e-mail below from Committee on Human Rights at National Academies of Sciences, Engineering, and Medicine, and the attached statement. The virologists association should join in for the effort!

Thanks,

SJ

*Shou-Jiang Gao*

---

**From:** Zhang, Lin <[ZhangLx@upmc.edu](mailto:ZhangLx@upmc.edu)>  
**Sent:** Wednesday, July 31, 2019 5:49 PM  
**To:** Moore, Patrick S <[psm9@pitt.edu](mailto:psm9@pitt.edu)>; Chang, Yuan <[yc70@pitt.edu](mailto:yc70@pitt.edu)>; Gao, Shou-jiang <[gaos8@upmc.edu](mailto:gaos8@upmc.edu)>; Yu, Jian <[YuJ2@upmc.edu](mailto:YuJ2@upmc.edu)>  
**Subject:** **FW: Assistance with sign-on statement about monitoring of Chinese scholars and students**

Pat,

I have been busy reaching out to several organizations for this. Thanks.

Lin

---

**From:** Evers, Patty <[PEvers@nas.edu](mailto:PEvers@nas.edu)>

**Sent:** Wednesday, July 31, 2019 11:35 AM

**To:** Zhang, Lin <[ZhangLx@upmc.edu](mailto:ZhangLx@upmc.edu)>

**Subject:** Assistance with sign-on statement about monitoring of Chinese scholars and students

Dear Dr. Lin Zhang,

I work with Rebecca Everly at the Committee on Human Rights of the National Academies of Sciences, Engineering, Medicine. Becca is out of the office this week, so I am writing to tell you about an initiative that PEN America and Scholars at Risk (SAR) are working on. They have prepared a statement (see attached) in response to the FBI's move to advise some U.S. universities to develop protocols for monitoring students and scholars from Chinese state-affiliated research institutions. The statement was prepared in consultation with the American Association of University Professors and the Association of American Colleges and Universities. They are now reaching out to a broad coalition of organizations (scientific, educational, freedom of expression, etc.) who may be interested in signing it. We wondered whether the Association of Chinese Americans in Cancer Research might be interested in joining this initiative. If you think they would and/or you know of any other organizations who might be interested, would you be able to help us to connect our SAR colleague with them? Unfortunately, the timing is tight - they hope to issue the statement this Friday, August 2, or Monday, August 5.

Thank you for your consideration.

Best regards,  
Patty Evers

\*\*\*\*\*

Patricia Evers  
Deputy Director  
Committee on Human Rights  
National Academies of Sciences, Engineering, and Medicine  
[500 Fifth Street, NW](#)  
[Washington, DC 20001](#)  
Tel: 202-334-2690

---

**From:** Saif, Linda <saif.2@osu.edu>  
**Sent:** Sunday, July 26, 2020 11:37 AM  
**To:** Lu, Shan  
**Subject:** Re: audience question and congress video

Sorry—just trying to view it to respond to your request from below:

"Please take a quick look within the next 24 hours, and let us know by replying to this email if you found any issue."

Linda  
Linda J. Saif, PhD  
Distinguished University Professor  
Food Animal Health Research Program  
OARDC/The Ohio State University  
1680 Madison Ave  
Wooster, Oh 44691

---

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Date:** Sunday, July 26, 2020 11:34 AM  
**To:** Linda Saif <[saif.2@osu.edu](mailto:saif.2@osu.edu)>  
**Subject:** RE: audience question and congress video

What kind of issue? Probably hard to address content since it was a live recording.

---

**From:** Saif, Linda <[saif.2@osu.edu](mailto:saif.2@osu.edu)>  
**Sent:** Sunday, July 26, 2020 11:32 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** Re: audience question and congress video

Thanks—very helpful to find it—but if already uploaded to YouTube is there still chance to address any issues?

Linda  
Linda J. Saif, PhD  
Distinguished University Professor  
Food Animal Health Research Program  
OARDC/The Ohio State University  
1680 Madison Ave  
Wooster, Oh 44691

---

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Date:** Sunday, July 26, 2020 10:48 AM  
**To:** Linda Saif <[saif.2@osu.edu](mailto:saif.2@osu.edu)>  
**Subject:** RE: audience question and congress video

[https://www.youtube.com/channel/UC9\\_-f8tDAqOmVEZWqGeuFow](https://www.youtube.com/channel/UC9_-f8tDAqOmVEZWqGeuFow)

try this link and you should be able to find 4 from July 21 (2<sup>nd</sup> congress) and 4 previous ones.



---

**From:** Saif, Linda <[saif.2@osu.edu](mailto:saif.2@osu.edu)>  
**Sent:** Sunday, July 26, 2020 10:46 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** RE: audience question and congress video

Hi Shan Lu,  
Can you please send this link for the July 21 recording?  
I can only find the first one on U tube.  
Thanks,  
Linda

---

**From:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Sent:** Saturday, July 25, 2020 10:56 PM  
**To:** ISVCongress.org <[info@isvcongress.org](mailto:info@isvcongress.org)>  
**Cc:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Subject:** audience question and congress video

Dear Speakers (and co-chairs, session chairs and moderator),

We have put the 2<sup>nd</sup> congress videos to YouTube. Please take a quick look within the next 24 hours, and let us know by replying to this email if you found any issue. You can go to YouTube and search for “International Society for Vaccines”.

We also put together the questions from audience and attach here for your reference. They were collected based on the time they were asked so some may not match with the speakers. Dr. Manon Cox will contact you separately to see if you would like to provide answers to questions related to your presentation/your vaccine program.

Total registration for 2<sup>nd</sup> Virtual Congress: 3500. Peak time attendees at 2<sup>nd</sup> Virtual Congress: 1850. The video recordings for the 1<sup>st</sup> Virtual Congress more than 3500 views up to this point.

Once again, thanks for your excellent presentations and your support to ISV.

Best.

Shan

---

**From:** Saif, Linda <saif.2@osu.edu>  
**Sent:** Sunday, July 26, 2020 11:32 AM  
**To:** Lu, Shan  
**Subject:** Re: audience question and congress video

Thanks—very helpful to find it—but if already uploaded to YouTube is there still chance to address any issues?  
Linda

Linda J. Saif, PhD  
Distinguished University Professor  
Food Animal Health Research Program  
OARDC/The Ohio State University  
1680 Madison Ave  
Wooster, Oh 44691

---

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Date:** Sunday, July 26, 2020 10:48 AM  
**To:** Linda Saif <[saif.2@osu.edu](mailto:saif.2@osu.edu)>  
**Subject:** RE: audience question and congress video

[https://www.youtube.com/channel/UC9\\_-f8tDAqOmVEZWqGeuFow](https://www.youtube.com/channel/UC9_-f8tDAqOmVEZWqGeuFow)

try this link and you should be able to find 4 from July 21 (2<sup>nd</sup> congress) and 4 previous ones.

---

**From:** Saif, Linda <[saif.2@osu.edu](mailto:saif.2@osu.edu)>  
**Sent:** Sunday, July 26, 2020 10:46 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** RE: audience question and congress video

Hi Shan Lu,  
Can you please send this link for the July 21 recording?  
I can only find the first one on U tube.  
Thanks,  
Linda

---

**From:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Sent:** Saturday, July 25, 2020 10:56 PM  
**To:** ISVCongress.org <[info@isvcongress.org](mailto:info@isvcongress.org)>  
**Cc:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Subject:** audience question and congress video

Dear Speakers (and co-chairs, session chairs and moderator),

We have put the 2<sup>nd</sup> congress videos to YouTube. Please take a quick look within the next 24 hours, and let us know by replying to this email if you found any issue. You can go to YouTube and search for "International Society for Vaccines".

We also put together the questions from audience and attach here for your reference. They were collected based on the time they were asked so some may not match with the speakers. Dr. Manon Cox will contact you separately to see if you would like to provide answers to questions related to your presentation/your vaccine program.

Total registration for 2<sup>nd</sup> Virtual Congress: 3500. Peak time attendees at 2<sup>nd</sup> Virtual Congress: 1850. The video recordings for the 1<sup>st</sup> Virtual Congress more than 3500 views up to this point.

Once again, thanks for your excellent presentations and your support to ISV.

Best.

Shan

---

**From:** YiWei Tang <yiweitangmd@gmail.com>  
**Sent:** Friday, July 24, 2020 5:38 AM  
**To:** wen yumei  
**Cc:** Lu, Shan; 袁正宏; zhangwenhong; Winter999  
**Subject:** Re: Becker co-editors-in-chief

Very impressive CV. I support the process with sincere hope that he will be able to dedicate enough time to the role. I also like to suggest that Xiaodong have a proposal to provide reasonable honorarium for him and Shan's work.

Yi-Wei

On Fri, Jul 24, 2020 at 8:15 AM wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)> wrote:

Dear All

I think Becker is a good candidate for Co-editors-in-chief. Please respond within two days for your comment. Otherwise, Shan and I will invite him. YM Wen

-----Original Messages-----

**From:** "Sabine Fischbach" <[fischbach@staff.uni-marburg.de](mailto:fischbach@staff.uni-marburg.de)>  
**Sent Time:** 2020-07-23 13:28:07 (Thursday)  
**To:** "'wen yumei'" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
**Cc:** [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu)  
**Subject:** CV - now attached

Dear Dr. Wen,

sorry – I forgot to send the document. Now it is attached.

Best regards

Sabine Fischbach

---

**Von:** Sabine Fischbach [mailto:[fischbach@staff.uni-marburg.de](mailto:fischbach@staff.uni-marburg.de)]  
**Gesendet:** Mittwoch, 22. Juli 2020 13:17  
**An:** 'wen yumei' <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
**Betreff:** WG: co-editors in chief

Dear Dr. Wen,

Please find attached the CV of Dr. Stephan Becker.

Best regards

Sabine Fischbach

---

**Von:** Hans-Dieter Klenk [<mailto:klenk@staff.uni-marburg.de>]

**Gesendet:** Mittwoch, 22. Juli 2020 11:34

**An:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>

**Cc:** Lu\_Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; YiWei Tang <[yiweitangmd@gmail.com](mailto:yiweitangmd@gmail.com)>; yuan zhenhong <[zhyuan@shmu.edu.cn](mailto:zhyuan@shmu.edu.cn)>; Winter999 <[Winter999@hotmail.com](mailto:Winter999@hotmail.com)>; zhangwenhong <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>; Sabine Fischbach <[fischbach@staff.uni-marburg.de](mailto:fischbach@staff.uni-marburg.de)>

**Betreff:** Re: co-editors in chief

Dear Yu-mei,

The scientist I suggested as co-editor in chief is Stephan Becker who is my successor as director of the Marburg institute. He is an expert in emerging viruses and now also heavily engaged in COVID-19 research. His CV will follow.

Regards

Hans

Prof. Dr. Hans-Dieter Klenk  
Institut für Virologie  
Hans-Meerwein-Str. 2  
35043 Marburg  
Germany

Tel.: +49 6421 286 6191

Sek.: +49 6421 286 6254

Fax: +49 6421 286 8962

E-Mail: [klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)

Am 21.07.2020 um 02:45 schrieb wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>:

Hi, Hans.

We are still looking for an editor-in-chief for EMI from Europe. As mentined before, you suggested that one scientist from your institute might be a candidate. Due to your long term support and contriubtion to EMI, with your guidance,we would like to consider this candidate as one of the editors-in-chief.

Would you please ask him, if he is willing to take this post, and send us his CV?

Thank you. Germany is great in participating combating COvVID-19. Regards,

Yu-mei

---

**From:** yuan zhenghong <zhyuan@shmu.edu.cn>  
**Sent:** Friday, July 24, 2020 12:17 AM  
**To:** wen yumei  
**Cc:** Lu, Shan; zhangwenhong; YiWei Tang; Winter999  
**Subject:** Re: Becker co-editors-in-chief

I support the decision. Best ,Zhenghong

-----原始邮件-----

发件人:"wen yumei" <ymwen@shmu.edu.cn>

发送时间:2020-07-24 08:15:34 (星期五)

收件人: "Lu\_ Shan" <Shan.Lu@umassmed.edu>, "袁正宏" <Zhyuan@shmu.edu.cn>, zhangwenhong <zhangwenhong@fudan.edu.cn>, "YiWei Tang" <yiweitangmd@gmail.com>, Winter999 <Winter999@hotmail.com>

抄送:

主题: Becker co-editors-in-chief

Dear All

I think Becker is a good candidate for Co-editors-in-chief. Please respond within two days for your comment. Otherwise, Shan and I will invite him. YMWen

-----Original Messages-----

**From:** "Sabine Fischbach" <fischbach@staff.uni-marburg.de>

**Sent Time:**2020-07-23 13:28:07 (Thursday)

**To:** "wen yumei" <ymwen@shmu.edu.cn>

**Cc:** shan.lu@umassmed.edu

**Subject:** CV - now attached

Dear Dr. Wen,

sorry – I forgot to send the document. Now it is attached.

Best regards

Sabine Fischbach

---

**Von:** Sabine Fischbach [mailto:fischbach@staff.uni-marburg.de]

**Gesendet:** Mittwoch, 22. Juli 2020 13:17

**An:** 'wen yumei' <ymwen@shmu.edu.cn>

**Betreff:** WG: co-editors in chief

Dear Dr. Wen,

Please find attached the CV of Dr. Stephan Becker.

Best regards  
Sabine Fischbach

---

**Von:** Hans-Dieter Klenk [<mailto:klenk@staff.uni-marburg.de>]

**Gesendet:** Mittwoch, 22. Juli 2020 11:34

**An:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>

**Cc:** Lu\_ Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; YiWei Tang <[yiweitangmd@gmail.com](mailto:yiweitangmd@gmail.com)>; yuan zhenhong <[zhyuan@shmu.edu.cn](mailto:zhyuan@shmu.edu.cn)>; Winter999 <[Winter999@hotmail.com](mailto:Winter999@hotmail.com)>; zhangwenhong <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>; Sabine Fischbach <[fischbach@staff.uni-marburg.de](mailto:fischbach@staff.uni-marburg.de)>

**Betreff:** Re: co-editors in chief

Dear Yu-mei,

The scientist I suggested as co-editor in chief is Stephan Becker who is my successor as director of the Marburg institute. He is an expert in emerging viruses and now also heavily engaged in COVID-19 research. His CV will follow.

Regards  
Hans

Prof. Dr. Hans-Dieter Klenk  
Institut für Virologie  
Hans-Meerwein-Str. 2  
35043 Marburg  
Germany

Tel.: +49 6421 286 6191

Sek.: +49 6421 286 6254

Fax: +49 6421 286 8962

E-Mail: [klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)

Am 21.07.2020 um 02:45 schrieb wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>:

Hi, Hans.

We are still looking for an editor-in-chief for EMI from Europe. As mentined before, you suggested that one scientist from your institute might be a candidate. Due to your long term support and contriubtion to EMI, with your guidance,we would like to consider this candidate as one of the editors-in-chief. Would you please ask him, if he is willing to take this post, and send us his CV?

Thank you. Germany is great in participating combating COvVID-19. Regards,  
Yu-mei





---

**From:** Liu, Shan-Lu <liu.6244@osu.edu>  
**Sent:** Friday, February 14, 2020 2:26 PM  
**To:** Zheng, Zhi-Ming (Thomas) (NIH/NCI) [E]; Lu, Shan  
**Subject:** Re: Boston case

Zhi-Ming:  
I shared this with our group yesterday.

Thanks.

Shan-Lu

---

**From:** "Zheng, Zhi-Ming (Thomas) (NIH/NCI) [E]" <zhenegt@exchange.nih.gov>  
**Date:** Friday, February 14, 2020 at 12:39 PM  
**To:** Shan-Lu Liu <liu.6244@osu.edu>, "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Subject:** FW: Boston case

This is for your reference. You may upload it to our group.

Thanks,

Thomas

---

**From:** Hans-Dieter Klenk <klenk@staff.uni-marburg.de>  
**Sent:** Wednesday, July 29, 2020 1:03 PM  
**To:** Lu, Shan  
**Cc:** wen yumei; Sabine Fischbach  
**Subject:** Re: co-editors in chief

Dear Shan,

I am quite confident that Stephan Becker will accept your invitation to become co-editor in chief. At least this was my impression when I talked with him about it. Right now his is on vacation. So I will talk with him again when he is back.

Best wishes  
Hans

Prof. Dr. Hans-Dieter Klenk  
Institut für Virologie  
Hans-Meerwein-Str. 2  
35043 Marburg  
Germany

Tel.: +49 6421 286 6191  
Sek.: +49 6421 286 6254  
Fax: +49 6421 286 8962  
[E-Mail: klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)

Am 29.07.2020 um 17:47 schrieb Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>:

Dear Hans,

Thanks for your great support! Prof Wen and all of us were very impressed by the CV of Dr. Stephen Becker. We would very much like to invite Stephen to be the co-editor. Please see attached invitation letter from Prof Wen. Please feel free to introduce us to him at your convenience.

Best.

Shan

---

**From:** Hans-Dieter Klenk <[klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)>  
**Sent:** Wednesday, July 22, 2020 5:34 AM  
**To:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; YiWei Tang <[yiweitangmd@gmail.com](mailto:yiweitangmd@gmail.com)>; yuan zhenhong <[zhyuan@shmu.edu.cn](mailto:zhyuan@shmu.edu.cn)>; Winter999 <[Winter999@hotmail.com](mailto:Winter999@hotmail.com)>; zhangwenhong <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>; Sabine Fischbach <[fischbach@staff.uni-marburg.de](mailto:fischbach@staff.uni-marburg.de)>  
**Subject:** Re: co-editors in chief

Dear Yu-mei,

The scientist I suggested as co-editor in chief is Stephan Becker who is my successor as director of the Marburg institute. He is an expert in emerging viruses and now also heavily engaged in COVID-19 research. His CV will follow.

Regards  
Hans

Prof. Dr. Hans-Dieter Klenk  
Institut für Virologie  
Hans-Meerwein-Str. 2  
35043 Marburg  
Germany

Tel.: +49 6421 286 6191  
Sek.: +49 6421 286 6254  
Fax: +49 6421 286 8962  
[E-Mail: klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)

Am 21.07.2020 um 02:45 schrieb wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>:

Hi, Hans.

We are still looking for an editor-in-chief for EMI from Europe. As mentioned before, you suggested that one scientist from your institute might be a candidate. Due to your long term support and contribution to EMI, with your guidance, we would like to consider this candidate as one of the editors-in-chief. Would you please ask him, if he is willing to take this post, and send us his CV?

Thank you. Germany is great in participating combating COVID-19. Regards,  
Yu-mei

<Invitation Letter-20200729-final.pdf>

---

**From:** Hans-Dieter Klenk <klenk@staff.uni-marburg.de>  
**Sent:** Sunday, August 30, 2020 6:30 AM  
**To:** wen yumei  
**Cc:** Lu, Shan  
**Subject:** Re: co-editors in chief

Dear Yumei and Shan,

Here are some suggestions in alphabetical order:

Christian Drosten ([christian.drosten@charite.de](mailto:christian.drosten@charite.de)). He is the director of the Virology Institute of the Humboldt University in Berlin. He is still very young (48), a good scientist and the most popular covid communicator the German news media. He has also several EMI publications.

Stephan Günther ([guenther@bnitm.de](mailto:guenther@bnitm.de)). He is at the Bernhard Nocht Institute for Tropical Medicine in Hamburg and one of the German leaders in emerging viruses.

Marion Koopmans ([m.koopmans@erasmusmc.nl](mailto:m.koopmans@erasmusmc.nl)). She is the director of the Virology Institute at Erasmus University Rotterdam/Netherlands which is also a leading institution in emerging infections.

Albert Osterhaus ([albert.osterhaus@tiho-nannover.de](mailto:albert.osterhaus@tiho-nannover.de)). He is the predecessor of Koopmans and now the director of a new institute on emerging infections in Hannover. He is a little over 70 and, thus, in the age you suggested.

If I can be of further help, please let me know.

Regards

Hans

Prof. Dr. Hans-Dieter Klenk  
Institut für Virologie  
Hans-Meerwein-Str. 2  
35043 Marburg  
Germany

Tel.: +49 6421 286 6191

Sek.: +49 6421 286 6254

Fax: +49 6421 286 8962

[E-Mail: klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)

Am 30.08.2020 um 02:36 schrieb wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>:

Hans, Thank you for your support and efforts for EMI.

Maybe you can help to recommend some one who has good background in emerging disease, while is retired and is not so active in scientific research from Europe for us. Hope when COVID-19 is under control soon, we can meet again. Yu-mei

-----Original Messages-----

**From:** "Hans-Dieter Klenk" <[klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)>

**Sent Time:** 2020-08-29 18:02:29 (Saturday)

**To:** "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>

**Cc:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Subject:** Re: co-editors in chief

Dear Yumei, dear Shan,

I am very sorry that Stephan Becker did not accept your invitation to become co-editor in chief of EMI. When I approached him first a few weeks ago, I was quite confident that he would accept. If you want me to suggest alternatives from Europe I will be happy to do so.

With my best wishes

Hans

Prof. Dr. Hans-Dieter Klenk  
Institut für Virologie  
Hans-Meerwein-Str. 2  
35043 Marburg  
Germany

Tel.: +49 6421 286 6191

Sek.: +49 6421 286 6254

Fax: +49 6421 286 8962

E-Mail: [klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)

Am 30.07.2020 um 01:59 schrieb wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>:

Hans, Thank you very much for your strong support of EMI. Yu-Mei

-----Original Messages-----

**From:** "Hans-Dieter Klenk" <[klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)>

**Sent Time:** 2020-07-30 01:03:15 (Thursday)

**To:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Cc:** "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>, "Sabine Fischbach" <[fischbach@staff.uni-marburg.de](mailto:fischbach@staff.uni-marburg.de)>

**Subject:** Re: co-editors in chief

Dear Shan,

I am quite confident that Stephan Becker will accept your invitation to become co-editor in chief. At least this was my impression when I talked with him about it. Right now his is on vacation. So I will talk with him again when he is back.

Best wishes

Hans

Prof. Dr. Hans-Dieter Klenk  
Institut für Virologie  
Hans-Meerwein-Str. 2  
35043 Marburg  
Germany

Tel.: +49 6421 286 6191  
Sek.: +49 6421 286 6254  
Fax: +49 6421 286 8962  
[E-Mail: klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)

Am 29.07.2020 um 17:47 schrieb Lu, Shan  
<[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>:

Dear Hans,

Thanks for your great support! Prof Wen and all of us were very impressed by the CV of Dr. Stephen Becker. We would very much like to invite Stephen to be the co-editor. Please see attached invitation letter from Prof Wen. Please feel free to introduce us to him at your convenience.

Best.

Shan

---

**From:** Hans-Dieter Klenk <[klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)>  
**Sent:** Wednesday, July 22, 2020 5:34 AM  
**To:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; YiWei Tang <[yiweitangmd@gmail.com](mailto:yiweitangmd@gmail.com)>; yuan zhenhong <[zhyuan@shmu.edu.cn](mailto:zhyuan@shmu.edu.cn)>; Winter999 <[Winter999@hotmail.com](mailto:Winter999@hotmail.com)>; zhangwenhong <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>; Sabine Fischbach <[fischbach@staff.uni-marburg.de](mailto:fischbach@staff.uni-marburg.de)>  
**Subject:** Re: co-editors in chief

Dear Yu-mei,

The scientist I suggested as co-editor in chief is Stephan Becker who is my successor as director of the Marburg institute. He is an expert in emerging viruses and now also heavily engaged in COVID-19 research. His CV will follow.

Regards  
Hans

Prof. Dr. Hans-Dieter Klenk  
Institut für Virologie  
Hans-Meerwein-Str. 2  
35043 Marburg  
Germany

Tel.: +49 6421 286 6191  
Sek.: +49 6421 286 6254  
Fax: +49 6421 286 8962  
[E-Mail: klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)

Am 21.07.2020 um 02:45 schrieb wen yumei  
<[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>:

Hi, Hans.

We are still looking for an editor-in-chief for EMI from Europe. As mentined before, you suggested that one scientist from your institute might be a candidate. Due to your long term support and contriubtion to EMI, with your guidance,we would like to consider this candidate as one of the editors-in-chief. Would you please ask him, if he is willing to take this post, and send us his CV?

Thank you. Germany is great in participating combating COvVID-19. Regards,  
Yu-mei

<Invitation Letter-20200729-final.pdf>



---

**From:** Hans-Dieter Klenk <klenk@staff.uni-marburg.de>  
**Sent:** Saturday, August 29, 2020 6:02 AM  
**To:** wen yumei  
**Cc:** Lu, Shan  
**Subject:** Re: co-editors in chief

Dear Yumei, dear Shan,

I am very sorry that Stephan Becker did not accept your invitation to become co-editor in chief of EMI. When I approached him first a few weeks ago, I was quite confident that he would accept. If you want me to suggest alternatives from Europe I will be happy to do so.

With my best wishes  
Hans

Prof. Dr. Hans-Dieter Klenk  
Institut für Virologie  
Hans-Meerwein-Str. 2  
35043 Marburg  
Germany

Tel.: +49 6421 286 6191  
Sek.: +49 6421 286 6254  
Fax: +49 6421 286 8962  
[E-Mail: klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)

Am 30.07.2020 um 01:59 schrieb wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>:

Hans, Thank you very much for your strong support of EMI. Yu-Mei

-----Original Messages-----

**From:** "Hans-Dieter Klenk" <[klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)>  
**Sent Time:** 2020-07-30 01:03:15 (Thursday)  
**To:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>, "Sabine Fischbach" <[fischbach@staff.uni-marburg.de](mailto:fischbach@staff.uni-marburg.de)>  
**Subject:** Re: co-editors in chief

Dear Shan,

I am quite confident that Stephan Becker will accept your invitation to become co-editor in chief. At least this was my impression when I talked with him about it. Right now his is on vacation. So I will talk with him again when he is back.

Best wishes  
Hans

Prof. Dr. Hans-Dieter Klenk  
Institut für Virologie  
Hans-Meerwein-Str. 2  
35043 Marburg  
Germany

Tel.: +49 6421 286 6191  
Sek.: +49 6421 286 6254  
Fax: +49 6421 286 8962  
[E-Mail: klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)

Am 29.07.2020 um 17:47 schrieb Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>:

Dear Hans,

Thanks for your great support! Prof Wen and all of us were very impressed by the CV of Dr. Stephen Becker. We would very much like to invite Stephen to be the co-editor. Please see attached invitation letter from Prof Wen. Please feel free to introduce us to him at your convenience.

Best.

Shan

---

**From:** Hans-Dieter Klenk <[klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)>  
**Sent:** Wednesday, July 22, 2020 5:34 AM  
**To:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; YiWei Tang <[yiweitangmd@gmail.com](mailto:yiweitangmd@gmail.com)>; yuan zhenhong <[zhyuan@shmu.edu.cn](mailto:zhyuan@shmu.edu.cn)>; Winter999 <[Winter999@hotmail.com](mailto:Winter999@hotmail.com)>; zhangwenhong <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>; Sabine Fischbach <[fischbach@staff.uni-marburg.de](mailto:fischbach@staff.uni-marburg.de)>  
**Subject:** Re: co-editors in chief

Dear Yu-mei,

The scientist I suggested as co-editor in chief is Stephan Becker who is my successor as director of the Marburg institute. He is an expert in emerging viruses and now also heavily engaged in COVID-19 research. His CV will follow.

Regards  
Hans

Prof. Dr. Hans-Dieter Klenk  
Institut für Virologie  
Hans-Meerwein-Str. 2  
35043 Marburg  
Germany

Tel.: +49 6421 286 6191  
Sek.: +49 6421 286 6254

Fax: +49 6421 286 8962

E-Mail: [klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)

Am 21.07.2020 um 02:45 schrieb wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>:

Hi, Hans.

We are still looking for an editor-in-chief for EMI from Europe. As mentioned before, you suggested that one scientist from your institute might be a candidate. Due to your long term support and contribution to EMI, with your guidance, we would like to consider this candidate as one of the editors-in-chief. Would you please ask him, if he is willing to take this post, and send us his CV?

Thank you. Germany is great in participating combating COvVID-19.

Regards,

Yu-mei

<Invitation Letter-20200729-final.pdf>

---

**From:** Hans-Dieter Klenk <klenk@staff.uni-marburg.de>  
**Sent:** Wednesday, July 22, 2020 5:34 AM  
**To:** wen yumei  
**Cc:** Lu, Shan; YiWei Tang; yuan zhenhong; Winter999; zhangwenhong; Sabine Fischbach  
**Subject:** Re: co-editors in chief

Dear Yu-mei,

The scientist I suggested as co-editor in chief is Stephan Becker who is my successor as director of the Marburg institute. He is an expert in emerging viruses and now also heavily engaged in COVID-19 research. His CV will follow.

Regards  
Hans

Prof. Dr. Hans-Dieter Klenk  
Institut für Virologie  
Hans-Meerwein-Str. 2  
35043 Marburg  
Germany

Tel.: +49 6421 286 6191  
Sek.: +49 6421 286 6254  
Fax: +49 6421 286 8962  
[E-Mail: klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)

Am 21.07.2020 um 02:45 schrieb wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>:

Hi, Hans.

We are still looking for an editor-in-chief for EMI from Europe. As mentined before, you suggested that one scientist from your institute might be a candidate. Due to your long term support and contriubtion to EMI, with your guidance,we would like to consider this candidate as one of the editors-in-chief.

Would you please ask him, if he is willing to take this post, and send us his CV?

Thank you. Germany is great in participating combating COvVID-19. Regards,

Yu-mei

---

**From:** Qiao Wang <qiaoqiaolang163@vip.163.com>  
**Sent:** Saturday, October 24, 2020 10:52 PM  
**To:** Lu, Shan  
**Cc:** wen yumei; yuan zhenhong; zgyi@fudan.edu.cn; yhxie; jieliangchen; xywang; bwang3  
**Subject:** Re: Congratulation

Wow! Very High Compliment!

Charles indeed admires your work and contributions, and you richly deserve this compliment.

Qiao

> On Oct 25, 2020, at 09:42, Lu, Shan <Shan.Lu@umassmed.edu> wrote:  
>  
> Congratulations, Prof Wen!  
>  
> Charlie is a true gentleman, smart and humble.  
>  
> Shan  
>  
> -----Original Message-----  
> From: wen yumei <ymwen@shmu.edu.cn>  
> Sent: Saturday, October 24, 2020 9:19 PM  
> To: yuan zhenhong <zhyuan@shmu.edu.cn>  
> Cc: zgyi@fudan.edu.cn; yhxie <yhxie@fudan.edu.cn>; Qiao Wang  
> <qiaoqiaolang163@vip.163.com>; jieliangchen  
> <jieliangchen@fudan.edu.cn>; xywang <xywang@shmu.edu.cn>; bwang3  
> <bwang3@fudan.edu.cn>; Lu, Shan <Shan.Lu@umassmed.edu>  
> Subject: Fw: Re: Congratulation  
>  
> See the response from Charlie, I am really honored. Wen  
>  
>  
> -----Original Messages-----  
> From: "Charles Rice" <ricec@rockefeller.edu> Sent Time: 2020-10-25  
> 03:45:22 (Sunday)  
> To: "wen yumei" <ymwen@shmu.edu.cn>  
> Cc:  
> Subject: Re: Congratulation  
>  
> Thanks Yu-Mei! As one of your many admirers, your note means a great  
> deal to me. It has been a true pleasure and honor to get to know you  
> and your amazing group of trainees. Looking back, it has been a  
> remarkable period for science yet there are many challenges ahead (not  
> to mention that other persistent troublemaker, HBV!). I hope you are  
> well and I look forward to the next time our paths cross. Warm  
> regards, Charlie  
>

>> On Oct 5, 2020, at 8:29 AM, wen yumei <ymwen@shmu.edu.cn> wrote:

>>

>> Dear Charlie,

>> The news of you and the other two scientists received the Nobel Prize was immediately spread in our lab, and everybody is thrilled, because of your long time collaboration with us and some of them were trained in your lab.

>> Congratulation ! Your contribution in virology is worldwide recognized, and of course your outstanding contribution in HCV has saved the lives of many people.

>> Thank you for helping Zhenghong and our lab in all aspects, and hope

>> you all the best, and keep fit. Yu-mei

>>

>>

>>

>>

>

>

>

>

>

---

**From:** kyyuen <kyyuen@hku.hk>  
**Sent:** Saturday, October 24, 2020 8:02 PM  
**To:** Lu, Shan  
**Cc:** Tang, Yi-Wei; 石正丽; Liu, Shan-Lu; Naveen Vankadari; Su, Lishan; litsh@263.net; peng.zhou@wh.iov.cn; M. Yu-Mei Wen (ymwen@shmu.edu.cn); Martin martin; Josaphouitch, Alexa; Qiao, Jessica; Min Yang; editorial2@emi2012.org  
**Subject:** Re: Congratulations - your EMI papers are included in T&F's top ten OA articles of 2020

Dear Shan and all,  
Many many congratulations for the great success. Very glad to see the rising impact factor of EMI!  
Ky

從我的iPhone傳送

Lu, Shan <Shan.Lu@umassmed.edu>於2020年10月25日 上午3:25寫道：

Dear Drs. Zhengli Shi/Peng Zhou, Kwok-Yung Yuen, Lishan Su/Shan-lu Liu, Taisheng Li, Yi-Wei Tang and Naveen Vankadari,

On behalf of Prof Wen and EMI, congratulations!

I assume you have received an email notice from T&F (see one sample below) that one of your EMI papers was included as one of the top 10 Open Access papers from the entire T&F family (over 2700 journals). This is from [a blog post on our Author Services website](#) (click and find the site). Attached is the PDF copy list I produced for your reference.

Your EMI papers are ranked #1, #3, #4, #5, #8 and #10, six out of top ten, for entire 2020 up to this point! This is an incredible achievement to each of you. I believe such numbers of down load read will be ranked very high with any other major publishing houses.

EMI would like to thank you for your great work and contribution to the global health effort in this difficult time with COVID-19 pandemic.

EMI is very grateful to authors like you who have made EMI one of the leading biomedical journals in the world. Your creativity, sensitivity, fact searching and out of box thinking have constantly pushed the frontier of science and medicine. EMI is proud to be part of your great endeavour.

EMI is thinking to create new tools and forums to further promote your research findings so more people can be benefited. In the near future, EMI will launch an "EMI Virtual Journal Club (VJC)" program in which each time, one leading EMI paper will be presented by the original authors online, open to the global scientific community so the authors of scientific papers will be able to have direct communications with their readers. Your papers will be the candidates for our initial launch. More details will be shared with you soon and I would like to invite you to be part of our first group of VJC authors.

Best.

Shan

---

**From:** Bergan, Rachel <[Rachel.Bergan@tandf.co.uk](mailto:Rachel.Bergan@tandf.co.uk)>  
**Sent:** Thursday, October 22, 2020 5:10 PM  
**To:** Tang, Yi-Wei <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>  
**Subject:** Your paper features in T&F's top ten OA articles of 2020

Dear Yi-Wei,

I'm very pleased to let you know that your recent article "Laboratory diagnosis of emerging human coronavirus infections – the state of the art" was one of the most-downloaded open access articles published by Taylor & Francis so far this year.

Many congratulations!

To mark Open Access Week, we have published [a blog post on our Author Services website](#) about the Top 10, including links to the articles, and details of each Altmetric score to reflect the discussion of your article online and in the media.

**This is a great excuse to further highlight your research to your contacts and communities.** We will be promoting the blog post on our social media platforms: [Twitter](#), [LinkedIn](#), and [Facebook](#). You could share our posts/tweets or write your own (please use the same hashtags).

We'll also be featuring the Top 10 in our [Insights newsletter](#), to further reach researchers and the wider academic community.

Please do not hesitate to contact me if you have any further questions or queries.

Kind Regards,  
Rachel

Rachel Bergan (she/her)  
Communications Coordinator  
Taylor & Francis Group

Email: [rachel.bergan@tandf.co.uk](mailto:rachel.bergan@tandf.co.uk)  
Tel: +44 (0) 20 755 19259  
4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN, UK

<image001.png>



<image002.png>

**Information Classification: General**

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

<top 10 papers from T&F Open Access -2020.pdf>

the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

---

**From:** Su, Lishan <lishan\_su@med.unc.edu>  
**Sent:** Sunday, October 25, 2020 11:35 AM  
**To:** Lu, Shan; Tang, Yi-Wei; kyyuen; 石正丽; Liu, Shan-Lu; Naveen Vankadari; litsh@263.net; peng.zhou@wh.iov.cn  
**Cc:** M. Yu-Mei Wen (ymwen@shmu.edu.cn); Martin martin; Josaphouitch, Alexa; Qiao, Jessica; Min Yang; editorial2@emi2012.org  
**Subject:** Re: Congratulations - your EMI papers are included in T&F's top ten OA articles of 2020

Thanks, Shan!

I commend you for your great "taste" or judgment in choosing the right manuscripts for EMI during the early frantic phase of the pandemic!

Congrats.!

ps: please see my new contact information below.

---Lishan

Lishan Su, PhD  
Laboratory of Viral Pathogenesis and Immunotherapy  
Director, Division of Virology, Pathogenesis and Cancer  
Institute of Human Virology  
Professor of Pharmacology, and Microbiology & Immunology  
University of Maryland School of Medicine  
[lsu@ihv.umaryland.edu](mailto:lsu@ihv.umaryland.edu)

---

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Date:** Saturday, October 24, 2020 at 3:25 PM  
**To:** "Tang, Yi-Wei" <yi-wei.tang@cepheid.com>, kyyuen <kyyuen@hku.hk>, 石正丽 <zlishi@wh.iov.cn>, "Liu, Shan-Lu" <liu.6244@osu.edu>, Naveen Vankadari <naveen.vankadari@monash.edu>, "Su, Lishan" <lishan\_su@med.unc.edu>, "litsh@263.net" <litsh@263.net>, "peng.zhou@wh.iov.cn" <peng.zhou@wh.iov.cn>  
**Cc:** Yumei Wen <ymwen@shmu.edu.cn>, Martin martin <winter999@hotmail.com>, "Josaphouitch, Alexa" <Alexa.Josaphouitch@taylorandfrancis.com>, "Qiao, Jessica" <Jessica.Qiao@tandfchina.com>, Min Yang <min.yang@emi2012.org>, "editorial2@emi2012.org" <editorial2@emi2012.org>  
**Subject:** FW: Congratulations - your EMI papers are included in T&F's top ten OA articles of 2020

Dear Drs. Zhengli Shi/Peng Zhou, Kwok-Yung Yuen, Lishan Su/Shan-lu Liu, Taisheng Li, Yi-Wei Tang and Naveen Vankadari,

On behalf of Prof Wen and EMI, congratulations!

I assume you have received an email notice from T&F (see one sample below) that one of your EMI papers was included as one of the top 10 Open Access papers from the entire T&F family (over 2700 journals). This is from [a blog post on our Author Services website](#) (click and find the site). Attached is the PDF copy list I produced for your reference.

Your EMI papers are ranked #1, #3, #4, #5, #8 and #10, six out of top ten, for entire 2020 up to this point! This is an incredible achievement to each of you. I believe such numbers of download read will be ranked very high with any other major publishing houses.

EMI would like to thank you for your great work and contribution to the global health effort in this difficult time with COVID-19 pandemic.

EMI is very grateful to authors like you who have made EMI one of the leading biomedical journals in the world. Your creativity, sensitivity, fact searching and out of box thinking have constantly pushed the frontier of science and medicine. EMI is proud to be part of your great endeavour.

EMI is thinking to create new tools and forums to further promote your research findings so more people can be benefited. In the near future, EMI will launch an "EMI Virtual Journal Club (VJC)" program in which each time, one leading EMI paper will be presented by the original authors online, open to the global scientific community so the authors of scientific papers will be able to have direct communications with their readers. Your papers will be the candidates for our initial launch. More details will be shared with you soon and I would like to invite you to be part of our first group of VJC authors.

Best.

Shan

---

**From:** Bergan, Rachel <[Rachel.Bergan@tandf.co.uk](mailto:Rachel.Bergan@tandf.co.uk)>  
**Sent:** Thursday, October 22, 2020 5:10 PM  
**To:** Tang, Yi-Wei <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>  
**Subject:** Your paper features in T&F's top ten OA articles of 2020

Dear Yi-Wei,

I'm very pleased to let you know that your recent article "Laboratory diagnosis of emerging human coronavirus infections – the state of the art" was one of the most-downloaded open access articles published by Taylor & Francis so far this year.

Many congratulations!

To mark Open Access Week, we have published [a blog post on our Author Services website](#) about the Top 10, including links to the articles, and details of each Altmetric score to reflect the discussion of your article online and in the media.

**This is a great excuse to further highlight your research to your contacts and communities.** We will be promoting the blog post on our social media platforms: [Twitter](#), [LinkedIn](#), and [Facebook](#). You could share our posts/tweets or write your own (please use the same hashtags).

We'll also be featuring the Top 10 in our [Insights newsletter](#), to further reach researchers and the wider academic community.

Please do not hesitate to contact me if you have any further questions or queries.

Kind Regards,  
Rachel

Rachel Bergan (she/her)  
Communications Coordinator  
Taylor & Francis Group

Email: [rachel.bergan@tandf.co.uk](mailto:rachel.bergan@tandf.co.uk)

Tel: +44 (0) 20 755 19259

4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN, UK



## 4 skills for researchers of the future



### Information Classification: General

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

---

**From:** Wang Linfa <linfa.wang@duke-nus.edu.sg>  
**Sent:** Monday, May 4, 2020 11:39 AM  
**To:** Min Yang  
**Cc:** TEMI-production@journals.tandf.co.uk; Lu, Shan  
**Subject:** Re: Copyright for your manuscript TEMI-2020-0499.R1

I have uploaded both a few hours ago

Thanks

Sent from my iPhone

On 4 May 2020, at 10:50 PM, Min Yang <min.yang@emi2012.org> wrote:

- External Email -

Dear Dr Wang,

Regarding your manuscript TEMI-2020-0499.R1, we would be appreciated if you could process and finish the copyright paperwork and the author review corrections soon as to avoid any delay in publication.

Please feel free to let me know if any questions.

Thanks and regards,

Min Yang

*Emerging Microbes & Infections* (EMI) Editorial Office  
4F Fuxing Building  
131 Dongan Road  
Shanghai  
China  
Tel: 86-21-54237992  
E-mail: min.yang@emi2012.org

---

Important: This email is confidential and may be privileged. If you are not the intended recipient, please delete it and notify us immediately; you should not copy or use it for any purpose, nor disclose its contents to any other person. Thank you.

---

**From:** Naglaa Ahmed <naglaa.abdallah@agr.cu.edu.eg>  
**Sent:** Wednesday, April 15, 2020 6:46 AM  
**To:** Lu, Shan  
**Cc:** wen yumei; Editorial Office  
**Subject:** Re: COVID-19 paper

Thank you Shan for your reply.  
Best regards,  
Naglaa

On Saturday, April 11, 2020, Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> wrote:

Dear Naglaa,

Thanks for your inquiry. At this point, we predict real wet lab data regarding to the Spike-receptor interaction because there are quite a few papers for modeling and it is time to show the real biological data.

Best.

Shan Lu, MD, PhD

Editor-in-Chief

Emerging Microbes and Infections (EMI)

[www.tandfonline.com/TEMI](http://www.tandfonline.com/TEMI)

**From:** Naglaa Ahmed <[naglaa.abdallah@agr.cu.edu.eg](mailto:naglaa.abdallah@agr.cu.edu.eg)>  
**Sent:** Saturday, April 11, 2020 3:01 PM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>; Editorial Office <[editorial@emi2012.org](mailto:editorial@emi2012.org)>  
**Subject:** Re: COVID-19 paper

Dear Dr. Shan,

We would like to submit a paper entitled "COVID-19 spike-host cell receptor GRP78 binding site prediction exploitation of natural resources for developing anti- COVID-19 via virtual screening and molecular docking study". Do you think it will fit with EMI? Could we accelerate the acceptance and publication?

Thanks,

Naglaa

On Sat, Apr 4, 2020 at 6:57 PM Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> wrote:

Dear Prof Abdallah,

Thanks for your interest in EMI.

Without knowing the details of your paper, it is very hard to answer whether it will fit EMI. At this point, EMI is receiving over 60-100 COVID-19 related papers every week. EMI is very selective to COVID-19 papers. Given the large number of submissions, we can not provide a free publication to most papers unless they are specially invited to cover certain unique topics.

Best.

Shan

**From:** Naglaa Ahmed <[naglaa.abdallah@agr.cu.edu.eg](mailto:naglaa.abdallah@agr.cu.edu.eg)>

**Sent:** Saturday, April 4, 2020 3:24 AM

**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; [shupingtong@fudan.edu.cn](mailto:shupingtong@fudan.edu.cn)

**Subject:** COVID-19 paper

Dear Yu-Mei and Wenand Shan Lu,

I am the Editor in Chief of GM Crops & Food (<https://www.tandfonline.com/toc/kgmc20/current>) and we have a paper on COVID-19 that we want to submit to the Emerging Microbes and Infections. As it is a hot subject, we are concerned about the time it will take for publication, also will we be waived from the fees. Most of the journals have special issue for it and publications are free, but as we are T&F members, I would prefer to publish on one of its journals.

Thanks,

Naglaa





Prof. Naglaa Abdallah

Chief of Party,

Center of Excellence for Agriculture,

Faculty of Agriculture, Cairo University

Cairo University, Egypt.

Mobile +201223179109

Email. [Naglaa.abdallah@coeag.org](mailto:Naglaa.abdallah@coeag.org)

--

Prof. Naglaa Abdallah

Faculty of Agriculture,

Cairo University, Egypt.

--

Prof. Naglaa Abdallah  
Faculty of Agriculture,  
Cairo University, Egypt.  
Editor-In-Chief GM Crops & Food  
<https://www.tandfonline.com/toc/kgmc20/current>

---

**From:** Naglaa Ahmed <naglaa.abdallah@agr.cu.edu.eg>  
**Sent:** Saturday, April 11, 2020 3:01 PM  
**To:** Lu, Shan  
**Cc:** wen yumei; Editorial Office  
**Subject:** Re: COVID-19 paper

Dear Dr. Shan,

We would like to submit a paper entitled "COVID-19 spike-host cell receptor GRP78 binding site prediction exploitation of natural resources for developing anti- COVID-19 via virtual screening and molecular docking study". Do you think it will fit with EMI? Could we accelerate the acceptance and publication?

Thanks,  
Naglaa

On Sat, Apr 4, 2020 at 6:57 PM Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> wrote:

Dear Prof Abdallah,

Thanks for your interest in EMI.

Without knowing the details of your paper, it is very hard to answer whether it will fit EMI. At this point, EMI is receiving over 60-100 COVID-19 related papers every week. EMI is very selective to COVID-19 papers. Given the large number of submissions, we can not provide a free publication to most papers unless they are specially invited to cover certain unique topics.

Best.

Shan

**From:** Naglaa Ahmed <[naglaa.abdallah@agr.cu.edu.eg](mailto:naglaa.abdallah@agr.cu.edu.eg)>  
**Sent:** Saturday, April 4, 2020 3:24 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; [shupingtong@fudan.edu.cn](mailto:shupingtong@fudan.edu.cn)  
**Subject:** COVID-19 paper

Dear Yu-Mei and Wenand Shan Lu,

I am the Editor in Chief of GM Crops & Food (<https://www.tandfonline.com/toc/kgmc20/current>) and we have a paper on COVID-19 that we want to submit to the Emerging Microbes and Infections. As it is a hot subject, we are concerned

about the time it will take for publication, also will we be waived from the fees. Most of the journals have special issue for it and publications are free, but as we are T&F members, I would prefer to publish on one of its journals.

Thanks,

Naglaa

.

--



Prof. Naglaa Abdallah

Chief of Party,

Center of Excellence for Agriculture,

Faculty of Agriculture, Cairo University

Cairo University, Egypt.

Mobile +201223179109

Email. [Naglaa.abdallah@coeag.org](mailto:Naglaa.abdallah@coeag.org)

--

Prof. Naglaa Abdallah  
Faculty of Agriculture,  
Cairo University, Egypt.

**From:** wen yumei <ymwen@shmu.edu.cn >  
**Sent:** Friday, April 10, 2020 9:25 PM  
**To:** Xiang Chunsheng  
**Cc:** Lu, Shan  
**Subject:** Re: COVID-19 paper

Dear Dr. Xiang,

Thanks for considering EMI for your interesting study. I have forwarded your paper package to our editorial board who did a quick initial screening.

Currently, EMI received about 60-80 COVID-19 related papers each week and most are very high quality. This is too many for EMI to publish. We have established a screening system by key editors and invited experts. Only those papers meeting the high priority will be sent out for peer-review. Unfortunately the screening group does not feel that your paper will fit our priority at this point. A few years ago, EMI has decided to generally decline any paper with limited clinical cases. Your report only has two cases and there is no controls. It may fit better with a basic research specialty journal focusing on stem cell subject.

Again, we appreciate your interest in EMI and best wishes to your great work.

YMWen

-----Original Messages-----

**From:** "项春生" <cxiang@zju.edu.cn >  
**Sent Time:** 2020-04-10 12:51:24 (Friday)  
**To:** ymwen@shmu.edu.cn  
**Cc:**  
**Subject:** COVID-19 paper

Hello, Academician Wen! The attachment is the manuscript we are going to submit. Thank you for your review.

I also attach the work we did during H7N9 in 2013. The paper has been published in Engineering. The results of the study show that: The mortality of ARDS patients in the stem cell treatment group was significantly lower than that in the control group, which were 17.6% and 54.5%, respectively. During the treatment of No acute toxicity or other serious adverse reactions related to stem cell infusion were found. Four of the patients underwent a 5-year laboratory examination, Long-term follow-up of lung function and quality of life showed that MSC provides a safe and effective therapy for saving severe lung diseases induced by H7N9.

Thanks again!

5/17/2021

Dear Dr. Xiang, Thanks for considering EMI for your interesting study. I have forwarded your paper package to our editorial board.

First Affiliated Hospital of Zhejiang University School of Medicine

---

**From:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
**Sent:** Sunday, August 9, 2020 8:56 PM  
**To:** Lu, Shan  
**Cc:** Min Yang (min.yang@emi2012.org); M. Yu-Mei Wen (ymwen@shmu.edu.cn)  
**Subject:** RE: Delay of TEMI-2020-1123

Thank you, Shan.

Yi-Wei

-----Original Message-----

From: Lu, Shan <Shan.Lu@umassmed.edu>  
Sent: Sunday, August 9, 2020 10:43 PM  
To: Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
Cc: Min Yang (min.yang@emi2012.org) <min.yang@emi2012.org>; M. Yu-Mei Wen (ymwen@shmu.edu.cn) <ymwen@shmu.edu.cn>  
Subject: RE: Delay of TEMI-2020-1123

Thanks, Yi-Wei.

And thank you for another busy weekend hard work to screen 30 new papers. I just processed them after you.

I realize that you are very busy with new job in China. Please do not hesitate to let me know if you need any help or assistance from me, in any way I can.

Best.

Shan

-----Original Message-----

From: Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
Sent: Sunday, August 9, 2020 1:33 AM  
To: Lu, Shan <Shan.Lu@umassmed.edu>  
Cc: Min Yang (min.yang@emi2012.org) <min.yang@emi2012.org>; M. Yu-Mei Wen (ymwen@shmu.edu.cn) <ymwen@shmu.edu.cn>  
Subject: RE: Delay of TEMI-2020-1123

Well received.

-----Original Message-----

From: Lu, Shan <Shan.Lu@umassmed.edu>  
Sent: Saturday, August 8, 2020 10:43 PM  
To: Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
Cc: Min Yang (min.yang@emi2012.org) <min.yang@emi2012.org>; M. Yu-Mei Wen (ymwen@shmu.edu.cn) <ymwen@shmu.edu.cn>  
Subject: RE: Delay of TEMI-2020-1123

Hi, Yi-Wei,

We know what happened before we wrote to you as we can monitor everything within S1 system. So your reply does not address the issue I asked you.

Our system, as I explained again at our July 5th RE meeting, is not inviting more reviewers if the originally invited reviewer(s) does not submit reviews on time. It is then RE's responsibility to write something, with or without input from other new experts. Nevertheless, we can not re-start the whole process by inviting a set of new reviewers which will add at least another two more weeks. Of course, this can be flexible, if RE can invite someone who can provide a quick review in a few days, it is ok.

We put this responsibility to REs, and if REs can not fill their responsibilities on time, then it is EIC's responsibility to write a review and make a decision without further delay. Only by doing so, EMI has maintained an excellent record without ever delaying a review in the past.

We will treat TEMI-2020-1123 as a special case and let you finish the review with newly invited reviewers to late Aug which is more than 2 months from the beginning. I will personally write a letter to authors apologizing for EMI's poor mismanagement of this paper. We can not just wait for authors to write to us which is a bad business practice.

I am copying Prof Wen to avoid any potential later confusion.

Best.

Shan

-----Original Message-----

From: Tang, Yi-Wei <yi-wei.tang@cepheid.com>

Sent: Saturday, August 8, 2020 4:38 AM

To: Lu, Shan <Shan.Lu@umassmed.edu>

Cc: Min Yang (min.yang@emi2012.org) <min.yang@emi2012.org>

Subject: RE: Emerging Microbes & Infections - Automated weekly digest of unread conversations

Shan,

We got one extremely tardy reviewer, but recently two additional reviewers have agreed to review it, so it is a good news.

Min,

If the authors ask again, please tell them what happened so far.

Yi-Wei

-----Original Message-----

From: Lu, Shan <Shan.Lu@umassmed.edu>

Sent: Friday, August 7, 2020 11:33 AM

To: Tang, Yi-Wei <yi-wei.tang@cepheid.com>

Subject: RE: Emerging Microbes & Infections - Automated weekly digest of unread conversations

Hi, Yi-Wei,

I realized you tried to find two more reviewers on 1123. However, it is about two months soon for this review. You need check with the reviewers to see if they can give you an early submission of reviews. Just a simple review with

some key points with great details. Also, we need to let the authors know. We never had any paper out for so long. You can draft a letter and Min can send it to authors.

Thanks.

Shan

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.



---

**From:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
**Sent:** Sunday, August 9, 2020 1:33 AM  
**To:** Lu, Shan  
**Cc:** Min Yang (min.yang@emi2012.org); M. Yu-Mei Wen (ymwen@shmu.edu.cn)  
**Subject:** RE: Delay of TEMI-2020-1123

Well received.

-----Original Message-----

From: Lu, Shan <Shan.Lu@umassmed.edu>  
Sent: Saturday, August 8, 2020 10:43 PM  
To: Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
Cc: Min Yang (min.yang@emi2012.org) <min.yang@emi2012.org>; M. Yu-Mei Wen (ymwen@shmu.edu.cn) <ymwen@shmu.edu.cn>  
Subject: RE: Delay of TEMI-2020-1123

Hi, Yi-Wei,

We know what happened before we wrote to you as we can monitor everything within S1 system. So your reply does not address the issue I asked you.

Our system, as I explained again at our July 5th RE meeting, is not inviting more reviewers if the originally invited reviewer(s) does not submit reviews on time. It is then RE's responsibility to write something, with or without input from other new experts. Nevertheless, we can not re-start the whole process by inviting a set of new reviewers which will add at least another two more weeks. Of course, this can be flexible, if RE can invite someone who can provide a quick review in a few days, it is ok.

We put this responsibility to REs, and if REs can not fill their responsibilities on time, then it is EIC's responsibility to write a review and make a decision without further delay. Only by doing so, EMI has maintained an excellent record without ever delaying a review in the past.

We will treat TEMI-2020-1123 as a special case and let you finish the review with newly invited reviewers to late Aug which is more than 2 months from the beginning. I will personally write a letter to authors apologizing for EMI's poor mismanagement of this paper. We can not just wait for authors to write to us which is a bad business practice.

I am copying Prof Wen to avoid any potential later confusion.

Best.

Shan

-----Original Message-----

From: Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
Sent: Saturday, August 8, 2020 4:38 AM  
To: Lu, Shan <Shan.Lu@umassmed.edu>  
Cc: Min Yang (min.yang@emi2012.org) <min.yang@emi2012.org>  
Subject: RE: Emerging Microbes & Infections - Automated weekly digest of unread conversations

Shan,

We got one extremely tardy reviewer, but recently two additional reviewers have agreed to review it, so it is a good news.

Min,

If the authors ask again, please tell them what happened so far.

Yi-Wei

-----Original Message-----

From: Lu, Shan <Shan.Lu@umassmed.edu>

Sent: Friday, August 7, 2020 11:33 AM

To: Tang, Yi-Wei <yi-wei.tang@cepheid.com>

Subject: RE: Emerging Microbes & Infections - Automated weekly digest of unread conversations

Hi, Yi-Wei,

I realized you tried to find two more reviewers on 1123. However, it is about two months soon for this review. You need check with the reviewers to see if they can give you an early submission of reviews. Just a simple review with some key points with great details. Also, we need to let the authors know. We never had any paper out for so long. You can draft a letter and Min can send it to authors.

Thanks.

Shan

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

---

**From:** Josaphouitch, Alexa <Alexa.Josaphouitch@taylorandfrancis.com>  
**Sent:** Thursday, September 3, 2020 10:51 AM  
**To:** Lu, Shan  
**Cc:** Cochran, Sarah; M. Yu-Mei Wen (ymwen@shmu.edu.cn); editorial@emi2012.org  
**Subject:** RE: Discussion about ethics query  
**Attachments:** Emails to authors regarding image concerns.docx

Hi Shan,

I consulted a member of the Ethics & Integrity team to draft the attached emails that can be sent to the corresponding authors. I can send these emails on your behalf, if you would prefer. If you would like to correspond with the authors, please include me so that I can continue to inform our Ethics & Integrity team and all of us can decide the appropriate action.

I'll add this to our agenda for next week, so we can discuss more.

Thank you!

Sincerely,  
Alexa

---

Information Classification: General

**From:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Sent:** Tuesday, September 1, 2020 4:02 PM  
**To:** Josaphouitch, Alexa <Alexa.Josaphouitch@taylorandfrancis.com>  
**Cc:** Cochran, Sarah <sarah.cochran@taylorandfrancis.com>; M. Yu-Mei Wen (ymwen@shmu.edu.cn) <ymwen@shmu.edu.cn>; editorial@emi2012.org  
**Subject:** RE: Discussion about ethics query

Hi, Alexa,

Thank you for alerting me on these two papers from the same authors.

It is very concerning to see such behavior like another type of pandemic. EMI will take a zero tolerance policy.

It is worthwhile noting these two papers were published before EMI joined T&F family but I appreciate that T&F is taking the responsibility to alert us.

I fully agree with the next step. However, given the scope of this misconduct, I wonder if T&F has any template that I can use to "Contact Jie Yan for explanation and request ALL original images, not just those flagged on PubPeer".

Best.

Shan

---

**From:** Josaphouitch, Alexa <[Alexa.Josaphouitch@taylorandfrancis.com](mailto:Alexa.Josaphouitch@taylorandfrancis.com)>  
**Sent:** Tuesday, September 1, 2020 2:36 PM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

Cc: Cochran, Sarah <[sarah.cochran@taylorandfrancis.com](mailto:sarah.cochran@taylorandfrancis.com)>

Subject: Discussion about ethics query

Dear Shan,

I hope you are well.

I'm emailing you to determine the best time to discuss an ethics query regarding two articles published in *Emerging Microbes & Infections*. We could discuss this at our monthly call next week or I have availability on Thursday and Friday.

A member of the Ethics & Integrity team was alerted via a [blog post](#) about two immunology and infectious disease researchers, David Ojcius and Jie Yan. Approximately [32](#) of Ojcius' papers have been flagged for image manipulation and Yan is a co-author for the majority of them. Below is information on the articles in question published in *EMI*, PubPeer comments, Yan's response, the images we're concerned about, and next steps.

Since Taylor & Francis is a COPE member, we refer to the appropriate COPE flowchart to handle ethics queries. T&F's [Editor Code of Conduct](#) describes the collaborative relationship an Editor and Portfolio Manager use to approach ethics queries. In our call, I would like to discuss the best next steps to addressing this.

Thank you and I look forward to talking more with you about this.


| Journal / pub year | Article                                                                                                                                                                                       | PubPeer comment?                             | Issue                                                              | Next Steps                                                                                          | Primary COPE flowchart                                              |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|--------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|
| TEMI, 2019         | <a href="#">A leptospiral AAA+ chaperone-Ntn peptidase complex, HslUV, contributes to the intracellular survival of Leptospira interrogans in hosts and the transmission of leptospirosis</a> | <a href="#">Yes</a><br><br>Jie Yan responded | Image manipulation in Figures 6 & 7, which are of cell staining.   | Contact Jie Yan for explanation and request ALL original images, not just those flagged on PubPeer. | <a href="#">Image manipulation in a published article</a>           |
| TEMI, 2018         | <a href="#">A novel Fas-binding outer membrane protein and lipopolysaccharide of Leptospira interrogans induce macrophage apoptosis through the Fas/FasL-caspase-8/-3 pathway</a>             | <a href="#">Yes</a><br><br>Jie Yan responded | Image manipulation in Figures 1C, 2A, 2C, which are flow cytometry | Contact Jie Yan for explanation and request ALL original images, not just those flagged on PubPeer. | <a href="#">Suspected fabricated data in a published manuscript</a> |

Sincerely,  
Alexa

Alexa Josaphouitch

Portfolio Manager for Hematology and Immunology Journals

Taylor & Francis Group  
530 Walnut Street, Suite 850, Philadelphia, PA 19106  
Tel: (215) 606-4170  
Fax: (215) 207-0050  
Email: [alexa.josaphouitch@taylorandfrancis.com](mailto:alexa.josaphouitch@taylorandfrancis.com)  
Web: [www.tandfonline.com](http://www.tandfonline.com)  
(she/her/hers)



Information Classification: General

---

**From:** kyyuen <kyyuen@hku.hk>  
**Sent:** Thursday, January 23, 2020 10:10 AM  
**To:** Shibo; Lu, Shan  
**Cc:** Jasper Chan (jaspchan@gmail.com)  
**Subject:** RE: Dr. Zhengli She's accession no provided

Dear Shibo and Shan,  
No need to delay as we now only analyze our OWN sequence from a HKU Shenzhen hospital patient.  
We would not quote any other sequences.  
Many thanks again.  
KY

---

**From:** Shibo [mailto:shibojiang@fudan.edu.cn]  
**Sent:** Thursday, 23 January 2020 11:03 PM  
**To:** kyyuen  
**Subject:** Fwd: Dr. Zhengli She's accession no provided

Dear KY,

Dr Shan Lu told me that the EMI cannot do anything about your manuscript change now, but you can change it at proofs stage (you can say that you got the permission from Dr. Zhengli Shi to use the gene sequence of 2019-nCoV (GISAID accession no. EPI\_ISL\_402124).

Shibo

Sent from my iPhone

Begin forwarded message:

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Date:** January 23, 2020 at 6:50:17 PM GMT+8  
**To:** "shibojiang@fudan.edu.cn" <shibojiang@fudan.edu.cn>  
**Cc:** 杨旻 EMI <minyang@163.com>  
**Subject:** RE: Dr. Zhengli She's accession no provided

Hi, Shibo,

I don't think we can do anything at this point. As I explained the other day, a paper in a publishing system can not be randomly or easily changed or replaced. The only next opportunity is at the proofs stage.

Best.

Shan

**From:** shibojiang@fudan.edu.cn <shibojiang@fudan.edu.cn>  
**Sent:** Thursday, January 23, 2020 4:10 AM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>

**Cc:** 杨旻 EMI <minyang@163.com>

**Subject:** Dr. Zhengli Shi's accession no provided

Dear Shan,

Dr. Zhengli Shi put her accession no in the commentary so that Dr. Yongzheng Zhang cannot complain to us. Is it possible to ask the publisher to replace the original one with one before online publication.

In addition, Dr. Shi agreed to provide KY the permission if he wants.

Thanks,

Shibo

---

**From:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
**Sent:** Friday, December 27, 2019 8:04 AM  
**To:** wen yumei; Lu, Shan  
**Cc:** ZhangWenhong; yuan zhenghong; min.yang@emi2012.org; Emily; Martin martin  
**Subject:** Re: draft EMI 2019 best paper award list

Ditto.

Happy New Year.

Yi-Wei

Get [Outlook for iOS](#)

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Friday, December 27, 2019 7:17:22 PM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Cc:** ZhangWenhong <zhangwenhong@fudan.edu.cn>; Tang, Yi-Wei <yi-wei.tang@cepheid.com>; yuan zhenghong <zhyuan@shmu.edu.cn>; min.yang@emi2012.org <min.yang@emi2012.org>; Emily <editorial2@emi2012.org>; Martin martin <winter999@hotmail.com>  
**Subject:** Re: draft EMI 2019 best paper award list

Excellent result。 Thank everyone. Best regards to Shan, A happy New Year to you, who is the best organizer for EMI. Yu-mei Wen

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:** 2019-12-27 13:13:43 (Friday)  
**To:** "wen yumei" <ymwen@shmu.edu.cn>, ZhangWenhong <zhangwenhong@fudan.edu.cn>, "Tang, Yi-Wei" <yi-wei.tang@cepheid.com>, "yuan zhenghong" <zhyuan@shmu.edu.cn>  
**Cc:** "min.yang@emi2012.org" <min.yang@emi2012.org>, Emily <editorial2@emi2012.org>, "Martin martin" <winter999@hotmail.com>  
**Subject:** draft EMI 2019 best paper award list

Dear Prof Wen and others,

Based on the nominations from you, I have put together the draft list. The number of votes received for each paper is provided. It is nice to see that our nominations are very close. I wrote "EMI Comments" but please feel free to revise as needed.



Please let me know if you have any questions before I notify the authors.

Best.

Shan

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Friday, December 27, 2019 6:17 AM  
**To:** Lu, Shan  
**Cc:** ZhangWenhong; Tang, Yi-Wei; yuan zhenghong; min.yang@emi2012.org; Emily; Martin martin  
**Subject:** Re: draft EMI 2019 best paper award list

Excellent result。 Thank everyone. Best regards to Shan, A happy New Year to you, who is the best organizer for EMI.  
Yu-mei Wen

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:** 2019-12-27 13:13:43 (Friday)  
**To:** "wen yumei" <ymwen@shmu.edu.cn>, ZhangWenhong <zhangwenhong@fudan.edu.cn>, "Tang, Yi-Wei" <yi-wei.tang@cepheid.com>, "yuan zhenghong" <zhyuan@shmu.edu.cn>  
**Cc:** "min.yang@emi2012.org" <min.yang@emi2012.org>, Emily <editorial2@emi2012.org>, "Martin martin" <winter999@hotmail.com>  
**Subject:** draft EMI 2019 best paper award list

Dear Prof Wen and others,

Based on the nominations from you, I have put together the draft list. The number of votes received for each paper is provided. It is nice to see that our nominations are very close. I wrote "EMI Comments" but please feel free to revise as needed.

Please let me know if you have any questions before I notify the authors.

Best.

Shan

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Tuesday, July 28, 2020 1:48 PM  
**To:** Lu, Shan  
**Subject:** Re: draft letter

Thank you and well done. YM wen

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:** 2020-07-28 09:04:48 (Tuesday)  
**To:** "M. Yu-Mei Wen (ymwen@shmu.edu.cn)" <ymwen@shmu.edu.cn>  
**Cc:**  
**Subject:** draft letter

Hi, Prof Wen,

Below is the draft of invitation. Please feel free to revise as you see fit.

\*\*\*\*\*

Prof. Dr. Stephan Becker

Director, Institut für Virologie, Philipps-Universität Marburg

Germany

Dear Dr. Becker,

Based on the recommendation of Prof Hans Klenk, we are writing to invite you to serve as the co-editor-in-chief of Emerging Microbes & Infections (EMI), [www.tandfonline.com/TEMI](http://www.tandfonline.com/TEMI).

EMI is a fast growing biomedical scientific journal with the focus on emerging infections. Prof Klenk served as one of the founding co-Editor-in-Chiefs and made great contribution to EMI. EMI will be honored if you can accept our invitation as you are a leader in the field. Your scientific experience and leadership ability will be very valuable for the

further development of EMI. As we learned from the recent COVID-19 pandemics, more scientific research and global collaboration are in great demand. We hope that EMI can play an even more important role in the world.

We realize that you are very busy. It is flexible in terms of how much time you can afford to work with EMI. The most important is your vision and global connection in the field of emerging infections which will guide the future direction of EMI.

If you are available for a video conference, we can set it up so we can discuss further on the details of your appointment.

Looking forward to hearing from you.

Sincerely yours,

Yu-Mei Wen

Shan Lu

Editors-in-Chief

EMI

---

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Sunday, January 12, 2020 12:54 AM  
**To:** Shi Zhengli; Guo Deyin  
**Cc:** Du Lanying\_NYBC; Lu, Shan  
**Subject:** Re: Emerging and Re-emerging CoV-introduction-20200111  
**Attachments:** Editorial\_WARS-CoV\_EMI\_20200112.docx

Sorry, there is a typo in the title of the outline, "termination" should be "terminology". Alternatively, we may remove this word from the title.

Shibo

-----原始邮件-----

发件人:"Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>  
发送时间:2020-01-12 12:48:49 (星期日)  
收件人: "Shi Zhengli" <zshi@wh.iov.cn>, "Guo Deyin" <guodeyin@mail.sysu.edu.cn>, "Du Lanying\_NYBC" <ldu@nybc.org>  
抄送: "Lu Shan" <shan.lu@umassmed.edu>  
主题: Emerging and Re-emerging CoV-introduction-20200111

Dear Drs. Shi, Guo and Du,

EMI has assembled a special issue entitled "Emerging and Re-emerging Coronaviruses". As the Guest Editor for this special issue, I invite you to contribute research or review articles related to the "Wuhan coronavirus" to this special issue in the future.

Now I am going to write an Editorial about "Wuhan coronavirus" (about 2500-3000 words). I invite you to write a few paragraphs related to the topic of your expertise for this Editorial (the the outline of the manuscript attached). Each of us can write 800-1000 words. I will assemble them together and finalize the manuscript.

If you agree, please write it as soon as possible. I plan to submit it before next weekend.

Thank you very much for your consideration,

Shibo

**Emerging and Re-emerging Coronaviruses**  
**Guest Editor:** Shibo Jiang (Fudan University, China)

Emerging and re-emerging coronaviruses, including Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and the latest "Wuhan Coronavirus", may cause epidemics or potentially pandemics of highly pathogenic human infectious diseases, posing great threats to the global health. EMI Special Topic - Emerging and Re-emerging Coronaviruses covers

research and review articles on the basic, translational and clinical studies related to these coronaviruses.

---

**From:** Wang Linfa <linfa.wang@duke-nus.edu.sg>  
**Sent:** Monday, April 20, 2020 11:40 PM  
**To:** Lu, Shan  
**Subject:** RE: Emerging Microbes & Infections - Decision on Manuscript ID TEMI-2020-0499.R1

Sorry, there is key typo in the previous email, it should be:

" Sincere thanks for fast review on this paper and we can NOW (not "not") claim we are the FIRST to document the lack of cross neutralization by SARS sera against SARS-CoV-2, despite previous publications indicating some level of cross neutralization using hyperimmune sera and/or pseudovirus!"

Yes, eagerly waiting for the other submission, which has some interesting data on 17-year old SARS sera.

Cheers,

LF

Linfa (Lin-Fa) WANG, PhD FTSE  
Professor & Director  
Programme in Emerging Infectious Disease Duke-NUS Medical School,  
8 College Road, Singapore 169857  
Tel: +65 6516 8397

-----Original Message-----

From: Lu, Shan <Shan.Lu@umassmed.edu>  
Sent: Tuesday, 21 April 2020 11:33 AM  
To: Wang Linfa <linfa.wang@duke-nus.edu.sg>  
Subject: RE: Emerging Microbes & Infections - Decision on Manuscript ID TEMI-2020-0499.R1

- External Email -

Congratulations!

EMI is very well read. You can check at our web site. EMI is really taking off this year based on our past progress.

Let's see what happens to your next paper.

-----Original Message-----

From: Wang Linfa <linfa.wang@duke-nus.edu.sg>  
Sent: Monday, April 20, 2020 11:16 PM  
To: Lu, Shan <Shan.Lu@umassmed.edu>  
Subject: FW: Emerging Microbes & Infections - Decision on Manuscript ID TEMI-2020-0499.R1

Dear Shan,

Sincere thanks for fast review on this paper and we can not claim we are the FIRST to document the lack of cross neutralization by SARS sera against SARS-CoV-2, despite previous publications indicating some level of cross neutralization using hyperimmune sera and/or pseudovirus!

Hope it will get a good citation for EMI as well.

Cheers,

LF

Linfa (Lin-Fa) WANG, PhD FTSE  
Professor & Director  
Programme in Emerging Infectious Disease Duke-NUS Medical School,  
8 College Road, Singapore 169857  
Tel: +65 6516 8397

-----Original Message-----

From: Emerging Microbes and Infections <onbehalf@manuscriptcentral.com>

Sent: Tuesday, 21 April 2020 11:04 AM

To: Danielle Anderson <danielle.anderson@duke-nus.edu.sg>; Tan Chee Wah <cheewah.tan@duke-nus.edu.sg>; Chia Wan Ni <wanni.chia@duke-nus.edu.sg>; barnaby\_young@ncid.sg; Martin Linster <martin.linster@duke-nus.edu.sg>; Jenny Low Guek Hong (SHHQ - SGH) <jenny.low@singhealth.com.sg>; Tan Yee Joo <mictyj@nus.edu.sg>; Mark\_Ic\_Cheng@ncid.sg; Gavin James Smith <gavin.smith@duke-nus.edu.sg>; Wang Linfa <linfa.wang@duke-nus.edu.sg>; David\_Lye@ncid.sg; Yee\_Sin\_Leo@ncid.sg

Subject: Emerging Microbes & Infections - Decision on Manuscript ID TEMI-2020-0499.R1

- External Email -

20-Apr-2020

Dear Professor Wang:

Ref: Lack of cross neutralization by SARS patient sera towards SARS-CoV-2

Our reviewers have now considered your paper and have recommended publication in Emerging Microbes & Infections. We are pleased to accept your paper in its current form which will now be forwarded to the publisher for copy editing and typesetting. The reviewer comments are included at the bottom of this letter, along with those of the editor who coordinated the review of your paper.

You will receive proofs for checking, and instructions for transfer of copyright in due course.

The publisher also requests that proofs are checked through the publisher's tracking system and returned within 48 hours of receipt.

Taylor & Francis strives to be compliant with the open access (OA) policies of the major national and international funding bodies. Information about funder compliance and OA policies can be found on our Author Services website. Details of our Green OA policy, including deposit in institutional and subject repositories, can be found on the Sharing your work (<https://nam01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fauthorservices.taylorandfrancis.com%2Fsharing-your->



work%2F&data=02%7C01%7CShan.Lu%40umassmed.edu%7Cb16d32810b2345fa7ff608d7e5a5ad0f%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637230372077069086&sdata=ngSl6jLriXWu2%2B8SLrne5IxLwvI7InMHZAUo%2BCT0u1w%3D&reserved=0) page. We recommend that you retain your Accepted Manuscript for this purpose.

For more information regarding the versions of your article that can be used to meet Green OA requirements, and the embargo period that applies, please see the open access journal finder (<https://nam01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fauthorservices.taylorandfrancis.com%2Fjournal-list%2F&data=02%7C01%7CShan.Lu%40umassmed.edu%7Cb16d32810b2345fa7ff608d7e5a5ad0f%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637230372077069086&sdata=15kw%2BUwHMD5ps5yfObGHmQwXirT8WGqz6Dk64qBcNHc%3D&reserved=0>) page.

Thank you for your contribution to Emerging Microbes & Infections and we look forward to receiving further submissions from you.

Sincerely,

Shan Lu  
Editor-in-Chief  
Emerging Microbes & Infections

---

Important: This email is confidential and may be privileged. If you are not the intended recipient, please delete it and notify us immediately; you should not copy or use it for any purpose, nor disclose its contents to any other person. Thank you.

---

Important: This email is confidential and may be privileged. If you are not the intended recipient, please delete it and notify us immediately; you should not copy or use it for any purpose, nor disclose its contents to any other person. Thank you.

---

**From:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
**Sent:** Tuesday, May 12, 2020 7:03 PM  
**To:** Lu, Shan; wen yumei  
**Cc:** Min Yang  
**Subject:** RE: Emerging Microbes & Infections Reviewer notification of decision on Manuscript TEMI-2020-0696

Thank you, Shan. These are concise and clear review comments from the two reviewers. Maybe the authors should focus on the finding without extending too far.

Yi-Wei

-----Original Message-----

From: Lu, Shan <Shan.Lu@umassmed.edu>  
Sent: Wednesday, May 13, 2020 3:54 AM  
To: wen yumei <ymwen@shmu.edu.cn>; Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
Cc: Min Yang <min.yang@emi2012.org>  
Subject: FW: Emerging Microbes & Infections Reviewer notification of decision on Manuscript TEMI-2020-0696

Dear Prof Wen and Yi-Wei,

We got both reviewers' opinion back. They felt the study is important, but there is only one case so it is not possible to conclude whether the milk antibody can be protective. Furthermore, there is no IgA data as it is very important in milk for IgA.

Hope authors can address these simple questions, and resubmit their new draft soon.

Best.

Shan

-----Original Message-----

From: Emerging Microbes and Infections <onbehalf@manuscriptcentral.com>  
Sent: Tuesday, May 12, 2020 10:13 AM  
To: temi-peerreview@journals.tandf.co.uk  
Cc: Lu, Shan <Shan.Lu@umassmed.edu>  
Subject: Emerging Microbes & Infections Reviewer notification of decision on Manuscript TEMI-2020-0696

12-May-2020

Dear Reviewers,

Thank you for reviewing the manuscript TEMI-2020-0696 entitled "Antibodies in the breast milk of a maternal woman with COVID-19" for Emerging Microbes & Infections. We greatly appreciate the voluntary contribution that each reviewer gives to the Journal and hope that we may continue to seek your assistance with the refereeing process for Emerging Microbes & Infections.

The decision that we arrived at for this article was: Major Revision, basing the decision on your review and those of the other referees.

A copy of your comments to the author, along with those of any other referees, follows at the end of this letter for your information. Any files that referees uploaded for the attention of the author are attached as a PDF proof.

Yours sincerely,

Professor Shan Lu  
Editor-in-Chief, Emerging Microbes & Infections Shan.Lu@umassmed.edu

Referee comments to the author:

Reviewer: 1

Recommendation: Unacceptable as is, but worth considering if extensively revised

Comments:

The manuscript submitted by Dong et al. entitled "Antibodies in the breast milk of a maternal woman with COVID-19". The authors claimed the finding suggest that breastfeeding might benefit the neonates. However, only IgG was detected, but the value between 11 and 21 days after birth was negligible. IgA, the major isotype that supposedly to be secreted into milk, should have been checked. Because the titers of IgG in neonate's serum (from mother) between birth to 25 days after birth was 1:1675 (or higher), which was overwhelmingly higher than 1:2-3 in the milk (barely above the background), one cannot say that it suggest breastfeeding might benefit the neonates, especially there were no data on IgA in the milk.

English usage within this manuscript needs improvement.

Additional Questions:

As a thank you and to acknowledge the contribution of our reviewers, the journal may publish a list of the names of those who have reviewed at the end of the year. This will not be linked to any specific paper and will only be done if the list of reviewers is long enough to protect the anonymity of the review process for individual papers. If you would prefer for your name <b>not to be included</b> in a published list of reviewers, please indicate this below.: No

Reviewer: 2

Recommendation: Unacceptable as is, but worth considering if extensively revised

Comments:

At present, only one case is included in the study, the credibility is reduced, and it is suggested to expand the sample size as much as possible

Additional Questions:

As a thank you and to acknowledge the contribution of our reviewers, the journal may publish a list of the names of those who have reviewed at the end of the year. This will not be linked to any specific paper and will only be done if the list of reviewers is long enough to protect the anonymity of the review process for individual papers. If you would prefer for your name <b>not to be included</b> in a published list of reviewers, please indicate this below.: No Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

---

**From:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
**Sent:** Sunday, July 26, 2020 8:26 PM  
**To:** Lu, Shan  
**Cc:** wen yumei; Min Yang (min.yang@emi2012.org)  
**Subject:** RE: Emerging Microbes & Infections - Automated weekly digest of unread conversations

Shan,

Well received. My workload including travels at Danaher/Cepheid has been dramatically increased recently and lots of trips were not arranged till the last minute. But I will try my best to notify you my coming trips over three days. Meantime, could you or Min remind me again the "dash" board that the papers need to be prescreened, so I will do this whenever I get time.

I will do something on 1046 and 1123 today.

Yi-Wei

Ps, I will be on a trip to Xi'an starting tomorrow, but I will be back on Friday.

-----Original Message-----

From: Lu, Shan <Shan.Lu@umassmed.edu>  
Sent: Monday, July 27, 2020 2:58 AM  
To: Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
Cc: wen yumei <ymwen@shmu.edu.cn>  
Subject: RE: Emerging Microbes & Infections - Automated weekly digest of unread conversations

Dear Yi-Wei,

I just completed this week's assignment work and thank you so much for doing screening for most of them.

Best.

Shan

-----Original Message-----

From: Lu, Shan  
Sent: Sunday, July 26, 2020 10:35 AM  
To: Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
Cc: wen yumei <ymwen@shmu.edu.cn>  
Subject: RE: Emerging Microbes & Infections - Automated weekly digest of unread conversations

Dear Yi-Wei,

As I explained to you before, I have nothing to do with this email. It is part of the T&F system which generates an automatic reminder in various deadline situations and I can not change it. I also get a same reminder since I am also responsible for anything not done at EMI. The email itself also indicated "This is an automated request.....".

Managing a journal is a huge commitment. The work will come and accumulate each day and each week no matter whether we have time or not. For the past 8 years, I had no vacation or holiday when I did not check in EMI everyday. I had to go to a local dirty 网吧 in China when the internet connection in hotel is not good.

However, I have always provided all support to you in the past when you told me you would be out of town, taking a vacation or making a trip to China so I did any pending work for you and we will not miss the deadlines. In the current case, I will do the same here and process the pending papers later today.

It will be nice if you can send me a notice before you are going away in the future so I will not wait for you, and you may not receive such an automatic notice.

At the same time, it will be nice if you can process the following papers under your assignment:

TEMI-2020-1046: 33 days overdue to find reviewers. Only one reviewer and comment is back. Please make a recommendation.

TEMI-2020-1123: 26 days overdue to find reviewers. Only one agreed to review. Now 15 days overdue (should make a decision at 7 days). High risk situation.

Please feel free to let me know if you need any help.

Best.

Shan

-----Original Message-----

From: Tang, Yi-Wei <yi-wei.tang@cepheid.com>

Sent: Sunday, July 26, 2020 4:52 AM

To: temi-peerreview@journals.tandf.co.uk; Lu, Shan <Shan.Lu@umassmed.edu>; Min Yang (min.yang@emi2012.org) <min.yang@emi2012.org>

Subject: RE: Emerging Microbes & Infections - Automated weekly digest of unread conversations

I was out of town and back this morning.

I think this one reminder email can work but you need to give at least three days...

Yi-Wei

-----Original Message-----

From: Emerging Microbes and Infections <onbehalf@manuscriptcentral.com>

Sent: Sunday, July 26, 2020 9:00 AM

To: Tang, Yi-Wei <yi-wei.tang@cepheid.com>

Subject: Emerging Microbes & Infections - Automated weekly digest of unread conversations

25-Jul-2020

Dear Dr Tang:

This is an automated request for your participation in the following conversation(s) since last week:

TEMI-2020-1284 Natural infection of SARS-CoV-2 in cats TEMI-2020-1284

TEMI-2020-1280 Sensitivity of induced sputum test is greater than that of throat swab test for detecting SARS-CoV-2 in patients with COVID-19: a multi-centre cross-sectional study TEMI-2020-1280

TEMI-2020-1283 Novel plasmid borne fimbriae-associated gene cluster participates in biofilm formation in Escherichia coli TEMI-2020-1283

TEMI-2020-1282 Redondoviridae and periodontitis: A case-control study and identification of five novel redondoviruses from periodontal tissues  
 TEMI-2020-1282

TEMI-2020-1281 Hepatitis B virus detected in a golden monkey fatal case, China TEMI-2020-1281

TEMI-2020-1271 Molecular regulation of autophagy in antimicrobial immunity TEMI-2020-1271

TEMI-2020-1279 First report of novel Feline Chapparravirus in China, in 2020 TEMI-2020-1279

TEMI-2020-1226 The clinical characteristics of COVID-19 patients with pneumonia in family clusters TEMI-2020-1226

TEMI-2020-1269 Repressed Hypoxia inducible factor-1 in diabetes aggravates pulmonary aspergillus fumigatus infection through modulation of inflammatory responses TEMI-2020-1269

TEMI-2020-1277 SARS-CoV-2 spike produced in insect cells elicits high neutralization titers in non-human primates TEMI-2020-1277

TEMI-2020-1278 Conjugation of human  $\beta$ -defensin 2 to spike protein receptor-binding domain induces antigen-specific protective immunity against Middle East respiratory syndrome coronavirus infection in human dipeptidyl peptidase 4 transgenic mice TEMI-2020-1278

TEMI-2020-1276 Multicenter evaluation of two chemiluminescence and three lateral flow immunoassays for the diagnosis of COVID-19 and assessment of antibody dynamic responses to SARS-CoV-2 in Taiwan TEMI-2020-1276

TEMI-2020-1275 Whole-genome Sequencing of Rough Brucella melitensis in China Provides Insights into its Genetic Features TEMI-2020-1275

TEMI-2020-1274 Clinical characteristics of 324 discharged COVID-19 patients in Shenzhen during the recovery period: a cohort study TEMI-2020-1274

TEMI-2020-1266 Epidemiological characteristics and the entire evolution of Coronavirus Disease 2019 in Wuhan, China TEMI-2020-1266

TEMI-2020-1272 Signal peptide has great potential as target for developing therapeutic drugs for novel coronavirus infection TEMI-2020-1272

TEMI-2020-1270 Accurate Serology for SARS-CoV-2 and common Human Coronaviruses using a Multiplex Approach TEMI-2020-1270

TEMI-2020-1265 Probiotics Use is Associated with Improved Clinical Outcomes among Hospitalized Patients with Covid-19  
 TEMI-2020-1265

TEMI-2020-1010 Comparative transcriptome analysis reveals the intensive early-stage responses of host cells to SARS-CoV-2 infection TEMI-2020-1010

TEMI-2020-1268 Viral Dynamics of COVID-19 Patients of Different Clinical Types TEMI-2020-1268

TEMI-2020-1259 Specific immune signatures of COVID-19 convalescent patients across two clinical cohorts TEMI-2020-1259

TEMI-2020-1263 Efficacy of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers among Hospitalized COVID-19 Patients with Hypertension: a multicenter retrospective cohort study TEMI-2020-1263

TEMI-2020-1262 Oligonucleotide-capped nanoporous anodic alumina biosensor as diagnostic tool for rapid and accurate detection of Candida auris in clinical samples TEMI-2020-1262

TEMI-2020-1243 The role of Hepatitis B virus X protein on Hepatocellular Carcinoma metastasis adjusts to nutrient microenvironment through autophagy-mediated Sirtuin 3 protein degradation TEMI-2020-1243

TEMI-2020-1256 Infection of pig breeders with G3P[13] porcine rotavirus A during an outbreak on a swine farm in China TEMI-2020-1256

TEMI-2020-1261 Artesunate and dihydroartemisinin inhibit rabies virus replication TEMI-2020-1261

TEMI-2020-1260 A Systematic Review of the Clinical Studies in Humans for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2: Clinical manifestation, diagnosis, and clinical trials. TEMI-2020-1260

TEMI-2020-1257 CT scan does not make a diagnosis of COVID-19: a cautionary case report TEMI-2020-1257

TEMI-2020-1255 Emergence in Eastern China of a Novel Reassortnat Avian influenza Virus (H10N3) with High Pathogenicity to Mice TEMI-2020-1255

TEMI-2020-1232 Hematological characteristics of patients with novel coronavirus pneumonia in intensive care unit TEMI-2020-1232

TEMI-2020-1222 Multiple drug resistant lineage of Enterotoxigenic Escherichia coli ST182 with serotype O169:H41 in airline waste TEMI-2020-1222

TEMI-2020-1245 Survey on Usage of Weekly Hydroxychloroquine Prophylaxis against COVID19 amongst Healthcare Workers in India TEMI-2020-1245

TEMI-2020-1253 Crystal structure of AmpC BER leads to the discovery of broad inhibition activities of marine natural products against  $\beta$ -lactamases TEMI-2020-1253

TEMI-2020-1250 A single nucleotide distinguishes SARS-CoV-2 in Wuhan outbreak in December 2019 from that in Beijing Xinfadi in June 2020, China TEMI-2020-1250

TEMI-2020-1246 The genetic variation landscape of African swine fever virus reveals frequent positive selection on amino acid replacements TEMI-2020-1246

TEMI-2020-1242 Investigation and mitigation of a hospital COVID-19 cluster associated with a SARS-CoV-2 superspreading event TEMI-2020-1242

TEMI-2020-1254 Talaromyces marneffei promotes M2 polarization of human macrophages by downregulating SOCS3 expression and activating TLR9 pathway TEMI-2020-1254

TEMI-2020-1244 Longitudinal clinical and radiographic evaluation reveals interleukin-6 as an indicator of persistent pulmonary injury in COVID-19 TEMI-2020-1244 The link below will take you to a queue with all of your unread conversations:

[https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.proofpoint.com%2Fv%2Furl%3Fu%3Dhttps-3A\\_\\_nam01.safelinks.protection.outlook.com\\_-3Furl-3Dhttps-253A-252F-252Furldefense.proofpoint.com-252Fv2-252Furl-253Fu-253Dhttps-2D3A-5F-5Fmc.manuscriptcentral.com-5Ftemi-2D3FURL-2D5FMASK-2D3D51664aadcf243a085a5a6199f87d325-2526d-253DDwIFaQ-2526c-253D9mghv0deYPYDGP-2DW745IEdQLV1kHpn4XJRvR6xMRXtA-2526r-253DSOVakuu2E4HoaHBSZ5JSdOWTU0zcfLMPHqDYeFUmv3Y-2526m-253DQrvZuj2S2UplX4o9NFER8TgvaVE-5FVBr-5Fn62GDdU7lvQ-2526s-253DJyYpfvpRpyuzOQEmzez6qX-5FOM8oygWDAVFbtS7R4h2A-2526e-253D-26amp-3Bdata-3D02-257C01-257CShan.Lu-2540umassmed.edu-257Cb809295f92084f0c05b008d8314120ac-257Cee9155fe2da34378a6c44405faf57b2e-257C0-257C0-257C637313503076994812-26amp-3Bsdata-3DZJ8gtj-252FSilYJOe5AD0RHE8EOjdHMRBE-252FYmsvTWBNhrk-253D-26amp-3Breserved-3D0%26d%3DDwIGaQ%26c%3D9mghv0deYPYDGP-W745IEdQLV1kHpn4XJRvR6xMRXtA%26r%3DSOVakuu2E4HoaHBSZ5JSdOWTU0zcfLMPHqDYeFUmv3Y%26m%3D2kssb87CI4g1cuvz1FIS4aYloythw6u7eBrc01iXF6o%26s%3DLSqm-kZhAqMv\\_lqJmyJwKrWeByD2ZYolOdG0CJUffm4%26e%3D&data=02%7C01%7CShan.Lu%40umassmed.edu%7C4d3279c1d6c541e39a0508d831c3be8f%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637314064067956990&psdata=WSLThPKBXSHu4wtvu4Np%2Bcvu5U7w4uc%2B9oggJobeuMM%3D&reserved=0](https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.proofpoint.com%2Fv%2Furl%3Fu%3Dhttps-3A__nam01.safelinks.protection.outlook.com_-3Furl-3Dhttps-253A-252F-252Furldefense.proofpoint.com-252Fv2-252Furl-253Fu-253Dhttps-2D3A-5F-5Fmc.manuscriptcentral.com-5Ftemi-2D3FURL-2D5FMASK-2D3D51664aadcf243a085a5a6199f87d325-2526d-253DDwIFaQ-2526c-253D9mghv0deYPYDGP-2DW745IEdQLV1kHpn4XJRvR6xMRXtA-2526r-253DSOVakuu2E4HoaHBSZ5JSdOWTU0zcfLMPHqDYeFUmv3Y-2526m-253DQrvZuj2S2UplX4o9NFER8TgvaVE-5FVBr-5Fn62GDdU7lvQ-2526s-253DJyYpfvpRpyuzOQEmzez6qX-5FOM8oygWDAVFbtS7R4h2A-2526e-253D-26amp-3Bdata-3D02-257C01-257CShan.Lu-2540umassmed.edu-257Cb809295f92084f0c05b008d8314120ac-257Cee9155fe2da34378a6c44405faf57b2e-257C0-257C0-257C637313503076994812-26amp-3Bsdata-3DZJ8gtj-252FSilYJOe5AD0RHE8EOjdHMRBE-252FYmsvTWBNhrk-253D-26amp-3Breserved-3D0%26d%3DDwIGaQ%26c%3D9mghv0deYPYDGP-W745IEdQLV1kHpn4XJRvR6xMRXtA%26r%3DSOVakuu2E4HoaHBSZ5JSdOWTU0zcfLMPHqDYeFUmv3Y%26m%3D2kssb87CI4g1cuvz1FIS4aYloythw6u7eBrc01iXF6o%26s%3DLSqm-kZhAqMv_lqJmyJwKrWeByD2ZYolOdG0CJUffm4%26e%3D&data=02%7C01%7CShan.Lu%40umassmed.edu%7C4d3279c1d6c541e39a0508d831c3be8f%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637314064067956990&psdata=WSLThPKBXSHu4wtvu4Np%2Bcvu5U7w4uc%2B9oggJobeuMM%3D&reserved=0)

Sincerely,

Jorgie Lyn Luna

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

---

**From:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
**Sent:** Tuesday, July 28, 2020 5:52 PM  
**To:** Lu, Shan; Yumei Wen (ymwen@shmu.edu.cn)  
**Cc:** Min Yang (min.yang@emi2012.org)  
**Subject:** RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-1295 has been submitted online

Thank you, Shan.

-----Original Message-----

From: Lu, Shan <Shan.Lu@umassmed.edu>  
Sent: Tuesday, July 28, 2020 3:44 AM  
To: Tang, Yi-Wei <yi-wei.tang@cepheid.com>; Yumei Wen (ymwen@shmu.edu.cn) <ymwen@shmu.edu.cn>  
Cc: Min Yang (min.yang@emi2012.org) <min.yang@emi2012.org>  
Subject: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-1295 has been submitted online

Hi, Yi-Wei,

Thanks for your manuscript. I will process right away for peer-review.

Shan

-----Original Message-----

From: Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
Sent: Sunday, July 26, 2020 11:06 PM  
To: Yumei Wen (ymwen@shmu.edu.cn) <ymwen@shmu.edu.cn>; Lu, Shan <Shan.Lu@umassmed.edu>  
Cc: Min Yang (min.yang@emi2012.org) <min.yang@emi2012.org>  
Subject: FW: Emerging Microbes & Infections - Manuscript ID TEMI-2020-1295 has been submitted online

Teacher Wen, Shan,

This is the metanalysis manuscript that I requested/solicited several weeks ago.

Thank you for your attention.

Yi-Wei

-----Original Message-----

From: Emerging Microbes and Infections <onbehalf@manuscriptcentral.com>  
Sent: Monday, July 27, 2020 10:49 AM  
To: 14301050265@fudan.edu.cn  
Cc: 14301050265@fudan.edu.cn; jingwenai1990@126.com; Loeffelholz, Michael J <Michael.Loeffelholz@cepheid.com>; Tang, Yi-Wei <yi-wei.tang@cepheid.com>; wenhongzhang\_hs@126.com  
Subject: Emerging Microbes & Infections - Manuscript ID TEMI-2020-1295 has been submitted online

26-Jul-2020

Dear Dr Wang:



Your manuscript entitled "Meta-analysis of Diagnostic Performance of Serology Tests for COVID-19: Impact of Assay Design and Post-symptom-onset Intervals" has been successfully submitted online and is presently being given full consideration for publication in Emerging Microbes & Infections.

Your manuscript ID is TEMI-2020-1295.

Please mention the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your street address or e-mail address, please log in to ScholarOne Manuscripts at [https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.proofpoint.com%2Fv%2Furl%3Fu%3Dhttps-3A\\_\\_nam01.safelinks.protection.outlook.com\\_-3Furl-3Dhttps-253A-252F-252Furldefense.proofpoint.com-252Fv2-252Furl-253Fu-253Dhttps-2D3A-5F-5Fmc.manuscriptcentral.com-5Ftemi-2526d-253DDwlCaQ-2526c-253D9mghv0deYPYDGP-2DW745IEdQLV1kHpn4XJRvR6xMRxA-2526r-253DSOVakuu2E4HoaHBSZ5JSdOWTU0zcfLMPHqDyEfUmV3Y-2526m-253DtfB4dOcr1rGcvnx-5FNsfFjoLFtZOKeHNQhWvcDMY6CM-2526s-253Dez3HB-5FMAebfAU7ZCUkFyDW9dO55rkAf-5FxnSRGIk27sw-2526e-253D-26amp-3Bdata-3D02-257C01-257CShan.Lu-2540umassmed.edu-257C6cd112c13f8a4ac9591e08d831d9f8c9-257Cee9155fe2da34378a6c44405faf57b2e-257C0-257C0-257C637314159543094312-26amp-3Bsdata-3DWx8U2Qqe55L5OEmFDin4I3PnFnEJVsGKNmAaOq6lLcQ-253D-26amp-3Breserved-3D0%26d%3DDwlGaQ%26c%3D9mghv0deYPYDGP-W745IEdQLV1kHpn4XJRvR6xMRxA%26r%3DSOVakuu2E4HoaHBSZ5JSdOWTU0zcfLMPHqDyEfUmV3Y%26m%3DhQ0An3ohW3CVyhSswvFpMKsd5omi-7yECPK1PkyP6LQ%26s%3DbwsJ2I4BWKgyMkPv2zyqodt31IMtNg3EfhVD-wVpzi%26e%3D&data=02%7C01%7CShan.Lu%40umassmed.edu%7Ce20d970d22ee40cdd66308d833407f90%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637315699404352395&sdata=RMSfMLrZpdNjCaLssiqqtyg9Npbl3YfG3VXewgwnnxM%3D&reserved=0](https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.proofpoint.com%2Fv%2Furl%3Fu%3Dhttps-3A__nam01.safelinks.protection.outlook.com_-3Furl-3Dhttps-253A-252F-252Furldefense.proofpoint.com-252Fv2-252Furl-253Fu-253Dhttps-2D3A-5F-5Fmc.manuscriptcentral.com-5Ftemi-2526d-253DDwlCaQ-2526c-253D9mghv0deYPYDGP-2DW745IEdQLV1kHpn4XJRvR6xMRxA-2526r-253DSOVakuu2E4HoaHBSZ5JSdOWTU0zcfLMPHqDyEfUmV3Y-2526m-253DtfB4dOcr1rGcvnx-5FNsfFjoLFtZOKeHNQhWvcDMY6CM-2526s-253Dez3HB-5FMAebfAU7ZCUkFyDW9dO55rkAf-5FxnSRGIk27sw-2526e-253D-26amp-3Bdata-3D02-257C01-257CShan.Lu-2540umassmed.edu-257C6cd112c13f8a4ac9591e08d831d9f8c9-257Cee9155fe2da34378a6c44405faf57b2e-257C0-257C0-257C637314159543094312-26amp-3Bsdata-3DWx8U2Qqe55L5OEmFDin4I3PnFnEJVsGKNmAaOq6lLcQ-253D-26amp-3Breserved-3D0%26d%3DDwlGaQ%26c%3D9mghv0deYPYDGP-W745IEdQLV1kHpn4XJRvR6xMRxA%26r%3DSOVakuu2E4HoaHBSZ5JSdOWTU0zcfLMPHqDyEfUmV3Y%26m%3DhQ0An3ohW3CVyhSswvFpMKsd5omi-7yECPK1PkyP6LQ%26s%3DbwsJ2I4BWKgyMkPv2zyqodt31IMtNg3EfhVD-wVpzi%26e%3D&data=02%7C01%7CShan.Lu%40umassmed.edu%7Ce20d970d22ee40cdd66308d833407f90%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637315699404352395&sdata=RMSfMLrZpdNjCaLssiqqtyg9Npbl3YfG3VXewgwnnxM%3D&reserved=0) and edit your user information as appropriate.

You can also view the status of your manuscript at any time by checking your Author Center after logging in to [https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.proofpoint.com%2Fv%2Furl%3Fu%3Dhttps-3A\\_\\_nam01.safelinks.protection.outlook.com\\_-3Furl-3Dhttps-253A-252F-252Furldefense.proofpoint.com-252Fv2-252Furl-253Fu-253Dhttps-2D3A-5F-5Fmc.manuscriptcentral.com-5Ftemi-2526d-253DDwlCaQ-2526c-253D9mghv0deYPYDGP-2DW745IEdQLV1kHpn4XJRvR6xMRxA-2526r-253DSOVakuu2E4HoaHBSZ5JSdOWTU0zcfLMPHqDyEfUmV3Y-2526m-253DtfB4dOcr1rGcvnx-5FNsfFjoLFtZOKeHNQhWvcDMY6CM-2526s-253Dez3HB-5FMAebfAU7ZCUkFyDW9dO55rkAf-5FxnSRGIk27sw-2526e-253D-26amp-3Bdata-3D02-257C01-257CShan.Lu-2540umassmed.edu-257C6cd112c13f8a4ac9591e08d831d9f8c9-257Cee9155fe2da34378a6c44405faf57b2e-257C0-257C0-257C637314159543094312-26amp-3Bsdata-3DWx8U2Qqe55L5OEmFDin4I3PnFnEJVsGKNmAaOq6lLcQ-253D-26amp-3Breserved-3D0%26d%3DDwlGaQ%26c%3D9mghv0deYPYDGP-W745IEdQLV1kHpn4XJRvR6xMRxA%26r%3DSOVakuu2E4HoaHBSZ5JSdOWTU0zcfLMPHqDyEfUmV3Y%26m%3DhQ0An3ohW3CVyhSswvFpMKsd5omi-7yECPK1PkyP6LQ%26s%3DbwsJ2I4BWKgyMkPv2zyqodt31IMtNg3EfhVD-wVpzi%26e%3D&data=02%7C01%7CShan.Lu%40umassmed.edu%7Ce20d970d22ee40cdd66308d833407f90%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637315699404352395&sdata=RMSfMLrZpdNjCaLssiqqtyg9Npbl3YfG3VXewgwnnxM%3D&reserved=0](https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.proofpoint.com%2Fv%2Furl%3Fu%3Dhttps-3A__nam01.safelinks.protection.outlook.com_-3Furl-3Dhttps-253A-252F-252Furldefense.proofpoint.com-252Fv2-252Furl-253Fu-253Dhttps-2D3A-5F-5Fmc.manuscriptcentral.com-5Ftemi-2526d-253DDwlCaQ-2526c-253D9mghv0deYPYDGP-2DW745IEdQLV1kHpn4XJRvR6xMRxA-2526r-253DSOVakuu2E4HoaHBSZ5JSdOWTU0zcfLMPHqDyEfUmV3Y-2526m-253DtfB4dOcr1rGcvnx-5FNsfFjoLFtZOKeHNQhWvcDMY6CM-2526s-253Dez3HB-5FMAebfAU7ZCUkFyDW9dO55rkAf-5FxnSRGIk27sw-2526e-253D-26amp-3Bdata-3D02-257C01-257CShan.Lu-2540umassmed.edu-257C6cd112c13f8a4ac9591e08d831d9f8c9-257Cee9155fe2da34378a6c44405faf57b2e-257C0-257C0-257C637314159543094312-26amp-3Bsdata-3DWx8U2Qqe55L5OEmFDin4I3PnFnEJVsGKNmAaOq6lLcQ-253D-26amp-3Breserved-3D0%26d%3DDwlGaQ%26c%3D9mghv0deYPYDGP-W745IEdQLV1kHpn4XJRvR6xMRxA%26r%3DSOVakuu2E4HoaHBSZ5JSdOWTU0zcfLMPHqDyEfUmV3Y%26m%3DhQ0An3ohW3CVyhSswvFpMKsd5omi-7yECPK1PkyP6LQ%26s%3DbwsJ2I4BWKgyMkPv2zyqodt31IMtNg3EfhVD-wVpzi%26e%3D&data=02%7C01%7CShan.Lu%40umassmed.edu%7Ce20d970d22ee40cdd66308d833407f90%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637315699404352395&sdata=RMSfMLrZpdNjCaLssiqqtyg9Npbl3YfG3VXewgwnnxM%3D&reserved=0) .

Thank you for submitting your manuscript to Emerging Microbes & Infections.

Sincerely,

Emerging Microbes & Infections Editorial Office Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate

the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

---

**From:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
**Sent:** Monday, August 17, 2020 3:39 AM  
**To:** Lu, Shan  
**Cc:** ZhangWenhong; Yumei Wen (ymwen@shmu.edu.cn)  
**Subject:** RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-1295

Shan,

Thank you very much for rethinking your decision and gave us several options. We do feel comments from the two reviewers are addressable and we will work on and submit a revision with the two reviewers' comments carefully addressed.

Regarding the related metanalysis papers so far published elsewhere (at least two now: one in BMJ and one in JMV), I think ours is much better in terms of quality and contents. I would like to point out that we have the best team for the metanalysis and literature reviewers. While Wenhong's team is in the front using these serology assays, Michael and I are the sole two curators reviewing serology papers within the ASM COVID-19 Registry.

Yi-Wei

-----Original Message-----

From: Lu, Shan <Shan.Lu@umassmed.edu>  
Sent: Saturday, August 15, 2020 9:08 PM  
To: Tang, Yi-Wei <yi-wei.tang@cepheid.com>; Yumei Wen (ymwen@shmu.edu.cn) <ymwen@shmu.edu.cn>  
Cc: ZhangWenhong <zhangwenhong@fudan.edu.cn>  
Subject: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-1295

Dear Yi-Wei,

The review of your Meta-analysis is complete. Unfortunately, both reviewers felt strongly that this analysis was not done correctly. Therefore I am sorry that I had to make a decision to reject it to follow the EMI rule when both reviewers are not supporting a paper.

I did not provide my opinion from the beginning as I want to give this paper a fair chance to be reviewed. After getting reviewers' feedback, I do agree with them. Currently the quality of various serology tests vary dramatically. The reported data are not consistent and it is very hard to do a meta-analysis. While your analysis did point out problems, it still supports the use of certain serology tests.

At the same time, BMJ already published a similar Meta-Analysis and their conclusion is "Currently, available evidence does not support the continued use of existing point-of-care serological tests."

At the same time, I do think that serology study is very important. I will be happy to support you to 1) re-submit it with substantial revision if you want to fight for it, and it will be re-reviewed by the same reviewers. Or 2) to write a review to describe the issues and challenges in this field with the same original literature references.

At any rate, I am open to your feedback and suggestion.

Best.

Shan

p.s. I am attaching your paper, the BMJ paper and EMI decision letter for easy reference.

-----Original Message-----

From: Tang, Yi-Wei <yi-wei.tang@cepheid.com>

Sent: Tuesday, July 28, 2020 5:52 PM

To: Lu, Shan <Shan.Lu@umassmed.edu>; Yumei Wen (ymwen@shmu.edu.cn) <ymwen@shmu.edu.cn>

Cc: Min Yang (min.yang@emi2012.org) <min.yang@emi2012.org>

Subject: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-1295 has been submitted online

Thank you, Shan.

-----Original Message-----

From: Lu, Shan <Shan.Lu@umassmed.edu>

Sent: Tuesday, July 28, 2020 3:44 AM

To: Tang, Yi-Wei <yi-wei.tang@cepheid.com>; Yumei Wen (ymwen@shmu.edu.cn) <ymwen@shmu.edu.cn>

Cc: Min Yang (min.yang@emi2012.org) <min.yang@emi2012.org>

Subject: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-1295 has been submitted online

Hi, Yi-Wei,

Thanks for your manuscript. I will process right away for peer-review.

Shan

-----Original Message-----

From: Tang, Yi-Wei <yi-wei.tang@cepheid.com>

Sent: Sunday, July 26, 2020 11:06 PM

To: Yumei Wen (ymwen@shmu.edu.cn) <ymwen@shmu.edu.cn>; Lu, Shan <Shan.Lu@umassmed.edu>

Cc: Min Yang (min.yang@emi2012.org) <min.yang@emi2012.org>

Subject: FW: Emerging Microbes & Infections - Manuscript ID TEMI-2020-1295 has been submitted online

Teacher Wen, Shan,

This is the metanalysis manuscript that I requested/solicited several weeks ago.

Thank you for your attention.

Yi-Wei

-----Original Message-----

From: Emerging Microbes and Infections <onbehalf@manuscriptcentral.com>

Sent: Monday, July 27, 2020 10:49 AM

To: 14301050265@fudan.edu.cn

Cc: 14301050265@fudan.edu.cn; jingwenai1990@126.com; Loeffelholz, Michael J <Michael.Loeffelholz@cepheid.com>;

Tang, Yi-Wei <yi-wei.tang@cepheid.com>; wenhongzhang\_hs@126.com

Subject: Emerging Microbes & Infections - Manuscript ID TEMI-2020-1295 has been submitted online

26-Jul-2020

Dear Dr Wang:

Your manuscript entitled "Meta-analysis of Diagnostic Performance of Serology Tests for COVID-19: Impact of Assay Design and Post-symptom-onset Intervals" has been successfully submitted online and is presently being given full consideration for publication in Emerging Microbes & Infections.

Your manuscript ID is TEMI-2020-1295.

Please mention the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your street address or e-mail address, please log in to ScholarOne Manuscripts at [https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.proofpoint.com%2Fv%2Furl%3Fu%3Dhttps-3A\\_\\_nam01.safelinks.protection.outlook.com\\_-3Furl-3Dhttps-253A-252F-252Furldefense.proofpoint.com-252Fv2-252Furl-253Fu-253Dhttps-2D3A-5F-5Fnam01.safelinks.protection.outlook.com-5F-2D3Furl-2D3Dhttps-2D253A-2D252F-2D252Furldefense.proofpoint.com-2D252Fv2-2D252Furl-2D253Fu-2D253Dhttps-2D2D3A-2D5F-2D5Fmc.manuscriptcentral.com-2D5Ftemi-2D2526d-2D253DDwlCaQ-2D2526c-2D253D9mghv0deYPYDGP-2D2DW745IEdQLV1kHpn4XJRvR6xMRXtA-2D2526r-2D253DSOVakuu2E4HoaHBSZ5JSdOWTU0zcfLMPHqDyEfUmV3Y-2526m-253DhQ0An3ohW3CVyhSswvFpMKsd5omi-2D7yECPK1PkyP6LQ-2526s-253DbwsJ2I4BWKGGyMkPv2zyqodt31IMtNg3EfHVD-2DwVpZl-2526e-253D-26amp-3Bdata-3D02-257C01-257CShan.Lu-2540umassmed.edu-257Ce20d970d22ee40cdd66308d833407f90-257Cee9155fe2da34378a6c44405faf57b2e-257C0-257C0-257C637315699404352395-26amp-3Bsdata-3DRMSfMLrZpdNjCaLssiqqtyg9NpbL3YfG3VXewgwnnxM-253D-26amp-3Breserved-3D0%26d%3DDwlGaQ%26c%3D9mghv0deYPYDGP-W745IEdQLV1kHpn4XJRvR6xMRXtA%26r%3DSOVakuu2E4HoaHBSZ5JSdOWTU0zcfLMPHqDyEfUmV3Y%26m%3D67LlfB8COvOTavHnV0J-DYwX87PoiBBiWE-SWfAIWsl%26s%3DHaMuBsDrRQIW8Dqoh9APJjdMAD9fmmzf77jl8a02Efw%26e%3D&data=02%7C01%7CShan.Lu%40umassmed.edu%7C5cce7cf9b40145dde6fb08d842809e40%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637332467478481580&sdata=wjb3Mv7STSnfEZMIHzjOOyOs3nqk3qj2g%2FKEQRbRGto%3D&reserved=0](https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.proofpoint.com%2Fv%2Furl%3Fu%3Dhttps-3A__nam01.safelinks.protection.outlook.com_-3Furl-3Dhttps-253A-252F-252Furldefense.proofpoint.com-252Fv2-252Furl-253Fu-253Dhttps-2D3A-5F-5Fnam01.safelinks.protection.outlook.com-5F-2D3Furl-2D3Dhttps-2D253A-2D252F-2D252Furldefense.proofpoint.com-2D252Fv2-2D252Furl-2D253Fu-2D253Dhttps-2D2D3A-2D5F-2D5Fmc.manuscriptcentral.com-2D5Ftemi-2D2526d-2D253DDwlCaQ-2D2526c-2D253D9mghv0deYPYDGP-2D2DW745IEdQLV1kHpn4XJRvR6xMRXtA-2D2526r-2D253DSOVakuu2E4HoaHBSZ5JSdOWTU0zcfLMPHqDyEfUmV3Y-2D2526m-2D253DtFb4dOcr1lrGcvnx-2D5FNsfFjoLftZOkEHNQhWvcDMY6CM-2D2526s-2D253Dez3HB-2D5FMAebfAU7ZCUkFyDW9dO55rkAf-2D5FxnSRGlk27sw-2D2526e-2D253D-2D26amp-2D3Bdata-2D3D02-2D257C01-2D257CShan.Lu-2D2540umassmed.edu-2D257C6cd112c13f8a4ac9591e08d831d9f8c9-2D257Cee9155fe2da34378a6c44405faf57b2e-2D257C0-2D257C0-2D257C637314159543094312-2D26amp-2D3Bsdata-2D3DWx8U2Qqe55L5OEmFDin4I3PnFnEJVSGKnMAaOq6lLcQ-2D253D-2D26amp-2D3Breserved-2D3D0-2526d-253DDwlGaQ-2526c-253D9mghv0deYPYDGP-2DW745IEdQLV1kHpn4XJRvR6xMRXtA-2526r-253DSOVakuu2E4HoaHBSZ5JSdOWTU0zcfLMPHqDyEfUmV3Y-2526m-253DhQ0An3ohW3CVyhSswvFpMKsd5omi-2D7yECPK1PkyP6LQ-2526s-253DbwsJ2I4BWKGGyMkPv2zyqodt31IMtNg3EfHVD-2DwVpZl-2526e-253D-26amp-3Bdata-3D02-257C01-257CShan.Lu-2540umassmed.edu-257Ce20d970d22ee40cdd66308d833407f90-257Cee9155fe2da34378a6c44405faf57b2e-257C0-257C0-257C637315699404352395-26amp-3Bsdata-3DRMSfMLrZpdNjCaLssiqqtyg9NpbL3YfG3VXewgwnnxM-253D-26amp-3Breserved-3D0%26d%3DDwlGaQ%26c%3D9mghv0deYPYDGP-W745IEdQLV1kHpn4XJRvR6xMRXtA%26r%3DSOVakuu2E4HoaHBSZ5JSdOWTU0zcfLMPHqDyEfUmV3Y%26m%3D67LlfB8COvOTavHnV0J-DYwX87PoiBBiWE-SWfAIWsl%26s%3DHaMuBsDrRQIW8Dqoh9APJjdMAD9fmmzf77jl8a02Efw%26e%3D&data=02%7C01%7CShan.Lu%40umassmed.edu%7C5cce7cf9b40145dde6fb08d842809e40%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637332467478481580&sdata=wjb3Mv7STSnfEZMIHzjOOyOs3nqk3qj2g%2FKEQRbRGto%3D&reserved=0) and edit your user information as appropriate.

You can also view the status of your manuscript at any time by checking your Author Center after logging in to [https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.proofpoint.com%2Fv%2Furl%3Fu%3Dhttps-3A\\_\\_nam01.safelinks.protection.outlook.com\\_-3Furl-3Dhttps-253A-252F-252Furldefense.proofpoint.com-252Fv2-252Furl-253Fu-253Dhttps-2D3A-5F-5Fnam01.safelinks.protection.outlook.com-5F-2D3Furl-2D3Dhttps-2D253A-2D252F-2D252Furldefense.proofpoint.com-2D252Fv2-2D252Furl-2D253Fu-2D253Dhttps-2D2D3A-2D5F-2D5Fmc.manuscriptcentral.com-2D5Ftemi-2D2526d-2D253DDwlCaQ-2D2526c-2D253D9mghv0deYPYDGP-2D2DW745IEdQLV1kHpn4XJRvR6xMRXtA-2D2526r-2D253DSOVakuu2E4HoaHBSZ5JSdOWTU0zcfLMPHqDyEfUmV3Y-2D2526m-2D253DtFb4dOcr1lrGcvnx-2D5FNsfFjoLftZOkEHNQhWvcDMY6CM-2D2526s-2D253Dez3HB-2D5FMAebfAU7ZCUkFyDW9dO55rkAf-2D5FxnSRGlk27sw-2D2526e-2D253D-2D26amp-2D3Bdata-2D3D02-2D257C01-2D257CShan.Lu-2D2540umassmed.edu-2D257C6cd112c13f8a4ac9591e08d831d9f8c9-2D257Cee9155fe2da34378a6c44405faf57b2e-2D257C0-2D257C0-2D257C637314159543094312-2D26amp-2D3Bsdata-2D3DWx8U2Qqe55L5OEmFDin4I3PnFnEJVSGKnMAaOq6lLcQ-2D253D-2D26amp-2D3Breserved-2D3D0-2526d-253DDwlGaQ-2526c-253D9mghv0deYPYDGP-2DW745IEdQLV1kHpn4XJRvR6xMRXtA-2526r-253DSOVakuu2E4HoaHBSZ5JSdOWTU0zcfLMPHqDyEfUmV3Y-2526m-253DhQ0An3ohW3CVyhSswvFpMKsd5omi-2D7yECPK1PkyP6LQ-2526s-253DbwsJ2I4BWKGGyMkPv2zyqodt31IMtNg3EfHVD-2DwVpZl-2526e-253D-26amp-3Bdata-3D02-257C01-257CShan.Lu-2540umassmed.edu-257Ce20d970d22ee40cdd66308d833407f90-257Cee9155fe2da34378a6c44405faf57b2e-257C0-257C0-257C637315699404352395-26amp-3Bsdata-3DRMSfMLrZpdNjCaLssiqqtyg9NpbL3YfG3VXewgwnnxM-253D-26amp-3Breserved-3D0%26d%3DDwlGaQ%26c%3D9mghv0deYPYDGP-](https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.proofpoint.com%2Fv%2Furl%3Fu%3Dhttps-3A__nam01.safelinks.protection.outlook.com_-3Furl-3Dhttps-253A-252F-252Furldefense.proofpoint.com-252Fv2-252Furl-253Fu-253Dhttps-2D3A-5F-5Fnam01.safelinks.protection.outlook.com-5F-2D3Furl-2D3Dhttps-2D253A-2D252F-2D252Furldefense.proofpoint.com-2D252Fv2-2D252Furl-2D253Fu-2D253Dhttps-2D2D3A-2D5F-2D5Fmc.manuscriptcentral.com-2D5Ftemi-2D2526d-2D253DDwlCaQ-2D2526c-2D253D9mghv0deYPYDGP-2D2DW745IEdQLV1kHpn4XJRvR6xMRXtA-2D2526r-2D253DSOVakuu2E4HoaHBSZ5JSdOWTU0zcfLMPHqDyEfUmV3Y-2D2526m-2D253DtFb4dOcr1lrGcvnx-2D5FNsfFjoLftZOkEHNQhWvcDMY6CM-2D2526s-2D253Dez3HB-2D5FMAebfAU7ZCUkFyDW9dO55rkAf-2D5FxnSRGlk27sw-2D2526e-2D253D-2D26amp-2D3Bdata-2D3D02-2D257C01-2D257CShan.Lu-2D2540umassmed.edu-2D257C6cd112c13f8a4ac9591e08d831d9f8c9-2D257Cee9155fe2da34378a6c44405faf57b2e-2D257C0-2D257C0-2D257C637314159543094312-2D26amp-2D3Bsdata-2D3DWx8U2Qqe55L5OEmFDin4I3PnFnEJVSGKnMAaOq6lLcQ-2D253D-2D26amp-2D3Breserved-2D3D0-2526d-253DDwlGaQ-2526c-253D9mghv0deYPYDGP-2DW745IEdQLV1kHpn4XJRvR6xMRXtA-2526r-253DSOVakuu2E4HoaHBSZ5JSdOWTU0zcfLMPHqDyEfUmV3Y-2526m-253DhQ0An3ohW3CVyhSswvFpMKsd5omi-2D7yECPK1PkyP6LQ-2526s-253DbwsJ2I4BWKGGyMkPv2zyqodt31IMtNg3EfHVD-2DwVpZl-2526e-253D-26amp-3Bdata-3D02-257C01-257CShan.Lu-2540umassmed.edu-257Ce20d970d22ee40cdd66308d833407f90-257Cee9155fe2da34378a6c44405faf57b2e-257C0-257C0-257C637315699404352395-26amp-3Bsdata-3DRMSfMLrZpdNjCaLssiqqtyg9NpbL3YfG3VXewgwnnxM-253D-26amp-3Breserved-3D0%26d%3DDwlGaQ%26c%3D9mghv0deYPYDGP-)

W745IEdQLV1kHpn4XJRvR6xMRXtA%26r%3DSOVakuu2E4HoaHBSZ5JSdOWTU0zcfLMPPhQdYeFUmv3Y%26m%3D67LifB8  
COvOTavHnV0J-DYwX87PoiBBiwE-  
SWfAIWsl%26s%3DHaMuBsDrRQIW8Dqoh9APJjdMAD9fmmzf77jl8a02Efw%26e%3D&data=02%7C01%7CShan.Lu%  
40umassmed.edu%7C5cce7cf9b40145dde6fb08d842809e40%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C6  
37332467478491581&sdata=5NBA0dYzk84ipGNBL%2FMgfg2A6UvF4gha1%2FeaHXX6%2BFg%3D&reserved=0  
.

Thank you for submitting your manuscript to Emerging Microbes & Infections.

Sincerely,

Emerging Microbes & Infections Editorial Office Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

---

**From:** Du, Lanying <LDu@nybc.org>  
**Sent:** Saturday, January 18, 2020 9:27 AM  
**To:** Shibo Jiang (姜世勃); Lu, Shan  
**Cc:** Yang Min 杨旻; min.yang@emi2012.org; Shi Zhengli  
**Subject:** Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Dear Prof. Jiang,

Thank you for inviting me as a co-author on this timely and important commentary. I agree to be the co-author.

Best regards,  
Lanying

\*\*\*\*\*

Lanying Du, Ph.D.  
Member & Head  
Viral Immunology Laboratory  
Lindsley F. Kimball Research Institute  
New York Blood Center  
310 East 67th Street  
New York, NY 10065, USA  
Tel: 212-570-3459;  
Email: [ldu@nybc.org](mailto:ldu@nybc.org).

---

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Saturday, January 18, 2020 3:25 AM  
**To:** Lu Shan <shan.lu@umassmed.edu>  
**Cc:** Yang Min 杨旻 <minyang0216@163.com>; min.yang@emi2012.org <min.yang@emi2012.org>; Shi Zhengli <zshi@wh.iov.cn>; Du, Lanying <LDu@nybc.org>  
**Subject:** Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Dear Prof. Lu,

Per your request, I just submitted the invited Commentary to EMI online (see the attachment). During the submission, I accidentally put in the contact information of Drs. Lu Lu and Shuai Xia (my postdoc), rather than Drs. Shi and Du, into the authors' list. I thus immediately called Min about the possibility of withdrawing and resubmitting the manuscript. Min told me that I would not have to withdraw the manuscript since the authors' information in the manuscript is correct, but I would have to inform Drs. Lu and Xia that they may receive the email from EMI about this manuscript. I informed them already.

I will cite Prof. Yuen's paper once the citation information is available during the proof-reading stage.

Thank you very much for your consideration,

Shibo

-----原始邮件-----

发件人: "Emerging Microbes and Infections" <onbehalf@manuscriptcentral.com>

发送时间: 2020-01-18 15:21:06 (星期六)

收件人: shibojiang@fudan.edu.cn

抄送: shibojiang@fudan.edu.cn

主题: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

18-Jan-2020

Dear Professor Jiang:

Your manuscript entitled "An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies" has been successfully submitted online and is presently being given full consideration for publication in Emerging Microbes & Infections.

Your manuscript ID is TEMI-2020-0055.

Please mention the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your street address or e-mail address, please log in to ScholarOne Manuscripts at <https://mc.manuscriptcentral.com/temi> and edit your user information as appropriate.

You can also view the status of your manuscript at any time by checking your Author Center after logging in to <https://mc.manuscriptcentral.com/temi>.

Thank you for submitting your manuscript to Emerging Microbes & Infections.

Sincerely,

Emerging Microbes & Infections Editorial Office



**LIFESA** VING INNOVATION SINCE 1964



[Donate Blood](#) | [Volunteer](#) | [Support NYBC](#)

This email transmission and any documents, files or previous email messages attached to it may contain information that is confidential or legally privileged. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you are hereby notified that you must not read this transmission and that any disclosure, copying, printing, distribution or use of this transmission is strictly prohibited. If you have received this transmission in error, please immediately notify the sender by telephone or return email and delete the original transmission and its attachments without reading or saving in any manner.



---

**From:** Liu, Shan-Lu <liu.6244@osu.edu>  
**Sent:** Thursday, February 13, 2020 8:57 AM  
**To:** temi-peerreview@journals.tandf.co.uk  
**Cc:** Lu, Shan; Su, Lishan  
**Subject:** Re: Emerging Microbes & Infections - TEMI-2020-0121 - changes required to your submission  
**Attachments:** Liu et al\_EMI Commentary\_15 references.docx  
  
**Importance:** High

Hi Jorgie:

I have modified as instructed and attached the new one to this email. Please help upload and proceed.

Thank you.

Shan-Lu

Shan-Lu Liu, M.D., Ph.D.  
Professor  
Co-Director, Viruses and Emerging Pathogens Program Infectious Diseases Institute Center for Retrovirus Research  
Departments of Veterinary Biosciences, Microbial Infection and Immunity, and Microbiology The Ohio State University  
1900 Coffey Rd, Room 480 VMAB  
Columbus, Ohio 43210  
Phone: (614) 292-8690  
Fax: (614) 292-6473  
Email: liu.6244@osu.edu; shan-lu.liu@osumc.edu

On 2/13/20, 8:43 AM, "Emerging Microbes and Infections" <onbehalf@manuscriptcentral.com> wrote:

13-Feb-2020

Dear Professor Liu,

Your above referenced manuscript, entitled "SARS-CoV-2: no evidence of a laboratory origin" requires some further changes before it is ready for reviewing in Emerging Microbes & Infections. Your submission has been returned to you and is located in your Author Center as a draft, so that you due to these reasons:

1. No line numbering

Kindly add a line numbering in your main document.

2. Exceeded reference count

Kindly be informed that the reference count for the commentary article should not be more than 15.

Your submission along with all files you submitted is now in your Author Center, at  
[https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.com%2Fv3%2F\\_\\_https%3A%2F%2Fmc.manuscriptcentral.com%2Ftemi\\_\\_%3B!!KGKeukY!nGv1RgRJ1P-](https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.com%2Fv3%2F__https%3A%2F%2Fmc.manuscriptcentral.com%2Ftemi__%3B!!KGKeukY!nGv1RgRJ1P-)

OGXuZi8b2hKGjXxDFOmBwDONuR\_njCdWERJF1HkBIv4Sggqr9udyWYmI%24&data=02%7C01%7CShan.Lu%40umass  
med.edu%7Cde7fc6818f7047e0d79008d7b08c97ea%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637171990  
355158902&sdata=nRqMhNxdKKXJTS3Gah0eHjsq926D2xz32DK1nzopo%2BA%3D&reserved=0 Please read  
the Quick Guide to Continuing your Submission, which shows how you can access your manuscript, and submit it back to  
the site. The Guide is located at  
[https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.com%2Fv3%2F\\_\\_http%3A%2F%2Fm  
c.manuscriptcentral.com%2Fsocietyimages%2Ftandf\\_qs0%2FContinuning\\*20a\\*20Submission\\_screenshot.pdf\\_\\_%3BJSU!  
!KGKeukY!nGv1RgRJ1P-](https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.com%2Fv3%2F__http%3A%2F%2Fm<br/>c.manuscriptcentral.com%2Fsocietyimages%2Ftandf_qs0%2FContinuning*20a*20Submission_screenshot.pdf__%3BJSU!<br/>!KGKeukY!nGv1RgRJ1P-)  
OGXuZi8b2hKGjXxDFOmBwDONuR\_njCdWERJF1HkBIv4Sggqr9re6Z8tA%24&data=02%7C01%7CShan.Lu%40umass  
med.edu%7Cde7fc6818f7047e0d79008d7b08c97ea%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637171990  
355158902&sdata=JEIO3OLwBEDXtpTKWpzb2Az5%2FliUA32F5Sn1KhHtVy8%3D&reserved=0

You may contact the Editorial Office if you have further questions.

Sincerely,

Jorgie Lyn Luna  
Emerging Microbes & Infections Editorial Office  
[temi-peerreview@journals.tandf.co.uk](mailto:temi-peerreview@journals.tandf.co.uk)

---

**From:** Su, Lishan <lishan\_su@med.unc.edu>  
**Sent:** Thursday, February 13, 2020 10:06 AM  
**To:** Liu, Shan-Lu; Lu, Shan  
**Subject:** Re: Emerging Microbes & Infections - TEMI-2020-0121 - changes required to your submission

Great job!

-Lishan

---

**From:** Liu, Shan-Lu <liu.6244@osu.edu>  
**Sent:** Thursday, February 13, 2020 10:04:30 AM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Cc:** Su, Lishan <lishan\_su@med.unc.edu>  
**Subject:** Re: Emerging Microbes & Infections - TEMI-2020-0121 - changes required to your submission

Thanks, Shan for your efficient action!

On 2/13/20, 9:56 AM, "Lu, Shan" <Shan.Lu@umassmed.edu> wrote:

Your paper is now accepted. Hope you have received the decision letter.

Best.

Shan

-----Original Message-----

From: Liu, Shan-Lu <liu.6244@osu.edu>  
Sent: Thursday, February 13, 2020 8:57 AM  
To: temi-peerreview@journals.tandf.co.uk  
Cc: Lu, Shan <Shan.Lu@umassmed.edu>; Su, Lishan <lishan\_su@med.unc.edu>  
Subject: Re: Emerging Microbes & Infections - TEMI-2020-0121 - changes required to your submission  
Importance: High

Hi Jorgie:

I have modified as instructed and attached the new one to this email. Please help upload and proceed.

Thank you.

Shan-Lu

Shan-Lu Liu, M.D., Ph.D.  
Professor  
Co-Director, Viruses and Emerging Pathogens Program Infectious Diseases Institute Center for Retrovirus Research  
Departments of Veterinary Biosciences, Microbial Infection and Immunity, and Microbiology The Ohio State University  
1900 Coffey Rd, Room 480 VMAB  
Columbus, Ohio 43210  
Phone: (614) 292-8690  
Fax: (614) 292-6473

On 2/13/20, 8:43 AM, "Emerging Microbes and Infections" <onbehalf@manuscriptcentral.com> wrote:

---

**From:** Liu, Shan-Lu <liu.6244@osu.edu>  
**Sent:** Thursday, February 13, 2020 10:05 AM  
**To:** Lu, Shan  
**Cc:** Su, Lishan  
**Subject:** Re: Emerging Microbes & Infections - TEMI-2020-0121 - changes required to your submission

Thanks, Shan for your efficient action!

On 2/13/20, 9:56 AM, "Lu, Shan" <Shan.Lu@umassmed.edu> wrote:

Your paper is now accepted. Hope you have received the decision letter.

Best.

Shan

-----Original Message-----

From: Liu, Shan-Lu <liu.6244@osu.edu>  
Sent: Thursday, February 13, 2020 8:57 AM  
To: temi-peerreview@journals.tandf.co.uk  
Cc: Lu, Shan <Shan.Lu@umassmed.edu>; Su, Lishan <lishan\_su@med.unc.edu>  
Subject: Re: Emerging Microbes & Infections - TEMI-2020-0121 - changes required to your submission  
Importance: High

Hi Jorgie:

I have modified as instructed and attached the new one to this email. Please help upload and proceed.

Thank you.

Shan-Lu

Shan-Lu Liu, M.D., Ph.D.

Professor

Co-Director, Viruses and Emerging Pathogens Program Infectious Diseases Institute Center for Retrovirus Research  
Departments of Veterinary Biosciences, Microbial Infection and Immunity, and Microbiology The Ohio State University  
1900 Coffey Rd, Room 480 VMAB  
Columbus, Ohio 43210  
Phone: (614) 292-8690  
Fax: (614) 292-6473  
Email: liu.6244@osu.edu; shan-lu.liu@osumc.edu

On 2/13/20, 8:43 AM, "Emerging Microbes and Infections" <onbehalf@manuscriptcentral.com> wrote:

13-Feb-2020

Dear Professor Liu,



---

**From:** Liu, Shan-Lu <liu.6244@osu.edu>  
**Sent:** Monday, March 16, 2020 12:06 PM  
**To:** editorial@emi2012.org  
**Cc:** Lu, Shan  
**Subject:** Re: Emerging Microbes & Infections - Invitation to Review Manuscript ID TEMI-2020-0297

Sorry I am too busy this time on an NIH R01 due April 10 and also teaching...

I suggest Jingyou Yu at BIDMC - Barouch Med Vaccine Research: jyu9@bidmc.harvard.edu, who is my former student and now working on with Dan Barouch.

Shan-Lu

Shan-Lu Liu, M.D., Ph.D.  
Professor  
Co-Director, Viruses and Emerging Pathogens Program Infectious Diseases Institute Center for Retrovirus Research  
Departments of Veterinary Biosciences, Microbial Infection and Immunity, and Microbiology The Ohio State University  
1900 Coffey Rd, Room 480 VMAB  
Columbus, Ohio 43210  
Phone: (614) 292-8690  
Fax: (614) 292-6473  
Email: liu.6244@osu.edu; shan-lu.liu@osumc.edu

On 3/16/20, 10:59 AM, "Emerging Microbes and Infections" <onbehalf@manuscriptcentral.com> wrote:

16-Mar-2020  
Dear Professor Shan-Lu Liu:

The above manuscript, entitled "Patterns of IgG and IgM antibody response in COVID-19 patients" has been submitted to Emerging Microbes & Infections.

I would be grateful if you would kindly agree to act as a reviewer for this paper. The abstract appears at the end of this letter.

Please let me know as soon as possible if you will be able to accept my invitation to review. To do this please either click the appropriate link below to automatically register your reply with our online manuscript submission and review system, or e-mail me with your reply.

\*\*\* PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a webpage to confirm.  
\*\*\*

Agreed:  
[https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.com%2Fv3%2F\\_\\_https%3A%2F%2Fmc.manuscriptcentral.com%2Ftemi%3FURL\\_MASK%3De0e65f17ed01492f9a17f88b22a7e78c\\_\\_%3B!!KGKeukY!!bTDMdkuQfyzCO36Gg1ZNH2NY8GqwjkFqj5cW8AFJzyd8bjaxwod\\_ULapKdjN5vJhY%24&data=02%7C01%7CShan.Lu%40u.massmed.edu%7Cb4f58da814234cde674308d7c9c3f713%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637199715832949203&sdata=PgilWFOGnZAsel6wtxD2cR806jWoZL31Sgkn%2BhLyTJY%3D&reserved=0](https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.com%2Fv3%2F__https%3A%2F%2Fmc.manuscriptcentral.com%2Ftemi%3FURL_MASK%3De0e65f17ed01492f9a17f88b22a7e78c__%3B!!KGKeukY!!bTDMdkuQfyzCO36Gg1ZNH2NY8GqwjkFqj5cW8AFJzyd8bjaxwod_ULapKdjN5vJhY%24&data=02%7C01%7CShan.Lu%40u.massmed.edu%7Cb4f58da814234cde674308d7c9c3f713%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637199715832949203&sdata=PgilWFOGnZAsel6wtxD2cR806jWoZL31Sgkn%2BhLyTJY%3D&reserved=0)

Declined:

[https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.com%2Fv3%2F\\_\\_https%3A%2F%2Fmc.manuscriptcentral.com%2Ftemi%3FURL\\_MASK%3Dd668a2f0d19949819370934aab6a9dff\\_\\_%3B!!KGKeukY!!bTDMDkuQfyzCO36Gg1ZNH2NY8GqwjknFqj5cW8AFJzyd8bjaxwod\\_ULapKdTu3g-Kc%24&data=02%7C01%7CShan.Lu%40umassmed.edu%7Cb4f58da814234cde674308d7c9c3f713%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637199715832949203&sdata=ICqRPbgfrrNXltynm0WuyS7TxL8wQBYw6y6h%2FbbLPPk%3D&reserved=0](https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.com%2Fv3%2F__https%3A%2F%2Fmc.manuscriptcentral.com%2Ftemi%3FURL_MASK%3Dd668a2f0d19949819370934aab6a9dff__%3B!!KGKeukY!!bTDMDkuQfyzCO36Gg1ZNH2NY8GqwjknFqj5cW8AFJzyd8bjaxwod_ULapKdTu3g-Kc%24&data=02%7C01%7CShan.Lu%40umassmed.edu%7Cb4f58da814234cde674308d7c9c3f713%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637199715832949203&sdata=ICqRPbgfrrNXltynm0WuyS7TxL8wQBYw6y6h%2FbbLPPk%3D&reserved=0)

Unavailable:

[https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.com%2Fv3%2F\\_\\_https%3A%2F%2Fmc.manuscriptcentral.com%2Ftemi%3FURL\\_MASK%3Dc807f5087cd349d8984fbe9acd70db79\\_\\_%3B!!KGKeukY!!bTDMDkuQfyzCO36Gg1ZNH2NY8GqwjknFqj5cW8AFJzyd8bjaxwod\\_ULapKdDkCqqR8%24&data=02%7C01%7CShan.Lu%40umassmed.edu%7Cb4f58da814234cde674308d7c9c3f713%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637199715832949203&sdata=sCqY0MSALOB%2BopjbdkDrUW2K%2FYuFh1iANjmCKy17ya4%3D&reserved=0](https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.com%2Fv3%2F__https%3A%2F%2Fmc.manuscriptcentral.com%2Ftemi%3FURL_MASK%3Dc807f5087cd349d8984fbe9acd70db79__%3B!!KGKeukY!!bTDMDkuQfyzCO36Gg1ZNH2NY8GqwjknFqj5cW8AFJzyd8bjaxwod_ULapKdDkCqqR8%24&data=02%7C01%7CShan.Lu%40umassmed.edu%7Cb4f58da814234cde674308d7c9c3f713%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637199715832949203&sdata=sCqY0MSALOB%2BopjbdkDrUW2K%2FYuFh1iANjmCKy17ya4%3D&reserved=0)

Should you accept my invitation to review this manuscript, you will be sent an email with a direct link to the scoresheet, which will be made available to you. You will then have access to the manuscript and reviewer instructions in your Reviewer Center.

If you are unable to review the manuscript, click on the “decline” option to register your response. This will direct you to a screen where you will be given the opportunity to provide details of any alternative reviewers.

I realise that our expert reviewers greatly contribute to the high standards of the Journal, and I thank you for your present and/or future participation.

Sincerely,  
Professor Shan Lu  
Emerging Microbes & Infections

#### MANUSCRIPT DETAILS

TITLE: Patterns of IgG and IgM antibody response in COVID-19 patients

AUTHORS: Dr Xuemei Liu

ABSTRACT:



---

**From:** Wang Linfa <linfa.wang@duke-nus.edu.sg>  
**Sent:** Monday, April 13, 2020 1:16 PM  
**To:** Lu, Shan  
**Subject:** Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0595 has been submitted online

Thanks for doing your best!

Sent from my iPhone

> On 14 Apr 2020, at 1:13 AM, Lu, Shan <Shan.Lu@umassmed.edu> wrote:

>  
> - External Email -  
>

>  
>  
> Great. We will take care of it.  
>

> The other still waits for some feedback. We will push as much as I can.  
>

> Best.

>  
> Shan

>  
> -----Original Message-----

> From: Wang Linfa <linfa.wang@duke-nus.edu.sg>

> Sent: Monday, April 13, 2020 12:18 PM

> To: Lu, Shan <Shan.Lu@umassmed.edu>

> Subject: FW: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0595 has been submitted online

> Importance: High

>  
> Dear Shan,

>  
> Just to let you know that another serology paper has been submitted to EMI as promised.  
>

> Thanks  
>

> LF  
>

> Linfa (Lin-Fa) WANG, PhD FTSE  
> Professor & Director  
> Programme in Emerging Infectious Disease Duke-NUS Medical School,  
> 8 College Road, Singapore 169857  
> Tel: +65 6516 8397  
>

>  
>  
>  
> 13-Apr-2020  
>

> Dear Professor Wang:

>  
> Your manuscript entitled "Serological differentiation between COVID-19 and SARS infections" has been successfully submitted online and is presently being given full consideration for publication in Emerging Microbes & Infections.  
>  
> Your manuscript ID is TEMI-2020-0595.  
>  
> Please mention the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your street address or e-mail address, please log in to ScholarOne Manuscripts at <https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fmc.manuscriptcentral.com%2Ftemi&data=02%7C01%7CShan.Lu%40umassmed.edu%7C412437ee930d4584194e08d7dfce6098%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637223949870597134&sdata=WwuPZnDTI1lihv55iOYB5Wd13Cjl6JBMYPm8ka15VBQ%3D&mp;reserved=0> and edit your user information as appropriate.  
>  
> You can also view the status of your manuscript at any time by checking your Author Center after logging in to <https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fmc.manuscriptcentral.com%2Ftemi&data=02%7C01%7CShan.Lu%40umassmed.edu%7C412437ee930d4584194e08d7dfce6098%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637223949870597134&sdata=WwuPZnDTI1lihv55iOYB5Wd13Cjl6JBMYPm8ka15VBQ%3D&mp;reserved=0>.  
>  
> Thank you for submitting your manuscript to Emerging Microbes & Infections.  
>  
> Sincerely,  
> Emerging Microbes & Infections Editorial Office  
>  
> \_\_\_\_\_  
>  
> Important: This email is confidential and may be privileged. If you are not the intended recipient, please delete it and notify us immediately; you should not copy or use it for any purpose, nor disclose its contents to any other person.  
Thank you.

---

Important: This email is confidential and may be privileged. If you are not the intended recipient, please delete it and notify us immediately; you should not copy or use it for any purpose, nor disclose its contents to any other person.  
Thank you.

---

**From:** Dr. Johannes Möst <jm@mb-lab.com>  
**Sent:** Tuesday, June 16, 2020 1:54 AM  
**To:** Lu, Shan  
**Cc:** editorial@emi2012.org; ymw@shmu.edu.cn  
**Subject:** Re: Emerging Microbes & Infections, Manuscript ID TEMI-2020-0796

Dear editor,

Thank you very much. I'm really grateful for your rapid response. As I wrote before I'm aware of the enormous workload you have to manage in the present (and ongoing) situation. I think we just had a bit of bad luck with the reviewers.

So thank you once again.

Best regards

Johannes

--

Univ.-Doz. Dr. Johannes Möst

Mikrobiologisches Labor

Franz-Fischer-Straße 7b

6020 Innsbruck

Tel.: +43 (0)512-563380

FAX: +43 (0)512-563380-40

[https://nam01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.mb-](https://nam01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.mb-lab.com%2F&data=02%7C01%7CShan.Lu%40umassmed.edu%7Cec8f493dea1f47d81b0608d811b9ac12%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637278836456771036&sdata=DpRVHlgJnzdVSYW37RUPw%2BCenXwcYX1HUiSjVyoUlw%3D&reserved=0)

[lab.com%2F&data=02%7C01%7CShan.Lu%40umassmed.edu%7Cec8f493dea1f47d81b0608d811b9ac12%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637278836456771036&sdata=DpRVHlgJnzdVSYW37RUPw%2BCenXwcYX1HUiSjVyoUlw%3D&reserved=0](https://nam01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.mb-lab.com%2F&data=02%7C01%7CShan.Lu%40umassmed.edu%7Cec8f493dea1f47d81b0608d811b9ac12%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637278836456771036&sdata=DpRVHlgJnzdVSYW37RUPw%2BCenXwcYX1HUiSjVyoUlw%3D&reserved=0)

---

**From:** TEMI-peerreview@journals.tandf.co.uk  
**Sent:** Monday, January 20, 2020 4:04 AM  
**To:** Lu, Shan; shibojiang@fudan.edu.cn  
**Cc:** zlshi@wh.iov.cn; minyang0216@163.com; min.yang@emi2012.org; ldu@nybc.org  
**Subject:** RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 #TrackingId:5437168

Dear Prof. Jiang,

Thank you for your email.

This is to kindly let you know that I have now processed your paper and I have noticed that the paper does not contain a line numbering. Having this, I have returned your manuscript in your author centre in order for you to add a line numbering in your main document and make the necessary amendments in your co-authors list.

Rest assured that once received, I will then proceed your paper to Prof. Lu immediately.

Please let me know if you have any questions or concerns.

Kind regards,

**Jorgie Lyn Luna** - Journal Editorial Office  
Taylor & Francis Group  
4 Park Square | Milton Park | Abingdon | Oxon | OX14 4RN UK  
Web: [www.tandfonline.com](http://www.tandfonline.com)

Taylor & Francis is a trading name of Informa UK Limited,  
registered in England under no. 1072954

Emerging Microbes & Infections

---

**From:** Shan.Lu@umassmed.edu  
**Sent:** 18-01-2020 07:21  
**To:** shibojiang@fudan.edu.cn, Shan.Lu@umassmed.edu  
**Cc:** minyang0216@163.com, min.yang@emi2012.org, zlshi@wh.iov.cn, ldu@nybc.org  
**Subject:** RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055

Hi, Shibo,

Thanks for submitting this timely Commentary. At the same time, you need to ensure the two co-authors agree to this draft of paper, especially the agreement from Prof. Shi.

At this stage, JEO who is in charge of the first step QC will need to go through the draft and may contact you with any required formatting revisions. I am copying her here and she may take a little time to process since we are in Weekend now. But you should not write to her directly per T&F rules unless she contacts you.

Dear Jorgie Lyn Luna,

Please see communication with Prof Jiang on this new submission TEMI-2020-0055. What I would like are the following:

- 1) Please conduct a quick QC/format and let this MS moving to my desk asap, if there is no any QC/format issue.
- 2) It is ok to send it back to corresponding author Prof Jiang if there is QC issue right away, and he will process such revisions right away, including the wrong emails from two co-authors. Then please monitor the re-submission and again send it to me asap after your QC check.

Thanks.

Shan

-----Original Message-----

From: Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>

Sent: Saturday, January 18, 2020 3:25 AM

To: Lu, Shan <Shan.Lu@umassmed.edu>

Cc: Yang Min 杨旻 <minyang0216@163.com>; min.yang@emi2012.org; Shi Zhengli <zlshi@wh.iov.cn>; Du Lanying\_NYBC <ldu@nybc.org>

Subject: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Dear Prof. Lu,

Per your request, I just submitted the invited Commentary to EMI online (see the attachment). During the submission, I accidentally put in the contact information of Drs. Lu Lu and Shuai Xia (my postdoc), rather than Drs. Shi and Du, into the authors' list. I thus immediately called Min about the possibility of withdrawing and resubmitting the manuscript. Min told me that I would not have to withdraw the manuscript since the authors' information in the manuscript is correct, but I would have to inform Drs. Lu and Xia that they may receive the email from EMI about this manuscript. I informed them already.

I will cite Prof. Yuen's paper once the citation information is available during the proof-reading stage.

Thank you very much for your consideration,

Shibo

-----原始邮件-----

发件人: "Emerging Microbes and Infections" <onbehalf@manuscriptcentral.com>

发送时间: 2020-01-18 15:21:06 (星期六)

收件人: shibojiang@fudan.edu.cn

抄送: shibojiang@fudan.edu.cn

主题: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

18-Jan-2020

Dear Professor Jiang:

Your manuscript entitled "An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies" has been successfully submitted online and is presently being given full consideration for publication in Emerging Microbes & Infections.

Your manuscript ID is TEMI-2020-0055.

Please mention the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your street address or e-mail address, please log in to ScholarOne Manuscripts at <https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fmc.manuscriptcentral.com%2Ftemi&data=02%7C01%7Cshan.lu%40umassmed.edu%7C5bf67dcea80543172df308d79beffa7f%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637149327594484021&sdata=q3fFDQyJZmoHlceFvohL5YzdF2gO11sH HBts3o6gm3l%3D&reserved=0> and edit your user information as appropriate.

You can also view the status of your manuscript at any time by checking your Author Center after logging in to <https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fmc.manuscriptcentral.com%2Ftemi&data=02%7C01%7Cshan.lu%40umassmed.edu%7C5bf67dcea80543172df308d79beffa7f%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637149327594484021&sdata=q3fFDQyJZmoHlceFvohL5YzdF2gO11sH HBts3o6gm3l%3D&reserved=0>.

Thank you for submitting your manuscript to Emerging Microbes & Infections.

Sincerely,  
Emerging Microbes & Infections Editorial Office

---

**From:** Mireia Pelegrin <mireia.pelegrin@inserm.fr>  
**Sent:** Wednesday, November 4, 2020 5:58 AM  
**To:** Lu, Shan  
**Cc:** wen yumei; Callaghan, Cindi; Min Yang  
**Subject:** Re: Emerging Microbes and Infections  
**Attachments:** Cover Letter EMI-04112020.pdf; Lambour et al.pdf; Graphical abstract.pdf

Dear Dr. Lu,

Following our previous email exchanges about Editorial Members of EMI, I would like to submit a paper of my group to EMI.

As you asked me to let you know before the submission, here I send you: (i) the cover letter explaining why I believe this work is important and it might be of great interest to EMI readership, (ii) the manuscript and (iii) the graphical abstract.

Please let me know whether and how I have to proceed to the manuscript submission through the EMI submission portal.

Best regards

Mireia Pelegrin

**PLEASE NOTE MY NEW ADDRESS**

INSERM U1183  
CHU Saint Eloi, IRMB  
80 Avenue Augustin Fliche  
34295 Montpellier cedex 5

Tel: 04 67 33 07 31  
[E-mail: mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)

Le 28 sept. 2018 à 18:29, Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> a écrit :

Dear Mireia,

It is good to know you are so committed. You are welcome to submit a paper to EMI, and please do let me know before submitting so I can pay special attention to it.

Best.

Shan

---

**From:** mireia PELEGRIN <[mireia.pelegrin@igmm.cnrs.fr](mailto:mireia.pelegrin@igmm.cnrs.fr)>  
**Sent:** Friday, September 28, 2018 12:21 PM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>; Callaghan, Cindi <[Cindi.Callaghan@umassmed.edu](mailto:Cindi.Callaghan@umassmed.edu)>; Min Yang

<[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>

**Subject:** Re: Emerging Microbes and Infections

Dear Dr. Lu,

Thank you very much for your message. I will be happy to promote EMI and contribute to increase its impact in the field.

As Editorial member, I would like to submit an original research article from our group. I will come back to you when I will be able to envisage a realistic date for submission.

Looking forward to working with you

Best regards

Mireia

Le 15 sept. 2018 à 10:02, Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> a écrit :

Dear Dr. Pelegri,

I would like to follow up on Prof Wen's email below and welcome you to join the Editorial Board of Emerging Microbes and Infections (EMI). Your term will be for two years (2019-2020).

As you can see from the attached table, an editorial member of EMI is expected to perform EITHER four peer-reviews on the manuscripts submitted to EMI within a 12-month period, OR, to submit one paper from yourself (with your co-authors as needed) either in the form of the original research article or a review within a calendar year. But more importantly, given your expertise in the field of emerging infections, you are expected to promote EMI and advise on EMI's editorial directions (including inviting or suggesting experts who may be able to contribute a high impact review in a particular area of emerging infectious diseases).

EMI has been published by SpringerNature in the last 6 years. It is published only in the form of Open Access (OA). You can find our journal at [www.nature.com/emi](http://www.nature.com/emi)

Please do not hesitate to let me know if you have any questions.

We are looking forward to working with you and welcome onboard!

Best.

Shan

\*\*\*\*\*

Shan Lu, MD, PhD  
Deputy Editor-in-Chief  
EMI

Professor  
Department of Medicine  
U Mass Medical School



55 Lake Ave North  
Worcester, MA 01655  
USA  
Tel. 1-508-856-6791  
e-mail: [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu)

**From:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
**Sent:** Tuesday, August 28, 2018 11:23 PM  
**To:** mireia PELEGRIN <[mireia.pelegrin@igmm.cnrs.fr](mailto:mireia.pelegrin@igmm.cnrs.fr)>  
**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** Re: Fwd: Flyer for Immunotherapy for Infectious Diseases Conference

Dear Mieria

Thank you for agreeing to serve on the editorial board . The new editorial board of EMI is going to hold a meeting Oct 12 in shanghai. I wonder if you can come for the meeting at such a short notice, . If you can come to this meeting, we will provide you USD 1500 for your trip, and host you three night hotel accommodation in Shanghai.

if you cannot make it, we will send you the minute of this meeting.

In addition, Prof shan Lu will send you our notice for serving on the board, and hope you will kindly offer us your contribution. Regards, Yu-mei

-----原始邮件-----

发件人:"mireia PELEGRIN" <[mireia.pelegrin@igmm.cnrs.fr](mailto:mireia.pelegrin@igmm.cnrs.fr)>

发送时间:2018-08-28 20:35:22 (星期二)

收件人: igmm-igmm

<[igmm@igmm.cnrs.fr](mailto:igmm@igmm.cnrs.fr)>, [irim@irim.cnrs.fr](mailto:irim@irim.cnrs.fr), [cemipai@cemipai.cnrs.fr](mailto:cemipai@cemipai.cnrs.fr), "Melusine Lariviere" <[melusine.lariviere@univ-tours.fr](mailto:melusine.lariviere@univ-tours.fr)>, "Ana Sofia Maceira Antunes" <[ana-sofia.antunes@mabdesign.fr](mailto:ana-sofia.antunes@mabdesign.fr)>, "LECINE Patrick" <[Patrick.LECINE@bioaster.org](mailto:Patrick.LECINE@bioaster.org)>, "Hugo MOUQUET" <[hugo.mouquet@pasteur.fr](mailto:hugo.mouquet@pasteur.fr)>, "Francis Barin" <[barin@univ-tours.fr](mailto:barin@univ-tours.fr)>, "Francois-Loïc Cosset" <[flcosset@ens-lyon.fr](mailto:flcosset@ens-lyon.fr)>, "floriane fusil" <[floriane.fusil@ens-lyon.fr](mailto:floriane.fusil@ens-lyon.fr)>, "VANDE PERRE PHILIPPE" <[p-van\\_de\\_perre@chu-montpellier.fr](mailto:p-van_de_perre@chu-montpellier.fr)>, "TUAILLON EDOUARD" <[e-tuaillon@chu-montpellier.fr](mailto:e-tuaillon@chu-montpellier.fr)>, "Philippe Roingeard" <[philippe.roingeard@univ-tours.fr](mailto:philippe.roingeard@univ-tours.fr)>, j-reynes <[j-reynes@chu-montpellier.fr](mailto:j-reynes@chu-montpellier.fr)>, "Karl Stefic" <[karl.stefic@univ-tours.fr](mailto:karl.stefic@univ-tours.fr)>, "Mar Naranjo Gomez" <[mmnaranjogomez@gmail.com](mailto:mmnaranjogomez@gmail.com)>, [mengji.lu@uni-due.de](mailto:mengji.lu@uni-due.de), "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>, [ulf.dittmer@uni-due.de](mailto:ulf.dittmer@uni-due.de), "naranjo Mar" <[mar.naranjo-gomez@igmm.cnrs.fr](mailto:mar.naranjo-gomez@igmm.cnrs.fr)>, [falk.nimmerjahn@fau.de](mailto:falk.nimmerjahn@fau.de)

抄送:

主题: Fwd: Flyer for Immunotherapy for Infectious Diseases Conference

Dear colleagues,

Here I send you information on a upcoming conference on Immunotherapy for infectious diseases that might be of interest. Do not hesitate to share this information with your collaborators and colleagues.

Best regards  
Mireia

We invite you to attend our upcoming **Immunotherapy for Infectious Diseases Conference** (agenda attached) on **November 12-14, 2018**, in Galveston, TX, USA. We would like to draw your attention to economical registration of **\$660 (meals included)**. Based on the positive response from the scientific community, we are also exploring the possibility to convert this into a Gordon Research Conference.

Please encourage your students and postdocs to submit abstracts for poster and competitive selected oral presentations through our website [www.IDImmunotherapy.com](http://www.IDImmunotherapy.com). Please feel free to print and post the attached flyer and forward this email to others who may be interested.

<image001.jpg>

**Srishtee Arora | Postdoctoral Research Associate**  
**Dr. Magnus Hook Laboratory**  
**Center for Infectious and Inflammatory Diseases**  
**Institute of Biosciences & Technology | Texas A&M University**  
**2121 W. Holcombe Blvd. | Houston, TX 77030**  
**ph: 713-677-7555 | [sarora@ibt.tamhsc.edu](mailto:sarora@ibt.tamhsc.edu)**  
**TEXAS A&M UNIVERSITY | FEARLESS on Every Front**

<image001.jpg>

Mireia PELEGRIN  
Institut de Génétique Moléculaire de Montpellier  
CNRS  
1919 route de Mende  
34293 - Montpellier Cedex 05  
France  
Tel : (33) (0)4 34 35 96 68  
Fax : (33) (0)4 34 35 96 34  
[e-mail : mireia.pelegrin@igmm.cnrs.fr](mailto:mireia.pelegrin@igmm.cnrs.fr)  
<http://www.igmm.cnrs.fr/>

Mireia PELEGRIN  
Institut de Génétique Moléculaire de Montpellier  
CNRS  
1919 route de Mende  
34293 - Montpellier Cedex 05  
France  
Tel : (33) (0)4 34 35 96 68  
Fax : (33) (0)4 34 35 96 34  
[e-mail : mireia.pelegri@igmm.cnrs.fr](mailto:mireia.pelegri@igmm.cnrs.fr)  
<http://www.igmm.cnrs.fr/>

PLEASE NOTE MY NEW ADDRESS

Mireia Pelegrin  
INSERM U1183  
CHU Saint Eloi, IRMB  
80 Avenue Augustin Fliche  
34295 Montpellier cedex 5

Tel: 04 67 33 07 31  
[E-mail: mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)

---

**From:** Mireia Pelegrin <mireia.pelegrin@inserm.fr>  
**Sent:** Sunday, November 8, 2020 12:59 PM  
**To:** Lu, Shan  
**Cc:** wen yumei; Min Yang  
**Subject:** Re: Emerging Microbes and Infections

Thank you very much for your feedback.

Best

Mireia

Le 7 nov. 2020 à 19:05, Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> a écrit :

Thanks.

I will look for your submission. Our publisher T&F will do a first round quality review on Monday and if passed, it will land on my desk. At this point, EMI is using a screening system to decide which paper will be sent out for peer-review. Your paper will by-pass this step since both Prof Wen and I have read it. Then we will see how reviewers will think about your paper.

Best.

Shan

---

**From:** Mireia Pelegrin <[mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)>  
**Sent:** Saturday, November 7, 2020 7:34 AM  
**To:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>  
**Subject:** Re: Emerging Microbes and Infections

Dear Yu-Mei and Shan,

Thanks again for your suggestions. I added in the manuscript several sentences in the introduction and discussion of the manuscript to point out how and why this work is important in the field of emerging viral infections. I also added more references on mAb currently developed to treat emerging viral infections, in addition to the ones already included in the manuscript I previously sent you.

I have just submitted the new version of the manuscript in the EMI submission portal.

Best regards

Mireia

Le 7 nov. 2020 à 02:37, wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)> a écrit :

I agree that she add several sentences for use in combating emerging diseases. YMW

-----Original Messages-----

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Sent Time:** 2020-11-06 23:36:09 (Friday)

**To:** "Mireia Pelegrin" <[mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)>

**Cc:** "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>, "Min Yang" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>

**Subject:** RE: Emerging Microbes and Infections

I agree with you.

Please submit and we will sent it out for peer review which will make the final decision.

Best.

Shan

---

**From:** Mireia Pelegrin <[mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)>

**Sent:** Friday, November 6, 2020 9:24 AM

**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Cc:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>; Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>

**Subject:** Re: Emerging Microbes and Infections

Dear Shan,

Thanks for your positive answer and your feedback.

Indeed our findings on the role of antibodies and inflammatory conditions in the functional activation of monocytes and neutrophils are directly linked to emerging infections as these cell-types can mediate protective immunity, immunosuppression or immunopatholgy (as in the case of SARS-CoV2 infection). This is mentioned in the manuscript but it can be further discussed if required.

A better understanding of IC-FcγR interactions in neutrophils and monocytes can help the improvement of immunotherapies of emerging infections and answer fundamental questions related to antibody-mediated immunopathology.

Best regards

Mireia

Le 6 nov. 2020 à 14:51, Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> a écrit :

Dear Mireia,

Good to hear from you and thanks for submitting a paper to EMI.

By taking a quick look, the manuscript is quite interesting considering the understudied potentials of therapeutic mAb which are now gaining more and more applications.

The only issue is that your paper does not focus on emerging infections as that is the scope of our journal. However, since mAb may be used for emerging infections, it is ok for you to submit to EMI now and you can add a little more on how such work can be linked to emerging infections.

Min from EMI office will watch for your submission. Please let her know if you need any assistance.

Best.

Shan

---

**From:** Mireia Pelegrin <[mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)>  
**Sent:** Wednesday, November 4, 2020 5:58 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>; Callaghan, Cindi <[Cindi.Callaghan@umassmed.edu](mailto:Cindi.Callaghan@umassmed.edu)>; Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>  
**Subject:** Re: Emerging Microbes and Infections

Dear Dr. Lu,

Following our previous email exchanges about Editorial Members of EMI, I would like to submit a paper of my group to EMI.

As you asked me to let you know before the submission, here I send you: (i) the cover letter explaining why I believe this work is important and it might be of great interest to EMI readership, (ii) the manuscript and (iii) the graphical abstract.

Please let me know whether and how I have to proceed to the manuscript submission through the EMI submission portal.

Best regards

Mireia Pelegrin

**PLEASE NOTE MY NEW ADDRESS**  
INSERM U1183

CHU Saint Eloi, IRMB

80 Avenue Augustin Fliche

34295 Montpellier cedex 5

Tel: 04 67 33 07 31

E-mail: [mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)

Le 28 sept. 2018 à 18:29, Lu, Shan  
<[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> a écrit :

Dear Mireia,

It is good to know you are so committed. You are welcome to submit a paper to EMI, and please do let me know before submitting so I can pay special attention to it.

Best.

Shan

---

**From:** mireia PELEGRIN <[mireia.pelegrin@igmm.cnrs.fr](mailto:mireia.pelegrin@igmm.cnrs.fr)>  
**Sent:** Friday, September 28, 2018 12:21 PM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>; Callaghan, Cindi <[Cindi.Callaghan@umassmed.edu](mailto:Cindi.Callaghan@umassmed.edu)>; Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>  
**Subject:** Re: Emerging Microbes and Infections

Dear Dr. Lu,

Thank you very much for your message. I will be happy to promote EMI and contribute to increase its impact in the field.

As Editorial member, I would like to submit an original research article from our group. I will come back to you when I will be able to envisage a realistic date for submission.

Looking forward to working with you

Best regards

Mireia



Le 15 sept. 2018 à 10:02, Lu, Shan  
<[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> a écrit :

Dear Dr. Pelegriin,

I would like to follow up on Prof Wen's email below and welcome you to join the Editorial Board of Emerging Microbes and Infections (EMI). Your term will be for two years (2019-2020).

As you can see from the attached table, an editorial member of EMI is expected to perform EITHER four peer-reviews on the manuscripts submitted to EMI within a 12-month period, OR, to submit one paper from yourself (with your co-authors as needed) either in the form of the original research article or a review within a calendar year. But more importantly, given your expertise in the field of emerging infections, you are expected to promote EMI and advise on EMI's editorial directions (including inviting or suggesting experts who may be able to contribute a high impact review in a particular area of emerging infectious diseases).

EMI has been published by SpringerNature in the last 6 years. It is published only in the form of Open Access (OA). You can find our journal at [www.nature.com/emi](http://www.nature.com/emi)

Please do not hesitate to let me know if you have any questions.

We are looking forward to working with you and welcome onboard!

Best.

Shan

\*\*\*\*\*

Shan Lu, MD, PhD

Deputy Editor-in-Chief

EMI

Professor

Department of Medicine

U Mass Medical School

55 Lake Ave North

Worcester, MA 01655

USA

Tel. 1-508-856-6791

e-mail: [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu)

**From:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>

**Sent:** Tuesday, August 28, 2018 11:23 PM

**To:** mireia PELEGRIN

<[mireia.pelegrin@igmm.cnrs.fr](mailto:mireia.pelegrin@igmm.cnrs.fr)>

**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Subject:** Re: Fwd: Flyer for Immunotherapy  
for Infectious Diseases Conference

Dear Mieria

Thank you for agreeing to serve on the editorial board . The new editorial board of EMI is going to hold a meeting Oct 12 in shanghai. I wohnder if you can come for the meeting at such a short notice, . If you can come to this meetiong, we will provide you USD 1500 for your trip, and host you three night hotel accommodation in Shanghai.

if you cannot make it, we will send you the minute of this meeting.

In addiiotn, Prof shan Lu will send you our notice for serving on the

board, and hope you will kindly  
offer us your contribution.  
Regards, Yu-mei

-----原始邮件-----

发件人:"mireia PELEGRIN"  
<[mireia.pelegrin@igmm.cnrs.fr](mailto:mireia.pelegrin@igmm.cnrs.fr)>  
发送时间:2018-08-28 20:35:22 (星期二)  
收件人: igmm-igmm  
<[igmm@igmm.cnrs.fr](mailto:igmm@igmm.cnrs.fr)>, [irim@irim.cnrs.fr](mailto:irim@irim.cnrs.fr), [cemipai@cemipai.cnrs.fr](mailto:cemipai@cemipai.cnrs.fr),  
"Melusine Lariviere"  
<[melusine.lariviere@univ-tours.fr](mailto:melusine.lariviere@univ-tours.fr)>, "Ana Sofia Maceira  
Antunes" <[ana-sofia.antunes@mabdesign.fr](mailto:ana-sofia.antunes@mabdesign.fr)>,  
"LECINE Patrick"  
<[Patrick.LECINE@bioaster.org](mailto:Patrick.LECINE@bioaster.org)>,  
"Hugo MOUQUET"  
<[hugo.mouquet@pasteur.fr](mailto:hugo.mouquet@pasteur.fr)>,  
"Francis Barin" <[barin@univ-tours.fr](mailto:barin@univ-tours.fr)>, "Francois-Loïc Cosset"  
<[flcosset@ens-lyon.fr](mailto:flcosset@ens-lyon.fr)>, "floriane  
fusil" <[floriane.fusil@ens-lyon.fr](mailto:floriane.fusil@ens-lyon.fr)>,  
"VANDE PERRE PHILIPPE" <[p-van\\_de\\_perre@chu-montpellier.fr](mailto:p-van_de_perre@chu-montpellier.fr)>,  
"TUAILLON  
EDOUARD" <[e-tuaillon@chu-montpellier.fr](mailto:e-tuaillon@chu-montpellier.fr)>,  
"Philippe  
Roingeard"  
<[philippe.roingeard@univ-tours.fr](mailto:philippe.roingeard@univ-tours.fr)>, j-reynes <[j-reynes@chu-montpellier.fr](mailto:j-reynes@chu-montpellier.fr)>,  
"Karl Stefic"  
<[karl.stefic@univ-tours.fr](mailto:karl.stefic@univ-tours.fr)>, "Mar  
Naranjo Gomez"  
<[mmnaranjogomez@gmail.com](mailto:mmnaranjogomez@gmail.com)>,  
[mengji.lu@uni-due.de](mailto:mengji.lu@uni-due.de), "wen  
yumei"  
<[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>, [ulf.dittmer@uni-due.de](mailto:ulf.dittmer@uni-due.de), "naranjo Mar"  
<[mar.naranjo-gomez@igmm.cnrs.fr](mailto:mar.naranjo-gomez@igmm.cnrs.fr)>, [falk.nimmerjahn@fau.de](mailto:falk.nimmerjahn@fau.de)  
抄送:  
主题: Fwd: Flyer for

Immunotherapy for Infectious  
Diseases Conference

Dear colleagues,

Here I send you information on  
a upcoming conference on  
Immunotherapy for infectious  
diseases that might be of  
interest.

Do no hesitate to share this  
information with your  
collaborators and colleagues.

Best regards

Mireia

We invite you to attend  
our  
upcoming **Immunothera  
py for Infectious  
Diseases  
Conference** (agenda  
attached) on **November  
12-14, 2018**, in  
Galveston, TX,  
USA. We would like to  
draw your attention to  
economical registration  
of **\$660 (meals  
included)**. Based on the  
positive response from  
the scientific community,  
we are also exploring the  
possibility to convert this  
into a Gordon Research  
Conference.

Please encourage your  
students and postdocs to

submit abstracts for  
poster and competitive  
selected oral  
presentations through  
our  
website [www.IDImmunotherapy.com](http://www.IDImmunotherapy.com). Please feel  
free to print and post the  
attached flyer and  
forward this email to  
others who may be  
interested.

<image001.jpg>

**Srishtee  
Arora | Postdoctoral Research  
Associate**

**Dr.  
Magnus Hook Laboratory**

**Center for Infectious  
and Inflammatory  
Diseases**

**Institute of  
Biosciences &  
Technology | Texas  
A&M University**

**2121 W. Holcombe  
Blvd. | Houston, TX  
77030**

**ph: 713-677-  
7555 | [sarora@ibt.tamhsc.edu](mailto:sarora@ibt.tamhsc.edu)**

**TEXAS A&M  
UNIVERSITY |  
FEARLESS on Every  
Front**

<image001.jpg>

Mireia PELEGRIN

Institut de Génétique Moléculaire de  
Montpellier

CNRS

1919 route de Mende

34293 - Montpellier Cedex 05

France

Tel : (33) (0)4 34 35 96 68

Fax : (33) (0)4 34 35 96 34

[e-mail : mireia.pelegrin@igmm.cnrs.fr](mailto:mireia.pelegrin@igmm.cnrs.fr)

<http://www.igmm.cnrs.fr/>

<EMI EB responsabilites-  
20180902.xlsx>

Mireia PELEGRIN

Institut de Génétique Moléculaire de Montpellier

CNRS

1919 route de Mende

34293 - Montpellier Cedex 05

France

Tel : (33) (0)4 34 35 96 68

Fax : (33) (0)4 34 35 96 34

[e-mail : mireia.pelegrin@igmm.cnrs.fr](mailto:mireia.pelegrin@igmm.cnrs.fr)

<http://www.igmm.cnrs.fr/>

PLEASE NOTE MY NEW ADDRESS

Mireia Pelegrin

INSERM U1183

CHU Saint Eloi, IRMB

80 Avenue Augustin Fliche

34295 Montpellier cedex 5

Tel: 04 67 33 07 31

[E-mail: mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)

PLEASE NOTE MY NEW ADDRESS

Mireia Pelegrin

INSERM U1183

CHU Saint Eloi, IRMB

80 Avenue Augustin Fliche

34295 Montpellier cedex 5

Tel: 04 67 33 07 31

[E-mail: mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)

PLEASE NOTE MY NEW ADDRESS

Mireia Pelegrin

INSERM U1183

CHU Saint Eloi, IRMB

80 Avenue Augustin Fliche

34295 Montpellier cedex 5

Tel: 04 67 33 07 31

[E-mail: mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)

PLEASE NOTE MY NEW ADDRESS

Mireia Pelegrin

INSERM U1183

CHU Saint Eloi, IRMB  
80 Avenue Augustin Fliche  
34295 Montpellier cedex 5

Tel: 04 67 33 07 31

[E-mail: mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)



---

**From:** Mireia Pelegrin <mireia.pelegrin@inserm.fr>  
**Sent:** Saturday, November 7, 2020 7:34 AM  
**To:** wen yumei  
**Cc:** Lu, Shan; Min Yang  
**Subject:** Re: Emerging Microbes and Infections  
**Attachments:** Lambour et al Merged.pdf

Dear Yu-Mei and Shan,

Thanks again for your suggestions. I added in the manuscript several sentences in the introduction and discussion of the manuscript to point out how and why this work is important in the field of emerging viral infections. I also added more references on mAb currently developed to treat emerging viral infections, in addition to the ones already included in the manuscript I previously sent you.

I have just submitted the new version of the manuscript in the EMI submission portal.  
Best regards

Mireia

Le 7 nov. 2020 à 02:37, wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)> a écrit :

I agree that she add several sentences for use in combating emerging diseases. YMW

-----Original Messages-----

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Sent Time:** 2020-11-06 23:36:09 (Friday)  
**To:** "Mireia Pelegrin" <[mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)>  
**Cc:** "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>, "Min Yang" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>  
**Subject:** RE: Emerging Microbes and Infections

I agree with you.

Please submit and we will sent it out for peer review which will make the final decision.

Best.

Shan

---

**From:** Mireia Pelegrin <[mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)>  
**Sent:** Friday, November 6, 2020 9:24 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>; Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>  
**Subject:** Re: Emerging Microbes and Infections

Dear Shan,

Thanks for your positive answer and your feedback.

Indeed our findings on the role of antibodies and inflammatory conditions in the functional activation of monocytes and neutrophils are directly linked to emerging infections as these cell-types can mediate protective immunity, immunosuppression or immunopathology (as in the case of SARS-CoV2 infection). This is mentioned in the manuscript but it can be further discussed if required.

A better understanding of IC-FcγR interactions in neutrophils and monocytes can help the improvement of immunotherapies of emerging infections and answer fundamental questions related to antibody-mediated immunopathology.

Best regards

Mireia

Le 6 nov. 2020 à 14:51, Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> a écrit :

Dear Mireia,

Good to hear from you and thanks for submitting a paper to EMI.

By taking a quick look, the manuscript is quite interesting considering the understudied potentials of therapeutic mAb which are now gaining more and more applications.

The only issue is that your paper does not focus on emerging infections as that is the scope of our journal. However, since mAb may be used for emerging infections, it is ok for you to submit to EMI now and you can add a little more on how such work can be linked to emerging infections.

Min from EMI office will watch for your submission. Please let her know if you need any assistance.

Best.

Shan

---

**From:** Mireia Pelegrin <[mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)>  
**Sent:** Wednesday, November 4, 2020 5:58 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>; Callaghan, Cindi <[Cindi.Callaghan@umassmed.edu](mailto:Cindi.Callaghan@umassmed.edu)>; Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>  
**Subject:** Re: Emerging Microbes and Infections

Dear Dr. Lu,

Following our previous email exchanges about Editorial Members of EMI, I would like to submit a paper of my group to EMI.

As you asked me to let you know before the submission, here I send you: (i) the cover letter explaining why I believe this work is important and it might be of great interest to EMI readership, (ii) the manuscript and (iii) the graphical abstract.

Please let me know whether and how I have to proceed to the manuscript submission through the EMI submission portal.

Best regards

Mireia Pelegrin

**PLEASE NOTE MY NEW ADDRESS**  
INSERM U1183

CHU Saint Eloi, IRMB

80 Avenue Augustin Fliche

34295 Montpellier cedex 5

Tel: 04 67 33 07 31  
E-mail: [mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)

Le 28 sept. 2018 à 18:29, Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> a écrit :

Dear Mireia,

It is good to know you are so committed. You are welcome to submit a paper to EMI, and please do let me know before submitting so I can pay special attention to it.

Best.

Shan

---

**From:** mireia PELEGRIN <[mireia.pelegrin@igmm.cnrs.fr](mailto:mireia.pelegrin@igmm.cnrs.fr)>  
**Sent:** Friday, September 28, 2018 12:21 PM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>; Callaghan, Cindi <[Cindi.Callaghan@umassmed.edu](mailto:Cindi.Callaghan@umassmed.edu)>; Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>  
**Subject:** Re: Emerging Microbes and Infections

Dear Dr. Lu,

Thank you very much for your message. I will be happy to promote EMI and contribute to increase its impact in the field.

As Editorial member, I would like to submit an original research article from our group. I will come back to you when I will be able to envisage a realistic date for submission.

Looking forward to working with you

Best regards

Mireia

Le 15 sept. 2018 à 10:02, Lu, Shan  
<[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> a écrit :

Dear Dr. Pelegrin,

I would like to follow up on Prof Wen's email below and welcome you to join the Editorial Board of Emerging Microbes and Infections (EMI). Your term will be for two years (2019-2020).

As you can see from the attached table, an editorial member of EMI is expected to perform EITHER four peer-reviews on the manuscripts submitted to EMI within a 12-month period, OR, to submit one paper from yourself (with your co-authors as needed) either in the form of the original research article or a review within a calendar year. But more importantly, given your expertise in the field of emerging infections, you are expected to promote EMI and advise on EMI's editorial directions (including inviting or suggesting experts who may be able to contribute a high impact review in a particular area of emerging infectious diseases).

EMI has been published by SpringerNature in the last 6 years. It is published only in the form of Open Access (OA). You can find our journal at [www.nature.com/emi](http://www.nature.com/emi)

Please do not hesitate to let me know if you have any questions.

We are looking forward to working with you and welcome onboard!

Best.

Shan

\*\*\*\*\*

Shan Lu, MD, PhD

Deputy Editor-in-Chief

EMI

Professor

Department of Medicine

U Mass Medical School

55 Lake Ave North

Worcester, MA 01655

USA

Tel. 1-508-856-6791

e-mail: [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu)

**From:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>

**Sent:** Tuesday, August 28, 2018 11:23 PM

**To:** mireia PELEGRIN <[mireia.pelegrin@igmm.cnrs.fr](mailto:mireia.pelegrin@igmm.cnrs.fr)>

**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Subject:** Re: Fwd: Flyer for Immunotherapy for Infectious Diseases Conference

Dear Mieria

Thank you for agreeing to serve on the editorial board . The new editorial board of EMI is going to hold a meeting Oct 12 in shanghai. I wohnder if you can come for the meeting at such a short notice, . If you can come to this meetiong, we will provide you USD 1500 for your trip, and host you three night hotel accommodation in Shanghai.

if you cannot make it, we will send you the minute of this meeting.

In addiiotn, Prof shan Lu will sendn you our notice for serving on the board, and hope you will kindly offer us your contributaion. Regards, Yu-mei

-----原始邮件-----

发件人:"mireia PELEGRIN"

<[mireia.pelegrin@igmm.cnrs.fr](mailto:mireia.pelegrin@igmm.cnrs.fr)>

发送时间:2018-08-28 20:35:22 (星期二)

收件人: igmm-igmm

<[igmm@igmm.cnrs.fr](mailto:igmm@igmm.cnrs.fr)>, [irim@irim.cnrs.fr](mailto:irim@irim.cnrs.fr), [cemipai@cemipai.cnrs.fr](mailto:cemipai@cemipai.cnrs.fr), "Melusine Lariviere"

<[melusine.lariviere@univ-tours.fr](mailto:melusine.lariviere@univ-tours.fr)>, "Ana Sofia Maceira Antunes" <[ana-sofia.antunes@mabdesign.fr](mailto:ana-sofia.antunes@mabdesign.fr)>, "LECINE Patrick"

<[Patrick.LECINE@bioaster.org](mailto:Patrick.LECINE@bioaster.org)>, "Hugo MOUQUET" <[hugo.mouquet@pasteur.fr](mailto:hugo.mouquet@pasteur.fr)>,"Francis Barin" <[barin@univ-tours.fr](mailto:barin@univ-tours.fr)>, "Francois-

Loïc Cosset" <[flcosset@ens-lyon.fr](mailto:flcosset@ens-lyon.fr)>, "floriane fusil" <[floriane.fusil@ens-lyon.fr](mailto:floriane.fusil@ens-lyon.fr)>, "VANDE

PERRE PHILIPPE" <[p-van\\_de\\_perre@chu-montpellier.fr](mailto:p-van_de_perre@chu-montpellier.fr)>, "TUAILLON EDOUARD" <[e-tuailon@chu-montpellier.fr](mailto:e-tuailon@chu-montpellier.fr)>, "Philippe

Roingeard" <[philippe.roingeard@univ-tours.fr](mailto:philippe.roingeard@univ-tours.fr)>, j-reynes <[j-reynes@chu-montpellier.fr](mailto:j-reynes@chu-montpellier.fr)>, "Karl

Stefic" <[karl.stefic@univ-tours.fr](mailto:karl.stefic@univ-tours.fr)>, "Mar Naranjo Gomez"

<[mmnaranjogomez@gmail.com](mailto:mmnaranjogomez@gmail.com)>, [mengji.lu@uni-due.de](mailto:mengji.lu@uni-due.de), "wen yumei"

<[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>, [ulf.dittmer@uni-due.de](mailto:ulf.dittmer@uni-due.de), "naranjo Mar" <[mar.naranjo-gomez@igmm.cnrs.fr](mailto:mar.naranjo-gomez@igmm.cnrs.fr)>, [falk.nimmerjahn@fau.de](mailto:falk.nimmerjahn@fau.de)

抄送:

主题: Fwd: Flyer for Immunotherapy for Infectious Diseases Conference

Dear colleagues,

Here I send you information on a upcoming conference on Immunotherapy for infectious diseases that might be of interest.

Do no hesitate to share this information with your collaborators and colleagues.

Best regards

Mireia

We invite you to attend our upcoming **Immunotherapy for Infectious Diseases Conference** (agenda attached) on **November 12-14, 2018**, in Galveston, TX, USA. We would like to draw your attention to economical registration of **\$660 (meals included)**. Based on the positive response from the scientific community, we are also exploring the possibility to convert this into a Gordon Research Conference.

Please encourage your students and postdocs to submit abstracts for poster and competitive selected oral presentations through our website [www.IDImmunotherapy.com](http://www.IDImmunotherapy.com). Please feel free to print and post the attached flyer and forward this email to others who may be interested.

<image001.jpg>

**Srishtee Arora | Postdoctoral  
Research Associate**

**Dr. Magnus Hook Laboratory**

**Center for Infectious and  
Inflammatory Diseases**

**Institute of Biosciences & Technology |  
Texas A&M University**

**2121 W. Holcombe Blvd. | Houston, TX  
77030**

**ph: 713-677-  
7555 | [sarora@ibt.tamhsc.edu](mailto:sarora@ibt.tamhsc.edu)**

**TEXAS A&M UNIVERSITY | FEARLESS  
on Every Front**



<image001.jpg>

Mireia PELEGRIN

Institut de Génétique Moléculaire de Montpellier

CNRS

1919 route de Mende

34293 - Montpellier Cedex 05

France

Tel : (33) (0)4 34 35 96 68

Fax : (33) (0)4 34 35 96 34

e-mail : [mireia.pelegrin@igmm.cnrs.fr](mailto:mireia.pelegrin@igmm.cnrs.fr)

<http://www.igmm.cnrs.fr/>

<EMI EB responsabilites-20180902.xlsx>

Mireia PELEGRIN

Institut de Génétique Moléculaire de Montpellier

CNRS

1919 route de Mende

34293 - Montpellier Cedex 05

France

Tel : (33) (0)4 34 35 96 68

Fax : (33) (0)4 34 35 96 34

[e-mail : mireia.pelegrin@igmm.cnrs.fr](mailto:mireia.pelegrin@igmm.cnrs.fr)

<http://www.igmm.cnrs.fr/>

PLEASE NOTE MY NEW ADDRESS

Mireia Pelegrin

INSERM U1183

CHU Saint Eloi, IRMB

80 Avenue Augustin Fliche

34295 Montpellier cedex 5

Tel: 04 67 33 07 31

[E-mail: mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)

PLEASE NOTE MY NEW ADDRESS

Mireia Pelegrin

INSERM U1183

CHU Saint Eloi, IRMB

80 Avenue Augustin Fliche

34295 Montpellier cedex 5

Tel: 04 67 33 07 31

[E-mail: mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)

PLEASE NOTE MY NEW ADDRESS

Mireia Pelegrin

INSERM U1183

CHU Saint Eloi, IRMB

80 Avenue Augustin Fliche

34295 Montpellier cedex 5

Tel: 04 67 33 07 31  
[E-mail: mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)

---

**From:** Mireia Pelegrin <mireia.pelegrin@inserm.fr>  
**Sent:** Wednesday, November 11, 2020 3:36 PM  
**To:** Lu, Shan  
**Cc:** wen yumei; Min Yang  
**Subject:** Re: Emerging Microbes and Infections

Dear Shan,

Thank you very much for the update on the submission and for applying the APC waiver. I do really appreciate.

Best

Mireia

Le 11 nov. 2020 à 15:46, Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> a écrit :

Dear Mireia,

We have reviewed your formal submission and it has been sent out for peer-review.

I realized that you applied for a APC waiver which is currently only provided to authors from low- or middle-income countries. Since we did invite you a couple years before and we happened to have a special opportunity from T&F to give one time waiver, I did asked T&F to give you that waiver. However, this would be one-time only and just want to let you know. At the same time, we do hope our Editorial Members to contribute their work to EMI.

Best.

Shan

---

**From:** Mireia Pelegrin <[mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)>  
**Sent:** Sunday, November 8, 2020 12:59 PM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>; Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>  
**Subject:** Re: Emerging Microbes and Infections

Thank you very much for your feedback.

Best

Mireia

Le 7 nov. 2020 à 19:05, Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> a écrit :

Thanks.

I will look for your submission. Our publisher T&F will do a first round quality review on Monday and if passed, it will land on my desk. At this point, EMI is using a screening system to decide which paper will be sent out for peer-review. Your paper will by-pass this step since both Prof Wen and I have read it. Then we will see how reviewers will think about your paper.

Best.

Shan

---

**From:** Mireia Pelegrin <[mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)>  
**Sent:** Saturday, November 7, 2020 7:34 AM  
**To:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>  
**Subject:** Re: Emerging Microbes and Infections

Dear Yu-Mei and Shan,

Thanks again for your suggestions. I added in the manuscript several sentences in the introduction and discussion of the manuscript to point out how and why this work is important in the field of emerging viral infections. I also added more references on mAb currently developed to treat emerging viral infections, in addition to the ones already included in the manuscript I previously sent you.

I have just submitted the new version of the manuscript in the EMI submission portal.  
Best regards

Mireia

Le 7 nov. 2020 à 02:37, wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)> a écrit :

I agree that she add several sentences for use in combating emerging diseases.  
YMW

-----Original Messages-----

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Sent Time:** 2020-11-06 23:36:09 (Friday)  
**To:** "Mireia Pelegrin" <[mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)>  
**Cc:** "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>, "Min Yang" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>  
**Subject:** RE: Emerging Microbes and Infections

I agree with you.

Please submit and we will sent it out for peer review which will make the final decision.

Best.

Shan

---

**From:** Mireia Pelegrin <[mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)>  
**Sent:** Friday, November 6, 2020 9:24 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>; Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>  
**Subject:** Re: Emerging Microbes and Infections

Dear Shan,

Thanks for your positive answer and your feedback.

Indeed our findings on the role of antibodies and inflammatory conditions in the functional activation of monocytes and neutrophils are directly linked to emerging infections as these cell-types can mediate protective immunity, immunosuppression or immunopathology (as in the case of SARS-CoV2 infection). This is mentioned in the manuscript but it can be further discussed if required.

A better understanding of IC-FcγR interactions in neutrophils and monocytes can help the improvement of immunotherapies of emerging infections and answer fundamental questions related to antibody-mediated immunopathology.

Best regards

Mireia

Le 6 nov. 2020 à 14:51, Lu, Shan  
<[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> a écrit :

Dear Mirela,

Good to hear from you and thanks for submitting a paper to EMI.

By taking a quick look, the manuscript is quite interesting considering the understudied potentials of therapeutic mAb which are now gaining more and more applications.

The only issue is that your paper does not focus on emerging infections as that is the scope of our journal. However, since mAb may be used for emerging infections, it is ok for you to submit to EMI now and you can add a little more on how such work can be linked to emerging infections.

Min from EMI office will watch for your submission. Please let her know if you need any assistance.

Best.

Shan

---

**From:** Mireia Pelegrin <[mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)>  
**Sent:** Wednesday, November 4, 2020 5:58 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>; Callaghan, Cindi <[Cindi.Callaghan@umassmed.edu](mailto:Cindi.Callaghan@umassmed.edu)>; Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>  
**Subject:** Re: Emerging Microbes and Infections

Dear Dr. Lu,

Following our previous email exchanges about Editorial Members of EMI, I would like to submit a paper of my group to EMI.

As you asked me to let you know before the submission, here I send you: (i) the cover letter explaining why I believe this work is important and it might be of great interest to EMI readership, (ii) the manuscript and (iii) the graphical abstract.

Please let me know whether and how I have to proceed to the manuscript submission through the EMI submission portal.

Best regards

Mireia Pelegrin

**PLEASE NOTE MY NEW ADDRESS**  
INSERM U1183

CHU Saint Eloi, IRMB

80 Avenue Augustin Fliche

34295 Montpellier cedex 5

Tel: 04 67 33 07 31

[E-mail: mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)

Le 28 sept. 2018 à 18:29, Lu, Shan  
<[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> a écrit :

Dear Mireia,

It is good to know you are so committed. You are welcome to submit a paper to EMI, and please do let me know before submitting so I can pay special attention to it.

Best.

Shan



---

**From:** mireia PELEGRIN  
<[mireia.pelegrin@igmm.cnrs.fr](mailto:mireia.pelegrin@igmm.cnrs.fr)>  
**Sent:** Friday, September 28, 2018 12:21 PM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>;  
Callaghan, Cindi  
<[Cindi.Callaghan@umassmed.edu](mailto:Cindi.Callaghan@umassmed.edu)>; Min  
Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>  
**Subject:** Re: Emerging Microbes and  
Infections

Dear Dr. Lu,

Thank you very much for your message. I will be happy to promote EMI and contribute to increase its impact in the field.

As Editorial member, I would like to submit an original research article from our group. I will come back to you when I will be able to envisage a realistic date for submission.

Looking forward to working with you

Best regards

Mireia

Le 15 sept. 2018 à  
10:02, Lu, Shan  
<[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
[d.edu](mailto:Shan.Lu@umassmed.edu)> a écrit :

Dear Dr. Pelegrin,

I would like to follow up on Prof Wen's email below and welcome you to join the Editorial Board of Emerging Microbes and Infections (EMI). Your term will be for two years (2019-2020).

As you can see from the attached table, an editorial member of EMI is expected to perform EITHER four peer-reviews on the manuscripts submitted to EMI within a 12-month period, OR, to submit one paper from yourself (with your co-authors as needed) either in the form of the original research article or a review within a calendar year. But more importantly, given your expertise in the field of emerging infections, you are expected to promote EMI and advise on EMI's editorial directions (including inviting or suggesting experts who may be able to contribute a high impact review in a particular area of emerging infectious diseases).

EMI has been published by SpringerNature in the last 6 years. It is published only in the form of Open Access (OA). You can find our journal at [www.nature.com/emi](http://www.nature.com/emi)

Please do not hesitate to let me know if you have any questions.

We are looking forward to working with you and welcome onboard!

Best.

Shan

\*\*\*\*\*

Shan Lu, MD, PhD

Deputy Editor-in-Chief

EMI

Professor

Department of Medicine

U Mass Medical School

55 Lake Ave North

Worcester, MA 01655

USA

Tel. 1-508-856-6791

e-mail: [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu)  
[u](#)

**From:** wen yumei  
<[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
**Sent:** Tuesday, August  
28, 2018 11:23 PM  
**To:** mireia PELEGRIN  
<[mireia.pelegrin@igmm.cnrs.fr](mailto:mireia.pelegrin@igmm.cnrs.fr)>  
**Cc:** Lu, Shan  
<[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** Re: Fwd: Flyer  
for Immunotherapy for  
Infectious Diseases  
Conference

Dear Mieria

Thank you for  
agreeing to serve on  
the editorial board .  
The new editorial  
board of EMI is  
going to hold a  
meeting Oct 12 in  
shanghai. I wonder  
if you can come for  
the meeting at such a  
short notice, . If you  
can come to this  
meeting, we will  
provide you USD  
1500 for your trip,  
and host you three  
night hotel  
accommodation in  
Shanghai.

if you cannot make  
it, we will send you  
the minute of this  
meeting.

In addition, Prof shan  
Lu will send you  
our notice for  
serving on the board,  
and hope you will  
kindly offer us your  
contribution.  
Regards, Yu-mei

-----原始邮件-----

发件人:"mireia  
PELEGRIN"  
<[mireia.pelegrin@igmm.cnrs.fr](mailto:mireia.pelegrin@igmm.cnrs.fr)>

发送时间:2018-08-  
28 20:35:22 (星期  
二)

收件人: igmm-

igmm  
<[igmm@igmm.cnrs.fr](mailto:igmm@igmm.cnrs.fr)>, [irim@irim.cnrs.fr](mailto:irim@irim.cnrs.fr), [cemipai@cemipai.cnrs.fr](mailto:cemipai@cemipai.cnrs.fr), "Melusine Lariviere"  
<[melusine.lariviere@univ-tours.fr](mailto:melusine.lariviere@univ-tours.fr)>,  
"Ana Sofia Maceira Antunes" <[ana-sofia.antunes@mabdesign.fr](mailto:ana-sofia.antunes@mabdesign.fr)>,  
"LECINE Patrick" <[Patrick.LECINE@bioaster.org](mailto:Patrick.LECINE@bioaster.org)>,  
"Hugo MOUQUET" <[hugo.mouquet@pasteur.fr](mailto:hugo.mouquet@pasteur.fr)>, "Francis Barin"  
<[barin@univ-tours.fr](mailto:barin@univ-tours.fr)>, "Francois-Loïc Cosset"  
<[fcosset@ens-lyon.fr](mailto:fcosset@ens-lyon.fr)>, "floriane fusil"  
<[floriane.fusil@ens-lyon.fr](mailto:floriane.fusil@ens-lyon.fr)>, "VANDE PERRE PHILIPPE"  
<[p-van-de-perre@chu-montpellier.fr](mailto:p-van-de-perre@chu-montpellier.fr)>,  
"TUAILLON EDOUARD" <[e-tuailon@chu-montpellier.fr](mailto:e-tuailon@chu-montpellier.fr)>,  
"Philippe Roingeard" <[philippe.roingeard@univ-tours.fr](mailto:philippe.roingeard@univ-tours.fr)>, j-reynes <[j-reynes@chu-montpellier.fr](mailto:j-reynes@chu-montpellier.fr)>,  
"Karl Stefic" <[karl.stefic@univ-tours.fr](mailto:karl.stefic@univ-tours.fr)>, "Mar Naranjo Gomez" <[mmnaranjogomez@gmail.com](mailto:mmnaranjogomez@gmail.com)>, [men-gji.lu@uni-due.de](mailto:men-gji.lu@uni-due.de),  
"wen yumei" <[ymwen@shmu.edu](mailto:ymwen@shmu.edu)>

.cn>, [ulf.dittmer@uni-due.de](mailto:ulf.dittmer@uni-due.de), "naranjo Mar" <[mar.naranjo-gomez@igmm.cnrs.fr](mailto:mar.naranjo-gomez@igmm.cnrs.fr)>, [falk.nimmerjahn@fau.de](mailto:falk.nimmerjahn@fau.de)

抄送:

主题: Fwd: Flyer  
for Immunotherapy  
for Infectious  
Diseases Conference

Dear colleagues,

Here I send you  
information on a  
upcoming  
conference on  
Immunotherapy  
for infectious  
diseases that  
might be of  
interest.

Do no hesitate to  
share this  
information with  
your collaborators  
and colleagues.

Best regards

Mireia

We  
invite  
you to  
attend  
our

upcom  
ing **Im  
munot  
herap  
y for  
Infecti  
ous  
Disea  
ses  
Confe  
rence**  
(agend  
a  
attach  
ed)  
on **No  
vemb  
er 12-  
14,  
2018,**  
in  
Galves  
ton,  
TX,  
USA.  
We  
would  
like to  
draw  
your  
attenti  
on to  
econo  
mical  
registr  
ation  
of **\$66  
0**  
**(meal  
s  
includ  
ed).**  
Based  
on the  
positiv  
e  
respon  
se  
from  
the  
scientif  
ic  
comm  
unity,  
we are  
also  
explori  
ng the  
possibi  
lity to  
conver  
t this  
into  
a Gord  
on  
Resea  
rch

Conference.

Please encourage your students and postdocs to submit abstracts for poster and competitive selected oral presentations through our website [www.IDImunotherapy.com](http://www.IDImunotherapy.com).

Please feel free to print and post the attached flyer and forward this email to others who may be interested.

<image001.jpg>

**Sris  
htee**



**Arora | Postdoctoral Research Associate**

**Dr. Magnus Hook Laboratory**

**Center for Infectious and Inflammatory Diseases**

**Institute of Biosciences & Technology | Texas A&M University**

**2121 W. Holcombe Blvd. | Houston, TX 77030**

**ph: 713-677-7555 | [sara](#)**

[@ibt  
.tam  
hsc.  
edu](mailto:@ibt.tam.hsc.edu)

TEXA  
S  
A&M  
UNIVE  
RSITY  
|  
FEAR  
LESS  
on  
Every  
Front

<ima  
ge00  
1.jpg  
>

Mireia PELEGRIN

Institut de Génétique  
Moléculaire de  
Montpellier

CNRS

1919 route de Mende

34293 - Montpellier  
Cedex 05

France

Tel : (33) (0)4 34 35 96  
68

Fax : (33) (0)4 34 35 96  
34

e-mail :  
[mireia.pelegrin@igmm.c  
nrs.fr](mailto:mireia.pelegrin@igmm.cnrs.fr)

<http://www.igmm.cnrs.fr/>

<EMI EB  
responsibilites-  
20180902.xlsx>

Mireia PELEGRIN

Institut de Génétique Moléculaire de  
Montpellier

CNRS

1919 route de Mende

34293 - Montpellier Cedex 05

France

Tel : (33) (0)4 34 35 96 68

Fax : (33) (0)4 34 35 96 34

[e-mail : mireia.pelegrin@igmm.cnrs.fr](mailto:mireia.pelegrin@igmm.cnrs.fr)

<http://www.igmm.cnrs.fr/>

PLEASE NOTE MY NEW ADDRESS

Mireia Pelegrin

INSERM U1183

CHU Saint Eloi, IRMB

80 Avenue Augustin Fliche

34295 Montpellier cedex 5

Tel: 04 67 33 07 31

[E-mail: mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)

PLEASE NOTE MY NEW ADDRESS

Mireia Pelegrin

INSERM U1183

CHU Saint Eloi, IRMB

80 Avenue Augustin Fliche

34295 Montpellier cedex 5

Tel: 04 67 33 07 31

[E-mail: mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)

PLEASE NOTE MY NEW ADDRESS

Mireia Pelegrin

INSERM U1183

CHU Saint Eloi, IRMB

80 Avenue Augustin Fliche

34295 Montpellier cedex 5

Tel: 04 67 33 07 31

[E-mail: mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)

PLEASE NOTE MY NEW ADDRESS

Mireia Pelegrin

INSERM U1183

CHU Saint Eloi, IRMB

80 Avenue Augustin Fliche

34295 Montpellier cedex 5

Tel: 04 67 33 07 31

[E-mail: mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)

PLEASE NOTE MY NEW ADDRESS

Mireia Pelegrin

INSERM U1183

CHU Saint Eloi, IRMB

80 Avenue Augustin Fliche

34295 Montpellier cedex 5

Tel: 04 67 33 07 31

[E-mail: mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)

---

**From:** Mireia Pelegrin <mireia.pelegrin@inserm.fr>  
**Sent:** Friday, November 6, 2020 9:24 AM  
**To:** Lu, Shan  
**Cc:** wen yumei; Min Yang  
**Subject:** Re: Emerging Microbes and Infections

Dear Shan,

Thanks for your positive answer and your feedback.

Indeed our findings on the role of antibodies and inflammatory conditions in the functional activation of monocytes and neutrophils are directly linked to emerging infections as these cell-types can mediate protective immunity, immunosuppression or immunopathology (as in the case of SARS-CoV2 infection). This is mentioned in the manuscript but it can be further discussed if required.

A better understanding of IC-FcγR interactions in neutrophils and monocytes can help the improvement of immunotherapies of emerging infections and answer fundamental questions related to antibody-mediated immunopathology.

Best regards

Mireia

Le 6 nov. 2020 à 14:51, Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> a écrit :

Dear Mireia,

Good to hear from you and thanks for submitting a paper to EMI.

By taking a quick look, the manuscript is quite interesting considering the understudied potentials of therapeutic mAb which are now gaining more and more applications.

The only issue is that your paper does not focus on emerging infections as that is the scope of our journal. However, since mAb may be used for emerging infections, it is ok for you to submit to EMI now and you can add a little more on how such work can be linked to emerging infections.

Min from EMI office will watch for your submission. Please let her know if you need any assistance.

Best.

Shan

---

**From:** Mireia Pelegrin <[mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)>  
**Sent:** Wednesday, November 4, 2020 5:58 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>; Callaghan, Cindi <[Cindi.Callaghan@umassmed.edu](mailto:Cindi.Callaghan@umassmed.edu)>; Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>  
**Subject:** Re: Emerging Microbes and Infections

Dear Dr. Lu,

Following our previous email exchanges about Editorial Members of EMI, I would like to submit a paper of my group to EMI.

As you asked me to let you know before the submission, here I send you: (i) the cover letter explaining why I believe this work is important and it might be of great interest to EMI readership, (ii) the manuscript and (iii) the graphical abstract.

Please let me know whether and how I have to proceed to the manuscript submission through the EMI submission portal.

Best regards

Mireia Pelegrin

**PLEASE NOTE MY NEW ADDRESS**

INSERM U1183

CHU Saint Eloi, IRMB

80 Avenue Augustin Fliche

34295 Montpellier cedex 5

Tel: 04 67 33 07 31

E-mail: [mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)

Le 28 sept. 2018 à 18:29, Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> a écrit :

Dear Mireia,

It is good to know you are so committed. You are welcome to submit a paper to EMI, and please do let me know before submitting so I can pay special attention to it.

Best.

Shan

---

**From:** mireia PELEGRIN <[mireia.pelegrin@igmm.cnrs.fr](mailto:mireia.pelegrin@igmm.cnrs.fr)>

**Sent:** Friday, September 28, 2018 12:21 PM

**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Cc:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>; Callaghan, Cindi <[Cindi.Callaghan@umassmed.edu](mailto:Cindi.Callaghan@umassmed.edu)>; Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>

**Subject:** Re: Emerging Microbes and Infections

Dear Dr. Lu,

Thank you very much for your message. I will be happy to promote EMI and contribute to increase its impact in the field.

As Editorial member, I would like to submit an original research article from our group. I will come back to you when I will be able to envisage a realistic date for submission.

Looking forward to working with you

Best regards  
Mireia

Le 15 sept. 2018 à 10:02, Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> a écrit :

Dear Dr. Pelegriin,

I would like to follow up on Prof Wen's email below and welcome you to join the Editorial Board of Emerging Microbes and Infections (EMI). Your term will be for two years (2019-2020).

As you can see from the attached table, an editorial member of EMI is expected to perform EITHER four peer-reviews on the manuscripts submitted to EMI within a 12-month period, OR, to submit one paper from yourself (with your co-authors as needed) either in the form of the original research article or a review within a calendar year. But more importantly, given your expertise in the field of emerging infections, you are expected to promote EMI and advise on EMI's editorial directions (including inviting or suggesting experts who may be able to contribute a high impact review in a particular area of emerging infectious diseases).

EMI has been published by SpringerNature in the last 6 years. It is published only in the form of Open Access (OA). You can find our journal at [www.nature.com/emi](http://www.nature.com/emi)

Please do not hesitate to let me know if you have any questions.

We are looking forward to working with you and welcome onboard!

Best.

Shan

\*\*\*\*\*

Shan Lu, MD, PhD  
Deputy Editor-in-Chief  
EMI

Professor  
Department of Medicine  
U Mass Medical School  
55 Lake Ave North  
Worcester, MA 01655  
USA

Tel. 1-508-856-6791  
e-mail: [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu)

**From:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
**Sent:** Tuesday, August 28, 2018 11:23 PM  
**To:** mireia PELEGRIN <[mireia.pelegrin@igmm.cnrs.fr](mailto:mireia.pelegrin@igmm.cnrs.fr)>  
**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** Re: Fwd: Flyer for Immunotherapy for Infectious Diseases Conference

Dear Mieria

Thank you for agreeing to serve on the editorial board . The new editorial board of EMI is going to hold a meeting Oct 12 in shanghai. I wonder if you can come for the meeting at such a short notice, . If you can come to this meeting, we will provide you USD 1500 for your trip, and host you three night hotel accommodation in Shanghai.  
if you cannot make it, we will send you the minute of this meeting.  
In addition, Prof shan Lu will send you our notice for serving on the board, and hope you will kindly offer us your contribution.  
Regards, Yu-mei

-----原始邮件-----

发件人:"mireia PELEGRIN" <[mireia.pelegrin@igmm.cnrs.fr](mailto:mireia.pelegrin@igmm.cnrs.fr)>  
发送时间:2018-08-28 20:35:22 (星期二)  
收件人: igmm-igmm  
<[igmm@igmm.cnrs.fr](mailto:igmm@igmm.cnrs.fr)>, [irim@irim.cnrs.fr](mailto:irim@irim.cnrs.fr), [cemipai@cemipai.cnrs.fr](mailto:cemipai@cemipai.cnrs.fr), "Melusine Lariviere" <[melusine.lariviere@univ-tours.fr](mailto:melusine.lariviere@univ-tours.fr)>, "Ana Sofia Maceira Antunes" <[ana-sofia.antunes@mabdesign.fr](mailto:ana-sofia.antunes@mabdesign.fr)>, "LECINE Patrick" <[Patrick.LECINE@bioaster.org](mailto:Patrick.LECINE@bioaster.org)>, "Hugo MOUQUET" <[hugo.mouquet@pasteur.fr](mailto:hugo.mouquet@pasteur.fr)>, "Francis Barin" <[barin@univ-tours.fr](mailto:barin@univ-tours.fr)>, "Francois-Loïc Cosset" <[flcosset@ens-lyon.fr](mailto:flcosset@ens-lyon.fr)>, "floriane fusil" <[floriane.fusil@ens-lyon.fr](mailto:floriane.fusil@ens-lyon.fr)>, "VANDE PERRE PHILIPPE" <[p-van\\_de\\_perre@chu-montpellier.fr](mailto:p-van_de_perre@chu-montpellier.fr)>, "TUAILLON EDOUARD" <[e-tuailon@chu-montpellier.fr](mailto:e-tuailon@chu-montpellier.fr)>, "Philippe Roingeard" <[philippe.roingeard@univ-tours.fr](mailto:philippe.roingeard@univ-tours.fr)>, j-reynes <[j-reynes@chu-montpellier.fr](mailto:j-reynes@chu-montpellier.fr)>, "Karl Stefic" <[karl.stefic@univ-tours.fr](mailto:karl.stefic@univ-tours.fr)>, "Mar Naranjo Gomez" <[mmnaranjogomez@gmail.com](mailto:mmnaranjogomez@gmail.com)>, [mengji.lu@uni-due.de](mailto:mengji.lu@uni-due.de), "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>, [ulf.dittmer@uni-due.de](mailto:ulf.dittmer@uni-due.de), "naranjo Mar" <[mar.naranjo-gomez@igmm.cnrs.fr](mailto:mar.naranjo-gomez@igmm.cnrs.fr)>, [falk.nimmerjahn@fau.de](mailto:falk.nimmerjahn@fau.de)  
抄送:  
主题: Fwd: Flyer for Immunotherapy for Infectious Diseases Conference



Dear colleagues,

Here I send you information on a upcoming conference on Immunotherapy for infectious diseases that might be of interest.

Do no hesitate to share this information with your collaborators and colleagues.

Best regards  
Mireia

We invite you to attend our upcoming **Immunotherapy for Infectious Diseases Conference** (agenda attached) on **November 12-14, 2018**, in Galveston, TX, USA. We would like to draw your attention to economical registration of **\$660 (meals included)**. Based on the positive response from the scientific community, we are also exploring the possibility to convert this into a Gordon Research Conference.

Please encourage your students and postdocs to submit abstracts for poster and competitive selected oral presentations through our website [www.IDImmunotherapy.com](http://www.IDImmunotherapy.com). Please feel free to print and post the attached flyer and forward this email to others who may be interested.

<image001.jpg>

**Srishtee Arora | Postdoctoral Research Associate**  
**Dr. Magnus Hook Laboratory**  
**Center for Infectious and Inflammatory Diseases**  
**Institute of Biosciences & Technology | Texas A&M University**  
**2121 W. Holcombe Blvd. | Houston, TX 77030**  
**ph: 713-677-7555 | [sarora@ibt.tamhsc.edu](mailto:sarora@ibt.tamhsc.edu)**  
**TEXAS A&M UNIVERSITY | FEARLESS on Every Front**

<image001.jpg>

Mireia PELEGRIN  
Institut de Génétique Moléculaire de Montpellier  
CNRS  
1919 route de Mende  
34293 - Montpellier Cedex 05  
France  
Tel : (33) (0)4 34 35 96 68  
Fax : (33) (0)4 34 35 96 34  
[e-mail : mireia.pelegrin@igmm.cnrs.fr](mailto:mireia.pelegrin@igmm.cnrs.fr)  
<http://www.igmm.cnrs.fr/>

<EMI EB responsabilites-20180902.xlsx>

Mireia PELEGRIN  
Institut de Génétique Moléculaire de Montpellier  
CNRS  
1919 route de Mende  
34293 - Montpellier Cedex 05  
France  
Tel : (33) (0)4 34 35 96 68  
Fax : (33) (0)4 34 35 96 34  
[e-mail : mireia.pelegrin@igmm.cnrs.fr](mailto:mireia.pelegrin@igmm.cnrs.fr)  
<http://www.igmm.cnrs.fr/>

PLEASE NOTE MY NEW ADDRESS

Mireia Pelegrin  
INSERM U1183  
CHU Saint Eloi, IRMB  
80 Avenue Augustin Fliche  
34295 Montpellier cedex 5

Tel: 04 67 33 07 31  
[E-mail: mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)

PLEASE NOTE MY NEW ADDRESS

Mireia Pelegrin  
INSERM U1183  
CHU Saint Eloi, IRMB  
80 Avenue Augustin Fliche  
34295 Montpellier cedex 5

Tel: 04 67 33 07 31  
[E-mail: mireia.pelegrin@inserm.fr](mailto:mireia.pelegrin@inserm.fr)



---

**From:** Min Yang <min.yang@emi2012.org>  
**Sent:** Thursday, December 12, 2019 8:15 PM  
**To:** Lu, Shan; wen yumei  
**Cc:** shan.lu; Winter999  
**Subject:** Re: EMI 12/15 Lunch Meeting

Well noted.

Best,  
Min

获取 [Outlook for iOS](#)

---

发件人: Lu, Shan <Shan.Lu@umassmed.edu>  
发送时间: Thursday, December 12, 2019 5:31:19 PM  
收件人: wen yumei <ymwen@shmu.edu.cn>  
抄送: Min Yang <min.yang@emi2012.org>; shan.lu <shan.lu@emi2012.org>; Winter999 <Winter999@hotmail.com>  
主题: Re: EMI 12/15 Lunch Meeting

Yes, I forgot to mention that Prof Ning will also join us. Xiaodong please adjust the number of people.

Thanks.

Shan

Sent from my iPhone

On Dec 12, 2019, at 4:13 PM, wen yumei <ymwen@shmu.edu.cn> wrote:

My husband will come with me at lunch. YM Wen

-----Original Messages-----

**From:** "Min Yang" <min.yang@emi2012.org>  
**Sent Time:** 2019-12-12 15:09:23 (Thursday)  
**To:** "wen yumei" <ymwen@shmu.edu.cn>, "Lu, Shan" <Shan.Lu@umassmed.edu>, yuanzhenghong <yuanzhenghong@shphc.org.cn>, "Tang, Yi-Wei" <yi-wei.tang@cepheid.com>, "yiweitangmd@gmail.com" <yiweitangmd@gmail.com>, "Martin martin" <winter999@hotmail.com>, Emily <editorial2@emi2012.org>  
**Cc:** "Editorial Office" <editorial@emi2012.org>  
**Subject:** EMI 12/15 Lunch Meeting

[Dear All EMI Leaders, Min Yu and other EMI colleagues,](#)

Thank you very much for attending EMI 12/15 Lunch Meeting, please check and confirm the following information.

**What:** EMI 12/15 Lunch Meeting

**Where:** Shanghai Min(上海小南国). 5F, Junyaoguoji Plaza, No.798, Zhaojiabang Rd, Xuhui District, Shanghai.

**When:** 12:00 noon, December 15, 2019.

**Contact:** Yang Min 13817220577

Should you have any questions, please feel free to let me know.

Thanks and regards,

Min Yang

Emerging Microbes & Infections (EMI) Editorial Office

4F Fuxing Building

131 Dongan Road

Shanghai

China

Tel: 86-21-54237992

E-mail: editorial@emi2012.org

---

**From:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
**Sent:** Monday, December 16, 2019 4:18 AM  
**To:** Lu, Shan  
**Cc:** Min Yang; wen yumei; yuanzhenghong; yiweitangmd@gmail.com; Martin martin; Emily; Editorial Office  
**Subject:** Re: EMI 12/15 Lunch Meeting

Ok, thank you.

Get [Outlook for iOS](#)

---

**From:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Sent:** Monday, December 16, 2019 4:40:20 PM  
**To:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
**Cc:** Min Yang <min.yang@emi2012.org>; wen yumei <ymwen@shmu.edu.cn>; yuanzhenghong <yuanzhenghong@shphc.org.cn>; yiweitangmd@gmail.com <yiweitangmd@gmail.com>; Martin martin <winter999@hotmail.com>; Emily <editorial2@emi2012.org>; Editorial Office <editorial@emi2012.org>  
**Subject:** Re: EMI 12/15 Lunch Meeting

Hi YiWei

I am about to board the flight and hope to give you a quick reply.

We should not use the read # as the key or only factor for selection as it will never be fair to all the papers even we give more time or pick any cut-off date. We can include it as a reference but we need to read the whole list to select based on the significance of papers as how each of us sees them differently. Otherwise we can just use the read # and will not need the input from this group.

One example is that the top two most read papers in 2019 are from the same group on the same topic. I don't think we should select both, probably only select the full article one, not the short Letter.

We can not include 2018 papers as T&F is funding this award thus I think we should select from 2019.

So please pick up 4 top papers based on your scientific judgement, with the read# as a reference. Using the voting form min yang prepared.

Thanks.

Shan

Sent from my iPhone

On Dec 16, 2019, at 9:55 AM, Tang, Yi-Wei <yi-wei.tang@cepheid.com> wrote:

It was so nice to meet most of you yesterday.

Shan, Min, I have a question about the \*2019 EMI Publication (views) which was attached with the voting form/table. I think it is very important to indicate the publication date in 2019 (to add into the “status” column?): the paper published earlier in the year surely had more “views”.

Having this said, maybe we should choose 2018 EMI best paper first? The views should be counted one full year time after the paper gets on line. Alternatively, using the data on Table 1.3 of the Press Confidential Publishing Report?

Thank you, Yi-Wei

---

**From:** Min Yang <min.yang@emi2012.org>  
**Sent:** Thursday, December 12, 2019 3:09 PM  
**To:** wen yumei <ymwen@shmu.edu.cn>; Lu, Shan <Shan.Lu@umassmed.edu>; yuanzhenghong <yuanzhenghong@shphc.org.cn>; Tang, Yi-Wei <yi-wei.tang@cepheid.com>; yiweitangmd@gmail.com; Martin martin <winter999@hotmail.com>; Emily <editorial2@emi2012.org>  
**Cc:** Editorial Office <editorial@emi2012.org>  
**Subject:** EMI 12/15 Lunch Meeting

Dear All EMI Leaders, Min Yu and other EMI colleagues,

Thank you very much for attending EMI 12/15 Lunch Meeting, please check and confirm the following information.

**What:** EMI 12/15 Lunch Meeting

**Where:** Shanghai Min(上海小南国). 5F, Junyaguoji Plaza, No.798, Zhaojiabang Rd, Xuhui District, Shanghai.

**When:** 12:00 noon, December 15, 2019.

**Contact:** Yang Min 13817220577

Should you have any questions, please feel free to let me know.

Thanks and regards,

Min Yang

Emerging Microbes & Infections (EMI) Editorial Office  
4F Fuxing Building  
131 Dongan Road  
Shanghai  
China  
Tel: 86-21-54237992  
E-mail: [editorial@emi2012.org](mailto:editorial@emi2012.org)

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

---

**From:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
**Sent:** Sunday, December 15, 2019 8:55 PM  
**To:** Min Yang; wen yumei; Lu, Shan; yuanzhenghong; yiweitangmd@gmail.com; Martin martin; Emily  
**Cc:** Editorial Office  
**Subject:** RE: EMI 12/15 Lunch Meeting

It was so nice to meet most of you yesterday.

Shan, Min, I have a question about the \*2019 EMI Publication (views) which was attached with the voting form/table. I think it is very important to indicate the publication date in 2019 (to add into the "status" column?): the paper published earlier in the year surely had more "views".

Having this said, maybe we should choose 2018 EMI best paper first? The views should be counted one full year time after the paper gets on line. Alternatively, using the data on Table 1.3 of the Press Confidential Publishing Report?

Thank you, Yi-Wei

---

**From:** Min Yang <min.yang@emi2012.org>  
**Sent:** Thursday, December 12, 2019 3:09 PM  
**To:** wen yumei <ymwen@shmu.edu.cn>; Lu, Shan <Shan.Lu@umassmed.edu>; yuanzhenghong <yuanzhenghong@shphc.org.cn>; Tang, Yi-Wei <yi-wei.tang@cepheid.com>; yiweitangmd@gmail.com; Martin martin <winter999@hotmail.com>; Emily <editorial2@emi2012.org>  
**Cc:** Editorial Office <editorial@emi2012.org>  
**Subject:** EMI 12/15 Lunch Meeting

Dear All EMI Leaders, Min Yu and other EMI colleagues,

Thank you very much for attending EMI 12/15 Lunch Meeting, please check and confirm the following information.

**What:** [EMI 12/15 Lunch Meeting](#)

**Where:** [Shanghai Min\(上海小南国\). 5F, Junyaoguoji Plaza, No.798, Zhaojiabang Rd, Xuhui District, Shanghai.](#)

**When:** [12:00 noon, December 15, 2019.](#)

**Contact:** [Yang Min 13817220577](#)

Should you have any questions, please feel free to let me know.

Thanks and regards,

Min Yang

Emerging Microbes & Infections (EMI) Editorial Office  
4F Fuxing Building  
131 Dongan Road  
Shanghai  
China  
Tel: 86-21-54237992  
E-mail: [editorial@emi2012.org](mailto:editorial@emi2012.org)



Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

---

**From:** 步志高 <buzhigao@caas.cn>  
**Sent:** Wednesday, February 12, 2020 12:59 AM  
**To:** josaphouitch, alexa  
**Cc:** hexijun@caas.cn; editorial@emi2012.org; wen yumei; Lu, Shan; min.yang@emi2012.org  
**Subject:** Re: EMI 2019 Best Paper Award - First Place

Dear all,

Thank you so much for the good news! We highly appreciate the recognition from the editors, the journal EMI, and Taylor & Francis.

Best wishes,

Zhigao

-----原始邮件-----

发件人:"Josaphouitch, Alexa" <Alexa.Josaphouitch@taylorandfrancis.com>

发送时间:2020-02-11 20:01:50 (星期二)

收件人: "hexijun@caas.cn" <hexijun@caas.cn>, "buzhigao@caas.cn" <buzhigao@caas.cn>

抄送: "editorial@emi2012.org" <editorial@emi2012.org>, "wen yumei" <ymwen@shmu.edu.cn>, "Lu, Shan" <Shan.Lu@umassmed.edu>, "min.yang@emi2012.org" <min.yang@emi2012.org>

主题: EMI 2019 Best Paper Award - First Place

Dear Dongming Zhao, Renqiang Liu, Xianfeng Zhang, Fang Li, Jingfei Wang, Jiwen Zhang, Xing Liu, Lulu Wang, Jiaor Zhang, Xinzhou Wu, Yuntao Guan, Weiye Chen, Xijun Wang, Xijun He & Zhigao Bu,

On behalf of Editors-in-Chief, Yu-Mei Wen and Shan Lu, EMI and Taylor & Francis, we would like to congratulate you on winning first place for *Emerging Microbes & Infections* 2019 Best Papers Award for the paper entitled "Replication and virulence in pigs of the first African swine fever virus isolated in China."

EMI made this decision based on the fact that your paper is a timely report with thorough molecular virology work to isolate the pathogen which caused the outbreak of African Swine Fever Virus in China.

In addition to the attached certificate, a link on the journal's homepage will be included to [celebrate the news](#). The first-place winner also receives 1,000 USD. Please contact Alexa Josaphouitch, [alexa.jo@taylorandfrancis.com](mailto:alexa.jo@taylorandfrancis.com), for more details about the monetary award.

Thank you and congratulations on your achievement!

Sincerely,

**Alexa Josaphouitch**

Portfolio Manager for Hematology and Immunology Journals

Taylor & Francis Group  
530 Walnut Street, Suite 850, Philadelphia, PA 19106  
Tel: (215) 606-4170  
Fax: (215) 207-0050  
Email: [alexa.josaphouitch@taylorandfrancis.com](mailto:alexa.josaphouitch@taylorandfrancis.com)  
Web: [www.tandfonline.com](http://www.tandfonline.com)  
(she/her/hers)

Information Classification: General

---

Zhigao Bu, PhD, Professor, General Director of Institute,  
Chief Scientist of Zoonoses and Exotic Diseases,  
Harbin Veterinary Research Institute,  
Chinese Academy of Agricultural Sciences,  
678 Haping Road, Harbin 150069, Heilongjiang Province, P.R.China  
Tel: 86-451-51997177  
Fax: 86-451-51997166  
Email: [buzhigao@caas.cn](mailto:buzhigao@caas.cn)

---

**From:** Min Yang <min.yang@emi2012.org>  
**Sent:** Wednesday, February 12, 2020 10:17 PM  
**To:** Liu, Shan-Lu; Su, Lishan; Saif, Linda; Weiss, Susan  
**Cc:** Lu, Shan  
**Subject:** Re: EMI commentary

Dear Dr Liu,

Thank you for your support to EMI.

According to the attachment, it looks like your submission is a DRAFT still which has not been submitted successfully yet.

Could you please check and confirm?

Thanks and regards,

Min Yang

*Emerging Microbes & Infections* (EMI) Editorial Office  
4F Fuxing Building  
131 Dongan Road  
Shanghai  
China  
Tel: 86-21-54237992  
E-mail: min.yang@emi2012.org

---

发件人: "Liu, Shan-Lu" <liu.6244@osu.edu>  
日期: 2020年2月13日 星期四 上午10:58  
收件人: "Su, Lishan" <lishan\_su@med.unc.edu>, "Saif, Linda" <saif.2@osu.edu>, "Weiss, Susan" <weissr@pennmedicine.upenn.edu>  
抄送: Min Yang <min.yang@emi2012.org>, "Lu, Shan" <Shan.Lu@umassmed.edu>  
主题: EMI commentary

Dear all,

I have just submitted a commentary to EMI. See attached the submitted version.

Thank you.

Shan-Lu



Shan-Lu Liu, M.D., Ph.D.  
Professor  
Co-Director, Viruses and Emerging Pathogens Program  
Infectious Diseases Institute  
Center for Retrovirus Research  
Departments of Veterinary Biosciences, Microbial Infection and Immunity, and Microbiology  
The Ohio State University

1900 Coffey Rd, Room 480 VMAB  
Columbus, Ohio 43210  
Phone: (614) 292-8690  
Fax: (614) 292-6473  
Email: [liu.6244@osu.edu](mailto:liu.6244@osu.edu); [shan-lu.liu@osumc.edu](mailto:shan-lu.liu@osumc.edu)

Thanks and regards,

Min Yang

*Emerging Microbes & Infections* (EMI) Editorial Office  
4F Fuxing Building  
131 Dongan Road  
Shanghai  
China  
Tel: 86-21-54237992  
E-mail: [min.yang@emi2012.org](mailto:min.yang@emi2012.org)

---

发件人: "Liu, Shan-Lu" <[liu.6244@osu.edu](mailto:liu.6244@osu.edu)>  
日期: 2020年2月13日 星期四 上午10:58  
收件人: "Su, Lishan" <[lishan\\_su@med.unc.edu](mailto:lishan_su@med.unc.edu)>, "Saif, Linda" <[saif.2@osu.edu](mailto:saif.2@osu.edu)>, "Weiss, Susan" <[weissr@pennmedicine.upenn.edu](mailto:weissr@pennmedicine.upenn.edu)>  
抄送: Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>, "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
主题: EMI commentary

Dear all,

I have just submitted a commentary to EMI. See attached the submitted version.

Thank you.

Shan-Lu



Shan-Lu Liu, M.D., Ph.D.  
Professor  
Co-Director, Viruses and Emerging Pathogens Program  
Infectious Diseases Institute  
Center for Retrovirus Research  
Departments of Veterinary Biosciences, Microbial Infection and Immunity, and Microbiology  
The Ohio State University  
1900 Coffey Rd, Room 480 VMAB  
Columbus, Ohio 43210  
Phone: (614) 292-8690  
Fax: (614) 292-6473  
Email: [liu.6244@osu.edu](mailto:liu.6244@osu.edu); [shan-lu.liu@osumc.edu](mailto:shan-lu.liu@osumc.edu)

---

**From:** KY Yuen <kyyuen@hku.hk>  
**Sent:** Tuesday, January 28, 2020 7:50 AM  
**To:** Lu, Shan; 'Shibo Jiang (姜世勃)'; 'Wen Yumei'; 'Yuan Zhenghong 袁正宏'; 'Zhang Wenhong'  
**Cc:** 'Yang Min 杨旻'; 'min.yang'; TEMI-peerreview@journals.tandf.co.uk; jaspchan@gmail.com  
**Subject:** RE: EMI first 2019-CoV paper is online!

Dear Professor Lu,  
We are very glad to publish in EMI and wish that this baby nurtured by you, Professor Shibo Jiang and Professor Wen will continue to flourish.  
Warm regards.  
KY

---

**From:** Lu, Shan [mailto:Shan.Lu@umassmed.edu]  
**Sent:** Tuesday, January 28, 2020 8:48 PM  
**To:** KY Yuen; 'Shibo Jiang (姜世勃)'; 'Wen Yumei'; 'Yuan Zhenghong 袁正宏'; 'Zhang Wenhong'  
**Cc:** 'Yang Min 杨旻'; 'min.yang'; TEMI-peerreview@journals.tandf.co.uk; jaspchan@gmail.com  
**Subject:** RE:EMI first 2019-CoV paper is online!

Dear Prof Yuen,

Congratulations!

While there are several papers published on this new virus, I believe that yours is the first high quality, strong science based report about this concerning pathogen.

Through this process, EMI also learned a lot on how to publish an important paper timely.

Shan

---

**From:** KY Yuen <kyyuen@hku.hk>  
**Sent:** Tuesday, January 21, 2020 9:57 PM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>; 'Shibo Jiang (姜世勃)' <shibojiang@fudan.edu.cn>; 'Wen Yumei' <ymwen@shmu.edu.cn>; 'Yuan Zhenghong 袁正宏' <zhyuan@shmu.edu.cn>; 'Zhang Wenhong' <zhangwenhong@fudan.edu.cn>  
**Cc:** 'Yang Min 杨旻' <minyang0216@163.com>; 'min.yang' <min.yang@emi2012.org>; TEMI-peerreview@journals.tandf.co.uk; jaspchan@gmail.com  
**Subject:** RE: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Dear Professor,  
Thank you for your very clear explanation.  
We will try our best to return the galley proof once we got it.  
And wish EMI the best.  
KY

---

**From:** Lu, Shan [mailto:Shan.Lu@umassmed.edu]  
**Sent:** Wednesday, January 22, 2020 10:52 AM  
**To:** Shibo Jiang (姜世勃); Wen Yumei; Yuan Zhenghong 袁正宏; Zhang Wenhong

**Cc:** Yang Min 杨旻; min.yang; Yuen KY; [TEMI-peerreview@journals.tandf.co.uk](mailto:TEMI-peerreview@journals.tandf.co.uk)

**Subject:** RE: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Hi, Shibo,

This is a good time for you and others to learn the process of EMI as part of Taylor & Francis. I will use Prof Yuen's paper as an example.

1. Initial paper QC: any new paper will go through the initial screening process by JEO who is a free service provided by T&F to ensure the timely and highly quality screening on new manuscripts. Regular time: 1-2 days depending on the quality of manuscripts and the exact time of submission into EMI system as the time difference between the authors and JEO may vary.  
In the case of Prof Yuen's paper: 0.5 day due to my request to JEO
2. Peer review: from Editor-in-Chief to Review Editor to outside reviewers: usually 2-4 weeks.  
In the case of Prof Yuen's paper: 4 hrs.
3. Transfer accepted draft to Production: JEO will do a final check to ensure the quality of paper format etc after multiple revisions (even though there is no revision in Prof Yuen's case) is suitable for production. It can vary between 2 hrs to 2 days (the JEO is located in Southeast Asia and she does not work during the weekends).  
In the case of Prof Yuen's paper: 2 days (it is a bad luck because it happened to be weekend at the time of Yuen's paper acceptance).
4. Production: type setting and internal QC review. This is subcontracted by people in India or some other places. Regular time: 2-4 weeks.  
In the case of Prof Yuen's paper: estimated to be within 5 days because I requested T&F to put this paper into a fast track production.
5. Proofs to Prof Yuen, authors' final review and resubmitting back to Production, and final uploading online. It varies greatly pending authors' return time, but it is about 2-4 days.  
In the case of Prof Yuen's case: unknown yet.

So in summary, EMI has done our best within the system to reduce the regular time of 2 months to about a total of 7 days which I trust is the fastest a big publisher can do. So you are wrong that EMI editorial office staff did not cause any delay on weekends or holidays. It is the big publisher who is trying to control cost and using various subcontractors in developing countries that will generate huge de-centralized operation and delay due to time difference in diverse geographic regions.

I don't believe any big publisher can do better than this, including Nature or NEJM. It is very possible that the small publishers can have a way to cut it shorter as shown in your examples. This is a trade off for big publishers.

At the same time, I never fully believe the so called early publishing or first publishing for such rushing as we are observing. The time difference will only be a few days, and ultimately it is the content of papers, rather than the early date matters. Also we need to be careful about the quality of typesetting in a rush, or the controversy of "stealing data" as in the exact case you just cited which can only generate more negative impact than any real gain.

Regarding to how to cite Prof Yuen's paper, I don't think it is an issue at all. Your paper will be published later than his, so you can still cite his paper (since you know the entire title, authors etc., even EMI issue, year), but leave out the page numbers. You can add the page number when you receive the Proofs of your own paper. As a pro, you should know this better than anyone.

Shan



**From:** Shibo Jiang (姜世勃) <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>

**Sent:** Tuesday, January 21, 2020 12:30 AM

**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; Wen Yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>; Yuan Zhenghong 袁正宏 <[zhyuan@shmu.edu.cn](mailto:zhyuan@shmu.edu.cn)>; Zhang Wenhong <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>

**Cc:** Yang Min 杨旻 <[minyang0216@163.com](mailto:minyang0216@163.com)>; min.yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>; Yuen KY <[kyyuen@hku.hk](mailto:kyyuen@hku.hk)>; [TEMI-peerreview@journals.tandf.co.uk](mailto:TEMI-peerreview@journals.tandf.co.uk)

**Subject:** Re: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Dear Prof. Lu and Wen,

The day before yesterday, Drs. Hong Tang and Pei Hao at Pasteu Institute called me and asked me that they wanted to submit a manuscript about the genetic analysis of 2019-nCoV to EMI and whether we can process their manuscript in the fast track. I told them that EMI had already accepted a paper two days ago and this paper has presented very extensive analysis of this new virus. Therefore, they decided to submit their manuscript to *SCIENCE CHINA Life Sciences* (<https://mp.weixin.qq.com/s/JC0fCMsZlgGPYy4L7xMpTg>) and it was immediately accepted and published online today. However, Prof. Yuen's paper is still not online today. We want to cite Prof. Yuen's paper in our manuscripts, but we cannot get the citation link. Similarly, we submitted a minireview to JMV. It was also immediately accepted and published it online next day.

I understand that the staff of the editorial office of EMI have to take off in the weekends and holidays, but is it possible to ask the publishers to give special consideration for those extremely important papers for publication at fast speed?

Thank you very much for your consideration,

Shibo

-----原始邮件-----

发件人:"Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

发送时间:2020-01-18 19:42:02 (星期六)

收件人: zlshi <[zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn)>, "Shibo Jiang (姜世勃)" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>

抄送: "Yang Min 杨旻" <[minyang0216@163.com](mailto:minyang0216@163.com)>, "min.yang" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>, "Du, Lanying" <[ldu@nybc.org](mailto:ldu@nybc.org)>

主题: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Dear Prof Shi,

Thanks for your confirmation and EMI is happy to see you as one of the authors.

Best.

Shan

---

**From:** zlshi <[zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn)>

**Sent:** Saturday, January 18, 2020 6:37 AM

**To:** Shibo Jiang (姜世勃) <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>; Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Cc:** Yang Min 杨旻 <[minyang0216@163.com](mailto:minyang0216@163.com)>; min.yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>; Du, Lanying <[ldu@nybc.org](mailto:ldu@nybc.org)>

**Subject:** Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Dear Prof. Jiang,

Thank you for your inviting me as a co-author of this commentary. As the sequence is now open to the public, I'll be happy to be the co-author.

Best regards,

Zhengli,

---

SHI Zhengli, Ph. D

Senior Scientist & Professor

Wuhan Institute of Virology, Chinese Academy of Sciences

44 Xiao Hong Shan

430071 Wuhan, Hubei

China

Tel & Fax: (0086) 27 87197240

Email: [zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn)

---

**From:** [Shibo Jiang \(姜世勃\)](#)

**Date:** 2020-01-18 16:25

**To:** [Lu Shan](#)

**CC:** [Yang Min 杨旻](#); [min.yang](#); [Shi Zhengli](#); [Du Lanying NYBC](#)

**Subject:** Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Dear Prof. Lu,

Per your request, I just submitted the invited Commentary to EMI online (see the attachment). During the submission, I accidentally put in the contact information of Drs. Lu Lu and Shuai Xia (my postdoc), rather than Drs. Shi and Du, into the authors' list. I thus immediately called Min about the possibility of withdrawing and resubmitting the manuscript. Min told me that I would not have to withdraw the manuscript since the authors' information in the manuscript is correct, but I would have to inform Drs. Lu and Xia that they may receive the email from EMI about this manuscript. I informed them already.

I will cite Prof. Yuen's paper once the citation information is available during the proof-reading stage.

Thank you very much for your consideration,

Shibo

-----原始邮件-----

发件人: "Emerging Microbes and Infections" <[onbehalf@manuscriptcentral.com](mailto:onbehalf@manuscriptcentral.com)>

发送时间: 2020-01-18 15:21:06 (星期六)

收件人: [shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)

抄送: [shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)

主题: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

18-Jan-2020

Dear Professor Jiang:

Your manuscript entitled "An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies" has been successfully submitted online and is presently being given full consideration for publication in Emerging Microbes & Infections.

Your manuscript ID is TEMI-2020-0055.

Please mention the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your street address or e-mail address, please log in to ScholarOne Manuscripts at <https://mc.manuscriptcentral.com/temi> and edit your user information as appropriate.

You can also view the status of your manuscript at any time by checking your Author Center after logging in to <https://mc.manuscriptcentral.com/temi>.

Thank you for submitting your manuscript to Emerging Microbes & Infections.

Sincerely,

Emerging Microbes & Infections Editorial Office

---

**From:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
**Sent:** Wednesday, July 1, 2020 1:31 AM  
**To:** Martin martin; Lu, Shan; wen yumei; Wenhua Zhang; Yuan Zhenghong 袁正宏  
**Cc:** Min Yang  
**Subject:** RE: EMI meetings

July 5th at 10am will work for me. Please send an Outlook/Zoom meeting invitation.

Yi-Wei

---

**From:** Martin martin <winter999@hotmail.com>  
**Sent:** Wednesday, July 1, 2020 11:00 AM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>; Tang, Yi-Wei <yi-wei.tang@cepheid.com>; wen yumei <ymwen@shmu.edu.cn>; Wenhua Zhang <wenhua\_zhang@aziacapitalpartners.us>; Yuan Zhenghong 袁正宏 <zhyuan@shmu.edu.cn>  
**Cc:** Min Yang <min.yang@emi2012.org>  
**Subject:** Re: EMI meetings

I am ok with the time.  
xiaodong

---

**From:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Sent:** Wednesday, July 1, 2020 2:32 AM  
**To:** Tang, Yi-Wei <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>; wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>; Wenhua Zhang <[wenhua\\_zhang@aziacapitalpartners.us](mailto:wenhua_zhang@aziacapitalpartners.us)>; Yuan Zhenghong 袁正宏 <[zhyuan@shmu.edu.cn](mailto:zhyuan@shmu.edu.cn)>; Martin martin <[winter999@hotmail.com](mailto:winter999@hotmail.com)>  
**Cc:** Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>  
**Subject:** RE: EMI meetings

Hi, Prof Wen and others,

After getting feedback from everyone, it seems that Yi-Wei will not be available on July 4<sup>th</sup>.

So may I ask if July 5<sup>th</sup> is good for you? And we are thinking 10am China time in the morning of July 5. Please confirm if that is ok. We will use Zoom.

Also here is the draft agenda for our meeting based on discuss I had with Prof Wen today:

Agenda:

1. Prof Wen: welcome and introduction;
2. Shan Lu: EMI work in the first half of 2020 and plans for the next phase
3. Xiaodong Zhang: EMI financial report for 2019 and part of 2020
4. Everyone: Open discussion

Please feel free to add more topics.

Shan

---

**From:** Tang, Yi-Wei <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>  
**Sent:** Sunday, June 28, 2020 9:49 PM  
**To:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>; Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** Wenhua Zhang <[wenhua\\_zhang@aziacapitalpartners.us](mailto:wenhua_zhang@aziacapitalpartners.us)>; Yuan Zhenghong 袁正宏 <[zhyuan@shmu.edu.cn](mailto:zhyuan@shmu.edu.cn)>; Martin martin <[winter999@hotmail.com](mailto:winter999@hotmail.com)>  
**Subject:** RE: EMI meetings

Ditto.

Shan and Xiaodong, please have a meeting agenda passed to board members ahead of time, so we can prepare for them.

Thank you, Yi-Wei

**From:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
**Sent:** Monday, June 29, 2020 9:42 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** Tang, Yi-Wei <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>; Wenhua Zhang <[wenhua\\_zhang@aziacapitalpartners.us](mailto:wenhua_zhang@aziacapitalpartners.us)>; Yuan Zhenghong 袁正宏 <[zhyuan@shmu.edu.cn](mailto:zhyuan@shmu.edu.cn)>; Martin martin <[winter999@hotmail.com](mailto:winter999@hotmail.com)>  
**Subject:** Re: EMI meetings

July fourth anytime will be good for me. Wen

-----Original Messages-----

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Sent Time:** 2020-06-29 00:44:54 (Monday)  
**To:** "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>, "Tang, Yi-Wei" <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>, "Wenhua Zhang" <[wenhua\\_zhang@aziacapitalpartners.us](mailto:wenhua_zhang@aziacapitalpartners.us)>, "Yuan Zhenghong 袁正宏" <[zhyuan@shmu.edu.cn](mailto:zhyuan@shmu.edu.cn)>  
**Cc:** "Martin martin" <[winter999@hotmail.com](mailto:winter999@hotmail.com)>  
**Subject:** EMI meetings

Dear Prof Wen and other senior EMI leaders,

I finally may have a little break to organize a few meetings/activities planned for EMI. In addition, I have been personally involved in multiple online conferences so I have a better understanding of such IT issues now. Xiaodong' team is also better prepared for EMI related work after working with me in the last several weeks.

The first one is a virtual meeting as suggested by Prof Wen, among 6 of us to have a high-level meeting. We can plan to have it in one of the weekends.

- a. I propose July 4<sup>th</sup> or July 5 period. Please let me know if you have time or you would like to prefer some other time. Since everyone except me is based in China, I am ok to have a meeting in day time Shanghai.
- b. Objectives: review the work from first half of 2020 and identify the main tasks for the rest of 2020. Also review the plans for additional activities (I will present).

More meetings/activities will be discussed in the coming weeks along with the above meeting.

Please reply by Tuesday 8pm China time if you can be available for a meeting during 7/4-7/5 period.

Best.

Shan

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

---

**From:** Martin martin <winter999@hotmail.com>  
**Sent:** Tuesday, June 30, 2020 11:00 PM  
**To:** Lu, Shan; Tang, Yi-Wei; wen yumei; Wenhua Zhang; Yuan Zhenghong 袁正宏  
**Cc:** Min Yang  
**Subject:** Re: EMI meetings

I am ok with the time.  
xiaodong

---

**From:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Sent:** Wednesday, July 1, 2020 2:32 AM  
**To:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>; wen yumei <ymwen@shmu.edu.cn>; Wenhua Zhang <wenhua\_zhang@aziacapitalpartners.us>; Yuan Zhenghong 袁正宏 <zhyuan@shmu.edu.cn>; Martin martin <winter999@hotmail.com>  
**Cc:** Min Yang <min.yang@emi2012.org>  
**Subject:** RE: EMI meetings

Hi, Prof Wen and others,

After getting feedback from everyone, it seems that Yi-Wei will not be available on July 4<sup>th</sup>.

So may I ask if July 5<sup>th</sup> is good for you? And we are thinking 10am China time in the morning of July 5. Please confirm if that is ok. We will use Zoom.

Also here is the draft agenda for our meeting based on discuss I had with Prof Wen today:

Agenda:

1. Prof Wen: welcome and introduction;
2. Shan Lu: EMI work in the first half of 2020 and plans for the next phase
3. Xiaodong Zhang: EMI financial report for 2019 and part of 2020
4. Everyone: Open discussion

Please feel free to add more topics.

Shan

---

**From:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
**Sent:** Sunday, June 28, 2020 9:49 PM  
**To:** wen yumei <ymwen@shmu.edu.cn>; Lu, Shan <Shan.Lu@umassmed.edu>  
**Cc:** Wenhua Zhang <wenhua\_zhang@aziacapitalpartners.us>; Yuan Zhenghong 袁正宏 <zhyuan@shmu.edu.cn>; Martin martin <winter999@hotmail.com>  
**Subject:** RE: EMI meetings

Ditto.



Shan and Xiaodong, please have a meeting agenda passed to board members ahead of time, so we can prepare for them.

Thank you, Yi-Wei

**From:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>

**Sent:** Monday, June 29, 2020 9:42 AM

**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Cc:** Tang, Yi-Wei <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>; Wenhua Zhang <[wenhua\\_zhang@aziacapitalpartners.us](mailto:wenhua_zhang@aziacapitalpartners.us)>; Yuan Zhenghong 袁正宏 <[zhyuan@shmu.edu.cn](mailto:zhyuan@shmu.edu.cn)>; Martin martin <[winter999@hotmail.com](mailto:winter999@hotmail.com)>

**Subject:** Re: EMI meetings

July fourth anytime will be good for me. Wen

-----Original Messages-----

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Sent Time:** 2020-06-29 00:44:54 (Monday)

**To:** "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>, "Tang, Yi-Wei" <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>, "Wenhua Zhang" <[wenhua\\_zhang@aziacapitalpartners.us](mailto:wenhua_zhang@aziacapitalpartners.us)>, "Yuan Zhenghong 袁正宏" <[zhyuan@shmu.edu.cn](mailto:zhyuan@shmu.edu.cn)>

**Cc:** "Martin martin" <[winter999@hotmail.com](mailto:winter999@hotmail.com)>

**Subject:** EMI meetings

Dear Prof Wen and other senior EMI leaders,

I finally may have a little break to organize a few meetings/activities planned for EMI. In addition, I have been personally involved in multiple online conferences so I have a better understanding of such IT issues now. Xiaodong' team is also better prepared for EMI related work after working with me in the last several weeks.

The first one is a virtual meeting as suggested by Prof Wen, among 6 of us to have a high-level meeting. We can plan to have it in one of the weekends.

- a. I propose July 4<sup>th</sup> or July 5 period. Please let me know if you have time or you would like to prefer some other time. Since everyone except me is based in China, I am ok to have a meeting in day time Shanghai.
- b. Objectives: review the work from first half of 2020 and identify the main tasks for the rest of 2020. Also review the plans for additional activities (I will present).

More meetings/activities will be discussed in the coming weeks along with the above meeting.

Please reply by Tuesday 8pm China time if you can be available for a meeting during 7/4-7/5 period.

Best.

Shan

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate

the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

---

**From:** Min Yang <min.yang@emi2012.org>  
**Sent:** Wednesday, July 1, 2020 9:25 AM  
**To:** Lu, Shan; wen yumei  
**Cc:** Tang, Yi-Wei; Wenhua Zhang; Yuan Zhenghong 袁正宏; Martin martin; xinyi  
**Subject:** Re: EMI meetings

Dear Prof Wen,

Could you please let us know your preferred time for zoom connection testing?  
It will take about 10 mins by computer.

Thanks and regards,

Min Yang

*Emerging Microbes & Infections* (EMI) Editorial Office  
4F Fuxing Building  
131 Dongan Road  
Shanghai  
China  
Tel: 86-21-54237992  
E-mail: min.yang@emi2012.org

---

发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>  
日期: 2020年7月1日 星期三 下午9:20  
收件人: wen yumei <ymwen@shmu.edu.cn>  
抄送: "Tang, Yi-Wei" <yi-wei.tang@cepheid.com>, Wenhua Zhang <wenhua\_zhang@aziacapitalpartners.us>, Yuan Zhenghong 袁正宏 <zhyuan@shmu.edu.cn>, Martin martin <winter999@hotmail.com>, Min Yang <min.yang@emi2012.org>, xinyi <1563993396@qq.com>  
主题: RE: RE: EMI meetings

Prof Wen,

Thanks.

Then we will have the meeting on July 5<sup>th</sup>, 10am Shanghai time. We will use Zoom. Yang Min and Xinyi (IT support) will contact you individually to help you check zoom connection etc.

Best.

Shan

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Wednesday, July 1, 2020 9:10 AM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Cc:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>; Wenhua Zhang <wenhua\_zhang@aziacapitalpartners.us>; Yuan

Zhenghong 袁正宏 <zhyuan@shmu.edu.cn>; Martin martin <winter999@hotmail.com>; Min Yang <min.yang@emi2012.org>

**Subject:** Re: RE: EMI meetings

July 5th is OK with me. Wen

-----Original Messages-----

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Sent Time:** 2020-07-01 10:32:25 (Wednesday)

**To:** "Tang, Yi-Wei" <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>, "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>, "Wenhua Zhang" <[wenhua\\_zhang@aziacapitalpartners.us](mailto:wenhua_zhang@aziacapitalpartners.us)>, "Yuan Zhenghong 袁正宏" <[zhyuan@shmu.edu.cn](mailto:zhyuan@shmu.edu.cn)>, "Martin martin" <[winter999@hotmail.com](mailto:winter999@hotmail.com)>

**Cc:** "Min Yang" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>

**Subject:** RE: EMI meetings

Hi, Prof Wen and others,

After getting feedback from everyone, it seems that Yi-Wei will not be available on July 4<sup>th</sup>.

So may I ask if July 5<sup>th</sup> is good for you? And we are thinking 10am China time in the morning of July 5. Please confirm if that is ok. We will use Zoom.

Also here is the draft agenda for our meeting based on discuss I had with Prof Wen today:

Agenda:

1. Prof Wen: welcome and introduction;
2. Shan Lu: EMI work in the first half of 2020 and plans for the next phase
3. Xiaodong Zhang: EMI financial report for 2019 and part of 2020
4. Everyone: Open discussion

Please feel free to add more topics.

Shan

---

**From:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
**Sent:** Sunday, June 28, 2020 9:49 PM  
**To:** wen yumei; Lu, Shan  
**Cc:** Wenhua Zhang; Yuan Zhenghong 袁正宏; Martin martin  
**Subject:** RE: EMI meetings

Ditto.

Shan and Xiaodong, please have a meeting agenda passed to board members ahead of time, so we can prepare for them.

Thank you, Yi-Wei

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Monday, June 29, 2020 9:42 AM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Cc:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>; Wenhua Zhang <wenhua\_zhang@aziacapitalpartners.us>; Yuan Zhenghong 袁正宏 <zhyuan@shmu.edu.cn>; Martin martin <winter999@hotmail.com>  
**Subject:** Re: EMI meetings

July fourth anytime will be good for me. Wen

-----Original Messages-----

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Sent Time:** 2020-06-29 00:44:54 (Monday)  
**To:** "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>, "Tang, Yi-Wei" <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>, "Wenhua Zhang" <[wenhua\\_zhang@aziacapitalpartners.us](mailto:wenhua_zhang@aziacapitalpartners.us)>, "Yuan Zhenghong 袁正宏" <[zhyuan@shmu.edu.cn](mailto:zhyuan@shmu.edu.cn)>  
**Cc:** "Martin martin" <[winter999@hotmail.com](mailto:winter999@hotmail.com)>  
**Subject:** EMI meetings

Dear Prof Wen and other senior EMI leaders,

I finally may have a little break to organize a few meetings/activities planned for EMI. In addition, I have been personally involved in multiple online conferences so I have a better understanding of such IT issues now. Xiaodong' team is also better prepared for EMI related work after working with me in the last several weeks.

The first one is a virtual meeting as suggested by Prof Wen, among 6 of us to have a high-level meeting. We can plan to have it in one of the weekends.

- a. I propose July 4<sup>th</sup> or July 5 period. Please let me know if you have time or you would like to prefer some other time. Since everyone except me is based in China, I am ok to have a meeting in day time Shanghai.

- b. Objectives: review the work from first half of 2020 and identify the main tasks for the rest of 2020. Also review the plans for additional activities (I will present).

More meetings/activities will be discussed in the coming weeks along with the above meeting.

Please reply by Tuesday 8pm China time if you can be available for a meeting during 7/4-7/5 period.

Best.

Shan

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

---

**From:** Min Yang <min.yang@emi2012.org>  
**Sent:** Wednesday, October 21, 2020 9:00 AM  
**To:** wen yumei  
**Cc:** Lu, Shan; yuan zhenghong; ZhangWenhong; Tang, Yi-Wei  
**Subject:** Re: EMI Q3 Most Read Paper Selection-due on 28 October 2020

Dear Prof Wen,

Well received with thanks.

Thanks and regards,  
Min

获取 [Outlook for iOS](#)

---

发件人: wen yumei <ymwen@shmu.edu.cn>  
发送时间: Wednesday, October 21, 2020 2:27:23 PM  
收件人: Min Yang <min.yang@emi2012.org>  
抄送: Lu, Shan <Shan.Lu@umassmed.edu>; yuan zhenghong <zhyuan@shmu.edu.cn>; ZhangWenhong <zhangwenhong@fudan.edu.cn>; Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
主题: Re: EMI Q3 Most Read Paper Selection-due on 28 October 2020

I am sending my evaluation, not based on teh numbers buton the significance. Wen

-----Original Messages-----

**From:** "Min Yang" <min.yang@emi2012.org>  
**Sent Time:** 2020-10-20 22:04:49 (Tuesday)  
**To:** "wen yumei" <ymwen@shmu.edu.cn>, "Lu, Shan" <Shan.Lu@umassmed.edu>, "yuan zhenghong" <zhyuan@shmu.edu.cn>, ZhangWenhong <zhangwenhong@fudan.edu.cn>, "Tang, Yi-Wei" <yi-wei.tang@cepheid.com>  
**Cc:**  
**Subject:** EMI Q3 Most Read Paper Selection-due on 28 October 2020

Dear All EMI Founders,

Recently, we are updating EMI's most read recent articles' list for the 3<sup>rd</sup> quarter, in that case, could you please check the attached EMI publication list for Q3 and tick the 5 articles you would like to select no later than 28 October 20, 2020?

Thank you for your time and please do not hesitate to let me know if you have any questions.

Thanks and regards,

Min Yang

*Emerging Microbes & Infections* (EMI) Editorial Office  
4F Fuxing Building

131 Dongan Road  
Shanghai  
China  
Tel: 86-21-54237992  
E-mail: min.yang@emi2012.org



---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Wednesday, October 21, 2020 2:27 AM  
**To:** Min Yang  
**Cc:** Lu, Shan; yuan zhenghong; ZhangWenhong; Tang, Yi-Wei  
**Subject:** Re: EMI Q3 Most Read Paper Selection-due on 28 October 2020  
**Attachments:** EMI 2020 Q3 Publication-20201009 (2)wen.xlsx

I am sending my evaluation, not based on the numbers but on the significance. Wen

-----Original Messages-----

**From:** "Min Yang" <min.yang@emi2012.org>  
**Sent Time:** 2020-10-20 22:04:49 (Tuesday)  
**To:** "wen yumei" <ymwen@shmu.edu.cn>, "Lu, Shan" <Shan.Lu@umassmed.edu>, "yuan zhenghong" <zhyuan@shmu.edu.cn>, ZhangWenhong <zhangwenhong@fudan.edu.cn>, "Tang, Yi-Wei" <yi-wei.tang@cepheid.com>  
**Cc:**  
**Subject:** EMI Q3 Most Read Paper Selection-due on 28 October 2020

Dear All EMI Founders,

Recently, we are updating EMI's most read recent articles' list for the 3<sup>rd</sup> quarter, in that case, could you please check the attached EMI publication list for Q3 and tick the 5 articles you would like to select no later than 28 October 20, 2020?

Thank you for your time and please do not hesitate to let me know if you have any questions.

Thanks and regards,

Min Yang

*Emerging Microbes & Infections* (EMI) Editorial Office  
4F Fuxing Building

131 Dongan Road  
Shanghai  
China  
Tel: 86-21-54237992  
E-mail: min.yang@emi2012.org

---

**From:** Min Yang <min.yang@emi2012.org>  
**Sent:** Wednesday, January 8, 2020 10:12 PM  
**To:** Lu, Shan; 'Shibo Jiang (姜世勃)'  
**Cc:** Emily  
**Subject:** RE: EMI special issue on Emerging CoV

Ok, I will generate the list asap.

Thank you,  
Min

---

**From:** Lu, Shan  
**Sent:** Wednesday, January 8, 2020 9:54 PM  
**To:** 'Shibo Jiang (姜世勃)' <shibojiang@fudan.edu.cn>  
**Cc:** Min Yang <min.yang@emi2012.org>; Emily <editorial2@emi2012.org>  
**Subject:** RE: EMI special issue on Emerging CoV

I got the feedback from Dr. Shi. She thanks my invitation but stated that this may not be a good time for her to accept our invitation. So you can be the sole GE at this point. Once we established it, we can find another GE.

On the title, I think yours is too much like a "political statement". I think we can make it simple and scientific. How about **"Emerging and Re-emerging Coronaviruses"**?

Next, please draft an overall introduction of this special issue.

Min Yang: please go through past EMI papers and find all corona viruses related papers and generate a list so they can be included in this special issue. Min Yu may help to see if there is any easy way to identify such papers. With a first rough list, Prof Jiang can suggest more key words to identify such EMI papers.

Shan

**From:** Shibo Jiang (姜世勃) <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>  
**Sent:** Tuesday, January 7, 2020 4:43 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** 'Min Yang' <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>; Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>  
**Subject:** Re: EMI special issue on Emerging CoV

Thanks, Shan.

I will work together with Min Yu and Min Yang, under your guidance, on this special issue.

It is a good idea to include all manuscripts related to the emerging CoVs in this special issue. I suggest to change the title to **"Combating the pathogenic emerging and re-emerging coronaviruses"** (I include "Re-emerging CoV" because we cannot exclude the possibility of SARS epidemic in the future).

I will draft a short description of this special issue.

Please send an invitation to Dr. Zhengli Shi as soon as possible. If she agrees, I will discuss with her about the list of potential authors and topics and we should sent out invitation letters together.

Best,

Shibo

-----Original Messages-----

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Sent Time:** 2020-01-07 14:31:54 (Tuesday)

**To:** "Shibo Jiang (姜世勃)" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>

**Cc:** "Min Yang" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>, Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>

**Subject:** EMI special issue on Emerging CoV

Hi, Shibo,

Here I am connecting you to Min Yu and Min Yang of EMI editorial office on the set up of a new special issue.

First, you will serve as the guest editor (before the 2<sup>nd</sup> person is finalized).

Second, we need to define what is the scope of this special issue. I don't think we should make this one for the pending Wuhan pathogen. The emerging CoV itself is interesting and has enough papers for us to set up a special issue.

Third, based on the decision of above, we can name the title of special issue.

Fourth, you then need to draft a short description of this special issue (using other EMI one as the example but the descriptions for some of them are not very good, but the overall length can be used as a template).

After the above are done, we can draft together an invitation letter and develop a list of potential experts who may contribute to this special issue. Min Yu will work on this with us.

At the same time, Min Yang will work with you to identify those published EMI papers related to this topic and pull them into this special issue now (as part of the process to build this special issue).

Best.

Shan

---

**From:** yuan zhenghong <zhyuan@shmu.edu.cn>  
**Sent:** Wednesday, July 8, 2020 9:26 AM  
**To:** Lu, Shan  
**Cc:** wen yumei; Min Yang; 'jingee'; Emily  
**Subject:** Re: EMI Special topic-Hepatitis

Dear Shan

Thank you for the email.

The title and brief description looks nice and I don't think it need to be revised now.

I will discuss with Prof Wen to invite Guest editor overseas and try to organize some high impact papers.

It will be best if EMI office can send me the list of hepatitis related papers published in the last few years.

Best

Zhenghong

-----原始邮件-----

发件人:"Lu, Shan" <Shan.Lu@umassmed.edu>

发送时间:2020-07-08 20:19:46 (星期三)

收件人:"yuan zhenghong" <zhyuan@shmu.edu.cn>

抄送: "wen yumei" <ymwen@shmu.edu.cn>, "Min Yang" <min.yang@emi2012.org>, 'jingee' <jingee@fudan.edu.cn>, Emily <editorial2@emi2012.org>

主题: EMI Special topic-Hepatitis

Dear Zhenghong,

To follow up what Prof Wen instructed at our July 5<sup>th</sup> meeting, I have made further arrangement with EMI office to support your role as the Guest Editor for EMI's special topic on hepatitis.

- **The current title is: Hepatitis – updates from the classical emerging infections.** It looks quite nice but please let us know if you would like to revise.
- **The brief description – “Hepatitis viruses (HAV, HBV, HCV, HDV, HEV) belong to diverse virus families and are transmitted by different routes. Some are enveloped and the genome can be single-stranded RNA or double-stranded DNA. Though HAV and HEV usually cause acute infections, chronic HEV infections have been observed recently. Various mechanisms for persistent infections by HBV or HCV, and their roles leading to liver cirrhosis and hepatocellular carcinoma have been further explored. Novel data on the molecular biology of hepatitis viruses, antiviral drugs, and new therapeutic targets have been presented regularly. EMI Special Topic - Viral Hepatitis will cover these hepatitis viruses in terms of biology, pathogenesis, immune response, therapy, and prevention, with special emphasis on recent progress.”** Please let us know if you would like to revise. it seems fine to me and you can update later if busy now.
- **The 2<sup>nd</sup> Guest Editor:** based on our discussion on July 5, it will be ideal to have another international person to be the co-Guest Editor. Again, it is not in rush but if you do have one, please feel free to invite, or Prof Wen may invite with you together.
- **Update the list.** EMI has published quite a lot of hepatitis related papers in the last few years but they have not been updated to be included in this special topic. Emily Yu from EMI office will work to search for them and add then add to this topic.
- **Future invitation of reviews and high impact papers:** please feel free to invite or ask EMI office to invite any papers which can further enhance value of this specific topic

Please feel free to guide everyone at EMI office on however you would like to lead this special topic. You can also assign anyone from your lab to help you if needed.

Best.

Shan

---

**From:** jingee <jingee@fudan.edu.cn>  
**Sent:** Thursday, August 13, 2020 7:48 AM  
**To:** ZhangWenhong; Lu, Shan  
**Cc:** wen yumei; Min Yang; Emily; 孙峰  
**Subject:** RE: EMI Special topic-TB

Dear Profs,

The TB special topic is already updated. Please have a look and the link is as follows:

<https://think.taylorandfrancis.com/tuberculosis-what-is-new/>

Best Regards,  
Jing

-----  
Jing Wu  
[jingee@fudan.edu.cn](mailto:jingee@fudan.edu.cn)  
Department of Infectious Diseases  
Huashan Hospital, Fudan University

原始邮件

**发件人:** Shan" <Shan.Lu@umassmed.edu>  
**收件人:** jingee<jingee@fudan.edu.cn>; ZhangWenhong <zhangwenhong@fudan.edu.cn>  
**抄送:** wen yumei<ymwen@shmu.edu.cn>; Min Yang<min.yang@emi2012.org>; Emily<editorial2@emi2012.org>; 孙峰  
<aaronsf1125@126.com>  
**发送时间:** 2020年8月11日(周二) 10:26  
**主题:** RE: EMI Special topic-TB

Hi, Jing,

It sounds a good plan. Thanks.

Shan

**From:** jingee <[jingee@fudan.edu.cn](mailto:jingee@fudan.edu.cn)>  
**Sent:** Monday, August 10, 2020 9:11 PM  
**To:** ZhangWenhong <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>; Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>; Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>; Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>; 孙

峰 <[aaronsf1125@126.com](mailto:aaronsf1125@126.com)>

**Subject:** RE: EMI Special topic-TB

Dear Prof Lu and Zhang,

About SP, I'm talking with Clara. She may help adding some lables. I will ask her if she can renew all the papers this week.

About the new TB paper, I will take care it and I' m asking an assoicate professor in our group to be a reviewer.

Best Regards,

Jing

Jing Wu

[jingee@fudan.edu.cn](mailto:jingee@fudan.edu.cn)

Department of Infectious Diseases

Huashan Hospital, Fudan University

原始邮件

**发件人:** Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**收件人:** ZhangWenhong <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>

**抄送:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>; Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>; Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>; 'jingee' <[jingee@fudan.edu.cn](mailto:jingee@fudan.edu.cn)>; 孙峰 <[aaronsf1125@126.com](mailto:aaronsf1125@126.com)>

**发送时间:** 2020年8月11日(周二) 03:13

**主题:** RE: EMI Special topic-TB

Dear Wenhong,



During this past weekend, I assigned another new TB paper to you as the Review Editor. So you will be getting busy from now.

At this point, I think you and Jing still need to pay more attention to TB Special Topic.

The old TB papers are still NOT uploaded. Please find someone else to work on this if Jing is too busy.

In addition, you can ask Jing or anyone else you prefer to search and invite reviewers to new papers assigned to you.

- Please feel free to reject any paper you don't feel high quality. Since now we try to send ALL new hepatitis papers to you, we are not doing any screening. Some of them may not have good quality. Please do not hesitate to reject them. You can just let me know "low priority" or any other reason (confidential to me or public ready for reviewers).

Please do not hesitate to let me know if you need any help.

Best.

Shan

---

**From:** Min Yang <min.yang@emi2012.org>  
**Sent:** Wednesday, July 22, 2020 9:23 PM  
**To:** Lu, Shan; 'jingee'; ZhangWenhong  
**Cc:** wen yumei; Emily; 孙峰  
**Subject:** Re: EMI Special topic-TB

Sure, I will write a separate email to connect Jing and Clara.

Meanwhile, we have already prepared an updated version of all special topics and will make it shown in the web soon.

Thanks and regards,

Min Yang

*Emerging Microbes & Infections* (EMI) Editorial Office  
4F Fuxing Building  
131 Dongan Road  
Shanghai  
China  
Tel: 86-21-54237992  
E-mail: min.yang@emi2012.org

---

发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>  
日期: 2020年7月23日 星期四 上午12:05  
收件人: 'jingee' <jingee@fudan.edu.cn>, ZhangWenhong <zhangwenhong@fudan.edu.cn>  
抄送: wen yumei <ymwen@shmu.edu.cn>, Min Yang <min.yang@emi2012.org>, Emily <editorial2@emi2012.org>, 孙峰 <aaronsf1125@126.com>  
主题: RE: EMI Special topic-TB

Hi Jing,

Thanks for getting this list.

Article types should be automatically shown in the list.

We have been listing papers based on the chronological order but we can ask T&F if they can add a year label to separate papers in different years. At the same time, I am not sure that is really important.

The "label" may be useful but one paper may have more than meanings/significance. I guess the "search" function can be enhanced to serve the same purpose. We can talk to T&F software department.

The key is to upload these papers to TB topic asap. Min, can you introduce Jing to Clara to link them so in the future, Jing can give Clara any new TB related papers to be added?

Shan

**From:** jingee <jingee@fudan.edu.cn>  
**Sent:** Wednesday, July 22, 2020 9:17 AM

**To:** Lu, Shan <Shan.Lu@umassmed.edu>; ZhangWenhong <zhangwenhong@fudan.edu.cn>

**Cc:** wen yumei <ymwen@shmu.edu.cn>; Min Yang <min.yang@emi2012.org>; Emily <editorial2@emi2012.org>; 孙峰 <aaronsf1125@126.com>

**Subject:** Re: EMI Special topic-TB

Dear Prof Lu,

The web page of special topics is just a list of papers. It's hard to find proper papers as it lacks filters. How about adding some filters such as Year, Article type and Labels for the papers?

Please have a look at the Excel table of the TB papers with the proper information especially the labels.

Regards,

Jing Wu

[jingee@fudan.edu.cn](mailto:jingee@fudan.edu.cn)

Department of Infectious Diseases

Huashan Hospital, Fudan University

原始邮件

发件人: ZhangWenhong <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>

收件人: Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

抄送: wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>; Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>; Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>;

'jingee' <[jingee@fudan.edu.cn](mailto:jingee@fudan.edu.cn)>; 孙峰 <[aaronsf1125@126.com](mailto:aaronsf1125@126.com)>

发送时间: 2020年7月9日(周四) 05:39

主题: Re: EMI Special topic-TB

Dear Shan,

Thanks and I will follow the topics and discuss with you later.

Wenhong

-----原始邮件-----

发件人: "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

发送时间: 2020-07-08 20:26:31 (星期三)

收件人: ZhangWenhong <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>

抄送: "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>, "Min Yang" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>, Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>, 'jingee' <[jingee@fudan.edu.cn](mailto:jingee@fudan.edu.cn)>

主题: EMI Special topic-TB

Dear Wenhong,

To follow up what Prof Wen instructed at our July 5<sup>th</sup> meeting, I have made further arrangement with EMI office to support your role as the Guest Editor for EMI's special topic on TB.

- **The current title is: Tuberculosis (TB) -what is new.** It looks quite nice but please let us know if you would like to revise.
- **The brief description – “The EMI Special Topic on TB incorporates research reports and high quality reviews on the following areas of TB research: epidemiology, fundamental research, development of new diagnostics and biomarkers, development of new drugs and vaccines, and public health issues related to this important pathogen.”** Please let us know if you would like to revise. it seems fine to me and you can update later if busy now.
- The 2<sup>nd</sup> Guest Editor: based on our discussion on July 5, it will be ideal to have another international person to be the co-Guest Editor. Again, it is not in rush but if you do have one, please feel free to invite, or Prof Wen may invite with you together.
- Update the list. EMI has published quite a lot of TB related papers in the last few years but they have not been updated to be included in this special topic. Wu Jing from EMI office will work to search for them and add then add to this topic.
- Future invitation of reviews and high impact papers: please feel free to invite or ask EMI office to invite any papers which can further enhance value of this specific topic

Please feel free to guide everyone at EMI office on however you would like to lead this special topic.

Best.

Shan

--

张文宏 Wenhong Zhang, M.D. & Ph.D. Professor of Medicine Director, Division of Infectious Diseases Huashan Hospital, Fudan University PI, Institute of Biomedical Science, Fudan University 12 M. Wulumuqi Road Shanghai 200040, China Phone: (8621)52888123 Fax: (8621)52888714 Email: [zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)

---

**From:** jingee <jingee@fudan.edu.cn>  
**Sent:** Monday, August 10, 2020 9:11 PM  
**To:** ZhangWenhong; Lu, Shan  
**Cc:** wen yumei; Min Yang; Emily; 孙峰  
**Subject:** RE: EMI Special topic-TB

Dear Prof Lu and Zhang,

About SP, I'm talking with Clara. She may help adding some lables. I will ask her if she can renew all the papers this week.

About the new TB paper, I will take care it and I'm asking an assoicate professor in our group to be a reviewer.

Best Regards,  
Jing

Jing Wu  
[jingee@fudan.edu.cn](mailto:jingee@fudan.edu.cn)  
Department of Infectious Diseases  
Huashan Hospital, Fudan University

原始邮件

发件人: Shan" <Shan.Lu@umassmed.edu>  
收件人: ZhangWenhong<zhangwenhong@fudan.edu.cn>  
抄送: wen yumei<ymwen@shmu.edu.cn>; Min Yang<min.yang@emi2012.org>; Emily<editorial2@emi2012.org>;  
'jingee'<jingee@fudan.edu.cn>; 孙峰<aaronsf1125@126.com>  
发送时间: 2020年8月11日(周二) 03:13  
主题: RE: EMI Special topic-TB

Dear Wenhong,

During this past weekend, I assigned another new TB paper to you as the Review Editor. So you will be getting busy from now.

At this point, I think you and Jing still need to pay more attention to TB Special Topic.

The old TB papers are still NOT uploaded. Please find someone else to work on this if Jing is too busy.

In addition, you can ask Jing or anyone else you prefer to search and invite reviewers to new papers assigned to you.

- Please feel free to reject any paper you don't feel high quality. Since now we try to send ALL new hepatitis papers to you, we are not doing any screening. Some of them may not have good quality. Please do not hesitate to reject them. You can just let me know "low priority" or any other reason (confidential to me or public ready for reviewers).

Please do not hesitate to let me know if you need any help.

Best.

Shan

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Friday, January 1, 2021 7:36 PM  
**To:** xinyi  
**Cc:** zhangwenhong; Winter999; Lu, Shan; Min&nbsp;Yang&nbsp;&nbsp;杨旻; 袁正宏; YiWei Tang  
**Subject:** Re: EMI symposium poster  
  
**Importance:** High

I think we should make a poster in English, and can this symposium be open through Zoom or other webs for abroad?  
How can the public get access to this symposium? Wen

-----Original Messages-----

**From:** xinyi <1563993396@qq.com>  
**Sent Time:** 2020-12-30 12:42:45 (Wednesday)  
**To:** "wen yumei" <ymwen@shmu.edu.cn>  
**Cc:** zhangwenhong <zhangwenhong@fudan.edu.cn>, Winter999 <Winter999@hotmail.com>, "Lu, Shan" <Shan.Lu@umassmed.edu>, "Min&nbsp;Yang&nbsp;&nbsp;杨旻" <min.yang@emi2012.org>  
**Subject:** EMI symposium poster

Dear Prof Wen,  
The attachment is for your information.

Thanks

Best Regards,  
Xinyi

----- 原始邮件 -----

发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>;  
发送时间: 2020年12月28日(星期一) 晚上11:53  
收件人: "wen yumei" <ymwen@shmu.edu.cn>; "xinyi" <1563993396@qq.com>;  
抄送: "zhangwenhong" <zhangwenhong@fudan.edu.cn>; "Winter999" <Winter999@hotmail.com>;  
主题: RE: 回复 : RE: EMI symposium

Yes, it was a draft and was hoping to get your formal version. Now it will be updated.

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Monday, December 28, 2020 7:16 AM  
**To:** xinyi <1563993396@qq.com>  
**Cc:** zhangwenhong <zhangwenhong@fudan.edu.cn>; Winter999 <Winter999@hotmail.com>; Lu, Shan <Shan.Lu@umassmed.edu>  
**Subject:** Re: 回复 : RE: EMI symposium

Please note, I am from Fudan University, Shanghai Medical College. It was not correctly stated. YM Wen

-----Original Messages-----

**From:**xinyi <[1563993396@qq.com](mailto:1563993396@qq.com)>

**Sent Time:**2020-12-28 11:46:20 (Monday)

**To:** "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>

**Cc:** zhangwenhong <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>, Winter999 <[Winter999@hotmail.com](mailto:Winter999@hotmail.com)>, "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Subject:** 回复: RE: EMI symposium

Prof. Wen,

Attachment is EMI symposium program, please review.

Thanks.

Best Regards,

Xinyi

----- 原始邮件 -----

**发件人:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>;

**发送时间:** 2020年12月24日(星期四) 晚上9:15

**收件人:** "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>;

**抄送:** "zhangwenhong" <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>; "Winter999" <[Winter999@hotmail.com](mailto:Winter999@hotmail.com)>; "xinyi" <[1563993396@qq.com](mailto:1563993396@qq.com)>;

**主题:** RE: EMI symposium

Thanks, Prof Wen.

Xinyi from Xiaodong's group will follow up with you to arrange the recording of your opening remarks (no more than 5 min). We will send you the official program soon for your ref.



Also, please let us know if you have a photo that we can use.

Best.

Shan

**From:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
**Sent:** Thursday, December 24, 2020 1:34 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** Re: EMI symposium

Very good suggestion. I like it. YM Wen

Beisdes, please ask min Yang to send out seasons greetings to our oversea editorial board members.. Wen

-----Original Messages-----

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Sent Time:** 2020-12-23 23:58:34 (Wednesday)  
**To:** "M. Yu-Mei Wen ([ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn))" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
**Cc:** zhangwenhong <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>, "袁正宏" <[Zhyuan@shmu.edu.cn](mailto:Zhyuan@shmu.edu.cn)>, zhangwenhong <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>, "Tang, Yi-Wei" <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>, Winter999 <[Winter999@hotmail.com](mailto:Winter999@hotmail.com)>  
**Subject:** EMI symposium

Dear Prof Wen and others,

Wenhong and Xiaodong approached me last week about their plan to organize a new year symposium by their group, and suggested to work with EMI together.

I think this is a good idea since we have been thinking organizing an EMI conference for a few years but never make it. This can be a good start with the online conference.

After further discussion with Wenhong and Xiaodong, we prepared a draft invitation to potential speakers (see attached). It is scheduled on Jan 10 to give a summary and future outlook of COVID-19.

It will be a small group of leading experts (about 6 people or so) and their talks will be pre-recorded. Then we can put them together as one full symposium. Prof Wen should give a short opening remark to start the symposium.

We are reaching out to potential speakers. Once we have the responses, a formal program can be prepared.

Please let me, Wenhong and Xiaodong know your advice and comment so we can finalize the plan.

Thanks.

Shan

---

**From:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
**Sent:** Wednesday, December 23, 2020 8:44 PM  
**To:** Lu, Shan; M. Yu-Mei Wen (ymwen@shmu.edu.cn)  
**Cc:** zhangwenhong; 袁正宏; zhangwenhong; Winter999  
**Subject:** RE: EMI symposium

Great action; thank Shan, Wenhong and Xiaodong for organizing this.

Happy Holidays.

Yi-Wei

---

**From:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Sent:** Wednesday, December 23, 2020 11:59 PM  
**To:** M. Yu-Mei Wen (ymwen@shmu.edu.cn) <ymwen@shmu.edu.cn>  
**Cc:** zhangwenhong <zhangwenhong@fudan.edu.cn>; 袁正宏 <Zhyuan@shmu.edu.cn>; zhangwenhong <zhangwenhong@fudan.edu.cn>; Tang, Yi-Wei <yi-wei.tang@cepheid.com>; Winter999 <Winter999@hotmail.com>  
**Subject:** EMI symposium

Dear Prof Wen and others,

Wenhong and Xiaodong approached me last week about their plan to organize a new year symposium by their group, and suggested to work with EMI together.

I think this is a good idea since we have been thinking organizing an EMI conference for a few years but never make it. This can be a good start with the online conference.

After further discussion with Wenhong and Xiaodong, we prepared a draft invitation to potential speakers (see attached). It is scheduled on Jan 10 to give a summary and future outlook of COVID-19.

It will be a small group of leading experts (about 6 people or so) and their talks will be pre-recorded. Then we can put them together as one full symposium. Prof Wen should give a short opening remark to start the symposium.

We are reaching out to potential speakers. Once we have the responses, a formal program can be prepared.

Please let me, Wenhong and Xiaodong know your advice and comment so we can finalize the plan.

Thanks.

Shan

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

---

**From:** Martin martin <winter999@hotmail.com>  
**Sent:** Monday, September 16, 2019 3:36 AM  
**To:** Lu, Shan; wen yumei  
**Subject:** Re: EMI update

Hi Shan,

It seems an excellent solution for the EMI, I met her last time and found her a smart girl.  
let us work out her payment when after the decision will be made.  
Sorry, I am not available on 27/9 morning cause I will be engaged in another meeting.  
Xiaodong

---

**From:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Sent:** Sunday, September 15, 2019 2:12 PM  
**To:** wen yumei <ymwen@shmu.edu.cn>; Martin martin <winter999@hotmail.com>  
**Subject:** EMI update

Dear Prof Wen and Xiaodong,

I would like to let you know that we may have a good solution in search of EMI Editorial Staff.

Yu, Min (last name Yu, see her contact at the bottom of this email) is the currently assigned Managing Editor from T&F to EMI (Xiaodong met her in June during our meeting). Due to the global reorganization of T&F journals, the biomedical journals will be grouped together and managed by a group head based in New York. This will happen later this year. While this will not affect EMI in our regular operation, it is a good change so EMI's importance will be further highlighted. I plan to talk to the new Biomedical Head when he is available.

Because of this change, Yu Min will no longer work with EMI and assigned to other non-bio journals. She understands that we are looking for an editorial office help and she is interested in working for us on a part time/contractor basis. She told me that it is not a problem for her to still work T&F for other work.

She had undergraduate and maybe some graduate education in biology, and had worked for two different international publishing companies. During the last several months she has worked with EMI, I like her a lot. She is smart and very efficient. She can solve many things we had with T&F quickly. With her inside knowledge about T&F and long time work experience with scientific journal operation, she will be the great choice for us.

I explained to her what kind of work I would expect her to do and she is ok with them. I asked her to send us a copy of her Bio so I can share with you once I receive it.

Please let me know if you have any question and advice. If you approve, I can continue our discussion with her to work out the details including salary etc, and then let Xiaodong to work on the business agreement etc.

\*\*\*\*\*

I will be in China in coming week for a very short visit. I can potentially meet you in the early morning of 9/27, say at 9am, as I will take the noon flight to San Francisco on the same day.

\*\*\*\*\*

Shan

\*\*\*\*\*

## Min Yu

Managing Editor | Taylor & Francis Asia Pacific



an Informa business

Room 2102-2103 Culture Square | No.59 Jia Zhongguancun St. Beijing 100872 | P.R.China

北京市中关村大街甲 59 号文化大厦 2102-2103 室，邮编：100872

**Mobile:** +86 15201162252

[Min.Yu@tandfchina.com](mailto:Min.Yu@tandfchina.com)

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Saturday, January 30, 2021 9:33 PM  
**To:** Lu, Shan  
**Subject:** Re: EMI update

Please call me today at 8-9PM Shanghai time.

-----原始邮件-----

发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>  
发送时间: 2021-01-30 03:03:28 (星期六)  
收件人: "'M. Yu-Mei Wen (ymwen@shmu.edu.cn)'" <ymwen@shmu.edu.cn>  
抄送:  
主题: EMI update

Dear Prof Wen,

I would like to discuss with you on a few things about EMI.

- Please see the selection of best papers for 2020 (see attached). I will call you during the weekend if you have time.
- We are in the middle of EMI web site update. It is not finished but you can take a look. Please go to [www.emi2012.org](http://www.emi2012.org) Only focus at the home page. I added Hans Klenk as Emeritus EIC and hope you can agree.
- T&F sent a summary (see attached) and we can go over them.
- Other things during our talk over phone.

Best

Shan



---

**From:** YiWei Tang <yiweitangmd@gmail.com>  
**Sent:** Saturday, November 23, 2019 2:35 AM  
**To:** Lu, Shan  
**Cc:** ZhangWenhong; Martin martin; yuan zhenghong; wen yumei  
**Subject:** Re: EMI year end gathering

Thank you for arranging the lunch meeting. Yes, I plan to attend.

Yi-Wei

On Sat, Nov 23, 2019 at 9:34 AM Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> wrote:

Dear EMI colleagues,

I have discussed with Prof Wen and Xiaodong to have a gathering for us, plus EMI staff members at the noon time on Dec. 15, Sunday.

The purpose is to meet and review the work of EMI in 2019, after it has been moved to T&F.

In addition, we hired a part time new staff member, Min Yu, in addition to the original editorial staff Min Yang and Jing Wu. Three junior scientists from Hua Shan Hospital will terminate their work for EMI by the end of this year. They will also join us for lunch.

Xiaodong will send out the location and exact time later once we are close to Dec. 15.

Thanks.

Shan



\*\*\*\*\*

**From:** ZhangWenhong <zhangwenhong@fudan.edu.cn>  
**Sent:** Tuesday, November 26, 2019 5:00 PM  
**To:** Lu, Shan  
**Cc:** Martin martin; yuan zhenghong; yiweitangmd@gmail.com; wen yumei  
**Subject:** Re: EMI year end gathering

Thank you Professor Lu for the arrangement! I cannot participate in this meaningful gathering because of my participation in the Standing Committee of the Infectious Disease Branch of the  
After the update, we will continue to maintain support for the editorial department. Wen Hongshang

-----The original message-----

From 人 : "Lu, Shan" <Shan.Lu@umassmed.edu>

**Sending time:** 2019-11-23 09:34:56 (Saturday)

To : ZhangWenhong <zhangwenhong@fudan.edu.cn>, "Martin martin" <winter999@hotmail.com>, "yuan zhenghong" <zhyuan@shmu.edu.cn>, "yiweitangmd@gmail.com" <yiweitangmd@gmail.com>, "wen yumei" <ymwen@shmu.edu.cn>

CC :

Main **topic:** the EMI year End Gathering

Dear EMI colleagues,

I have discussed with Prof Wen and Xiaodong to have a gathering for us, plus EMI staff members at the noon time on Dec. 15, Sunday.

The purpose is to meet and review the work of EMI in 2019, after it has been moved to T&F.

In addition, we hired a part time new staff member, Min Yu, in addition to the original editorial staff Min Yang and Jing Wu. Three junior scientists from Hua Shan Hospital will terminate their work for EMI by the end of this year. They will also join us for lunch.

Xiaodong will send out the location and exact time later once we are close to Dec. 15.

Thanks.

1

-  
Wenhong Zhang, MD & Ph.D. Professor of Medicine Director, Division of Infectious Diseases Huashan Hospital,  
Fudan University PI, Institute of Biomedical Science, Fudan University 12 M. Wulumuqi Road Shanghai 200040, China  
Phone: (8621)52888123 Fax: (8621)52888714 Email: zhangwenhong@fudan.edu.cn

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Friday, November 22, 2019 11:03 PM  
**To:** Lu, Shan  
**Subject:** Re: EMI year end gathering

Thank you。 Wen

-----原始邮件-----

发件人:"Lu, Shan" <Shan.Lu@umassmed.edu>

发送时间:2019-11-23 09:34:56 (星期六)

收件人: ZhangWenhong <zhangwenhong@fudan.edu.cn>, "Martin martin" <winter999@hotmail.com>, "yuan zhenghong" <zhyuan@shmu.edu.cn>, "yiweitangmd@gmail.com" <yiweitangmd@gmail.com>, "wen yumei" <ymwen@shmu.edu.cn>

抄送:

主题: EMI year end gathering

Dear EMI colleagues,

I have discussed with Prof Wen and Xiaodong to have a gathering for us, plus EMI staff members at the noon time on Dec. 15, Sunday.

The purpose is to meet and review the work of EMI in 2019, after it has been moved to T&F.

In addition, we hired a part time new staff member, Min Yu, in addition to the original editorial staff Min Yang and Jing Wu. Three junior scientists from Hua Shan Hospital will terminate their work for EMI by the end of this year. They will also join us for lunch.

Xiaodong will send out the location and exact time later once we are close to Dec. 15.

Thanks.

Shan



---

**From:** KY Yuen <kyyuen@hku.hk>  
**Sent:** Tuesday, February 23, 2021 8:38 PM  
**To:** Lu, Shan; Wen Yumei  
**Subject:** RE: EMI's 2020 Best Paper Award - First Place

Dear Professor Lu and Professor Wen,  
Many many thanks again for your kind support throughout the years.  
Will come back to you with the comprehensive review on SARS-CoV-2 and COVID by tomorrow.  
Warm regards.  
KY

---

**From:** Lu, Shan [mailto:Shan.Lu@umassmed.edu]  
**Sent:** Wednesday, February 24, 2021 6:02 AM  
**To:** 'kyyuen@hku.hk'  
**Subject:** RE: EMI's 2020 Best Paper Award - First Place

Dear KY,

I would like to personally congratulate you and your team for this honor. Your sharp clinical observation and subsequent timely report really made the most critical contribution to the early identification of SARS-CoV-2. EMI is honored to have the opportunity to be the place you selected for one of early publications.

Best

Shan

---

**From:** Josaphouitch, Alexa <Alexa.Josaphouitch@taylorandfrancis.com>  
**Sent:** Tuesday, February 23, 2021 2:31 PM  
**To:** khkok@hku.hk; kyyuen@hku.hk  
**Cc:** editorial@emi2012.org; Lu, Shan <Shan.Lu@umassmed.edu>; M. Yu-Mei Wen (ymwen@shmu.edu.cn) <ymwen@shmu.edu.cn>; 'Min Yang' <min.yang@emi2012.org>  
**Subject:** EMI's 2020 Best Paper Award - First Place

Dear Jasper Fuk-Woo Chan, Kin-Hang Kok, Zheng Zhu, Hin Chu, Kelvin Kai-Wang To, Shuofeng Yuan & Kwok-Yung Yuen,

On behalf of Editors-in-Chief, Yu-Mei Wen and Shan Lu, EMI and Taylor & Francis, we would like to congratulate you on winning first place for *Emerging Microbes & Infections* 2020 Best Paper Award for the paper entitled, "Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan."

EMI made this decision based on the fact that your paper is one of the first COVID-19 reports in the world with well described SARS-CoV-2 viral gene structure.

In addition to the attached certificate, a link on the journal's homepage will be included to [celebrate the news](#). The first-place winner also receives 1,000 USD. Please contact Alexa Josaphouitch, [alexa.jo@taylorandfrancis.com](mailto:alexa.jo@taylorandfrancis.com), for more details about the monetary award.

Thank you and congratulations on your achievement!

Sincerely,

Alexa Josaphouitch

Portfolio Manager for Hematology and Immunology Journals

Taylor & Francis Group

530 Walnut Street, Suite 850, Philadelphia, PA 19106


Tel: (212) 600-3459

Fax: (215) 207-0050



Email: [alexa.josaphouitch@taylorandfrancis.com](mailto:alexa.josaphouitch@taylorandfrancis.com)

Web: [www.tandfonline.com](http://www.tandfonline.com)


(she/her/hers)



EXPLORE OUR  
HEMATOLOGY  
JOURNALS  
CLICK HERE FOR MORE INFO



EXPLORE OUR  
IMMUNOLOGY  
JOURNALS  
CLICK HERE FOR MORE INFO



Information Classification: General

---



Virus-free. [www.avg.com](http://www.avg.com)

---

**From:** Saif, Linda <saif.2@osu.edu>  
**Sent:** Tuesday, February 23, 2021 5:37 PM  
**To:** Lu, Shan; Liu, Shan-Lu; 'lsu@med.unc.edu'; 'Weiss, Susan'  
**Subject:** Re: EMI's 2020 Best Paper Award - Third Place

Wow!  
Linda

Linda J Saif, MS, PD  
Distinguished University Professor  
OARDC/CFAES/CVM  
1680 Madison Ave  
Wooster, Ohio 44691



---

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Date:** Tuesday, February 23, 2021 at 5:09 PM  
**To:** "Liu, Shan-Lu" <liu.6244@osu.edu>, "'lsu@med.unc.edu'" <lsu@med.unc.edu>, linda saif <saif.2@osu.edu>, "'Weiss, Susan'" <weissr@pennmedicine.upenn.edu>  
**Subject:** RE: EMI's 2020 Best Paper Award - Third Place

Dear Shan-Lu, Lishan, Linda and Susan,

Congratulations to your paper being selected to receive the Annual Best Paper award. Only four papers receiving such honor among 300 published EMI papers in 2021.

I would like personally thank you for your support to EMI. We are looking forward to having more opportunities to serve the global scientific community in emerging infections.

Best.

Shan

\*\*\*\*\*

*Shan Lu, MD, PhD  
Editor-in-Chief  
Emerging Microbes & Infections  
&  
Professor  
Department of Medicine  
University of Massachusetts Medical School  
55 Lake Ave. North  
Worcester, MA 01655  
USA  
T. 1-508-856-6791  
E. shan.lu@umassmed.edu*

---

**From:** Josaphouitch, Alexa <Alexa.Josaphouitch@taylorandfrancis.com>  
**Sent:** Tuesday, February 23, 2021 2:31 PM  
**To:** Liu.6244@osu.edu; lsu@med.unc.edu  
**Cc:** editorial@emi2012.org; Lu, Shan <Shan.Lu@umassmed.edu>; M. Yu-Mei Wen (ymwen@shmu.edu.cn) <ymwen@shmu.edu.cn>; 'Min Yang' <min.yang@emi2012.org>  
**Subject:** EMI's 2020 Best Paper Award - Third Place

Dear Shan-Lu Liu, Linda J. Saif, Susan R. Weiss & Lishan Su,

On behalf of Editors-in-Chief, Yu-Mei Wen and Shan Lu, EMI and Taylor & Francis, we would like to congratulate you on winning third place for *Emerging Microbes & Infections* 2020 Best Papers Award for the paper entitled, "No credible evidence supporting claims of the laboratory engineering of SARS-CoV-2."

EMI made this decision based on the fact that your paper provided scientific analysis to reject the theory that SARS-CoV-2 is a laboratory engineered virus.

In addition to the attached certificate, a link on the journal's homepage will be included to [celebrate the news](#). The third-place winner also receives 250 USD. Please contact Alexa Josaphouitch, [alexa.jo@taylorandfrancis.com](mailto:alexa.jo@taylorandfrancis.com), for more details about the monetary award.

Thank you and congratulations on your achievement!

Sincerely,

**Alexa Josaphouitch**

Portfolio Manager for Hematology and Immunology Journals

Taylor & Francis Group

530 Walnut Street, Suite 850, Philadelphia, PA 19106


Tel: (212) 600-3459

Fax: (215) 207-0050

Email: [alexa.josaphouitch@taylorandfrancis.com](mailto:alexa.josaphouitch@taylorandfrancis.com)

Web: [www.tandfonline.com](http://www.tandfonline.com)

(she/her/hers)



Information Classification: General



---

**From:** clynoel <clynoel@hku.hk>  
**Sent:** Wednesday, February 24, 2021 2:03 AM  
**To:** 'Josaphouitch, Alexa'; alexa.jo@taylorandfrancis.com  
**Cc:** editorial@emi2012.org; Lu, Shan; 'M. Yu-Mei Wen'; 'Min Yang'; kyyuen; Raven Kok  
**Subject:** Re: EMI's 2020 Best Paper Award - First Place

Dear Alexa,

Thank you so much for great news. Please let me know what information is needed for arranging the monetary award. Many thanks!

Best Regards,  
Noel Chau  
for Professor KY Yuen  
Department of Microbiology  
Tel: 2255 2402

---

**From:** KY Yuen <kyyuen@hku.hk>  
**Sent:** 24 February 2021 9:39  
**To:** 'Josaphouitch, Alexa'; Raven Kok; clynoel  
**Cc:** editorial@emi2012.org; 'Lu, Shan'; 'M. Yu-Mei Wen'; 'Min Yang'  
**Subject:** RE: EMI's 2020 Best Paper Award - First Place

Dear Alexa and all,  
Many thanks again for your very encouraging message.  
Noel, my staff, will contact you on the details of the award.  
Warm regards.  
KY

---

**From:** Josaphouitch, Alexa [mailto:Alexa.Josaphouitch@taylorandfrancis.com]  
**Sent:** Wednesday, February 24, 2021 3:31 AM  
**To:** khkok@hku.hk; kyyuen@hku.hk  
**Cc:** editorial@emi2012.org; Lu, Shan; M. Yu-Mei Wen (ymwen@shmu.edu.cn); 'Min Yang'  
**Subject:** EMI's 2020 Best Paper Award - First Place

Dear Jasper Fuk-Woo Chan, Kin-Hang Kok, Zheng Zhu, Hin Chu, Kelvin Kai-Wang To, Shuofeng Yuan & Kwok-Yung Yuen,

On behalf of Editors-in-Chief, Yu-Mei Wen and Shan Lu, EMI and Taylor & Francis, we would like to congratulate you on winning first place for *Emerging Microbes & Infections* 2020 Best Paper Award for the paper entitled, "Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan."

EMI made this decision based on the fact that your paper is one of the first COVID-19 reports in the world with well described SARS-CoV-2 viral gene structure.

In addition to the attached certificate, a link on the journal's homepage will be included to [celebrate the news](#). The first-place winner also receives 1,000 USD. Please contact Alexa Josaphouitch, [alexa.jo@taylorandfrancis.com](mailto:alexa.jo@taylorandfrancis.com), for more details about the monetary award.

Thank you and congratulations on your achievement!

Sincerely,

**Alexa Josaphouitch**

Portfolio Manager for Hematology and Immunology Journals

Taylor & Francis Group

530 Walnut Street, Suite 850, Philadelphia, PA 19106


Tel: (212) 600-3459

Fax: (215) 207-0050



Email: [alexa.josaphouitch@taylorandfrancis.com](mailto:alexa.josaphouitch@taylorandfrancis.com)

Web: [www.tandfonline.com](http://www.tandfonline.com)


(she/her/hers)



EXPLORE OUR  
HEMATOLOGY  
JOURNALS  
CLICK HERE FOR MORE INFO



EXPLORE OUR  
IMMUNOLOGY  
JOURNALS  
CLICK HERE FOR MORE INFO



Information Classification: General

---



Virus-free. [www.avg.com](http://www.avg.com)

---

**From:** KY Yuen <kyyuen@hku.hk>  
**Sent:** Tuesday, February 23, 2021 8:40 PM  
**To:** 'Josaphouitch, Alexa'; khkok@hku.hk; 'clynoel'  
**Cc:** editorial@emi2012.org; Lu, Shan; 'M. Yu-Mei Wen'; 'Min Yang'  
**Subject:** RE: EMI's 2020 Best Paper Award - First Place

Dear Alexa and all,  
Many thanks again for your very encouraging message.  
Noel, my staff, will contact you on the details of the award.  
Warm regards.  
KY

---

**From:** Josaphouitch, Alexa [mailto:Alexa.Josaphouitch@taylorandfrancis.com]  
**Sent:** Wednesday, February 24, 2021 3:31 AM  
**To:** khkok@hku.hk; kyyuen@hku.hk  
**Cc:** editorial@emi2012.org; Lu, Shan; M. Yu-Mei Wen (ymwen@shmu.edu.cn); 'Min Yang'  
**Subject:** EMI's 2020 Best Paper Award - First Place

Dear Jasper Fuk-Woo Chan, Kin-Hang Kok, Zheng Zhu, Hin Chu, Kelvin Kai-Wang To, Shuofeng Yuan & Kwok-Yung Yuen,

On behalf of Editors-in-Chief, Yu-Mei Wen and Shan Lu, EMI and Taylor & Francis, we would like to congratulate you on winning first place for *Emerging Microbes & Infections* 2020 Best Paper Award for the paper entitled, "Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan."

EMI made this decision based on the fact that your paper is one of the first COVID-19 reports in the world with well described SARS-CoV-2 viral gene structure.


In addition to the attached certificate, a link on the journal's homepage will be included to [celebrate the news](#). The first-place winner also receives 1,000 USD. Please contact Alexa Josaphouitch, [alexa.jo@taylorandfrancis.com](mailto:alexa.jo@taylorandfrancis.com), for more details about the monetary award.

Thank you and congratulations on your achievement!

Sincerely,

**Alexa Josaphouitch**

Portfolio Manager for Hematology and Immunology Journals  
Taylor & Francis Group  
530 Walnut Street, Suite 850, Philadelphia, PA 19106  
Tel: (212) 600-3459  
Fax: (215) 207-0050  
Email: [alexa.josaphouitch@taylorandfrancis.com](mailto:alexa.josaphouitch@taylorandfrancis.com)  
Web: [www.tandfonline.com](http://www.tandfonline.com)  
(she/her/hers)





Virus-free. [www.avg.com](http://www.avg.com)

---

**From:** Josaphouitch, Alexa <Alexa.Josaphouitch@taylorandfrancis.com>  
**Sent:** Sunday, February 9, 2020 1:07 PM  
**To:** Lu, Shan  
**Cc:** editorial@emi2012.org; wen yumei  
**Subject:** RE: follow up

Dear Shan,

Yes, I will copy all three of you as well as Min.

Prof Wen, Yu-mei it's great to e-meet you!

Thanks!

Sincerely,  
Alexa

---

Information Classification: General

**From:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Sent:** Sunday, February 9, 2020 12:07 PM  
**To:** Josaphouitch, Alexa <Alexa.Josaphouitch@taylorandfrancis.com>  
**Cc:** editorial@emi2012.org; wen yumei <ymwen@shmu.edu.cn>  
**Subject:** RE: follow up

Dear Alexa,

Great! thanks for your hard work.

Here I would like to introduce Prof Wen, Yu-mei who is the founding Editor-in-Chief EMI. Please cc her and me when you send the notice to authors. (also cc [editorial@emi2019.org](mailto:editorial@emi2019.org) ).

Best.

Shan

---

**From:** Josaphouitch, Alexa <[Alexa.Josaphouitch@taylorandfrancis.com](mailto:Alexa.Josaphouitch@taylorandfrancis.com)>  
**Sent:** Sunday, February 9, 2020 11:48 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** RE: follow up

Hi Shan,

The Best Paper Award page has been updated with the appropriate language. I have scheduled emails to send to the winners tomorrow afternoon.

Thanks!

Sincerely,  
Alexa

---

Information Classification: General

**From:** Josaphouitch, Alexa  
**Sent:** Thursday, January 30, 2020 12:27 PM  
**To:** 'Lu, Shan' <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** RE: follow up

Hi Shan,

I received updates from marketing. These are now included in the attachments.

Thanks!

Sincerely,  
Alexa

---

Information Classification: General

**From:** Josaphouitch, Alexa  
**Sent:** Tuesday, January 28, 2020 8:30 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** RE: follow up

Hi Shan,

I've added the EMI editorial office email to the contact page. I've also attached the word document version if you'd like to edit the report before sending it to the board.

Thanks!

Sincerely,  
Alexa

---

Information Classification: General

**From:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Sent:** Monday, January 27, 2020 2:55 PM  
**To:** Josaphouitch, Alexa <[Alexa.Josaphouitch@taylorandfrancis.com](mailto:Alexa.Josaphouitch@taylorandfrancis.com)>  
**Cc:** 'editorial@emi2012.org' <[editorial@emi2012.org](mailto:editorial@emi2012.org)>  
**Subject:** RE: follow up

Hi, Alexa,

This is great. In the future, I may not distribute the entire document to EB group but for the first time, I may share it with them so they can see what we will get regularly.

For the last page "contact": it will be great if you can add one for EMI editorial office: [editorial@emi2012.org](mailto:editorial@emi2012.org)

Thanks.

Shan

---

**From:** Josaphouitch, Alexa <[Alexa.Josaphouitch@taylorandfrancis.com](mailto:Alexa.Josaphouitch@taylorandfrancis.com)>

**Sent:** Monday, January 27, 2020 1:35 PM

**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Subject:** RE: follow up

Hi Shan,

Thanks for sending your edits! Once the changes have been made to the award page, I will send the emails.

I've attached a draft of the EMI report. The marketing section needs to be updated, but the Singapore office is currently closed due to the New Year. Please let me know if you'd like me to make any changes.

Thanks!

Sincerely,  
Alexa

---

**Information Classification:** General

**From:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Sent:** Wednesday, January 22, 2020 11:00 AM

**To:** Josaphouitch, Alexa <[Alexa.Josaphouitch@taylorandfrancis.com](mailto:Alexa.Josaphouitch@taylorandfrancis.com)>

**Subject:** RE: follow up

See below.

---

**From:** Josaphouitch, Alexa <[Alexa.Josaphouitch@taylorandfrancis.com](mailto:Alexa.Josaphouitch@taylorandfrancis.com)>

**Sent:** Wednesday, January 22, 2020 9:51 AM

**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Subject:** RE: follow up

Hi Shan,

I've followed your format.

1. Would you like to use the language of "second place" and "third place" instead of runner up? It's not a problem to change this.  
**Yes, please change and use the second place etc. , or any wording to reflect the 2<sup>nd</sup> and 3<sup>rd</sup> places.**
2. I was unsure if you reviewed Min's edits to the emails. I've attached that here. Now that the page is created, I'll add the link to the emails and send the certificates.  
**Sorry I did not respond at the time. Yes, I have read again, and made a final version (see attached).**
3. I have been following up with our press team and will provide an update as soon as possible. I have also been talking to Sarah and Todd so this is on our radar and we are determining the best steps. I agree that this is a huge opportunity for the journal.  
**Thanks a lot!**
4. Clara recently sent an update about the most read articles page. Let me know if you have any questions.

I have been responding to her. Min also just sent her a new list. Hope she can process it soon.

5. We are firming up end-of-year numbers so I will have the report within the next two weeks. Let me know if you need this sooner for the meeting.

It will be great if you can have the 2019 EMI report (as the one you showed me earlier) as I need to reach EB members asap, with multiple reasons.

Please let me know if you have any questions!

Sincerely,  
Alexa

## Alexa Josaphouitch

Portfolio Manager - Medicine and Health Journals  
Taylor & Francis Group  
530 Walnut Street, Suite 850, Philadelphia, PA 19106  
Tel: (215) 606-4170  
Fax: (215) 207-0050  
Email: [alexa.josaphouitch@taylorandfrancis.com](mailto:alexa.josaphouitch@taylorandfrancis.com)  
Web: [www.tandfonline.com](http://www.tandfonline.com)  
(she/her/hers)

### Information Classification: General

---

**From:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Sent:** Tuesday, January 21, 2020 4:39 PM

**To:** Josaphouitch, Alexa <[Alexa.Josaphouitch@taylorandfrancis.com](mailto:Alexa.Josaphouitch@taylorandfrancis.com)>

**Cc:** 'Min Yang' <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>; Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>

**Subject:** follow up

Hi, Alexa,

I would like to follow up on a few items:

1. Best paper awards

I noticed that one area at EMI homepage was created for this announcement which looks good for the overall design. However, one paper was labeled as "2019 Winner" and the other three labeled as "2019 runner-up". This wording is somewhat different from what we used as we separated the level of awards among the last three. I wonder if we can change them back to the original wording we used?

2. Related to the same issue: did you send out the notice/award certificate to the authors? It may also be important to keep the same wording between certificate and online posting.

3. **The outbreak of a new Coronavirus infection**: it has much escalated since our last email. The first case in US has just been reported today by US CDC. So the news preparation from EMI and T&F is extremely important. Have you heard anything from T&F central news office? I plan to reach out to T&F highest level of management for this issue if I do not hear any concrete feedback.

4. We also need to update the "Browse EMI's most read articles" which is at our home page. This area was created in the 3<sup>rd</sup> quarter of 2019 with the plan that it will need to be updated each quarter. EMI office will work with you to update it and the update needs to be marketed by a mass email campaign per our design when it was set up.

5. An updated report as you prepared for me when you first joined EMI. While the one you prepared then was up to Oct 2019, I wonder if you can prepare one for entire 2019 so I can use it for our annual report to our editorial board members.



We can go over these and please feel free to let me know with any questions.

Best.

Shan

\*\*\*\*\*

Shan Lu, MD, PhD

Editor-in-Chief

Emerging Microbes and Infections (EMI)

[www.tandfonline.com/TEMI](http://www.tandfonline.com/TEMI)

[editorial@2012EMI.org](mailto:editorial@2012EMI.org)

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Sunday, February 21, 2021 7:04 PM  
**To:** Lu, Shan  
**Subject:** Re: FW: Application for APC waiver or discount

I agree it is not fair to waive for his paper. Just tell him it is the rule of EMI to waive ONLY excellent papers from developing countries. thus, regrettably, his paper cannot be waived for the publication fee. Wen

> -----原始邮件-----

> 发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>

> 发送时间: 2021-02-22 06:50:01 (星期一)

> 收件人: "M. Yu-Mei Wen (ymwen@shmu.edu.cn)" <ymwen@shmu.edu.cn>

> 抄送:

> 主题: FW: Application for APC waiver or discount

>

> Hi, Prof Wen,

>

> I would like to share with you the email I just replied to Jiang, Shibo.

>

> He submitted a short commentary with Shao Yimin and another person to promote the life virus challenge for COVID-19 vaccine development. The paper is ok although such idea is not novel and Stanley Plotkin published much better article on this topic last year. I asked Plotkin and others to provide some quick and very useful feedback within only 3 days. And the paper will be accepted when Jiang submits his revised draft.

>

> Then he suddenly asked for waiver of publishing fee which is only \$900. I can not believe he does not have money. It is just his personal habit to try to squeeze any benefit whenever he can. Giving him the waive is not fair to many other authors from developing countries. Plus, we just did him a favor to get this paper reviewed and published so soon. I am not sure whether any other high quality journal is so interested in publishing this commentary.

>

> I can talk to you over the phone to discuss further.

>

> Best.

>

> Shan

>

> -----Original Message-----

> From: Lu, Shan

> Sent: Sunday, February 21, 2021 5:42 PM

> To: 'Shibo Jiang (姜世勃)' <shibojiang@fudan.edu.cn>

> Subject: RE: Application for APC waiver or discount

>

> Hi, Shibo,

>

> Are you kidding me? I was treating your short commentary as a special case due to your past involvement with EMI. Even KY's excellent review will take longer process. I did not expect you will treat us like this.

>

> T&F APC waiver is mainly designed for people from poor developing countries so your application will not be approved. You are very famous for being the most successful business person academically and commercially. You and your co-authors are among the top funded scientists in the entire China and yet you can not afford to pay \$900? EMI will have big trouble if an APC waiver is granted to you and your co-author as it will be hard for us to face other authors from much difficult condition than you guys.

>

> I thought you told me that you have to quit EMI responsibility because you were quite sick so I am surprised to know you have published too many research articles in the last year. Usually with so many papers, the authors should have more reward with fame and funding.

>

> Since the founding of EMI, several of us as the founders have to contribute not only time but also all kinds of resources while we have not personally being paid a single penny for our service. EMI has done multiple special favors to you and your group (such as the urgent publication which led your Gates funding) because you are part of the Fudan group. We would look forward to seeing at least some basic support if not more contribution.

>

> Maybe we should consult Prof Wen to see if she thinks you are poor as she may know your situation better than anyone else.

>

> Best.

>

> Shan

>

> -----Original Message-----

> From: Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>

> Sent: Sunday, February 21, 2021 7:22 AM

> To: editorial@emi2012.org; Lu, Shan <Shan.Lu@umassmed.edu>

> Cc: Yang Min 杨旻 <minyang0216@163.com>

> Subject: Application for APC waiver or discount

>

> Dear Prof. Lu,

>

> Because of publishing too many research articles in this budget year, I do not have enough budget left to pay for the APC for publication of our Commentary (ID TEMI-2021-0175) in EMI. Here I am applying for an APC waiver or discount. I would appreciate it very much if you could approve my application and provide me an APC waiver or discount code before submission of our revised manuscript online.

>

> Thank you very much for your consideration,

>

> Shibo

> \*\*\*\*\*

> Shibo Jiang, M.D.

> Professor and Director, Institute of Medical Microbiology Key

> Laboratory of Medical Molecular Virology (MOE/NHC/CAMS) School of

> Basic Medical Sciences, Fudan University

> 131 Dong An Road, Fuxing Building, 4th Fl, Rm 413 Xuhui District,

> Shanghai 200032, China

> Phone: +86-21-54237673

> E-mail: shibojiang@fudan.edu.cn

> Website:

> <https://nam10.safelinks.protection.outlook.com/?url=http%3A%2F%2Fmedic>

> [ine.fudan.edu.cn%2Fen%2Fshow.aspx%3Finfo\\_lb%3D27%26flag%3D3%26info\\_id%](http://ine.fudan.edu.cn%2Fen%2Fshow.aspx%3Finfo_lb%3D27%26flag%3D3%26info_id%3D124&data=04%7C01%7Cshan.lu%40umassmed.edu%7C8c5a3dd7228846ae0510)

> [3D124&data=04%7C01%7Cshan.lu%40umassmed.edu%7C8c5a3dd7228846ae0510](http://ine.fudan.edu.cn%2Fen%2Fshow.aspx%3Finfo_lb%3D27%26flag%3D3%26info_id%3D124&data=04%7C01%7Cshan.lu%40umassmed.edu%7C8c5a3dd7228846ae0510)

> 08d8d6c55736%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C1%7C637495490366  
> 801285%7CUnknown%7CTWFpbGZsb3d8eyJWljoIMC4wLjAwMDAiLCJQIjoiV2luMzliLCJ  
> BTil6lk1haWwiLCJXVCI6Mn0%3D%7C3000&data=pGASzwErpq%2FDMupfDyH3WS6  
> KumWU0dJQYBTZWnw9a2U%3D&reserved=0  
> Publications:  
> https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fpubm  
> ed.ncbi.nlm.nih.gov%2F%3Fterm%3Dshibo%2Bjiang%26sort%3Ddate%26size%3D2  
> 00&data=04%7C01%7Cshan.lu%40umassmed.edu%7C8c5a3dd7228846ae051008d  
> 8d6c55736%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C1%7C637495490366801  
> 285%7CUnknown%7CTWFpbGZsb3d8eyJWljoIMC4wLjAwMDAiLCJQIjoiV2luMzliLCJBTi  
> I6lk1haWwiLCJXVCI6Mn0%3D%7C3000&data=t6ovlxBFkPaHgGRU3MLey3VpQFO5  
> l3ltQoCMWtHZk%2F4%3D&reserved=0  
>  
>  
>

>> -----原始邮件-----

>> 发件人: "Emerging Microbes and Infections"

>> <onbehalfof@manuscriptcentral.com>

>> 发送时间: 2021-02-19 23:02:23 (星期五)

>> 收件人: 14111010010@fudan.edu.cn, yshao@bjmu.edu.cn,

>> shibojiang@fudan.edu.cn

>> 抄送:

>> 主题: Emerging Microbes & Infections - Decision on Manuscript ID

>> TEMI-2021-0175

>>

>> 19-Feb-2021

>>

>> Dear Professor Jiang:

>>

>> Your manuscript entitled "Human challenge trials to assess the efficacy of currently approved COVID-19 vaccines against SARS-CoV-2 variants", which you submitted to Emerging Microbes & Infections, has been reviewed. The reviewer comments are included at the bottom of this letter.

>>

>> The reviews are in general favourable and suggest that, subject to minor revisions, your paper could be suitable for publication. Please consider these suggestions, and I look forward to receiving your revision.

>>

>> When you revise your manuscript please highlight the changes you make in the manuscript by using the track changes mode in MS Word or by using bold or coloured text.

>>

>> In addition, please submit a clean, editable version of your revised paper. These files should be in either Word (.doc) or LaTeX format. Any figures should be saved as either .ps, .eps, .tif or .jpeg file types.

>>

>> To start the revision, please click on the link below:

>>

>> \*\*\* PLEASE NOTE: This is a two-step process. After clicking on the

>> link, you will be directed to a webpage to confirm. \*\*\*

>>

>> https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fmc

>> .m

>> anuscriptcentral.com%2Ftemi%3FURL\_MASK%3De6fbe9bcea3944fca4baf20ae84

>> 87

>> 3c7&data=04%7C01%7Cshan.lu%40umassmed.edu%7C7ebf278d564248ec09e6  
>> 08  
>> d8d663588e%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637495069491  
>> 30  
>> 8875%7CUnknown%7CTWFpbGZsb3d8eyJWlloiMC4wLjAwMDAiLCJQIjoiV2luMzliLCJ  
>> BT  
>> il6lk1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=LcqHwhK1nn%2Bely3o4dokQ2p  
>> qk  
>> 2QHbNppscwmcigzfew%3D&reserved=0  
>>  
>> This will direct you to the first page of your revised manuscript. Please enter your responses to the comments made by the reviewer(s) in the space provided. You can use this space to document any changes you made to the original manuscript. Please be as specific as possible in your response to the reviewer(s).  
>>  
>> This link will remain active until you have submitted your revised manuscript. If you begin a revision and intend to finish it at a later time, please note that your draft will appear in the “Revised Manuscripts in Draft” queue in your Author Center.  
>>  
>> IMPORTANT: Your original files are available to you when you upload your revised manuscript. Please delete any redundant files before completing the submission.  
>>  
>> Because we are trying to facilitate timely publication of manuscripts submitted to Emerging Microbes & Infections, your revised manuscript should be uploaded by 21-Mar-2021. If it is not possible for you to submit your revision by this date, we may have to consider your paper as a new submission.  
>>  
>> Once again, thank you for submitting your manuscript to Emerging Microbes & Infections and I look forward to receiving your revision.  
>>  
>> Sincerely,  
>>  
>> Shan Lu  
>> Editor-in-Chief  
>> Emerging Microbes & Infections  
>>  
>>  
>> Review Editor Comments to the Author:  
>>  
>> This is an important topic and we did a fast review with input from some of the leading authorities in this area. Here is the key summary:  
>>  
>> 1. Reviewers in general agree with the authors about the need for human challenges to determine what protection is offered by current vaccines against the new strains.  
>> 2. However, the reviewers felt that the paper needs more discussion about how to do those studies. This paper is more like a public decision debate but not enough scientific and technical details to accomplish such challenge studies.  
>> 3. For example, can you extrapolate from monkey challenges to humans, as the authors suggest?  
>> 4. Does one need to challenge unvaccinated subjects to show infectivity? Do you then challenge current vaccinees with the same dose?  
>> 5. If they are resistant to the dose infectious for seronegatives, do you increase the challenge dose to determine how much current virus they can resist vs. mutant virus?  
>> 6. Is it necessary that the challenges be compared in people with the same titers, or can people with different titers be challenged?  
>> 7. Do we need to measure both IgA and IgG antibodies?

> >

> > The point here is that challenge studies must be done with a lot of insight so that the answers obtained are valid. By the way, people with high immunity will resist challenge with the mutants, but people with lower titers will not. So the protection is not a black and white with variants. Rather there is a quantitative range and different variants may be different, and may also depending on the individual vaccines. Therefore a small group of challenge studies may not truly reflect the population protection efficacy of a vaccine. It is the same idea that a lab based neutralizing assay can not predict the field vaccine protection. The authors need to be very careful not turning the small group challenge study into something like a lab based neutralizing assay.

>

>

>

>

>

---

**From:** Naveen Vankadari <naveen.vankadari@monash.edu>  
**Sent:** Sunday, October 25, 2020 9:25 PM  
**To:** Lu, Shan; ymwen@shmu.edu.cn  
**Subject:** Re: FW: Congratulations - your EMI papers are included in T&F's top ten OA articles of 2020

Dear Prof. Shan and Wen,

It was so delighting to see our research work been most cited and downloaded, and considered as one of the TOP10. It's our pleasure to publish in esteemed journal EMI and we are happy to communicate our further research articles to EMI.

Request or possiblity:

**[Emerging COVID-19 coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD2](#)**

- <https://doi.org/10.1080/22221751.2020.1739565>

On the above article, is it possible to add "DPP4" as another keyword in the keyword section?

CD26 is another name is DPP4, and few research studies lately are addressing using the word DPP4 instead of CD26. I believe the addition of the word "DPP4" in keywords will enhance views and boost citations.

Thank you and look forward to your opinion.

Sincerely,

Dr. Naveen Vankadari, MS., PhD

Research Fellow,

Monash University, Australia

On Sun, 25 Oct 2020 at 06:25, Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> wrote:

Dear Drs. Zhengli Shi/Peng Zhou, Kwok-Yung Yuen, Lishan Su/Shan-lu Liu, Taisheng Li, Yi-Wei Tang and Naveen Vankadari,

On behalf of Prof Wen and EMI, congratulations!

I assume you have received an email notice from T&F (see one sample below) that one of your EMI papers was included as one of the top 10 Open Access papers from the entire T&F family (over 2700 journals). This is from [a blog post on our Author Services website](#) (click and find the site). Attached is the PDF copy list I produced for your reference.

Your EMI papers are ranked #1, #3, #4, #5, #8 and #10, six out of top ten, for entire 2020 up to this point! This is an incredible achievement to each of you. I believe such numbers of down load read will be ranked very high with any other major publishing houses.

EMI would like to thank you for your great work and contribution to the global health effort in this difficult time with COVID-19 pandemic.

EMI is very grateful to authors like you who have made EMI one of the leading biomedical journals in the world. Your creativity, sensitivity, fact searching and out of box thinking have constantly pushed the frontier of science and medicine. EMI is proud to be part of your great endeavour.

EMI is thinking to create new tools and forums to further promote your research findings so more people can be benefited. In the near future, EMI will launch an “EMI Virtual Journal Club (VJC)” program in which each time, one leading EMI paper will be presented by the original authors online, open to the global scientific community so the authors of scientific papers will be able to have direct communications with their readers. Your papers will be the candidates for our initial launch. More details will be shared with you soon and I would like to invite you to be part of our first group of VJC authors.

Best.

Shan

---

**From:** Bergan, Rachel <[Rachel.Bergan@tandf.co.uk](mailto:Rachel.Bergan@tandf.co.uk)>  
**Sent:** Thursday, October 22, 2020 5:10 PM  
**To:** Tang, Yi-Wei <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>  
**Subject:** Your paper features in T&F's top ten OA articles of 2020

Dear Yi-Wei,

I'm very pleased to let you know that your recent article “Laboratory diagnosis of emerging human coronavirus infections – the state of the art” was one of the most-downloaded open access articles published by Taylor & Francis so far this year.



Many congratulations!

To mark Open Access Week, we have published [a blog post on our Author Services website](#) about the Top 10, including links to the articles, and details of each Altmetric score to reflect the discussion of your article online and in the media.

**This is a great excuse to further highlight your research to your contacts and communities.** We will be promoting the blog post on our social media platforms: [Twitter](#), [LinkedIn](#), and [Facebook](#). You could share our posts/tweets or write your own (please use the same hashtags).

We'll also be featuring the Top 10 in our [Insights newsletter](#), to further reach researchers and the wider academic community.

Please do not hesitate to contact me if you have any further questions or queries.

Kind Regards,

Rachel

Rachel Bergan (she/her)

Communications Coordinator

Taylor & Francis Group

Email: [rachel.bergan@tandf.co.uk](mailto:rachel.bergan@tandf.co.uk)

Tel: +44 (0) 20 755 19259

4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN, UK

## 4 skills for researchers of the future



### Information Classification: General

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

--  
--

Dr. NAVEEN VANKADARI M.S., PhD  
Research Fellow

**Monash Biomedicine Discovery Institute**  
**Faculty of Medicine, Nursing and Health Science**  
Monash University  
Level G 11, 19 Innovation Walk, Clayton Campus  
Wellington Road, Clayton, VIC 3800  
Australia

T: +61 3 990 29229 M: +61 0 416074778  
E: [naveen.vankadari@monash.edu](mailto:naveen.vankadari@monash.edu)

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Saturday, October 24, 2020 9:21 PM  
**To:** Lu, Shan  
**Subject:** Re: FW: Congratulations - your EMI papers are included in T&F's top ten OA articles of 2020

Thank you Shan, for informing all authors. Thank you again for your thoughtfulness, and your contribution to EMI. Wen

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>

**Sent Time:** 2020-10-25 03:25:03 (Sunday)

**To:** "Tang, Yi-Wei" <yi-wei.tang@cepheid.com>, kyyuen <kyyuen@hku.hk>, "石正丽" <zlshi@wh.iov.cn>, "Liu, Shan-Lu" <liu.6244@osu.edu>, "Naveen Vankadari" <naveen.vankadari@monash.edu>, "Su, Lishan" <lishan\_su@med.unc.edu>, "litsh@263.net" <litsh@263.net>, "peng.zhou@wh.iov.cn" <peng.zhou@wh.iov.cn>

**Cc:** "M. Yu-Mei Wen (ymwen@shmu.edu.cn)" <ymwen@shmu.edu.cn>, "Martin martin" <winter999@hotmail.com>, "Josaphouitch, Alexa" <Alexa.Josaphouitch@taylorandfrancis.com>, "Qiao, Jessica" <Jessica.Qiao@tandfchina.com>, "Min Yang" <min.yang@emi2012.org>, "editorial2@emi2012.org" <editorial2@emi2012.org>

**Subject:** FW: Congratulations - your EMI papers are included in T&F's top ten OA articles of 2020

Dear Drs. Zhengli Shi/Peng Zhou, Kwok-Yung Yuen, Lishan Su/Shan-lu Liu, Taisheng Li, Yi-Wei Tang and Naveen Vankadari,

On behalf of Prof Wen and EMI, congratulations!

I assume you have received an email notice from T&F (see one sample below) that one of your EMI papers was included as one of the top 10 Open Access papers from the entire T&F family (over 2700 journals). This is from [a blog post on our Author Services website](#) (click and find the site). Attached is the PDF copy list I produced for your reference.

Your EMI papers are ranked #1, #3, #4, #5, #8 and #10, six out of top ten, for entire 2020 up to this point! This is an incredible achievement to each of you. I believe such numbers of down load read will be ranked very high with any other major publishing houses.

EMI would like to thank you for your great work and contribution to the global health effort in this difficult time with COVID-19 pandemic.

EMI is very grateful to authors like you who have made EMI one of the leading biomedical journals in the world. Your creativity, sensitivity, fact searching and out of box thinking have constantly pushed the frontier of science and medicine. EMI is proud to be part of your great endeavour.

EMI is thinking to create new tools and forums to further promote your research findings so more people can be benefited. In the near future, EMI will launch an “EMI Virtual Journal Club (VJC)” program in which each time, one leading EMI paper will be presented by the original authors online, open to the global scientific community so the authors of scientific papers will be able to have direct communications with their readers. Your papers will be the candidates for our initial launch. More details will be shared with you soon and I would like to invite you to be part of our first group of VJC authors.

Best.

Shan

---

**From:** Bergan, Rachel <[Rachel.Bergan@tandf.co.uk](mailto:Rachel.Bergan@tandf.co.uk)>  
**Sent:** Thursday, October 22, 2020 5:10 PM  
**To:** Tang, Yi-Wei <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>  
**Subject:** Your paper features in T&F's top ten OA articles of 2020

Dear Yi-Wei,

I'm very pleased to let you know that your recent article “Laboratory diagnosis of emerging human coronavirus infections – the state of the art” was one of the most-downloaded open access articles published by Taylor & Francis so far this year.

Many congratulations!

To mark Open Access Week, we have published [a blog post on our Author Services website](#) about the Top 10, including links to the articles, and details of each Altmetric score to reflect the discussion of your article online and in the media.

**This is a great excuse to further highlight your research to your contacts and communities.** We will be promoting the blog post on our social media platforms: [Twitter](#), [LinkedIn](#), and [Facebook](#). You could share our posts/tweets or write your own (please use the same hashtags).

We'll also be featuring the Top 10 in our [Insights newsletter](#), to further reach researchers and the wider academic community.

Please do not hesitate to contact me if you have any further questions or queries.

Kind Regards,

Rachel

Rachel Bergan (she/her)

Communications Coordinator

Taylor & Francis Group

Email: [rachel.bergan@tandf.co.uk](mailto:rachel.bergan@tandf.co.uk)

Tel: +44 (0) 20 755 19259

4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN, UK



Information Classification: General

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

\*\*\*\*\*

**From:** YiWei Tang <yiweitangmd@gmail.com>  
**Sent:** Saturday, May 9, 2020 7:31 PM  
**To:** Lu, Shan  
**Cc:** wen yumei;  
**Subject:** Re: Fw: Emerging microbes & infections

I remembered this manuscript. Maybe Min can give reviewers a gentle reminder?

I know as the money period is over, no journals can now process COVID-19 papers as quickly as previously.

Yi-Wei

On Sat, May 9, 2020 at 10:25 AM Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> wrote:

I responded to your wechat earlier. Please check it.

It is a normal timing for such review. It will take about 1 week to go through QC and initial screening. Then outside peer review will take at least 2 weeks. So the total is minimally 21 days. So far, from April 25 to May 8, it is only 13 days. Let the authors to wait. Otherwise they can withdraw if they like.

Shan

**From:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
**Sent:** Friday, May 8, 2020 9:58 PM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; YiWei Tang <[yiweitangmd@gmail.com](mailto:yiweitangmd@gmail.com)>  
**Cc:** Yang Min <[minyang0216@163.com](mailto:minyang0216@163.com)>  
**Subject:** Fw: Fw: Emerging microbes & infections

This letter was submitted on April 25th. Please check, as this is still under review. YMW

-----The original message-----

发件人: "CHEN WEI" <[cw0226@foxmail.com](mailto:cw0226@foxmail.com)>

Sending time : 2020-05-09 06:50:43 (Saturday)

Write Face : "Mei Wen 玉 hospital 士" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>

CC :

Subject : Fw: Emerging microbes & infections

Hello, Mr. Wen, the attachment is the submission, thank you!

1

---

## Page 2

Chen Wei

---Original---

**From:** "董韵竹" <[13811429044@163.com](mailto:13811429044@163.com)>

**Date:** Sat, May 9, 2020 06:48 AM

**To:** "CHEN WEI" <[cw0226@foxmail.com](mailto:cw0226@foxmail.com)>;

**Subject:** Emerging microbes & infections

Mr. Chen, the attached compressed file is the manuscript submitted to EMI.

Rhyme





---

**From:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
**Sent:** Thursday, March 11, 2021 9:37 PM  
**To:** wen yumei; Lu, Shan  
**Cc:** zhangwenhong; yuan zhenghong; Martin martin  
**Subject:** RE: FW: EMI - Retraction draft for "A leptospiral AAA+ chaperone-Ntn peptidase complex..."

Thank you, Shan and Teacher Wen, for sharing this information. I wonder if it is possible to find and generate a "black name/institution" list so our review editor and reviewers can get a pre-attention on this in our future processing.

Yi-Wei

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Friday, March 12, 2021 10:33 AM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Cc:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>; zhangwenhong <zhangwenhong@fudan.edu.cn>; yuan zhenghong <zhyuan@shmu.edu.cn>; Martin martin <winter999@hotmail.com>  
**Subject:** Re: FW: EMI - Retraction draft for "A leptospiral AAA+ chaperone-Ntn peptidase complex..."

The decision of T&F is important and timely. Also, this decision is made under strict scientific investigation. I hope ZHYuan will inform his group as well as other groups in our lab, and ask the PIs to be very careful in publishing papers.  
YM  
Wen

-----原始邮件-----

发件人:"Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
发送时间:2021-03-12 05:58:16 (星期五)  
收件人: "M. Yu-Mei Wen ([ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn))" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>, "Tang, Yi-Wei" <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>, zhangwenhong <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>, "yuan zhenghong" <[zhyuan@shmu.edu.cn](mailto:zhyuan@shmu.edu.cn)>, "Martin martin" <[winter999@hotmail.com](mailto:winter999@hotmail.com)>  
抄送:  
主题: FW: EMI - Retraction draft for "A leptospiral AAA+ chaperone-Ntn peptidase complex..."

Dear Prof Wen and other colleagues,

I would like to inform you that one of EMI papers published in 2017 will be retracted by T&F after a lengthy investigation. There are certain image issues in that published paper. There is a special group at T&F dedicated to such issues and they made this decision. T&F was in charge of this investigation and has kept me and Prof Wen updated.

There is another paper from the same group/PI with some image issues. However, on that paper, the decision from T&F is to allow a correction with authors' new data/photo. That decision will come out later.

It is very unfortunate that we are seeing more of such patterns in scientific publishing. Luckily EMI has been doing a good job and we have not received much complaints except this group. We all need to pay attention and educate our students and even colleagues about the potential damage of such mistakes to their work and reputation. EMI also has to be very careful to monitor and prevent such issues as it can ruin our reputation very quickly.

Please feel free to let me know if you have any questions/comments.

Best.

Shan

---

**From:** Josaphouitch, Alexa <[Alexa.Josaphouitch@taylorandfrancis.com](mailto:Alexa.Josaphouitch@taylorandfrancis.com)>  
**Sent:** Thursday, March 11, 2021 3:10 PM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** EMI - Retraction draft for "A leptospiral AAA+ chaperone–Ntn peptidase complex..."

Dear Shan,

Attached is the retraction statement for article, "[A leptospiral AAA+ chaperone–Ntn peptidase complex, HslUV, contributes to the intracellular survival of Leptospira interrogans in hosts and the transmission of leptospirosis.](#)" I will send this to the authors today for their review as well.

Thank you!


Sincerely,

Alexa

**Alexa Josaphouitch**

Portfolio Manager for Hematology and Immunology Journals  
Taylor & Francis Group  
530 Walnut Street, Suite 850, Philadelphia, PA 19106

Tel: (212) 600-3459  
Fax: (215) 207-0050  
Email: [alexa.josaphouitch@taylorandfrancis.com](mailto:alexa.josaphouitch@taylorandfrancis.com)  
Web: [www.tandfonline.com](http://www.tandfonline.com)  
(she/her/hers)



Information Classification: General

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Wednesday, November 13, 2019 8:25 PM  
**To:** Lu, Shan; tangy  
**Subject:** Re: FW: EMI presubmission enquiry

If the mechnaism is relevant for development of antifungal strategy, then ,that is acceptable. Wen

-----原始邮件-----

发件人:"Lu, Shan" <Shan.Lu@umassmed.edu>  
发送时间:2019-11-13 21:17:22 (星期三)  
收件人: "tangy@mskcc.org" <tangy@mskcc.org>  
抄送: "wen yumei" <ymwen@shmu.edu.cn>  
主题: FW: EMI presubmission enquiry

Hi, Yi-wei,

What do you think about this paper. *Candida albicans is not an emerging infection. The new mechanism may be interesting but if it is not an emerging infection, how significant it is?*

Shan

**From:** Guanghai Huang [mailto:huanggh@fudan.edu.cn]  
**Sent:** Wednesday, November 13, 2019 2:51 AM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Cc:** ymwen@shmu.edu.cn  
**Subject:** EMI presubmission enquiry

Dear Profs. Lu and Wen,

I am writing to inquire if our manuscript (see the attached file) is fit for the scope of EMI. To our knowledge, this is the first study to uncover the genetic regulatory mechanism of mating projection development in the major human fungal pathogen *Candida albicans*. This biology process is important for sexual reproduction in *C. albicans* and is thus important for the development of antifungal resistance and the evolution of new traits.

Thank you in advance for your consideration!

Best regards,

Guanghua

Guanghua Huang, Ph.D

State Key Laboratory of Genetic Engineering

School of Life Sciences

Fudan University

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Thursday, August 22, 2019 9:33 PM  
**To:** Lu, Shan  
**Subject:** Re: FW: Invitation to join EMI as an editorial member

Sure.I have known him for many years. YM

-----原始邮件-----

发件人:"Lu, Shan" <Shan.Lu@umassmed.edu>  
发送时间:2019-08-23 09:11:31 (星期五)  
收件人: "wen yumei" <ymwen@shmu.edu.cn>  
抄送:  
主题: FW: Invitation to join EMI as an editorial member

Dear Prof Wen,

For your information, Prof Malik Peiris has been added to the EMI Editorial Board who was nominated last year but only had time to finish his appointment. He is a very prominent virologist and US NAC member, with great work in emerging infections.

Shan

---

**From:** malik [mailto:malik@hku.hk]  
**Sent:** Thursday, August 22, 2019 8:44 PM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Cc:** min.yang@emi2012.org; 'Yu, Min' <Min.Yu@tandfchina.com>  
**Subject:** RE: Invitation to join EMI as an editorial member

Dear Shan,

Find below. Please edit or change as required to fit the format you need. Let me know if this needs to be modified or adjusted.

Malik Peiris is a clinical and public health virologist with a particular interest in emerging virus disease at the animal-human interface using a “One Health” approach, including influenza, coronaviruses (SARS, MERS), arboviruses and others. His current research encompasses the pathogenesis, innate immune responses, transmission, ecology and epidemiology of human and animal (poultry, swine, wild birds) influenza viruses and coronaviruses (SARS, MERS) in humans and animals. He was elected a Fellow of the Royal Society of London in 2006, Fellow of the American Academy of Microbiology in 2016 and Foreign Associate of National Academy of Sciences in 2017.

Malik

---

**From:** Lu, Shan [<mailto:Shan.Lu@umassmed.edu>]  
**Sent:** Friday, August 23, 2019 2:31 AM  
**To:** malik <[malik@hku.hk](mailto:malik@hku.hk)>  
**Cc:** [min.yang@emi2012.org](mailto:min.yang@emi2012.org); 'Yu, Min' <[Min.Yu@tandfchina.com](mailto:Min.Yu@tandfchina.com)>  
**Subject:** RE: Invitation to join EMI as an editorial member

Dear Malik,

Hope this email will find you well. I wonder if you can send me a short bio so we can add your name to EMI editorial board list at EMI web site.

Best.

Shan



---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Monday, May 18, 2020 4:51 AM  
**To:** Tang, Yi-Wei  
**Cc:** Lu, Shan  
**Subject:** Re: FW: Letter from the Curator-in-Chief - May 10th 2020

Good work。 thanks.YMW

-----Original Messages-----

**From:** "Tang, Yi-Wei" <yi-wei.tang@cepheid.com>  
**Sent Time:** 2020-05-16 13:41:49 (Saturday)  
**To:** "Lu, Shan" <Shan.Lu@umassmed.edu>, "Yumei Wen (ymwen@shmu.edu.cn)" <ymwen@shmu.edu.cn>  
**Cc:**  
**Subject:** FW: Letter from the Curator-in-Chief - May 10th 2020

FYI.

---

**From:** Nguyen, Khoi Nguyen <NNguyen@asmusa.org>  
**Sent:** Thursday, May 14, 2020 10:02 PM  
**To:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>; Lynn W. Enquist (lenquist@Princeton.EDU) <lenquist@Princeton.EDU>; Covid-19 Registry <Covid-19registry@asmusa.org>  
**Subject:** RE: Letter from the Curator-in-Chief - May 10th 2020

Hello Yi-Wei,

Thanks for recommending these resources. Lynn has approved to post the special edition of the COVID-19 EMI journal. We will post them soon.

For CLSI guidelines, I will link to the free COVID resources that they offer.

Thanks,

Nguyen

---

**From:** Tang, Yi-Wei <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>  
**Sent:** Tuesday, May 12, 2020 11:18 PM  
**To:** Lynn W. Enquist ([lenquist@Princeton.EDU](mailto:lenquist@Princeton.EDU)) <[lenquist@Princeton.EDU](mailto:lenquist@Princeton.EDU)>; Covid-19 Registry <[Covid-19registry@asmusa.org](mailto:Covid-19registry@asmusa.org)>  
**Subject:** FW: Letter from the Curator-in-Chief - May 10th 2020

Lynn,

This is a unique one that journal EMI is doing for COVID-19 researches. Please advise if this could be a Research Resource for our Registry.

Thank you, Yi-Wei

---

**From:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Sent:** Wednesday, May 13, 2020 9:59 AM  
**To:** Tang, Yi-Wei <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>  
**Subject:** RE: Letter from the Curator-in-Chief - May 10th 2020

<https://think.taylorandfrancis.com/emerging-reemerging-coronaviruses/>

---

**From:** Tang, Yi-Wei <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>  
**Sent:** Tuesday, May 12, 2020 9:55 PM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** FW: Letter from the Curator-in-Chief - May 10th 2020

Shan,

Are there any unique resources at EMI site or related places that I can recommend to ASM COVID-19 Registry?

Yi-Wei

---

**From:** Enquist, Lynn W. <[lenquist@Princeton.EDU](mailto:lenquist@Princeton.EDU)>  
**Sent:** Tuesday, May 12, 2020 10:00 PM  
**To:** Tang, Yi-Wei <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>  
**Cc:** Covid-19 Registry <[Covid-19registry@asmusa.org](mailto:Covid-19registry@asmusa.org)>; Weigang Qiu ([Weigang@GENECTR.HUNTER.CUNY.EDU](mailto:Weigang@GENECTR.HUNTER.CUNY.EDU)) <[Weigang@genectr.hunter.cuny.edu](mailto:Weigang@genectr.hunter.cuny.edu)>  
**Subject:** Re: Letter from the Curator-in-Chief - May 10th 2020

Thank you. Very interesting resource indeed.

Lynn

Sent from my iPhone

On May 11, 2020, at 9:54 PM, Tang, Yi-Wei <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)> wrote:

Lynn,

Please allow me to recommend below to our COVID-19 Registry as a **Research Resource**.

Thank you.

Yi-Wei

---

**From:** Weigang Qiu <[Weigang@GENECTR.HUNTER.CUNY.EDU](mailto:Weigang@GENECTR.HUNTER.CUNY.EDU)>

**Sent:** Tuesday, May 12, 2020 12:27 PM

**To:** Tang, Yi-Wei <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>

**Subject:** RE: Letter from the Curator-in-Chief - May 10th 2020

Title: CoV Genome Tracker

Link: <http://cov.genometracker.org/>

Reference: Akther S., E. Bezrucenkovas, B. Sulkow, C. Panlasigui, L. Li, W.Qiu & L. Di (2020). CoV Genome Tracker: tracing genomic footprints of Covid-19 pandemic. doi: <https://doi.org/10.1101/2020.04.10.036343>

A brief description:

The CoV Genome Tracker aims for real-time tracking of Covid-19 pandemic based on genome sequences and associated metadata released to the GISAID database

([www.gisaid.org](http://www.gisaid.org)). It provides real-time comparative analysis of SARS-CoV-2 genomes, including viral phylogeny, geographic origins, and genome mutations. A companion web browser provides a broader evolutionary context including gene-by-gene sequence alignments, phylogenetic trees, and sequence variability at each codon positions.

The CoV Genome Tracker is similar to the CoV Genome Browser maintained by Neststrain.org (<https://nextstrain.org/ncov/global>) in data source and scope. The CoV Genome Tracker is however novel in using an interactive phylogenetic network, which is a more accurate model than phylogenetic tree for the newly evolved SARS-CoV-2 populations.

Typical usages of CoV Genome Tracker include:

- Epidemiology: One could search and browse viral information by geographic origins, isolate names, and phylogenetic positions.
  - Research: One could browse mutational changes, viral phylogeny, and codon-by-code sequence variability.
  - Education & presentation: One could use it as an interactive teaching tool (for CoV genome structure, phylogeny, and evolution), as well as a presentation tool (for a live audience or using screenshots).
- 

Weigang Qiu, Ph.D. Professor

Department of Biological Sciences

Hunter College of the City University of New York

Belfer Research Building

413 East 69th Street, Room 402

New York, NY 10021

Office Tel: 1-212-896-0445

Lab Tel: 1-212-896-0446

Fax: 212-772-5227

Email: [weigang@genectr.hunter.cuny.edu](mailto:weigang@genectr.hunter.cuny.edu)

Lab website: <http://diverge.hunter.cuny.edu/labwiki/>

Google

Map: <https://www.google.com/maps/place/413+E+69th+St,+New+York,+NY+10021/@40.7655886,-73.9561743,17z/data=!3m1!4b1!4m2!3m1!1s0x89c258c3d235f76f:0x4f3d0d5d8a78fe6?hl=en>

Google Scholar:

[https://scholar.google.com/citations?hl=en&user=Ds6u39QAAAAJ&view\\_op=list\\_works&sortby=pubdate](https://scholar.google.com/citations?hl=en&user=Ds6u39QAAAAJ&view_op=list_works&sortby=pubdate)

NCBI Publications:

<https://www.ncbi.nlm.nih.gov/myncbi/browse/collection/42770924/?sort=date&direction=descending>

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Tuesday, November 10, 2020 8:41 PM  
**To:** Lu, Shan  
**Subject:** Re: FW: RE: CONFIDENTIAL: Image concerns in EMI Article

Thanks. Got it. Wen

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:** 2020-11-11 01:03:12 (Wednesday)  
**To:** "M. Yu-Mei Wen (ymwen@shmu.edu.cn)" <ymwen@shmu.edu.cn>  
**Cc:**  
**Subject:** FW: RE: CONFIDENTIAL: Image concerns in EMI Article

Dear Prof Wen,

I would like to give you an update on the inquiry to two EMI papers from Dr. Yan Jie's lab.

The authors and T&F have communicated back and forth a few times. Ms. Alexa Josaphouitch, the manager in charge of EMI, sent the most recent email (below) to authors. It is a good summary on what have been presented and reviewed (different color means each round of discussion).

I just had the regular monthly meeting with T&F this morning. The potential decision on these two papers is that they may have to be retracted by T&F if the authors failed to provide evidence that can support the original data.

Let me know if you have any questions.

Best.

Shan

---

**From:** Josaphouitch, Alexa <Alexa.Josaphouitch@taylorandfrancis.com>  
**Sent:** Monday, November 9, 2020 3:26 PM  
**To:** med\_bp@zju.edu.cn  
**Cc:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Subject:** RE: RE: CONFIDENTIAL: Image concerns in EMI Article

Dear Shilei Dong, Xu'ai Lin, and Jie Yan,

Thank you for providing images for Figures 4, 6, & 7. Unfortunately, they are not in the format we requested. Our reasons are as follows:

- Figure 1A-D PCR & blot: **Not provided. Per author, it is lost. It is the author's responsibility to keep track of these images, so we cannot accept this excuse. 10/21.** 1A: provided, matches article. 1B: image is cropped – we need the full blot and all lanes. 1C: provided, matches article, unusual horizontal line in blots. 1D: images are cropped – we need the full blot and all lanes.
- Figure 3C&E blot: **Not provided. Per author, it is lost. It is the author's responsibility to keep track of these images, so we cannot accept this excuse.**

10/21. 3C&E: images are cropped – we need the full blot and all lanes.

- Figure 4 cell stains: **Authors say “we provide the individual, uncropped, unprocessed image of Figure 4A.” However, the images provided are not the originals. This is evident by the low quality of the figures, which, while saved as TIF images, are only 72 dpi. The Olympus confocal microscope used in your study would not produce original images with this low quality. The minimum publishing standard is 300 dpi, so the images you've provided meet only 25% of the expected quality.**

10/21: higher quality images not provided.

- Figure 6 cell stains: **Authors “guess...cells in figure 6A simply looked similar after being fixed and stained.” This is highly unlikely to occur in nature and the images the author has provided are not the originals, for the same reasons as Figure 4, above.**

10/21: higher quality images not provided.

- Figure 7A histopathology: **Authors say “one image of Figure 7E, which was not part of this experiment, was inadvertently used during preparation of the figures since they look similar and are stored in the same folder.” The author's response does not address why the image appears in other manuscripts with different color staining. Additionally, the images provided are not the originals, for the same reasons as figures 4 and 6, above.**

10/21: higher quality images not provided.

- Figure 7B histopathology: **The images provided are not the originals, for the same reasons as figures 4, 6, and 7A, above.**

10/21: higher quality images not provided.

- Figure 7E cell stains: Authors say the repeating image was a mistake and speculate how this could have occurred. Again, it is the author's, not his collaborators, responsibility to keep track of these images. They are presented in 3 different papers as results of 3 different experiments. Only one experiment/article can be valid. Furthermore, the images are not the originals. This is evident because, for example, the image provided for panel 7D/hslUV ("untitled0121.tif") appears in another article (Kassegne, 2014) within a larger image. This shows that the image you've provided is cropped and not the original, full-framed image.

10/21: labeled incorrectly as 7D. Image is not the original – it has a rectangular red frame that does not match the square frame within figure 7E.

In summary, none of the images you've provided support the integrity of your article. If you cannot provide the original images, please provide an acceptable justification. If you are unable to justify the problems I've listed above in your next email, we will be unable to consider a correction due to the magnitude of errors.

Additionally, please note we are pending a response regarding your other article, "[A novel Fas-binding outer membrane protein and lipopolysaccharide of Leptospira interrogans induce macrophage apoptosis through the Fas/FasL-caspase-8/-3 pathway.](#)" Please keep our expectations in mind when you are able to respond.

Please provide a response or an update **by Nov. 23.**

Sincerely,

Alexa Josaphouitch

Portfolio Manager for Hematology and Immunology Journals

Taylor & Francis Group

530 Walnut Street, Suite 850, Philadelphia, PA 19106

Tel: (215) 606-4170

Fax: (215) 207-0050

Email: [alexa.josaphouitch@taylorandfrancis.com](mailto:alexa.josaphouitch@taylorandfrancis.com)

Web: [www.tandfonline.com](http://www.tandfonline.com)

(she/her/hers)

From: [med\\_bp@zju.edu.cn](mailto:med_bp@zju.edu.cn) <[med\\_bp@zju.edu.cn](mailto:med_bp@zju.edu.cn)>

Sent: Wednesday, October 21, 2020 10:46 AM

To: Josaphouitch, Alexa <[Alexa.Josaphouitch@taylorandfrancis.com](mailto:Alexa.Josaphouitch@taylorandfrancis.com)>



Cc: [Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)

Subject: Re: RE: CONFIDENTIAL: Image concerns in EMI Article

Dear Dr. Alexa Josaphouitch,

We have received your letter of October 7th, and thanks for your comments. We rechecked, sought and provided the images that you mentioned in your last letter. We are sorry that we did not provide the images related to PCR & Western blot in our last email for misunderstanding your point, and we provide these images in the attachment this time. Those 72dpi-images of Figure 4A and 6A provided in our last email are indeed the true uncropped, unprocessed original images, and they were directly captured and exported from the Olympus FV10-ASW software that connects to the Olympus confocal microscope FV1000. It is worth mentioning that the Olympus FV10-ASW software, a typical software used in the confocal microscopy, can only export 72dpi-image. In order to improve the print resolution and meet the requirements of submission instructions of the journal, we adjusted the 72dpi of the image to 300 dpi during assembling the Figure 4 & 6. Those 72dpi-images of Figure 7A & 7B provided in our last email are also indeed the true original images. They were directly captured from the cellSens Standard Software that connects to the Olympus BX61 microscope and can only export 72dpi-image. Then the images were adjusted to 300 dpi, for the same reasons as Figure 4A & 6A mentioned above. As requested, the point-by-point responses to your other questions are provided in an attached file named "point-by-point response letter" in detail.

The all images mentioned above will be sent by the first author's email ([dsl166@126.com](mailto:dsl166@126.com)), because of this mailbox may not be able to successfully send large attachment.

We sincerely request the journal to give us a chance for corrigendum. Thank you for your kind consideration.

Best regards,

Shilei Dong (the first author)

Xu'ai Lin

Jie Yan

-----原始邮件-----

发件人:"Josaphouitch, Alexa" <[Alexa.Josaphouitch@taylorandfrancis.com](mailto:Alexa.Josaphouitch@taylorandfrancis.com)>

发送时间:2020-10-07 23:44:14 (星期三)

收件人:"[med\\_bp@zju.edu.cn](mailto:med_bp@zju.edu.cn)" <[med\\_bp@zju.edu.cn](mailto:med_bp@zju.edu.cn)>

抄送:"[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

主题: RE: CONFIDENTIAL: Image concerns in EMI Article

Dear Shilei Dong, Xu'ai Lin, and Jie Yan,

Thank you for providing images for Figures 4, 6, & 7. Unfortunately, they are not in the format we requested. Our reasons are as follows:

- Figure 1A-D PCR & blot: **Not provided. Per author, it is lost. It is the author's responsibility to keep track of these images, so we cannot accept this.**
- Figure 3C&E blot: **Not provided. Per author, it is lost. It is the author's responsibility to keep track of these images, so we cannot accept this.**
- Figure 4 cell stains: **Authors say, "we provide the individual, uncropped, unprocessed image of Figure 4A." However, the images provided are not the originals. This is evident by the low quality of the figures, which, while saved as TIF images, are only 72 dpi. The Olympus confocal microscope used in your study would not produce original images with this low quality. The minimum publishing standard is 300 dpi, so the images provided meet only 25% of the expected quality.**
- Figure 6 cell stains: **Authors "guess...cells in figure 6A simply looked similar after being fixed and stained." This is highly unlikely to occur in nature and the images the author has provided are not the originals, for the same reasons as Figure 4, above.**
- Figure 7A histopathology: **Authors say, "one image of Figure 7E, which was not part of this experiment, was inadvertently used during preparation of the figures since they look similar and are stored in the same folder." The author's response does not address why the image appears in other manuscripts with different color staining. Additionally, the images provided are not the originals, for the same reasons as figures 4 and 6, above.**
- Figure 7B histopathology: **The images provided are not the originals, for the same reasons as figures 4, 6, and 7A, above.**
- Figure 7E cell stains: **Authors say the repeating image was a mistake. Again, it is the author's responsibility to keep track of these images. They are presented in 3 different papers as results of 3 different experiments. Only one experiment/article can be valid. Furthermore, the images are not the originals. This is evident because, for example, the image provided for panel 7D/hsiUV ("untitled0121.tif") appears in another article (Kassegne, 2014) within a larger image. This shows that the image provided is cropped and not the original, full-framed image.**

In summary, none of the images provided support the integrity of the article. If you cannot provide the original images, please provide an acceptable justification. If you are unable to justify the problems listed above in your next email, we will be unable to consider a correction due to the magnitude of errors.

Please respond **by October 21.**

Sincerely,

# Alexa Josaphouitch

Portfolio Manager for Hematology and Immunology Journals

Taylor & Francis Group

530 Walnut Street, Suite 850, Philadelphia, PA 19106

Tel: (215) 606-4170

Fax: (215) 207-0050

Email: [alexa.josaphouitch@taylorandfrancis.com](mailto:alexa.josaphouitch@taylorandfrancis.com)

Web: [www.tandfonline.com](http://www.tandfonline.com)

(she/her/hers)

**From:** [med\\_bp@zju.edu.cn](mailto:med_bp@zju.edu.cn) <[med\\_bp@zju.edu.cn](mailto:med_bp@zju.edu.cn)>

**Sent:** Thursday, September 24, 2020 5:08 AM

**To:** Josaphouitch, Alexa <[Alexa.Josaphouitch@taylorandfrancis.com](mailto:Alexa.Josaphouitch@taylorandfrancis.com)>

**Cc:** [Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)

**Subject:** Re: CONFIDENTIAL: Image concerns in EMI Article

Dear Dr. Alexa Josaphouitch,

Thank you for bringing these issues to our attention. We have checked the data carefully after we received the comments from you and PubPeer about our publication in Emerging Microbes & Infections in 2017 (A leptospiral AAA+ chaperone–Ntn peptidase complex, HslUV, contributes to the intracellular survival of *Leptospira interrogans* in hosts and the transmission of leptospirosis). We found that one image of Figure 7E, which was not part of this experiment, was inadvertently used during preparation of the figures since they look similar and are stored in the same folder. In addition, some panels appear to be showing similar *Leptospira* cells in Figure 6A, and we are not yet sure the cause of this issue, but we did not manipulate the images intentionally. Our guess is that these *Leptospira* cells in figure 6A simply looked similarly after being fixed and stained. We repeated this experiments several times at that time, and we also provide alternative images of our repeated experiments this time, which give similar results. The experiments were designed and completed by us in our laboratory after the idea of this research was put forward. We are very sorry for these issues which appeared in our publication, but we believe that the mistake in Figure 7E and issues in Figure 6A do not affect the conclusion of this study. The point-by-point responses to the comments from PubPeer are provided in an attached file named “point by point response letter”.

As requested, we provide the individual uncropped, unprocessed image of Figure 4A, Figure 6A, and Figure 7A, B&E in the attachment. The red frames on some original pictures indicate the areas which chosen for the publication. In addition, we provide part of the related original data not shown in the publication in another folder in the attachment. The PCR and western blot assays for the detection of leptospiral *hslU* and *hslV* genes and their expression products were carried out in our laboratory from the year 2011 to 2014, and the corresponding figures are Figures 1A, B, C&D, Figures 3C&E, Supplementary Figure S2A&B, Supplementary Figure S3A&B, and Supplementary Figure S4A&E respectively. During this period, we usually stored one copy of the cropped images that we need from the common computer connected to Image Analyzer (Bio-Rad, Hercules, CA, USA) just after the images of the gels or western blot membranes were captured, while the corresponding original pictures were routinely saved in the common computer for backup. We tried to find out the original, but they have been cleared from the computer during regular maintenance. We are very sorry for this mistake, and can repeat the experiments if necessary.

The first author will send you the original figures from his email at the same time.

We sincerely request the journal to give us a chance for corrigendum. Thank you for your kind consideration.

Best regards,

Shilei Dong (the first author)

Xu'ai Lin

Jie Yan

5:07 PM, Sep. 24, 2020

-----原始邮件-----

发件人: "Josaphouitch, Alexa" <[Alexa.Josaphouitch@taylorandfrancis.com](mailto:Alexa.Josaphouitch@taylorandfrancis.com)>

发送时间: 2020-09-11 00:08:44 (星期五)

收件人: "[lxai122@163.com](mailto:lxai122@163.com)" <[lxai122@163.com](mailto:lxai122@163.com)>, "[med\\_bp@zju.edu.cn](mailto:med_bp@zju.edu.cn)" <[med\\_bp@zju.edu.cn](mailto:med_bp@zju.edu.cn)>

抄送: "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

主题: CONFIDENTIAL: Image concerns in EMI Article

Dear Dr. Lin and Dr. Yan,

I am writing to you today in regards to your article, "[A leptospiral AAA+ chaperone–Ntn peptidase complex, HslUV, contributes to the intracellular survival of Leptospira interrogans in hosts and the transmission of leptospirosis](#)" published in *Emerging Microbes & Infections*. It has come to our attention [via PubPeer](#) that some images in this paper may have been manipulated. The alleged manipulation relates to Figures 6 & 7.

At this stage I would appreciate if you could please provide me with an explanation for the alleged image manipulation. I also request that you provide the original raw images used for:

1. PCR (gel electrophoresis) in Figures 1A&C as well as supplementary figures;
2. Western blots in Figures 1B&D and 3C&E as well as supplementary figures;
3. Cell staining images in Figures 4A, 6A, and 7A, B, & E.

Please provide the individual uncropped, unprocessed image for each gel electrophoresis, western blot, and cell staining images shown. Molecular weight markers should be included or indicated on the original western blot or gel electrophoresis image. Each image file should be in TIFF format and the figure files must be named clearly to enable identification with the corresponding image in the paper. Please do not supply any replacement images until after I have checked the original files.

Please provide these files **by September 24**. I look forward to hearing from you.

Sincerely,

**Alexa Josaphouitch**

Portfolio Manager for Hematology and Immunology Journals

Taylor & Francis Group

530 Walnut Street, Suite 850, Philadelphia, PA 19106


Tel: (215) 606-4170

Fax: (215) 207-0050

Email: [alexa.josaphouitch@taylorandfrancis.com](mailto:alexa.josaphouitch@taylorandfrancis.com)

Web: [www.tandfonline.com](http://www.tandfonline.com)

(she/her/hers)



Information Classification: General

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Monday, January 20, 2020 11:56 PM  
**To:** Lu, Shan  
**Subject:** Re: FW: Re: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055  
#TrackingId:5437168

I have two comments

1. In addition to study the virological aspects of this new virus, it is also necessary to study the immune responses of this virus infection in patients. To compare the cytokine responses in severe patients and general patients may lead to use of appropriate therapeutics.

2. To develop antigen-antibody diagnostic reagents for this virus will benefit to reveal the sero-epidemiology of this virus, including detection of asymptomatic carriers.

Can you and I write a commentary on the importance of studying the immune aspects of this virus?

For your ref. YM Wen

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:** 2020-01-21 03:40:14 (Tuesday)  
**To:** "wen yumei" <ymwen@shmu.edu.cn>  
**Cc:**  
**Subject:** FW: Re: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 #TrackingId:5437168

Prof Wen,

Shibo submitted a commentary (which I agreed in this format to him) on the new Wuhan CoV (see enclosed). Do you mind do a quick reading and see if you would like to make any comments to him and any changes needed? You can write these in your reply email to me so I can incorporate in the e-system to him.

Best.

Shan

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Monday, January 20, 2020 5:40 AM  
**To:** TEMI-peerreview@journals.tandf.co.uk  
**Cc:** Lu, Shan <Shan.Lu@umassmed.edu>; zlshi@wh.iov.cn; minyang0216@163.com; min.yang@emi2012.org; ldu@nybc.org  
**Subject:** Re: Re: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 #TrackingId:5437168

Dear Jorgie.

We have updated the manuscript's information, added line number, and resubmitted it already.

Thank you very much for your help,

Shibo

-----原始邮件-----

发件人:"Shibo Jiang (姜世勃)" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>

发送时间:2020-01-20 17:45:07 (星期一)

收件人: [TEMI-peerreview@journals.tandf.co.uk](mailto:TEMI-peerreview@journals.tandf.co.uk)

抄送: [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu), [zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn), [minyang0216@163.com](mailto:minyang0216@163.com), [min.yang@emi2012.org](mailto:min.yang@emi2012.org), [ldu@nybc.org](mailto:ldu@nybc.org)

主题: Re: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 #TrackingId:5437168

Thanks,Jorgie.

We will update the patients' information and add line number before resubmission tonight.

Shibo

-----原始邮件-----

发件人:TEMI-peerreview@journals.tandf.co.uk

发送时间:2020-01-20 17:03:46 (星期一)

收件人: [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu), [shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)

抄送: [zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn), [minyang0216@163.com](mailto:minyang0216@163.com), [min.yang@emi2012.org](mailto:min.yang@emi2012.org), [ldu@nybc.org](mailto:ldu@nybc.org)

主题: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 #TrackingId:5437168

Dear Prof. Jiang,

Thank you for your email.

This is to kindly let you know that I have now processed your paper and I have noticed that the paper does not contain a line numbering. Having this, I have returned your manuscript in your author centre in order for you to add a line numbering in your main document and make the necessary amendments in your co-authors list.

Rest assured that once received, I will then proceed your paper to Prof. Lu immediately.

Please let me know if you have any questions or concerns.

Kind regards,

**Jorgie Lyn Luna** - Journal Editorial Office  
Taylor & Francis Group  
4 Park Square | Milton Park | Abingdon | Oxon | OX14 4RN UK  
Web: [www.tandfonline.com](http://www.tandfonline.com)

Taylor & Francis is a trading name of Informa UK Limited,  
registered in England under no. 1072954

Emerging Microbes & Infections

---

**From:**Shan.Lu@umassmed.edu  
**Sent:**18-01-2020 07:21  
**To:**shibojiang@fudan.edu.cn,Shan.Lu@umassmed.edu  
**Cc:**minyang0216@163.com,min.yang@emi2012.org,zlshi@wh.iov.cn,ldu@nybc.org  
**Subject:**RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055

Hi, Shibo,

Thanks for submitting this timely Commentary. At the same time, you need to ensure the two co-authors agree to this draft of paper, especially the agreement from Prof. Shi.

At this stage, JEO who is in charge of the first step QC will need to go through the draft and may contact you with any required formatting revisions. I am copying her here and she may take a little time to process since we are in Weekend now. But you should not write to her directly per T&F rules unless she contacts you.

Dear Jorgie Lyn Luna,

Please see communication with Prof Jiang on this new submission TEMI-2020-0055. What I would like are the following:

- 1) Please conduct a quick QC/format and let this MS moving to my desk asap, if there is no any QC/format issue.
- 2) It is ok to send it back to corresponding author Prof Jiang if there is QC issue right away, and he will process such revisions right away, including the wrong emails from two co-authors. Then please monitor the re-submission and again send it to me asap after your QC check.

Thanks.

Shan



-----Original Message-----

From: Shibo Jiang (姜世勃) <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>

Sent: Saturday, January 18, 2020 3:25 AM

To: Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

Cc: Yang Min 杨旻 <[minyang0216@163.com](mailto:minyang0216@163.com)>; [min.yang@emi2012.org](mailto:min.yang@emi2012.org); Shi Zhengli <[zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn)>; Du

Lanying\_NYBC <[ldu@nybc.org](mailto:ldu@nybc.org)>

Subject: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Dear Prof. Lu,

Per your request, I just submitted the invited Commentary to EMI online (see the attachment). During the submission, I accidentally put in the contact information of Drs. Lu Lu and Shuai Xia (my postdoc), rather than Drs. Shi and Du, into the authors' list. I thus immediately called Min about the possibility of withdrawing and resubmitting the manuscript. Min told me that I would not have to withdraw the manuscript since the authors' information in the manuscript is correct, but I would have to inform Drs. Lu and Xia that they may receive the email from EMI about this manuscript. I informed them already.

I will cite Prof. Yuen's paper once the citation information is available during the proof-reading stage.

Thank you very much for your consideration,

Shibo

-----原始邮件-----

发件人: "Emerging Microbes and Infections" <[onbehalf@manuscriptcentral.com](mailto:onbehalf@manuscriptcentral.com)>

发送时间: 2020-01-18 15:21:06 (星期六)

收件人: [shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)

抄送: [shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)

主题: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

18-Jan-2020

Dear Professor Jiang:

Your manuscript entitled "An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies" has been successfully submitted online and is presently being given full consideration for publication in Emerging Microbes & Infections.

Your manuscript ID is TEMI-2020-0055.

Please mention the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your street address or e-mail address, please log in to ScholarOne Manuscripts at

<https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fmc.manuscriptcentral.com%2Ftemi&data=02%7C01%7Cshan.lu%40umassmed.edu%7C5bf67dcea80543172df308d79beffa7f%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637149327594484021&sdata=q3fFDQyJZmoHlceFvohL5YzdF2gO11sHHBts3o6gm3l%3D&reserved=0> and edit your user information as appropriate.

You can also view the status of your manuscript at any time by checking your Author Center after logging in to

<https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fmc.manuscriptcentral.com%2Ftemi&>

[data=02%7C01%7Cshan.lu%40umassmed.edu%7C5bf67dcea80543172df308d79beffa7f%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637149327594484021&sdata=q3fFDQyJZmoHlceFvohL5YzdF2gO11sHHBts3o6gm3l%3D&reserved=0](https://www.elsevier.com/locate/journalofinfection?data=02%7C01%7Cshan.lu%40umassmed.edu%7C5bf67dcea80543172df308d79beffa7f%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637149327594484021&sdata=q3fFDQyJZmoHlceFvohL5YzdF2gO11sHHBts3o6gm3l%3D&reserved=0).

Thank you for submitting your manuscript to Emerging Microbes & Infections.

Sincerely,  
Emerging Microbes & Infections Editorial Office

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Sunday, August 2, 2020 9:48 PM  
**To:** Lu, Shan  
**Cc:** YiWei Tang; Editorial Office  
**Subject:** Re: FW: Request for assessment via expedited peer review process - COVID-19 rapid review

I think this article should be reviewed. Wen

-----原始邮件-----

发件人:"Lu, Shan" <Shan.Lu@umassmed.edu>  
发送时间:2020-08-03 00:59:26 (星期一)  
收件人: "M. Yu-Mei Wen (ymwen@shmu.edu.cn)" <ymwen@shmu.edu.cn>, "YiWei Tang" <yiweitangmd@gmail.com>  
抄送: "Editorial Office" <editorial@emi2012.org>  
主题: FW: Request for assessment via expedited peer review process - COVID-19 rapid review

Dear Prof Wen,

We received the inquiry below. Please advise if we need to send this paper out for peer-review.

Yi-Wei, please feel free to comment.

Best.

Shan

---

发件人: "[tymleung@connect.hku.hk](mailto:tymleung@connect.hku.hk)" <[tymleung@connect.hku.hk](mailto:tymleung@connect.hku.hk)>  
日期: 2020年7月30日 星期四 上午1:42  
收件人: Editorial Office <[editorial@emi2012.org](mailto:editorial@emi2012.org)>  
抄送: 'wongick' <[wongick@hku.hk](mailto:wongick@hku.hk)>, 'Celine Chui' <[cceline@connect.hku.hk](mailto:cceline@connect.hku.hk)>  
主题: Request for assessment via expedited peer review process - COVID-19 rapid review

29<sup>th</sup> July 2020

Prof Yu-Mei Wen

Editor-in-Chief

*EMI*

Dear Prof Wen,

We write to request for our review article entitled “Short- and Potential Long-term Adverse Health Outcomes of COVID-19: A Rapid Review” to be considered for publication in *EMI* via the expedited peer review process.

Our research team has brainstormed the current evidence gap in COVID-19 research. We have identified that there are current knowledge gaps in the long-term health outcomes of COVID-19 survivors. By 28 July 2020, more than 10 million patients of COVID-19, which is around 70% of the infected cases, have recovered from the infection. All were released from medical care without information on monitoring of any potential long-term adverse health outcomes. Therefore, jointly with our clinical professors with different expertise and experience in treating and research on COVID-19, Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS), we conducted a review to summarize current evidence on the short-term adverse outcomes and assessed the risk of potential long-term adverse effects of COVID-19 with reference to similar coronaviruses outbreaks, namely MERS and SARS, to inform our research and practice. We found that major adverse outcomes affect different body systems including: immune system (Guillain-Barré syndrome and multisystem inflammatory syndrome in children), respiratory system (lung fibrosis and pulmonary thromboembolism), cardiovascular system (cardiomyopathy and coagulopathy), neurological system (sensory dysfunction and stroke), as well as impaired gastrointestinal, hepatic and renal function. Mental health in patients with COVID-19 was also found to be adversely affected. The vast majority of COVID-19 survivors have less than six months of follow-up after recovery; hence there is limited data on children with prenatal exposure of SARS-CoV-2. However, based on previous evidence from SARS outbreak, we believe monitoring outcomes of prenatal exposure to SARS-CoV-2 is of paramount importance.

Given the increasing numbers of recovered COVID-19 patients and aging compared to the time of the SARS and MERS outbreak, it is likely that the extent to which follow-up healthcare services are adopted for COVID-19 survivors will be much greater than for SARS and MERS globally. Understanding the short- and long-term adverse health outcomes of COVID-19 is an important step towards the development of a more holistic approach for clinical management.

We believe our manuscript will be of considerable interest to *EMI* readers. Expedited review of our manuscript will provide *EMI* readers timely evidence-based information on the monitoring and management of short- and long-term adverse health outcomes of COVID-19 before more patients are released from medical care. This manuscript has not been previously published, and is not under consideration for publication elsewhere.

We enclose the manuscript for your consideration.

Thank you for considering our manuscript.

Yours sincerely,

Miriam Leung

Centre for Safe Medication Practice and Research

Department of Pharmacology & Pharmacy

T +852 2831 5109 | F +852 2817 0859

1/F, Jockey Club Building for Interdisciplinary Research, 5 Sassoon Road, Pokfulam, Hong Kong



**HKU  
Med**

LKS Faculty of Medicine  
Department of Pharmacology  
& Pharmacy  
香港大學藥理及藥劑學系



---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Wednesday, January 6, 2021 12:35 AM  
**To:** Lu, Shan  
**Subject:** Re: FW: Sir Professor Peter Lachmann

Yes, I received his Christmas greetings Dec 24, and got a mail from his wife on Dec 26 announcing he passed away. I have already sent a letter to his wife. Please send a letter from EMI YM Wen

-----原始邮件-----

发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>  
发送时间: 2021-01-06 05:52:30 (星期三)  
收件人: "M. Yu-Mei Wen (ymwen@shmu.edu.cn)" <ymwen@shmu.edu.cn>  
抄送: "min.yang@emi2012.org" <min.yang@emi2012.org>  
主题: FW: Sir Professor Peter Lachmann

Dear Prof Wen,

I got this email and wonder if you received the same. Prof Peter Lachmann was among the first invited by you to write a commentary to EMI in our early days. I may write an email to ICS and share our condolence.


Best.

Shan

---

**From:** International Complement Society <sheilah.jewart@complement.org>  
**Sent:** Tuesday, January 5, 2021 9:08 AM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Subject:** Sir Professor Peter Lachmann

Join the ICS mailing list to stay up to date on complement meetings and events.



**Complement....We Are The Experts!™**

## Sir Prof Peter Lachmann



Dear Colleagues,

With deep sadness, we must inform you that Sir Professor Peter Lachmann passed away on December 26, 2020, after having enjoyed celebrating his 89th birthday and the Christmas days with his family.

He was very energetic till his very last days equipped with a brilliant and sharp mind until his final hour.

Sylvia, a perfect alter-ego partner and companion for Peter for so many decades, told us that he went to sleep contented and never woke up - a deserved peaceful end for a great mind!

He has shaped the complement field for many decades and was one of its titans - we have already missed him at the last complement conferences and we will certainly miss him now even more.

Sylvia also provided us with one of Peter's favorite poems from Omar Khayyam and we also think that feels apposite:

With them the Seed of Wisdom did I sow,  
And with my own hand labour'd it to grow:  
And this was all the Harvest that I reap'd --  
"I came like Water and like Wind I go."

On behalf of the International Complement Society (ICS) and the European Complement Network (ECN)

Peter Garred, President of ICS

Reinhard Würzner, President of ECN



A more formal obituary will be published in the next issue of FoC. If you have thoughts and memories about Peter that you want to be incorporated in the obituary, please write to our administrator at [sheilah.jewart@complement.org](mailto:sheilah.jewart@complement.org).

---

International Complement Society | 9037 Ron Den Lane, Windermere, FL 34786 |  
[sheilah.jewart@complement.org](mailto:sheilah.jewart@complement.org) | [www.complement.org](http://www.complement.org)

STAY CONNECTED:



International Complement Society, 9037 RON DEN LANE, WINDERMERE, FL 34786

[SafeUnsubscribe™ shan.lu@umassmed.edu](#)

[Forward this email](#) | [About our service provider](#)

Sent by [sheilah.jewart@complement.org](mailto:sheilah.jewart@complement.org) powered by



Try email marketing for free today!

---

**From:** 蔡启良 <Qiliang Cai> <qiliang@fudan.edu.cn>  
**Sent:** Sunday, September 20, 2020 5:59 AM  
**To:** Lu, Shan  
**Cc:** M. Yu-Mei Wen (ymwen@shmu.edu.cn)  
**Subject:** Re: FW: TEMI-2020-1002.R1

Dear Shan,

Thanks for reminder! The mns is a nice discovery and knew from a well recognized group, that is why I preferred for revision after first round review. However, for second aournd review once I got the revised mns back, none of original reviewers is responsive, and I have to select other 6 new reviewers. That is why a little bit delay...

Actually, I would like to make a decision based on the revised version, however, I realized the rebutall cover letter was written by first authour instead of correponsding author, and the mns was also not submitted by the account of either one of two corresponding authors, which is unnormal and somehow fishy!! That's why I insist to send out for secon round peer-review...

Anyway, I will make a quick decision once I receive the rebuttal letter with point by point response.

Best,

Qiliang

> -----原始邮件-----

> 发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>

> 发送时间: 2020-09-20 01:30:17 (星期日)

> 收件人: "蔡启良<Qiliang Cai>" <qiliang@fudan.edu.cn>

> 抄送: "M. Yu-Mei Wen (ymwen@shmu.edu.cn)" <ymwen@shmu.edu.cn>

> 主题: FW: TEMI-2020-1002.R1

>

> Dear Qiliang,

>

> You have had this paper for quite a while and you did not take any active step to process it timely. As we discussed, if no reviewer accepting the invitation for a revised paper, you can make the decision as the Review Editor.

>

> This author is from UTMB - a major US-based emerging infectious disease institute. We don't want to generate any unnecessary negative impression.

>

> I have responded to the authors and copied you (in the form of BCC so they don't see you).

>

> Thanks.

>

> Shan

>

> -----Original Message-----

> From: Emerging Microbes and Infections

> <onbehalf@manuscriptcentral.com>

> Sent: Saturday, September 19, 2020 1:12 PM  
> To: Lu, Shan <Shan.Lu@umassmed.edu>  
> Cc: peshi@utmb.edu  
> Subject: TEMI-2020-1002.R1  
>  
> Dr. Lu,  
>  
> I'm writing in regards to manuscript TEMI-2020-1002.R1 and its status. We submitted a revised version of the manuscript addressing all reviewers comments on Aug. 28th and have been looking forward to the journal's decision. We would appreciate a timeline on when to expect that decision as it will assist us in making current and future plans.  
>  
> Best,  
>  
> Coleman Baker

--

Qiliang Cai, Ph.D.  
Professor, Deputy director  
MOE&NHC&CAMS Key Laboratory of Medical Molecular Virology School of Basic Medical Sciences Shanghai  
Medical College Fudan University Shanghai, 200032 P. R. China  
Tel:(+86)21-5423-7716  
Email: qiliang@fudan.edu.cn  
Lab website:  
<https://nam10.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.viralcancer.fudan.edu.cn%2F&data=02%7C01%7Cshan.lu%40umassmed.edu%7C41aa4cb669c1451387da08d85d4bcd35%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637361927444551781&sdata=QqKLvE9eGxV5UPxm%2BDfFeZq8z5qA4nd4faih3UTJg6Y%3D&mp;reserved=0>

---

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Thursday, March 26, 2020 6:52 AM  
**To:** Emerging Microbes and Infections  
**Cc:** Lu, Shan  
**Subject:** Re: Fwd: Emerging Microbes & Infections - Invitation to re-review Manuscript ID TEMI-2019-0764.R1

I already declined to review it because of "conflict of interest" (we are workin on similar project).

Please send your email to my Fudan's email system since we generally cannot open my email at NYBC (SJiang@nybc.org) when I work in Shanghai.

Shibo

**From:** Emerging Microbes and Infections <onbehalf@manuscriptcentral.com>  
**Date:** March 26, 2020 at 3:24:21 PM GMT+8  
**To:** "Jiang, Shibo" <SJiang@nybc.org>  
**Subject:** Emerging Microbes & Infections - Invitation to re-review Manuscript ID TEMI-2019-0764.R1  
**Reply-To:** editorial@emi2012.org

26-Mar-2020

Dear Shibo Jiang:

A revised version of "Particulate multivalent presentation of the receptor binding domain induces protective immune responses against MERS-CoV" by Okba, Nisreen; Widjaja, Ivy; van Dieren, Brenda; Aebischer, Andrea; van Amerongen, Geert; de Waal, Leon; Stittelaar, Koert; Schipper, Debby; Martina, Byron; van den Brand, Judith; Beer, Martin; Bosch, Berend-Jan; Haagmans, Bart (TEMI-2019-0764.R1) was submitted to Emerging Microbes & Infections. You served as a reviewer for the original version of this manuscript.

I would greatly appreciate if you can agree to serve as the reviewer for this revised draft. Your input on the evaluation of this revision is pivotal to determining if your concerns have been adequately addressed.

To respond to this invitation to review, please click one of the links below:

\*\*\* PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a webpage to confirm. \*\*\*

Agreed: [https://mc.manuscriptcentral.com/temi?URL\\_MASK=7d760d7327124b958751a7c4d682aafc](https://mc.manuscriptcentral.com/temi?URL_MASK=7d760d7327124b958751a7c4d682aafc)

Declined: [https://mc.manuscriptcentral.com/temi?URL\\_MASK=137789b420e543488b353f3d21f2684b](https://mc.manuscriptcentral.com/temi?URL_MASK=137789b420e543488b353f3d21f2684b)

Unavailable:

[https://mc.manuscriptcentral.com/temi?URL\\_MASK=89e746bfd48e438cae88c4ae1a22d007](https://mc.manuscriptcentral.com/temi?URL_MASK=89e746bfd48e438cae88c4ae1a22d007)

If you agree to review this revision, you will have access to all previous versions of the manuscript and reviews as well as the author(s) response to the reviews. I would ask for your comments within 14 days from your acceptance.

Thank you for your continued support of Emerging Microbes & Infections.

Sincerely,  
Professor Shan Lu  
Emerging Microbes & Infections

#### MANUSCRIPT DETAILS

TITLE: Particulate multivalent presentation of the receptor binding domain induces protective immune responses against MERS-CoV

AUTHOR: Dr Nisreen Okba

#### ABSTRACT:

Middle East respiratory syndrome coronavirus (MERS-CoV) is a WHO priority pathogen for which vaccines are urgently needed. Using an immune-focusing approach, we created self-assembling particles multivalently displaying critical regions of the MERS-CoV spike protein –fusion peptide, heptad repeat 2, and receptor binding domain (RBD) – and tested their immunogenicity and protective capacity in rabbits. Using a ‘plug-and-display’ SpyTag/SpyCatcher system, we coupled RBD to lumazine synthase (LS) particles producing multimeric RBD-presenting particles (RBD-LS). RBD-LS vaccination induced antibody responses of high magnitude and quality (avidity, MERS-CoV neutralizing capacity, and mucosal immunity) with cross-clade neutralization. The antibody responses were associated with blocking viral replication and upper and lower respiratory tract protection against MERS-CoV infection in rabbits. This arrayed multivalent presentation of the viral RBD using the antigen-SpyTag/LS-SpyCatcher is a promising MERS-CoV vaccine candidate and this platform may be applied for the rapid development of vaccines against other emerging viruses.



**LIFESAVING INNOVATION SINCE 1964**



[Donate Blood](#) | [Volunteer](#) | [Support NYBC](#)

This email transmission and any documents, files or previous email messages attached to it may contain information that is confidential or legally privileged. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you are hereby notified that you must not read this transmission and that any disclosure, copying, printing, distribution or use of this transmission is strictly prohibited. If you have received this transmission in error, please immediately notify the sender by telephone or return email and delete the original transmission and its attachments without reading or saving in any manner.

---

**From:** Klenk Hans-Dieter <klenk@staff.uni-marburg.de>  
**Sent:** Monday, December 23, 2019 8:11 AM  
**To:** Lu, Shan  
**Cc:** wen yumei  
**Subject:** Re: Greetings

Dear Yumei and Shan,

I sent Friedrich Goetz an email to get in touch with me. When I have talked to him, I will get in touch with you.

Merry Christmas and Happy New Year  
Hans

Prof. Dr. H. D. Klenk  
Institut für Virologie  
Hans-Meerwein-Str. 2  
35043 Marburg  
Germany

Tel.: +49 6421 286 6191  
Sek.: +49 6421 286 6254  
Fax: +49 6421 286 8962  
E-Mail: klenk@staff.uni-marburg.de

> Am 23.12.2019 um 12:58 schrieb Lu, Shan <Shan.Lu@umassmed.edu>:  
>  
> Thank you, Prof Wen for informing Hans about this. I will write another email to you and Han based on the last email to Gotz and your both so Hans can connect me with Gotz.  
> Best.  
>  
> Shan  
>  
> -----Original Message-----  
> From: wen yumei [mailto:ymwen@shmu.edu.cn]  
> Sent: Monday, December 23, 2019 6:33 AM  
> To: Klenk <Klenk@staff.uni-marburg.de>  
> Cc: Lu, Shan <Shan.Lu@umassmed.edu>  
> Subject: Greetings  
>  
> Dear Hans: Hope you and your family a merry christmas and happy new year.  
> We have not heard from Gotz, though Shan has sent letters to invite him to join EMI editorial board. Can you hlep us to contact ham? incase he missed the mails. u-me  
>  
>  
>  
>  
>

---

**From:** Zheng, Zhi-Ming (Thomas) (NIH/NCI) [E] <zhengt@exchange.nih.gov>  
**Sent:** Sunday, January 3, 2021 2:17 PM  
**To:** Lu, Shan; Editorial Office  
**Cc:** M. Yu-Mei Wen (ymwen@shmu.edu.cn); min.yang@emi2012.org; editorial2@emi2012.org; 'jingee'  
**Subject:** RE: Happy New Year from EMI

Dear Shan,

Thank you for your excellent work and news updates about the EMI! I should say that you did a great job in promoting EMI to a top ranking journal, in particular by rapid publication of those leading SARS-CoV2 studies in 2020. I am so proud of being a member in the editorial board and I am sure the EMI will stand up as a flag journal in the field. Hope we will all go through the year 2021 safely!

Cheers,

Zhi-Ming

---

**From:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Sent:** Thursday, December 31, 2020 11:34 AM  
**To:** Editorial Office <editorial@emi2012.org>  
**Cc:** M. Yu-Mei Wen (ymwen@shmu.edu.cn) <ymwen@shmu.edu.cn>; min.yang@emi2012.org; editorial2@emi2012.org; 'jingee' <jingee@fudan.edu.cn>  
**Subject:** Happy New Year from EMI

Dear EMI Editorial Board Members,

On behalf of Prof Wen, Editor-in-Chief of EMI, and EMI Editorial Office, I would like to thank everyone in the big EMI family, especially review editors and editorial members for your great support in 2020 which brought unprecedented challenges to all of us. We hope you and your family have been safe and well, and wish you a Happy New Year for 2021!

EMI was launched in 2012 with the full realization that emerging infections are major threats to human society in the 21<sup>st</sup> century and our journal is strategically placed in China. EMI has stood up from the first report by Prof KY Yuan in January 2020 about the first evidence of human-to-human transmission to devote fully in the fight against COVID-19 for the whole year. EMI covered a broad range of topics from basic virology, epidemiology, diagnosis, treatment, vaccines and anti-conspiracy among others. We also covered reports from many countries including Africa.

In 2020, EMI received about 1800 total submissions and published 303 papers while we published 173 papers in 2019, a 195% increase.

The quality of EMI papers are also improving significantly: 30 papers published in 2020 had more than 10,000 download reads, the top one had more than 100,000 download reads. Six EMI papers are among the top 10 open access papers from over 2500 journals within the Taylor & Francis family. Quite a few papers received immediate citation: the top one received 674 citations and another three had over 200 citations each.

Looking forward in 2021, EMI is expecting to further improve the quality of published papers and spread the key scientific knowledge to more people such as the following:



- We hope to invite more high quality reviews by leading experts in their own fields. You are welcome to nominate and self-nominate for high quality reviews;
- EMI will launch a completely novel Virtual Journal Club (VJC) which is like a small seminar focusing on one EMI paper with the lead author presenting that paper live with global readers. More details will be shared with you in the near future.
- A completely re-designed EMI own website: [www.emi2012.org](http://www.emi2012.org) which will provide more information about EMI, EMI papers and community interaction beyond the current Taylor & Francis paper website ([www.tandfonline.com/TEMI](http://www.tandfonline.com/TEMI)).
- A more regular update and communication will be established with you so we want to have more direct involvement from you.

2022 will be the 10<sup>th</sup> Anniversary for EMI. We hope EMI will reach a new level by then. We will celebrate with you together and look for the exciting work in the next 10 years.

EMI started with a very humble background, and we remain to be optimistic and believe the mission of EMI. We hope to receive your continued support. Please let us know any feedback you may have.

Best.

Shan

\*\*\*\*\*

Shan Lu, MD, PhD  
Co-Editor-in-Chief  
Emerging Microbes and Infections (EMI)  
[www.tandfonline.com/TEMI](http://www.tandfonline.com/TEMI)  
[editorial@2012EMI.org](mailto:editorial@2012EMI.org)

---

**From:** gpzhao@sibs.ac.cn  
**Sent:** Saturday, January 2, 2021 9:03 AM  
**To:** Lu, Shan; Editorial Office  
**Cc:** 闻玉梅; YangMin (EMI) ; editorial2@emi2012.org; 'jingee'  
**Subject:** Re: Happy New Year from EMI

Dear Shan:

I am really impressed by the great progress we have achieved over the years. Thus I have to pay my sincere respects to you and all of the members of the editorial staff.

Thank you very much and have a very happy New Year!

Yours

GPZ

---

gpzhao@sibs.ac.cn

---

**From:** [Lu, Shan](#)  
**Date:** 2021-01-01 00:33  
**To:** [Editorial Office](#)  
**CC:** [M. Yu-Mei Wen \(ymwen@shmu.edu.cn\)](#); [min.yang@emi2012.org](#); [editorial2@emi2012.org](#); 'jingee'  
**Subject:** Happy New Year from EMI

Dear EMI Editorial Board Members,

On behalf of Prof Wen, Editor-in-Chief of EMI, and EMI Editorial Office, I would like to thank everyone in the big EMI family, especially review editors and editorial members for your great support in 2020 which brought unprecedented challenges to all of us. We hope you and your family have been safe and well, and wish you a Happy New Year for 2021!

EMI was launched in 2012 with the full realization that emerging infections are major threats to human society in the 21<sup>st</sup> century and our journal is strategically placed in China. EMI has stood up from the first report by Prof KY Yuan in January 2020 about the first evidence of human-to-human transmission to devote fully in the fight against COVID-19 for the whole year. EMI covered a broad range of topics from basic virology, epidemiology, diagnosis, treatment, vaccines and anti-conspiracy among others. We also covered reports from many countries including Africa.

In 2020, EMI received about 1800 total submissions and published 303 papers while we published 173 papers in 2019, a 195% increase.

The quality of EMI papers are also improving significantly: 30 papers published in 2020 had more than 10,000 download reads, the top one had more than 100,000 download reads. Six EMI papers are among the top 10

open access papers from over 2500 journals within the Taylor & Francis family. Quite a few papers received immediate citation: the top one received 674 citations and another three had over 200 citations each.

Looking forward in 2021, EMI is expecting to further improve the quality of published papers and spread the key scientific knowledge to more people such as the following:

- We hope to invite more high quality reviews by leading experts in their own fields. You are welcome to nominate and self-nominate for high quality reviews;
- EMI will launch a completely novel Virtual Journal Club (VJC) which is like a small seminar focusing on one EMI paper with the lead author presenting that paper live with global readers. More details will be shared with you in the near future.
- A completely re-designed EMI own website: [www.emi2012.org](http://www.emi2012.org) which will provide more information about EMI, EMI papers and community interaction beyond the current Taylor & Francis paper website ([www.tandfonline.com/TEMI](http://www.tandfonline.com/TEMI)).
- A more regular update and communication will be established with you so we want to have more direct involvement from you.

2022 will be the 10<sup>th</sup> Anniversary for EMI. We hope EMI will reach a new level by then. We will celebrate with you together and look for the exciting work in the next 10 years.

EMI started with a very humble background, and we remain to be optimistic and believe the mission of EMI. We hope to receive your continued support. Please let us know any feedback you may have.

Best.

Shan

\*\*\*\*\*

Shan Lu, MD, PhD  
Co-Editor-in-Chief  
Emerging Microbes and Infections (EMI)  
[www.tandfonline.com/TEMI](http://www.tandfonline.com/TEMI)  
[editorial@2012EMI.org](mailto:editorial@2012EMI.org)

---

**From:** Jing-Ren Zhang <zhanglab@mail.tsinghua.edu.cn>  
**Sent:** Thursday, December 31, 2020 7:52 PM  
**To:** Lu, Shan  
**Cc:** Editorial Office; wen yumei; min.yang@emi2012.org; editorial2@emi2012.org; jingee  
**Subject:** Re: Happy New Year from EMI

Dear Shan,

Happy New Year!

Best wishes,  
Jingren

On Jan 1, 2021, at 12:33 AM, Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> wrote:

Dear EMI Editorial Board Members,

On behalf of Prof Wen, Editor-in-Chief of EMI, and EMI Editorial Office, I would like to thank everyone in the big EMI family, especially review editors and editorial members for your great support in 2020 which brought unprecedented challenges to all of us. We hope you and your family have been safe and well, and wish you a Happy New Year for 2021!

EMI was launched in 2012 with the full realization that emerging infections are major threats to human society in the 21<sup>st</sup> century and our journal is strategically placed in China. EMI has stood up from the first report by Prof KY Yuan in January 2020 about the first evidence of human-to-human transmission to devote fully in the fight against COVID-19 for the whole year. EMI covered a broad range of topics from basic virology, epidemiology, diagnosis, treatment, vaccines and anti-conspiracy among others. We also covered reports from many countries including Africa.

In 2020, EMI received about 1800 total submissions and published 303 papers while we published 173 papers in 2019, a 195% increase.

The quality of EMI papers are also improving significantly: 30 papers published in 2020 had more than 10,000 download reads, the top one had more than 100,000 download reads. Six EMI papers are among the top 10 open access papers from over 2500 journals within the Taylor & Francis family. Quite a few papers received immediate citation: the top one received 674 citations and another three had over 200 citations each.

Looking forward in 2021, EMI is expecting to further improve the quality of published papers and spread the key scientific knowledge to more people such as the following:

- We hope to invite more high quality reviews by leading experts in their own fields. You are welcome to nominate and self-nominate for high quality reviews;
- EMI will launch a completely novel Virtual Journal Club (VJC) which is like a small seminar focusing on one EMI paper with the lead author presenting that paper live with global readers. More details will be shared with you in the near future.

- A completely re-designed EMI own website: [www.emi2012.org](http://www.emi2012.org) which will provide more information about EMI, EMI papers and community interaction beyond the current Taylor & Francis paper website ([www.tandfonline.com/TEMI](http://www.tandfonline.com/TEMI)).
- A more regular update and communication will be established with you so we want to have more direct involvement from you.

2022 will be the 10<sup>th</sup> Anniversary for EMI. We hope EMI will reach a new level by then. We will celebrate with you together and look for the exciting work in the next 10 years.

EMI started with a very humble background, and we remain to be optimistic and believe the mission of EMI. We hope to receive your continued support. Please let us know any feedback you may have.

Best.

Shan

\*\*\*\*\*

Shan Lu, MD, PhD  
Co-Editor-in-Chief  
Emerging Microbes and Infections (EMI)  
[www.tandfonline.com/TEMI](http://www.tandfonline.com/TEMI)  
[editorial@2012EMI.org](mailto:editorial@2012EMI.org)

---

**From:** Jiang, Wei <jianw@musc.edu>  
**Sent:** Thursday, November 28, 2019 12:14 PM  
**To:** Liu, Shan-Lu; zhengzhiming4@gmail.com; haitguo@iupui.edu; tzhou@mail.nih.gov; GCheng@mednet.ucla.edu; liangy@umn.edu; rli@vcu.edu; wjma@ksu.edu; xjmeng@vt.edu; Zhijian.Chen@UTSouthwestern.edu; mluo@gsu.edu; zhangyj@umd.edu; xzhu1@umd.edu; jqu@kumc.edu; lijun@uic.edu; fengwei.bai@usm.edu; andyu@iupui.edu; reachxw@vt.edu; gluo@uab.edu; ldu@nybc.org; hxu@tulane.edu; liu\_fy@berkeley.edu; shitao.li@okstate.edu; Lu, Shan; haihu@UTMB.edu; wenzheho@temple.edu; Qfeng4@central.uh.edu; tang@bio.fsu.edu; feng.li@sdsu.edu; ruilu@lsu.edu; sxian2@unl.edu; qiyi.tang@howard.edu; dingsw@ucr.edu; guohua@missouri.edu; bling@tulane.edu; junwang@pharmacy.arizona.edu; lifang@umn.edu; wang518@umd.edu; gaos8@upmc.edu; pewang@uchc.edu; xiangy@uthscsa.edu; fzu@bio.fsu.edu; chen.liang@mcgill.ca; lyuan@vt.edu; fgao@duke.edu; wangjw28@163.com; xfyu1@zju.edu.cn; bzhaoh@partners.org; zyang@ksu.edu; yu.cong@nih.gov; weiming.yuan@usc.edu; Zongdi.feng@nationwidechildrens.org; juh13@psu.edu; hengx@missouri.edu; lsu@med.unc.edu; ywu8@gmu.edu; jwu@whu.edu.cn; tshuo@uic.edu; Shibojian@fudan.edu.cn; sjian@nybc.org; pinwang@usc.edu; rzhaoh@som.umaryland.edu; shuylong@mail.sysu.edu.cn; xuefeng.liu@georgetown.edu; yuxingli@som.umaryland.edu; Wang, Shixia; yhe@ipbcams.ac.cn; Pinghui.feng@usc.edu; ju-tao.guo@bblumberg.org; lin.liu@okstate.edu; hua.zhu@rutgers.edu; Jinhong.chang@bblumberg.org; jianzhu1012@gmail.com; ronghai@ucr.edu; jun.zhu@nih.gov; jliu4@uams.edu; xiangpeng.kong@med.nyu.edu; haoquanwu@outlook.com; Wenjun.liu@defence.gov.au; Liang.shan@wustl.edu; hliao@duke.edu; yuan2@upenn.edu; zxing@umn.edu; hongmin.li@health.ny.gov; pzheng@ihv.umaryland.edu; yaliu@ihv.umaryland.edu; jxw103@case.edu; xiangguo.qiu@canada.ca; Feng Shao; zshi@wh.iov.cn; klan@whu.edu.cn; zengmsh@mail.sysu.edu.cn; Nan Yan; Zhang, Rong; liliwang@upenn.edu; Linheng Li; kli1@uthsc.edu; tsx@case.edu; ssun@mdanderson.org; ysang@tnstate.edu; wu@crystal.harvard.edu; Sun.Jie@mayo.edu; peijun@strubi.ox.ac.uk; jiayu@coh.org; bchen@crystal.harvard.edu; Wen, Haitao; Qu, Feng; Hezhao.Ji@umanitoba.ca; Li, Zihai; zhengyo@msu.edu; zhanglinqi@tsinghua.edu.cn; wxiao@temple.edu; Whu@temple.edu; RSun@mednet.ucla.edu; Gao, Guangping; pzheng@ihv.umaryland.edu; GMSWANG@nus.edu.sg; peshi@UTMB.EDU; yaliu@ihv.umaryland.edu; ziyang-yan@uiowa.edu; lqiao@luc.edu; yong.xiong@yale.edu; Wang, Qihong; shuping\_tong\_md@brown.edu; pinghuif@usc.edu; gaof@im.ac.cn  
**Subject:** Re: Happy Thanksgiving and meeting next year, June 12-13, 2020

Thank you for sharing the information, this was a fantastic meeting, I did enjoy it at Kunming!

Wei Jiang, M.D. & M.S.  
Associate Professor  
Department of Microbiology and Immunology  
Division of Infectious Diseases, Department of Medicine  
Medical University of South Carolina  
173 Ashley Ave. BSB208D  
Charleston, SC 29425  
Lab phone 843-876-2457  
jianw@musc.edu

---

**From:** Liu, Shan-Lu <liu.6244@osu.edu>  
**Sent:** Thursday, November 28, 2019 10:57 AM  
**To:** zhengzhiming4@gmail.com <zhengzhiming4@gmail.com>; haitguo@iupui.edu <haitguo@iupui.edu>; tzhou@mail.nih.gov <tzhou@mail.nih.gov>; GCheng@mednet.ucla.edu <GCheng@mednet.ucla.edu>; liangy@umn.edu

<liangy@umn.edu>; rli@vcu.edu <rli@vcu.edu>; wjma@ksu.edu <wjma@ksu.edu>; xjmeng@vt.edu <xjmeng@vt.edu>;  
 Zhijian.Chen@UTSouthwestern.edu <Zhijian.Chen@UTSouthwestern.edu>; mluo@gsu.edu <mluo@gsu.edu>;  
 zhangyj@umd.edu <zhangyj@umd.edu>; xzhu1@umd.edu <xzhu1@umd.edu>; jqiu@kumc.edu <jqiu@kumc.edu>;  
 lijun@uic.edu <lijun@uic.edu>; fengwei.bai@usm.edu <fengwei.bai@usm.edu>; andyu@iupui.edu <andyu@iupui.edu>;  
 reachxw@vt.edu <reachxw@vt.edu>; gluo@uab.edu <gluo@uab.edu>; ldu@nybc.org <ldu@nybc.org>; hxu@tulane.edu  
 <hxu@tulane.edu>; liu\_fy@berkeley.edu <liu\_fy@berkeley.edu>; shitao.li@okstate.edu <shitao.li@okstate.edu>;  
 Shan.lu@umassmed.edu <Shan.lu@umassmed.edu>; haihu@UTMB.edu <haihu@UTMB.edu>; wenzheho@temple.edu  
 <wenzheho@temple.edu>; Qfeng4@central.uh.edu <Qfeng4@central.uh.edu>; tang@bio.fsu.edu <tang@bio.fsu.edu>;  
 feng.li@sdsstate.edu <feng.li@sdsstate.edu>; ruilu@lsu.edu <ruilu@lsu.edu>; sxiang2@unl.edu <sxiang2@unl.edu>;  
 qiyi.tang@howard.edu <qiyi.tang@howard.edu>; dingsw@ucr.edu <dingsw@ucr.edu>; guohua@missouri.edu  
 <guohua@missouri.edu>; bling@tulane.edu <bling@tulane.edu>; junwang@pharmacy.arizona.edu  
 <junwang@pharmacy.arizona.edu>; lifang@umn.edu <lifang@umn.edu>; wang518@umd.edu <wang518@umd.edu>;  
 gaos8@upmc.edu <gaos8@upmc.edu>; pewang@uchc.edu <pewang@uchc.edu>; xiangy@uthscsa.edu  
 <xiangy@uthscsa.edu>; fzhu@bio.fsu.edu <fzhu@bio.fsu.edu>; chen.liang@mcgill.ca <chen.liang@mcgill.ca>;  
 lyuan@vt.edu <lyuan@vt.edu>; fgao@duke.edu <fgao@duke.edu>; wangjw28@163.com <wangjw28@163.com>;  
 xfyu1@zju.edu.cn <xfyu1@zju.edu.cn>; bzhao@partners.org <bzhao@partners.org>; Jiang, Wei <jianw@musc.edu>;  
 zyang@ksu.edu <zyang@ksu.edu>; yu.cong@nih.gov <yu.cong@nih.gov>; weiming.yuan@usc.edu  
 <weiming.yuan@usc.edu>; Zongdi.feng@nationwidechildrens.org <Zongdi.feng@nationwidechildrens.org>;  
 juh13@psu.edu <juh13@psu.edu>; hengx@missouri.edu <hengx@missouri.edu>; lsu@med.unc.edu  
 <lsu@med.unc.edu>; ywu8@gmu.edu <ywu8@gmu.edu>; jwu@whu.edu.cn <jwu@whu.edu.cn>; tshuo@uic.edu  
 <tshuo@uic.edu>; Shibojiang@fudan.edu.cn <Shibojiang@fudan.edu.cn>; sjiang@nybc.org <sjiang@nybc.org>;  
 pinwang@usc.edu <pinwang@usc.edu>; rzhao@som.umaryland.edu <rzhao@som.umaryland.edu>;  
 shuylong@mail.sysu.edu.cn <shuylong@mail.sysu.edu.cn>; xuefeng.liu@georgetown.edu  
 <xuefeng.liu@georgetown.edu>; yuxingli@som.umaryland.edu <yuxingli@som.umaryland.edu>;  
 shixia.wang@umassmed.edu <shixia.wang@umassmed.edu>; yhe@ipbcams.ac.cn <yhe@ipbcams.ac.cn>;  
 Pinghui.feng@usc.edu <Pinghui.feng@usc.edu>; ju-tao.guo@bblumberg.org <ju-tao.guo@bblumberg.org>;  
 lin.liu@okstate.edu <lin.liu@okstate.edu>; hua.zhu@rutgers.edu <hua.zhu@rutgers.edu>;  
 Jinhong.chang@bblumberg.org <Jinhong.chang@bblumberg.org>; jianzhu1012@gmail.com <jianzhu1012@gmail.com>;  
 ronghai@ucr.edu <ronghai@ucr.edu>; jun.zhu@nih.gov <jun.zhu@nih.gov>; jliu4@uams.edu <jliu4@uams.edu>;  
 xiangpeng.kong@med.nyu.edu <xiangpeng.kong@med.nyu.edu>; haoquanwu@outlook.com  
 <haoquanwu@outlook.com>; Wenjun.liu@defence.gov.au <Wenjun.liu@defence.gov.au>; Liang.shan@wustl.edu  
 <Liang.shan@wustl.edu>; hliao@duke.edu <hliao@duke.edu>; yuan2@upenn.edu <yuan2@upenn.edu>;  
 zxing@umn.edu <zxing@umn.edu>; hongmin.li@health.ny.gov <hongmin.li@health.ny.gov>;  
 pzheng@ihv.umaryland.edu <pzheng@ihv.umaryland.edu>; yaliu@ihv.umaryland.edu <yaliu@ihv.umaryland.edu>;  
 jxw103@case.edu <jxw103@case.edu>; xiangguo.qiu@canada.ca <xiangguo.qiu@canada.ca>; Feng Shao  
 <shaofeng@nibs.ac.cn>; zlshi@wh.iov.cn <zlshi@wh.iov.cn>; klan@whu.edu.cn <klan@whu.edu.cn>;  
 zengmsh@mail.sysu.edu.cn <zengmsh@mail.sysu.edu.cn>; Nan Yan <Nan.Yan@UTSouthwestern.edu>; Zhang, Rong  
 <rongzhang@wustl.edu>; liliwang@upenn.edu <liliwang@upenn.edu>; Linheng Li <LIL@stowers.org>; kli1@uthsc.edu  
 <kli1@uthsc.edu>; tsx@case.edu <tsx@case.edu>; ssun@mdanderson.org <ssun@mdanderson.org>;  
 ysang@tstate.edu <ysang@tstate.edu>; Liu, Shan-Lu <liu.6244@osu.edu>; wu@crystal.harvard.edu  
 <wu@crystal.harvard.edu>; Sun.Jie@mayo.edu <Sun.Jie@mayo.edu>; peijun@strubi.ox.ac.uk <peijun@strubi.ox.ac.uk>;  
 jiayu@coh.org <jiayu@coh.org>; bchen@crystal.harvard.edu <bchen@crystal.harvard.edu>; Wen, Haitao  
 <Haitao.Wen@osumc.edu>; Qu, Feng <qu.28@osu.edu>; Hezhao.Ji@umanitoba.ca <Hezhao.Ji@umanitoba.ca>; Li, Zihai  
 <zihai@musc.edu>; zhengyo@msu.edu <zhengyo@msu.edu>; zhanglinqi@tsinghua.edu.cn  
 <zhanglinqi@tsinghua.edu.cn>; wxiao@temple.edu <wxiao@temple.edu>; Whu@temple.edu <Whu@temple.edu>;  
 RSun@mednet.ucla.edu <RSun@mednet.ucla.edu>; Guangping.Gao@umassmed.edu  
 <Guangping.Gao@umassmed.edu>; PZheng@ihv.umaryland.edu <PZheng@ihv.umaryland.edu>;  
 GMSWANG@nus.edu.sg <GMSWANG@nus.edu.sg>; peshi@UTMB.EDU <peshi@UTMB.EDU>; yaliu@ihv.umaryland.edu  
 <yaliu@ihv.umaryland.edu>; ziyang-yan@uiowa.edu <ziyang-yan@uiowa.edu>; lqiao@luc.edu <lqiao@luc.edu>;  
 yong.xiong@yale.edu <yong.xiong@yale.edu>; Wang, Qihong <wang.655@osu.edu>; shuping\_tong\_md@brown.edu  
 <shuping\_tong\_md@brown.edu>; pinghuif@usc.edu <pinghuif@usc.edu>; gaof@im.ac.cn <gaof@im.ac.cn>

**Subject:** Happy Thanksgiving and meeting next year, June 12-13, 2020

CAUTION: External

Dear friends and colleagues,

I wish you all a great Thanksgiving holiday!

A few updates:

1. We will have our first scientific meeting on June 12-13, 2020, right before the ASV annual meeting (June 13-17) in Fort Collins, Colorado State University. Organizing and scientific committees will be formed soon.
2. I am excited to share that Dr. Xiang-Jin (XJ) Meng of Virginia Tech, a distinguished virology and a member of the US National Academy of Science, will be the keynote speaker of this meeting. Details will follow.
3. In addition to scientific programs, we will also hold an election; a new leadership team will be elected to serve our community for the next two years.
4. Attached please find a brief report of our Kunming meeting, along with a few photos.

Please let me know if you have comments and suggestions.

All best wishes, and happy holidays!

Shan-Lu



Shan-Lu Liu, M.D., Ph.D.

Professor

Co-Director, Viruses and Emerging Pathogens Program

Infectious Diseases Institute

Center for Retrovirus Research

Departments of Veterinary Biosciences, Microbial Infection and Immunity, and Microbiology

The Ohio State University

1900 Coffey Rd, Room 480 VMAB

Columbus, Ohio 43210

Phone: (614) 292-8690

Fax: (614) 292-6473

Email: [liu.6244@osu.edu](mailto:liu.6244@osu.edu); [shan-lu.liu@osumc.edu](mailto:shan-lu.liu@osumc.edu)



---

**From:** Tsan Xiao <tsx@case.edu>  
**Sent:** Thursday, November 28, 2019 2:30 PM  
**To:** Liu, Shan-Lu  
**Cc:** zhengzhiming4@gmail.com; haitguo@iupui.edu; tzhou@mail.nih.gov; GCheng@mednet.ucla.edu; liangy@umn.edu; rli@vcu.edu; wjma@ksu.edu; xjmeng@vt.edu; Zhijian.Chen@UTSouthwestern.edu; mluo@gsu.edu; zhangyj@umd.edu; xzhu1@umd.edu; jqiu@kumc.edu; lijun@uic.edu; fengwei.bai@usm.edu; andyu@iupui.edu; reachxw@vt.edu; gluo@uab.edu; ldu@nybc.org; hxu@tulane.edu; liu\_fy@berkeley.edu; shitao.li@okstate.edu; Lu, Shan; haihu@UTMB.edu; wenzheho@temple.edu; Qfeng4@central.uh.edu; tang@bio.fsu.edu; feng.li@sdstate.edu; ruilu@lsu.edu; sxian2@unl.edu; qiyi.tang@howard.edu; dingsw@ucr.edu; guohua@missouri.edu; bling@tulane.edu; junwang@pharmacy.arizona.edu; lifang@umn.edu; wang518@umd.edu; gaos8@upmc.edu; pewang@uchc.edu; xiangy@uthscsa.edu; fzhu@bio.fsu.edu; chen.liang@mcgill.ca; lyuan@vt.edu; fgao@duke.edu; wangjw28@163.com; xfyu1@zju.edu.cn; bzhao@partners.org; jianw@musc.edu; zyang@ksu.edu; yu.cong@nih.gov; weiming.yuan@usc.edu; Zongdi.feng@nationwidechildrens.org; juh13@psu.edu; hengx@missouri.edu; lsu@med.unc.edu; ywu8@gmu.edu; jwu@whu.edu.cn; tshuo@uic.edu; Shibojiang@fudan.edu.cn; sjiang@nybc.org; pinwang@usc.edu; rzhao@som.umaryland.edu; shuylong@mail.sysu.edu.cn; xuefeng.liu@georgetown.edu; yuxingli@som.umaryland.edu; Wang, Shixia; yhe@ipbcams.ac.cn; Pinghui.feng@usc.edu; ju-tao.guo@bblumberg.org; lin.liu@okstate.edu; hua.zhu@rutgers.edu; Jinhong.chang@bblumberg.org; jianzhu1012@gmail.com; ronghai@ucr.edu; jun.zhu@nih.gov; jliu4@uams.edu; xiangpeng.kong@med.nyu.edu; haoquanwu@outlook.com; Wenjun.liu@defence.gov.au; Liang.shan@wustl.edu; hliao@duke.edu; yuan2@upenn.edu; zxing@umn.edu; hongmin.li@health.ny.gov; pzheng@ihv.umaryland.edu; yaliu@ihv.umaryland.edu; jxw103@case.edu; xiangguo.qiu@canada.ca; Feng Shao; zlshi@wh.iov.cn; klan@whu.edu.cn; zengmsh@mail.sysu.edu.cn; Nan Yan; Zhang, Rong; liliwang@upenn.edu; Linheng Li; kli1@uthsc.edu; ssun@mdanderson.org; ysang@tnstate.edu; wu@crystal.harvard.edu; Sun.Jie@mayo.edu; peijun@strubi.ox.ac.uk; jiayu@coh.org; bchen@crystal.harvard.edu; Wen, Haitao; Qu, Feng; Hezhao.Ji@umanitoba.ca; Li, Zihai; zhengyo@msu.edu; zhanglinqi@tsinghua.edu.cn; wxiao@temple.edu; Whu@temple.edu; RSun@mednet.ucla.edu; Gao, Guangping; GMSWANG@nus.edu.sg; peshi@UTMB.EDU; ziyang-yan@uiowa.edu; lqiao@luc.edu; yong.xiong@yale.edu; Wang, Qihong; shuping\_tong\_md@brown.edu; pinghuif@usc.edu; gaof@im.ac.cn  
**Subject:** Re: Happy Thanksgiving and meeting next year, June 12-13, 2020

Thanks for sharing. Happy holidays!

Sam

On Thu, Nov 28, 2019, 12:19 PM Liu, Shan-Lu <[liu.6244@osu.edu](mailto:liu.6244@osu.edu)> wrote:

Dear friends and colleagues,

I wish you all a great Thanksgiving holiday!


A few updates:

1. We will have our first scientific meeting on June 12-13, 2020, right before the ASV annual meeting (June 13-17) in Fort Collins, Colorado State University. Organizing and scientific committees will be formed soon.
2. I am excited to share that Dr. Xiang-Jin (XJ) Meng of Virginia Tech, a distinguished virology and a member of the US National Academy of Science, will be the keynote speaker of this meeting. Details will follow.
3. In addition to scientific programs, we will also hold an election; a new leadership team will be elected to serve our community for the next two years.
4. Attached please find a brief report of our Kunming meeting, along with a few photos.

Please let me know if you have comments and suggestions.

All best wishes, and happy holidays!

Shan-Lu



Shan-Lu Liu, M.D., Ph.D.

Professor

Co-Director, Viruses and Emerging Pathogens Program

Infectious Diseases Institute

Center for Retrovirus Research

Departments of Veterinary Biosciences, Microbial Infection and Immunity, and Microbiology

The Ohio State University

1900 Coffey Rd, Room 480 VMAB

Columbus, Ohio 43210

Phone: (614) 292-8690

Fax: (614) 292-6473

Email: [liu.6244@osu.edu](mailto:liu.6244@osu.edu); [shan-lu.liu@osumc.edu](mailto:shan-lu.liu@osumc.edu)



---

**From:** Tang, Qiyi <qiyi.tang@Howard.edu>  
**Sent:** Tuesday, July 7, 2020 11:47 PM  
**To:** Liu, Shan-Lu; zhengzhiming4@gmail.com; haitguo@iupui.edu; tzhou@mail.nih.gov; GCheng@mednet.ucla.edu; liangy@umn.edu; rli@vcu.edu; wjma@ksu.edu; xjmeng@vt.edu; Zhijian.Chen@UTSouthwestern.edu; mluo@gsu.edu; zhangyj@umd.edu; xzhu1@umd.edu; jqu@kumc.edu; lijun@uic.edu; fengwei.bai@usm.edu; andyu@iupui.edu; reachxw@vt.edu; gluo@uab.edu; ldu@nybc.org; hxx@tulane.edu; liu\_fy@berkeley.edu; shitao.li@okstate.edu; Lu, Shan; haihu@UTMB.edu; wenzheho@temple.edu; Qfeng4@central.uh.edu; tang@bio.fsu.edu; feng.li@sdsu.edu; ruilu@lsu.edu; sxian2@unl.edu; dingsw@ucr.edu; guohua@missouri.edu; bling@tulane.edu; junwang@pharmacy.arizona.edu; lifang@umn.edu; wang518@umd.edu; gaos8@upmc.edu; pewang@uchc.edu; xiangy@uthscsa.edu; fzhu@bio.fsu.edu; chen.liang@mcgill.ca; lyuan@vt.edu; fgao@duke.edu; wangjw28@163.com; xfyu1@zju.edu.cn; bzha@partners.org; jianw@usc.edu; zyang@ksu.edu; yu.cong@nih.gov; weiming.yuan@usc.edu; Zongdi.feng@nationwidechildrens.org; juh13@psu.edu; hengx@missouri.edu; lsu@med.unc.edu; ywu8@gmu.edu; jwu@whu.edu.cn; tshuo@uic.edu; Shibojiang@fudan.edu.cn; sjiang@nybc.org; pinwang@usc.edu; rzha@som.umaryland.edu; shuylong@mail.sysu.edu.cn; xuefeng.liu@georgetown.edu; yuxingli@som.umaryland.edu; Wang, Shixia; yhe@ipbcams.ac.cn; Pinghui.feng@usc.edu; ju-tao.guo@bblumberg.org; lin.liu@okstate.edu; hua.zhu@rutgers.edu; Jinhong.chang@bblumberg.org; jianzhu1012@gmail.com; ronghai@ucr.edu; jun.zhu@nih.gov; jliu4@uams.edu; xiangpeng.kong@med.nyu.edu; haoquanwu@outlook.com; Wenjun.liu@defence.gov.au; Liang.shan@wustl.edu; hliao@duke.edu; yuan2@upenn.edu; zxing@umn.edu; hongmin.li@health.ny.gov; pzheng@ihv.umaryland.edu; yaliu@ihv.umaryland.edu; jxw103@case.edu; xiangguo.qiu@canada.ca; Feng Shao; zshi@wh.iov.cn; klan@whu.edu.cn; zengmsh@mail.sysu.edu.cn; Nan Yan; Zhang, Rong; liliwang@upenn.edu; Linheng Li; kli1@uthsc.edu; tsx@case.edu; ssun@mdanderson.org; ysang@tnstate.edu; wu@crystal.harvard.edu; Sun.Jie@mayo.edu; peijun@strubi.ox.ac.uk; jiayu@coh.org; bchen@crystal.harvard.edu; Wen, Haitao; Qu, Feng; Hezhao.Ji@umanitoba.ca; Li, Zihai; zhengyo@msu.edu; zhanglinqi@tsinghua.edu.cn; wxiao@temple.edu; Whu@temple.edu; RSun@mednet.ucla.edu; Gao, Guangping; pzheng@ihv.umaryland.edu; GMSWANG@nus.edu.sg; peshi@UTMB.EDU; yaliu@ihv.umaryland.edu; ziyang-yan@uiowa.edu; lqiao@luc.edu; yong.xiong@yale.edu; Wang, Qihong; shuping\_tong\_md@brown.edu; pinghuif@usc.edu; gaof@im.ac.cn  
**Subject:** Re: Happy Thanksgiving and meeting next year, June 12-13, 2020

Hi professors,

I apologize if you are bothered by this email. I am helping my friend, Ed Seto to advertise his recruiting post-doc:

### Postdoctoral Position

Applications are invited for a postdoctoral fellowship to study the structures, functions, and mechanisms of histone deacetylases. Candidates with experiences in biochemical, molecular, and cell biological approaches are preferred.

Recent selected articles from our lab:

PMID: 32540961

PMID: 32457045

PMID: 31162605

PMID: 30517871

PMID: 30456376

PMID: 29958910

Please send a CV and names of three references to:

Ed Seto, Ph.D.

Email: [seto@gwu.edu](mailto:seto@gwu.edu)

---

**From:** Theresa Chang <changth@njms.rutgers.edu>  
**Sent:** Monday, September 14, 2020 1:23 PM  
**To:** Lu, Shan  
**Cc:** M. Yu-Mei Wen (ymwen@shmu.edu.cn); Min Yang  
**Subject:** Re: Inquiry: review status (TEMI-2020-1361)

Dear Dr. Lu,

Thank you for your response. We are grateful that our manuscript was reviewed. I understand the workload. I saw the timeline of other published papers so got a little worried. The submission site did not ask us to suggest reviewers but I should have suggested the reviewers in my cover letter to minimize the troubles you had gone through. I received the comments and feel that we can address them. We recently received the approval to work at BSL3 facility and found that HNP1 and RC101 blocked viral infection by replication competent GFP virus but we wish to repeat the experiment two more times. Regarding A549 cells, the infection of A549 cells is not as robust as Vero or cells overexpressing ACE2. But A549 cells have high abundance of CD147 and replication competent virus does get in. Nevertheless, we believe that defensins act on viral entry, which may be hACE2 independent.

Would you reconsider your decision and let us revise the manuscript to address the comments? Of course, we will understand if your decision is final.

Kind Regards,  
Theresa

On Sep 14, 2020, at 12:35 PM, Lu, Shan <Shan.Lu@umassmed.edu> wrote:

Dear Dr. Chang,

Given the large volume of submission, currently EMI is going through two phases of review.

For the first, a screening review is conducted by EMI editors and selected experts if needed so only about 25% of submitted manuscripts will pass based on the current priority of EMI. Your manuscript passed this phase of review.

The second phase is the external peer-review. Due to the high demand of review for COVID-19 papers, it is not so easy to secure experts to accept our invitation. In your case, we invited 38 candidates and only three agreed to review which takes some time. Generally this is not a good sign as reviewers still accept the invitation to a "high quality" paper based on their perception.

We gave reviewers two weeks' time and strictly enforce such deadline. At this point, two reviewers came back with not so positive opinion. I was hoping to wait the 3<sup>rd</sup> one and make the final decision in a few days. Since you are in hurry, I just made the decision as we share the sentiment from the first two reviewers. You should receive the formal decision email in a few minutes.

Thank you for your interest in EMI and best wishes to your research.

Best.

Shan

\*\*\*\*\*

*Shan Lu, MD, PhD*  
*Professor*  
*Department of Medicine*  
*U Mass Med School*  
*Worcester, MA01605*  
*USA*  
*Tel. 1-508-856-6791*  
*Email: shan.lu@umassmed.edu*

---

**From:** Theresa Chang <changth@njms.rutgers.edu>  
**Sent:** Monday, September 14, 2020 11:50 AM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Subject:** Fwd: Inquiry: review status (TEMI-2020-1361)

Dear Dr. Wen and Dr. Lu,

I am writing to follow up the status of our manuscript (TEMI-2020-1361) submitted on Aug 12, 2020. I understand your and reviewers' busy schedules. I apologize for not being able to find the information about the turnover time for the review process of your journal. We are anxious about your decision. We feel our study is important as the effect of antimicrobial peptides in viral pathogenesis is under studied. Considering the potential functions of neutrophils to protect hosts or exacerbate disease outcomes depending on the stage of viral infection, our study can have potential clinical relevance.

I thank you for giving us an opportunity to submit our manuscript for your consideration.

Kind Regards,

Theresa

Theresa L. Chang, PhD  
Principal Investigator, Public Health Research Institute  
Associate Professor, Microbiology, Biochemistry and Molecular Genetics  
Rutgers, New Jersey Medical School  
225 Warren Street, Newark, NJ 07103  
Office: [973-854-3265](tel:973-854-3265); Lab: [973-854-3266](tel:973-854-3266).  
<https://phri.njms.rutgers.edu/faculty-and-research/faculty/theresa-chang/>

---

**From:** Perlman, Stanley <stanley-perlman@uiowa.edu>  
**Sent:** Monday, July 20, 2020 11:50 AM  
**To:** Munster, Vincent (NIH/NIAID) [E]  
**Cc:** Lu, Shan; Gibson, Edward  
**Subject:** Re: Invitation

Vincent,

We are finalizing tomorrow's panel discussion. Will you be able to present, as planned?

Take care.

Stanley

Stanley Perlman, MD, Ph.D.  
Professor  
Depts of Microbiology and Immunology, and Pediatrics  
BSB 3-712  
University of Iowa  
Iowa City, IA 52242  
319-335-8549

On Jun 30, 2020, at 9:19 PM, Munster, Vincent (NIH/NIAID) [E] <[vincent.munster@nih.gov](mailto:vincent.munster@nih.gov)> wrote:

Dear Dr. Lu,

I would be happy to accept the invitation,

Kind regards,

Vincent Munster, PhD  
Chief Virus Ecology Section  
Rocky Mountain Laboratories  
NIAID/NIH

---

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Date:** Tuesday, June 30, 2020 at 6:14 PM  
**To:** "[vincent.munster@nih.gov](mailto:vincent.munster@nih.gov)" <[vincent.munster@nih.gov](mailto:vincent.munster@nih.gov)>  
**Cc:** "Perlman, Stanley" <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>, "Gibson, Edward" <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Subject:** Invitation

Dear Dr. Munster,



International Society for Vaccines (ISV, [www.isv-online.com](http://www.isv-online.com)) is organizing a virtual congress series focusing on COVID-19 vaccines and the first one held on June 22 was quite successful with about 1600 registered attendees.

On behalf of the Officers and Board of the ISV, we would be delighted if you were able to accept our invitation to speak at the 2nd *ISV Virtual Congress on COVID 19 Vaccines*, to be held on July 21, Tuesday. The exact time is yet to be finalized but most likely to be in the morning of your local time.

For this series of mini symposium updates we will host over the summer, vaccine developers, academics, policy makers and NGOs will share progress and their collective wisdom on the latest updates of COVID-19 vaccines to the global community. The program for the 1<sup>st</sup> congress is attached for your reference.

We plan to have a panel discussion session on the 2<sup>nd</sup> Virtual Congress dedicated to **Animal Models for Vaccines development against COVID-19** in which you will serve as a panelist to present your opinion on how to select the optimal animal models for COVID-19 vaccine development. Prof Stanley Perlman (copied here) will be the panel moderator and he nominated you to join the panel.

If you can accept our invitation to speak, the Conference Secretariat ([Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)) cc'd in, will contact you with more specific details for invited speakers.

Please feel free to contact us if you have any questions.

Looking forward to hearing from you.

Best regards,

On behalf of the ISV COVID-19 Congress co-chairs

Linda Klavinskis, Kings College London - UK

Margaret Liu, ProTherimmune - USA

Shan Lu, University of Massachusetts Medical School – USA

\*\*\*\*\*

*Shan Lu, MD, PhD*

*Professor*

*Department of Medicine*

*U Mass Med School*

*Worcester, MA01605*

*USA*

*Tel. 1-508-856-6791*

*Email: [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu)*

---

**From:** Munster, Vincent (NIH/NIAID) [E] <vincent.munster@nih.gov>  
**Sent:** Monday, July 20, 2020 12:01 PM  
**To:** Perlman, Stanley  
**Cc:** Lu, Shan; Gibson, Edward  
**Subject:** Re: Invitation

Yes,

How about the need for pre-clinical development studies for fast-tracked vaccine development?

This will largely discuss CEPI and Chadox?

5 minutes = 5-7 slides?

And the we have a round-table / round zoom?

Cheers,

Vincent Munster, PhD  
Chief Virus Ecology Section  
Rocky Mountain Laboratories  
NIAID/NIH

---

**From:** "Perlman, Stanley" <stanley-perlman@uiowa.edu>  
**Date:** Monday, July 20, 2020 at 9:50 AM  
**To:** "vincent.munster@nih.gov" <vincent.munster@nih.gov>  
**Cc:** "Lu, Shan" <Shan.Lu@umassmed.edu>, "Gibson, Edward" <Edward.Gibson@umassmed.edu>  
**Subject:** Re: Invitation

Vincent,

We are finalizing tomorrow's panel discussion. Will you be able to present, as planned?

Take care.

Stanley

Stanley Perlman, MD, Ph.D.  
Professor  
Depts of Microbiology and Immunology, and Pediatrics  
BSB 3-712  
University of Iowa  
Iowa City, IA 52242  
319-335-8549

On Jun 30, 2020, at 9:19 PM, Munster, Vincent (NIH/NIAID) [E] <[vincent.munster@nih.gov](mailto:vincent.munster@nih.gov)> wrote:

Dear Dr. Lu,

I would be happy to accept the invitation,

Kind regards,

Vincent Munster, PhD  
Chief Virus Ecology Section  
Rocky Mountain Laboratories  
NIAID/NIH

---

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Date:** Tuesday, June 30, 2020 at 6:14 PM  
**To:** "[vincent.munster@nih.gov](mailto:vincent.munster@nih.gov)" <[vincent.munster@nih.gov](mailto:vincent.munster@nih.gov)>  
**Cc:** "Perlman, Stanley" <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>, "Gibson, Edward" <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Subject:** Invitation

Dear Dr. Munster,

International Society for Vaccines (ISV, [www.isv-online.com](http://www.isv-online.com)) is organizing a virtual congress series focusing on COVID-19 vaccines and the first one held on June 22 was quite successful with about 1600 registered attendees.

On behalf of the Officers and Board of the ISV, we would be delighted if you were able to accept our invitation to speak at the 2nd *ISV Virtual Congress* on COVID 19 Vaccines, to be held on July 21, Tuesday. The exact time is yet to be finalized but most likely to be in the morning of your local time.

For this series of mini symposium updates we will host over the summer, vaccine developers, academics, policy makers and NGOs will share progress and their collective wisdom on the latest updates of COVID-19 vaccines to the global community. The program for the 1<sup>st</sup> congress is attached for your reference.

We plan to have a panel discussion session on the 2<sup>nd</sup> Virtual Congress dedicated to **Animal Models for Vaccines development against COVID-19** in which you will serve as a panelist to present your opinion on how to select the optimal animal models for COVID-19 vaccine development. Prof Stanley Perlman (copied here) will be the panel moderator and he nominated you to join the panel.

If you can accept our invitation to speak, the Conference Secretariat ([Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)) cc'd in, will contact you with more specific details for invited speakers.

Please feel free to contact us if you have any questions.

Looking forward to hearing from you.

Best regards,

On behalf of the ISV COVID-19 Congress co-chairs

Linda Klavinskis, Kings College London - UK

Margaret Liu, ProTherimmune - USA

Shan Lu, University of Massachusetts Medical School – USA

\*\*\*\*\*

*Shan Lu, MD, PhD*

*Professor*

*Department of Medicine*

*U Mass Med School*

*Worcester, MA01605*

*USA*

*Tel. 1-508-856-6791*

*Email: [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu)*

---

**From:** Munster, Vincent (NIH/NIAID) [E] <vincent.munster@nih.gov>  
**Sent:** Monday, July 20, 2020 2:39 PM  
**To:** Lu, Shan  
**Cc:** Perlman, Stanley; Gibson, Edward  
**Subject:** Re: Invitation

Sounds good, I can do 1:30 mountain time

On Jul 20, 2020, at 11:12, Lu, Shan <Shan.Lu@umassmed.edu> wrote:

Hi, Vincent,

Sounds good.

5-7 slides are great. then is the round table.

We will need to have a quick IT training as this Live-Event function is very different any online meeting software. Would you be able to join a 10-min training this afternoon?

Best.

Shan

---

**From:** Munster, Vincent (NIH/NIAID) [E] <vincent.munster@nih.gov>  
**Sent:** Monday, July 20, 2020 12:01 PM  
**To:** Perlman, Stanley <stanley-perlman@uiowa.edu>  
**Cc:** Lu, Shan <Shan.Lu@umassmed.edu>; Gibson, Edward <Edward.Gibson@umassmed.edu>  
**Subject:** Re: Invitation

Yes,

How about the need for pre-clinical development studies for fast-tracked vaccine development?

This will largely discuss CEPI and Chadox?

5 minutes = 5-7 slides?

And the we have a round-table / round zoom?

Cheers,

Vincent Munster, PhD  
Chief Virus Ecology Section  
Rocky Mountain Laboratories  
NIAID/NIH

---

**From:** "Perlman, Stanley" <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Date:** Monday, July 20, 2020 at 9:50 AM  
**To:** "vincent.munster@nih.gov" <[vincent.munster@nih.gov](mailto:vincent.munster@nih.gov)>  
**Cc:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>, "Gibson, Edward" <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Subject:** Re: Invitation

Vincent,

We are finalizing tomorrow's panel discussion. Will you be able to present, as planned?

Take care.

Stanley

Stanley Perlman, MD, Ph.D.  
Professor  
Depts of Microbiology and Immunology, and Pediatrics  
BSB 3-712  
University of Iowa  
Iowa City, IA 52242  
319-335-8549

On Jun 30, 2020, at 9:19 PM, Munster, Vincent (NIH/NIAID) [E] <[vincent.munster@nih.gov](mailto:vincent.munster@nih.gov)> wrote:

Dear Dr. Lu,

I would be happy to accept the invitation,

Kind regards,

Vincent Munster, PhD  
Chief Virus Ecology Section  
Rocky Mountain Laboratories  
NIAID/NIH

---

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Date:** Tuesday, June 30, 2020 at 6:14 PM  
**To:** "vincent.munster@nih.gov" <[vincent.munster@nih.gov](mailto:vincent.munster@nih.gov)>  
**Cc:** "Perlman, Stanley" <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>, "Gibson, Edward" <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Subject:** Invitation

Dear Dr. Munster,

International Society for Vaccines (ISV, [www.isv-online.com](http://www.isv-online.com)) is organizing a virtual congress series focusing on COVID-19 vaccines and the first one held on June 22 was quite successful with about 1600 registered attendees.

On behalf of the Officers and Board of the ISV, we would be delighted if you were able to accept our invitation to speak at the 2nd *ISV Virtual Congress* on COVID 19 Vaccines, to be held on July 21, Tuesday. The exact time is yet to be finalized but most likely to be in the morning of your local time.

For this series of mini symposium updates we will host over the summer, vaccine developers, academics, policy makers and NGOs will share progress and their collective wisdom on the latest updates of COVID-19 vaccines to the global community. The program for the 1<sup>st</sup> congress is attached for your reference.

We plan to have a panel discussion session on the 2<sup>nd</sup> Virtual Congress dedicated to **Animal Models for Vaccines development against COVID-19** in which you will serve as a panelist to present your opinion on how to select the optimal animal models for COVID-19 vaccine development. Prof Stanley Perlman (copied here) will be the panel moderator and he nominated you to join the panel.

If you can accept our invitation to speak, the Conference Secretariat ([Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)) cc'd in, will contact you with more specific details for invited speakers.

Please feel free to contact us if you have any questions.

Looking forward to hearing from you.

Best regards,

On behalf of the ISV COVID-19 Congress co-chairs

Linda Klavinskis, Kings College London - UK

Margaret Liu, ProTherimmune - USA

Shan Lu, University of Massachusetts Medical School – USA

\*\*\*\*\*

*Shan Lu, MD, PhD*

*Professor*

*Department of Medicine*

*U Mass Med School*

*Worcester, MA01605*

*USA*

*Tel. 1-508-856-6791*

*Email: [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu)*

---

**From:** Saif, Linda <saif.2@osu.edu>  
**Sent:** Tuesday, July 7, 2020 8:18 AM  
**To:** Lu, Shan  
**Subject:** Re: invitation from ISV

Sorry I forgot to ask about the time on July 21 for my talk?

Thanks

Linda

Linda J. Saif, PhD

Distinguished University Professor

Food Animal Health Research Program

OARDC/The Ohio State University

1680 Madison Ave

Wooster, Oh 44691

---

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Date:** Thursday, June 25, 2020 9:43 AM  
**To:** Linda Saif <[saif.2@osu.edu](mailto:saif.2@osu.edu)>  
**Cc:** "Gibson, Edward" <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Subject:** RE: invitation from ISV

Dear Linda,

Thank you so much! I will follow with more details.

Shan

---

**From:** Saif, Linda <[saif.2@osu.edu](mailto:saif.2@osu.edu)>  
**Sent:** Wednesday, June 24, 2020 9:05 PM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** Re: invitation from ISV

Hi Shan,

So sorry I missed the June 22 event and talks!

Yes I would be happy to speak on the topic noted.

I am also attaching a link to a brief COVID-19 vaccine review that I wrote that you may want to share with your members or others. In it I summarized some information on animal models related to SARS and MERS and challenges for SARS CoV-2 vaccines.

<https://www.emjreviews.com/allergy-immunology/article/vaccines-for-covid-19-perspectives-prospects-and-challenges-based-on-candidate-sars-mers-and-animal-coronavirus-vaccines/>

Another topic that could be of general interest might be a review of veterinary coronavirus vaccines, some of which have been widely used for years.

Thanks for the invitation and I am happy to hear that the commentary was widely downloaded—it remains relevant I think in terms of the ongoing issues about the origin of SARS-CoV-2.

Regards,

Linda

Linda J. Saif, PhD



Distinguished University Professor  
Food Animal Health Research Program  
OARDC/The Ohio State University  
1680 Madison Ave  
Wooster, Oh 44691

---

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Date:** Wednesday, June 24, 2020 7:00 PM  
**To:** Linda Saif <[saif.2@osu.edu](mailto:saif.2@osu.edu)>  
**Cc:** "Gibson, Edward" <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Subject:** invitation from ISV

Dear Linda,

Hope everything is well with you.

It has been quite a while since last time you published a commentary with Shan-Lu Liu and Lishan Su at our journal EMI. It is now one of the highest download read papers in our history: 69420. Congratulations!

On behalf of the Officers and Board of the *International Society for Vaccines* (ISV) <https://www.isv-online.org> we would be delighted if you were able to accept our invitation to speak at the 2nd ISV Virtual Congress on COVID 19 Vaccines, to be held on July 21, Tuesday. The exact time is yet to be finalized but most likely to be in the morning of your local time.

This will be the second of a series of mini symposium updates we will host over the summer, where vaccine developers, academics, policy makers and NGO's share progress and their collective wisdom on the latest updates to the wider global community.

We had a very successful 1<sup>ST</sup> Congress just a few days ago on June 22. We had 1600 registrations and a top-level speakers (see attached program for your reference).

We plan to have one scientific sessions on the 2<sup>nd</sup> Virtual Congress dedicated to **Animal Models for COVID-19 Vaccine Development** in which your expertise would fit perfectly.

If you can accept our invitation to speak, the Conference Secretariat ([Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)) cc'd in, will contact you with more specific details for invited speakers.

Please feel free to contact us if you have any questions.

Looking forward to hearing from you.

Best regards,

Shan

On behalf of the ISV COVID-19 Congress co-chairs

Linda Klavinskis, Kings College London - UK  
Margaret Liu, ProTherimmune - USA

Shan Lu, University of Massachusetts Medical School – USA

\*\*\*\*\*

*Shan Lu, MD, PhD*

*Professor*

*Department of Medicine*

*U Mass Med School*

*Worcester, MA01605*

*USA*

*Tel. 1-508-856-6791*

*Email: [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu)*

---

**From:** Saif, Linda <saif.2@osu.edu>  
**Sent:** Wednesday, June 24, 2020 9:05 PM  
**To:** Lu, Shan  
**Subject:** Re: invitation from ISV

Hi Shan,

So sorry I missed the June 22 event and talks!

Yes I would be happy to speak on the topic noted.

I am also attaching a link to a brief COVID-19 vaccine review that I wrote that you may want to share with your members or others. In it I summarized some information on animal models related to SARS and MERS and challenges for SARS CoV-2 vaccines.

<https://www.emjreviews.com/allergy-immunology/article/vaccines-for-covid-19-perspectives-prospects-and-challenges-based-on-candidate-sars-mers-and-animal-coronavirus-vaccines/>

Another topic that could be of general interest might be a review of veterinary coronavirus vaccines, some of which have been widely used for years.

Thanks for the invitation and I am happy to hear that the commentary was widely downloaded—it remains relevant I think in terms of the ongoing issues about the origin of SARS-CoV-2.

Regards,  
Linda

Linda J. Saif, PhD  
Distinguished University Professor  
Food Animal Health Research Program  
OARDC/The Ohio State University  
1680 Madison Ave  
Wooster, Oh 44691

---

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Date:** Wednesday, June 24, 2020 7:00 PM  
**To:** Linda Saif <[saif.2@osu.edu](mailto:saif.2@osu.edu)>  
**Cc:** "Gibson, Edward" <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Subject:** invitation from ISV

Dear Linda,

Hope everything is well with you.

It has been quite a while since last time you published a commentary with Shan-Lu Liu and Lishan Su at our journal EMI. It is now one of the highest download read papers in our history: 69420. Congratulations!

On behalf of the Officers and Board of the *International Society for Vaccines* (ISV) <https://www.isv-online.org> we would be delighted if you were able to accept our invitation to speak at the 2nd ISV Virtual Congress on COVID 19 Vaccines, to be held on July 21, Tuesday. The exact time is yet to be finalized but most likely to be in the morning of your local time.

This will be the second of a series of mini symposium updates we will host over the summer, where vaccine developers, academics, policy makers and NGO's share progress and their collective wisdom on the latest updates to the wider global community.

We had a very successful 1<sup>ST</sup> Congress just a few days ago on June 22. We had 1600 registrations and a top-level speakers (see attached program for your reference).

We plan to have one scientific sessions on the 2<sup>nd</sup> Virtual Congress dedicated to **Animal Models for COVID-19 Vaccine Development** in which your expertise would fit perfectly.

If you can accept our invitation to speak, the Conference Secretariat ([Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)) cc'd in, will contact you with more specific details for invited speakers.

Please feel free to contact us if you have any questions.

Looking forward to hearing from you.

Best regards,

Shan

On behalf of the ISV COVID-19 Congress co-chairs

Linda Klavinskis, Kings College London - UK  
Margaret Liu, ProTherimmune - USA  
Shan Lu, University of Massachusetts Medical School – USA

\*\*\*\*\*

*Shan Lu, MD, PhD*  
*Professor*  
*Department of Medicine*  
*U Mass Med School*  
*Worcester, MA01605*  
*USA*  
*Tel. 1-508-856-6791*  
*Email: [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu)*

---

**From:** Munster, Vincent (NIH/NIAID) [E] <vincent.munster@nih.gov>  
**Sent:** Tuesday, June 30, 2020 10:19 PM  
**To:** Lu, Shan  
**Cc:** Perlman, Stanley; Gibson, Edward  
**Subject:** Re: Invitation

Dear Dr. Lu,

I would be happy to accept the invitation,

Kind regards,

Vincent Munster, PhD  
Chief Virus Ecology Section  
Rocky Mountain Laboratories  
NIAID/NIH

---

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Date:** Tuesday, June 30, 2020 at 6:14 PM  
**To:** "vincent.munster@nih.gov" <vincent.munster@nih.gov>  
**Cc:** "Perlman, Stanley" <stanley-perlman@uiowa.edu>, "Gibson, Edward" <Edward.Gibson@umassmed.edu>  
**Subject:** Invitation

Dear Dr. Munster,

International Society for Vaccines (ISV, [www.isv-online.com](http://www.isv-online.com)) is organizing a virtual congress series focusing on COVID-19 vaccines and the first one held on June 22 was quite successful with about 1600 registered attendees.

On behalf of the Officers and Board of the ISV, we would be delighted if you were able to accept our invitation to speak at the 2nd *ISV Virtual Congress* on COVID 19 Vaccines, to be held on July 21, Tuesday. The exact time is yet to be finalized but most likely to be in the morning of your local time.

For this series of mini symposium updates we will host over the summer, vaccine developers, academics, policy makers and NGOs will share progress and their collective wisdom on the latest updates of COVID-19 vaccines to the global community. The program for the 1<sup>st</sup> congress is attached for your reference.

We plan to have a panel discussion session on the 2<sup>nd</sup> Virtual Congress dedicated to **Animal Models for Vaccines development against COVID-19** in which you will serve as a panelist to present your opinion on how to select the optimal animal models for COVID-19 vaccine development. Prof Stanley Perlman (copied here) will be the panel moderator and he nominated you to join the panel.

If you can accept our invitation to speak, the Conference Secretariat ([Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)) cc'd in, will contact you with more specific details for invited speakers.

Please feel free to contact us if you have any questions.

Looking forward to hearing from you.

Best regards,

On behalf of the ISV COVID-19 Congress co-chairs

Linda Klavinskis, Kings College London - UK

Margaret Liu, ProTherimmune - USA

Shan Lu, University of Massachusetts Medical School – USA

\*\*\*\*\*

*Shan Lu, MD, PhD*

*Professor*

*Department of Medicine*

*U Mass Med School*

*Worcester, MA01605*

*USA*

*Tel. 1-508-856-6791*

*Email: [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu)*

---

**From:** Britta Wahren <britta.wahren@ki.se>  
**Sent:** Friday, April 2, 2021 1:28 PM  
**To:** Peter Nara; Manon Cox  
**Cc:** rahmed@emory.edu; randy.albrecht@mssm.edu; abarrett@utmb.edu; annied@epivax.com; denise.doolan@jcu.edu.au; rellis.hvi@gmail.com; emilio.emini@gatesfoundation.org; adolfo.garcia-sastre@mssm.edu; nathalie.garcon@bioaster.org; marc.girard36@wanadoo.fr; bruno.guy@sanofipasteur.com; adrian.hill@ndm.ox.ac.uk; kenishii@biken.osaka-u.ac.jp; kathrin.jansen@pfizer.com; marie-paule.kieny@inserm.fr; linda.klavinskis@kcl.ac.uk; klinmand@gmail.com; paul.lambert@unige.ch; mlevine@medicine.umaryland.edu; liu@protherimmune.com; Lu, Shan; offit@email.chop.edu; j.oxford@qmul.ac.uk; immgcpa@micro.ufrj.br; peter.palese@mssm.edu; punnee.pit@mahidol.ac.th; stanley.plotkin@vaxconsult.com; rino.r.rappuoli@gsk.com; jhrhee@chonnam.ac.kr; tedross@uga.edu; connie.s.schmaljohn.civ@mail.mil; matthias.schnell@jefferson.edu; johnwshiver@gmail.com; slifkam@ohsu.edu; indresh.srivastava@sanofi.com; ftangy@pasteur.fr; jeffreyulmerllc@gmail.com; dweiner@wistar.org; ymwen@shmu.edu.cn; anna-lise.williamson@uct.ac.za; Klavinskis, Linda; Lu, Shan; Gibson, Edward  
**Subject:** RE: ISV Congress 2021: Your input is requested

Dear Peter, everybody

I agree with the notion that we have a zoom fatigue.

Response to Q 3. It is a good idea to make talks (short) that can be seen afterwards, with attractive titles, maybe certain subjects per se.

I think everybody should be permitted to submit 2-4 slides on a certain subject. Perhaps a subject for each pathogen to make it simple,

The also concentrate the most interesting ones to sessions.

Response to Qs 1 and 2. No, but thank you for asking! Britta, ISV fellow.

---

**From:** Peter Nara <nara@bmi-md.com>  
**Sent:** Friday, 2 April 2021 15:20  
**To:** Manon Cox <manoncox@gmail.com>  
**Cc:** rahmed@emory.edu; randy.albrecht@mssm.edu; abarrett@utmb.edu; annied@epivax.com; denise.doolan@jcu.edu.au; rellis.hvi@gmail.com; emilio.emini@gatesfoundation.org; adolfo.garcia-sastre@mssm.edu; nathalie.garcon@bioaster.org; marc.girard36@wanadoo.fr; bruno.guy@sanofipasteur.com; adrian.hill@ndm.ox.ac.uk; kenishii@biken.osaka-u.ac.jp; kathrin.jansen@pfizer.com; marie-paule.kieny@inserm.fr; linda.klavinskis@kcl.ac.uk; klinmand@gmail.com; paul.lambert@unige.ch; mlevine@medicine.umaryland.edu; liu@protherimmune.com; shan.lu@umassmed.edu; offit@email.chop.edu; j.oxford@qmul.ac.uk; immgcpa@micro.ufrj.br; peter.palese@mssm.edu; punnee.pit@mahidol.ac.th; stanley.plotkin@vaxconsult.com; rino.r.rappuoli@gsk.com; jhrhee@chonnam.ac.kr; tedross@uga.edu; connie.s.schmaljohn.civ@mail.mil; matthias.schnell@jefferson.edu; johnwshiver@gmail.com; slifkam@ohsu.edu; indresh.srivastava@sanofi.com; ftangy@pasteur.fr; jeffreyulmerllc@gmail.com; Britta Wahren <britta.wahren@ki.se>; dweiner@wistar.org; ymwen@shmu.edu.cn; anna-lise.williamson@uct.ac.za; Klavinskis, Linda <linda.klavinskis@kcl.ac.uk>; Lu, Shan <Shan.Lu@umassmed.edu>; Gibson, Edward <Edward.Gibson@umassmed.edu>  
**Subject:** Re: ISV Congress 2021: Your input is requested

Sure... be glad to. Also as one of the ISV Fellows ...;

Peter Nara

Sent from my iPhone

On Apr 1, 2021, at 9:09 AM, Manon Cox <[manoncox@gmail.com](mailto:manoncox@gmail.com)> wrote:

**Please respond to this email no later than April 8<sup>th</sup>, 2021**

Dear ISV-fellows:

As you may have expected, ISV officers decided that it would be too risky to organize this years' ISV congress as an in-person meeting given the uncertainties surrounding travel during the ongoing COVID situation.

I am honoured that I was asked to Chair the next (virtual) ISV congress scheduled for September 12 -15, 2021. Not an easy task as many of us have reached a certain Zoom fatigue and ISV has already organized multiple successful short seminars with excellent attendance.

We would like to come up with an original conference design that will attract many of our colleagues and young scientists. I am seeking **your help** in coming up with ideas and topics for this conference.

The plan is to offer some pre-recorded sessions on relevant topics such as New Vaccines on the Horizon; Regulatory Affairs; RNA vaccines – what is next? etc. and keynote lectures. These sessions can be watched by attendees at any given point in time.

We are also looking to arrange submission for presentations or posters in a somewhat different format, such as asking people who apply for a “oral presentation” to send in a 5-minute pre-recorded pitch. We can make a collage of the best presentations and/or select speakers this way.

In addition, to this we would like to offer some dynamic interaction where participants can sign up to break-out rooms to discuss topics of interest. For example, one session could be “Meet the ISV fellows”; “Meet the Key Note Speakers” or “Meet the Poster presenters”.

I would like to conclude with three specific questions:

- 1) Would you be willing to help organize?
- 2) Would you be willing to be present in a break-out room to meet w attendees?
- 3) Do you have ideas/suggestions for format and/or content?

Thank you in advance for your response!

Warm regards, Manon



*Sending email to Karolinska Institutet (KI) will result in KI processing your personal data. [You can read more about KI's processing of personal data here.](#)*

---

**From:** Perlman, Stanley <stanley-perlman@uiowa.edu>  
**Sent:** Monday, July 20, 2020 8:23 AM  
**To:** Lu, Shan; Klavinskis, Linda  
**Cc:** Gibson, Edward  
**Subject:** Re: ISV Congress Panel Discussion

Shan,

Did Vincent accept the initial invitation or did you never hear from him?

Stanley

Stanley Perlman, M.D., Ph.D.  
Professor  
Department of Microbiology  
University of Iowa

---

**From:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Sent:** Monday, July 20, 2020 5:55 AM  
**To:** Perlman, Stanley <stanley-perlman@uiowa.edu>; Klavinskis, Linda <linda.klavinskis@kcl.ac.uk>  
**Cc:** Gibson, Edward <Edward.Gibson@umassmed.edu>  
**Subject:** ISV Congress Panel Discussion

Dear Stanley,

As I discussed with you yesterday, Vincent Munster still has not responded to our emails at this point. We need to have a backup plan.

First, do you feel if you need to contact him to find out what is happening, and verify if he will join us?

If for some reason, he can not join us, should we just have two panelists Bart Haggmans and Linda Saif? It may provide more room for their discussion, and certainly you can contribute more discussion beyond just moderating.

My co-chair Linda Klavinskis mentioned other possible back up panelist, but given the short time notice and preparation, we are not inviting at this point.

Your advice is greatly appreciate.

Best.

Shan

---

**From:** Perlman, Stanley <stanley-perlman@uiowa.edu>  
**Sent:** Monday, June 22, 2020 2:17 PM  
**To:** Lu, Shan; Gibson, Edward  
**Cc:** 'cindicallaghan@isv-online.org'; 'EdwardGibson@isvcongress.org'  
**Subject:** Re: ISV Virtual Congress Reminder

Shan,

Thanks for inviting me. It was a great meeting. Next time, the meeting coincides with the Cold Spring Symposium, of which I am a co-organizer. I will need to be in two places at the same time!

Stanley

Stanley Perlman, M.D., Ph.D.  
Professor  
Department of Microbiology  
University of Iowa

---

**From:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Sent:** Monday, June 22, 2020 12:36 PM  
**To:** Perlman, Stanley <stanley-perlman@uiowa.edu>; Gibson, Edward <Edward.Gibson@umassmed.edu>  
**Cc:** 'cindicallaghan@isv-online.org' <cindicallaghan@isv-online.org>; 'EdwardGibson@isvcongress.org' <EdwardGibson@isvcongress.org>  
**Subject:** RE: ISV Virtual Congress Reminder

Dear Stanley,

Thank you so much for giving a wonderful presentation even with such a short time slot! You have very deep thinking from great knowledge about CoV.

Please keep in touch! I also still hope to get some good papers from you for EMI.

Best.

Shan

\*\*\*\*\*

*Shan Lu, MD, PhD*  
*Co-chair, ISV Virtual Congress*  
*President Emeritus, International Society for Vaccines*  
*Editor-in-Chief*  
*Emerging Microbes & Infections*  
*Professor*  
*Department of Medicine*  
*U Mass Med School*  
*Worcester, MA01605*  
*USA*  
*Tel. 1-508-856-6791*  
*Email: [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu)*

---

**From:** Perlman, Stanley <stanley-perlman@uiowa.edu>  
**Sent:** Sunday, June 21, 2020 9:40 PM  
**To:** Gibson, Edward <Edward.Gibson@umassmed.edu>  
**Cc:** Lu, Shan <Shan.Lu@umassmed.edu>; 'cindicallaghan@isv-online.org' <cindicallaghan@isv-online.org>; 'EdwardGibson@isvcongress.org' <EdwardGibson@isvcongress.org>  
**Subject:** Re: ISV Virtual Congress Reminder

Ted,

I will start as part of the audience at 9 am and then switch to the speaker mode at 11 am EDT.

Stanley Perlman, M.D., Ph.D.  
Professor  
Department of Microbiology  
University of Iowa

---

**From:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Sent:** Sunday, June 21, 2020 8:38 PM  
**To:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; 'cindicallaghan@isv-online.org' <[cindicallaghan@isv-online.org](mailto:cindicallaghan@isv-online.org)>; 'EdwardGibson@isvcongress.org' <[EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org)>  
**Subject:** ISV Virtual Congress Reminder

Dear Professor Perlman,

We are very excited that our virtual congress will start in 12 hrs. Here are a few key last-minute reminders to you:

- You will join the congress as a speaker so there is no link for you to connect.
- As in our training you need to join through your desktop Microsoft Teams software: Double click to bring it up >> enter the Guest ID and the password we sent you >> you are inside Teams >> looking at the left side of Teams field locate a button called "Calendar" >> click that to open calendar and find "First ISV COVID-19 Vaccine Virtual Congress" box, click that once>> on the new page, find a small box called "Join", click it once, then you should be joining the presenter's room.
- After you have joined the presenter room, you will see quite a few monitors. If the congress is live, you need to keep quiet. If you mute yourself or are placed on mute, please unmute yourself prior to your presentation.
- You need to follow the instruction of your session chair.
- When your name is mentioned by your chair, your video will have a RED outside box, that means you are live and you should start talking.
- Please see attached instructions if you need any reminders.

Please feel free to let us know if you have any questions. You can reply to Edward and Cindi (cc 'ed here).

If there is any issue requiring a phone call, here is the international free dialing number. You will need to email us to let us know a call is required.

18005018979 toll-free within US and Canada  
Access Code: 8566791

Also, we will record the congress and make it available for public viewing. Please let us know if you have any concern or objection within 12 hrs after the congress. Your support is greatly appreciated.

Best.

Shan Lu

Co-Chair

ISV 1<sup>st</sup> Virtual Congress

<https://isvcongress.org/>



---

**From:** Perlman, Stanley <stanley-perlman@uiowa.edu>  
**Sent:** Monday, June 22, 2020 3:04 PM  
**To:** Lu, Shan  
**Cc:** Gibson, Edward; cindicallaghan@isv-online.org; EdwardGibson@isvcongress.org  
**Subject:** Re: ISV Virtual Congress Reminder

Virtual

Stanley Perlman, MD, Ph.D.  
Professor  
Depts of Microbiology and Immunology, and Pediatrics  
BSB 3-712  
University of Iowa  
Iowa City, IA 52242  
319-335-8549

On Jun 22, 2020, at 1:58 PM, Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> wrote:

Sorry to hear that. Will that one be real or virtual? I will keep that in mind.

Shan

---

**From:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Sent:** Monday, June 22, 2020 2:17 PM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Cc:** '[cindicallaghan@isv-online.org](mailto:cindicallaghan@isv-online.org)' <[cindicallaghan@isv-online.org](mailto:cindicallaghan@isv-online.org)>; '[EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org)' <[EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org)>  
**Subject:** Re: ISV Virtual Congress Reminder

Shan,

Thanks for inviting me. It was a great meeting. Next time, the meeting coincides with the Cold Spring Symposium, of which I am a co-organizer. I will need to be in two places at the same time!

Stanley

Stanley Perlman, M.D., Ph.D.  
Professor  
Department of Microbiology  
University of Iowa

---

**From:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Sent:** Monday, June 22, 2020 12:36 PM  
**To:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>; Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Cc:** '[cindicallaghan@isv-online.org](mailto:cindicallaghan@isv-online.org)' <[cindicallaghan@isv-online.org](mailto:cindicallaghan@isv-online.org)>; '[EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org)'

<[EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org)>

**Subject:** RE: ISV Virtual Congress Reminder

Dear Stanley,

Thank you so much for giving a wonderful presentation even with such a short time slot! You have very deep thinking from great knowledge about CoV.

Please keep in touch! I also still hope to get some good papers from you for EMI.

Best.

Shan

\*\*\*\*\*

*Shan Lu, MD, PhD  
Co-chair, ISV Virtual Congress  
President Emeritus, International Society for Vaccines  
Editor-in-Chief  
Emerging Microbes & Infections  
Professor  
Department of Medicine  
U Mass Med School  
Worcester, MA01605  
USA  
Tel. 1-508-856-6791  
Email: [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu)*

---

**From:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>

**Sent:** Sunday, June 21, 2020 9:40 PM

**To:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>

**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; '[cindicallaghan@isv-online.org](mailto:cindicallaghan@isv-online.org)' <[cindicallaghan@isv-online.org](mailto:cindicallaghan@isv-online.org)>; '[EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org)' <[EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org)>

**Subject:** Re: ISV Virtual Congress Reminder

Ted,

I will start as part of the audience at 9 am and then switch to the speaker mode at 11 am EDT.

Stanley Perlman, M.D., Ph.D.  
Professor  
Department of Microbiology  
University of Iowa

---

**From:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>

**Sent:** Sunday, June 21, 2020 8:38 PM

**To:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>

**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; '[cindicallaghan@isv-online.org](mailto:cindicallaghan@isv-online.org)' <[cindicallaghan@isv-online.org](mailto:cindicallaghan@isv-online.org)>; '[EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org)' <[EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org)>

**Subject:** ISV Virtual Congress Reminder

Dear Professor Perlman,

We are very excited that our virtual congress will start in 12 hrs. Here are a few key last-minute reminders to you:

- You will join the congress as a speaker so there is no link for you to connect.
- As in our training you need to join through your desktop Microsoft Teams software: Double click to bring it up >> enter the Guest ID and the password we sent you >> you are inside Teams >> looking at the left side of Teams field locate a button called “Calendar” >> click that to open calendar and find “First ISV COVID-19 Vaccine Virtual Congress” box, click that once>> on the new page, find a small box called “Join”, click it once, then you should be joining the presenter’s room.
- After you have joined the presenter room, you will see quite a few monitors. If the congress is live, you need to keep quiet. If you mute yourself or are placed on mute, please unmute yourself prior to your presentation.
- You need to follow the instruction of your session chair.
- When your name is mentioned by your chair, your video will have a RED outside box, that means you are live and you should start talking.
- Please see attached instructions if you need any reminders.

Please feel free to let us know if you have any questions. You can reply to Edward and Cindi (cc ’ed here).

If there is any issue requiring a phone call, here is the international free dialing number. You will need to email us to let us know a call is required.

18005018979 toll-free within US and Canada  
Access Code: 8566791

Also, we will record the congress and make it available for public viewing. Please let us know if you have any concern or objection within 12 hrs after the congress. Your support is greatly appreciated.

Best.

Shan Lu  
Co-Chair  
ISV 1<sup>st</sup> Virtual Congress  
<https://isvcongress.org/>  
<image001.png>



---

**From:** Perlman, Stanley <stanley-perlman@uiowa.edu>  
**Sent:** Tuesday, June 30, 2020 1:17 PM  
**To:** Lu, Shan  
**Subject:** Re: ISV Virtual Congress Reminder

Shan,

I am sorry for the delay in answering your email. I am happy to serve as a moderator. I will balance my attendance at the two meetings. Bart Haagmans is a good choice since he has done preclinical vaccine work. Vincent Munster at RML would be another good choice.

Over the next few sessions, there should be more information from Phase 1-3 trials available and this information would be interesting to discuss.

Stanley

Stanley Perlman, MD, Ph.D.  
Professor  
Depts of Microbiology and Immunology, and Pediatrics  
BSB 3-712  
University of Iowa  
Iowa City, IA 52242  
319-335-8549

On Jun 30, 2020, at 6:23 AM, Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> wrote:

Hi, Stanley,

I am following up on my email below.

We are thinking to have the last panel discussion to focus on CoV animal models, and wonder if you can serve as the moderator (see draft program attached, please do not share with anyone yet). I realize that you need to run Cold Spring Harbor meeting on July 21, but is it possible for you to take no more than 1-hr away from that meeting to ours? The magic virtual world may make this possible to split you into two places 😊

Bart Naagermans from Europe was nominated to be another panel member. What is your opinion?

Best.

Shan

---

**From:** Lu, Shan  
**Sent:** Sunday, June 28, 2020 2:32 PM  
**To:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Subject:** RE: ISV Virtual Congress Reminder

Hi, Stanley,

The congress video is at YouTube now. Feel free to check [https://www.youtube.com/channel/UC9 - f8tDAqOmVEZWqGeuFow](https://www.youtube.com/channel/UC9-f8tDAqOmVEZWqGeuFow) and let's know with any feedback.

I would like to get your advice on questions related to the next congress.

1. Animal models: I am thinking to put the animal models as the topic for panel discussion as we did this time. Who do you think are the good candidates as panelists for this topic? I assume that you also do a lot of animal model work? ideally the animal models useful for vaccines, not just pathogenesis research.
2. For future congresses, what other key topics you would like to cover?

Thanks.

Shan

---

**From:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Sent:** Monday, June 22, 2020 3:04 PM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>; [cindicallaghan@isv-online.org](mailto:cindicallaghan@isv-online.org); [EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org)  
**Subject:** Re: ISV Virtual Congress Reminder

Virtual

Stanley Perlman, MD, Ph.D.  
Professor  
Depts of Microbiology and Immunology, and Pediatrics  
BSB 3-712  
University of Iowa  
Iowa City, IA 52242  
319-335-8549

On Jun 22, 2020, at 1:58 PM, Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> wrote:

Sorry to hear that. Will that one be real or virtual? I will keep that in mind.

Shan

---

**From:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Sent:** Monday, June 22, 2020 2:17 PM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Cc:** '[cindicallaghan@isv-online.org](mailto:cindicallaghan@isv-online.org)' <[cindicallaghan@isv-online.org](mailto:cindicallaghan@isv-online.org)>; '[EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org)' <[EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org)>  
**Subject:** Re: ISV Virtual Congress Reminder

Shan,

Thanks for inviting me. It was a great meeting. Next time, the meeting coincides with the Cold Spring Symposium, of which I am a co-organizer. I will need to be in two places at the same time!

Stanley

Stanley Perlman, M.D., Ph.D.  
Professor  
Department of Microbiology  
University of Iowa

---

**From:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Sent:** Monday, June 22, 2020 12:36 PM  
**To:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>; Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Cc:** 'cindicallaghan@isv-online.org' <[cindicallaghan@isv-online.org](mailto:cindicallaghan@isv-online.org)>; 'EdwardGibson@isvcongress.org' <[EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org)>  
**Subject:** RE: ISV Virtual Congress Reminder

Dear Stanley,

Thank you so much for giving a wonderful presentation even with such a short time slot! You have very deep thinking from great knowledge about CoV.

Please keep in touch! I also still hope to get some good papers from you for EMI.

Best.

Shan

\*\*\*\*\*

*Shan Lu, MD, PhD  
Co-chair, ISV Virtual Congress  
President Emeritus, International Society for Vaccines  
Editor-in-Chief  
Emerging Microbes & Infections  
Professor  
Department of Medicine  
U Mass Med School  
Worcester, MA01605  
USA  
Tel. 1-508-856-6791  
Email: [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu)*

---

**From:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Sent:** Sunday, June 21, 2020 9:40 PM  
**To:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; 'cindicallaghan@isv-online.org' <[cindicallaghan@isv-online.org](mailto:cindicallaghan@isv-online.org)>; 'EdwardGibson@isvcongress.org' <[EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org)>  
**Subject:** Re: ISV Virtual Congress Reminder

Ted,

I will start as part of the audience at 9 am and then switch to the speaker mode at 11 am EDT.

Stanley Perlman, M.D., Ph.D.  
Professor  
Department of Microbiology  
University of Iowa

---

**From:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Sent:** Sunday, June 21, 2020 8:38 PM  
**To:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; '[cindicallaghan@isv-online.org](mailto:cindicallaghan@isv-online.org)'  
<[cindicallaghan@isv-online.org](mailto:cindicallaghan@isv-online.org)>; '[EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org)'  
<[EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org)>  
**Subject:** ISV Virtual Congress Reminder

Dear Professor Perlman,

We are very excited that our virtual congress will start in 12 hrs. Here are a few key last-minute reminders to you:

- You will join the congress as a speaker so there is no link for you to connect.
- As in our training you need to join through your desktop Microsoft Teams software: Double click to bring it up >> enter the Guest ID and the password we sent you >> you are inside Teams >> looking at the left side of Teams field locate a button called "Calendar" >> click that to open calendar and find "First ISV COVID-19 Vaccine Virtual Congress" box, click that once>> on the new page, find a small box called "Join", click it once, then you should be joining the presenter's room.
- After you have joined the presenter room, you will see quite a few monitors. If the congress is live, you need to keep quiet. If you mute yourself or are placed on mute, please unmute yourself prior to your presentation.
- You need to follow the instruction of your session chair.
- When your name is mentioned by your chair, your video will have a RED outside box, that means you are live and you should start talking.
- Please see attached instructions if you need any reminders.

Please feel free to let us know if you have any questions. You can reply to Edward and Cindi (cc 'ed here).

If there is any issue requiring a phone call, here is the international free dialing number. You will need to email us to let us know a call is required.

18005018979 toll-free within US and Canada  
Access Code: 8566791

Also, we will record the congress and make it available for public viewing. Please let us know if you have any concern or objection within 12 hrs after the congress. Your support is greatly appreciated.

Best.

Shan Lu  
Co-Chair  
ISV 1<sup>st</sup> Virtual Congress  
<https://isvcongress.org/>

<image001.png>

<2nd ISV Virtual Congress draft program 0630.docx>

---

**From:** Perlman, Stanley <stanley-perlman@uiowa.edu>  
**Sent:** Tuesday, June 30, 2020 5:02 PM  
**To:** Lu, Shan  
**Subject:** Re: ISV Virtual Congress Reminder

[vincent.munster@nih.gov](mailto:vincent.munster@nih.gov)

Will you contact him directly?  
Let me know if you need my help. He is generally very responsive.

Stanley Perlman, MD, Ph.D.  
Professor  
Depts of Microbiology and Immunology, and Pediatrics  
BSB 3-712  
University of Iowa  
Iowa City, IA 52242  
319-335-8549

On Jun 30, 2020, at 3:24 PM, Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> wrote:

Hi, Stanley,

No problem as being a CoV expert, you must be super busy at this time.

My co-chairs also like the idea so you are now officially the moderator for the final panel discussion session: "the role of animal models in covid 19 vaccine development".

Can you connect me to Vincent Munster so I can invite him formally?

Best.

Shan

---

**From:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Sent:** Tuesday, June 30, 2020 1:17 PM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** Re: ISV Virtual Congress Reminder

Shan,

I am sorry for the delay in answering your email. I am happy to serve as a moderator. I will balance my attendance at the two meetings. Bart Haagmans is a good choice since he has done preclinical vaccine work. Vincent Munster at RML would be another good choice.

Over the next few sessions, there should be more information from Phase 1-3 trials available and this information would be interesting to discuss.

Stanley

Stanley Perlman, MD, Ph.D.  
Professor  
Depts of Microbiology and Immunology, and Pediatrics  
BSB 3-712  
University of Iowa  
Iowa City, IA 52242  
319-335-8549

On Jun 30, 2020, at 6:23 AM, Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> wrote:

Hi, Stanley,

I am following up on my email below.

We are thinking to have the last panel discussion to focus on CoV animal models, and wonder if you can serve as the moderator (see draft program attached, please do not share with anyone yet). I realize that you need to run Cold Spring Harbor meeting on July 21, but is it possible for you to take no more than 1-hr away from that meeting to ours? The magic virtual world may make this possible to split you into two places 😊

Bart Naagermans from Europe was nominated to be another panel member. What is your opinion?

Best.

Shan

---

**From:** Lu, Shan  
**Sent:** Sunday, June 28, 2020 2:32 PM  
**To:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Subject:** RE: ISV Virtual Congress Reminder

Hi, Stanley,

The congress video is at YouTube now. Feel free to check [https://www.youtube.com/channel/UC9\\_-f8tDAqOmVEZWqGeuFow](https://www.youtube.com/channel/UC9_-f8tDAqOmVEZWqGeuFow) and let's know with any feedback.

I would like to get your advice on questions related to the next congress.

1. Animal models: I am thinking to put the animal models as the topic for panel discussion as we did this time. Who do you think are the good candidates as panelists for this topic? I assume that you also do a lot of animal model work? ideally the animal models useful for vaccines, not just pathogenesis research.
2. For future congresses, what other key topics you would like to cover?

Thanks.

Shan

---

**From:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Sent:** Monday, June 22, 2020 3:04 PM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>; [cindicallaghan@isv-online.org](mailto:cindicallaghan@isv-online.org); [EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org)  
**Subject:** Re: ISV Virtual Congress Reminder

Virtual

Stanley Perlman, MD, Ph.D.  
Professor  
Depts of Microbiology and Immunology, and Pediatrics  
BSB 3-712  
University of Iowa  
Iowa City, IA 52242  
319-335-8549

On Jun 22, 2020, at 1:58 PM, Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> wrote:

Sorry to hear that. Will that one be real or virtual? I will keep that in mind.

Shan

---

**From:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Sent:** Monday, June 22, 2020 2:17 PM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Cc:** '[cindicallaghan@isv-online.org](mailto:cindicallaghan@isv-online.org)' <[cindicallaghan@isv-online.org](mailto:cindicallaghan@isv-online.org)>; '[EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org)' <[EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org)>  
**Subject:** Re: ISV Virtual Congress Reminder

Shan,

Thanks for inviting me. It was a great meeting. Next time, the meeting coincides with the Cold Spring Symposium, of which I am a co-organizer. I will need to be in two places at the same time!

Stanley

Stanley Perlman, M.D., Ph.D.  
Professor  
Department of Microbiology  
University of Iowa

---

**From:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Sent:** Monday, June 22, 2020 12:36 PM



**To:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>; Gibson, Edward  
<[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Cc:** '[cindicallaghan@isv-online.org](mailto:cindicallaghan@isv-online.org)' <[cindicallaghan@isv-online.org](mailto:cindicallaghan@isv-online.org)>;  
'[EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org)' <[EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org)>  
**Subject:** RE: ISV Virtual Congress Reminder

Dear Stanley,

Thank you so much for giving a wonderful presentation even with such a short time slot! You have very deep thinking from great knowledge about CoV.

Please keep in touch! I also still hope to get some good papers from you for EMI.

Best.

Shan

\*\*\*\*\*

*Shan Lu, MD, PhD  
Co-chair, ISV Virtual Congress  
President Emeritus, International Society for Vaccines  
Editor-in-Chief  
Emerging Microbes & Infections  
Professor  
Department of Medicine  
U Mass Med School  
Worcester, MA01605  
USA  
Tel. 1-508-856-6791  
Email: [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu)*

---

**From:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Sent:** Sunday, June 21, 2020 9:40 PM  
**To:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; '[cindicallaghan@isv-online.org](mailto:cindicallaghan@isv-online.org)' <[cindicallaghan@isv-online.org](mailto:cindicallaghan@isv-online.org)>;  
'[EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org)' <[EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org)>  
**Subject:** Re: ISV Virtual Congress Reminder

Ted,

I will start as part of the audience at 9 am and then switch to the speaker mode at 11 am EDT.

Stanley Perlman, M.D., Ph.D.  
Professor  
Department of Microbiology  
University of Iowa

**From:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Sent:** Sunday, June 21, 2020 8:38 PM  
**To:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; '[cindicallaghan@isv-online.org](mailto:cindicallaghan@isv-online.org)' <[cindicallaghan@isv-online.org](mailto:cindicallaghan@isv-online.org)>; '[EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org)' <[EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org)>  
**Subject:** ISV Virtual Congress Reminder

Dear Professor Perlman,

We are very excited that our virtual congress will start in 12 hrs. Here are a few key last-minute reminders to you:

- You will join the congress as a speaker so there is no link for you to connect.
- As in our training you need to join through your desktop Microsoft Teams software: Double click to bring it up >> enter the Guest ID and the password we sent you >> you are inside Teams >> looking at the left side of Teams field locate a button called "Calendar" >> click that to open calendar and find "First ISV COVID-19 Vaccine Virtual Congress" box, click that once>> on the new page, find a small box called "Join", click it once, then you should be joining the presenter's room.
- After you have joined the presenter room, you will see quite a few monitors. If the congress is live, you need to keep quiet. If you mute yourself or are placed on mute, please unmute yourself prior to your presentation.
- You need to follow the instruction of your session chair.
- When your name is mentioned by your chair, your video will have a RED outside box, that means you are live and you should start talking.
- Please see attached instructions if you need any reminders.

Please feel free to let us know if you have any questions. You can reply to Edward and Cindi (cc 'ed here).

If there is any issue requiring a phone call, here is the international free dialing number. You will need to email us to let us know a call is required.

18005018979 toll-free within US and Canada  
Access Code: 8566791

Also, we will record the congress and make it available for public viewing. Please let us know if you have any concern or objection within 12 hrs after the congress. Your support is greatly appreciated.

Best.

Shan Lu  
Co-Chair  
ISV 1<sup>st</sup> Virtual Congress

<https://isvcongress.org/>

<image001.png>

<2nd ISV Virtual Congress draft program 0630.docx>

---

**From:** Perlman, Stanley <stanley-perlman@uiowa.edu>  
**Sent:** Sunday, June 21, 2020 9:40 PM  
**To:** Gibson, Edward  
**Cc:** Lu, Shan; 'cindicallaghan@isv-online.org'; 'EdwardGibson@isvcongress.org'  
**Subject:** Re: ISV Virtual Congress Reminder

Ted,

I will start as part of the audience at 9 am and then switch to the speaker mode at 11 am EDT.

Stanley Perlman, M.D., Ph.D.  
Professor  
Department of Microbiology  
University of Iowa

---

**From:** Gibson, Edward <Edward.Gibson@umassmed.edu>  
**Sent:** Sunday, June 21, 2020 8:38 PM  
**To:** Perlman, Stanley <stanley-perlman@uiowa.edu>  
**Cc:** Lu, Shan <Shan.Lu@umassmed.edu>; 'cindicallaghan@isv-online.org' <cindicallaghan@isv-online.org>; 'EdwardGibson@isvcongress.org' <EdwardGibson@isvcongress.org>  
**Subject:** ISV Virtual Congress Reminder

Dear Professor Perlman,

We are very excited that our virtual congress will start in 12 hrs. Here are a few key last-minute reminders to you:

- You will join the congress as a speaker so there is no link for you to connect.
- As in our training you need to join through your desktop Microsoft Teams software: Double click to bring it up >> enter the Guest ID and the password we sent you >> you are inside Teams >> looking at the left side of Teams field locate a button called "Calendar" >> click that to open calendar and find "First ISV COVID-19 Vaccine Virtual Congress" box, click that once>> on the new page, find a small box called "Join", click it once, then you should be joining the presenter's room.
- After you have joined the presenter room, you will see quite a few monitors. If the congress is live, you need to keep quiet. If you mute yourself or are placed on mute, please unmute yourself prior to your presentation.
- You need to follow the instruction of your session chair.
- When your name is mentioned by your chair, your video will have a RED outside box, that means you are live and you should start talking.
- Please see attached instructions if you need any reminders.

Please feel free to let us know if you have any questions. You can reply to Edward and Cindi (cc 'ed here).

If there is any issue requiring a phone call, here is the international free dialing number. You will need to email us to let us know a call is required.

18005018979 toll-free within US and Canada  
Access Code: 8566791

Also, we will record the congress and make it available for public viewing. Please let us know if you have any concern or objection within 12 hrs after the congress. Your support is greatly appreciated.

Best.

Shan Lu

Co-Chair

ISV 1<sup>st</sup> Virtual Congress

<https://isvcongress.org/>



\*\*\*\*\*

**From:** Shi Zhengli<zlshi@wh.iov.cn>  
**Sent:** Sunday, February 9, 2020 8:41 AM  
**To:** Lu, Shan  
**Cc:** Shibo Jiang (姜世勃); Yang Min 杨敏; min.yang@emi2012.org; 'Shuying Liu'  
**Subject:** Re: Jiang et al. EMI 9:1, 275-277

Hello, Teacher Lu!

thank you for your letter. I apologize for the mistake we made. We are willing to make a correction. I asked the students to recalculate the evolutionary tree.

Thank you also for your comprehensive explanation at the meeting today.

Good luck!

Shi Zhengli

-----The original message-----

From 人 : "Lu, Shan" <Shan.Lu@umassmed.edu>

**Sending time:** 2020-02-09 21:15:31 (Sunday)

To : "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>, "Shi Zhengli" <zlshi@wh.iov.cn>

Cc : "Yang Min 杨旻" <minyang0216@163.com>, "min.yang@emi2012.org" <min.yang@emi2012.org>, "Shuying Liu" <SYL-consulting@outlook.com>

Main **topic:** Jiang et Al the EMI. 9:.. 1, 275-277

Hello, teacher!

Two days ago, a colleague in my laboratory found that the following chapters of you and Shibo's co-authors had two problems: the number of amino acids was incorrect. Because of location positioning ( the numbering for each functional domain) error. Shibo and I mentioned it. Today he told you to also talk to him, Hope to correct.

DOI: 10.1080/22221751.2020.1723441, An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies.

I welcome you to post a correction erratum. I don't know if it is necessary to modify the diagram. Even if it is necessary, I think it is worth it. Welcome to tell you what you mean. Then the EMI editorial department came to coordinate with T&F on how to publish erratum.

1

6/1/2021 Hello, teacher! Two days ago, a colleague in my laboratory discovered that there are two problems with the following text of your co-author and Shibo:  
Thank you!

Lu

ps There are 3399 downloads of your papers to read today. Congratulations!

\*\*\*\*\*

**From:** Shi Zhengli<zlshi@wh.iov.cn>  
**Sent:** Sunday, February 9, 2020 8:47 AM  
**To:** Lu, Shan  
**Cc:** Shibo Jiang (姜世勃); Yang Min 杨敏; min.yang@emi2012.org; 'Shuying Liu'  
**Subject:** Re: Jiang et al. EMI 9:1, 275-277

Teacher Lu:

I communicated with the student just now. The phylogenetic tree was constructed using the correct S gene sequence. An error occurred when uploading the sequence to GenBank. We need i  
 Correct it.

Hereby explain.

Sorry for this error.

Zhengli

-----The original message-----

From 人 : "Lu, Shan" <Shan.Lu@umassmed.edu>

**Sending time:** 2020-02-09 21:15:31 (Sunday)

To : "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>, "Shi Zhengli" <zlshi@wh.iov.cn>

Cc : "Yang Min 杨旻" <minyang0216@163.com>, "min.yang@emi2012.org" <min.yang@emi2012.org>, "Shuying Liu" <SYL-consulting@outlook.com>

Main **topic:** Jiang et Al the EMI. 9:... 1, 275-277

Hello, teacher!

Two days ago, a colleague in my laboratory found that the following chapters of you and Shibo's co-authors had two problems: the number of amino acids was incor  
 Because of location positioning ( the numbering for each functional domain) error. Shibo and I mentioned it. Today he told you to also talk to him,  
 Hope to correct.

DOI: 10.1080/22221751.2020.1723441, An emerging coronavirus causing pneumonia outbreak in  
 Wuhan, China: calling for developing therapeutic and prophylactic strategies.

I welcome you to post a correction erratum. I don't know if it is necessary to modify the diagram. Even if it is necessary, I think it is worth it. Welcome to tell you what you mean  
 见, then the EMI editorial department came to coordinate with T&F on how to publish erratum.



6/1/2021 Hello, teacher! Two days ago, a colleague in my laboratory discovered that there are two problems with the following text of your co-author and Shibo:

Thank you!

Lu

ps There are 3399 downloads of your papers to read today. Congratulations!

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Sunday, April 5, 2020 8:56 PM  
**To:** Editorial Office  
**Cc:** Lu, Shan  
**Subject:** Re: Join as an Editorial Board Member: New International Journal "Coronaviruses"

Thank you for your invitation. I am currently co-editors -in-chief of Emergning Microbies and Infections, and we already have a special section on coronaviruses. Therefore, I decline your invitation. Yu-mei Wen

-----Original Messages-----

**From:** "Editorial Office" <editorialoffice@benthamsience.net>  
**Sent Time:** 2020-04-05 18:30:54 (Sunday)  
**To:** ymwen@shmu.edu.cn  
**Cc:**  
**Subject:** Join as an Editorial Board Member: New International Journal "Coronaviruses"

### Coronaviruses

April 5, 2020

Dr. Yumei Wen

Institute of Medical Microbiology, Key Laboratory of Medical Molecular Virology, Ministry of Education/Ministry of Health, Fudan University, China

China

Dear Dr. Wen,

I am pleased to inform you that an exciting new international journal "**Coronaviruses**" is being launched later this summer by a reputable international science publisher '*Bentham Science*' under the Editorship of Prof. Di Liu, Professor at Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China. I happen to be an Honorary Advisor to the journal and it will be launched under my supervision as well as that of Prof. Atta-ur-Rahman who is a Fellow of Royal Society (London) and an Academician of the Chinese Academy of Sciences. I am also serving as an Honorary Adviser to another Bentham journal **Current Medicinal Chemistry** for the last several years (<https://benthamsience.com/journals/current-medicinal-chemistry/editorial-board/>)

It is my pleasure to invite you to be considered for the position of an Editorial Board Member for this important journal. All Board Members are expected to each contribute or solicit at least one review article in the field of the journal annually.

If you are interested and if you are an expert in the field of virology, then please send your C.V. and list of International Publications by return email.

With kind regards,

Sincerely,

**Prof. Dr. Ferid Murad**

***Nobel Laureate***

Stanford University

Email: [info@benthamscience.net](mailto:info@benthamscience.net)

[If you prefer not to receive any further emails, please send us an email with the subject line "UNSUBSCRIBE"]

---

**From:** Jie Fu <jfu9799@gmail.com>  
**Sent:** Saturday, January 25, 2020 11:25 PM  
**To:** Lu, Shan  
**Cc:** liu.6244@osu.edu  
**Subject:** Re: Letter to Wu Han

Thanks. I will forward to wherever I think it might be useful.

On Sat, Jan 25, 2020, 11:08 PM Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> wrote:

Hi, Jie,

Thanks for your interest to join. The early version has been circulated to various government and news organizations. I just add your name to V9 which will be used from this point on. A copy is attached for your reference and distribution as you see fit.

Best.

Shan

**From:** Jie Fu <[jfu9799@gmail.com](mailto:jfu9799@gmail.com)>  
**Sent:** Saturday, January 25, 2020 3:50 PM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; [liu.6244@osu.edu](mailto:liu.6244@osu.edu)  
**Subject:** Letter to Wu Han

,

Hello Dr. Lu and Dr. Liu,

I just read the letter that you and others drafted. I support this letter and hope to sign this letter as well. My name is Jie Fu and I work at NYC Public Health Laboratory, Virology Unit.

Here is my name in Chinese:

傅洁

纽约市公共卫生实验室

Thanks,

Jie Fu, Ph.D.

Chief, Virology Lab

NYC PHL

---

**From:** Liu, Shan-Lu <liu.6244@osu.edu>  
**Sent:** Sunday, January 26, 2020 12:12 AM  
**To:** Jie Fu; Lu, Shan  
**Subject:** Re: Letter to Wu Han  
**Attachments:** 控制2019-nCoV建议-20200123-v10.pdf

LIU.6244@OSU.EDU appears similar to someone who previously sent you email, but may not be that person. [Learn why this could be a risk](#) [Feedback](#)

See the updated version attached. Will be corrected shortly I hope.

Shan-Lu

---

**From:** Jie Fu <jfu9799@gmail.com>  
**Date:** Saturday, January 25, 2020 at 11:32 PM  
**To:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Cc:** Shan-Lu Liu <liu.6244@osu.edu>  
**Subject:** Re: Letter to Wu Han

By the way, when you have the next version, please add "市". I work for New York City (纽约市)Public Health Laboratory.

On Sat, Jan 25, 2020, 11:25 PM Jie Fu <[jfu9799@gmail.com](mailto:jfu9799@gmail.com)> wrote:

Thanks. I will forward to wherever I think it might be useful.

On Sat, Jan 25, 2020, 11:08 PM Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> wrote:

Hi, Jie,

Thanks for your interest to join. The early version has been circulated to various government and news organizations. I just add your name to V9 which will be used from this point on. A copy is attached for your reference and distribution as you see fit.

Best.

Shan

---

**From:** Jie Fu <[jfu9799@gmail.com](mailto:jfu9799@gmail.com)>  
**Sent:** Saturday, January 25, 2020 3:50 PM

**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; [liu.6244@osu.edu](mailto:liu.6244@osu.edu)

**Subject:** Letter to Wu Han

,

Hello Dr. Lu and Dr. Liu,

I just read the letter that you and others drafted. I support this letter and hope to sign this letter as well. My name is Jie Fu and I work at NYC Public Health Laboratory, Virology Unit.

Here is my name in Chinese:

傅洁

纽约市公共卫生实验室

Thanks,

Jie Fu, Ph.D.

Chief, Virology Lab

NYC PHL

---

**From:** Jie Fu <jfu9799@gmail.com>  
**Sent:** Saturday, January 25, 2020 11:29 PM  
**To:** Lu, Shan  
**Cc:** liu.6244@osu.edu  
**Subject:** Re: Letter to Wu Han

By the way, when you have the next version, please add "市". I work for New York City (纽约市)Public Health Laboratory.

On Sat, Jan 25, 2020, 11:25 PM Jie Fu <jfu9799@gmail.com> wrote:

Thanks. I will forward to wherever I thi k it might be useful.

On Sat, Jan 25, 2020, 11:08 PM Lu, Shan <Shan.Lu@umassmed.edu> wrote:

Hi, Jie,

Thanks for your interest to join. The early version has been circulated to various government and news organizations. I just add your name to V9 which will be used from this point one. A copy is attached for your reference and distribution as you see fit.

Best.

Shan

**From:** Jie Fu <jfu9799@gmail.com>  
**Sent:** Saturday, January 25, 2020 3:50 PM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>; liu.6244@osu.edu  
**Subject:** Letter to Wu Han

,

Hello Dr. Lu and Dr. Liu,

I just read the letter that you and others drafted. I support this letter and hope to sign this letter as well. My name is Jie Fu and I work at NYC Public Health Laboratory, Virology Unit.



Here is my name in Chinese:

傅洁

纽约市公共卫生实验室

Thanks,

Jie Fu, Ph.D.

Chief, Virology Lab

NYC PHL

---

**From:** Christian Brechot <cbrechot@gvn.org>  
**Sent:** Saturday, October 24, 2020 10:30 PM  
**To:** wen yumei  
**Cc:** Lu, Shan; 袁正宏  
**Subject:** Re: message

Dear Yu-Mei

I also enjoyed meeting you again through Zoom and enjoyed your presentation.

Thank you so much for the offer to be a co-editor of the EMI. I find it very interesting. Yet I am really much too much overwhelmed and would not be able to deliver.

Best regards

christian

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Sunday, October 25, 2020 2:46 AM  
**To:** Christian Brechot <cbrechot@gvn.org>  
**Cc:** shan.lu@umassmed.edu <shan.lu@umassmed.edu>; 袁正宏 <Zhyuan@shmu.edu.cn>  
**Subject:** message

Dear Christian,

It was my pleasure to see you and participate at the same web meeting recently hosted by David Ho. I still remember your last visit to our lab, and informed me regarding your plan to organize a web with Bob Gallo among virological labs.

Since the retirement of Prof Hans Klenk as co-editors-in-chief from the journal Emerging Microbes and Infections (EMI), we are looking for another co-editors-in-chief to join us. In fact, co-editors-in-chief, Prof Shan Lu from UMass, has been looking after EMI, and has taken a lot of responsibility of EMI, and this journal has grown into a well recognized journal on infectious diseases. If interested, please go to our web to know more about EMI. It will be our honor to invite you to join us as a co-editors-in-chief. If interested, Shan Lu will contact you for more details.

Regards, Yu-mei

---

**From:** TEMI-peerreview@journals.tandf.co.uk  
**Sent:** Wednesday, July 22, 2020 12:33 AM  
**To:** Lu, Shan; peshi@utmb.edu  
**Subject:** RE: MS Update #TrackingId:6766278

Dear Dr. Baker,

Thank you for your inquiry.

Checking the system from here, I can confirm that the above submission is currently under review. It has currently received one review and the editor is selecting one more expert who will oversee your paper.

As soon as the editor receives the comments back from all reviewers and a decision has been rendered, he will inform you directly.

Many thanks for your patience and understanding. Should you require any further assistance, please do let me know.

Kind regards,

**Jorgie Lyn Luna** - Journal Editorial Office  
Taylor & Francis Group  
4 Park Square | Milton Park | Abingdon | Oxon | OX14 4RN UK  
Web: [www.tandfonline.com](http://www.tandfonline.com)

Taylor & Francis is a trading name of Informa UK Limited,  
registered in England under no. 1072954



Emerging Microbes & Infections

---

**From:** peshi@UTMB.EDU  
**Sent:** 22-07-2020 03.13 AM  
**To:** TEMI-peerreview@journals.tandf.co.uk, shan.lu@umassmed.edu  
**Cc:**  
**Subject:** RE: MS Update

Dear Jorgie and Shan,

I'm writing to check the review status of our manuscript we submitted on June 5th. We understand the difficulty in finding reviewers under the current pandemic, but look forward to reviewers' suggestions soon.

Thank you for your time and help.

Best regards,  
Pei-Yong

Pei-Yong Shi, Ph.D.  
I.H. Kempner Professor of Human Genetics  
Vice Chair for Innovation and Commercialization  
Department of Biochemistry & Molecular Biology  
University of Texas Medical Branch  
Galveston, Texas 77555  
Phone: 409-772-6370

---

**From:** TEMI-peerreview@journals.tandf.co.uk <TEMI-peerreview@journals.tandf.co.uk>  
**Sent:** Friday, July 10, 2020 3:25 AM  
**To:** Baker, Coleman K. <ckbaker@UTMB.EDU>  
**Cc:** Shi, Pei yong <peshi@UTMB.EDU>  
**Subject:** Re: MS Update #TrackingId:6766278

**WARNING:** This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Dr. Baker,

Thank you for your email.

I have checked the status of your manuscript within our online submission system and I can confirm that your submission is currently progressing through peer review without any problems.

I am unable to provide any more specific information regarding your submission at this time, aside from assuring you that we will do our best to deliver a decision to you as soon as possible.


Please do not hesitate to contact me if you have any further questions or concerns.

Best regards,

Ms. Lyrez Lopez

On Behalf of

Jorgie Lyn Luna



**Emerging Microbes & Infections**

---

**From:**onbehalf@manuscriptcentral.com

**Sent:**09-07-2020 07:56

**To:**Lyrez.Lopez@spi-global.com

**Cc:**peshi@utmb.edu

**Subject:**Re: MS Update

EMI,

I was hoping for an update on our manuscript "Identifying optimal capsid duplication length for the stability of reporter flaviviruses" (TEMI-2020-1002). We submitted over a month ago and have not had any updates on its progress. Could we get an estimate on how long the review process typically takes for EMI and when we can expect to receive the reviews?

Thanks,

Coleman Baker

---

**From:** Shi, Pei yong <peshi@UTMB.EDU>  
**Sent:** Wednesday, July 22, 2020 6:47 AM  
**To:** TEMI-peerreview@journals.tandf.co.uk; Lu, Shan  
**Subject:** RE: MS Update #TrackingId:6766278

Dear Jorgie,

Thank you for the reply. I look forward to the reviewers' suggestion soon.

Best regards,  
Pei-Yong

Pei-Yong Shi, Ph.D.  
I.H. Kempner Professor of Human Genetics  
Vice Chair for Innovation and Commercialization  
Department of Biochemistry & Molecular Biology  
University of Texas Medical Branch  
Galveston, Texas 77555  
Phone: 409-772-6370  
Email: peshi@utmb.edu

---

**From:** TEMI-peerreview@journals.tandf.co.uk <TEMI-peerreview@journals.tandf.co.uk>  
**Sent:** Tuesday, July 21, 2020 11:33 PM  
**To:** shan.lu@umassmed.edu; Shi, Pei yong <peshi@UTMB.EDU>  
**Subject:** RE: MS Update #TrackingId:6766278

**WARNING:** This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Dr. Baker,

Thank you for your inquiry.

Checking the system from here, I can confirm that the above submission is currently under review. It has currently received one review and the editor is selecting one more expert who will oversee your paper.

As soon as the editor receives the comments back from all reviewers and a decision has been rendered, he will inform you directly.

Many thanks for your patience and understanding. Should you require any further assistance, please do let me know.

Kind regards,

**Jorgie Lyn Luna** - Journal Editorial Office  
Taylor & Francis Group  
4 Park Square | Milton Park | Abingdon | Oxon | OX14 4RN UK  
Web: [www.tandfonline.com](http://www.tandfonline.com)



Emerging Microbes & Infections

---

**From:** peshi@UTMB.EDU  
**Sent:** 22-07-2020 03:13 AM  
**To:** TEMI-peerreview@journals.tandf.co.uk, shan.lu@umassmed.edu  
**Cc:**  
**Subject:** RE: MS Update

Dear Jorgie and Shan,

I'm writing to check the review status of our manuscript we submitted on June 5th. We understand the difficulty in finding reviewers under the current pandemic, but look forward to reviewers' suggestions soon.

Thank you for your time and help.

Best regards,  
Pei-Yong

Pei-Yong Shi, Ph.D.  
I.H. Kempner Professor of Human Genetics  
Vice Chair for Innovation and Commercialization  
Department of Biochemistry & Molecular Biology  
University of Texas Medical Branch  
Galveston, Texas 77555  
Phone: 409-772-6370

---

**From:** [TEMI-peerreview@journals.tandf.co.uk](mailto:TEMI-peerreview@journals.tandf.co.uk) <[TEMI-peerreview@journals.tandf.co.uk](mailto:TEMI-peerreview@journals.tandf.co.uk)>  
**Sent:** Friday, July 10, 2020 3:25 AM  
**To:** Baker, Coleman K. <[ckbaker@UTMB.EDU](mailto:ckbaker@UTMB.EDU)>  
**Cc:** Shi, Pei yong <[peshi@UTMB.EDU](mailto:peshi@UTMB.EDU)>  
**Subject:** Re: MS Update #TrackingId:6766278

**WARNING:** This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Dr. Baker,

Thank you for your email.

I have checked the status of your manuscript within our online submission system and I can confirm that your submission is currently progressing through peer review without any problems.

I am unable to provide any more specific information regarding your submission at this time, aside from assuring you that we will do our best to deliver a decision to you as soon as possible.


Please do not hesitate to contact me if you have any further questions or concerns.

Best regards,

Ms. Lyrez Lopez

On Behalf of

Jorgie Lyn Luna



## Emerging Microbes & Infections

---

**From:**onbehalf@manuscriptcentral.com

**Sent:**09-07-2020 07:56

**To:**Lyrez.Lopez@spi-global.com

**Cc:**peshi@utmb.edu

**Subject:**Re: MS Update

EMI,

I was hoping for an update on our manuscript "Identifying optimal capsid duplication length for the stability of reporter flaviviruses" (TEMI-2020-1002). We submitted over a month ago and have not had any updates on its progress. Could we get an estimate on how long the review process typically takes for EMI and when we can expect to receive the reviews?

Thanks,

Coleman Baker



---

**From:** Shi, Pei yong <peshi@UTMB.EDU>  
**Sent:** Tuesday, July 21, 2020 3:13 PM  
**To:** TEMI-peerreview@journals.tandf.co.uk; Lu, Shan  
**Subject:** RE: MS Update #TrackingId:6766278

Dear Jorgie and Shan,

I'm writing to check the review status of our manuscript we submitted on June 5th. We understand the difficulty in finding reviewers under the current pandemic, but look forward to reviewers' suggestions soon.

Thank you for your time and help.

Best regards,  
Pei-Yong

Pei-Yong Shi, Ph.D.  
I.H. Kempner Professor of Human Genetics  
Vice Chair for Innovation and Commercialization  
Department of Biochemistry & Molecular Biology  
University of Texas Medical Branch  
Galveston, Texas 77555  
Phone: 409-772-6370

---

**From:** TEMI-peerreview@journals.tandf.co.uk <TEMI-peerreview@journals.tandf.co.uk>  
**Sent:** Friday, July 10, 2020 3:25 AM  
**To:** Baker, Coleman K. <ckbaker@UTMB.EDU>  
**Cc:** Shi, Pei yong <peshi@UTMB.EDU>  
**Subject:** Re: MS Update #TrackingId:6766278

**WARNING:** This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Dr. Baker,

Thank you for your email.

I have checked the status of your manuscript within our online submission system and I can confirm that your submission is currently progressing through peer review without any problems.

I am unable to provide any more specific information regarding your submission at this time, aside from assuring you that we will do our best to deliver a decision to you as soon as possible.

Please do not hesitate to contact me if you have any further questions or concerns.

Best regards,

Ms. Lyrez Lopez

On Behalf of

Jorgie Lyn Luna



**Emerging Microbes & Infections**

---

**From:** onbehalf@manuscriptcentral.com

**Sent:** 09-07-2020 07:56

**To:** Lyrez.Lopez@spi-global.com

**Cc:** peshi@utmb.edu

**Subject:** Re: MS Update

EMI,

I was hoping for an update on our manuscript "Identifying optimal capsid duplication length for the stability of reporter flaviviruses" (TEMI-2020-1002). We submitted over a month ago and have not had any updates on its progress. Could we get an estimate on how long the review process typically takes for EMI and when we can expect to receive the reviews?

Thanks,

Coleman Baker

---

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Monday, February 17, 2020 2:45 AM  
**To:** Lu, Shan  
**Cc:** wen yumei  
**Subject:** Re: New Guest Editor for EMI CoV special topic

Great, Thanks!  
Shibo

-----原始邮件-----

发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>  
发送时间: 2020-02-17 12:39:00 (星期一)  
收件人: "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>  
抄送: "wen yumei" <ymwen@shmu.edu.cn>  
主题: New Guest Editor for EMI CoV special topic

Dear Shibo,

I am sorry that you decided to resign as the Guest Editor due to the health issue. As we discussed, I have invited Dr. Susan Weiss from U Penn as the new guest editor for EMI's "Emerging and re-emerging CoV" topic, and she has happily accepted my invitation.

Please check at the [page](#) to see the change.

Please take good care of yourself!

Best.

Shan

---

**From:** yuan zhenghong <zhyuan@shmu.edu.cn>  
**Sent:** Wednesday, August 12, 2020 12:59 AM  
**To:** Lu, Shan  
**Cc:** M. Yu-Mei Wen (ymwen@shmu.edu.cn); Min Yang (min.yang@emi2012.org); Emily  
**Subject:** Re: New HBV paper

Dear Shan, thank you for your kind advice. I will try my best and if there is any question, I will ask you for help. Best wishes, Zhenghong

-----原始邮件-----

发件人:"Lu, Shan" <Shan.Lu@umassmed.edu>

发送时间:2020-08-10 10:46:05 (星期一)

收件人: "yuan zhenghong" <zhyuan@shmu.edu.cn>

抄送: "M. Yu-Mei Wen (ymwen@shmu.edu.cn)" <ymwen@shmu.edu.cn>, "Min Yang (min.yang@emi2012.org)" <min.yang@emi2012.org>, Emily <editorial2@emi2012.org>

主题: New HBV paper

Dear Zhenghong,

This week I send one more new HBV paper to you as the RE.

At this point, I think you and the Hepatitis Special Topic are doing well. The old papers are loaded and you are getting good sense on how to run the review. This will be my last reminder to you:

- You can let Min Yang know how do you want to find new assignment. Min can send you an email, or you can check in EMI system every 2-3 days. Please let her know.
- Please feel free to reject any paper you don't feel high quality. Since now we try to send ALL new hepatitis papers to you, we are not doing any screening. Some of them may not have good quality. Please do not hesitate to reject them. You can just let me know "low priority" or any other reason (confidential to me or public ready for reviewers). I have a standard template to reject new papers at screening stage so we don't have to provide much reason besides that new paper is not fitting EMI current priority.
- You have the full freedom to find any reviewers you want. If you need help, you can let Min Yang or Emily Yu (copied here) to help you invite or finding reviewers.
- We aims to have 2-3 reviewers, but in the worst situation 1 is ok. But we don't want to delay. So you will need to invite as many as possible, and keep inviting until you get 2-3. Emily can show you how to do this if needed.
- You will be the one to make a decision based on reviewers' comments. I will basically follow your decision and sign off as EIC.

I think you will be fine but please feel free to let me know if you need any help.

Best.

Shan

---

**From:** Min Yang <min.yang@emi2012.org>  
**Sent:** Tuesday, January 12, 2021 10:33 AM  
**To:** wen yumei; Lu, Shan; Tang, Yi-Wei; Zhyuan@shmu.edu.cn; zhangwenhong@fudan.edu.cn; Winter999@hotmail.com  
**Subject:** Re: Nomination for 2020 Best EMI papers  
**Attachments:** Nomination List for 2020 Best EMI Papers.xlsx

Dear EMI Leaders,

I have well received the first round of selections with thanks and the final list has been generated as attached. Now we are going to move on to step 2, please vote for the top 4 papers for 2020 Best EMI Papers among the list by numbering them in the excel.

We will be having 4 top papers for 2020: one for first prize, one for 2<sup>nd</sup> prize and two for 3<sup>rd</sup> prize.

If you have any questions or concerns, please feel free to let me know.

Regards,  
Min

-----Original Messages-----

**From:** "Min Yang" <min.yang@emi2012.org>  
**Sent Time:** 2021-01-05 00:00:39 (Tuesday)  
**To:** "Lu, Shan" <Shan.Lu@umassmed.edu>, "M. Yu-Mei Wen (ymwen@shmu.edu.cn)" <ymwen@shmu.edu.cn>, zhangwenhong <zhangwenhong@fudan.edu.cn>, "yi-wei.tang@cepheid.com" <yi-wei.tang@cepheid.com>, Winter999 <Winter999@hotmail.com>, "袁正宏" <Zhyuan@shmu.edu.cn>  
**Cc:**  
**Subject:** Re: Nomination for 2020 Best EMI papers

Dear EMI Leaders,

As mentioned by Prof Lu, attached please find the publication list for 2020.

Please nominate your top papers (at least 5-10) by replying to this email by 11 Jan, 2021.

Meanwhile, please do not hesitate to contact me if you have any questions.

Thanks and regards,

Min Yang

*Emerging Microbes & Infections* (EMI) Editorial Office  
4F Fuxing Building

131 Dongan Road  
Shanghai  
China  
Tel: 86-21-54237992  
E-mail: min.yang@emi2012.org

---

发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>  
日期: 2021年1月3日 星期日 上午8:45  
收件人: "M. Yu-Mei Wen (ymwen@shmu.edu.cn)" <ymwen@shmu.edu.cn>, zhangwenhong  
<zhangwenhong@fudan.edu.cn>, "yi-wei.tang@cepheid.com" <yi-wei.tang@cepheid.com>, Winter999  
<Winter999@hotmail.com>, 袁正宏 <Zhyuan@shmu.edu.cn>  
抄送: Min Yang <min.yang@emi2012.org>  
主题: Nomination for 2020 Best EMI papers

Dear Prof Wen and others,

As in last year, we will need to select 4 best papers for 2020. As you may recall, T&F will pay for the cash prize and we can nominate 4 top papers: one for first prize, one for 2<sup>nd</sup> prize and two for 3<sup>rd</sup> prize.

We can continue the same way as in the last year:

Step one: each of us can nominate at least 5 – 10 papers from the list of 2020 EMI papers. This will narrow down the candidates since we published about 300 papers in 2020.

Step two: we each will vote top 4 among nominated list.

Please let me know if you want to do it differently. At the same time, Min will prepare the list and send it to this group by Monday.

Best.

Shan



---

**From:** Min Yang <min.yang@emi2012.org>  
**Sent:** Thursday, January 14, 2021 3:14 AM  
**To:** wen yumei  
**Cc:** Lu, Shan; Tang, Yi-Wei; Zhyuan@shmu.edu.cn; zhangwenhong@fudan.edu.cn; Winter999@hotmail.com  
**Subject:** Re: Nomination for 2020 Best EMI papers

Dear Prof Wen,

Well received, thank you.

Regards,  
Min

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Thursday, January 14, 2021 4:11:43 PM  
**To:** Min Yang <min.yang@emi2012.org>  
**Cc:** Lu, Shan <Shan.Lu@umassmed.edu>; Tang, Yi-Wei <yi-wei.tang@cepheid.com>; Zhyuan@shmu.edu.cn <Zhyuan@shmu.edu.cn>; zhangwenhong@fudan.edu.cn <zhangwenhong@fudan.edu.cn>; Winter999@hotmail.com <Winter999@hotmail.com>  
**Subject:** Re: Re: Nomination for 2020 Best EMI papers

See my attached selection. Wen

-----原始邮件-----

发件人: "Min Yang" <min.yang@emi2012.org>

发送时间: 2021-01-12 23:33:29 (星期二)

收件人: "wen yumei" <ymwen@shmu.edu.cn>, "Lu, Shan" <Shan.Lu@umassmed.edu>, "Tang, Yi-Wei" <yi-wei.tang@cepheid.com>, "Zhyuan@shmu.edu.cn" <Zhyuan@shmu.edu.cn>, "zhangwenhong@fudan.edu.cn" <zhangwenhong@fudan.edu.cn>, "Winter999@hotmail.com" <Winter999@hotmail.com>

抄送:

主题: Re: Nomination for 2020 Best EMI papers

Dear EMI Leaders,

I have well received the first round of selections with thanks and the final list has been generated as attached. Now we are going to move on to step 2, please vote for the top 4 papers for 2020 Best EMI Papers among the list by numbering them in the excel.

We will be having 4 top papers for 2020: one for first prize, one for 2<sup>nd</sup> prize and two for 3<sup>rd</sup> prize.

If you have any questions or concerns, please feel free to let me know.

Regards,

Min

-----Original Messages-----

**From:** "Min Yang" <min.yang@emi2012.org>

**Sent Time:** 2021-01-05 00:00:39 (Tuesday)

**To:** "Lu, Shan" <Shan.Lu@umassmed.edu>, "M. Yu-Mei Wen (ymwen@shmu.edu.cn)" <ymwen@shmu.edu.cn>, zhangwenhong <zhangwenhong@fudan.edu.cn>, "yi-wei.tang@cepheid.com" <yi-wei.tang@cepheid.com>, Winter999 <Winter999@hotmail.com>, "袁正宏" <Zhyuan@shmu.edu.cn>

**Cc:**

**Subject:** Re: Nomination for 2020 Best EMI papers

Dear EMI Leaders,

As mentioned by Prof Lu, attached please find the publication list for 2020.

Please nominate your top papers (at least 5-10) by replying to this email by 11 Jan, 2021.

Meanwhile, please do not hesitate to contact me if you have any questions.

Thanks and regards,

Min Yang

*Emerging Microbes & Infections* (EMI) Editorial Office  
4F Fuxing Building

131 Dongan Road  
Shanghai  
China  
Tel: 86-21-54237992  
E-mail: min.yang@emi2012.org

---

发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>

日期: 2021 年 1 月 3 日 星期日 上午 8:45

收件人: "M. Yu-Mei Wen (ymwen@shmu.edu.cn)" <ymwen@shmu.edu.cn>, zhangwenhong <zhangwenhong@fudan.edu.cn>, "yi-wei.tang@cepheid.com" <yi-wei.tang@cepheid.com>, Winter999 <Winter999@hotmail.com>, 袁正宏 <Zhyuan@shmu.edu.cn>

抄送: Min Yang <min.yang@emi2012.org>

主题: Nomination for 2020 Best EMI papers

Dear Prof Wen and others,

As in last year, we will need to select 4 best papers for 2020. As you may recall, T&F will pay for the cash prize and we can nominate 4 top papers: one for first prize, one for 2<sup>nd</sup> prize and two for 3<sup>rd</sup> prize.

We can continue the same way as in the last year:

Step one: each of us can nominate at least 5 – 10 papers from the list of 2020 EMI papers. This will narrow down the candidates since we published about 300 papers in 2020.

Step two: we each will vote top 4 among nominated list.

Please let me know if you want to do it differently. At the same time, Min will prepare the list and send it to this group by Monday.

Best.

Shan

---

**From:** Min Yang <min.yang@emi2012.org>  
**Sent:** Monday, January 4, 2021 11:01 AM  
**To:** Lu, Shan; M. Yu-Mei Wen (ymwen@shmu.edu.cn); zhangwenhong; yi-wei.tang@cepheid.com; Winter999; 袁正宏  
**Subject:** Re: Nomination for 2020 Best EMI papers  
**Attachments:** EMI Publication in 2020-20210104.xlsx

Dear EMI Leaders,

As mentioned by Prof Lu, attached please find the publication list for 2020.  
Please nominate your top papers (at least 5-10) by replying to this email by 11 Jan, 2021.

Meanwhile, please do not hesitate to contact me if you have any questions.

Thanks and regards,

Min Yang

*Emerging Microbes & Infections* (EMI) Editorial Office  
4F Fuxing Building  
131 Dongan Road  
Shanghai  
China  
Tel: 86-21-54237992  
E-mail: min.yang@emi2012.org

---

发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>  
日期: 2021年1月3日 星期日 上午8:45  
收件人: "M. Yu-Mei Wen (ymwen@shmu.edu.cn)" <ymwen@shmu.edu.cn>, zhangwenhong <zhangwenhong@fudan.edu.cn>, "yi-wei.tang@cepheid.com" <yi-wei.tang@cepheid.com>, Winter999 <Winter999@hotmail.com>, 袁正宏 <Zhyuan@shmu.edu.cn>  
抄送: Min Yang <min.yang@emi2012.org>  
主题: Nomination for 2020 Best EMI papers

Dear Prof Wen and others,

As in last year, we will need to select 4 best papers for 2020. As you may recall, T&F will pay for the cash prize and we can nominate 4 top papers: one for first prize, one for 2<sup>nd</sup> prize and two for 3<sup>rd</sup> prize.

We can continue the same way as in the last year:

Step one: each of us can nominate at least 5 – 10 papers from the list of 2020 EMI papers. This will narrow down the candidates since we published about 300 papers in 2020.

Step two: we each will vote top 4 among nominated list.

Please let me know if you want to do it differently. At the same time, Min will prepare the list and send it to this group by Monday.

Best.

Shan

---

**From:** Saif, Linda <saif.2@osu.edu>  
**Sent:** Monday, July 27, 2020 10:49 AM  
**To:** B.L. Haagmans; Manon Cox; stanley-perlman@uiowa.edu; vincent.munster@nih.gov  
**Cc:** Lu, Shan; Klavinskis, Linda; Gibson, Edward  
**Subject:** Re: Panel Discussion last week

Hi All,  
Unfortunately I agree with this concern unless someone wanted to assemble our slides into a brief review/overview and then maybe each of us could address a few of the key questions related to these?  
Regards,  
Linda

Linda J. Saif, PhD  
Distinguished University Professor  
Food Animal Health Research Program  
OARDC/The Ohio State University  
1680 Madison Ave  
Wooster, Oh 44691

---

**From:** "B.L. Haagmans" <[b.haagmans@erasmusmc.nl](mailto:b.haagmans@erasmusmc.nl)>  
**Date:** Monday, July 27, 2020 10:42 AM  
**To:** Manon Cox <[manoncox@nextwavebio.com](mailto:manoncox@nextwavebio.com)>, "Stanley-Perlman@uiowa.edu" <[Stanley-Perlman@uiowa.edu](mailto:Stanley-Perlman@uiowa.edu)>, "vincent.munster@nih.gov" <[vincent.munster@nih.gov](mailto:vincent.munster@nih.gov)>, Linda Saif <[saif.2@osu.edu](mailto:saif.2@osu.edu)>  
**Cc:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>, "Klavinskis, Linda" <[linda.klavinskis@kcl.ac.uk](mailto:linda.klavinskis@kcl.ac.uk)>, "Gibson, Edward" <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Subject:** RE: Panel Discussion last week

Dear Manon,

Sounds good but I don't have time left to do this .... Just too many other commitments at the moment.  
Best regards  
Bart

---

**Van:** Manon Cox <[manoncox@nextwavebio.com](mailto:manoncox@nextwavebio.com)>  
**Verzonden:** maandag 27 juli 2020 14:50  
**Aan:** [stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu); [vincent.munster@nih.gov](mailto:vincent.munster@nih.gov); B.L. Haagmans <[b.haagmans@erasmusmc.nl](mailto:b.haagmans@erasmusmc.nl)>; [saif.2@osu.edu](mailto:saif.2@osu.edu)  
**CC:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; Klavinskis, Linda <[linda.klavinskis@kcl.ac.uk](mailto:linda.klavinskis@kcl.ac.uk)>; Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Onderwerp:** Panel Discussion last week

Dear Panel Members!

On behalf of ISV I would like to thank you for your contribution to the discussion on challenges for COVID-19 vaccine development and the role of animal models last week.

As you can see from the list of questions sent by Shan earlier there were many more for the panel than you were able to address during the short time available.

We are wondering whether you would be interested in writing a paper/review that includes your presentation and addresses relevant questions from the audience.

If there is sufficient interest from the speakers we could see whether we could arrange a special edition of Vaccine or publish in the Journal Shan recommended which is EMI ([www.tandfonline.com/TEMI](http://www.tandfonline.com/TEMI)) with a higher impact factor (5.7-6.2 range in the last two years) than most vaccine journals. It also published quite a few exciting COVID-19 papers, and it is open access.

We would love to hear from you!

So here is the list of questions for the panel that Shan submitted last week once again –

#### **Panel discussion**

**Bart Haagmans, PhD, Erasmus University; Vincent Munster, PhD, NIAID / NIH; Dr. Linda Saif, The Ohio State University**

#### **Title: Challenges for COVID-19 Vaccines Development: The Role of Animal Models**

- There was an outbreak of SARS-CoV2 in mink farms in the Netherlands. Will this be an interesting animal model to study SARS-CoV2?
- Guinea pig or mini-pig with metabolic syndrome might demonstrate efficacy against severe disease?
- Still don't have knowledge about if the cats can spread the virus to human??
- How does the different microbiome affect the efficacy of vaccines?
- What is the best animal model to study Covid-19?
- How about dogs as dogs are almost universally domesticated
- The chimpanzee cannot seriously be considered as a challenge model?
- Overall, there seems to be little justification for the continuing use of NHP for SARS CoV-2
- Please comment on what would you consider be best models for evaluating antivirals for treatment of disease vs prevention of infection/transmission by vaccines?
- Do you think that in veterinary medicine we must work in a vaccine for animals for covid?
- And don't forget, microbiome is not just about the gut... It can be very important with regard to mucosal immunity
- Does any model reflect the human nasal tract? Most animals forage
- Gut microbiome has to do with oral vaccines. Does it affect injected vaccines too?
- What about rabbits?
- Is it possible to infer the viral infectious dose in humans by working with animals?
- What models are best suited for assess VAERD and ADE?
- Have anyone used an animal model to test the effectiveness of wearing a mask to prevent the spread of COVID-19
- How are the Africans captured in the development and clinical trials of the COVID 19 vaccines, putting human genomics in consideration?

Sincerely!

Manon

Manon Cox  
Founder & CEO  
NextWaveBio

[manoncox@nextwavebio.com](mailto:manoncox@nextwavebio.com)

Phone: 203 249 3898





---

**From:** tangy@mskcc.org  
**Sent:** Friday, August 30, 2019 7:17 AM  
**To:** Lu, Shan  
**Cc:** ymw@shmu.edu.cn  
**Subject:** RE: paper from well known authors

Thank you, Shan.

I will forward this article to Barney.

Yi-Wei

---

**From:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Sent:** Thursday, August 29, 2019 11:19 PM  
**To:** Tang, Yi-Wei/Laboratory Medicine <tangy@mskcc.org>  
**Cc:** wen yumei <ymw@shmu.edu.cn>  
**Subject:** [EXTERNAL] paper from well known authors

Hi, Yi-Wei,

The other day you commented the important EMI authors to Graham.

Here is another paper I just accepted after minor revision from Prof Ab Osterhaus who is very famous for emerging infections. While this particular paper may not be one of his best ones, it is significant that he selected our journal when he needs to publish something.

Shan

\*\*\* Only open attachments or links from trusted senders. Report phishing to [infosec@mskcc.org](mailto:infosec@mskcc.org) \*\*\*

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Monday, April 6, 2020 8:35 AM  
**To:** Lu, Shan  
**Subject:** Re: please comment

Shan; I am afraid this is not a good approach, and is very risky.

1. How can you guarantee that the virus excreted from the vaccinee will not be spread in the community?
2. Maybe after being transmitted in hosts, the virus might increase its virulence.
3. There are still many unknowns regarding the replication, transmission and pathogenesis of this virus.
4. The chance of using this approach will not be implemented in any countries.

Therefore I am against this bold idea.

However, I would suggest that to prevent COVID-19 to recur in this winter, it is preferable to immunize the population with influenza vaccines, which might cause interference between viruses, and make some contribution.

Another approach to be considered is to immunize the population with agents that would enhance innate immunity, which I called "first aid vaccines", I was told that in some developing countries they are using BCG for prevention, while I think alum may be a good candidate. YMW

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:** 2020-04-06 12:56:30 (Monday)  
**To:** "wen yumei" <ymwen@shmu.edu.cn>  
**Cc:**  
**Subject:** please comment

Dear Prof Wen,

I am having a somewhat crazy idea on how to control the current COVID-19. I plan to submit it to EMI but I would like to get your feedback first.

Thanks.

Shan



---

**From:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
**Sent:** Thursday, April 16, 2020 10:16 PM  
**To:** Lu, Shan; Emily; Min Yang  
**Cc:** Yumei Wen (ymwen@shmu.edu.cn)  
**Subject:** RE: Please help

Great. Thank you.

---

**From:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Sent:** Friday, April 17, 2020 10:14 AM  
**To:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>; Emily <editorial2@emi2012.org>; Min Yang <min.yang@emi2012.org>  
**Cc:** Yumei Wen (ymwen@shmu.edu.cn) <ymwen@shmu.edu.cn>  
**Subject:** RE: Please help

Yes, we do have the system. Min Yang will check RE's invitations, as she reminds RE as needed. Similarly, she can also check on the responses of invited reviewers.

Shan

---

**From:** Tang, Yi-Wei <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>  
**Sent:** Thursday, April 16, 2020 9:44 PM  
**To:** Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>  
**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; Yumei Wen ([ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)) <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
**Subject:** Please help  
**Importance:** High

EMI editorial officers,

Can I get your help on monitoring COVID-19 papers? It will be great if you could check them daily and let the review reviewer know.

I have just checked couple myself:

1. 0537 – I emailed one of reviewers (Charles Stratton) he said he has not received invitation. Could you resend invitations to all reviewer candidates to make sure they received and responded.
2. 0325 – I noticed one declined reviewer candidates suggested couple; please go ahead to invite them.

We really need to move our process quickly; your prompt help is highly appreciated.

Yi-Wei

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

---

**From:** Josaphouitch, Alexa <Alexa.Josaphouitch@taylorandfrancis.com>  
**Sent:** Wednesday, September 16, 2020 3:43 PM  
**To:** Lu, Shan  
**Cc:** M. Yu-Mei Wen (ymwen@shmu.edu.cn); Min Yang  
**Subject:** RE: Please respond to questions about your recently published paper at EMI

Dear Shan,

Thank you for sending the author's response. At this point, I will refer this to our Ethics & Integrity team so they can advise on the next best step.

It's likely a correction will be needed to add the references. However, I'm unsure how to resolve the image issue. I'll also ask the Ethics team about your question regarding data published in one language and then in an international journal.

Thanks!

Sincerely,  
Alexa

---

**Information Classification:** General

**From:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Sent:** Wednesday, September 16, 2020 12:11 PM  
**To:** Josaphouitch, Alexa <Alexa.Josaphouitch@taylorandfrancis.com>  
**Cc:** M. Yu-Mei Wen (ymwen@shmu.edu.cn) <ymwen@shmu.edu.cn>; Min Yang <min.yang@emi2012.org>  
**Subject:** FW: Please respond to questions about your recently published paper at EMI

Dear Alexa,

The author from Germany responded. It appears to be innocent error. What is your advice? It is hard to re-publish the entire paper. Maybe the authors can be allowed to put an addendum at EMI site for:

- 1) Mentioning the source of that photo and acknowledge the original Russian owner who did not ask for authorship.
- 2) To mention the data / papers published in Russia. By the way, is this allowed when same data published in one language (with no publish access or knowledge) and then at the international journals like EMI?

Best.

Shan

---

**From:** Kehrmann, Jan <[Jan.Kehrmann@uk-essen.de](mailto:Jan.Kehrmann@uk-essen.de)>  
**Sent:** Wednesday, September 16, 2020 2:43 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** 'popp@hykomed.de' <[popp@hykomed.de](mailto:popp@hykomed.de)>; [tsogbadrakh@nczd.gov.mn](mailto:tsogbadrakh@nczd.gov.mn); Buer, Jan, Prof. Dr. med. <[Jan.Buer@uk-essen.de](mailto:Jan.Buer@uk-essen.de)>; [ts\\_gana@gmx.de](mailto:ts_gana@gmx.de); [delgermaa@nczd.gov.mn](mailto:delgermaa@nczd.gov.mn); [otgonbayar@nczd.gov.mn](mailto:otgonbayar@nczd.gov.mn)  
**Subject:** AW: Please respond to questions about your recently published paper at EMI

Dear Prof. Lu,

Thank you for your email regarding our manuscript entitled „Two fatal cases of plague after consumption of raw marmot organs“. We apologize for your inconveniences with regard to our study. On behalf of all authors I have attached our answer to this email. We remain to your disposal for any queries you may have.

Best regards,  
Jan Kehrmann

Dr. med. Jan Kehrmann  
Universitätsklinikum Essen (AöR)  
Institut für Medizinische Mikrobiologie  
Virchowstrasse 179  
D- 45147 Essen  
Telefon +49 201 / 723-85913  
Fax +49 201 / 723-5602

E-Mail: [jan.kehrmann@uk-essen.de](mailto:jan.kehrmann@uk-essen.de)  
Internet [www.uk-essen.de](http://www.uk-essen.de)  
Homepage des Instituts: [www.uk-essen.de/mikrobiologie](http://www.uk-essen.de/mikrobiologie)

---

**Von:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Gesendet:** Monday, September 07, 2020 6:31 AM  
**An:** Kehrmann, Jan <[Jan.Kehrmann@uk-essen.de](mailto:Jan.Kehrmann@uk-essen.de)>  
**Cc:** Editorial Office <[editorial@emi2012.org](mailto:editorial@emi2012.org)>  
**Betreff:** Please respond to questions about your recently published paper at EMI

Dear Dr Jan Kehrmann,

We received an inquiry about your recently published paper at EMI (see email below and attached EMI paper).

It is very concerning if your paper used copyrighted materials, inaccurate information/data or using data without the approval from your collaborators. We request a prompt response from you and other co-authors as listed within no more than 10 days.

Best.

Shan Lu, MD, PhD  
Editor-in-Chief  
Emerging Microbes and Infections (EMI)  
[www.tandfonline.com/TEMI](http://www.tandfonline.com/TEMI)

发件人: Sergey Balakhonov <[balakhonov.irk@mail.ru](mailto:balakhonov.irk@mail.ru)>  
答复: Sergey Balakhonov <[balakhonov.irk@mail.ru](mailto:balakhonov.irk@mail.ru)>  
日期: 2020年8月28日 星期五 下午2:27  
收件人: Editorial Office <[editorial@emi2012.org](mailto:editorial@emi2012.org)>  
主题: the article by Jan Kehrmann et al.

Dear Prof. Yu-Mei Wen and Prof. Shan Lu,  
  
the Journal Editors of Emerging Microbes & Infections,

We have great respect for the Journal: Emerging Microbes & Infections and would like to draw your attention to incorrect use of some materials cited in the article by Jan Kehrman et al. "Two fatal cases of plague after consumption of raw marmot organs".

DOI:10.1080/22221751.2020.1807412.

The results of the survey of the natural plague focus in Bayan Ulgii aimag represented in the article (namely "The infection prevalence of marmots and their associated fleas in Bayan Ulgii aimag was 20.2% in 2018 and 16.8% in 2019. It was determined from testing 287 small rodents and 261 fleas in 2018 and 397 small rodents and 312 fleas in 2019 in this area by serological tests and PCR: in case of positivity, bacteriological culture was performed additionally ") were obtained during collaborative Russian-Mongolian monitoring of the Mongolian part of transboundary natural plague focus. Field and laboratory works were financed with support of the Russian side.

Research results were published:

Korzun V.M., Balakhonov S.V., Denisov A.V., Rozhdestvensky E.N., Tokmakova E.G., Sanarov P.P., Akulova S.S., Kosilko S.A., Otgonbayar D., Orgilbayar L., Batzhav D., Urzhikh Ch., Togoldor N., Makhbal A., Tsogbadrakh N., Tserennorov D. Epizootic Situation in the Mongolian Part of the Transboundary Sailugem Natural Plague Focus in 2018. Problemy Osobo Opasnykh Infektsii [Problems of Particularly Dangerous Infections]. 2019; 2:79–86. (In Russian). DOI: 10.21055/0370-1069-2019-2-79-86

V.M. Korzun, S.V. Balakhonov, A.V. Denisov, E.N. Rozhdestvensky, E.G. Tokmakova, E.I. Filatov, Ya.A. Korobko, S.A. Kosilko, D. Otgonbayar, D. Ganbold, D. Batzhav, Ch. Urzhikh, N. Togoldor, Zh. Balshiker, H. Daurenbek, N. Tsogbadrakh, D. Tserennorov. The basic results of epizootological inspection of the Mongolian part of Sailugem natural plague focus in 2019. Dalnevostochnyi Zhurnal Infektsionnoi Patologii [Far-Eastern Journal of Infectious Pathology]. –2019.–№37.–P.53–54. (In Russian) [https://portal.uk-essen.de/link?id=AiAAAABGd7m3lfMOLOIhx3uNR\\_1Qav4Ffx8-jQB0torD82ts JsAAACuPb6U5J454lhBs5mayWBfdK1cJSo7DatgKjkLhLq4NhDvdpdacDVdeBoZA3zheS Sgo5x2F9nzy cGGlhwhiXwT3UXpcdC1dF0 wSBjhrKZV7Lt0MPDXOUKoYBk3LbCzEstkFFN06rGsnAugREHNzxryHLmf0CPjvAWrb48ZnMI9nRz05q TMUe7qEp93pQiWa-hC7dRF7yN1Z nA2](https://portal.uk-essen.de/link?id=AiAAAABGd7m3lfMOLOIhx3uNR_1Qav4Ffx8-jQB0torD82ts JsAAACuPb6U5J454lhBs5mayWBfdK1cJSo7DatgKjkLhLq4NhDvdpdacDVdeBoZA3zheS Sgo5x2F9nzy cGGlhwhiXwT3UXpcdC1dF0 wSBjhrKZV7Lt0MPDXOUKoYBk3LbCzEstkFFN06rGsnAugREHNzxryHLmf0CPjvAWrb48ZnMI9nRz05q TMUe7qEp93pQiWa-hC7dRF7yN1Z nA2)

and also in different other scientific information sources.

In addition, they were surprised to find a photo taken by V.M. Korzun without reference to the author: Figure B. Picture of *Marmota sibirica*. At the same time, we emphasize that the photo shows the gray *Marmota baibacina* but not the Mongolian *Marmota sibirica*.

Let me hope for your understanding of the inadmissibility of incorrect use of copyright materials without appropriate references.

Sincerely,



Sergey Balakhonov, Science Doctor (Medicine), Professor, Director of Irkutsk Anti plague Research Institute of Siberia and Far East. 78 Trilisser st. Irkutsk 664047, Russia. Phone:+7-3952-22-01-35. Fax: +7-3952-22-01-40. E-mail: [adm@chumin.irkutsk.ru](mailto:adm@chumin.irkutsk.ru) , [balakhonov.irk@mail.ru](mailto:balakhonov.irk@mail.ru)

Vladimir Korzun, Science Doctor (Biology), Head of Zoological-and-Parazitological Department of Irkutsk Anti plague Research Institute of Siberia and Far East. 78 Trilisser st. Irkutsk 664047, Russia. Phone:+7-3952-22-01-37. E-mail: [vkorzun@inbox.ru](mailto:vkorzun@inbox.ru)

Sergey Balakhonov, PhD, ScD, Prof.  
Director  
Anti-Plague Research Institute of  
Siberia and Far East  
664047 Trilissera st. 78  
Irkutsk, Russia  
phone:+7-3952-22-01-35  
fax: +7-3952-22-01-40  
e-mail: [balakhonov.irk@mail.ru](mailto:balakhonov.irk@mail.ru)

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Monday, September 14, 2020 8:07 PM  
**To:** antonin.bal@chu-lyon.fr; Lu, Shan; YiWei Tang  
**Cc:** editorial@emi2012.org; laurence.josset@chu-lyon.fr; bruno.lina@chu-lyon.fr; gregory.queromes@univ-lyon1.fr; gregory.destras@chu-lyon.fr  
**Subject:** Re: Pre-submission inquiry\_Characterization of newly SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster

Laurence Josset, PharmD PhD

Thank you for your mail. After discussion with Prof. Shan Lu, co-editor-in-chief, we welcome you to submit your article through EMI website: [www.tandfonline.com/TEMI](http://www.tandfonline.com/TEMI) . However, there are many submissions to EMI, your submission will be evaluated through a strict review system, and this letter does not mean acceptance. Regards, Yu-mei Wen

-----Original Messages-----

**From:** antonin.bal@chu-lyon.fr  
**Sent Time:** 2020-09-14 17:05:58 (Monday)  
**To:** ymwen@shmu.edu.cn, editorial@emi2012.org  
**Cc:** laurence.josset@chu-lyon.fr, antonin.bal@chu-lyon.fr, bruno.lina@chu-lyon.fr, gregory.queromes@univ-lyon1.fr, gregory.destras@chu-lyon.fr  
**Subject:** Pre-submission inquiry\_Characterization of newly SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster

Dear Pr. Wen,

We would like to submit a pre-submission inquiry regarding the suitability of our manuscript entitled **“Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster during routine genomic surveillance, Lyon, France”** for publication in *Emerging Microbes & Infections*, as an Original Article. (bioRxiv: <https://www.biorxiv.org/content/10.1101/2020.08.07.241653v1.full>)

Since February we have sequenced **229 SARS-CoV-2 whole genome** with a metagenomic next-generation sequencing approach as part of the routine surveillance performed at the French National Reference Center for Respiratory Viruses. We detected **two newly discovered frame-shifting deletion variants of the ORF6** (34- and 26-nucleotide deletions). **The 34-nucleotide deletion variant was found in 6 samples** (from 5 patients and **1 health-care worker**) within a cluster of COVID-19 cases from a single geriatric unit at the university hospital of Lyon. Both the presence of the 34-nucleotide deletion variant limited to a hospital unit and the clustering of the corresponding whole genome sequences by phylogeny analysis strongly **suggested a nosocomial transmission between patients**. Interestingly, **prolonged viral excretion of the 34-nucleotide deletion variant was found in a stool sample** 14 days after initial diagnosis for one patient. Furthermore, clinical data revealed **no significant difference in disease severity** between patients harboring the wild-type or the 34-nucleotide ORF6 deletion variant. The in vitro infection of the two deletion variants on primate endothelial kidney cells (BGM) and human lung adenocarcinoma cells (Calu-3) yielded **comparable replication kinetics** with the wild-type strain. In addition, **high viral loads** were found in vivo regardless of the presence or absence of the ORF6 deletion.

Overall, our study highlights **the transmission and replication capacity of two newly described deletion variants in the same ORF6 region**. Given the role of ORF6 in interferon modulation, further characterization, such as mechanistic interactions and interferon monitoring in patients should be performed. By the identification of the first nosocomial cluster harboring a large deletion newly described, **we emphasize the importance of real-time genomic surveillance for the detection of circulating variants and for the investigation of COVID-19 clusters**.

We would be very grateful if you could consider this pre-submission inquiry and look forward to hearing from you.

Yours sincerely,

Laurence Josset, PharmD PhD  
Research Assistant Professor  
National reference center for respiratory viruses (Pr. Bruno Lina)  
University hospital of Lyon, France

---

**From:** Perlman, Stanley <stanley-perlman@uiowa.edu>  
**Sent:** Saturday, June 20, 2020 10:47 PM  
**To:** Gibson, Edward  
**Cc:** Lu, Shan; Perlman, Stanley  
**Subject:** Re: Presenter Information for ISV 1st COVID-19 Virtual Congress  
**Attachments:** Human vaccination.pptx

My presentation is attached. It took me exactly 5 minutes to deliver, so it may be a bit too long. I will work to make it a little shorter. 5 minutes is like a long elevator talk.

Stanley

Stanley Perlman, M.D., Ph.D.  
Professor  
Department of Microbiology  
University of Iowa

---

**From:** Gibson, Edward <Edward.Gibson@umassmed.edu>  
**Sent:** Friday, June 19, 2020 5:33 PM  
**To:** Perlman, Stanley <stanley-perlman@uiowa.edu>  
**Cc:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Subject:** RE: Presenter Information for ISV 1st COVID-19 Virtual Congress

Yes absolutely. I will send tomorrow once the link is available.

Ted

---

**From:** Perlman, Stanley <stanley-perlman@uiowa.edu>  
**Sent:** Friday, June 19, 2020 6:32 PM  
**To:** Gibson, Edward <Edward.Gibson@umassmed.edu>  
**Cc:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Subject:** Re: Presenter Information for ISV 1st COVID-19 Virtual Congress

Ted,

Ok. Could you also send me a link so that I can attend the meeting not as a presenter?

Stanley

Stanley Perlman, MD, Ph.D.  
Professor  
Depts of Microbiology and Immunology, and Pediatrics  
BSB 3-712  
University of Iowa  
Iowa City, IA 52242  
319-335-8549

On Jun 19, 2020, at 5:28 PM, Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)> wrote:

Dear Dr. Perlman,

Thanks again for joining the training session today. We have put together some instructions and an individualized program for your use. As noted please be sure to send me your slides no later than **Sunday, 6/21, 9:00AM (EDT)**.

Please let me know if you have any questions.

Thank you.

Regards,

Ted Gibson

---

**From:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Sent:** Friday, June 19, 2020 11:25 AM  
**To:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Subject:** Re: Presenter Information for ISV 1st COVID-19 Virtual Congress

Ted,

Can you give me a call? I cannot download the Teams Download Application. 319 335 8549

Stanley Perlman, M.D., Ph.D.  
Professor  
Department of Microbiology  
University of Iowa

---

**From:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Sent:** Thursday, June 18, 2020 4:13 PM  
**To:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>; Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** RE: Presenter Information for ISV 1st COVID-19 Virtual Congress

Thanks, yes 10:15 (CDT) 11:15 (EDT) works well.

Also, please be sure to download the Teams Desktop Application [HERE](#) (if you haven't already). Please click "Download for desktop". Once the Teams application is installed on your computer please open and login with the guest sign in info below:

**Login:** [Guest12@isvcongress.org](mailto:Guest12@isvcongress.org)  
**Password:** Yag413450

Once you are signed into teams please go to the calendar located on the left side and click the meeting "Dr. PerlmanTraining." Please click the "Join" blue button to enter the meeting as a presenter. I have included some snips below. Please let me know if you have any questions prior to the training. Thanks again.

<image003.png>

.....

<image004.png>

.....

<image005.png>

Regards,

Ted Gibson

---

**From:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Sent:** Thursday, June 18, 2020 4:51 PM  
**To:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Subject:** Re: Presenter Information for ISV 1st COVID-19 Virtual Congress

10:15 ok?

Stanley Perlman, MD, Ph.D.  
Professor  
Depts of Microbiology and Immunology, and Pediatrics  
BSB 3-712  
University of Iowa  
Iowa City, IA 52242  
319-335-8549

On Jun 18, 2020, at 3:48 PM, Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)> wrote:

Hi Dr. Perlman, yes and thank you. Would you be able to do 10AM CDT? Otherwise can you let me know some available times? Thanks.

Ted

---


**From:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Sent:** Thursday, June 18, 2020 4:43 PM  
**To:** ISV Congress <[info@isvcongress.org](mailto:info@isvcongress.org)>  
**Subject:** Re: Presenter Information for ISV 1st COVID-19 Virtual Congress

I just realized that I did not sign up for a practice session. Can we do this tomorrow?

Stanley

Stanley Perlman, MD, Ph.D.  
Professor  
Depts of Microbiology and Immunology, and Pediatrics  
BSB 3-712  
University of Iowa  
Iowa City, IA 52242  
319-335-8549

On Jun 13, 2020, at 9:55 AM, ISV Congress <[info@isvcongress.org](mailto:info@isvcongress.org)> wrote:



Dear Presenters (including Chairs),  
Once again, ISV would like to thank you for accepting our invitation to update the world with the newest information of SARS-CoV-2 and the progress of COVID-19 vaccine development at the 1<sup>st</sup> ISV Virtual Congress ([www.isvcongress.org](http://www.isvcongress.org)), to be held on Monday, June 22, 2020. Below is the starting time depending on where you will be:

**Monday, June 22, 2020**

Los Angeles

0600-0900

New York 0900-1200

London 1400-1700

Paris 1500-1800

Beijing 2100-2400

Tokyo-Seoul 2200-0100

Sydney 2300-0200

The meeting will be run on the Microsoft Teams platform. If you do not already have the Teams desktop application, please download via the below link. Please be aware you **cannot** present in the live event from the web version of Teams.

<https://www.microsoft.com/en-us/microsoft-365/microsoft-teams/download-app>

We will work with each of you individually to ensure that you're comfortable with Teams. By June 15, Monday noon (EDT), please let us know two 30-minute blocks of time (from June 15 to June 17) that you're available for training, and hold these times in your calendar. Please reply to me at [EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org). You can also reach me at any time with questions.

Also, if you have an assistant/PA, please provide us with their name, email address and phone number for our use as a second method to reach you.

We look forward to this first virtual congress!

Ted Gibson

Congress Secretariat

ISV COVID-19 Vaccine Virtual Congress Series

[EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org)

+1-508-856-1179



*If you no longer wish to receive email from us, please click [here](#):*

<Panelist Instructions - Stanley Perlman.pdf>

---

**From:** Gibson, Edward  
**Sent:** Friday, June 19, 2020 6:29 PM  
**To:** 'Perlman, Stanley'; Lu, Shan  
**Subject:** RE: Presenter Information for ISV 1st COVID-19 Virtual Congress  
**Attachments:** Panelist Instructions - Stanley Perlman.pdf

Dear Dr. Perlman,

Thanks again for joining the training session today. We have put together some instructions and an individualized program for your use. As noted please be sure to send me your slides no later than **Sunday, 6/21, 9:00AM (EDT)**.

Please let me know if you have any questions.

Thank you.

Regards,

Ted Gibson

---

**From:** Perlman, Stanley <stanley-perlman@uiowa.edu>  
**Sent:** Friday, June 19, 2020 11:25 AM  
**To:** Gibson, Edward <Edward.Gibson@umassmed.edu>  
**Subject:** Re: Presenter Information for ISV 1st COVID-19 Virtual Congress

Ted,

CAn you give me a call? I cannot download the Teams Download Application. 319 335 8549

Stanley Perlman, M.D., Ph.D.  
Professor  
Department of Microbiology  
University of Iowa

---

**From:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Sent:** Thursday, June 18, 2020 4:13 PM  
**To:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>; Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** RE: Presenter Information for ISV 1st COVID-19 Virtual Congress

Thanks, yes 10:15 (CDT) 11:15 (EDT) works well.



Also, please be sure to download the Teams Desktop Application [HERE](#) (if you haven't already). Please click "Download for desktop". Once the Teams application is installed on your computer please open and login with the guest sign in info below:

**Login:** [Guest12@isvcongress.org](mailto:Guest12@isvcongress.org)

**Password:** Yag413450



Once you are signed into teams please go to the calendar located on the left side and click the meeting “Dr. PerlmanTraining.” Please click the “Join” blue button to enter the meeting as a presenter. I have included some snips below. Please let me know if you have any questions prior to the training. Thanks again.



## Stanley Perlman Training



### Invite attendees

To invite attendees, copy the link and share it or send it in a calendar invite.

Get attendee link

Learn more

Friday, June 19, 2020  
11:15 AM - 11:45 AM (30 minutes)  
Microsoft Teams Meeting

Join

Chat

Cancel meeting

Live event resources

Refresh

Organizer

Edward Gibson  
Producer, Organ

Event group

ISVCongress.c  
Producer

Guest 12  
Presenter

Close

Regards,

Ted Gibson

**From:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>

**Sent:** Thursday, June 18, 2020 4:51 PM

**To:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>

**Subject:** Re: Presenter Information for ISV 1st COVID-19 Virtual Congress

10:15 ok?

Stanley Perlman, MD, Ph.D.

Professor

Depts of Microbiology and Immunology, and Pediatrics

BSB 3-712

University of Iowa

Iowa City, IA 52242

319-335-8549

On Jun 18, 2020, at 3:48 PM, Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)> wrote:

Hi Dr. Perlman, yes and thank you. Would you be able to do 10AM CDT? Otherwise can you let me know some available times? Thanks.

Ted

---

**From:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Sent:** Thursday, June 18, 2020 4:43 PM  
**To:** ISV Congress <[info@isvcongress.org](mailto:info@isvcongress.org)>  
**Subject:** Re: Presenter Information for ISV 1st COVID-19 Virtual Congress

I just realized that I did not sign up for a practice session. Can we do this tomorrow?

Stanley

Stanley Perlman, MD, Ph.D.  
Professor  
Depts of Microbiology and Immunology, and Pediatrics  
BSB 3-712  
University of Iowa  
Iowa City, IA 52242  
319-335-8549

On Jun 13, 2020, at 9:55 AM, ISV Congress <[info@isvcongress.org](mailto:info@isvcongress.org)> wrote:



Dear Presenters (including Chairs),  
Once again, ISV would like to thank you for accepting our invitation to update the world with the newest information of SARS-CoV-2 and the progress of COVID-19 vaccine development at the 1<sup>st</sup> ISV Virtual Congress ([www.isvcongress.org](http://www.isvcongress.org)), to be held on Monday, June 22, 2020. Below is the starting time depending on where you will be:

**Monday, June 22, 2020**

Los Angeles  
0600-0900  
New York 0900-1200  
London 1400-1700  
Paris 1500-1800  
Beijing 2100-2400  
Tokyo-Seoul 2200-0100  
Sydney 2300-0200

The meeting will be run on the Microsoft Teams platform. If you do not already have the Teams desktop application, please download via the below link. Please be aware you **cannot** present in the live event from the web version of Teams.

<https://www.microsoft.com/en-us/microsoft-365/microsoft-teams/download-app>

We will work with each of you individually to ensure that you're comfortable with Teams. By June 15, Monday noon (EDT), please let us know two 30-minute blocks of time (from June 15

to June 17) that you're available for training, and hold these times in your calendar. Please reply to me at [EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org). You can also reach me at any time with questions.

Also, if you have an assistant/PA, please provide us with their name, email address and phone for our use as a second method to reach you.

We look forward to this first virtual congress!

Ted Gibson

Congress Secretariat

ISV COVID-19 Vaccine Virtual Congress Series

[EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org)

+1-508-856-1179



*If you no longer wish to receive email from us, please click [here](#):*

---

**From:** Gibson, Edward  
**Sent:** Friday, June 19, 2020 6:34 PM  
**To:** 'Perlman, Stanley'  
**Cc:** Lu, Shan  
**Subject:** RE: Presenter Information for ISV 1st COVID-19 Virtual Congress

Yes absolutely. I will send tomorrow once the link is available.

Ted

---

**From:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Sent:** Friday, June 19, 2020 6:32 PM  
**To:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** Re: Presenter Information for ISV 1st COVID-19 Virtual Congress

Ted,

Ok. Could you also send me a link so that I can attend the meeting not as a presenter?

Stanley

Stanley Perlman, MD, Ph.D.  
Professor  
Depts of Microbiology and Immunology, and Pediatrics  
BSB 3-712  
University of Iowa  
Iowa City, IA 52242  
319-335-8549

On Jun 19, 2020, at 5:28 PM, Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)> wrote:

Dear Dr. Perlman,

Thanks again for joining the training session today. We have put together some instructions and an individualized program for your use. As noted please be sure to send me your slides no later than **Sunday, 6/21, 9:00AM (EDT)**.

Please let me know if you have any questions.

Thank you.

Regards,

Ted Gibson

---

**From:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Sent:** Friday, June 19, 2020 11:25 AM

**To:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Subject:** Re: Presenter Information for ISV 1st COVID-19 Virtual Congress

Ted,

Can you give me a call? I cannot download the Teams Download Application. 319 335 8549

Stanley Perlman, M.D., Ph.D.  
Professor  
Department of Microbiology  
University of Iowa

---

**From:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Sent:** Thursday, June 18, 2020 4:13 PM  
**To:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>; Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** RE: Presenter Information for ISV 1st COVID-19 Virtual Congress

Thanks, yes 10:15 (CDT) 11:15 (EDT) works well.

Also, please be sure to download the Teams Desktop Application [HERE](#) (if you haven't already). Please click "Download for desktop". Once the Teams application is installed on your computer please open and login with the guest sign in info below:

**Login:** [Guest12@isvcongress.org](mailto:Guest12@isvcongress.org)  
**Password:** Yag413450

Once you are signed into teams please go to the calendar located on the left side and click the meeting "Dr. PerlmanTraining." Please click the "Join" blue button to enter the meeting as a presenter. I have included some snips below. Please let me know if you have any questions prior to the training. Thanks again.

<image003.png>

.....

<image004.png>

.....

<image005.png>

Regards,

Ted Gibson

---

**From:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Sent:** Thursday, June 18, 2020 4:51 PM  
**To:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Subject:** Re: Presenter Information for ISV 1st COVID-19 Virtual Congress

10:15 ok?

Stanley Perlman, MD, Ph.D.  
Professor  
Depts of Microbiology and Immunology, and Pediatrics

BSB 3-712  
University of Iowa  
Iowa City, IA 52242  
319-335-8549

On Jun 18, 2020, at 3:48 PM, Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)> wrote:

Hi Dr. Perlman, yes and thank you. Would you be able to do 10AM CDT? Otherwise can you let me know some available times? Thanks.

Ted

---


**From:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Sent:** Thursday, June 18, 2020 4:43 PM  
**To:** ISV Congress <[info@isvcongress.org](mailto:info@isvcongress.org)>  
**Subject:** Re: Presenter Information for ISV 1st COVID-19 Virtual Congress

I just realized that I did not sign up for a practice session. Can we do this tomorrow?

Stanley

Stanley Perlman, MD, Ph.D.  
Professor  
Depts of Microbiology and Immunology, and Pediatrics  
BSB 3-712  
University of Iowa  
Iowa City, IA 52242  
319-335-8549

On Jun 13, 2020, at 9:55 AM, ISV Congress <[info@isvcongress.org](mailto:info@isvcongress.org)> wrote:



Dear Presenters (including Chairs),  
Once again, ISV would like to thank you for accepting our invitation to update the world with the newest information of SARS-CoV-2 and the progress of COVID-19 vaccine development at the 1<sup>st</sup> ISV Virtual Congress ([www.isvcongress.org](http://www.isvcongress.org)), to be held on Monday, June 22, 2020. Below is the starting time depending on where you will be:

**Monday, June 22, 2020**

Los Angeles  
0600-0900  
New York 0900-1200  
London 1400-1700

Paris 1500-1800  
Beijing 2100-2400  
Tokyo-Seoul 2200-0100  
Sydney 2300-0200

The meeting will be run on the Microsoft Teams platform. If you do not already have the Teams desktop application, please download via the below link. Please be aware you **cannot** present in the live event from the web version of Teams.

<https://www.microsoft.com/en-us/microsoft-365/microsoft-teams/download-app>

We will work with each of you individually to ensure that you're comfortable with Teams. By June 15, Monday noon (EDT), please let us know two 30-minute blocks of time (from June 15 to June 17) that you're available for training, and hold these times in your calendar. Please reply to me at [EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org). You can also reach me at any time with questions.

Also, if you have an assistant/PA, please provide us with their name, email address and phone for our use as a second method to reach you.

We look forward to this first virtual congress!

Ted Gibson

Congress Secretariat

ISV COVID-19 Vaccine Virtual Congress Series

[EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org)

+1-508-856-1179



*If you no longer wish to receive email from us, please click [here](#):*

<Panelist Instructions - Stanley Perlman.pdf>



---

**From:** Gibson, Edward  
**Sent:** Sunday, June 21, 2020 6:02 PM  
**To:** 'Perlman, Stanley'  
**Cc:** Lu, Shan  
**Subject:** RE: Presenter Information for ISV 1st COVID-19 Virtual Congress

Hi Dr. Perlman, please see below however since you are at the end of the event there is no need to sign out and back in as an attendee. You can just stay in as a presenter. Thank you and see you tomorrow.

Please click [HERE](#) for the Live Event link as an attendee.

Regards,

Ted Gibson

---

**From:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Sent:** Sunday, June 21, 2020 3:00 PM  
**To:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Subject:** Re: Presenter Information for ISV 1st COVID-19 Virtual Congress

Don't forget to send the link.  
Stanley

Sent from my iPhone

On Jun 19, 2020, at 5:33 PM, Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)> wrote:

Yes absolutely. I will send tomorrow once the link is available.

Ted

---

**From:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Sent:** Friday, June 19, 2020 6:32 PM  
**To:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** Re: Presenter Information for ISV 1st COVID-19 Virtual Congress

Ted,

Ok. Could you also send me a link so that I can attend the meeting not as a presenter?

Stanley

Stanley Perlman, MD, Ph.D.  
Professor  
Depts of Microbiology and Immunology, and Pediatrics  
BSB 3-712  
University of Iowa

Iowa City, IA 52242  
319-335-8549

On Jun 19, 2020, at 5:28 PM, Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)> wrote:

Dear Dr. Perlman,

Thanks again for joining the training session today. We have put together some instructions and an individualized program for your use. As noted please be sure to send me your slides no later than **Sunday, 6/21, 9:00AM (EDT)**.

Please let me know if you have any questions.

Thank you.

Regards,

Ted Gibson

---

**From:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Sent:** Friday, June 19, 2020 11:25 AM  
**To:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Subject:** Re: Presenter Information for ISV 1st COVID-19 Virtual Congress

Ted,

Can you give me a call? I cannot download the Teams Download Application. 319 335 8549

Stanley Perlman, M.D., Ph.D.  
Professor  
Department of Microbiology  
University of Iowa

---

**From:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Sent:** Thursday, June 18, 2020 4:13 PM  
**To:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>; Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** RE: Presenter Information for ISV 1st COVID-19 Virtual Congress

Thanks, yes 10:15 (CDT) 11:15 (EDT) works well.

Also, please be sure to download the Teams Desktop Application [HERE](#) (if you haven't already). Please click "Download for desktop". Once the Teams application is installed on your computer please open and login with the guest sign in info below:

**Login:** [Guest12@isvcongress.org](mailto:Guest12@isvcongress.org)  
**Password:** Yag413450

Once you are signed into teams please go to the calendar located on the left side and click the meeting "Dr. PerlmanTraining." Please click the "Join" blue button to enter the meeting as a presenter. I have included some snips below. Please let me know if you have any questions prior to the training. Thanks again.

<image003.png>

.....

<image004.png>

.....

<image005.png>

Regards,

Ted Gibson

---

**From:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Sent:** Thursday, June 18, 2020 4:51 PM  
**To:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Subject:** Re: Presenter Information for ISV 1st COVID-19 Virtual Congress

10:15 ok?

Stanley Perlman, MD, Ph.D.  
Professor  
Depts of Microbiology and Immunology, and Pediatrics  
BSB 3-712  
University of Iowa  
Iowa City, IA 52242  
319-335-8549

On Jun 18, 2020, at 3:48 PM, Gibson, Edward  
<[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)> wrote:

Hi Dr. Perlman, yes and thank you. Would you be able to do 10AM  
CDT? Otherwise can you let me know some available times? Thanks.

Ted

---


**From:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Sent:** Thursday, June 18, 2020 4:43 PM  
**To:** ISV Congress <[info@isvcongress.org](mailto:info@isvcongress.org)>  
**Subject:** Re: Presenter Information for ISV 1st COVID-19 Virtual Congress

I just realized that I did not sign up for a practice session. Can we do this tomorrow?

Stanley

Stanley Perlman, MD, Ph.D.  
Professor  
Depts of Microbiology and Immunology, and Pediatrics  
BSB 3-712  
University of Iowa  
Iowa City, IA 52242  
319-335-8549

On Jun 13, 2020, at 9:55 AM, ISV Congress  
<[info@isvcongress.org](mailto:info@isvcongress.org)> wrote:



Dear Presenters (including Chairs),  
Once again, ISV would like to thank you for accepting our invitation to update the world's  
newest information of SARS-CoV-2 and the progress of COVID-19 vaccine development at the  
1<sup>st</sup> ISV Virtual Congress ([www.isvcongress.org](http://www.isvcongress.org)), to be held on Monday, June 22, 2020.  
The starting time is depending on where you will be:

**Monday, June 22, 2020**

Los Angeles  
0600-0900  
New York 0900-1200  
London 1400-1700  
Paris 1500-1800  
Beijing 2100-2400  
Tokyo-Seoul 2200-0100  
Sydney 2300-0200

The meeting will be run on the Microsoft Teams platform. If you do not already have the  
Teams desktop application, please download via the below link. Please be aware  
you **cannot** present in the live event from the web version of Teams.

<https://www.microsoft.com/en-us/microsoft-365/microsoft-teams/download-app>

We will work with each of you individually to ensure that you're comfortable with Teams.  
On Monday, June 15, Monday noon (EDT), please let us know two 30-minute blocks of time (from  
June 15 to June 17) that you're available for training, and hold these times in your calendar.  
Please reply to me at [EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org). You can also reach me at any time with  
questions.

Also, if you have an assistant/PA, please provide us with their name, email address and phone number  
for our use as a second method to reach you.

We look forward to this first virtual congress!


Ted Gibson

Congress Secretariat

ISV COVID-19 Vaccine Virtual Congress Series

[EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org)

+1-508-856-1179



*If you no longer wish to receive email from us, please click [here](#).*

<Panelist Instructions - Stanley Perlman.pdf>

---

**From:** Perlman, Stanley <stanley-perlman@uiowa.edu>  
**Sent:** Friday, June 19, 2020 6:32 PM  
**To:** Gibson, Edward  
**Cc:** Lu, Shan  
**Subject:** Re: Presenter Information for ISV 1st COVID-19 Virtual Congress

Ted,

Ok. Could you also send me a link so that I can attend the meeting not as a presenter?

Stanley

Stanley Perlman, MD, Ph.D.  
Professor  
Depts of Microbiology and Immunology, and Pediatrics  
BSB 3-712  
University of Iowa  
Iowa City, IA 52242  
319-335-8549

On Jun 19, 2020, at 5:28 PM, Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)> wrote:

Dear Dr. Perlman,

Thanks again for joining the training session today. We have put together some instructions and an individualized program for your use. As noted please be sure to send me your slides no later than **Sunday, 6/21, 9:00AM (EDT)**.

Please let me know if you have any questions.

Thank you.

Regards,

Ted Gibson

---

**From:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Sent:** Friday, June 19, 2020 11:25 AM  
**To:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Subject:** Re: Presenter Information for ISV 1st COVID-19 Virtual Congress

Ted,

Can you give me a call? I cannot download the Teams Download Application. 319 335 8549

Stanley Perlman, M.D., Ph.D.  
Professor

Department of Microbiology  
University of Iowa

---

**From:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Sent:** Thursday, June 18, 2020 4:13 PM  
**To:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>; Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** RE: Presenter Information for ISV 1st COVID-19 Virtual Congress

Thanks, yes 10:15 (CDT) 11:15 (EDT) works well.

Also, please be sure to download the Teams Desktop Application [HERE](#) (if you haven't already). Please click "Download for desktop". Once the Teams application is installed on your computer please open and login with the guest sign in info below:

**Login:** [Guest12@isvcongress.org](mailto:Guest12@isvcongress.org)  
**Password:** Yag413450

Once you are signed into teams please go to the calendar located on the left side and click the meeting "Dr. PerlmanTraining." Please click the "Join" blue button to enter the meeting as a presenter. I have included some snips below. Please let me know if you have any questions prior to the training. Thanks again.

<image003.png>

.....

<image004.png>

.....

<image005.png>

Regards,

Ted Gibson

---

**From:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Sent:** Thursday, June 18, 2020 4:51 PM  
**To:** Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)>  
**Subject:** Re: Presenter Information for ISV 1st COVID-19 Virtual Congress

10:15 ok?

Stanley Perlman, MD, Ph.D.  
Professor  
Depts of Microbiology and Immunology, and Pediatrics  
BSB 3-712  
University of Iowa  
Iowa City, IA 52242  
319-335-8549

On Jun 18, 2020, at 3:48 PM, Gibson, Edward <[Edward.Gibson@umassmed.edu](mailto:Edward.Gibson@umassmed.edu)> wrote:

Hi Dr. Perlman, yes and thank you. Would you be able to do 10AM CDT? Otherwise can you let me know some available times? Thanks.

Ted

---


**From:** Perlman, Stanley <[stanley-perlman@uiowa.edu](mailto:stanley-perlman@uiowa.edu)>  
**Sent:** Thursday, June 18, 2020 4:43 PM  
**To:** ISV Congress <[info@isvcongress.org](mailto:info@isvcongress.org)>  
**Subject:** Re: Presenter Information for ISV 1st COVID-19 Virtual Congress

I just realized that I did not sign up for a practice session. Can we do this tomorrow?

Stanley

Stanley Perlman, MD, Ph.D.  
Professor  
Depts of Microbiology and Immunology, and Pediatrics  
BSB 3-712  
University of Iowa  
Iowa City, IA 52242  
319-335-8549

On Jun 13, 2020, at 9:55 AM, ISV Congress <[info@isvcongress.org](mailto:info@isvcongress.org)> wrote:



Dear Presenters (including Chairs),  
Once again, ISV would like to thank you for accepting our invitation to update the world with the newest information of SARS-CoV-2 and the progress of COVID-19 vaccine development at the 1<sup>st</sup> ISV Virtual Congress ([www.isvcongress.org](http://www.isvcongress.org)), to be held on Monday, June 22, 2020. Below is the starting time depending on where you will be:

**Monday, June 22, 2020**

Los Angeles  
0600-0900  
New York 0900-1200  
London 1400-1700  
Paris 1500-1800  
Beijing 2100-2400  
Tokyo-Seoul 2200-0100  
Sydney 2300-0200

The meeting will be run on the Microsoft Teams platform. If you do not already have the Teams desktop application, please download via the below link. Please be aware you **cannot** present in the live event from the web version of Teams.

<https://www.microsoft.com/en-us/microsoft-365/microsoft-teams/download-app>



We will work with each of you individually to ensure that you're comfortable with Teams. By June 15, Monday noon (EDT), please let us know two 30-minute blocks of time (from June 15 to June 17) that you're available for training, and hold these times in your calendar. Please reply to me at [EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org). You can also reach me at any time with questions.

Also, if you have an assistant/PA, please provide us with their name, email address and phone number for our use as a second method to reach you.

We look forward to this first virtual congress!

Ted Gibson

Congress Secretariat

ISV COVID-19 Vaccine Virtual Congress Series

[EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org)

+1-508-856-1179



*If you no longer wish to receive email from us, please click [here](#).*

<Panelist Instructions - Stanley Perlman.pdf>

---

**From:** TEMI-production@journals.tandf.co.uk  
**Sent:** Friday, September 18, 2020 11:03 AM  
**To:** Lu, Shan  
**Cc:** editorial@emi2012.org; zlshi@wh.iov.cn; alexa.josaphouitch@taylorandfrancis.com; simon.wesson@tandf.co.uk; ymw@shmu.edu.cn; jml8328@126.com; mark.j.jones@informa.com  
**Subject:** RE: Press release: A serological survey of SARS-CoV-2 in cat in Wuhan -- 1817796 #TrackingId:7281285

Dear Professor Shan,

It's nice to hear this news!

Best wishes,

Karthick

Emerging Microbes & Infections

---

**From:** Shan.Lu@umassmed.edu  
**Sent:** 18-09-2020 07.46 PM  
**To:** TEMI-production@journals.tandf.co.uk  
**Cc:** editorial@emi2012.org; zlshi@wh.iov.cn; alexa.josaphouitch@taylorandfrancis.com; simon.wesson@tandf.co.uk; ymw@shmu.edu.cn; jml8328@126.com; mark.j.jones@informa.com  
**Subject:** RE: Press release: A serological survey of SARS-CoV-2 in cat in Wuhan -- 1817796

Dear Karthick,

Yes, we did see it. Thank you very much. This paper has already attracted a lot of attention.

Best.

Shan

**From:** TEMI-production@journals.tandf.co.uk <TEMI-production@journals.tandf.co.uk>  
**Sent:** Friday, September 18, 2020 1:55 AM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Cc:** editorial@emi2012.org; zlshi@wh.iov.cn; alexa.josaphouitch@taylorandfrancis.com; simon.wesson@tandf.co.uk; ymw@shmu.edu.cn; jml8328@126.com; mark.j.jones@informa.com  
**Subject:** RE: Press release: A serological survey of SARS-CoV-2 in cat in Wuhan -- 1817796 #TrackingId:7281285

Dear Professor Shan and all,

Good morning!

We have a good news that "A serological survey of SARS-CoV-2 in cat in Wuhan" paper is published online. Also, we have published few more papers as well.

Best wishes,

Karthick

Emerging Microbes & Infections

---

**From:** Shan.Lu@umassmed.edu  
**Sent:** 16-09-2020 06:58 PM  
**To:** TEMI-production@journals.tandf.co.uk  
**Cc:** editorial@emi2012.org, zlshi@wh.iov.cn, alexa.josaphouitch@taylorandfrancis.com, ymw@shmu.edu.cn, jml8328@126.com, mark.j.jones@informa.com  
**Subject:** RE: Press release: A serological survey of SARS-CoV-2 in cat in Wuhan -- 1817796

Thanks. Sorry I just sent one email to you and please ignore it.

Best.

Shan

**From:** [TEMI-production@journals.tandf.co.uk](mailto:TEMI-production@journals.tandf.co.uk) <[TEMI-production@journals.tandf.co.uk](mailto:TEMI-production@journals.tandf.co.uk)>  
**Sent:** Wednesday, September 16, 2020 9:26 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** [editorial@emi2012.org](mailto:editorial@emi2012.org); [zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn); [alexa.josaphouitch@taylorandfrancis.com](mailto:alexa.josaphouitch@taylorandfrancis.com); [ymw@shmu.edu.cn](mailto:ymw@shmu.edu.cn); [jml8328@126.com](mailto:jml8328@126.com); [mark.j.jones@informa.com](mailto:mark.j.jones@informa.com)  
**Subject:** Re: Press release: A serological survey of SARS-CoV-2 in cat in Wuhan -- 1817796 #TrackingId:7281285

Dear Professor Shan,

Hope you are having a nice day!

Hope you have been provided the status of this paper from Ethics and Editorial team. Now all the issues are resolved.

We will publish the paper online by Friday most probably tomorrow.

Thank you for your patience.

Best wishes,

Karthick

Emerging Microbes & Infections

---

**From:** Shan.Lu@umassmed.edu  
**Sent:** 15-09-2020 10:22  
**To:** Simon.Wesson@tandf.co.uk, karthick@novatechset.com  
**Cc:** editorial@emi2012.org, jml8328@126.com, zlshi@wh.iov.cn, ymw@shmu.edu.cn, Alexa.Josaphouitch@taylorandfrancis.com  
**Subject:** Re: Press release: A serological survey of SARS-CoV-2 in cat in Wuhan -- 1817796

Dear Simon,

Today is the day of ending embargo. I noticed a huge jump of views (4261) although it is toward the AMO version. This never happened in the past and I assume that you must have sent out the PR to quite a lot of news outlets. This confirms the approach we have been planning is working.

Dr. Shi and Dr. Jin,

It will be interesting if you can let us in about one week so we can know if any news group contacted you for this paper.

Dear Karthick,

It is somewhat disappointing that we did not see the real final published paper at EMI site (except AMO). It will be really nice if the clean copy of published paper is available to readers.

Best.

Shan

---

**From:** Wesson, Simon <[Simon.Wesson@tandf.co.uk](mailto:Simon.Wesson@tandf.co.uk)>

**Sent:** Monday, September 7, 2020 10:59 AM

**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; 126.com <[jml8328@126.com](mailto:jml8328@126.com)>

**Cc:** Editorial Office <[editorial@emi2012.org](mailto:editorial@emi2012.org)>

**Subject:** RE: Re:RE: Re:Press release: A serological survey of SARS-CoV-2 in cat in Wuhan

Hello Shan

Yes I think that would be sensible to add in, around the part where we mention no deaths. Does that work for you both?

Thanks

---

**Information Classification:** General

**From:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Sent:** 07 September 2020 15:25

**To:** Wesson, Simon <[Simon.Wesson@tandf.co.uk](mailto:Simon.Wesson@tandf.co.uk)>; 126.com <[jml8328@126.com](mailto:jml8328@126.com)>

**Cc:** Editorial Office <[editorial@emi2012.org](mailto:editorial@emi2012.org)>

**Subject:** RE: Re:RE: Re:Press release: A serological survey of SARS-CoV-2 in cat in Wuhan

Hi, Simon and Meilin,

This press release reads well. I just wonder if we should add that there was no actual COVID-19 virus detected from these cats.

Best.

Shan

\*\*\*\*\*

Shan Lu, MD, PhD

Editor-in-Chief

Emerging Microbes and Infections (EMI)

[www.tandfonline.com/TEMI](http://www.tandfonline.com/TEMI)

**From:** Wesson, Simon <[Simon.Wesson@tandf.co.uk](mailto:Simon.Wesson@tandf.co.uk)>  
**Sent:** Monday, September 7, 2020 5:39 AM  
**To:** 126.com <[jml8328@126.com](mailto:jml8328@126.com)>; Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** RE: Re:RE: Re:Press release: A serological survey of SARS-CoV-2 in cat in Wuhan

Hi both

Just to say that I've spoken to the production team here and the article will not be 100% ready for Wednesday. Therefore to make sure there are no issues of us doing a release that leads to no article online I have set a new embargo and publication date of Tuesday 15 September.  
The press release is good to go and as soon as the final article is ready I can begin distribution under embargo too.

Best wishes  
Simon

**From:** 126.com <[jml8328@126.com](mailto:jml8328@126.com)>  
**Sent:** 05 September 2020 15:17  
**To:** Wesson, Simon <[Simon.Wesson@tandf.co.uk](mailto:Simon.Wesson@tandf.co.uk)>  
**Subject:** Re:RE: Re:Press release: A serological survey of SARS-CoV-2 in cat in Wuhan

Dear Simon,

Good afternoon. I'm quite satisfied with the final press release.

Thank you again for your efforts.

Best wishes,

Yours sincerely,

Meilin Jin

--

Meilin Jin, Ph.D  
Professor of Molecular Microbiology & Animal Infectious Diseases  
State Key Laboratory of Agricultural Microbiology  
College of Veterinary Medicine  
Huazhong Agricultural University  
Shizishan Street 1, Wuhan 430070  
P.R. China  
Phone: +86-27-8728 6905  
Fax: +86-27-8728 2608  
E-mail: [jml8328@126.com](mailto:jml8328@126.com)

---

**From:** TEMI-production@journals.tandf.co.uk  
**Sent:** Friday, September 18, 2020 1:55 AM  
**To:** Lu, Shan  
**Cc:** editorial@emi2012.org; zlshi@wh.iov.cn; alexa.josaphouitch@taylorandfrancis.com; simon.wesson@tandf.co.uk; ymw@shmu.edu.cn; jml8328@126.com; mark.j.jones@informa.com  
**Subject:** RE: Press release: A serological survey of SARS-CoV-2 in cat in Wuhan -- 1817796 #TrackingId:7281285

Dear Professor Shan and all,

Good morning!

We have a good news that "A serological survey of SARS-CoV-2 in cat in Wuhan" paper is published online. Also, we have published few more papers as well.

Best wishes,

Karthick

Emerging Microbes & Infections

---

**From:** Shan.Lu@umassmed.edu  
**Sent:** 16-09-2020 06.58 PM  
**To:** TEMI-production@journals.tandf.co.uk  
**Cc:** editorial@emi2012.org; zlshi@wh.iov.cn; alexa.josaphouitch@taylorandfrancis.com; ymw@shmu.edu.cn; jml8328@126.com; mark.j.jones@informa.com  
**Subject:** RE: Press release: A serological survey of SARS-CoV-2 in cat in Wuhan -- 1817796

Thanks. Sorry I just sent one email to you and please ignore it.

Best.

Shan

**From:** TEMI-production@journals.tandf.co.uk <TEMI-production@journals.tandf.co.uk>  
**Sent:** Wednesday, September 16, 2020 9:26 AM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Cc:** editorial@emi2012.org; zlshi@wh.iov.cn; alexa.josaphouitch@taylorandfrancis.com; ymw@shmu.edu.cn; jml8328@126.com; mark.j.jones@informa.com  
**Subject:** Re: Press release: A serological survey of SARS-CoV-2 in cat in Wuhan -- 1817796 #TrackingId:7281285

Dear Professor Shan,

Hope you are having a nice day!

Hope you have been provided the status of this paper from Ethics and Editorial team. Now all the issues are resolved.

We will publish the paper online by Friday most probably tomorrow.

Thank you for your patience.

Best wishes,

Karthick

Emerging Microbes & Infections

---

**From:**Shan.Lu@umassmed.edu

**Sent:**15-09-2020 10:22

**To:**Simon.Wesson@tandf.co.uk,karthick@novatechset.com

**Cc:**editorial@emi2012.org,jml8328@126.com,zlshi@wh.iov.cn,ymwen@shmu.edu.cn,Alexa.Josaphouitch@taylorandfrancis.com

**Subject:**Re: Press release: A serological survey of SARS-CoV-2 in cat in Wuhan -- 1817796

Dear Simon,

Today is the day of ending embargo. I noticed a huge jump of views (4261) although it is toward the AMO version. This never happened in the past and I assume that you must have sent out the PR to quite a lot of news outlets. This confirms the approach we have been planning is working.

Dr. Shi and Dr. Jin,

It will be interesting if you can let us in about one week so we can know if any news group contacted you for this paper.

Dear Karthick,

It is somewhat disappointing that we did not see the real final published paper at EMI site (except AMO). It will be really nice if the clean copy of published paper is available to readers.

Best.

Shan

---

**From:** Wesson, Simon <[Simon.Wesson@tandf.co.uk](mailto:Simon.Wesson@tandf.co.uk)>

**Sent:** Monday, September 7, 2020 10:59 AM

**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; 126.com <[jml8328@126.com](mailto:jml8328@126.com)>

**Cc:** Editorial Office <[editorial@emi2012.org](mailto:editorial@emi2012.org)>

**Subject:** RE: Re:RE: Re:Press release: A serological survey of SARS-CoV-2 in cat in Wuhan

Hello Shan

Yes I think that would be sensible to add in, around the part where we mention no deaths. Does that work for you both?

Thanks

---

**Information Classification:** General

**From:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Sent:** 07 September 2020 15:25

**To:** Wesson, Simon <[Simon.Wesson@tandf.co.uk](mailto:Simon.Wesson@tandf.co.uk)>; 126.com <[jml8328@126.com](mailto:jml8328@126.com)>

**Cc:** Editorial Office <[editorial@emi2012.org](mailto:editorial@emi2012.org)>

**Subject:** RE: Re:RE: Re:Press release: A serological survey of SARS-CoV-2 in cat in Wuhan

Hi, Simon and Meilin,

This press release reads well. I just wonder if we should add that there was no actual COVID-19 virus detected from these cats.

Best.

Shan

\*\*\*\*\*

Shan Lu, MD, PhD

Editor-in-Chief

Emerging Microbes and Infections (EMI)

[www.tandfonline.com/TEMI](http://www.tandfonline.com/TEMI)

[editorial@2012EMI.org](mailto:editorial@2012EMI.org)

---

**From:** Wesson, Simon <[Simon.Wesson@tandf.co.uk](mailto:Simon.Wesson@tandf.co.uk)>

**Sent:** Monday, September 7, 2020 5:39 AM

**To:** 126.com <[jml8328@126.com](mailto:jml8328@126.com)>; Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Subject:** RE: Re:RE: Re:Press release: A serological survey of SARS-CoV-2 in cat in Wuhan

Hi both

Just to say that I've spoken to the production team here and the article will not be 100% ready for Wednesday. Therefore to make sure there are no issues of us doing a release that leads to no article online I have set a new embargo and publication date of Tuesday 15 September.

The press release is good to go and as soon as the final article is ready I can begin distribution under embargo too.

Best wishes

Simon

**From:** 126.com <[jml8328@126.com](mailto:jml8328@126.com)>

**Sent:** 05 September 2020 15:17

**To:** Wesson, Simon <[Simon.Wesson@tandf.co.uk](mailto:Simon.Wesson@tandf.co.uk)>

**Subject:** Re:RE: Re:Press release: A serological survey of SARS-CoV-2 in cat in Wuhan

Dear Simon,

Good afternoon. I'm quite satisfied with the final press release.

Thank you again for your efforts.

Best wishes,

Yours sincerely,



Meilin Jin

--

Meilin Jin, Ph.D  
Professor of Molecular Microbiology & Animal Infectious Diseases  
State Key Laboratory of Agricultural Microbiology  
College of Veterinary Medicine  
Huazhong Agricultural University  
Shizishan Street 1, Wuhan 430070  
P.R. China  
Phone: +86-27-8728 6905  
Fax: +86-27-8728 2608  
E-mail: [jml8328@126.com](mailto:jml8328@126.com)

---

**From:** Macit İlkit <macitilkit@gmail.com>  
**Sent:** Monday, May 4, 2020 10:32 AM  
**To:** Lu, Shan  
**Cc:** ymwen@shmu.edu.cn; editorial@emi2012.org; Amir Arastehfar; min.yang@emi2012.org  
**Subject:** Re: Presubmission inquiry  
**Attachments:** Main file-EMI-C. parapsilosis study, Turkey.docx; Table 1.docx; Figure 1.tif; Figure 2.tif; Figure 3.tif; Supplementray Files.docx

Dear Professor Shan Lu,

Thanks indeed for your kind reply despite being extremely busy.  
Attached please kindly find the enclosed files containing the manuscript, tables, figures, and supplementary files.  
I keep looking forward to hearing from you

Best regards,

Macit İlkit

Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>, 4 May 2020 Pzt, 16:54 tarihinde şunu yazdı:

Dear Prof Macit İlkit

Thanks for your interest in submitting a paper to EMI.

EMI now does have a pre-screening system for papers submitted. We will get back to authors in about 1 week if the submission is not considered high priority for EMI at this point. Since you sent it here to me and Prof Wen, I will need to check it with my screening team colleagues and get back to you soon.

EMI is currently overwhelmed by many COVID-19 papers. I apologize for any possible delay.

Best.

Shan Lu, MD, PhD

Editor-in-Chief

Emerging Microbes and Infections (EMI)

[www.tandfonline.com/TEMI](http://www.tandfonline.com/TEMI)

**From:** Macit Ilkit <[macitilkit@gmail.com](mailto:macitilkit@gmail.com)>  
**Sent:** Friday, May 1, 2020 3:13 PM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; [ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn); [editorial@emi2012.org](mailto:editorial@emi2012.org)  
**Cc:** Amir Arastehfar <[a.arastehfar.nl@gmail.com](mailto:a.arastehfar.nl@gmail.com)>  
**Subject:** Presubmission inquiry

Prof Shan Lu

Prof Yu-Mei Wen

Editors-in-Chiefs

*Emerging Microbes and Infections.*

Dear Editors:

Currently, we have finalized a comprehensive study on emerging azole-resistant *C. parapsilosis* bloodstream infection in the fifth largest hospital in Turkey for a period of 13 years and we would like to send a presubmission inquiry and we hope that our findings will be suitable for publication in *Emerging Microbes and Infections*.

Our paper describes the emergence of clonal fluconazole-resistant *Candida parapsilosis* blood isolates harboring known accountable mutations in *ERG11* from the fifth largest hospital in Turkey, Ege University, Izmir. Fluconazole resistance (FLZR) was detected in 26.4% of the whole isolates ( $n=60/227$ ) recovered from 2007-2019 and FLZR showed an increasing trend reaching the highest peak in 2018. *ERG11*, *TAC1*, *UPC2*, and *MRR1* loci implicated in azole-resistance were sequenced for 91 isolates, including all resistant ( $n=60$ ), susceptible dose-dependent ( $n=3$ ), and susceptible ( $n=28$ ) isolates. Upon emergence in 2011, FLZR isolates carrying Y132F or Y132F+K143R in Erg11p conquered many wards in our hospital. Interestingly Y132F isolates tripled in 2015-2019 when the azole use was three times more than 2007-2014, while 1.8 times increase in the number of Y132F+K143R isolates in 2007-2014 coincided with 6-fold increase in voriconazole prophylaxis. Shockingly, Y132F isolates were significantly associated with mortality compared to Y132F+K143R isolates ( $r^2=0.44$ ,  $p < 0.004$ ), showing that Y132F isolates are implicated in both FLZR and

mortality. Moreover, comparing the biofilm production revealed that Y132F isolates produced significantly less biofilm than those FLZR isolates lacking this mutation ( $r^2=0.66$ ,  $p < 0.001$ ), which may question the hypothesis that Y132F isolates have a higher propensity to stay in the hospital settings. To discover the clonality of our isolates ( $n=227$ ), they were all subjected to AFLP and microsatellite typing. AFLP indistinguishably clustered all isolates together, while the application of microsatellite typing revealed distinct clusters. Interestingly, FLZR isolates clustered in three distinct clusters containing only FLZR isolates carrying Y132F or Y132F+K143R mutations in *Erg11p* showing the clonal expansion of these isolates in our hospital. This study showed that future environmental screening studies are required to find the source of infection followed by the application of strict infection control strategies to control the clonal spread of *C. parapsilosis* in our hospital. Moreover, appropriate antifungal stewardship is necessary to reduce the burden of fatal FLZR isolates carrying mutations in *Erg11p*.

Looking forward to hearing from you.

Sincerely,

Prof Macit Ilkit

Division of Mycology, Department of Microbiology, Faculty of Medicine, Çukurova University, Adana, 01330, Turkey

---

**From:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
**Sent:** Friday, March 26, 2021 7:43 PM  
**To:** Lu, Shan  
**Cc:** M. Yu-Mei Wen (ymwen@shmu.edu.cn)  
**Subject:** RE: Presubmission inquiry

Shan,

I recommend an editorial rejection. The authors did lots of isolate analysis, and found lots of “negative” findings. I think it is too complicated to make a conclusion of “...may lie in the higher tolerance to host-related stresses” based on isolates collected in a short period of time from one single hospital.

Yi-Wei

---

**From:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Sent:** Friday, March 26, 2021 9:01 PM  
**To:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
**Cc:** M. Yu-Mei Wen (ymwen@shmu.edu.cn) <ymwen@shmu.edu.cn>  
**Subject:** FW: Presubmission inquiry

Hi, Yi-Wei,

What is your opinion about this inquiry?

Best.

Shan

---

**From:** Amir Arastehfar <[a.arastehfar.nl@gmail.com](mailto:a.arastehfar.nl@gmail.com)>  
**Sent:** Wednesday, March 24, 2021 5:09 PM  
**To:** [editorial@emi2012.org](mailto:editorial@emi2012.org); Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; [ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)  
**Subject:** Presubmission inquiry

Dear Dr. Lu and Wen,

Currently, we have finalized a study addressing a question behind the deadly outbreaks caused by fluconazole-resistant *Candida parapsilosis* carrying Y132F isolates for which we would like to send a presubmission inquiry to hear your opinion and if you find it interesting for the readership of the Emerging Microbes and Infections. Attached also, please find the draft, figures, and tables.

Although neglected, deadly infections due to outbreaks caused by fluconazole-resistant *Candida parapsilosis* (FLZR-CP) carrying Y132F in the azole drug-target are increasingly identified in South-East Asian, European,

Latin American, and African countries. Once established, eradication of such outbreaks is challenging and relapse of outbreaks persistently occurs despite applying disinfectants. Despite all these clinical significances, the reason behind such outbreaks remained enigmatic. Herein, for the first time, we used an extensive number of *C. parapsilosis* blood isolates ( $n=96$ ) collected during the outbreaks and subjected them to biofilm formation and host-related stresses. Our experiments indicated that Y132F isolates are not biofilm producers, but interestingly they are significantly more tolerant to low pH, oxidative stress, low sugar concentrations, high salt concentration, and high temperature. Moreover, Y132F isolates did not show any growth defect compared to fluconazole-susceptible isolates when grown in stress-free YPD broth. Our macrophage analysis revealed that the survival after phagocytosis is the same for all isolates tested but isolates carrying Y132F had significantly higher CFU counts in the supernatant, which could be an indication of being more immunoevasive or causing more damages to macrophages. Our epidemiological analysis exploring the burden of FLZR-CP in a center struggling with a persistent outbreak since 2012 onward further reinforced the significance of our study. Alarming, patients infected with FLZR-CP and Y132F isolates constituted 90% and 57% of the patients infected with *C. parapsilosis* during 2020-2021, respectively, and the latter was associated with a much more mortality rate, required treatment with multiple antifungal drugs and caused outbreaks in several wards. Collectively, our study revealed that tolerance to host-related stresses, but not biofilm formation, maybe the reason behind the the exponential expansion of Y132F *C. parapsilosis* isolates and that clonal outbreaks due to Y132F *C. parapsilosis* require immediate attention and warrants judicious antifungal use and strict infection control to stop the surge of this deadly bug.

Kind regards

Amir Arastehfar, Postdoc Fellow Infectious Diseases, Center for Discovery and Innovation, Nutley, New Jersey, the USA

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

---

**From:** Zheng, Zhi-Ming (Thomas) (NIH/NCI) [E] <[zhengt@exchange.nih.gov](mailto:zhengt@exchange.nih.gov)>  
**Sent:** Friday, February 14, 2020 3:58 PM  
**To:** Liu, Shan-Lu; Lu, Shan  
**Subject:** RE: Professional Liability Insurance

You may call the company for the details. We at NIH are now having this to cover us in case of something happening to us.

Zhi-Ming

---

**From:** Liu, Shan-Lu <[liu.6244@osu.edu](mailto:liu.6244@osu.edu)>  
**Sent:** Friday, February 14, 2020 3:47 PM  
**To:** Zheng, Zhi-Ming (Thomas) (NIH/NCI) [E] <[zhengt@exchange.nih.gov](mailto:zhengt@exchange.nih.gov)>; Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** Re: Professional Liability Insurance

Thanks Zhi-Ming for sharing the info. It looks like this is for federal employees only?

Shan-Lu

---

**From:** "Zheng, Zhi-Ming (Thomas) (NIH/NCI) [E]" <[zhengt@exchange.nih.gov](mailto:zhengt@exchange.nih.gov)>  
**Date:** Friday, February 14, 2020 at 12:48 PM  
**To:** Shan-Lu Liu <[liu.6244@osu.edu](mailto:liu.6244@osu.edu)>, "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** FW: Professional Liability Insurance

Hi Shan-Lu and Shan,

I would encourage you all to have this professional liability insurance to protect yourselves, at the current toxic atmosphere. Here below is the link. I have been under this insurance and NIH covers half of our payment. At the end, I paid ~\$200/year.

Best,

Zhi-Ming

---

**From:** Wray, Tripp (NIH/NCI) [E] <[tripp.wray@nih.gov](mailto:tripp.wray@nih.gov)>  
**Sent:** Monday, December 16, 2019 3:44 PM  
**Subject:** Professional Liability Insurance

Good afternoon,

In response to those of you interested in liability insurance, I thought it would be best to send the information to everyone in one email. The Starr Wright Insurance Agency is the group that I have seen other scientists use. It is \$400/year and the NIH will reimburse you 50%. The reimbursement process is annual and quite simple.

The product page for Starr Wright is [here](#) and the recommended amount is the Managers/Supervisors Career Protection plan. You would need to complete the purchase online and the plan is effective immediately upon them receiving the first payment whether you choose to pay it all or pay in installments.

After you have contacted Starr Wright and purchased your professional liability insurance, you would send the final receipt and certificate to your respective admin person to begin the reimbursement process. Let me know if you have any questions and I would be happy to answer them.

Thank you,

Tripp Wray

NCI/NIH



---

**From:** Matthew R MCKAY <m.mckay@ust.hk>  
**Sent:** Thursday, February 6, 2020 9:00 AM  
**To:** Lu, Shan  
**Cc:** ymwen@shmu.edu.cn; Ahmed Abdul QUADEER; Editorial Office  
**Subject:** Re: Publication query regarding our pre-print on potential vaccine targets for 2019-nCoV (novel coronavirus)

Dear Prof. Lu,

Thank you for the quick response.

Our predictions, while computational, are based on a large amount of experimental work for SARS, as well as sequence data for 2019-nCoV. We hope they will guide further experimental studies towards vaccine development.

We understand, however, your preference for new bench/animal studies. As such, we will explore alternative venues.

Thanks again and best regards,  
Matthew

On 6 Feb 2020, at 9:47 PM, Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> wrote:

Dear Prof. McKay,

Thank you for your interest in EMI to publish your work.

If your work is mainly based on computer modeling and prediction, EMI will prefer to see at least some real bench and/or animal (or human) data to validate your findings.

You can still submit your manuscript to EMI. Currently, EMI is experiencing a large number of submissions. A screening system is established with the participation of key editors and selected experts if needed. Only those with high priority to EMI at this point will be sent out for peer-review.

No matter what the outcome of screening may be, our decision does not in any way indicate that your study is not important.

Best.

Shan Lu, MD, PhD  
Editor-in-Chief  
Emerging Microbes and Infections (EMI)  
[www.tandfonline.com/TEMI](http://www.tandfonline.com/TEMI)  
[editorial@2012EMI.org](mailto:editorial@2012EMI.org)

---

**From:** Matthew R MCKAY <[m.mckay@ust.hk](mailto:m.mckay@ust.hk)>  
**Sent:** Thursday, February 6, 2020 8:38 AM  
**To:** [ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn); Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** Ahmed Abdul QUADEER <[aaquadeer@connect.ust.hk](mailto:aaquadeer@connect.ust.hk)>

**Subject:** Publication query regarding our pre-print on potential vaccine targets for 2019-nCoV (novel coronavirus)

Dear Prof. Wen and Prof. Lu,

We are writing to seek your feedback regarding a potential publication in *Emerging Microbes and Infection*.

Specifically, we have prepared a research article tentatively entitled:

**Preliminary identification of potential vaccine targets for 2019-nCoV based on SARS-CoV immunological studies**

and we would like to enquire about the interest from your journal as a possible publication venue.

Our work proposes a novel study that leverages known immunological information for SARS-CoV together with available sequence data for 2019-nCoV to identify potential targets for subunit vaccine design for 2019-nCoV. As a main discovery, we identify a set of screened B cell and T cell epitopes that are promising candidates for potentially inducing protective immune responses against 2019-nCoV. These are epitopes in the structural proteins (namely, the spike and nucleocapsid proteins) that have been reported to induce immune responses in SARS-CoV, and which we find to map identically to genetic regions of 2019-nCoV. Some of these epitopes have known functional importance, lying within the receptor binding motif. In the T-cell case, to help with potential immunogen design, we also use population-based MHC statistics to provide sets of epitopes that are estimated to cover a very large fraction of the global population, including that in China.

We believe these results are highly relevant and timely, and may be useful in guiding current experimental efforts towards developing a vaccine for 2019-nCoV.

We have uploaded a pre-print to the bioRxiv server (<https://www.biorxiv.org/content/10.1101/2020.02.03.933226v1>), and I have copied the abstract below. We have also prepared a slightly updated version, based on additional sequences available as of 6th Feb. (the current pre-print uses sequences available up to 29th Jan 2020).

Given the nature of this topic, it is of course important for us to consider avenues for possible rapid publication. Hence, we would appreciate your feedback about whether our work may be appealing for consideration for your journal, and if so, whether a suitably rapid review mechanism would be possible.

We would also be happy to provide any further information, as desired.

Sincerely,

Matthew McKay (corresponding author, together with Dr. Ahmed Quadeer, cc'd).

—————  
Matthew R. McKay  
Professor  
Department of Electronic and Computer Engineering  
Department of Chemical and Biological Engineering  
Hong Kong University of Science and Technology  
Clear Water Bay, Kowloon, Hong Kong  
Web: <https://www.mckayspcb.com/>

Abstract

The beginning of 2020 has seen the emergence of the 2019 novel coronavirus (2019-nCoV) outbreak. Since the first reported case in the Wuhan city of China, 2019-nCoV has spread to other cities in China as well as to multiple countries across four continents. There is an imminent need to better understand this novel virus and to develop ways to control its spread. In this study, we sought to gain insights for vaccine design against 2019-nCoV by considering the high genetic similarity between 2019-nCoV and the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), and leveraging existing immunological studies of SARS-CoV. By screening the experimentally-determined SARS-CoV-derived B cell and T cell epitopes in the immunogenic structural proteins of SARS-CoV, we identified a set of B cell and T cell epitopes derived from the spike (S) and nucleocapsid (N) proteins that map identically to 2019-nCoV proteins. As no mutation has been observed in these identified epitopes among the available 2019-nCoV sequences (as of 29 January 2020), immune targeting of these epitopes may potentially offer protection against 2019-nCoV. For the T cell epitopes, we performed a population coverage analysis of the associated MHC alleles and proposed a set of epitopes that is estimated to provide broad coverage globally, as well as in China. Our findings provide a screened set of epitopes that can help guide experimental efforts towards the development of vaccines against 2019-nCoV.

---

**From:** Yaqoub Ashhab <yashhab@ppu.edu>  
**Sent:** Thursday, February 18, 2021 6:25 AM  
**To:** ymw@shmu.edu.cn  
**Cc:** Lu, Shan; YiWei Tang  
**Subject:** Re: Publishing in Emerging Microbes & Infections

Dear Prof. Yumei Wen,

Thank you so much for your email. I very much appreciate your kind and supportive reply. I respect and will certainly accept the decision of your screening. As I mentioned earlier, my request to have a full waiver is valid -if and only if- the work passes your very professional and strict evaluation processes (both editorial and reviewing phases).

I will send the work through the electronic system in the coming few days.

Thank you for your consideration.

Sincerely yours,

Yaqoub Ashhab

On Wed, Feb 17, 2021 at 3:40 PM wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)> wrote:

Thank you for your mail. If the article is worthwhile for publishing in EMI, the editorial office will find ways to solve the problem. However, the screening for whether the paper can be under review is very strict, and if you still decide to submit the paper, please submit through our website. Regards, YM Wen

-----原始邮件-----

发件人:"Yaqoub Ashhab" <[yashhab@ppu.edu](mailto:yashhab@ppu.edu)>

发送时间:2021-02-17 19:49:39 (星期三)

收件人: [ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)

抄送:

主题: Publishing in Emerging Microbes & Infections

Dear Prof. Yumei Wen,

I hope this email finds you well and safe.

As a result of 6 years work in studying reemergence of brucellosis infectious disease in Palestine, we have a ready to submit manuscript and we believe that your journal "Emerging Microbes & Infections" is the most appropriate journal for submitting our work for consideration. Unfortunately, we could not receive any funding for this project and all the work cost was paid from the pocket money of the research team (PI and students).

As the journal states in the authors guidelines, they kindly offer 50% discount of APC for authors from countries with low-middle income, which include Palestine (West-Bank and Gaza strip). I am writing this email before submitting our manuscript to explore the possibility of having a full waiver for the APC (in case the work is accepted).

Thank you for your consideration. We appreciate your time and look forward to your response.

Sincerely yours,

Yaqoub Ashhab

Corresponding author and PI: Yaqoub Ashhab, PhD.  
Palestine Polytechnic University,  
PO-Box: 198 Hebron, Palestine  
Tel: +972-599438883  
Fax: +972-2-2236244

---

**From:** Yaqoub Ashhab <yashhab@ppu.edu>  
**Sent:** Tuesday, February 23, 2021 8:10 AM  
**To:** Lu, Shan  
**Cc:** ymwen@shmu.edu.cn; YiWei Tang; min.yang@emi2012.org  
**Subject:** Re: Publishing in Emerging Microbes & Infections

Dear Prof. Shan Lu,

Thank you for your email. I have just submitted the manuscript through your electronic system. I appreciate your strict selection criteria and I will fully respect your final decision.

Kindest regards

Yaqoub

On Thu, Feb 18, 2021 at 7:43 PM Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> wrote:

Dear Dr. Yaqoub Ashhab

From this point on, I will take over on the review and other issues related to your submission.

All new submissions will be subject to an editorial review and only about 20% of them will pass this review and sent for external peer-review. This stage of review is very fast, usually within one week after we receive your submission when it passes the QC check by T&F staff which we have no control. If you submit today, I would anticipate QC check be done by early next week.

Please feel free to let me know if you have any questions.

Best.

Shan

\*\*\*\*\*

Shan Lu, MD, PhD

Editor-in-Chief

Emerging Microbes and Infections (EMI)

[www.tandfonline.com/TEMI](http://www.tandfonline.com/TEMI)

[editorial@2012EMI.org](mailto:editorial@2012EMI.org)

---

**From:** Yaqoub Ashhab <[yashhab@ppu.edu](mailto:yashhab@ppu.edu)>

**Sent:** Thursday, February 18, 2021 6:25 AM

**To:** [ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)

**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; YiWei Tang <[yiweitangmd@gmail.com](mailto:yiweitangmd@gmail.com)>

**Subject:** Re: Publishing in Emerging Microbes & Infections

Dear Prof. Yumei Wen,

Thank you so much for your email. I very much appreciate your kind and supportive reply. I respect and will certainly accept the decision of your screening. As I mentioned earlier, my request to have a full waiver is valid – if and only if– the work passes your very professional and strict evaluation processes (both editorial and reviewing phases).

I will send the work through the electronic system in the coming few days.

Thank you for your consideration.

Sincerely yours,

Yaqoub Ashhab

On Wed, Feb 17, 2021 at 3:40 PM wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)> wrote:

Thank you for your mail. If the article is worthwhile for publishing in EMI, the editorial office will find ways to solve the

problem. However, the screening for whether the paper can be under review is very strict,

and if you still decide to submit the paper, please submit through our website. Regards,  
YM Wen

-----原始邮件-----

发件人: "Yaqoub Ashhab" <[yashhab@ppu.edu](mailto:yashhab@ppu.edu)>

发送时间: 2021-02-17 19:49:39 (星期三)

收件人: [ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)

抄送:

主题: Publishing in Emerging Microbes & Infections

Dear Prof. Yumei Wen,

I hope this email finds you well and safe.

As a result of 6 years work in studying reemergence of brucellosis infectious disease in Palestine, we have a ready to submit manuscript and we believe that your journal "Emerging Microbes & Infections" is the most appropriate journal for submitting our work for consideration. Unfortunately, we could not receive any funding for this project and all the work cost was paid from the pocket money of the research team (PI and students).

As the journal states in the authors guidelines, they kindly offer 50% discount of APC for authors from countries with low-middle income, which include Palestine (West-Bank and Gaza strip). I am writing this email before submitting our manuscript to explore the possibility of having a full waiver for the APC (in case the work is accepted).

Thank you for your consideration. We appreciate your time and look forward to your response.

Sincerely yours,

Yaqoub Ashhab

Corresponding author and PI: Yaqoub Ashhab, PhD.  
Palestine Polytechnic University,

PO-Box: 198 Hebron, Palestine

Tel: +972-599438883

Fax: +972-2-2236244



---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Wednesday, February 17, 2021 8:40 AM  
**To:** Yaqoub Ashhab  
**Cc:** Lu, Shan; YiWei Tang  
**Subject:** Re: Publishing in Emerging Microbes & Infections

Thank you for your mail. If the article is worthwhile for publishing in EMI, the editorial office will find ways to solve the problem. However, the screening for whether the paper can be under review is very strict, and if you still decide to submit the paper, please submit through our website. Regards, YM Wen

-----原始邮件-----

发件人: "Yaqoub Ashhab" <yashhab@ppu.edu>  
发送时间: 2021-02-17 19:49:39 (星期三)  
收件人: ymwen@shmu.edu.cn  
抄送:  
主题: Publishing in Emerging Microbes & Infections

Dear Prof. Yumei Wen,

I hope this email finds you well and safe.

As a result of 6 years work in studying reemergence of brucellosis infectious disease in Palestine, we have a ready to submit manuscript and we believe that your journal "Emerging Microbes & Infections" is the most appropriate journal for submitting our work for consideration. Unfortunately, we could not receive any funding for this project and all the work cost was paid from the pocket money of the research team (PI and students).

As the journal states in the authors guidelines, they kindly offer 50% discount of APC for authors from countries with low-middle income, which include Palestine (West-Bank and Gaza strip). I am writing this email before submitting our manuscript to explore the possibility of having a full waiver for the APC (in case the work is accepted).

Thank you for your consideration. We appreciate your time and look forward to your response.

Sincerely yours,

Yaqoub Ashhab

Corresponding author and PI: Yaqoub Ashhab, PhD.  
Palestine Polytechnic University,  
PO-Box: 198 Hebron, Palestine  
Tel: +972-599438883  
Fax: +972-2-2236244

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Friday, August 30, 2019 12:00 AM  
**To:** Lu, Shan  
**Subject:** Re: RE: ...EMI update - Aug 29, 2019...

Please send me the advertisement, I will contact danyiWen, and Mingwei Wang

-----原始邮件-----

发件人:"Lu, Shan" <Shan.Lu@umassmed.edu>  
发送时间:2019-08-30 11:00:06 (星期五)  
收件人: "Zhi-Ming Zheng" <zhengzhiming4@gmail.com>  
抄送: "tangy@mskcc.org" <tangy@mskcc.org>, "wen yumei" <ymwen@shmu.edu.cn>  
主题: RE: ...EMI update - Aug 29, 2019...

As soon as possible. But we may not find the right person easily so feel free to check with us even later.

**From:** Zhi-Ming Zheng [mailto:zhengzhiming4@gmail.com]  
**Sent:** Thursday, August 29, 2019 10:44 PM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Cc:** tangy@mskcc.org; wen yumei <ymwen@shmu.edu.cn>  
**Subject:** Re: ...EMI update - Aug 29, 2019...

Thanks for the notice. I immediately went to EMI and found it is much easier to see the newest publication right away!

Regarding your recruitment for your editorial assistant. I will keep in mind that we may have some NIH postdoctoral fellow who may want to try this opportunity when he/she want to go back to China. How soon do you need to fill the position?

Best.

Zhi-Ming

On Thu, Aug 29, 2019 at 10:15 PM Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> wrote:

Dear Zhi-Ming

Based on your suggestion, EMI has reversed the order of new papers published in 2019 at our website: the newest on top as you suggested.

As result, your paper on blood transmission of HPV is now among the top ones and early for people to find. It has attracted 274 reads in just one month.

Dear Yi-Wei,

Your paper co-authored with Hongzhou on HIV diagnosis is now published online. It attracted 324 reads in 3 days!

Thank you both for sending good papers to EMI.

Shan

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Sunday, November 15, 2020 7:58 PM  
**To:** Lu, Shan  
**Subject:** Re: RE: ...screening done for this week...

I appreciate you work as a superman. However, please take care not to overload yourself. I feel guilty not to share your responsibility. Wen

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:** 2020-11-16 02:57:57 (Monday)  
**To:** "Tang, Yi-Wei" <yi-wei.tang@cepheid.com>  
**Cc:**  
**Subject:** RE: ...screening done for this week...

Hi, Yi-Wei,

To save you some time, I have just gone through the remaining new papers and made decisions on many of them. There are only 8 papers which I would leave to you to take a look as they may be more worthy than the others.

If you can not get time to do it, let me know so I can finish them in the next day or so.

I have to force myself to stick with the timeline as I have one NIH grant review due tomorrow, two online talks in the coming week, one paper deadline and one patent final version among other things in the next few days.

Thanks.

Shan

---

**From:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
**Sent:** Saturday, November 14, 2020 5:29 PM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Subject:** RE: ...screening done for this week...

Ok! I have just done some of them following this. I will have rests done later today or tomorrow.

Thank you, Yi-Wei

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Sunday, May 10, 2020 8:37 PM  
**To:** Tang, Yi-Wei  
**Cc:** Lu, Shan; Yuan Zhenghong 袁正宏; zhangwenhong; Martin martin  
**Subject:** Re: RE: a new idea: EMI Virtual Journal Club

I agree with this idea of virtual journal club.YMWen

-----Original Messages-----

**From:** "Tang, Yi-Wei" <yi-wei.tang@cepheid.com>  
**Sent Time:** 2020-05-10 11:51:37 (Sunday)  
**To:** "Lu, Shan" <Shan.Lu@umassmed.edu>, "wen yumei" <ymwen@shmu.edu.cn>, "Yuan Zhenghong 袁正宏" <zhyuan@shmu.edu.cn>, zhangwenhong <zhangwenhong@fudan.edu.cn>  
**Cc:** "Martin martin" <winter999@hotmail.com>  
**Subject:** RE: a new idea: EMI Virtual Journal Club

Thank you, Shan. I fully support this action . .

Yi-Wei

---

**From:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Sent:** Saturday, May 9, 2020 11:06 AM  
**To:** wen yumei <ymwen@shmu.edu.cn>; Tang, Yi-Wei <yi-wei.tang@cepheid.com>; Yuan Zhenghong 袁正宏 <zhyuan@shmu.edu.cn>; zhangwenhong <zhangwenhong@fudan.edu.cn>  
**Cc:** Martin martin <winter999@hotmail.com>  
**Subject:** a new idea: EMI Virtual Journal Club

Dear Prof Wen and other EMI leaders,

Recently I developed an idea to develop a Virtual Journal Club to introduce key EMI papers to the global scientific community.

Journal Club is a very common format of academic study. The new development of online meeting and training provides a unique opportunity to develop an online journal club.

Please see attached ppt for the entire plan.

I have discussed this with Xiaodong who has a lot of experience in running online meetings. He likes this idea very much.

I have had some technical discussion with EMI editorial staff and Xiaodong's staff. Technically it is feasible.

Please let me know your feedback. We can try an online meeting among use first to discuss this.

Best.

Shan

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

---

**From:** ZhangWenhong <zhangwenhong@fudan.edu.cn>  
**Sent:** Monday, May 11, 2020 2:09 PM  
**To:** Lu, Shan  
**Cc:** Tang, Yi-Wei; wen yumei; Yuan Zhenghong 袁正宏; Martin martin  
**Subject:** Re: RE: a new idea: EMI Virtual Journal Club

Dear Shan, That's great. Wenhong

-----原始邮件-----

发件人:"Lu, Shan" <Shan.Lu@umassmed.edu>

发送时间:2020-05-11 07:25:14 (星期一)

收件人: "Tang, Yi-Wei" <yi-wei.tang@cepheid.com>, "wen yumei" <ymwen@shmu.edu.cn>, "Yuan Zhenghong 袁正宏" <zhyuan@shmu.edu.cn>, zhangwenhong <zhangwenhong@fudan.edu.cn>

抄送: "Martin martin" <winter999@hotmail.com>

主题: RE: a new idea: EMI Virtual Journal Club

Thanks, Yi-Wei.

I am starting with Xiaodong and try a few to test how we can run this new idea.

Shan

---

**From:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
**Sent:** Saturday, May 9, 2020 11:52 PM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>; wen yumei <ymwen@shmu.edu.cn>; Yuan Zhenghong 袁正宏 <zhyuan@shmu.edu.cn>; zhangwenhong <zhangwenhong@fudan.edu.cn>  
**Cc:** Martin martin <winter999@hotmail.com>  
**Subject:** RE: a new idea: EMI Virtual Journal Club

Thank you, Shan. I fully support this action • .

Yi-Wei



---

**From:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Sent:** Saturday, May 9, 2020 11:06 AM

**To:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>; Tang, Yi-Wei <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>; Yuan Zhenghong 袁正宏 <[zh yuan@shmu.edu.cn](mailto:zh yuan@shmu.edu.cn)>; zhangwenhong <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>

**Cc:** Martin martin <[winter999@hotmail.com](mailto:winter999@hotmail.com)>

**Subject:** a new idea: EMI Virtual Journal Club

Dear Prof Wen and other EMI leaders,

Recently I developed an idea to develop a Virtual Journal Club to introduce key EMI papers to the global scientific community.

Journal Club is a very common format of academic study. The new development of online meeting and training provides a unique opportunity to develop an online journal club.

Please see attached ppt for the entire plan.

I have discussed this with Xiaodong who has a lot of experience in running online meetings. He likes this idea very much.

I have had some technical discussion with EMI editorial staff and Xiaodong's staff. Technically it is feasible.

Please let me know your feedback. We can try an online meeting among use first to discuss this.

Best.

Shan

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

--

张文宏 Wenhong Zhang, M.D. & Ph.D. Professor of Medicine Director, Division of Infectious Diseases Huashan Hospital, Fudan University PI, Institute of Biomedical Science, Fudan University 12 M. Wulumuqi Road Shanghai 200040, China  
Phone: (8621)52888123 Fax: (8621)52888714 Email: zhangwenhong@fudan.edu.cn

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Sunday, June 7, 2020 4:54 AM  
**To:** Lu, Shan  
**Cc:** zhangwenhong; 袁正宏; YiWei Tang  
**Subject:** Re: RE: A thought about EMI

Facing this uncertain circumstances, we need to plan beforehand.

Please send me the current review editors, and responsibility, we may expand the list in the future

Hope the IF of EMI will not drop markedly. However, IF is not the only criteria for a journal. Wen

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:** 2020-06-07 11:17:32 (Sunday)  
**To:** "wen yumei" <ymwen@shmu.edu.cn>, "Tang, Yi-Wei" <yi-wei.tang@cepheid.com>  
**Cc:** zhangwenhong <zhangwenhong@fudan.edu.cn>, "袁正宏" <Zhyuan@shmu.edu.cn>, Winter999 <Winter999@hotmail.com>  
**Subject:** RE: A thought about EMI

Hi, Yi-Wei and Prof Wen,

Yes, I agree that we are seeing less COVID-19 papers, from about 60-70 per week to around 40 per week. This is natural and expected, because

1. We rejected a lot of them so people realized what is the standard for EMI and those with low quality will not submit to EMI which is a good thing.
2. Also COVID-19 will be over at some point, so it is hard to have so many papers. Actually, there are already too many papers including EMI papers on COVID-19 which was never seen with any one viral outbreak, even considering the scope of global pandemic. Many are "inflated" papers as the global scientific community starts to criticize the over production of papers but limited impact to real control of pandemic.

Looking back at EMI, we have published large numbers of COVID-19 papers already, but very selective actively from the correct authors. I was just about to send a note to Review Editors to further increase the standard of such papers so we can publish less papers in the rest of 2020.

One reason is the impact of total numbers of papers (see table below). In the first three months, EMI published a total 84 papers while we only published 50 papers, about 68% increase. (Date for the 2<sup>nd</sup> Quarter will be ready soon). If we follow this, the total papers in 2020 will be at least ~336 while we only published close to 200 in 2019. While we had many high quality COVID-19 papers, this big increase in denominator (分母) will generate significant negative impact to EMI's IF next year.

| 2019-2020 EMI Q1 Publications |         |        |        |            |       |
|-------------------------------|---------|--------|--------|------------|-------|
| Year                          | Article | Review | Letter | Commentary | Total |
| 2019                          | 44      | 0      | 5      | 1          | 50    |
| 2020                          | 54      | 9      | 15     | 6          | 84    |

We need to tighten further the standard of acceptance. We should only accept those extremely good COVID-19 papers. At the same time, we need to continue our good work in other emerging infectious diseases which are key to support our long term growth, once COVID-19 wave is over.

Even for the IF number we will learn soon learn within the next 1-2 weeks, I am worried that it may drop because we had a lot of more papers published last year.

I would agree with Ye-Wei's idea to solicitate reviews and metanalysis, but be very selective.

Prof Wen, I have been discussing with Xiaodong and hope to organize several events: 1) founders' meeting, 2) invited EB members/authors conference (once in end of June), and 3) virtual Journal Club, starting in early July. It took us some time to finally decide using Microsoft Teams as it is not so easy to have a good quality software which can work for both US and China. 1) and 2) can be run close to each other.

I will get back with details and dates soon.

Shan

**From:** wen yumei <ymwen@shmu.edu.cn>

**Sent:** Saturday, June 6, 2020 10:54 PM

**To:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>

**Cc:** Lu, Shan <Shan.Lu@umassmed.edu>; zhangwenhong <zhangwenhong@fudan.edu.cn>; 袁正宏 <Zhyuan@shmu.edu.cn>; Winter999 <Winter999@hotmail.com>

**Subject:** Re: A thought about EMI

I agree to start to organize and please give us the detailed plan, so all founders will know and follow the outcome.

Attached is a revised paper on antibodies Huang JH submitted to JAMA, which is expected to be accepted .

Another paper on Nature collaborated by Fudan and Ruijin , the modified experimental virological diagnostic technology was developed by Yi ZG from our lab, and I have asked him to write an article on this technology .Hope Yiwei will comment.

As we have not been able to meet and discuss important issues on EMI for quite sometime, I suggest that we hold a tele-meeting with all founders in June. Hope all will discuss on the future of EMI, at this unstable situation. If agreed, please give me the time and dates when you will be available. YM Wen

-----Original Messages-----

**From:** "Tang, Yi-Wei" <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>

**Sent Time:** 2020-06-07 10:14:30 (Sunday)

**To:** "[shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu)" <[shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu)>, "Yumei Wen ([ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn))" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>

**Cc:**

**Subject:** A thought about COVID-19 manuscripts

Teacher Wen, Shan,

By screening EMI papers, I noticed that less and less new manuscripts on COVID-19 have been submitted to EMI recently. I wonder if we can solicit a series of metanalysis and literature review articles from authoritative groups. As you know, I have been involved as a curator in ASM's COVID-19 Registry curating lots of good resources and papers: <https://asm.org/COVID/COVID-19-Research-Registry/Home>. Quickly going through the curator list, Zhengli Shi, Susan Weiss, and Linda Saif are on it. With your permission, I think I could start soliciting for (maybe participating in) a metanalysis on serology. The review paper Michael Loeffelholz and I contributed for EMI has reached over 50,000 hits and 100 citations in Google Scholar. Hopefully these authoritative metanalysis papers will reach similar influences.

Yi-Wei

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

-----

**From:** Shibo Jiang <shibojiang@fudan.edu.cn>  
**Sent:** Monday, February 22, 2021 12:49 AM  
**To:** Lu, Shan  
**Cc:** Wen Yumei  
**Subject:** Re: RE: Application for APC waiver or discount

Dear Prof. Lu,

I am very sorry for misunderstanding the T&F's policy that APC waiver is mainly designed for people from poor developing countries. Since several high-profile journals actively waived my publication fee when publishing my Commentaries, Correspondences and Letter to Editor recently, I mistakenly thought that T&F may have similar policy.

Thanking for your praise, I am not "the most successful business person academically and commercially" or "among the top funded scientists in the entire China", rather than one of the poorest PIs in our school. I have tried very hard to get funds to support my studies on the development of pan-CoV fusion inhibitors and pan- $\beta$ -CoV-B vaccines, but have failed so far. Because of the age restriction policy in China, I, as a researcher at 67-year-old, was not allowed to be a PI to apply for grants from the National Health Commission or Ministry of Science and Technology of China, but only allowed to apply for no more than two grants from NSFC.

Currently, I have only one NSFC grant (¥ 2.75 millions for 3 years), which is far not enough to support my 12 Ph.D. students. That is why I have no funds to hire a postdoc. Previously, I could reimburse some of my publication fee from my 横向经费 (the funds from companies) or my colleague's accounts, but this is not allowed after the announcement of new financial policy (all the funds must be 专款专用). I did invite some of my colleagues to join me in writing manuscripts, but most of my invitations were declined if the targeted journal's IF is <10 and if they are not corresponding authors. Due to the "破四唯" policy, publication of too many papers by a researcher will destroy his/her reputation because only 5 representative papers are allowed in an application for promotion or grant.

I have never said that I want to quit EMI responsibility. I only consulted with you last year whether you could ask a non-Chinese EMI editor to replace me for handling the manuscripts for the special issue for coronaviruses. I have still done my best to do the work that you have assigned to me. Indeed, it is me to propose early of last year the special issue for coronaviruses and suggest you to assign Prof. KY Yuen as the "guest editor" to handle the manuscript for this special issue. You agreed with my proposal for the special issue, but asked me, not KY, as the editor responsible for the special issue. Soon after the announcement, I received many calls from the researchers in China, asking me whether I could handle their manuscripts for this special issue through the fast-track review system. I told them that, different from the

"guest editors" to handle the manuscripts for the special issues of other journals, I, as an editorial board member of EMI, have no authority to make decision on the manuscripts submitted to EMI for the special issue. Most of them became very angry with me, thinking that I just used it as an excuse to reject their papers. That is why I consulted with you whether you could assign a non-Chinese EMI editor to replace me for handling the manuscripts for this special issue, since it is not easy for the Chinese researchers to call a non-Chinese EMI editor in a foreign country.

I have not gotten more reward with funding after I published more than 40 papers in high-profile journals last year. I did receive an award of ~¥ 15,000 recently from our school for these publications last year, but I gave all the award to the junior staff in my group.

I will still do my best to make contribution to our lovely journal, EMI.

Best wishes,

1

---

## Page 2

Shibo

> -----Original Mail-----

> 发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>

> Sending time: 2021-02-22 06:42:46 (Monday)

> To: "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>

> CC:

> 主题: RE: Application for APC waiver or discount

>

> Hi, Shibo,

>

> Are you kidding me? I was treating your short commentary as a special case due to your past involvement with EMI. Even KY's excellent review will take longer process. I did not expect you will treat us like this.

>

> T&F APC waiver is mainly designed for people from poor developing countries so your application will not be approved. You are very famous for being the most successful business person academically and commercially. You and your co-authors are among the top funded scientists in the entire China and yet you can not afford to pay \$900? EMI will have big trouble if an APC waiver is granted to you and your co-author as it will be hard for us to face other authors from much difficult condition than you guys.

>

> I thought you told me that you have to quit EMI responsibility because you were quite sick so I am surprised to know you have published too many research articles in the last year. Usually with so many papers, the authors should have more reward with fame and funding.

>

> Since the founding of EMI, several of us as the founders have to contribute not only time but also all kinds of resources while we have not personally being paid a single penny for our service. EMI has done multiple special favors to you and your group (such as the urgent publication which led your Gates funding) because you are part of the Fudan group. We

would look forward to seeing at least some basic support if not more contribution.

> Maybe we should consult Prof Wen to see if she thinks you are poor as she may know your situation better than anyone else.

>

> Best.

>

> Shan

>

> -----Original Message-----

> From: Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>

> Sent: Sunday, February 21, 2021 7:22 AM

> To: editorial@emi2012.org; Lu, Shan <Shan.Lu@umassmed.edu>

> Cc: Yang Min 杨敏 <minyang0216@163.com>

> Subject: Application for APC waiver or discount

>

> Dear Prof. Lu,

>

> Because of publishing too many research articles in this budget year, I do not have enough budget left to pay for the APC for publication of our Commentary (ID TEMI-2021-0175) in EMI. Here I am applying for an APC waiver or discount. I would appreciate it very much if you could approve my application and provide me an APC waiver or discount code before submission of our revised manuscript online.

>

2

### Page 3

> Thank you very much for your consideration,

>

> Shibo

> \*\*\*\*\*

> Shibo Jiang, MD

> Professor and Director, Institute of Medical Microbiology Key

> Laboratory of Medical Molecular Virology (MOE/NHC/CAMS) School of

> Basic Medical Sciences, Fudan University

> 131 Dong An Road, Fuxing Building, 4th Fl, Rm 413 Xuhui District,

> Shanghai 200032, China

> Phone: +86-21-54237673

> E-mail: shibojiang@fudan.edu.cn

> Website:

> <https://nam10.safelinks.protection.outlook.com/?url=http%3A%2F%2Fmedic>

> [ine.fudan.edu.cn%2Fen%2Fshow.aspx%3Finfo\\_lb%3D27%26flag%3D3%26info\\_id%3D124&data=04%7C01%7Cshan.lu%40umassmed.edu%7C93501d3cd5004814770d08d8d6f591c0%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637495697503053933%7CUnknown%7CTWFPbGZsb3d8eyJWljojMC4wLjAwMDAiLCJQIjojV2luMzIiLCJBTiIl6lk1haWwiLCJXVCi6Mn0%3D%7C1000&sdata=77z3O24udfncRCCedeHDvMT%2B9rZG2T5aBu1XwUOwxAU%3D&reserved=0](https://ine.fudan.edu.cn%2Fen%2Fshow.aspx%3Finfo_lb%3D27%26flag%3D3%26info_id%3D124&data=04%7C01%7Cshan.lu%40umassmed.edu%7C93501d3cd5004814770d08d8d6f591c0%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637495697503053933%7CUnknown%7CTWFPbGZsb3d8eyJWljojMC4wLjAwMDAiLCJQIjojV2luMzIiLCJBTiIl6lk1haWwiLCJXVCi6Mn0%3D%7C1000&sdata=77z3O24udfncRCCedeHDvMT%2B9rZG2T5aBu1XwUOwxAU%3D&reserved=0)

> 3D124&data=04%7C01%7Cshan.lu%40umassmed.edu%7C93501d3cd5004814770d

> 08d8d6f591c0%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637495697503

> 053933%7CUnknown%7CTWFPbGZsb3d8eyJWljojMC4wLjAwMDAiLCJQIjojV2luMzIiLCJ

> BTiIl6lk1haWwiLCJXVCi6Mn0%3D%7C1000&sdata=77z3O24udfncRCCedeHDvMT%2

> B9rZG2T5aBu1XwUOwxAU%3D&reserved=0



> Publications:  
 > https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fpubm  
 > ed.ncbi.nlm.nih.gov%2F%3Fterm%3Dshibo%2Bjiang%26sort%3Ddate%26size%3D2  
 > 00&amp;data=04%7C01%7Cshan.lu%40umassmed.edu%7C93501d3cd5004814770d08d  
 > 8d6f591c0%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637495697503063  
 > 886%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzliLCJBTi  
 > I6Ik1haWwILCJXVCi6Mn0%3D%7C1000&amp;sdata=Cf5hVuwdAaBjU4onnALxTAERzs9H  
 > SyjcSQh7jf6snFs%3D&amp;reserved=0  
 >  
 >  
 >

>> -----Original Mail-----

>> 发件人: "Emerging Microbes and Infections"

>> <onbehalf@manuscriptcentral.com>

>> Sending time: 2021-02-19 23:02:23 (Friday)

>> Recipient: 14111010010@fudan.edu.cn, yshao@bjmu.edu.cn,

>> shibojiang@fudan.edu.cn

>> CC:

>> 主题: Emerging Microbes & Infections - Decision on Manuscript ID

>> TEMI-2021-0175

>>

>> 19-Feb-2021

>>

>> Dear Professor Jiang:

>>

>> Your manuscript entitled "Human challenge trials to assess the efficacy of currently approved COVID-19 vaccines against SARS-CoV-2 variants", which you submitted to Emerging Microbes & Infections, has been reviewed. The reviewer comments are included at the bottom of this letter.

>>

>> The reviews are in general favourable and suggest that, subject to minor revisions, your paper could be suitable for publication. Please consider these suggestions, and I look forward to receiving your revision.

3

## Page 4

>>

>> When you revise your manuscript please highlight the changes you make in the manuscript by using the track changes mode in MS Word or by using bold or coloured text.

>>

>> In addition, please submit a clean, editable version of your revised paper. These files should be in either Word (.doc) or LaTeX format. Any figures should be saved as either .ps, .eps, .tif or .jpeg file types.

>>

>> To start the revision, please click on the link below:

>>

>> \*\*\* PLEASE NOTE: This is a two-step process. After clicking on the

>> link, you will be directed to a webpage to confirm. \*\*\*

>> <https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fmc>

>> .m

>> [anuscriptcentral.com%2Ftemi%3FURL\\_MASK%3De6fbe9bcea3944fca4baf20ae84](https://anuscriptcentral.com%2Ftemi%3FURL_MASK%3De6fbe9bcea3944fca4baf20ae84)

>> 87

>> [3c7&data=04%7C01%7Cshan.lu%40umassmed.edu%7C7ebf278d564248ec09e6](https://3c7&data=04%7C01%7Cshan.lu%40umassmed.edu%7C7ebf278d564248ec09e6)

>> 08

>> [d8d663588e%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637495069491](https://d8d663588e%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637495069491)

>> 30

>> [8875%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJ](https://8875%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJ)

>> BT

>> [il6lk1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=LcqHwhK1nn%2BeLy3o4dokQ2p](https://il6lk1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=LcqHwhK1nn%2BeLy3o4dokQ2p)

>> qk

>> [2QHbNppscwmcigzfew%3D&reserved=0](https://2QHbNppscwmcigzfew%3D&reserved=0)

>>

>> This will direct you to the first page of your revised manuscript. Please enter your responses to the comments made by the reviewer(s) in the space provided. You can use this space to document any changes you made to the original manuscript. Please be as specific as possible in your response to the reviewer(s).

>>

>> This link will remain active until you have submitted your revised manuscript. If you begin a revision and intend to finish it at a later time, please note that your draft will appear in the "Revised Manuscripts in Draft" queue in your Author Center.

>>

>> IMPORTANT: Your original files are available to you when you upload your revised manuscript. Please delete any redundant files before completing the submission.

>>

>> Because we are trying to facilitate timely publication of manuscripts submitted to Emerging Microbes & Infections, your revised manuscript should be uploaded by 21-Mar-2021. If it is not possible for you to submit your revision by this date, we may have to consider your paper as a new submission.

>>

>> Once again, thank you for submitting your manuscript to Emerging Microbes & Infections and I look forward to receiving your revision.

>>

>> Sincerely,

>>

>> Shan Lu

>> Editor-in-Chief

>> Emerging Microbes & Infections

>>

>>

>> Review Editor Comments to the Author:

>>

>> This is an important topic and we did a fast review with input from some of the leading authorities in this area. Here

is the key summary:

> > 1. Reviewers in general agree with the authors about the need for human challenges to determine what protection is offered by current vaccines against the new strains.

> > 2. However, the reviewers felt that the paper needs more discussion about how to do those studies. This paper is more like a public decision debate but not enough scientific and technical details to accomplish such challenge studies.

> > 3. For example, can you extrapolate from monkey challenges to humans, as the authors suggest?

> > 4. Does one need to challenge unvaccinated subjects to show infectivity? Do you then challenge current vaccinees with the same dose?

> > 5. If they are resistant to the dose infectious for seronegatives, do you increase the challenge dose to determine how much current virus they can resist vs. mutant virus?

> > 6. Is it necessary that the challenges be compared in people with the same titers, or can people with different titers be challenged?

> > 7. Do we need to measure both IgA and IgG antibodies?

> >

> > The point here is that challenge studies must be done with a lot of insight so that the answers obtained are valid. By the way, people with high immunity will resist challenge with the mutants, but people with lower titers will not. So the protection is not a black and white with variants. Rather there is a quantitative range and different variants may be different, and may also depending on the individual vaccines. Therefore a small group of challenge studies may not truly reflect the population protection efficacy of a vaccine. It is the same idea that a lab based neutralizing assay can not predict the field vaccine protection. The authors need to be very careful not turning the small group challenge study into something like a lab based neutralizing assay.

>

>

>

>

>



---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Tuesday, August 20, 2019 3:28 AM  
**To:** Lu, Shan  
**Subject:** Re: RE: Application for the Senior Editor Position of EMI

OK.I agree. However, can we first give the person 3 months for trial? Wen

-----原始邮件-----

发件人:"Lu, Shan" <Shan.Lu@umassmed.edu>

发送时间:2019-08-20 12:32:44 (星期二)

收件人: "'Martin martin'" <winter999@hotmail.com>, "wen yumei" <ymwen@shmu.edu.cn>

抄送:

主题: RE: Application for the Senior Editor Position of EMI

Ok.

At the same time, the candidate seems anxious and would like to start soon if we want to offer her EMI position as otherwise she would need to apply for other positions. So I will wait for Prof Wen's feedback.

At the same time, I may engage the candidate with more specifics such as her expected salary etc.

Best.

Shan

---

**From:** Martin martin <winter999@hotmail.com>  
**Sent:** Monday, August 19, 2019 10:28 PM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>; wen yumei <ymwen@shmu.edu.cn>  
**Subject:** Re: Application for the Senior Editor Position of EMI

Hi, Shan,

I am Ok with this candidate, I can join the interview when you be in Shanghai.

xiaodong

---

**From:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Sent:** Sunday, August 18, 2019 12:20 PM

**To:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>; Martin martin <[winter999@hotmail.com](mailto:winter999@hotmail.com)>

**Subject:** FW: Application for the Senior Editor Position of EMI

Dear Prof Wen and Xiaodong,

Here is another applicant. I have talked to her after receiving her email and resume. She seems to be a good candidate for us. Please take a look.

One issue is that she lives in Beijing and she does not plan to move at this point. Given the open access journal, I am fine with a person working from other city. We can organize some regular in person meetings in Shanghai, such as a quarterly meeting to go over things, especially when I am back.

At this stage, the key to see if you feel that she is acceptable to EMI. So far we have not had much responses beside her and the other person working with Bio-Rad whom I talked to and she does not want to apply the job after my discussion with her by phone. So this new applicant is the only candidate at this point.

I can arrange her to talk to you by phone if you like. We can also have an in-person interview when I am back in late Sept to Shanghai.

Best.

Shan

**From:** muqimeng [<mailto:muqimeng@126.com>]

**Sent:** Wednesday, August 14, 2019 9:42 AM

**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; [min.yang@emi2012.org](mailto:min.yang@emi2012.org)

**Subject:** Application for the Senior Editor Position of EMI

Dear Professor,

I would like to apply the Senior Editor Position of EMI. The position is attractive for me, and I think I am competent for it. I have more than two years' editorial experience in peer review journal publishing and nearly three years' academic research experience.

I have attached my resume both in English and Chinese.

Looking forward to your reply and thanks for your consideration.

Best regards

Mu Qimeng

---

**From:** Wang, Hua <wang.707@osu.edu>  
**Sent:** Thursday, August 29, 2019 8:48 AM  
**To:** tangy@mskcc.org; zhengt@exchange.nih.gov; paul06liu@yahoo.com; Lu, Shan  
**Cc:** huiz@bcm.edu; Liu, Shan-Lu  
**Subject:** RE: Re: C100 Co-Sponsor Confirmation & Registration Instructions for Sino-Micro

Thanks Yiwei for connecting all. Yes voices need to be heard for science and the society. -Hua

---

**From:** tangy@mskcc.org [mailto:tangy@mskcc.org]  
**Sent:** Thursday, August 29, 2019 8:13 AM  
**To:** zhengt@exchange.nih.gov; paul06liu@yahoo.com; Shan.Lu@umassmed.edu  
**Cc:** huiz@bcm.edu; Liu, Shan-Lu <liu.6244@osu.edu>; Wang, Hua <wang.707@osu.edu>  
**Subject:** RE: Re: C100 Co-Sponsor Confirmation & Registration Instructions for Sino-Micro

Thank you, everyone.

I am copying Hua Wang, Sino-Micro current President, in the message. Maybe SCBA and Sino-Micro can work together for a better position for science.

<http://www.sinomicro.org/index.php>

Yi-Wei

---

**From:** Zheng, Zhi-Ming (Thomas) (NIH/NCI) [E] <zhengt@exchange.nih.gov>  
**Sent:** Wednesday, August 28, 2019 6:26 PM  
**To:** Paul Liu <paul06liu@yahoo.com>; Tang, Yi-Wei/Laboratory Medicine <tangy@mskcc.org>; Shan.Lu@umassmed.edu  
**Cc:** Zheng, Hui <huiz@bcm.edu>; Liu, Shan-Lu <liu.6244@osu.edu>  
**Subject:** [EXTERNAL] RE: Re: C100 Co-Sponsor Confirmation & Registration Instructions for Sino-Micro

Excellent! Thanks for the notice, Paul!

Thomas

---

**From:** Paul Liu <[paul06liu@yahoo.com](mailto:paul06liu@yahoo.com)>  
**Sent:** Wednesday, August 28, 2019 4:57 PM  
**To:** [tangy@mskcc.org](mailto:tangy@mskcc.org); [Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu); Zheng, Zhi-Ming (Thomas) (NIH/NCI) [E] <[zhengt@exchange.nih.gov](mailto:zhengt@exchange.nih.gov)>  
**Cc:** Zheng, Hui <[huiz@bcm.edu](mailto:huiz@bcm.edu)>; Liu, Shan-Lu <[liu.6244@osu.edu](mailto:liu.6244@osu.edu)>  
**Subject:** Re: Re: C100 Co-Sponsor Confirmation & Registration Instructions for Sino-Micro

Thomas,

Thanks for your message. Things are under control. There are five SCBA members attending the C100 meeting (including Shan and Hui, while Shan-Lu has a schedule conflict so he cannot attend) and I will be on the conference call this Friday, representing SCBA.

Paul



On Wednesday, August 28, 2019, 04:15:46 PM EDT, Zheng, Zhi-Ming (Thomas) (NIH/NCI) [E] <[zhengt@exchange.nih.gov](mailto:zhengt@exchange.nih.gov)> wrote:

Thanks for the notice, Yi-Wei and Shan! I would strongly suggest to have Paul, Hui and Shan-Lu on the conference call as I copied to.

Best,

Thomas

---

**From:** [tangy@mskcc.org](mailto:tangy@mskcc.org) <[tangy@mskcc.org](mailto:tangy@mskcc.org)>  
**Sent:** Wednesday, August 28, 2019 9:11 AM  
**To:** [Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu); Zheng, Zhi-Ming (Thomas) (NIH/NCI) [E] <[zhengt@exchange.nih.gov](mailto:zhengt@exchange.nih.gov)>  
**Subject:** FW: Re: C100 Co-Sponsor Confirmation & Registration Instructions for Sino-Micro

FYI.

Yi-Wei

---

**From:** Tang, Yi-Wei/Laboratory Medicine  
**Sent:** Wednesday, August 28, 2019 9:01 AM  
**To:** 'Christina Lu' <[clu@committee100.org](mailto:clu@committee100.org)>; [wang.707@osu.edu](mailto:wang.707@osu.edu)  
**Cc:** Silicon Valley Conference <[svconf@committee100.org](mailto:svconf@committee100.org)>; 'Chuanwu Xi' ([cxi@umich.edu](mailto:cxi@umich.edu)) <[cxi@umich.edu](mailto:cxi@umich.edu)>; [yongqunh@med.umich.edu](mailto:yongqunh@med.umich.edu)  
**Subject:** RE: [EXTERNAL] Re: C100 Co-Sponsor Confirmation & Registration Instructions for Sino-Micro

I will be able to join the conference call. Please send me an Outlook invitation along with a call bridge/number.

Yi-Wei

**Yi-Wei Tang, MD, PhD, D(ABMM), F(AAM), FIDSA**

Chief of Clinical Microbiology Service

Center for Laboratory Medicine

Memorial Sloan Kettering Cancer Center

Professor of Pathology and Laboratory Medicine

Weill Medical College of Cornell University

327 East 64th St, Rm 521

New York, NY 10065, USA

Tel: 646-608-1380; Fax: (929) 321-7208; Email: [tangy@mskcc.org](mailto:tangy@mskcc.org)

<http://www.mskcc.org/cancer-care/doctor/yi-wei-tang>

**From:** Christina Lu <[clu@committee100.org](mailto:clu@committee100.org)>

**Sent:** Tuesday, August 27, 2019 4:31 PM

**To:** [wang.707@osu.edu](mailto:wang.707@osu.edu)

**Cc:** Silicon Valley Conference <[svconf@committee100.org](mailto:svconf@committee100.org)>; Tang, Yi-Wei/Laboratory Medicine <[tangy@mskcc.org](mailto:tangy@mskcc.org)>; 'Chuanwu Xi' ([cxi@umich.edu](mailto:cxi@umich.edu)) <[cxi@umich.edu](mailto:cxi@umich.edu)>; [yonggunh@med.umich.edu](mailto:yonggunh@med.umich.edu)

**Subject:** [EXTERNAL] Re: C100 Co-Sponsor Confirmation & Registration Instructions for Sino-Micro

Dear Dr. Wang,

I write to follow-up on the below and ask if you or a representative from Sino-Micro are planning to join the **conference call for our co-sponsors on Friday, August 30 at 2PM Pacific Time / 5pm Eastern Time?** The purpose of the call is to provide you updates on the conference agenda and answer any questions you may have about the roundtable discussion. It would be greatly appreciated if you could let me know if a representative will be joining from Sino-Micro.

Thank you.

Best regards,

Christina



National Program Director

**COMMITTEE OF 100** | *EXTRAORDINARY CHINESE AMERICANS* - Ensuring Full Inclusion in America, Advancing U.S.-China Relations

[257 Park Ave. South, 19th Floor, New York, NY 10010](#)

T: (212) 371-6565 | C: (646) 623-7904 | E: [clu@committee100.org](mailto:clu@committee100.org)

[www.committee100.org](http://www.committee100.org)

On Mon, Aug 19, 2019 at 4:25 PM Christina Lu <[clu@committee100.org](mailto:clu@committee100.org)> wrote:

Dear Dr. Wang,

Thank you for serving as a **co-sponsor** at Committee of 100's upcoming conference entitled "**Science and Technology Caught Between the United States and China: The Challenges Facing Chinese American Researchers**". This one-day, by-invitation high-level conference will take place on **September 28, 2019** at the **Four Seasons Hotel Silicon Valley in Palo Alto**. Please find attached your co-sponsor confirmation letter. Once we receive your logo, we will add it to the flier.

Please register using the below custom codes for Sino-Micro. When you enter the codes separately, you will find the price of the "General Admission Ticket" will change.

To register your 6 complimentary tickets [please click here](#) (the roundtable representative is included in the six). Please enter "**SINOMICROcomp**" in the promotional code box. Please register your 6 complimentary tickets no later than **September 8, 2019**. If there are unassigned tickets after September 8, the complimentary seats will be released back to C100 to be re-assigned.

For your other members who would like to attend, [please click here](#) and instruct them to enter "**SINOMICROdiscount**" in the promotional code box. This code also allows you and your members to purchase additional tickets at the **discount rate of \$45**. Please note that seating is limited and discounted tickets are offered exclusively for interested members of our conference partners. This rate will not be available to the public at large.

Please find attached a copy of the **conference flier** for you to share internally with your members.

I would also like to inform you that we will have a **conference call for our co-sponsors** on **Friday, August 30 at 2PM Pacific Time / 5pm Eastern Time**. The purpose of the call is to provide you updates on the conference agenda and answer any additional questions. Please confirm a representative from your organization can join the call. Call-in details will be provided upon confirmation.

We are grateful for your partnership towards the success of this conference. Please do not hesitate to reach out to me if you have any questions.

Best regards,  
Christina Lu



National Program Director

**COMMITTEE OF 100** | *EXTRAORDINARY CHINESE AMERICANS* - Ensuring Full Inclusion in America, Advancing U.S.-China Relations

[257 Park Ave. South, 19th Floor, New York, NY 10010](#)

T: (212) 371-6565 | C: (646) 623-7904 | E: [clu@committee100.org](mailto:clu@committee100.org)

[www.committee100.org](http://www.committee100.org)

----- Forwarded message -----

From: **Wang, Hua** <[wang.707@osu.edu](mailto:wang.707@osu.edu)>

Date: Mon, Aug 19, 2019 at 12:54 PM

Subject: RE: Sino-micro's position

To: Frank H. Wu <[frankhwu@committee100.org](mailto:frankhwu@committee100.org)>

Cc: [tangy@mskcc.org](mailto:tangy@mskcc.org) <[tangy@mskcc.org](mailto:tangy@mskcc.org)>, 'Chuanwu Xi' ([cxi@umich.edu](mailto:cxi@umich.edu)) <[cxi@umich.edu](mailto:cxi@umich.edu)>, [yongqunh@med.umich.edu](mailto:yongqunh@med.umich.edu) <[yongqunh@med.umich.edu](mailto:yongqunh@med.umich.edu)>, Christina Lu <[clu@committee100.org](mailto:clu@committee100.org)>

Sure. Oliver, can you help send our "official" log to Christina? Thank you so much!!-Hua

---

**From:** Frank H. Wu [mailto:[frankhwu@committee100.org](mailto:frankhwu@committee100.org)]

**Sent:** Monday, August 19, 2019 12:53 PM

**To:** Wang, Hua <[wang.707@osu.edu](mailto:wang.707@osu.edu)>

**Cc:** [tangy@mskcc.org](mailto:tangy@mskcc.org); 'Chuanwu Xi' ([cxi@umich.edu](mailto:cxi@umich.edu)) <[cxi@umich.edu](mailto:cxi@umich.edu)>; [yongqunh@med.umich.edu](mailto:yongqunh@med.umich.edu); Christina Lu <[clu@committee100.org](mailto:clu@committee100.org)>

**Subject:** Re: Sino-micro's position

Great! Christina Lu of the C100 office is cc'd. Would you send your logo?

Frank H. Wu

William L. Prosser Distinguished Professor, University of California Hastings College of the Law

President, Committee of 100

On Aug 19, 2019, at 09:45, Wang, Hua <[wang.707@osu.edu](mailto:wang.707@osu.edu)> wrote:

Dear Professor Wu,

Thank you very much for considering Sino-micro and informing us about the conference on "Science and Technology Caught Between the United States and China, The Challenges Facing Chinese American Researchers", organized by Committee 100. I have consulted our past presidents and president-elect, as well as sent out a ballot on the topic to the board. Besides unanimous support from the past and current senior officers, dominant majority of the board members voted "yes" supporting Sino-Micro to be a co-sponsor of the event.

Due to academic obligations, most board members won't be able to attend the event in person. I will share with you additional information on potential participation when available.

Thank you again very much for your leadership on this topic of great important to academia and our broad society. We look forward to working with you.

Sincerely,

Hua Wang, Ph.D.

President, Sino-Micro

Professor, Food Science, Microbiology, Interdisciplinary Nutrition

The Ohio State University

2015 Fyffe Court

Columbus, OH 43210

[Wang.707@osu.edu](mailto:Wang.707@osu.edu)

---

**From:** tangy@mskcc.org  
**Sent:** Thursday, August 29, 2019 8:13 AM  
**To:** zhengt@exchange.nih.gov; paul06liu@yahoo.com; Lu, Shan  
**Cc:** huiz@bcm.edu; liu.6244@osu.edu; wang.707@osu.edu  
**Subject:** RE: Re: C100 Co-Sponsor Confirmation & Registration Instructions for Sino-Micro

Thank you, everyone.

I am copying Hua Wang, Sino-Micro current President, in the message. Maybe SCBA and Sino-Micro can work together for a better position for science.

<http://www.sinomicro.org/index.php>

Yi-Wei

---

**From:** Zheng, Zhi-Ming (Thomas) (NIH/NCI) [E] <zhengt@exchange.nih.gov>  
**Sent:** Wednesday, August 28, 2019 6:26 PM  
**To:** Paul Liu <paul06liu@yahoo.com>; Tang, Yi-Wei/Laboratory Medicine <tangy@mskcc.org>; Shan.Lu@umassmed.edu  
**Cc:** Zheng, Hui <huiz@bcm.edu>; Liu, Shan-Lu <liu.6244@osu.edu>  
**Subject:** [EXTERNAL] RE: Re: C100 Co-Sponsor Confirmation & Registration Instructions for Sino-Micro

Excellent! Thanks for the notice, Paul!

Thomas

---

**From:** Paul Liu <[paul06liu@yahoo.com](mailto:paul06liu@yahoo.com)>  
**Sent:** Wednesday, August 28, 2019 4:57 PM  
**To:** [tangy@mskcc.org](mailto:tangy@mskcc.org); [Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu); Zheng, Zhi-Ming (Thomas) (NIH/NCI) [E] <[zhengt@exchange.nih.gov](mailto:zhengt@exchange.nih.gov)>  
**Cc:** Zheng, Hui <[huiz@bcm.edu](mailto:huiz@bcm.edu)>; Liu, Shan-Lu <[liu.6244@osu.edu](mailto:liu.6244@osu.edu)>  
**Subject:** Re: Re: C100 Co-Sponsor Confirmation & Registration Instructions for Sino-Micro

Thomas,

Thanks for your message. Things are under control. There are five SCBA members attending the C100 meeting (including Shan and Hui, while Shan-Lu has a schedule conflict so he cannot attend) and I will be on the conference call this Friday, representing SCBA.

Paul

On Wednesday, August 28, 2019, 04:15:46 PM EDT, Zheng, Zhi-Ming (Thomas) (NIH/NCI) [E] <[zhengt@exchange.nih.gov](mailto:zhengt@exchange.nih.gov)> wrote:

Thanks for the notice, Yi-Wei and Shan! I would strongly suggest to have Paul, Hui and Shan-Lu on the conference call as I copied to.

Best,

Thomas

---

**From:** [tangy@mskcc.org](mailto:tangy@mskcc.org) <[tangy@mskcc.org](mailto:tangy@mskcc.org)>  
**Sent:** Wednesday, August 28, 2019 9:11 AM  
**To:** [Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu); Zheng, Zhi-Ming (Thomas) (NIH/NCI) [E] <[zhengt@exchange.nih.gov](mailto:zhengt@exchange.nih.gov)>  
**Subject:** FW: Re: C100 Co-Sponsor Confirmation & Registration Instructions for Sino-Micro

FYI.

Yi-Wei

---

**From:** Tang, Yi-Wei/Laboratory Medicine  
**Sent:** Wednesday, August 28, 2019 9:01 AM  
**To:** 'Christina Lu' <[clu@committee100.org](mailto:clu@committee100.org)>; [wang.707@osu.edu](mailto:wang.707@osu.edu)  
**Cc:** Silicon Valley Conference <[svconf@committee100.org](mailto:svconf@committee100.org)>; 'Chuanwu Xi' ([cxi@umich.edu](mailto:cxi@umich.edu)) <[cxi@umich.edu](mailto:cxi@umich.edu)>; [yongqunh@med.umich.edu](mailto:yongqunh@med.umich.edu)  
**Subject:** RE: [EXTERNAL] Re: C100 Co-Sponsor Confirmation & Registration Instructions for Sino-Micro

I will be able to join the conference call. Please send me an Outlook invitation along with a call bridge/number.

Yi-Wei

**Yi-Wei Tang, MD, PhD, D(ABMM), F(AAM), FIDSA**

Chief of Clinical Microbiology Service

Center for Laboratory Medicine

Memorial Sloan Kettering Cancer Center

Professor of Pathology and Laboratory Medicine

Weill Medical College of Cornell University

327 East 64th St, Rm 521

New York, NY 10065, USA



Tel: 646-608-1380; Fax: (929) 321-7208; Email: [tangy@mskcc.org](mailto:tangy@mskcc.org)

<http://www.mskcc.org/cancer-care/doctor/yi-wei-tang>

**From:** Christina Lu <[clu@committee100.org](mailto:clu@committee100.org)>

**Sent:** Tuesday, August 27, 2019 4:31 PM

**To:** [wang.707@osu.edu](mailto:wang.707@osu.edu)

**Cc:** Silicon Valley Conference <[svconf@committee100.org](mailto:svconf@committee100.org)>; Tang, Yi-Wei/Laboratory Medicine <[tangy@mskcc.org](mailto:tangy@mskcc.org)>; 'Chuanwu Xi' (<[cxi@umich.edu](mailto:cxi@umich.edu)>) <[cxi@umich.edu](mailto:cxi@umich.edu)>; [yonggunh@med.umich.edu](mailto:yonggunh@med.umich.edu)

**Subject:** [EXTERNAL] Re: C100 Co-Sponsor Confirmation & Registration Instructions for Sino-Micro

Dear Dr. Wang,

I write to follow-up on the below and ask if you or a representative from Sino-Micro are planning to join the **conference call for our co-sponsors** on **Friday, August 30 at 2PM Pacific Time / 5pm Eastern Time?** The purpose of the call is to provide you updates on the conference agenda and answer any questions you may have about the roundtable discussion. It would be greatly appreciated if you could let me know if a representative will be joining from Sino-Micro.

Thank you.

Best regards,

Christina



National Program Director

**COMMITTEE OF 100** | **EXTRAORDINARY CHINESE AMERICANS** - Ensuring Full Inclusion in America, Advancing U.S.-China Relations

[257 Park Ave. South, 19th Floor, New York, NY 10010](#)

On Mon, Aug 19, 2019 at 4:25 PM Christina Lu <[clu@committee100.org](mailto:clu@committee100.org)> wrote:

Dear Dr. Wang,

Thank you for serving as a **co-sponsor** at Committee of 100's upcoming conference entitled "**Science and Technology Caught Between the United States and China: The Challenges Facing Chinese American Researchers**". This one-day, by-invitation high-level conference will take place on **September 28, 2019** at the **Four Seasons Hotel Silicon Valley in Palo Alto**. Please find attached your co-sponsor confirmation letter. Once we receive your logo, we will add it to the flier.

Please register using the below custom codes for Sino-Micro. When you enter the codes separately, you will find the price of the "General Admission Ticket" will change.

To register your 6 complimentary tickets [please click here](#) (the roundtable representative is included in the six). Please enter "**SINOMICROcomp**" in the promotional code box. Please register your 6 complimentary tickets no later than **September 8, 2019**. If there are unassigned tickets after September 8, the complimentary seats will be released back to C100 to be re-assigned.

For your other members who would like to attend, [please click here](#) and instruct them to enter "**SINOMICROdiscount**" in the promotional code box. This code also allows you and your members to purchase additional tickets at the **discount rate of \$45**. Please note that seating is limited and discounted tickets are offered exclusively for interested members of our conference partners. This rate will not be available to the public at large.

Please find attached a copy of the **conference flier** for you to share internally with your members.

I would also like to inform you that we will have a **conference call for our co-sponsors** on **Friday, August 30 at 2PM Pacific Time / 5pm Eastern Time**. The purpose of the call is to provide you updates on the conference agenda and answer any additional questions. Please confirm a representative from your organization can join the call. Call-in details will be provided upon confirmation.

We are grateful for your partnership towards the success of this conference. Please do not hesitate to reach out to me if you have any questions.

Best regards,  
Christina Lu



National Program Director

**COMMITTEE OF 100** | *EXTRAORDINARY CHINESE AMERICANS* - Ensuring Full Inclusion in America, Advancing U.S.-China Relations

[257 Park Ave. South, 19th Floor, New York, NY 10010](#)

T: (212) 371-6565 | C: (646) 623-7904 | E: [clu@committee100.org](mailto:clu@committee100.org)

[www.committee100.org](http://www.committee100.org)

----- Forwarded message -----

From: **Wang, Hua** <[wang.707@osu.edu](mailto:wang.707@osu.edu)>

Date: Mon, Aug 19, 2019 at 12:54 PM

Subject: RE: Sino-micro's position

To: Frank H. Wu <[frankhwu@committee100.org](mailto:frankhwu@committee100.org)>

Cc: [tangy@mskcc.org](mailto:tangy@mskcc.org) <[tangy@mskcc.org](mailto:tangy@mskcc.org)>, 'Chuanwu Xi' (<[cxi@umich.edu](mailto:cxi@umich.edu)> <[cxi@umich.edu](mailto:cxi@umich.edu)>, [yongqunh@med.umich.edu](mailto:yongqunh@med.umich.edu) <[yongqunh@med.umich.edu](mailto:yongqunh@med.umich.edu)>, Christina Lu <[clu@committee100.org](mailto:clu@committee100.org)>

Sure. Oliver, can you help send our "official" log to Christina? Thank you so much!!-Hua

---

**From:** Frank H. Wu [mailto:[frankhwu@committee100.org](mailto:frankhwu@committee100.org)]

**Sent:** Monday, August 19, 2019 12:53 PM

**To:** Wang, Hua <[wang.707@osu.edu](mailto:wang.707@osu.edu)>

**Cc:** [tangy@mskcc.org](mailto:tangy@mskcc.org); 'Chuanwu Xi' (<[cxi@umich.edu](mailto:cxi@umich.edu)> <[cxi@umich.edu](mailto:cxi@umich.edu)>; [yongqunh@med.umich.edu](mailto:yongqunh@med.umich.edu); Christina Lu <[clu@committee100.org](mailto:clu@committee100.org)>

**Subject:** Re: Sino-micro's position

Great! Christina Lu of the C100 office is cc'd. Would you send your logo?

Frank H. Wu

William L. Prosser Distinguished Professor, University of California Hastings College of the Law

President, Committee of 100

On Aug 19, 2019, at 09:45, Wang, Hua <[wang.707@osu.edu](mailto:wang.707@osu.edu)> wrote:

Dear Professor Wu,

Thank you very much for considering Sino-micro and informing us about the conference on "Science and Technology Caught Between the United States and China, The Challenges Facing Chinese American Researchers", organized by Committee 100. I have consulted our past presidents and president-elect, as well as sent out a ballot on the topic to the board. Besides unanimous support from the past and current senior officers, dominant majority of the board members voted "yes" supporting Sino-Micro to be a co-sponsor of the event.

Due to academic obligations, most board members won't be able to attend the event in person. I will share with you additional information on potential participation when available.

Thank you again very much for your leadership on this topic of great important to academia and our broad society. We look forward to working with you.

Sincerely,

Hua Wang, Ph.D.

President, Sino-Micro

Professor, Food Science, Microbiology, Interdisciplinary Nutrition

The Ohio State University

2015 Fyffe Court

Columbus, OH 43210

[Wang.707@osu.edu](mailto:Wang.707@osu.edu)

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Sunday, August 30, 2020 8:46 PM  
**To:** Hans-Dieter Klenk  
**Cc:** Lu, Shan  
**Subject:** Re: Re: co-editors in chief

Thank you again, and hope all will be well soon. Yu-mei

-----Original Messages-----

**From:** "Hans-Dieter Klenk" <klenk@staff.uni-marburg.de>  
**Sent Time:** 2020-08-30 18:30:02 (Sunday)  
**To:** "wen yumei" <ymwen@shmu.edu.cn>  
**Cc:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Subject:** Re: co-editors in chief

Dear Yumei and Shan,

Here are some suggestions in alphabetical order:

Christian Drosten ([christian.drosten@charite.de](mailto:christian.drosten@charite.de)). He is the director of the Virology Institute of the Humboldt University in Berlin. He is still very young (48), a good scientist and the most popular covid communicator the German news media. He has also several EMI publications.

Stephan Günther ([guenther@bnitm.de](mailto:guenther@bnitm.de)). He is at the Bernhard Nocht Institute for Tropical Medicine in Hamburg and one of the German leaders in emerging viruses.

Marion Koopmans ([m.koopmans@erasmusmc.nl](mailto:m.koopmans@erasmusmc.nl)). She is the director of the Virology Institute at Erasmus University Rotterdam/Netherlands which is also a leading institution in emerging infections.

Albert Osterhaus ([albert.osterhaus@tiho-nannover.de](mailto:albert.osterhaus@tiho-nannover.de)). He is the predecessor of Koopmans and now the director of a new institute on emerging infections in Hannover. He is a little over 70 and, thus, in the age you suggested.

If I can be of further help, please let me know.

Regards

Hans

Prof. Dr. Hans-Dieter Klenk  
Institut für Virologie  
Hans-Meerwein-Str. 2  
35043 Marburg  
Germany

Tel.: +49 6421 286 6191

Sek.: +49 6421 286 6254

Fax: +49 6421 286 8962

E-Mail: [klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)

Am 30.08.2020 um 02:36 schrieb wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>:

Hans, Thank you for your support and efforts for EMI.

Maybe you can help to recommend some one who has good background in emerging disease, while is retired and is not so active in scientific research from Europe for us. Hope when COVID-19 is under control soon, we can meet again. Yu-mei

-----Original Messages-----

**From:** "Hans-Dieter Klenk" <[klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)>

**Sent Time:** 2020-08-29 18:02:29 (Saturday)

**To:** "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>

**Cc:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Subject:** Re: co-editors in chief

Dear Yumei, dear Shan,

I am very sorry that Stephan Becker did not accept your invitation to become co-editor in chief of EMI. When I approached him first a few weeks ago, I was quite confident that he would accept. If you want me to suggest alternatives from Europe I will be happy to do so.

With my best wishes

Hans

Prof. Dr. Hans-Dieter Klenk  
Institut für Virologie  
Hans-Meerwein-Str. 2  
35043 Marburg  
Germany

Tel.: +49 6421 286 6191

Sek.: +49 6421 286 6254

Fax: +49 6421 286 8962

**E-Mail:** [klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)

Am 30.07.2020 um 01:59 schrieb wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>:

Hans, Thank you very much for your strong support of EMI. Yu-Mei

-----Original Messages-----

**From:** "Hans-Dieter Klenk" <[klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)>

**Sent Time:** 2020-07-30 01:03:15 (Thursday)

**To:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Cc:** "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>, "Sabine Fischbach" <[fischbach@staff.uni-](mailto:fischbach@staff.uni-)

[marburg.de](http://marburg.de)>

**Subject:** Re: co-editors in chief

Dear Shan,

I am quite confident that Stephan Becker will accept your invitation to become co-editor in chief. At least this was my impression when I talked with him about it. Right now his is on vacation. So I will talk with him again when he is back.

Best wishes

Hans

Prof. Dr. Hans-Dieter Klenk  
Institut für Virologie  
Hans-Meerwein-Str. 2  
35043 Marburg  
Germany

Tel.: +49 6421 286 6191

Sek.: +49 6421 286 6254

Fax: +49 6421 286 8962

E-Mail: [klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)

Am 29.07.2020 um 17:47 schrieb Lu, Shan

<[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>:

Dear Hans,

Thanks for your great support! Prof Wen and all of us were very impressed by the CV of Dr. Stephen Becker. We would very much like to invite Stephen to be the co-editor. Please see attached invitation letter from Prof Wen. Please feel free to introduce us to him at your convenience.

Best.

Shan

---

**From:** Hans-Dieter Klenk <[klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)>

**Sent:** Wednesday, July 22, 2020 5:34 AM

**To:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>

**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; YiWei Tang

<[yiweitangmd@gmail.com](mailto:yiweitangmd@gmail.com)>; yuan zhenhong

<[zhyuan@shmu.edu.cn](mailto:zhyuan@shmu.edu.cn)>; Winter999 <[Winter999@hotmail.com](mailto:Winter999@hotmail.com)>;

zhangwenhong <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>; Sabine Fischbach

<[fischbach@staff.uni-marburg.de](mailto:fischbach@staff.uni-marburg.de)>

**Subject:** Re: co-editors in chief

Dear Yu-mei,

The scientist I suggested as co-editor in chief is Stephan Becker who is my successor as director of the Marburg institute. He is an expert in emerging viruses and now also heavily engaged in COVID-19 research. His CV will follow.

Regards  
Hans

Prof. Dr. Hans-Dieter Klenk  
Institut für Virologie  
Hans-Meerwein-Str. 2  
35043 Marburg  
Germany

Tel.: +49 6421 286 6191  
Sek.: +49 6421 286 6254  
Fax: +49 6421 286 8962  
[E-Mail: klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)

Am 21.07.2020 um 02:45 schrieb wen yumei  
<[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>:

Hi, Hans.  
We are still looking for an editor-in-chief for EMI from Europe. As mentined before, you suggested that one scientist from your institute might be a candidate. Due to your long term support and contriubtion to EMI, with your guidance,we would like to consider this candidate as one of the editors-in-chief. Would you please ask him, if he is willing to take this post, and send us his CV?  
Thank you. Germany is great in participating combating COvVID-19. Regards,  
Yu-me

<Invitation Letter-20200729-final.pdf>



---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Saturday, August 29, 2020 8:37 PM  
**To:** Hans-Dieter Klenk  
**Cc:** Lu, Shan  
**Subject:** Re: Re: co-editors in chief

Hans, Thank you for your support and efforts for EMI.

Maybe you can help to recommend some one who has good background in emerging disease, while is retired and is not so active in scientific research from Europe for us. Hope when COVID-19 is under control soon, we can meet again. Yu-me

-----Original Messages-----

**From:** "Hans-Dieter Klenk" <klenk@staff.uni-marburg.de>  
**Sent Time:** 2020-08-29 18:02:29 (Saturday)  
**To:** "wen yumei" <ymwen@shmu.edu.cn>  
**Cc:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Subject:** Re: co-editors in chief

Dear Yumei, dear Shan,

I am very sorry that Stephan Becker did not accept your invitation to become co-editor in chief of EMI. When I approached him first a few weeks ago, I was quite confident that he would accept. If you want me to suggest alternatives from Europe I will be happy to do so.

With my best wishes  
Hans

Prof. Dr. Hans-Dieter Klenk  
Institut für Virologie  
Hans-Meerwein-Str. 2  
35043 Marburg  
Germany

Tel.: +49 6421 286 6191  
Sek.: +49 6421 286 6254  
Fax: +49 6421 286 8962  
[E-Mail: klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)

Am 30.07.2020 um 01:59 schrieb wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>:

Hans, Thank you very much for your strong support of EMI. Yu-Mei

-----Original Messages-----

**From:** "Hans-Dieter Klenk" <[klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)>

**Sent Time:**2020-07-30 01:03:15 (Thursday)

**To:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Cc:** "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>, "Sabine Fischbach" <[fischbach@staff.uni-marburg.de](mailto:fischbach@staff.uni-marburg.de)>

**Subject:** Re: co-editors in chief

Dear Shan,

I am quite confident that Stephan Becker will accept your invitation to become co-editor in chief. At least this was my impression when I talked with him about it. Right now his is on vacation. So I will talk with him again when he is back.

Best wishes

Hans

Prof. Dr. Hans-Dieter Klenk  
Institut für Virologie  
Hans-Meerwein-Str. 2  
35043 Marburg  
Germany

Tel.: +49 6421 286 6191

Sek.: +49 6421 286 6254

Fax: +49 6421 286 8962

[E-Mail: klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)

Am 29.07.2020 um 17:47 schrieb Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>:

Dear Hans,

Thanks for your great support! Prof Wen and all of us were very impressed by the CV of Dr. Stephen Becker. We would very much like to invite Stephen to be the co-editor. Please see attached invitation letter from Prof Wen. Please feel free to introduce us to him at your convenience.

Best.

Shan

---

**From:** Hans-Dieter Klenk <[klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)>

**Sent:** Wednesday, July 22, 2020 5:34 AM

**To:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>

**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; YiWei Tang <[yiweitangmd@gmail.com](mailto:yiweitangmd@gmail.com)>;

yuan zhenhong <[zhyuan@shmu.edu.cn](mailto:zhyuan@shmu.edu.cn)>; Winter999 <[Winter999@hotmail.com](mailto:Winter999@hotmail.com)>;

zhangwenhong <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>; Sabine Fischbach

<[fischbach@staff.uni-marburg.de](mailto:fischbach@staff.uni-marburg.de)>

**Subject:** Re: co-editors in chief

Dear Yu-mei,

The scientist I suggested as co-editor in chief is Stephan Becker who is my successor as director of the Marburg institute. He is an expert in emerging viruses and now also heavily engaged in COVID-19 research. His CV will follow.

Regards  
Hans

Prof. Dr. Hans-Dieter Klenk  
Institut für Virologie  
Hans-Meerwein-Str. 2  
35043 Marburg  
Germany

Tel.: +49 6421 286 6191  
Sek.: +49 6421 286 6254  
Fax: +49 6421 286 8962  
[E-Mail: klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)

Am 21.07.2020 um 02:45 schrieb wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>:

Hi, Hans.

We are still looking for an editor-in-chief for EMI from Europe. As mentined before, you suggested that one scientist from your institute might be a candidate. Due to your long term support and contriubtion to EMI, with your guidance,we would like to consider this candidate as one of the editors-in-chief. Would you please ask him, if he is willing to take this post, and send us his CV?

Thank you. Germany is great in participating combating COvVID-19.

Regards,  
Yu-mei

<Invitation Letter-20200729-final.pdf>

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Wednesday, July 29, 2020 8:00 PM  
**To:** Hans-Dieter Klenk  
**Cc:** Lu, Shan; Sabine Fischbach  
**Subject:** Re: Re: co-editors in chief

Hans, Thank you very much for your strong support of EMI. Yu-Mei

-----Original Messages-----

**From:** "Hans-Dieter Klenk" <klenk@staff.uni-marburg.de>  
**Sent Time:** 2020-07-30 01:03:15 (Thursday)  
**To:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Cc:** "wen yumei" <ymwen@shmu.edu.cn>, "Sabine Fischbach" <fischbach@staff.uni-marburg.de>  
**Subject:** Re: co-editors in chief

Dear Shan,

I am quite confident that Stephan Becker will accept your invitation to become co-editor in chief. At least this was my impression when I talked with him about it. Right now his is on vacation. So I will talk with him again when he is back.

Best wishes  
Hans

Prof. Dr. Hans-Dieter Klenk  
Institut für Virologie  
Hans-Meerwein-Str. 2  
35043 Marburg  
Germany

Tel.: +49 6421 286 6191  
Sek.: +49 6421 286 6254  
Fax: +49 6421 286 8962  
[E-Mail: klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)

Am 29.07.2020 um 17:47 schrieb Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>:

Dear Hans,

Thanks for your great support! Prof Wen and all of us were very impressed by the CV of Dr. Stephen Becker. We would very much like to invite Stephen to be the co-editor. Please see attached invitation letter from Prof Wen. Please feel free to introduce us to him at your convenience.

Best.

Shan

---

**From:** Hans-Dieter Klenk <[klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)>  
**Sent:** Wednesday, July 22, 2020 5:34 AM  
**To:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; YiWei Tang <[yiweitangmd@gmail.com](mailto:yiweitangmd@gmail.com)>; yuan zhenhong <[zhyuan@shmu.edu.cn](mailto:zhyuan@shmu.edu.cn)>; Winter999 <[Winter999@hotmail.com](mailto:Winter999@hotmail.com)>; zhangwenhong <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>; Sabine Fischbach <[fischbach@staff.uni-marburg.de](mailto:fischbach@staff.uni-marburg.de)>  
**Subject:** Re: co-editors in chief

Dear Yu-mei,

The scientist I suggested as co-editor in chief is Stephan Becker who is my successor as director of the Marburg institute. He is an expert in emerging viruses and now also heavily engaged in COVID-19 research. His CV will follow.

Regards

Hans

Prof. Dr. Hans-Dieter Klenk  
Institut für Virologie  
Hans-Meerwein-Str. 2  
35043 Marburg  
Germany

Tel.: +49 6421 286 6191  
Sek.: +49 6421 286 6254  
Fax: +49 6421 286 8962  
E-Mail: [klenk@staff.uni-marburg.de](mailto:klenk@staff.uni-marburg.de)

Am 21.07.2020 um 02:45 schrieb wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>:

Hi, Hans.

We are still looking for an editor-in-chief for EMI from Europe. As mentined before, you suggested that one scientist from your institute might be a candidate. Due to your long term support and contriubtion to EMI, with your guidance,we would like to consider this candidate as one of the editors-in-chief. Would you please ask him, if he is willing to take this post, and send us his CV?

Thank you. Germany is great in participating combating COvVID-19. Regards,  
Yu-mei

<Invitation Letter-20200729-final.pdf>

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Sunday, October 25, 2020 5:57 PM  
**To:** Qiao Wang  
**Cc:** Lu, Shan; yuan zhenhong; zgyl@fudan.edu.cn; yhxie; jieliangchen; xywang; bwang3  
**Subject:** Re: Re: Congratulation

Hope our young scientists will appreciate Charlie, a gentlemna's comment, smart and humble, and surppas all of us in the future. YM Wen

> -----Original Messages-----

> From: "Qiao Wang" <qiaoqiaolang163@vip.163.com> Sent Time: 2020-10-25  
> 10:52:07 (Sunday)  
> To: "Lu, Shan" <Shan.Lu@umassmed.edu>  
> Cc: "wen yumei" <ymwen@shmu.edu.cn>, "yuan zhenhong"  
> <zhyuan@shmu.edu.cn>, "zgyl@fudan.edu.cn" <zgyl@fudan.edu.cn>, yhxie  
> <yhxie@fudan.edu.cn>, jieliangchen <jieliangchen@fudan.edu.cn>, xywang  
> <xywang@shmu.edu.cn>, bwang3 <bwang3@fudan.edu.cn>  
> Subject: Re: Congratulation

>  
>  
> Wow! Very High Compliment!  
> Charles indeed admires your work and contributions, and you richly deserve this compliment.  
>  
> Qiao

>  
> > On Oct 25, 2020, at 09:42, Lu, Shan <Shan.Lu@umassmed.edu> wrote:  
> >  
> > Congratulations, Prof Wen!  
> >  
> > Charlie is a true gentleman, smart and humble.  
> >  
> > Shan

> > -----Original Message-----

> > From: wen yumei <ymwen@shmu.edu.cn>  
> > Sent: Saturday, October 24, 2020 9:19 PM  
> > To: yuan zhenhong <zhyuan@shmu.edu.cn>  
> > Cc: zgyl@fudan.edu.cn; yhxie <yhxie@fudan.edu.cn>; Qiao Wang  
> > <qiaoqiaolang163@vip.163.com>; jieliangchen  
> > <jieliangchen@fudan.edu.cn>; xywang <xywang@shmu.edu.cn>; bwang3  
> > <bwang3@fudan.edu.cn>; Lu, Shan <Shan.Lu@umassmed.edu>  
> > Subject: Fw: Re: Congratulation

> >  
> > See the response from Charlie, I am really honored. Wen  
> >  
> >  
> > -----Original Messages-----

> > From: "Charles Rice" <ricec@rockefeller.edu> Sent Time: 2020-10-25

> > 03:45:22 (Sunday)

> > To: "wen yumei" <ymwen@shmu.edu.cn>

> > Cc:

> > Subject: Re: Congratulation

> >

> > Thanks Yu-Mei! As one of your many admirers, your note means a great

> > deal to me. It has been a true pleasure and honor to get to know you

> > and your amazing group of trainees. Looking back, it has been a

> > remarkable period for science yet there are many challenges ahead

> > (not to mention that other persistent troublemaker, HBV!). I hope

> > you are well and I look forward to the next time our paths cross.

> > Warm regards, Charlie

> >

> >> On Oct 5, 2020, at 8:29 AM, wen yumei <ymwen@shmu.edu.cn> wrote:

> >>

> >> Dear Charlie,

> >> The news of you and the other two scientists received the Nobel Prize was immediately spread in our lab, and everybody is thrilled, because of your long time collaboration with us and some of them were trained in your lab.

> >> Congratulation ! Your contribution in virology is worldwide recognized, and of course your outstanding contribution in HCV has saved the lives of many people.

> >> Thank you for helping Zhenghong and our lab in all aspects, and

> >> hope you all the best, and keep fit. Yu-mei

> >>

> >>

> >>

> >>

> >

> >

> >

> >

> >

>

---

**From:** TEMI-production@journals.tandf.co.uk  
**Sent:** Tuesday, May 5, 2020 3:26 AM  
**To:** linfa.wang@duke-nus.edu.sg; min.yang@emi2012.org  
**Cc:** Lu, Shan  
**Subject:** Re: Re: Copyright for your manuscript TEMI-2020-0499.R1 #TrackingId:6254511

Dear Dr Wang,

Yes, I received both.

Thank you very much!

Regards,

Karthick

Emerging Microbes & Infections

---

**From:** linfa.wang@duke-nus.edu.sg  
**Sent:** 04-05-2020 09:09  
**To:** karthick@novatechset.com, min.yang@emi2012.org  
**Cc:** Shan.Lu@umassmed.edu  
**Subject:** Re: Re: Copyright for your manuscript TEMI-2020-0499.R1

I have uploaded both a few hours ago

Thanks

Sent from my iPhone

On 4 May 2020, at 10:50 PM, Min Yang <min.yang@emi2012.org> wrote:

- External Email -

Dear Dr Wang,

Regarding your manuscript TEMI-2020-0499.R1, we would be appreciated if you could process and finish the copyright paperwork and the author review corrections soon as to avoid any delay in publication.

Please feel free to let me know if any questions.



Thanks and regards,

Min Yang

*Emerging Microbes & Infections* (EMI) Editorial Office  
4F Fuxing Building

131 Dongan Road  
Shanghai  
China  
Tel: 86-21-54237992  
E-mail: [min.yang@emi2012.org](mailto:min.yang@emi2012.org)

---

Important: This email is confidential and may be privileged. If you are not the intended recipient, please delete it and notify us immediately; you should not copy or use it for any purpose, nor disclose its contents to any other person. Thank you.

**From:** wen yumei <ymwen@shmu.edu.cn >  
**Sent:** Friday, April 10, 2020 9:45 PM  
**To:** Lu, Shan  
**Subject:** Re: RE: COVID-19 Paper

Thank you for rejecting the article from Lilanjuan.

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu >  
**Sent Time:** 2020-04-10 20:28:55 (Friday)  
**To:** "wen yumei" <ymwen@shmu.edu.cn >  
**Cc:**  
**Subject:** RE: COVID-19 Paper

Hi, Prof Wen,

Here is my draft response for your reference:

\*\*\*\*\*

Dear Dr. Xiang,

Thanks for considering EMI for your interesting study. I have forwarded your paper package to our editorial board who did a quick initial screening.

Currently, EMI received about 60-80 COVID-19 related papers each week and most are very high quality. This is too many for EMI to publish. We have established a screening system by key editors and invited experts. Only those papers meeting the high priority will be sent out for peer-review. Unfortunately the screening group does not feel that your paper will fit our priority at this point. A few years ago, EMI has decided to generally decline any paper with limited clinical cases. Your report only has two cases and there is no controls. It may fit better with a basic research specialty journal focusing on stem cell subject.

Again, we appreciate your interest in EMI and best wishes to your great work.

**From:**wen yumei <ymwen@ shmu.edu.cn >  
**Sent:** Friday, April 10, 2020 6:56 AM  
**To:**Lu, Shan <Shan.Lu @ umassmed.edu >  
**Subject:** Fw: COVID-19 paper

Shan: This article was sent to me by Li and her associates asking for rapid publication in EMI. There were only two patients treated, without any controls. They tried to prove the application of this technology in H7N9 in the journal Engineering is worthless, as that journal is an official journal of CAE, which I regret could have published that article..

I do not think this article is appropriate for our journal. Please write a rejection letter diplomatically to me, so I can forward to them as our response. YMW

-----Original Messages-----

**From:** "项春" <cxiang@ zju.edu.cn  
**Sent Time:** 2020-04-10 12:51:24 (Friday)  
**To:**ymwen@ shmu.edu.cn  
**Cc:**  
**Subject:** Discussion on COVID-19

Hello, Academician Wen! The attachment is the manuscript we are going to submit. Thank you for your review.

I also attach the work we did during H7N9 in 2013. The paper has been published in Engineering. The results of the study show: the receiving room The mortality of ARDS patients in the mesenchymal stem cell treatment group was significantly lower than that in the control group, which were 17.6% and 54.5%, respectively. Receiving During the period, no acute toxicity or other serious adverse reactions related to stem cell infusion were found. A 5-year laboratory test was performed on 4 of these patients Long-term follow-up of lung function and quality of life showed that MSC provides a safe and effective therapy for saving severe lung diseases induced by H7N9.

Thanks again!

Xiang Chun生

The First Affiliated Hospital of Zhejiang Medical College

---

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Thursday, January 23, 2020 6:05 AM  
**To:** Lu, Shan  
**Cc:** 杨旻 EMI  
**Subject:** Re: RE: Dr. Zhengli She's accession no provided

OK, we will change it at that stage.  
Thanks,  
Shibo

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:** 2020-01-23 18:50:11 (Thursday)  
**To:** "shibojiang@fudan.edu.cn" <shibojiang@fudan.edu.cn>  
**Cc:** "杨旻 EMI" <minyang@163.com>  
**Subject:** RE: Dr. Zhengli She's accession no provided

Hi, Shibo,

I don't think we can do anything at this point. As I explained the other day, a paper in a publishing system can not be randomly or easily changed or replaced. The only next opportunity is at the proofs stage.

Best.

Shan

**From:** shibojiang@fudan.edu.cn <shibojiang@fudan.edu.cn>  
**Sent:** Thursday, January 23, 2020 4:10 AM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Cc:** 杨旻 EMI <minyang@163.com>  
**Subject:** Dr. Zhengli She's accession no provided

Dear Shan,

Dr. Zhengli Shi put her accession no in the commentary so that Dr. Yongzheng Zhang cannot complain to us. Is it possible to ask the publisher to replace the original one with one before online publication.

In addition, Dr. Shi agreed to provide KY the permission if he wants.

Thanks,

Shibo

\*\*\*\*\*

**From:** ZhangWenhong <zhangwenhong@fudan.edu.cn>  
**Sent:** Friday, December 27, 2019 5:32 PM  
**To:** wen yumei  
**Cc:** Lu, Shan; Tang, Yi-Wei; yuan zhenghong; min.yang@emi2012.org; Emily; Martin martin  
**Subject:** Re: Re: draft EMI 2019 best paper award list

Thank you Mr. Wen, Shan, and all the associate editors and teachers of the editorial department. I am very happy to see our article has been nominated. Thank you EMI for providing the pla  
! Wenhong

-----The original message-----

From 人 : "wen yumei" <ymwen@shmu.edu.cn>

**Sending time:** 2019-12-27 19:17:22 (Friday)

To : "Lu, Shan" <Shan.Lu@umassmed.edu>

Cc : ZhangWenhong <zhangwenhong@fudan.edu.cn>, "Tang, Yi-Wei" <yi-wei.tang@cepheid.com>, "yuan zhenghong" <zhyuan@shmu.edu.cn>, "min.yang@emi2012.org" <min.yang@emi2012.org>, Emily <editorial2@emi2012.org>, "Martin martin" <winter999@hotmail.com>

Main **topic:** Re: Draft the EMI 2019 Best Paper Award List

Excellent result. Thank everyone. Best regards to Shan, A happy New Year to you, who is the best organizer for EMI.  
Yu-mei Wen

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>

**Sent Time:** 2019-12-27 13:13:43 (Friday)

**To:** "wen yumei" <ymwen@shmu.edu.cn>, ZhangWenhong <zhangwenhong@fudan.edu.cn>, "Tang, Yi-Wei" <yi-wei.tang@cepheid.com>, "yuan zhenghong" <zhyuan@shmu.edu.cn>

**Cc:** "min.yang@emi2012.org" <min.yang@emi2012.org>, Emily <editorial2@emi2012.org>, "Martin martin" <winter999@hotmail.com>

**Subject:** draft EMI 2019 best paper award list

Dear Prof Wen and others,

Based on the nominations from you, I have put together the draft list. The number of votes received for each paper is provided. It is nice to see that our nominations are very close. I wrote "EMI Comments" but please feel free to revise as needed.

Please let me know if you have any questions before I notify the authors.

6/1/2021 Thank you Mr. Wen, Shan, and all the associate editors and teachers of the editorial department. I am very happy to see our article has been nominated. T...  
Best.

Shan

-  
Wenhong Zhang, MD & Ph.D. Professor of Medicine Director, Division of Infectious Diseases Huashan Hospital,  
Fudan University PI, Institute of Biomedical Science, Fudan University 12 M. Wulumuqi Road Shanghai 200040, China  
Phone: (8621)52888123 Fax: (8621)52888714 Email: zhangwenhong@fudan.edu.cn

---

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Sunday, January 12, 2020 9:14 AM  
**To:** Lu, Shan  
**Cc:** Shi Zhengli; Guo Deyin; Du Lanying\_NYBC; min.yang@emi2012.org  
**Subject:** Re: RE: Emerging and Re-emerging CoV-introduction-20200111  
**Attachments:** Commentary\_WARS-CoV\_EMI\_20200112.docx; Figure\_WARS-CoV\_EMI.pptx; Shi ZL\_Cross-neutraliz SL-CoV by anti-SARS-CoV antibodies\_Sci China\_Life Sci\_2017.pdf; Xia S\_Pan-coronavirus fusion inhibitor targeting HR1\_Sci Adv\_2019.pdf

Thanks, Shan.

We will follow the requirements to write a Commentary with <1500 words. Therefore, each of us will write about 500 words with 5 references. I will assemble them together.

I already prepared a figure (see the attachment). Hope Zhengli can provide the phylogenetic tree (the one in the figure was downloaded from a website) in Figure 1B and check whether the amino acid numbers of the functional domains in Figure 1B were corrected labeled.

Please let me know whether you agree with the putative order of the authors in the cover page.

I attached two papers that will be cited in this Commentary.

Thanks,

Shibo

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:** 2020-01-12 20:32:37 (Sunday)  
**To:** "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>, "Shi Zhengli" <zlshi@wh.iov.cn>, "Guo Deyin" <guodeyin@mail.sysu.edu.cn>  
**Cc:** "Du Lanying\_NYBC" <ldu@nybc.org>, "min.yang@emi2012.org" <min.yang@emi2012.org>  
**Subject:** RE: Emerging and Re-emerging CoV-introduction-20200111

Dear Shibo and others,

Thanks for your initiative and EMI greatly appreciate your effort. At the same time, I need to remind you the format of EMI papers.

1. EMI does not have "editorial". Instead, from what you proposed, it may fit "Commentary".
2. For Commentary, you need to read the following from EMI website ([www.tandfonline.com/temi](http://www.tandfonline.com/temi)):



- Should be written with the following elements in the following order: title page; keywords; main text; acknowledgments; declaration of interest statement; references; appendices (as appropriate); table(s) with caption(s) (on individual pages); figures; figure captions (as a list).
- Should be no more than 1,500 words, inclusive of tables, references, figure captions, footnotes.
- Read [making your article more discoverable](#), including information on choosing a title and search engine optimization.
- Comments are an analysis of recently published papers of particular interest. This is a commission-only section. It should contain no more than 2 display items, and cite no more than 15 references.

3. For this particular case, I am ok for you to comment on the recent discovery of a new CoV in Wuhan, instead of a particular paper (certainly you can comment a paper if it is coming out in the near future).

Please make sure that this commentary will focus on the new virus, rather just re-state what are already in CoV literature (including your old work), especially only 1500 words including everything is allowed.

I will serve as the review editor on your paper since Shibo is going to be one of the authors. But the review will be quick.

Best.

Shan

**From:** Shibo Jiang (姜世勃) <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>

**Sent:** Sunday, January 12, 2020 12:54 AM

**To:** Shi Zhengli <[zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn)>; Guo Deyin <[guodeyin@mail.sysu.edu.cn](mailto:guodeyin@mail.sysu.edu.cn)>

**Cc:** Du Lanying\_NYBC <[ldu@nybc.org](mailto:ldu@nybc.org)>; Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Subject:** Re: Emerging and Re-emerging CoV-introduction-20200111

Sorry, there is a typo in the title of the outline, "termination" should be "terminology". Alternatively, we may remove this word from the title.

Shibo

-----原始邮件-----

发件人: "Shibo Jiang (姜世勃)" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>

发送时间: 2020-01-12 12:48:49 (星期日)

收件人: "Shi Zhengli" <[zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn)>, "Guo Deyin" <[guodeyin@mail.sysu.edu.cn](mailto:guodeyin@mail.sysu.edu.cn)>, "Du Lanying\_NYBC" <[ldu@nybc.org](mailto:ldu@nybc.org)>

抄送: "Lu Shan" <[shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu)>

主题: Emerging and Re-emerging CoV-introduction-20200111

Dear Drs. Shi, Guo and Du,

EMI has assembled a special issue entitled "Emerging and Re-emerging Coronaviruses". As the Guest Editor for this special issue, I invite you to contribute research or review articles related to the "Wuhan coronavirus" to this special issue in the future.

Now I am going to write an Editorial about "Wuhan coronavirus" (about 2500-3000 words). I invite you to write a few paragraphs related to the topic of your expertise for this Editorial (the the outline of the manuscript attached). Each of us can write 800-1000 words. I will assemble them together and finalize the manuscript.

If you agree, please write it as soon as possible. I plan to submit it before next weekend.

Thank you very much for your consideration,

Shibo

### **Emerging and Re-emerging Coronaviruses**

**Guest Editor:** Shibo Jiang (Fudan University, China)

Emerging and re-emerging coronaviruses, including Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and the latest "Wuhan Coronavirus", may cause epidemics or potentially pandemics of highly pathogenic human infectious diseases, posing great threats to the global health. EMI Special Topic - Emerging and Re-emerging Coronaviruses covers research and review articles on the basic, translational and clinical studies related to these coronaviruses.

---

**From:** TEMI-peerreview@journals.tandf.co.uk  
**Sent:** Thursday, February 13, 2020 9:14 AM  
**To:** liu.6244@osu.edu  
**Cc:** Lu, Shan; lishan\_su@med.unc.edu  
**Subject:** Re: Re: Emerging Microbes & Infections - TEMI-2020-0121 - changes required to your submission  
#TrackingId:5633996

Dear Professor Liu,

Thank you very much for sending this file.

Kindly be informed that I have now uploaded in the system on your behalf and proceeded your paper to the editor.

Please let me know if you have further questions or concerns.

Kind regards,

**Jorgie Lyn Luna** - Journal Editorial Office  
Taylor & Francis Group  
4 Park Square | Milton Park | Abingdon | Oxon | OX14 4RN UK  
Web: [www.tandfonline.com](http://www.tandfonline.com)

Taylor & Francis is a trading name of Informa UK Limited,  
registered in England under no. 1072954

Emerging Microbes & Infections

---

**From:** liu.6244@osu.edu  
**Sent:**  
**To:** liu.6244@osu.edu  
**Cc:** Shan.Lu@umassmed.edu, lishan\_su@med.unc.edu  
**Subject:** Re: Re: Emerging Microbes & Infections - TEMI-2020-0121 - changes required to your submission

Hi Jorgie:

I have modified as instructed and attached the new one to this email. Please help upload and proceed.

Thank you.

Shan-Lu

Shan-Lu Liu, M.D., Ph.D.  
Professor  
Co-Director, Viruses and Emerging Pathogens Program  
Infectious Diseases Institute  
Center for Retrovirus Research  
Departments of Veterinary Biosciences, Microbial Infection and Immunity, and Microbiology  
The Ohio State University

1900 Coffey Rd, Room 480 VMAB  
Columbus, Ohio 43210  
Phone: (614) 292-8690  
Fax: (614) 292-6473  
Email: liu.6244@osu.edu; shan-lu.liu@osumc.edu

On 2/13/20, 8:43 AM, "Emerging Microbes and Infections" <onbehalf@manuscriptcentral.com> wrote:

13-Feb-2020

Dear Professor Liu,

Your above referenced manuscript, entitled "SARS-CoV-2: no evidence of a laboratory origin" requires some further changes before it is ready for reviewing in Emerging Microbes & Infections. Your submission has been returned to you and is located in your Author Center as a draft, so that you due to these reasons:

1. No line numbering

Kindly add a line numbering in your main document.

2. Exceeded reference count

Kindly be informed that the reference count for the commentary article should not be more than 15.

Your submission along with all files you submitted is now in your Author Center, at [https://urldefense.com/v3/\\_\\_https://mc.manuscriptcentral.com/temi\\_!!KGKeukY!nGv1RgRJ1P-OGXuZi8b2hKGjXxDFOmBwDONuR\\_njCdwERJF1HkBIV4Sggqr9udyWYmI\\$](https://urldefense.com/v3/__https://mc.manuscriptcentral.com/temi_!!KGKeukY!nGv1RgRJ1P-OGXuZi8b2hKGjXxDFOmBwDONuR_njCdwERJF1HkBIV4Sggqr9udyWYmI$) Please read the Quick Guide to Continuing your Submission, which shows how you can access your manuscript, and submit it back to the site. The Guide is located at [https://urldefense.com/v3/\\_\\_http://mc.manuscriptcentral.com/societyimages/tandf\\_qs0/Continuning\\*20a\\*20Submission\\_screenshot.pdf\\_\\_;JSU!!KGKeukY!nGv1RgRJ1P-OGXuZi8b2hKGjXxDFOmBwDONuR\\_njCdwERJF1HkBIV4Sggqr9re6Z8tA\\$](https://urldefense.com/v3/__http://mc.manuscriptcentral.com/societyimages/tandf_qs0/Continuning*20a*20Submission_screenshot.pdf__;JSU!!KGKeukY!nGv1RgRJ1P-OGXuZi8b2hKGjXxDFOmBwDONuR_njCdwERJF1HkBIV4Sggqr9re6Z8tA$)

You may contact the Editorial Office if you have further questions.

Sincerely,

Jorgie Lyn Luna  
Emerging Microbes & Infections Editorial Office  
[temi-peerreview@journals.tandf.co.uk](mailto:temi-peerreview@journals.tandf.co.uk)

---

**From:** TEMI-peerreview@journals.tandf.co.uk  
**Sent:** Tuesday, March 10, 2020 1:40 AM  
**To:** Lu, Shan; micnkmi@nus.edu.sg; mictyj@nus.edu.sg; ymw@shmu.edu.cn  
**Cc:** editorial@emi2012.org; miczz@nus.edu.sg  
**Subject:** Re: Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235 #TrackingId:5820255

Dear Dr. Mohd-Ismail,

Thank you for your email.

This is to kindly confirm that your paper TEMI-2020-0235 has been withdrawn from the Journal.

Should there be anything else that I can further assist you with, please do let me know.

Kind regards,

**Jorgie Lyn Luna** - Journal Editorial Office  
Taylor & Francis Group  
4 Park Square | Milton Park | Abingdon | Oxon | OX14 4RN UK  
Web: [www.tandfonline.com](http://www.tandfonline.com)  
Taylor & Francis is a trading name of Informa UK Limited,  
registered in England under no. 1072954  
Emerging Microbes & Infections

---

**From:** mictyj@nus.edu.sg  
**Sent:** 10-03-2020 12:19 PM  
**To:** Shan.Lu@umassmed.edu, micnkmi@nus.edu.sg, ymw@shmu.edu.cn  
**Cc:** miczz@nus.edu.sg, TEMI-peerreview@journals.tandf.co.uk, editorial@emi2012.org  
**Subject:** Re: Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235

Dear Dr Lu,  
Yes, we formally withdraw.

Regards,  
Yee Joo Tan  
Corresponding author.

---

**From:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Sent:** Tuesday, 10 March 2020 12:13 PM  
**To:** Nur Khairiah Binte Mohd Ismail <micnkmi@nus.edu.sg>; ymw@shmu.edu.cn <ymw@shmu.edu.cn>  
**Cc:** Tan Yee Joo <mictyj@nus.edu.sg>; Zheng Zhiqiang <miczz@nus.edu.sg>; TEMI-peerreview@journals.tandf.co.uk <TEMI-peerreview@journals.tandf.co.uk>; editorial@emi2012.org <editorial@emi2012.org>  
**Subject:** RE: Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235 #TrackingId:5820255

- External Email -

Dear Khairiah

Sorry for the miscommunication. As you know, it is hard to switch or add new data/figure in the middle of paper review. It will bring your paper back to the original submission stage to put together a new paper, and we have to ask the reviewers to hold who may or may not have time to do so. This will generated much delay in the review of your paper.

You can always add new data during the revision.

However, we fully respect authors' wish and will approve your request to withdraw your paper without further review. You can go to our website and log in to the system to formally withdraw your submission. I can let the reviewers know your decision right now.

Best.

Shan Lu, MD, PhD  
Editor-in-Chief  
Emerging Microbes and Infections (EMI)  
[www.tandfonline.com/TEMI](http://www.tandfonline.com/TEMI)  
[editorial@2012EMI.org](mailto:editorial@2012EMI.org)

---

**From:** Nur Khairiah Binte Mohd Ismail <micnkmi@nus.edu.sg>  
**Sent:** Monday, March 9, 2020 11:23 PM  
**To:** ymwen@shmu.edu.cn; Lu, Shan <Shan.Lu@umassmed.edu>  
**Cc:** Tan Yee Joo <mictyj@nus.edu.sg>; Zheng Zhiqiang <miczz@nus.edu.sg>; TEMI-peerreview@journals.tandf.co.uk; editorial@emi2012.org  
**Subject:** RE: Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235 #TrackingId:5820255

Dear Editors-in-Chief,

I would like to withdraw my manuscript titled "Monoclonal antibodies for the S2 subunit of spike of SARS-CoV cross-react with the newly-emerged SARS-CoV-2" from further consideration by your journal. The manuscript ID is TEMI-2020-0235 and the date of submission was 02-Mar-2020. Due to fundamental errors in the way some of the figures are displayed, it is unlikely that this manuscript will receive a favourable review. Unfortunately, despite several emails to the Editorial Office, we have not been able to rectify this issue.

Please confirm that the withdrawal process is complete as we need to resubmit this ASAP.

I apologize for any inconvenience caused.

Sincerely,  
Khairiah

---

**From:** [TEMI-peerreview@journals.tandf.co.uk](mailto:TEMI-peerreview@journals.tandf.co.uk) [<mailto:TEMI-peerreview@journals.tandf.co.uk>]  
**Sent:** Tuesday, 10 March, 2020 9:14 AM  
**To:** [editorial@emi2012.org](mailto:editorial@emi2012.org); Nur Khairiah Binte Mohd Ismail  
**Subject:** Re: Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235 #TrackingId:5820255

- External Email -

Dear Dr. Mohd-Ismail,

Thank you for your email.

With regards to the update on your submission, I can confirm that your paper, TEMI-2020-0235 is under review and with some reviewers awaiting their approval to review.

As soon as the reviewer comments are completed and an editorial decision has been reached, the editor will correspond with you directly.

Should you require further assistance or have other queries, please do not hesitate to contact me.

Kind regards,

**Jorgie Lyn Luna** - Journal Editorial Office

Taylor & Francis Group

4 Park Square | Milton Park | Abingdon | Oxon | OX14 4RN UK

Web: [www.tandfonline.com](http://www.tandfonline.com)

Taylor & Francis is a trading name of Informa UK Limited,  
registered in England under no. 1072954

Emerging Microbes & Infections

---

**From:** micnkmi@nus.edu.sg

**Sent:** 09-03-2020 10:42

**To:** editorial@emi2012.org, JorgieLyn.Luna@spi-global.com

**Cc:**

**Subject:** Re: Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235

Dear Editors,

May I get an update on the status of this case? Thank you.

Best regards,

Khairiah

---

**From:** Nur Khairiah Binte Mohd Ismail

**Sent:** 08 March 2020 08:51

**To:** Editorial Office <[editorial@emi2012.org](mailto:editorial@emi2012.org)>

**Subject:** Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235

Dear Jorgie,

Please let us know as soon as possible if we are still able to edit the figures. I have also reached out to you previously via the submission portal with the updated figures. If it's not possible or we don't hear back from you soon, we may consider to withdraw the submission. Hope to hear from you soon.

Dear Min,

Thank you for attending to our query.

Best regards,

Khairiah

----- Original message -----

From: Editorial Office <[editorial@emi2012.org](mailto:editorial@emi2012.org)>

Date: 06/03/2020 17:41 (GMT+08:00)

To: Nur Khairiah Binte Mohd Ismail <[micnkmi@nus.edu.sg](mailto:micnkmi@nus.edu.sg)>

Subject: Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235

- External Email -

Dear Author,

Thank you for reaching us.  
My colleague Miss Jorgie will assist you on this.

Hi Jorgie,

FYI.

Could you please help dealing with this case?

Many thanks,  
Min

获取 [Outlook for iOS](#)

---

发件人: Nur Khairiah Binte Mohd Ismail <[micnkmi@nus.edu.sg](mailto:micnkmi@nus.edu.sg)>

发送时间: Friday, March 6, 2020 4:12:35 PM

收件人: Editorial Office <[editorial@emi2012.org](mailto:editorial@emi2012.org)>

主题: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235

Dear Editors-in-Chief,

Following submission of manuscript ID TEMI-2020-0235 to EMI on 2 March 2020, we found that several of the figures were not displayed properly in the PDF proof. May we replace these figures before they are sent out for review?

Thank you.

Best regards,  
Khairiah

Nur Khairiah Mohd Ismail  
Research Fellow | TYJ Lab | Department of Microbiology & Immunology | MD4 | Yong Loo Lin School of  
Medicine | National University of Singapore | 5 Science Drive 2 | Singapore 117545 | Tel: +65 6601 3024 |

---

Important: This email is confidential and may be privileged. If you are not the intended recipient, please delete it and notify us immediately; you should not copy or use it for any purpose, nor disclose its contents to any other person. Thank you.

---

Important: This email is confidential and may be privileged. If you are not the intended recipient, please delete it and notify us immediately; you should not copy or use it for any purpose, nor disclose its contents to any other person. Thank you.

---



Important: This email is confidential and may be privileged. If you are not the intended recipient, please delete it and notify us immediately; you should not copy or use it for any purpose, nor disclose its contents to any other person. Thank you.

---

Important: This email is confidential and may be privileged. If you are not the intended recipient, please delete it and notify us immediately; you should not copy or use it for any purpose, nor disclose its contents to any other person. Thank you.

---


**From:** Tan Yee Joo <mictyj@nus.edu.sg>  
**Sent:** Tuesday, March 10, 2020 12:18 AM  
**To:** Lu, Shan; Nur Khairiah Binte Mohd Ismail; ymwen@shmu.edu.cn  
**Cc:** Zheng Zhiqiang; TEMI-peerreview@journals.tandf.co.uk; editorial@emi2012.org  
**Subject:** Re: Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235 #TrackingId:5820255

Dear Dr Lu,  
Yes, we formally withdraw.

Regards,  
Yee Joo Tan  
Corresponding author.

---

**From:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Sent:** Tuesday, 10 March 2020 12:13 PM  
**To:** Nur Khairiah Binte Mohd Ismail <micnkmi@nus.edu.sg>; ymwen@shmu.edu.cn <ymwen@shmu.edu.cn>  
**Cc:** Tan Yee Joo <mictyj@nus.edu.sg>; Zheng Zhiqiang <miczz@nus.edu.sg>; TEMI-peerreview@journals.tandf.co.uk <TEMI-peerreview@journals.tandf.co.uk>; editorial@emi2012.org <editorial@emi2012.org>  
**Subject:** RE: Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235 #TrackingId:5820255

 - External Email -

Dear Khairiah

Sorry for the miscommunication. As you know, it is hard to switch or add new data/figure in the middle of paper review. It will bring your paper back to the original submission stage to put together a new paper, and we have to ask the reviewers to hold who may or may not have time to do so. This will generated much delay in the review of your paper.

You can always add new data during the revision.

However, we fully respect authors' wish and will approve your request to withdraw your paper without further review. You can go to our website and log in to the system to formally withdraw your submission. I can let the reviewers know your decision right now.

Best.

Shan Lu, MD, PhD  
Editor-in-Chief  
Emerging Microbes and Infections (EMI)  
[www.tandfonline.com/TEMI](http://www.tandfonline.com/TEMI)  
[editorial@2012EMI.org](mailto:editorial@2012EMI.org)

---

**From:** Nur Khairiah Binte Mohd Ismail <micnkmi@nus.edu.sg>  
**Sent:** Monday, March 9, 2020 11:23 PM  
**To:** ymwen@shmu.edu.cn; Lu, Shan <Shan.Lu@umassmed.edu>

**Cc:** Tan Yee Joo <mictyj@nus.edu.sg>; Zheng Zhiqiang <miczz@nus.edu.sg>; TEMI-peerreview@journals.tandf.co.uk; editorial@emi2012.org

**Subject:** RE: Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235 #TrackingId:5820255

Dear Editors-in-Chief,

I would like to withdraw my manuscript titled "Monoclonal antibodies for the S2 subunit of spike of SARS-CoV cross-react with the newly-emerged SARS-CoV-2" from further consideration by your journal. The manuscript ID is TEMI-2020-0235 and the date of submission was 02-Mar-2020. Due to fundamental errors in the way some of the figures are displayed, it is unlikely that this manuscript will receive a favourable review. Unfortunately, despite several emails to the Editorial Office, we have not been able to rectify this issue.

Please confirm that the withdrawal process is complete as we need to resubmit this ASAP.

I apologize for any inconvenience caused.

Sincerely,  
Khairiah

---

**From:** [TEMI-peerreview@journals.tandf.co.uk](mailto:TEMI-peerreview@journals.tandf.co.uk) [<mailto:TEMI-peerreview@journals.tandf.co.uk>]

**Sent:** Tuesday, 10 March, 2020 9:14 AM

**To:** [editorial@emi2012.org](mailto:editorial@emi2012.org); Nur Khairiah Binte Mohd Ismail

**Subject:** Re: Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235 #TrackingId:5820255

- External Email -

Dear Dr. Mohd-Ismail,

Thank you for your email.

With regards to the update on your submission, I can confirm that your paper, TEMI-2020-0235 is under review and with some reviewers awaiting their approval to review. As soon as the reviewer comments are completed and an editorial decision has been reached, the editor will correspond with you directly.

Should you require further assistance or have other queries, please do not hesitate to contact me.

Kind regards,

**Jorgie Lyn Luna** - Journal Editorial Office

Taylor & Francis Group

4 Park Square | Milton Park | Abingdon | Oxon | OX14 4RN UK

Web: [www.tandfonline.com](http://www.tandfonline.com)

Taylor & Francis is a trading name of Informa UK Limited,  
registered in England under no. 1072954

Emerging Microbes & Infections

---

**From:** micnkmi@nus.edu.sg

**Sent:** 09-03-2020 10:42

**To:** editorial@emi2012.org, JorgieLyn.Luna@spi-global.com

**Cc:**

**Subject:** Re: Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235

Dear Editors,

May I get an update on the status of this case? Thank you.

Best regards,  
Khairiah

---

**From:** Nur Khairiah Binte Mohd Ismail  
**Sent:** 08 March 2020 08:51  
**To:** Editorial Office <[editorial@emi2012.org](mailto:editorial@emi2012.org)>  
**Subject:** Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235

Dear Jorgie,

Please let us know as soon as possible if we are still able to edit the figures. I have also reached out to you previously via the submission portal with the updated figures. If it's not possible or we don't hear back from you soon, we may consider to withdraw the submission. Hope to hear from you soon.


Dear Min,

Thank you for attending to our query.

Best regards,  
Khairiah

----- Original message -----

From: Editorial Office <[editorial@emi2012.org](mailto:editorial@emi2012.org)>  
Date: 06/03/2020 17:41 (GMT+08:00)  
To: Nur Khairiah Binte Mohd Ismail <[micnkmi@nus.edu.sg](mailto:micnkmi@nus.edu.sg)>  
Subject: Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235

 - External Email -

Dear Author,

Thank you for reaching us.  
My colleague Miss Jorgie will assist you on this.

Hi Jorgie,

FYI.

Could you please help dealing with this case?

Many thanks,

Min

获取 [Outlook for iOS](#)

---

发件人: Nur Khairiah Binte Mohd Ismail <[micnkmi@nus.edu.sg](mailto:micnkmi@nus.edu.sg)>

发送时间: Friday, March 6, 2020 4:12:35 PM

收件人: Editorial Office <[editorial@emi2012.org](mailto:editorial@emi2012.org)>

主题: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235

Dear Editors-in-Chief,

Following submission of manuscript ID TEMI-2020-0235 to EMI on 2 March 2020, we found that several of the figures were not displayed properly in the PDF proof. May we replace these figures before they are sent out for review?

Thank you.

Best regards,  
Khairiah

Nur Khairiah Mohd Ismail

Research Fellow | TYJ Lab | Department of Microbiology & Immunology | MD4 | Yong Loo Lin School of Medicine | National University of Singapore | 5 Science Drive 2 | Singapore 117545 | Tel: +65 6601 3024 |

---

Important: This email is confidential and may be privileged. If you are not the intended recipient, please delete it and notify us immediately; you should not copy or use it for any purpose, nor disclose its contents to any other person. Thank you.

---

Important: This email is confidential and may be privileged. If you are not the intended recipient, please delete it and notify us immediately; you should not copy or use it for any purpose, nor disclose its contents to any other person. Thank you.

---

Important: This email is confidential and may be privileged. If you are not the intended recipient, please delete it and notify us immediately; you should not copy or use it for any purpose, nor disclose its contents to any other person. Thank you.

---

Important: This email is confidential and may be privileged. If you are not the intended recipient, please delete it and notify us immediately; you should not copy or use it for any purpose, nor disclose its contents to any other person. Thank you.

---

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Saturday, January 18, 2020 8:04 AM  
**To:** Lu, Shan  
**Cc:** Shi Zhengli; Du Lanying\_NYBC  
**Subject:** Re: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055

Thanks, Prof. Lu.

We will work on formatting revisions if JEO contacts me.

By the way, I forgot to tell you that Prof. Deying Guo declined to be a co-author for this Commentary after I informed him that the name of WARS-CoV would not be included in this manuscript.

Have a nice weekend,

Shibo

> -----原始邮件-----

> 发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>

> 发送时间: 2020-01-18 19:21:30 (星期六)

> 收件人: "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>, "TEMI-peerreview@journals.tandf.co.uk" <TEMI-peerreview@journals.tandf.co.uk>

> 抄送: "Yang Min 杨旻" <minyang0216@163.com>, "min.yang@emi2012.org" <min.yang@emi2012.org>, "Shi Zhengli" <zshi@wh.iov.cn>, "Du Lanying\_NYBC" <ldu@nybc.org>

> 主题: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055

>

> Hi, Shibo,

>

> Thanks for submitting this timely Commentary. At the same time, you need to ensure the two co-authors agree to this draft of paper, especially the agreement from Prof. Shi.

>

> At this stage, JEO who is in charge of the first step QC will need to go through the draft and may contact you with any required formatting revisions. I am copying her here and she may take a little time to process since we are in Weekend now. But you should not write to her directly per T&F rules unless she contacts you.

>

> Dear Jorgie Lyn Luna,

>

> Please see communication with Prof Jiang on this new submission TEMI-2020-0055. What I would like are the following:

>

> 1) Please conduct a quick QC/format and let this MS moving to my desk asap, if there is no any QC/format issue.

> 2) It is ok to send it back to corresponding author Prof Jiang if there is QC issue right away, and he will process such revisions right away, including the wrong emails from two co-authors. Then please monitor the re-submission and again send it to me asap after your QC check.

>

> Thanks.

>  
> Shan  
>  
>  
>  
> -----Original Message-----  
> From: Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
> Sent: Saturday, January 18, 2020 3:25 AM  
> To: Lu, Shan <Shan.Lu@umassmed.edu>  
> Cc: Yang Min 杨旻 <minyang0216@163.com>; min.yang@emi2012.org; Shi Zhengli <zlshi@wh.iov.cn>; Du Lanying\_NYBC <ldu@nybc.org>  
> Subject: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online  
>  
> Dear Prof. Lu,  
>  
> Per your request, I just submitted the invited Commentary to EMI online (see the attachment). During the submission, I accidentally put in the contact information of Drs. Lu Lu and Shuai Xia (my postdoc), rather than Drs. Shi and Du, into the authors' list. I thus immediately called Min about the possibility of withdrawing and resubmitting the manuscript. Min told me that I would not have to withdraw the manuscript since the authors' information in the manuscript is correct, but I would have to inform Drs. Lu and Xia that they may receive the email from EMI about this manuscript. I informed them already.  
>  
> I will cite Prof. Yuen's paper once the citation information is available during the proof-reading stage.  
>  
> Thank you very much for your consideration,  
>  
> Shibo  
>  
>  
> -----原始邮件-----  
> 发件人: "Emerging Microbes and Infections" <onbehalfof@manuscriptcentral.com>  
> 发送时间: 2020-01-18 15:21:06 (星期六)  
> 收件人: shibojiang@fudan.edu.cn  
> 抄送: shibojiang@fudan.edu.cn  
> 主题: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online  
>  
> 18-Jan-2020  
>  
> Dear Professor Jiang:  
>  
> Your manuscript entitled "An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies" has been successfully submitted online and is presently being given full consideration for publication in Emerging Microbes & Infections.  
>  
> Your manuscript ID is TEMI-2020-0055.  
>  
> Please mention the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your street address or e-mail address, please log in to ScholarOne Manuscripts at <https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fmc.manuscriptcentral.com%2Ftemi&data=02%7C01%7Cshan.lu%40umassmed.edu%7Cb88e3a16d4b84e4b9a4c08d79c16e446%7Cee9155fe2da34378a6c44405faf>

57b2e%7C0%7C0%7C637149494467294604&data=KeW6aOiMwJL9XWiHK0zxaVnwzxm%2BXjf2SqxFW78yels%3D  
&reserved=0 and edit your user information as appropriate.

>

> You can also view the status of your manuscript at any time by checking your Author Center after logging in to  
<https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fmc.manuscriptcentral.com%2Ftemi&data=02%7C01%7Cshan.lu%40umassmed.edu%7Cb88e3a16d4b84e4b9a4c08d79c16e446%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637149494467304595&data=NhYn8TzJwHouqjVXPwM%2BybqbBs3kTKNXuBzdAeVc3nM%3D&reserved=0>

>

> Thank you for submitting your manuscript to Emerging Microbes & Infections.

>

> Sincerely,

> Emerging Microbes & Infections Editorial Office

>

>

>

>

>



---

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Monday, January 20, 2020 2:56 AM  
**To:** Lu, Shan  
**Cc:** zlshi; Yang Min 杨旻; min.yang; Du, Lanying  
**Subject:** Re: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Dear Prof. Lu and Ms. Yang,

I want to update the patients' information from:

"As of 17 January 2020, a total 45 cases were confirmed positive for 2019-nCoV, including 15 being discharged, 5 in serious condition and 2 having died. In addition, two persons who were traveling in Wuhan recently but now in Thailand and Japan, respectively, were detected positive for 2019-nCoV. Both of them did not visit the seafood market, but might have close contact with some pneumonia patients during their trip in Wuhan, raising the concern of limited human-to-human transmission of 2019-nCoV."

to:

"On 19 January 2020, Wuhan Health Commission reported that a total 198 cases in the 25 to 89 year old range were confirmed positive for 2019-nCoV, including 25 being discharged and 3 having died. Among the 170 patients under treatment in hospitals, 126, 35, and 9 are mild, severe, and critical condition, respectively (<http://www.thatsmags.com/china/post/30618/new-coronavirus-spreads-to-over-130-in-china-death-toll-rises>). In addition, 2 patients in Thailand, one in Japan, and one in South Korea, were detected positive for 2019-nCoV. They did not visit the specific seafood market, but might have close contact with some pneumonia patients during their trip in Wuhan, raising the concern of limited human-to-human transmission of 2019-nCoV."

Should we do it now or during the proof-reading stage? Please let us know.

Thanks,

Shibo

-----原始邮件-----

发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>

发送时间: 2020-01-18 19:42:02 (星期六)

收件人: zlshi <zlshi@wh.iov.cn>, "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>

抄送: "Yang Min 杨旻" <minyang0216@163.com>, "min.yang" <min.yang@emi2012.org>, "Du, Lanying" <ldu@nybc.org>

主题: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Dear Prof Shi,

Thanks for your confirmation and EMI is happy to see you as one of the authors.

Best.

Shan

---

**From:** zlshi <zlshi@wh.iov.cn>

**Sent:** Saturday, January 18, 2020 6:37 AM

**To:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>; Lu, Shan <Shan.Lu@umassmed.edu>

**Cc:** Yang Min 杨旻 <minyang0216@163.com>; min.yang <min.yang@emi2012.org>; Du, Lanying <ldu@nybc.org>

**Subject:** Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Dear Prof. Jiang,

Thank you for your inviting me as a co-author of this commentary. As the sequence is now open to the public, I'll be happy to be the co-author.

Best regards,

Zhengli,

---

SHI Zhengli, Ph. D

Senior Scientist & Professor

Wuhan Institute of Virology, Chinese Academy of Sciences

44 Xiao Hong Shan

430071 Wuhan, Hubei

China

Tel & Fax: (0086) 27 87197240

Email: [zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn)

**From:** [Shibo Jiang \(姜世勃\)](#)

**Date:** 2020-01-18 16:25

**To:** [Lu Shan](#)

**CC:** [Yang Min 杨旻](#); [min.yang](#); [Shi Zhengli](#); [Du Lanying NYBC](#)

**Subject:** Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Dear Prof. Lu,

Per your request, I just submitted the invited Commentary to EMI online (see the attachment). During the submission, I accidentally put in the contact information of Drs. Lu Lu and Shuai Xia (my postdoc), rather than Drs. Shi and Du, into the authors' list. I thus immediately called Min about the possibility of withdrawing and resubmitting the manuscript. Min told me that I would not have to withdraw the manuscript since the authors' information in the manuscript is correct, but I would have to inform Drs. Lu and Xia that they may receive the email from EMI about this manuscript. I informed them already.

I will cite Prof. Yuen's paper once the citation information is available during the proof-reading stage.

Thank you very much for your consideration,

Shibo

-----原始邮件-----

发件人: "Emerging Microbes and Infections" <[onbehalf@manuscriptcentral.com](mailto:onbehalf@manuscriptcentral.com)>

发送时间: 2020-01-18 15:21:06 (星期六)

收件人: [shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)

抄送: [shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)

主题: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

18-Jan-2020

Dear Professor Jiang:

Your manuscript entitled "An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies" has been successfully submitted online and is presently being given full consideration for publication in Emerging Microbes & Infections.

Your manuscript ID is TEMI-2020-0055.

Please mention the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your street address or e-mail address, please log in to ScholarOne Manuscripts at <https://mc.manuscriptcentral.com/temi> and edit your user information as appropriate.

You can also view the status of your manuscript at any time by checking your Author Center after logging in to <https://mc.manuscriptcentral.com/temi>.

Thank you for submitting your manuscript to Emerging Microbes & Infections.

Sincerely,

Emerging Microbes & Infections Editorial Office

---

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Monday, January 20, 2020 4:45 AM  
**To:** TEMI-peerreview@journals.tandf.co.uk  
**Cc:** Lu, Shan; zlshi@wh.iov.cn; minyang0216@163.com; min.yang@emi2012.org; ldu@nybc.org  
**Subject:** Re: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 #TrackingId:5437168

Thanks,Jorgie.

We will update the patients' information and add line number before resubmission tonight.

Shibo

-----原始邮件-----

发件人:TEMI-peerreview@journals.tandf.co.uk  
发送时间:2020-01-20 17:03:46 (星期一)  
收件人: shan.lu@umassmed.edu, shibojiang@fudan.edu.cn  
抄送: zlshi@wh.iov.cn, minyang0216@163.com, min.yang@emi2012.org, ldu@nybc.org  
主题: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 #TrackingId:5437168

Dear Prof. Jiang,

Thank you for your email.

This is to kindly let you know that I have now processed your paper and I have noticed that the paper does not contain a line numbering. Having this, I have returned your manuscript in your author centre in order for you to add a line numbering in your main document and make the necessary amendments in your co-authors list.

Rest assured that once received, I will then proceed your paper to Prof. Lu immediately.

Please let me know if you have any questions or concerns.

Kind regards,

**Jorgie Lyn Luna** - Journal Editorial Office  
Taylor & Francis Group  
4 Park Square | Milton Park | Abingdon | Oxon | OX14 4RN UK  
Web: [www.tandfonline.com](http://www.tandfonline.com)

Taylor & Francis is a trading name of Informa UK Limited,  
registered in England under no. 1072954

Emerging Microbes & Infections

-----  
**From:** Shan.Lu@umassmed.edu  
**Sent:** 18-01-2020 07:21  
**To:** shibojiang@fudan.edu.cn, Shan.Lu@umassmed.edu  
**Cc:** minyang0216@163.com, min.yang@emi2012.org, zlshi@wh.iov.cn, ldu@nybc.org  
**Subject:** RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055

Hi, Shibo,

Thanks for submitting this timely Commentary. At the same time, you need to ensure the two co-authors agree to this draft of paper, especially the agreement from Prof. Shi.

At this stage, JEO who is in charge of the first step QC will need to go through the draft and may contact you with any required formatting revisions. I am copying her here and she may take a little time to process since we are in Weekend now. But you should not write to her directly per T&F rules unless she contacts you.

Dear Jorgie Lyn Luna,

Please see communication with Prof Jiang on this new submission TEMI-2020-0055. What I would like are the following:

- 1) Please conduct a quick QC/format and let this MS moving to my desk asap, if there is no any QC/format issue.
- 2) It is ok to send it back to corresponding author Prof Jiang if there is QC issue right away, and he will process such revisions right away, including the wrong emails from two co-authors. Then please monitor the re-submission and again send it to me asap after your QC check.

Thanks.

Shan

-----Original Message-----

From: Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
Sent: Saturday, January 18, 2020 3:25 AM  
To: Lu, Shan <Shan.Lu@umassmed.edu>  
Cc: Yang Min 杨旻 <minyang0216@163.com>; min.yang@emi2012.org; Shi Zhengli <zlshi@wh.iov.cn>; Du Lanying\_NYBC <ldu@nybc.org>  
Subject: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Dear Prof. Lu,

Per your request, I just submitted the invited Commentary to EMI online (see the attachment). During the submission, I accidentally put in the contact information of Drs. Lu Lu and Shuai Xia (my postdoc), rather than Drs. Shi and Du, into the authors' list. I thus immediately called Min about the possibility of withdrawing and resubmitting the manuscript. Min told me that I would not have to withdraw the manuscript since the authors' information in the manuscript is correct, but I would have to inform Drs. Lu and Xia that they may receive the email from EMI about this manuscript. I informed them already.

I will cite Prof. Yuen's paper once the citation information is available during the proof-reading stage.

Thank you very much for your consideration,

Shibo

-----原始邮件-----

发件人: "Emerging Microbes and Infections" <onbehalf@manuscriptcentral.com>

发送时间: 2020-01-18 15:21:06 (星期六)

收件人: shibojiang@fudan.edu.cn

抄送: shibojiang@fudan.edu.cn

主题: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

18-Jan-2020

Dear Professor Jiang:

Your manuscript entitled "An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies" has been successfully submitted online and is presently being given full consideration for publication in Emerging Microbes & Infections.

Your manuscript ID is TEMI-2020-0055.

Please mention the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your street address or e-mail address, please log in to ScholarOne Manuscripts at <https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fmc.manuscriptcentral.com%2Ftemi&data=02%7C01%7Cshan.lu%40umassmed.edu%7C5bf67dcea80543172df308d79beffa7f%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637149327594484021&sdata=q3fFDQyJZmoHlceFvohL5YzdF2gO11sHHBts3o6gm3l%3D&reserved=0> and edit your user information as appropriate.

You can also view the status of your manuscript at any time by checking your Author Center after logging in to <https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fmc.manuscriptcentral.com%2Ftemi&data=02%7C01%7Cshan.lu%40umassmed.edu%7C5bf67dcea80543172df308d79beffa7f%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637149327594484021&sdata=q3fFDQyJZmoHlceFvohL5YzdF2gO11sHHBts3o6gm3l%3D&reserved=0>.

Thank you for submitting your manuscript to Emerging Microbes & Infections.

Sincerely,  
Emerging Microbes & Infections Editorial Office

---

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Tuesday, January 21, 2020 12:30 AM  
**To:** Lu, Shan; Wen Yumei; Yuan Zhenghong 袁正宏; Zhang Wenhong  
**Cc:** Yang Min 杨旻; min.yang; Yuen KY; TEMI-peerreview@journals.tandf.co.uk  
**Subject:** Re: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Dear Prof. Lu and Wen,

The day before yesterday, Drs. Hong Tang and Pei Hao at Pasteu Institute called me and asked me that they wanted to submit a manuscript about the genetic analysis of 2019-nCoV to EMI and whether we can process their manuscript in the fast track. I told them that EMI had already accepted a paper two days ago and this paper has presented very extensive analysis of this new virus. Therefore, they decided to submit their manuscript to *SCIENCE CHINA Life Sciences* (<https://mp.weixin.qq.com/s/JC0fCMsZlgGPYy4L7xMpTg>) and it was immediately accepted and published online today. However, Prof. Yuen's paper is still not online today. We want to cite Prof. Yuen's paper in our manuscripts, but we cannot get the citation link. Similarly, we submitted a minireview to JMV. It was also immediately accepted and published it online next day.

I understand that the staff of the editorial office of EMI have to take off in the weekends and holidays, but is it possible to ask the publishers to give special consideration for those extremely important papers for publication at fast speed?

Thank you very much for your consideration,

Shibo

-----原始邮件-----

发件人:"Lu, Shan" <Shan.Lu@umassmed.edu>

发送时间:2020-01-18 19:42:02 (星期六)

收件人: zlschi <zlschi@wh.iov.cn>, "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>

抄送: "Yang Min 杨旻" <minyang0216@163.com>, "min.yang" <min.yang@emi2012.org>, "Du, Lanying" <ldu@nybc.org>

主题: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Dear Prof Shi,

Thanks for your confirmation and EMI is happy to see you as one of the authors.

Best.

Shan



---

**From:** zlshi <zlshi@wh.iov.cn>

**Sent:** Saturday, January 18, 2020 6:37 AM

**To:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>; Lu, Shan <Shan.Lu@umassmed.edu>

**Cc:** Yang Min 杨旻 <minyang0216@163.com>; min.yang <min.yang@emi2012.org>; Du, Lanying <ldu@nybc.org>

**Subject:** Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Dear Prof. Jiang,

Thank you for your inviting me as a co-author of this commentary. As the sequence is now open to the public, I'll be happy to be the co-author.

Best regards,

Zhengli,

---

SHI Zhengli, Ph. D

Senior Scientist & Professor

Wuhan Institute of Virology, Chinese Academy of Sciences

44 Xiao Hong Shan

430071 Wuhan, Hubei

China

Tel & Fax: (0086) 27 87197240

Email: [zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn)

---

**From:** [Shibo Jiang \(姜世勃\)](#)

**Date:** 2020-01-18 16:25

**To:** [Lu Shan](#)

**CC:** [Yang Min 杨旻](#); [min.yang](#); [Shi Zhengli](#); [Du Lanying NYBC](#)

Dear Prof. Lu,

Per your request, I just submitted the invited Commentary to EMI online (see the attachment). During the submission, I accidentally put in the contact information of Drs. Lu Lu and Shuai Xia (my postdoc), rather than Drs. Shi and Du, into the authors' list. I thus immediately called Min about the possibility of withdrawing and resubmitting the manuscript. Min told me that I would not have to withdraw the manuscript since the authors' information in the manuscript is correct, but I would have to inform Drs. Lu and Xia that they may receive the email from EMI about this manuscript. I informed them already.

I will cite Prof. Yuen's paper once the citation information is available during the proof-reading stage.

Thank you very much for your consideration,

Shibo

-----原始邮件-----

发件人: "Emerging Microbes and Infections" <[onbehalf@manuscriptcentral.com](mailto:onbehalf@manuscriptcentral.com)>

发送时间: 2020-01-18 15:21:06 (星期六)

收件人: [shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)

抄送: [shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)

主题: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

18-Jan-2020

Dear Professor Jiang:

Your manuscript entitled "An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies" has been successfully submitted online and is presently being given full consideration for publication in Emerging Microbes & Infections.

Your manuscript ID is TEMI-2020-0055.

Please mention the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your street address or e-mail address, please log in to ScholarOne Manuscripts at <https://mc.manuscriptcentral.com/temi> and edit your user information as appropriate.

You can also view the status of your manuscript at any time by checking your Author Center after logging in to <https://mc.manuscriptcentral.com/temi>.

Thank you for submitting your manuscript to Emerging Microbes & Infections.

Sincerely,

Emerging Microbes & Infections Editorial Office

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Wednesday, May 13, 2020 5:02 AM  
**To:** Tang, Yi-Wei  
**Cc:** Lu, Shan; Min Yang  
**Subject:** Re: RE: Emerging Microbes & Infections Reviewer notification of decision on Manuscript TEMI-2020-0696

Please send the comments to the authors.

Though it was only one case, I think this paper describes very important issues. especially for infants and infected mothers. It was very difficult to get samples form infants, especially in highly isolated areas. In addition, the collection of samples from the infected mother after delivery is also very difficult.

After minor revision, I would suggest to accept this paper.

> -----Original Messages-----

> From: "Tang, Yi-Wei" <yi-wei.tang@cepheid.com> Sent Time: 2020-05-13

> 07:02:31 (Wednesday)

> To: "Lu, Shan" <Shan.Lu@umassmed.edu>, "wen yumei" <ymwen@shmu.edu.cn>

> Cc: "Min Yang" <min.yang@emi2012.org>

> Subject: RE: Emerging Microbes & Infections Reviewer notification of  
> decision on Manuscript TEMI-2020-0696

>

> Thank you, Shan. These are concise and clear review comments from the two reviewers. Maybe the authors should focus on the finding without extending too far.

>

> Yi-Wei

>

> -----Original Message-----

> From: Lu, Shan <Shan.Lu@umassmed.edu>

> Sent: Wednesday, May 13, 2020 3:54 AM

> To: wen yumei <ymwen@shmu.edu.cn>; Tang, Yi-Wei

> <yi-wei.tang@cepheid.com>

> Cc: Min Yang <min.yang@emi2012.org>

> Subject: FW: Emerging Microbes & Infections Reviewer notification of  
> decision on Manuscript TEMI-2020-0696

>

> Dear Prof Wen and Yi-Wei,

>

> We got both reviewers' opinion back. They felt the study is important, but there is only one case so it is not possible to conclude whether the milk antibody can be protective. Furthermore, there is no IgA data as it is very important in milk for IgA.

>

> Hope authors can address these simple questions, and resubmit their new draft soon.

>

> Best.

>

> Shan

>

> -----Original Message-----

> From: Emerging Microbes and Infections

> <onbehalf@manuscriptcentral.com>

> Sent: Tuesday, May 12, 2020 10:13 AM  
 > To: temi-peerreview@journals.tandf.co.uk  
 > Cc: Lu, Shan <Shan.Lu@umassmed.edu>  
 > Subject: Emerging Microbes & Infections Reviewer notification of  
 > decision on Manuscript TEMI-2020-0696  
 >  
 > 12-May-2020  
 >  
 > Dear Reviewers,  
 >  
 > Thank you for reviewing the manuscript TEMI-2020-0696 entitled "Antibodies in the breast milk of a maternal woman with COVID-19" for Emerging Microbes & Infections. We greatly appreciate the voluntary contribution that each reviewer gives to the Journal and hope that we may continue to seek your assistance with the refereeing process for Emerging Microbes & Infections.  
 >  
 > The decision that we arrived at for this article was: Major Revision, basing the decision on your review and those of the other referees.  
 >  
 > A copy of your comments to the author, along with those of any other referees, follows at the end of this letter for your information. Any files that referees uploaded for the attention of the author are attached as a PDF proof.  
 >  
 > Yours sincerely,  
 >  
 > Professor Shan Lu  
 > Editor-in-Chief, Emerging Microbes & Infections Shan.Lu@umassmed.edu  
 >  
 > Referee comments to the author:  
 > Reviewer: 1  
 >  
 > Recommendation: Unacceptable as is, but worth considering if  
 > extensively revised  
 >  
 > Comments:  
 > The manuscript submitted by Dong et al. entitled "Antibodies in the breast milk of a maternal woman with COVID-19". The authors claimed the finding suggest that breastfeeding might benefit the neonates. However, only IgG was detected, but the value between 11 and 21 days after birth was negligible. IgA, the major isotype that supposedly to be secreted into milk, should have been checked. Because the titers of IgG in neonate's serum (from mother) between birth to 25 days after birth was 1:1675 (or higher), which was overwhelmingly higher than 1:2-3 in the milk (barely above the background), one cannot say that it suggest breastfeeding might benefit the neonates, especially there were no data on IgA in the milk.  
 >  
 > English usage within this manuscript needs improvement.  
 >  
 >  
 > Additional Questions:  
 > As a thank you and to acknowledge the contribution of our reviewers,  
 > the journal may publish a list of the names of those who have reviewed  
 > at the end of the year. This will not be linked to any specific paper  
 > and will only be done if the list of reviewers is long enough to  
 > protect the anonymity of the review process for individual papers. If  
 > you would prefer for your name **not** to be included in a  
 > published list of reviewers, please indicate this below.: No

>  
>  
> Reviewer: 2  
>  
> Recommendation: Unacceptable as is, but worth considering if  
> extensively revised  
>  
> Comments:  
> At present, only one case is included in the study, the credibility is  
> reduced, and it is suggested to expand the sample size as much as  
> possible  
>  
> Additional Questions:  
> As a thank you and to acknowledge the contribution of our reviewers,  
> the journal may publish a list of the names of those who have reviewed at the end of the year. This will not be linked  
to any specific paper and will only be done if the list of reviewers is long enough to protect the anonymity of the review  
process for individual papers. If you would prefer for your name <b>not to be included</b> in a published list of  
reviewers, please indicate this below.: No Please be advised that this email may contain confidential information. If you  
are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender  
disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided  
that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual  
signature that is included in any attachment.

---

**From:** Nur Khairiah Binte Mohd Ismail <micnkmi@nus.edu.sg>  
**Sent:** Monday, March 9, 2020 11:23 PM  
**To:** ymw@shmu.edu.cn; Lu, Shan  
**Cc:** Tan Yee Joo; Zheng Zhiqiang; TEMI-peerreview@journals.tandf.co.uk; editorial@emi2012.org  
**Subject:** RE: Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235 #TrackingId:5820255

Dear Editors-in-Chief,

I would like to withdraw my manuscript titled "Monoclonal antibodies for the S2 subunit of spike of SARS-CoV cross-react with the newly-emerged SARS-CoV-2" from further consideration by your journal. The manuscript ID is TEMI-2020-0235 and the date of submission was 02-Mar-2020. Due to fundamental errors in the way some of the figures are displayed, it is unlikely that this manuscript will receive a favourable review. Unfortunately, despite several emails to the Editorial Office, we have not been able to rectify this issue.

Please confirm that the withdrawal process is complete as we need to resubmit this ASAP.

I apologize for any inconvenience caused.

Sincerely,  
Khairiah

---

**From:** TEMI-peerreview@journals.tandf.co.uk [mailto:TEMI-peerreview@journals.tandf.co.uk]  
**Sent:** Tuesday, 10 March, 2020 9:14 AM  
**To:** editorial@emi2012.org; Nur Khairiah Binte Mohd Ismail  
**Subject:** Re: Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235 #TrackingId:5820255

- External Email -

Dear Dr. Mohd-Ismail,

Thank you for your email.

With regards to the update on your submission, I can confirm that your paper, TEMI-2020-0235 is under review and with some reviewers awaiting their approval to review. As soon as the reviewer comments are completed and an editorial decision has been reached, the editor will correspond with you directly.

Should you require further assistance or have other queries, please do not hesitate to contact me.

Kind regards,

**Jorgie Lyn Luna** - Journal Editorial Office  
Taylor & Francis Group  
4 Park Square | Milton Park | Abingdon | Oxon | OX14 4RN UK  
Web: [www.tandfonline.com](http://www.tandfonline.com)  
Taylor & Francis is a trading name of Informa UK Limited,  
registered in England under no. 1072954  
**Emerging Microbes & Infections**

-----  
**From:** micnkmi@nus.edu.sg  
**Sent:** 09-03-2020 10:42  
**To:** editorial@emi2012.org, JorgieLyn.Luna@spi-global.com  
**Cc:**  
**Subject:** Re: Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235

Dear Editors,

May I get an update on the status of this case? Thank you.

Best regards,  
Khairiah

---

**From:** Nur Khairiah Binte Mohd Ismail  
**Sent:** 08 March 2020 08:51  
**To:** Editorial Office <editorial@emi2012.org>  
**Subject:** Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235

Dear Jorgie,

Please let us know as soon as possible if we are still able to edit the figures. I have also reached out to you previously via the submission portal with the updated figures. If it's not possible or we don't hear back from you soon, we may consider to withdraw the submission. Hope to hear from you soon.


Dear Min,

Thank you for attending to our query.

Best regards,  
Khairiah

----- Original message -----

**From:** Editorial Office <editorial@emi2012.org>  
**Date:** 06/03/2020 17:41 (GMT+08:00)  
**To:** Nur Khairiah Binte Mohd Ismail <micnkmi@nus.edu.sg>  
**Subject:** Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235

 - External Email -

Dear Author,

Thank you for reaching us.  
My colleague Miss Jorgie will assist you on this.

Hi Jorgie,



FYI.

Could you please help dealing with this case?

Many thanks,  
Min

获取 [Outlook for iOS](#)

---

发件人: Nur Khairiah Binte Mohd Ismail <micnkmi@nus.edu.sg>  
发送时间: Friday, March 6, 2020 4:12:35 PM  
收件人: Editorial Office <editorial@emi2012.org>  
主题: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0235

Dear Editors-in-Chief,

Following submission of manuscript ID TEMI-2020-0235 to EMI on 2 March 2020, we found that several of the figures were not displayed properly in the PDF proof. May we replace these figures before they are sent out for review?

Thank you.

Best regards,  
Khairiah

Nur Khairiah Mohd Ismail  
Research Fellow | TYJ Lab | Department of Microbiology & Immunology | MD4 | Yong Loo Lin School of  
Medicine | National University of Singapore | 5 Science Drive 2 | Singapore 117545 | Tel: +65 6601 3024 |

---

Important: This email is confidential and may be privileged. If you are not the intended recipient, please delete it and notify us immediately; you should not copy or use it for any purpose, nor disclose its contents to any other person. Thank you.

---

Important: This email is confidential and may be privileged. If you are not the intended recipient, please delete it and notify us immediately; you should not copy or use it for any purpose, nor disclose its contents to any other person. Thank you.

---

Important: This email is confidential and may be privileged. If you are not the intended recipient, please delete it and notify us immediately; you should not copy or use it for any purpose, nor disclose its contents to any other person. Thank you.

---

**From:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
**Sent:** Monday, December 16, 2019 5:55 PM  
**To:** wen yumei  
**Cc:** Lu, Shan; Min Yang; yuanzhenghong; yiweitangmd@gmail.com; Martin martin; Emily; Editorial Office  
**Subject:** RE: Re: EMI 12/15 Lunch Meeting

Ok, I will send my vote to Shan only 😊.

Yi-Wei

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Monday, December 16, 2019 8:10 PM  
**To:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
**Cc:** Lu, Shan <Shan.Lu@umassmed.edu>; Min Yang <min.yang@emi2012.org>; yuanzhenghong <yuanzhenghong@shphc.org.cn>; yiweitangmd@gmail.com; Martin martin <winter999@hotmail.com>; Emily <editorial2@emi2012.org>; Editorial Office <editorial@emi2012.org>  
**Subject:** Re: Re: EMI 12/15 Lunch Meeting

I agree and hope that each of us gives a personal view, which may be quite different, but interesting. YMwen

-----Original Messages-----

**From:** "Tang, Yi-Wei" <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>  
**Sent Time:** 2019-12-16 17:18:29 (Monday)  
**To:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** "Min Yang" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>, "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>, yuanzhenghong <[yuanzhenghong@shphc.org.cn](mailto:yuanzhenghong@shphc.org.cn)>, "yiweitangmd@gmail.com" <[yiweitangmd@gmail.com](mailto:yiweitangmd@gmail.com)>, "Martin martin" <[winter999@hotmail.com](mailto:winter999@hotmail.com)>, Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>, "Editorial Office" <[editorial@emi2012.org](mailto:editorial@emi2012.org)>  
**Subject:** Re: EMI 12/15 Lunch Meeting

Ok, thank you.

Get [Outlook for iOS](#)

---

**From:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Sent:** Monday, December 16, 2019 4:40:20 PM  
**To:** Tang, Yi-Wei <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>  
**Cc:** Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>; wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>; yuanzhenghong <[yuanzhenghong@shphc.org.cn](mailto:yuanzhenghong@shphc.org.cn)>; [yiweitangmd@gmail.com](mailto:yiweitangmd@gmail.com) <[yiweitangmd@gmail.com](mailto:yiweitangmd@gmail.com)>; Martin martin <[winter999@hotmail.com](mailto:winter999@hotmail.com)>; Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>; Editorial Office <[editorial@emi2012.org](mailto:editorial@emi2012.org)>  
**Subject:** Re: EMI 12/15 Lunch Meeting

Hi YiWei

I am about to board the flight and hope to give you a quick reply.

We should not use the read # as the key or only factor for selection as it will never be fair to all the papers even we give more time or pick any cut-off date. We can include it as a reference but we need to read the whole list to select based

on the significance of papers as how each of us sees them differently. Otherwise we can just use the read # and will not need the input from this group.

One example is that the top two most read papers in 2019 are from the same group on the same topic. I don't think we should select both, probably only select the full article one, not the short Letter.

We can not include 2018 papers as T&F is funding this award thus I think we should select from 2019.

So please pick up 4 top papers based on your scientific judgement, with the read# as a reference. Using the voting form min yang prepared.

Thanks.

Shan

Sent from my iPhone

On Dec 16, 2019, at 9:55 AM, Tang, Yi-Wei <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)> wrote:

It was so nice to meet most of you yesterday.

Shan, Min, I have a question about the \*2019 EMI Publication (views) which was attached with the voting form/table. I think it is very important to indicate the publication date in 2019 (to add into the "status" column?): the paper published earlier in the year surely had more "views".

Having this said, maybe we should choose 2018 EMI best paper first? The views should be counted one full year time after the paper gets on line. Alternatively, using the data on Table 1.3 of the Press Confidential Publishing Report?

Thank you, Yi-Wei

---

**From:** Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>

**Sent:** Thursday, December 12, 2019 3:09 PM

**To:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>; Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; yuanzhenghong <[yuanzhenghong@shphc.org.cn](mailto:yuanzhenghong@shphc.org.cn)>; Tang, Yi-Wei <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>; [yiweitangmd@gmail.com](mailto:yiweitangmd@gmail.com); Martin martin <[winter999@hotmail.com](mailto:winter999@hotmail.com)>; Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>

**Cc:** Editorial Office <[editorial@emi2012.org](mailto:editorial@emi2012.org)>

**Subject:** EMI 12/15 Lunch Meeting

Dear All EMI Leaders, Min Yu and other EMI colleagues,

Thank you very much for attending EMI 12/15 Lunch Meeting, please check and confirm the following information.

**What:** EMI 12/15 Lunch Meeting

**Where:** Shanghai Min(上海小南国). 5F, Junyaguoji Plaza, No.798, Zhaojiabang Rd, Xuhui District, Shanghai.

**When:** 12:00 noon, December 15, 2019.

**Contact:** Yang Min 13817220577

Should you have any questions, please feel free to let me know.

Thanks and regards,

Min Yang

Emerging Microbes & Infections (EMI) Editorial Office  
4F Fuxing Building  
131 Dongan Road  
Shanghai  
China  
Tel: 86-21-54237992  
E-mail: [editorial@emi2012.org](mailto:editorial@emi2012.org)

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Tuesday, January 28, 2020 8:08 AM  
**To:** KY Yuen  
**Cc:** Lu, Shan; 'Shibo Jiang (姜世勃)'; 'Yuan Zhenghong 袁正宏'; 'Zhang Wenhong'; 'Yang Min 杨旻'; 'min.yang'; TEMI-peerreview@journals.tandf.co.uk; jaspchan@gmail.com  
**Subject:** Re: RE: EMI first 2019-CoV paper is online!

Congratulation. Hope all are well with you and your group. YMWen

-----Original Messages-----

**From:** "KY Yuen" <kyyuen@hku.hk>  
**Sent Time:** 2020-01-28 20:49:51 (Tuesday)  
**To:** "'Lu, Shan'" <Shan.Lu@umassmed.edu>, "'Shibo Jiang (姜世勃)'" <shibojiang@fudan.edu.cn>, "'Wen Yumei'" <ymwen@shmu.edu.cn>, "'Yuan Zhenghong 袁正宏'" <zhyuan@shmu.edu.cn>, "'Zhang Wenhong'" <zhangwenhong@fudan.edu.cn>  
**Cc:** "'Yang Min 杨旻'" <minyang0216@163.com>, "'min.yang'" <min.yang@emi2012.org>, TEMI-peerreview@journals.tandf.co.uk, jaspchan@gmail.com  
**Subject:** RE: EMI first 2019-CoV paper is online!

Dear Professor Lu,

We are very glad to publish in EMI and wish that this baby nurtured by you, Professor Shibo Jiang and Professor Wen will continue to flourish.

Warm regards.

KY

---

**From:** Lu, Shan [mailto:Shan.Lu@umassmed.edu]  
**Sent:** Tuesday, January 28, 2020 8:48 PM  
**To:** KY Yuen; 'Shibo Jiang (姜世勃)'; 'Wen Yumei'; 'Yuan Zhenghong 袁正宏'; 'Zhang Wenhong'  
**Cc:** 'Yang Min 杨旻'; 'min.yang'; TEMI-peerreview@journals.tandf.co.uk; jaspchan@gmail.com  
**Subject:** RE:EMI first 2019-CoV paper is online!

Dear Prof Yuen,

Congratulations!

While there are several papers published on this new virus, I believe that yours is the first high quality, strong science based report about this concerning pathogen.

Through this process, EMI also learned a lot on how to publish an important paper timely.

Shan

---

**From:** KY Yuen <kyyuen@hku.hk>  
**Sent:** Tuesday, January 21, 2020 9:57 PM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>; 'Shibo Jiang (姜世勃)' <shibojiang@fudan.edu.cn>; 'Wen Yumei' <ymwen@shmu.edu.cn>; 'Yuan Zhenghong 袁正宏' <zhyuan@shmu.edu.cn>; 'Zhang Wenhong' <zhangwenhong@fudan.edu.cn>  
**Cc:** 'Yang Min 杨旻' <minyang0216@163.com>; 'min.yang' <min.yang@emi2012.org>; TEMI-peerreview@journals.tandf.co.uk; jaspchan@gmail.com  
**Subject:** RE: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Dear Professor,

Thank you for your very clear explanation.

We will try our best to return the galley proof once we got it.

And wish EMI the best.

KY

---

**From:** Lu, Shan [<mailto:Shan.Lu@umassmed.edu>]  
**Sent:** Wednesday, January 22, 2020 10:52 AM  
**To:** Shibo Jiang (姜世勃); Wen Yumei; Yuan Zhenghong 袁正宏; Zhang Wenhong  
**Cc:** Yang Min 杨旻; min.yang; Yuen KY; [TEMI-peerreview@journals.tandf.co.uk](mailto:TEMI-peerreview@journals.tandf.co.uk)  
**Subject:** RE: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Hi, Shibo,

This is a good time for you and others to learn the process of EMI as part of Taylor & Francis. I will use Prof Yuen's paper as an example.

1. Initial paper QC: any new paper will go through the initial screening process by JEO who is a free service provided by T&F to ensure the timely and highly quality screening on new manuscripts. Regular time: 1-2 days depending on the quality of manuscripts and the exact time of submission into EMI system as the time difference between the authors and JEO may vary.

In the case of Prof Yuen's paper: 0.5 day due to my request to JEO

2. Peer review: from Editor-in-Chief to Review Editor to outside reviewers: usually 2-4 weeks.

In the case of Prof Yuen's paper: 4 hrs.

3. Transfer accepted draft to Production: JEO will do a final check to ensure the quality of paper format etc after multiple revisions (even though there is no revision in Prof Yuen's case) is suitable for production. It can vary between 2 hrs to 2 days (the JEO is located in Southeast Asia and she does not work during the weekends).

In the case of Prof Yuen's paper: 2 days (it is a bad luck because it happened to be weekend at the time of Yuen's paper acceptance.

4. Production: type setting and internal QC review. This is subcontracted by people in India or some other places. Regular time: 2-4 weeks.

In the case of Prof Yuen's paper: estimated to be within 5 days because I requested T&F to put this paper into a fast track production.

5. Proofs to Prof Yuen, authors' final review and resubmitting back to Production, and final uploading online. It varies greatly pending authors' return time, but it is about 2-4 days.

In the case of Prof Yuen's case: unknown yet.

So in summary, EMI has done our best within the system to reduce the regular time of 2 months to about a total of 7 days which I trust is the fastest a big publisher can do. So you are wrong that EMI editorial office staff did not cause any delay on weekends or holidays. It is the big publisher who is trying to control cost and using various subcontractors in developing countries that will generate huge de-centralized operation and delay due to time difference in diverse geographic regions.

I don't believe any big publisher can do better than this, including Nature or NEJM. It is very possible that the small publishers can have a way to cut it shorter as shown in your examples. This is a trade off for big publishers.

At the same time, I never fully believe the so called early publishing or first publishing for such rushing as we are observing. The time difference will only be a few days, and ultimately it is the content of papers, rather than the early date matters. Also we need to be careful about the quality of typesetting in a rush, or the controversy of "stealing data" as in the exact case you just cited which can only generate more negative impact than any real gain.

Regarding to how to cite Prof Yuen's paper, I don't think it is an issue at all. Your paper will be published later than his, so you can still cite his paper (since you know the entire title, authors etc., even EMI issue, year), but leave out the page numbers. You can add the page number when you receive the Proofs of your own paper. As a pro, you should know this better than anyone.

Shan

**From:** Shibo Jiang (姜世勃) <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>

**Sent:** Tuesday, January 21, 2020 12:30 AM

**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; Wen Yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>; Yuan Zhenghong 袁正宏 <[zhyuan@shmu.edu.cn](mailto:zhyuan@shmu.edu.cn)>; Zhang Wenhong <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>

**Cc:** Yang Min 杨旻 <[minyang0216@163.com](mailto:minyang0216@163.com)>; min.yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>; Yuen KY <[kyyuen@hku.hk](mailto:kyyuen@hku.hk)>; [TEMI-peerreview@journals.tandf.co.uk](mailto:TEMI-peerreview@journals.tandf.co.uk)

**Subject:** Re: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Dear Prof. Lu and Wen,

The day before yesterday, Drs. Hong Tang and Pei Hao at Pasteur Institute called me and asked me that they wanted to submit a manuscript about the genetic analysis of 2019-nCoV to EMI and whether we can process their manuscript in the fast track. I told them that EMI had already accepted a paper two days ago and this paper has presented very extensive analysis of this new virus. Therefore, they decided to submit their manuscript to *SCIENCE CHINA Life Sciences* (<https://mp.weixin.qq.com/s/JC0fCMsZlgGPYy4L7xMpTg>) and it was immediately accepted and published online today. However, Prof. Yuen's paper is still not online today. We want to cite Prof. Yuen's paper in our manuscripts, but we cannot get the citation link. Similarly, we submitted a minireview to JMV. It was also immediately accepted and published it online next day.

I understand that the staff of the editorial office of EMI have to take off in the weekends and holidays, but is it possible to ask the publishers to give special consideration for those extremely important papers for publication at fast speed?

Thank you very much for your consideration,

Shibo

-----原始邮件-----

发件人:"Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

发送时间:2020-01-18 19:42:02 (星期六)

收件人: zlschi <[zlschi@wh.iov.cn](mailto:zlschi@wh.iov.cn)>, "Shibo Jiang (姜世勃)" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>



抄送: "Yang Min 杨旻" <[minyang0216@163.com](mailto:minyang0216@163.com)>, "min.yang" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>, "Du, Lanying" <[ldu@nybc.org](mailto:ldu@nybc.org)>

主题: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Dear Prof Shi,

Thanks for your confirmation and EMI is happy to see you as one of the authors.

Best.

Shan

---

**From:** zlshi <[zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn)>

**Sent:** Saturday, January 18, 2020 6:37 AM

**To:** Shibo Jiang (姜世勃) <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>; Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Cc:** Yang Min 杨旻 <[minyang0216@163.com](mailto:minyang0216@163.com)>; min.yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>; Du, Lanying <[ldu@nybc.org](mailto:ldu@nybc.org)>

**Subject:** Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Dear Prof. Jiang,

Thank you for your inviting me as a co-author of this commentary. As the sequence is now open to the public, I'll be happy to be the co-author.

Best regards,

Zhengli,

---

SHI Zhengli, Ph. D

Senior Scientist & Professor

Wuhan Institute of Virology, Chinese Academy of Sciences

44 Xiao Hong Shan

430071 Wuhan, Hubei

China

Tel & Fax: (0086) 27 87197240

Email: [zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn)

---

**From:** [Shibo Jiang \(姜世勃\)](#)

**Date:** 2020-01-18 16:25

**To:** [Lu Shan](#)

**CC:** [Yang Min 杨旻](#); [min.yang](#); [Shi Zhengli](#); [Du Lanying NYBC](#)

**Subject:** Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Dear Prof. Lu,

Per your request, I just submitted the invited Commentary to EMI online (see the attachment). During the submission, I accidentally put in the contact information of Drs. Lu Lu and Shuai Xia (my postdoc), rather than Drs. Shi and Du, into the authors' list. I thus immediately called Min about the possibility of withdrawing and resubmitting the manuscript. Min told me that I would not have to withdraw the manuscript since the authors' information in the manuscript is correct, but I would have to inform Drs. Lu and Xia that they may receive the email from EMI about this manuscript. I informed them already.

I will cite Prof. Yuen's paper once the citation information is available during the proof-reading stage.

Thank you very much for your consideration,

Shibo

-----原始邮件-----

发件人: "Emerging Microbes and Infections" <[onbehalf@manuscriptcentral.com](mailto:onbehalf@manuscriptcentral.com)>

发送时间: 2020-01-18 15:21:06 (星期六)

收件人: [shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)

抄送: [shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)

主题: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

18-Jan-2020

Dear Professor Jiang:

Your manuscript entitled "An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies" has been successfully submitted online and is presently being given full consideration for publication in Emerging Microbes & Infections.

Your manuscript ID is TEMI-2020-0055.

Please mention the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your street address or e-mail address, please log in to ScholarOne Manuscripts at <https://mc.manuscriptcentral.com/temi> and edit your user information as appropriate.

You can also view the status of your manuscript at any time by checking your Author Center after logging in to <https://mc.manuscriptcentral.com/temi>.

Thank you for submitting your manuscript to Emerging Microbes & Infections.

Sincerely,

Emerging Microbes & Infections Editorial Office



---

**From:** Martin martin <winter999@hotmail.com>  
**Sent:** Sunday, June 28, 2020 10:17 PM  
**To:** yuan zhenghong; wen yumei  
**Cc:** Lu, Shan; Tang, Yi-Wei; Wenhua Zhang  
**Subject:** Re: Re: EMI meetings

July 4th daytime will be ok with me.  
xiaodong

---

**From:** yuan zhenghong <zhyuan@shmu.edu.cn>  
**Sent:** Monday, June 29, 2020 2:09 AM  
**To:** wen yumei <ymwen@shmu.edu.cn>  
**Cc:** Lu, Shan <Shan.Lu@umassmed.edu>; Tang, Yi-Wei <yi-wei.tang@cepheid.com>; Wenhua Zhang <wenhua\_zhang@aziacapitalpartners.us>; Martin martin <winter999@hotmail.com>  
**Subject:** Re: Re: EMI meetings

July fourth anytime is ok for me, thank you, Zhenghong

-----原始邮件-----

**发件人:** "wen yumei" <ymwen@shmu.edu.cn>  
**发送时间:** 2020-06-29 09:41:59 (星期一)  
**收件人:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**抄送:** "Tang, Yi-Wei" <yi-wei.tang@cepheid.com>, "Wenhua Zhang" <wenhua\_zhang@aziacapitalpartners.us>, "Yuan Zhenghong 袁正宏" <zhyuan@shmu.edu.cn>, "Martin martin" <winter999@hotmail.com>  
**主题:** Re: EMI meetings

July fourth anytime will be good for me. Wen

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:** 2020-06-29 00:44:54 (Monday)  
**To:** "wen yumei" <ymwen@shmu.edu.cn>, "Tang, Yi-Wei" <yi-wei.tang@cepheid.com>, "Wenhua Zhang" <wenhua\_zhang@aziacapitalpartners.us>, "Yuan Zhenghong 袁正宏" <zhyuan@shmu.edu.cn>  
**Cc:** "Martin martin" <winter999@hotmail.com>  
**Subject:** EMI meetings

Dear Prof Wen and other senior EMI leaders,

I finally may have a little break to organize a few meetings/activities planned for EMI. In addition, I have been personally involved in multiple online conferences so I have a better understanding of such IT issues now. Xiaodong' team is also better prepared for EMI related work after working with me in the last several weeks.

The first one is a virtual meeting as suggested by Prof Wen, among 6 of us to have a high-level meeting. We can plan to have it in one of the weekends.

- a. I propose July 4<sup>th</sup> or July 5 period. Please let me know if you have time or you would like to prefer some other time. Since everyone except me is based in China, I am ok to have a meeting in day time Shanghai.
- b. Objectives: review the work from first half of 2020 and identify the main tasks for the rest of 2020. Also review the plans for additional activities (I will present).

More meetings/activities will be discussed in the coming weeks along with the above meeting.

Please reply by Tuesday 8pm China time if you can be available for a meeting during 7/4-7/5 period.

Best.

Shan

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Monday, June 29, 2020 8:48 PM  
**To:** Tang, Yi-Wei  
**Cc:** Lu, Shan; Wenhua Zhang; Yuan Zhenghong 袁正宏; Martin martin  
**Subject:** Re: Re: EMI meetings

Thank you. IF as expected will be lower than the previous year. Not bad. Wen

-----Original Messages-----

**From:** "Tang, Yi-Wei" <yi-wei.tang@cepheid.com>  
**Sent Time:** 2020-06-29 18:58:56 (Monday)  
**To:** "wen yumei" <ymwen@shmu.edu.cn>, "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Cc:** "Wenhua Zhang" <wenhua\_zhang@aziacapitalpartners.us>, "Yuan Zhenghong 袁正宏" <zhyuan@shmu.edu.cn>, "Martin martin" <winter999@hotmail.com>  
**Subject:** Re: EMI meetings

# 2020 最新 SCI 影响因子查询

Emerging Microbes & Infections

影响因子

2019年: 5.776

2018年: 6.212

RANK

869

扫码进入公众号 ➡

回复「**影响因子**」即可查询





Get [Outlook for iOS](#)

---

**From:** Tang, Yi-Wei  
**Sent:** Monday, June 29, 2020 9:48:53 AM  
**To:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>; Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** Wenhua Zhang <[wenhua\\_zhang@aziacapitalpartners.us](mailto:wenhua_zhang@aziacapitalpartners.us)>; Yuan Zhenghong 袁正宏 <[zhyuan@shmu.edu.cn](mailto:zhyuan@shmu.edu.cn)>; Martin martin <[winter999@hotmail.com](mailto:winter999@hotmail.com)>  
**Subject:** RE: EMI meetings

Ditto.

Shan and Xiaodong, please have a meeting agenda passed to board members ahead of time, so we can prepare for them.

Thank you, Yi-Wei

**From:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
**Sent:** Monday, June 29, 2020 9:42 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** Tang, Yi-Wei <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>; Wenhua Zhang <[wenhua\\_zhang@aziacapitalpartners.us](mailto:wenhua_zhang@aziacapitalpartners.us)>; Yuan Zhenghong 袁正宏 <[zhyuan@shmu.edu.cn](mailto:zhyuan@shmu.edu.cn)>; Martin martin <[winter999@hotmail.com](mailto:winter999@hotmail.com)>  
**Subject:** Re: EMI meetings

July fourth anytime will be good for me. Wen

-----Original Messages-----

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Sent Time:** 2020-06-29 00:44:54 (Monday)  
**To:** "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>, "Tang, Yi-Wei" <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>, "Wenhua Zhang" <[wenhua\\_zhang@aziacapitalpartners.us](mailto:wenhua_zhang@aziacapitalpartners.us)>, "Yuan Zhenghong 袁正宏" <[zhyuan@shmu.edu.cn](mailto:zhyuan@shmu.edu.cn)>  
**Cc:** "Martin martin" <[winter999@hotmail.com](mailto:winter999@hotmail.com)>  
**Subject:** EMI meetings

Dear Prof Wen and other senior EMI leaders,

I finally may have a little break to organize a few meetings/activities planned for EMI. In addition, I have been personally involved in multiple online conferences so I have a better understanding of such IT issues now. Xiaodong' team is also better prepared for EMI related work after working with me in the last several weeks.

The first one is a virtual meeting as suggested by Prof Wen, among 6 of us to have a high-level meeting. We can plan to have it in one of the weekends.

- a. I propose July 4<sup>th</sup> or July 5 period. Please let me know if you have time or you would like to prefer some other time. Since everyone except me is based in China, I am ok to have a meeting in day time Shanghai.
- b. Objectives: review the work from first half of 2020 and identify the main tasks for the rest of 2020. Also review the plans for additional activities (I will present).

More meetings/activities will be discussed in the coming weeks along with the above meeting.

Please reply by Tuesday 8pm China time if you can be available for a meeting during 7/4-7/5 period.

Best.

Shan

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Wednesday, July 1, 2020 9:10 AM  
**To:** Lu, Shan  
**Cc:** Tang, Yi-Wei; Wenhua Zhang; Yuan Zhenghong 袁正宏; Martin martin; Min Yang  
**Subject:** Re: RE: EMI meetings

July 5th is OK with me. Wen

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:** 2020-07-01 10:32:25 (Wednesday)  
**To:** "Tang, Yi-Wei" <yi-wei.tang@cepheid.com>, "wen yumei" <ymwen@shmu.edu.cn>, "Wenhua Zhang" <wenhua\_zhang@aziacapitalpartners.us>, "Yuan Zhenghong 袁正宏" <zhyuan@shmu.edu.cn>, "Martin martin" <winter999@hotmail.com>  
**Cc:** "Min Yang" <min.yang@emi2012.org>  
**Subject:** RE: EMI meetings

Hi, Prof Wen and others,

After getting feedback from everyone, it seems that Yi-Wei will not be available on July 4<sup>th</sup>.

So may I ask if July 5<sup>th</sup> is good for you? And we are thinking 10am China time in the morning of July 5. Please confirm if that is ok. We will use Zoom.

Also here is the draft agenda for our meeting based on discuss I had with Prof Wen today:

Agenda:

1. Prof Wen: welcome and introduction;
2. Shan Lu: EMI work in the first half of 2020 and plans for the next phase
3. Xiaodong Zhang: EMI financial report for 2019 and part of 2020
4. Everyone: Open discussion

Please feel free to add more topics.

Shan

---

**From:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
**Sent:** Sunday, June 28, 2020 9:49 PM  
**To:** wen yumei <ymwen@shmu.edu.cn>; Lu, Shan <Shan.Lu@umassmed.edu>  
**Cc:** Wenhua Zhang <wenhua\_zhang@aziacapitalpartners.us>; Yuan Zhenghong 袁正宏 <zhyuan@shmu.edu.cn>; Martin martin <winter999@hotmail.com>  
**Subject:** RE: EMI meetings

Ditto.

Shan and Xiaodong, please have a meeting agenda passed to board members ahead of time, so we can prepare for them.

Thank you, Yi-Wei

**From:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
**Sent:** Monday, June 29, 2020 9:42 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** Tang, Yi-Wei <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>; Wenhua Zhang <[wenhua\\_zhang@aziacapitalpartners.us](mailto:wenhua_zhang@aziacapitalpartners.us)>; Yuan Zhenghong 袁正宏 <[zhyuan@shmu.edu.cn](mailto:zhyuan@shmu.edu.cn)>; Martin martin <[winter999@hotmail.com](mailto:winter999@hotmail.com)>  
**Subject:** Re: EMI meetings

July fourth anytime will be good for me. Wen

-----Original Messages-----

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Sent Time:** 2020-06-29 00:44:54 (Monday)  
**To:** "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>, "Tang, Yi-Wei" <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>, "Wenhua Zhang" <[wenhua\\_zhang@aziacapitalpartners.us](mailto:wenhua_zhang@aziacapitalpartners.us)>, "Yuan Zhenghong 袁正宏" <[zhyuan@shmu.edu.cn](mailto:zhyuan@shmu.edu.cn)>  
**Cc:** "Martin martin" <[winter999@hotmail.com](mailto:winter999@hotmail.com)>  
**Subject:** EMI meetings

Dear Prof Wen and other senior EMI leaders,

I finally may have a little break to organize a few meetings/activities planned for EMI. In addition, I have been personally involved in multiple online conferences so I have a better understanding of such IT issues now. Xiaodong' team is also better prepared for EMI related work after working with me in the last several weeks.

The first one is a virtual meeting as suggested by Prof Wen, among 6 of us to have a high-level meeting. We can plan to have it in one of the weekends.

- a. I propose July 4<sup>th</sup> or July 5 period. Please let me know if you have time or you would like to prefer some other time. Since everyone except me is based in China, I am ok to have a meeting in day time Shanghai.
- b. Objectives: review the work from first half of 2020 and identify the main tasks for the rest of 2020. Also review the plans for additional activities (I will present).

More meetings/activities will be discussed in the coming weeks along with the above meeting.

Please reply by Tuesday 8pm China time if you can be available for a meeting during 7/4-7/5 period.

Best.

Shan

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Thursday, February 20, 2020 9:49 PM  
**To:** Lu, Shan  
**Cc:** Tang, Yi-Wei; Yuan Zhenghong 袁正宏; Martin martin; zhangwenhong  
**Subject:** Re: RE: EMI SARS2 related papers

This is a critical time for EMI to show its efficiency and aim for launching this journal. This will indeed help the developing countries for alert of this viral disease.

Hope we will keep on to make a record.

Thank all.

Just to make a note, the cc address of the previous mail for Zhangwenhong was wrong. Please correct. YM Wen

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>

**Sent Time:** 2020-02-21 10:38:48 (Friday)

**To:** "Tang, Yi-Wei" <yi-wei.tang@cepheid.com>, "wen yumei" <ymwen@shmu.edu.cn>, "Wenhua Zhang" <wenhua\_zhang@aziacapitalpartners.us>, "Yuan Zhenghong 袁正宏" <zhyuan@shmu.edu.cn>, "Martin martin" <winter999@hotmail.com>

**Cc:**

**Subject:** RE: EMI SARS2 related papers

Hi, Yi-wei,

I don't have any details yet. But it is a major and important step. ASM journals as you know well, can put the accepted papers online quickly. It is mainly the online hardware work. I was not sure if T&F is able to put some big commitment to do it. But it looks like they are going to do right away. I will keep you and everyone posted.

Looking forward to your lab diagnostic paper. This time, we completely beat EID. If there is no EMI, many papers will go to EID.

Shan

---

**From:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>

**Sent:** Thursday, February 20, 2020 9:25 PM

**To:** Lu, Shan <Shan.Lu@umassmed.edu>; wen yumei <ymwen@shmu.edu.cn>; Wenhua Zhang <wenhua\_zhang@aziacapitalpartners.us>; Yuan Zhenghong 袁正宏 <zhyuan@shmu.edu.cn>; Martin martin <winter999@hotmail.com>

**Subject:** RE: EMI SARS2 related papers

---

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Wednesday, January 8, 2020 10:38 PM  
**To:** Min Yang  
**Cc:** Lu, Shan; Emily  
**Subject:** Re: RE: EMI special issue on Emerging CoV

Hi Shan,

Can we invite Prof. Qiliang Cai or Tianlei Ying or Rong Zhang as a GE for this special issue? We can meet together convincingly to discuss the related topics often. Although many senior experts in this field may agree to act as the GE for this special issue, they may not be willing to handle many manuscripts by him/herself. I do have a concern that there will be many manuscripts to be submitted to EMI for this special issue very soon. I may not have enough time to deal with the authors and their manuscripts.

Shibo

-----Original Messages-----

**From:** "Min Yang" <min.yang@emi2012.org>  
**Sent Time:** 2020-01-09 11:12:25 (Thursday)  
**To:** "Lu, Shan" <Shan.Lu@umassmed.edu>, "'Shibo Jiang (姜世勃)'" <shibojiang@fudan.edu.cn>  
**Cc:** Emily <editorial2@emi2012.org>  
**Subject:** RE: EMI special issue on Emerging CoV

Ok, I will generate the list asap.

Thank you,

Min

---

**From:** Lu, Shan  
**Sent:** Wednesday, January 8, 2020 9:54 PM  
**To:** 'Shibo Jiang (姜世勃)' <shibojiang@fudan.edu.cn>  
**Cc:** Min Yang <min.yang@emi2012.org>; Emily <editorial2@emi2012.org>  
**Subject:** RE: EMI special issue on Emerging CoV

I got the feedback from Dr. Shi. She thanks my invitation but stated that this may not be a good time for her to accept our invitation. So you can be the sole GE at this point. Once we established it, we can find another GE.

On the title, I think yours is too much like a "political statement". I think we can make it simple and scientific. How about **"Emerging and Re-emerging Coronaviruses"**?

Next, please draft an overall introduction of this special issue.

Min Yang: please go through past EMI papers and find all corona viruses related papers and generate a list so they can be included in this special issue. Min Yu may help to see if there is any easy way to identify such papers. With a first rough list, Prof Jiang can suggest more key words to identify such EMI papers.

Shan

**From:** Shibo Jiang (姜世勃) <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>  
**Sent:** Tuesday, January 7, 2020 4:43 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** 'Min Yang' <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>; Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>  
**Subject:** Re: EMI special issue on Emerging CoV

Thanks, Shan.

I will work together with Min Yu and Min Yang, under your guidance, on this special issue.

It is a good idea to include all manuscripts related to the emerging CoVs in this special issue. I suggest to change the title to **"Combating the pathogenic emerging and re-emerging coronaviruses"** (I include "Re-emerging CoV" because we cannot exclude the possibility of SARS epidemic in the future).

I will draft a short description of this special issue.

Please send an invitation to Dr. Zhengli Shi as soon as possible. If she agrees, I will discuss with her about the list of potential authors and topics and we should sent out invitation letters together.

Best,

Shibo

-----Original Messages-----

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Sent Time:** 2020-01-07 14:31:54 (Tuesday)  
**To:** "'Shibo Jiang (姜世勃)'" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>  
**Cc:** "'Min Yang'" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>, Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>  
**Subject:** EMI special issue on Emerging CoV

Hi, Shibo,

Here I am connecting you to Min Yu and Min Yang of EMI editorial office on the set up of a new special issue.



First, you will serve as the guest editor (before the 2<sup>nd</sup> person is finalized).

Second, we need to define what is the scope of this special issue. I don't think we should make this one for the pending Wuhan pathogen. The emerging CoV itself is interesting and has enough papers for us to set up a special issue.

Third, based on the decision of above, we can name the title of special issue.

Fourth, you then need to draft a short description of this special issue (using other EMI one as the example but the descriptions for some of them are not very good, but the overall length can be used as a template).

After the above are done, we can draft together an invitation letter and develop a list of potential experts who may contribute to this special issue. Min Yu will work on this with us.

At the same time, Min Yang will work with you to identify those published EMI papers related to this topic and pull them into this special issue now (as part of the process to build this special issue).

Best.

Shan

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Monday, January 11, 2021 4:27 AM  
**To:** Lu, Shan  
**Cc:** zhangwenhong; Winter999; 'Min Yang 杨旻'; xinyi  
**Subject:** Re: RE: EMI symposium

Congratulation for the success, and thanks to everyone' YM Wen

-----原始邮件-----

发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>

发送时间: 2021-01-10 23:41:55 (星期日)

收件人: "wen yumei" <ymwen@shmu.edu.cn>

抄送: zhangwenhong <zhangwenhong@fudan.edu.cn>, Winter999 <Winter999@hotmail.com>, "'Min Yang 杨旻'" <min.yang@emi2012.org>, xinyi <1563993396@qq.com>

主题: RE: EMI symposium

Dear Prof Wen,

EMI Symposium was launched this morning China time. It was a big success with over 1000 people attending while we only did minimal marketing. All six speakers gave very high quality presentations.

Thank you so much for your great support and your opening speech was well done and fitted the symposium very well.

Through this activity, EMI learned a lot how to run an activity with both domestic and international audience which will help us with more conferences and our planned virtual journal clubs.

We also established the EMI channel at YouTube which you can access at [EMI YouTube Channel](#). It may not work to use regular online access from China. Min can help you to arrange VPN for this. But you can forward the link to your friends internationally. Just one note: for this time, only Prof KY Yuen's talk is in English. We will add more English based content there soon.

Best.

Shan

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Monday, January 4, 2021 10:29 PM  
**To:** Lu, Shan  
**Cc:** zhangwenhong  
**Subject:** Re: Re: EMI symposium poster  
**Attachments:** EMI Symposium-2021-wen.pptx

Attached is my PPT which was recorded this morning. For your ref. Wen

-----原始邮件-----

发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>

发送时间: 2021-01-02 12:55:32 (星期六)

收件人: "wen yumei" <ymwen@shmu.edu.cn>

抄送:

主题: Re: EMI symposium poster

Yes, I have already informed T&F last week. They will work with us on symposiums and the virtual journal club programs.

Sent from my iPhone

On Jan 1, 2021, at 8:52 PM, wen yumei <ymwen@shmu.edu.cn> wrote:

I think this will be a very good platform to communicate with scientists and organizations abroad. We can invite institutes or organizations to contact us for collaborating symposium with our journal in the future. To link a journal with a series of symposia will be something new. Maybe T&F will be interested to support such an attempt.

Anyway, I will use PPT in English and talk in Chinese. YM

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>

**Sent Time:** 2021-01-02 09:12:51 (Saturday)

**To:** "wen yumei" <ymwen@shmu.edu.cn>, xinyi <1563993396@qq.com>

**Cc:** zhangwenhong <zhangwenhong@fudan.edu.cn>, Winter999 <Winter999@hotmail.com>,

"Min &nbsp;Yang &nbsp;&nbsp;杨旻" <min.yang@emi2012.org>, "袁正宏" <Zhyuan@shmu.edu.cn>,

"YiWei Tang" <yiweitangmd@gmail.com>

**Subject:** RE: EMI symposium poster

Prof Wen,

You raised a lot of good questions. At this point, it is run by Xiaodong's team and EMI is only supporting in content (invited speakers). I had similar questions and had multiple discussions with their team. Here is a summary:

- This particular symposium will be mainly in Chinese (from all the speakers except Prof KY Yuan), and the audience is mainly targeted to China's audience. Xiaodong's team has more experience in China's market. Doing internationally will require a different set of tech skills and follow the control of China's regulations.
- There was a poster in English when I drafted. But because the content now is only in Chinese so we will not expect to extract non-Chinese language audience.
- At the same time, it was planned to run it by YouTube so it can be available outside China and may be translated into English.
- There is bar-code (二维码) on the flyer and Chinese audience now are very familiar with this system to press that and join the program. It can be Zoom or other platform as long as they are registered/log in.
- At the same time, we have been discussing to have different versions: one for professional people (which is about 3-4 hours) and other one is for general public (may be edited to fit a shorter time). We are talking how to announce this arrangement and let people select which one to join. Once decided, it will be announced at that time.

Once we learned this time, we can run future Symposiums in English.

Best.

Shan

**From:** wen yumei <ymwen@shmu.edu.cn>

**Sent:** Friday, January 1, 2021 7:36 PM

**To:** xinyi <1563993396@qq.com>

**Cc:** zhangwenhong <zhangwenhong@fudan.edu.cn>; Winter999 <Winter999@hotmail.com>; Lu, Shan <Shan.Lu@umassmed.edu>; Min&nbsp;Yang&nbsp;&nbsp;杨旻 <min.yang@emi2012.org>; 袁正宏 <Zhyuan@shmu.edu.cn>; YiWei Tang <yiweitangmd@gmail.com>

**Subject:** Re: EMI symposium poster

**Importance:** High

I think we should make a poster in English, and can this symposium be open through Zoom or other webs for abroad? How can the public get access to this symposium? Wen

-----Original Messages-----

**From:** xinyi <[1563993396@qq.com](mailto:1563993396@qq.com)>

**Sent Time:** 2020-12-30 12:42:45 (Wednesday)

**To:** "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>

**Cc:** zhangwenhong <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>, Winter999 <[Winter999@hotmail.com](mailto:Winter999@hotmail.com)>, "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>, "Min&nbsp;Yang&nbsp;&nbsp;杨旻" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>

**Subject:** EMI symposium poster

Dear Prof Wen,

The attchment is for your information.

Thanks

Best Regards,

Xinyi

----- 原始邮件 -----

发件人: "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>;

发送时间: 2020年12月28日(星期一) 晚上11:53

收件人: "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>; "xinyi" <[1563993396@qq.com](mailto:1563993396@qq.com)>;

抄送: "zhangwenhong" <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>; "Winter999" <[Winter999@hotmail.com](mailto:Winter999@hotmail.com)>;

主题: RE: 回复: RE: EMI symposium

Yes, it was a draft and was hoping to get your formal version. Now it will be updated.

**From:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>

**Sent:** Monday, December 28, 2020 7:16 AM

**To:** xinyi <[1563993396@qq.com](mailto:1563993396@qq.com)>

**Cc:** zhangwenhong <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>; Winter999 <[Winter999@hotmail.com](mailto:Winter999@hotmail.com)>; Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Subject:** Re: 回复: RE: EMI symposium

Please note, I am from Fudan University, Shanghai Medical College. It was not correctly stated. YM Wen

-----Original Messages-----

**From:**xinyi <[1563993396@qq.com](mailto:1563993396@qq.com)>

**Sent Time:**2020-12-28 11:46:20 (Monday)

**To:** "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>

**Cc:** zhangwenhong <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>, Winter999 <[Winter999@hotmail.com](mailto:Winter999@hotmail.com)>, "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Subject:** 回复: RE: EMI symposium

Prof. Wen,

Attachment is EMI symposium program, please review.

Thanks.

Best Regards,

Xinyi

----- 原始邮件 -----

发件人: "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>;

发送时间: 2020年12月24日(星期四) 晚上9:15

收件人: "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>;

抄送: "zhangwenhong" <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>; "Winter999" <[Winter999@hotmail.com](mailto:Winter999@hotmail.com)>; "xinyi" <[1563993396@qq.com](mailto:1563993396@qq.com)>;

主题: RE: EMI symposium

Thanks, Prof Wen.

Xinyi from Xiaodong's group will follow up with you to arrange the recording of your opening remarks (no more than 5 min). We will send you the official program soon for your ref.

Also, please let us know if you have a photo that we can use.

Best.

Shan

**From:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
**Sent:** Thursday, December 24, 2020 1:34 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** Re: EMI symposium

Very good suggestion. I like it. YM Wen

Beisdes, please ask min Yang to send out seaseons greetings to our oversea editorial board members.. Wen

-----Original Messages-----

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Sent Time:** 2020-12-23 23:58:34 (Wednesday)  
**To:** "M. Yu-Mei Wen" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
**Cc:** zhangwenhong <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>, "袁正宏" <[Zhyuan@shmu.edu.cn](mailto:Zhyuan@shmu.edu.cn)>, zhangwenhong <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>, "Tang, Yi-Wei" <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>, Winter999 <[Winter999@hotmail.com](mailto:Winter999@hotmail.com)>  
**Subject:** EMI symposium

Dear Prof Wen and others,

Wenhong and Xiaodong approached me last week about their plan to organize a new year symposium by their group, and suggested to work with EMI together.

I think this is a good idea since we have been thinking organizing an EMI conference for a few years but never make it. This can be a good start with the online conference.

After further discussion with Wenhong and Xiaodong, we prepared a draft invitation to potential speakers (see attached). It is scheduled on Jan 10 to give a summary and future outlook of COVID-19.



It will be a small group of leading experts (about 6 people or so) and their talks will be pre-recorded. Then we can put them together as one full symposium. Prof Wen should give a short opening remark to start the symposium.

We are reaching out to potential speakers. Once we have the responses, a formal program can be prepared.

Please let me, Wenhong and Xiaodong know your advice and comment so we can finalize the plan.

Thanks.

Shan

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Friday, December 25, 2020 6:51 AM  
**To:** Lu, Shan  
**Subject:** Re: RE: EMI symposium  
**Attachments:** wen-photo.jpg

I will wait for the agenda. Attached is a photo for the symposium. Wen

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:** 2020-12-24 21:15:36 (Thursday)  
**To:** "wen yumei" <ymwen@shmu.edu.cn>  
**Cc:** zhangwenhong <zhangwenhong@fudan.edu.cn>, Winter999 <Winter999@hotmail.com>, xinyi <1563993396@qq.com>  
**Subject:** RE: EMI symposium

Thanks, Prof Wen.

Xinyi from Xiaodong's group will follow up with you to arrange the recording of your opening remarks (no more than 5 min). We will send you the official program soon for your ref.

Also, please let us know if you have a photo that we can use.

Best.

Shan

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Thursday, December 24, 2020 1:34 AM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Subject:** Re: EMI symposium

Very good suggestion. I like it. YM Wen

Beisdes, please ask min Yang to send out seasons greetings to our oversea editorial board members.. Wen

-----Original Messages-----

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Sent Time:** 2020-12-23 23:58:34 (Wednesday)

**To:** "M. Yu-Mei Wen ([ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn))" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>

**Cc:** zhangwenhong <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>, "袁正宏" <[Zhyuan@shmu.edu.cn](mailto:Zhyuan@shmu.edu.cn)>, zhangwenhong <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>, "Tang, Yi-Wei" <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>, Winter999 <[Winter999@hotmail.com](mailto:Winter999@hotmail.com)>

**Subject:** EMI symposium

Dear Prof Wen and others,

Wenhong and Xiaodong approached me last week about their plan to organize a new year symposium by their group, and suggested to work with EMI together.

I think this is a good idea since we have been thinking organizing an EMI conference for a few years but never make it. This can be a good start with the online conference.

After further discussion with Wenhong and Xiaodong, we prepared a draft invitation to potential speakers (see attached). It is scheduled on Jan 10 to give a summary and future outlook of COVID-19.

It will be a small group of leading experts (about 6 people or so) and their talks will be pre-recorded. Then we can put them together as one full symposium. Prof Wen should give a short opening remark to start the symposium.

We are reaching out to potential speakers. Once we have the responses, a formal program can be prepared.

Please let me, Wenhong and Xiaodong know your advice and comment so we can finalize the plan.

Thanks.

Shan



---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Tuesday, September 17, 2019 9:23 PM  
**To:** Lu, Shan  
**Cc:** Martin martin  
**Subject:** Re: RE: EMI update

Thanks to xiaodong. A good candidate, for you to consider. YMWen

-----原始邮件-----

发件人:"Lu, Shan" <Shan.Lu@umassmed.edu>  
发送时间:2019-09-16 19:46:25 (星期一)  
收件人: "Martin martin" <winter999@hotmail.com>, "wen yumei" <ymwen@shmu.edu.cn>  
抄送:  
主题: RE: EMI update

Thanks, Xiaodong.

Here is her Bio.

Shan

---

**From:** Martin martin [mailto:winter999@hotmail.com]  
**Sent:** Monday, September 16, 2019 3:36 AM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>; wen yumei <ymwen@shmu.edu.cn>  
**Subject:** Re: EMI update

Hi Shan,

It seems an excellent solution for the EMI, I met her last time and found her a smart girl.

let us work out her payment when after the decision will be made.

Sorry, I am not available on 27/9 morning cause I will be engaged in an another meeting.

Xiaodong

---

**From:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Sent:** Sunday, September 15, 2019 2:12 PM  
**To:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>; Martin martin <[winter999@hotmail.com](mailto:winter999@hotmail.com)>  
**Subject:** EMI update

Dear Prof Wen and Xiaodong,

I would like to let you know that we may have a good solution in search of EMI Editorial Staff.

Yu, Min (last name Yu, see her contact at the bottom of this email) is the currently assigned Managing Editor from T&F to EMI (Xiaodong met her in June during our meeting). Due to the global reorganization of T&F journals, the biomedical journals will be grouped together and managed by a group head based in New York. This will happen later this year. While this will not affect EMI in our regular operation, it is a good change so EMI's importance will be further highlighted. I plan to talk to the new Biomedical Head when he is available.

Because of this change, Yu Min will no longer work with EMI and assigned to other non-bio journals. She understands that we are looking for an editorial office help and she is interested in working for us on a part time/contractor basis. She told me that it is not a problem for her to still work T&F for other work.

She had undergraduate and maybe some graduate education in biology, and had worked for two different international publishing companies. During the last several months she has worked with EMI, I like her a lot. She is smart and very efficient. She can solve many things we had with T&F quickly. With her inside knowledge about T&F and long time work experience with scientific journal operation, she will be the great choice for us.

I explained to her what kind of work I would expect her to do and she is ok with them. I asked her to send us a copy of her Bio so I can share with you once I receive it.

Please let me know if you have any question and advice. If you approve, I can continue our discussion with her to work out the details including salary etc, and then let Xiaodong to work on the business agreement etc.

\*\*\*\*\*

I will be in China in coming week for a very short visit. I can potentially meet you in the early morning of 9/27, say at 9am, as I will take the noon flight to San Francisco on the same day.

\*\*\*\*\*

Shan

\*\*\*\*\*

**Min Yu**

Managing Editor | Taylor & Francis Asia Pacific



an Informa business

Room 2102-2103 Culture Square | No.59 Jia Zhongguancun St. Beijing 100872 | P.R.China

北京市中关村大街甲59号文化大厦 2102-2103室, 邮编: 100872

**Mobile:** +86 15201162252

[Min.Yu@tandfchina.com](mailto:Min.Yu@tandfchina.com)

\*\*\*\*\*

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Thursday, November 28, 2019 4:28 AM  
**To:** Lu, Shan  
**Cc:** ZhangWenhong; Martin martin; yuan zhenghong; yiweitangmd@gmail.com  
**Subject:** Re: RE: EMI year end gathering

Shan: Thank you for the minute, and your summary. I will attend the meeting Dec 15th, and will discuss with all on these issues. YMW

-----The original message-----

发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>

**Sending time:** 2019-11-27 22:10:20 (Wednesday)

Recipient : ZhangWenhong <zhangwenhong@fudan.edu.cn>

抄送: "Martin martin" <winter999@hotmail.com>, "yuan zhenghong" <zhyuan@shmu.edu.cn>, "yiweitangmd@gmail.com" <yiweitangmd@gmail.com>, "wen yumei" <ymwen@shmu.edu.cn>

Main **topic:** RE: End year the EMI Gathering

Dear Prof Wen and others,

First, thanks to Yi-Wei and Wenhong for your feedback.

I would like to provide some further highlights about EMI so it will get some basic information to you to prepare for our meeting on 12/15, and these will be useful for those who can not attend.

- EMI has been transferred to T&F platform for close to one year, and I would say that the overall outcome is much better than my best estimate, with the following data:
  - o I have not heard a single complaint from authors, EB members or reviewers about our transfer. Our strategy to establish EMI as an independent brand name has been working, not as part of Nature or T&F.
  - o The overall development of EMI is accelerating (see data below)
  - o The communication/support from T&F is much better than what we had with NPG in the previous years.
- Some key data related to EMI in 2019
  - o EMI processed 642 papers in the first 10 months of 2019. The final acceptance rate is 143 papers (24.3%)
  - o The full text downloads through standard EMI site at T&F is 203,144 for the first 10 months. This number to me is shocking! It is almost double of routine well established journals as I was told by T&F experts.

- o While 42.3% downloads are from Asia (including China), the combination of USA/Canada and Europe is 47.2% which indicates that EMI is well recognized beside just China which has been one of the key



- o objectives from the start of EMI.
- o Among the top 10 key downloads (and also by the “10 most read” parameter), 6 papers are from 2019. This is a very good sign to point to the sustainable nature of EMI reputation and to keep the high IF in the coming years.
- o The two papers from 哈兽研 on ASFV and one paper from 文宏 lab on using CRISPR to diagnose TB are among the most read papers.
- o NIH library and US CDC library are two key institutions outside China to download EMI papers indicating the global leading researchers in related areas are paying high level attention to EMI.
- o A special 10-month summary prepared by T&F is attached.
- Interaction with T&F
  - o T&F is treating EMI as a special flagship journal after some initial struggling to find a good arrangement. T&F has recently reorganized their journal line-up and EMI is now part of the Medicine/Health group with its head based in New York-Philadelphia area.
  - o Three levels of T&F managers (portfolio manager responsible for EMI, her director and the group director) paid a special visit to me last week and we had several hours productive discussion). The meeting minutes is attached.
  - o More specific work is planned: the operation of an even more active Editorial Board, a further improved marketing program, and re-activated Special Topics program.
- EMI internal operation
  - o Personnel: we are very fortunate to recruit a part time experienced staff member so we can have a better operation management rather than depending on other volunteers who have their own work.
  - o Finance: EMI is anticipating a very healthy revenue in 2019 and coming years. EMI is stopping the arrangement with original donor to fund EMI employees.
  - o We established a new Email system using Microsoft 365 which is more stable with much powerful functions.
  - o We re-launched EMI's own web site: [www.emi2012.org](http://www.emi2012.org) which will provide a much needed extra and flexible platform to introduce EMI.
- Recruitment of more senior members
  - o In 2019, we added a few leading experts in their specific fields: Friedrich Götz (bacteria), Malik Peiris (flu), Yuping Ran (fungus)
  - o We are working to identify some rare areas that are missing from EMI EB, based on the papers we have received.
- Key next step work
  - o Inviting leading experts for high impact reviews. I have invited several to submit and we need to invite more.
  - o Promote EMI at various international conferences.
  - o Election of best EMI papers in 2019
  - o How to distribute financial revenue in 2020
  - o A possible update on EMI cover

There are more to discuss, and please add anything you may be interested. The above will give us something to start with. Please feel free to provide your feedback before or during our meeting.

Best.

Shan

**From:** ZhangWenhong [mailto:zhangwenhong@fudan.edu.cn]  
**Sent:** Tuesday, November 26, 2019 5:00 PM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Cc:** Martin martin <winter999@hotmail.com>; yuan zhenghong <zhyuan@shmu.edu.cn>; yiweitangmd@gmail.com; wen yumei <ymwen@shmu.edu.cn>  
**Subject:** Re: EMI year end gathering

Thank you Professor Lu for the arrangement! I cannot participate in this meaningful gathering because of my participation in the Standing Committee of the Infectious Disease Branch of the Chinese Academy of Sciences. After the staff is updated, we will continue to maintain support for the editorial staff. 文Hongshang

-----The original message-----

发件人: "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

Sending time : 2019-11-23 09:34:56 (Saturday)

收件人: ZhangWenhong <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>, "Martin martin" <[winter999@hotmail.com](mailto:winter999@hotmail.com)>, "yuan zhenghong" <[zhyuan@shmu.edu.cn](mailto:zhyuan@shmu.edu.cn)>, "yiweitangmd@gmail.com" <[yiweitangmd@gmail.com](mailto:yiweitangmd@gmail.com)>, "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>

CC :

Subject : EMI year end gathering

Dear EMI colleagues,

I have discussed with Prof Wen and Xiaodong to have a gathering for us, plus EMI staff members at the noon time on Dec. 15, Sunday.

The purpose is to meet and review the work of EMI in 2019, after it has been moved to T&F.

In addition, we hired a part time new staff member, Min Yu, in addition to the original editorial staff Min Yang and Jing Wu. Three junior scientists from Hua Shan Hospital will terminate their work for EMI by the end of this year. They will also join us for lunch.

Xiaodong will send out the location and exact time later once we are close to Dec. 15.

Thanks.

3

---

**Page 4**

Shan

--

张文宏 Wenhong Zhang, M.D. & Ph.D. Professor of Medicine Director, Division of Infectious Diseases Huashan Hospital, Fudan University PI, Institute of Biomedical Science, Fudan University 12 M. Wulumuqi Road Shanghai 200040, China  
Phone: (8621)52888123 Fax: (8621)52888714 Email: [zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)



\*\*\*\*\*

**From:** yuan zhenghong <zhyuan@shmu.edu.cn>  
**Sent:** Monday, December 9, 2019 8:58 AM  
**To:** Lu, Shan  
**Cc:** Martin martin; wen yumei; ZhangWenhong; yiweitangmd@gmail.com  
**Subject:** Re: Re: EMI year end gathering

Dear Shan, I am free in the morning and will attend the meeting at noon. However, I have group meeting at 1 pm. See you, Zhenghong

-----The original message-----

发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>

**Sending time:** 2019-12-09 15:57:38 (Monday)

To : "Martin martin" <winter999@hotmail.com>

Cc : "wen yumei" <ymwen@shmu.edu.cn>, ZhangWenhong <zhangwenhong@fudan.edu.cn>, "yuan zhenghong" <zhyuan@shmu.edu.cn>, "yiweitangmd@gmail.com" <yiweitangmd@gmail.com>

Main **topic:** Re: End year the EMI Gathering

I believe here is the list:

Prof Wen, Yi-Wei, you and me.

Min and min, Jing and 3 from Huashan

So it should be 10 people.

I will check with Zhenghong to see if he can join us.

Shan

Sent from my iPhone

On Dec 9, 2019, at 3:18 PM, Martin martin <winter999@hotmail.com> wrote:

Hi, Shan,

For the Sunday gathering, do you have any idea that how many people will attend? I plan to book the restaurant in 小南国(the one near the FENGLIN campus), what do you think?  
Xiaodong

**From:** wen yumei <ymwen@shmu.edu.cn>

**Sent:** Thursday, November 28, 2019 9:28 AM

**To:** Lu, Shan <Shan.Lu@umassmed.edu>

**Cc:** ZhangWenhong <zhangwenhong@fudan.edu.cn>; Martin martin <winter999@hotmail.com>; yuan zhenghong <zhyuan@shmu.edu.cn>; yiweitangmd@gmail.com <yiweitangmd@gmail.com>

**Subject:** Re: RE: EMI year end gathering

Shan: Thank you for the minute, and your summary. I will attend the meeting Dec 15th, and will discuss with all on these issues. YMW

-----The original message-----

发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>

**Sending time:** 2019-11-27 22:10:20 (Wednesday)

Recipient : ZhangWenhong <zhangwenhong@fudan.edu.cn>

抄送: "Martin martin" <winter999@hotmail.com>, "yuan zhenghong" <zhyuan@shmu.edu.cn>, "yiweitangmd@gmail.com" <yiweitangmd@gmail.com>, "wen yumei" <ymwen@shmu.edu.cn>

Main topic: RE: End year the EMI Gathering

Dear Prof Wen and others,

First, thanks to Yi-Wei and Wenhong for your feedback.

I would like to provide some further highlights about EMI so it will get some basic information to you to prepare for our meeting on 12/15, and these will be useful for those who can not attend.

- EMI has been transferred to T&F platform for close to one year, and I would say that the overall outcome is much better than my best estimate, with the following data:
  - o I have not heard a single complaint from authors, EB members or reviewers about our transfer. Our strategy to establish EMI as an independent brand name has been working, not as part of Nature or T&F.
  - o The overall development of EMI is accelerating (see data below)
  - o The communication/support from T&F is much better than what we had with NPG in the previous years.
- Some key data related to EMI in 2019
  - o EMI processed 642 papers in the first 10 months of 2019. The final acceptance rate is 143 papers (24.3%)
  - o The full text downloads through standard EMI site at T&F is 203,144 for the first 10 months. This number to me is shocking! It is almost double of routine well established journals as I was told by T&F experts.
  - o While 42.3% downloads are from Asia (including China), the combination of USA/Canada and Europe is 47.2% which indicates that EMI is well recognized beside just China which has been one of the key objectives from the start of EMI.
  - o Among the top 10 key downloads (and also by the "10 most read" parameter), 6 papers are from 2019. This is a very good sign to point to the sustainable nature of EMI reputation and to keep the high IF in the coming years.
  - o The two papers from 哈兽研 on ASFV and one paper from 文宏lab on using CRISPR to diagnose TB are among the most read papers.
  - o NIH library and US CDC library are two key institutions outside China to download EMI papers indicating the global leading researchers in related areas are paying high level attention to EMI.
  - o A special 10-month summary prepared by T&F is attached.
- Interaction with T&F

2

- o T&F is treating EMI as a special flagship journal after some initial struggling to find a good arrangement. T&F has recently reorganized their journal line-up and EMI is now part of the Medicine/Health group with its head based in New York-Philadelphia area.
- o Three levels of T&F managers (portfolio manager responsible for EMI, her director and the group director) paid a special visit to me last week and we had several hours productive discussion). The meeting minutes is attached.
- o More specific work is planned: the operation of an even more active Editorial Board, a further improved marketing program, and re-activated Special Topics program.
- EMI internal operation
  - o Personnel: we are very fortunate to recruit a part time experienced staff member so we can have a better operation management rather than depending on other volunteers who have their own work.
  - o Finance: EMI is anticipating a very healthy revenue in 2019 and coming years. EMI is stopping the arrangement with original donor to fund EMI employees.
  - o We established a new Email system using Microsoft 365 which is more stable with much powerful functions.

Hi, Shan, For the Sunday gathering, do you have any idea that how many people will attend? I plan to book the restaurant in 小

- o We re-launched EMI's own web site: [www.emi2012.org](http://www.emi2012.org) which will provide a much needed extra and flexible platform to introduce EMI.
- Recruitment of more senior members
  - o In 2019, we added a few leading experts in their specific fields: Friedrich Götz (bacteria), Malik Peiris (flu), Yuping Ran (fungus)
  - o We are working to identify some rare areas that are missing from EMI EB, based on the papers we have received.
- Key next step work
  - o Inviting leading experts for high impact reviews. I have invited several to submit and we need to invite more.
  - o Promote EMI at various international conferences.
  - o Election of best EMI papers in 2019
  - o How to distribute financial revenue in 2020
  - o A possible update on EMI cover

There are more to discuss, and please add anything you may be interested. The above will give us something to start with. Please feel free to provide your feedback before or during our meeting.

Best.

Shan

**From:** ZhangWenhong [mailto:[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)]  
**Sent:** Tuesday, November 26, 2019 5:00 PM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** Martin martin <[winter999@hotmail.com](mailto:winter999@hotmail.com)>; yuan zhenghong <[zhyuan@shmu.edu.cn](mailto:zhyuan@shmu.edu.cn)>; yiweitangmd@gmail.com; wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
**Subject:** Re: EMI year end gathering

3

Page 4

Thank you Professor Lu for the arrangement! I cannot participate in this meaningful gathering because I am in Beijing to participate in the Standing Committee of the Infectious meeting. However, after the editorial staff is updated, we will continue to maintain support for the editorial staff. 文Hongshang

-----The original message-----

发件人: "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
 Sending time : 2019-11-23 09:34:56 (Saturday)  
 收件人: ZhangWenhong <[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)>, "Martin martin" <[winter999@hotmail.com](mailto:winter999@hotmail.com)>, "yuan zhenghong" <[zhyuan@shmu.edu.cn](mailto:zhyuan@shmu.edu.cn)>, "[yiweitangmd@gmail.com](mailto:yiweitangmd@gmail.com)" <[yiweitangmd@gmail.com](mailto:yiweitangmd@gmail.com)>, "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
 CC :  
 Subject : EMI year end gathering

Dear EMI colleagues,

I have discussed with Prof Wen and Xiaodong to have a gathering for us, plus EMI staff members at the noon time on Dec. 15, Sunday.

The purpose is to meet and review the work of EMI in 2019, after it has been moved to T&F.

6/1/2021

Hi, Shan, For the Sunday gathering, do you have any idea that how many people will attend? I plan to book the restaurant in 小

In addition, we hired a part time new staff member, Min Yu, in addition to the original editorial staff  
Min Yang and Jing Wu. Three junior scientists from Hua Shan Hospital will terminate their work for  
EMI by the end of this year. They will also join us for lunch.

Xiaodong will send out the location and exact time later once we are close to Dec. 15.

Thanks.

Shan

--

张文宏 Wenhong Zhang, M.D. & Ph.D. Professor of Medicine Director, Division of Infectious Diseases  
Huashan Hospital, Fudan University PI, Institute of Biomedical Science, Fudan University 12 M.

4

---

**Page 5**

Wulumuqi Road Shanghai 200040, China Phone: (8621)52888123 Fax: (8621)52888714 Email:  
[zhangwenhong@fudan.edu.cn](mailto:zhangwenhong@fudan.edu.cn)





---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Saturday, April 4, 2020 9:56 PM  
**To:** Lu, Shan  
**Cc:** KY Yuen; Editorial Office  
**Subject:** Re: RE: Fast track submission of TEMI-2020-0510 to EMI for your kind consideration

I agree with Shan's comment.

If the mutations were observed from patients or latent infections, it will be necessary to state the origins of these mutations. In addition, have these mutations been found in other coronaviruses? YMW

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:** 2020-04-05 00:51:22 (Sunday)  
**To:** "KY Yuen" <kyyuen@hku.hk>  
**Cc:** "Editorial Office" <editorial@emi2012.org>, "wen yumei" <ymwen@shmu.edu.cn>  
**Subject:** RE: Fast track submission of TEMI-2020-0510 to EMI for your kind consideration

Dear KY,

I was about to write to you for something else which I will still write to you in a separate email later.

Congratulations to you and your colleagues for a long list of important papers published in many leading journals.

I am very interested in this new submission and I will process it quickly. One question to this report: are these variants naturally occurring from infected COVID-19 patients, or generated during cell culture in your lab? Also, I am not sure I understand this phrase "15- 0-bp deletions" in the following sentence in Abstract: "we found a series of variants which contain 15- 0-bp deletions (Del-mut) or point mutations respectively at the S1/S2 junction."

As you may know, EMI has implemented a new system that a newly accepted paper can be published online in about 1 day after its acceptance. It will be in its original preprint format but it offers a significant benefit to authors who can see their research report available to the general scientific community quickly.

Please let your colleague formally submit this report to EMI when it is possible.

Best.

Shan

---

**From:** KY Yuen <kyyuen@hku.hk>  
**Sent:** Saturday, April 4, 2020 6:11 AM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Subject:** Fast track submission of TEMI-2020-0510 to EMI for your kind consideration

Dear Editor Professor Lu,

My team has noticed an interesting phenomenon about a series of attenuated SARS-CoV-2 variants with a deletion or point mutations at the S1/S2 junction.

We believe this finding on a series of deleted mutant variant of SARS-CoV-2 (Del-mut) and point mutation mutants which have lost the polybasic cleavage site in the S1/S2 junction of the spike protein, may be essential for efficient virus replication and transmission in humans.

This finding provides information critical for understanding the properties of SARS-CoV-2 and material useful for research concerning drug screening and vaccine development.

We would be most grateful if you can expedite the review of this important work which should be highly cited.

Warmest regards.  
KY

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Sunday, February 21, 2021 8:47 PM  
**To:** Lu, Shan  
**Subject:** Re: RE: FW: Application for APC waiver or discount

Good.

> -----原始邮件-----

> 发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>

> 发送时间: 2021-02-22 08:29:59 (星期一)

> 收件人: "wen yumei" <ymwen@shmu.edu.cn>

> 抄送:

> 主题: RE: FW: Application for APC waiver or discount

>

> Dear Prof Wen,

>

> Thanks for agreeing with the decision. We can waive those invited by us. But a person can not be too greedy to get his paper pushed to be accepted but not paying a small fee.

>

> I already replied.

>

> Best

>

> Shan

>

> -----Original Message-----

> From: wen yumei <ymwen@shmu.edu.cn>

> Sent: Sunday, February 21, 2021 7:04 PM

> To: Lu, Shan <Shan.Lu@umassmed.edu>

> Subject: Re: FW: Application for APC waiver or discount

>

> I agree it is not fair to waive for his paper. Just tell him it is the

> rule of EMI to waive ONLY excellent papers from developing countries.

> thus, regrettably, his paper cannot be waived for the publication.fee.

> Wen

>

>> -----原始邮件-----

>> 发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>

>> 发送时间: 2021-02-22 06:50:01 (星期一)

>> 收件人: "M. Yu-Mei Wen (ymwen@shmu.edu.cn)" <ymwen@shmu.edu.cn>

>> 抄送:

>> 主题: FW: Application for APC waiver or discount

>>

>> Hi, Prof Wen,

>>

>> I would like to share with you the email I just replied to Jiang, Shibo.

>>

>> He submitted a short commentary with Shao Yimin and another person to promote the life virus challenge for COVID-19 vaccine development. The paper is ok although such idea is not novel and Stanley Plotkin published much better article on this topic last year. I asked Plotkin and others to provide some quick and very useful feedback within only 3 days. And the paper will be accepted when Jiang submits his revised draft.

>>

>> Then he suddenly asked for waiver of publishing fee which is only \$900. I can not believe he does not have money. It is just his personal habit to try to squeeze any benefit whenever he can. Giving him the waive is not fair to many other authors from developing countries. Plus, we just did him a favor to get this paper reviewed and published so soon. I am not sure whether any other high quality journal is so interested in publishing this commentary.

>>

>> I can talk to you over the phone to discuss further.

>>

>> Best.

>>

>> Shan

>>

>> -----Original Message-----

>> From: Lu, Shan

>> Sent: Sunday, February 21, 2021 5:42 PM

>> To: 'Shibo Jiang (姜世勃)' <shibojiang@fudan.edu.cn>

>> Subject: RE: Application for APC waiver or discount

>>

>> Hi, Shibo,

>>

>> Are you kidding me? I was treating your short commentary as a special case due to your past involvement with EMI. Even KY's excellent review will take longer process. I did not expect you will treat us like this.

>>

>> T&F APC waiver is mainly designed for people from poor developing countries so your application will not be approved. You are very famous for being the most successful business person academically and commercially. You and your co-authors are among the top funded scientists in the entire China and yet you can not afford to pay \$900? EMI will have big trouble if an APC wavier is granted to you and your co-author as it will be hard for us to face other authors from much difficult condition than you guys.

>>

>> I thought you told me that you have to quit EMI responsibility because you were quite sick so I am surprised to know you have published too many research articles in the last year. Usually with so many papers, the authors should have more reward with fame and funding.

>>

>> Since the founding of EMI, several of us as the founders have to contribute not only time but also all kinds of resources while we have not personally being paid a single penny for our service. EMI has done multiple special favors to you and your group (such as the urgent publication which led your Gates funding) because you are part of the Fudan group. We would look forward to seeing at least some basic support if not more contribution.

>>

>> Maybe we should consult Prof Wen to see if she thinks you are poor as she may know your situation better than anyone else.

>>

>> Best.

>>

>> Shan

>>

>> -----Original Message-----

> > From: Shibo Jiang (姜世勃) <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>

> > Sent: Sunday, February 21, 2021 7:22 AM

> > To: editorial@emi2012.org; Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

> > Cc: Yang Min 杨旻 <[minyang0216@163.com](mailto:minyang0216@163.com)>

> > Subject: Application for APC waiver or discount

> >

> > Dear Prof. Lu,

> >

> > Because of publishing too many research articles in this budget year, I do not have enough budget left to pay for the APC for publication of our Commentary (ID TEMI-2021-0175) in EMI. Here I am applying for an APC waiver or dis-count. I would appreciate it very much if you could approve my application and provide me an APV waiver or dis-count code before submission of our revised manuscript online.

> >

> > Thank you very much for your consideration,

> >

> > Shibo

> > \*\*\*\*\*

> > Shibo Jiang, M.D.

> > Professor and Director, Institute of Medical Microbiology Key

> > Laboratory of Medical Molecular Virology (MOE/NHC/CAMS) School of

> > Basic Medical Sciences, Fudan University

> > 131 Dong An Road, Fuxing Building, 4th Fl, Rm 413 Xuhui District,

> > Shanghai 200032, China

> > Phone: +86-21-54237673

> > E-mail: [shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)

> > Website:

> > [https://nam10.safelinks.protection.outlook.com/?url=http%3A%2F%2Fmedine.fudan.edu.cn%2Fen%2Fshow.aspx%3Finfo\\_lb%3D27%26flag%3D3%26info\\_i%3D124&amp;data=04%7C01%7Cshan.lu%40umassmed.edu%7C8c5a3dd7228846ae0510d8d6c55736%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C1%7C637495490366801285%7CUnknown%7CTWFpbGZsb3d8eyJWlloiMC4wLjAwMDAiLCJQIjoiV2luMzliLCJlbGkihaWwiLCJXVCi6Mn0%3D%7C3000&amp;sdata=pGASzwErpq%2FDMuPfDyH3WU0dJQYBTZWnw9a2U%3D&amp;reserved=0](https://nam10.safelinks.protection.outlook.com/?url=http%3A%2F%2Fmedine.fudan.edu.cn%2Fen%2Fshow.aspx%3Finfo_lb%3D27%26flag%3D3%26info_i%3D124&amp;data=04%7C01%7Cshan.lu%40umassmed.edu%7C8c5a3dd7228846ae0510d8d6c55736%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C1%7C637495490366801285%7CUnknown%7CTWFpbGZsb3d8eyJWlloiMC4wLjAwMDAiLCJQIjoiV2luMzliLCJlbGkihaWwiLCJXVCi6Mn0%3D%7C3000&amp;sdata=pGASzwErpq%2FDMuPfDyH3WU0dJQYBTZWnw9a2U%3D&amp;reserved=0)

> > Publications:

> > <https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F%3Fterm%3Dshibo%2Bjiang%26sort%3Ddate%26size%3D200&amp;data=04%7C01%7Cshan.lu%40umassmed.edu%7C8c5a3dd7228846ae0510d8d6c55736%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C1%7C637495490366801285%7CUnknown%7CTWFpbGZsb3d8eyJWlloiMC4wLjAwMDAiLCJQIjoiV2luMzliLCJlbGkihaWwiLCJXVCi6Mn0%3D%7C3000&amp;sdata=t6ovlxBFkPaHgGRU3MLey3VpQFI6lk1haWwiLCJXVCi6Mn0%3D%7C3000&amp;sdata=t6ovlxBFkPaHgGRU3MLey3VpQF>

> > O5

```
> > !3ltQoCMWtHZk%2F4%3D&reserved=0
> >
> >
> >
> > > -----原始邮件-----
> > > 发件人: "Emerging Microbes and Infections"
> > > <onbehalf@manuscriptcentral.com>
> > > 发送时间: 2021-02-19 23:02:23 (星期五)
> > > 收件人: 14111010010@fudan.edu.cn, yshao@bjmu.edu.cn,
> > > shibojiang@fudan.edu.cn
> > > 抄送:
> > > 主题: Emerging Microbes & Infections - Decision on Manuscript ID
> > > TEMI-2021-0175
> > >
> > > 19-Feb-2021
> > >
> > > Dear Professor Jiang:
> > >
> > > Your manuscript entitled "Human challenge trials to assess the efficacy of currently approved COVID-19 vaccines
against SARS-CoV-2 variants", which you submitted to Emerging Microbes & Infections, has been reviewed. The
reviewer comments are included at the bottom of this letter.
> > >
> > > The reviews are in general favourable and suggest that, subject to minor revisions, your paper could be suitable for
publication. Please consider these suggestions, and I look forward to receiving your revision.
> > >
> > > When you revise your manuscript please highlight the changes you make in the manuscript by using the track
changes mode in MS Word or by using bold or coloured text.
> > >
> > > In addition, please submit a clean, editable version of your revised paper. These files should be in either Word
(.doc) or LaTeX format. Any figures should be saved as either .ps, .eps, .tif or .jpeg file types.
> > >
> > > To start the revision, please click on the link below:
> > >
> > > *** PLEASE NOTE: This is a two-step process. After clicking on the
> > > link, you will be directed to a webpage to confirm. ***
> > >
> > > https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2F
> > > mc
> > > .m
> > > anuscriptcentral.com%2Ftemi%3FURL_MASK%3De6fbe9bcea3944fca4baf20ae
> > > 84
> > > 87
> > > 3c7&data=04%7C01%7Cshan.lu%40umassmed.edu%7C7ebf278d564248ec09
> > > e6
> > > 08
> > > d8d663588e%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C6374950694
> > > 91
> > > 30
> > > 8875%7CUnknown%7CTWFpbGZsb3d8eyJWljojMC4wLjAwMDAiLCJQIjoiV2luMzliL
> > > CJ
> > > BT
```

>>> il6lk1haWwiLCJXVCI6Mn0%3D%7C1000&data=LcqHwhK1nn%2Bely3o4dokQ

>>> 2p

>>> qk

>>> 2QHbNppscwmcigzfew%3D&reserved=0

>>>

>>> This will direct you to the first page of your revised manuscript. Please enter your responses to the comments made by the reviewer(s) in the space provided. You can use this space to document any changes you made to the original manuscript. Please be as specific as possible in your response to the reviewer(s).

>>>

>>> This link will remain active until you have submitted your revised manuscript. If you begin a revision and intend to finish it at a later time, please note that your draft will appear in the “Revised Manuscripts in Draft” queue in your Author Center.

>>>

>>> IMPORTANT: Your original files are available to you when you upload your revised manuscript. Please delete any redundant files before completing the submission.

>>>

>>> Because we are trying to facilitate timely publication of manuscripts submitted to Emerging Microbes & Infections, your revised manuscript should be uploaded by 21-Mar-2021. If it is not possible for you to submit your revision by this date, we may have to consider your paper as a new submission.

>>>

>>> Once again, thank you for submitting your manuscript to Emerging Microbes & Infections and I look forward to receiving your revision.

>>>

>>> Sincerely,

>>>

>>> Shan Lu

>>> Editor-in-Chief

>>> Emerging Microbes & Infections

>>>

>>>

>>> Review Editor Comments to the Author:

>>>

>>> This is an important topic and we did a fast review with input from some of the leading authorities in this area. Here is the key summary:

>>>

>>> 1. Reviewers in general agree with the authors about the need for human challenges to determine what protection is offered by current vaccines against the new strains.

>>> 2. However, the reviewers felt that the paper needs more discussion about how to do those studies. This paper is more like a public decision debate but not enough scientific and technical details to accomplish such challenge studies.

>>> 3. For example, can you extrapolate from monkey challenges to humans, as the authors suggest?

>>> 4. Does one need to challenge unvaccinated subjects to show infectivity? Do you then challenge current vaccinees with the same dose?

>>> 5. If they are resistant to the dose infectious for seronegatives, do you increase the challenge dose to determine how much current virus they can resist vs. mutant virus?

>>> 6. Is it necessary that the challenges be compared in people with the same titers, or can people with different titers be challenged?

>>> 7. Do we need to measure both IgA and IgG antibodies?

>>>

>>> The point here is that challenge studies must be done with a lot of insight so that the answers obtained are valid. By the way, people with high immunity will resist challenge with the mutants, but people with lower titers will not. So the protection is not a black and white with variants. Rather there is a quantitative range and different variants may be different, and may also depending on the individual vaccines. Therefore a small group of challenge studies may not truly

reflect the population protection efficacy of a vaccine. It is the same idea that a lab based neutralizing assay can not predict the field vaccine protection. The authors need to be very careful not turning the small group challenge study into something like a lab based neutralizing assay.

> >  
> >  
> >  
> >  
> >  
> >  
>  
>  
>  
>  
>



---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Saturday, October 24, 2020 10:16 PM  
**To:** Lu, Shan  
**Subject:** Re: RE: FW: Congratulations - your EMI papers are included in T&F's top ten OA articles of 2020

Ning's disease is stable right now. I donot expect cure, stabe is OK currently. thank you。

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:** 2020-10-25 10:03:04 (Sunday)  
**To:** "wen yumei" <ymwen@shmu.edu.cn>  
**Cc:**  
**Subject:** RE: FW: Congratulations - your EMI papers are included in T&F's top ten OA articles of 2020

Thank your support. It is my job.

Hope things are well with you and Prof Ning.

Best.

Shan

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Saturday, October 24, 2020 9:21 PM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Subject:** Re: FW: Congratulations - your EMI papers are included in T&F's top ten OA articles of 2020

Thank you Shan, for informing all authors. Thank you again for your thoughtfulness, and your contribution to EMI. Wen

-----Original Messages-----

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Sent Time:** 2020-10-25 03:25:03 (Sunday)  
**To:** "Tang, Yi-Wei" <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>, kyyuen <[kyyuen@hku.hk](mailto:kyyuen@hku.hk)>, "石正丽" <[zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn)>, "Liu, Shan-Lu" <[liu.6244@osu.edu](mailto:liu.6244@osu.edu)>, "Naveen Vankadari" <[naveen.vankadari@monash.edu](mailto:naveen.vankadari@monash.edu)>, "Su, Lishan"

<[lishan\\_su@med.unc.edu](mailto:lishan_su@med.unc.edu)>, "[litsh@263.net](mailto:litsh@263.net)" <[litsh@263.net](mailto:litsh@263.net)>, "[peng.zhou@wh.iov.cn](mailto:peng.zhou@wh.iov.cn)" <[peng.zhou@wh.iov.cn](mailto:peng.zhou@wh.iov.cn)>  
**Cc:** "M. Yu-Mei Wen ([ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn))" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>, "Martin martin" <[winter999@hotmail.com](mailto:winter999@hotmail.com)>, "Josaphouitch, Alexa" <[Alexa.Josaphouitch@taylorandfrancis.com](mailto:Alexa.Josaphouitch@taylorandfrancis.com)>, "Qiao, Jessica" <[Jessica.Qiao@tandfchina.com](mailto:Jessica.Qiao@tandfchina.com)>, "Min Yang" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>, "[editorial2@emi2012.org](mailto:editorial2@emi2012.org)" <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>  
**Subject:** FW: Congratulations - your EMI papers are included in T&F's top ten OA articles of 2020

Dear Drs. Zhengli Shi/Peng Zhou, Kwok-Yung Yuen, Lishan Su/Shan-lu Liu, Taisheng Li, Yi-Wei Tang and Naveen Vankadari,

On behalf of Prof Wen and EMI, congratulations!

I assume you have received an email notice from T&F (see one sample below) that one of your EMI papers was included as one of the top 10 Open Access papers from the entire T&F family (over 2700 journals). This is from [a blog post on our Author Services website](#) (click and find the site). Attached is the PDF copy list I produced for your reference.

Your EMI papers are ranked #1, #3, #4, #5, #8 and #10, six out of top ten, for entire 2020 up to this point! This is an incredible achievement to each of you. I believe such numbers of down load read will be ranked very high with any other major publishing houses.

EMI would like to thank you for your great work and contribution to the global health effort in this difficult time with COVID-19 pandemic.

EMI is very grateful to authors like you who have made EMI one of the leading biomedical journals in the world. Your creativity, sensitivity, fact searching and out of box thinking have constantly pushed the frontier of science and medicine. EMI is proud to be part of your great endeavour.

EMI is thinking to create new tools and forums to further promote your research findings so more people can be benefited. In the near future, EMI will launch an "EMI Virtual Journal Club (VJC)" program in which each time, one leading EMI paper will be presented by the original authors online, open to the global scientific community so the authors of scientific papers will be able to have direct communications with their readers. Your papers will be the candidates for our initial launch. More details will be shared with you soon and I would like to invite you to be part of our first group of VJC authors.

Best.

Shan

---

**From:** Bergan, Rachel <[Rachel.Bergan@tandf.co.uk](mailto:Rachel.Bergan@tandf.co.uk)>  
**Sent:** Thursday, October 22, 2020 5:10 PM  
**To:** Tang, Yi-Wei <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>  
**Subject:** Your paper features in T&F's top ten OA articles of 2020

Dear Yi-Wei,

I'm very pleased to let you know that your recent article "Laboratory diagnosis of emerging human coronavirus infections – the state of the art" was one of the most-downloaded open access articles published by Taylor & Francis so far this year.

Many congratulations!

To mark Open Access Week, we have published [a blog post on our Author Services website](#) about the Top 10, including links to the articles, and details of each Altmetric score to reflect the discussion of your article online and in the media.

**This is a great excuse to further highlight your research to your contacts and communities.** We will be promoting the blog post on our social media platforms: [Twitter](#), [LinkedIn](#), and [Facebook](#). You could share our posts/tweets or write your own (please use the same hashtags).

We'll also be featuring the Top 10 in our [Insights newsletter](#), to further reach researchers and the wider academic community.

Please do not hesitate to contact me if you have any further questions or queries.

Kind Regards,

Rachel

Rachel Bergan (she/her)

Communications Coordinator

Taylor & Francis Group

Email: [rachel.bergan@tandf.co.uk](mailto:rachel.bergan@tandf.co.uk)

Tel: +44 (0) 20 755 19259

4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN, UK



**4 skills for  
researchers  
of the future**



Information Classification: General

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Thursday, November 14, 2019 5:14 AM  
**To:** Lu, Shan  
**Subject:** Re: RE: FW: EMI presubmission enquiry

Dec 16th will be fine with me. Wen

-----原始邮件-----

发件人:"Lu, Shan" <Shan.Lu@umassmed.edu>  
发送时间:2019-11-14 09:28:53 (星期四)  
收件人: "wen yumei" <ymwen@shmu.edu.cn>  
抄送:  
主题: RE: FW: EMI presubmission enquiry

Dear Prof Wen,

Yes, I have got Yi-wei's reply that he also agrees to ask this paper to be submitted for peer-review.

By the way, I plan to be in China in early Dec. Dec. 6 -Dec. 16. I can potentially come to meet you on Dec. 9 or Dec. 16. Please let me know which one you prefer. Thanks.

Shan

**From:** wen yumei [mailto:ymwen@shmu.edu.cn]  
**Sent:** Wednesday, November 13, 2019 8:25 PM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>; tangy <tangy@mskcc.org>  
**Subject:** Re: FW: EMI presubmission enquiry

If the mechanism is relevant for development of antifungal strategy, then, that is acceptable. Wen

-----原始邮件-----

发件人:"Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

发送时间:2019-11-13 21:17:22 (星期三)  
收件人: "[tangy@mskcc.org](mailto:tangy@mskcc.org)" <[tangy@mskcc.org](mailto:tangy@mskcc.org)>  
抄送: "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
主题: FW: EMI presubmission enquiry

Hi, Yi-wei,

What do you think about this paper. *Candida albicans* is not an emerging infection. The new mechanism may be interesting but if it is not an emerging infection, how significant it is?

Shan

**From:** Guanghai Huang [<mailto:huanggh@fudan.edu.cn>]  
**Sent:** Wednesday, November 13, 2019 2:51 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** [ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)  
**Subject:** EMI presubmission enquiry

Dear Profs. Lu and Wen,

I am writing to inquire if our manuscript (see the attached file) is fit for the scope of EMI. To our knowledge, this is the first study to uncover the genetic regulatory mechanism of mating projection development in the major human fungal pathogen *Candida albicans*. This biology process is important for sexual reproduction in *C. albicans* and is thus important for the development of antifungal resistance and the evolution of new traits.

Thank you in advance for your consideration!

Best regards,

Guanghai

Guanghai Huang, Ph.D

State Key Laboratory of Genetic Engineering

School of Life Sciences

Fudan University



---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Tuesday, January 21, 2020 9:16 PM  
**To:** Lu, Shan  
**Subject:** Re: RE: FW: Re: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 #TrackingId:5437168

OK.go ahead with the processing. Wen

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:** 2020-01-22 05:54:41 (Wednesday)  
**To:** "wen yumei" <ymwen@shmu.edu.cn>  
**Cc:**  
**Subject:** RE: FW: Re: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 #TrackingId:5437168

Hi Prof Wen,

Thanks for your feedback. I will share them to authors but they may not have time to revise as they want to get it published soon.

It is a good idea to write a commentary on the immunology aspect of this new virus. But I don't think I have enough knowledge on this as I suspect the cytokine storm is very complicated and it involves multiple cytokines and pathways. Please feel free to write if you are interested, and may include some other junior peoples in your group to assist you.

Best.

Shan

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Monday, January 20, 2020 11:56 PM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Subject:** Re: FW: Re: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 #TrackingId:5437168



I have two comments

1. In addition to study the virological aspects of this new virus, it is also necessary to study the immune responses of this virus infection in patients. To compare the cytokine responses in severe patients and general patients may lead to use of appropriate therapeutics.
2. To develop antigen-antibody diagnostic reagents for this virus will benefit to reveal the sero-epidemiology of this virus, including detection of asymptomatic carriers.

Can you and I write a commentary on the importance of studying the immune aspects of this virus?

For your ref. YM Wen

-----Original Messages-----

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Sent Time:** 2020-01-21 03:40:14 (Tuesday)

**To:** "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>

**Cc:**

**Subject:** FW: Re: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 #TrackingId:5437168

Prof Wen,

Shibo submitted a commentary (which I agreed in this format to him) on the new Wuhan CoV (see enclosed). Do you mind do a quick reading and see if you would like to make any comments to him and any changes needed? You can write these in your reply email to me so I can incorporate in the e-system to him.

Best.

Shan

**From:** Shibo Jiang (姜世勃) <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>

**Sent:** Monday, January 20, 2020 5:40 AM

**To:** [TEMI-peerreview@journals.tandf.co.uk](mailto:TEMI-peerreview@journals.tandf.co.uk)

**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; [zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn); [minyang0216@163.com](mailto:minyang0216@163.com); [min.yang@emi2012.org](mailto:min.yang@emi2012.org); [ldu@nybc.org](mailto:ldu@nybc.org)

**Subject:** Re: Re: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 #TrackingId:5437168

Dear Jorgie.

We have updated the manuscript's information, added line number, and resubmitted it already.

Thank you very much for your help,

Shibo

-----原始邮件-----

发件人:"Shibo Jiang (姜世勃)" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>

发送时间:2020-01-20 17:45:07 (星期一)

收件人: [TEMI-peerreview@journals.tandf.co.uk](mailto:TEMI-peerreview@journals.tandf.co.uk)

抄送: [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu), [zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn), [minyang0216@163.com](mailto:minyang0216@163.com), [min.yang@emi2012.org](mailto:min.yang@emi2012.org), [ldu@nybc.org](mailto:ldu@nybc.org)

主题: Re: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 #TrackingId:5437168

Thanks,Jorgie.

We will update the patients' information and add line number before resubmission tonight.

Shibo

-----原始邮件-----

发件人:TEMI-peerreview@journals.tandf.co.uk

发送时间:2020-01-20 17:03:46 (星期一)

收件人: [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu), [shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)

抄送: [zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn), [minyang0216@163.com](mailto:minyang0216@163.com), [min.yang@emi2012.org](mailto:min.yang@emi2012.org), [ldu@nybc.org](mailto:ldu@nybc.org)

主题: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 #TrackingId:5437168

Dear Prof. Jiang,

Thank you for your email.

This is to kindly let you know that I have now processed your paper and I have noticed that the paper does not contain a line numbering. Having this, I have returned your manuscript in your author centre in order for you to add a line numbering in your main document and make the necessary amendments in your co-authors list.

Rest assured that once received, I will then proceed your paper to Prof. Lu immediately.

Please let me know if you have any questions or concerns.

Kind regards,

**Jorgie Lyn Luna** - Journal Editorial Office  
Taylor & Francis Group  
4 Park Square | Milton Park | Abingdon | Oxon | OX14 4RN UK  
Web: [www.tandfonline.com](http://www.tandfonline.com)

Taylor & Francis is a trading name of Informa UK Limited,  
registered in England under no. 1072954

Emerging Microbes & Infections

---

**From:** Shan.Lu@umassmed.edu  
**Sent:** 18-01-2020 07:21  
**To:** shibojiang@fudan.edu.cn, Shan.Lu@umassmed.edu  
**Cc:** minyang0216@163.com, min.yang@emi2012.org, zlshi@wh.iov.cn, ldu@nybc.org  
**Subject:** RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055

Hi, Shibo,

Thanks for submitting this timely Commentary. At the same time, you need to ensure the two co-authors agree to this draft of paper, especially the agreement from Prof. Shi.

At this stage, JEO who is in charge of the first step QC will need to go through the draft and may contact you with any required formatting revisions. I am copying her here and she may take a little time to process since we are in Weekend now. But you should not write to her directly per T&F rules unless she contacts you.

Dear Jorgie Lyn Luna,

Please see communication with Prof Jiang on this new submission TEMI-2020-0055. What I would like are the following:

- 1) Please conduct a quick QC/format and let this MS moving to my desk asap, if there is no any QC/format issue.
- 2) It is ok to send it back to corresponding author Prof Jiang if there is QC issue right away, and he will process such revisions right away, including the wrong emails from two co-authors. Then please monitor the re-submission and again send it to me asap after your QC check.

Thanks.

Shan

-----Original Message-----

From: Shibo Jiang (姜世勃) <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>

Sent: Saturday, January 18, 2020 3:25 AM

To: Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

Cc: Yang Min 杨旻 <[minyang0216@163.com](mailto:minyang0216@163.com)>; min.yang@emi2012.org; Shi Zhengli <[zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn)>;

Du Lanying\_NYBC <[ldu@nybc.org](mailto:ldu@nybc.org)>

Subject: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Dear Prof. Lu,

Per your request, I just submitted the invited Commentary to EMI online (see the attachment). During the submission, I accidentally put in the contact information of Drs. Lu Lu and Shuai Xia (my postdoc), rather than Drs. Shi and Du, into the authors' list. I thus immediately called Min about the possibility of withdrawing and resubmitting the manuscript. Min told me that I would not have to withdraw the manuscript since the authors' information in the manuscript is correct, but I would have to inform Drs. Lu and Xia that they may receive the email from EMI about this manuscript. I informed them already.

I will cite Prof. Yuen's paper once the citation information is available during the proof-reading stage.

Thank you very much for your consideration,

Shibo

-----原始邮件-----

发件人: "Emerging Microbes and Infections" <[onbehalf@manuscriptcentral.com](mailto:onbehalf@manuscriptcentral.com)>

发送时间: 2020-01-18 15:21:06 (星期六)

收件人: [shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)

抄送: [shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)

主题: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

18-Jan-2020

Dear Professor Jiang:

Your manuscript entitled "An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies" has been successfully submitted online and is presently being given full consideration for publication in Emerging Microbes & Infections.

Your manuscript ID is TEMI-2020-0055.

Please mention the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your street address or e-mail address, please log in to ScholarOne Manuscripts at

<https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fmc.manuscriptcentral.com%2Ftemi&data=02%7C01%7Cshan.lu%40umassmed.edu%7C5bf67dcea80543172df308d79beffa7f%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637149327594484021&sdata=q3fFDQyJZmoHlceFvohL5Yzdf2qO11sHHBts3o6gm3l%3D&reserved=0> and edit your user information as appropriate.

You can also view the status of your manuscript at any time by checking your Author Center after logging in to

<https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fmc.manuscriptcentral.com%2Ftemi&data=02%7C01%7Cshan.lu%40umassmed.edu%7C5bf67dcea80543172df308d79beffa7f%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637149327594484021&sdata=q3fFDQyJZmoHlceFvohL5Yzdf2qO11sHHBts3o6gm3l%3D&reserved=0>.

Thank you for submitting your manuscript to Emerging Microbes & Infections.

Sincerely,



---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Tuesday, January 21, 2020 8:42 PM  
**To:** Lu, Shan  
**Subject:** Re: RE: FW: Re: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 #TrackingId:5437168  
**Attachments:** 建议-新冠病毒--2020-1-18.docx

I am attaching a suggestion to the govenment and NSCF via CAE for your ref. Wen

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:** 2020-01-22 05:54:41 (Wednesday)  
**To:** "wen yumei" <ymwen@shmu.edu.cn>  
**Cc:**  
**Subject:** RE: FW: Re: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 #TrackingId:5437168

Hi Prof Wen,

Thanks for your feedback. I will share them to authors but they may not have time to revise as they want to get it published soon.

It is a good idea to write a commentary on the immunology aspect of this new virus. But I don't think I have enough knowledge on this as I suspect the cytokine storm is very complicated and it involves multiple cytokines and pathways. Please feel free to write if you are interested, and may include some other junior peoples in your group to assist you.

Best.

Shan

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Monday, January 20, 2020 11:56 PM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Subject:** Re: FW: Re: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 #TrackingId:5437168

I have two comments

1. In addition to study the virological aspects of this new virus, it is also necessary to study the immune responses of this virus infection in patients. To compare the cytokine responses in severe patients and general patients may lead to use of appropriate therapeutics.
2. To develop antigen-antibody diagnostic reagents for this virus will benefit to reveal the sero-epidemiology of this virus, including detection of asymptomatic carriers.

Can you and I write a commentary on the importance of studying the immune aspects of this virus?

For your ref. YM Wen

-----Original Messages-----

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Sent Time:** 2020-01-21 03:40:14 (Tuesday)

**To:** "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>

**Cc:**

**Subject:** FW: Re: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 #TrackingId:5437168

Prof Wen,

Shibo submitted a commentary (which I agreed in this format to him) on the new Wuhan CoV (see enclosed). Do you mind do a quick reading and see if you would like to make any comments to him and any changes needed? You can write these in your reply email to me so I can incorporate in the e-system to him.

Best.

Shan

**From:** Shibo Jiang (姜世勃) <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>

**Sent:** Monday, January 20, 2020 5:40 AM

**To:** [TEMI-peerreview@journals.tandf.co.uk](mailto:TEMI-peerreview@journals.tandf.co.uk)

**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; [zishi@wh.iov.cn](mailto:zishi@wh.iov.cn); [minyang0216@163.com](mailto:minyang0216@163.com); [min.yang@emi2012.org](mailto:min.yang@emi2012.org); [ldu@nybc.org](mailto:ldu@nybc.org)

**Subject:** Re: Re: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 #TrackingId:5437168

Dear Jorgie.

We have updated the manuscript's information, added line number, and resubmitted it already.

Thank you very much for your help,

Shibo

-----原始邮件-----

发件人:"Shibo Jiang (姜世勃)" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>

发送时间:2020-01-20 17:45:07 (星期一)

收件人: [TEMI-peerreview@journals.tandf.co.uk](mailto:TEMI-peerreview@journals.tandf.co.uk)

抄送: [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu), [zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn), [minyang0216@163.com](mailto:minyang0216@163.com), [min.yang@emi2012.org](mailto:min.yang@emi2012.org), [ldu@nybc.org](mailto:ldu@nybc.org)

主题: Re: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 #TrackingId:5437168

Thanks,Jorgie.

We will update the patients' information and add line number before resubmission tonight.

Shibo

-----原始邮件-----

发件人:TEMI-peerreview@journals.tandf.co.uk

发送时间:2020-01-20 17:03:46 (星期一)

收件人: [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu), [shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)

抄送: [zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn), [minyang0216@163.com](mailto:minyang0216@163.com), [min.yang@emi2012.org](mailto:min.yang@emi2012.org), [ldu@nybc.org](mailto:ldu@nybc.org)

主题: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 #TrackingId:5437168

Dear Prof. Jiang,

Thank you for your email.

This is to kindly let you know that I have now processed your paper and I have noticed that the paper does not contain a line numbering. Having this, I have returned your manuscript in your author centre in order for you to add a line numbering in your main document and make the necessary amendments in your co-authors list.

Rest assured that once received, I will then proceed your paper to Prof. Lu immediately.



Please let me know if you have any questions or concerns.

Kind regards,

**Jorgie Lyn Luna** - Journal Editorial Office  
Taylor & Francis Group  
4 Park Square | Milton Park | Abingdon | Oxon | OX14 4RN UK  
Web: [www.tandfonline.com](http://www.tandfonline.com)

Taylor & Francis is a trading name of Informa UK Limited,  
registered in England under no. 1072954

Emerging Microbes & Infections

---

**From:** Shan.Lu@umassmed.edu  
**Sent:** 18-01-2020 07:21  
**To:** shibojiang@fudan.edu.cn, Shan.Lu@umassmed.edu  
**Cc:** minyang0216@163.com, min.yang@emi2012.org, zlshi@wh.iov.cn, ldu@nybc.org  
**Subject:** RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055

Hi, Shibo,

Thanks for submitting this timely Commentary. At the same time, you need to ensure the two co-authors agree to this draft of paper, especially the agreement from Prof. Shi.

At this stage, JEO who is in charge of the first step QC will need to go through the draft and may contact you with any required formatting revisions. I am copying her here and she may take a little time to process since we are in Weekend now. But you should not write to her directly per T&F rules unless she contacts you.

Dear Jorgie Lyn Luna,

Please see communication with Prof Jiang on this new submission TEMI-2020-0055. What I would like are the following:

- 1) Please conduct a quick QC/format and let this MS moving to my desk asap, if there is no any QC/format issue.
- 2) It is ok to send it back to corresponding author Prof Jiang if there is QC issue right away, and he will process such revisions right away, including the wrong emails from two co-authors. Then please monitor the re-submission and again send it to me asap after your QC check.

Thanks.

Shan

-----Original Message-----

From: Shibo Jiang (姜世勃) <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>

Sent: Saturday, January 18, 2020 3:25 AM

To: Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

Cc: Yang Min 杨旻 <[minyang0216@163.com](mailto:minyang0216@163.com)>; min.yang@emi2012.org; Shi Zhengli <[zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn)>;

Du Lanying\_NYBC <[ldu@nybc.org](mailto:ldu@nybc.org)>

Subject: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Dear Prof. Lu,

Per your request, I just submitted the invited Commentary to EMI online (see the attachment). During the submission, I accidentally put in the contact information of Drs. Lu Lu and Shuai Xia (my postdoc), rather than Drs. Shi and Du, into the authors' list. I thus immediately called Min about the possibility of withdrawing and resubmitting the manuscript. Min told me that I would not have to withdraw the manuscript since the authors' information in the manuscript is correct, but I would have to inform Drs. Lu and Xia that they may receive the email from EMI about this manuscript. I informed them already.

I will cite Prof. Yuen's paper once the citation information is available during the proof-reading stage.

Thank you very much for your consideration,

Shibo

-----原始邮件-----

发件人: "Emerging Microbes and Infections" <[onbehalf@manuscriptcentral.com](mailto:onbehalf@manuscriptcentral.com)>

发送时间: 2020-01-18 15:21:06 (星期六)

收件人: [shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)

抄送: [shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)

主题: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

18-Jan-2020

Dear Professor Jiang:

Your manuscript entitled "An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies" has been successfully submitted online and is presently being given full consideration for publication in Emerging Microbes & Infections.

Your manuscript ID is TEMI-2020-0055.

Please mention the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your street address or e-mail address, please log in to ScholarOne Manuscripts at

<https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fmc.manuscriptcentral.com%2Ftemi&data=02%7C01%7Cshan.lu%40umassmed.edu%7C5bf67dcea80543172df308d79beffa7f%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637149327594484021&sdata=q3fFDQyJZmoHlceFvohL5Yzdf2qO11sHHBts3o6gm3l%3D&reserved=0> and edit your user information as appropriate.

You can also view the status of your manuscript at any time by checking your Author Center after logging in to

<https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fmc.manuscriptcentral.com%2Ftemi&data=02%7C01%7Cshan.lu%40umassmed.edu%7C5bf67dcea80543172df308d79beffa7f%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637149327594484021&sdata=q3fFDQyJZmoHlceFvohL5Yzdf2qO11sHHBts3o6gm3l%3D&reserved=0>.

Thank you for submitting your manuscript to Emerging Microbes & Infections.

Sincerely,



---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Monday, December 23, 2019 8:12 PM  
**To:** Klenk Hans-Dieter  
**Cc:** Lu, Shan  
**Subject:** Re: Re: Greetings

Hans, As ever, thank you for your help. Yu-mei

> -----原始邮件-----

> 发件人: "Klenk Hans-Dieter" <klenk@staff.uni-marburg.de>

> 发送时间: 2019-12-23 21:11:21 (星期一)

> 收件人: "Lu, Shan" <Shan.Lu@umassmed.edu>

> 抄送: "wen yumei" <ymwen@shmu.edu.cn>

> 主题: Re: Greetings

>

> Dear Yumei and Shan,

>

> I sent Friedrich Goetz an email to get in touch with me. When I have talked to him, I will get in touch with you.

>

> Merry Christmas and Happy New Year

> Hans

>

> Prof. Dr. H. D. Klenk

> Institut für Virologie

> Hans-Meerwein-Str. 2

> 35043 Marburg

> Germany

>

> Tel.: +49 6421 286 6191

> Sek.: +49 6421 286 6254

> Fax: +49 6421 286 8962

> E-Mail: klenk@staff.uni-marburg.de

>

>> Am 23.12.2019 um 12:58 schrieb Lu, Shan <Shan.Lu@umassmed.edu>:

>>

>> Thank you, Prof Wen for informing Hans about this. I will write another email to you and Han based on the last email to Gotz and your both so Hans can connect me with Gotz.

>> Best.

>>

>> Shan

>>

>> -----Original Message-----

>> From: wen yumei [mailto:ymwen@shmu.edu.cn]

>> Sent: Monday, December 23, 2019 6:33 AM

>> To: Klenk <Klenk@staff.uni-marburg.de>

>> Cc: Lu, Shan <Shan.Lu@umassmed.edu>

> > Subject: Greetings

> >

> > Dear Hans: Hope you and your family a merry christmas and happy new year.

> > We have not heard from Gotz, though Shan has sent letters to invite him to join EMI editorial board. Can you hlep us to contact ham? incase he missed the mails. u-me

> >

> >

> >

> >

> >

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Wednesday, January 8, 2020 10:14 PM  
**To:** dyjin  
**Cc:** Lu, Shan  
**Subject:** Re: RE: invitation

Thank you. That will be very timely with the Wuhan new coronavirus outbreak. YM Wen

> -----Original Messages-----

> From: dyjin <dyjin@hku.hk>  
> Sent Time: 2020-01-09 10:57:54 (Thursday)  
> To: "wen yumei" <ymwen@shmu.edu.cn>  
> Cc: "shan.lu@umassmed.edu" <shan.lu@umassmed.edu>  
> Subject: RE: invitation

>  
> Dear Dr. Wen,  
>  
> I can write another review for EMI.  
>  
> Best regards,  
> Dong-Yan

>  
>  
>  
>

> -----Original Message-----

> From: wen yumei <ymwen@shmu.edu.cn>  
> Sent: Thursday, January 9, 2020 10:56 AM  
> To: dyjin <dyjin@hku.hk>  
> Cc: shan.lu@umassmed.edu  
> Subject: invitation

>  
> Dongyan:  
> Based on your previous review published in 2016, on host innate antiviral response and emerging human coronaviruses, would you please write another reivew on the emerging of new or old human coronaviruses in association with host responses for EMI? Thank you for your consideration. YMWen

>  
>  
>  
>  
>

\*\*\*\*\*

**From:** zlshe <zlshe@wh.iov.cn>  
**Sent:** Sunday, February 9, 2020 11:10 PM  
**To:** Shibo Jiang (姜世勃); Du, Lanying  
**Cc:** Lu, Shan; Yang Min 杨旻; min.yang; Shuying Liu  
**Subject:** Re: Re: Jiang et al. EMI 9:1, 275-277

Dear Prof. Jiang,

Thank you for the erratum. I've no further comment.

Sorry again for the error.

Best regards,  
Zhengli,

SHI Zhengli, Ph. D  
Senior Scientist & Professor  
Wuhan Institute of Virology, Chinese Academy of Sciences  
44 Xiao Hong Shan  
430071 Wuhan, Hubei  
China  
Tel & Fax: (0086) 27 87197240  
Email: [zlshe@wh.iov.cn](mailto:zlshe@wh.iov.cn)

**From:** Shibo Jiang (姜世勃)  
**Date:** 2020-02-10 11:44  
**To:** 石Zhengli ; Du Lanying\_NYBC  
**CC:** Lu, Shan ; Yang Min Yang Min ; min.yang@emi2012.org ; 'Liu Shuying'  
**Subject:** Re: RE: RE: Re: Jiang et al. EMI 9:1, 275-277  
Dear Drs. Shi and Du,

I prepared the letter to editor and the updated Figure, including Figure 1B (see the attachment). Please check and modify it if necessary. If you have no change, I will submit it to EMI as soon as possible.

I also attached the original version downloaded online. You can go through it and make correction if it is really necessary.

Thanks,

Shibo

-----The original message-----

From : "Lu, Shan" <Shan.Lu@umassmed.edu>  
Sending time : 2020-02-10 11:18:51 (Monday)

1

To : "Shi Zhengli" <zlshe@wh.iov.cn>  
Cc : "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>, "Yang Min 杨旻"

6/1/2021

Dear Prof. Jiang, Thank you for the erratum. I've no further comment. Sorry again for the error. Best regards, Zhengli, SHI Zheng

<minyang0216@163.com>, "min.yang@emi2012.org" <min.yang@emi2012.org>, "Shuying Liu" <SYL-consulting@outlook.com>

Subject : RE: RE: Re: Jiang et al. EMI 9:1, 275-277

Sounds good. No worries.

So Shibo, please produce a simple erratum along with a new Fig 1 including the revised Fig 1b. Since Prof Shi is going to update her GenBank information, there is no need to mention this episode as I can see. Just mention that you need to update your figure to follow the numbering tradition in SARS field.

I will link you to T&F JEO to see how to submit.

Best.

Shan.

**From:** Shi Zhengli<zlshi@wh.iov.cn>

**Sent:** Sunday, February 9, 2020 10:11 PM

**To:** Lu, Shan <Shan.Lu@umassmed.edu>

**Cc:** Shibo Jiang (姜世博) <shibojiang@fudan.edu.cn>; Yang Min 杨旻<minyang0216@163.com>; min.yang@emi2012.org;'Shuying Liu' <SYL-consulting@outlook.com>

**Subject:** Re: RE: Re: Jiang et al. EMI 9:1, 275-277

Dear Prof. Liu,

I'm very sorry to make this errors. We have requested to update the GenBank information and the sequence annotation will be updated very soon.

My suggestion is to make an erratum.

2

---

**Page 3**

Best regards,

Zhengli,

-----The original message-----

Outgoing Face : "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>



6/1/2021

Dear Prof. Jiang, Thank you for the erratum. I've no further comment. Sorry again for the error. Best regards, Zhengli, SHI Zheng

Sending time : 2020-02-10 01:31:16 (Monday)

To : "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>, "石正丽" <zlshi@wh.iov.cn>

Cc : "Yang Min 杨旻" <minyang0216@163.com>, "min.yang@emi2012.org "

<min.yang@emi2012.org>, "Shuying Liu" <SYL-consulting@outlook.com>

Subject : RE: Re: Jiang et al. EMI 9:1, 275-277

Hi, everyone,

We did further investigation. Here is what we found:

It appears that the sequences initially published at Genbank by Dr. Yongzheng Zhang, and later by others, all used the SARS sequences as the basis (starting site for S and the resulting aa numbering).

At the same time, Prof Shi's group uploaded her group's 2019-nCoV sequences in a different way, based on SARSr-CoV TG13. At least we found the following are involved.

WIV02 (GenBank: MN996527.1)

WIV04 (GenBank: MN996528.1)

WIV05 (GenBank: MN996529.1)

WIV06 (GenBank: MN996530.1)

So, how to treat the EMI paper by Jiang et al. (EMI 9:275-277), there are two possible solutions:

3

---

Page 4

1. Produce an erratum with a revised Fig 1b, which will include the corrected starting point of S, and revised S leader size and the total size of S, along the numbering of S subdomains).

We will select this option if you want to revise your Genbank submissions.

2. Publish another commentary which will describe this situation of different entries in Genbank so there will be no confusion to others in the field.

We will select this option if the sequences submitted by Prof Shi will stay as they are.

I (and EMI) will respect whatever decision will be.

Shan

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>

**Sent:** Sunday, February 9, 2020 8:54 AM

**To:** Shi Zhengli <zlshi@wh.iov.cn>

**Cc:** Lu, Shan <Shan.Lu@umassmed.edu>; Yang Min Yang Min <minyang0216@163.com>;

6/1/2021

Dear Prof. Jiang, Thank you for the erratum. I've no further comment. Sorry again for the error. Best regards, Zhengli, SHI Zheng

[min.yang@emi2012.org](mailto:min.yang@emi2012.org) ; 'Shuying Liu' <[SYL-consulting@outlook.com](mailto:SYL-consulting@outlook.com)>  
**Subject:** Re: Re: Jiang et al. EMI 9:1, 275-277

Thank you Lu and teacher,

Let me modify that picture. We emailed you the revised pictures and text directly, right? What else needs to be done Explain?

Shibo

4

---

## Page 5

-----The original message-----

From : "石正丽" <[zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn)>

Sending time : 2020-02-09 21:46:59 (weekday)

Write Face : "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

Cc : "Shibo Jiang (姜世勃)" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>, "Yang Min 杨旻" <[minyang0216@163.com](mailto:minyang0216@163.com)>, "min.yang@emi2012.org" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>, "Shuying Liu" <[SYL-consulting@outlook.com](mailto:SYL-consulting@outlook.com)>

Subject : Re: Jiang et al. EMI 9:1, 275-277

Master Lu:

I communicated with the student just now. The phylogenetic tree was constructed using the correct S gene sequence. When the sequence was uploaded to GenBank, it was wrong. We need to make corrections on the right.

Hereby explain.

I'm not always sorry for this kind of error.

Zhengli

-----The original message-----

Outgoing Face : "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

Sending time : 2020-02-09 21:15:31 (weekday)

To : "Shibo Jiang (姜世勃)" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>, "Shi Zhengli" <[zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn)>

Cc : "Yang Min 杨旻" <[minyang0216@163.com](mailto:minyang0216@163.com)>, "min.yang@emi2012.org" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>, "Shuying Liu" <[SYL-consulting@outlook.com](mailto:SYL-consulting@outlook.com)>

Subject : Jiang et al. EMI 9:1, 275-277

Hello, teacher!

Two days ago, a colleague in my laboratory discovered that there are two problems with the next chapter of the co-author of you and Shibo: the number of amino acids is wrong. Wrong, the numbering for each functional domain is wrong. Shibo and I mentioned it. Nowadays  
He told you to also talk to him and hope to correct it.

5

---

**Page 6**

DOI: 10.1080/22221751.2020.1723441, An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies.

I welcome you to post a correction erratum. I don't know if it is necessary to modify the diagram, even if it is necessary, I think it is worth it. welcome  
Tell you what you think, and then the EMI editorial department will come to coordinate with T&F on how to issue erratum.

Thank you!

Lu

ps There are 3399 downloads of your papers to read today. Congratulations!

6

-----

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Sunday, February 9, 2020 8:54 AM  
**To:** Shi Zhengli  
**Cc:** Lu, Shan; Yang Min 杨旻; min.yang@emi2012.org; 'Shuying Liu'  
**Subject:** Re: Re: Jiang et al. EMI 9:1, 275-277

Thank you teacher Lu and teacher,

Let me modify that picture. We emailed you the revised pictures and text directly, right? Is there any explanation needed?

Shibo

-----The original message-----

From 人 : "Shi Zhengli" <zlsli@wh.iov.cn>

**Sending time:** 2020-02-09 21:46:59 (Sunday)

To : "Lu, Shan" <Shan.Lu@umassmed.edu>

Cc : "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>, "Yang Min 杨旻" <minyang0216@163.com>, "min.yang@emi2012.org" <min.yang@emi2012.org>, "Shuying Liu" <SYL-consulting@outlook.com>

**Main problem:** Re: the EMI Jiang et Al. 9:.. 1, 275-277

Teacher Lu:

I communicated with the student just now. The phylogenetic tree was constructed using the correct S gene sequence. An error occurred when uploading the sequence to GenBank. We need Correct it.

Hereby explain.

Sorry for this error.

Zhengli

-----The original message-----

From 人 : "Lu, Shan" <Shan.Lu@umassmed.edu>

**Sending time:** 2020-02-09 21:15:31 (Sunday)

To : "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>, "Shi Zhengli" <zlsli@wh.iov.cn>

Cc : "Yang Min 杨旻" <minyang0216@163.com>, "min.yang@emi2012.org" <min.yang@emi2012.org>, "Shuying

Liu" <SYL-consulting@outlook.com>

**Main topic:** Jiang et Al the EMI. 9:.. 1, 275-277

6/1/2021

Thank you, Teacher Lu and Teacher, let me revise the picture. We are emailing you the revised pictures and text directly, yes

Hello, teacher!

Two days ago, a colleague in my laboratory found that the following chapters of you and Shibo's co-authors had two problems: the number of amino acids was incorrect. Because of location positioning (the numbering for each functional domain) error. Shibo and I mentioned it. Today he told you to also talk to him, Hope to correct.

DOI: 10.1080/22221751.2020.1723441, An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies.

I welcome you to post a correction erratum. I don't know if it is necessary to modify the diagram. Even if it is necessary, I think it is worth it. Welcome to tell you what you mean, then the EMI editorial department came to coordinate with T&F on how to publish erratum.

Thank you!

Lu

ps There are 3399 downloads of your papers to read today. Congratulations!

---

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Saturday, February 1, 2020 12:45 AM  
**To:** Lu, Shan  
**Cc:** Min Yang  
**Subject:** Re: RE: Jiang\_Rename 2019-nCoV as PARS-CoV\_2020-2-1

Hi, Shan,

Thank you very much for your prompt reply. I may just submit it to bioRxiv before submitting it to another journal, which may take a long time for review.

Shibo

-----原始邮件-----

发件人:"Lu, Shan" <Shan.Lu@umassmed.edu>  
发送时间:2020-02-01 13:36:22 (星期六)  
收件人: "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>  
抄送: "Min Yang" <min.yang@emi2012.org>  
主题: RE: Jiang\_Rename 2019-nCoV as PARS-CoV\_2020-2-1

Hi, Shibo,

Thanks again for sending another interesting paper to EMI. After much thinking, I suspect WHO will not consider this suggestion if the paper is from EMI. I will support you to submit this paper to Lancet or something like that and it may increase the chance for your idea to be accepted.

Good luck to your paper!

Best.

Shan

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Friday, January 31, 2020 10:44 PM

**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Cc:** Lu Shan\_EMI <shan.lu@emi2012.org>  
**Subject:** Jiang\_Rename 2019-nCoV as PARS-CoV\_2020-2-1

Dear Shan,

After extensive discussion in my group, we strongly believe that the names of "severe acute respiratory infection (SARI)", "novel coronavirus-infected pneumonia (NCIP)", "severe acute respiratory infection coronavirus (SARI-CoV)", "novel coronavirus-infected pneumonia coronavirus (NCIP-CoV)" will be changed to the terms like SARS-CoV and MERS-CoV.

Therefore, we suggest to rename them as "pneumonia-associated respiratory syndrome (PARS) coronavirus (PARS-CoV), to retain equivalent terminology as SARS-CoV and MERS-CoV. We want to submit it to EMI and at the same time to bioRxiv. In this way, this manuscript may be widely cited, so that WHO may accept our suggestion eventually.

I just wonder whether you are interested or not. If not, we will submit it to another journal.

Thank you very much for your consideration,

Shibo

---

**From:** 应天雷 <tlying@fudan.edu.cn>  
**Sent:** Monday, January 27, 2020 7:06 AM  
**To:** Lu, Shan  
**Cc:** 闻老师  
**Subject:** Re: RE: Manuscript submission from Tianlei  
**Attachments:** revised manuscript.pdf

Dear Prof. Lu,

I have submitted the revised manuscript via EMI online submission system. Attached please find the newest version of this manuscript.

As suggested, I have removed a part of the structure analysis in Fig 1d, and added the ELISA result I performed during this weekend in Fig 1e, which also clearly showed that only the antibody CR3022 could recognize 2019-nCoV RBD. I also revised Fig 1f to make it read more clearly. I did not perform Western experiment, because potent monoclonal antibodies typically bind to conformational epitopes instead of linear epitopes, so Western is not suitable for the characterization of these antibodies. Furthermore, both ELISA and BLI experiments confirmed the finding that only CR3022 could potentially bind the new coronavirus.

In this study, we not only identified a potent human monoclonal antibody (CR3022) against 2019-nCoV, but also found that some of the most potent SARS-CoV-specific neutralizing antibodies (e.g., m396, CR3014) that target the ACE2 binding site of SARS-CoV failed to bind 2019-nCoV spike protein, indicating that the difference in the RBD of SARS-CoV and 2019-nCoV has a critical impact for the cross-reactivity of neutralizing antibodies. Therefore, it is still necessary to develop 2019-nCoV-specific monoclonal antibodies and vaccines. We feel that the fast publication of this manuscript would contribute to the understanding of 2019-nCoV and the development of vaccines and therapeutics.

Thanks a lot!

Best wishes  
Tianlei

> -----原始邮件-----

> 发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>

> 发送时间: 2020-01-25 01:27:49 (星期六)

> 收件人: ""应天雷"" <tlying@fudan.edu.cn>, "闻老师" <ymwen@shmu.edu.cn>

> 抄送:

> 主题: RE: Manuscript submission from Tianlei

>

> Hi, Tianlei,

>

> Thanks for your paper. I have taken a quick look and I would like to have some basic ELISA and Western (with good negative controls) in addition to the fancy affinity measurement. You can reduce some structure/sequence analysis data which are included in many similar papers at this point, but you can keep them if you like.

>

> Since T&F QC people is off for the weekend, please add the data I asked during the weekend and re-submit it soon.

>

> Best.



>  
> Shan  
>  
> -----Original Message-----  
> From: 应天雷 <tlying@fudan.edu.cn>  
> Sent: Friday, January 24, 2020 12:20 PM  
> To: Lu, Shan <Shan.Lu@umassmed.edu>; 闻老师 <ymwen@shmu.edu.cn>  
> Subject: Manuscript submission from Tianlei  
>  
> Dear Prof. Lu,  
>  
> We just submitted a manuscript entitled "Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody" (Manuscript ID: TEMI-2020-0062) for your consideration as a letter in EMI. Attached please find the combined file we used for submission. Would be very appreciated if you could handle the manuscript promptly. Thanks a lot!  
>  
> Best wishes  
> Tianlei  
>  
>  
>  
>  
>  
>  
>  
>  
>  
>

\*\*\*\*\*

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Sunday, September 27, 2020 4:49 AM  
**To:** Lu, Shan  
**Subject:** Re: Re: message

OK. Please try to do your best to lessen the negative effect to the corresponding author., but within reasonable ways.  
 NIng is getting worse and worse during the treatment with drug+ antibody. He refused to take food with a poor appetite, and only drinks soup and take some fruit for 10 days. I feel very depressed and worried. I will discuss with his doctor after the long holiday. I feel we should not over treat him and affect his living quality. Wen

> -----Original Messages-----

> From: "Lu, Shan" <Shan.Lu@umassmed.edu> Sent Time: 2020-09-27 04:21:35

> (Sunday)

> To: "wen yumei" <ymwen@shmu.edu.cn>

> Cc:

> Subject: Re: message

>

> Dear Prof Wen,

>

> I could not receive 短信 because I am not in China.

>

> EMI has no control on these two papers as T&F wrote to him directly. To make things more complicated is the involvement of another European (?) person. I thought I copied emails to you but I will review the whole story and put together to you.

>

> Then I can discuss with you by wechat phone call.

>

> Best.

>

> Shan

>

> Sent from my iPhone

>

>> On Sep 26, 2020, at 3:44 PM, wen yumei <ymwen@shmu.edu.cn> wrote:

>>

>> Shan, I have forwarded you a SMS, not WeChat from Department of Microbiology, Zhejiang Medical College · Yan Jie, to me, regarding an article on leptospiral which was accused as repeated use of figures in EMI. I have known this professor for many years, and he was a good scientist. He wrote to show that they designed and did all the experiments, while the student and he did not check the figures carefully.

>> He asked if they can write to the journal and make a revision on errors, instead of withdrawing the article.

>> I have written and asked you about this issue, but have not yet

>> heard from you. Please respond. YMW

>>

>>

6/1/2021

OK. Please try to do your best to lessen the negative effect to the corresponding author., but wihtin reasonable ways. NIng is g

> >  
> >

1

---

**Page 2**



---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Thursday, January 14, 2021 3:12 AM  
**To:** Min Yang  
**Cc:** Lu, Shan; Tang, Yi-Wei; Zhyuan@shmu.edu.cn; zhangwenhong@fudan.edu.cn; Winter999@hotmail.com  
**Subject:** Re: Re: Nomination for 2020 Best EMI papers  
**Attachments:** Nomination List for 2020 Best EMI Papers (2)-.xlsx

See my attached selection. Wen

-----原始邮件-----

发件人:"Min Yang" <min.yang@emi2012.org>

发送时间:2021-01-12 23:33:29 (星期二)

收件人: "wen yumei" <ymwen@shmu.edu.cn>, "Lu, Shan" <Shan.Lu@umassmed.edu>, "Tang, Yi-Wei" <yi-wei.tang@cepheid.com>, "Zhyuan@shmu.edu.cn" <Zhyuan@shmu.edu.cn>, "zhangwenhong@fudan.edu.cn" <zhangwenhong@fudan.edu.cn>, "Winter999@hotmail.com" <Winter999@hotmail.com>

抄送:

主题: Re: Nomination for 2020 Best EMI papers

Dear EMI Leaders,

I have well received the first round of selections with thanks and the final list has been generated as attached. Now we are going to move on to step 2, please vote for the top 4 papers for 2020 Best EMI Papers among the list by numbering them in the excel.

We will be having 4 top papers for 2020: one for first prize, one for 2<sup>nd</sup> prize and two for 3<sup>rd</sup> prize.

If you have any questions or concerns, please feel free to let me know.

Regards,

Min

-----Original Messages-----

**From:** "Min Yang" <min.yang@emi2012.org>

**Sent Time:**2021-01-05 00:00:39 (Tuesday)

**To:** "Lu, Shan" <Shan.Lu@umassmed.edu>, "M. Yu-Mei Wen (ymwen@shmu.edu.cn)" <ymwen@shmu.edu.cn>, zhangwenhong <zhangwenhong@fudan.edu.cn>, "yi-wei.tang@cepheid.com" <yi-wei.tang@cepheid.com>, Winter999 <Winter999@hotmail.com>, "袁正宏" <Zhyuan@shmu.edu.cn>

**Cc:**

**Subject:** Re: Nomination for 2020 Best EMI papers

Dear EMI Leaders,

As mentioned by Prof Lu, attached please find the publication list for 2020.

Please nominate your top papers (at least 5-10) by replying to this email by 11 Jan, 2021.

Meanwhile, please do not hesitate to contact me if you have any questions.

Thanks and regards,

Min Yang

*Emerging Microbes & Infections* (EMI) Editorial Office  
4F Fuxing Building

131 Dongan Road  
Shanghai  
China  
Tel: 86-21-54237992  
E-mail: min.yang@emi2012.org

---

发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>

日期: 2021年1月3日 星期日 上午8:45

收件人: "M. Yu-Mei Wen (ymwen@shmu.edu.cn)" <ymwen@shmu.edu.cn>, zhangwenhong <zhangwenhong@fudan.edu.cn>, "yi-wei.tang@cepheid.com" <yi-wei.tang@cepheid.com>, Winter999 <Winter999@hotmail.com>, 袁正宏 <Zhyuan@shmu.edu.cn>

抄送: Min Yang <min.yang@emi2012.org>

主题: Nomination for 2020 Best EMI papers

Dear Prof Wen and others,

As in last year, we will need to select 4 best papers for 2020. As you may recall, T&F will pay for the cash prize and we can nominate 4 top papers: one for first prize, one for 2<sup>nd</sup> prize and two for 3<sup>rd</sup> prize.

We can continue the same way as in the last year:

Step one: each of us can nominate at least 5 – 10 papers from the list of 2020 EMI papers. This will narrow down the candidates since we published about 300 papers in 2020.

Step two: we each will vote top 4 among nominated list.

Please let me know if you want to do it differently. At the same time, Min will prepare the list and send it to this group by Monday.

Best.

Shan

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Monday, September 14, 2020 7:56 PM  
**To:** Lu, Shan  
**Subject:** Re: RE: Pre-submission inquiry\_Characterization of newly SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster

Thank you. I will reply and ask them to submit through EMI website: [www.tandfonline.com/TEMI](http://www.tandfonline.com/TEMI)

YOu can either call me evening this friday, 18th or sunday 20th. Shoubao does not seem to respond to CD38. I wonder if there are still other treatment. YMWen

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:** 2020-09-14 20:45:12 (Monday)  
**To:** "wen yumei" <ymwen@shmu.edu.cn>  
**Cc:**  
**Subject:** RE: Pre-submission inquiry\_Characterization of newly SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster

Hi, Prof Wen,

I agree. Do you want me to reply, or you will reply. Please ask them to submit through EMI website: [www.tandfonline.com/TEMI](http://www.tandfonline.com/TEMI)

Also, I plan to have a call with you in the near future to go over some recent events if you have time.

Best.

Shan

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Monday, September 14, 2020 5:22 AM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Subject:** Fw: Pre-submission inquiry\_Characterization of newly SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster



Yhough there is no clinical significance,I am inclined to ask them yo submit, to promote genomic studies combined with clinical studies worldwide. . Please comment. Wen

-----Original Messages-----

**From:**antonin.bal@chu-lyon.fr

**Sent Time:**2020-09-14 17:05:58 (Monday)

**To:** [ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn), [editorial@emi2012.org](mailto:editorial@emi2012.org)

**Cc:** [laurence.josset@chu-lyon.fr](mailto:laurence.josset@chu-lyon.fr), [antonin.bal@chu-lyon.fr](mailto:antonin.bal@chu-lyon.fr), [bruno.lina@chu-lyon.fr](mailto:bruno.lina@chu-lyon.fr), [gregory.queromes@univ-lyon1.fr](mailto:gregory.queromes@univ-lyon1.fr), [gregory.destras@chu-lyon.fr](mailto:gregory.destras@chu-lyon.fr)

**Subject:** Pre-submission inquiry\_Characterization of newly SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster

Dear Pr. Wen,

We would like to submit a pre-submission inquiry regarding the suitability of our manuscript entitled “**Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster during routine genomic surveillance, Lyon, France**” for publication in *Emerging Microbes & Infections*, as an Original Article. (bioRxiv: <https://www.biorxiv.org/content/10.1101/2020.08.07.241653v1.full>)

Since February we have sequenced **229 SARS-CoV-2 whole genome** with a metagenomic next-generation sequencing approach as part of the routine surveillance performed at the French National Reference Center for Respiratory Viruses. We detected **two newly discovered frame-shifting deletion variants of the ORF6** (34- and 26-nucleotide deletions). **The 34-nucleotide deletion variant was found in 6 samples** (from 5 patients and **1 health-care worker**) within a cluster of COVID-19 cases from a single geriatric unit at the university hospital of Lyon. Both the presence of the 34-nucleotide deletion variant limited to a hospital unit and the clustering of the corresponding whole genome sequences by phylogeny analysis strongly **suggested a nosocomial transmission between patients**. Interestingly, **prolonged viral excretion of the 34-nucleotide deletion variant was found in a stool sample** 14 days after initial diagnosis for one patient. Furthermore, clinical data revealed **no significant difference in disease severity** between patients harboring the wild-type or the 34-nucleotide ORF6 deletion variant. The in vitro infection of the two deletion variants on primate endothelial kidney cells (BGM) and human lung adenocarcinoma cells (Calu-3) yielded **comparable replication kinetics** with the wild-type strain. In addition, **high viral loads** were found in vivo regardless of the presence or absence of the ORF6 deletion.

Overall, our study highlights **the transmission and replication capacity of two newly described deletion variants in the same ORF6 region**. Given the role of ORF6 in interferon modulation, further characterization, such as mechanistic interactions and interferon monitoring in patients should be performed. By the identification of the first nosocomial cluster harboring a large deletion newly described, **we emphasize the importance of real-time genomic surveillance for the detection of circulating variants and for the investigation of COVID-19 clusters**.

We would be very grateful if you could consider this pre-submission inquiry and look forward to hearing from you.

Yours sincerely,

Laurence Josset, PharmD PhD

Research Assistant Professor

National reference center for respiratory viruses (Pr. Bruno Lina)

University hospital of Lyon, France

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Tuesday, March 24, 2020 8:47 AM  
**To:** Lu, Shan  
**Cc:** zhangwenhong  
**Subject:** Re: RE: Presubmission enquiries

Please help to respond , which I cannot do diplomatically as you. Wen

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:** 2020-03-24 09:17:49 (Tuesday)  
**To:** "wen yumei" <ymwen@shmu.edu.cn>  
**Cc:** zhangwenhong <zhangwenhong@fudan.edu.cn>  
**Subject:** RE: Presubmission enquiries

Hi, Prof Wen,

This paper first reviewed the involvement of cytokines in COVID-19 using published data from China groups, then reviewed the use of metronidazole to control cytokines in various studies, but none of them is in COVID-19. So this is a purely hypothesis paper. The writing is poor. I don't feel much value with this paper.

I am looking forward to learn from Wenhong on his opinion.

Best.

Shan

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Monday, March 23, 2020 8:53 PM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Cc:** zhangwenhong <zhangwenhong@fudan.edu.cn>  
**Subject:** Fw: Presubmission enquiries

Shan and Wenhong:

i am not a clinician, and thus hope you will decide on the quality of this paper. Wen

-----Original Messages-----

**From:** "Dr Fatemeh Heidary" <[drfatemehheidari@yahoo.com](mailto:drfatemehheidari@yahoo.com)>

**Sent Time:** 2020-03-24 08:23:29 (Tuesday)

**To:** "[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>

**Cc:**

**Subject:** Presubmission enquiries

**Dear Prof Yu-Mei Wen**

I am highly interested to submit the attached review article to your valuable Journal.

Prior to official submission, refer to the importance of the COVID-19 outbreak and to save the time, it would be highly appreciated if may let me know the compatibility of the attached manuscript to the scope of your Journal and the possibility of the prompt peer-review process.

In this review, we presented strong immunological evidence to introduce Metronidazole as the supplementary treatment regimen to the COVID-19.

The main contribution of our paper is a better understanding of Metronidazole as the available and cost-effective treatment against COVID-19. In vitro and in vivo studies revealed that Metronidazole decreases the following cytokines including IL8, IL6, IL1B, TNF $\alpha$ , IL12, and IFN $\gamma$ , as well as CRP, and neutrophils count. Interestingly, those parameters are shown to be increased during COVID-19.

We have read and understood your journal's policies on copyright, ethics, etc., and believe that neither the manuscript nor the study violates any of these. Furthermore, it has been uploaded to pre-print server as below:

[https://papers.ssrn.com/sol3/papers.cfm?abstract\\_id=3559020](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3559020)

I hope our work meets your expectations. Thank you for your consideration.

And of course, our best wishes to you, your colleagues and your families in this time of crisis.

Sincerely, Heidary

---

**Fatemeh Heidary** MD, MPH, PhD, FICO, FAAO

PhD in Clinical Immunology

Fellowship in Ocular Pathology

Head of Ophthalmology Division,

Taleghani Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Thursday, June 4, 2020 10:47 PM  
**To:** Lu, Shan  
**Cc:** Min Yang  
**Subject:** Re: RE: Presubmission Inquiry letter

Please add my name as co-editor-chief , because he sent me the letter. Wen

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:** 2020-06-05 10:18:04 (Friday)  
**To:** "nguyenhainam@kuhp.kyoto-u.ac.jp" <nguyenhainam@kuhp.kyoto-u.ac.jp>  
**Cc:** "wen yumei" <ymwen@shmu.edu.cn>, "Min Yang" <min.yang@emi2012.org>  
**Subject:** RE: Presubmission Inquiry letter

Dear Dr. Nguyen,

Thanks for your interest in EMI. However, given the large submissions EMI has been receiving, it is not possible for us to process your manuscript at this point.

Best.

Shan Lu, MD, PhD

Editor-in-Chief

Emerging Microbes and Infections (EMI)

[www.tandfonline.com/TEMI](http://www.tandfonline.com/TEMI)

[editorial@2012EMI.org](mailto:editorial@2012EMI.org)

-----Original Messages-----

**From:** "Nguyen Hai Nam" <[nguyenhainam@kuhp.kyoto-u.ac.jp](mailto:nguyenhainam@kuhp.kyoto-u.ac.jp)>  
**Sent Time:** 2020-06-05 06:20:08 (Friday)  
**To:** [ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)  
**Cc:**  
**Subject:** Presubmission Inquiry letter

Dear Dr. Yu-Mei Wen,

In response to the spread of the coronavirus disease 2019 (COVID-19), public health authorities and international organizations from countries around the world had proposed and recommended many control measures for it. However, finding the relevant strategy that can control the pandemic without causing adverse impacts on other aspects of societies is still extremely challenging. Together with the world against this pandemic, our specialized team for infectious disease research has written the report entitled “Early centralized isolation strategy for all confirmed cases of COVID-19 remains a core intervention to disrupt the pandemic spreading significantly”. We are writing to inquire about the suitability of our report for the Emerging Microbes and Infections. We believe that our point of view, as well as our given information related to current situations in selected countries, would be satisfied to the readers of your leading journal, and we hope you will consider evaluating the manuscript to see if it falls within your journal’s scope.

If you have any questions about the manuscript, please don’t hesitate to let us know.

Thank you very much, and I look forward to your reply.

Best regards,

Nguyen Hai Nam

*Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan.*

*Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, 70000, Vietnam.*

Nguyen Tien Huy

*School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki 852-8523, Japan.*

\*\*\*\*\*

## **Abstract**

In response to the spread of the coronavirus disease 2019 (COVID-19), plenty of control measures had been proposed and recommended by public health authorities and international organizations from countries around the world. However, its controlling is still extremely challenging. In the aim of assessing the impact of current control measures on the number of new cases, 13 countries with highest confirmed cases, highest mortality rate, and having a close relationship with the outbreak's origin such as China, Hong Kong, Korea, Japan, Singapore, Taiwan, Italy, Spain, France, Germany, United Kingdom (UK), the United States of America (USA), and Canada were enrolled and analyzed. In the study, we analyzed the impact of each control measure adopted by the government of these targeted countries according to its timing to highlight and assess its significance in keeping the outbreak under control. Our analysis determined that early centralized isolation was represented as a core intervention in significantly disrupting the pandemic spreading. This strategy helped in successfully controlling the crisis in the early stage when the total number of cases under 100 without the requirement of the closure of cities and public areas that could impose such a negative impact to the society and economy. Moreover, when the number of cases increased with the apparition of new clusters, coordination between centralized isolation and social distancing would facilitate controlling the crisis efficiently.



---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Thursday, February 6, 2020 6:11 PM  
**To:** Lu, Shan  
**Subject:** Re: RE: Publication query regarding our pre-print on potential vaccine targets for 2019-nCoV (novel coronavirus)

I fully agree with you on this issue. It was said that computer prediction is painting a horse on a paper, whether the horse can run or not, depends on biology. YM

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:** 2020-02-06 21:47:11 (Thursday)  
**To:** "Matthew R MCKAY" <m.mckay@ust.hk>, "ymwen@shmu.edu.cn" <ymwen@shmu.edu.cn>  
**Cc:** "Ahmed Abdul QUADEER" <aaquadeer@connect.ust.hk>, "Editorial Office" <editorial@emi2012.org>  
**Subject:** RE: Publication query regarding our pre-print on potential vaccine targets for 2019-nCoV (novel coronavirus)

Dear Prof. McKay,

Thank you for your interest in EMI to publish your work.

If your work is mainly based on computer modeling and prediction, EMI will prefer to see at least some real bench and/or animal (or human) data to validate your findings.

You can still submit your manuscript to EMI. Currently, EMI is experiencing a large number of submissions. A screening system is established with the participation of key editors and selected experts if needed. Only those with high priority to EMI at this point will be sent out for peer-review.

No matter what the outcome of screening may be, our decision does not in any way indicate that your study is not important.

Best.

Shan Lu, MD, PhD

Editor-in-Chief

Emerging Microbes and Infections (EMI)

[www.tandfonline.com/TEMI](http://www.tandfonline.com/TEMI)

[editorial@2012EMI.org](mailto:editorial@2012EMI.org)

---

**From:** Matthew R MCKAY <m.mckay@ust.hk>

**Sent:** Thursday, February 6, 2020 8:38 AM

**To:** ymwen@shmu.edu.cn; Lu, Shan <Shan.Lu@umassmed.edu>

**Cc:** Ahmed Abdul QUADEER <aaquadeer@connect.ust.hk>

**Subject:** Publication query regarding our pre-print on potential vaccine targets for 2019-nCoV (novel coronavirus)

Dear Prof. Wen and Prof. Lu,

We are writing to seek your feedback regarding a potential publication in *Emerging Microbes and Infection*.

Specifically, we have prepared a research article tentatively entitled:

**Preliminary identification of potential vaccine targets for 2019-nCoV based on SARS-CoV immunological studies**

and we would like to enquire about the interest from your journal as a possible publication venue.

Our work proposes a novel study that leverages known immunological information for SARS-CoV together with available sequence data for 2019-nCoV to identify potential targets for subunit vaccine design for 2019-nCoV. As a main discovery, we identify a set of screened B cell and T cell epitopes that are promising candidates for potentially inducing protective immune responses against 2019-nCoV. These are epitopes in the structural proteins (namely, the spike and nucleocapsid proteins) that have been reported to induce immune responses in SARS-CoV, and which we find to map identically to genetic regions of 2019-nCoV. Some of these epitopes have known functional importance, lying within the receptor binding motif. In the T-cell case, to help with potential immunogen design, we also use population-based MHC statistics to provide sets of epitopes that are estimated to cover a very large fraction of the global population, including that in China.

We believe these results are highly relevant and timely, and may be useful in guiding current experimental efforts towards developing a vaccine for 2019-nCoV.

We have uploaded a pre-print to the bioRxiv server (<https://www.biorxiv.org/content/10.1101/2020.02.03.933226v1>), and I have copied the abstract below. We have also prepared a slightly updated version, based on additional sequences available as of 6th Feb. (the current pre-print uses sequences available up to 29th Jan 2020).

Given the nature of this topic, it is of course important for us to consider avenues for possible rapid publication. Hence, we would appreciate your feedback about whether our work may be appealing for consideration for your journal, and if so, whether a suitably rapid review mechanism would be possible.

We would also be happy to provide any further information, as desired.

Sincerely,

Matthew McKay (corresponding author, together with Dr. Ahmed Quadeer, cc'd).

-----  
Matthew R. McKay

Professor

Department of Electronic and Computer Engineering

Department of Chemical and Biological Engineering

Hong Kong University of Science and Technology

Clear Water Bay, Kowloon, Hong Kong

Web: <https://www.mckayspcb.com/>

#### Abstract

The beginning of 2020 has seen the emergence of the 2019 novel coronavirus (2019-nCoV) outbreak. Since the first reported case in the Wuhan city of China, 2019-nCoV has spread to other cities in China as well as to multiple countries across four continents. There is an imminent need to better understand this novel virus and to develop ways to control its spread. In this study, we sought to gain insights for vaccine design against 2019-nCoV by considering the high genetic similarity between

2019-nCoV and the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), and leveraging existing immunological studies of SARS-CoV. By screening the experimentally-determined SARS-CoV-derived B cell and T cell epitopes in the immunogenic structural proteins of SARS-CoV, we identified a set of B cell and T cell epitopes derived from the spike (S) and nucleocapsid (N) proteins that map identically to 2019-nCoV proteins. As no mutation has been observed in these identified epitopes among the available 2019-nCoV sequences (as of 29 January 2020), immune targeting of these epitopes may potentially offer protection against 2019-nCoV. For the T cell epitopes, we performed a population coverage analysis of the associated MHC alleles and proposed a set of epitopes that is estimated to provide broad coverage globally, as well as in China. Our findings provide a screened set of epitopes that can help guide experimental efforts towards the development of vaccines against 2019-nCoV.

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Tuesday, November 17, 2020 5:55 PM  
**To:** Lu, Shan  
**Subject:** Re: RE: RE: ...screening done for this week...

You are always very thoughtful. Wen

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:** 2020-11-16 13:19:34 (Monday)  
**To:** "wen yumei" <ymwen@shmu.edu.cn>  
**Cc:**  
**Subject:** RE: RE: ...screening done for this week...

Thank you, Prof Wen.

You should not feel guilty at all. It is my job and responsibility. The only reason I copied you on my email is to keep you posted on the overall situation. You don't need to do anything. But I appreciate your support.

I will try to give you and everyone another update by the end of year. thanks for your trust.

Best.

Shan

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Sunday, November 15, 2020 7:58 PM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Subject:** Re: RE: ...screening done for this week...

I appreciate you work as a superman. However, please take care not to overload yourself. I feel guilty not to share your responsibility. Wen

-----Original Messages-----

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Sent Time:** 2020-11-16 02:57:57 (Monday)  
**To:** "Tang, Yi-Wei" <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>  
**Cc:**  
**Subject:** RE: ...screening done for this week...

Hi, Yi-Wei,

To save you some time, I have just gone through the remaining new papers and made decisions on many of them. There are only 8 papers which I would leave to you to take a look as they may be more worthy than the others.

If you can not get time to do it, let me know so I can finish them in the next day or so.

I have to force myself to stick with the timeline as I have one NIH grant review due tomorrow, two online talks in the coming week, one paper deadline and one patent final version among other things in the next few days.

Thanks.

Shan

---

**From:** Tang, Yi-Wei <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>  
**Sent:** Saturday, November 14, 2020 5:29 PM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** RE: ...screening done for this week...

Ok! I have just done some of them following this. I will have rests done later today or tomorrow.

Thank you, Yi-Wei

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Tuesday, August 20, 2019 9:04 PM  
**To:** Lu, Shan  
**Subject:** Re: RE: RE: Application for the Senior Editor Position of EMI

Thank you.

When you will be in Shanghai early September, we need to discuss further on these two issues:

Co-editor-in-chief from Europe

invite good reviews for EMI. I have gone through the recent articles published in EMI, the topics are not "hot" enough, and we need good reviews to ensure our citation. YM Wen

-----原始邮件-----

发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>  
发送时间: 2019-08-21 04:16:06 (星期三)  
收件人: "'wen yumei'" <ymwen@shmu.edu.cn>  
抄送:  
主题: RE: RE: Application for the Senior Editor Position of EMI

Hi Prof Wen,

I was thinking the same. We can offer the position with 3-month probation period.

I will process accordingly.

Shan

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Tuesday, August 20, 2019 3:28 AM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Subject:** Re: RE: Application for the Senior Editor Position of EMI

OK. I agree. However, can we first give the person 3 months for trial? Wen

-----原始邮件-----

发件人: "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
发送时间: 2019-08-20 12:32:44 (星期二)  
收件人: "'Martin martin'" <[winter999@hotmail.com](mailto:winter999@hotmail.com)>, "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>

抄送:

主题: RE: Application for the Senior Editor Position of EMI

Ok.

At the same time, the candidate seems anxious and would like to start soon if we want to offer her EMI position as otherwise she would need to apply for other positions. So I will wait for Prof Wen's feedback.

At the same time, I may engage the candidate with more specifics such as her expected salary etc.

Best.

Shan

---

**From:** Martin martin <[winter999@hotmail.com](mailto:winter999@hotmail.com)>

**Sent:** Monday, August 19, 2019 10:28 PM

**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>

**Subject:** Re: Application for the Senior Editor Position of EMI

Hi, Shan,

I am Ok with this candidate, I can join the interview when you be in Shanghai.

xiaodong

---

**From:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Sent:** Sunday, August 18, 2019 12:20 PM

**To:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>; Martin martin <[winter999@hotmail.com](mailto:winter999@hotmail.com)>

**Subject:** FW: Application for the Senior Editor Position of EMI

Dear Prof Wen and Xiaodong,



Here is another applicant. I have talked to her after receiving her email and resume. She seems to be a good candidate for us. Please take a look.

One issue is that she lives in Beijing and she does not plan to move at this point. Given the open access journal, I am fine with a person working from other city. We can organize some regular in person meetings in Shanghai, such as a quarterly meeting to go over things, especially when I am back.

At this stage, the key to see if you feel that she is acceptable to EMI. So far we have not had much responses beside her and the other person working with Bio-Rad whom I talked to and she does not want to apply the job after my discussion with her by phone. So this new applicant is the only candidate at this point.

I can arrange her to talk to you by phone if you like. We can also have an in-person interview when I am back in late Sept to Shanghai.

Best.

Shan

**From:** muqimeng [<mailto:muqimeng@126.com>]  
**Sent:** Wednesday, August 14, 2019 9:42 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; [min.yang@emi2012.org](mailto:min.yang@emi2012.org)  
**Subject:** Application for the Senior Editor Position of EMI

Dear Professor,

I would like to apply the Senior Editor Position of EMI. The position is attractive for me, and I think I am competent for it. I have more than two years' editorial experience in peer review journal publishing and nearly three years' academic research experience.

I have attached my resume both in English and Chinese.

Looking forward to your reply and thanks for your consideration.

Best regards



---

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Monday, February 22, 2021 9:44 AM  
**To:** Lu, Shan  
**Cc:** Wen Yumei  
**Subject:** Re: RE: RE: Application for APC waiver or discount

Thanks, Shan.

Shibo

> -----原始邮件-----

> 发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>

> 发送时间: 2021-02-22 21:04:07 (星期一)

> 收件人: "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>

> 抄送: "Wen Yumei" <ymwen@shmu.edu.cn>

> 主题: RE: RE: Application for APC waiver or discount

>

> Dear Shibo,

>

> Thanks. Let's focus back to the science of papers. Looking forward to receiving your revised commentary so we can publish it soon.

>

> Best.

>

> Shan

>

> -----Original Message-----

> From: Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>

> Sent: Monday, February 22, 2021 12:49 AM

> To: Lu, Shan <Shan.Lu@umassmed.edu>

> Cc: Wen Yumei <ymwen@shmu.edu.cn>

> Subject: Re: RE: Application for APC waiver or discount

>

> Dear Prof. Lu,

>

> I am very sorry for misunderstanding the T&F's policy that APC waiver is mainly designed for people from poor developing countries. Since several high-profile journals actively waived my publication fee when publishing my Commentaries, Correspondences and Letter to Editor recently, I mistakenly thought that T&F may have similar policy.

>

> Thanking for your praise, I am not "the most successful business person academically and commercially" or "among the top funded scientists in the entire China", rather than one of the poorest PIs in our school. I have tried very hard to get funds to support my studies on the development of pan-CoV fusion inhibitors and pan- $\beta$ -CoV-B vaccines, but have failed so far. Because of the age restriction policy in China, I, as a researcher at 67-year-old, was not allowed to be a PI to apply for grants from the National Health Commission or Ministry of Science and Technology of China, but only allowed to apply for no more than two grants from NSFC.

>

> Currently, I have only one NSFC grant ( ¥ 2.75 millions for 3 years), which is far not enough to support my 12 Ph.D. students. That is why I have no funds to hire a postdoc. Previously, I could reimburse some of my publication fee from my 横向经费 ( the funds from companies) or my colleague's accounts, but this is not allowed after the announcement of new financial policy (all the funds must be 专款专用 ) 。 I did invite some of my colleagues to join me in writing manuscripts, but most of my invitations were declined if the targeted journal's IF is <10 and if they are not corresponding authors. Due to the "破四唯" policy, publication of too many papers by a researcher will destroy his/her reputation because only 5 representative papers are allowed in an application for promotion or grant.

>

> I have never said that I want to quit EMI responsibility. I only consulted with you last year whether you could ask a non-Chinese EMI editor to replace me for handling the manuscripts for the special issue for coronaviruses. I have still done my best to do the work that you have assigned to me. Indeed, it is me to propose early of last year the special issue for coronaviruses and suggest you to assign Prof. KY Yuen as the "guest editor" to handle the manuscript for this special issue. You agreed with my proposal for the special issue, but asked me, not KY, as the editor responsible for the special issue. Soon after the announcement, I received many calls from the researchers in China, asking me whether I could handle their manuscripts for this special issue through the fast-track review system. I told them that, different from the "guest editors" to handle the manuscripts for the special issues of other journals, I, as an editorial board member of EMI, have no authority to make decision on the manuscripts submitted to EMI for the special issue. Most of them became very angry with me, thinking that I just used it as an excuse to reject their papers. That is why I consulted with you whether you could assign a non-Chinese EMI editor to replace me for handling the manuscripts for this special issue, since it is not easy for the Chinese researchers to call a non-Chinese EMI editor in a foreign country.

>

> I have not gotten more reward with funding after I published more than 40 papers in high-profile journals last year. I did receive an award of ~ ¥ 15,000 recently from our school for these publications last year, but I gave all the award to the junior staff in my group.

>

> I will still do my best to make contribution to our lovely journal, EMI.

>

> Best wishes,

>

> Shibo

>

>> -----原始邮件-----

>> 发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>

>> 发送时间: 2021-02-22 06:42:46 (星期一)

>> 收件人: "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>

>> 抄送:

>> 主题: RE: Application for APC waiver or discount

>>

>> Hi, Shibo,

>>

>> Are you kidding me? I was treating your short commentary as a special case due to your past involvement with EMI. Even KY's excellent review will take longer process. I did not expect you will treat us like this.

>>

>> T&F APC waiver is mainly designed for people from poor developing countries so your application will not be approved. You are very famous for being the most successful business person academically and commercially. You and your co-authors are among the top funded scientists in the entire China and yet you can not afford to pay \$900? EMI will have big trouble if an APC wavier is granted to you and your co-author as it will be hard for us to face other authors from much difficult condition than you guys.

>>

>> I thought you told me that you have to quit EMI responsibility because you were quite sick so I am surprised to know you have published too many research articles in the last year. Usually with so many papers, the authors should have more reward with fame and funding.

>>

>> Since the founding of EMI, several of us as the founders have to contribute not only time but also all kinds of resources while we have not personally being paid a single penny for our service. EMI has done multiple special favors to you and your group (such as the urgent publication which led your Gates funding) because you are part of the Fudan group. We would look forward to seeing at least some basic support if not more contribution.

>>

>> Maybe we should consult Prof Wen to see if she thinks you are poor as she may know your situation better than anyone else.

>>

>> Best.

>>

>> Shan

>>

>> -----Original Message-----

>> From: Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>

>> Sent: Sunday, February 21, 2021 7:22 AM

>> To: editorial@emi2012.org; Lu, Shan <Shan.Lu@umassmed.edu>

>> Cc: Yang Min 杨旻 <minyang0216@163.com>

>> Subject: Application for APC waiver or discount

>>

>> Dear Prof. Lu,

>>

>> Because of publishing too many research articles in this budget year, I do not have enough budget left to pay for the APC for publication of our Commentary (ID TEMI-2021-0175) in EMI. Here I am applying for an APC waiver or discount. I would appreciate it very much if you could approve my application and provide me an APC waiver or discount code before submission of our revised manuscript online.

>>

>> Thank you very much for your consideration,

>>

>> Shibo

>> \*\*\*\*\*

>> Shibo Jiang, M.D.

>> Professor and Director, Institute of Medical Microbiology Key

>> Laboratory of Medical Molecular Virology (MOE/NHC/CAMS) School of

>> Basic Medical Sciences, Fudan University

>> 131 Dong An Road, Fuxing Building, 4th Fl, Rm 413 Xuhui District,

>> Shanghai 200032, China

>> Phone: +86-21-54237673

>> E-mail: shibojiang@fudan.edu.cn

>> Website:

>> [https://nam10.safelinks.protection.outlook.com/?url=http%3A%2F%2Fmedic.fudan.edu.cn%2Fen%2Fshow.aspx%3Finfo\\_lb%3D27%26flag%3D3%26info\\_id%3D124&data=04%7C01%7Cshan.lu%40umassmed.edu%7C93501d3cd50048147708d8d6f591c0%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637495697503053933%7CUnknown%7CTWFPbGZsb3d8eyJWljoIMC4wLjAwMDAiLCJQIjoiV2luMzliL](https://nam10.safelinks.protection.outlook.com/?url=http%3A%2F%2Fmedic.fudan.edu.cn%2Fen%2Fshow.aspx%3Finfo_lb%3D27%26flag%3D3%26info_id%3D124&data=04%7C01%7Cshan.lu%40umassmed.edu%7C93501d3cd50048147708d8d6f591c0%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637495697503053933%7CUnknown%7CTWFPbGZsb3d8eyJWljoIMC4wLjAwMDAiLCJQIjoiV2luMzliL)

>> CJ  
>> BTil6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&data=77z3O24udfncRCCedeHDvMT  
>> %2  
>> B9rZG2T5aBu1XwUOwxAU%3D&reserved=0  
>> Publications:  
>> https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fpu  
>> bm  
>> ed.ncbi.nlm.nih.gov%2F%3Fterm%3Dshibo%2Bjiang%26sort%3Ddate%26size%3  
>> D2  
>> 00&data=04%7C01%7Cshan.lu%40umassmed.edu%7C93501d3cd5004814770d0  
>> 8d  
>> 8d6f591c0%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C6374956975030  
>> 63  
>> 886%7CUnknown%7CTWFpbGZsb3d8eyJWljoIMC4wLjAwMDAiLCJQIjoiV2luMzliLCJB  
>> Ti  
>> l6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&data=Cf5hVuwdAaBjU4onnALxTAERzs  
>> 9H  
>> SyjcSQh7jf6snFs%3D&reserved=0  
>>  
>>  
>>

>>> -----原始邮件-----

>>> 发件人: "Emerging Microbes and Infections"  
>>> <onbehalf@manuscriptcentral.com>  
>>> 发送时间: 2021-02-19 23:02:23 (星期五)  
>>> 收件人: 14111010010@fudan.edu.cn, yshao@bjmu.edu.cn,  
>>> shibojiang@fudan.edu.cn  
>>> 抄送:  
>>> 主题: Emerging Microbes & Infections - Decision on Manuscript ID  
>>> TEMI-2021-0175  
>>>  
>>> 19-Feb-2021  
>>>  
>>> Dear Professor Jiang:  
>>>  
>>> Your manuscript entitled "Human challenge trials to assess the efficacy of currently approved COVID-19 vaccines against SARS-CoV-2 variants", which you submitted to Emerging Microbes & Infections, has been reviewed. The reviewer comments are included at the bottom of this letter.  
>>>  
>>> The reviews are in general favourable and suggest that, subject to minor revisions, your paper could be suitable for publication. Please consider these suggestions, and I look forward to receiving your revision.  
>>>  
>>> When you revise your manuscript please highlight the changes you make in the manuscript by using the track changes mode in MS Word or by using bold or coloured text.  
>>>  
>>> In addition, please submit a clean, editable version of your revised paper. These files should be in either Word (.doc) or LaTeX format. Any figures should be saved as either .ps, .eps, .tif or .jpeg file types.  
>>>  
>>> To start the revision, please click on the link below:  
>>>  
>>> \*\*\* PLEASE NOTE: This is a two-step process. After clicking on the

> > >

> > > <https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2F>

> > > mc

>>> .m

> > > anuscriptcentral.com%2Ftemi%3FURL\_MASK%3De6fbe9bcea3944fca4baf20ae

>>> 84

> > > 87

> > > 3c7&data=04%7C01%7Cshan.lu%40umassmed.edu%7C7ebf278d564248ec09

> > > e6

> > > 08

```
> > > d8d663588e%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C6374950694
```

>>> 91

> > > 30

> > > 8875%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzliL

> > > CJ

> > > BT

```
> > > il6lk1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=LcqHwhK1nn%2Bely3o4dokQ
```

$$> > > 2p$$
$$> > > q_k$$

> > > 2QHbNppscwmcigzfew%3D&reserved=0

> > >

> > This will direct you to the first page of your revised manuscript. Please enter your responses to the comments made by the reviewer(s) in the space provided. You can use this space to document any changes you made to the original manuscript. Please be as specific as possible in your response to the reviewer(s).

&gt; &gt; &gt;

> > This link will remain active until you have submitted your revised manuscript. If you begin a revision and intend to finish it at a later time, please note that your draft will appear in the “Revised Manuscripts in Draft” queue in your Author Center.

&gt; &gt; &gt;

> > IMPORTANT: Your original files are available to you when you upload your revised manuscript. Please delete any redundant files before completing the submission.

> > >

> > Because we are trying to facilitate timely publication of manuscripts submitted to Emerging Microbes & Infections, your revised manuscript should be uploaded by 21-Mar-2021. If it is not possible for you to submit your revision by this date, we may have to consider your paper as a new submission.

&gt;&gt;&gt;

> > > Once again, thank you for submitting your manuscript to Emerging Microbes & Infections and I look forward to receiving your revision.

> > >

> > > Sincerely,

> > >

> > > Shan Lu

>>> Editor-in-Chief

### >>> Emerging Microbes & Infections

> > >

&gt; &gt; &gt;

> > > Review Editor Comments to the Author:

&gt;&gt;&gt;

> > This is an important topic and we did a fast review with input from some of the leading authorities in this area. Here is the key summary:

&gt;&gt;&gt;

>>> 1. Reviewers in general agree with the authors about the need for human challenges to determine what protection is offered by current vaccines against the new strains.

>>> 2. However, the reviewers felt that the paper needs more discussion about how to do those studies. This paper is more like a public decision debate but not enough scientific and technical details to accomplish such challenge studies.

>>> 3. For example, can you extrapolate from monkey challenges to humans, as the authors suggest?

>>> 4. Does one need to challenge unvaccinated subjects to show infectivity? Do you then challenge current vaccinees with the same dose?

>>> 5. If they are resistant to the dose infectious for seronegatives, do you increase the challenge dose to determine how much current virus they can resist vs. mutant virus?

>>> 6. Is it necessary that the challenges be compared in people with the same titers, or can people with different titers be challenged?

>>> 7. Do we need to measure both IgA and IgG antibodies?

>>>

>>> The point here is that challenge studies must be done with a lot of insight so that the answers obtained are valid. By the way, people with high immunity will resist challenge with the mutants, but people with lower titers will not. So the protection is not a black and white with variants. Rather there is a quantitative range and different variants may be different, and may also depending on the individual vaccines. Therefore a small group of challenge studies may not truly reflect the population protection efficacy of a vaccine. It is the same idea that a lab based neutralizing assay can not predict the field vaccine protection. The authors need to be very careful not turning the small group challenge study into something like a lab based neutralizing assay.

>>

>>

>>

>>

>>

>>

>

>

>

>

>



---

**From:** yuan zhenghong <zhyuan@shmu.edu.cn>  
**Sent:** Sunday, October 25, 2020 7:46 PM  
**To:** wen yumei  
**Cc:** Qiao Wang; Lu, Shan; zgyi@fudan.edu.cn; yhxie; jieliangchen; xywang; bwang3  
**Subject:** Re: Re: Re: Congratulation

Dear Prof Wen, thank you for your encouragement and support. We will try our best. Best wishes, Zhenghong

> -----原始邮件-----

> 发件人: "wen yumei" <ymwen@shmu.edu.cn>  
> 发送时间: 2020-10-26 05:57:27 (星期一)  
> 收件人: "Qiao Wang" <qiaoqiaolang163@vip.163.com>  
> 抄送: "Lu, Shan" <Shan.Lu@umassmed.edu>, "yuan zhenhong"  
> <zhyuan@shmu.edu.cn>, "zgyi@fudan.edu.cn" <zgyi@fudan.edu.cn>, yhxie  
> <yhxie@fudan.edu.cn>, jieliangchen <jieliangchen@fudan.edu.cn>, xywang  
> <xywang@shmu.edu.cn>, bwang3 <bwang3@fudan.edu.cn>  
> 主题: Re: Re: Congratulation

>  
> Hope our young scientists will appreciate Charlie, a gentlemna's  
> comment, smart and humble, and surppas all of us in the future. YM Wen  
>

> > -----Original Messages-----

> > From: "Qiao Wang" <qiaoqiaolang163@vip.163.com> Sent Time:  
> > 2020-10-25 10:52:07 (Sunday)  
> > To: "Lu, Shan" <Shan.Lu@umassmed.edu>  
> > Cc: "wen yumei" <ymwen@shmu.edu.cn>, "yuan zhenhong"  
> > <zhyuan@shmu.edu.cn>, "zgyi@fudan.edu.cn" <zgyi@fudan.edu.cn>, yhxie  
> > <yhxie@fudan.edu.cn>, jieliangchen <jieliangchen@fudan.edu.cn>,  
> > xywang <xywang@shmu.edu.cn>, bwang3 <bwang3@fudan.edu.cn>  
> > Subject: Re: Congratulation

> >  
> >  
> > Wow! Very High Compliment!  
> > Charles indeed admires your work and contributions, and you richly deserve this compliment.

> >  
> > Qiao

> >  
> >  
> > > On Oct 25, 2020, at 09:42, Lu, Shan <Shan.Lu@umassmed.edu> wrote:

> > >  
> > > Congratulations, Prof Wen!

> > >  
> > > Charlie is a true gentleman, smart and humble.

> > >  
> > > Shan  
> > >

>>> -----Original Message-----

>>> From: wen yumei <ymwen@shmu.edu.cn>

>>> Sent: Saturday, October 24, 2020 9:19 PM

>>> To: yuan zhenhong <zhyuan@shmu.edu.cn>

>>> Cc: zgyi@fudan.edu.cn; yhxie <yhxie@fudan.edu.cn>; Qiao Wang

>>> <qiaoqiaolang163@vip.163.com>; jieliangchen

>>> <jieliangchen@fudan.edu.cn>; xywang <xywang@shmu.edu.cn>; bwang3

>>> <bwang3@fudan.edu.cn>; Lu, Shan <Shan.Lu@umassmed.edu>

>>> Subject: Fw: Re: Congratulation

>>>

>>> See the response from Charlie, I am really honored. Wen

>>>

>>>

>>> -----Original Messages-----

>>> From: "Charles Rice" <ricec@rockefeller.edu> Sent Time: 2020-10-25

>>> 03:45:22 (Sunday)

>>> To: "wen yumei" <ymwen@shmu.edu.cn>

>>> Cc:

>>> Subject: Re: Congratulation

>>>

>>> Thanks Yu-Mei! As one of your many admirers, your note means a

>>> great deal to me. It has been a true pleasure and honor to get to

>>> know you and your amazing group of trainees. Looking back, it has

>>> been a remarkable period for science yet there are many challenges

>>> ahead (not to mention that other persistent troublemaker, HBV!). I

>>> hope you are well and I look forward to the next time our paths

>>> cross. Warm regards, Charlie

>>>

>>>> On Oct 5, 2020, at 8:29 AM, wen yumei <ymwen@shmu.edu.cn> wrote:

>>>>

>>>> Dear Charlie,

>>>> The news of you and the other two scientists received the Nobel Prize was immediately spread in our lab, and everybody is thrilled, because of your long time collaboration with us and some of them were trained in your lab.

>>>> Congratulation ! Your contribution in virology is worldwide recognized, and of course your outstanding contribution in HCV has saved the lives of many people.

>>>> Thank you for helping Zhenghong and our lab in all aspects, and

>>>> hope you all the best, and keep fit. Yu-mei

>>>>

>>>>

>>>>

>>>>

>>>>

>>>>

>>>>

>>>>

>>>>

>>>>

>>>>

>>>>

>>>>

>>>>

>>>>



---

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Tuesday, January 21, 2020 10:22 PM  
**To:** Lu, Shan  
**Cc:** Wen Yumei; Yuan Zhenghong 袁正宏; Zhang Wenhong; Yang Min 杨旻; min.yang; Yuen KY; TEMI-peerreview@journals.tandf.co.uk  
**Subject:** Re: RE: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Dear Shan,

Thank you very much for educating us about the manuscript processes by a big publisher. Indeed, this is the first time for me to know the whole story about paper publication.

I apologize to the editorial staff for my misunderstanding.

Let's working together to promote and increase the visibility of EMI.

Cheers,

Shibo

-----原始邮件-----

发件人:"Lu, Shan" <Shan.Lu@umassmed.edu>

发送时间:2020-01-22 10:51:37 (星期三)

收件人: "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>, "Wen Yumei" <ymwen@shmu.edu.cn>, "Yuan Zhenghong 袁正宏" <zhyuan@shmu.edu.cn>, "Zhang Wenhong" <zhangwenhong@fudan.edu.cn>

抄送: "Yang Min 杨旻" <minyang0216@163.com>, "min.yang" <min.yang@emi2012.org>, "Yuen KY" <kyyuen@hku.hk>, "TEMI-peerreview@journals.tandf.co.uk" <TEMI-peerreview@journals.tandf.co.uk>

主题: RE: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Hi, Shibo,

This is a good time for you and others to learn the process of EMI as part of Taylor & Francis. I will use Prof Yuen's paper as an example.

1. Initial paper QC: any new paper will go through the initial screening process by JEO who is a free service provided by T&F to ensure the timely and highly quality screening on new manuscripts. Regular time: 1-2 days depending on the quality of manuscripts and the exact time of submission into EMI system as the time difference between the authors and JEO may vary.

In the case of Prof Yuen's paper: 0.5 day due to my request to JEO

2. Peer review: from Editor-in-Chief to Review Editor to outside reviewers: usually 2-4 weeks.

In the case of Prof Yuen's paper: 4 hrs.

3. Transfer accepted draft to Production: JEO will do a final check to ensure the quality of paper format etc after multiple revisions (even though there is no revision in Prof Yuen's case) is suitable for production. It can vary between 2 hrs to 2 days (the JEO is located in Southeast Asia and she does not work during the weekends).

In the case of Prof Yuen's paper: 2 days (it is a bad luck because it happened to be weekend at the time of Yuen's paper acceptance.

4. Production: type setting and internal QC review. This is subcontracted by people in India or some other places. Regular time: 2-4 weeks.

In the case of Prof Yuen's paper: estimated to be within 5 days because I requested T&F to put this paper into a fast track production.

5. Proofs to Prof Yuen, authors' final review and resubmitting back to Production, and final uploading online. It varies greatly pending authors' return time, but it is about 2-4 days.

In the case of Prof Yuen's case: unknown yet.

So in summary, EMI has done our best within the system to reduce the regular time of 2 months to about a total of 7 days which I trust is the fastest a big publisher can do. So you are wrong that EMI editorial office staff did not cause any delay on weekends or holidays. It is the big publisher who is trying to control cost and using various subcontractors in developing countries that will generate huge de-centralized operation and delay due to time difference in diverse geographic regions.

I don't believe any big publisher can do better than this, including Nature or NEJM. It is very possible that the small publishers can have a way to cut it shorter as shown in your examples. This is a trade off for big publishers.

At the same time, I never fully believe the so called early publishing or first publishing for such rushing as we are observing. The time difference will only be a few days, and ultimately it is the content of papers, rather than the early date matters. Also we need to be careful about the quality of typesetting in a rush, or the controversy of "stealing data" as in the exact case you just cited which can only generate more negative impact than any real gain.

Regarding to how to cite Prof Yuen's paper, I don't think it is an issue at all. Your paper will be published later than his, so you can still cite his paper (since you know the entire title, authors etc., even EMI issue, year), but leave out the page numbers. You can add the page number when you receive the Proofs of your own paper. As a pro, you should know this better than anyone.

Shan

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>

**Sent:** Tuesday, January 21, 2020 12:30 AM

**To:** Lu, Shan <Shan.Lu@umassmed.edu>; Wen Yumei <ymwen@shmu.edu.cn>; Yuan Zhenghong 袁正宏 <zhyuan@shmu.edu.cn>; Zhang Wenhong <zhangwenhong@fudan.edu.cn>

**Cc:** Yang Min 杨旻 <minyang0216@163.com>; min.yang <min.yang@emi2012.org>; Yuen KY <kyyuen@hku.hk>; TEMI-peerreview@journals.tandf.co.uk

**Subject:** Re: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Dear Prof. Lu and Wen,

The day before yesterday, Drs. Hong Tang and Pei Hao at Pasteu Institute called me and asked me that they wanted to submit a manuscript about the genetic analysis of 2019-nCoV to EMI and whether we can process their manuscript in the fast track. I told them that EMI had already accepted a paper two days ago and this paper has presented very extensive analysis of this new virus. Therefore, they decided to submit their manuscript to *SCIENCE CHINA Life Sciences* (<https://mp.weixin.qq.com/s/JC0fCMsZlgGPYy4L7xMpTg>) and it was immediately accepted and published online today. However, Prof. Yuen's paper is still not online today. We want to cite Prof. Yuen's paper in our manuscripts, but we cannot get the citation link. Similarly, we submitted a minireview to JMV. It was also immediately accepted and published it online next day.

I understand that the staff of the editorial office of EMI have to take off in the weekends and holidays, but is it possible to ask the publishers to give special consideration for those extremely important papers for publication at fast speed?

Thank you very much for your consideration,

Shibo

-----原始邮件-----

发件人: "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

发送时间: 2020-01-18 19:42:02 (星期六)

收件人: zlshi <[zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn)>, "Shibo Jiang (姜世勃)" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>

抄送: "Yang Min 杨旻" <[minyang0216@163.com](mailto:minyang0216@163.com)>, "min.yang" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>, "Du, Lanying" <[ldu@nybc.org](mailto:ldu@nybc.org)>

主题: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Dear Prof Shi,

Thanks for your confirmation and EMI is happy to see you as one of the authors.

Best.

Shan

---

**From:** zlshi <[zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn)>

**Sent:** Saturday, January 18, 2020 6:37 AM

**To:** Shibo Jiang (姜世勃) <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>; Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Cc:** Yang Min 杨旻 <[minyang0216@163.com](mailto:minyang0216@163.com)>; min.yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>; Du, Lanying <[ldu@nybc.org](mailto:ldu@nybc.org)>

**Subject:** Re: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Dear Prof. Jiang,

Thank you for your inviting me as a co-author of this commentary. As the sequence is now open to the public, I'll be happy to be the co-author.

Best regards,

Zhengli,

---

SHI Zhengli, Ph. D

Senior Scientist & Professor

Wuhan Institute of Virology, Chinese Academy of Sciences

44 Xiao Hong Shan

430071 Wuhan, Hubei

China

Tel & Fax: (0086) 27 87197240

Email: [zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn)

**From:** [Shibo Jiang \(姜世勃\)](#)

**Date:** 2020-01-18 16:25

**To:** [Lu Shan](#)

**CC:** [Yang Min 杨旻](#); [min.yang](#); [Shi Zhengli](#); [Du Lanying NYBC](#)

**Subject:** Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Dear Prof. Lu,

Per your request, I just submitted the invited Commentary to EMI online (see the attachment). During the submission, I accidentally put in the contact information of Drs. Lu Lu and Shuai Xia (my postdoc), rather than Drs. Shi and Du, into the authors' list. I thus immediately called Min about the possibility of withdrawing and resubmitting the manuscript. Min told me that I would not have to withdraw the manuscript since the authors' information in the manuscript is correct, but I would have to inform Drs. Lu and Xia that they may receive the email from EMI about this manuscript. I informed them already.

I will cite Prof. Yuen's paper once the citation information is available during the proof-reading stage.

Thank you very much for your consideration,

Shibo

-----原始邮件-----

发件人: "Emerging Microbes and Infections" <[onbehalf@manuscriptcentral.com](mailto:onbehalf@manuscriptcentral.com)>

发送时间: 2020-01-18 15:21:06 (星期六)

收件人: [shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)

抄送: [shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)

主题: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online



18-Jan-2020

Dear Professor Jiang:

Your manuscript entitled "An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies" has been successfully submitted online and is presently being given full consideration for publication in Emerging Microbes & Infections.

Your manuscript ID is TEMI-2020-0055.

Please mention the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your street address or e-mail address, please log in to ScholarOne Manuscripts at <https://mc.manuscriptcentral.com/temi> and edit your user information as appropriate.

You can also view the status of your manuscript at any time by checking your Author Center after logging in to <https://mc.manuscriptcentral.com/temi>.

Thank you for submitting your manuscript to Emerging Microbes & Infections.

Sincerely,

Emerging Microbes & Infections Editorial Office



---

**From:** 蔡启良<Qiliang Cai> <qiliang@fudan.edu.cn>  
**Sent:** Saturday, February 22, 2020 12:44 AM  
**To:** Lu, Shan  
**Cc:** wen yumei  
**Subject:** Re: RE: RE: Emerging Microbes & Infections

Dear Shan,

Sorry for confusion! I meant that I am happy to continue to work as RE and will try my best to serve. However, I am totally fine to take your assignment if you have other better candidates.

Look forward to see you!

Best,

Qiliang

-----原始邮件-----

发件人:"Lu, Shan" <Shan.Lu@umassmed.edu>  
发送时间:2020-02-22 12:05:16 (星期六)  
收件人: "蔡启良<Qiliang Cai>" <qiliang@fudan.edu.cn>  
抄送:  
主题: RE: RE: Emerging Microbes & Infections

Hi, Qiliang,

Thanks and no problem. I fully understand how busy you are. As you indicated, I will try to maintain you as a reviewer but not let you to work as RE to process a lot of papers. One other RE is also stepping down due to other work and a few more will be added to handle the huge volume of papers we need to process.

Hope we can meet soon if the CoV outbreak is under control. Please take care!

Best.

Shan

**From:** 蔡启良<Qiliang Cai> <qiliang@fudan.edu.cn>  
**Sent:** Friday, February 21, 2020 9:29 PM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Subject:** Re: RE: Emerging Microbes & Infections

Dear Shan,

Very glad to hear from you and hope you well! I would be happy to help, and continue to put my efforts to improve EMI. It may just a little bit slow response some time due to instant heavy works, and hope you could understand.

Best,

Qiliang

-----原始邮件-----

发件人:"Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
发送时间:2020-02-21 03:43:26 (星期五)  
收件人:"qiliang@fudan.edu.cn" <[qiliang@fudan.edu.cn](mailto:qiliang@fudan.edu.cn)>  
抄送:  
主题: RE: Emerging Microbes & Infections

Dear Qiliang,

Long time no talk. Hope this email will find you well, in particular under the cloud of the current SARS2.

I meant to contact you for some time but the work of EMI and other things have kept me too busy to reach you. As I learned that you are taking more administrative responsibility nowadays, I wonder if you would like to continue to serve as Review Editor for EMI. EMI has grown further in the last year, and with the recent SARS2, we had more submissions. The work load is very huge. We need to give RE more work load but I realize that it may be hard for you. So please let me know your thought and I am happy to arrange anyway you want. No matter what arrangement, you should continue to be the Editorial Board member along with everyone else for the current term.

Please let me know your opinion. We can talk over the wechat if you would like.

Best.

Shan

\*\*\*\*\*

*Shan Lu, MD, PhD*

*Professor*

*Department of Medicine*

*U Mass Med School*

*Worcester, MA01605*

*USA*

*Tel. 1-508-856-6791*

*Email: [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu)*

--

Qiliang Cai, Ph.D. Professor, Deputy director MOE&NHC&CAMS Key Laboratory of Medical Molecular Virology School of Basic Medical Sciences Shanghai Medical College Fudan University Shanghai, 200032 P. R. China [Tel:\(+86\)21-5423-7716](tel:+862154237716)  
Email: [qiliang@fudan.edu.cn](mailto:qiliang@fudan.edu.cn) Lab website: [www.viralcancer.fudan.edu.cn](http://www.viralcancer.fudan.edu.cn)

--

Qiliang Cai, Ph.D. Professor, Deputy director MOE&NHC&CAMS Key Laboratory of Medical Molecular Virology School of Basic Medical Sciences Shanghai Medical College Fudan University Shanghai, 200032 P. R. China Tel:(+86)21-5423-7716  
Email: [qiliang@fudan.edu.cn](mailto:qiliang@fudan.edu.cn) Lab website: [www.viralcancer.fudan.edu.cn](http://www.viralcancer.fudan.edu.cn)

---

**From:** TEMI-peerreview@journals.tandf.co.uk  
**Sent:** Monday, January 20, 2020 6:08 AM  
**To:** shibojiang@fudan.edu.cn  
**Cc:** Lu, Shan; zlshi@wh.iov.cn; minyang0216@163.com; min.yang@emi2012.org; ldu@nybc.org  
**Subject:** Re: Re: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 #TrackingId:5437168

Dear Prof. Jiang,

Thank you very much for your resubmission.

This is to kindly confirm that your manuscript has been now proceeded to Prof. Lu.

Should there be anything else that I can further assist you with, please do let me know.

Kind regards,

**Jorgie Lyn Luna** - Journal Editorial Office  
Taylor & Francis Group  
4 Park Square | Milton Park | Abingdon | Oxon | OX14 4RN UK  
Web: [www.tandfonline.com](http://www.tandfonline.com)

Taylor & Francis is a trading name of Informa UK Limited,  
registered in England under no. 1072954

Emerging Microbes & Infections

---

**From:** shibojiang@fudan.edu.cn  
**Sent:** 20-01-2020 06.40 PM  
**To:** TEMI-peerreview@journals.tandf.co.uk, shibojiang@fudan.edu.cn  
**Cc:** shan.lu@umassmed.edu, zlshi@wh.iov.cn, minyang0216@163.com, min.yang@emi2012.org, ldu@nybc.org  
**Subject:** Re: Re: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055

Dear Jorgie,

We have updated the manuscript's information, added line number, and resubmitted it already.

Thank you very much for your help,

Shibo

-----原始邮件-----

发件人: "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>

发送时间: 2020-01-20 17:45:07 (星期一)

收件人: TEMI-peerreview@journals.tandf.co.uk

抄送: shan.lu@umassmed.edu, zlshi@wh.iov.cn, minyang0216@163.com, min.yang@emi2012.org, ldu@nybc.org

主题: Re: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 #TrackingId:5437168

Thanks,Jorgie.

We will update the patients' information and add line number before resubmission tonight.

Shibo

-----原始邮件-----

发件人:TEMI-peerreview@journals.tandf.co.uk

发送时间:2020-01-20 17:03:46 (星期一)

收件人: shan.lu@umassmed.edu, shibojiang@fudan.edu.cn

抄送: zlshi@wh.iov.cn, minyang0216@163.com, min.yang@emi2012.org, ldu@nybc.org

主题: RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 #TrackingId:5437168

Dear Prof. Jiang,

Thank you for your email.

This is to kindly let you know that I have now processed your paper and I have noticed that the paper does not contain a line numbering. Having this, I have returned your manuscript in your author centre in order for you to add a line numbering in your main document and make the necessary amendments in your co-authors list.

Rest assured that once received, I will then proceed your paper to Prof. Lu immediately.

Please let me know if you have any questions or concerns.

Kind regards,

**Jorgie Lyn Luna** - Journal Editorial Office

Taylor & Francis Group

4 Park Square | Milton Park | Abingdon | Oxon | OX14 4RN UK

Web: [www.tandfonline.com](http://www.tandfonline.com)

Taylor & Francis is a trading name of Informa UK Limited,  
registered in England under no. 1072954

Emerging Microbes & Infections

-----  
**From:** Shan.Lu@umassmed.edu

**Sent:** 18-01-2020 07:21

**To:** shibojiang@fudan.edu.cn, Shan.Lu@umassmed.edu

**Cc:** minyang0216@163.com, min.yang@emi2012.org, zlshi@wh.iov.cn, ldu@nybc.org

**Subject:** RE: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055

Hi, Shibo,

Thanks for submitting this timely Commentary. At the same time, you need to ensure the two co-authors agree to this draft of paper, especially the agreement from Prof. Shi.

At this stage, JEO who is in charge of the first step QC will need to go through the draft and may contact you with any required formatting revisions. I am copying her here and she may take a little time to process since we are in Weekend now. But you should not write to her directly per T&F rules unless she contacts you.

Dear Jorgie Lyn Luna,

Please see communication with Prof Jiang on this new submission TEMI-2020-0055. What I would like are the following:

- 1) Please conduct a quick QC/format and let this MS moving to my desk asap, if there is no any QC/format issue.
- 2) It is ok to send it back to corresponding author Prof Jiang if there is QC issue right away, and he will process such revisions right away, including the wrong emails from two co-authors. Then please monitor the re-submission and again send it to me asap after your QC check.

Thanks.

Shan

-----Original Message-----

From: Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>

Sent: Saturday, January 18, 2020 3:25 AM

To: Lu, Shan <Shan.Lu@umassmed.edu>

Cc: Yang Min 杨旻 <minyang0216@163.com>; min.yang@emi2012.org; Shi Zhengli <zlshi@wh.iov.cn>; Du Lanying\_NYBC <ldu@nybc.org>

Subject: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

Dear Prof. Lu,

Per your request, I just submitted the invited Commentary to EMI online (see the attachment). During the submission, I accidentally put in the contact information of Drs. Lu Lu and Shuai Xia (my postdoc), rather than Drs. Shi and Du, into the authors' list. I thus immediately called Min about the possibility of withdrawing and resubmitting the manuscript. Min told me that I would not have to withdraw the manuscript since the authors' information in the manuscript is correct, but I would have to inform Drs. Lu and Xia that they may receive the email from EMI about this manuscript. I informed them already.

I will cite Prof. Yuen's paper once the citation information is available during the proof-reading stage.

Thank you very much for your consideration,

Shibo

-----原始邮件-----

发件人: "Emerging Microbes and Infections" <onbehalf@manuscriptcentral.com>



发送时间: 2020-01-18 15:21:06 (星期六)

收件人: shibojiang@fudan.edu.cn

抄送: shibojiang@fudan.edu.cn

主题: Emerging Microbes & Infections - Manuscript ID TEMI-2020-0055 has been submitted online

18-Jan-2020

Dear Professor Jiang:

Your manuscript entitled "An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies" has been successfully submitted online and is presently being given full consideration for publication in Emerging Microbes & Infections.

Your manuscript ID is TEMI-2020-0055.

Please mention the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your street address or e-mail address, please log in to ScholarOne Manuscripts at <https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fmc.manuscriptcentral.com%2Ftemi&data=02%7C01%7Cshan.lu%40umassmed.edu%7C5bf67dcea80543172df308d79beffa7f%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637149327594484021&sdata=q3fFDQyJZmoHlceFvohL5YzdF2gO11sHHBts3o6gm3l%3D&reserved=0> and edit your user information as appropriate.

You can also view the status of your manuscript at any time by checking your Author Center after logging in to

<https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fmc.manuscriptcentral.com%2Ftemi&data=02%7C01%7Cshan.lu%40umassmed.edu%7C5bf67dcea80543172df308d79beffa7f%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637149327594484021&sdata=q3fFDQyJZmoHlceFvohL5YzdF2gO11sHHBts3o6gm3l%3D&reserved=0>.

Thank you for submitting your manuscript to Emerging Microbes & Infections.

Sincerely,  
Emerging Microbes & Infections Editorial Office

---

**From:** Min Yang <min.yang@emi2012.org>  
**Sent:** Thursday, January 9, 2020 11:29 PM  
**To:** Shibo Jiang (姜世勃); Lu, Shan  
**Cc:** Emily  
**Subject:** RE: RE: RE: EMI special issue on Emerging CoV  
**Attachments:** Special Topic on Coronaviruses.docx

Dear Prof Lu and Jiang,

I have gone through all EMI past publications on coronaviruses and found 21 articles qualified.  
Attached please find the article list.

Please feel free to let me know if you need any further assistance.

Thanks and regards,

Min Yang

Emerging Microbes & Infections (EMI) Editorial Office  
4F Fuxing Building  
131 Dongan Road  
Shanghai  
China  
Tel: 86-21-54237992  
E-mail: editorial@emi2012.org

**From:** Shibo Jiang (姜世勃)  
**Sent:** Thursday, January 9, 2020 7:16 PM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Cc:** Min Yang <min.yang@emi2012.org>; Emily <editorial2@emi2012.org>  
**Subject:** Re: RE: RE: EMI special issue on Emerging CoV

Dear Shan,

Thank you very much for sharing with me your concern about asking junior or non-expert people, particularly Chinese experts, to serve as GE. I understand it now. I will try my best to work on it at this stage and let you know if I feel too tired to handle too many manuscripts in the future.

Best,

Shibo

-----原始邮件-----

发件人: "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

发送时间: 2020-01-09 14:56:45 (星期四)

收件人: "'Shibo Jiang (姜世勃)'" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>, "Min Yang" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>

抄送: Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>

主题: RE: RE: EMI special issue on Emerging CoV

Hi, Shibo,

I don't think it is a good idea to ask junior or non-expert people to serve as GE. One more important factor is that we need to make sure EMI is not just a "Chinese people" journal which will kill us very soon. If you can not serve, I will find someone else.

The best approach at this point may be is to have you as the GE and you can see how much work is involved, and you can feel free to drop if you feel the work is too much. The Editorial office and T&F will do most of the work. Please let me know.

Shan

**From:** Shibo Jiang (姜世勃) <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>

**Sent:** Wednesday, January 8, 2020 10:38 PM

**To:** Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>

**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>

**Subject:** Re: RE: EMI special issue on Emerging CoV

Hi Shan,

Can we invite Prof. Qiliang Cai or Tianlei Ying or Rong Zhang as a GE for this special issue? We can meet together convincedly to discuss the related topics often. Although many senior experts in this field may agree to act as the GE for this special issue, they may not be willing to handle many manuscripts by him/herself. I do have a concern that there will be many manuscripts to be submitted to EMI for this special issue very soon. I may not have enough time to deal with the authors and their manuscripts.

Shibo

-----Original Messages-----

**From:** "Min Yang" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>  
**Sent Time:** 2020-01-09 11:12:25 (Thursday)  
**To:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>, "'Shibo Jiang (姜世勃)'" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>  
**Cc:** Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>  
**Subject:** RE: EMI special issue on Emerging CoV

Ok, I will generate the list asap.

Thank you,

Min

---

**From:** Lu, Shan  
**Sent:** Wednesday, January 8, 2020 9:54 PM  
**To:** 'Shibo Jiang (姜世勃)' <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>  
**Cc:** Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>; Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>  
**Subject:** RE: EMI special issue on Emerging CoV

I got the feedback from Dr. Shi. She thanks my invitation but stated that this may not be a good time for her to accept our invitation. So you can be the sole GE at this point. Once we established it, we can find another GE.

On the title, I think yours is too much like a "political statement". I think we can make it simple and scientific. How about "Emerging and Re-emerging Coronaviruses" ?

Next, please draft an overall introduction of this special issue.

Min Yang: please go through past EMI papers and find all corona viruses related papers and generate a list so they can be included in this special issue. Min Yu may help to see if there is any easy way to identify such papers. With a first rough list, Prof Jiang can suggest more key words to identify such EMI papers.

Shan

**From:** Shibo Jiang (姜世勃) <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>  
**Sent:** Tuesday, January 7, 2020 4:43 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** 'Min Yang' <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>; Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>  
**Subject:** Re: EMI special issue on Emerging CoV

Thanks, Shan.

I will work together with Min Yu and Min Yang, under your guidance, on this special issue.

It is a good idea to include all manuscripts related to the emerging CoVs in this special issue. I suggest to change the title to “**Combating the pathogenic emerging and re-emerging coronaviruses**” (I include "Re-emerging CoV" because we cannot exclude the possibility of SARS epidemic in the future).

I will draft a short description of this special issue.

Please send an invitation to Dr. Zhengli Shi as soon as possible. If she agrees, I will discuss with her about the list of potential authors and topics and we should sent out invitation letters together.

Best,

Shibo

-----Original Messages-----

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Sent Time:** 2020-01-07 14:31:54 (Tuesday)  
**To:** "Shibo Jiang (姜世勃)" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>  
**Cc:** "Min Yang" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>, Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>  
**Subject:** EMI special issue on Emerging CoV

Hi, Shibo,

Here I am connecting you to Min Yu and Min Yang of EMI editorial office on the set up of a new special issue.

First, you will serve as the guest editor (before the 2<sup>nd</sup> person is finalized).

Second, we need to define what is the scope of this special issue. I don't think we should make this one for the pending Wuhan pathogen. The emerging CoV itself is interesting and has enough papers for us to set up a special issue.

Third, based on the decision of above, we can name the title of special issue.

Fourth, you then need to draft a short description of this special issue (using other EMI one as the example but the descriptions for some of them are not very good, but the overall length can be used as a template).

After the above are done, we can draft together an invitation letter and develop a list of potential experts who may contribute to this special issue. Min Yu will work on this with us.

At the same time, Min Yang will work with you to identify those published EMI papers related to this topic and pull them into this special issue now (as part of the process to build this special issue).

Best.

Shan

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Friday, April 10, 2020 9:45 PM  
**To:** Lu, Shan  
**Subject:** Re: RE: Re: Fw: New York Magazine Query

You are right. I am helping her to help our lab. Wen

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:** 2020-04-11 09:42:25 (Saturday)  
**To:** "wen yumei" <ymwen@shmu.edu.cn>  
**Cc:**  
**Subject:** RE: Re: Fw: New York Magazine Query

I am sorry to hear that you have to do so much for her. You may give such job to Shibo Jiang and let them to handle these. It is not fair to you to do all of these for her.

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Friday, April 10, 2020 9:32 PM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Subject:** Fw: Re: Fw: New York Magazine Query

See the forwarded letter. she does not know anything on immunity, and does not want to learn. Wen

-----Original Messages-----

**From:** "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
**Sent Time:** 2020-04-11 09:29:36 (Saturday)  
**To:** "Jinghe Huang" <[jinghehuang@fudan.edu.cn](mailto:jinghehuang@fudan.edu.cn)>  
**Cc:**  
**Subject:** Re: Fw: New York Magazine Query

Please first draft a response, and I will give you my advise. Wen

-----Original Messages-----

**From:** "Jinghe Huang" <[jinghehuang@fudan.edu.cn](mailto:jinghehuang@fudan.edu.cn)>  
**Sent Time:** 2020-04-10 23:38:50 (Friday)  
**To:** "闻玉梅老师" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>

Cc:

Subject: Fw: New York Magazine Query

Dear Wen Laoshi,

Our preprint attracted a lot of attentions by scientific community and media. 35 news stories cited and reported our results. It was also cited in the weekly report of the U.S. department of Science and Technology. A reporter of Nature News called me and talked about our manuscript. I also got an email from a reporter of *New York* magazine with the following complicated questions. Do you have any suggestion about those questions? Thank you very much.

Very best regards,

Jinghe

-----原始邮件-----

发件人:"James Walsh" <[james.walsh@nymag.com](mailto:james.walsh@nymag.com)>

发送时间:2020-04-09 22:34:37 (星期四)

收件人: [Jinghehuang@fudan.edu.cn](mailto:Jinghehuang@fudan.edu.cn)

抄送:

主题: New York Magazine Query

Professor Huang,

I am a reporter for *New York* magazine and I am working on a story about COVID-19 immunity. I am wondering if you might be able to answer a few questions for me about your recent antibody research? I would appreciate any help, insight, or clarity you might be able to provide.

- Based on your research, might the low antibody count in younger people mean that younger people are more likely to be reinfected?
- If someone fought back an infection with T cells or cytokines, would they be able to fight reinfection with T Cells or cytokines?
- Do antibody levels fluctuate over time? i.e., Might someone recently recovered have high levels of antibodies than someone who recovered earlier? How might this affect immunity?
- How do you think your research correlates to [recent reports from South Korea](#) on reinfection?

Again, any help or insight you might be able to offer would go a long way! Thank you!



Sincerely,  
James Walsh

--

**James Walsh • Writer**



Intelligencer and New York Magazine are part of **Vox Media**.

\*\*\*\*\*

**From:** Shi Zhengli<zlshi@wh.iov.cn>  
**Sent:** Sunday, February 9, 2020 10:11 PM  
**To:** Lu, Shan  
**Cc:** Shibo Jiang (姜世勃); Yang Min 杨敏; min.yang@emi2012.org; 'Shuying Liu'  
**Subject:** Re: RE: Re: Jiang et al. EMI 9:1, 275-277

Dear Prf. Liu,

I'm very sorry to make this errors. We have requested to update the GenBank information and the sequence annotation will be updated very soon.

My suggestion is to make an erratum.

Best regards,

Zhengli,

-----The original message-----

From 人 : "Lu, Shan" <Shan.Lu@umassmed.edu>

**Sending time:** 2020-02-10 01:31:16 (Monday)

To : "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>, "石正丽" <zlshi@wh.iov.cn>

Cc : "Yang Min 杨旻" <minyang0216@163.com>, "min.yang@emi2012.org" <min.yang@emi2012.org>, "Shuying Liu" <SYL-consulting@outlook.com>

Main **topic:** REs: Re: the EMI Jiang et Al. 9:... 1, 275-277

Hi, everyone,

We did further investigation. Here is what we found:

It appears that the sequences initially published at Genbank by Dr. Yongzheng Zhang, and later by others, all used the SARS sequences as the basis (starting site for S and the resulting aa numbering).

At the same time, Prof Shi's group uploaded her group's 2019-nCoV sequences in a different way, based on SARSr-CoV TG13. At least we found the following are involved.

WIV02 (GenBank: MN996527.1)

1

WIV04 (GenBank: MN996528.1)

6/1/2021 Dear Prf. Liu, I'm very sorry to make this errors. We have requested to update the GenBank information and the sequence annotati  
WIV05 (GenBank: MN996529.1)  
WIV06 (GenBank: MN996530.1)

So, how to treat the EMI paper by Jiang et al. (EMI 9:275-277), there are two possible solutions:

1. Produce an erratum with a revised Fig 1b, which will include the corrected starting point of S, and revised S leader size and the total size of S, along the numbering of S subdomains).

We will select this option if you want to revise your Genbank submissions.

2. Publish another commentary which will describe this situation of different entries in Genbank so there will be no confusion to others in the field.

We will select this option if the sequences submitted by Prof Shi will stay as they are.

I (and EMI) will respect whatever decision will be.

Shan

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Sunday, February 9, 2020 8:54 AM  
**To:** Shi Zhengli <zlshi@wh.iov.cn>  
**Cc:** Lu, Shan <Shan.Lu@umassmed.edu>; Yang Min 杨旻 <minyang0216@163.com>; min.yang@emi2012.org; 'Shuying Liu' <SYL-consulting@outlook.com>  
**Subject:** Re: Re: Jiang et al. EMI 9:1, 275-277

Thank you Lu and teacher,

Let me modify that picture. We emailed you the revised pictures and text directly, right? Is there any explanation needed?

2

---

## Page 3

Shibo

-----The original message-----

From : "石正丽" <zlshi@wh.iov.cn>  
Sending time : 2020-02-09 21:46:59 (weekday)  
Write Face : "Lu, Shan" <Shan.Lu@umassmed.edu>  
Cc : "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>, "Yang Min 杨旻" <minyang0216@163.com>, "min.yang@emi2012.org" <min.yang@emi2012.org>, "Shuying Liu" <SYL-consulting@outlook.com>  
Subject : Re: Jiang et al. EMI 9:1, 275-277

Master Lu:

I communicated with the student just now. The phylogenetic tree was constructed using the correct S gene sequence. An error occurred when uploading the sequence to GenBank. We need

6/1/2021

Dear Prof. Liu, I'm very sorry to make this errors. We have requested to update the GenBank information and the sequence annotati

Correct it.

Hereby explain.

I'm not always sorry for this kind of error.

Zhengli

-----The original message-----

Outgoing Face : "Lu, Shan" < [Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu) >

Sending time : 2020-02-09 21:15:31 (weekday)

To : "Shibo Jiang (姜世勃)" < [shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn) >, "Shi Zhengli" < [zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn) >

Cc : "Yang Min 杨旻" < [minyang0216@163.com](mailto:minyang0216@163.com) >, " min.yang@emi2012.org " < [min.yang@emi2012.org](mailto:min.yang@emi2012.org) >, "Shuying Liu" < [SYL-consulting@outlook.com](mailto:SYL-consulting@outlook.com) >

Subject : Jiang et al. EMI 9:1, 275-277

Hello, teacher!

Two days ago, a colleague in my laboratory found that the following chapters of you and Shibo's co-authors had two problems: the number of amino acids was incorrect because of location positioning ( the numbering for each functional domain) error. Shibo and I mentioned it. Today he told you to also talk to him, Hope to correct.

3

---

## Page 4

DOI: 10.1080/22221751.2020.1723441, An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies.

I welcome you to post a correction erratum. I don't know if it is necessary to modify the diagram. Even if it is necessary, I think it is worth it. Welcome to tell me what you mean, then the EMI editorial department came to coordinate with T&F on how to publish erratum.

Thank you!

Lu

ps There are 3399 downloads of your papers to read today. Congratulations!



-----

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Thursday, July 2, 2020 12:46 AM  
**To:** yuan zhenghong; Lu, Shan  
**Cc:** Tang, Yi-Wei; Winter999; zhangwenhong  
**Subject:** Re: Re: Re: meeting on Saturday

I am confused. according to mails previously, beacuse Yiwei will not be free on July 4,the time was changed to Sunday, July 5th.

Please confirm the date nad time again. Wen

-----Original Messages-----

**From:** "yuan zhenghong" <zhyuan@shmu.edu.cn>  
**Sent Time:** 2020-07-01 21:41:19 (Wednesday)  
**To:** "wen yumei" <ymwen@shmu.edu.cn>  
**Cc:** "Tang, Yi-Wei" <yi-wei.tang@cepheid.com>, Winter999 <Winter999@hotmail.com>, zhangwenhong <zhangwenhong@fudan.edu.cn>  
**Subject:** Re: Re: meeting on Saturday

Hello, Mr. Wen and everyone, please tell me the appropriate time on Saturday, I will arrange the Zoom conference system, thank you, Zhenghong

-----The original message-----

**发件人:** "wen yumei" <ymwen@shmu.edu.cn>  
**Sending time:** 2020-07-01 21:07:21 (Wednesday)  
**收件人:** "Tang, Yi-Wei" <yi-wei.tang@cepheid.com>  
**抄送:** Winter999 <Winter999@hotmail.com>, zhangwenhong <zhangwenhong@fudan.edu.cn>, "yuan zhenhong" <zhyuan@shmu.edu.cn>  
**Main topic:** Re: Meeting ON Saturday

Shan called Me yesterday, and I asked him regarding the adinistrative part of owrk. He told me he is negotiating with the publisher on some issues, which I doubt that Xiaodong can manage. Regarding the economic part, he said that all were managed by xiaodong. I think it is better that you and me and wenhong, xiaodong and zhenghong can get together on Satruday by one phone, and we can talk with Shan together.

Hope all can meet on Saturday, and zhenghong arrange the phone call meeting. Wen

-----Original Messages-----

6/1/2021

I am confused. according to mails previously, beacuse Yiwei will not be free on July 4,the time was changed to Sunday, July 5th.

**From:** "Tang, Yi-Wei" <yi-wei.tang@cepheid.com>

**Sent Time:** 2020-07-01 08:12:58 (Wednesday)

**To:** "Yumei Wen (ymwen@shmu.edu.cn)" <ymwen@shmu.edu.cn>

**Cc:**

**Subject:** FW: EMI manuscript - Tc toxins

Teacher Wen,

1

---

## Page 2

Could you give me some advice? I wonder if a phone chat between Shan and me before our founders' meeting will be helpful?

Thank you, Yi-Wei

of a manual signature that is included in any attachment.





---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Monday, September 28, 2020 8:27 AM  
**To:** Lu, Shan  
**Subject:** Re: RE: Re: message

I did take time to go through the documents, and I agree with you that they should write rebuttal if they have evidence to show it.

Anyway, Yan seemed to have involved too deeply with the other person in California. I told him they should make a clear response to the accusation. They may contact you. Anyway, we should keep EMI with high standard. YM Wen

> -----Original Messages-----

> From: "Lu, Shan" <Shan.Lu@umassmed.edu> Sent Time: 2020-09-27 21:53:25

> (Sunday)

> To: "wen yumei" <ymwen@shmu.edu.cn>

> Cc:

> Subject: RE: Re: message

>

> Dear Prof Wen,

>

> I am really sorry to hear the health status of Dr. Ning. It is very hard at this time. Please take care of yourself. You are right that over treatment is not useful. At the same time, please try to use all the measures to make him comfortable including any pain medication as we do all the time in US. You may consult your daughter and other medical colleagues.

>

> Please don't worry about this investigation with Yan's two papers. If you approve, please ask Dr. Yan to contact me so you don't need to handle this at the current unique time.

>

> I have attached two documents for your reference only if you have time and are able to study them.

>

> 1) a very short summary and emails related to this investigation.

> 2) the full copy of the original blog post which provided detailed and comprehensive reporting on the data fabrication of Yan's papers, and the involvement of David Ojcius who has a bad history of such issues, along with Yan in many papers (not published at EMI). The link of this blog post was in the original email to you but you may not have the chance to access the link. It took me some time today to download this entire online blog report for your reference.

>

> My opinion is that this case is quite complicated and Yan is deeply involved with this David Ojcius in many papers. It is for EMI's best interest to follow what the decision that T&F may have. I will do my best to discuss with them. The ultimate goal is to protect the integrity and reputation of EMI and I trust you would agree.

>

> I will keep you posted on anything I will be doing on this case, and you can just read it if you have the time or mood to do so.

>

> Best regards.

>

> Shan

>

> -----Original Message-----

> From: wen yumei <ymwen@shmu.edu.cn>

> Sent: Sunday, September 27, 2020 4:49 AM

> To: Lu, Shan <Shan.Lu@umassmed.edu>  
 > Subject: Re: Re: message  
 >  
 > OK. Please try to do your best to lessen the negative effect to the corresponding author., but within reasonable ways.  
 > Ning is getting worse and worse during the treatment with drug+  
 > antibody. He refused to take food with a poor appetite, and only  
 > drinks soup and take some fruit for 10 days. I feel very depressed and  
 > worried. I will discuss with his doctor after the long holiday. I feel  
 > we should not over treat him and affect his living quality. Wen  
 >  
 >  
 >> -----Original Messages-----  
 >> From: "Lu, Shan" <Shan.Lu@umassmed.edu> Sent Time: 2020-09-27  
 >> 04:21:35  
 >> (Sunday)  
 >> To: "wen yumei" <ymwen@shmu.edu.cn>  
 >> Cc:  
 >> Subject: Re: message  
 >>  
 >> Dear Prof Wen,  
 >>  
 >> I could not receive 短信 because I am not in China.  
 >>  
 >> EMI has no control on these two papers as T&F wrote to him directly. To make things more complicated is the involvement of another European (?) person. I thought I copied emails to you but I will review the whole story and put together to you.  
 >>  
 >> Then I can discuss with you by wechat phone call.  
 >>  
 >> Best.  
 >>  
 >> Shan  
 >>  
 >> Sent from my iPhone  
 >>  
 >>> On Sep 26, 2020, at 3:44 PM, wen yumei <ymwen@shmu.edu.cn> wrote:  
 >>>  
 >>> Shan, I have forwarded you a 短信, not 微信 from 浙江医学院微生物教研室·严杰· to me, regarding an article on leptospiral which was accused as repeated use of figures in EMI. I have known this professor for many years, and he was a good scientist. He wrote to show that they designed and did all the experiments, while the student and he did not check the figures carefully.  
 >>> He asked if they can write to the journal and make a revision on errors, instead of withdrawing the article.  
 >>> I have written and asked you about this issue, but have not yet  
 >>> heard from you. Please respond. YMW  
 >>>  
 >>>  
 >>>  
 >>>  
 >>>  
 >  
 >  
 >  
 >

>

-----

**From:** Shibo Jiang <shibojiang@fudan.edu.cn>  
**Sent:** Wednesday, January 22, 2020 11:12 AM  
**To:** Lu, Shan  
**Subject:** Re: RE: RE: Presubmission inquiry

Thanks, Shan.  
Will do.  
Shibo

-----The original message-----

发件人:"Lu, Shan" <Shan.Lu@umassmed.edu>

**Sending time:** 2020-01-23 00:05:31 (Thursday)

To : "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>

CC :

Main topic: RE: RE: Presubmission Inquiry

Yes, to a journal, a short paper (only one fig) is much easier to accept in this case. Ask your students to go EMI online to find the rules for a short paper.

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Wednesday, January 22, 2020 10:14 AM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Subject:** Re: RE: Presubmission inquiry

Thanks, Shan.

Sorry for not describing it clearer - Prof Wen's suggestion was sent to me via phone message (see below), not her comments on our Commentary:

Wen: Can you consider doing an analysis of the genome and function of the new coronavirus and other coronaviruses, and submit your paper as soon as possible?

Jiang: Thank you, Master Wen! We have been working on it for nearly a day, and the draft is now complete.

Smell: Very good!

Thanks for your suggestion to change our article to letter. I will discuss with Lu, Tianlei, Lanying and Zhengli about this approach after holidays (they are already on vacation now). If they agree, I will change it to letter for submission as soon as possible.

Best,

1

---

## Page 2

Shibo

-----The original message-----

发件人:"Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

Sending time : 2020-01-22 22:06:08 (Wednesday)

To : "Shibo Jiang (姜世勃)" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>

CC :

Subject : RE: Presubmission inquiry

Hi, Shibo,

Thanks.

I don't think this is the work Prof Wen asked. It is still only modeling/gene sequence analysis. She was asking to have actual experimental work. Also, she was interested in getting more immunology studies to understand the pathogenesis.

This paper very soon will be similar to several others. You can decide whether you want to submit EMI or not. It will be nice if you can put in a short report but the number of Fig/table has to be limited. If it is the full article, I may need to have some external review (quickly) to ensure the details are all correct.

I will respect whatever the decision you will make.

By the way, the new special topic for "Emerging and Re-emerging CoV" is done on design and it will be online very soon. I trust that you will like it.

Shan

**From:** Shibo Jiang (姜世勃) <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>

**Sent:** Wednesday, January 22, 2020 8:22 AM

**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Subject:** Presubmission inquiry

2

---

**Page 3**

Dear Shan,

As suggested by Prof. Wen, we have completed this project and written a research paper. Please quickly check the manuscript (I am still working on it) and let me know whether you are interested in it or whether it is suitable for EMI. If yes, I will submit it to EMI immediately after I complete the revision. If not, I will submit it to another journal.

Thank you very much for your consideration,

Shibo

---

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Monday, February 22, 2021 10:38 AM  
**To:** Lu, Shan  
**Cc:** Wen Yumei  
**Subject:** Re: RE: RE: RE: Application for APC waiver or discount

Thanks, Shan.

I will check my email frequently. If we receive the copyright and galley proof, we will process them immediately.

Best,

Shibo

> -----原始邮件-----

> 发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>

> 发送时间: 2021-02-22 23:18:15 (星期一)

> 收件人: "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>

> 抄送: "Wen Yumei" <ymwen@shmu.edu.cn>

> 主题: RE: RE: RE: Application for APC waiver or discount

>

> Your paper is officially accepted. I asked T&F to process it as fast as they can. Please check your email regularly as they will send you two emails: first about copyright and later about galley proof.

>

> Best.

>

> Shan

>

> -----Original Message-----

> From: Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>

> Sent: Monday, February 22, 2021 9:44 AM

> To: Lu, Shan <Shan.Lu@umassmed.edu>

> Cc: Wen Yumei <ymwen@shmu.edu.cn>

> Subject: Re: RE: RE: Application for APC waiver or discount

>

> Thanks, Shan.

>

> Shibo

>

>> -----原始邮件-----

>> 发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>

>> 发送时间: 2021-02-22 21:04:07 (星期一)

>> 收件人: "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>

>> 抄送: "Wen Yumei" <ymwen@shmu.edu.cn>

>> 主题: RE: RE: Application for APC waiver or discount

>>

>> Dear Shibo,

>>

>> Thanks. Let's focus back to the science of papers. Looking forward to receiving your revised commentary so we can publish it soon.

>>

>> Best.

>>

>> Shan

>>

>> -----Original Message-----

>> From: Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>

>> Sent: Monday, February 22, 2021 12:49 AM

>> To: Lu, Shan <Shan.Lu@umassmed.edu>

>> Cc: Wen Yumei <ymwen@shmu.edu.cn>

>> Subject: Re: RE: Application for APC waiver or discount

>>

>> Dear Prof. Lu,

>>

>> I am very sorry for misunderstanding the T&F's policy that APC waiver is mainly designed for people from poor developing countries. Since several high-profile journals actively waived my publication fee when publishing my Commentaries, Correspondences and Letter to Editor recently, I mistakenly thought that T&F may have similar policy.

>>

>> Thanking for your praise, I am not "the most successful business person academically and commercially" or "among the top funded scientists in the entire China", rather than one of the poorest PIs in our school. I have tried very hard to get funds to support my studies on the development of pan-CoV fusion inhibitors and pan- $\beta$ -CoV-B vaccines, but have failed so far. Because of the age restriction policy in China, I, as a researcher at 67-year-old, was not allowed to be a PI to apply for grants from the National Health Commission or Ministry of Science and Technology of China, but only allowed to apply for no more than two grants from NSFC.

>>

>> Currently, I have only one NSFC grant (¥ 2.75 millions for 3 years), which is far not enough to support my 12 Ph.D. students. That is why I have no funds to hire a postdoc. Previously, I could reimburse some of my publication fee from my 横向经费 (the funds from companies) or my colleague's accounts, but this is not allowed after the announcement of new financial policy (all the funds must be 专款专用)。I did invite some of my colleagues to join me in writing manuscripts, but most of my invitations were declined if the targeted journal's IF is <10 and if they are not corresponding authors. Due to the "破四唯" policy, publication of too many papers by a researcher will destroy his/her reputation because only 5 representative papers are allowed in an application for promotion or grant.

>>

>> I have never said that I want to quit EMI responsibility. I only consulted with you last year whether you could ask a non-Chinese EMI editor to replace me for handling the manuscripts for the special issue for coronaviruses. I have still done my best to do the work that you have assigned to me. Indeed, it is me to propose early of last year the special issue for coronaviruses and suggest you to assign Prof. KY Yuen as the "guest editor" to handle the manuscript for this special issue. You agreed with my proposal for the special issue, but asked me, not KY, as the editor responsible for the special issue. Soon after the announcement, I received many calls from the researchers in China, asking me whether I could handle their manuscripts for this special issue through the fast-track review system. I told them that, different from the "guest editors" to handle the manuscripts for the special issues of other journals, I, as an editorial board member of EMI, have no authority to make decision on the manuscripts submitted to EMI for the special issue. Most of them became very angry with me, thinking that I just used it as an excuse to reject their papers. That is why I consulted with you whether you could assign a non-Chinese EMI editor to replace me for handling the manuscripts for this special issue, since it is not easy for the Chinese researchers to call a non-Chinese EMI editor in a foreign country.



>>

>> I have not gotten more reward with funding after I published more than 40 papers in high-profile journals last year. I did receive an award of ~¥15,000 recently from our school for these publications last year, but I gave all the award to the junior staff in my group.

>>

>> I will still do my best to make contribution to our lovely journal, EMI.

>>

>> Best wishes,

>>

>> Shibo

>>

>>> -----原始邮件-----

>>> 发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>

>>> 发送时间: 2021-02-22 06:42:46 (星期一)

>>> 收件人: "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>

>>> 抄送:

>>> 主题: RE: Application for APC waiver or discount

>>>

>>> Hi, Shibo,

>>>

>>> Are you kidding me? I was treating your short commentary as a special case due to your past involvement with EMI. Even KY's excellent review will take longer process. I did not expect you will treat us like this.

>>>

>>> T&F APC waiver is mainly designed for people from poor developing countries so your application will not be approved. You are very famous for being the most successful business person academically and commercially. You and your co-authors are among the top funded scientists in the entire China and yet you can not afford to pay \$900? EMI will have big trouble if an APC wavier is granted to you and your co-author as it will be hard for us to face other authors from much difficult condition than you guys.

>>>

>>> I thought you told me that you have to quit EMI responsibility because you were quite sick so I am surprised to know you have published too many research articles in the last year. Usually with so many papers, the authors should have more reward with fame and funding.

>>>

>>> Since the founding of EMI, several of us as the founders have to contribute not only time but also all kinds of resources while we have not personally being paid a single penny for our service. EMI has done multiple special favors to you and your group (such as the urgent publication which led your Gates funding) because you are part of the Fudan group. We would look forward to seeing at least some basic support if not more contribution.

>>>

>>> Maybe we should consult Prof Wen to see if she thinks you are poor as she may know your situation better than anyone else.

>>>

>>> Best.

>>>

>>> Shan

>>>

>>> -----Original Message-----

>>> From: Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>

>>> Sent: Sunday, February 21, 2021 7:22 AM

>>> To: editorial@emi2012.org; Lu, Shan <Shan.Lu@umassmed.edu>

>>> Cc: Yang Min 杨旻 <minyang0216@163.com>

> > Subject: Application for APC waiver or discount  
> >  
> > Dear Prof. Lu,  
> >  
> > Because of publishing too many research articles in this budget year, I do not have enough budget left to pay for the APC for publication of our Commentary (ID TEMI-2021-0175) in EMI. Here I am applying for an APC waiver or discount. I would appreciate it very much if you could approve my application and provide me an APV waiver or discount code before submission of our revised manuscript online.  
> >  
> > Thank you very much for your consideration,  
> >  
> > Shibo  
> > \*\*\*\*\*  
> > Shibo Jiang, M.D.  
> > Professor and Director, Institute of Medical Microbiology Key  
> > Laboratory of Medical Molecular Virology (MOE/NHC/CAMS) School of  
> > Basic Medical Sciences, Fudan University  
> > 131 Dong An Road, Fuxing Building, 4th Fl, Rm 413 Xuhui District,  
> > Shanghai 200032, China  
> > Phone: +86-21-54237673  
> > E-mail: shibojiang@fudan.edu.cn  
> > Website:  
> > https://nam10.safelinks.protection.outlook.com/?url=http%3A%2F%2Fm  
> > ed  
> > ic  
> > ine.fudan.edu.cn%2Fen%2Fshow.aspx%3Finfo\_lb%3D27%26flag%3D3%26info  
> > \_i  
> > d%  
> > 3D124&data=04%7C01%7Cshan.lu%40umassmed.edu%7C93501d3cd5004814  
> > 77  
> > 0d  
> > 08d8d6f591c0%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C63749569  
> > 75  
> > 03  
> > 053933%7CUnknown%7CTWFpbGZsb3d8eyJWljojMC4wLjAwMDAiLCJQIjoiV2luMzI  
> > iL  
> > CJ  
> > BTil6Ik1haWwiLCJXVCi6Mn0%3D%7C1000&sdata=77z3O24udfncRCCedeHDv  
> > MT  
> > %2  
> > B9rZG2T5aBu1XwUOWxAU%3D&reserved=0  
> > Publications:  
> > https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2F  
> > pu  
> > bm  
> > ed.ncbi.nlm.nih.gov%2F%3Fterm%3Dshibo%2Bjiang%26sort%3Ddate%26size  
> > %3  
> > D2  
> > 00&data=04%7C01%7Cshan.lu%40umassmed.edu%7C93501d3cd5004814770  
> > d0  
> > 8d  
> > 8d6f591c0%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C63749569750



>>>> 87  
>>>> 3c7&data=04%7C01%7Cshan.lu%40umassmed.edu%7C7ebf278d564248ec  
>>>> 09  
>>>> e6  
>>>> 08  
>>>> d8d663588e%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C63749506  
>>>> 94  
>>>> 91  
>>>> 30  
>>>> 8875%7CUnknown%7CTWFpbGZsb3d8eyJWljojMC4wLjAwMDAiLCJQIjoiV2luMzI  
>>>> iL  
>>>> CJ  
>>>> BT  
>>>> il6lk1haWwiLCJXVCI6Mn0%3D%7C1000&data=LcqHwhK1nn%2Bely3o4do  
>>>> kQ  
>>>> 2p  
>>>> qk  
>>>> 2QHbNppscwmcigzfew%3D&reserved=0  
>>>>  
>>>> This will direct you to the first page of your revised manuscript. Please enter your responses to the comments made by the reviewer(s) in the space provided. You can use this space to document any changes you made to the original manuscript. Please be as specific as possible in your response to the reviewer(s).  
>>>>  
>>>> This link will remain active until you have submitted your revised manuscript. If you begin a revision and intend to finish it at a later time, please note that your draft will appear in the “Revised Manuscripts in Draft” queue in your Author Center.  
>>>>  
>>>> IMPORTANT: Your original files are available to you when you upload your revised manuscript. Please delete any redundant files before completing the submission.  
>>>>  
>>>> Because we are trying to facilitate timely publication of manuscripts submitted to Emerging Microbes & Infections, your revised manuscript should be uploaded by 21-Mar-2021. If it is not possible for you to submit your revision by this date, we may have to consider your paper as a new submission.  
>>>>  
>>>> Once again, thank you for submitting your manuscript to Emerging Microbes & Infections and I look forward to receiving your revision.  
>>>>  
>>>> Sincerely,  
>>>>  
>>>> Shan Lu  
>>>> Editor-in-Chief  
>>>> Emerging Microbes & Infections  
>>>>  
>>>>  
>>>> Review Editor Comments to the Author:  
>>>>  
>>>> This is an important topic and we did a fast review with input from some of the leading authorities in this area. Here is the key summary:  
>>>>  
>>>> 1. Reviewers in general agree with the authors about the need for human challenges to determine what protection is offered by current vaccines against the new strains.

>>> 2. However, the reviewers felt that the paper needs more discussion about how to do those studies. This paper is more like a public decision debate but not enough scientific and technical details to accomplish such challenge studies.

>>> 3. For example, can you extrapolate from monkey challenges to humans, as the authors suggest?

>>> 4. Does one need to challenge unvaccinated subjects to show infectivity? Do you then challenge current vaccinees with the same dose?

>>> 5. If they are resistant to the dose infectious for seronegatives, do you increase the challenge dose to determine how much current virus they can resist vs. mutant virus?

>>> 6. Is it necessary that the challenges be compared in people with the same titers, or can people with different titers be challenged?

>>> 7. Do we need to measure both IgA and IgG antibodies?

>>>

>>> The point here is that challenge studies must be done with a lot of insight so that the answers obtained are valid. By the way, people with high immunity will resist challenge with the mutants, but people with lower titers will not. So the protection is not a black and white with variants. Rather there is a quantitative range and different variants may be different, and may also depending on the individual vaccines. Therefore a small group of challenge studies may not truly reflect the population protection efficacy of a vaccine. It is the same idea that a lab based neutralizing assay can not predict the field vaccine protection. The authors need to be very careful not turning the small group challenge study into something like a lab based neutralizing assay.

>>>

>>>

>>>

>>>

>>>

>>

>>

>>

>>

>>

>

>

>

>

>

>

---

**From:** 蔡启良<Qiliang Cai> <qiliang@fudan.edu.cn>  
**Sent:** Saturday, February 22, 2020 4:09 AM  
**To:** Lu, Shan  
**Cc:** wen yumei  
**Subject:** Re: RE: RE: RE: Emerging Microbes & Infections

Dear Shan,

Thanks for the info! I believe I did not refuse to review any mns that I was assigned, and finished most cases on time last year:) Anyway, I am ok with any decision you have made.

Best,

Qiliang

-----原始邮件-----

发件人:"Lu, Shan" <Shan.Lu@umassmed.edu>  
发送时间:2020-02-22 13:51:54 (星期六)  
收件人: "蔡启良<Qiliang Cai>" <qiliang@fudan.edu.cn>  
抄送: "wen yumei" <ymwen@shmu.edu.cn>  
主题: RE: RE: RE: Emerging Microbes & Infections

Dear Qiliang,

Sorry I did not understand what you mean.

I gave you last year the lowest number of papers because you were too slow and missing many deadlines. You are welcome to continue as a Review Editor in this year but I will need to give the same number of papers as others so it is fair to other RE.

There is no limit how many review editors we can have so it is not a problem to have you and other review editors at the same time. There was a discussion at the end of 2019 meeting among editors including prof Wen and it was decided that I will discuss with you whether you will be able to do the full scale work as a review editor.

Please let me know and I am happy with any decision you may have.

Best.

Shan

**From:** 蔡启良<Qiliang Cai> <qiliang@fudan.edu.cn>  
**Sent:** Saturday, February 22, 2020 12:44 AM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Cc:** wen yumei <ymwen@shmu.edu.cn>  
**Subject:** Re: RE: RE: Emerging Microbes & Infections

Dear Shan,

Sorry for confusion! I meant that I am happy to continue to work as RE and will try my best to serve. However, I am totally fine to take your assignment if you have other better candidates.

Look forward to see you!

Best,

Qiliang

-----原始邮件-----

发件人:"Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
发送时间:2020-02-22 12:05:16 (星期六)  
收件人: "蔡启良<Qiliang Cai>" <[qiliang@fudan.edu.cn](mailto:qiliang@fudan.edu.cn)>  
抄送:  
主题: RE: RE: Emerging Microbes & Infections

Hi, Qiliang,

Thanks and no problem. I fully understand how busy you are. As you indicated, I will try to maintain you as a reviewer but not let you to work as RE to process a lot of papers. One other RE is also stepping down due to other work and a few more will be added to handle the huge volume of papers we need to process.

Hope we can meet soon if the CoV outbreak is under control. Please take care!

Best.

Shan

**From:** 蔡启良<Qiliang Cai> <[qiliang@fudan.edu.cn](mailto:qiliang@fudan.edu.cn)>

**Sent:** Friday, February 21, 2020 9:29 PM

**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Subject:** Re: RE: Emerging Microbes & Infections

Dear Shan,

Very glad to hear from you and hope you well! I would be happy to help, and continue to put my efforts to improve EMI. It may just a little bit slow response some time due to instant heavy works, and hope you could understand.

Best,

Qiliang

-----原始邮件-----

发件人:"Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

发送时间:2020-02-21 03:43:26 (星期五)

收件人: "'qiliang@fudan.edu.cn'" <[qiliang@fudan.edu.cn](mailto:qiliang@fudan.edu.cn)>

抄送:

主题: RE: Emerging Microbes & Infections

Dear Qiliang,

Long time no talk. Hope this email will find you well, in particular under the cloud of the current SARS2.

I meant to contact you for some time but the work of EMI and other things have kept me too busy to reach you. As I learned that you are taking more administrative responsibility nowadays, I wonder if you would like to continue to serve as Review Editor for EMI. EMI has grown further in the last year, and with the recent SARS2, we had more submissions. The work load is very huge. We need to give RE more work load but I realize that it may be hard for you. So please let me know your thought and I am happy to arrange anyway you want. No matter what arrangement, you should continue to be the Editorial Board member along with everyone else for the current term.

Please let me know your opinion. We can talk over the wechat if you would like.



Best.

Shan

\*\*\*\*\*

*Shan Lu, MD, PhD*

*Professor*

*Department of Medicine*

*U Mass Med School*

*Worcester, MA01605*

*USA*

*Tel. 1-508-856-6791*

*Email: [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu)*

--

Qiliang Cai, Ph.D. Professor, Deputy director MOE&NHC&CAMS Key Laboratory of Medical Molecular Virology School of Basic Medical Sciences Shanghai Medical College Fudan University Shanghai, 200032 P. R. China [Tel:\(+86\)21-5423-7716](tel:+862154237716) Email: [qiliang@fudan.edu.cn](mailto:qiliang@fudan.edu.cn) Lab website: [www.viralcancer.fudan.edu.cn](http://www.viralcancer.fudan.edu.cn)

--

Qiliang Cai, Ph.D. Professor, Deputy director MOE&NHC&CAMS Key Laboratory of Medical Molecular Virology School of Basic Medical Sciences Shanghai Medical College Fudan University Shanghai, 200032 P. R. China [Tel:\(+86\)21-5423-7716](tel:+862154237716) Email: [qiliang@fudan.edu.cn](mailto:qiliang@fudan.edu.cn) Lab website: [www.viralcancer.fudan.edu.cn](http://www.viralcancer.fudan.edu.cn)

--

Qiliang Cai, Ph.D. Professor, Deputy director MOE&NHC&CAMS Key Laboratory of Medical Molecular Virology School of Basic Medical Sciences Shanghai Medical College Fudan University Shanghai, 200032 P. R. China Tel:(+86)21-5423-7716 Email: [qiliang@fudan.edu.cn](mailto:qiliang@fudan.edu.cn) Lab website: [www.viralcancer.fudan.edu.cn](http://www.viralcancer.fudan.edu.cn)

---

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Thursday, January 9, 2020 11:37 PM  
**To:** Min Yang  
**Cc:** Lu, Shan; Emily  
**Subject:** Re: RE: RE: RE: EMI special issue on Emerging CoV

Thanks, Min.

Shibo

-----原始邮件-----

发件人:"Min Yang" <min.yang@emi2012.org>

发送时间:2020-01-10 12:29:22 (星期五)

收件人: "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>, "Lu, Shan" <Shan.Lu@umassmed.edu>

抄送: Emily <editorial2@emi2012.org>

主题: RE: RE: RE: EMI special issue on Emerging CoV

Dear Prof Lu and Jiang,

I have gone through all EMI past publications on coronaviruses and found 21 articles qualified.

Attached please find the article list.

Please feel free to let me know if you need any further assistance.

Thanks and regards,

Min Yang

Emerging Microbes & Infections (EMI) Editorial Office

4F Fuxing Building

131 Dongan Road

Shanghai

China

Tel: 86-21-54237992

E-mail: [editorial@emi2012.org](mailto:editorial@emi2012.org)

**From:** Shibo Jiang (姜世勃)

**Sent:** Thursday, January 9, 2020 7:16 PM

**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Cc:** Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>; Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>

**Subject:** Re: RE: RE: EMI special issue on Emerging CoV

Dear Shan,

Thank you very much for sharing with me your concern about asking junior or non-expert people, particularly Chinese experts, to serve as GE. I understand it now. I will try my best to work on it at this stage and let you know if I feel too tired to handle too many manuscripts in the future.

Best,

Shibo

-----原始邮件-----

发件人: "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

发送时间: 2020-01-09 14:56:45 (星期四)

收件人: "Shibo Jiang (姜世勃)" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>, "Min Yang" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>

抄送: Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>

主题: RE: RE: EMI special issue on Emerging CoV

Hi, Shibo,

I don't think it is a good idea to ask junior or non-expert people to serve as GE. One more important factor is that we need to make sure EMI is not just a "Chinese people" journal which will kill us very soon. If you can not serve, I will find someone else.

The best approach at this point may be to have you as the GE and you can see how much work is involved, and you can feel free to drop if you feel the work is too much. The Editorial office and T&F will do most of the work. Please let me know.

Shan

**From:** Shibo Jiang (姜世勃) <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>  
**Sent:** Wednesday, January 8, 2020 10:38 PM  
**To:** Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>  
**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>  
**Subject:** Re: RE: EMI special issue on Emerging CoV

Hi Shan,

Can we invite Prof. Qiliang Cai or Tianlei Ying or Rong Zhang as a GE for this special issue? We can meet together convincingly to discuss the related topics often. Although many senior experts in this field may agree to act as the GE for this special issue, they may not be willing to handle many manuscripts by him/herself. I do have a concern that there will be many manuscripts to be submitted to EMI for this special issue very soon. I may not have enough time to deal with the authors and their manuscripts.

Shibo

-----Original Messages-----

**From:** "Min Yang" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>  
**Sent Time:** 2020-01-09 11:12:25 (Thursday)  
**To:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>, "Shibo Jiang (姜世勃)" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>  
**Cc:** Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>  
**Subject:** RE: EMI special issue on Emerging CoV

Ok, I will generate the list asap.

Thank you,

Min

---

**From:** Lu, Shan  
**Sent:** Wednesday, January 8, 2020 9:54 PM  
**To:** 'Shibo Jiang (姜世勃)' <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>  
**Cc:** Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>; Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>  
**Subject:** RE: EMI special issue on Emerging CoV

I got the feedback from Dr. Shi. She thanks my invitation but stated that this may not be a good time for her to accept our invitation. So you can be the sole GE at this point. Once we established it, we can find another GE.

On the title, I think yours is too much like a “political statement”. I think we can make it simple and scientific. How about **“Emerging and Re-emerging Coronaviruses”**?

Next, please draft an overall introduction of this special issue.

Min Yang: please go through past EMI papers and find all corona viruses related papers and generate a list so they can be included in this special issue. Min Yu may help to see if there is any easy way to identify such papers. With a first rough list, Prof Jiang can suggest more key words to identify such EMI papers.

Shan

**From:** Shibo Jiang (姜世勃) <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>  
**Sent:** Tuesday, January 7, 2020 4:43 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** 'Min Yang' <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>; Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>  
**Subject:** Re: EMI special issue on Emerging CoV

Thanks, Shan.

I will work together with Min Yu and Min Yang, under your guidance, on this special issue.

It is a good idea to include all manuscripts related to the emerging CoVs in this special issue. I suggest to change the title to **“Combating the pathogenic emerging and re-emerging coronaviruses”** (I include "Re-emerging CoV" because we cannot exclude the possibility of SARS epidemic in the future).

I will draft a short description of this special issue.

Please send an invitation to Dr. Zhengli Shi as soon as possible. If she agrees, I will discuss with her about the list of potential authors and topics and we should sent out invitation letters together.

Best,

Shibo

-----Original Messages-----

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Sent Time:** 2020-01-07 14:31:54 (Tuesday)

**To:** "'Shibo Jiang (姜世勃)'" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>

**Cc:** "'Min Yang'" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>, Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>

**Subject:** EMI special issue on Emerging CoV

Hi, Shibo,

Here I am connecting you to Min Yu and Min Yang of EMI editorial office on the set up of a new special issue.

First, you will serve as the guest editor (before the 2<sup>nd</sup> person is finalized).

Second, we need to define what is the scope of this special issue. I don't think we should make this one for the pending Wuhan pathogen. The emerging CoV itself is interesting and has enough papers for us to set up a special issue.

Third, based on the decision of above, we can name the title of special issue.

Fourth, you then need to draft a short description of this special issue (using other EMI one as the example but the descriptions for some of them are not very good, but the overall length can be used as a template).

After the above are done, we can draft together an invitation letter and develop a list of potential experts who may contribute to this special issue. Min Yu will work on this with us.

At the same time, Min Yang will work with you to identify those published EMI papers related to this topic and pull them into this special issue now (as part of the process to build this special issue).

Best.

Shan



\*\*\*\*\*

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Sunday, February 9, 2020 10:45 PM  
**To:** Shi Zhengli; Du Lanying\_NYBC  
**Cc:** Lu, Shan; Yang Min 杨敏; min.yang@emi2012.org; 'Shuying Liu'  
**Subject:** Re: RE: RE: Re: Jiang et al. EMI 9:1, 275-277  
**Attachments:** Figure 1\_2019-nCoV\_commentary\_EMI\_2020-2-9.tif; Jiang\_Commentary\_2019-nCoV\_EMI\_2020.pdf; Jiang\_Letter to editor\_EMI\_2020-2-10.docx

Dear Drs. Shi and Du,

I prepared the letter to editor and the updated Figure, including Figure 1B (see the attachment). Please check and modify it if necessary. If you have no change, I will submit it to EMI as soon as possible.

I also attached the original version downloaded online. You can go through it and make correction if it is really necessary.

Thanks,

Shibo

-----The original message-----

From 人 : "Lu, Shan" <Shan.Lu@umassmed.edu>

**Sending time:** 2020-02-10 11:18:51 (Monday)

To : "Shi Zhengli" <zlshi@wh.iov.cn>

Cc : "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>, "Yang Min 杨旻" <minyang0216@163.com>, "min.yang@emi2012.org" <min.yang@emi2012.org>, "Shuying Liu" <SYL-consulting@outlook.com>

Main **topic:** REs: REs: Re: the EMI Jiang et Al. 9:.. 1, 275-277

Sounds good. No worries.

So Shibo, please produce a simple erratum along with a new Fig 1 including the revised Fig 1b. Since Prof Shi is going to update her GenBank information, there is no need to mention this episode as I can see. Just mention that you need to update your figure to follow the numbering tradition in SARS field.

I will link you to T&F JEO to see how to submit.

Best.



**From:** Shi Zhengli<zlshi@wh.iov.cn>  
**Sent:** Sunday, February 9, 2020 10:11 PM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Cc:** Shibo Jiang (姜世博) <shibojiang@fudan.edu.cn>; Yang Min 杨旻<minyang0216@163.com>;  
min.yang@emi2012.org; Shuying Liu' <SYL-consulting@outlook.com>  
**Subject:** Re: RE: Re: Jiang et al. EMI 9:1, 275-277

Dear Prof. Liu,

I'm very sorry to make this errors. We have requested to update the GenBank information and the sequence  
annotation will be updated very soon.

My suggestion is to make an erratum.

Best regards,

Zhengli,

-----The original message-----

Outgoing Face : "Lu, Shan" < [Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu) >

Sending time : 2020-02-10 01:31:16 (Monday)

To : "Shibo Jiang (姜世博)" < [shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn) >, "石正丽" < [zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn) >

Cc : "Yang Min 杨旻" < [minyang0216@163.com](mailto:minyang0216@163.com) >, " min.yang@emi2012.org " < [min.yang@emi2012.org](mailto:min.yang@emi2012.org) >, "Shuying  
Liu" < [SYL-consulting@outlook.com](mailto:SYL-consulting@outlook.com) >

Subject : RE: Re: Jiang et al. EMI 9:1, 275-277

Hi, everyone,

We did further investigation. Here is what we found:

2

---

## Page 3

It appears that the sequences initially published at Genbank by Dr. Yongzheng Zhang, and later by others, all used the  
SARS sequences as the basis (starting site for S and the resulting aa numbering).

At the same time, Prof Shi's group uploaded her group's 2019-nCoV sequences in a different way, based on SARSr-CoV  
TG13. At least we found the following are involved.

WIV02 (GenBank: MN996527.1)

WIV04 (GenBank: MN996528.1)

6/1/2021 Dear Drs. Shi and Du, I prepared the letter to editor and the updated Figure, including Figure 1B (see the attachment). Please c  
WIV05 (GenBank: MN996529.1)  
WIV06 (GenBank: MN996530.1)

So, how to treat the EMI paper by Jiang et al. (EMI 9:275-277), there are two possible solutions:

1. Produce an erratum with a revised Fig 1b, which will include the corrected starting point of S, and revised S leader size and the total size of S, along the numbering of S subdomains).

We will select this option if you want to revise your Genbank submissions.

2. Publish another commentary which will describe this situation of different entries in Genbank so there will be no confusion to others in the field.

We will select this option if the sequences submitted by Prof Shi will stay as they are.

I (and EMI) will respect whatever decision will be.

Shan

**From:** Shibo Jiang (姜世勃) <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>  
**Sent:** Sunday, February 9, 2020 8:54 AM  
**To:** Shi Zhengli <[zshi@wh.iov.cn](mailto:zshi@wh.iov.cn)>

3

---

## Page 4

**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; Yang Min 杨旻 <[minyang0216@163.com](mailto:minyang0216@163.com)>; [min.yang@emi2012.org](mailto:min.yang@emi2012.org); 'Shuying Liu' <[SYL-consulting@outlook.com](mailto:SYL-consulting@outlook.com)>  
**Subject:** Re: Re: Jiang et al. EMI 9:1, 275-277

Thank you Lu and teacher,

Let me modify that picture. We emailed you the revised pictures and text directly, right? Is there any explanation needed?

Shibo

-----The original message-----

**From:** "石正丽" <[zshi@wh.iov.cn](mailto:zshi@wh.iov.cn)>  
**Sending time:** 2020-02-09 21:46:59 (weekday)  
**Write Face:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** "Shibo Jiang (姜世勃)" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>, "Yang Min 杨旻" <[minyang0216@163.com](mailto:minyang0216@163.com)>, "[min.yang@emi2012.org](mailto:min.yang@emi2012.org)" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>, "Shuying Liu" <[SYL-consulting@outlook.com](mailto:SYL-consulting@outlook.com)>  
**Subject:** Re: Jiang et al. EMI 9:1, 275-277

Master Lu:

I communicated with the student just now. The phylogenetic tree was constructed using the correct S gene sequence. An error occurred when uploading the sequence to GenBank. We need

Correct it.

Hereby explain.

I'm not always sorry for this kind of error.

Zhengli

-----The original message-----

Outgoing Face : "Lu, Shan" < [Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu) >

Sending time : 2020-02-09 21:15:31 (weekday)

To : "Shibo Jiang (姜世勃)" < [shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn) >, "Shi Zhengli" < [zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn) >

Cc : "Yang Min 杨旻" < [minyang0216@163.com](mailto:minyang0216@163.com) >, "min.yang@emi2012.org" < [min.yang@emi2012.org](mailto:min.yang@emi2012.org) >, "Shuying

4

---

## Page 5

Liu" < [SYL-consulting@outlook.com](mailto:SYL-consulting@outlook.com) >

Subject : Jiang et al. EMI 9:1, 275-277

Hello, teacher!

Two days ago, a colleague in my laboratory discovered that there are two problems with the next chapter of the co-author of you and Shibo: the number of amino  
The location of the gene ( the numbering for each functional domain) is wrong. Shibo and I mentioned it. Today he told you to talk to him  
To, hope to correct.

DOI: 10.1080/22221751.2020.1723441, An emerging coronavirus causing pneumonia outbreak in  
Wuhan, China: calling for developing therapeutic and prophylactic strategies.

I welcome you to post a correction erratum. I don't know if it is necessary to modify the diagram. Even if it is necessary, I think it is worth it. Welcome to tell you what you mean  
见, then the EMI editorial department came to coordinate with T&F on how to publish erratum.

Thank you!

Lu

ps There are 3399 downloads of your papers to read today. Congratulations!



-----

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Sunday, February 9, 2020 10:25 PM  
**To:** Lu, Shan  
**Cc:** Shi Zhengli; Yang Min Yang Min; min.yang@emi2012.org; Shuying Liu  
**Subject:** Re: RE: RE: Re: Jiang et al. EMI 9:1, 275-277

Yes, I will. Once I prepared, I will send it to Drs. Shi and Du for approval before submission.

Thanks,

Shibo

-----The original message-----

From 人 : "Lu, Shan" <Shan.Lu@umassmed.edu>

**Sending time:** 2020-02-10 11:18:51 (Monday)

To : "Shi Zhengli" <zlshi@wh.iov.cn>

Cc : "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>, "Yang Min 杨旻" <minyang0216@163.com>, "min.yang@emi2012.org" <min.yang@emi2012.org>, "Shuying Liu" <SYL-consulting@outlook.com>

Main **topic:** REs: REs: Re: the EMI Jiang et Al. 9:.. 1, 275-277

Sounds good. No worries.

So Shibo, please produce a simple erratum along with a new Fig 1 including the revised Fig 1b. Since Prof Shi is going to update her GenBank information, there is no need to mention this episode as I can see. Just mention that you need to update your figure to follow the numbering tradition in SARS field.

I will link you to T&F JEO to see how to submit.

Best.

Shan.

**From:** Shi Zhengli<zlshi@wh.iov.cn>  
**Sent:** Sunday, February 9, 2020 10:11 PM

**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Cc:** Shibo Jiang (姜世博) <shibojiang@fudan.edu.cn>; Yang Min 杨旻 <minyang0216@163.com>; min.yang@emi2012.org; 'Shuying Liu' <SYL-consulting@outlook.com>  
**Subject:** Re: RE: Re: Jiang et al. EMI 9:1, 275-277

Dear Prf. Liu,

I'm very sorry to make this errors. We have requested to update the GenBank information and the sequence annotation will be updated very soon.

My suggestion is to make an erratum.

Best regards,

Zhengli,

-----The original message-----

Outgoing Face : "Lu, Shan" < [Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu) >  
Sending time : 2020-02-10 01:31:16 (Monday)  
To : "Shibo Jiang (姜世博)" < [shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn) >, "石正丽" < [zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn) >  
Cc : "Yang Min 杨旻" < [minyang0216@163.com](mailto:minyang0216@163.com) >, " min.yang@emi2012.org " < [min.yang@emi2012.org](mailto:min.yang@emi2012.org) >, "Shuying Liu" < [SYL-consulting@outlook.com](mailto:SYL-consulting@outlook.com) >  
Subject : RE: Re: Jiang et al. EMI 9:1, 275-277

Hi, everyone,

We did further investigation. Here is what we found:

It appears that the sequences initially published at Genbank by Dr. Yongzheng Zhang, and later by others, all used the SARS sequences as the basis (starting site for S and the resulting aa numbering).

2

---

## Page 3

At the same time, Prof Shi's group uploaded her group's 2019-nCoV sequences in a different way, based on SARSr-CoV TG13. At least we found the following are involved.

WIV02 (GenBank: MN996527.1)

WIV04 (GenBank: MN996528.1)

WIV05 (GenBank: MN996529.1)

WIV06 (GenBank: MN996530.1)

So, how to treat the EMI paper by Jiang et al. (EMI 9:275-277), there are two possible solutions:

1. Produce an erratum with a revised Fig 1b, which will include the corrected starting point of S, and revised S leader size and the total size of S, along the numbering of S subdomains).

We will select this option if you want to revise your Genbank submissions.

2. Publish another commentary which will describe this situation of different entries in Genbank so there will be no confusion to others in the field.

We will select this option if the sequences submitted by Prof Shi will stay as they are.

I (and EMI) will respect whatever decision will be.

Shan

**From:** Shibo Jiang (姜世勃) <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>

**Sent:** Sunday, February 9, 2020 8:54 AM

**To:** Shi Zhengli <[zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn)>

**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; Yang Min 杨旻 <[minyang0216@163.com](mailto:minyang0216@163.com)>; [min.yang@emi2012.org](mailto:min.yang@emi2012.org); 'Shuying Liu' <[SYL-consulting@outlook.com](mailto:SYL-consulting@outlook.com)>

**Subject:** Re: Re: Jiang et al. EMI 9:1, 275-277

3

---

## Page 4

Thank you Lu and teacher,

Let me modify that picture. We emailed you the revised pictures and text directly, right? Is there any explanation needed?

Shibo

-----The original message-----

From : "石正丽" <[zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn)>

Sending time : 2020-02-09 21:46:59 (weekday)

Write Face : "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

Cc : "Shibo Jiang (姜世勃)" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>, "Yang Min 杨旻" <[minyang0216@163.com](mailto:minyang0216@163.com)>, "[min.yang@emi2012.org](mailto:min.yang@emi2012.org)" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>, "Shuying Liu" <[SYL-consulting@outlook.com](mailto:SYL-consulting@outlook.com)>

Subject : Re: Jiang et al. EMI 9:1, 275-277

Master Lu:

I communicated with the student just now. The phylogenetic tree was constructed using the correct S gene sequence. An error occurred when uploading the sequence to GenBank. We need to correct it.

Hereby explain.

I'm not always sorry for this kind of error.

Zhengli

-----The original message-----

Outgoing Face : "Lu, Shan" <Shan.Lu@umassmed.edu >

Sending time : 2020-02-09 21:15:31 (weekday)

To : "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn >, "Shi Zhengli" <zlshi@wh.iov.cn >

Cc : "Yang Min 杨旻" <minyang0216@163.com >, " min.yang@emi2012.org " <min.yang@emi2012.org >, "Shuying Liu" <SYL-consulting@outlook.com >

Subject : Jiang et al. EMI 9:1, 275-277

Hello, teacher!

4

---

## Page 5

Two days ago, a colleague in my laboratory discovered that there are two problems with the next chapter of the co-author of you and Shibo: the number of amino  
The location of the gene ( the numbering for each functional domain) is wrong. Shibo and I mentioned it. Today he told you to talk to him  
To, hope to correct.

DOI: 10.1080/22221751.2020.1723441, An emerging coronavirus causing pneumonia outbreak in  
Wuhan, China: calling for developing therapeutic and prophylactic strategies.

I welcome you to post a correction erratum. I don't know if it is necessary to modify the diagram. Even if it is necessary, I think it is worth it. Welcome to tell you what you mean  
见, then the EMI editorial department came to coordinate with T&F on how to publish erratum.

Thank you!

Lu

ps There are 3399 downloads of your papers to read today. Congratulations!





---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Monday, September 28, 2020 7:12 PM  
**To:** Lu, Shan  
**Subject:** Re: RE: RE: Re: message

Just do whatever you think appropriate. I am not committed to yan, if he did something wrong. Wen

> -----Original Messages-----

> From: "Lu, Shan" <Shan.Lu@umassmed.edu> Sent Time: 2020-09-28 21:30:21

> (Monday)

> To: "wen yumei" <ymwen@shmu.edu.cn>

> Cc:

> Subject: RE: RE: Re: message

>

> Thanks, Prof Wen.

>

> I have been very supportive to authors no matter what kind of difficulty they may have. I am a very flexible person and always try to find a reasonable solution good for everyone. In this case, I just don't want EMI will be involved in a public scandal as you know now the social media can be very harsh. With one such case not handled properly, all of our hard work in the last 8 years will be gone in one second. That is why I let T&F to handle this not EMI.

>

> I will be careful and keep you posted on any communications I will have with T&F and authors (if they contact me).

>

> You take care!

>

> Shan

>

> -----Original Message-----

> From: wen yumei <ymwen@shmu.edu.cn>

> Sent: Monday, September 28, 2020 8:27 AM

> To: Lu, Shan <Shan.Lu@umassmed.edu>

> Subject: Re: RE: Re: message

>

> I did take time to go through the documents, and I agree with you that they should write rebuttal if they have evidence to show it.

> Anyway, Yan seemed to have involved too deeply with the other person

> in California. I told him they should make a clear response to the

> accusation. They may contact you. Anyway, we should keep EMI with high

> standard. YM Wen

>

>

> > -----Original Messages-----

> > From: "Lu, Shan" <Shan.Lu@umassmed.edu> Sent Time: 2020-09-27

> > 21:53:25

> > (Sunday)

> > To: "wen yumei" <ymwen@shmu.edu.cn>

> > Cc:

> > Subject: RE: Re: message

>>

>> Dear Prof Wen,

>>

>> I am really sorry to hear the health status of Dr. Ning. It is very hard at this time. Please take care of yourself. You are right that over treatment is not useful. At the same time, please try to use all the measures to make him comfortable including any pain medication as we do all the time in US. You may consult your daughter and other medical colleagues.

>>

>> Please don't worry about this investigation with Yan's two papers. If you approve, please ask Dr. Yan to contact me so you don't need to handle this at the current unique time.

>>

>> I have attached two documents for your reference only if you have time and are able to study them.

>>

>> 1) a very short summary and emails related to this investigation.

>> 2) the full copy of the original blog post which provided detailed and comprehensive reporting on the data fabrication of Yan's papers, and the involvement of David Ojcius who has a bad history of such issues, along with Yan in many papers (not published at EMI). The link of this blog post was in the original email to you but you may not have the chance to access the link. It took me some time today to download this entire online blog report for your reference.

>>

>> My opinion is that this case is quite complicated and Yan is deeply involved with this David Ojcius in many papers. It is for EMI's best interest to follow what the decision that T&F may have. I will do my best to discuss with them. The ultimate goal is to protect the integrity and reputation of EMI and I trust you would agree.

>>

>> I will keep you posted on anything I will be doing on this case, and you can just read it if you have the time or mood to do so.

>>

>> Best regards.

>>

>> Shan

>>

>> -----Original Message-----

>> From: wen yumei <ymwen@shmu.edu.cn>

>> Sent: Sunday, September 27, 2020 4:49 AM

>> To: Lu, Shan <Shan.Lu@umassmed.edu>

>> Subject: Re: Re: message

>>

>> OK. Please try to do your best to lessen the negative effect to the corresponding author., but within reasonable ways.

>> Ning is getting worse and worse during the treatment with drug+

>> antibody. He refused to take food with a poor appetite, and only

>> drinks soup and take some fruit for 10 days. I feel very depressed

>> and worried. I will discuss with his doctor after the long holiday.

>> I feel we should not over treat him and affect his living quality.

>> Wen

>>

>>

>>> -----Original Messages-----

>>> From: "Lu, Shan" <Shan.Lu@umassmed.edu> Sent Time: 2020-09-27

>>> 04:21:35

>>> (Sunday)

>>> To: "wen yumei" <ymwen@shmu.edu.cn>

>>> Cc:

>>> Subject: Re: message

>>>  
>>> Dear Prof Wen,  
>>>  
>>> I could not receive 短信 because I am not in China.  
>>>  
>>> EMI has no control on these two papers as T&F wrote to him directly. To make things more complicated is the involvement of another European (?) person. I thought I copied emails to you but I will review the whole story and put together to you.  
>>>  
>>> Then I can discuss with you by wechat phone call.  
>>>  
>>> Best.  
>>>  
>>> Shan  
>>>  
>>> Sent from my iPhone  
>>>  
>>>> On Sep 26, 2020, at 3:44 PM, wen yumei <ymwen@shmu.edu.cn> wrote:  
>>>>  
>>>> Shan, I have forwarded you a 短信, not 微信 from 浙江医学院微生物教研室·严杰· to me, regarding an article on leptospiral which was accused as repeated use of figures in EMI. I have known this professor for many years, and he was a good scientist. He wrote to show that they designed and did all the experiments, while the student and he did not check the figures carefully.  
>>>> He asked if they can write to the journal and make a revision on errors, instead of withdrawing the article.  
>>>> I have written and asked you about this issue, but have not yet  
>>>> heard from you. Please respond. YMW  
>>>>  
>>>>  
>>>>  
>>>>  
>>  
>>  
>>  
>>  
>>  
>>  
>  
>  
>  
>  
>

---

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Saturday, January 11, 2020 1:48 AM  
**To:** Lu, Shan  
**Cc:** Min Yang; Emily  
**Subject:** Re: RE: RE: RE: EMI special issue on Emerging CoV

Dear Prof. Lu,

Thank you very much for your trust on me to organize the special issue - Emerging and reemerging coronaviruses. I would like to suggest a speedy process of the important manuscripts related to Wuhan CoV, so as to boost up the impact factor further. You can select some important manuscripts from the submitted manuscripts or pre-submission inquiry and send to me or other experts in CoV field who can respond very quickly for review. If I or the experts think that these manuscripts are indeed excellent or important, they can be accepted immediately or accepted after minor revision. Perhaps you have already done in such way before. Please let me know.

Shibo

Emerging and reemerging coronaviruses  
**Guest Editor:** Shibo Jiang (Fudan University, China)

Emerging and reemerging coronaviruses, including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and the latest Wuhan coronavirus (WH-CoV), may cause epidemics or pandemics of highly pathogenic infectious diseases, posing great threats to the global public health. EMI Special Topic - Emerging and reemerging coronaviruses covers research and review articles on the basic, translational and clinical studies of these coronaviruses that infect humans.

-----原始邮件-----

发件人:"Lu, Shan" <Shan.Lu@umassmed.edu>

发送时间:2020-01-10 20:02:59 (星期五)

收件人: "'Shibo Jiang (姜世勃)'" <shibojiang@fudan.edu.cn>, "Min Yang" <min.yang@emi2012.org>

抄送: Emily <editorial2@emi2012.org>

主题: RE: RE: RE: RE: EMI special issue on Emerging CoV

This is great. Since we have so many papers related to this area, it provides more reason that we need to establish this special issue.

Shibo, can you provide the one short paragraph introduction for this special issue no later than next Monday? It is perfect ok if you ask some of your associates to draft for you if that saves your time. We need to launch it asap.

You can check on the similar introductions for other EMI special issues. While many of them need some update, it should give you the general idea what kind of introduction is needed.

Best.

Shan

**From:** Shibo Jiang (姜世勃) <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>  
**Sent:** Thursday, January 9, 2020 11:37 PM  
**To:** Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>  
**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>  
**Subject:** Re: RE: RE: RE: EMI special issue on Emerging CoV

Thanks, Min.

Shibo

-----原始邮件-----

发件人: "Min Yang" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>  
发送时间: 2020-01-10 12:29:22 (星期五)  
收件人: "Shibo Jiang (姜世勃)" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>, "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
抄送: Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>  
主题: RE: RE: RE: EMI special issue on Emerging CoV

Dear Prof Lu and Jiang,

I have gone through all EMI past publications on coronaviruses and found 21 articles qualified.

Attached please find the article list.

Please feel free to let me know if you need any further assistance.

Thanks and regards,

Min Yang

Emerging Microbes & Infections (EMI) Editorial Office

4F Fuxing Building

131 Dongan Road

Shanghai

China

Tel: 86-21-54237992

E-mail: [editorial@emi2012.org](mailto:editorial@emi2012.org)

**From:** Shibo Jiang (姜世勃)

**Sent:** Thursday, January 9, 2020 7:16 PM

**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Cc:** Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>; Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>

**Subject:** Re: RE: RE: EMI special issue on Emerging CoV

Dear Shan,

Thank you very much for sharing with me your concern about asking junior or non-expert people, particularly Chinese experts, to serve as GE. I understand it now. I will try my best to work on it at this stage and let you know if I feel too tired to handle too many manuscripts in the future.

Best,

Shibo

-----原始邮件-----

发件人:"Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

发送时间:2020-01-09 14:56:45 (星期四)

收件人: ""Shibo Jiang (姜世勃)"" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>, "Min Yang" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>

抄送: Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>

主题: RE: RE: EMI special issue on Emerging CoV

Hi, Shibo,

I don't think it is a good idea to ask junior or non-expert people to serve as GE. One more important factor is that we need to make sure EMI is not just a "Chinese people" journal which will kill us very soon. If you can not serve, I will find someone else.

The best approach at this point may be is to have you as the GE and you can see how much work is involved, and you can feel free to drop if you feel the work is too much. The Editorial office and T&F will do most of the work. Please let me know.

Shan



---

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Saturday, January 11, 2020 11:52 PM  
**To:** Lu, Shan  
**Cc:** Min Yang; Emily  
**Subject:** Re: RE: RE: RE: RE: EMI special issue on Emerging CoV

Hi Shan,

Thanks for your correction.

Shibo

-----原始邮件-----

发件人:"Lu, Shan" <Shan.Lu@umassmed.edu>  
发送时间:2020-01-12 05:47:45 (星期日)  
收件人: "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>  
抄送: "Min Yang" <min.yang@emi2012.org>, Emily <editorial2@emi2012.org>  
主题: RE: RE: RE: RE: EMI special issue on Emerging CoV

Hi, Shibo,

This is great. I made some minor formatting changes (see below and attached).

If you agree, then EMI office will work with T&F to set up this new Special Issue at EMI site.

Shan

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Friday, January 10, 2020 7:54 AM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Cc:** Min Yang <min.yang@emi2012.org>; Emily <editorial2@emi2012.org>  
**Subject:** Re: RE: RE: RE: EMI special issue on Emerging CoV

Thanks, Shan.

I quickly draft the following paragraph. Please make correction if necessary. Shibo

## Emerging and Re-emerging Coronaviruses

**Guest Editor:** Shibo Jiang (Fudan University, China)

Emerging and re-emerging coronaviruses, including Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and the latest "Wuhan Coronavirus", may cause epidemics or potentially pandemics of highly pathogenic human infectious diseases, posing great threats to the global health. EMI Special Topic - Emerging and Re-emerging Coronaviruses covers research and review articles on the basic, translational and clinical studies related to these coronaviruses.

-----原始邮件-----

发件人:"Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

发送时间:2020-01-10 20:02:59 (星期五)

收件人: "Shibo Jiang (姜世勃)" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>, "Min Yang" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>

抄送: Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>

主题: RE: RE: RE: RE: EMI special issue on Emerging CoV

This is great. Since we have so many papers related to this area, it provides more reason that we need to establish this special issue.

Shibo, can you provide the one short paragraph introduction for this special issue no later than next Monday? It is perfect ok if you ask some of your associates to draft for you if that saves your time. We need to launch it asap.

You can check on the similar introductions for other EMI special issues. While many of them need some update, it should give you the general idea what kind of introduction is needed.

Best.

Shan

**From:** Shibo Jiang (姜世勃) <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>  
**Sent:** Thursday, January 9, 2020 11:37 PM  
**To:** Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>  
**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>  
**Subject:** Re: RE: RE: RE: EMI special issue on Emerging CoV

Thanks, Min.

Shibo

-----原始邮件-----

发件人:"Min Yang" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>  
发送时间:2020-01-10 12:29:22 (星期五)  
收件人: "Shibo Jiang (姜世勃)" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>, "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
抄送: Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>  
主题: RE: RE: RE: EMI special issue on Emerging CoV

Dear Prof Lu and Jiang,

I have gone through all EMI past publications on coronaviruses and found 21 articles qualified.

Attached please find the article list.

Please feel free to let me know if you need any further assistance.

Thanks and regards,

Min Yang

Emerging Microbes & Infections (EMI) Editorial Office

4F Fuxing Building

131 Dongan Road

Shanghai

China

Tel: 86-21-54237992

E-mail: [editorial@emi2012.org](mailto:editorial@emi2012.org)

**From:** Shibo Jiang (姜世勃)

**Sent:** Thursday, January 9, 2020 7:16 PM

**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Cc:** Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>; Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>

**Subject:** Re: RE: RE: EMI special issue on Emerging CoV

Dear Shan,

Thank you very much for sharing with me your concern about asking junior or non-expert people, particularly Chinese experts, to serve as GE. I understand it now. I will try my best to work on it at this stage and let you know if I feel too tired to handle too many manuscripts in the future.

Best,

Shibo

-----原始邮件-----

发件人: "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

发送时间: 2020-01-09 14:56:45 (星期四)

收件人: "Shibo Jiang (姜世勃)" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>, "Min Yang" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>

抄送: Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>

主题: RE: RE: EMI special issue on Emerging CoV

Hi, Shibo,

I don't think it is a good idea to ask junior or non-expert people to serve as GE. One more important factor is that we need to make sure EMI is not just a "Chinese people" journal which will kill us very soon. If you can not serve, I will find someone else.

The best approach at this point may be is to have you as the GE and you can see how much work is involved, and you can feel free to drop if you feel the work is too much. The Editorial office and T&F will do most of the work. Please let me know.

Shan

**From:** Shibo Jiang (姜世勃) <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>  
**Sent:** Wednesday, January 8, 2020 10:38 PM  
**To:** Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>  
**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>  
**Subject:** Re: RE: EMI special issue on Emerging CoV

Hi Shan,

Can we invite Prof. Qiliang Cai or Tianlei Ying or Rong Zhang as a GE for this special issue? We can meet together convincedly to discuss the related topics often. Although many senior experts in this field may agree to act as the GE for this special issue, they may not be willing to handle many manuscripts by him/herself. I do have a concern that there will be many manuscripts to be submitted to EMI for this special issue very soon. I may not have enough time to deal with the authors and their manuscripts.

Shibo

-----Original Messages-----

**From:** "Min Yang" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>  
**Sent Time:** 2020-01-09 11:12:25 (Thursday)  
**To:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>, "Shibo Jiang (姜世勃)" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>  
**Cc:** Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>  
**Subject:** RE: EMI special issue on Emerging CoV

Ok, I will generate the list asap.

Thank you,

Min

---

**From:** Lu, Shan  
**Sent:** Wednesday, January 8, 2020 9:54 PM  
**To:** 'Shibo Jiang (姜世勃)' <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>  
**Cc:** Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>; Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>  
**Subject:** RE: EMI special issue on Emerging CoV

I got the feedback from Dr. Shi. She thanks my invitation but stated that this may not be a good time for her to accept our invitation. So you can be the sole GE at this point. Once we established it, we can find another GE.

On the title, I think yours is too much like a “political statement”. I think we can make it simple and scientific. How about **“Emerging and Re-emerging Coronaviruses”**?

Next, please draft an overall introduction of this special issue.

Min Yang: please go through past EMI papers and find all corona viruses related papers and generate a list so they can be included in this special issue. Min Yu may help to see if there is any easy way to identify such papers. With a first rough list, Prof Jiang can suggest more key words to identify such EMI papers.

Shan

**From:** Shibo Jiang (姜世勃) <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>  
**Sent:** Tuesday, January 7, 2020 4:43 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** 'Min Yang' <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>; Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>  
**Subject:** Re: EMI special issue on Emerging CoV

Thanks, Shan.

I will work together with Min Yu and Min Yang, under your guidance, on this special issue.

It is a good idea to include all manuscripts related to the emerging CoVs in this special issue. I suggest to change the title to **“Combating the pathogenic emerging and re-emerging coronaviruses”** (I include “Re-emerging CoV” because we cannot exclude the possibility of SARS epidemic in the future).

I will draft a short description of this special issue.

Please send an invitation to Dr. Zhengli Shi as soon as possible. If she agrees, I will discuss with her about the list of potential authors and topics and we should sent out invitation letters together.

Best,

Shibo

-----Original Messages-----

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Sent Time:** 2020-01-07 14:31:54 (Tuesday)

**To:** "'Shibo Jiang (姜世勃)'" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>

**Cc:** "'Min Yang'" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>, Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>

**Subject:** EMI special issue on Emerging CoV

Hi, Shibo,

Here I am connecting you to Min Yu and Min Yang of EMI editorial office on the set up of a new special issue.

First, you will serve as the guest editor (before the 2<sup>nd</sup> person is finalized).

Second, we need to define what is the scope of this special issue. I don't think we should make this one for the pending Wuhan pathogen. The emerging CoV itself is interesting and has enough papers for us to set up a special issue.

Third, based on the decision of above, we can name the title of special issue.

Fourth, you then need to draft a short description of this special issue (using other EMI one as the example but the descriptions for some of them are not very good, but the overall length can be used as a template).

After the above are done, we can draft together an invitation letter and develop a list of potential experts who may contribute to this special issue. Min Yu will work on this with us.

At the same time, Min Yang will work with you to identify those published EMI papers related to this topic and pull them into this special issue now (as part of the process to build this special issue).

Best.

Shan





---

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Saturday, January 11, 2020 11:51 PM  
**To:** Lu, Shan  
**Cc:** Min Yang; Emily  
**Subject:** Re: RE: RE: RE: RE: EMI special issue on Emerging CoV

Thanks, Shan.

I will follow your instruction to work on this special issue as efficiently as possible.

Best,

Shibo

-----原始邮件-----

发件人:"Lu, Shan" <Shan.Lu@umassmed.edu>  
发送时间:2020-01-12 05:59:42 (星期日)  
收件人: "'Shibo Jiang (姜世勃)'" <shibojiang@fudan.edu.cn>  
抄送: "Min Yang" <min.yang@emi2012.org>, Emily <editorial2@emi2012.org>  
主题: RE: RE: RE: RE: RE: EMI special issue on Emerging CoV

Hi, Shibo,

While the set up a web-based special issue may take some time (hopefully not too long) by T&F, I agree with you that we can start working under this special issue. It can be very similar to other special issues and the regular Review Editors system.

Basically, if there is CoV related paper received, I will send it to you and you can select the reviewers just like a regular Review Editor. In this system, you will need to find 2-3 reviewers and provide your decision once you hear back from their review. Min Yang can add you to have the online access as a review editor so you can invite, change invite and make decisions. Then I will make a decision based on your decision (in general, I always follow Review Editor's decision).

In addition to the above basic system, we can handle certain unique situations:

1. Soliciting papers: any of us can invite papers but just be careful not promising anything as we can not be 100% sure the end results. Any invited papers will still need to go through the online submission which will save time at the end.

2. I can discuss with you on whether an accelerated review is needed, which is based on the special situation and particular paper dependent. In my experience, the immediate acceptance has limited value to authors in long run. A good review can only help authors.

Thanks for your enthusiasm, and let's start working.

Shan

**From:** Shibo Jiang (姜世勃) <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>  
**Sent:** Saturday, January 11, 2020 1:48 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>; Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>  
**Subject:** Re: RE: RE: RE: RE: EMI special issue on Emerging CoV

Dear Prof. Lu,

Thank you very much for your trust on me to organize the special issue - Emerging and reemerging coronaviruses. I would like to suggest a speedy process of the important manuscripts related to Wuhan CoV, so as to boost up the impact factor further. You can select some important manuscripts from the submitted manuscripts or pre-submission inquiry and send to me or other experts in CoV field who can respond very quickly for review. If I or the experts think that these manuscripts are indeed excellent or important, they can be accepted immediately or accepted after minor revision. Perhaps you have already done in such way before. Please let me know.

Shibo

Emerging and reemerging coronaviruses  
**Guest Editor:** Shibo Jiang (Fudan University, China)

Emerging and reemerging coronaviruses, including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and the latest Wuhan coronavirus (WH-CoV), may cause epidemics or pandemics of highly pathogenic infectious diseases, posing great threats to the global public health. EMI Special Topic - Emerging and reemerging coronaviruses covers research and review articles on the basic, translational and clinical studies of these coronaviruses that infect humans.

-----原始邮件-----

发件人: "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

发送时间: 2020-01-10 20:02:59 (星期五)

收件人: "Shibo Jiang (姜世勃)" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>, "Min Yang" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>

抄送: Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>

主题: RE: RE: RE: RE: EMI special issue on Emerging CoV

This is great. Since we have so many papers related to this area, it provides more reason that we need to establish this special issue.

Shibo, can you provide the one short paragraph introduction for this special issue no later than next Monday? It is perfect ok if you ask some of your associates to draft for you if that saves your time. We need to launch it asap.

You can check on the similar introductions for other EMI special issues. While many of them need some update, it should give you the general idea what kind of introduction is needed.

Best.

Shan

**From:** Shibo Jiang (姜世勃) <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>

**Sent:** Thursday, January 9, 2020 11:37 PM

**To:** Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>

**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>

**Subject:** Re: RE: RE: RE: EMI special issue on Emerging CoV

Thanks, Min.

Shibo

-----原始邮件-----

发件人: "Min Yang" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>

发送时间: 2020-01-10 12:29:22 (星期五)

收件人: "Shibo Jiang (姜世勃)" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>, "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

抄送: Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>

主题: RE: RE: RE: EMI special issue on Emerging CoV

Dear Prof Lu and Jiang,

I have gone through all EMI past publications on coronaviruses and found 21 articles qualified.

Attached please find the article list.

Please feel free to let me know if you need any further assistance.

Thanks and regards,

Min Yang

Emerging Microbes & Infections (EMI) Editorial Office

4F Fuxing Building

131 Dongan Road

Shanghai

China

Tel: 86-21-54237992

E-mail: [editorial@emi2012.org](mailto:editorial@emi2012.org)

**From:** Shibo Jiang (姜世勃)

**Sent:** Thursday, January 9, 2020 7:16 PM

**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Cc:** Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>; Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>

**Subject:** Re: RE: RE: EMI special issue on Emerging CoV

Dear Shan,

Thank you very much for sharing with me your concern about asking junior or non-expert people, particularly Chinese experts, to serve as GE. I understand it now. I will try my best to work on it at this stage and let you know if I feel too tired to handle too many manuscripts in the future.

Best,

Shibo

-----原始邮件-----

发件人:"Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

发送时间:2020-01-09 14:56:45 (星期四)

收件人: "Shibo Jiang (姜世勃)" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>, "Min Yang" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>

抄送: Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>

主题: RE: RE: EMI special issue on Emerging CoV

Hi, Shibo,

I don't think it is a good idea to ask junior or non-expert people to serve as GE. One more important factor is that we need to make sure EMI is not just a "Chinese people" journal which will kill us very soon. If you can not serve, I will find someone else.

The best approach at this point may be to have you as the GE and you can see how much work is involved, and you can feel free to drop if you feel the work is too much. The Editorial office and T&F will do most of the work. Please let me know.

Shan

---

**From:** 蔡启良<Qiliang Cai> <qiliang@fudan.edu.cn>  
**Sent:** Sunday, February 23, 2020 12:14 PM  
**To:** Lu, Shan  
**Cc:** wen yumei  
**Subject:** Re: RE: RE: RE: RE: Emerging Microbes & Infections

Ok, will try my best!

Txs,

Q

-----原始邮件-----

发件人:"Lu, Shan" <Shan.Lu@umassmed.edu>  
发送时间:2020-02-22 23:10:25 (星期六)  
收件人: "蔡启良<Qiliang Cai>" <qiliang@fudan.edu.cn>  
抄送: "wen yumei" <ymwen@shmu.edu.cn>  
主题: RE: RE: RE: RE: Emerging Microbes & Infections

That is great. We welcome anyone who wants to spend time for EMI.

Ok, how about this. Let's try three months. I will treat you like the other RE from now on. You can let me know how you feel by the end of May. Then we can make adjustment at that time.

Please confirm if you agree.

Thanks.

Shan

**From:** 蔡启良<Qiliang Cai> <qiliang@fudan.edu.cn>  
**Sent:** Saturday, February 22, 2020 4:09 AM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Cc:** wen yumei <ymwen@shmu.edu.cn>  
**Subject:** Re: RE: RE: RE: Emerging Microbes & Infections

Dear Shan,

Thanks for the info! I believe I did not refuse to review any mns that I was assigned, and finished most cases on time last year:) Anyway, I am ok with any decision you have made.

Best,

Qiliang

-----原始邮件-----

发件人:"Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

发送时间:2020-02-22 13:51:54 (星期六)

收件人:"蔡启良<Qiliang Cai>" <[qiliang@fudan.edu.cn](mailto:qiliang@fudan.edu.cn)>

抄送:"wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>

主题: RE: RE: RE: Emerging Microbes & Infections

Dear Qiliang,

Sorry I did not understand what you mean.

I gave you last year the lowest number of papers because you were too slow and missing many deadlines. You are welcome to continue as a Review Editor in this year but I will need to give the same number of papers as others so it is fair to other RE.

There is no limit how many review editors we can have so it is not a problem to have you and other review editors at the same time. There was a discussion at the end of 2019 meeting among editors including prof Wen and it was decided that I will discuss with you whether you will be able to do the full scale work as a review editor.

Please let me know and I am happy with any decision you may have.

Best.

Shan

**From:** 蔡启良<Qiliang Cai> <[qiliang@fudan.edu.cn](mailto:qiliang@fudan.edu.cn)>  
**Sent:** Saturday, February 22, 2020 12:44 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
**Subject:** Re: RE: RE: Emerging Microbes & Infections

Dear Shan,

Sorry for confusion! I meant that I am happy to continue to work as RE and will try my best to serve. However, I am totally fine to take your assignment if you have other better candidates.

Look forward to see you!

Best,

Qiliang

-----原始邮件-----

发件人:"Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
发送时间:2020-02-22 12:05:16 (星期六)  
收件人:"蔡启良<Qiliang Cai>" <[qiliang@fudan.edu.cn](mailto:qiliang@fudan.edu.cn)>  
抄送:  
主题: RE: RE: Emerging Microbes & Infections

Hi, Qiliang,

Thanks and no problem. I fully understand how busy you are. As you indicated, I will try to maintain you as a reviewer but not let you to work as RE to process a lot of papers. One other RE is also stepping down due to other work and a few more will be added to handle the huge volume of papers we need to process.

Hope we can meet soon if the CoV outbreak is under control. Please take care!

Best.

Shan

**From:** 蔡启良<Qiliang Cai> <[qiliang@fudan.edu.cn](mailto:qiliang@fudan.edu.cn)>  
**Sent:** Friday, February 21, 2020 9:29 PM



**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** Re: RE: Emerging Microbes & Infections

Dear Shan,

Very glad to hear from you and hope you well! I would be happy to help, and continue to put my efforts to improve EMI. It may just a little bit slow response some time due to instant heavy works, and hope you could understand.

Best,

Qiliang

-----原始邮件-----

发件人:"Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
发送时间:2020-02-21 03:43:26 (星期五)  
收件人: "qiliang@fudan.edu.cn" <[qiliang@fudan.edu.cn](mailto:qiliang@fudan.edu.cn)>  
抄送:  
主题: RE: Emerging Microbes & Infections

Dear Qiliang,

Long time no talk. Hope this email will find you well, in particular under the cloud of the current SARS2.

I meant to contact you for some time but the work of EMI and other things have kept me too busy to reach you. As I learned that you are taking more administrative responsibility nowadays, I wonder if you would like to continue to serve as Review Editor for EMI. EMI has grown further in the last year, and with the recent SARS2, we had more submissions. The work load is very huge. We need to give RE more work load but I realize that it may be hard for you. So please let me know your thought and I am happy to arrange anyway you want. No matter what arrangement, you should continue to be the Editorial Board member along with everyone else for the current term.

Please let me know your opinion. We can talk over the wechat if you would like.

Best.

Shan

\*\*\*\*\*

*Shan Lu, MD, PhD*

*Professor*

*Department of Medicine*

*U Mass Med School*

*Worcester, MA01605*

*USA*

*Tel. 1-508-856-6791*

*Email: [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu)*

--

Qiliang Cai, Ph.D. Professor, Deputy director MOE&NHC&CAMS Key Laboratory of Medical Molecular Virology School of Basic Medical Sciences Shanghai Medical College Fudan University Shanghai, 200032 P. R. China [Tel:\(+86\)21-5423-7716](tel:+862154237716) Email: [qiliang@fudan.edu.cn](mailto:qiliang@fudan.edu.cn) Lab website: [www.viralcancer.fudan.edu.cn](http://www.viralcancer.fudan.edu.cn)

--

Qiliang Cai, Ph.D. Professor, Deputy director MOE&NHC&CAMS Key Laboratory of Medical Molecular Virology School of Basic Medical Sciences Shanghai Medical College Fudan University Shanghai, 200032 P. R. China [Tel:\(+86\)21-5423-7716](tel:+862154237716) Email: [qiliang@fudan.edu.cn](mailto:qiliang@fudan.edu.cn) Lab website: [www.viralcancer.fudan.edu.cn](http://www.viralcancer.fudan.edu.cn)

--

Qiliang Cai, Ph.D. Professor, Deputy director MOE&NHC&CAMS Key Laboratory of Medical Molecular Virology School of Basic Medical Sciences Shanghai Medical College Fudan University Shanghai, 200032 P. R. China [Tel:\(+86\)21-5423-7716](tel:+862154237716) Email: [qiliang@fudan.edu.cn](mailto:qiliang@fudan.edu.cn) Lab website: [www.viralcancer.fudan.edu.cn](http://www.viralcancer.fudan.edu.cn)

--

Qiliang Cai, Ph.D. Professor, Deputy director MOE&NHC&CAMS Key Laboratory of Medical Molecular Virology School of Basic Medical Sciences Shanghai Medical College Fudan University Shanghai, 200032 P. R. China Tel:(+86)21-5423-7716 Email: [qiliang@fudan.edu.cn](mailto:qiliang@fudan.edu.cn) Lab website: [www.viralcancer.fudan.edu.cn](http://www.viralcancer.fudan.edu.cn)

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Saturday, February 22, 2020 8:17 PM  
**To:** Lu, Shan  
**Subject:** Re: RE: RE: RE: Emerging Microbes & Infections

Thank you for your patience. If for me, I will tell him he did not do the work on time. Wen

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:** 2020-02-22 23:10:25 (Saturday)  
**To:** "蔡启良<Qiliang Cai>" <qiliang@fudan.edu.cn>  
**Cc:** "wen yumei" <ymwen@shmu.edu.cn>  
**Subject:** RE: RE: RE: RE: Emerging Microbes & Infections

That is great. We welcome anyone who wants to spend time for EMI.

Ok, how about this. Let's try three months. I will treat you like the other RE from now on. You can let me know how you feel by the end of May. Then we can make adjustment at that time.

Please confirm if you agree.

Thanks.

Shan

**From:** 蔡启良<Qiliang Cai> <qiliang@fudan.edu.cn>  
**Sent:** Saturday, February 22, 2020 4:09 AM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Cc:** wen yumei <ymwen@shmu.edu.cn>  
**Subject:** Re: RE: RE: RE: Emerging Microbes & Infections

Dear Shan,

Thanks for the info! I believe I did not refuse to review any mns that I was assigned, and finished most cases on time last year:) Anyway, I am ok with any decision you have made.

Best,

Qiliang

-----原始邮件-----

发件人:"Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

发送时间:2020-02-22 13:51:54 (星期六)

收件人:"蔡启良<Qiliang Cai>" <[qiliang@fudan.edu.cn](mailto:qiliang@fudan.edu.cn)>

抄送:"wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>

主题: RE: RE: RE: Emerging Microbes & Infections

Dear Qiliang,

Sorry I did not understand what you mean.

I gave you last year the lowest number of papers because you were too slow and missing many deadlines. You are welcome to continue as a Review Editor in this year but I will need to give the same number of papers as others so it is fair to other RE.

There is no limit how many review editors we can have so it is not a problem to have you and other review editors at the same time. There was a discussion at the end of 2019 meeting among editors including prof Wen and it was decided that I will discuss with you whether you will be able to do the full scale work as a review editor.

Please let me know and I am happy with any decision you may have.

Best.

Shan

**From:** 蔡启良<Qiliang Cai> <[qiliang@fudan.edu.cn](mailto:qiliang@fudan.edu.cn)>

**Sent:** Saturday, February 22, 2020 12:44 AM

**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Cc:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>

**Subject:** Re: RE: RE: Emerging Microbes & Infections

Dear Shan,

Sorry for confusion! I meant that I am happy to continue to work as RE and will try my best to serve. However, I am totally fine to take your assignment if you have other better candidates.

Look forward to see you!

Best,

Qiliang

-----原始邮件-----

发件人: "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

发送时间: 2020-02-22 12:05:16 (星期六)

收件人: "蔡启良<Qiliang Cai>" <[qiliang@fudan.edu.cn](mailto:qiliang@fudan.edu.cn)>

抄送:

主题: RE: RE: Emerging Microbes & Infections

Hi, Qiliang,

Thanks and no problem. I fully understand how busy you are. As you indicated, I will try to maintain you as a reviewer but not let you to work as RE to process a lot of papers. One other RE is also stepping down due to other work and a few more will be added to handle the huge volume of papers we need to process.

Hope we can meet soon if the CoV outbreak is under control. Please take care!

Best.

Shan

**From:** 蔡启良<Qiliang Cai> <[qiliang@fudan.edu.cn](mailto:qiliang@fudan.edu.cn)>

**Sent:** Friday, February 21, 2020 9:29 PM

**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Subject:** Re: RE: Emerging Microbes & Infections

Dear Shan,

Very glad to hear from you and hope you well! I would be happy to help, and continue to put my efforts to improve EMI. It may just a little bit slow response some time due to instant heavy works, and hope you could understand.

Best,

Qiliang

-----原始邮件-----

发件人:"Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

发送时间:2020-02-21 03:43:26 (星期五)

收件人: "qiliang@fudan.edu.cn" <[qiliang@fudan.edu.cn](mailto:qiliang@fudan.edu.cn)>

抄送:

主题: RE: Emerging Microbes & Infections

Dear Qiliang,

Long time no talk. Hope this email will find you well, in particular under the cloud of the current SARS2.

I meant to contact you for some time but the work of EMI and other things have kept me too busy to reach you. As I learned that you are taking more administrative responsibility nowadays, I wonder if you would like to continue to serve as Review Editor for EMI. EMI has grown further in the last year, and with the recent SARS2, we had more submissions. The work load is very huge. We need to give RE more work load but I realize that it may be hard for you. So please let me know your thought and I am happy to arrange anyway you want. No matter what arrangement, you should continue to be the Editorial Board member along with everyone else for the current term.

Please let me know your opinion. We can talk over the wechat if you would like.

Best.

Shan

\*\*\*\*\*

*Shan Lu, MD, PhD*

*Professor*

*Department of Medicine*

*U Mass Med School*

*Worcester, MA01605*

*USA*

*Tel. 1-508-856-6791*

*Email: [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu)*

--

Qiliang Cai, Ph.D. Professor, Deputy director MOE&NHC&CAMS Key Laboratory of Medical Molecular Virology School of Basic Medical Sciences Shanghai Medical College Fudan University Shanghai, 200032 P. R. China [Tel:\(+86\)21-5423-7716](tel:+862154237716) Email: [qiliang@fudan.edu.cn](mailto:qiliang@fudan.edu.cn) Lab website: [www.viralcancer.fudan.edu.cn](http://www.viralcancer.fudan.edu.cn)

--

Qiliang Cai, Ph.D. Professor, Deputy director MOE&NHC&CAMS Key Laboratory of Medical Molecular Virology School of Basic Medical Sciences Shanghai Medical College Fudan University Shanghai, 200032 P. R. China [Tel:\(+86\)21-5423-7716](tel:+862154237716) Email: [qiliang@fudan.edu.cn](mailto:qiliang@fudan.edu.cn) Lab website: [www.viralcancer.fudan.edu.cn](http://www.viralcancer.fudan.edu.cn)

--

Qiliang Cai, Ph.D. Professor, Deputy director MOE&NHC&CAMS Key Laboratory of Medical Molecular Virology School of Basic Medical Sciences Shanghai Medical College Fudan University Shanghai, 200032 P. R. China [Tel:\(+86\)21-5423-7716](tel:+862154237716) Email: [qiliang@fudan.edu.cn](mailto:qiliang@fudan.edu.cn) Lab website: [www.viralcancer.fudan.edu.cn](http://www.viralcancer.fudan.edu.cn)

-----

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Thursday, March 5, 2020 8:27 PM  
**To:** Lu, Shan  
**Cc:** Yang Min 杨敏; min.yang@emi2012.org; Du Lanying\_NYBC  
**Subject:** Re: RE: RE: RE: RE: Jiang et al. EMI 9:1, 275-277  
**Attachments:** Jiang\_Commentary\_2019-nCoV\_EMI\_2020.pdf

Thanks, Prof. Lu.

I checked it and found that the correction in Fig. 1 was correct (see the attachment).

Best,

Shibo

-----The original message-----

From 人 : "Lu, Shan" <Shan.Lu@umassmed.edu>

**Sending time:** 2020-03-06 08:10:19 (Friday)

To : "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>

Cc : "Yang Min 杨旻" <minyang0216@163.com>, "min.yang@emi2012.org" <min.yang@emi2012.org>, "Du Lanying\_NYBC" <ldu@nybc.org>

Main **topic:** REs: REs: REs: REs: Re: the EMI Jiang et al. 9:.. 1, 275-277

Hi, Shibo and co-authors,

The correction has been just published online. Please go to EMI website to check and make sure the correction was correct.

[www.tandfonline.com/TEMI](http://www.tandfonline.com/TEMI)

Best.

Shan

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Wednesday, February 12, 2020 10:56 PM



**To:** Lu, Shan <Shan.Lu@umassmed.edu>

**Cc:** Yang Min 杨敏<minyang0216@163.com>; min.yang@emi2012.org; Du Lanying\_NYBC <ldu@nybc.org>

**Subject:** Re: RE: RE: RE: RE: Jiang et al. EMI 9:1, 275-277

Hi Shan,

Sorry, Dr. Du already informed me that she agreed to submit this erratum, but asked me to adjust the lengths of NTD and RBD in the figure. I thought that Dr. Du also replied you. Since you told us that you would discuss with the publisher how to handle it, I thought that you would let us know how to do it next.

The attached please find the erratum and the revised figure.

Thanks,

Shibo

-----The original message-----

Outgoing Face : "Lu, Shan" < [Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu) >

Sending time : 2020-02-13 11:34:06 (Thursday)

To : "Shibo Jiang (姜世勃)" < [shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn) >

Cc : "Yang Min 杨旻" < [minyang0216@163.com](mailto:minyang0216@163.com) >, " min.yang@emi2012.org " < [min.yang@emi2012.org](mailto:min.yang@emi2012.org) >

Subject : RE: RE: RE: RE: Jiang et al. EMI 9:1, 275-277

Hi, Shibo,

I have seen the reply from Dr. Shi, but never saw one from Dr. DU?

We need to have your final confirmation so we can check with T&F to see how to publish this erratum.

2

---

## Page 3

Shan

ps WE are going to produce a WeChat promotion of EMI's Special Topic of Emerging and Re-emerging pathogenic CoV". We will let you know once it is launched. Be prepared to be even more famous!

**From:** Shibo Jiang (姜世勃) < [shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn) >

**Sent:** Sunday, February 9, 2020 10:45 PM

**To:** Shi Zhengli < [zshi@wh.iov.cn](mailto:zshi@wh.iov.cn) >; Du Lanying\_NYBC < [ldu@nybc.org](mailto:ldu@nybc.org) >

**Cc:** Lu, Shan < [Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu) >; Yang Min 杨旻< [minyang0216@163.com](mailto:minyang0216@163.com) >; min.yang@emi2012.org ;Shuying

Liu' <SYL-consulting@outlook.com >  
**Subject:** Re: RE: RE: Re: Jiang et al. EMI 9:1, 275-277

Dear Drs. Shi and Du,

I prepared the letter to editor and the updated Figure, including Figure 1B (see the attachment). Please check and modify it if necessary. If you have no change, I will submit it to EMI as soon as possible.

I also attached the original version downloaded online. You can go through it and make correction if it is really necessary.

Thanks,

Shibo

-----The original message-----

Outgoing Face : "Lu, Shan" <Shan.Lu@umassmed.edu >

Sending time : 2020-02-10 11:18:51 (Monday)

Write Face : "石 Lai" <zls@wh.iov.cn >

Cc : "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn >, "Yang Min 杨旻" <minyang0216@163.com >, "min.yang@emi2012.org" <min.yang@emi2012.org >, "Shuying Liu" <SYL-consulting@outlook.com >

Subject : RE: RE: Re: Jiang et al. EMI 9:1, 275-277

Sounds good. No worries.

3

---

## Page 4

So Shibo, please produce a simple erratum along with a new Fig 1 including the revised Fig 1b. Since Prof Shi is going to update her GenBank information, there is no need to mention this episode as I can see. Just mention that you need to update your figure to follow the numbering tradition in SARS field.

I will link you to T&F JEO to see how to submit.

Best.

Shan.

**From:** Shi Zhengli <zls@wh.iov.cn >

**Sent:** Sunday, February 9, 2020 10:11 PM

**To:** Lu, Shan <Shan.Lu@umassmed.edu >

**Cc:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn >; Yang Min 杨旻 <minyang0216@163.com >; min.yang@emi2012.org ; Shuying Liu' <SYL-consulting@outlook.com >

**Subject:** Re: RE: Re: Jiang et al. EMI 9:1, 275-277

Dear Prof. Liu,

I'm very sorry to make this errors. We have requested to update the GenBank information and the sequence annotation will be updated very soon.

My suggestion is to make an erratum.

Best regards,

Zhengli,

4

## Page 5

-----The original message-----

Outgoing Face : "Lu, Shan" <Shan.Lu@umassmed.edu >

Sending time : 2020-02-10 01:31:16 (Monday)

To : "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn >, "石正丽" <zlshi@wh.iov.cn >

Cc : "Yang Min 杨旻" <minyang0216@163.com >, " min.yang@emi2012.org " <min.yang@emi2012.org >, "Shuying Liu" <SYL-consulting@outlook.com >

Subject : RE: Re: Jiang et al. EMI 9:1, 275-277

Hi, everyone,

We did further investigation. Here is what we found:

It appears that the sequences initially published at Genbank by Dr. Yongzheng Zhang, and later by others, all used the SARS sequences as the basis (starting site for S and the resulting aa numbering).

At the same time, Prof Shi's group uploaded her group's 2019-nCoV sequences in a different way, based on SARSr-CoV TG13. At least we found the following are involved.

WIV02 (GenBank: MN996527.1)

WIV04 (GenBank: MN996528.1)

WIV05 (GenBank: MN996529.1)

WIV06 (GenBank: MN996530.1)

So, how to treat the EMI paper by Jiang et al. (EMI 9:275-277), there are two possible solutions:

1. Produce an erratum with a revised Fig 1b, which will include the corrected starting point of S, and revised S leader size and the total size of S, along the numbering of S subdomains).

We will select this option if you want to revise your Genbank submissions.

2. Publish another commentary which will describe this situation of different entries in Genbank so there will be no confusion to others in the field.

We will select this option if the sequences submitted by Prof Shi will stay as they are.

5

---

## Page 6

I (and EMI) will respect whatever decision will be.

Shan

**From:** Shibo Jiang (姜世勃) <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>

**Sent:** Sunday, February 9, 2020 8:54 AM

**To:** Shi Zhengli <[zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn)>

**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; Yang Min Yang Min <[minyang0216@163.com](mailto:minyang0216@163.com)>; [min.yang@emi2012.org](mailto:min.yang@emi2012.org) ;

'Shuying Liu' <[SYL-consulting@outlook.com](mailto:SYL-consulting@outlook.com)>

**Subject:** Re: Re: Jiang et al. EMI 9:1, 275-277

Thank you Lu and teacher,

Let me modify that picture. We emailed you the revised pictures and text directly, right? Is there any explanation needed?

Shibo

-----The original message-----

From : "石正丽" <[zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn)>

Sending time : 2020-02-09 21:46:59 (weekday)

Write Face : "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

Cc : "Shibo Jiang (姜世勃)" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>, "Yang Min 杨旻" <[minyang0216@163.com](mailto:minyang0216@163.com)> ,

"[min.yang@emi2012.org](mailto:min.yang@emi2012.org)" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)> , "Shuying Liu" <[SYL-consulting@outlook.com](mailto:SYL-consulting@outlook.com)>

Subject : Re: Jiang et al. EMI 9:1, 275-277

Master Lu:

I communicated with the student just now. The phylogenetic tree was constructed using the correct S gene sequence. An error occurred when uploading the sequence to GenBank. We n Correct it.

Hereby explain.

I'm not always sorry for this kind of error.

6

---

## Page 7

Zhengli

-----The original message-----

Outgoing Face : "Lu, Shan" < [Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu) >

Sending time : 2020-02-09 21:15:31 (weekday)

To : "Shibo Jiang (姜世勃)" < [shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn) >, "Shi Zhengli" < [zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn) >

Cc : "Yang Min 杨旻" < [minyang0216@163.com](mailto:minyang0216@163.com) >, " min.yang@emi2012.org " < [min.yang@emi2012.org](mailto:min.yang@emi2012.org) >, "Shuying Liu" < [SYL-consulting@outlook.com](mailto:SYL-consulting@outlook.com) >

Subject : Jiang et al. EMI 9:1, 275-277

Hello, teacher!

Two days ago, a colleague in my laboratory discovered that there are two problems with the next chapter of the co-author of you and Shibo: the number of amin  
The location of the gene ( the numbering for each functional domain) is wrong. Shibo and I mentioned it. Today he told you to talk to him  
To, hope to correct.

DOI: 10.1080/22221751.2020.1723441, An emerging coronavirus causing pneumonia outbreak  
in Wuhan, China: calling for developing therapeutic and prophylactic strategies.

I welcome you to post a correction erratum. I don't know if it is necessary to modify the diagram. Even if it is necessary, I think it is worth it. Welcome to tell you  
Feeling, and then the EMI editorial department came to coordinate with T&F on how to publish erratum.

Thank you!

Lu

ps There are 3399 downloads of your papers to read today. Congratulations!



\*\*\*\*\*

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Wednesday, February 12, 2020 10:56 PM  
**To:** Lu, Shan  
**Cc:** Yang Min 杨敏; min.yang@emi2012.org; Du Lanying\_NYBC  
**Subject:** Re: RE: RE: RE: Re: Jiang et al. EMI 9:1, 275-277  
**Attachments:** Jiang\_Erratum\_EMI\_2020-2-10.docx; Figure 1\_2019-nCoV\_commentary\_EMI\_2020-2-9.tiff

Hi Shan,

Sorry, Dr. Du already informed me that she agreed to submit this erratum, but asked me to adjust the lengths of NTD and RBD in the figure. I thought that Dr. Du also replied you. Since you told us that you would discuss with the publisher how to handle it, I thought that you would let us know how to do it next.

The attached please find the erratum and the revised figure.

Thanks,

Shibo

-----The original message-----

From 人 : "Lu, Shan" <Shan.Lu@umassmed.edu>

**Sending time:** 2020-02-13 11:34:06 (Thursday)

To : "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>

Cc : "Yang Min 杨旻" <minyang0216@163.com>, "min.yang@emi2012.org" <min.yang@emi2012.org>

Main **topic:** REs: REs: REs: Re: the EMI Jiang et Al. 9:.. 1, 275-277

Hi, Shibo,

I have seen the reply from Dr. Shi, but never saw one from Dr. DU?

We need to have your final confirmation so we can check with T&F to see how to publish this erratum.

Shan

ps WE are going to produce a WeChat promotion of EMI's Special Topic of Emerging and Re-emerging pathogenic CoV". We will let you know once it is launched. Be prepared to be even more famous!

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Sunday, February 9, 2020 10:45 PM  
**To:** Shi Zhengli <zlshi@wh.iov.cn>; Du Lanying\_NYBC <ldu@nybc.org>  
**Cc:** Lu, Shan <Shan.Lu@umassmed.edu>; Yang Min 杨旻 <minyang0216@163.com>; min.yang@emi2012.org; Shuying Liu' <SYL-consulting@outlook.com>  
**Subject:** Re: RE: RE: Re: Jiang et al. EMI 9:1, 275-277

Dear Drs. Shi and Du,

I prepared the letter to editor and the updated Figure, including Figure 1B (see the attachment). Please check and modify it if necessary. If you have no change, I will submit it to EMI as soon as possible.

I also attached the original version downloaded online. You can go through it and make correction if it is really necessary.

Thanks,

Shibo

-----The original message-----

Outgoing Face : "Lu, Shan" < [Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu) >

Sending time : 2020-02-10 11:18:51 (Monday)

Write Face : "石 Lai" < [zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn) >

Cc : "Shibo Jiang (姜世勃)" < [shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn) >, "Yang Min 杨旻" < [minyang0216@163.com](mailto:minyang0216@163.com) >, " [min.yang@emi2012.org](mailto:min.yang@emi2012.org) " < [min.yang@emi2012.org](mailto:min.yang@emi2012.org) >, "Shuying Liu" < [SYL-consulting@outlook.com](mailto:SYL-consulting@outlook.com) >

Subject : RE: RE: Re: Jiang et al. EMI 9:1, 275-277

Sounds good. No worries.

2

---

## Page 3

So Shibo, please produce a simple erratum along with a new Fig 1 including the revised Fig 1b. Since Prof Shi is going to update her GenBank information, there is no need to mention this episode as I can see. Just mention that you need to update your figure to follow the numbering tradition in SARS field.

I will link you to T&F JEO to see how to submit.

Best.

Shan.



**From:** Shi Zhengli <zlshi@wh.iov.cn >  
**Sent:** Sunday, February 9, 2020 10:11 PM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu >  
**Cc:** Shibo Jiang (姜世博) <shibojiang@fudan.edu.cn >; Yang Min 杨敏 <minyang0216@163.com >; min.yang@emi2012.org ; 'Shuying Liu' <SYL-consulting@outlook.com >  
**Subject:** Re: RE: Re: Jiang et al. EMI 9:1, 275-277

Dear Prf. Liu,

I'm very sorry to make this errors. We have requested to update the GenBank information and the sequence annotation will be updated very soon.

My suggestion is to make an erratum.

Best regards,

Zhengli,

-----The original message-----

Outgoing Face : "Lu, Shan" <Shan.Lu@umassmed.edu >

3

---

## Page 4

Sending time : 2020-02-10 01:31:16 (Monday)

To : "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn >, "石正丽" <zlshi@wh.iov.cn >

Cc : "Yang Min 杨旻" <minyang0216@163.com >, " min.yang@emi2012.org " < min.yang@emi2012.org >, "Shuying Liu" <SYL-consulting@outlook.com >

Subject : RE: Re: Jiang et al. EMI 9:1, 275-277

Hi, everyone,

We did further investigation. Here is what we found:

It appears that the sequences initially published at Genbank by Dr. Yongzheng Zhang, and later by others, all used the SARS sequences as the basis (starting site for S and the resulting aa numbering).

At the same time, Prof Shi's group uploaded her group's 2019-nCoV sequences in a different way, based on SARSr-CoV TG13. At least we found the following are involved.

WIV02 (GenBank: MN996527.1)

WIV04 (GenBank: MN996528.1)

WIV05 (GenBank: MN996529.1)

WIV06 (GenBank: MN996530.1)

So, how to treat the EMI paper by Jiang et al. (EMI 9:275-277), there are two possible solutions:

1. Produce an erratum with a revised Fig 1b, which will include the corrected starting point of S, and revised S leader size and the total size of S, along the numbering of S subdomains).

We will select this option if you want to revise your Genbank submissions.

2. Publish another commentary which will describe this situation of different entries in Genbank so there will be no confusion to others in the field.

We will select this option if the sequences submitted by Prof Shi will stay as they are.

I (and EMI) will respect whatever decision will be.

4

## Page 5

Shan

**From:** Shibo Jiang (姜世勃) <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>

**Sent:** Sunday, February 9, 2020 8:54 AM

**To:** Shi Zhengli <[zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn)>

**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; Yang Min Yang Min <[minyang0216@163.com](mailto:minyang0216@163.com)>; [min.yang@emi2012.org](mailto:min.yang@emi2012.org) ;

'Shuying Liu' <[SYL-consulting@outlook.com](mailto:SYL-consulting@outlook.com)>

**Subject:** Re: Re: Jiang et al. EMI 9:1, 275-277

Thank you Lu and teacher,

Let me modify that picture. We emailed you the revised pictures and text directly, right? Is there any explanation needed?

Shibo

-----The original message-----

From : "石正丽" <[zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn)>

Sending time : 2020-02-09 21:46:59 (weekday)

Write Face : "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

Cc : "Shibo Jiang (姜世勃)" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>, "Yang Min 杨旻" <[minyang0216@163.com](mailto:minyang0216@163.com)>, "

[min.yang@emi2012.org](mailto:min.yang@emi2012.org)" <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>, "Shuying Liu" <[SYL-consulting@outlook.com](mailto:SYL-consulting@outlook.com)>

Subject : Re: Jiang et al. EMI 9:1, 275-277

Master Lu:

I communicated with the student just now. The phylogenetic tree was constructed using the correct S gene sequence. An error occurred when uploading the sequence to GenBank. We ne Correct it.

Hereby explain.

I'm not always sorry for this kind of error.

5

---

**Page 6**

Zhengli

-----The original message-----

Outgoing Face : "Lu, Shan" < [Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu) >

Sending time : 2020-02-09 21:15:31 (weekday)

To : "Shibo Jiang (姜世勃)" < [shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn) >, "Shi Zhengli" < [zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn) >

Cc : "Yang Min 杨旻" < [minyang0216@163.com](mailto:minyang0216@163.com) >, "min.yang@emi2012.org" < [min.yang@emi2012.org](mailto:min.yang@emi2012.org) >, "Shuying

Liu" < [SYL-consulting@outlook.com](mailto:SYL-consulting@outlook.com) >

Subject : Jiang et al. EMI 9:1, 275-277

Hello, teacher!

Two days ago, a colleague in my laboratory discovered that there are two problems with the next chapter of the co-author of you and Shibo: the number of amino acids in the gene (the numbering for each functional domain) is wrong. Shibo and I mentioned it. Today he told you to talk to him to hope to correct.

DOI: 10.1080/22221751.2020.1723441, An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies.

I welcome you to post a correction erratum. I don't know if it is necessary to modify the diagram. Even if it is necessary, I think it is worth it. Welcome to tell me what you mean, then the EMI editorial department came to coordinate with T&F on how to publish erratum.

Thank you!

Lu

ps There are 3399 downloads of your papers to read today. Congratulations!

6

---

**From:** ZhangWenhong <zhangwenhong@fudan.edu.cn>  
**Sent:** Sunday, January 5, 2020 11:57 AM  
**To:** wen yumei  
**Cc:** Shibo Jiang (姜世勃); Lu, Shan; 袁正宏  
**Subject:** Re: Re: Re: Re: Special Issue for EMI\_Highly Pathogenic Emerging CoVs

Dear Wen Laoshi and Shan,

As Shan mentioned, if some clinical physician at xxx Hospital in Wuhan to give the histopathologic evaluation of lung tissues and clinical outcomes of patients with viral pneumonia caused by "Wuhan virus" infection will be fine in the clinical aspects.

After the confirmation of the virus, I can contact the hospitals in Wuhan and help prepare the clinical paper if no objection from the government.

All the best,

Wenhong

> -----原始邮件-----

> 发件人: "wen yumei" <ymwen@shmu.edu.cn>  
> 发送时间: 2020-01-05 17:02:19 (星期日)  
> 收件人: "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>  
> 抄送: "Lu Shan" <shan.lu@umassmed.edu>, "袁正宏" <Zhyuan@shmu.edu.cn>,  
> zhangwenhong <zhangwenhong@fudan.edu.cn>  
> 主题: Re: Re: Re: Special Issue for EMI\_Highly Pathogenic Emerging CoVs

>  
> Thank you. Got it.  
> Shan, ZH, WH Please comment. Wen

>  
>  
>> -----Original Messages-----

>> From: "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn> Sent Time:  
>> 2020-01-05 16:19:10 (Sunday)  
>> To: "wen yumei" <ymwen@shmu.edu.cn>  
>> Cc: "Lu Shan" <shan.lu@umassmed.edu>  
>> Subject: Re: Re: Special Issue for EMI\_Highly Pathogenic Emerging  
>> CoVs

>>  
>> Thanks, Prof. Wen.  
>>

>> I attached these documents again and also put in this email (see below). Please let em know if you cannot receive them again.  
>>

>> <https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fww>  
>> [w.sciencemag.org/2020/01/20/novel-human-virus-pneumonia-ca](https://www.sciencemag.org/2020/01/20/novel-human-virus-pneumonia-ca)  
>> [ses-linked-seafood-market-china-stir-concern&data=02%7C01%7Cshan](https://ses-linked-seafood-market-china-stir-concern&data=02%7C01%7Cshan)  
>> [.lu%40umassmed.edu/2020/01/20/4378a6c44405faf57b2e%7C0%7C1%7C637138402149410537&sdata=gN7KXMOG](https://www.umassmed.edu/2020/01/20/4378a6c44405faf57b2e%7C0%7C1%7C637138402149410537&sdata=gN7KXMOG)  
>> [KIF%2Br7XySoqYfyWETN9o1PL1zSeqEC2sqlc%3D&reserved=0](https://www.kif%2Br7XySoqYfyWETN9o1PL1zSeqEC2sqlc%3D&reserved=0)  
>>  
>> <https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fww>  
>> [w.statnews.com/2020/01/20/mystery-pneumonia-outbreak-china%2](https://www.statnews.com/2020/01/20/mystery-pneumonia-outbreak-china%2)  
>> [F&data=02%7C01%7Cshan.lu%40umassmed.edu/2020/01/20/d792004249%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C1%7C637138402149](https://www.f&data=02%7C01%7Cshan.lu%40umassmed.edu/2020/01/20/d792004249%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C1%7C637138402149)  
>> [410537&sdata=IKR3H1PZJM85fr7y3IKr1FoVXH7qZvmN7QLvzPvzsjg%3D&](https://www.410537&sdata=IKR3H1PZJM85fr7y3IKr1FoVXH7qZvmN7QLvzPvzsjg%3D&reserved=0)  
>> [reserved=0](https://www.reserved=0)  
>>  
>> <https://nam01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fexp>  
>> [ertscape.com/2020/01/20/middle%2Beast%2Brespiratory%2Bsyndrome%2Bcoronav](https://www.ertscape.com/2020/01/20/middle%2Beast%2Brespiratory%2Bsyndrome%2Bcoronav)  
>> [irus&data=02%7C01%7Cshan.lu%40umassmed.edu/2020/01/20/c08d792004249%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C1%7C637138402](https://www.irus&data=02%7C01%7Cshan.lu%40umassmed.edu/2020/01/20/c08d792004249%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C1%7C637138402)  
>> [149410537&sdata=UyxAmaFSgbXIEHs4%2BhMeldl6JxDgOszVEorQU8oaPU%3D](https://www.149410537&sdata=UyxAmaFSgbXIEHs4%2BhMeldl6JxDgOszVEorQU8oaPU%3D)  
>> [&reserved=0](https://www.&reserved=0)  
>>  
>>  
>> Combating the Highly Pathogenic Emerging Coronavirus ("Wuhan Virus")  
>> (Special issue for Emerging Microbes and Infection)  
>>  
>> Guest Editors for the Special issue of Emerging Microbes and  
>> Infection  
>>  
>> Shibo Jiang at Fudan University  
>> Kwok-Yung Yuen at University of Hong Kong  
>>  
>> Potential authors and topics (deadline of submission: 04/30/2020)  
>>  
>> 1. Shibo Jiang and Kwok-Yung Yuen  
>> Editorial (Combating Highly Pathogenic Emerging Coronavirus ("Wuhan  
>> Virus"))  
>>  
>> 2. Zhenli Shi, Wuhan Institute of Virology, Chinese Academy of Sciences  
>> Identification of "Wuhan Virus"  
>>  
>> 3. Wenjie Tan, National Institute for Viral Disease Control and Prevention Chinese Center for Disease Control and  
Prevention, Beijing, China.  
>> George F. Gao, National Institute for Viral Disease Control and  
>> Prevention, China Characterization of "Wuhan Virus"  
>>  
>> 4. ???? at xxx Hospital in Wuhan  
>> Histopathologic evaluation of lung tissues and clinical outcomes of  
>> patients with viral pneumonia caused by "Wuhan virus" infection  
>>  
>> 5. Kwok-Yung Yuen, University of Hong Kong  
>> "Wuhan virus" infection: virus-host cell interactions and implications on pathogenesis  
>> OR "Wuhan virus" quasispecies and its epidemiology characteristics.

>>

>> 6. Lanying Du, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA. LDu@nybc.org.

>> Fang Li, College of Veterinary Medicine, University of Minnesota,  
>> Saint Paul, MN, USA. lifang@umn.edu Crystallographic analysis of  
>> RBD/receptor complex and RBD-based coronavirus vaccine

>>

>> 7. Lu Lu, Shibo Jiang, Fudan University  
>> Pan-CoV fusion/entry inhibitors

>>

>> 8. Ralph Baric, the University of North Carolina  
>> Broad spectrum antiviral agents against human and zoonotic  
>> coronaviruses

>>

>> 9. Stanley Perlman, Interdisciplinary Program in Immunology, University of Iowa, Iowa City, IA 52242, USA  
>> Cellular immune responses against human and zoonotic coronaviruses:  
>> implication for vaccine development

>>

>> 10. Ziad A. Memish, Infectious Diseases Division, Prince Mohamed Bin Abdulaziz Hospital, Ministry of Health,  
Riyadh, Saudi Arabia; Hubert Department of Global Health, Emory University, Atlanta, GA, USA. zmemish@yahoo.com.  
>> Treatment and prevention of highly pathogenic human coronavirus  
>> infection

>>

>>

>>

>>> -----原始邮件-----

>>> 发件人: "wen yumei" <ymwen@shmu.edu.cn>

>>> 发送时间: 2020-01-05 15:45:17 (星期日)

>>> 收件人: "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>

>>> 抄送: "Lu Shan\_EMI" <shan.lu@emi2012.org>, "Lu Shan"  
>>> <shan.lu@umassmed.edu>

>>> 主题: Re: Special Issue for EMI\_Highly Pathogenic Emerging CoVs

>>>

>>> If the Wuhan virus is a neww coronavirus, this will be a good opportunity for EMI.

>>> I have not got the attachment you mentioned. Wen

>>>

>>>

>>>> -----Original Messages-----

>>>> From: "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn> Sent Time:  
>>>> 2020-01-05 15:38:10 (Sunday)

>>>> To: "Lu Shan\_EMI" <shan.lu@emi2012.org>, "Wen Yumei"  
>>>> <ymwen@shmu.edu.cn>

>>>> Cc: "Lu Shan" <shan.lu@umassmed.edu>

>>>> Subject: Special Issue for EMI\_Highly Pathogenic Emerging CoVs

>>>>

>>>> Dear Prof. Lu and Wen,

>>>>

>>>> On January 3, 2020, the Wuhan Municipal Health Commission reported to WHO regarding a cluster of viral  
pneumonia cases in Wuhan, which has attracted attention worldwide. Based on the news reports of Science and many  
media (see the attachments), the unknown "Wuhan virus" is very likely the SARS-like coronavirus (SL-CoV). We and  
other groups have well prepared to work on this new virus once its DNA sequence is announced and a number of high

profile journals are well prepared to accept the manuscripts from these groups. To compute with these journals, I propose to organize a special issue for EMI entitled "Combating the Highly Pathogenic Emerging Coronavirus ("Wuhan Virus")" by inviting the world-renowned experts in this field (see the attached Expertscape) who may work on this new virus to contribute research or review articles to this special issue. We should give priority to these manuscripts for rapid publication.

>>>>

>>>> I remember in 2013 when the H7N9 epidemic started, we quickly analyzed the HA sequence of H7N9 and submitted the manuscript without any experimental data to Microbes and Infection just two weeks after its sequence was released. The paper was immediately accepted for publication (just a few days after the NEJM paper published) and this paper was cited for almost 50 times in a few months by many high profile journals, including Science and NEJM. Therefore, the timing is most important.

>>>>

>>>> If you agree with my proposal, I will contact with Prof. KY Yuen and send out our invitation letter immediately after WHO or China CDC confirms that the "Wuhan virus" is indeed a newly emerging SL-CoV.

>>>>

>>>> Thank you very much for your consideration,

>>>>

>>>> Shibo

>>>>

>>>>

>>>>

>>>>

>>>>

>>>

>>>

>>>

>>>

>>>

>>

>>

>>

>>

>>

>

>

>

>

>

--

张文宏

Wenhong Zhang, M.D. & Ph.D.

Professor of Medicine

Director, Division of Infectious Diseases Huashan Hospital, Fudan University PI, Institute of Biomedical Science, Fudan University

12 M. Wulumuqi Road

Shanghai 200040, China

Phone: (8621)52888123

Fax: (8621)52888714

Email: zhangwenhong@fudan.edu.cn





---

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Sunday, January 5, 2020 10:22 AM  
**To:** wen yumei  
**Cc:** Lu, Shan; 袁正宏; zhangwenhong; Yuen KY  
**Subject:** Re: Re: Re: Re: Special Issue for EMI\_Highly Pathogenic Emerging CoVs

Thanks, Prof. Wen.

Prof. KY Yuen agreed to serve as a Co-guest Editor for this special issue proposed.

Please also see Prof. Zhang WH's comments published today:

<https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fmp.weixin.qq.com%2Fs%2FC1PKSrWyllGBHwNo gcfU2w&data=02%7C01%7Cshan.lu%40umassmed.edu%7C438977b07b314527e1db08d791f318ae%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C1%7C637138345610273797&sdata=MDPhg4z3a1EcX7JqB%2BQxQklJsHAr1zlxzDLoeY0FiME%3D&reserved=0>

Best,

Shibo

> -----原始邮件-----

> 发件人: "wen yumei" <ymwen@shmu.edu.cn>  
> 发送时间: 2020-01-05 17:02:19 (星期日)  
> 收件人: "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>  
> 抄送: "Lu Shan" <shan.lu@umassmed.edu>, "袁正宏" <Zhyuan@shmu.edu.cn>,  
> zhangwenhong <zhangwenhong@fudan.edu.cn>  
> 主题: Re: Re: Re: Special Issue for EMI\_Highly Pathogenic Emerging CoVs

>  
> Thank you. Got it.  
> Shan, ZH, WH Please comment. Wen  
>  
>

>> -----Original Messages-----

>> From: "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn> Sent Time:  
>> 2020-01-05 16:19:10 (Sunday)  
>> To: "wen yumei" <ymwen@shmu.edu.cn>  
>> Cc: "Lu Shan" <shan.lu@umassmed.edu>  
>> Subject: Re: Re: Special Issue for EMI\_Highly Pathogenic Emerging  
>> CoVs

>>  
>> Thanks, Prof. Wen.  
>>

>> I attached these documents again and also put in this email (see below). Please let em know if you cannot receive them again.

>>  
>> <https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fww.sciencemag.org%2Fnews%2F2020%2F01%2Fnovel-human-virus-pneumonia-ca>

>> ses-linked-seafood-market-china-stir-concern&data=02%7C01%7Cshan  
>> .lu%40umassmed.edu%7C438977b07b314527e1db08d791f318ae%7Cee9155fe2da3  
>> 4378a6c44405faf57b2e%7C0%7C1%7C637138345610273797&sdata=8NgFq1mv  
>> 3s%2BFh4LWjVCmh%2BX27kWI777k4KsrXK7l8hc%3D&reserved=0  
>>  
>> https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fww  
>> w.statnews.com%2F2020%2F01%2F04%2Fmystery-pneumonia-outbreak-china%2  
>> F&data=02%7C01%7Cshan.lu%40umassmed.edu%7C438977b07b314527e1db08  
>> d791f318ae%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C1%7C637138345610  
>> 273797&sdata=ZDmRZ6SxRC1M1vF%2FlzNP4C7lvWW6gtAjmRiiWb7ke%2BA%3D&  
>> amp;reserved=0  
>>  
>> https://nam01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fexp  
>> ertscape.com%2Fex%2Fmiddle%2Beast%2Brespiratory%2Bsyndrome%2Bcoronav  
>> irus&data=02%7C01%7Cshan.lu%40umassmed.edu%7C438977b07b314527e1d  
>> b08d791f318ae%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C1%7C637138345  
>> 610273797&sdata=fk2zeuxJEFTjYRFhuAm2Y6ox7f2LVYSKm4QfrFvVSgM%3D&a  
>> mp;reserved=0  
>>  
>>  
>> Combating the Highly Pathogenic Emerging Coronavirus ("Wuhan Virus")  
>> (Special issue for Emerging Microbes and Infection)  
>>  
>> Guest Editors for the Special issue of Emerging Microbes and  
>> Infection  
>>  
>> Shibo Jiang at Fudan University  
>> Kwok-Yung Yuen at University of Hong Kong  
>>  
>> Potential authors and topics (deadline of submission: 04/30/2020)  
>>  
>> 1. Shibo Jiang and Kwok-Yung Yuen  
>> Editorial (Combating Highly Pathogenic Emerging Coronavirus ("Wuhan  
>> Virus"))  
>>  
>> 2. Zhenli Shi, Wuhan Institute of Virology, Chinese Academy of Sciences  
>> Identification of "Wuhan Virus"  
>>  
>> 3. Wenjie Tan, National Institute for Viral Disease Control and Prevention Chinese Center for Disease Control and  
Prevention, Beijing, China.  
>> George F. Gao, National Institute for Viral Disease Control and  
>> Prevention, China Characterization of "Wuhan Virus"  
>>  
>> 4. ??? at xxx Hospital in Wuhan  
>> Histopathologic evaluation of lung tissues and clinical outcomes of  
>> patients with viral pneumonia caused by "Wuhan virus" infection  
>>  
>> 5. Kwok-Yung Yuen, University of Hong Kong  
>> "Wuhan virus" infection: virus-host cell interactions and implications on pathogenesis  
>> OR "Wuhan virus" quasispecies and its epidemiology characteristics.  
>>  
>> 6. Lanying Du, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA. LDu@nybc.org.

>> Fang Li, College of Veterinary Medicine, University of Minnesota,  
>> Saint Paul, MN, USA. lifang@umn.edu Crystallographic analysis of  
>> RBD/receptor complex and RBD-based coronavirus vaccine  
>>  
>> 7. Lu Lu, Shibo Jiang, Fudan University  
>> Pan-CoV fusion/entry inhibitors  
>>  
>> 8. Ralph Baric, the University of North Carolina  
>> Broad spectrum antiviral agents against human and zoonotic  
>> coronaviruses  
>>  
>> 9. Stanley Perlman, Interdisciplinary Program in Immunology, University of Iowa, Iowa City, IA 52242, USA  
>> Cellular immune responses against human and zoonotic coronaviruses:  
>> implication for vaccine development  
>>  
>> 10. Ziad A. Memish, Infectious Diseases Division, Prince Mohamed Bin Abdulaziz Hospital, Ministry of Health,  
Riyadh, Saudi Arabia; Hubert Department of Global Health, Emory University, Atlanta, GA, USA. zmemish@yahoo.com.  
>> Treatment and prevention of highly pathogenic human coronavirus  
>> infection  
>>  
>>  
>>  
>>> -----原始邮件-----  
>>> 发件人: "wen yumei" <ymwen@shmu.edu.cn>  
>>> 发送时间: 2020-01-05 15:45:17 (星期日)  
>>> 收件人: "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>  
>>> 抄送: "Lu Shan\_EMI" <shan.lu@emi2012.org>, "Lu Shan"  
>>> <shan.lu@umassmed.edu>  
>>> 主题: Re: Special Issue for EMI\_Highly Pathogenic Emerging CoVs  
>>>  
>>> If the Wuhan virus is a neww coronavirus, this will be a good opportunity for EMI.  
>>> I have not got the attachment you mentioned. Wen  
>>>  
>>>  
>>>> -----Original Messages-----  
>>>> From: "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn> Sent Time:  
>>>> 2020-01-05 15:38:10 (Sunday)  
>>>> To: "Lu Shan\_EMI" <shan.lu@emi2012.org>, "Wen Yumei"  
>>>> <ymwen@shmu.edu.cn>  
>>>> Cc: "Lu Shan" <shan.lu@umassmed.edu>  
>>>> Subject: Special Issue for EMI\_Highly Pathogenic Emerging CoVs  
>>>>  
>>>> Dear Prof. Lu and Wen,  
>>>>  
>>>> On January 3, 2020, the Wuhan Municipal Health Commission reported to WHO regarding a cluster of viral  
pneumonia cases in Wuhan, which has attracted attention worldwide. Based on the news reports of Science and many  
media (see the attachments), the unknown "Wuhan virus" is very likely the SARS-like coronavirus (SL-CoV). We and  
other groups have well prepared to work on this new virus once its DNA sequence is announced and a number of high  
profile journals are well prepared to accept the manuscripts from these groups. To compute with these journals, I  
propose to organize a special issue for EMI entitled "Combating the Highly Pathogenic Emerging Coronavirus ("Wuhan

Virus")" by inviting the world-renowned experts in this field (see the attached Expertscape) who may work on this new virus to contribute research or review articles to this special issue. We should give priority to these manuscripts for rapid publication.

>>>>

>>>> I remember in 2013 when the H7N9 epidemic started, we quickly analyzed the HA sequence of H7N9 and submitted the manuscript without any experimental data to Microbes and Infection just two weeks after its sequence was released. The paper was immediately accepted for publication (just a few days after the NEJM paper published) and this paper was cited for almost 50 times in a few months by many high profile journals, including Science and NEJM. Therefore, the timing is most important.

>>>>

>>>> If you agree with my proposal, I will contact with Prof. KY Yuen and send out our invitation letter immediately after WHO or China CDC confirms that the "Wuhan virus" is indeed a newly emerging SL-CoV.

>>>>

>>>> Thank you very much for your consideration,

>>>>

>>>> Shibo

>>>>

>>>>

>>>>

>>>>

>>>>

>>>

>>>

>>>

>>>

>>>

>>

>>

>>

>>

>>

>

>

>

>

>

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Tuesday, February 25, 2020 9:43 PM  
**To:** Lu, Shan  
**Subject:** Re: RE: RE: Review from Jin Dong-yan

Thank you.Wen

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:** 2020-02-26 09:34:55 (Wednesday)  
**To:** "wen yumei" <ymwen@shmu.edu.cn>  
**Cc:**  
**Subject:** RE: RE: Review from Jin Dong-yan

Dear Prof Wen,

Dr. Jin Dong-Yan submitted a revised paper. I have accepted as you instructed earlier.

His responses are copied below for your ref.

Thanks.

Shan

\*\*\*\*\*

Dear Prof. Lu,

Thank you very much for arranging a rapid review of our manuscript entitled "A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defense: Lessons from other pathogenic viruses" submitted to EMI last week.

We have revised our paper according to reviewers' comments. We have also updated some parts of our manuscript to reflect new papers that appeared last week. A point-point response is as follows.

Reviewer: 1

1. It is risky to discuss about the asymptomatic SARS-CoV-2 carrier without providing a clear position. First, is there any solid and published case or clusters of cases that were asymptomatic carriers? Second, given the uncertainty of diagnostic kits, how will anyone to claim whether the labeling of asymptomatic carriers are true and correct? At the same time, the authors showed reservation about such definition, but some further emphasis on the confusing nature of such public concern is needed.

Response: We have referenced a new report (Ref. 54), clarified our position (i.e. asymptomatic shedding exists but is uncommon) and provided more explanation (pp. 15-16; lines 339-340, 342-343, 353-358). We have tried to provide a more balanced view on this critical issue. In fact, I recently discussed this face to face with Dr. Peter Palese who does not believe asymptomatic virus shedding. It is indeed very controversial, but avoiding this completely in the review might not be wise. We are of the opinion that asymptomatic and presymptomatic virus shedding does occur, but might not play a critical role in most circumstances.

2. any potential implication from the current report can be suggested, especially in the area of immune regulation? Currently, most novel treatment efforts are on the drug development against some target of virus itself.

Response: We have added more discussion on drugs targeting the immune response. The beneficial effects of type I interferon and its possible adverse effect have been discussed (p. 15, lines 328-332). We have also highlighted inhibitors of NLRP3 inflammasomes such as MCC950 and INP58 (p. 21, lines 468-469).

Reviewer: 2

I do not think it is appropriate to include HIV in this review, and I advise the authors to delete this part from the review.

Response: We do not agree with the reviewer. We feel that the discussion of HIVs is relevant, informative and instructive. However, we have added more explanation to highlight the theme or trend of interspecies transmission of animal viruses in pp. 10-11 (lines 226-229) so that readers can appreciate why we include HIVs for comparison at the very beginning.

With these revisions, I hope that you will find our revised review acceptable for publication in EMI. I am looking forward to hearing from you soon.

Sincerely,

Dong-Yan Jin, PhD

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Sunday, February 23, 2020 9:10 PM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Subject:** Re: RE: Review from Jin Dong-yan

Thank you. Wen

-----Original Messages-----

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Sent Time:**2020-02-24 04:09:54 (Monday)  
**To:** "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
**Cc:**  
**Subject:** RE: Review from Jin Dong-yan

Hi, Prof Wen,

Thanks for your quick feedback and good review. I have made minor revision. Please see below my comments:

The authors have significant experience in the topic of this review. it is timely given the current CoV outbreak.

1. it is risky to discuss about the asymptomatic SARS-CoV-2 carrier without providing a clear position. First, is there any solid and published case or clusters of cases that were asymptomatic carriers? Second, given the uncertainty of diagnostic kits, how will anyone claim whether the labeling of asymptomatic carriers are true and correct? At the same time, the authors showed reservation about such definition, but some further emphasis on the confusing nature of such public concern is needed.

2. any potential implication from the current report can be suggested, especially in the area of immune regulation? Currently, most novel treatment efforts are on the drug development against some target of virus itself.

I will accept once the revised version is back.

Thanks.

Shan

**From:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
**Sent:** Sunday, February 23, 2020 4:59 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** Re: Review from Jin Dong-yan

For Jin's review, my comment is

This is a well written review, including the characteristics of several coronaviruses between SARS and COVID-19 outbreaks. Further more, it reviewed virus-host interactions, which have not been reviewed in other articles.

However, I do not think it is appropriate to include HIV in this review, and I advise the authors to delete this part from the review.

Please be the other reviewer, and give your comments.

After revision, I think it is worthy to be accepted.

Regards,

Yu-Mei Wen

-----Original Messages-----

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Sent Time:** 2020-02-22 13:58:13 (Saturday)

**To:** "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>

**Cc:**

**Subject:** Review from Jin Dong-yan

Dear Prof Wen,

Jin Dong-yan submitted a review based on your invitation. I am attaching it here for your reference. Please let me know if you have any comments so I can enter into the system that he can revise. Or if you have anyone who can review this paper.

At the same time, I am very happy to accept at any time you would like to do so.

Best.

Shan



---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Sunday, January 5, 2020 4:02 AM  
**To:** Shibo Jiang (姜世勃)  
**Cc:** Lu, Shan; 袁正宏; zhangwenhong  
**Subject:** Re: Re: Re: Special Issue for EMI\_Highly Pathogenic Emerging CoVs

Thank you. Got it.  
Shan, ZH, WH Please comment. Wen

> -----Original Messages-----

> From: "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn> Sent Time:  
> 2020-01-05 16:19:10 (Sunday)  
> To: "wen yumei" <ymwen@shmu.edu.cn>  
> Cc: "Lu Shan" <shan.lu@umassmed.edu>  
> Subject: Re: Re: Special Issue for EMI\_Highly Pathogenic Emerging CoVs  
>  
> Thanks, Prof. Wen.  
>  
> I attached these documents again and also put in this email (see below). Please let em know if you cannot receive them again.  
>  
> <https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.sciencemag.org%2Fnews%2F2020%2F01%2Fnovel-human-virus-pneumonia-cases-linked-seafood-market-china-stir-concern&data=02%7C01%7Cshan.lu%40umassmed.edu%7C1251e72e060e4c9fce5308d791be0000%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637138117561072062&sdata=8yDEOgZFvTr2c2ABed8gGgH1ZZPCP41HlanFQD1gvBk%3D&reserved=0>  
>  
> <https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.statnews.com%2F2020%2F01%2F04%2Fmystery-pneumonia-outbreak-china%2F&data=02%7C01%7Cshan.lu%40umassmed.edu%7C1251e72e060e4c9fce5308d791be0000%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637138117561072062&data=pxyEXfqCrZUmPtaMlvwqxihg06tLfo3a0Hju1A8pRbo%3D&reserved=0>  
>  
> <https://nam01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fexpertscape.com%2Fex%2Fmiddle%2Fbeast%2Frespiratory%2Fsyndrome%2Fcoronavirus&data=02%7C01%7Cshan.lu%40umassmed.edu%7C1251e72e060e4c9fce5308d791be0000%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637138117561072062&sdata=gF50ygRmS8C7AREx5lk8Ze4dLqyJvrGUB4MxmrB%2F9ws%3D&reserved=0>  
>  
>  
> Combating the Highly Pathogenic Emerging Coronavirus ("Wuhan Virus")  
> (Special issue for Emerging Microbes and Infection)  
>  
> Guest Editors for the Special issue of Emerging Microbes and Infection  
>  
> Shibo Jiang at Fudan University

> Kwok-Yung Yuen at University of Hong Kong

>

> Potential authors and topics (deadline of submission: 04/30/2020)

>

> 1. Shibo Jiang and Kwok-Yung Yuen

> Editorial (Combating Highly Pathogenic Emerging Coronavirus ("Wuhan Virus"))

>

> 2. Zhenli Shi, Wuhan Institute of Virology, Chinese Academy of Sciences

> Identification of "Wuhan Virus"

>

> 3. Wenjie Tan, National Institute for Viral Disease Control and Prevention Chinese Center for Disease Control and Prevention, Beijing, China.

> George F. Gao, National Institute for Viral Disease Control and Prevention, China Characterization of "Wuhan Virus"

>

> 4. ???? at xxx Hospital in Wuhan

> Histopathologic evaluation of lung tissues and clinical outcomes of patients with viral pneumonia caused by "Wuhan virus" infection

>

> 5. Kwok-Yung Yuen, University of Hong Kong

> "Wuhan virus" infection: virus-host cell interactions and implications on pathogenesis

> OR "Wuhan virus" quasispecies and its epidemiology characteristics.

>

> 6. Lanying Du, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA. LDu@nybc.org.

> Fang Li, College of Veterinary Medicine, University of Minnesota, Saint Paul, MN, USA. lifang@umn.edu Crystallographic analysis of RBD/receptor complex and RBD-based coronavirus vaccine

>

> 7. Lu Lu, Shibo Jiang, Fudan University

> Pan-CoV fusion/entry inhibitors

>

> 8. Ralph Baric, the University of North Carolina

> Broad spectrum antiviral agents against human and zoonotic coronaviruses

>

> 9. Stanley Perlman, Interdisciplinary Program in Immunology, University of Iowa, Iowa City, IA 52242, USA

> Cellular immune responses against human and zoonotic coronaviruses:

> implication for vaccine development

>

> 10. Ziad A. Memish, Infectious Diseases Division, Prince Mohamed Bin Abdulaziz Hospital, Ministry of Health, Riyadh, Saudi Arabia; Hubert Department of Global Health, Emory University, Atlanta, GA, USA. zmemish@yahoo.com.

> Treatment and prevention of highly pathogenic human coronavirus infection

>

>

>

>> -----原始邮件-----

>> 发件人: "wen yumei" <ymwen@shmu.edu.cn>

>> 发送时间: 2020-01-05 15:45:17 (星期日)

>> 收件人: "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>

>

>  
>  
>

-----

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Tuesday, February 16, 2021 10:28 AM  
**To:** Lu, Shan  
**Cc:** min.yang@emi2012.org  
**Subject:** Re: RE: RE: Su S\_HCS of COVID-19 vaccines\_EMI

Thanks, Prof. Lu.

I will monitor carefully any feedback email so I can make any necessary changes if asked.

Best,

Shibo

-----The original message-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sending time:** 2021-02-16 23:21:02 (Tuesday)  
**To:** "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>  
**Cc:** "min.yang@emi2012.org" <min.yang@emi2012.org>  
**Subject:** RE: RE: Su S\_HCS of COVID-19 vaccines\_EMI

It looks like your MS has not passed the QC step by T&F. Please continue to monitor any feedback email so you can make any necessary changes if asked. Once your paper has a EMI #, let me know, and I will watch closely once it is on my desk.

Best.

Shan

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Tuesday, February 16, 2021 10:18 AM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Cc:** min.yang@emi2012.org  
**Subject:** Re: RE: Su S\_HCS of COVID-19 vaccines\_EMI

Dear Prof. Lu,

1

Thank you very much for informing me that EMI is very interested and will process our paper asap.

As you suggested, I cited Dr. Plotkin's commentary published in Vaccine at the end of this manuscript (see the attachment). Considering the word limit for our manuscript, I did not cite more information from their paper. However, we can add more information in response to the reviewers' comments.

Thank you again for your support and consideration,

Shibo

-----The original message-----

From: "Lu, Shan" <Shan.Lu@umassmed.edu>

Sending time: 2021-02-16 23:04:45 (Tuesday)

To: "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>

Cc: "min.yang@emi2012.org" <min.yang@emi2012.org>

Subject: RE: Su S\_HCS of COVID-19 vaccines\_EMI

Hi, Shibo,

I fully support human challenge. EMI is very interested and will process this paper asap. I will ask a few experts in this area to make some comments.

Best.

Shan

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>

**Sent:** Tuesday, February 16, 2021 9:23 AM

2

---

**Page 3**

**To:** Lu, Shan <Shan.Lu@umassmed.edu>; Lu Shan\_EMI <shan.lu@emi2012.org>

**Subject:** Su S\_HCS of COVID-19 vaccines\_EMI

Teacher Lu, hello and happy new year!

At the beginning of August last year, led by Professor Shao Yiming from China's CDC, our five experts informed the "State Council's New Coronary Pneumonia E The "Scientific Research Team" proposed the use of "human challenge tests" to accelerate the development of new coronavirus vaccines. Although China is develop The country with the earliest and the largest number of bed trials (three vaccines had completed Phase II clinical trials at that time), but due to the outbreak of the ne When it is controlled, it is no longer possible to carry out Phase III clinical trials to test the effectiveness of vaccines in China, which has greatly delayed the develop Our proposal quickly received the attention of relevant Chinese departments, and immediately established a special working committee, established a working mecl The leadership, organization, coordination and implementation of this work. But since the two vaccines were launched in the United States at the end of last year, th

Experts believe that it is no longer necessary to carry out post-human challenge trials.

However, although a number of new crown vaccines have been approved for marketing, the epidemic of new mutant strains has caused global panic. Last week, the Announced the suspension of AstraZeneca's new crown vaccine in South Africa. Although there is no clinical trial, according to epidemiological investigations, it is Mutant strains are inefficient or ineffective. Several new crown vaccines that China has approved for marketing may face such a dilemma in the future. Therefore, v The "human challenge test" is used to quickly evaluate the effectiveness of these new crown vaccines that have been approved for marketing against mutant infectio These new crown vaccines approved for marketing are safe, so the risk of conducting "human challenge trials" is lower.

We wrote a comment, and hope to post it on EMI. After publication, we will forward it to the WHO, hoping that our suggestions will be available in other countries Get a response. Would you please see if this review is suitable for publication at EMI? If appropriate, are there any changes to be made? Please advise.

Thank you!

Shibo

\*\*\*\*\*

Professor Jiang Shibo

Fudan Institute of Microbiology and Pathogens

Fudan University School of Basic Medical Sciences, Shanghai Medical College, Ministry of Education/Health Commission/Key Laboratory of Medical Division of

Room 413, 4th Floor, Fosun Building, No. 131 Dong'an Road, Xuhui District, Shanghai (Postal Code: 200032)

3

---

#### Page 4

E-mail: shibojiang@fudan.edu.cn

Office Tel: (0)21-54237673 Phone: 189-6408-2556

Website: [http://medicine.fudan.edu.cn/show.aspx?info\\_lb=30&flag=2&info\\_id=3122](http://medicine.fudan.edu.cn/show.aspx?info_lb=30&flag=2&info_id=3122)

Published arguments: <https://pubmed.ncbi.nlm.nih.gov/?term=shibo+jiang&sort=date&size=200>





---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Saturday, January 18, 2020 1:41 AM  
**To:** Lu, Shan  
**Cc:** 'KY Yuen'; 'Shibo Jiang'  
**Subject:** Re: RE: RE: URGENT submission for fast track review

Shane : Thank you for all your excellent work for EMI, and hope that EMI will be better and better in the future. YM Wen

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:** 2020-01-17 21:27:40 (Friday)  
**To:** "wen yumei" <ymwen@shmu.edu.cn>  
**Cc:** "'KY Yuen'" <kyyuen@hku.hk>, "'Shibo Jiang'" <shibojiang@fudan.edu.cn>  
**Subject:** RE: RE: URGENT submission for fast track review

Dear Prof Wen,

Thanks for your feedback and advice. Before seeing your email below, I have already accepted Prof Yuen's paper at EMI. Hopefully it will come out soon.

At the same time, I am happy to share with this group that EMI is in the middle of launching a new special issue called "Emerging and Re-emerging CoV" which will be an electronic issue and collects past, current and future papers related to any CoV published at EMI. At this point, EMI has already published 37 CoV papers and we will keep collecting. Shibo will serve as the founding Guest Editor of this special issue.

This way, EMI can establish a unique presence and promote the research and publishing of CoV work.

I believe competition, but don't feel a short time competition will bring any long lasting outcome. At EMI, we just keep working very hard, day in and day out, all year long, year after year, which is hard for anyone to repeat. The quality and reputation are ultimately count, not citations.

Best.

Shan

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Friday, January 17, 2020 7:56 AM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Cc:** 'KY Yuen' <kyyuen@hku.hk>; 'Shibo Jiang' <shibojiang@fudan.edu.cn>  
**Subject:** Re: RE: URGENT submission for fast track review

Shan, KY, SB:

There will be more and more competition on the new coronaairus. Since the preparation of the mnuscrit may need more time, it is important that we publish some articles ASAP.Maybe there will be some shortcomings in the paper, we can add a comment to the article.

Please proceed fast in this issue.

My further suggestion for the administrative officials ,is that

- 1) Generation of neutraliziing monoclonal antibodies from convalescnet patients may be could be effective for treatment of patients.
- 2) Collaboation on constant survey on human coronzvirus, especially on the muataions of S and E genes as for influenza virus, may be helpful in the future for early detection n of new coronavirus..
3. Basic studies on the immune responses and pathogenesis of human coronavirus should be supported continuously,even after the outbreaks.
4. From the public health aspects, epidmiological studies on human respirtatoy infections and analysis of different types of host responses as well as populational epidemiology need to be pursued.

YM Wen

.

-----Original Messages-----

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Sent Time:**2020-01-17 05:23:47 (Friday)  
**To:** "'KY Yuen'" <[kyyuen@hku.hk](mailto:kyyuen@hku.hk)>, "'Shibo Jiang'" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>, "'wen yumei'" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
**Cc:**  
**Subject:** RE: URGENT submission for fast track review

Dear KY,

Thanks for your fast work. I will process it at our fastest pace.

Shan

---

**From:** KY Yuen <[kyyuen@hku.hk](mailto:kyyuen@hku.hk)>  
**Sent:** Thursday, January 16, 2020 10:00 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; 'Shibo Jiang' <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>; 'wen yumei' <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
**Cc:** 'KY Yuen' <[kyyuen@hku.hk](mailto:kyyuen@hku.hk)>  
**Subject:** URGENT submission for fast track review

Dear Editor Professor Lu, Professor Jiang and Professor Wen,

I understand from Prof. SB Jiang that EMI may consider fast track review on papers related to the novel coronavirus causing the Wuhan outbreak.

We respectfully submit the attached paper on a comprehensive bioinformatics analysis of the 6 available virus genomes as attached. There are interesting novel findings which would be widely cited, but only if the paper comes out FIRST. As in previous outbreaks such Zika viruses, such publications are likely to improve the impact factor of EMI.

Your kind and speedy attention to this submission is most appreciated. Our paper will be uploaded to EMI website before midnight in order to speed up the whole process.

Warmest regards and an early happy Chinese New Year.

Kwok-Yung

From HKU microbiology



---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Sunday, February 23, 2020 9:10 PM  
**To:** Lu, Shan  
**Subject:** Re: RE: Review from Jin Dong-yan

Thank you. Wen

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:** 2020-02-24 04:09:54 (Monday)  
**To:** "wen yumei" <ymwen@shmu.edu.cn>  
**Cc:**  
**Subject:** RE: Review from Jin Dong-yan

Hi, Prof Wen,

Thanks for your quick feedback and good review. I have made minor revision. Please see below my comments:

The authors have significant experience in the topic of this review. it is timely given the current CoV outbreak.

1. it is risky to discuss about the asymptomatic SARS-CoV-2 carrier without providing a clear position. First, is there any solid and published case or clusters of cases that were asymptomatic carriers? Second, given the uncertainty of diagnostic kits, how will anyone claim whether the labeling of asymptomatic carriers are true and correct? At the same time, the authors showed reservation about such definition, but some further emphasis on the confusing nature of such public concern is needed.
2. any potential implication from the current report can be suggested, especially in the area of immune regulation? Currently, most novel treatment efforts are on the drug development against some target of virus itself.

I will accept once the revised version is back.

Thanks.

Shan

**From:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
**Sent:** Sunday, February 23, 2020 4:59 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** Re: Review from Jin Dong-yan

For Jin's review, my comment is

This is a well written review, including the characteristics of several coronaviruses between SARS and COVID-19 outbreaks. Further more, it reviewed virus-host interactions, which have not been reviewed in other articles.

However, I do not think it is appropriate to include HIV in this review, and I advise the authors to delete this part from the review.

Please be the other reviewer, and give your comments.

After revision, I think it is worthy to be accepted.

Regards,

Yu-Mei Wen

-----Original Messages-----

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Sent Time:** 2020-02-22 13:58:13 (Saturday)  
**To:** "wen yumei" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
**Cc:**  
**Subject:** Review from Jin Dong-yan

Dear Prof Wen,

Jin Dong-yan submitted a review based on your invitation. I am attaching it here for your reference. Please let me know if you have any comments so I can enter into the system that he can revise. Or if you have anyone who can review this paper.

At the same time, I am very happy to accept at any time you would like to do so.

Best.



---

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Sunday, January 5, 2020 3:19 AM  
**To:** wen yumei  
**Cc:** Lu, Shan  
**Subject:** Re: Re: Special Issue for EMI\_Highly Pathogenic Emerging CoVs  
**Attachments:** Special Issue for EMI\_Highly Pathogenic Emerging SL-CoVs.docx;  
Coronavirus\_Worldwide\_Experts\_cape.pdf; Science\_Novel human virus\_Pneumonia cases linked to  
seafood market in China stir concern\_2020-1-4.docx; STAT\_Experts search for answers in limited  
information about mystery pneumonia outbreak in China\_2020-14.docx

Thanks, Prof. Wen.

I attached these documents again and also put in this email (see below). Please let em know if you cannot receive them again.

<https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.sciencemag.org%2Fnews%2F2020%2F01%2Fnovel-human-virus-pneumonia-cases-linked-seafood-market-china-stir-concern&data=02%7C01%7Cshan.lu%40umassmed.edu%7Cba8f2a46f6be4e9a55b008d791b7f5f2%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637138092170804365&sdata=00Onf37PVzHPfUTH3X0ewL7TyJHTgU8x%2FXP8KyucSIA%3D&reserved=0>

<https://nam01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.statnews.com%2F2020%2F01%2F04%2Fmystery-pneumonia-outbreak-china%2F&data=02%7C01%7Cshan.lu%40umassmed.edu%7Cba8f2a46f6be4e9a55b008d791b7f5f2%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637138092170804365&sdata=bRogxzn1Zs34MIIOghk03oN2I2mbPKZDI5H7SXnobHM%3D&reserved=0>

<https://nam01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fexpertscape.com%2Fex%2Fmiddle%2FBeast%2FRespiratory%2FSyndrome%2Bcoronavirus&data=02%7C01%7Cshan.lu%40umassmed.edu%7Cba8f2a46f6be4e9a55b008d791b7f5f2%7Cee9155fe2da34378a6c44405faf57b2e%7C0%7C0%7C637138092170809357&sdata=e9xWHalWWhNq2RRni0l8EWkpfS8wZw1O5RpWhGVKqUo%3D&reserved=0>

Combating the Highly Pathogenic Emerging Coronavirus ("Wuhan Virus") (Special issue for Emerging Microbes and Infection)

Guest Editors for the Special issue of Emerging Microbes and Infection

Shibo Jiang at Fudan University  
Kwok-Yung Yuen at University of Hong Kong

Potential authors and topics (deadline of submission: 04/30/2020)

1. Shibo Jiang and Kwok-Yung Yuen  
Editorial (Combating Highly Pathogenic Emerging Coronavirus ("Wuhan Virus"))
2. Zhenli Shi, Wuhan Institute of Virology, Chinese Academy of Sciences  
Identification of "Wuhan Virus"



3. Wenjie Tan, National Institute for Viral Disease Control and Prevention Chinese Center for Disease Control and Prevention, Beijing, China.  
George F. Gao, National Institute for Viral Disease Control and Prevention, China Characterization of "Wuhan Virus"
4. ??? at xxx Hospital in Wuhan  
Histopathologic evaluation of lung tissues and clinical outcomes of patients with viral pneumonia caused by "Wuhan virus" infection
5. Kwok-Yung Yuen, University of Hong Kong  
"Wuhan virus" infection: virus-host cell interactions and implications on pathogenesis  
OR "Wuhan virus" quasispecies and its epidemiology characteristics.
6. Lanying Du, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA. LDu@nybc.org.  
Fang Li, College of Veterinary Medicine, University of Minnesota, Saint Paul, MN, USA. lifang@umn.edu Crystallographic analysis of RBD/receptor complex and RBD-based coronavirus vaccine
7. Lu Lu, Shibo Jiang, Fudan University  
Pan-CoV fusion/entry inhibitors
8. Ralph Baric, the University of North Carolina  
Broad spectrum antiviral agents against human and zoonotic coronaviruses
9. Stanley Perlman, Interdisciplinary Program in Immunology, University of Iowa, Iowa City, IA 52242, USA  
Cellular immune responses against human and zoonotic coronaviruses: implication for vaccine development
10. Ziad A. Memish, Infectious Diseases Division, Prince Mohamed Bin Abdulaziz Hospital, Ministry of Health, Riyadh, Saudi Arabia; Hubert Department of Global Health, Emory University, Atlanta, GA, USA. zmemish@yahoo.com.  
Treatment and prevention of highly pathogenic human coronavirus infection

> -----原始邮件-----

> 发件人: "wen yumei" <ymwen@shmu.edu.cn>

> 发送时间: 2020-01-05 15:45:17 (星期日)

> 收件人: "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>

> 抄送: "Lu Shan\_EMI" <shan.lu@emi2012.org>, "Lu Shan"

> <shan.lu@umassmed.edu>

> 主题: Re: Special Issue for EMI\_Highly Pathogenic Emerging CoVs

>

> If the Wuhan virus is a neww coronavirus, this will be a good opportunity for EMI.

> I have not got the attachment you mentioned. Wen

>

>

> > -----Original Messages-----

> > From: "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn> Sent Time:

> > 2020-01-05 15:38:10 (Sunday)

> > To: "Lu Shan\_EMI" <shan.lu@emi2012.org>, "Wen Yumei"

> > <ymwen@shmu.edu.cn>

> > Cc: "Lu Shan" <shan.lu@umassmed.edu>

> > Subject: Special Issue for EMI\_Highly Pathogenic Emerging CoVs

>>  
>> Dear Prof. Lu and Wen,  
>>  
>> On January 3, 2020, the Wuhan Municipal Health Commission reported to WHO regarding a cluster of viral pneumonia cases in Wuhan, which has attracted attention worldwide. Based on the news reports of Science and many media (see the attachments), the unknown "Wuhan virus" is very likely the SARS-like coronavirus (SL-CoV). We and other groups have well prepared to work on this new virus once its DNA sequence is announced and a number of high profile journals are well prepared to accept the manuscripts from these groups. To compute with these journals, I propose to organize a special issue for EMI entitled "Combating the Highly Pathogenic Emerging Coronavirus ("Wuhan Virus")" by inviting the world-renowned experts in this field (see the attached Expertscape) who may work on this new virus to contribute research or review articles to this special issue. We should give priority to these manuscripts for rapid publication.  
>>  
>> I remember in 2013 when the H7N9 epidemic started, we quickly analyzed the HA sequence of H7N9 and submitted the manuscript without any experimental data to Microbes and Infection just two weeks after its sequence was released. The paper was immediately accepted for publication (just a few days after the NEJM paper published) and this paper was cited for almost 50 times in a few months by many high profile journals, including Science and NEJM. Therefore, the timing is most important.  
>>  
>> If you agree with my proposal, I will contact with Prof. KY Yuen and send out our invitation letter immediately after WHO or China CDC confirms that the "Wuhan virus" is indeed a newly emerging SL-CoV.  
>>  
>> Thank you very much for your consideration,  
>>  
>> Shibo  
>>  
>>  
>>  
>>  
>>  
>  
>  
>  
>  
>

\*\*\*\*\*

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Tuesday, February 16, 2021 10:18 AM  
**To:** Lu, Shan  
**Cc:** min.yang@emi2012.org  
**Subject:** Re: RE: Su S\_HCS of COVID-19 vaccines\_EMI  
**Attachments:** Su S\_HCS of COVID-19 vaccines\_EMI\_2021-2-16.docx

Dear Prof. Lu,

Thank you very much for informing me that EMI is very interested and will process our paper asap.

As you suggested, I cited Dr. Plotkin's commentary published in Vaccine at the end of this manuscript (see the attachment). Considering the word limit for our manuscript, I did not cite more information from their paper. However, we can add more information, in response to the reviewers' comments.

Thank you again for your support and consideration,

Shibo

-----The original message-----

From: "Lu, Shan" <Shan.Lu@umassmed.edu>  
Sending time: 2021-02-16 23:04:45 (Tuesday)  
To: "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>  
Cc: "min.yang@emi2012.org" <min.yang@emi2012.org>  
Subject: RE: Su S\_HCS of COVID-19 vaccines\_EMI

Hi, Shibo,

I fully support human challenge. EMI is very interested and will process this paper asap. I will ask a few experts in this area to make some comments.

Best.

Shan

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Tuesday, February 16, 2021 9:23 AM

**To:** Lu, Shan <Shan.Lu@umassmed.edu>; Lu Shan\_EMI <shan.lu@emi2012.org>

**Subject:** Su S\_HCS of COVID-19 vaccines\_EMI

Teacher Lu, hello and happy new year!

At the beginning of August last year, led by Professor Shao Yiming from China's CDC, our five experts informed the "State Council's New Coronary Pneumonia Expert Scientific Research Team" proposed the use of "human challenge tests" to accelerate the development of new coronavirus vaccines. Although China is developing the country with the earliest and the largest number of bed trials (three vaccines had completed Phase II clinical trials at that time), but due to the outbreak of the new virus, when it is controlled, it is no longer possible to carry out Phase III clinical trials to test the effectiveness of vaccines in China, which has greatly delayed the development. Our proposal quickly received the attention of relevant Chinese departments, and immediately established a special working committee, established a working mechanism. The leadership, organization, coordination and implementation of this work. But since the two vaccines were launched in the United States at the end of last year, the experts believe that it is no longer necessary to carry out post-human challenge trials.

However, although a number of new crown vaccines have been approved for marketing, the epidemic of new mutant strains has caused global panic. Last week, the WHO announced the suspension of AstraZeneca's new crown vaccine in South Africa. Although there is no clinical trial, according to epidemiological investigations, it is believed that mutant strains are inefficient or ineffective. Several new crown vaccines that China has approved for marketing may face such a dilemma in the future. Therefore, the "human challenge test" is used to quickly evaluate the effectiveness of these new crown vaccines that have been approved for marketing against mutant infection. These new crown vaccines approved for marketing are safe, so the risk of conducting "human challenge trials" is lower.

We wrote a comment, and hope to post it on EMI. After publication, we will forward it to the WHO, hoping that our suggestions will be available in other countries to get a response. Would you please see if this review is suitable for publication at EMI? If appropriate, are there any changes to be made? Please advise.

Thank you!

Shibo

\*\*\*\*\*

Professor Jiang Shibo

Fudan Institute of Microbiology and Pathogens

Fudan University School of Basic Medical Sciences, Shanghai Medical College, Ministry of Education/Health Commission/Key Laboratory of Medical Division of

2

---

### Page 3

Room 413, 4th Floor, Fosun Building, No. 131 Dong'an Road, Xuhui District, Shanghai (Postal Code: 200032)

E-mail: shibojiang@fudan.edu.cn

Office Tel: (0)21-54237673 Phone: 189-6408-2556

Website: [http://medicine.fudan.edu.cn/show.aspx?info\\_lb=30&flag=2&info\\_id=3122](http://medicine.fudan.edu.cn/show.aspx?info_lb=30&flag=2&info_id=3122)

Published arguments: <https://pubmed.ncbi.nlm.nih.gov/?term=shibo+jiang&sort=date&size=200>



---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Saturday, October 10, 2020 12:08 AM  
**To:** Lu, Shan  
**Subject:** Re: RE: Submission inquiry\_Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster

Thank you. YM

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:** 2020-10-06 22:59:16 (Tuesday)  
**To:** "wen yumei" <ymwen@shmu.edu.cn>  
**Cc:**  
**Subject:** RE: Submission inquiry\_Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster

It is under review. I will reply to the authors

Shan

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Tuesday, October 6, 2020 8:50 AM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Subject:** Fw: Submission inquiry\_Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster

For your ref. Wen

-----Original Messages-----

**From:** "QUEROMES GREGORY" <[gregory.queromes@univ-lyon1.fr](mailto:gregory.queromes@univ-lyon1.fr)>  
**Sent Time:** 2020-10-05 21:37:16 (Monday)  
**To:** "[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>, "[editorial@emi2012.org](mailto:editorial@emi2012.org)" <[editorial@emi2012.org](mailto:editorial@emi2012.org)>  
**Cc:** "[laurence.josset@chu-lyon.fr](mailto:laurence.josset@chu-lyon.fr)" <[laurence.josset@chu-lyon.fr](mailto:laurence.josset@chu-lyon.fr)>, "[bruno.lina@chu-lyon.fr](mailto:bruno.lina@chu-lyon.fr)" <[bruno.lina@chu-lyon.fr](mailto:bruno.lina@chu-lyon.fr)>, "[gregory.destras@chu-lyon.fr](mailto:gregory.destras@chu-lyon.fr)" <[gregory.destras@chu-lyon.fr](mailto:gregory.destras@chu-lyon.fr)>, "[antonin.bal@chu-lyon.fr](mailto:antonin.bal@chu-lyon.fr)" <[antonin.bal@chu-lyon.fr](mailto:antonin.bal@chu-lyon.fr)>, "Emilie FROBERT" <[emilie.frobert@chu-lyon.fr](mailto:emilie.frobert@chu-lyon.fr)>  
**Subject:** Submission inquiry\_Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster

Dear Pr. Wen,

Having submitted our manuscript describing a nosocomial cluster of a SARS-CoV-2 ORF6 deletion variant in France (Manuscript ID TEMI-2020-1518) to EMI September 17th, we were hoping to receive an update on your review of our manuscript.

We look forward to hearing from you and exchanging on our research.

Best regards,

Laurence Josset, PharmD PhD  
Research Assistant Professor  
National reference center for respiratory viruses (Pr. Bruno Lina)  
University hospital of Lyon, France

Grégory Quéromès

*PhD student - CIRI U1111 "Virology and Human Pathology" Team*

*University of Lyon - Claude Bernard Lyon 1 - France*

*MSc - Molecular Microbiology, Pathogenesis, and Microbial Ecology*

---

**From:** [antonin.bal@chu-lyon.fr](mailto:antonin.bal@chu-lyon.fr) <[antonin.bal@chu-lyon.fr](mailto:antonin.bal@chu-lyon.fr)>

**Sent:** Thursday, September 17, 2020 06:10

**To:** [ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn); [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu); [yiweitangmd@gmail.com](mailto:yiweitangmd@gmail.com)

**Cc:** [editorial@emi2012.org](mailto:editorial@emi2012.org); [laurence.josset@chu-lyon.fr](mailto:laurence.josset@chu-lyon.fr); [bruno.lina@chu-lyon.fr](mailto:bruno.lina@chu-lyon.fr); QUEROMES GREGORY;  
[gregory.destras@chu-lyon.fr](mailto:gregory.destras@chu-lyon.fr); [antonin.bal@chu-lyon.fr](mailto:antonin.bal@chu-lyon.fr)

**Subject:** RE: [SPAM] Re: Pre-submission inquiry\_ Characterization of newly SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster

Thank you very much for your response.

The manuscript has been submitted (Manuscript ID TEMI-2020-1518). We are looking forward to hearing from you.

Best regards,

Laurence Josset, PharmD PhD  
Research Assistant Professor  
National reference center for respiratory viruses (Pr. Bruno Lina)  
University hospital of Lyon, France

De : wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>

Envoyé : mardi 15 septembre 2020 02:06:54

À : BAL, Antonin; [shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu); YiWei Tang

Cc : [editorial@emi2012.org](mailto:editorial@emi2012.org); JOSSET, Laurence; LINA, Bruno; [gregory.queromes@univ-lyon1.fr](mailto:gregory.queromes@univ-lyon1.fr); DESTRAS, Gregory

Objet : [SPAM] Re: Pre-submission inquiry\_Characterization of newly SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster

Laurence Josset, PharmD PhD

Thank you for your mail. After discussion with Prof. Shan Lu, co-editor-in-chief, we welcome you to submit your article through EMI website: [www.tandfonline.com/TEMI](http://www.tandfonline.com/TEMI) . However, there are many submissions to EMI, your submission will be evaluated through a strict review system, and this letter does not mean acceptance. Regards, Yu-mei Wen

-----Original Messages-----

From: antonin.bal@chu-lyon.fr

Sent Time: 2020-09-14 17:05:58 (Monday)

To: [ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn), [editorial@emi2012.org](mailto:editorial@emi2012.org)

Cc: [laurence.josset@chu-lyon.fr](mailto:laurence.josset@chu-lyon.fr), [antonin.bal@chu-lyon.fr](mailto:antonin.bal@chu-lyon.fr), [bruno.lina@chu-lyon.fr](mailto:bruno.lina@chu-lyon.fr), [gregory.queromes@univ-lyon1.fr](mailto:gregory.queromes@univ-lyon1.fr), [gregory.destras@chu-lyon.fr](mailto:gregory.destras@chu-lyon.fr)

Subject: Pre-submission inquiry\_Characterization of newly SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster

Dear Pr. Wen,

We would like to submit a pre-submission inquiry regarding the suitability of our manuscript entitled **"Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster during routine genomic surveillance, Lyon, France"** for publication in *Emerging Microbes & Infections*, as an Original Article. (bioRxiv: <https://www.biorxiv.org/content/10.1101/2020.08.07.241653v1.full>)

Since February we have sequenced **229 SARS-CoV-2 whole genome** with a metagenomic next-generation sequencing approach as part of the routine surveillance performed at the French National Reference Center for Respiratory Viruses. We detected **two newly discovered frame-shifting deletion variants of the ORF6** (34- and 26-nucleotide deletions). **The 34-nucleotide deletion variant was found in 6 samples** (from 5 patients and **1 health-care worker**) within a cluster of COVID-19 cases from a single geriatric unit at the university hospital of Lyon. Both the presence of the 34-nucleotide deletion variant limited to a hospital unit and the clustering of the corresponding whole genome sequences by phylogeny analysis strongly **suggested a nosocomial transmission between patients**. Interestingly, **prolonged viral excretion of the 34-nucleotide deletion variant was found in a stool sample** 14 days after initial diagnosis for one patient. Furthermore, clinical data revealed **no significant difference in disease severity** between patients harboring the wild-type or the 34-nucleotide ORF6 deletion variant. The in vitro infection of the two deletion variants on primate endothelial kidney cells (BGM) and human lung adenocarcinoma cells (Calu-3) yielded **comparable replication kinetics** with the wild-type strain. In addition, **high viral loads** were found in vivo regardless of the presence or absence of the ORF6 deletion.



Overall, our study highlights **the transmission and replication capacity of two newly described deletion variants in the same ORF6 region**. Given the role of ORF6 in interferon modulation, further characterization, such as mechanistic interactions and interferon monitoring in patients should be performed. By the identification of the first nosocomial cluster harboring a large deletion newly described, **we emphasize the importance of real-time genomic surveillance for the detection of circulating variants and for the investigation of COVID-19 clusters**.

We would be very grateful if you could consider this pre-submission inquiry and look forward to hearing from you.

Yours sincerely,

Laurence Josset, PharmD PhD

Research Assistant Professor

National reference center for respiratory viruses (Pr. Bruno Lina)

University hospital of Lyon, France

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Saturday, March 21, 2020 9:50 PM  
**To:** Lu, Shan  
**Cc:** Tang, Yi-Wei; Yuan Zhenghong 袁正宏; ZhangWenhong; Martin martin  
**Subject:** Re: RE: Taylor & Francis author update: your accepted manuscript is now online

Very good news. Will help us to recruit more good papers in the future. Wen

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:** 2020-03-21 12:56:23 (Saturday)  
**To:** "Tang, Yi-Wei" <yi-wei.tang@cepheid.com>, "Yumei Wen (ymwen@shmu.edu.cn)" <ymwen@shmu.edu.cn>, "Yuan Zhenghong 袁正宏" <zhyuan@shmu.edu.cn>, ZhangWenhong <zhangwenhong@fudan.edu.cn>, "Martin martin" <winter999@hotmail.com>  
**Cc:**  
**Subject:** RE: Taylor & Francis author update: your accepted manuscript is now online

Thanks, Yi-Wei.

Prof Wen and others,

With this new function, an accepted paper can be published online in about 24 hours. The paper is in its original manuscript format, and the real published paper in EMI format will replace this one later when it is formally published. This is the way that ASM, Lancet and other big publishing houses try to do. I am happy that EMI also now has this feature. It will be very significant when we want to publish important papers, like the one from KY Yuen in late Jan.

Best.

Shan

---

**From:** Tang, Yi-Wei <yi-wei.tang@cepheid.com>  
**Sent:** Friday, March 20, 2020 11:33 PM  
**To:** Yumei Wen (ymwen@shmu.edu.cn) <ymwen@shmu.edu.cn>; Yuan Zhenghong 袁正宏 <zhyuan@shmu.edu.cn>; ZhangWenhong <zhangwenhong@fudan.edu.cn>; Lu, Shan <Shan.Lu@umassmed.edu>; Martin martin

<winter999@hotmail.com>

**Subject:** FW: Taylor & Francis author update: your accepted manuscript is now online

Teacher Wen and EMI founding members,

The lag time between accepting and publication in EMI has been solved thanks to efforts of Shan and T&F staff! By coincidence, the review I authored on lab diag of COVID-19 is online as the lucky one on the first set . .

Thank you, Shan, very much for making this happen in a timely manner.

Yi-Wei

---

**From:** Taylor & Francis <[noreply@tandfonline.com](mailto:noreply@tandfonline.com)>

**Sent:** Saturday, March 21, 2020 12:20 AM

**To:** Tang, Yi-Wei <[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)>

**Subject:** Taylor & Francis author update: your accepted manuscript is now online



The online platform for Taylor & Francis Group content

[Author Services](#) | [FAQ](#) | [Twitter](#) | [Facebook](#)

Dear author,

We're delighted to let you know your accepted manuscript [Laboratory Diagnosis of Emerging Human Coronavirus Infections — The State of the Art](#) is now Open Access on Taylor & Francis Online. This is the version of your manuscript which has been through peer review and been accepted by the journal editor.

After your manuscript has been typeset, you'll be able to check the proofs. We will then email you when the final version of your article (the Version of Record) is published, and when it has been assigned to an issue. But what should you do now?

**Register now to access your Authored Works**

Your [Authored Works](#) is where you can view all articles you have published with Taylor & Francis. You can check how many people have viewed your articles and how many times they have been cited, as well as access your Altmetric data enabling you to quickly assess the impact of your work.

**How to register**

You will need to register with the email you used whilst your manuscript was going through production. This is:

[yi-wei.tang@cepheid.com](mailto:yi-wei.tang@cepheid.com)

Once you've completed the quick registration you'll be sent an email asking you to confirm. Click on the verification link and you can then login (using the above email address) whenever you want to by going to **Taylor & Francis Online**. Once you have logged in, click on "**Your Account**" at the top of the page to see the latest updates on your article.

#### **Next steps**

We'll be in touch to let you know when your proofs are ready, but if you have any queries in the interim don't hesitate to get in touch with your production editor.

Kind regards,

Stewart Gardiner  
Global Production Director, Journals  
Taylor & Francis Group

Interested in insights, tips, and updates for Taylor & Francis authors? Be part of our researcher community on:

[Twitter](#)

[Facebook](#)

[Taylor & Francis Author Services](#)



Taylor & Francis

Please do not reply to this email. To ensure that you receive your alerts and information from Taylor & Francis Online, please add "[alerts@tandfonline.com](mailto:alerts@tandfonline.com)" and "[info@tandfonline.com](mailto:info@tandfonline.com)" to your safe senders list.

Taylor & Francis, an Informa business.

Taylor & Francis is a trading name of Informa UK Limited, registered in England under no. 1072954. Registered office: 5 Howick Place, London, SW1P 1WG.

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

---

**From:** TEMI-peerreview@journals.tandf.co.uk  
**Sent:** Monday, September 21, 2020 1:31 AM  
**To:** Lu, Shan; ckbaker@utmb.edu  
**Cc:** qiliang@fudan.edu.cn; min.yang@emi2012.org; peshi@utmb.edu  
**Subject:** Re: RE: TEMI-2020-1002.R1 #TrackingId:7313624

Hi Prof. Lu,

Thank you for your email.

I have checked their submission and I can kindly confirm that the point by point response is uploaded in their submission at the bottom part of the PDF proof.

Reviewer: 1

#### Comments to the Author

In this study, Baker *et al.* presented optimized methods that help to increase the stability of reporter genes in recombinant flaviviruses. The work provides the critical knowledge to improve available reagents and have important implications in molecular virology research for flaviviruses. The manuscript was easy to read but the science is a bit hard to follow, missing justifications for individual experiments in the early part of the manuscript. My only reservation is that if the authors would like to show these reporter viruses work as well as wildtype recombinant viruses, the authors should have provided the data for the comparison in parallel.

Response: We thank the reviewer for the positive and constructive comments.

#### Major concern:

1. Whilst the introduction is nicely written, there is only a brief paragraph summarizing the major finding. It could have been expanded to elaborate the experimental design and purposes of different assays.

Response: Done. We have added our working hypothesis, rationale, and summary of our findings.

2. It is unclear how important the serial passage experiments are in a practical sense. It is necessary to demonstrate the stability. One can imagine that recombinant viruses will most likely be rescued directly from plasmids if it is a molecular virology study for a population of viruses with specific genetic signatures.

Response: It is true we could always make new stocks of reporter viruses from our infectious clones. However, diagnostic labs do not have such expertise and equipment to make new virus stocks from the infectious cDNA plasmids. Therefore, it is important to establish stable reporter viruses that could be propagated in regular cell culture. This will allow the wide use of the reporter virus system. We have added this point in Discussion.

3. A major flaw of the study design is that the grow kinetics was compared amongst the same virus carrying different lengths of duplicated capsid sequences. The comparison between the reporter-carrying recombinant viruses and wildtype recombinant viruses could have been performed to determine if the insertion of reporter genes has an impact on the replication kinetics of recombinant viruses.

Response: Done. We have added the new data to compare the replication kinetics between the parental wild-type ZIKV and the reporter ZIKV C38 on Vero cells (Fig. S4)

4. L216: It is not entirely rigorous using immunofluorescence, a semi-quantitative or even not a quantitative assay, to compare how robust recombinant viruses replicate. This is especially true when secondary antibodies are used and can "amplify" signals that pick up antigens. Perhaps the authors could bring up the replication kinetics data generated in Vero cells first as supportive evidence.

Response: Done. We have added the suggested point.

However, should Dr. Baker wish to upload it in the "cover letter" section they may do so by going to "Step 6: Details and Comments"

**Edit Author-Supplied Data for TEMI-2020-1002.R2**

« Save & Return

---

- Step 1: View and Respond to Decision Letter >
- Step 2: Type, Title, & Abstract >
- Step 3: Keywords >
- Step 4: Authors & Institutions >
- Step 5: Details & Comments >**
- Step 6: Review & Submit >

You are editing author-supplied data for TEMI-2020-10

New Date Submitted

## Step 5: Details & Commen

\* = Required Fields

---

### Cover Letter

**Write Cover Letter**

**Upload Cover Letter**

Response\_to\_review\_.docx

Remove

Should there be anything else that I can further assist you with, please do let me know.

Kind regards,

**Jorgie Lyn Luna** - Journal Editorial Office  
Taylor & Francis Group  
4 Park Square | Milton Park | Abingdon | Oxon | OX14 4RN UK  
Web: [www.tandfonline.com](http://www.tandfonline.com)

Taylor & Francis is a trading name of Informa UK Limited,  
registered in England under no. 1072954



Emerging Microbes & Infections

---

**From:** Shan.Lu@umassmed.edu  
**Sent:** 20-09-2020 08:44  
**To:** JorgieLyn.Luna@spi-global.com, ckbaker@UTMB.EDU  
**Cc:** peshi@UTMB.EDU, min.yang@emi2012.org, qiliang@fudan.edu.cn  
**Subject:** Re: RE: TEMI-2020-1002.R1

Dear Coleman,

Thanks for sending the rebuttal letter. There are multiple ways to send the rebuttal letter. There is a special place to enter it while you only wrote a very small "cover letter" like content. You can also attach it as a regular document just like the paper itself. I will ask our JEO to help you on this.

Our decision is ready once you have uploaded your rebuttal in our system as part the record.

Dear Jorgie,

Can you help the authors to upload attached rebuttal letter, or instruct them how to upload it?  
Thanks.

Shan

---

**From:** Baker, Coleman K. <ckbaker@UTMB.EDU>  
**Sent:** Saturday, September 19, 2020 2:49 PM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Cc:** Shi, Pei yong <peshi@UTMB.EDU>  
**Subject:** Re: TEMI-2020-1002.R1

Dr. Lu,

Thank you for the prompt reply. I apologize for not including the response document. I was under the impression that I had included it. I can't find a place to upload it online but I have attached our point by point response to this email. We are at the very last stage of publishing a review on the recent advances in reporter flavivirus construction, for which this publication makes a significant contribution. We would like to include the full citation in that review once this paper is accepted. Could you help make sure a decision is reached quickly? We would greatly appreciate that.

**Coleman Baker**  
Graduate Assistant  
Pei-Yong Shi Laboratory



On Sep 19, 2020, at 12:26 PM, Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> wrote:

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Dr. Baker,

I have checked with the Review Editor. There are two reasons which caused the delay.

First, the original reviewer has not been responsive to your revision.

Second, we did not see a rebuttal letter which outlines responses to each of the original comments. Can you provide that or did we miss that?

Best.

Shan

-----Original Message-----

From: Emerging Microbes and Infections <[onbehalf@manuscriptcentral.com](mailto:onbehalf@manuscriptcentral.com)>

Sent: Saturday, September 19, 2020 1:12 PM

To: Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

Cc: [peshi@utmb.edu](mailto:peshi@utmb.edu)

Subject: TEMI-2020-1002.R1

Dr. Lu,

I'm writing in regards to manuscript TEMI-2020-1002.R1 and its status. We submitted a revised version of the manuscript addressing all reviewers comments on Aug. 28th and have been looking forward to the journal's decision. We would appreciate a timeline on when to expect that decision as it will assist us in making current and future plans.

Best,

Coleman Baker

---

**From:** TEMI-peerreview@journals.tandf.co.uk  
**Sent:** Wednesday, February 24, 2021 11:28 PM  
**To:** Lu, Shan; shibojiang@fudan.edu.cn  
**Cc:** minyang0216@163.com; ssu14@fudan.edu.cn; min.yang@emi2012.org  
**Subject:** RE: Re: TEMI-2021-0204 and TEMI-2021-0175.R2 #TrackingId:8409496

Dear Prof. Lu,

Thank you for your email.

This is to kindly confirm that the manuscript TEMI-2021-0175.R2 has been now forwarded to production.

Please let me know if there is anything else that I can further assist you with.

Kind regards,

**Jorgie Lyn Luna** - Journal Editorial Office  
Taylor & Francis Group  
4 Park Square | Milton Park | Abingdon | Oxon | OX14 4RN UK  
Web: [www.tandfonline.com](http://www.tandfonline.com)

Taylor & Francis is a trading name of Informa UK Limited,  
registered in England under no. 1072954



Emerging Microbes & Infections

---

**From:** Shan.Lu@umassmed.edu  
**Sent:** 25-02-2021 11.52 AM  
**To:** TEMI-peerreview@journals.tandf.co.uk, shibojiang@fudan.edu.cn  
**Cc:** minyang0216@163.com, ssu14@fudan.edu.cn, min.yang@emi2012.org  
**Subject:** RE: Re: TEMI-2021-0204 and TEMI-2021-0175.R2

I have made the "Accept" decision.

Dear Jorgie,

Please move this paper to production right away.

Min: please contact the production team to ensure that it is on the fast track production.

Thanks everyone for your work and coordination.

Best.

Shan

---

**From:** TEMI-peerreview@journals.tandf.co.uk <TEMI-peerreview@journals.tandf.co.uk>  
**Sent:** Wednesday, February 24, 2021 10:36 PM  
**To:** shibojiang@fudan.edu.cn  
**Cc:** Lu, Shan <Shan.Lu@umassmed.edu>; minyang0216@163.com; ssu14@fudan.edu.cn  
**Subject:** Re: Re: TEMI-2021-0204 and TEMI-2021-0175.R2 #TrackingId:8409496

Dear Professor Shibo Jiang,

Thank you very much for your response and confirmation.

Kindly be informed that your submission TEMI-2021-0204 has been now withdrawn from consideration and the paper TEMI-2021-0175.R2 is now with the editor. He will get in touch with you once he reaches a decision for your manuscript.

Should you have any questions or concerns, please do let me know.

Kind regards,

**Jorgie Lyn Luna** - Journal Editorial Office  
Taylor & Francis Group  
4 Park Square | Milton Park | Abingdon | Oxon | OX14 4RN UK  
Web: [www.tandfonline.com](http://www.tandfonline.com)

Taylor & Francis is a trading name of Informa UK Limited,  
registered in England under no. 1072954



Emerging Microbes & Infections

---

**From:** shibojiang@fudan.edu.cn  
**Sent:** 25-02-2021 11:28  
**To:** JorgieLyn.Luna@spi-global.com

**Cc:**shan.lu@umassmed.edu,minyang0216@163.com,ssu14@fudan.edu.cn

**Subject:**Re: Re: TEMI-2021-0204 and TEMI-2021-0175.R2

Dear Jorgie,

We received Prof. Shan Lu's email yesterday, asking us to resubmit our revised manuscript without any corrections. Dr. Su mistakenly resubmitted it as a new manuscript (TEMI-2021-0204). Now she resubmitted it via the old link, generating a new submission number (TEMI-2021-0175.R2). Therefore, please withdraw our latest manuscript submission TEMI-2021-0204.

Sorry for the inconvenience that has caused to you,

Shibo

> -----原始邮件-----

> 发件人: "Emerging Microbes and Infections" <[onbehalf@manuscriptcentral.com](mailto:onbehalf@manuscriptcentral.com)>

> 发送时间: 2021-02-25 10:50:31 (星期四)

> 收件人: [shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)

> 抄送:

> 主题: TEMI-2021-0204 and TEMI-2021-0175.R2

>

> 24-Feb-2021

>

> TEMI-2021-0204 - Human challenge trials to assess the efficacy of currently approved COVID-19 vaccines against SARS-CoV-2 variants

>

> Dear Professor Shibo Jiang,

>

> I hope you are doing well.

>

> Upon checking the system, I have noted that your above manuscript is a duplicate submission of your previous paper entitled "Human challenge trials to assess the efficacy of currently approved COVID-19 vaccines against SARS-CoV-2 variants" with the manuscript ID of TEMI-2021-0175.R2.

>

> Kindly be informed that this journal refrains authors to send more than one copy of the submissions to avoid any issues in the future.

>

> Please resubmit your manuscript TEMI-2021-0175.R2 to proceed with further consideration and evaluation.

>

> With this, may I confirm if I can now withdraw your latest manuscript submission TEMI-2021-0204?

>

> Many thanks and I look forward to hearing from you.

>

>

> Sincerely,

>

- > Miss Jorgie Luna
- > Emerging Microbes & Infections

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Tuesday, November 19, 2019 2:52 AM  
**To:** Klenk Hans-Dieter  
**Cc:** Lu, Shan  
**Subject:** Re: Re: Thanks

Dear Hans.Thank you. I do think Friedrich Goetz is a good candidate.We will contact him. Regards, Yu-mei

> -----原始邮件-----

> 发件人: "Klenk Hans-Dieter" <klenk@staff.uni-marburg.de>

> 发送时间: 2019-11-18 23:48:46 (星期一)

> 收件人: "Wen Yumei" <ymwen@shmu.edu.cn>

> 抄送: "shan.lu@umassmed.edu" <shan.lu@umassmed.edu>

> 主题: Re: Thanks

>

> Dear Yumei, dear Shan,

>

> When I talked to Andreas Peschel about EMI, he told me that he has too many other obligations to get involved with EMI, but he suggested to ask Friedrich Goetz, his colleague and former mentor. I then contacted F. Goetz (friedrich.goetz@uni-tuebingen.de) whom you know since he was also at the recent Shanghai meeting, and he showed interest. So you might approach him. I think he would be a good choice.

>

> Regards

> Hans

>

> Prof. Dr. H. D. Klenk

> Institut für Virologie

> Hans-Meerwein-Str. 2

> 35043 Marburg

> Germany

>

> Tel.: +49 6421 286 6191

> Sek.: +49 6421 286 6254

> Fax: +49 6421 286 8962

> E-Mail: klenk@staff.uni-marburg.de

>

>> Am 26.10.2019 um 05:10 schrieb Wen Yumei <ymwen@shmu.edu.cn>:

>>

>> Dear Hans :

>> Thank you for your mail, and your recommendation.

>> I will discuss with Shan, and inform you.

>> As ever, you are always our guest of honor to evaluate the progress

>> of our lab, and hope to see you again after 2 years.Regards to your

>> wife. Yu-mei

>>

>>

> > -----原始邮件-----

> > 发件人: "Klenk Hans-Dieter" <klenk@staff.uni-marburg.de>

> > 发送时间: 2019-10-25 17:38:20 (星期五)

> > 收件人: "wen yumei" <ymwen@shmu.edu.cn>

> > 抄送:

> > 主题: Thanks

> >

> > Dear Yumei,

> >

> > Yesterday I returned safely from my trip to Shanghai. It was a great pleasure to participate in the excellent meeting and to see you in good health. You asked me about a possible new editor for EMI, preferably a bacteriologist from Europe. Andreas Peschel might be such a candidate. He seems to be an excellent scientist to me and, quite importantly, you know each other. I have not approached him yet, but I will be happy to do so if you want.

> >

> > My wife thanks you for the beautiful gift and sends her regards.

> >

> > With my best wishes for you and your husband Hans

> >

> > Prof. Dr. H. D. Klenk

> > Institut für Virologie

> > Hans-Meerwein-Str. 2

> > 35043 Marburg

> > Germany

> >

> > Tel.: +49 6421 286 6191

> > Sek.: +49 6421 286 6254

> > Fax: +49 6421 286 8962

> > E-Mail: klenk@staff.uni-marburg.de

> >

> >

> >

> >

> >

---

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Friday, February 14, 2020 1:29 AM  
**To:** Lu, Shan  
**Cc:** Min Yang  
**Subject:** Re: RE: To apply for resignation of the Guest Editor position

Hi, Shan,

Thank you very much for your understanding and support. Yes, please keep my name for a brief time before Susan accepts this position.

Best wishes,

Shibo

-----原始邮件-----

发件人:"Lu, Shan" <Shan.Lu@umassmed.edu>  
发送时间:2020-02-14 14:20:03 (星期五)  
收件人: "Shibo Jiang (姜世勃)" <shibojiang@fudan.edu.cn>  
抄送: "Min Yang" <min.yang@emi2012.org>  
主题: RE: To apply for resignation of the Guest Editor position

Hi, Shibo,

Sorry to hear and hope everything is well with you. Don't worry about GE for EMI. I may invited Susan Weiss to serve. I will keep your name for a brief time if you don't mind and we will change it once Susan (or someone else) agrees to serve.

Please see attached list (please do not share with others). I did not ask you to review each of them since the workload will be too huge.

Our decision to establish this special topic had the perfect timing and thank you for your founding work.

Please keep in touch and hope everything will be well with you.



Best.

Shan

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Friday, February 14, 2020 1:13 AM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Subject:** To apply for resignation of the Guest Editor position

Dear Prof. Lu,

Because of a serious health problem, I apply for resignation of the Guest Editor position. Hope you can identify a well-established expert in the coronavirus field to replace me as soon as possible.

Thank you very much for your consideration,

Shibo

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Monday, August 26, 2019 9:17 PM  
**To:** Lu, Shan  
**Subject:** Re: RE: To Dr.Wen - Virologica Sinica, Volume 34, Issue 4

Only for your ref. I think to get fgod reviews is more important. wen

-----原始邮件-----

发件人:"Lu, Shan" <Shan.Lu@umassmed.edu>

发送时间:2019-08-26 02:50:43 (星期一)

收件人: "wen yumei" <ymwen@shmu.edu.cn>, "YiWei Tang" <yiweitangmd@gmail.com>, "Zheng, Zhi-Ming (Thomas) (NIH/NCI) [E]" <zhenget@exchange.nih.gov>

抄送: "杨旻" <minyang0216@163.com>

主题: RE: To Dr.Wen - Virologica Sinica, Volume 34, Issue 4

Hi, Prof Wen,

After receiving your e-mail, I have checked at the website of Virologica Sinica,  
<https://link.springer.com/journal/volumesAndIssues/12250>

The website is not much different from EMI in terms of design. Since it is not Open Access only journal, they have printed issues which use different cover for each issue which is quite colorful and unique.

It is run by Elsevier and the website is hard to find (see above) without a distinct site url address (such as ours: [www.tandfonline.com/TEM](http://www.tandfonline.com/TEM) ).

The email you cited below is a marketing email and it may be the model we should learn from. It will require EMI staff to select papers from certain period to highlight the findings. More importantly we need to get T&F to agree to set up such email campaigns. It is a debatable practice: some think it can promote the journal and papers and others think it generate too many emails to a wide range of recipients with a negative impression as scientist generally do not like to receive marketing materials.

I will discuss with T&F on this.

Shan

**From:** wen yumei [mailto:ymwen@shmu.edu.cn]

**Sent:** Saturday, August 24, 2019 10:36 PM

**To:** Lu, Shan <Shan.Lu@umassmed.edu>; YiWei Tang <yiweitangmd@gmail.com>; Zheng, Zhi-Ming (Thomas) (NIH/NCI) [E] <zhenegt@exchange.nih.gov>

**Cc:** 杨旻 <minyang0216@163.com>

**Subject:** Fw: To Dr.Wen - Virologica Sinica, Volume 34, Issue 4

See forwrding message, which may serve as a ref for EMI.

-----原始邮件-----

发件人:Virologica-1 <[virosin@wh.iov.cn](mailto:virosin@wh.iov.cn)>

发送时间:2019-08-24 12:08:09 (星期六)

收件人: [ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)

抄送:

主题: To Dr.Wen - Virologica Sinica, Volume 34, Issue 4

If you do not wish to receive this newsletter please click here [Unsubscribe](#).



Dear Dr. Wen,



It is my pleasure to present you the review, research articles, letters and meeting report recently published in *Virologica Sinica*.

Your suggestions are welcome!

Zheng-Li Shi, Ph.D.  
Editor-in-Chief, *Virologica Sinica*

Browse the website [www.virosin.org](http://www.virosin.org) for more information

Enjoy **rapid & free** publication in *Virologica Sinica*



**Virologica Sinica** is an academic journal which aims at presenting the cutting-edge basic and applied research on viruses all over the world. The journal publishes peer-reviewed original research articles and reviews, as well as commentaries and letters to the editor, to encompass the latest developments in all branches of virology, including research on animal, plant and microbe viruses. *Virologica Sinica*, the official journal of Chinese Society for Microbiology, will serve as a platform for the communication and exchange of academic information and ideas in an international context.

The journal is indexed by: Science Citation Index (SCI), JCR, PubMed/Medline, Scopus, BIOSIS, Google Scholar, and SCImago.



About the cover: Mitochondria are multifunctional eukaryotic organelles with diverse roles, including energy production and distribution, apoptosis, innate immunity, metabolic regulation, cell-cycle control and signal transduction. The interactions between viruses and the host mitochondria are crucial for virus replication and pathogenicity. Yang Yang *et al.* found that Enterovirus A71 (EV-A71) infection resulted in a perinuclear redistribution of the mitochondria, and the microtubule skeleton and the dynein motor complex were required for this redistribution. They further revealed that the interaction between EV-A71 2BC protein and mitochondrial Rho GTPase 1 played a crucial role in the regulation of mitochondrial motility, and the mitochondria redistribution was required for EV-A71 replication and proliferation. Their study reports a novel function of the EV-A71 2BC protein and provides an insight into the regulation of organelle transport in the EV-A71-infected cells. Please see page 397–411 for details.

### Why *Virologica Sinica*?



Indexed/Abstracted by SCI, PubMed/Medline, Scopus, Google Scholar



Global visibility and increasing impact



Publish special issues and topics



Rapid peer review and publication



No page/color charges, open-access options



Free language editing

2019, Vol. 34, Issue 4

#### Review

#### Specific and Selective Bacteriophages in the Fight against Multidrugresistant *Acinetobacter baumannii*

**Free Full Text (HTML)** **Free Full Text (PDF)**

Natalia Bagińska, Anna Pichlak, Andrzej Górski, Ewa Jończyk-Matysiak

*Acinetobacter baumannii* causes serious infections especially in immunocompromised and/or hospitalized patients. Several *A. baumannii* strains are multidrug resistant and infect wounds, bones, and the respiratory tract. Current studies are focused on finding new effective agents against *A. baumannii*. Phage therapy is a promising means to fight this bacterium and many studies on procuring and applying new phages against *A. baumannii* are currently being conducted. As shown in animal

models, phages against multidrug-resistant *A. baumannii* may control bacterial infections caused by this pathogen and may be a real hope to solve this dangerous health problem.



---

## Research Article

### Prevalence of HIV Indeterminate Western Blot Tests and Follow-up of HIV Antibody Sero-Conversion in Southeastern China

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

*Shouli Wu, Min Gao, Jian Zheng, Pingping Yan, Wei Wang, Xiaoli Lu, Yuefeng Qiu, Yansheng Yan*

HIV-indeterminate Western blotting (WB) results are typically obtained in WB confirmatory assays, and the number of indeterminate samples may increase with the detection of HIV infections, which will present considerable challenges for the management of HIV/AIDS. Nucleic acid detection has been used as a laboratory test for screening suspected or indeterminate samples. However, the effectiveness of these assays for the differential diagnosis of HIV-indeterminate WB samples remained undetermined. In this study, 210 subjects with HIV-indeterminate WB results were detected from 6360 positive HIV screening samples between 2015 and 2016 in southeastern China, in which HIV-indeterminate WB results accounted for 3.30%. The highest proportion of indeterminate results was observed in pregnant and lying-in women receiving physical examinations (16.67%), followed by that in voluntary blood donors (8.82%). The most common WB band patterns were p24, gp160 and p24, and gp160. The follow-up study revealed that the highest negative and positive conversion rates of HIV antibodies were in samples with a single p24 band (80.28%), and with gp160 and p24 bands (86.21%), respectively. Among the Env, Gag, and Pol antibodies, samples with a Gag band showed the highest negative conversion rate (81.25%), whereas the highest positive conversion rate was observed in samples with an Env band (56.76%). In addition, quantitative and qualitative HIV nucleic acid testing exhibited the highest sensitivity (96.3%) and specificity (97.85%), respectively. Our results indicate a lower proportion of HIV indeterminate WB results in southeastern China compared to previous reports, and the follow-up re-examination of patients with HIV indeterminate results should be performed. Nucleic acid testing facilitates the identification of HIV infections.



---

## Research Article

### Cross-sectional Seroprevalence and Genotype of Hepatitis E Virus in Humans and Swine in a High-density Pig-farming Area in Central China

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

*Yilin Shu, Yameng Chen, Sheng Zhou, Shoude Zhang, Qin Wan, Changcai Zhu, Zhijiang Zhang, Hailong Wu, Jianbo Zhan, Ling Zhang*

Hepatitis E virus (HEV) infection is a common public health problem in developing countries. However, the current prevalence of HEV and the relationship of HEV genotype between swine and human within high-density pig-farming areas in central China are still inadequately understood. Here, cross-sectional serological and genotypic surveys of HEV among the 1232 general population, 273 workers occupationally exposed to swine, and 276 pigs in a high-density pig-breeding area, were undertaken by ELISA and nested RT-PCR methods. Anti-HEV IgG was detected in 26.22% of general population and 48.35% of occupational workers. The prevalence of swine serum HEV-Ag was 6.52%. The prevalence of anti-HEV IgG was significantly higher among the workers occupationally exposed to swine than among the general population. An increased HEV seropositivity risk among the general population was associated with either being a peasant or male and was very strongly associated with the increase of age. Among the occupationally exposed group, the prevalence of anti-HEV IgG antibodies increased with age and working years. Among the 30 HEV-IgM-positive people, the infection rates of clerks in the

public, peasants, pork retailers, and pig farmers were higher than those of others. A phylogenetic analysis revealed that all the isolates belonged to subgenotype 4<sub>d</sub>, and four people and four pigs shared 97.04%–100% sequence homology. This study revealed a high HEV seroprevalence among the general population and workers occupationally exposed to swine in the Anlu City, and supports the notion that swine are a source of human HEV infection.



---

## Research Article

### Complementation of Wild-Type and Drug-Resistant Hepatitis B Virus Genomes to Maintain Viral Replication and Rescue Virion Production under Nucleos(t)ide Analogs

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

*Chunchen Wu, Baolin Li, Xiaoyong Zhang, Kaitao Zhao, Yingshan Chen, Yifei Yuan, Yan Liu, Rongjuan Chen, Dongping Xu, Xinwen Chen, Mengji Lu*

As the open reading frames of hepatitis B virus (HBV) genomes are overlapping, resistance mutations (MTs) in HBV polymerase may result in stop codon MTs in hepatitis B surface proteins, which are usually detected as a mixed population with wild-type (WT) HBV. The question was raised how the coexistence of nucleos(t)ide analogs (NAs) resistance MTs and WT sequences affects HBV replication. In the present study, HBV genomes with frequently detected reverse transcriptase (RT)/surface truncation MTs, rtA181T/sW172\*, rtV191I/sW182\* and rtM204I/sW196\*, were phenotypically characterized alone or together with their WT counterparts in different ratios by transient transfection in the absence or presence of NAs. In the absence of NAs, RT/surface truncation MTs impaired the expression and secretion of HBV surface proteins, and had a dose-dependent negative effect on WT HBV virion secretion. However, in the presence of NAs, coexistence of MTs with WT maintained viral replication, and the presence of WT was able to rescue the production of MT HBV virions. Our findings reveal that complementation of WT and MT HBV genomes is highly effective under drug treatment.



---

## Research Article

### Effect of Loss-of-function of the Herpes Simplex Virus-1 microRNA H6-5p on Virus Replication

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

*Rongquan Huang, Xusha Zhou, Shuqi Ren, Xianjie Liu, Zhiyuan Han, Grace Guoying Zhou*

To date, 29 distinct microRNAs (miRNAs) have been reported to be expressed during herpes simplex virus infections. Sequence analysis of mature herpes simplex virus-1 (HSV-1) miRNAs revealed five sets of miRNAs that are complementary to each other: miR-H6-5p/H1-3p, miR-H6-3p/H1-5p, H2-5p/H14-3p, miR-H2-3p/H14-5p, and miR-H7/H27. However, the roles of individual miRNAs and consequences of this complementarity remain unclear. Here, we focus on two of these complementary miRNAs, miR-H6-5p and miR-H1-3p, using loss-of-function experiments *in vitro* and in a mouse model of infection using an miRNA sponge approach, including tandem multiplex artificial miRNA-binding sequences that do not match perfectly to the target miRNA inserted downstream of a green fluorescent protein reporter gene. Infection with recombinant virus expressing the miR-H6-5p sponge reduced viral protein levels and virus yield. Decreased accumulation of viral proteins was also observed at early stages of infection in the presence of both an miR-H6-5p inhibitor and plasmid-expressed miR-H1-3p. Moreover, establishment of latency and reactivation did not differ between the recombinant virus expressing the miR-H6-5p sponge and wild-type HSV-1. Taken together, these data suggest that miR-H6-5p has an as-yet-unidentified role in the early stages of viral infection, and its complement miR-H1-3p suppresses this role in later stages of infection. This report extends understanding of the roles of miRNAs in infection by herpes simplex

viruses, supporting a model of infection in which the production of virus and its virulent effects are tightly controlled to maximize persistence in the host and population.



---

## Research Article

### Mitochondria Redistribution in Enterovirus A71 Infected Cells and Its Effect on Virus Replication

**Free Full Text (HTML)** **Free Full Text (PDF)**

*Yang Yang, Haolong Cong, Ning Du, Xiaodong Han, Lei Song, Wenliang Zhang, Chunrui Li, Po Tien*

Enterovirus A71 (EV-A71) is one of the main causative agents of hand, foot and mouth disease (HFMD) and it also causes severe neurologic complications in infected children. The interactions between some viruses and the host mitochondria are crucial for virus replication and pathogenicity. In this study, it was observed that EV-A71 infection resulted in a perinuclear redistribution of the mitochondria. The mitochondria rearrangement was found to require the microtubule network, the dynein complex and a low cytosolic calcium concentration. Subsequently, the EV-A71 non-structural protein 2BC was identified as the viral protein capable of inducing mitochondria clustering. The protein was found localized on mitochondria and interacted with the mitochondrial Rho GTPase 1 (RHOT1) that is a key protein required for attachment between the mitochondria and the motor proteins, which are responsible for the control of mitochondria movement. Additionally, suppressing mitochondria clustering by treating cells with nocodazole, EHNA, thapsigargin or A23187 consistently inhibited EV-A71 replication, indicating that mitochondria recruitment played a crucial role in the EV-A71 life cycle. This study identified a novel function of the EV-A71 2BC protein and provided a potential model for the regulation of mitochondrial motility in EV-A71 infection.



---

## Research Article

### Trans Complementation of Replication-defective Omsk Hemorrhagic Fever Virus for Antiviral Study

**Free Full Text (HTML)** **Free Full Text (PDF)**

*Qiuyan Zhang, Na Li, Chenglin Deng, Zherui Zhang, Xiaodan Li, Kentaro Yoshii, Hanqing Ye, Bo Zhang*

Omsk hemorrhagic fever virus (OHFV) is a tick-borne flavivirus classified as a biosafety level-4 (BSL4) pathogen. Studies of OHFV are restricted to be conducted within BSL4 laboratories. Currently, no commercial vaccines or antiviral drugs are available against OHFV infection. In this study, we recovered a replication-deficient OHFV with an NS1 deletion (OHFV-ΔNS1) and reporter virus replacing NS1 with the *Gaussia* luciferase (Gluc) (OHFV-ΔNS1-Gluc). Both the defective OHFV-ΔNS1 and OHFV-ΔNS1-Gluc virus could only replicate efficiently in the BHK21 cell line expressing NS1 (BHK21<sub>NS1</sub>) but not in naïve BHK21 cells. The Gluc reporter gene of OHFV-ΔNS1-Gluc virus was maintained stably after serial passaging of BHK21<sub>NS1</sub> cells and was used to surrogate the replication of OHFV. Using NITD008, OHFV-ΔNS1-Gluc virus was validated for antiviral screening, and high-throughput screening parameters were optimized in a 96-well plate format with a calculated Z' value above 0.5. The OHFV-ΔNS1-Gluc reporter virus is a powerful tool for antiviral screening as well as viral replication and pathogenesis studies in BSL2 laboratories.



---

## Research Article

## **In Vitro Infectious Risk Assessment of Heliothis virescens ascovirus 3j (HvAV-3j) toward Non-target Vertebrate Cells**

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

Huan Yu, Yi-Yi Ou-Yang, Ni Li, Madoka Nakai, Guo-Hua Huang

As specific pathogens of noctuid pests, including *Spodoptera exigua*, *S. litura*, *Helicoverpa armigera*, and *Mythimna separata*, ascoviruses are suitable for the development of bioinsecticides. In this study, the infectivity of Heliothis virescens ascovirus 3j (HvAV-3j) on insect and mammalian cells was evaluated. HvAV-3j infection induced drastic morphological changes in Sf9, HzAM1, SeFB, and HaFB cells, including swelling and detachment. Notably, the latter phenomena did not occur in HvAV-3j-inoculated mammalian cells (HEK293, 7402, HePG2, PK15, ST, and TM3). MTT assays indicated that HvAV-3j inhibited the growth of host insect cells from the 6th hpi, but no effects were detected in the HvAV-3j-inoculated mammalian cells. Furthermore, viral DNA replication, gene transcription, and protein expression were investigated, and the results consistently suggested that HvAV-3j viruses were not able to replicate their genomic DNA, transcribe, or express their proteins in the non-target vertebrate cells. The HvAV-3j genes were only transcribed and expressed in the four insect cell lines. These results indicated that HvAV-3j was infectious to cells derived from *S. frugiperda*, *S. exigua*, *H. armigera*, and *H. zea* but not to cells derived from human, pig, and mouse, suggesting that ascoviruses are safe to nontarget vertebrate cells.



---

## **Research Article**

### **Molecular Characterization and Expression Analysis of *ftr01*, *ftr42*, and *ftr58* in Zebrafish (*Danio rerio*)**

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

Wanmeng Liu, Ming Kuang, Ze Zhang, Yuanan Lu, Xueqin Liu

Tripartite motif (TRIM) proteins were shown to play an important role in innate antiviral immunity. FinTRIM (*ftr*) is a new subset of TRIM genes that do not possess obvious orthologs in higher vertebrates. However, little is known about its function. In this study, we used bioinformatic analysis to examine the phylogenetic relationships and conserved domains of zebrafish (*Danio rerio*) *ftr01*, *ftr42*, and *ftr58*, as well as qualitative real-time PCR to examine their expression patterns in zebrafish embryonic fibroblast (ZF4) cells and zebrafish tissues. Sequence analysis showed that the three finTRIMs are highly conserved, and all contain a RING domain, B-box domain, and SPRY-PRY domain. In addition, *ftr42* and *ftr58* had one coiled-coil domain (CCD), whereas *ftr01* had two CCDs. Tissue expression analysis revealed that the mRNA level of *ftr01* was the highest in the liver, whereas those of *ftr42* and *ftr58* were the highest in the gill; the expression of these finTRIMs was clearly upregulated not in the eyes, but in the liver, spleen, kidney, gill, and brain of zebrafish following spring viremia of carp virus (SVCV) infection. Similarly, the expression of these three finTRIM genes also increased in ZF4 cells after SVCV infection. Our study revealed that *ftr01*, *ftr42*, and *ftr58* may play an important role in antiviral immune responses, and these findings validate the need for more in-depth research on the finTRIM family in the future.



---

## **Research Article**

### **Construction of a One-Vector Multiplex CRISPR/Cas9 Editing System to Inhibit Nucleopolyhedrovirus Replication in Silkworms**

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)



Zhanqi Dong, Qi Qin, Zhigang Hu, Peng Chen, Liang Huang, Xinling Zhang, Ting Tian, Cheng Lu, Minhui Pan

Recently the developed single guide (sg)RNA-guided clustered regularly interspaced short palindromic repeats/associated protein 9 nuclease (CRISPR/Cas9) technology has opened a new avenue for antiviral therapy. The CRISPR/Cas9 system uniquely allows targeting of multiple genome sites simultaneously. However, there are relatively few applications of CRISPR/Cas9 multigene editing to target insect viruses. To address the need for sustained delivery of a multiplex CRISPR/ Cas9-based genome-editing vehicle against insect viruses, we developed a one-vector (pSL1180-Cas9-U6-sgRNA) system that expresses multiple sgRNA and Cas9 protein to excise *Bombyx mori* nucleopolyhedrovirus (BmNPV) in insect cells. We screened the immediate-early-1 gene (*ie-1*), the major envelope glycoprotein gene (*gp64*), and the late expression factor gene (*lef-11*), and identified multiple sgRNA editing sites through flow cytometry and viral DNA replication analysis. In addition, we constructed a multiplex editing vector (PSL1180-Cas9-sgIE1-sgLEF11-sgGP64, sgMultiple) to efficiently regulate multiplex gene-editing and inhibit BmNPV replication after viral infection. This is the first report of the application of a multiplex CRISPR/Cas9 system to inhibit insect virus replication. This multiplex system can significantly enhance the potential of CRISPR/Cas9-based multiplex genome engineering in insect virus.



---

## Research Article

### Improving Baculovirus Transduction of Mammalian Cells by Incorporation of Thogotovirus Glycoproteins

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

Liangbo Hu, Yimeng Li, Fei Deng, Zhihong Hu, Hualin Wang, Manli Wang

Baculovirus can transduce a wide range of mammalian cells and is considered a promising gene therapy vector. However, the low transduction efficiency of baculovirus into many mammalian cells limits its practical application. Co-expressing heterologous viral glycoproteins (GPs), such as vesicular stomatitis virus G protein (VSV G), with baculovirus native envelope protein GP64 is one of the feasible strategies for improving virus transduction. Tick-borne thogotoviruses infect mammals and their GPs share sequence/structure homology and common evolutionary origins with baculovirus GP64. Herein, we tested whether thogotovirus GPs could facilitate the entry of the prototype baculovirus *Autographa californica* multiple multiple nucleopolyhedrovirus (AcMNPV) into mammalian cells. The *gp* genes of two thogotoviruses, Thogoto virus and Dhori virus, were inserted into the AcMNPV genome. Both GPs were properly expressed and incorporated into the envelope of the recombinant AcMNPVs. The transduction rates of recombinant AcMNPVs expressing the two thogotovirus GPs increased for approximately 4–12 fold compared to the wild type AcMNPV in six of the 12 tested mammalian cell lines. It seemed that thogotovirus GPs provide the recombinant AcMNPVs with different cell tropisms and showed better performance in several mammalian cells compared to VSV G incorporated AcMNPV. Further studies showed that the improved transduction was a result of augmented virus-endosome fusion and endosome escaping, rather than increased cell binding or internalization. We found the AcMNPV envelope protein GP64-mediated fusion was enhanced by the thogotovirus GPs at relatively higher pH conditions. Therefore, the thogotovirus GPs represent novel candidates to improve baculovirus-based gene delivery vectors.



---

## Letter

## Establishment of Novel Monoclonal Fabs Specific for Epstein-Barr Virus Encoded Latent Membrane Protein 1

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

Gaoxin Li, Ling Ding, Xiaojing Ma, Qiliang Cai, Tianlei Ying, Fang Wei

Here we isolated the Fab clones 1-A11, 6-C6, 10-B2, and 15-H10 and confirmed their recognition of LMP1 expressed on the surface of EBV<sup>+</sup> B95.8 cells. Recognition of LMP1 on the cell membrane by clone 15-H10 was verified through immunofluorescent assay, while other clones failed the recognition. One of the possible reasons could be the stringent washing in this assay that ruptured the low affinity Fab-LMP1 binding. EBV infection is related with multiple diseases, and conventional approaches used in laboratory diagnostic tests for EBV infection and pathogenesis have their limitations [(generate false positive results or lack the ability to localize the expression of EBV within target cells) (Young and Rickinson 2004)]. The LMP1-specific Fab clones reported here need further evaluation in both affinity and specificity in testing EBV<sup>+</sup> patient samples, and hopefully it could have potential applications in EBV diagnostics and directly targeting EBV-related tumors in adoptive T cell therapy.



---


### Letter

## Genomic Characterization of the First Parechovirus in Bats

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

Chang Zhang, Jinliang Sheng, Zihan Zhao, Chao Yan, Changchun Tu, Biao He

As important hosts for several pathogenic viruses, bats harbor viruses from almost all families of vertebrate viruses, including several genera of family *Picornaviridae*, including *Hepatovirus*, *Kobuvirus*, *Crohivirus*, and *Sapelovirus* (Drexler *et al.* 2015; Wu *et al.* 2016; Yinda *et al.* 2017). However, PeVs were not reported in bats until our recent viral metagenomic analysis of 122 adult healthy bats (*Pipistrellus pipistrellus*) obtained from two locations in Xinjiang (Xinyuan, n = 46; Qapqal, n = 76) in 2016, revealing thousands of reads related to PeV (Zhang *et al.* 2018). PCR-based screening revealed that 6.5% and 10.5% bats from Xinyuan and Qapqal, respectively, harbored this virus, and preliminary phylogenetic analysis of 396-nt-long amplicons targeting the VP1 region (GenBank accession numbers: MH921430–MH921443) revealed > 91.5% identities among each other and 63.7%–64.2% identity with their closest phylogenetic neighbor, FPeV (Smits *et al.* 2013; Zhang *et al.* 2018). This study reports the complete genomic characterization of the first bat PeV to better understand its evolutionary history.



---

### Meeting Report

## Virology at the Lorne Infection and Immunity Conference 2019

[Free Full Text \(HTML\)](#) [Free Full Text \(PDF\)](#)

Sarah L. Londrigan, Gregor Ebert, Prasad N. Paradkar

The Lorne Infection and Immunity Conference is one of five scientific meetings held during each month of February at the Cumberland resort in the picturesque seaside town of Lorne, on the Great Ocean Road in Victoria (Australia). The specific aim of the meeting is to bring together basic, clinical and translational researchers—those who examine microbes and their impact on the innate or adaptive immune response, researchers who study the mechanisms that regulate immune responses, and those who apply this knowledge to preventing and treating infectious and inflammatory diseases. The average number of attendees is 220, with registrants appreciative of the welcoming and relaxed atmosphere.

Copyright © 2019. All rights reserved.  
*Virologica Sinica*



*Virologica Sinica* respects your right to privacy. To see the types of information we may hold or collect about you and how we may use that information, please see our [Privacy Policy](#).



-----

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Monday, February 24, 2020 8:24 PM  
**To:** Lu, Shan  
**Cc:** 'xywang'  
**Subject:** Re: RE: update on review editors and guest editors

Thanks to both of you. Wen

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:** 2020-02-24 23:21:26 (Monday)  
**To:** 'xywang' <xywang@shmu.edu.cn>, "wen yumei" <ymwen@shmu.edu.cn>  
**Cc:**  
**Subject:** RE: update on review editors and guest editors

Wow, all powerful candidates. I will get back to you.

**From:** xywang <xywang@shmu.edu.cn>  
**Sent:** Monday, February 24, 2020 9:38 AM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>; 'wen yumei' <ymwen@shmu.edu.cn>  
**Subject:** 答复: update on review editors and guest editors

Here you are:

Yin Yue, vice president of biometrics in the pharmaceutical industry, graduated from the Department of Mathematics in Beijing with a bachelor's degree, and obtained a Ph.D in biometrics from John Hoj

Feng Chen, PhD in Biostatistics, Professor, PhD supervisor. Nanjing Medical Research Institute, currently serving as the Chinese Society of Health Information (formerly the Chinese Society of Health S  
Chairman of the Professional Committee of Statistical Theory and Methodology, Deputy Director of the Chinese Branch of the International Society for Physical Statistics (IBS-China), China Clinical Tr  
(CCTS working group) group, deputy editor of the journal "China Health Statistics", one of the main drafters of my country's clinical trial biostatistics guidelines,  
ICSA member.

Zhao Yang, Professor and Dean of the Department of Biostatistics, Nanjing Medical School of Public Health, graduated from Nanjing Medical School

Jiang Zhiwei, General Manager of Beijing Kangterike Statistical Consulting Company, obtained a Ph.D in Biostatistics from the Fourth Military Medical Science

From: Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
Sending time: 2020 2月24日 20:23

收件人: xywang <xywang@shmu.edu.cn>; 'wen yumei' <ymwen@shmu.edu.cn>

主题: RE: update on review editors and guest editors

Dear Xuan-Yi,

Thanks for your offer. Please give me their names and rough background if you know. I have some other candidates as well. I may need to plan a little as we may only ask some of them to do a part time work based on each person's background.

Best,

Shan

**From:** xywang <xywang@shmu.edu.cn>

**Sent:** Monday, February 24, 2020 3:42 AM

**To:** 'wen yumei' <ymwen@shmu.edu.cn>; Lu, Shan <Shan.Lu@umassmed.edu>

**Cc:** 'Martin martin' <winter999@hotmail.com>

**Subject:** 答复: update on review editors and guest editors

Dear Profs. Wen and Lu,

I was noticed that EMI needs statisticians as RE, I have some candidates who own oversea background, and are working in Nanjing Medical University, and CRO company in mainland, if you think it's okay, I can contact them.

BTW, how many papers per week they have to process?

Best,

2

---

**Page 3**

Xuan-yi

Publish person: wen yumei <ymwen@shmu.edu.cn>

Delivery time: 2020 2月23日 11:05

Recipients: Lu, Shan <Shan.Lu@umassmed.edu>

抄送: Martin martin <winter999@hotmail.com>; xywang <xywang@shmu.edu.cn>

主题: Re: update on review editors and guest editors

Thank you for taking care of recruitment of review editors.

For statistics can Xuanyi help to find someone? YMW

-----Original Messages-----

**From:**"Lu, Shan" <Shan.Lu@umassmed.edu>

**Sent Time:**2020-02-23 01:39:39 (Sunday)

**To:** "wen yumei" <ymwen@shmu.edu.cn>

**Cc:** "Martin martin" <winter999@hotmail.com>

**Subject:** update on review editors and guest editors

Dear Prof Wen and Xiaodong,

During our last EMI senior leader year end lunch meeting on December 15 in Shanghai, I reported that Zhang Jing-Ren and Cai Qiliang are too busy to do a good job as Review Editor (RE) for EMI (can only take very few assignments due slow to take the assignment or follow up, long passing deadlines and requiring EMI office multiple reminder etc.). Therefore I said that I will need to talk to them and may remove them from RE work (while keep their EB members).

Since then, I have been too busy to process this until this week and I reached out to both of them. Zhang Jing-Ren stated that he can no longer working as a RE but will continue to support EMI in other ways. We will remove his name as RE from S1 system

Cai Qiliang appears still interested in continuing as RE. I agreed to let him to try 3 more months to see if he has the time and effort to do a good job as RE.

At the same time, we need more RE in certain areas. I have already invited Huang, Zuhu from Nanjing Medical University as the Review Editor in charge of clinical topics. He is a superb ID doctor for 40 years, and is well known to Prof Wen Xinhua and Zhang Wenhong. While he was the Jiangsu vice minister for health affairs, he still continues to do clinical and science work. Since the outbreak of SARS2, I asked him to do several paper reviews and he always got back to EMI within 1 day with excellent comments in good English. I have added him to the S1 system as RE.

3

---

## Page 4

We need to invite more REs to work in the following areas: bacteria, biostatistics and animal health. I will reach out to EB members.

On the side of specific topics, I am so happy that Susan Weiss from U Penn agreed to be on our EB and also serves as the Guest Editor for "emerging and re-emerging CoV" topic. We have another 6 topics and they are out of dated. I need to find updated Editors for them. I will draft a list and discuss with Prof Wen in the coming weeks.

Please feel free to let me know with your advice and feedback. (Xiaodong, I will work with you on the financial compensation to REs).

Shan



---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Monday, July 20, 2020 8:25 PM  
**To:** Cindi Callaghan  
**Cc:** Lu, Shan  
**Subject:** Re: RE: UPDATES: 2nd ISV COVID-19 Vaccines Virtual Congress

Thank you. YM Wen

-----Original Messages-----

**From:** "Cindi Callaghan" <CindiCallaghan@isv-online.org>  
**Sent Time:** 2020-07-21 00:35:42 (Tuesday)  
**To:** "Yu-Mei Wen" <ymwen@shmu.edu.cn>  
**Cc:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Subject:** RE: UPDATES: 2nd ISV COVID-19 Vaccines Virtual Congress

Dear Prof. Wen,

I'm writing to ensure that you're able to join the 2<sup>nd</sup> ISV COVID-19 Vaccines Virtual Congress on July 21 at 9am EDT.

Previously, I registered you and you should have received an email with the link to join the event. You may also click [HERE](#) to join the meeting.

The program is available at [www.ISVCongress.org](http://www.ISVCongress.org).

Please don't hesitate to contact me if you need any further assistance.

Best regards,

Cindi

\*\*\*\*\*

Cindi Callaghan





---

**From:** Lu, Shan  
**Sent:** Wednesday, July 15, 2020 6:49 AM  
**To:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
**Subject:** RE: UPDATES: 2nd ISV COVID-19 Vaccines Virtual Congress

Dear Prof Wen,

You don't need to be a member to join. Only asking if you are a member or not. You just check NO, and continue. It should be ok.

Also, if you are interested in watching the 1<sup>st</sup> Virtual congress which was held on June 22, you can check at YouTube [https://www.youtube.com/channel/UC9\\_-f8tDAqOmVEZWqGeuFow](https://www.youtube.com/channel/UC9_-f8tDAqOmVEZWqGeuFow)

However, YouTube is not accessible from China by regular way. You may ask Wang Bin to help you to 翻墙 to watch it. It is very easy but maybe not ask others to help you.

Shan

**From:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
**Sent:** Tuesday, July 14, 2020 8:25 PM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Subject:** Fw: UPDATES: 2nd ISV COVID-19 Vaccines Virtual Congress

I would like to join this virtual congress. However, they need my membership. Can you ask someone to help? Wen

-----Original Messages-----


**From:** "International Society for Vaccines" <[info@isv-online.org](mailto:info@isv-online.org)>

**Sent Time:** 2020-07-14 01:33:09 (Tuesday)

**To:** [ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)

**Cc:**

**Subject:** UPDATES: 2nd ISV COVID-19 Vaccines Virtual Congress



Dear Colleagues,

The International Society for Vaccines would like to thank everyone for the immediate responses we have already received for the **Second ISV COVID-19 Vaccines Virtual Congress** taking place **Tuesday, July 21st at 9:00AM (ET)**. The final program is online at <https://www.isvcongress.org/> and registration is OPEN!

The 2nd Virtual Congress will present to the global vaccine community another great speaker panel:

- The opening keynote speaker, **Dr. Larry Corey** from Fred Hutchinson Cancer Research Center, will describe the clinical study design of COVID-19 which is an unprecedented challenge in the history of vaccinology.
- The second keynote speaker, **Dr. Marion Gruber** from US FDA, will provide an overview on the regulatory review of COVID-19 vaccines.
- **Drs. Greg Glenn** (Novavax), **George Gao** (China CDC), **Hanneke Schuitemaker** (J&J/Janssen) and **Kena Swanson** (Pfizer) will present the progress of their respective COVID-19 vaccine programs.
- The final panel discussion will include world experts **Stanley Perlman** (University of Iowa; moderator), **Bart Haagmans** (Erasmus University), **Vincent Munster** (RML/NIH) and **Linda Saif** (The Ohio State University) to discuss the value of animal models for the development of COVID-19 vaccines.

---

#### Live Event Link:

Registrants only will receive the official live event link two days before the 2<sup>nd</sup> ISV Virtual Congress. Please do not forward this link to anyone as this event is for registered participants only.

---

#### Joining the Live Event:

To attend the Live event, click the link in forthcoming email referenced above and choose to join anonymously. This will direct you into the event. For best viewing experience we encourage everyone to download the free Teams Desktop Application [HERE](#) prior to the meeting.












For those in a country where there is online access restriction, you may need to use the international VPN system to have the access to ISV Virtual Congress. We will happy to assist you in testing your system before the congress.

---

Once again, thank you all for your participation and support.

Linda Klavinskis, PhD  
Margaret Liu, MD  
Shan Lu, MD, PhD  
*ISV COVID-19 Vaccine Virtual Congress co-Chairs*

[REGISTER HERE](#)

|                                                                                   |                                                                                   |                                                                                    |                                                                                     |
|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
|  |  |   |  |
|  |  |   |  |
|  |  |  |                                                                                     |

---

Please email [Info@ISVCongress.org](mailto:Info@ISVCongress.org) with any questions.

*If you no longer wish to receive email from us, please click [here](#):*

---

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Friday, January 17, 2020 8:23 AM  
**To:** Lu, Shan  
**Cc:** wen yumei  
**Subject:** Re: RE: URGENT submission for fast track review

Thanks, Shan.

Shibo

-----原始邮件-----

发件人:"Lu, Shan" <Shan.Lu@umassmed.edu>

发送时间:2020-01-17 21:18:33 (星期五)

收件人: "Shibo Jiang" <shibojiang@fudan.edu.cn>, " Shibo Jiang (姜世勃) " <shibojiang@fudan.edu.cn>, "wen yumei" <ymwen@shmu.edu.cn>

抄送:

主题: RE: URGENT submission for fast track review

Dear Prof Wen and Shibo,

I have written additional replies to KY and Susanna to calm down any issue they may have. So I think it is all set so we don't need to reply further.

Best.

Shan

---

**From:** Lu, Shan  
**Sent:** Friday, January 17, 2020 8:10 AM  
**To:** kyyuen <kyyuen@hku.hk>; skplau <skplau@hku.hk>  
**Cc:** Shibo Jiang <shibojiang@fudan.edu.cn>; wen yumei <ymwen@shmu.edu.cn>; pcywoo <pcywoo@hku.hk>; Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>; min.yang@emi2012.org; jingee@fudan.edu.cn; Emily <editorial2@emi2012.org>; jfwchan <jfwchan@hku.hk>; Kelvin To <kelvinto@hku.hk>; Raven Kok <khkok@hku.hk>  
**Subject:** RE: URGENT submission for fast track review

Dear KY and other HK colleagues,

We fully understand the hectic nature of this instance. There is no problem to me at all.

I would like to take this opportunity to thank Prof Yuen, Patrick, Susanna and other colleagues for the great support from day 1 EMI was launched. I had the pleasure to read and accept many of your papers at EMI. EMI is grateful for that.

I hope that I will have the chance to visit you in the near future to personally thank you for your great contribution to EMI and to the global health.

Best.

Shan

---

**From:** kyyuen <[kyyuen@hku.hk](mailto:kyyuen@hku.hk)>

**Sent:** Friday, January 17, 2020 8:05 AM

**To:** skplau <[skplau@hku.hk](mailto:skplau@hku.hk)>

**Cc:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; Shibo Jiang <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>; wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>; pcywoo <[pcywoo@hku.hk](mailto:pcywoo@hku.hk)>; Shibo Jiang (姜世勃) <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>; [min.yang@emi2012.org](mailto:min.yang@emi2012.org); [jingee@fudan.edu.cn](mailto:jingee@fudan.edu.cn); Emily <[editorial2@emi2012.org](mailto:editorial2@emi2012.org)>; jfwchan <[jfwchan@hku.hk](mailto:jfwchan@hku.hk)>; Kelvin To <[kelvinto@hku.hk](mailto:kelvinto@hku.hk)>; Raven Kok <[khkok@hku.hk](mailto:khkok@hku.hk)>

**Subject:** Re: URGENT submission for fast track review

Dear Professor Lu and all,

Let me apologise to Patrick and Susanna for not yet informing them while in a rush for this paper done within 48 hours as they are my dear team members for over 20 years.

Honesty and humility are what I have taught to my students as the top priority. I have to admit my mistakes and ask for your forgiveness for my lapse.

Sincerely yours,

Ky

skplau <[skplau@hku.hk](mailto:skplau@hku.hk)>於2020年1月17日 下午8:50寫道:

Dear Professor Lu

Sorry for the inconvenience. Patrick and I have not been informed or read the paper before its submission.

I wish our submission process could have been more proper. While I understand the urgency of such papers, the rights and interest of different researchers should also be carefully considered and respected.

Best regards

Susanna

On 18 Jan 2020, at 1:29 AM, Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> wrote:

Dear KY,

I am happy to inform you here that your new paper submitted to EMI under TEMI-2020-0053 has been accepted and you will receive a formal acceptance email shortly.

I am working hard to move the accepted draft through the production system as it may take a little under the regular process, and the weekend is coming up. But I will do my best to see how we can accelerate the production process. At least you can claim to the outside world that this paper is accepted by EMI.

At this stage, it is not possible (you should not try) to change the author names. You can do so when you receive the prove and you should process that quickly.

I will be interested in working with you to produce a news release. I will link you with other T&F colleagues who work in such area in a separate email.

Best.

Shan

---

**From:** kyyuen <[kyyuen@hku.hk](mailto:kyyuen@hku.hk)>  
**Sent:** Friday, January 17, 2020 7:24 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; Shibo Jiang <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>; wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>  
**Cc:** pcywoo <[pcywoo@hku.hk](mailto:pcywoo@hku.hk)>; skplau <[skplau@hku.hk](mailto:skplau@hku.hk)>  
**Subject:** Fwd: URGENT submission for fast track review

Dear Editor Professor Lu,

Below is the email from two of our coauthors Patrick and Susanna who are invited by another virology journal to submit a similar paper. They will now withdraw from the authorship of our paper.

We would resubmit again tonight after deleting their names. They are CC. In this email.

Apology for the inconvenience.

Ky

從我的iPhone傳送

以下為轉寄郵件:

**寄件人:** skplau <[skplau@hku.hk](mailto:skplau@hku.hk)>  
**日期:** 2020年1月17日 GMT+8 上午11:56:46  
**收件人:** kyyuen <[kyyuen@hku.hk](mailto:kyyuen@hku.hk)>, pcywoo <[pcywoo@hku.hk](mailto:pcywoo@hku.hk)>  
**副本:** Jasper Chan <[jaspchan@gmail.com](mailto:jaspchan@gmail.com)>  
**標題:** 回覆: URGENT submission for fast track review

Dear Prof Yuen and Jasper

Thanks a lot for including us in this paper. However, we have previously promised another journal to submit a paper on similar topic and will submit it soon. To avoid double publication, I think it is better for us to be skipped in your paper, either before you submit it or during revision process. Sorry for the inconvenience and thanks for your understanding.

Best regards

Susanna

---

**From:** KY Yuen <[kyyuen@hku.hk](mailto:kyyuen@hku.hk)>  
**Sent:** 17 January 2020 9:12  
**To:** pcywoo; skplau  
**Cc:** 'Jasper Chan'  
**Subject:** URGENT submission for fast track review

Dear Patrick and Susanna,

Attached is a quick paper on a comprehensive bioinformatics analysis of the 6 available 2019-nCoV genomes for submission to EMI

Your kind and speedy track change amendment is appreciated before evening.

Many thanks.  
KY



---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Friday, January 17, 2020 7:56 AM  
**To:** Lu, Shan  
**Cc:** 'KY Yuen'; 'Shibo Jiang'  
**Subject:** Re: RE: URGENT submission for fast track review

Shan, KY, SB :

There will be more and more competition on the new coronaairus. Since the preparation of the mnuscrit may need more time, it is important that we publish some articles ASAP.Maybe there will be some shortcomings in the paper, we can add a comment to the article.

Please proceed fast in this issue.

My further suggestion for the administrative officials ,is that

- 1) Generation of neutraliziing monoclonal antibodies from convalescnet patients may be could be effective for treatment of patients.
- 2) Collaboation on constant survey on human coronzvirus, especially on the muataions of S and E genes as for influenza virus, may be helpful in the future for early detection n of new coronavirus..
3. Basic studies on the immune responses and pathogenesis of human coronavirus should be supported continuously,even after the outbreaks.
4. From the public health aspects, epidmiological studies on human respirtatoy infections and analysis of different types of host responses as well as populational epidemiology need to be pursued.

YM Wen

.

-----Original Messages-----

**From:**"Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:**2020-01-17 05:23:47 (Friday)  
**To:** "'KY Yuen'" <kyyuen@hku.hk>, "'Shibo Jiang'" <shibojiang@fudan.edu.cn>, "'wen yumei'" <ymwen@shmu.edu.cn>  
**Cc:**  
**Subject:** RE: URGENT submission for fast track review

Dear KY,

Thanks for your fast work. I will process it at our fastest pace.

Shan

---

**From:** KY Yuen <kyyuen@hku.hk>  
**Sent:** Thursday, January 16, 2020 10:00 AM

**To:** Lu, Shan <Shan.Lu@umassmed.edu>; 'Shibo Jiang' <shibojiang@fudan.edu.cn>; 'wen yumei' <ymwen@shmu.edu.cn>  
**Cc:** 'KY Yuen' <kyyuen@hku.hk>  
**Subject:** URGENT submission for fast track review

Dear Editor Professor Lu, Professor Jiang and Professor Wen,

I understand from Prof. SB Jiang that EMI may consider fast track review on papers related to the novel coronavirus causing the Wuhan outbreak.

We respectfully submit the attached paper on a comprehensive bioinformatics analysis of the 6 available virus genomes as attached. There are interesting novel findings which would be widely cited, but only if the paper comes out FIRST. As in previous outbreaks such Zika viruses, such publications are likely to improve the impact factor of EMI.

Your kind and speedy attention to this submission is most appreciated. Our paper will be uploaded to EMI website before midnight in order to speed up the whole process.

Warmest regards and an early happy Chinese New Year.

Kwok-Yung

From HKU microbiology

---

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Friday, January 17, 2020 8:49 AM  
**To:** kyyuen  
**Cc:** Lu, Shan; wen yumei  
**Subject:** Re: Re: URGENT submission for fast track review

Yes, I also agree that the quality and reputation are ultimately count, not citations.

Dear Prof. Wen:

Thank you very much for proposing the topics for the special issue "Emerging and Reemerging Coronaviruses". I already asked Dr. Jinghe Huang to collaborate with some doctors in Wuhan to collect PBMCs from convalescent patients for generating human neutralizing monoclonal antibodies. Dr. Tianlei Ying's group has already started to screen 2019-nCoV-specific human mAbs from his phage libraries. Lu Lu and my group is now researching and developing peptide-based fusion/entry inhibitors against 2019-nCoV infection. Dr. Lanying Du's group is working on the research and development of anti-2019-nCoV vaccines. We will collaborate with KY's group and Zhengli Shi's group to test our peptides and antibodies in vitro, ex vivo and in vivo models against live virus infection. We are also contacting different commercial partners in a hope to get some funds to support these projects.

Best,

Shibo

-----原始邮件-----

发件人:kyyuen <kyyuen@hku.hk>

发送时间:2020-01-17 21:31:38 (星期五)

收件人: "Lu, Shan" <Shan.Lu@umassmed.edu>

抄送: "wen yumei" <ymwen@shmu.edu.cn>, "Shibo Jiang" <shibojiang@fudan.edu.cn>

主题: Re: URGENT submission for fast track review

I trust that Professor Lu is correct!

Citations are short lasting.

It is consistent good work and collaboration of the scientific community supporting EMI that finally counts.

從我的iPhone傳送

Lu, Shan <Shan.Lu@umassmed.edu>於2020年1月17日 下午9:27寫道 :

Dear Prof Wen,

Thanks for your feedback and advice. Before seeing your email below, I have already accepted Prof Yuen's paper at EMI. Hopefully it will come out soon.

At the same time, I am happy to share with this group that EMI is in the middle of launching a new special issue called "Emerging and Re-emerging CoV" which will be an electronic issue and collects past, current and future papers related to any CoV published at EMI. At this point, EMI has already published 37 CoV papers and we will keep collecting. Shibo will serve as the founding Guest Editor of this special issue.

This way, EMI can establish a unique presence and promote the research and publishing of CoV work.

I believe competition, but don't feel a short time competition will bring any long lasting outcome. At EMI, we just keep working very hard, day in and day out, all year long, year after year, which is hard for anyone to repeat. The quality and reputation are ultimately count, not citations.

Best.

Shan

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Friday, January 17, 2020 7:56 AM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Cc:** 'KY Yuen' <kyyuen@hku.hk>; 'Shibo Jiang' <shibojiang@fudan.edu.cn>  
**Subject:** Re: RE: URGENT submission for fast track review

Shan, KY, SB:

There will be more and more competition on the new coronovirus. Since the preparation of the manuscript may need more time, it is important that we publish some articles ASAP. Maybe there will be some shortcomings in the paper, we can add a comment to the article.

Please proceed fast in this issue.

My further suggestion for the administrative officials, is that

- 1) Generation of neutralizing monoclonal antibodies from convalescent patients may be effective for treatment of patients.
- 2) Collaboration on constant survey on human coronavirus, especially on the mutations of S and E genes as for influenza virus, may be helpful in the future for early detection of new coronavirus..
3. Basic studies on the immune responses and pathogenesis of human coronavirus should be supported continuously, even after the outbreaks.
4. From the public health aspects, epidemiological studies on human respiratory infections and analysis of different types of host responses as well as populational epidemiology need to be pursued.

YM Wen

-----Original Messages-----

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Sent Time:** 2020-01-17 05:23:47 (Friday)

**To:** "'KY Yuen'" <[kyyuen@hku.hk](mailto:kyyuen@hku.hk)>, "'Shibo Jiang'" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>, "'wen yumei'" <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>

**Cc:**

**Subject:** RE: URGENT submission for fast track review

Dear KY,

Thanks for your fast work. I will process it at our fastest pace.

Shan

---

**From:** KY Yuen <[kyyuen@hku.hk](mailto:kyyuen@hku.hk)>

**Sent:** Thursday, January 16, 2020 10:00 AM

**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; 'Shibo Jiang' <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>; 'wen yumei' <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>

**Cc:** 'KY Yuen' <[kyyuen@hku.hk](mailto:kyyuen@hku.hk)>

**Subject:** URGENT submission for fast track review

Dear Editor Professor Lu, Professor Jiang and Professor Wen,

I understand from Prof. SB Jiang that EMI may consider fast track review on papers related to the novel coronavirus causing the Wuhan outbreak.

We respectfully submit the attached paper on a comprehensive bioinformatics analysis of the 6 available virus genomes as attached. There are interesting novel findings which would be widely cited, but only if the paper comes out FIRST. As in previous outbreaks such Zika viruses, such publications are likely to improve the impact factor of EMI.

Your kind and speedy attention to this submission is most appreciated. Our paper will be uploaded to EMI website before midnight in order to speed up the whole process.

Warmest regards and an early happy Chinese New Year.

Kwok-Yung

From HKU microbiology

---

**From:** TEMI-production@journals.tandf.co.uk  
**Sent:** Sunday, February 16, 2020 11:21 PM  
**To:** Lu, Shan  
**Cc:** editorial@emi2012.org; liu.6244@osu.edu; lishan\_su@med.unc.edu  
**Subject:** Re: RE: Urgent: revised commentary for Emerging Microbes & Infections - TEMI-2020-0121  
#TrackingId:5653992

Dear Shan,

This has not entered production yet. I hope Jorgie can send the correct file to production.

Regards,

Malathi  
Emerging Microbes & Infections

---

**From:** Shan.Lu@umassmed.edu  
**Sent:**  
**To:** Shan.Lu@umassmed.edu  
**Cc:** lishan\_su@med.unc.edu, editorial@emi2012.org, liu.6244@osu.edu  
**Subject:** Re: RE: Urgent: revised commentary for Emerging Microbes & Infections - TEMI-2020-0121

Dear Jorgie,

I believe the accepted version of TEMI-2020-0121 is already being sent to production, right? If not, then replace it with the one attached (just sent from Dr. Shan-Lu Liu (not me). If it has been sent to production, then I will write below to Malathi.

Dear Malathi,

If this paper is already in production, please see if you can replace the original version with the attached version. If it is too late, the authors can make the change at the galley proofs step. Just to make sure that this paper should be treated as very urgent (the fast track).

Thanks.

Shan

---

**From:** Liu, Shan-Lu <liu.6244@osu.edu>  
**Sent:** Sunday, February 16, 2020 8:00 PM  
**To:** temi-peerreview@journals.tandf.co.uk  
**Cc:** Lu, Shan <Shan.Lu@umassmed.edu>; lishan\_su@med.unc.edu  
**Subject:** Re: Urgent: revised commentary for Emerging Microbes & Infections - TEMI-2020-0121

Here is the attachment, sorry!

---

Dear Jorgie,

After discussing with Dr. Shan Lu and all coauthors, we have decided to use a new title and also make minor changes to the text, including associated references. I have attached the updated commentary and hope that you will be able to help upload the new version for preparing the proof.

Thank you!

Shan-Lu



Shan-Lu Liu, M.D., Ph.D.

Professor

Co-Director, Viruses and Emerging Pathogens Program

Infectious Diseases Institute

Center for Retrovirus Research

Departments of Veterinary Biosciences, Microbial Infection and Immunity, and Microbiology

The Ohio State University

1900 Coffey Rd, Room 480 VMAB

Columbus, Ohio 43210

Phone: (614) 292-8690

Fax: (614) 292-6473

Email: [liu.6244@osu.edu](mailto:liu.6244@osu.edu); [shan-lu.liu@osumc.edu](mailto:shan-lu.liu@osumc.edu)

---

**From:** "[temi-peerreview@journals.tandf.co.uk](mailto:temi-peerreview@journals.tandf.co.uk)" <[temi-peerreview@journals.tandf.co.uk](mailto:temi-peerreview@journals.tandf.co.uk)>

**Date:** Thursday, February 13, 2020 at 9:14 AM

**To:** Shan-Lu Liu <[liu.6244@osu.edu](mailto:liu.6244@osu.edu)>

**Cc:** "[shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu)" <[shan.lu@umassmed.edu](mailto:shan.lu@umassmed.edu)>, "[lishan su@med.unc.edu](mailto:lishan_su@med.unc.edu)" <[lishan su@med.unc.edu](mailto:lishan_su@med.unc.edu)>

**Subject:** Re: Re: Emerging Microbes & Infections - TEMI-2020-0121 - changes required to your submission  
#TrackingId:5633996

Dear Professor Liu,

Thank you very much for sending this file.

Kindly be informed that I have now uploaded in the system on your behalf and proceeded your paper to the editor.

Please let me know if you have further questions or concerns.

Kind regards,

**Jorgie Lyn Luna** - Journal Editorial Office

Taylor & Francis Group

4 Park Square | Milton Park | Abingdon | Oxon | OX14 4RN UK

Web: [www.tandfonline.com](http://www.tandfonline.com)



Emerging Microbes & Infections

-----  
**From:** liu.6244@osu.edu  
**Sent:**  
**To:** liu.6244@osu.edu  
**Cc:** Shan.Lu@umassmed.edu, lishan\_su@med.unc.edu  
**Subject:** Re: Re: Emerging Microbes & Infections - TEMI-2020-0121 - changes required to your submission

Hi Jorgie:

I have modified as instructed and attached the new one to this email. Please help upload and proceed.

Thank you.

Shan-Lu

Shan-Lu Liu, M.D., Ph.D.  
Professor  
Co-Director, Viruses and Emerging Pathogens Program  
Infectious Diseases Institute  
Center for Retrovirus Research  
Departments of Veterinary Biosciences, Microbial Infection and Immunity, and Microbiology  
The Ohio State University  
1900 Coffey Rd, Room 480 VMAB  
Columbus, Ohio 43210  
Phone: (614) 292-8690  
Fax: (614) 292-6473  
Email: [liu.6244@osu.edu](mailto:liu.6244@osu.edu); [shan-lu.liu@osumc.edu](mailto:shan-lu.liu@osumc.edu)

On 2/13/20, 8:43 AM, "Emerging Microbes and Infections" <[onbehalf@manuscriptcentral.com](mailto:onbehalf@manuscriptcentral.com)> wrote:

13-Feb-2020

Dear Professor Liu,

Your above referenced manuscript, entitled "SARS-CoV-2: no evidence of a laboratory origin" requires some further changes before it is ready for reviewing in Emerging Microbes & Infections. Your submission has been returned to you and is located in your Author Center as a draft, so that you due to these reasons:

1. No line numbering

Kindly add a line numbering in your main document.

2. Exceeded reference count

Kindly be informed that the reference count for the commentary article should not be more than 15.

Your submission along with all files you submitted is now in your Author Center, at  
[https://urldefense.com/v3/https://mc.manuscriptcentral.com/temi\\_!!KGKeukY!nGv1RgRJ1P-OGXuZi8b2hKGjXxDFOmBwDONuR\\_njCdwERJF1HkBlV4Sggqr9udyWYml\\$](https://urldefense.com/v3/https://mc.manuscriptcentral.com/temi_!!KGKeukY!nGv1RgRJ1P-OGXuZi8b2hKGjXxDFOmBwDONuR_njCdwERJF1HkBlV4Sggqr9udyWYml$) Please read the Quick Guide to

Continuing your Submission, which shows how you can access your manuscript, and submit it back to the site. The Guide is located at

[https://urldefense.com/v3/\\_http://mc.manuscriptcentral.com/societyimages/tandf\\_gs0/Continuning\\*20a\\*20Submission\\_screenshot.pdf\\_";JSU!!KGKeukY!nGv1RgRJ1P-OGXuZi8b2hKGjXxDFOmBwDONuR\\_njCdwERJF1HkBIV4Sggqr9re6Z8tA\\$](https://urldefense.com/v3/_http://mc.manuscriptcentral.com/societyimages/tandf_gs0/Continuning*20a*20Submission_screenshot.pdf_)

You may contact the Editorial Office if you have further questions.

Sincerely,

Jorgie Lyn Luna  
Emerging Microbes & Infections Editorial Office  
[temi-peerreview@journals.tandf.co.uk](mailto:temi-peerreview@journals.tandf.co.uk)

---

**From:** TEMI-production@journals.tandf.co.uk  
**Sent:** Thursday, February 20, 2020 12:08 AM  
**To:** liu.6244@osu.edu  
**Cc:** Lu, Shan; lishan\_su@med.unc.edu  
**Subject:** Re: Re: Welcome to Taylor & Francis Production: Emerging Microbes & Infections 1733440  
#TrackingId:5682455

Hi Shan,

Your copyright form was rejected as there were no article title and author names filled in the form. Please fill and resubmit the form.

Regarding publication time, normally this would publish articles in 18 days. If editor asks us to prioritise, we will do. I will discuss with editor and get back to you on this.

Regards,

Malathi  
Emerging Microbes & Infections

---

**From:** liu.6244@osu.edu  
**Sent:**  
**To:** liu.6244@osu.edu  
**Cc:** lishan\_su@med.unc.edu, Shan.Lu@umassmed.edu  
**Subject:** Re: Re: Welcome to Taylor & Francis Production: Emerging Microbes & Infections 1733440

I am currently out of town, but may I ask my co-corresponding author Dr, Lishan Su, who is copied, to sign on the agreement on behalf of us.

Another piece of note, because this commentary is extremely time-sensitive, is it possible to process it with an accelerated speed? Last few days, similar comments have been published by other journals.

Thank you.

Shan-Lu Liu sent from iPhone

On Feb 19, 2020, at 3:51 PM, TEMI-production@journals.tandf.co.uk <cats@taylorandfrancis.com> wrote:

Article: SARS-CoV-2: no evidence of a laboratory origin

Journal: *Emerging Microbes & Infections* TEMI

Article ID: TEMI 1733440

Dear Shan-Lu Liu,

We are delighted that you have chosen to publish your article in *Emerging Microbes & Infections*. I will be your Production Editor and will work with you to oversee the production of your article through to publication. My contact details are given at the end of this email.

- Please print and sign the attached Author Publishing Agreement. Then return the completed agreement to Taylor & Francis, by uploading to CATS (see below), or post it to the address below.

Proofs will be ready for you to check in approximately 7 working days and we would like you to return your corrections within 3 days. Please let me know if there will be any difficulty in meeting this schedule.

We will be sending proofs to you through our workflow system, CATS (Central Article Tracking System).

- You can check the status of your paper online through the CATS system at:  
<https://cats.informa.com/PTS/in?ut=B2AB6692AA414D96905B59E6C51FA240>
- Your User Name is: lius876
- Your Password is: Liua4764#\$ (You will be required to change this first time you log in)
- The DOI of your paper is: 10.1080/22221751.2020.1733440. Once your article has published online, it will be available at the following permanent link: <https://doi.org/10.1080/22221751.2020.1733440> .

Yours sincerely,

Malathi Boopalan

Email:TEMI-production@journals.tandf.co.uk

<Copyright\_Form.pdf>

---

**From:** TEMI-production@journals.tandf.co.uk  
**Sent:** Thursday, February 20, 2020 12:15 AM  
**To:** liu.6244@osu.edu; lishan\_su@med.unc.edu  
**Cc:** Lu, Shan  
**Subject:** Re: Re: Welcome to Taylor & Francis Production: Emerging Microbes & Infections 1733440  
#TrackingId:5683534

Thank you, Lishan. It is approved.

Regards,

Malathi

Emerging Microbes & Infections

---

**From:** lishan\_su@med.unc.edu  
**Sent:**  
**To:** liu.6244@osu.edu, lishan\_su@med.unc.edu  
**Cc:** Shan.Lu@umassmed.edu  
**Subject:** Re: Re: Welcome to Taylor & Francis Production: Emerging Microbes & Infections 1733440

Signed form uploaded. Thanks!

-Lishan

---

**From:** "Liu, Shan-Lu" <liu.6244@osu.edu>  
**Date:** Wednesday, February 19, 2020 at 9:17 PM  
**To:** "Su, Lishan" <lishan\_su@med.unc.edu>  
**Cc:** "TEMI-production@journals.tandf.co.uk" <TEMI-production@journals.tandf.co.uk>, Shan Lu <Shan.Lu@umassmed.edu>  
**Subject:** Re: Welcome to Taylor & Francis Production: Emerging Microbes & Infections 1733440

No, title was from the original submission.

Shan-Lu Liu sent from iPhone

On Feb 19, 2020, at 6:05 PM, Su, Lishan <lishan\_su@med.unc.edu> wrote:

Are we still using the old title?

TEMI 1733440 SARS-CoV-2: no evidence of a laboratory origin

-Lishan

---

**From:** "Liu, Shan-Lu" <liu.6244@osu.edu>

**Date:** Wednesday, February 19, 2020 at 7:57 PM

**To:** "TEMI-production@journals.tandf.co.uk" <TEMI-production@journals.tandf.co.uk>

**Cc:** "Su, Lishan" <lishan\_su@med.unc.edu>, Shan Lu <Shan.Lu@umassmed.edu>

**Subject:** Re: Welcome to Taylor & Francis Production: Emerging Microbes & Infections 1733440

I am currently out of town, but may I ask my co-corresponding author Dr, Lishan Su, who is copied, to sign on the agreement on behalf of us.

Another piece of note, because this commentary is extremely time-sensitive, is it possible to process it with an accelerated speed? Last few days, similar comments have been published by other journals.

Thank you.

Shan-Lu Liu sent from iPhone

On Feb 19, 2020, at 3:51 PM, TEMI-production@journals.tandf.co.uk <cats@taylorandfrancis.com> wrote:

Article: SARS-CoV-2: no evidence of a laboratory origin

Journal: *Emerging Microbes & Infections* TEMI

Article ID: TEMI 1733440

Dear Shan-Lu Liu,

We are delighted that you have chosen to publish your article in *Emerging Microbes & Infections*. I will be your Production Editor and will work with you to oversee the production of your article through to publication. My contact details are given at the end of this email.

- Please print and sign the attached Author Publishing Agreement. Then return the completed agreement to Taylor & Francis, by uploading to CATS (see below), or post it to the address below.

Proofs will be ready for you to check in approximately 7 working days and we would like you to return your corrections within 3 days. Please let me know if there will be any difficulty in meeting this schedule.

We will be sending proofs to you through our workflow system, CATS (Central Article Tracking System).

- You can check the status of your paper online through the CATS system at: <https://cats.informa.com/PTS/in?ut=B2AB6692AA414D96905B59E6C51FA240>

- Your User Name is: lius876

- Your Password is: Liua4764#\$ (You will be required to change this first time you log in)
- The DOI of your paper is: 10.1080/22221751.2020.1733440. Once your article has published online, it will be available at the following permanent link:  
<https://doi.org/10.1080/22221751.2020.1733440> .

Yours sincerely,

Malathi Boopalan

Email:TEMI-production@journals.tandf.co.uk

<Copyright\_Form.pdf>

---

**From:** TEMI-production@journals.tandf.co.uk  
**Sent:** Thursday, February 20, 2020 12:11 AM  
**To:** liu.6244@osu.edu; lishan\_su@med.unc.edu  
**Cc:** Lu, Shan  
**Subject:** Re: Re: Welcome to Taylor & Francis Production: Emerging Microbes & Infections 1733440  
#TrackingId:5682821

Dear Lishan,

We have updated the title as "No credible evidence supporting claims of the laboratory engineering of SARS-CoV-2".

Regards,

Malathi  
Emerging Microbes & Infections

---

**From:**lishan\_su@med.unc.edu  
**Sent:**  
**To:**liu.6244@osu.edu,lishan\_su@med.unc.edu  
**Cc:**Shan.Lu@umassmed.edu  
**Subject:**Re: Re: Welcome to Taylor & Francis Production: Emerging Microbes & Infections 1733440

Are we still using the old title?

TEMI 1733440 SARS-CoV-2: no evidence of a laboratory origin

-Lishan

---

**From:** "Liu, Shan-Lu" <liu.6244@osu.edu>  
**Date:** Wednesday, February 19, 2020 at 7:57 PM  
**To:** "TEMI-production@journals.tandf.co.uk" <TEMI-production@journals.tandf.co.uk>  
**Cc:** "Su, Lishan" <lishan\_su@med.unc.edu>, Shan Lu <Shan.Lu@umassmed.edu>  
**Subject:** Re: Welcome to Taylor & Francis Production: Emerging Microbes & Infections 1733440

I am currently out of town, but may I ask my co-corresponding author Dr, Lishan Su, who is copied, to sign on the agreement on behalf of us.

Another piece of note, because this commentary is extremely time-sensitive, is it possible to process it with an accelerated speed? Last few days, similar comments have been published by other journals.

Thank you.

Shan-Lu Liu sent from iPhone



On Feb 19, 2020, at 3:51 PM, TEMI-production@journals.tandf.co.uk <cats@taylorandfrancis.com> wrote:

Article: SARS-CoV-2: no evidence of a laboratory origin

Journal: *Emerging Microbes & Infections* TEMI

Article ID: TEMI 1733440

Dear Shan-Lu Liu,

We are delighted that you have chosen to publish your article in *Emerging Microbes & Infections*. I will be your Production Editor and will work with you to oversee the production of your article through to publication. My contact details are given at the end of this email.

- Please print and sign the attached Author Publishing Agreement. Then return the completed agreement to Taylor & Francis, by uploading to CATS (see below), or post it to the address below.

Proofs will be ready for you to check in approximately 7 working days and we would like you to return your corrections within 3 days. Please let me know if there will be any difficulty in meeting this schedule.

We will be sending proofs to you through our workflow system, CATS (Central Article Tracking System).

- You can check the status of your paper online through the CATS system at:  
<https://cats.informa.com/PTS/in?ut=B2AB6692AA414D96905B59E6C51FA240>
- Your User Name is: lius876
- Your Password is: Liua4764#\$ (You will be required to change this first time you log in)
- The DOI of your paper is: 10.1080/22221751.2020.1733440. Once your article has published online, it will be available at the following permanent link: <https://doi.org/10.1080/22221751.2020.1733440> .

Yours sincerely,

Malathi Boopalan

Email: TEMI-production@journals.tandf.co.uk

<Copyright\_Form.pdf>

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Wednesday, April 22, 2020 10:11 PM  
**To:** Lu, Shan  
**Cc:** YiWei Tang  
**Subject:** Re: RE: Children's New Crown Paper

If possible, to support this publication from this hospital will promote their interest in research on infectious diseases, which is an important part of this emerging field. However, it is for you to decide on this. Anyway, I hope you and yiwei will give some advice for them to improve their work, as they have the specimens in their hospital, which we do not have access to these. YM Wen

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:** 2020-04-22 11:23:20 (Wednesday)  
**To:** "wen yumei" <ymwen@shmu.edu.cn>, "YiWei Tang" <yiweitangmd@gmail.com>  
**Cc:**  
**Subject:** RE: Children's New Crown Essay

Hi, Prof Wen,

Thanks for sending this MS to us.

This paper is clearly written but it does not offer much novelty. EMI already had a paper about children. There are many pediatric COVID-19 reports in literature already. I noticed that this paper is already submitted to EMI. Ye-Wei and I will review new papers in two days for our weekly screening. We can decide then. But if for some reason, you would like to support this paper, please let us know.

Also, I am attaching a master list of ALL COVID-19 papers EMI has received. This Excel file has the following "sheets":

1. Published or accepted: 32 until now. We have a very big diversity and most have very download reads.
2. New or under review: 55 at this point. More new ones will be rejected. Those under review will be accepted for about 70%.
3. Rejected: 278 so far. You can see from here that we have too many pure clinical papers to even consider.
4. Withdrawn: about 9

I have used this list to track our papers. Min updates daily except weekends. I will ask her to send you one copy each week so it is easy to read. I also share this list to T&F manager and Susan Weiss who is the Guest Editor for CoV special

5/17/2021

If possible, to support this publication from this hospital will promote their interest in research on infectious diseases, which

topic.

Best.

Shan

**From:** wen yumei <ymwen@shmu.edu.cn>

**Sent:** Tuesday, April 21, 2020 9:22 PM

**To:** Lu, Shan <Shan.Lu@umassmed.edu>; YiWei Tang <yiweitangmd@gmail.com>

**Subject:** Fw: Children's New Crown Paper

Please comment, Wen

-----Original Messages-----

**From:** xujin <janexu@fudan.edu.cn>

**Sent Time:** 2020-04-21 14:39:08 (Tuesday)

**To:** ymwen@shmu.edu.cn

**Cc:**

**Subject:** On Tong's New Crown Forum

Hello, Master Wen!

I took the liberty to disturb you! My name is Xu Jin from the Clinical Laboratory Center of the Sub-Fudan School Affiliated to Fudan University. I am mainly engaged in clinical virology. For related research work, I asked you to write a letter of recommendation for my "New Century Excellent Talents Project" a few years ago. Do you remember me?

During the COVID-19 outbreak, in response to the 9 COVID-19 children admitted to our hospital, I and the clinician began to investigate the pathogens during the whole process from the study of nucleic acid monitoring. It was observed that the detection rate of nasopharyngeal swab was 100%, the feces was 89%, the pharynx test was 33%, and the detoxification time of nasopharyngeal test (median 13 days) far more than the pharyngeal test (median 4 days), the detoxification time in the feces is quite long, and the oldest child is delayed until 46 days after being discharged from the hospital. The overall characteristics of sex are different from those of adults, which is of certain significance for understanding the detoxification characteristics of children with new coronary disease. After summarizing Letter and voting for EMI, I would like to ask the teacher for advice to see if it is suitable for publication.

The attachment is the content of the script, please pass it through.

Thank you very much for your help and support! I wish you good health!

Xu Jinshang

Clinical Laboratory Center of Fudan University Affiliated Sub-Hospital

2



---

**From:** Shibo Jiang (姜世勃) <shibojiang@fudan.edu.cn>  
**Sent:** Tuesday, February 23, 2021 11:36 PM  
**To:** Lu, Shan  
**Cc:** 'Min Yang'  
**Subject:** Re: RE: 回复: your commentary

Thanks, Shan.

No problem, we will submit it as soon as possible.

Shibo

-----原始邮件-----

发件人:"Lu, Shan" <Shan.Lu@umassmed.edu>  
发送时间:2021-02-24 11:52:36 (星期三)  
收件人: "shibojiang@fudan.edu.cn" <shibojiang@fudan.edu.cn>  
抄送: "'Min Yang'" <min.yang@emi2012.org>  
主题: RE: 回复 : your commentary

Hi, Shibo,

Yes, it was accepted but due to the tech error it was treated as a "Major Revision". I asked T&F JEO to correct it but it seems that they are not good at doing this quickly.

Do you mind just resubmit it back again, without any corrections? So I can ask JEO to process it to me for making the change.

Sorry for the trouble and please let us know once you re-submit it.

Thanks.

Shan

Yang Min: once Prof Jiang informs us his resubmission, please let Jorgie know to move it to EIC desk.

---

**From:** shibojiang@fudan.edu.cn <shibojiang@fudan.edu.cn>

**Sent:** Monday, February 22, 2021 8:17 PM

**To:** Lu, Shan <Shan.Lu@umassmed.edu>

**Cc:** 'Min Yang' <min.yang@emi2012.org>

**Subject:** 回复: your commentary

Dear Shan,

No problem, you already informed me that our manuscript was accepted in the separate email.

Thank you again for rapid processing our manuscript.

Shibo

发自我的荣耀手机

----- 原始邮件 -----

发件人: "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

日期: 2021年2月23日周二 早上8:10

收件人: "Shibo Jiang (姜世勃)" <[shibojiang@fudan.edu.cn](mailto:shibojiang@fudan.edu.cn)>

抄送: 'Min Yang' <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>

主题: RE: your commentary

Hi, Shibo,

I would like to apologize for an error in our tech system that a decision of "Major Revision" was entered instead of "Accept". I have personally asked JEO to correct on this and hope it will be resolved soon. We will keep you posted.

Best.

Shan

**From:** wen yumei <ymwen@shmu.edu.cn >  
**Sent:** Sunday, December 27, 2020 6:16 PM  
**To:** Lu, Shan  
**Subject:** Re: RE: An article by Mr. Gui Zhiliang

Thanks. I enjoyed sharing the paper you attached. Happy New Year. YMWen

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu >  
**Sent Time:** 2020-12-26 01:49:15 (Saturday)  
**To:** "wen yumei" <ymwen@shmu.edu.cn >  
**Cc:**  
**Subject:** RE: An article by Gui Zhiliang

Hi, Prof Wen,

Thanks for sharing. This can trigger too many things:

- China was actually quite good in mid-20 century with many trained from overseas
- Admiring your mother's vision. I fully agree and think China needs better psychiatry and even routine psychology counseling which in US are very common in schools, companies and public service

By the way, did you notice that I recruit a special paper about China's vaccine work during the 2<sup>nd</sup> World War? See attached. EMI published this paper around this summary, 45 years anniversary of ending WWII. NEJB had a short cometary at that time but I think EMI's is much better.

Shan

**From:** wen yumei <ymwen@shmu.edu.cn >  
**Sent:** Friday, December 25, 2020 6:54 AM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu >  
**Subject:** Fw: An article by Mr. Gui Zhiliang

1

Just to share with you. I am really impressed, as this article was in press 90 years ago. YMW

5/17/2021

Thanks. I enjoyed sharing the paper you attached. Happy New Year. YMWen -----Original Messages----- From:"Lu, Shan"

-----Original Messages-----

**From:** "范庭卫" <>fantingwei@ suda.edu.cn

**Sent Time:** 2020-12-23 15:56:28 (Wednesday)

**To:** "wen yumei" <>ymwen@ shmu.edu.cn

**Cc:** xiebin@ smhc.org.cn

**Subject:** A chapter of Gui Zhiliangxian

Wenyuan, hello:

I recently read a paper by Gui Zhiliang in 1930 (attachment). This is the paper she had just returned to China after studying. It can be seen that she put the development of mental illness in China Learning as a self-employed business.

This year marks the 120th anniversary of Gui Zhiliang's birth. After reading the letter and archives about Gui Zhiliang, I deeply feel her sense of responsibility for the development of psychiatry in China. Profession, admiration, worth learning.

It is the end of the year. Thank you Wen Yuan and Secretary Xie Bin for your care and help over the past year. I wish you a happy new year!

Sincerely, Fan Tingwei

Suzhou University

From: wen yumei <>ymwen@ shmu.edu.cn

Delivery date: 2020-02-20 12:49:52

: "Fan Tingwei" <>fantingwei@ suda.edu.cn

Cc: "Xie Bin" <>xiebin@ smhc.org.cn

Topic: Re: Re Research and Questions on Gui Zhiliangxian

Fan Xian, received. Thank you. The re-production of the cover can be very interesting by the application.

My relative once told me that she chose psychiatry because she likes philosophy. Psychiatry and health are sciences that are closer to philosophy in medicine.

In addition, she believes that in addition to physical health, mental and physical health are also important. In the preface of her book published in 1942, she wrote "China's small leaders are not only You must have a healthy body and a good spirit and morality."

2

---

## Page 3

Regarding the latter question, I don't know whether Guihua is a member, because Guihua has no medical experience.

-----Original Messages-----

**From:** "范庭卫" <>fantingwei@ suda.edu.cn

**Sent Time:** 2020-02-20 11:56:07 (Thursday)

**To:** "wen yumei" <>ymwen@ shmu.edu.cn

**Cc:**

**Subject:** Re Research and questions about Gui Zhiliangxian

Wen Yuan is good,

I recently contacted the U.S. Archives and attached a letter from Gui Zhiliang on June 5, 1925. please check.



I would like to ask you 2 questions.

The first question is, after Gui Zhiliang graduated from Wesley, why did he study medicine and choose to study psychiatry?

My inference is that at that time, the Anglican Wuchang Tongren Hospital wanted to build a "psychiatric department" and needed psychiatrists. This is just my analysis and judgment. Gui Zhiliangyong Didn't talk specifically about her professional choice?

The second question, was written at Wuchang Tongren Hospital from 1929 to 1930. Is Gui Zhiliang's sister Gui Zhiliang? Did Guihua ever serve as Central China?

School doctor?

In her book, Mishima, S. Seo mentioned Gui Zhiliang, a classmate who started studying in Wesleyan in the United States, and also mentioned Gui Zhiliang from Wuchang (Tongren) Hospital. Sister, once corresponded with her. Mishima, S. Seo didn't specify which sister it was. I judged it was Gui hua.

Thank you Wenyan! I was on TV and saw your speech about fighting the new crown virus, especially the use of hoods. I am now, in accordance with your approach, fully Use a hood. A good method that is scientific and practical.

Good luck!

Fan Tingwei

Suzhou University

From: wen yumei <>ymwen@shmu.edu.cn

Delivery date: 2020-01-25 20:31:04

: "Fan Tingwei" <>fantingwei@suda.edu.cn

Topic: Re: Research and Questions about Gui Zhiliangxian

3

## Page 4

见Reply·

-----Original Messages-----

**From:** "范庭卫" <>fantingwei@suda.edu.cn

**Sent Time:** 2020-01-24 12:01:23 (Friday)

**To:**ymwen@shmu.edu.cn

**Cc:**

**Subject:** Research and questions about Gui Zhiliangxian

Wen Yuan is good,

首先First, I wish you a happy Chinese New Year, a healthy body, and a happy family!

I am a teacher of the Department of Science in Suzhou University. In 2013, I wrote "Gu Zhiliang—Strongness in the War of Resistance". The information at that time was very incomplete, and it was made improvements.

Recently, I read Gui Zhiliang's letters from 1930-1931, and I am sorting them.

I have a question, please tell me about it. 1. Gui Zhiliang's residence in Beijing, Pei Chung Pu Hutong, the name of this hutong

I don't know, my place of residence is Shishi street·2· (after 1934, I went out--1940)

. 2. Gui Zhiliang and Wen also rumored that they got married in 1930?

do not know.

3.1 In 1931, what happened? .

Wen Ping 1931 ·9·Issued·

4. It is also rumored that the first name is Robert?

may.

Judging from the letters, in 1930, Gui Zhiliang planned to go to England to study for one year. The Chinese bishop and the American psychiatrist, both went for Gui Xian Yingxue made a recommendation. In 1932, Gui Zhiliang traveled to Britain via Shanghai, but encountered the war in Shanghai, and later moved to Hong Kong to go to Britain. 又 Suddenly heard My family was ill, but I canceled my study and work in the UK.

correct

4

---

## Page 5

Gui Zhiliang was dedicated to the study and research of psychiatry. Soon after he got married, he applied to study psychiatry in the UK. Soon after Wenping came out, I was going to Britain country. I really want to know that I got married in 1930 and heard of peace in 1931. In this way, the content of the letter is more accurate. At the same time, it can be more anti-Reflecting Gui Zhiliang's precious spirit in psychiatry studies.

I would take the liberty to write to you, please criticize and correct any inappropriateness.

Fan Tingwei

Department of Science, Suzhou School of Education

2020 1月24日 Divided

"

5/17/2021

Thanks. I enjoyed sharing the paper you attached. Happy New Year. YMWen -----Original Messages----- From:"Lu, Shan"

5

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Thursday, March 26, 2020 1:09 AM  
**To:** Lu, Shan  
**Subject:** Re: RE: 答复: Emerging Microbes & Infections

Excellent response. I think you should go the Department of foreign affairs. But I would not let you leave EMI.Wen

> -----Original Messages-----

> From: "Lu, Shan" <Shan.Lu@umassmed.edu> Sent Time: 2020-03-26 12:44:12  
 > (Thursday)

> To: "wen yumei" <ymwen@shmu.edu.cn>, "杨福全" <fqyang@ibp.ac.cn>

> Cc: "editorial@emi2012.org" <editorial@emi2012.org>

> Subject: RE: 答复: Emerging Microbes & Infections

>

> Dear Dr. Yang,

>

> Thank you very much for your email to alert us this issue. As Porf. Wen quickly responded to you, EMI takes your feedback very seriously and will address it right away.

>

> Yes, you did point in your email to me that " so the names such as Wuhan (2019-nCoV), Wuhan-Hu-Cov-1, Wuhan-Hu-1 should not be used for the novel Coronavirus". Because as you can see from our email exchanges included below, your review comment was not entered into the online system so the authors may have missed this comment. While EMI office tried to send your comment to authors by emails, the key message may have been lost during somewhat informal communication.

>

> Then when the revised paper was submitted back, EMI office failed to check this part and we sincerely apologize for the oversight, considering in mid-Feb everyone including EMI office staff are very concerned about the situation in Wuhan and we just tried to work very hard to get as much research data published as possible as a way of our contribution to the war against this deadly virus. We have been receiving more than 50 papers per week and we only have one full time staff who also could not go to work in her office in Shanghai.

>

> The other factor is that WHO had not formally named the virus as SARS-CoV-2 at that time. Actually, several leading virologists in China even suggested to name the virus as WARS with W representing Wuhan to remember the tragedy and lesson of this epidemic. Personally I don't think the authors were trying intentionally to bring a negative meaning to the name. It was just part of crazy situation at the early time.

>

> However, I personally share your feeling and will contact the authors to see if they can update their paper by revising the title. EMI will cover the cost for re-publishing the revised version if the authors agree and it is technically possible. I will keep you updated.

>

> Again, EMI would like to thank you for your great volunteer work as a reviewer and for your continued care to us by bringing this issue to our attention. Please do not hesitate to let me know if there is anything I have missed.

>

> Best.

>

> Shan

>

> -----Original Message-----

> From: wen yumei <ymwen@shmu.edu.cn>  
> Sent: Wednesday, March 25, 2020 11:51 PM

> To: Yang Fuquan <fqyang@ibp.ac.cn>

> Cc: editorial@emi2012.org; Lu, Shan <Shan.Lu@umassmed.edu>

> Subject: Re: 答复: Emerging Microbes & Infections  
>

> Letter received-. We will deal with it carefully and properly in accordance with the regulations of international magazines. Smell plum

>

>

>> -----Original Messages-----

>> From: "杨福全" <fqyang@ibp.ac.cn>

>> Sent Time: 2020-03-26 11:46:38 (Thursday)

>> To: ymwen@shmu.edu.cn, editorial@emi2012.org

>> Cc: Shan.Lu@umassmed.edu

>> Subject: 答复: Emerging Microbes & Infections

>>

>> Wen Yuan 士: Hello!

>> Please forgive me for taking the liberty to write to you! I am Yang Fuquan from the Institute of Physical Physics, Chinese Academy of Sciences. In February of this year, I was invited to Microbes and

>> Infections" a manuscript submitted for review by the editorial department (see attachment). The title of the article "Emerging WuHan (2019-nCoV)

>> Coronavirus: Glycan shield and structure prediction of Spike

>> glycoprotein and its interaction with Human

>> CD26" and its text are prefixed with the word "Wuhan" in front of Coronavirus and its related proteins. This practice seriously violates the naming principles of the WHO, and Unauthorized self-titled "Wuh

>> The word "an" is discriminatory and insulting, and has lost the spirit of scientific research. I have clearly pointed out this issue in the review comments and proposed amendments. Change your mind. However, what makes people angry is "Emergi

>> of Microbes and

>> The editor of "Infections" did not adopt my revised intentions and published the paper online with recent days (attached to 见). This approach includes me All Chinese people are totally unacceptable. hope

>> I hope the editorial department of "Emerging Microbes and Infections" will immediately correct the mistakes and make an apology.

>>

>> Good luck!

>>

>> Yang Fuquan

>>

>> ----- Original Email-----

>> From: Lu, Shan [mailto: Shan.Lu @ umassmed.edu ]

>> Delivery time: February 17, 2020 0:01

>> To: Yang Fuquan

>> Cc: Editorial Office

>> 主题: RE: Emerging Microbes & Infections

>>

2

## Page 3

>> Thanks I will ask EMI office to send your comments to the author in a separate email.

>>

>> Appreciate your great help! You take care since you are in the epicenter of this outbreak.

>>

>> Shan

>>

>> -----Original Message-----

>> From: Yang Fuquan <fqyang@ibp.ac.cn>

>> Sent: Sunday, February 16, 2020 10:58 AM

>> To: Lu, Shan <Shan.Lu@umassmed.edu>

>> Subject: Re: Emerging Microbes & Infections

>>

>>

>> Dear Prof. Lu,

>> Thank you very much for your e-mail. That is very funny.

>> My comments are as following:

>>

>> 1. This study is worthwhile work for the drug development.

>> 2. This study has compared the glycosylation sites in spike glycoproteins of 2019-nCoV and SARS-CoV-1, and the interaction with human CD26, and found a number of conserved glycosylation sites in spike glycoproteins between 2019-nCoV and SARS-CoV-1, and several unique glycosylation sites 2019-nCoV. This suggests that 2019-nCoV may take a slightly different immunogenicity in host cell interactions to that of SARS, but might have the same targets and can respond to a similar therapeutic approach to SARS.

>> 3. The novel Coronavirus found in Wuhan, in 2019 has only been named as 2019-nCoV by WHO, so the names such as Wuhan (2019-nCoV), Wuhan-Hu-Cov-1, Wuhan-Hu-1 should not be used for the novel Coronavirus and their proteins in the Title, Fig.S1, Fig.S2 and Table S1.

>>

>> Best regards

>> Fuquan

>>

>>

>>

>>> -----Original Mail-----

>>> 发件人: "Emerging Microbes and Infections"

>>> <onbehalf@manuscriptcentral.com>

>>> Sending time: 2020-02-16 23:27:06 (Sunday)

>>> Recipient: fqyang@ibp.ac.cn

>>> CC:

>>> 主题: Emerging Microbes & Infections

>>>

>>> 16-Feb-2020

>>>

>>> TEMI-2020-0082 - Emerging WuHan (2019-nCoV) Coronavirus: Glycan

>>> shield and structure prediction of Spike glycoprotein and its

>>> interaction with Human CD26

>>>

>>> Dear Professor Fuquan Yang:

>>>

>>> Thank you very much for sending in your decision to this paper. However, I did not see the reviewer's comments. In the comments box, I only found the following:

3

---

## Page 4

>>>

>>> "on't let your reviewing work go unnoticed! Researchers the world over use Publons to effortlessly track their valuable peer review contributions for any journal. If you opt in, your Publons profile will automatically be updated to show a verified record of this review in full compliance with the journal's review policy. If you don't have a Publons profile, you will be prompted to create a free account.Learn more about Publons "

>>>

>>> I wonder this may be some error. At any rate, we will send out the decision now and thank you for your quick feedback.

>>>

>>>

>>> Sincerely,

>>> Professor Shan Lu

>>> Emerging Microbes & Infections

>

>

>

>

>



**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Thursday, March 26, 2020 12:16 AM  
**To:** Lu, Shan  
**Subject:** Re: RE: Forward: Emerging Microbes & Infections

Please do so. I did not know this Yang. Please manage it. I can see how much work you are taking for EMI. Thank you.  
 YMW

> -----Original Messages-----

> From: "Lu, Shan" <Shan.Lu @ umassmed.edu> Sent Time: 2020-03-26 11:53:07

> (Thursday)

> To: "wen yumei" <ymwen@shmu.edu.cn>

> Cc:

> Subject: RE: Forward: Emerging Microbes & Infections

>

> This paper was submitted very early and at that time even several Chinese scientists suggested to use "Wuhan" to name the virus. It was part of the title by the authors. But the authors may not see his comments. I think Yang is overreacting to this so called name issue but we can try to communicate with the authors to see if they are willing to change the title. I can contact them and also communicate with Yang if you agree.

>

> Best.

>

> Shan

>

> -----Original Message-----

> From: wen yumei <ymwen@shmu.edu.cn>

> Sent: Wednesday, March 25, 2020 11:46 PM

> To: Lu, Shan <Shan.Lu @ umassmed.edu>

> Subject: Fw: Forward: Emerging Microbes & Infections

>

> I presume that was what he submitted, and we did not edit his paper,

> or we corrected his title? YM wen e

>

> -----Original Messages-----

> From: "杨福全" <fqyang@ibp.ac.cn>

> Sent Time: 2020-03-26 11:12:41 (Thursday)

> To: ymwen@shmu.edu.cn

> Cc: Shan.Lu @ umassmed.edu , who@chn.wpro.who.int

> Subject: Forward: Emerging Microbes & Infections

>

> Wenyan 士: Hello!

> Please forgive me for taking the liberty to write to you! I am Yang Fuquan from the Institute of Physical Physics, Chinese Academy of Sciences. In February of this year, I was invited to 1  
 Microbes and

> Infections" a manuscript submitted for review by the editorial department (attachment). The title of the article "Emerging WuHan (2019-nCoV)

> Coronavirus: Glycan shield and structure prediction of Spike  
 > glycoprotein and its interaction with Human



> CD26" and its text are prefixed with the word "Wuhan" in front of Coronavirus and its related proteins. This practice seriously violates the naming principles of WHO and Unauthorized self-titled "Wuhan"

> "The wording is discriminatory and insulting, and it has lost the scientific research spirit it should be. I have clearly pointed out this issue in the review comments and proposed amendmer Meaning. However, what makes people angry is the "Emerging

> Microbes and

> The editor of "Infections" did not adopt my revised intentions and published the paper online with recent days (Attachment 见). This approach is me and China 民 Completely unacceptable. Hope "Emerg

> The editorial department of ing Microbes and Infections immediately corrected the error and apologized to me for writing.

>

> Good luck!

>

> Yang Fuquan

>

> ----- Original email-----

> From 人 : Lu, Shan [mailto: Shan.Lu @ umassmed.edu ]

> Delivery time: February 17, 2020 0:01

> To: Yang Fuquan

> Cc: Editorial Office

> Subject: RE: Emerging Microbes & Infections

>

> Thanks I will ask EMI office to send your comments to the author in a separate email.

>

> Appreciate your great help! You take care since you are in the epicenter of this outbreak.

>

> Shan

>

> -----Original Message-----

> From: Yang Fuquan<fqyang@ ibp.ac.cn >

> Sent: Sunday, February 16, 2020 10:58 AM

> To: Lu, Shan < Shan.Lu @ umassmed.edu >

> Subject: Re: Emerging Microbes & Infections

>

>

> Dear Prof. Lu,

> Thank you very much for your e-mail. That is very funny.

> My comments are as following:

>

> 1. This study is worthwhile work for the drug development.

> 2. This study has compared the glycosylation sites in spike glycoproteins of 2019-nCoV and SARS-CoV-1, and the interation with human CD26, and found a number of conserved glycosylation sites in spike glycoproteins between 2019-nCoV and SARS-CoV-1, and several unique glycosylation sites 2019-nCoV. This suggests that 2019-nCoV may take a slightly different immunogenicity in host cell interactions to that of SARS, but might have the same targets and can respond to a similar therapeutic approach to SARS.

---

## Page 3

> 3. The novel Coronavirus found in Wuhan, in 2019 has only been named as 2019-nCoV by WHO, so the names such as Wuhan (2019-nCoV), Wuhan-Hu-Cov-1, Wuhan-Hu-1 should not be used for the novel Coronavirus and their proteins in the Title, Fig.S1, Fig.S2 and Table S1.

>

> Best regards

> Fuquan

>

>

>

>> -----Original Mail-----

>> From: "Emerging Microbes and Infections"

>> <onbehalf@ manuscriptcentral.com >

>> Sending time: 2020-02-16 23:27:06 (Sunday)

>> Recipient: fqyang@ ibp.ac.cn

>> CC:

5/17/2021

Please do so. I did not know this Yang. Please manage it. I can see how much work you are taking for EMI. Thank you. YMW>-

>> Subject: Emerging Microbes & Infections

>>

>> 16-Feb-2020

>>

>> TEMI-2020-0082-Emerging WuHan (2019-nCoV) Coronavirus: Glycan

>> shield and structure prediction of Spike glycoprotein and its

>> interaction with Human CD26

>>

>> Dear Professor Fuquan Yang:

>>

>> Thank you very much for sending in your decision to this paper. However, I did not see the reviewer's comments. In the comments box, I only found the following:

>>

>> "on't let your reviewing work go unnoticed! Researchers the world over use Publons to effortlessly track their valuable peer review contributions for any journal. If you opt in, your Publons profile will automatically be updated to show a verified record of this review in full compliance with the journal's review policy. If you don't have a Publons Profile, BE Prompted by Will you to the Create A as Free account.Learn More the About Publons "

>>

>> I wonder this may be some error. At any rate, we will send out the decision now and thank you for your quick feedback.

>>

>>

>> Sincerely,

>> Professor Shan Lu

>> Emerging Microbes & Infections

>

>

>

>

>

-----

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Friday, November 22, 2019 11:06 PM  
**To:** Lu, Shan  
**Cc:** xywang; Tang Yiwei  
**Subject:** Re: Re:

It is important, that they should link the results to clinical findings, especially some new findings in their cases. wen

-----The original message-----

From 人 : "Lu, Shan" <Shan.Lu@umassmed.edu>

**Sending time:** 2019-11-22 12:16:14 (Friday)

Recipient : xywang <xywang@shmu.edu.cn>

Cc : "wen yumei" <ymwen@shmu.edu.cn>, "汤一 Wei" <tangy@mskcc.org>

Main **topic:** Re:

Yes. Please tell them that there is no value to study regular gut viruses as it is hard for the authors to establish any link to diseases. It is a deadend. I am just trying to help them.

Thanks for your understanding.

Sent from my iPhone

On Nov 21, 2019, at 11:03 PM, xywang <xywang@shmu.edu.cn> wrote:

Dear Prof. Lu,

Many thanks for taking time to reviewing. Agree with you, the presentation of these data is inappropriate, anyway, may I forward the comments to authors?

Best,

Xuan-yi

1

**From:** Lu, Shan <Shan.Lu@umassmed.edu>

**Sent time:** November 21, 2019 12:46

Recipient : xywang <xywang@shmu.edu.cn>; wen yumei <ymwen@shmu.edu.cn>; 汤一wei  
<tangy@mskcc.org>

Main topic: Re:

Sorry I meant "there is NO direct evidence".

Shan

Sent from my iPhone

On Nov 20, 2019, at 11:40 PM, Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)> wrote:

Hi, Xuanyi

Thanks for bringing this paper to EMI. After a quick read, I have the following concerns:

1. While EV 71 or even CA68 is important as emerging infections, other EVs are not. hand-foot-mouth disease (HFMD) itself is not unusual and my son had it as many other kids as long as they are not the more serious types.
2. In this report, the study is quite confusing. This study is not even focusing on HFMD. Most are Aseptic meningitis, and the overall study data is very limited and superficial. It is even more confusing saying multiple EVs may be involved in causing CNS symptom while there is direct evidence.

Based on the above, I would not be interested in this paper.

Best.

Shan

2

---

Page 3

**From:** xywang [ <mailto:xywang@shmu.edu.cn> ]  
**Sent:** Wednesday, November 20, 2019 1:34 AM  
**To:** 'wen yumei' <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>; Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>; Tang Yi Wei <[tangy@mskcc.org](mailto:tangy@mskcc.org)>  
**Subject:**

Teacher Wen, Professor Lu, Professor Tang:

Attached is the enterovirus pathogen spectrum of the infectious disease department of our sub-hospital, which is for the next step in the development of domestic disease

6/1/2021

It is important, that they should link the results to clinical findings, especially some new findings in their cases. Wen -----  
Hair is very valuable for reference. Previously, there were no credible similar reports in China. Please review and take a look at  
Can it be published in EMI?

I wish Dongan!

Xuan Yi

Xuan-Yi Wang, MD & Ph.D.

Professor, Key Laboratory Medical Molecular Virology, MoE/MoH, Shanghai Medical  
College, Fudan University

Research Scientist, the Institutes of Biomedical Sciences, Fudan University

Deputy Director, National Engineering Laboratory for Therapeutic Vaccines

---

**From:** zlshi <zlshi@wh.iov.cn>  
**Sent:** Tuesday, September 15, 2020 10:55 PM  
**To:** Lu, Shan; Wesson, Simon; TEMI-production@journals.tandf.co.uk  
**Cc:** editorial; jml8328@126.com; ymwen; Josaphouitch, Alexa  
**Subject:** Re: RE:Press release: A serological survey of SARS-CoV-2 in cat in Wuhan

Dear Prog. Lu,

Thank you for your information. I didn't have any contact from the news group.

Best regards,  
Zhengli,

---

SHI Zhengli, Ph. D  
Senior Scientist & Professor  
Wuhan Institute of Virology, Chinese Academy of Sciences  
44 Xiao Hong Shan  
430071 Wuhan, Hubei  
China  
Tel & Fax: (0086) 27 87197240  
Email: [zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn)

---

**From:** [Lu, Shan](#)  
**Date:** 2020-09-16 00:52  
**To:** [Wesson, Simon](#); [TEMI-production@journals.tandf.co.uk](mailto:TEMI-production@journals.tandf.co.uk)  
**CC:** [Editorial Office](#); [126.com](#); [zlshi@wh.iov.cn](mailto:zlshi@wh.iov.cn); [M. Yu-Mei Wen \(ymwen@shmu.edu.cn\)](mailto:M.Yu-Mei.Wen@shmu.edu.cn); [Josaphouitch, Alexa](#)  
**Subject:** RE: Re:RE: Re:Press release: A serological survey of SARS-CoV-2 in cat in Wuhan

Dear Simon,

Today is the day of ending embargo. I noticed a huge jump of views (4261) although it is toward the AMO version. This never happened in the past and I assume that you must have sent out the PR to quite a lot of news outlets. This confirms the approach we have been planning is working.

Dr. Shi and Dr. Jin,  
It will be interesting if you can let us in about one week so we can know if any news group contacted you for this paper.

Dear Karthick,

It is somewhat disappointing that we did not see the real final published paper at EMI site (except AMO). It will be really nice if the clean copy of published paper is available to readers.

Best.  
Shan

---

**From:** Wesson, Simon <Simon.Wesson@tandf.co.uk>  
**Sent:** Monday, September 7, 2020 10:59 AM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>; 126.com <jml8328@126.com>  
**Cc:** Editorial Office <editorial@emi2012.org>  
**Subject:** RE: Re:RE: Re:Press release: A serological survey of SARS-CoV-2 in cat in Wuhan

Hello Shan

Yes I think that would be sensible to add in, around the part where we mention no deaths. Does that work for you both?

Thanks

Information Classification: General

---

**From:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Sent:** 07 September 2020 15:25

**To:** Wesson, Simon <[Simon.Wesson@tandf.co.uk](mailto:Simon.Wesson@tandf.co.uk)>; 126.com <[jml8328@126.com](mailto:jml8328@126.com)>

**Cc:** Editorial Office <[editorial@emi2012.org](mailto:editorial@emi2012.org)>

**Subject:** RE: Re:RE: Re:Press release: A serological survey of SARS-CoV-2 in cat in Wuhan

Hi, Simon and Meilin,

This press release reads well. I just wonder if we should add that there was no actual COVID-19 virus detected from these cats.

Best.

Shan

\*\*\*\*\*

Shan Lu, MD, PhD

Editor-in-Chief

Emerging Microbes and Infections (EMI)

[www.tandfonline.com/TEMI](http://www.tandfonline.com/TEMI)

[editorial@2012EMI.org](mailto:editorial@2012EMI.org)

---

**From:** Wesson, Simon <[Simon.Wesson@tandf.co.uk](mailto:Simon.Wesson@tandf.co.uk)>

**Sent:** Monday, September 7, 2020 5:39 AM

**To:** 126.com <[jml8328@126.com](mailto:jml8328@126.com)>; Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>

**Subject:** RE: Re:RE: Re:Press release: A serological survey of SARS-CoV-2 in cat in Wuhan

Hi both

Just to say that I've spoken to the production team here and the article will not be 100% ready for Wednesday. Therefore to make sure there are no issues of us doing a release that leads to no article online I have set a new embargo and publication date of Tuesday 15 September.

The press release is good to go and as soon as the final article is ready I can begin distribution under embargo too.

Best wishes

Simon

**From:** 126.com <[jml8328@126.com](mailto:jml8328@126.com)>

**Sent:** 05 September 2020 15:17

**To:** Wesson, Simon <[Simon.Wesson@tandf.co.uk](mailto:Simon.Wesson@tandf.co.uk)>

**Subject:** Re:RE: Re:Press release: A serological survey of SARS-CoV-2 in cat in Wuhan

Dear Simon,

Good afternoon. I'm quite satisfied with the final press release.

Thank you again for your efforts.

Best wishes,

Yours sincerely,

Meilin Jin

--

Meilin Jin, Ph.D

Professor of Molecular Microbiology & Animal Infectious Diseases

State Key Laboratory of Agricultural Microbiology

College of Veterinary Medicine

Huazhong Agricultural University

Shizishan Street 1, Wuhan 430070

P.R. China

Phone: +86-27-8728 6905

Fax: +86-27-8728 2608

E-mail: [jml8328@126.com](mailto:jml8328@126.com)

||



**From:** Chuan He <chuanhe@uchicago.edu>  
**Sent:** Tuesday, February 4, 2020 11:19 AM  
**To:** Lu, Shan;'YAN GAO'  
**Cc:** Yong-Jun.Liu ; Liu.6244  
**Subject:** Re: Re:RE: Future Science Award Online Closed-door Seminar Invitation Letter--Professor Lu Shan

Thanks Professor Lu for your support and participation!

Best wishes,

Chuan

**From:** Lu, Shan <Shan.Lu @ umassmed.edu>  
**Sent:** Tuesday, February 4, 2020 9:23 AM  
**To:** 'YAN GAO' <gaoyan@futureforum.org.cn>  
**Cc:** Yong-Jun.Liu <yong-jun.liu @ sanofi.com>; Chuan He <chuanhe@uchicago.edu>; Liu.6244 <Liu.6244@osu.edu>  
**Subject:** RE: Re:RE: Future Science Award Online Closed-door Seminar Invitation Letter--Professor Lu Shan

Ok, I will give one slide with my key outline.

**From:** YAN GAO <gaoyan@futureforum.org.cn>  
**Sent:** Tuesday, February 4, 2020 10:19 AM  
**To:** Lu, Shan <Shan.Lu @ umassmed.edu>  
**Cc:** Yong-Jun.Liu <yong-jun.liu @ sanofi.com>; chuanhe <chuanhe@uchicago.edu>; Liu.6244 <Liu.6244@osu.edu>  
**Subject:** Re:RE: Future Science Award Online Closed-door Seminar Invitation Letter--Professor Lu Shan

Master Lu,

It's okay, it depends on what you think is more suitable.

Yeon

----- Original -----

**From:** "Lu, Shan" <>; Shan.Lu @ umassmed.edu  
**Date:** Tue, Feb 4, 2020 11:18 PM  
**To:** "'YAN GAO'" <>; gaoyan@futureforum.org.cn  
**Cc:** " "; "chuanhe" <>; "Liu.6244" <>; Yong-Jun.Liu " <yong-jun.liu @ sanofi.com chuanhe@uchicago.edu Liu.6244@osu.edu  
**Subject:** RE: Re: RE: Future Science Award Online Closed Seminar Invitation Letter--Professor Lu

Ok, do I need to use slides, or only verbal presenting.

**From:** YAN GAO <>; gaoyan@futureforum.org.cn  
**Sent:** Tuesday, February 4, 2020 10:10 AM  
**To:** Lu, Shan <>; Shan.Lu @ umassmed.edu  
**Cc:** >; chuanhe <>; Liu.6244 <>; Yong-Jun.Liu <yong-jun.liu @ sanofi.com chuanhe@uchicago.edu Liu.6244@osu.edu  
**Subject:** Re:RE: Invitation Letter for Future Science Award Online Closed Seminar--Professor Lu

Great, thank you Master Lu,

Each guest took 8 minutes to share, and 2-3 minutes to answer questions, followed by a family discussion.

Yeon

----- Original -----

**From:** "Lu, Shan" <>Shan.Lu @ umassmed.edu  
**Date:** Tue, Feb 4, 2020 10:44 PM  
**To:** "YAN GAO" <>gaoyan@ futureforum.org.cn  
**Cc:** ">"; "chuanhe" <>"; "Liu.6244" <>"; Yong-Jun.Liu " <yong-jun.liu @ sanofi.com chuanhe@ uchicago.edu Liu.6244@ osu.edu  
**Subject:** RE: Invitation Letter for Future Science Award Online Closed Seminar--Professor Lu

Hi, Yeon,

Thank you for your invitation. I can participate as a guest speaker. What is the time for us to launch?

Lu

**From:** YAN GAO <>gaoyan@ futureforum.org.cn  
**Sent:** Tuesday, February 4, 2020 4:48 AM  
**To:** Lu, Shan <>Shan.Lu @ umassmed.edu  
**Cc:** ">"; chuanhe <>"; Liu.6244 <>"; Yong-Jun.Liu <yong-jun.liu @ sanofi.com chuanhe@ uchicago.edu Liu.6244@ osu.edu  
**Subject:** Invitation Letter for Online Closed Seminar of Future Science Awards--Professor Lu

Dear Master Lu, hello

I'm Yan Yan from the Secretariat of the Scientific Public Welfare Organization "Future Science Award".

Note and address the challenges.

It was recommended by Professor **He Chuan** of Chicago Institute of Science and Technology and Future Science Award Science Committee and **Liu Yongjun**, President of the Future Science Award Science Committee. Recommend, we are very honored to invite you to participate in the topic of " **Decoding the Novel Coronavirus - How to Scientifically Recognize and Deal with it** " Seminar.

This seminar will invite experts, scholars and scientists from the fields of virus, immunization, pharmaceuticals and bioinformatics, as well as experienced clinical doctors. I hope to decode the new coronavirus from multiple dimensions throughout the course of the disease, analyze the current status of effective treatment and clinical research. The research and development path of surgery, antiviral drugs and treatment.

Closed seminars are only open to future forum board members, members of the scientific committee and the platform for many years. The content of the meeting is subject to the approval of the Secretariat. It will never be released to the public.

[Seminar time]

Beijing Time 2月9日 Weekdays 9:00-11:30 AM

**【Participation Method】**  
**Network Conference System**

2

Page 3

**【Lecturer】**  
**Su, Professor of General Studies, North Carolina, USA [Confirmed]**  
**Zhong Wu, National Emergency Prevention and Control Drugs Technical Research Center, Academy of Military Medical Sciences [Confirmed]**  
**石Zhengli**, researcher at Wuhan Institute of Virology, Chinese Academy of Sciences **【Confirmed】**

I really hope to invite you to share and discuss online, with the agenda of the closed seminar, the list of invited guests and the introduction of the Future Science Award. If you have any questions, please feel free to contact us and look forward to your reply.

Future Science Award Secretariat  
 Yeon



---

**From:** Chuan He <chuanhe@uchicago.edu>  
**Sent:** Tuesday, February 4, 2020 11:19 AM  
**To:** Lu, Shan; 'YAN GAO'  
**Cc:** Yong-Jun.Liu; Liu.6244  
**Subject:** Re: Re:RE: Re:RE: 未来科学大奖线上闭门研讨会邀请函--卢山教授

Thanks Professor Lu for your support and participation!

Best wishes,

Chuan

---

**From:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Sent:** Tuesday, February 4, 2020 9:23 AM  
**To:** 'YAN GAO' <gaoyan@futureforum.org.cn>  
**Cc:** Yong-Jun.Liu <yong-jun.liu@sanofi.com>; Chuan He <chuanhe@uchicago.edu>; Liu.6244 <Liu.6244@osu.edu>  
**Subject:** RE: Re:RE: Re:RE: 未来科学大奖线上闭门研讨会邀请函--卢山教授

Ok, I will give one slide with my key outline.

**From:** YAN GAO <gaoyan@futureforum.org.cn>  
**Sent:** Tuesday, February 4, 2020 10:19 AM  
**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Cc:** Yong-Jun.Liu <yong-jun.liu@sanofi.com>; chuanhe <chuanhe@uchicago.edu>; Liu.6244 <Liu.6244@osu.edu>  
**Subject:** Re:RE: Re:RE: 未来科学大奖线上闭门研讨会邀请函--卢山教授

卢老师,

都可以的, 看您觉得怎么更合适。

高妍

----- Original -----

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>;  
**Date:** Tue, Feb 4, 2020 11:18 PM  
**To:** "'YAN GAO'" <[gaoyan@futureforum.org.cn](mailto:gaoyan@futureforum.org.cn)>;  
**Cc:** "Yong-Jun.Liu" <[yong-jun.liu@sanofi.com](mailto:yong-jun.liu@sanofi.com)>; "chuanhe" <[chuanhe@uchicago.edu](mailto:chuanhe@uchicago.edu)>; "Liu.6244" <[Liu.6244@osu.edu](mailto:Liu.6244@osu.edu)>;  
**Subject:** RE: Re:RE: 未来科学大奖线上闭门研讨会邀请函--卢山教授

Ok, do I need to use slides, or only verbal presenting.

**From:** YAN GAO <[gaoyan@futureforum.org.cn](mailto:gaoyan@futureforum.org.cn)>  
**Sent:** Tuesday, February 4, 2020 10:10 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** Yong-Jun.Liu <[yong-jun.liu@sanofi.com](mailto:yong-jun.liu@sanofi.com)>; chuanhe <[chuanhe@uchicago.edu](mailto:chuanhe@uchicago.edu)>; Liu.6244 <[Liu.6244@osu.edu](mailto:Liu.6244@osu.edu)>  
**Subject:** Re:RE: 未来科学大奖线上闭门研讨会邀请函--卢山教授

太好了，谢谢卢老师，  
每位嘉宾 8 分钟分享，和 2-3 分钟回答提问，接下来是大家一起讨论。

高妍

----- Original -----

**From:** "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>;  
**Date:** Tue, Feb 4, 2020 10:44 PM  
**To:** "YAN GAO" <[gaoyan@futureforum.org.cn](mailto:gaoyan@futureforum.org.cn)>;  
**Cc:** "Yong-Jun.Liu" <[yong-jun.liu@sanofi.com](mailto:yong-jun.liu@sanofi.com)>; "chuanhe" <[chuanhe@uchicago.edu](mailto:chuanhe@uchicago.edu)>; "Liu.6244" <[Liu.6244@osu.edu](mailto:Liu.6244@osu.edu)>;  
**Subject:** RE: 未来科学大奖线上闭门研讨会邀请函--卢山教授

Hi, 高妍,

谢谢你的邀请，我可以作为主讲嘉宾参加。我们几位的发言时间是多少？

卢山

**From:** YAN GAO <[gaoyan@futureforum.org.cn](mailto:gaoyan@futureforum.org.cn)>  
**Sent:** Tuesday, February 4, 2020 4:48 AM  
**To:** Lu, Shan <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
**Cc:** Yong-Jun.Liu <[yong-jun.liu@sanofi.com](mailto:yong-jun.liu@sanofi.com)>; chuanhe <[chuanhe@uchicago.edu](mailto:chuanhe@uchicago.edu)>; Liu.6244 <[Liu.6244@osu.edu](mailto:Liu.6244@osu.edu)>  
**Subject:** 未来科学大奖线上闭门研讨会邀请函--卢山教授

尊敬的卢老师，您好

我是科学公益组织“未来科学大奖”秘书处的高妍，目前新型冠状病毒疫情复杂严峻，已经上升至全球关注和应对的挑战。

经与未来科学大奖科学委员会成员、芝加哥大学何川教授和赛诺菲集团全球研发部总裁刘勇军老师推荐，我们非常荣幸地邀请您参与主题为“**解码新型冠状病毒—如何科学认知和应对新型病毒**”线上闭门研讨会。

本次研讨会将邀请病毒、免疫、制药和生物信息等方面的专家学者和科学家，以及经验丰富的临床医生，希望从全病程多维度解码新型冠状病毒，分析有效治疗和临床发展现况，共同探讨如何加速诊断技术、抗病毒药物及治疗的研发路径。

闭门研讨活动仅对未来论坛理事会成员、科学委员会成员及平台青年力量开放，会议内容在全体参会人员同意前绝不会对外发布。

**【研讨会时间】**

北京时间 2 月 9 日 星期日 上午 9:00-11:30

**【参与方式】**

网络会议系统

**【主讲嘉宾】**

苏立山，美国北卡罗莱纳大学教授【已确认】

钟武，军事医学研究院国家应急防控药物工程技术研究中心【已确认】

石正丽，中国科学院武汉病毒所研究员【已确认】

非常希望能邀请您来线上分享和讨论，附上闭门研讨会的议程及拟邀嘉宾名单和未来科学大奖简介  
如您有任何疑问，请随时联络，期待您的回复。

未来科学大奖秘书处

高妍

---

**From:** Perlman, Stanley <stanley-perlman@uiowa.edu>  
**Sent:** Friday, July 10, 2020 6:35 PM  
**To:** International Society for Vaccines  
**Cc:** Lu, Shan  
**Subject:** Re: Registration Open: 2nd ISV COVID-19 Vaccines Virtual Congress

Please correct Bart's name. It is Haagmans.

Stanley

Stanley Perlman, MD, Ph.D.  
Professor  
Depts of Microbiology and Immunology, and Pediatrics  
BSB 3-712  
University of Iowa  
Iowa City, IA 52242  
319-335-8549

On Jul 10, 2020, at 5:21 PM, International Society for Vaccines <[info@isv-online.org](mailto:info@isv-online.org)> wrote:



Dear Colleagues,

The International Society for Vaccines (ISV) ([www.isv-online.org](http://www.isv-online.org)) is pleased to announce the 2<sup>nd</sup> Congress of the ISV Virtual Congress Series on COVID-19 Vaccines will be held on July 21, Tuesday.

The Virtual Congress series provides a platform for key COVID-19 vaccine developers to share their progress and for the global vaccine community to contribute their collective wisdom so the entire global community can enjoy the benefits of vaccine protection in the near future.

The first Congress on June 22 was a huge success with 1600 registered attendees. Professor Kwok-Hung Yuen from Hong Kong University and Dr. Nick Jackson from CEPI provided the keynote speeches. Representatives from NIAID, INOVIO, University of Oxford and CanSinoBIO presented the progress of their respective COVID-19 vaccine programs. A special expert panel discussed the value and limitation of human challenge studies. A full set of video recordings of the 1<sup>st</sup> ISV Virtual Congress is available at YouTube: [https://www.youtube.com/channel/UC9\\_-f8tDAqOmVEZWqGeuFow](https://www.youtube.com/channel/UC9_-f8tDAqOmVEZWqGeuFow)

The 2nd Virtual Congress will present to the global vaccine community another great speaker panel:

- The opening keynote speaker, **Dr. Larry Corey** from Fred Hutch, will describe the clinical study design of COVID-19 which is an unprecedented challenge in the history of vaccinology.
- The other keynote speaker, **Dr. Marion Gruber** from US FDA, will provide an overview on the regulatory review of COVID-19 vaccines.
- Then **Drs. Greg Glenn** (Novavax), **George Gao** (China CDC), **Hanneke Schuitemaker** (J&J/Jansen) and **Kena Swanson** (Pfizer) will present the progress of their respective COVID-19 vaccine programs.
- The final panel discussion will include world experts **Stanley Perlman** (moderator), **Bart Haagermans**, **Vincent Munster** and **Linda Saif** to discuss the value of animal models for the development of COVID-19 vaccines.

Date and time for the 2<sup>nd</sup> ISV Virtual Congress:

**Tuesday, July 21, 2020**

Los Angeles

0600-0900

New York 0900-1200

London 1400-1700

Paris 1500-1800

Beijing 2100-2400

Tokyo/Seoul 2200-0100

Sydney 2300-0200

The virtual congress will be presented via Microsoft Teams. The July 21 Congress is free to worldwide scientists with an interest in COVID-19 vaccines. Pre-registration is required. Space is limited and ISV members will have priority.

Register now at [www.ISVCongress.org](http://www.ISVCongress.org).

Linda Klavinskis, PhD

Margaret Liu, MD

Shan Lu, MD, PhD

*ISV COVID-19 Vaccine Virtual Congress co-Chairs*

REGISTER HERE



KVS 대한백신학회  
THE KOREAN VACCINE SOCIETY



VGXI<sup>®</sup>  
QUALITY...IT'S IN OUR DNA<sup>®</sup>

GCPharma

humanVACCINES  
& IMMUNOTHERAPEUTICS

inovia  
PHARMACEUTICALS

SANOFI PASTEUR

EpiVax



Please email [Info@ISVCongress.org](mailto:Info@ISVCongress.org) with any questions.



*If you no longer wish to receive email from us, please click [here](#).*

**From:** Min Yang <min.yang@emi2012.org>  
**Sent:** Thursday, April 23, 2020 10:02 AM  
**To:** Lu, Shan; YiWei Tang  
**Cc:** wen yumei  
**Subject:** Re: response  
**Attachments:** TEMI-2020-0643\_Proof\_hi.pdf

Dear Prof Tang,


I have to say sorry as I just sent out the invitation letter out to Prof Wen for you.  
Hope this is ok with you.

Dear Prof Wen,

Please check and confirm if you have received the invitation email. If so, please find the below instructions which you may find helpful:

1. Click the “agree” link provided in the invitation email and it will lead you to the review system.
2. Click on “review” button of the menu.
3. Click on “review and score” and then you will find the paper.

Below please find the screenshot for your reference:



If you cannot find the email, please click: <https://mc.manuscriptcentral.com/temi> for log in.  
Kindly note your ID is ymwen@shmu.edu.cn.

# Log In

User ID

[Create an Account](#)

Password

[Reset Password](#)



Log In

 Log In With ORCID iD

I have also attached the pdf file of this paper for your reference, you can write your comment here if you like so that I can help get it uploaded to the system.

Please do not hesitate to let me know if any questions.

Thanks and regards,

Min Yang

*Emerging Microbes & Infections* (EMI) Editorial Office  
4F Fuxing Building  
131 Dongan Road  
Shanghai  
China  
Tel: 86-21-54237992  
E-mail: min.yang@emi2012.org

---

发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>  
日期: 2020年4月23日 星期四 下午8:30  
收件人: YiWei Tang <yiweitangmd@gmail.com>  
抄送: wen yumei <ymwen@shmu.edu.cn>, Min Yang <min.yang@emi2012.org>  
主题: RE: response

Hi, Yi-Wei,

I now assigned you as RE for TEMI-2020-0643.

Min: assist Prof Wen after Yi-Wei assigned her as a reviewer.

Shan

---

**From:** Lu, Shan

**Sent:** Thursday, April 23, 2020 6:29 AM

**To:** YiWei Tang <yiweitangmd@gmail.com>

**Cc:** wen yumei <ymwen@shmu.edu.cn>; Min Yang <min.yang@emi2012.org>

**Subject:** Re: response

Hi-Wei,

Great idea. You will be the RE and please invite Prof Wen as a reviewer. Min will help her to log in S1 system.

I will assign it to you soon.

Shan

Sent from my iPhone

On Apr 23, 2020, at 5:16 AM, YiWei Tang <[yiweitangmd@gmail.com](mailto:yiweitangmd@gmail.com)> wrote:

Shan,

If this is ok with you, I will be happy to be the review editor for this one. I will invite Teacher Wen as an official reviewer.

Thank you, Yi-Wei

On Thu, Apr 23, 2020 at 4:52 PM wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)> wrote:

Thank to you both. For a letter to editor, maybe you can give them some advice on the percentages of children patients sent to their hospital in Shanghai. Because this hospital is the only hospital to accept children COVID-19 patients. Also. if they can give some information on the epidemiology of these patients, that weillbe helpful. Wen

---

**From:** YiWei Tang <yiweitangmd@gmail.com>  
**Sent:** Thursday, April 23, 2020 6:43 PM  
**To:** Min Yang  
**Cc:** Lu, Shan; wen yumei  
**Subject:** Re: response

Thank you all.

Yi-Wei

On Thu, Apr 23, 2020 at 10:01 PM Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)> wrote:

Dear Prof Tang,

I have to say sorry as I just sent out the invitation letter out to Prof Wen for you.

Hope this is ok with you.

Dear Prof Wen,

Please check and confirm if you have received the invitation email. If so, please find the below instructions which you may find helpful:

1. Click the “agree” link provided in the invitation email and it will lead you to the review system.
2. Click on “review” button of the menu.
3. Click on “review and score” and then you will find the paper.

Below please find the screenshot for your reference:

Reviewer View Manuscripts

0 Review and Score >

0 Scores Submitted >

1 Invitations >

Legacy Instructions >

You Have a New Review Invitation

You have been invited to submit a new review [View Invitations](#)

## Review and Score

| ACTION                                 | DUE DATE | TYPE | ID/TITLE | STATUS |
|----------------------------------------|----------|------|----------|--------|
| There are no submissions in this queue |          |      |          |        |

If you cannot find the email, please click: <https://mc.manuscriptcentral.com/temi> for log in.

Kindly note your ID is [ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn).

# Log In

User ID [Create an Account](#)

Password [Reset Password](#)

[Log In](#)

Log In With ORCID iD

I have also attached the pdf file of this paper for your reference, you can write your comment here if you like so that I can help get it uploaded to the system.

Please do not hesitate to let me know if any questions.

Thanks and regards,

Min Yang

*Emerging Microbes & Infections* (EMI) Editorial Office  
4F Fuxing Building

131 Dongan Road  
Shanghai  
China  
Tel: 86-21-54237992  
E-mail: [min.yang@emi2012.org](mailto:min.yang@emi2012.org)

---

发件人: "Lu, Shan" <[Shan.Lu@umassmed.edu](mailto:Shan.Lu@umassmed.edu)>  
日期: 2020年4月23日 星期四 下午8:30  
收件人: YiWei Tang <[yiweitangmd@gmail.com](mailto:yiweitangmd@gmail.com)>  
抄送: wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>, Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>  
主题: RE: response

Hi, Yi-Wei,

I now assigned you as RE for TEMI-2020-0643.

Min: assist Prof Wen after Yi-Wei assigned her as a reviewer.

Shan

---

**From:** Lu, Shan  
**Sent:** Thursday, April 23, 2020 6:29 AM  
**To:** YiWei Tang <[yiweitangmd@gmail.com](mailto:yiweitangmd@gmail.com)>  
**Cc:** wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)>; Min Yang <[min.yang@emi2012.org](mailto:min.yang@emi2012.org)>  
**Subject:** Re: response

Hi-Wei,

Great idea. You will be the RE and please invite Prof Wen as a reviewer. Min will help her to log in S1 system.

I will assign it to you soon.

Shan

Sent from my iPhone

On Apr 23, 2020, at 5:16 AM, YiWei Tang <[yiweitangmd@gmail.com](mailto:yiweitangmd@gmail.com)> wrote:

Shan,

If this is ok with you, I will be happy to be the review editor for this one. I will invite Teacher Wen as an official reviewer.

Thank you, Yi-Wei

On Thu, Apr 23, 2020 at 4:52 PM wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)> wrote:

Thank to you both. For a letter to editor, maybe you can give them some advice on the percentages of children patients sent to their hospital in Shanghai. Because this hospital is the only hospital to accept children COVID-19 patients. Also. if they can give some information on the epidemiology of these



patients, that we'll be helpful. When

---

**From:** YiWei Tang <yiweitangmd@gmail.com>  
**Sent:** Thursday, April 23, 2020 5:16 AM  
**To:** wen yumei  
**Cc:** Lu, Shan  
**Subject:** Re: response

Shan,

If this is ok with you, I will be happy to be the review editor for this one. I will invite Teacher Wen as an official reviewer.

Thank you, Yi-Wei

On Thu, Apr 23, 2020 at 4:52 PM wen yumei <[ymwen@shmu.edu.cn](mailto:ymwen@shmu.edu.cn)> wrote:

Thank to you both. For a letter to editor, maybe you can give them some advice on the percentages of children patients sent to their hospital in Shanghai. Because this hospital is the only hospital to accept children COVID-19 patients. Also. if they can give some information on the epidemiology of these patients, that weillbe helpful. Wen

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Sunday, February 23, 2020 4:59 AM  
**To:** Lu, Shan  
**Subject:** Re: Review from Jin Dong-yan

For Jin's review, my comment is

This is a well written review, including the characteristics of several coronaviruses between SARS and COVID-19 outbreaks. Further more, it reviewed virus-host interactions, which have not been reviewed in other articles. However, I do not think it is appropriate to include HIV in this review, and I advise the authors to delete this part from the review.

Please be the other reviewer, and give your comments.

After revision, I think it is worthy to be accepted.

Regards,

Yu-Mei Wen

-----Original Messages-----

**From:** "Lu, Shan" <Shan.Lu@umassmed.edu>  
**Sent Time:** 2020-02-22 13:58:13 (Saturday)  
**To:** "wen yumei" <ymwen@shmu.edu.cn>  
**Cc:**  
**Subject:** Review from Jin Dong-yan

Dear Prof Wen,

Jin Dong-yan submitted a review based on your invitation. I am attaching it here for your reference. Please let me know if you have any comments so I can enter into the system that he can revise. Or if you have anyone who can review this paper.

At the same time, I am very happy to accept at any time you would like to do so.

Best.

Shan

---

**From:** wen yumei <ymwen@shmu.edu.cn>  
**Sent:** Thursday, August 22, 2019 10:30 PM  
**To:** Lu, Shan  
**Subject:** Re: reviews

Nice work. Can we ask Malik to write a review on Emerging Respiratory infections- Looking back and forward? or other topic?

There is a professor from Austria visiting us Franz Heinz, who is an expert in flavivirus. I plan to ask him to write a review for us regarding new information on flavivirus or Zika.

YMW  
See his publications

[ront Immunol.](#) 2018 May 30;9:1196. doi: 10.3389/fimmu.2018.01196. eCollection 2018.

## **Structural Influence on the Dominance of Virus-Specific CD4 T Cell Epitopes in Zika Virus Infection.**

[The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design.](#)

Rey FA, Stiasny K, Vaney MC, Dellarole M, Heinz FX.

EMBO Rep. 2018 Feb;19(2):206-224. doi: 10.15252/embr.201745302. Epub 2017 Dec 27. Review

-----原始邮件-----

发件人: "Lu, Shan" <Shan.Lu@umassmed.edu>

发送时间: 2019-08-23 09:11:31 (星期五)

收件人: "wen yumei" <ymwen@shmu.edu.cn>

抄送:

主题: FW: Invitation to join EMI as an editorial member

Dear Prof Wen,

For your information, Prof Malik Peiris has been added to the EMI Editorial Board who was nominated last year but only had time to finish his appointment. He is a very prominent virologist and US NAC member, with great work in emerging infections.

Shan

---

**From:** malik [mailto:malik@hku.hk]

**Sent:** Thursday, August 22, 2019 8:44 PM

**To:** Lu, Shan <Shan.Lu@umassmed.edu>  
**Cc:** min.yang@emi2012.org; 'Yu, Min' <Min.Yu@tandfchina.com>  
**Subject:** RE: Invitation to join EMI as an editorial member

Dear Shan,

Find below. Please edit or change as required to fit the format you need. Let me know if this needs to be modified or adjusted.

Malik Peiris is a clinical and public health virologist with a particular interest in emerging virus disease at the animal-human interface using a “One Health” approach, including influenza, coronaviruses (SARS, MERS), arboviruses and others. His current research encompasses the pathogenesis, innate immune responses, transmission, ecology and epidemiology of human and animal (poultry, swine, wild birds) influenza viruses and coronaviruses (SARS, MERS) in humans and animals. He was elected a Fellow of the Royal Society of London in 2006, Fellow of the American Academy of Microbiology in 2016 and Foreign Associate of National Academy of Sciences in 2017.

Malik

---

**From:** Lu, Shan [<mailto:Shan.Lu@umassmed.edu>]  
**Sent:** Friday, August 23, 2019 2:31 AM  
**To:** malik <[malik@hku.hk](mailto:malik@hku.hk)>  
**Cc:** [min.yang@emi2012.org](mailto:min.yang@emi2012.org); 'Yu, Min' <[Min.Yu@tandfchina.com](mailto:Min.Yu@tandfchina.com)>  
**Subject:** RE: Invitation to join EMI as an editorial member

Dear Malik,

Hope this email will find you well. I wonder if you can send me a short bio so we can add your name to EMI editorial board list at EMI web site.

Best.

Shan